@article{abbottRouxenYGastricBypass2025,
  title = {Roux-En-{{Y}} Gastric Bypass, Adjustable Gastric Banding, or Sleeve Gastrectomy for Severe Obesity ({{By-Band-Sleeve}}): A Multicentre, Open Label, Three-Group, Randomised Controlled Trial},
  shorttitle = {Roux-En-{{Y}} Gastric Bypass, Adjustable Gastric Banding, or Sleeve Gastrectomy for Severe Obesity ({{By-Band-Sleeve}})},
  author = {Abbott, Sally and Adams, Benita and Agrawal, Sanjay and Ahmed, Ahmed and Momani, Hazem Al and {Al-Khyatt}, Waleed and {Al-Taan}, Omer and Andrews, Robert C. and Antognozzi, Manuela and Awad, Sherif and Awan, Altaf and Balupuri, Shlok and Bellani, Samir and Bessent, John and Betts, Jonathan and Blazeby, Jane M. and Blencowe, Natalie and Brierley, Rachel and Brown, Julia and Byrne, James P. and Byrom, Richard and {Cappel-Porter}, Heike and Carter, Nicholas and Chalmers, Katy and Charalampakis, Vasileios and Clark, James and Clarke, Michael and Clay (deceased), Caroline and Coast, Joanna and Corrigan, Paul and Cota, Allwyn and Coulman, Karen and Cousins, Sian and Culliford, Lucy and Dabner, Lucy and Dabner, Sabrina and Daskalakis, Markos and Davies, Nick and Dexter, Simon and Dixon, John and Donovan, Jenny L. and Edmond, Janet and Edwards, Danielle and Evans, Rebecca and Fareed, Khaleelur and Fermont, Jilles M. and Finer, Nicholas and Finlay, Ian and Fong, Tracey and Furreed, Hassina and Gidman, Eleanor A. and Gilbert, Anna and Gilbert, Jeremy and Gladas, Kirsty and Greenslade, Beth and Hakky, Sherif and Hayden, Jeremy and Henderson, Jennifer and Henman, Jodie and Hewes, James and Heys, Rachael and Hollyman, Marianne and Hopkins, James and Horton, Helen and Jayathilaka, Buddika and Jennings, Neil and Kanavou, Sofia and Kaur, Surinder and Kelly, Jamie and Knight, Benjamin and {Koleva-Kolarova}, Rositsa and Lamb, Jenny and Leeder, Paul and Lin, Chiwen and Long, Amy and Loy, John and McCaie, Charlotte and Mckeon, Holly and Madhok, Brijesh and Mahawar, Kamal and Mahon, David and Maishman, Rachel and Mason, Matthew and Mathew, Priya and Matthias, Sarah and Mazza, Graziella and Mehta, Samir and Mekhail, Peter and Mikulski, Alexander and Monkhouse, Simon and Moon, Maria and Moorthy, Krishna and Moriarty, Catherine and Morris, Steve and Nijjar, Rajwinder and Noble, Hamish and Norton, Sally and O'Connell, Abby and O'Kane, Mary and Olbers, Torsten and Osborne, Alan and Palmer, Stephen and Paramasivan, Sangeetha and Pike, Katie and Pournaras, Dimitri and Pouwels, Koen and Priestley, Mark and Purkayastha, Sanjay and Ramsay, Craig and Realpe, Alba X. and Reeves, Barnaby C. and Richardson, Martin and Robertson, Andrew G. and Roderick, Paul and Rogers, Chris A. and Salter, Nicki and {Salter-Hewitt}, Jade and Sardo, Pedro Braga and Sarela, Abeezar Ismail and Singhal, Rishi and Small, Peter K. and Smith, Neil and Somers, Shaw and Super, Paul and Suter, Michel and Telfah, Muwaffaq and Thompson, Janice L. and Thorpe, Kerry and Townley, Jill and Tsironis, Christos and Welbourn, Richard and Whybrow, Paul and Wilding, John and Williamson, James and Wilson, Caroline and Wordsworth, Sarah and Wright, Rachael},
  year = {2025},
  month = may,
  journal = {The Lancet Diabetes \& Endocrinology},
  volume = {13},
  number = {5},
  pages = {410--426},
  publisher = {Elsevier},
  issn = {2213-8587, 2213-8595},
  doi = {10.1016/S2213-8587(25)00025-7},
  urldate = {2025-05-21},
  langid = {english},
  pmid = {40179925},
  file = {/Users/xx20081/Zotero/storage/TQKZTIPQ/Abbott et al. - 2025 - Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-B.pdf}
}

@article{abdel-azizLeptinLeptinGene2012,
  title = {Leptin, Leptin Gene and Leptin Receptor Gene Polymorphism in Heart Failure with Preserved Ejection Fraction},
  author = {{Abd El-Aziz}, Tarek A. and Mohamed, Randa H. and Mohamed, Rasha H. and Pasha, Heba F.},
  year = {2012},
  month = may,
  journal = {Heart and Vessels},
  volume = {27},
  number = {3},
  pages = {271--279},
  issn = {1615-2573},
  doi = {10.1007/s00380-011-0152-2},
  abstract = {Heart failure with a normal ejection fraction (HFNEF) is common in obesity and coronary artery disease (CAD). Both ischemia and reperfusion induce leptin (LEP) and leptin receptor (LEPR) gene expression. We aimed to investigate the possible associations of serum leptin, leptin gene and leptin receptor gene polymorphism with HFNEF in patients with CAD. 100 Egyptian CAD patients with HFNEF and 100 healthy subjects (the control group) were genotyped for LEP and LEPR polymorphism. Leptin levels were measured. Serum leptin levels were significantly increased in patients compared to the control group. There was a significant increase in the leptin gene (AA genotype) and the leptin receptor gene (RR genotype) in HFNEF patients compared to the control group. Leptin levels, leptin gene (AA genotype) and LEPR (RR genotype) were more associated with NYHA III than with NYHA I and II. We thus concluded that HFNEF is associated with increased serum leptin levels, and the LEP AA genotype or LEPR RR genotype carries at least a threefold increased risk of developing HFNEF.},
  langid = {english},
  pmid = {21584748},
  keywords = {Adult,Aged,Analysis of Variance,Biomarkers,Case-Control Studies,Chi-Square Distribution,Echocardiography Doppler,Egypt,Female,Gene Frequency,Genetic Predisposition to Disease,Heart Failure,Humans,Leptin,Lipids,Male,Middle Aged,Odds Ratio,Phenotype,Polymorphism Genetic,Receptors Leptin,Regression Analysis,Risk Assessment,Risk Factors,Severity of Illness Index,Stroke Volume,Ventricular Function Left}
}

@article{abdel-qadirContributionFamilialHeritable2007,
  title = {The Contribution of Familial and Heritable Risks in Heart Failure},
  author = {{Abdel-Qadir}, Husam M. and Lee, Douglas S.},
  year = {2007},
  month = may,
  journal = {Current Opinion in Cardiology},
  volume = {22},
  number = {3},
  pages = {214--219},
  issn = {0268-4705},
  doi = {10.1097/HCO.0b013e3280d9e855},
  abstract = {PURPOSE OF REVIEW: The purpose of this review is to summarize the recent literature regarding the familial heritability of heart failure and to discuss the possible mechanisms through which this risk is mediated. RECENT FINDINGS: Data from the Framingham Heart Study recently showed that the parental occurrence of heart failure increases the risk of heart failure in offspring. Although the mechanisms mediating this increased risk are not elucidated, heritable risks of heart failure may result from genes affecting the cardiac or vascular systems. Alternatively, familial risk may be mediated partly through the inheritance of recognized or as yet unidentified risk factors for heart failure. Heritable components or genetic loci for quantitative traits contribute to the development of hypertension, coronary artery disease, cardiomyopathies, valvular heart disease, and metabolic conditions, which collectively increase the risk of heart failure. SUMMARY: A careful assessment of the family history of heart failure and associated risk factors may identify treatable targets that can potentially reduce the likelihood of developing heart failure, and can assist in the implementation of preventive strategies for risk populations with stages A and B heart failure.},
  langid = {english},
  pmid = {17413278},
  keywords = {Genetic Diseases Inborn,Genetic Predisposition to Disease,Genotype,Heart Failure,Humans,Insulin Resistance,Obesity,Phenotype,Risk Assessment,Risk Factors}
}

@article{abramowitzEvaluatingPerformanceAgreement2024,
  title = {Evaluating {{Performance}} and {{Agreement}} of {{Coronary Heart Disease Polygenic Risk Scores}}},
  author = {Abramowitz, Sarah A. and Boulier, Kristin and Keat, Karl and Cardone, Katie M. and Shivakumar, Manu and DePaolo, John and Judy, Renae and Bermudez, Francisca and Mimouni, Nour and Neylan, Christopher and Kim, Dokyoon and Rader, Daniel J. and Ritchie, Marylyn D. and Voight, Benjamin F. and Pasaniuc, Bogdan and Levin, Michael G. and Damrauer, Scott M. and {Penn Medicine BioBank} and Rader, Daniel J and Ritchie, Marylyn D and Weaver, JoEllen and Naseer, Nawar and Sirugo, Giorgio and Poindexter, Afiya and Ko, Yi-An and Nerz, Kyle P. and Livingstone, Meghan and Vadivieso, Fred and DerOhannessian, Stephanie and Tran, Teo and Stephanowski, Julia and Santos, Salma and Haubein, Ned and Dunn, Joseph and Verma, Anurag and Kripke, Colleen M. and Risman, Marjorie and Judy, Renae and Wollack, Colin and Verma, Shefali S. and Damrauer, Scott M and Bradford, Yuki and Dudek, Scott and Drivas, Theodore},
  year = {2024},
  month = nov,
  journal = {JAMA},
  issn = {0098-7484},
  doi = {10.1001/jama.2024.23784},
  urldate = {2024-12-10},
  abstract = {OBJECTIVE To characterize the individual-level agreement of CHD PRSs that perform similarly at the population level. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study of participants from diverse backgrounds enrolled in the All of Us Research Program (AOU), Penn Medicine BioBank (PMBB), and University of California, Los Angeles (UCLA) ATLAS Precision Health Biobank with electronic health record and genotyping data. EXPOSURES Polygenic risk for CHD from published PRSs and new PRSs developed separately from testing samples. MAIN OUTCOMES AND MEASURES PRSs that performed population-level prediction similarly were identified by comparing calibration and discrimination of models of prevalent CHD. Individual-level agreement was tested with intraclass correlation coefficient (ICC) and Light {$\kappa$}. RESULTS A total of 48 PRSs were calculated for 171 095 AOU participants. The mean (SD) age was 56.4 (16.8) years. A total of 104 947 participants (61.3\%) were female. A total of 35 590 participants (20.8\%) were most genetically similar to an African reference population, 29 801 (17.4\%) to an admixed American reference population, 100 493 (58.7\%) to a European reference population, and the remaining to Central/South Asian, East Asian, and Middle Eastern reference populations. There were 17 589 participants (10.3\%) with and 153 506 participants without (89.7\%) CHD. When included in a model of prevalent CHD, 46 scores had practically equivalent Brier scores and area under the receiver operator curves (region of practical equivalence {\textpm}0.02). Twenty percent of participants had at least 1 score in both the top and bottom 5\% of risk. Continuous agreement of individual predictions was poor (ICC, 0.373 [95\% CI, 0.372-0.375]). Light {$\kappa$}, used to evaluate consistency of risk assignment, did not exceed 0.56. Analysis among 41 193 PMBB and 53 092 ATLAS participants yielded different sets of equivalent scores, which also lacked individual-level agreement. CONCLUSIONS AND RELEVANCE CHD PRSs that performed similarly at the population level demonstrated highly variable individual-level estimates of risk. Recognizing that CHD PRSs may generate incongruent individual-level risk estimates, effective clinical implementation will require refined statistical methods to quantify uncertainty and new strategies to communicate this uncertainty to patients and clinicians.},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/9DNYXN3I/Abramowitz et al. - 2024 - Evaluating Performance and Agreement of Coronary Heart Disease Polygenic Risk Scores.pdf}
}

@article{aDiversityScaleGenetic2024,
  title = {Diversity and Scale: {{Genetic}} Architecture of 2068 Traits in the {{VA Million Veteran Program}}},
  shorttitle = {Diversity and Scale},
  author = {A, Verma and Je, Huffman and A, Rodriguez and M, Conery and M, Liu and Yl, Ho and Y, Kim and Da, Heise and L, Guare and Va, Panickan and H, Garcon and F, Linares and L, Costa and I, Goethert and R, Tipton and J, Honerlaw and L, Davies and S, Whitbourne and J, Cohen and Dc, Posner and R, Sangar and M, Murray and X, Wang and Dr, Dochtermann and P, Devineni and Y, Shi and Tn, Nandi and Tl, Assimes and Ca, Brunette and Rj, Carroll and R, Clifford and S, Duvall and J, Gelernter and A, Hung and Sk, Iyengar and J, Joseph and R, Kember and H, Kranzler and Cm, Kripke and D, Levey and Sw, Luoh and Vc, Merritt and C, Overstreet and Jd, Deak and Sfa, Grant and R, Polimanti and P, Roussos and G, Shakt and Yv, Sun and N, Tsao and S, Venkatesh and G, Voloudakis and A, Justice and E, Begoli and R, Ramoni and G, Tourassi and S, Pyarajan and P, Tsao and Cj, O'Donnell and S, Muralidhar and J, Moser and Jp, Casas and Ag, Bick and W, Zhou and T, Cai and Bf, Voight and K, Cho and Jm, Gaziano and Rk, Madduri and S, Damrauer and Kp, Liao},
  year = {2024},
  month = jul,
  journal = {Science (New York, N.Y.)},
  volume = {385},
  number = {6706},
  publisher = {Science},
  issn = {1095-9203},
  doi = {10.1126/science.adj1182},
  urldate = {2025-06-09},
  abstract = {One of the justifiable criticisms of human genetic studies is the underrepresentation of participants from diverse populations. Lack of inclusion must be addressed at-scale to identify causal disease factors and understand the genetic causes of health disparities. We present genome-wide associations {\dots}},
  langid = {english},
  pmid = {39024449},
  file = {/Users/xx20081/Zotero/storage/UD3W5Z4V/A et al. - 2024 - Diversity and scale Genetic architecture of 2068 traits in the VA Million Veteran Program.pdf;/Users/xx20081/Zotero/storage/77FJA3AG/39024449.html}
}

@article{akwoMendelianRandomizationAssociation2023,
  title = {Mendelian Randomization and the Association of Fibroblast Growth Factor-23 with Heart Failure with Preserved Ejection Fraction},
  author = {Akwo, Elvis A. and {Robinson-Cohen}, Cassianne},
  year = {2023},
  month = jul,
  journal = {Current Opinion in Nephrology and Hypertension},
  volume = {32},
  number = {4},
  pages = {305--312},
  issn = {1473-6543},
  doi = {10.1097/MNH.0000000000000888},
  abstract = {PURPOSE OF REVIEW: Observational data provide compelling evidence for elevated fibroblast growth factor-23 (FGF23) as a risk factor for heart failure (HF), particularly heart failure with preserved ejection fraction (HFpEF). Given the limitations of observational studies, uncertainties persist regarding the causal role of FGF23 in the pathogenesis of HF and HFpEF. Recently, Mendelian randomization (MR) studies have been performed to examine causal associations between FGF23 and HF phenotypes. RECENT FINDINGS: The current review describes the methodological basis of the MR techniques used to examine the causal role of FGF23 on HF phenotypes, highlighting the importance of large-scale multiomics data. The findings from most of the MR studies indicate an absence of evidence of a causal effect of FGF23 on the risk of HF in general population settings. However, analysis using individual-level data showed a strong association between genetically-predicted FGF23 and HFpEF in individuals with a genetic predisposition to low estimated glomerular filtration (eGFR). SUMMARY: Evidence from MR analysis suggests a causal role of FGF23 in the pathogenesis of HFpEF in low eGFR settings - a finding supported by experimental, clinical, and epidemiological data. While future MR studies of FGF23 and HFpEF could provide further evidence, randomized trials of FGF23-lowering agents could provide the most definitive answers on the association in chronic kidney disease populations.},
  langid = {english},
  pmcid = {PMC10313786},
  pmid = {37016957},
  keywords = {Fibroblast Growth Factor-23,Heart Failure,Humans,Mendelian Randomization Analysis,Risk Factors,Stroke Volume}
}

@article{alebnaUpdateObesityObesity2024,
  title = {Update on Obesity, the Obesity Paradox, and Obesity Management in Heart Failure},
  author = {Alebna, Pamela L. and Mehta, Anurag and Yehya, Amin and {daSilva-deAbreu}, Adrian and Lavie, Carl J. and Carbone, Salvatore},
  year = {2024},
  journal = {Progress in Cardiovascular Diseases},
  volume = {82},
  pages = {34--42},
  issn = {1873-1740},
  doi = {10.1016/j.pcad.2024.01.003},
  abstract = {Obesity is a major public health challenge worldwide. It is costly, predisposes to many cardiovascular (CV) diseases (CVD), is increasing at an alarming rate, and disproportionately affects people of low-socioeconomic status. It has a myriad of deleterious effects on the body, particularly on the CV system. Obesity is a major risk factor for heart failure (HF) and highly prevalent in this population, particularly in those with HF with preserved ejection fraction (HFpEF), to the extent that an obesity HFpEF phenotype has been proposed in the literature. However, once HF is developed, an obesity paradox exists where those with obesity have better short- and mid-term survival than normal or underweight individuals, despite a greater risk for hospitalizations. It may be argued that excess energy reserve, younger patient population, higher tolerability of HF therapy and better nutritional status may account for at least part of the obesity paradox on survival. Furthermore, body mass index (BMI) may not be an accurate measure of body composition, especially in HF, where there is an excess volume status. BMI also fails to delineate fat-free mass and its components, which is a better predictor of functional capacity and cardiorespiratory fitness (CRF), which particularly is increasingly being recognized as a risk modifier in both healthy individuals and in persons with comorbidities, particularly in HF. Notably, when CRF is accounted for, the obesity paradox disappears, suggesting that improving CRF might represent a therapeutic target with greater importance than changes in body weight in the setting of HF. In this narrative review, we discuss the current trends in obesity, the causal link between obesity and HF, an update on the obesity paradox, and a description of the major flaws of BMI in this population. We also present an overview of the latest in HF therapy, weight loss, CRF, and the application of these therapeutic approaches in patients with HF and concomitant obesity.},
  langid = {english},
  pmid = {38199320},
  keywords = {Body mass index,Body Mass Index,Cardiovascular disease,Cardiovascular Diseases,Heart failure,Heart Failure,Humans,Obesity,Obesity Management,Obesity paradox,Obesity Paradox,Prognosis,Risk Factors,Stroke Volume},
  file = {/Users/xx20081/Zotero/storage/SIDTIEV6/Alebna et al. - 2024 - Update on obesity, the obesity paradox, and obesit.pdf}
}

@article{alebnaUpdateObesityObesity2024a,
  title = {Update on Obesity, the Obesity Paradox, and Obesity Management in Heart Failure},
  author = {Alebna, Pamela L. and Mehta, Anurag and Yehya, Amin and {daSilva-deAbreu}, Adrian and Lavie, Carl J. and Carbone, Salvatore},
  year = {2024},
  journal = {Progress in Cardiovascular Diseases},
  volume = {82},
  pages = {34--42},
  issn = {1873-1740},
  doi = {10.1016/j.pcad.2024.01.003},
  abstract = {Obesity is a major public health challenge worldwide. It is costly, predisposes to many cardiovascular (CV) diseases (CVD), is increasing at an alarming rate, and disproportionately affects people of low-socioeconomic status. It has a myriad of deleterious effects on the body, particularly on the CV system. Obesity is a major risk factor for heart failure (HF) and highly prevalent in this population, particularly in those with HF with preserved ejection fraction (HFpEF), to the extent that an obesity HFpEF phenotype has been proposed in the literature. However, once HF is developed, an obesity paradox exists where those with obesity have better short- and mid-term survival than normal or underweight individuals, despite a greater risk for hospitalizations. It may be argued that excess energy reserve, younger patient population, higher tolerability of HF therapy and better nutritional status may account for at least part of the obesity paradox on survival. Furthermore, body mass index (BMI) may not be an accurate measure of body composition, especially in HF, where there is an excess volume status. BMI also fails to delineate fat-free mass and its components, which is a better predictor of functional capacity and cardiorespiratory fitness (CRF), which particularly is increasingly being recognized as a risk modifier in both healthy individuals and in persons with comorbidities, particularly in HF. Notably, when CRF is accounted for, the obesity paradox disappears, suggesting that improving CRF might represent a therapeutic target with greater importance than changes in body weight in the setting of HF. In this narrative review, we discuss the current trends in obesity, the causal link between obesity and HF, an update on the obesity paradox, and a description of the major flaws of BMI in this population. We also present an overview of the latest in HF therapy, weight loss, CRF, and the application of these therapeutic approaches in patients with HF and concomitant obesity.},
  langid = {english},
  pmid = {38199320},
  keywords = {Body mass index,Body Mass Index,Cardiovascular disease,Cardiovascular Diseases,Heart failure,Heart Failure,Humans,Obesity,Obesity Management,Obesity paradox,Obesity Paradox,Prognosis,Risk Factors,Stroke Volume},
  file = {/Users/xx20081/Zotero/storage/DXPT84UP/Alebna et al. - 2024 - Update on obesity, the obesity paradox, and obesit.pdf}
}

@article{allisonMetaanalysisEffectExcluding1999,
  title = {Meta-Analysis of the Effect of Excluding Early Deaths on the Estimated Relationship between Body Mass Index and Mortality},
  author = {Allison, D. B. and Faith, M. S. and Heo, M. and {Townsend-Butterworth}, D. and Williamson, D. F.},
  year = {1999},
  month = jul,
  journal = {Obesity Research},
  volume = {7},
  number = {4},
  pages = {342--354},
  issn = {1071-7323},
  doi = {10.1002/j.1550-8528.1999.tb00417.x},
  abstract = {OBJECTIVES: Prospective cohort studies typically observe U- or J-shaped relationships between body mass index (BMI) (kg/m2) and mortality. However, some studies suggest that the elevated mortality at lower BMIs is due to confounding by pre-existing occult disease and recommend eliminating subjects who die during the first several (k) years of follow-up. This meta-analysis tests the effects of such early death exclusion on the BMI-mortality association. RESEARCH METHODS AND PROCEDURES: Studies identified from MEDLINE, review articles, ancestry analyses, and the "invisible college." INCLUDED STUDIES: 1) measured relative body weight at baseline; 2) included at least 1000 subjects; 3) reported results with and without early-death exclusion, or relevant data; and 4) did not study exclusively diseased populations. Blank tables were mailed to 131 investigators covering 59 databases. Completed tables (n = 16 databases), electronic raw data (n = 7 databases), and original articles (n = 6 databases) provided final data. Meta-analytic regressions compared the BMI-mortality association with and without early death exclusion. The sample included 29 studies and 1,954,345 subjects. RESULTS: The effect of eliminating early deaths was statistically significant but minuscule in magnitude. Implementation of early death exclusion was estimated to shift the BMI associated with minimum mortality only 0.4 units for men and 0.6 units for women at age 50. Even at a BMI 16, the estimated relative risk (compared to BMI 25) decreased only 0.008 units for men and 0.076 units for women at age 50. DISCUSSION: Results indicate that either pre-existing disease does not confound the BMI-mortality association or eliminating early deaths is inefficient for reducing that confounding.},
  langid = {english},
  pmid = {10440590},
  keywords = {Adolescent,Adult,Aged,Aged 80 and over,Animals,Body Mass Index,Cohort Studies,Databases Bibliographic,Female,Humans,Middle Aged,Mortality,Prospective Studies,Regression Analysis,Risk Factors,Sensitivity and Specificity,Smoking}
}

@article{almgrenGeneticDeterminantsCirculating,
  title = {Genetic Determinants of Circulating {{GIP}} and {{GLP-1}} Concentrations},
  author = {Almgren, Peter and Lindqvist, Andreas and Krus, Ulrika and Hakaste, Liisa and {Ottosson-Laakso}, Emilia and Asplund, Olof and Sonestedt, Emily and Prasad, Rashmi B. and Laurila, Esa and {Orho-Melander}, Marju and Melander, Olle and Tuomi, Tiinamaija and Holst, Jens Juul and Nilsson, Peter M. and Wierup, Nils and Groop, Leif and Ahlqvist, Emma},
  journal = {JCI Insight},
  volume = {2},
  number = {21},
  pages = {e93306},
  issn = {2379-3708},
  doi = {10.1172/jci.insight.93306},
  urldate = {2025-05-30},
  abstract = {The secretion of insulin and glucagon from the pancreas and the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) from the gastrointestinal tract is essential for glucose homeostasis. Several novel treatment strategies for type 2 diabetes (T2D) mimic GLP-1 actions or inhibit incretin degradation (DPP4 inhibitors), but none is thus far aimed at increasing the secretion of endogenous incretins. In order to identify new potential therapeutic targets for treatment of T2D, we performed a meta-analysis of a GWAS and an exome-wide association study of circulating insulin, glucagon, GIP, and GLP-1 concentrations measured during an oral glucose tolerance test in up to 7,828 individuals. We identified 6 genome-wide significant functional loci associated with plasma incretin concentrations in or near the SLC5A1 (encoding SGLT1), GIPR, ABO, GLP2R, F13A1, and HOXD1 genes and studied the effect of these variants on mRNA expression in pancreatic islet and on metabolic phenotypes. Immunohistochemistry showed expression of GIPR, ABO, and HOXD1 in human enteroendocrine cells and expression of ABO in pancreatic islets, supporting a role in hormone secretion. This study thus provides candidate genes and insight into mechanisms by which secretion and breakdown of GIP and GLP-1 are regulated., GWAS of circulating fasting and glucose-stimulated concentrations of incretins GIP and GLP-1 identifies new genetic loci involved in hormone secretion and metabolism},
  pmcid = {PMC5963138},
  pmid = {29093273},
  file = {/Users/xx20081/Zotero/storage/54J6ZMTK/Almgren et al. - Genetic determinants of circulating GIP and GLP-1 concentrations.pdf}
}

@article{alonsoTIGERGeneExpression2021,
  title = {{{TIGER}}: {{The}} Gene Expression Regulatory Variation Landscape of Human Pancreatic Islets},
  shorttitle = {{{TIGER}}},
  author = {Alonso, Lorena and Piron, Anthony and Mor{\'a}n, Ignasi and {Guindo-Mart{\'i}nez}, Marta and {Bon{\`a}s-Guarch}, S{\'i}lvia and Atla, Goutham and {Miguel-Escalada}, Irene and Royo, Romina and Puiggr{\`o}s, Montserrat and {Garcia-Hurtado}, Xavier and Suleiman, Mara and Marselli, Lorella and Esguerra, Jonathan L. S. and Turatsinze, Jean-Val{\'e}ry and Torres, Jason M. and Nylander, Vibe and Chen, Ji and Eliasson, Lena and Defrance, Matthieu and Amela, Ramon and Mulder, Hindrik and Gloyn, Anna L. and Groop, Leif and Marchetti, Piero and Eizirik, Decio L. and Ferrer, Jorge and Mercader, Josep M. and Cnop, Miriam and Torrents, David},
  year = {2021},
  month = oct,
  journal = {Cell Reports},
  volume = {37},
  number = {2},
  publisher = {Elsevier},
  issn = {2211-1247},
  doi = {10.1016/j.celrep.2021.109807},
  urldate = {2024-02-19},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}p{$>$}Genome-wide association studies (GWASs) identified hundreds of signals associated with type 2 diabetes (T2D). To gain insight into their underlying molecular mechanisms, we have created the translational human pancreatic islet genotype tissue-expression resource (TIGER), aggregating {$>$}500 human islet genomic datasets from five cohorts in the Horizon 2020 consortium T2DSystems. We impute genotypes using four reference panels and meta-analyze cohorts to improve the coverage of expression quantitative trait loci (eQTL) and develop a method to combine allele-specific expression across samples (cASE). We identify {$>$}1 million islet eQTLs, 53 of which colocalize with T2D signals. Among them, a low-frequency allele that reduces T2D risk by half increases \emph{CCND2} expression. We identify eight cASE colocalizations, among which we found a T2D-associated \emph{SLC30A8} variant. We make all data available through the TIGER portal (http://tiger.bsc.es), which represents a comprehensive human islet genomic data resource to elucidate how genetic variation affects islet function and translates into therapeutic insight and precision medicine for T2D.{$<$}/p{$>$}},
  langid = {english},
  pmid = {34644572},
  file = {/Users/xx20081/Zotero/storage/CW2MX4SH/Alonso et al. - 2021 - TIGER The gene expression regulatory variation la.pdf}
}

@article{alpertObesityCardiacRemodeling2018,
  title = {Obesity and {{Cardiac Remodeling}} in {{Adults}}: {{Mechanisms}} and {{Clinical Implications}}},
  shorttitle = {Obesity and {{Cardiac Remodeling}} in {{Adults}}},
  author = {Alpert, Martin A. and Karthikeyan, Kamalesh and Abdullah, Obai and Ghadban, Rugheed},
  year = {2018},
  journal = {Progress in Cardiovascular Diseases},
  volume = {61},
  number = {2},
  pages = {114--123},
  issn = {1873-1740},
  doi = {10.1016/j.pcad.2018.07.012},
  abstract = {Obesity, particularly severe obesity is capable of producing hemodynamic alterations that contribute to changes in cardiac morphology which may predispose to impairment of ventricular function and heart failure. These include a high cardiac output state in most, left ventricular (LV) hypertrophy, and LV diastolic dysfunction. Right heart involvement may result from LV failure, the hypercirculatory state, and sleep disordered breathing. In recent years experimental studies and some studies in humans suggest that certain neurohormonal and metabolic alterations that occur commonly in obesity may contribute to alterations in cardiac structure and function. These include activation of the renin-angiotensin-aldosterone and sympathetic nervous systems, hyperleptinemia due to leptin resistance, low circulating adiponectin levels, insulin resistance with hyperinsulinemia, and possibly cardiac lipotoxicity. This review will describe the ways in which these factors weave together to promote adaptations and maladaptations that result in alterations in cardiac structure and function which may contribute to the development of heart failure.},
  langid = {english},
  pmid = {29990533},
  keywords = {Animals,Cardiac output,Cardiovascular Diseases,Energy Metabolism,Heart,Hemodynamics,Humans,Left ventricular diastolic dysfunction,Left ventricular hypertrophy,Metabolic abnormalities,Myocardium,Neurohormonal abnormalities,Neurotransmitter Agents,Obesity,Prognosis,Risk Factors,Sleep disordered breathing,Ventricular Function Left,Ventricular Function Right,Ventricular Remodeling,Weight Loss},
  file = {/Users/xx20081/Zotero/storage/HP3UG7LX/Alpert et al. - 2018 - Obesity and Cardiac Remodeling in Adults Mechanis.pdf}
}

@article{aragamDiscoverySystematicCharacterization2022,
  title = {Discovery and Systematic Characterization of Risk Variants and Genes for Coronary Artery Disease in over a Million Participants},
  author = {Aragam, Krishna G. and Jiang, Tao and Goel, Anuj and Kanoni, Stavroula and Wolford, Brooke N. and Atri, Deepak S. and Weeks, Elle M. and Wang, Minxian and Hindy, George and Zhou, Wei and Grace, Christopher and Roselli, Carolina and Marston, Nicholas A. and Kamanu, Frederick K. and Surakka, Ida and Venegas, Loreto Mu{\~n}oz and Sherliker, Paul and Koyama, Satoshi and Ishigaki, Kazuyoshi and {\AA}svold, Bj{\o}rn O. and Brown, Michael R. and Brumpton, Ben and {de Vries}, Paul S. and Giannakopoulou, Olga and Giardoglou, Panagiota and Gudbjartsson, Daniel F. and G{\"u}ldener, Ulrich and Haider, Syed M. Ijlal and Helgadottir, Anna and Ibrahim, Maysson and Kastrati, Adnan and Kessler, Thorsten and Kyriakou, Theodosios and Konopka, Tomasz and Li, Ling and Ma, Lijiang and Meitinger, Thomas and Mucha, S{\"o}ren and Munz, Matthias and Murgia, Federico and Nielsen, Jonas B. and N{\"o}then, Markus M. and Pang, Shichao and Reinberger, Tobias and Schnitzler, Gavin and Smedley, Damian and Thorleifsson, Gudmar and {von Scheidt}, Moritz and Ulirsch, Jacob C. and {Biobank Japan} and {EPIC-CVD} and Arnar, David O. and Burtt, No{\"e}l P. and Costanzo, Maria C. and Flannick, Jason and Ito, Kaoru and Jang, Dong-Keun and Kamatani, Yoichiro and Khera, Amit V. and Komuro, Issei and Kullo, Iftikhar J. and Lotta, Luca A. and Nelson, Christopher P. and Roberts, Robert and Thorgeirsson, Gudmundur and Thorsteinsdottir, Unnur and Webb, Thomas R. and Baras, Aris and Bj{\"o}rkegren, Johan L. M. and Boerwinkle, Eric and Dedoussis, George and Holm, Hilma and Hveem, Kristian and Melander, Olle and Morrison, Alanna C. and {Orho-Melander}, Marju and Rallidis, Loukianos S. and Ruusalepp, Arno and Sabatine, Marc S. and Stefansson, Kari and Zalloua, Pierre and Ellinor, Patrick T. and Farrall, Martin and Danesh, John and Ruff, Christian T. and Finucane, Hilary K. and Hopewell, Jemma C. and Clarke, Robert and Gupta, Rajat M. and Erdmann, Jeanette and Samani, Nilesh J. and Schunkert, Heribert and Watkins, Hugh and Willer, Cristen J. and Deloukas, Panos and Kathiresan, Sekar and Butterworth, Adam S. and {CARDIoGRAMplusC4D Consortium}},
  year = {2022},
  month = dec,
  journal = {Nature Genetics},
  volume = {54},
  number = {12},
  pages = {1803--1815},
  issn = {1546-1718},
  doi = {10.1038/s41588-022-01233-6},
  abstract = {The discovery of genetic loci associated with complex diseases has outpaced the elucidation of mechanisms of disease pathogenesis. Here we conducted a genome-wide association study (GWAS) for coronary artery disease (CAD) comprising 181,522 cases among 1,165,690 participants of predominantly European ancestry. We detected 241 associations, including 30 new loci. Cross-ancestry meta-analysis with a Japanese GWAS yielded 38 additional new loci. We prioritized likely causal variants using functionally informed fine-mapping, yielding 42 associations with less than five variants in the 95\% credible set. Similarity-based clustering suggested roles for early developmental processes, cell cycle signaling and vascular cell migration and proliferation in the pathogenesis of CAD. We prioritized 220 candidate causal genes, combining eight complementary approaches, including 123 supported by three or more approaches. Using CRISPR-Cas9, we experimentally validated the effect of an enhancer in MYO9B, which appears to mediate CAD risk by regulating vascular cell motility. Our analysis identifies and systematically characterizes {$>$}250 risk loci for CAD to inform experimental interrogation of putative causal mechanisms for CAD.},
  langid = {english},
  pmcid = {PMC9729111},
  pmid = {36474045},
  keywords = {Coronary Artery Disease,Genome-Wide Association Study,Humans},
  file = {/Users/xx20081/Zotero/storage/ZDCNDFW3/Aragam et al. - 2022 - Discovery and systematic characterization of risk .pdf}
}

@article{aragamPolygenicScoresAssess2020,
  title = {Polygenic {{Scores}} to {{Assess Atherosclerotic Cardiovascular Disease Risk}}},
  author = {Aragam, Krishna G. and Natarajan, Pradeep},
  year = {2020},
  month = apr,
  journal = {Circulation Research},
  volume = {126},
  number = {9},
  pages = {1159--1177},
  publisher = {American Heart Association},
  doi = {10.1161/CIRCRESAHA.120.315928},
  urldate = {2024-12-10},
  abstract = {An individual's susceptibility to atherosclerotic cardiovascular disease is influenced by numerous clinical and lifestyle factors, motivating the multifaceted approaches currently endorsed for primary and secondary cardiovascular disease prevention. With growing knowledge of the genetic basis of atherosclerotic cardiovascular disease---in particular, coronary artery disease---and its contribution to disease pathogenesis, there is increased interest in understanding the potential clinical utility of a genetic predictor that might further refine the assessment and management of atherosclerotic cardiovascular disease risk. Rapid scientific and technological advances have enabled widespread genotyping efforts and dynamic research in the field of coronary artery disease genetic risk prediction. In this review, we describe how genomic analyses of coronary artery disease have been leveraged to create polygenic risk scores. We then discuss evaluations of the clinical utility of these scores, pertinent mechanistic insights gleaned, and practical considerations relevant to the implementation of polygenic risk scores in the health care setting.},
  file = {/Users/xx20081/Zotero/storage/HQN3JP59/Aragam and Natarajan - 2020 - Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk.pdf}
}

@article{arcaroBodyFatDistribution1999,
  title = {Body Fat Distribution Predicts the Degree of Endothelial Dysfunction in Uncomplicated Obesity},
  author = {Arcaro, G. and Zamboni, M. and Rossi, L. and Turcato, E. and Covi, G. and Armellini, F. and Bosello, O. and Lechi, A.},
  year = {1999},
  month = sep,
  journal = {International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity},
  volume = {23},
  number = {9},
  pages = {936--942},
  doi = {10.1038/sj.ijo.0801022},
  abstract = {OBJECTIVE: To ascertain in obesity the role of body fat distribution (the strongest predictor of morbility and mortality in obese subjects) in determining the degree of endothelial dysfunction, an early marker of atherosclerotic disease. SUBJECTS: 18 premenopausal women with uncomplicated obesity excluding other cardiovascular risk factors and 12 age-matched slim healthy women. MEASUREMENTS: Endothelium-dependent vasodilation, studied as diameter variation in response to an increase in shear-stress, was evaluated in the right common femoral artery of obese and slim subjects by a non invasive approach and compared to glyceril-trinitrate vasodilation. To characterize better the vascular functional and/or structural properties, we studied the arterial wall distensibility by an echo-tracking system. Adipose tissue regional distribution was determined by computerised axial tomography. RESULTS: The endothelium-dependent vasodilation was significantly impaired in obese subjects (P{$<$}0.005 versus non-obese subjects) while glyceril-trinitrate vasodilation and arterial distensibility were similar in the two groups. In our obese subjects endothelial-dependent vasodilation was inversely correlated to body fat distribution (visceral/subcutaneous adipose tissue ratio: r=- 0. 624, P=0.0058). In contrast, metabolic parameters (except C-peptide response during oral glucose tolerance test (OGTT): r=-0.587, P=0. 01), blood pressure values and body weight did not correlate with the endothelial function. CONCLUSION: Uncomplicated obesity per se is characterised by an alteration of the endothelial function; the degree of this vascular damage is predicted by body fat distribution independently of body weight and metabolic and other haemodynamic parameters, and correlates with an index of insulin secretion.},
  langid = {english},
  pmid = {10490799},
  keywords = {Adipose Tissue,Adult,Arteriosclerosis,Biomarkers,Blood Flow Velocity,Body Composition,Endothelium Vascular,Female,Femoral Artery,Hemodynamics,Humans,Insulin Resistance,Nitroglycerin,Obesity,Predictive Value of Tests,Premenopause,Radiography,Vasodilation,Vasodilator Agents}
}

@article{aronneContinuedTreatmentTirzepatide2024,
  title = {Continued {{Treatment With Tirzepatide}} for {{Maintenance}} of {{Weight Reduction}} in {{Adults With Obesity}}: {{The SURMOUNT-4 Randomized Clinical Trial}}},
  shorttitle = {Continued {{Treatment With Tirzepatide}} for {{Maintenance}} of {{Weight Reduction}} in {{Adults With Obesity}}},
  author = {Aronne, Louis J. and Sattar, Naveed and Horn, Deborah B. and Bays, Harold E. and Wharton, Sean and Lin, Wen-Yuan and Ahmad, Nadia N. and Zhang, Shuyu and Liao, Ran and Bunck, Mathijs C. and Jouravskaya, Irina and Murphy, Madhumita A. and {SURMOUNT-4 Investigators}},
  year = {2024},
  month = jan,
  journal = {JAMA},
  volume = {331},
  number = {1},
  pages = {38--48},
  issn = {0098-7484},
  doi = {10.1001/jama.2023.24945},
  urldate = {2025-01-21},
  abstract = {The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown.To assess the effect of tirzepatide, with diet and physical activity, on the maintenance of weight reduction.This phase 3, randomized withdrawal clinical trial conducted at 70 sites in 4 countries with a 36-week, open-label tirzepatide lead-in period followed by a 52-week, double-blind, placebo-controlled period included adults with a body mass index greater than or equal to 30 or greater than or equal to 27 and a weight-related complication, excluding diabetes.Participants (n\,=\,783) enrolled in an open-label lead-in period received once-weekly subcutaneous maximum tolerated dose (10 or 15 mg) of tirzepatide for 36 weeks. At week 36, a total of 670 participants were randomized (1:1) to continue receiving tirzepatide (n\,=\,335) or switch to placebo (n\,=\,335) for 52 weeks.The primary end point was the mean percent change in weight from week 36 (randomization) to week 88. Key secondary end points included the proportion of participants at week 88 who maintained at least 80\% of the weight loss during the lead-in period.Participants (n\,=\,670; mean age, 48 years; 473 [71\%] women; mean weight, 107.3 kg) who completed the 36-week lead-in period experienced a mean weight reduction of 20.9\%. The mean percent weight change from week 36 to week 88 was -5.5\% with tirzepatide vs 14.0\% with placebo (difference, -19.4\% [95\% CI, -21.2\% to -17.7\%]; P\,\&lt;\,.001). Overall, 300 participants (89.5\%) receiving tirzepatide at 88 weeks maintained at least 80\% of the weight loss during the lead-in period compared with 16.6\% receiving placebo (P\,\&lt;\,.001). The overall mean weight reduction from week 0 to 88 was 25.3\% for tirzepatide and 9.9\% for placebo. The most common adverse events were mostly mild to moderate gastrointestinal events, which occurred more commonly with tirzepatide vs placebo.In participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction.ClinicalTrials.gov Identifier: NCT04660643},
  file = {/Users/xx20081/Zotero/storage/2N5WHJAW/Aronne et al. - 2024 - Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity The.pdf;/Users/xx20081/Zotero/storage/66WYJRMG/2812936.html}
}

@misc{AssociationsTimevaryingObesity,
  title = {Associations of Time-Varying Obesity and Metabolic Syndrome with Risk of Incident Heart Failure and Its Subtypes: {{Findings}} from the {{Multi-Ethnic Study}} of {{Atherosclerosis}} - {{PubMed}}},
  urldate = {2024-07-04},
  howpublished = {https://pubmed.ncbi.nlm.nih.gov/34089770/},
  file = {/Users/xx20081/Zotero/storage/M3ANTEBA/34089770.html}
}

@article{atherImpactNoncardiacComorbidities2012,
  title = {Impact of Noncardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population with Heart Failure and Preserved versus Reduced Ejection Fraction},
  author = {Ather, Sameer and Chan, Wenyaw and Bozkurt, Biykem and Aguilar, David and Ramasubbu, Kumudha and Zachariah, Amit A. and Wehrens, Xander H. T. and Deswal, Anita},
  year = {2012},
  month = mar,
  journal = {Journal of the American College of Cardiology},
  volume = {59},
  number = {11},
  pages = {998--1005},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2011.11.040},
  abstract = {OBJECTIVES: The aim of this study was to evaluate the prevalence and prognostic impacts of noncardiac comorbidities in patients with heart failure (HF) with preserved ejection fraction (HFpEF) compared with those with HF with reduced ejection fraction (HFrEF). BACKGROUND: There is a paucity of information on the comparative prognostic significance of comorbidities between patients with HFpEF and those with HFrEF. METHODS: In a national ambulatory cohort of veterans with HF, the comorbidity burden of 15 noncardiac comorbidities and the impacts of these comorbidities on hospitalization and mortality were compared between patients with HFpEF and those with HFrEF. RESULTS: The cohort consisted of 2,843 patients with HFpEF and 6,599 with HFrEF with 2-year follow-up. Compared with patients with HFrEF, those with HFpEF were older and had higher prevalence of chronic obstructive pulmonary disease, diabetes, hypertension, psychiatric disorders, anemia, obesity, peptic ulcer disease, and cancer but a lower prevalence of chronic kidney disease. Patients with HFpEF had lower HF hospitalization, higher non-HF hospitalization, and similar overall hospitalization compared with those with HFrEF (p {$<$} 0.001, p {$<$} 0.001, and p = 0.19, respectively). An Increasing number of noncardiac comorbidities was associated with a higher risk for all-cause admissions (p {$<$} 0.001). Comorbidities had similar impacts on mortality in patients with HFpEF compared with those with HFrEF, except for chronic obstructive pulmonary disease, which was associated with a higher hazard (1.62 [95\% confidence interval: 1.36 to 1.92] vs. 1.23 [95\% confidence interval: 1.11 to 1.37], respectively, p = 0.01 for interaction) in patients with HFpEF. CONCLUSIONS: There is a higher noncardiac comorbidity burden associated with higher non-HF hospitalizations in patients with HFpEF compared with those with HFrEF. However, individually, most comorbidities have similar impacts on mortality in both groups. Aggressive management of comorbidities may have an overall greater prognostic impact in HFpEF compared to HFrEF.},
  langid = {english},
  pmcid = {PMC4687406},
  pmid = {22402071},
  keywords = {Aged,Aged 80 and over,Comorbidity,Female,Heart Failure,Humans,Male,Middle Aged,Prevalence,Retrospective Studies,Stroke Volume,United States}
}

@misc{AtlasPolygenicRisk,
  title = {An Atlas of Polygenic Risk Score Associations to Highlight Putative Causal Relationships across the Human Phenome {\textbar} {{eLife}}},
  urldate = {2024-02-03},
  howpublished = {https://elifesciences.org/articles/43657},
  file = {/Users/xx20081/Zotero/storage/RTFW9AN6/An atlas of polygenic risk score associations to h.pdf;/Users/xx20081/Zotero/storage/GAMS4EY5/43657.html}
}

@article{babelGlucocorticoidSignalingImpact2024,
  title = {Glucocorticoid Signaling and the Impact of High-Fat Diet on Adipogenesis {\emph{in Vivo}}},
  author = {Babel, Noah K. and Feldman, Brian J.},
  year = {2024},
  month = jan,
  journal = {Steroids},
  volume = {201},
  pages = {109336},
  issn = {0039-128X},
  doi = {10.1016/j.steroids.2023.109336},
  urldate = {2025-05-27},
  abstract = {Our research used glucocorticoids as a medically relevant molecular probe to identify a previously unrecognized ADAMTS1-PTN-Wnt pathway. We elucidated the role of this pathway in regulating adipose precursor cell (APC) behavior to either proliferate or differentiate in response to systemic cues, such as elevated caloric intake. Further, our studies identified the non-muscle myosin protein MYH9 as a key target of this pathway to modulate adipogenesis in vivo. These findings enable strategies toward developing novel therapeutics for obesity and related metabolic disorders.},
  file = {/Users/xx20081/Zotero/storage/569ZUCXJ/Babel and Feldman - 2024 - Glucocorticoid signaling and the impact of high-fat diet on adipogenesis in vivo.pdf;/Users/xx20081/Zotero/storage/KE2DH3WQ/S0039128X23001642.html}
}

@article{badhekaInfluenceObesityOutcomes2010,
  title = {Influence of {{Obesity}} on {{Outcomes}} in {{Atrial Fibrillation}}: {{Yet Another Obesity Paradox}}},
  shorttitle = {Influence of {{Obesity}} on {{Outcomes}} in {{Atrial Fibrillation}}},
  author = {Badheka, Apurva O. and Rathod, Ankit and Kizilbash, Mohammad A. and Garg, Neha and Mohamad, Tamam and Afonso, Luis and Jacob, Sony},
  year = {2010},
  month = jul,
  journal = {The American Journal of Medicine},
  volume = {123},
  number = {7},
  pages = {646--651},
  publisher = {Elsevier},
  issn = {0002-9343, 1555-7162},
  doi = {10.1016/j.amjmed.2009.11.026},
  urldate = {2024-08-06},
  langid = {english},
  keywords = {Atrial fibrillation,Obesity,Reverse epidemiology}
}

@article{badveEffectsGLP1Receptor2025,
  title = {Effects of {{GLP-1}} Receptor Agonists on Kidney and Cardiovascular Disease Outcomes: A Meta-Analysis of Randomised Controlled Trials},
  shorttitle = {Effects of {{GLP-1}} Receptor Agonists on Kidney and Cardiovascular Disease Outcomes},
  author = {Badve, Sunil V. and Bilal, Anika and Lee, Matthew M. Y. and Sattar, Naveed and Gerstein, Hertzel C. and Ruff, Christian T. and McMurray, John J. V. and Rossing, Peter and Bakris, George and Mahaffey, Kenneth W. and Mann, Johannes F. E. and Colhoun, Helen M. and Tuttle, Katherine R. and Pratley, Richard E. and Perkovic, Vlado},
  year = {2025},
  month = jan,
  journal = {The Lancet. Diabetes \& Endocrinology},
  volume = {13},
  number = {1},
  pages = {15--28},
  issn = {2213-8595},
  doi = {10.1016/S2213-8587(24)00271-7},
  abstract = {BACKGROUND: GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains uncertain. We aimed to comprehensively assess the effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes by performing a meta-analysis of randomised controlled trials. METHODS: For this meta-analysis, we searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for randomised controlled trials that included at least 500 participants with type 2 diabetes, compared a GLP-1 receptor agonist with placebo with at least 12 months of follow-up, and reported a primary clinical kidney or cardiovascular outcome, from database inception to March 26, 2024. Post hoc, we included the SELECT trial (NCT03574597), which enrolled participants with cardiovascular disease and a BMI of 27 kg/m2 or more without diabetes. Study-level summary data were extracted independently by two authors for inclusion in this random-effects analysis. The main kidney outcome was a composite outcome, consisting of kidney failure (kidney replacement therapy or a persistent estimated glomerular filtration rate [eGFR] {$<$}15 mL/min per 1{$\cdot$}73 m2), a sustained reduction in eGFR by at least 50\% or the nearest equivalent, or death from kidney failure. The main cardiovascular outcome was MACE, consisting of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. This study is registered with PROSPERO, CRD42024528864. FINDINGS: Of the 5140 records identified through the literature search, 11 trials, involving 85\,373 participants (29\,386 female, 55\,987 male), were included in the meta-analysis. In participants with type 2 diabetes (67\,769), GLP-1 receptor agonists reduced the composite kidney outcome by 18\% compared with placebo (hazard ratio [HR] 0{$\cdot$}82, 95\% CI 0{$\cdot$}73-0{$\cdot$}93; I2 =26{$\cdot$}41\%), kidney failure by 16\% (HR 0{$\cdot$}84, 0{$\cdot$}72-0{$\cdot$}99; I2 =0\%), MACE by 13\% (HR 0{$\cdot$}87, 0{$\cdot$}81-0{$\cdot$}93; I2 =49{$\cdot$}75\%), and all-cause death by 12\% (HR 0{$\cdot$}88, 0{$\cdot$}83-0{$\cdot$}93; I2 =0\%). The effect on the composite kidney outcome (HR 0{$\cdot$}81, 95\% CI 0{$\cdot$}72-0{$\cdot$}92; I2 =23{$\cdot$}11\%), kidney failure (HR 0{$\cdot$}84, 0{$\cdot$}72-0{$\cdot$}98; I2 =0\%), MACE (HR 0{$\cdot$}86, 0{$\cdot$}80-0{$\cdot$}92; I2 =48{$\cdot$}9\%), and all-cause death (HR 0{$\cdot$}87, 0{$\cdot$}82-0{$\cdot$}91; I2 =0\%) was similar when the SELECT trial was included, with no evidence of heterogeneity between this trial and those including participants with type 2 diabetes (pheterogeneity {$>$}0{$\cdot$}05). There was no difference in the risk of serious adverse events, including acute pancreatitis and severe hypoglycaemia, between the GLP-1 receptor agonist and placebo groups (risk ratio [RR] 0{$\cdot$}95, 95\% CI 0{$\cdot$}90-1{$\cdot$}01; I2 =88{$\cdot$}5\%). However, treatment discontinuation due to adverse events occurred more frequently in the GLP-1 receptor agonist groups (RR 1{$\cdot$}51, 95\% CI 1{$\cdot$}18-1{$\cdot$}94; I2 =96{$\cdot$}3\%). INTERPRETATION: We found evidence that GLP-1 receptor agonists significantly reduce clinically important kidney events, kidney failure, and cardiovascular events. FUNDING: None.},
  langid = {english},
  pmid = {39608381},
  keywords = {Cardiovascular Diseases,Diabetes Mellitus Type 2,Glucagon-Like Peptide-1 Receptor Agonists,Humans,Hypoglycemic Agents,Randomized Controlled Trials as Topic,Treatment Outcome}
}

@article{bajajCoronaryMicrovascularDysfunction2018,
  title = {Coronary {{Microvascular Dysfunction}} and {{Cardiovascular Risk}} in {{Obese Patients}}},
  author = {Bajaj, Navkaranbir S. and Osborne, Michael T. and Gupta, Ankur and Tavakkoli, Ali and Bravo, Paco E. and Vita, Tomas and Bibbo, Courtney F. and Hainer, Jon and Dorbala, Sharmila and Blankstein, Ron and Bhatt, Deepak L. and Di Carli, Marcelo F. and Taqueti, Viviany R.},
  year = {2018},
  month = aug,
  journal = {Journal of the American College of Cardiology},
  volume = {72},
  number = {7},
  pages = {707--717},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2018.05.049},
  abstract = {BACKGROUND: Besides body mass index (BMI), other discriminators of cardiovascular risk are needed in obese patients, who may or may not undergo consideration for bariatric surgery. Coronary microvascular dysfunction (CMD), defined as~impaired coronary flow reserve (CFR) in the absence of flow-limiting coronary artery disease, identifies patients at risk for adverse events independently of traditional risk factors. OBJECTIVES: The study sought to investigate the relationship among obesity, CMD, and adverse outcomes. METHODS: Consecutive patients undergoing evaluation for coronary artery disease with cardiac stress positron emission~tomography demonstrating normal perfusion (N~=~827) were followed for median 5.6 years for events, including death and hospitalization for myocardial infarction or heart failure. RESULTS: An inverted independent J-shaped relationship was observed between BMI and CFR, such that in obese patients CFR decreased linearly with increasing BMI (adjusted p~{$<$} 0.0001). In adjusted analyses, CFR but not BMI remained independently associated with events (for a 1-U decrease in CFR, adjusted hazard ratio: 1.95; 95\% confidence interval: 1.41 to 2.69; p~{$<$} 0.001; for a 10-U increase in BMI, adjusted hazard ratio: 1.20; 95\% confidence interval: 0.95~to~1.50; p~=~0.125) and improved model discrimination (C-index 0.71 to 0.74). In obese patients, individuals with~impaired CFR demonstrated a higher adjusted rate of events (5.7\% vs. 2.6\%; p~=~0.002), even in those not currently meeting indications for bariatric surgery (6.4\% vs. 2.6\%; p~=~0.04). CONCLUSIONS: In patients referred for testing, CMD was independently associated with elevated BMI and adverse outcomes, and was a better discriminator of risk than BMI and traditional risk factors. CFR may facilitate management of obese patients beyond currently used markers of risk.},
  langid = {english},
  pmcid = {PMC6592712},
  pmid = {30092946},
  keywords = {Aged,bariatric surgery,body mass index,Cardiovascular Diseases,Cohort Studies,Coronary Artery Disease,Coronary Circulation,coronary microvascular dysfunction,Female,Fractional Flow Reserve Myocardial,Humans,Male,Microcirculation,Middle Aged,obesity,Obesity,Positron-Emission Tomography,prognosis,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/IRVDP5K3/Bajaj et al. - 2018 - Coronary Microvascular Dysfunction and Cardiovascu.pdf}
}

@article{banackBadWorseCollider2015,
  title = {From Bad to Worse: Collider Stratification Amplifies Confounding Bias in the "Obesity Paradox"},
  shorttitle = {From Bad to Worse},
  author = {Banack, Hailey R. and Kaufman, Jay S.},
  year = {2015},
  month = oct,
  journal = {European Journal of Epidemiology},
  volume = {30},
  number = {10},
  pages = {1111--1114},
  issn = {1573-7284},
  doi = {10.1007/s10654-015-0069-7},
  abstract = {Smoking is often identified as a confounder of the obesity-mortality relationship. Selection bias can amplify the magnitude of an existing confounding bias. The objective of the present report is to demonstrate how confounding bias due to cigarette smoking is increased in the presence of collider stratification bias using an empirical example and directed acyclic graphs. The empirical example uses data from the Atherosclerosis Risk in Communities (ARIC) study, a prospective cohort study of 15,792 men and women in the United States. Poisson regression models were used to examine the confounding effect of smoking. In the total ARIC study population, smoking produced a confounding bias of {$<$}3 percentage points. This result was obtained by comparing the incidence rate ratio (IRR) for obesity from a model adjusted for smoking was 1.07 (95~\% CI 1.00, 1.15) with one that did not adjust for smoking was 1.10 (95~\% CI 1.03, 1.18). However, among smokers with CVD, the obesity IRR was 0.89 (95~\% CI 0.81, 0.99), while among non-smokers with CVD the obesity IRR was 1.20 (95~\% CI 1.03, 1.41). The empirical and graphical explanations presented suggest that the magnitude of the confounding bias induced by smoking is greater in the presence of collider stratification bias.},
  langid = {english},
  pmid = {26187718},
  keywords = {Bias,Causality,Confounding bias,Confounding Factors Epidemiologic,Humans,Linear Models,Models Statistical,Obesity,Obesity paradox,Selection bias,Selection Bias,Smoking},
  file = {/Users/xx20081/Zotero/storage/MWB7IKJ8/Banack and Kaufman - 2015 - From bad to worse collider stratification amplifi.pdf}
}

@article{banackDoesSelectionBias2015,
  title = {Does Selection Bias Explain the Obesity Paradox among Individuals with Cardiovascular Disease?},
  author = {Banack, Hailey R. and Kaufman, Jay S.},
  year = {2015},
  month = may,
  journal = {Annals of Epidemiology},
  volume = {25},
  number = {5},
  pages = {342--349},
  issn = {1047-2797},
  doi = {10.1016/j.annepidem.2015.02.008},
  urldate = {2024-08-08},
  abstract = {Objectives The objectives of this article are to demonstrate that the obesity paradox may be explained by collider stratification bias and to estimate the biasing effects of unmeasured common causes of cardiovascular disease (CVD) and mortality on the observed obesity-mortality relationship. Methods We use directed acyclic graphs, regression modeling, and sensitivity analyses to explore whether the observed protective effect of obesity among individuals with CVD can be plausibly attributed to selection bias. Data from the third National Health and Examination Survey was used for the analyses. Results The adjusted total effect of obesity on mortality was a risk difference (RD) of 0.03 (95\% confidence interval [CI]: 0.02, 0.05). However, the controlled direct effect of obesity on mortality among individuals without CVD was RD~=~0.03 (95\% CI: 0.01, 0.05) and RD~=~-0.12 (95\% CI:~-0.20,~-0.04) among individuals with CVD. The adjusted total effect estimate demonstrates an increased number of deaths among obese individuals relative to nonobese counterparts, whereas the controlled direct effect shows a paradoxical decrease in morality among obese individuals with CVD. Conclusions Sensitivity analysis demonstrates unmeasured confounding of the mediator-outcome relationship provides a sufficient explanation for the observed protective effect of obesity on mortality among individuals with CVD.},
  keywords = {Cardiovascular disease,Obesity,Selection bias,Sensitivity analysis},
  file = {/Users/xx20081/Zotero/storage/SYHP9V6X/S104727971500054X.html}
}

@article{banackObesityParadoxExplained2013,
  title = {The ``{{Obesity Paradox}}'' {{Explained}}},
  author = {Banack, Hailey R. and Kaufman, Jay S.},
  year = {2013},
  month = may,
  journal = {Epidemiology},
  volume = {24},
  number = {3},
  pages = {461},
  issn = {1044-3983},
  doi = {10.1097/EDE.0b013e31828c776c},
  urldate = {2024-08-06},
  abstract = {An abstract is unavailable.},
  langid = {american},
  file = {/Users/xx20081/Zotero/storage/JXNH4LCI/The__Obesity_Paradox__Explained.20.html}
}

@article{banackObesityParadoxUnderstanding2014,
  title = {The Obesity Paradox: {{Understanding}} the Effect of Obesity on Mortality among Individuals with Cardiovascular Disease},
  shorttitle = {The Obesity Paradox},
  author = {Banack, Hailey R. and Kaufman, Jay S.},
  year = {2014},
  month = may,
  journal = {Preventive Medicine},
  volume = {62},
  pages = {96--102},
  issn = {0091-7435},
  doi = {10.1016/j.ypmed.2014.02.003},
  urldate = {2024-08-06},
  abstract = {Objective To discuss possible explanations for the obesity paradox and explore whether the paradox can be attributed to a form of selection bias known as collider stratification bias. Method The paper is divided into three parts. First, possible explanations for the obesity paradox are reviewed. Second, a simulated example is provided to describe collider stratification bias and how it could generate the obesity paradox. Finally, an example is provided using data from 17,636 participants in the US National and Nutrition Examination Survey (NHANES III). Generalized linear models were fit to assess the effect of obesity on mortality both in the general population and among individuals with diagnosed cardiovascular disease (CVD). Additionally, results from a bias analysis are presented. Results In the general population, the adjusted risk ratio relating obesity and all-cause mortality was 1.24 (95\% CI 1.11, 1.39). Adjusted risk ratios comparing obese and non-obese among individuals with and without CVD were 0.79 (95\% CI 0.68, 0.91) and 1.30 (95\% CI=1.12, 1.50), indicating that obesity has a protective association among individuals with CVD. Conclusion Results demonstrate that collider stratification bias is one plausible explanation for the obesity paradox. After conditioning on CVD status in the design or analysis, obesity can appear protective among individuals with CVD.},
  keywords = {Cardiovascular disease,Epidemiology,Obesity paradox,Selection bias},
  file = {/Users/xx20081/Zotero/storage/54KB2DI5/Banack and Kaufman - 2014 - The obesity paradox Understanding the effect of o.pdf}
}

@article{banerjeeEpicardialFatParadox2023,
  title = {Epicardial {{Fat Paradox}} and {{Differential Effects}} of {{GLP-1 Receptor Agonists Across Heart Failure Phenotypes}}},
  author = {Banerjee, Mainak},
  year = {2023},
  month = dec,
  journal = {Circulation: Heart Failure},
  volume = {16},
  number = {12},
  pages = {e010966},
  publisher = {American Heart Association},
  doi = {10.1161/CIRCHEARTFAILURE.123.010966},
  urldate = {2024-04-04},
  keywords = {adiposity,diabetes type 2,heart failure,mortality,obesity paradox}
}

@article{Bart2012,
  title = {Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome},
  author = {Bart, Bradley A. and Goldsmith, Steven R. and Lee, Kerry L. and Givertz, Michael M. and O'Connor, Christopher M. and Bull, David A. and Redfield, Margaret M. and Deswal, Anita and Rouleau, Jean L. and LeWinter, Martin M. and Ofili, Elizabeth O. and Stevenson, Lynne W. and Semigran, Marc J. and Felker, G. Michael and Chen, Horng H. and Hernandez, Adrian F. and Anstrom, Kevin J. and McNulty, Steven E. and Velazquez, Eric J. and Ibarra, Jenny C. and Mascette, Alice M. and Braunwald, Eugene},
  year = {2012},
  month = dec,
  journal = {The New England journal of medicine},
  volume = {367},
  number = {24},
  pages = {2296--2304},
  publisher = {N Engl J Med},
  issn = {1533-4406},
  doi = {10.1056/NEJMOA1210357},
  abstract = {BACKGROUND: Ultrafiltration is an alternative strategy to diuretic therapy for the treatment of patients with acute decompensated heart failure. Little is known about the efficacy and safety of ultrafiltration in patients with acute decompensated heart failure complicated by persistent congestion and worsened renal function. METHODS: We randomly assigned a total of 188 patients with acute decompensated heart failure, worsened renal function, and persistent congestion to a strategy of stepped pharmacologic therapy (94 patients) or ultrafiltration (94 patients). The primary end point was the bivariate change from baseline in the serum creatinine level and body weight, as assessed 96 hours after random assignment. Patients were followed for 60 days. RESULTS: Ultrafiltration was inferior to pharmacologic therapy with respect to the bivariate end point of the change in the serum creatinine level and body weight 96 hours after enrollment (P=0.003), owing primarily to an increase in the creatinine level in the ultrafiltration group. At 96 hours, the mean change in the creatinine level was -0.04{\textpm}0.53 mg per deciliter (-3.5{\textpm}46.9 {$\mu$}mol per liter) in the pharmacologic-therapy group, as compared with +0.23{\textpm}0.70 mg per deciliter (20.3{\textpm}61.9 {$\mu$}mol per liter) in the ultrafiltration group (P=0.003). There was no significant difference in weight loss 96 hours after enrollment between patients in the pharmacologic-therapy group and those in the ultrafiltration group (a loss of 5.5{\textpm}5.1 kg [12.1{\textpm}11.3 lb] and 5.7{\textpm}3.9 kg [12.6{\textpm}8.5 lb], respectively; P=0.58). A higher percentage of patients in the ultrafiltration group than in the pharmacologic-therapy group had a serious adverse event (72\% vs. 57\%, P=0.03). CONCLUSIONS: In a randomized trial involving patients hospitalized for acute decompensated heart failure, worsened renal function, and persistent congestion, the use of a stepped pharmacologic-therapy algorithm was superior to a strategy of ultrafiltration for the preservation of renal function at 96 hours, with a similar amount of weight loss with the two approaches. Ultrafiltration was associated with a higher rate of adverse events. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT00608491.).},
  pmid = {23131078},
  keywords = {affs=[],affs=[]),Aged,Algorithms,Author(firstnames='A',Author(firstnames='B',Author(firstnames='C',Author(firstnames='D',Author(firstnames='E',Author(firstnames='G',Author(firstnames='H',Author(firstnames='I',Author(firstnames='J',Author(firstnames='K',Author(firstnames='L',Author(firstnames='M',Author(firstnames='N',Author(firstnames='P',Author(firstnames='R',Author(firstnames='S',Author(firstnames='T',Author(firstnames='W',Bradley A Bart,Cardio-Renal Syndrome / etiology,Cardio-Renal Syndrome / therapy*,CollabAuthor(name='Heart Failure Clinical Research Network',Comparative Study,Creatinine / blood,Diuretics / adverse effects,Diuretics / therapeutic use*,doi:10.1056/NEJMoa1210357,equal<sub>c</sub>ontrib=False),equal<sub>c</sub>ontrib=False)],Extramural,Female,Heart Failure / complications,Heart Failure / drug therapy,Heart Failure / mortality,Heart Failure / therapy*,Humans,Infusions,initials='A',initials='B',initials='C',initials='D',initials='E',initials='G',initials='H',initials='I',initials='J',initials='K',initials='L',initials='M',initials='N',initials='P',initials='R',initials='S',initials='T',initials='W',Intravenous,investigators=[Author(firstnames='E',iseditor=False,lastname='Abraham',lastname='Adams',lastname='Agresti',lastname='Altmus',lastname='Anand',lastname='Anello',lastname='Anstrom',lastname='Barbagelata',lastname='Barry',lastname='Bart',lastname='Berg',lastname='Boddicker',lastname='Boyle',lastname='Bozkurt',lastname='Braunwald',lastname='Brinegar',lastname='Brooks',lastname='Brown',lastname='Bull',lastname='Cai',lastname='Chadwick',lastname='Chee',lastname='Cocca-Spofford',lastname='Collins',lastname='Cornell',lastname='Cross',lastname='DeNofrio',lastname='Desvigne-Nickens',lastname='Deswal',lastname='Ducharme',lastname='Estep',lastname='Felker',lastname='Fleck',lastname='Fleurent',lastname='Gatzke',lastname='Geyen',lastname='Givertz',lastname='Goldsmith',lastname='Greenberg',lastname='Hanovich',lastname='Hegeman',lastname='Hernandez',lastname='Humbert',lastname='Ibarra',lastname='Johnson',lastname='Kaping',lastname='Keleti',lastname='Kennedy',lastname='Kfoury',lastname='Knight',lastname='Kwak',lastname='Lapointe',lastname='Lee',lastname='LeWinter',lastname='Lipinski',lastname='Lizzul',lastname='Mackendanz',lastname='Mascette',lastname='McNamara',lastname='McNulty',lastname='Meldrum',lastname='Milbrandt',lastname='Miller',lastname='Morrissette',lastname='Ofili',lastname='Parillo',lastname='Penn',lastname='Potash',lastname='Redfield',lastname='Rohrback',lastname='Rose',lastname='Rosenberg',lastname='Rouleau',lastname='Rowen',lastname='Ryan',lastname='Scanlon',lastname='Schuchard',lastname='Semigran',lastname='Shah',lastname='Sharp',lastname='Sheppard',lastname='Slawksy',lastname='Sopko',lastname='St Laurent',lastname='Stehlik',lastname='Steidley',lastname='Stevenson',lastname='Taff',lastname='Tracy',lastname='Tuinei',lastname='Vaughan',lastname='Velazquez',lastname='Virmani',lastname="O'Connor",Male,MEDLINE,Middle Aged,N.I.H.,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,PMC3690472,pmid:23131078,PubMed Abstract,Randomized Controlled Trial,Research Support,Steven R Goldsmith,suffix=None,Ultrafiltration* / adverse effects,Weight Loss / drug effects}
}

@article{bennObesityIncreasesHeart2022,
  title = {Obesity Increases Heart Failure Incidence and Mortality: Observational and {{Mendelian}} Randomization Studies Totalling over 1 Million Individuals},
  shorttitle = {Obesity Increases Heart Failure Incidence and Mortality},
  author = {Benn, Marianne and Marott, Sarah C W and {Tybj{\ae}rg-Hansen}, Anne and Nordestgaard, B{\o}rge G},
  year = {2022},
  month = dec,
  journal = {Cardiovascular Research},
  volume = {118},
  number = {18},
  pages = {3576--3585},
  issn = {0008-6363},
  doi = {10.1093/cvr/cvab368},
  urldate = {2024-08-24},
  abstract = {Whether high body mass index (BMI) causally influences development and prognosis of heart failure has implications for clinical practice. We tested the hypotheses that high BMI causally influences heart failure incidence and mortality.Using observational and Mendelian randomization causal, genetic analyses, we studied 106 121 individuals from the Copenhagen General Population Study, 18 407 from the Copenhagen City Heart Study, and 977 323 from publicly available databases. In observational analyses in the Copenhagen studies with 10 years of median follow-up, multivariable adjusted hazard ratios per 1 kg/m2 increment of BMI were 1.06 (95\% confidence interval: 1.05--1.07; P \&lt; 0.001; n = 124 528; events = 6589) for heart failure incidence, 1.04 (1.03--1.06; P \&lt; 0.001; n = 124 528; events = 1237) for heart failure mortality, and 1.01 (1.00--1.01; P \&lt; 0.001; n = 124 528; events = 24 144) for all-cause mortality. In genetic analyses in the Copenhagen studies, the age and sex adjusted causal risk ratios per 1 kg/m2 increment of BMI were 1.19 (1.05--1.36; P = 0.008; n = 118 200; events = 6541) for heart failure incidence, 1.27 (0.82--1.98; P = 0.28; n = 118 200; events = 889) for heart failure mortality, and 1.11 (1.02--1.22; P = 0.022; n = 118 200; events = 16 814) for all-cause mortality. Finally, combining genetic data from the Copenhagen studies, the Genetic Investigation of ANthropometric Traits, the Heart Failure Molecular Epidemiology for Therapeutic Targets, and the UK Biobank, the unadjusted causal risk ratios per 1 kg/m2 increment of BMI were 1.39 (1.27--1.52; P \&lt; 0.001; n = 1 095 523; events = 53 850) for heart failure incidence, 1.18 (1.00--1.38; P = 0.05; n = 576 853; events = 2373) for heart failure mortality, and 1.02 (1.00--1.04; P = 0.03; n = 576 853; events = 44 734) for all-cause mortality.High BMI causally increases the risk of both heart failure incidence and mortality.},
  file = {/Users/xx20081/Zotero/storage/XCCHHJ66/Benn et al. - 2022 - Obesity increases heart failure incidence and mort.pdf;/Users/xx20081/Zotero/storage/LRPGQ8IR/6483090.html}
}

@article{bentley-lewisBodyMassIndex2007,
  title = {Body Mass Index Predicts Aldosterone Production in Normotensive Adults on a High-Salt Diet},
  author = {{Bentley-Lewis}, Rhonda and Adler, Gail K. and Perlstein, Todd and Seely, Ellen W. and Hopkins, Paul N. and Williams, Gordon H. and Garg, Rajesh},
  year = {2007},
  month = nov,
  journal = {The Journal of Clinical Endocrinology and Metabolism},
  volume = {92},
  number = {11},
  pages = {4472--4475},
  issn = {0021-972X},
  doi = {10.1210/jc.2007-1088},
  abstract = {CONTEXT: The mechanisms underlying obesity-mediated cardiovascular disease are not fully understood. Aldosterone and insulin resistance both are associated with obesity and cardiovascular disease. OBJECTIVES: The objectives of this study were to test the hypotheses that aldosterone production is elevated and associated with insulin resistance in overweight adults on a high-sodium diet. PARTICIPANTS/INTERVENTIONS: Healthy normotensive adults were categorized as lean body mass index (BMI) less than 25 kg/m(2) (n = 63) or overweight BMI 25 kg/m(2) or greater (n = 57). After 7 d of a high-sodium diet, participants fasted overnight and remained supine throughout hemodynamic and laboratory assessments and angiotensin II (AngII) stimulation. RESULTS: The overweight group, compared with the lean group, had higher 24-h urinary aldosterone (9.0 +/- 0.8 vs. 6.6 +/- 0.5 microg per 24 h; P = 0.003) and higher AngII-stimulated serum aldosterone (11.4 +/- 1.0 vs. 9.0 +/- 0.6 ng/dl; P = 0.04). There were no differences in 24-h urinary cortisol or sodium or supine measurements of plasma renin activity, serum aldosterone, or serum potassium. The homeostasis model assessment of insulin resistance was predicted by urinary aldosterone excretion (r = 0.32, P = 0.03) and serum aldosterone response to AngII stimulation (r = 0.28, P = 0.02) independent of age and BMI. CONCLUSION: Urinary aldosterone excretion and AngII-stimulated aldosterone are increased in overweight, compared with lean, normotensive adults. The correlation of these measures of aldosterone production with insulin resistance suggests a potential role for aldosterone in the pathophysiology of obesity-mediated insulin resistance.},
  langid = {english},
  pmcid = {PMC4428584},
  pmid = {17726083},
  keywords = {Adult,Aldosterone,Angiotensin II,Body Mass Index,Diet,Female,Humans,Hydrocortisone,Infusions Intravenous,Insulin Resistance,Male,Middle Aged,Overweight,Renin,Sodium Dietary,Vasoconstrictor Agents},
  file = {/Users/xx20081/Zotero/storage/DIDR4T73/Bentley-Lewis et al. - 2007 - Body mass index predicts aldosterone production in.pdf}
}

@article{bergmannSemaglutideTreatmentOverweight2023,
  title = {Semaglutide for the Treatment of Overweight and Obesity: {{A}} Review},
  shorttitle = {Semaglutide for the Treatment of Overweight and Obesity},
  author = {Bergmann, Natasha Chidekel and Davies, Melanie J. and Lingvay, Ildiko and Knop, Filip K.},
  year = {2023},
  month = jan,
  journal = {Diabetes, Obesity \& Metabolism},
  volume = {25},
  number = {1},
  pages = {18--35},
  issn = {1462-8902},
  doi = {10.1111/dom.14863},
  urldate = {2025-01-21},
  abstract = {Obesity is a chronic, relapsing disease associated with multiple complications and a substantial morbidity, mortality and health care burden. Pharmacological treatments for obesity provide a valuable adjunct to lifestyle intervention, which often achieves only limited weight loss that is difficult to maintain. The Semaglutide Treatment Effect in People with obesity (STEP) clinical trial programme is evaluating once-weekly subcutaneous semaglutide 2.4~mg (a glucagon-like peptide-1 analogue) in people with overweight or obesity. Across STEP 1, 3, 4 and 8, semaglutide 2.4~mg was associated with mean weight losses of 14.9\%-17.4\% in individuals with overweight or obesity without type 2 diabetes from baseline to week 68; 69\%-79\% of participants achieved {$\geq$}10\% weight loss with semaglutide 2.4~mg (vs. 12\%-27\% with placebo) and 51\%-64\% achieved {$\geq$}15\% weight loss (vs. 5\%-13\% with placebo). In STEP 5, mean weight loss was -15.2\% with semaglutide 2.4~mg versus -2.6\% with placebo from baseline to week 104. In STEP 2 (individuals with overweight or obesity, and type 2 diabetes), mean weight loss was -9.6\% with semaglutide 2.4~mg versus -3.4\% with placebo from baseline to week 68. Improvements in cardiometabolic risk factors, including high blood pressure, atherogenic lipids and benefits on physical function and quality of life were seen with semaglutide 2.4~mg. The safety profile of semaglutide 2.4~mg was consistent across trials, primarily gastrointestinal adverse events. The magnitude of weight loss reported in the STEP trials offers the potential for clinically relevant improvement for individuals with obesity-related diseases.},
  pmcid = {PMC10092086},
  pmid = {36254579},
  file = {/Users/xx20081/Zotero/storage/ZS7HFI7R/Bergmann et al. - 2023 - Semaglutide for the treatment of overweight and obesity A review.pdf}
}

@article{bhaskaranAssociationBMIOverall2018,
  title = {Association of {{BMI}} with Overall and Cause-Specific Mortality: A Population-Based Cohort Study of 3{$\cdot$}6 Million Adults in the {{UK}}},
  shorttitle = {Association of {{BMI}} with Overall and Cause-Specific Mortality},
  author = {Bhaskaran, Krishnan and {dos-Santos-Silva}, Isabel and Leon, David A and Douglas, Ian J and Smeeth, Liam},
  year = {2018},
  month = dec,
  journal = {The Lancet. Diabetes \& Endocrinology},
  volume = {6},
  number = {12},
  pages = {944--953},
  issn = {2213-8587},
  doi = {10.1016/S2213-8587(18)30288-2},
  urldate = {2025-05-21},
  abstract = {Background BMI is known to be strongly associated with all-cause mortality, but few studies have been large enough to reliably examine associations between BMI and a comprehensive range of cause-specific mortality outcomes. Methods In this population-based cohort study, we used UK primary care data from the Clinical Practice Research Datalink (CPRD) linked to national mortality registration data and fitted adjusted Cox regression models to examine associations between BMI and all-cause mortality, and between BMI and a comprehensive range of cause-specific mortality outcomes (recorded by International Classification of Diseases, 10th revision [ICD-10] codes). We included all individuals with BMI data collected at age 16 years and older and with subsequent follow-up time available. Follow-up began at whichever was the latest of: start of CPRD research-standard follow up, the 5-year anniversary of the first BMI record, or on Jan 1, 1998 (start date for death registration data); follow-up ended at death or on March 8, 2016. Fully adjusted models were stratified by sex and adjusted for baseline age, smoking, alcohol use, diabetes, index of multiple deprivation, and calendar period. Models were fitted in both never-smokers only and the full study population. We also did an extensive range of sensitivity analyses. The expected age of death for men and women aged 40 years at baseline, by BMI category, was estimated from a Poisson model including BMI, age, and sex. Findings 3\hphantom{,}632\hphantom{,}674 people were included in the full study population; the following results are from the analysis of never-smokers, which comprised 1\hphantom{,}969\hphantom{,}648 people and 188\hphantom{,}057 deaths. BMI had a J-shaped association with overall mortality; the estimated hazard ratio per 5 kg/m2 increase in BMI was 0{$\cdot$}81 (95\% CI 0{$\cdot$}80--0{$\cdot$}82) below 25 kg/m2 and 1{$\cdot$}21 (1{$\cdot$}20--1{$\cdot$}22) above this point. BMI was associated with all cause of death categories except for transport-related accidents, but the shape of the association varied. Most causes, including cancer, cardiovascular diseases, and respiratory diseases, had a J-shaped association with BMI, with lowest risk occurring in the range 21--25 kg/m2. For mental and behavioural, neurological, and accidental (non-transport-related) causes, BMI was inversely associated with mortality up to 24--27 kg/m2, with little association at higher BMIs; for deaths from self-harm or interpersonal violence, an inverse linear association was observed. Associations between BMI and mortality were stronger at younger ages than at older ages, and the BMI associated with lowest mortality risk was higher in older individuals than in younger individuals. Compared with individuals of healthy weight (BMI 18{$\cdot$}5--24{$\cdot$}9 kg/m2), life expectancy from age 40 years was 4{$\cdot$}2 years shorter in obese (BMI {$\geq$}30{$\cdot$}0 kg/m2) men and 3{$\cdot$}5 years shorter in obese women, and 4{$\cdot$}3 years shorter in underweight (BMI {$<$}18{$\cdot$}5 kg/m2) men and 4{$\cdot$}5 years shorter in underweight women. When smokers were included in analyses, results for most causes of death were broadly similar, although marginally stronger associations were seen among people with lower BMI, suggesting slight residual confounding by smoking. Interpretation BMI had J-shaped associations with overall mortality and most specific causes of death; for mental and behavioural, neurological, and external causes, lower BMI was associated with increased mortality risk. Funding Wellcome Trust.},
  pmcid = {PMC6249991},
  pmid = {30389323},
  file = {/Users/xx20081/Zotero/storage/24B57RMF/Bhaskaran et al. - 2018 - Association of BMI with overall and cause-specific mortality a population-based cohort study of 36.pdf}
}

@article{bHeartFailureEpidemiology2023,
  title = {Heart {{Failure Epidemiology}} and {{Outcomes Statistics}}: {{A Report}} of the {{Heart Failure Society}} of {{America}}},
  shorttitle = {Heart {{Failure Epidemiology}} and {{Outcomes Statistics}}},
  author = {B, Bozkurt and T, Ahmad and Km, Alexander and Wl, Baker and K, Bosak and K, Breathett and Gc, Fonarow and P, Heidenreich and Je, Ho and E, Hsich and Ne, Ibrahim and Lm, Jones and Ss, Khan and P, Khazanie and T, Koelling and Hm, Krumholz and Kk, Khush and C, Lee and Aa, Morris and Rl, Page and A, Pandey and Mr, Piano and J, Stehlik and Lw, Stevenson and Jr, Teerlink and M, Vaduganathan and B, Ziaeian},
  year = {2023},
  month = oct,
  journal = {Journal of cardiac failure},
  volume = {29},
  number = {10},
  publisher = {J Card Fail},
  issn = {1532-8414},
  doi = {10.1016/j.cardfail.2023.07.006},
  urldate = {2024-07-03},
  abstract = {Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America},
  langid = {english},
  pmid = {37797885},
  file = {/Users/xx20081/Zotero/storage/95PRWDAI/B et al. - 2023 - Heart Failure Epidemiology and Outcomes Statistics.pdf;/Users/xx20081/Zotero/storage/V6YUYIHJ/37797885.html}
}

@misc{BiasDueParticipant,
  title = {Bias Due to Participant Overlap in Two-sample {{Mendelian}} Randomization - {{PMC}}},
  urldate = {2024-09-17},
  howpublished = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082560/},
  file = {/Users/xx20081/Zotero/storage/NQZB993Q/PMC5082560.html}
}

@article{billingsleySarcopenicObesityAssociated2022,
  title = {Sarcopenic {{Obesity Is Associated With Reduced Cardiorespiratory Fitness Compared With Nonsarcopenic Obesity}} in {{Patients With Heart Failure With Reduced Ejection Fraction}}},
  author = {Billingsley, {\relax HE} and Jm, Canada and Y, Kim and Ji, Damonte and Cr, Trankle and G, Halasz and V, Mihalick and A, Vecchi{\'e} and Rr, Markley and D, Kadariya and E, Bressi and H, Medina de Chazal and Jg, Chiabrando and J, Mbualungu and J, Turlington and R, Arena and Bw, Van Tassell and A, Abbate and S, Carbone},
  year = {2022},
  month = oct,
  journal = {Circulation. Heart failure},
  volume = {15},
  number = {10},
  publisher = {Circ Heart Fail},
  issn = {1941-3297},
  doi = {10.1161/CIRCHEARTFAILURE.122.009518},
  urldate = {2024-08-06},
  abstract = {In patients with HFrEF and obesity, sarcopenia, defined as low SMMI, is associated with a clinically significant reduction in CRF, independent of adiposity.},
  langid = {english},
  pmid = {36098058},
  file = {/Users/xx20081/Zotero/storage/ZUTAKPP8/He et al. - 2022 - Sarcopenic Obesity Is Associated With Reduced Card.pdf;/Users/xx20081/Zotero/storage/7Y9MVYYS/36098058.html}
}

@article{bloomInvestigatingLinkACAD102018,
  title = {Investigating the Link of {{ACAD10}} Deficiency to Type 2 Diabetes Mellitus},
  author = {Bloom, Kaitlyn and Mohsen, Al-Walid and Karunanidhi, Anuradha and El Demellawy, Dina and {Reyes-M{\'u}gica}, Miguel and Wang, Yudong and {Ghaloul-Gonzalez}, Lina and Otsubo, Chikara and Tobita, Kimi and Muzumdar, Radhika and Gong, Zhenwei and Tas, Emir and Basu, Shrabani and Chen, Jie and Bennett, Michael and Hoppel, Charles and Vockley, Jerry},
  year = {2018},
  month = jan,
  journal = {Journal of Inherited Metabolic Disease},
  volume = {41},
  number = {1},
  pages = {49--57},
  issn = {1573-2665},
  doi = {10.1007/s10545-017-0013-y},
  abstract = {The Native American Pima population has the highest incidence of insulin resistance (IR) and type 2 diabetes mellitus (T2DM) of any reported population, but the pathophysiologic mechanism is unknown. Genetic studies in Pima Indians have linked acyl-CoA dehydrogenase 10 (ACAD10) gene polymorphisms, among others, to this predisposition. The gene codes for a protein with a C-terminus region that is structurally similar to members of a family of flavoenzymes-the acyl-CoA dehydrogenases (ACADs)-that catalyze {$\alpha$},{$\beta$}-dehydrogenation reactions, including the first step in mitochondrial FAO (FAO), and intermediary reactions in amino acids catabolism. Dysregulation of FAO and an increase in plasma acylcarnitines are recognized as important in the pathophysiology of IR and T2DM. To investigate the deficiency of ACAD10 as a monogenic risk factor for T2DM in human, an Acad-deficient mouse was generated and characterized. The deficient mice exhibit an abnormal glucose tolerance test and elevated insulin levels. Blood acylcarnitine analysis shows an increase in long-chain species in the older mice. Nonspecific variable pattern of elevated short-terminal branch-chain acylcarnitines in a variety of tissues was also observed. Acad10 mice accumulate excess abdominal adipose tissue, develop an early inflammatory liver process, exhibit fasting rhabdomyolysis, and have abnormal skeletal muscle mitochondria. Our results identify Acad10 as a genetic determinant of T2DM in mice and provide a model to further investigate genetic determinants for insulin resistance in humans.},
  langid = {english},
  pmcid = {PMC5524623},
  pmid = {28120165},
  keywords = {Abdominal Fat,Acyl-CoA Dehydrogenase,Adiposity,Animals,Blood Glucose,Diabetes Mellitus Type 2,Disease Models Animal,Genetic Predisposition to Disease,Insulin,Insulin Resistance,Lipid Metabolism Inborn Errors,Liver,Mice 129 Strain,Mice Inbred C57BL,Mice Knockout,Mitochondria Muscle,Muscle Skeletal,Non-alcoholic Fatty Liver Disease,Obesity Abdominal,Phenotype,Rhabdomyolysis},
  file = {/Users/xx20081/Zotero/storage/64BG44EA/Bloom et al. - 2018 - Investigating the link of ACAD10 deficiency to type 2 diabetes mellitus.pdf}
}

@article{bmSaxagliptinCardiovascularOutcomes2013,
  title = {Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus},
  author = {Bm, Scirica and Dl, Bhatt and E, Braunwald and Pg, Steg and J, Davidson and B, Hirshberg and P, Ohman and R, Frederich and Sd, Wiviott and Eb, Hoffman and Ma, Cavender and Ja, Udell and Nr, Desai and O, Mosenzon and Dk, McGuire and Kk, Ray and La, Leiter and I, Raz},
  year = {2013},
  month = mar,
  journal = {The New England journal of medicine},
  volume = {369},
  number = {14},
  publisher = {N Engl J Med},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1307684},
  urldate = {2023-12-08},
  abstract = {DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. (Fun {\dots}},
  langid = {english},
  pmid = {23992601},
  file = {/Users/xx20081/Zotero/storage/92E2FC95/Bm et al. - 2013 - Saxagliptin and cardiovascular outcomes in patient.pdf;/Users/xx20081/Zotero/storage/TVK4WY7F/23992601.html}
}

@article{bobbertHighLeptinResistin2012,
  title = {High Leptin and Resistin Expression in Chronic Heart Failure: Adverse Outcome in Patients with Dilated and Inflammatory Cardiomyopathy},
  shorttitle = {High Leptin and Resistin Expression in Chronic Heart Failure},
  author = {Bobbert, Peter and Jenke, Alexander and Bobbert, Thomas and K{\"u}hl, Uwe and Rauch, Ursula and Lassner, Dirk and Scheibenbogen, Carmen and Poller, Wolfgang and Schultheiss, Heinz-Peter and Skurk, Carsten},
  year = {2012},
  month = nov,
  journal = {European Journal of Heart Failure},
  volume = {14},
  number = {11},
  pages = {1265--1275},
  issn = {1879-0844},
  doi = {10.1093/eurjhf/hfs111},
  abstract = {AIM: The expression of leptin and resistin is known to be positively correlated with the incidence of chronic heart failure (CHF). Both adipokines have been implicated in immunomodulation and cardiac remodelling. Therefore, we performed for the first time a clinical study to elucidate the effects of leptin and resistin on progression of CHF in patients with non-ischaemic dilated (DCM) and inflammatory (DCMi) cardiomyopathy. METHODS AND RESULTS: For the clinical study 120 patients were divided into a control (n = 16), DCM (n = 52), and DCMi (n = 52) group to determine the effect of leptin and resistin on CHF progression. Nuclear factor-{$\kappa$}B (NF-{$\kappa$}B) activation, reactive oxygen species generation, and tumour necrosis factor-{$\alpha$} (TNF-{$\alpha$}) and interleukin-6 (IL-6) expression following adipokine exposition were determined in vitro in cardiomyocytes. Leptin and resistin systemic plasma levels and not cardiac expression were significantly elevated in patients with DCM (leptin, 13.12 {\textpm} 17.2 ng/mL, P {$<$} 0.05; resistin, 6.87 {\textpm} 2.25 ng/mL, P {$<$} 0.05) and DCMi (leptin, 13.63 {\textpm} 16 ng/mL, P {$<$} 0.05; resistin, 7.27 {\textpm} 2.2 ng/mL, P {$<$} 0.05) compared with the control group (leptin, 7.34 {\textpm} 5.7 ng/mL; resistin, 4.4 {\textpm} 1.18 ng/mL). A multivariate linear regression model revealed low leptin and resistin plasma levels as contributors for favourable cardiac functional parameters at 6-month follow-up independent of inflammatory conditions. Cell culture experiments in vitro showed leptin and resistin to be potent regulators of TNF-{$\alpha$} and IL-6 expression in cardiomyocytes, leading to significantly increased redox stress in cardiac cells. CONCLUSIONS: High leptin and resistin expression in patients with DCM and DCMi is associated with CHF progression, i.e. severe cardiac dysfunction, independent of immune responses.},
  langid = {english},
  pmid = {22764185},
  keywords = {Adult,Biomarkers,Cardiomyopathies,Disease Progression,Female,Health Status Indicators,Heart Failure,Hemodynamics,Humans,Inflammation,Leptin,Male,Middle Aged,Multivariate Analysis,Prognosis,Resistin,ROC Curve,Statistics as Topic,Stroke Volume,Treatment Outcome,Ventricular Dysfunction Left},
  file = {/Users/xx20081/Zotero/storage/L3ZKRA7H/Bobbert et al. - 2012 - High leptin and resistin expression in chronic hea.pdf}
}

@misc{BodyMassIndex,
  title = {Body {{Mass Index}} and {{Adverse Cardiovascular Outcomes}} in {{Heart Failure Patients With Preserved Ejection Fraction}}},
  doi = {10.1161/CIRCHEARTFAILURE.110.959890},
  urldate = {2024-07-03},
  howpublished = {https://www.ahajournals.org/doi/epub/10.1161/CIRCHEARTFAILURE.110.959890},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/KFPEZZRD/Body Mass Index and Adverse Cardiovascular Outcome.pdf;/Users/xx20081/Zotero/storage/KFW3EMHW/CIRCHEARTFAILURE.110.html}
}

@misc{BodyMassIndexa,
  title = {Body {{Mass Index}} and {{Adverse Cardiovascular Outcomes}} in {{Heart Failure Patients With Preserved Ejection Fraction}} {\textbar} {{Circulation}}: {{Heart Failure}}},
  urldate = {2024-07-03},
  howpublished = {https://www.ahajournals.org/doi/full/10.1161/CIRCHEARTFAILURE.110.959890},
  file = {/Users/xx20081/Zotero/storage/2DMGPCMP/CIRCHEARTFAILURE.110.html}
}

@article{boerDecipheringOsteoarthritisGenetics2021,
  title = {Deciphering Osteoarthritis Genetics across 826,690 Individuals from 9 Populations},
  author = {Boer, Cindy G. and Hatzikotoulas, Konstantinos and Southam, Lorraine and Stef{\'a}nsd{\'o}ttir, Lilja and Zhang, Yanfei and {Coutinho de Almeida}, Rodrigo and Wu, Tian T. and Zheng, Jie and Hartley, April and {Teder-Laving}, Maris and Skogholt, Anne Heidi and Terao, Chikashi and Zengini, Eleni and Alexiadis, George and Barysenka, Andrei and Bjornsdottir, Gyda and Gabrielsen, Maiken E. and Gilly, Arthur and Ingvarsson, Thorvaldur and Johnsen, Marianne B. and Jonsson, Helgi and Kloppenburg, Margreet and Luetge, Almut and Lund, Sigrun H. and M{\"a}gi, Reedik and Mangino, Massimo and Nelissen, Rob R. G. H. H. and Shivakumar, Manu and Steinberg, Julia and Takuwa, Hiroshi and Thomas, Laurent F. and Tuerlings, Margo and {arcOGEN Consortium} and {HUNT All-In Pain} and {ARGO Consortium} and {Regeneron Genetics Center} and Babis, George C. and Cheung, Jason Pui Yin and Kang, Jae Hee and Kraft, Peter and Lietman, Steven A. and Samartzis, Dino and Slagboom, P. Eline and Stefansson, Kari and Thorsteinsdottir, Unnur and Tobias, Jonathan H. and Uitterlinden, Andr{\'e} G. and Winsvold, Bendik and Zwart, John-Anker and Davey Smith, George and Sham, Pak Chung and Thorleifsson, Gudmar and Gaunt, Tom R. and Morris, Andrew P. and Valdes, Ana M. and Tsezou, Aspasia and Cheah, Kathryn S. E. and Ikegawa, Shiro and Hveem, Kristian and Esko, T{\~o}nu and Wilkinson, J. Mark and Meulenbelt, Ingrid and Lee, Ming Ta Michael and {van Meurs}, Joyce B. J. and Styrk{\'a}rsd{\'o}ttir, Unnur and Zeggini, Eleftheria},
  year = {2021},
  month = sep,
  journal = {Cell},
  volume = {184},
  number = {18},
  pages = {4784-4818.e17},
  issn = {1097-4172},
  doi = {10.1016/j.cell.2021.07.038},
  abstract = {Osteoarthritis affects over 300 million people worldwide. Here, we conduct a genome-wide association study meta-analysis across 826,690 individuals (177,517 with osteoarthritis) and identify 100 independently associated risk variants across 11 osteoarthritis phenotypes, 52 of which have not been associated with the disease before. We report thumb and spine osteoarthritis risk variants and identify differences in genetic effects between weight-bearing and non-weight-bearing joints. We identify sex-specific and early age-at-onset osteoarthritis risk loci. We integrate functional genomics data from primary patient tissues (including articular cartilage, subchondral bone, and osteophytic cartilage) and identify high-confidence effector genes. We provide evidence for genetic correlation with phenotypes related to pain, the main disease symptom, and identify likely causal genes linked to neuronal processes. Our results provide insights into key molecular players in disease processes and highlight attractive drug targets to accelerate translation.},
  langid = {english},
  pmcid = {PMC8459317},
  pmid = {34450027},
  keywords = {drug targets,effector genes,Female,functional genomics,genetic architecture,Genetic Predisposition to Disease,Genetics Population,genome-wide association meta-analysis,Genome-Wide Association Study,Humans,osteoarthritis,Osteoarthritis,Phenotype,Polymorphism Single Nucleotide,Risk Factors,Sex Characteristics,Signal Transduction},
  file = {/Users/xx20081/Zotero/storage/HUGC6MKP/Boer et al. - 2021 - Deciphering osteoarthritis genetics across 826,690.pdf}
}

@article{bogersAssociationOverweightIncreased2007,
  title = {Association of Overweight with Increased Risk of Coronary Heart Disease Partly Independent of Blood Pressure and Cholesterol Levels: A Meta-Analysis of 21 Cohort Studies Including More than 300 000 Persons},
  shorttitle = {Association of Overweight with Increased Risk of Coronary Heart Disease Partly Independent of Blood Pressure and Cholesterol Levels},
  author = {Bogers, Rik P. and Bemelmans, Wanda J. E. and Hoogenveen, Rudolf T. and Boshuizen, Hendriek C. and Woodward, Mark and Knekt, Paul and {van Dam}, Rob M. and Hu, Frank B. and Visscher, Tommy L. S. and Menotti, Alessandro and Thorpe, Roland J. and Jamrozik, Konrad and Calling, Susanna and Strand, Bj{\o}rn Heine and Shipley, Martin J. and {BMI-CHD Collaboration Investigators}},
  year = {2007},
  month = sep,
  journal = {Archives of Internal Medicine},
  volume = {167},
  number = {16},
  pages = {1720--1728},
  issn = {0003-9926},
  doi = {10.1001/archinte.167.16.1720},
  abstract = {BACKGROUND: The extent to which moderate overweight (body mass index [BMI], 25.0-29.9 [calculated as weight in kilograms divided by height in meters squared]) and obesity (BMI, {$>$}/= 30.0) are associated with increased risk of coronary heart disease (CHD) through adverse effects on blood pressure and cholesterol levels is unclear, as is the risk of CHD that remains after these mediating effects are considered. METHODS: Relative risks (RRs) of CHD associated with moderate overweight and obesity with and without adjustment for blood pressure and cholesterol concentrations were calculated by the members of a collaboration of prospective cohort studies of healthy, mainly white persons and pooled by means of random-effects models (RRs for categories of BMI in 14 cohorts and for continuous BMI in 21 cohorts; total N = 302 296). RESULTS: A total of 18 000 CHD events occurred during follow-up. The age-, sex-, physical activity-, and smoking-adjusted RRs (95\% confidence intervals) for moderate overweight and obesity compared with normal weight were 1.32 (1.24-1.40) and 1.81 (1.56-2.10), respectively. Additional adjustment for blood pressure and cholesterol levels reduced the RR to 1.17 (1.11-1.23) for moderate overweight and to 1.49 (1.32-1.67) for obesity. The RR associated with a 5-unit BMI increment was 1.29 (1.22-1.35) before and 1.16 (1.11-1.21) after adjustment for blood pressure and cholesterol levels. CONCLUSIONS: Adverse effects of overweight on blood pressure and cholesterol levels could account for about 45\% of the increased risk of CHD. Even for moderate overweight, there is a significant increased risk of CHD independent of these traditional risk factors, although confounding (eg, by dietary factors) cannot be completely ruled out.},
  langid = {english},
  pmid = {17846390},
  keywords = {Blood Pressure,Cholesterol,Coronary Disease,Global Health,Humans,Incidence,Overweight,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/KT6E8V8D/Bogers et al. - 2007 - Association of overweight with increased risk of c.pdf}
}

@article{Bonaca2017,
  title = {Efficacy and Safety of Ticagrelor over Time in Patients with Prior {{MI}} in {{PEGASUS-TIMI}} 54},
  author = {Bonaca, Marc P. and Storey, Robert F. and Theroux, Pierre and Steg, P. Gabriel and Bhatt, Deepak L. and Cohen, Marc C. and Im, Kyung Ah and Murphy, Sabina A. and Magnani, Giulia and Ophuis, Ton Oude and Rudah, Mikhail and Parkhomenko, Alexander and Isaza, Daniel and Kamensky, Gabriel and Goudev, Assen and Montalescot, Gilles and Jensen, Eva C. and Johanson, Per and Braunwald, Eugene and Sabatine, Marc S.},
  year = {2017},
  month = sep,
  journal = {Journal of the American College of Cardiology},
  volume = {70},
  number = {11},
  pages = {1368--1375},
  publisher = {J Am Coll Cardiol},
  issn = {1558-3597},
  doi = {10.1016/J.JACC.2017.07.768},
  abstract = {Background Ticagrelor reduces ischemic risk in patients with prior myocardial infarction (MI). It remains unclear whether ischemic risk and the benefits of prolonged P2Y12 inhibition in this population remain consistent over time. Objectives The study sought to investigate the pattern of ischemic risk over time and whether the efficacy and safety of ticagrelor were similar early and late after randomization. Methods The PEGASUS-TIMI (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin--Thrombolysis In Myocardial Infarction) 54 trial randomized patients with prior MI (median 1.7 years prior) to ticagrelor 90 mg, ticagrelor 60 mg, or placebo on a background of aspirin. The rates of cardiovascular (CV) death, MI, and stroke as well as TIMI major bleeding were analyzed at yearly landmarks (years 1, 2, and 3). Results A total of 21,162 patients were randomized and followed for 33 months (median), with 28\% of patients {$\geq$}5 years from MI at trial conclusion. The risk of CV death, MI, or stroke in the placebo arm remained roughly constant over the trial at an {$\sim$}3\% annualized rate. The benefit of ticagrelor 60 mg was consistent at each subsequent landmark (year 1 hazard ratio [HR]: 0.82; 95\% confidence interval [CI]: 0.67 to 0.99; year 2 HR: 0.90; 95\% CI: 0.74 to 1.11; and year 3 HR: 0.79; 95\% CI: 0.62 to 1.00). TIMI major bleeding was increased with ticagrelor 60 mg at each landmark, but with the greatest hazard in the first year (year 1 HR: 3.22; year 2 HR: 2.07; year 3 HR: 1.65). Conclusions Patients with a history of MI remain at persistent high risk for CVD, MI, and stroke as late as 5 years after MI. The efficacy of low-dose ticagrelor is consistent over time with a trend toward less excess bleeding. (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin [PEGASUS]; NCT01225562)},
  pmid = {28882235},
  keywords = {Adenosine / administration & dosage,Adenosine / analogs & derivatives*,Aged,Cause of Death / trends,doi:10.1016/j.jacc.2017.07.768,Dose-Response Relationship,Drug,Electrocardiography,Female,Follow-Up Studies,Global Health,Humans,Male,Marc P Bonaca,Marc S Sabatine,MEDLINE,Middle Aged,Multicenter Study,Myocardial Infarction / diagnosis,Myocardial Infarction / drug therapy*,Myocardial Infarction / mortality,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,pmid:28882235,PubMed Abstract,Purinergic P2Y Receptor Antagonists / administration & dosage,Randomized Controlled Trial,Robert F Storey,Survival Rate / trends,Thrombolytic Therapy / methods*,Ticagrelor,Time Factors,Treatment Outcome}
}

@article{Borlaug2018,
  title = {Effect of Inorganic Nitrite vs Placebo on Exercise Capacity among Patients with Heart Failure with Preserved Ejection Fraction: {{The INDIE-HFpEF}} Randomized Clinical Trial},
  author = {Borlaug, Barry A. and Anstrom, Kevin J. and Lewis, Gregory D. and Shah, Sanjiv J. and Levine, James A. and Koepp, Gabe A. and Givertz, Michael M. and Felker, G. Michael and Lewinter, Martin M. and Mann, Douglas L. and Margulies, Kenneth B. and Smith, Andrew L. and Tang, W. H.Wilson and Whellan, David J. and Chen, Horng H. and {Davila-Roman}, Victor G. and McNulty, Steven and {Desvigne-Nickens}, Patrice and Hernandez, Adrian F. and Braunwald, Eugene and Redfield, Margaret M.},
  year = {2018},
  month = nov,
  journal = {JAMA : the journal of the American Medical Association},
  volume = {320},
  number = {17},
  pages = {1764--1773},
  publisher = {JAMA},
  issn = {1538-3598},
  doi = {10.1001/JAMA.2018.14852},
  abstract = {Importance: There are few effective treatments for heart failure with preserved ejection fraction (HFpEF). Short-term administration of inorganic nitrite or nitrate preparations has been shown to enhance nitric oxide signaling, which may improve aerobic capacity in HFpEF. Objective: To determine the effect of 4 weeks' administration of inhaled, nebulized inorganic nitrite on exercise capacity in HFpEF. Design, Setting, and Participants: Multicenter, double-blind, placebo-controlled, 2-treatment, crossover trial of 105 patients with HFpEF. Participants were enrolled from July 22, 2016, to September 12, 2017, at 17 US sites, with final date of follow-up of January 2, 2018. Interventions: Inorganic nitrite or placebo administered via micronebulizer device. During each 6-week phase of the crossover study, participants received no study drug for 2 weeks (baseline/washout) followed by study drug (nitrite or placebo) at 46 mg 3 times a day for 1 week followed by 80 mg 3 times a day for 3 weeks. Main Outcomes and Measures: The primary end point was peak oxygen consumption (mL/kg/min). Secondary end points included daily activity levels assessed by accelerometry, health status as assessed by the Kansas City Cardiomyopathy Questionnaire (score range, 0-100, with higher scores reflecting better quality of life), functional class, cardiac filling pressures assessed by echocardiography, N-terminal fragment of the prohormone brain natriuretic peptide levels, other exercise indices, adverse events, and tolerability. Outcomes were assessed after treatment for 4 weeks. Results: Among 105 patients who were randomized (median age, 68 years; 56\% women), 98 (93\%) completed the trial. During the nitrite phase, there was no significant difference in mean peak oxygen consumption as compared with the placebo phase (13.5 vs 13.7 mL/kg/min; difference, -0.20 [95\% CI, -0.56 to 0.16]; P =.27). There were no significant between-treatment phase differences in daily activity levels (5497 vs 5503 accelerometry units; difference, -15 [95\% CI, -264 to 234]; P =.91), Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (62.6 vs 61.9; difference, 1.1 [95\% CI, -1.4 to 3.5]; P =.39), functional class (2.5 vs 2.5; difference, 0.1 [95\% CI, -0.1 to 0.2]; P =.43), echocardiographic E/e{$\prime$} ratio (16.4 vs 16.6; difference, 0.1 [95\% CI, -1.2 to 1.3]; P =.93), or N-terminal fragment of the prohormone brain natriuretic peptide levels (520 vs 533 pg/mL; difference, 11 [95\% CI, -53 to 75]; P =.74). Worsening heart failure occurred in 3 participants (2.9\%) during the nitrite phase and 8 (7.6\%) during the placebo phase. Conclusions and Relevance: Among patients with HFpEF, administration of inhaled inorganic nitrite for 4 weeks, compared with placebo, did not result in significant improvement in exercise capacity. Trial Registration: ClinicalTrials.gov Identifier: NCT02742129.},
  pmid = {30398602},
  keywords = {Administration,affs=[]),Aged,and Blood Institute Heart Failure Clinical Research Network',Barry A Borlaug,CollabAuthor(name='National Heart,Cross-Over Studies,doi:10.1001/jama.2018.14852,Double-Blind Method,Exercise Test,Exercise Tolerance / drug effects*,Exercise Tolerance / physiology,Extramural,Female,Heart Failure / drug therapy*,Heart Failure / physiopathology,Humans,Inhalation,Inorganic Chemicals / pharmacology,Inorganic Chemicals / therapeutic use,investigators=[],Kevin J Anstrom,Lung,Male,MEDLINE,Middle Aged,Multicenter Study,N.I.H.,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,Nitrites / adverse effects,Nitrites / pharmacology,Nitrites / therapeutic use*,NLM,Oxygen Consumption,PMC6248105,pmid:30398602,PubMed Abstract,Randomized Controlled Trial,Research Support,Stroke Volume,Treatment Failure}
}

@article{borlaugEffectInorganicNitrite2018,
  title = {Effect of {{Inorganic Nitrite}} vs {{Placebo}} on {{Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction}}: {{The INDIE-HFpEF Randomized Clinical Trial}}},
  shorttitle = {Effect of {{Inorganic Nitrite}} vs {{Placebo}} on {{Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction}}},
  author = {Borlaug, Barry A. and Anstrom, Kevin J. and Lewis, Gregory D. and Shah, Sanjiv J. and Levine, James A. and Koepp, Gabe A. and Givertz, Michael M. and Felker, G. Michael and LeWinter, Martin M. and Mann, Douglas L. and Margulies, Kenneth B. and Smith, Andrew L. and Tang, W. H. Wilson and Whellan, David J. and Chen, Horng H. and {Davila-Roman}, Victor G. and McNulty, Steven and {Desvigne-Nickens}, Patrice and Hernandez, Adrian F. and Braunwald, Eugene and Redfield, Margaret M. and {National Heart, Lung, and Blood Institute Heart Failure Clinical Research Network}},
  year = {2018},
  month = nov,
  journal = {JAMA},
  volume = {320},
  number = {17},
  pages = {1764--1773},
  issn = {1538-3598},
  doi = {10.1001/jama.2018.14852},
  abstract = {IMPORTANCE: There are few effective treatments for heart failure with preserved ejection fraction (HFpEF). Short-term administration of inorganic nitrite or nitrate preparations has been shown to enhance nitric oxide signaling, which may improve aerobic capacity in HFpEF. OBJECTIVE: To determine the effect of 4 weeks' administration of inhaled, nebulized inorganic nitrite on exercise capacity in HFpEF. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled, 2-treatment, crossover trial of 105 patients with HFpEF. Participants were enrolled from July 22, 2016, to September 12, 2017, at 17 US sites, with final date of follow-up of January 2, 2018. INTERVENTIONS: Inorganic nitrite or placebo administered via micronebulizer device. During each 6-week phase of the crossover study, participants received no study drug for 2 weeks (baseline/washout) followed by study drug (nitrite or placebo) at 46 mg 3 times a day for 1 week followed by 80 mg 3 times a day for 3 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was peak oxygen consumption (mL/kg/min). Secondary end points included daily activity levels assessed by accelerometry, health status as assessed by the Kansas City Cardiomyopathy Questionnaire (score range, 0-100, with higher scores reflecting better quality of life), functional class, cardiac filling pressures assessed by echocardiography, N-terminal fragment of the prohormone brain natriuretic peptide levels, other exercise indices, adverse events, and tolerability. Outcomes were assessed after treatment for 4 weeks. RESULTS: Among 105 patients who were randomized (median age, 68 years; 56\% women), 98 (93\%) completed the trial. During the nitrite phase, there was no significant difference in mean peak oxygen consumption as compared with the placebo phase (13.5 vs 13.7 mL/kg/min; difference, -0.20 [95\% CI, -0.56 to 0.16]; P\,=\,.27). There were no significant between-treatment phase differences in daily activity levels (5497 vs 5503 accelerometry units; difference, -15 [95\% CI, -264 to 234]; P\,=\,.91), Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (62.6 vs 61.9; difference, 1.1 [95\% CI, -1.4 to 3.5]; P\,=\,.39), functional class (2.5 vs 2.5; difference, 0.1 [95\% CI, -0.1 to 0.2]; P\,=\,.43), echocardiographic E/e' ratio (16.4 vs 16.6; difference, 0.1 [95\% CI, -1.2 to 1.3]; P\,=\,.93), or N-terminal fragment of the prohormone brain natriuretic peptide levels (520 vs 533 pg/mL; difference, 11 [95\% CI, -53 to 75]; P\,=\,.74). Worsening heart failure occurred in 3 participants (2.9\%) during the nitrite phase and 8 (7.6\%) during the placebo phase. CONCLUSIONS AND RELEVANCE: Among patients with HFpEF, administration of inhaled inorganic nitrite for 4 weeks, compared with placebo, did not result in significant improvement in exercise capacity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02742129.},
  langid = {english},
  pmcid = {PMC6248105},
  pmid = {30398602},
  keywords = {Administration Inhalation,Aged,Cross-Over Studies,Double-Blind Method,Exercise Test,Exercise Tolerance,Female,Heart Failure,Humans,Inorganic Chemicals,Male,Middle Aged,Nitrites,Oxygen Consumption,Stroke Volume,Treatment Failure}
}

@article{borlaugSemaglutideHFpEFObesity2023,
  title = {Semaglutide in {{HFpEF}} across Obesity Class and by Body Weight Reduction: A Prespecified Analysis of the {{STEP-HFpEF}} Trial},
  shorttitle = {Semaglutide in {{HFpEF}} across Obesity Class and by Body Weight Reduction},
  author = {Borlaug, Barry A. and Kitzman, Dalane W. and Davies, Melanie J. and Rasmussen, S{\o}ren and Barros, Eric and Butler, Javed and Einfeldt, Mette Nygaard and Hovingh, G. Kees and M{\o}ller, Dani{\'e}l Vega and Petrie, Mark C. and Shah, Sanjiv J. and Verma, Subodh and Abhayaratna, Walter and Ahmed, Fozia Z. and Chopra, Vijay and Ezekowitz, Justin and Fu, Michael and Ito, Hiroshi and Lelonek, Ma{\l}gorzata and Melenovsky, Vojtech and N{\'u}{\~n}ez, Julio and Perna, Eduardo and Schou, Morten and Senni, Michele and {van der Meer}, Peter and Von Lewinski, Dirk and Wolf, Dennis and Kosiborod, Mikhail N.},
  year = {2023},
  month = sep,
  journal = {Nature Medicine},
  volume = {29},
  number = {9},
  pages = {2358--2365},
  publisher = {Nature Publishing Group},
  issn = {1546-170X},
  doi = {10.1038/s41591-023-02526-x},
  urldate = {2024-07-03},
  abstract = {In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This prespecified analysis examined the effects of semaglutide on dual primary endpoints (change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and body weight) and confirmatory secondary endpoints (change in 6-minute walk distance (6MWD), hierarchical composite (death, HF events, change in KCCQ-CSS and 6MWD) and change in C-reactive protein (CRP)) across obesity classes I--III (body mass index (BMI) 30.0--34.9\,kg\,m-2, 35.0--39.9\,kg\,m-2 and {$\geq$}40\,kg\,m-2) and according to body weight reduction with semaglutide after 52\,weeks. Semaglutide consistently improved all outcomes across obesity categories (P value for treatment effects\,{\texttimes}\,BMI interactions\,=\,not significant for all). In semaglutide-treated patients, improvements in KCCQ-CSS, 6MWD and CRP were greater with larger body weight reduction (for example, 6.4-point (95\% confidence interval (CI): 4.1, 8.8) and 14.4-m (95\% CI: 5.5, 23.3) improvements in KCCQ-CSS and 6MWD for each 10\% body weight reduction). In participants with obesity phenotype of HFpEF, semaglutide improved symptoms, physical limitations and exercise function and reduced inflammation and body weight across obesity categories. In semaglutide-treated patients, the magnitude of benefit was directly related to the extent of weight loss. Collectively, these data support semaglutide-mediated weight loss as a key treatment strategy in patients with obesity phenotype of HFpEF. ClinicalTrials.gov identifier: NCT04788511.},
  copyright = {2023 The Author(s)},
  langid = {english},
  keywords = {Drug discovery,Medical research},
  file = {/Users/xx20081/Zotero/storage/ECG746N7/Borlaug et al. - 2023 - Semaglutide in HFpEF across obesity class and by b.pdf}
}

@article{borneAnthropometricMeasuresRelation2014,
  title = {Anthropometric Measures in Relation to Risk of Heart Failure Hospitalization: A {{Swedish}} Population-Based Cohort Study},
  shorttitle = {Anthropometric Measures in Relation to Risk of Heart Failure Hospitalization},
  author = {Born{\'e}, Yan and Hedblad, Bo and Ess{\'e}n, Birgitta and Engstr{\"o}m, Gunnar},
  year = {2014},
  month = apr,
  journal = {European Journal of Public Health},
  volume = {24},
  number = {2},
  pages = {215--220},
  issn = {1101-1262},
  doi = {10.1093/eurpub/cks161},
  urldate = {2024-07-04},
  abstract = {Background: It is unclear which anthropometric measure is most useful for assessment of the cardiovascular risk. We investigated the association between different anthropometric measures and risk of heart failure (HF) hospitalization. Methods: BMI, waist--hip ratio (WHR), waist circumference (WC), body fat percentage (BF\%), weight and height were measured among 26\,653 subjects (aged 45--73 years) without history of myocardial infarction (MI), stroke or HF from the Malm{\"o} Diet and Cancer cohort at baseline in 1991--96. Incidence of HF hospitalizations was monitored during a mean follow-up of 15 years. Results: Seven hundred and twenty-seven subjects were hospitalized with HF as primary diagnosis, of whom 157 had an MI before or concurrent with the HF. After adjustment for potential confounding factors, the hazard ratios of HF hospitalization (fourth vs. first sex-specific quartile) were 1.80 (95\% CI: 1.45--2.24) for BMI, 1.87 (1.50--2.34) for WC, 1.77 (1.43--2.19) for WHR, 1.35 (1.09--1.68) for BF\%, 1.93 (1.57--2.39) for weight and 1.18 (0.96--1.44) for height. Significant interactions between BMI and WC and WHR, respectively, were observed, and the joint exposure of high BMI and high WC or high WHR further increased the risk. The results were similar in secondary analyses, i.e. excluding incident HF with previous MI during the follow-up. Conclusion: Our results support the view that raised BMI, WC, WHR or BF\% increases the risk of HF hospitalization. The joint exposure of high BMI and high WHR or high WC further increased the risk in an additive way.},
  file = {/Users/xx20081/Zotero/storage/LSCXVQL3/Born et al. - 2014 - Anthropometric measures in relation to risk of hea.pdf;/Users/xx20081/Zotero/storage/HDVEMKLL/445846.html}
}

@article{bozkurtContributoryRiskManagement2016,
  title = {Contributory {{Risk}} and {{Management}} of {{Comorbidities}} of {{Hypertension}}, {{Obesity}}, {{Diabetes Mellitus}}, {{Hyperlipidemia}}, and {{Metabolic Syndrome}} in {{Chronic Heart Failure}}},
  shorttitle = {Contributory {{Risk}} and {{Management}} of {{Comorbidities}} of {{Hypertension}}, {{Obesity}}, {{Diabetes Mellitus}}, {{Hyperlipidemia}}, and {{Metabolic Syndrome}} in {{Chronic Heart Failure}}},
  author = {Bozkurt, Biykem and Aguilar, David and Deswal, Anita and Dunbar, Sandra B. and Francis, Gary S. and Horwich, Tamara and Jessup, Mariell and Kosiborod, Mikhail and Pritchett, Allison M. and Ramasubbu, Kumudha and Rosendorff, Clive and Yancy, Clyde},
  year = {2016},
  month = dec,
  journal = {Circulation},
  volume = {134},
  number = {23},
  pages = {e535-e578},
  issn = {1524-4539},
  doi = {10.1161/CIR.0000000000000450},
  langid = {english},
  pmid = {27799274},
  keywords = {AHA Scientific Statements,American Heart Association,Cardiology,cardiovascular diseases,Chronic Disease,comorbidity,Comorbidity,Consensus,diabetes mellitus,Diabetes Mellitus,Evidence-Based Medicine,heart failure,Heart Failure,Humans,hyperlipidemia,Hyperlipidemias,hypertension,Hypertension,Incidence,Metabolic Syndrome,obesity,Obesity,Prognosis,Risk Assessment,risk factors,Risk Factors,United States},
  file = {/Users/xx20081/Zotero/storage/YZ4S7LHW/Bozkurt et al. - 2016 - Contributory Risk and Management of Comorbidities .pdf}
}

@article{bozkurtUniversalDefinitionClassification2021,
  title = {Universal {{Definition}} and {{Classification}} of {{Heart Failure}}: {{A Report}} of the {{Heart Failure Society}} of {{America}}, {{Heart Failure Association}} of the {{European Society}} of {{Cardiology}}, {{Japanese Heart Failure Society}} and {{Writing Committee}} of the {{Universal Definition}} of {{Heart Failure}}},
  shorttitle = {Universal {{Definition}} and {{Classification}} of {{Heart Failure}}},
  author = {Bozkurt, Biykem and Coats, Andrew Js and Tsutsui, Hiroyuki and Abdelhamid, Magdy and Adamopoulos, Stamatis and Albert, Nancy and Anker, Stefan D. and Atherton, John and B{\"o}hm, Michael and Butler, Javed and Drazner, Mark H. and Felker, G. Michael and Filippatos, Gerasimos and Fonarow, Gregg C. and Fiuzat, Mona and {Gomez-Mesa}, Juan-Esteban and Heidenreich, Paul and Imamura, Teruhiko and Januzzi, James and Jankowska, Ewa A. and Khazanie, Prateeti and Kinugawa, Koichiro and Lam, Carolyn S. P. and Matsue, Yuya and Metra, Marco and Ohtani, Tomohito and Francesco Piepoli, Massimo and Ponikowski, Piotr and Rosano, Giuseppe M. C. and Sakata, Yasushi and Seferovi{\'C}, Petar and Starling, Randall C. and Teerlink, John R. and Vardeny, Orly and Yamamoto, Kazuhiro and Yancy, Clyde and Zhang, Jian and Zieroth, Shelley},
  year = {2021},
  month = mar,
  journal = {Journal of Cardiac Failure},
  pages = {S1071-9164(21)00050-6},
  issn = {1532-8414},
  doi = {10.1016/j.cardfail.2021.01.022},
  abstract = {In this document, we propose a universal definition of heart failure (HF) as the following: HF is a clinical syndrome with symptoms and or signs caused by a structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and or objective evidence of pulmonary or systemic congestion. We propose revised stages of HF as follows. At-risk for HF (Stage A), for patients at risk for HF but without current or prior symptoms or signs of HF and without structural or biomarkers evidence of heart disease. Pre-HF (stage B), for patients without current or prior symptoms or signs of HF, but evidence of structural heart disease or abnormal cardiac function, or elevated natriuretic peptide levels. HF (Stage C), for patients with current or prior symptoms and/or signs of HF caused by a structural and/or functional cardiac abnormality. Advanced HF (Stage D), for patients with severe symptoms and/or signs of HF at rest, recurrent hospitalizations despite guideline-directed management and therapy (GDMT), refractory or intolerant to GDMT, requiring advanced therapies such as consideration for transplant, mechanical circulatory support, or palliative care. Finally, we propose a new and revised classification of HF according to left ventricular ejection fraction (LVEF). The classification includes HF with reduced EF (HFrEF): HF with an LVEF of {$\leq$}40\%; HF with mildly reduced EF (HFmrEF): HF with an LVEF of 41\% to 49\%; HF with preserved EF (HFpEF): HF with an LVEF of {$\geq$}50\%; and HF with improved EF (HFimpEF): HF with a baseline LVEF of {$\leq$}40\%, a {$\geq$}10-point increase from baseline LVEF, and a second measurement of LVEF of {$>$}40\%.},
  langid = {english},
  pmid = {33663906},
  keywords = {definition of heart failure,Heart failure,heart failure with mid-range ejection fraction,heart failure with preserved ejection fraction,heart failure with reduced ejection fraction,improved ejection fraction,stages of heart failure}
}

@article{bragazziBurdenHeartFailure2021,
  title = {Burden of Heart Failure and Underlying Causes in 195 Countries and Territories from 1990 to 2017},
  author = {Bragazzi, Nicola Luigi and Zhong, Wen and Shu, Jingxian and Abu Much, Arsalan and Lotan, Dor and Grupper, Avishay and Younis, Arwa and Dai, Haijiang},
  year = {2021},
  month = dec,
  journal = {European Journal of Preventive Cardiology},
  volume = {28},
  number = {15},
  pages = {1682--1690},
  issn = {2047-4881},
  doi = {10.1093/eurjpc/zwaa147},
  abstract = {AIMS: To provide the first systematic analysis of the burden and underlying causes of heart failure (HF) in 195 countries and territories from 1990 to 2017. METHODS AND RESULTS: We collected detailed information on prevalence, years lived with disability (YLDs), and underlying causes of HF from the Global Burden of Disease study 2017. Numbers and age-standardized rates of HF prevalence and YLDs were compared by age, sex, socio-demographic index (SDI), and location. The proportions of HF age-standardized prevalence rates due to 23 underlying causes were also presented. Globally, the age-standardized prevalence and YLD rates of HF in 2017 were 831.0 and 128.2 per 100~000 people, a decrease of -7.2\% and -0.9\% from 1990, respectively. Nevertheless, the absolute numbers of HF prevalent cases and YLDs have increased by 91.9\% and 106.0\% from 1990, respectively. There is significant geographic and socio-demographic variation in the levels and trends of HF burden from 1990 to 2017. Among all causes of HF, ischaemic heart disease accounted for the highest proportion (26.5\%) of age-standardized prevalence rate of HF in 2017, followed by hypertensive heart disease (26.2\%), chronic obstructive pulmonary disease (23.4\%). CONCLUSION: HF remains a serious public health problem worldwide, with increasing age-standardized prevalence and YLD rates in countries with relatively low SDI. More geo-specific strategies aimed at preventing underlying causes and improving medical care for HF are warranted to reduce the future burden of this condition.},
  langid = {english},
  pmid = {33571994},
  keywords = {Cause,Global,Global Burden of Disease,Heart failure,Heart Failure,Humans,Prevalence,Quality-Adjusted Life Years,Risk Factors,Year lived with disability},
  file = {/Users/xx20081/Zotero/storage/AAT6AT2G/Bragazzi et al. - 2021 - Burden of heart failure and underlying causes in 1.pdf}
}

@article{brionesAdipocytesProduceAldosterone2012,
  title = {Adipocytes Produce Aldosterone through Calcineurin-Dependent Signaling Pathways: Implications in Diabetes Mellitus-Associated Obesity and Vascular Dysfunction},
  shorttitle = {Adipocytes Produce Aldosterone through Calcineurin-Dependent Signaling Pathways},
  author = {Briones, Ana M. and Nguyen Dinh Cat, Aurelie and Callera, Glaucia E. and Yogi, Alvaro and Burger, Dylan and He, Ying and Corr{\^e}a, Jose W. and Gagnon, Anne Marie and {Gomez-Sanchez}, Celso E. and {Gomez-Sanchez}, Elise P. and Sorisky, Alexander and Ooi, Teik Chye and Ruzicka, Marcel and Burns, Kevin D. and Touyz, Rhian M.},
  year = {2012},
  month = may,
  journal = {Hypertension (Dallas, Tex.: 1979)},
  volume = {59},
  number = {5},
  pages = {1069--1078},
  issn = {1524-4563},
  doi = {10.1161/HYPERTENSIONAHA.111.190223},
  abstract = {We reported aldosterone as a novel adipocyte-derived factor that regulates vascular function. We aimed to investigate molecular mechanisms, signaling pathways, and functional significance of adipocyte-derived aldosterone and to test whether adipocyte-derived aldosterone is increased in diabetes mellitus-associated obesity, which contributes to vascular dysfunction. Studies were performed in the 3T3-L1 adipocyte cell line and mature adipocytes isolated from human and mouse (C57BL/6J) adipose tissue. Mesenteric arteries with and without perivascular fat and mature adipocytes were obtained from obese diabetic db/db and control db/+ mice. Aldosterone synthase (CYP11B2; mRNA and protein) was detected in 3T3-L1 and mature adipocytes, which secrete aldosterone basally and in response to angiotensin II (Ang II). In 3T3-L1 adipocytes, Ang II stimulation increased aldosterone secretion and CYP11B2 expression. Ang II effects were blunted by an Ang II type 1 receptor antagonist (candesartan) and inhibitors of calcineurin (cyclosporine A and FK506) and nuclear factor of activated T-cells (VIVIT). FAD286 (aldosterone synthase inhibitor) blunted adipocyte differentiation. In candesartan-treated db/db mice (1 mg/kg per day, 4 weeks) increased plasma aldosterone, CYP11B2 expression, and aldosterone secretion were reduced. Acetylcholine-induced relaxation in db/db mesenteric arteries containing perivascular fat was improved by eplerenone (mineralocorticoid receptor antagonist) without effect in db/+ mice. Adipocytes possess aldosterone synthase and produce aldosterone in an Ang II/Ang II type 1 receptor/calcineurin/nuclear factor of activated T-cells-dependent manner. Functionally adipocyte-derived aldosterone regulates adipocyte differentiation and vascular function in an autocrine and paracrine manner, respectively. These novel findings identify adipocytes as a putative link between aldosterone and vascular dysfunction in diabetes mellitus-associated obesity.},
  langid = {english},
  pmid = {22493070},
  keywords = {Adipocytes,Aldosterone,Animals,Benzimidazoles,Biphenyl Compounds,Calcineurin,Cells Cultured,Diabetes Complications,Diabetic Angiopathies,Disease Models Animal,Humans,Mice,Mice Inbred C57BL,Obesity,Random Allocation,Sensitivity and Specificity,Signal Transduction,Tetrazoles}
}

@techreport{brotmanAdiposeTissueEQTL2023,
  type = {Preprint},
  title = {Adipose Tissue {{eQTL}} Meta-Analysis Reveals the Contribution of Allelic Heterogeneity to Gene Expression Regulation and Cardiometabolic Traits},
  author = {Brotman, Sarah M. and {El-Sayed Moustafa}, Julia S. and Guan, Li and Broadaway, K. Alaine and Wang, Dongmeng and Jackson, Anne U. and Welch, Ryan and Currin, Kevin W. and Tomlinson, Max and Vadlamudi, Swarooparani and Stringham, Heather M. and Roberts, Amy L. and Lakka, Timo A. and Oravilahti, Anniina and Silva, Lilian Fernandes and Narisu, Narisu and Erdos, Michael R. and Yan, Tingfen and Bonnycastle, Lori L. and Raulerson, Chelsea K. and Raza, Yasrab and Yan, Xinyu and Parker, Stephen C.J. and Kuusisto, Johanna and Pajukanta, P{\"a}ivi and Tuomilehto, Jaakko and Collins, Francis S. and Boehnke, Michael and Love, Michael I. and Koistinen, Heikki A. and Laakso, Markku and Mohlke, Karen L. and Small, Kerrin S. and Scott, Laura J.},
  year = {2023},
  month = oct,
  institution = {Genomics},
  doi = {10.1101/2023.10.26.563798},
  urldate = {2024-02-04},
  abstract = {Abstract           Complete characterization of the genetic effects on gene expression is needed to elucidate tissue biology and the etiology of complex traits. Here, we analyzed 2,344 subcutaneous adipose tissue samples and identified 34K conditionally distinct expression quantitative trait locus (eQTL) signals in 18K genes. Over half of eQTL genes exhibited at least two eQTL signals. Compared to primary signals, non-primary signals had lower effect sizes, lower minor allele frequencies, and less promoter enrichment; they corresponded to genes with higher heritability and higher tolerance for loss of function. Colocalization of eQTL with conditionally distinct genome-wide association study signals for 28 cardiometabolic traits identified 3,605 eQTL signals for 1,861 genes. Inclusion of non-primary eQTL signals increased colocalized signals by 46\%. Among 30 genes with {$\geq$}2 pairs of colocalized signals, 21 showed a mediating gene dosage effect on the trait. Thus, expanded eQTL identification reveals more mechanisms underlying complex traits and improves understanding of the complexity of gene expression regulation.},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/XDSPXKKW/Brotman et al. - 2023 - Adipose tissue eQTL meta-analysis reveals the cont.pdf}
}

@misc{brotmanAdiposeTissueEQTL2023a,
  title = {Adipose Tissue {{eQTL}} Meta-Analysis Reveals the Contribution of Allelic Heterogeneity to Gene Expression Regulation and Cardiometabolic Traits},
  author = {Brotman, Sarah M. and Moustafa, Julia S. El-Sayed and Guan, Li and Broadaway, K. Alaine and Wang, Dongmeng and Jackson, Anne U. and Welch, Ryan and Currin, Kevin W. and Tomlinson, Max and Vadlamudi, Swarooparani and Stringham, Heather M. and Roberts, Amy L. and Lakka, Timo A. and Oravilahti, Anniina and Silva, Lilian Fernandes and Narisu, Narisu and Erdos, Michael R. and Yan, Tingfen and Bonnycastle, Lori L. and Raulerson, Chelsea K. and Raza, Yasrab and Yan, Xinyu and Parker, Stephen C. J. and Kuusisto, Johanna and Pajukanta, P{\"a}ivi and Tuomilehto, Jaakko and Collins, Francis S. and Boehnke, Michael and Love, Michael I. and Koistinen, Heikki A. and Laakso, Markku and Mohlke, Karen L. and Small, Kerrin S. and Scott, Laura J.},
  year = {2023},
  month = oct,
  primaryclass = {New Results},
  pages = {2023.10.26.563798},
  publisher = {bioRxiv},
  doi = {10.1101/2023.10.26.563798},
  urldate = {2024-02-04},
  abstract = {Complete characterization of the genetic effects on gene expression is needed to elucidate tissue biology and the etiology of complex traits. Here, we analyzed 2,344 subcutaneous adipose tissue samples and identified 34K conditionally distinct expression quantitative trait locus (eQTL) signals in 18K genes. Over half of eQTL genes exhibited at least two eQTL signals. Compared to primary signals, non-primary signals had lower effect sizes, lower minor allele frequencies, and less promoter enrichment; they corresponded to genes with higher heritability and higher tolerance for loss of function. Colocalization of eQTL with conditionally distinct genome-wide association study signals for 28 cardiometabolic traits identified 3,605 eQTL signals for 1,861 genes. Inclusion of non-primary eQTL signals increased colocalized signals by 46\%. Among 30 genes with {$\geq$}2 pairs of colocalized signals, 21 showed a mediating gene dosage effect on the trait. Thus, expanded eQTL identification reveals more mechanisms underlying complex traits and improves understanding of the complexity of gene expression regulation.},
  archiveprefix = {bioRxiv},
  chapter = {New Results},
  copyright = {{\copyright} 2023, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/DUMZYHGU/Brotman et al. - 2023 - Adipose tissue eQTL meta-analysis reveals the cont.pdf}
}

@article{brownContributionAldosteroneCardiovascular2013,
  title = {Contribution of Aldosterone to Cardiovascular and Renal Inflammation and Fibrosis},
  author = {Brown, Nancy J.},
  year = {2013},
  month = aug,
  journal = {Nature Reviews. Nephrology},
  volume = {9},
  number = {8},
  pages = {459--469},
  issn = {1759-507X},
  doi = {10.1038/nrneph.2013.110},
  abstract = {The steroid hormone aldosterone regulates sodium and potassium homeostasis. Aldosterone and activation of the mineralocorticoid receptor also causes inflammation and fibrosis of the heart, fibrosis and remodelling of blood vessels and tubulointerstitial fibrosis and glomerular injury in the kidney. Aldosterone and mineralocorticoid-receptor activation initiate an inflammatory response by increasing the generation of reactive oxygen species by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and mitochondria. High salt intake potentiates these effects, in part by activating the Rho family member Rac1, a regulatory subunit of reduced NADPH oxidase that activates the mineralocorticoid receptor. Studies in mice in which the mineralocorticoid receptor has been deleted from specific cell types suggest a key role for macrophages in promoting inflammation and fibrosis. Aldosterone can exert mineralocorticoid-receptor-independent effects via the angiotensin II receptor and via G-protein-coupled receptor 30. Mineralocorticoid-receptor antagonists are associated with decreased mortality in patients with heart disease and show promise in patients with kidney injury, but can elevate serum potassium concentration. Studies in rodents genetically deficient in aldosterone synthase or treated with a pharmacological aldosterone-synthase inhibitor are providing insight into the relative contribution of aldosterone compared with the contribution of mineralocorticoid-receptor activation in inflammation, fibrosis, and injury. Aldosterone-synthase inhibitors are under development in humans.},
  langid = {english},
  pmcid = {PMC3922409},
  pmid = {23774812},
  keywords = {Aldosterone,Animals,Aromatase Inhibitors,Cardiovascular System,Cytochrome P-450 CYP11B2,Endothelial Cells,Fadrozole,Fibrosis,Humans,Imidazoles,Inflammation,Kidney,Macrophages,Mineralocorticoid Receptor Antagonists,Myocardium,Myocytes Cardiac,Pyridines,Reactive Oxygen Species,Receptors Mineralocorticoid,Sodium Dietary},
  file = {/Users/xx20081/Zotero/storage/S9NN9ZTS/Brown - 2013 - Contribution of aldosterone to cardiovascular and .pdf}
}

@article{burgessAddressingCredibilityCrisis2024,
  title = {Addressing the Credibility Crisis in {{Mendelian}} Randomization},
  author = {Burgess, Stephen and Woolf, Benjamin and Mason, Amy M. and {Ala-Korpela}, Mika and Gill, Dipender},
  year = {2024},
  month = sep,
  journal = {BMC Medicine},
  volume = {22},
  number = {1},
  pages = {374},
  issn = {1741-7015},
  doi = {10.1186/s12916-024-03607-5},
  urldate = {2025-03-22},
  abstract = {Genome-wide association studies have enabled Mendelian randomization analyses to be performed at an industrial scale. Two-sample summary data Mendelian randomization analyses can be performed using publicly available data by anyone who has access to the internet. While this has led to many insightful papers, it has also fuelled an explosion of poor-quality Mendelian randomization publications, which threatens to undermine the credibility of the whole approach.},
  keywords = {Bias evaluation,Causal inference,Evidence synthesis,Genetic epidemiology,Instrumental variables,Risk of bias},
  file = {/Users/xx20081/Zotero/storage/2PAX2Q3V/Burgess et al. - 2024 - Addressing the credibility crisis in Mendelian randomization.pdf;/Users/xx20081/Zotero/storage/R663AXZF/s12916-024-03607-5.html}
}

@article{burgessBiasDueParticipant2016,
  title = {Bias Due to Participant Overlap in Two-Sample {{Mendelian}} Randomization},
  author = {Burgess, Stephen and Davies, Neil M. and Thompson, Simon G.},
  year = {2016},
  month = nov,
  journal = {Genetic Epidemiology},
  volume = {40},
  number = {7},
  pages = {597--608},
  issn = {1098-2272},
  doi = {10.1002/gepi.21998},
  abstract = {Mendelian randomization analyses are often performed using summarized data. The causal estimate from a one-sample analysis (in which data are taken from a single data source) with weak instrumental variables is biased in the direction of the observational association between the risk factor and outcome, whereas the estimate from a two-sample analysis (in which data on the risk factor and outcome are taken from non-overlapping datasets) is less biased and any bias is in the direction of the null. When using genetic consortia that have partially overlapping sets of participants, the direction and extent of bias are uncertain. In this paper, we perform simulation studies to investigate the magnitude of bias and Type 1 error rate inflation arising from sample overlap. We consider both a continuous outcome and a case-control setting with a binary outcome. For a continuous outcome, bias due to sample overlap is a linear function of the proportion of overlap between the samples. So, in the case of a null causal effect, if the relative bias of the one-sample instrumental variable estimate is 10\% (corresponding to an F parameter of 10), then the relative bias with 50\% sample overlap is 5\%, and with 30\% sample overlap is 3\%. In a case-control setting, if risk factor measurements are only included for the control participants, unbiased estimates are obtained even in a one-sample setting. However, if risk factor data on both control and case participants are used, then bias is similar with a binary outcome as with a continuous outcome. Consortia releasing publicly available data on the associations of genetic variants with continuous risk factors should provide estimates that exclude case participants from case-control samples.},
  langid = {english},
  pmcid = {PMC5082560},
  pmid = {27625185},
  keywords = {aggregated data,Bias,Case-Control Studies,Genetic Variation,Humans,instrumental variables,Male,Mendelian randomization,Mendelian Randomization Analysis,Models Genetic,Risk Factors,summarized data,weak instrument bias},
  file = {/Users/xx20081/Zotero/storage/FVF3ILCU/Burgess et al. - 2016 - Bias due to participant overlap in two-sample Mend.pdf}
}

@article{burgessGeneticPredictorsTraits2024,
  title = {Genetic Predictors of Traits in Elderly Subjects: Risk of Survival Bias and Reverse Causation},
  shorttitle = {Genetic Predictors of Traits in Elderly Subjects},
  author = {Burgess, Stephen and Zhou, Ang},
  year = {2024},
  month = jun,
  journal = {European Heart Journal},
  volume = {45},
  number = {24},
  pages = {2155--2157},
  issn = {0195-668X},
  doi = {10.1093/eurheartj/ehae295},
  urldate = {2024-07-29},
  abstract = {This editorial refers to `Body mass index, waist circumference, and mortality in subjects older than 80 years: a Mendelian randomization study', by Y. Lv et al., https://doi.org/10.1093/eurheartj/ehae206.In their study, published in this issue of the European Heart Journal, Lv et al. examine the relationships of body mass index (BMI) and waist circumference with mortality outcomes in a dataset of elderly Chinese individuals using conventional and genetic epidemiological approaches.1 They show that higher BMI and higher waist circumference are associated with lower risk of mortality in observational analyses. In genetic analyses, higher genetically predicted BMI was associated with a lower risk of mortality, but higher genetically predicted waist circumference was associated with a higher risk of mortality. These results differ from most previous investigations into the relationship between body size and mortality.2 However, on closer inspection, there are clear reasons that lead to these discrepancies. First, the population in this study is elderly, with all participants being over 80 years old, with the mean participant age at 90.6 years. Second, the distribution of BMI is low, with \&gt;40\% of participants having a BMI \&lt;18.5\>kg/m2. While obesity is generally associated with higher mortality risk, several observational analyses have reported the lowest level of disease risk at {$\sim$}25\>kg/m2,3 which is towards the top end of the BMI distribution in the Chinese dataset. Hence, while this analysis indicates that high BMI is good and other analyses have indicated that high BMI is bad, the findings presented here do not contradict the overall observational picture for middle-aged healthy populations, which is a U-shaped relationship. This analysis provides important information to aid prediction of mortality in underweight elderly individuals, who will differ from middle-aged populations not only in the population distribution of BMI, but also in the ratios of lean mass and muscle mass to fat mass.},
  file = {/Users/xx20081/Zotero/storage/ZYE9LIBH/7683470.html}
}

@article{burgessSensitivityAnalysesRobust2017,
  title = {Sensitivity {{Analyses}} for {{Robust Causal Inference}} from {{Mendelian Randomization Analyses}} with {{Multiple Genetic Variants}}},
  author = {Burgess, Stephen and Bowden, Jack and Fall, Tove and Ingelsson, Erik and Thompson, Simon G.},
  year = {2017},
  month = jan,
  journal = {Epidemiology (Cambridge, Mass.)},
  volume = {28},
  number = {1},
  pages = {30--42},
  issn = {1531-5487},
  doi = {10.1097/EDE.0000000000000559},
  abstract = {Mendelian randomization investigations are becoming more powerful and simpler to perform, due to the increasing size and coverage of genome-wide association studies and the increasing availability of summarized data on genetic associations with risk factors and disease outcomes. However, when using multiple genetic variants from different gene regions in a Mendelian randomization analysis, it is highly implausible that all the genetic variants satisfy the instrumental variable assumptions. This means that a simple instrumental variable analysis alone should not be relied on to give a causal conclusion. In this article, we discuss a range of sensitivity analyses that will either support or question the validity of causal inference from a Mendelian randomization analysis with multiple genetic variants. We focus on sensitivity analyses of greatest practical relevance for ensuring robust causal inferences, and those that can be undertaken using summarized data. Aside from cases in which the justification of the instrumental variable assumptions is supported by strong biological understanding, a Mendelian randomization analysis in which no assessment of the robustness of the findings to violations of the instrumental variable assumptions has been made should be viewed as speculative and incomplete. In particular, Mendelian randomization investigations with large numbers of genetic variants without such sensitivity analyses should be treated with skepticism.},
  langid = {english},
  pmcid = {PMC5133381},
  pmid = {27749700},
  keywords = {C-Reactive Protein,Causality,Coronary Artery Disease,Genetic Variation,Genome-Wide Association Study,Humans,Mendelian Randomization Analysis,Odds Ratio,Reproducibility of Results},
  file = {/Users/xx20081/Zotero/storage/RPNYHT5X/Burgess et al. - 2017 - Sensitivity Analyses for Robust Causal Inference f.pdf}
}

@article{burgosObesityParadoxCardiac2021,
  title = {Is the {{Obesity Paradox}} in {{Cardiac Surgery Really}} a {{Myth}}? {{Effect}} of {{Body Mass Index}} on {{Early}} and {{Late Clinical Outcomes}}},
  shorttitle = {Is the {{Obesity Paradox}} in {{Cardiac Surgery Really}} a {{Myth}}?},
  author = {Burgos, Lucrecia Mar{\'i}a and Ram{\'i}rez, Andreina Gil and Seoane, Leonardo and Espinoza, Juan and Furmento, Juan Francisco and Costabel, Juan Pablo and Benzad{\'o}n, Mariano and Navia, Daniel},
  year = {2021},
  month = feb,
  journal = {Journal of Cardiothoracic and Vascular Anesthesia},
  volume = {35},
  number = {2},
  pages = {492--498},
  publisher = {Elsevier},
  issn = {1053-0770, 1532-8422},
  doi = {10.1053/j.jvca.2020.03.051},
  urldate = {2024-08-22},
  langid = {english},
  pmid = {32423731},
  keywords = {body mass index,cardiac surgery,mortality,obesity,risk factors}
}

@article{burgosObesityParadoxCardiac2021a,
  title = {Is the {{Obesity Paradox}} in {{Cardiac Surgery Really}} a {{Myth}}? {{Effect}} of {{Body Mass Index}} on {{Early}} and {{Late Clinical Outcomes}}},
  shorttitle = {Is the {{Obesity Paradox}} in {{Cardiac Surgery Really}} a {{Myth}}?},
  author = {Burgos, {\relax LM} and A, Gil Ram{\'i}rez and L, Seoane and J, Espinoza and Jf, Furmento and Jp, Costabel and M, Benzad{\'o}n and D, Navia},
  year = {2021},
  month = feb,
  journal = {Journal of cardiothoracic and vascular anesthesia},
  volume = {35},
  number = {2},
  publisher = {J Cardiothorac Vasc Anesth},
  issn = {1532-8422},
  doi = {10.1053/j.jvca.2020.03.051},
  urldate = {2024-08-22},
  abstract = {OW patients had a lower mortality and better outcomes after cardiac surgery. However, when other preoperative variables were taken into account, BMI did not have independent effect on in-hospital and 1-year mortality.},
  langid = {english},
  pmid = {32423731},
  file = {/Users/xx20081/Zotero/storage/IJ3JCGX4/Burgos et al. - 2021 - Is the Obesity Paradox in Cardiac Surgery Really a.pdf;/Users/xx20081/Zotero/storage/W5IKUYGP/32423731.html}
}

@article{burmeisterHypothalamicGlucagonLikePeptide2017,
  title = {The {{Hypothalamic Glucagon-Like Peptide}} 1 {{Receptor Is Sufficient}} but {{Not Necessary}} for the {{Regulation}} of {{Energy Balance}} and {{Glucose Homeostasis}} in {{Mice}}},
  author = {Burmeister, Melissa A. and Ayala, Jennifer E. and Smouse, Hannah and {Landivar-Rocha}, Adriana and Brown, Jacob D. and Drucker, Daniel J. and Stoffers, Doris A. and Sandoval, Darleen A. and Seeley, Randy J. and Ayala, Julio E.},
  year = {2017},
  month = feb,
  journal = {Diabetes},
  volume = {66},
  number = {2},
  pages = {372--384},
  issn = {0012-1797},
  doi = {10.2337/db16-1102},
  urldate = {2024-08-15},
  abstract = {Pharmacological activation of the hypothalamic glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) promotes weight loss and improves glucose tolerance. This demonstrates that the hypothalamic GLP-1R is sufficient but does not show whether it is necessary for the effects of exogenous GLP-1R agonists (GLP-1RA) or endogenous GLP-1 on these parameters. To address this, we crossed mice harboring floxed Glp1r alleles to mice expressing Nkx2.1-Cre to knock down Glp1r expression throughout the hypothalamus (GLP-1RKD{$\Delta$}Nkx2.1cre). We also generated mice lacking Glp1r expression specifically in two GLP-1RA--responsive hypothalamic feeding nuclei/cell types, the paraventricular nucleus (GLP-1RKD{$\Delta$}Sim1cre) and proopiomelanocortin neurons (GLP-1RKD{$\Delta$}POMCcre). Chow-fed GLP-1RKD{$\Delta$}Nkx2.1cre mice exhibited increased food intake and energy expenditure with no net effect on body weight. When fed a high-fat diet, these mice exhibited normal food intake but elevated energy expenditure, yielding reduced weight gain. None of these phenotypes were observed in GLP-1RKD{$\Delta$}Sim1cre and GLP-1RKD{$\Delta$}POMCcre mice. The acute anorectic and glucose tolerance effects of peripherally dosed GLP-1RA exendin-4 and liraglutide were preserved in all mouse lines. Chronic liraglutide treatment reduced body weight in chow-fed GLP-1RKD{$\Delta$}Nkx2.1cre mice, but this effect was attenuated with high-fat diet feeding. In sum, classic homeostatic control regions are sufficient but not individually necessary for the effects of GLP-1RA on nutrient homeostasis.},
  pmcid = {PMC5248999},
  pmid = {27908915},
  file = {/Users/xx20081/Zotero/storage/7MKF9WR6/Burmeister et al. - 2017 - The Hypothalamic Glucagon-Like Peptide 1 Receptor .pdf}
}

@article{Butler2017,
  title = {Efficacy and Safety of Spironolactone in Acute Heart Failure: {{The ATHENA-HF}} Randomized Clinical Trial},
  author = {Butler, Javed and Anstrom, Kevin J. and Felker, G. Michael and Givertz, Michael M. and Kalogeropoulos, Andreas P. and Konstam, Marvin A. and Mann, Douglas L. and Margulies, Kenneth B. and McNulty, Steven E. and Mentz, Robert J. and Redfield, Margaret M. and Tang, W. H.Wilson and Whellan, David J. and Shah, Monica and {Desvigne-Nickens}, Patrice and Hernandez, Adrian F. and Braunwald, Eugene},
  year = {2017},
  month = sep,
  journal = {JAMA cardiology},
  volume = {2},
  number = {9},
  pages = {950--958},
  publisher = {JAMA Cardiol},
  issn = {2380-6591},
  doi = {10.1001/JAMACARDIO.2017.2198},
  abstract = {IMPORTANCE: Persistent congestion is associated with worse outcomes in acute heart failure (AHF). Mineralocorticoid receptor antagonists administered at high doses may relieve congestion, overcome diuretic resistance, and mitigate the effects of adverse neurohormonal activation in AHF. OBJECTIVE: To assess the effect of high-dose spironolactone and usual care on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared with usual care alone. DESIGN, SETTING, AND PARTICIPANTS: This double-blind and placebo (or low-dose)-controlled randomized clinical trial was conducted in 22 US acute care hospitals among patients with AHF who were previously receiving no or low-dose (12.5 mg or 25 mg daily) spironolactone and had NT-proBNP levels of 1000 pg/mL or more or B-type natriuretic peptide levels of 250 pg/mL or more, regardless of ejection fraction. INTERVENTIONS: High-dose spironolactone (100 mg) vs placebo or 25 mg spironolactone (usual care) daily for 96 hours MAIN OUTCOMES AND MEASURES: The primary end point was the change in NT-proBNP levels from baseline to 96 hours. Secondary end points included the clinical congestion score, dyspnea assessment, net urine output, and net weight change. Safety end points included hyperkalemia and changes in renal function. RESULTS: A total of 360 patients were randomized, of whom the median age was 65 years, 129 (36\%) were women, 200 (55.5\%) were white, 151 (42\%) were black, 8 (2\%) were Hispanic or Latino, 9 (2.5\%) were of other race/ethnicity, and the median left ventricular ejection fraction was 34\%. Baseline median (interquartile range) NT-proBNP levels were 4601 (2697-9596) pg/mL among the group treated with high-dose spironolactone and 3753 (1968-7633) pg/mL among the group who received usual care. There was no significant difference in the log NT-proBNP reduction between the 2 groups (-0.55 [95\% CI, -0.92 to -0.18] with high-dose spironolactone and -0.49 [95\% CI, -0.98 to -0.14] with usual care, P = .57). None of the secondary end point or day-30 all-cause mortality or heart failure hospitalization rate differed between the 2 groups. The changes in serum potassium and estimated glomerular filtration rate at 24, 48, 72, and 96 hours. were similar between the 2 groups. CONCLUSIONS AND RELEVANCE: Adding treatment with high-dose spironolactone to usual care for patients with AHF for 96 hours was well tolerated but did not improve the primary or secondary efficacy end points. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02235077.},
  pmid = {28700781},
  keywords = {Acute Disease,affs=[]),Aged,Brain / blood*,CollabAuthor(name='National Heart Lung and Blood Institute Heart Failure Clinical Research Network',doi:10.1001/jamacardio.2017.2198,Dose-Response Relationship,Double-Blind Method,Drug,Extramural,Female,Heart Failure / blood,Heart Failure / drug therapy*,Heart Failure / physiopathology,Hospitalization,Humans,investigators=[],Javed Butler,Kevin J Anstrom,Male,MEDLINE,Middle Aged,Mineralocorticoid Receptor Antagonists / administration & dosage*,Mineralocorticoid Receptor Antagonists / therapeutic use,Mortality,N.I.H.,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,Natriuretic Peptide,NCBI,NIH,NLM,Peptide Fragments / blood*,PMC5675712,pmid:28700781,PubMed Abstract,Randomized Controlled Trial,Research Support,Spironolactone / administration & dosage*,Spironolactone / therapeutic use,Stroke Volume}
}

@article{buttAnthropometricMeasuresAdverse2023,
  title = {Anthropometric Measures and Adverse Outcomes in Heart Failure with Reduced Ejection Fraction: Revisiting the Obesity Paradox},
  shorttitle = {Anthropometric Measures and Adverse Outcomes in Heart Failure with Reduced Ejection Fraction},
  author = {Butt, Jawad H and Petrie, Mark C and Jhund, Pardeep S and Sattar, Naveed and Desai, Akshay S and K{\o}ber, Lars and Rouleau, Jean L and Swedberg, Karl and Zile, Michael R and Solomon, Scott D and Packer, Milton and McMurray, John J V},
  year = {2023},
  month = mar,
  journal = {European Heart Journal},
  volume = {44},
  number = {13},
  pages = {1136--1153},
  issn = {0195-668X},
  doi = {10.1093/eurheartj/ehad083},
  urldate = {2024-01-16},
  abstract = {Structured Graphical AbstractThe upper part of the figure describes the calculation of each of the anthropometric measures. The lower part of the figure shows the risk of outcomes according to continuous body mass index (left panel) and waist-to-height ratio (right panel). The solid line represents the hazard ratio and the shaded area the 95\% confidence interval. The blue spline is adjusted for treatment and region. The red spline is adjusted for treatment, age, sex, region, systolic blood pressure, heart rate, estimated glomerular filtration rate, left ventricular ejection fraction, log of n-terminal pro-B-type natriuretic peptide, body mass index (only in the waist-to-height ratio analyses), New York Heart Association functional class, heart failure aetiology, duration of heart failure, prior heart failure hospitalization, a history of diabetes, and atrial fibrillation. BMI, body mass index; BRI, body roundness index; BSA, body surface area; BSI, body shape index; CI, confidence interval; HF, heart failure; HR, hazard ratio; RFM, relative fat mass; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio; WWI, weight-adjusted-waist index.},
  pmcid = {PMC10111968},
  pmid = {36944496},
  file = {/Users/xx20081/Zotero/storage/9VHJGDEY/Butt et al. - 2023 - Anthropometric measures and adverse outcomes in he.pdf}
}

@article{buttAnthropometricMeasuresAdverse2023a,
  title = {Anthropometric Measures and Adverse Outcomes in Heart Failure with Reduced Ejection Fraction: Revisiting the Obesity Paradox},
  shorttitle = {Anthropometric Measures and Adverse Outcomes in Heart Failure with Reduced Ejection Fraction},
  author = {Butt, Jawad H and Petrie, Mark C and Jhund, Pardeep S and Sattar, Naveed and Desai, Akshay S and K{\o}ber, Lars and Rouleau, Jean L and Swedberg, Karl and Zile, Michael R and Solomon, Scott D and Packer, Milton and McMurray, John J V},
  year = {2023},
  month = apr,
  journal = {European Heart Journal},
  volume = {44},
  number = {13},
  pages = {1136--1153},
  issn = {0195-668X},
  doi = {10.1093/eurheartj/ehad083},
  urldate = {2024-01-18},
  abstract = {Although body mass index (BMI) is the most commonly used anthropometric measure, newer indices such as the waist-to-height ratio, better reflect the location and amount of ectopic fat, as well as the weight of the skeleton, and may be more useful.The prognostic value of several newer anthropometric indices was compared with that of BMI in patients with heart failure (HF) and reduced ejection fraction (HFrEF) enrolled in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure. The primary outcome was HF hospitalization or cardiovascular death. The association between anthropometric indices and outcomes were comprehensively adjusted for other prognostic variables, including natriuretic peptides. An `obesity-survival paradox' related to lower mortality risk in those with BMI {$\geq$}25 kg/m2 (compared with normal weight) was identified but this was eliminated by adjustment for other prognostic variables. This paradox was less evident for waist-to-height ratio (as an exemplar of indices not incorporating weight) and eliminated by adjustment: the adjusted hazard ratio (aHR) for all-cause mortality, for quintile 5 vs. quintile 1, was 1.10 [95\% confidence interval (CI) 0.87--1.39]. However, both BMI and waist-to-height ratio showed that greater adiposity was associated with a higher risk of the primary outcome and HF hospitalization; this was more evident for waist-to-height ratio and persisted after adjustment e.g. the aHR for HF hospitalization for quintile 5 vs. quintile 1 of waist-to-height ratio was 1.39 (95\% CI 1.06--1.81).In patients with HFrEF, alternative anthropometric measurements showed no evidence for an `obesity-survival paradox'. Newer indices that do not incorporate weight showed that greater adiposity was clearly associated with a higher risk of HF hospitalization.},
  file = {/Users/xx20081/Zotero/storage/TJE6G7SU/Butt et al. - 2023 - Anthropometric measures and adverse outcomes in he.pdf}
}

@article{buttAnthropometricMeasuresAdverse2023b,
  title = {Anthropometric Measures and Adverse Outcomes in Heart Failure with Reduced Ejection Fraction: Revisiting the Obesity Paradox},
  shorttitle = {Anthropometric Measures and Adverse Outcomes in Heart Failure with Reduced Ejection Fraction},
  author = {Butt, Jawad H and Petrie, Mark C and Jhund, Pardeep S and Sattar, Naveed and Desai, Akshay S and K{\o}ber, Lars and Rouleau, Jean L and Swedberg, Karl and Zile, Michael R and Solomon, Scott D and Packer, Milton and McMurray, John J V},
  year = {2023},
  month = apr,
  journal = {European Heart Journal},
  volume = {44},
  number = {13},
  pages = {1136--1153},
  issn = {0195-668X},
  doi = {10.1093/eurheartj/ehad083},
  urldate = {2024-01-18},
  abstract = {Although body mass index (BMI) is the most commonly used anthropometric measure, newer indices such as the waist-to-height ratio, better reflect the location and amount of ectopic fat, as well as the weight of the skeleton, and may be more useful.The prognostic value of several newer anthropometric indices was compared with that of BMI in patients with heart failure (HF) and reduced ejection fraction (HFrEF) enrolled in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure. The primary outcome was HF hospitalization or cardiovascular death. The association between anthropometric indices and outcomes were comprehensively adjusted for other prognostic variables, including natriuretic peptides. An `obesity-survival paradox' related to lower mortality risk in those with BMI {$\geq$}25 kg/m2 (compared with normal weight) was identified but this was eliminated by adjustment for other prognostic variables. This paradox was less evident for waist-to-height ratio (as an exemplar of indices not incorporating weight) and eliminated by adjustment: the adjusted hazard ratio (aHR) for all-cause mortality, for quintile 5 vs. quintile 1, was 1.10 [95\% confidence interval (CI) 0.87--1.39]. However, both BMI and waist-to-height ratio showed that greater adiposity was associated with a higher risk of the primary outcome and HF hospitalization; this was more evident for waist-to-height ratio and persisted after adjustment e.g. the aHR for HF hospitalization for quintile 5 vs. quintile 1 of waist-to-height ratio was 1.39 (95\% CI 1.06--1.81).In patients with HFrEF, alternative anthropometric measurements showed no evidence for an `obesity-survival paradox'. Newer indices that do not incorporate weight showed that greater adiposity was clearly associated with a higher risk of HF hospitalization.}
}

@article{by-band-sleevecollaborativegroupRouxenYGastricBypass2023,
  title = {Roux-En-{{Y}} Gastric Bypass, Gastric Banding, or Sleeve Gastrectomy for Severe Obesity: {{Baseline}} Data from the {{By-Band-Sleeve}} Randomized Controlled Trial},
  shorttitle = {Roux-En-{{Y}} Gastric Bypass, Gastric Banding, or Sleeve Gastrectomy for Severe Obesity},
  author = {{By-Band-Sleeve Collaborative Group}},
  year = {2023},
  month = may,
  journal = {Obesity (Silver Spring, Md.)},
  volume = {31},
  number = {5},
  pages = {1290--1299},
  issn = {1930-739X},
  doi = {10.1002/oby.23746},
  abstract = {OBJECTIVE: This paper reports~the study design, participant characteristics, and recruitment results of By-Band-Sleeve, which investigated the clinical and cost-effectiveness of gastric bypass, gastric banding, and sleeve gastrectomy in adults with severe obesity in the UK. METHODS: A pragmatic open adaptive noninferiority trial with 3-year follow-up was conducted. Participants were randomly assigned to bypass or band initially and to sleeve after the adaptation. Co-primary end points are weight loss and health-related quality of life assessed using the EQ-5D utility index. RESULTS: Between December 2012 and August 2015, the study recruited into two groups and, after the adaptation, into three groups until September 2019. The study screened 6960 patients; 4732 (68\%) were eligible and 1351 (29\%) were randomized; 5 subsequently withdrew consent to use data, leaving 462, 464, and 420 assigned to bypass, band, and sleeve, respectively. Baseline data showed high levels of obesity (mean BMI~=~46.4~kg/m2; SD: 6.9) and comorbidities (e.g., 31\% diabetes), low scores for health-related quality of life, and high levels of anxiety and depression (e.g., 25\% abnormal scores). Nutritional parameters were poor, and the average equivalized household income was low ({\pounds}16,667). CONCLUSIONS: By-Band-Sleeve fully recruited. Participant characteristics are consistent with contemporary patients having bariatric surgery, and therefore the results will be generalizable.},
  langid = {english},
  pmid = {37140395},
  keywords = {Adult,Bariatric Surgery,Gastrectomy,Gastric Bypass,Gastroplasty,Humans,Laparoscopy,Obesity Morbid,Quality of Life,Treatment Outcome},
  file = {/Users/xx20081/Zotero/storage/IIHAM74U/By-Band-Sleeve Collaborative Group - 2023 - Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy for severe obesity Baseline data f.pdf}
}

@article{caiAdjustingColliderBias2022,
  title = {Adjusting for Collider Bias in Genetic Association Studies Using Instrumental Variable Methods},
  author = {Cai, Siyang and Hartley, April and Mahmoud, Osama and Tilling, Kate and Dudbridge, Frank},
  year = {2022},
  month = jul,
  journal = {Genetic Epidemiology},
  volume = {46},
  number = {5-6},
  pages = {303--316},
  issn = {1098-2272},
  doi = {10.1002/gepi.22455},
  abstract = {Genome-wide association studies have provided many genetic markers that can be used as instrumental variables to adjust for confounding in epidemiological studies. Recently, the principle has been applied to other forms of bias in observational studies, especially collider bias that arises when conditioning or stratifying on a variable that is associated with the outcome of interest. An important case is in studies of disease progression and survival. Here, we clarify the links between the genetic instrumental variable methods proposed for this problem and the established methods of Mendelian randomisation developed to account for confounding. We highlight the critical importance of weak instrument bias in this context and describe a corrected weighted least-squares procedure as a simple approach to reduce this bias. We illustrate the range of available methods on two data examples. The first, waist-hip ratio adjusted for body-mass index, entails statistical adjustment for a quantitative trait. The second, smoking cessation, is a stratified analysis conditional on having initiated smoking. In both cases, we find little effect of collider bias on the primary association results, but this may propagate into more substantial effects on further analyses such as polygenic risk scoring and Mendelian randomisation.},
  langid = {english},
  pmcid = {PMC9544531},
  pmid = {35583096},
  keywords = {ascertainment bias,Bias,Genome-Wide Association Study,Humans,index event bias,Least-Squares Analysis,Mendelian randomisation,Mendelian Randomization Analysis,selection bias,Waist-Hip Ratio},
  file = {/Users/xx20081/Zotero/storage/QXC5MJFQ/Cai et al. - 2022 - Adjusting for collider bias in genetic association.pdf}
}

@article{cappolaLossoffunctionDNASequence2011,
  title = {Loss-of-Function {{DNA}} Sequence Variant in the {{CLCNKA}} Chloride Channel Implicates the Cardio-Renal Axis in Interindividual Heart Failure Risk Variation},
  author = {Cappola, Thomas P. and Matkovich, Scot J. and Wang, Wei and {van Booven}, Derek and Li, Mingyao and Wang, Xuexia and Qu, Liming and Sweitzer, Nancy K. and Fang, James C. and Reilly, Muredach P. and Hakonarson, Hakon and Nerbonne, Jeanne M. and Dorn, Gerald W.},
  year = {2011},
  month = feb,
  journal = {Proceedings of the National Academy of Sciences of the United States of America},
  volume = {108},
  number = {6},
  pages = {2456--2461},
  issn = {1091-6490},
  doi = {10.1073/pnas.1017494108},
  abstract = {Common heart failure has a strong undefined heritable component. Two recent independent cardiovascular SNP array studies identified a common SNP at 1p36 in intron 2 of the HSPB7 gene as being associated with heart failure. HSPB7 resequencing identified other risk alleles but no functional gene variants. Here, we further show no effect of the HSPB7 SNP on cardiac HSPB7 mRNA levels or splicing, suggesting that the SNP marks the position of a functional variant in another gene. Accordingly, we used massively parallel platforms to resequence all coding exons of the adjacent CLCNKA gene, which encodes the K(a) renal chloride channel (ClC-K(a)). Of 51 exonic CLCNKA variants identified, one SNP (rs10927887, encoding Arg83Gly) was common, in linkage disequilibrium with the heart failure risk SNP in HSPB7, and associated with heart failure in two independent Caucasian referral populations (n = 2,606 and 1,168; combined P = 2.25 {\texttimes} 10(-6)). Individual genotyping of rs10927887 in the two study populations and a third independent heart failure cohort (combined n = 5,489) revealed an additive allele effect on heart failure risk that is independent of age, sex, and prior hypertension (odds ratio = 1.27 per allele copy; P = 8.3 {\texttimes} 10(-7)). Functional characterization of recombinant wild-type Arg83 and variant Gly83 ClC-K(a) chloride channel currents revealed {$\approx$} 50\% loss-of-function of the variant channel. These findings identify a common, functionally significant genetic risk factor for Caucasian heart failure. The variant CLCNKA risk allele, telegraphed by linked variants in the adjacent HSPB7 gene, uncovers a previously overlooked genetic mechanism affecting the cardio-renal axis.},
  langid = {english},
  pmcid = {PMC3038744},
  pmid = {21248228},
  keywords = {Alleles,Amino Acid Substitution,Chloride Channels,Cohort Studies,Exons,Female,Genotype,Heart Failure,HSP27 Heat-Shock Proteins,Humans,Kidney,Male,Mutation Missense,Myocardium,Polymorphism Single Nucleotide,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/5WJWZ8BG/Cappola et al. - 2011 - Loss-of-function DNA sequence variant in the CLCNK.pdf}
}

@article{carboneObesityHeartFailure2017,
  title = {Obesity and {{Heart Failure}}: {{Focus}} on the {{Obesity Paradox}}},
  shorttitle = {Obesity and {{Heart Failure}}},
  author = {Carbone, Salvatore and Lavie, Carl J. and Arena, Ross},
  year = {2017},
  month = feb,
  journal = {Mayo Clinic Proceedings},
  volume = {92},
  number = {2},
  pages = {266--279},
  publisher = {Elsevier},
  issn = {0025-6196, 1942-5546},
  doi = {10.1016/j.mayocp.2016.11.001},
  urldate = {2024-08-06},
  langid = {english},
  pmid = {28109619},
  keywords = {BMI,body mass index,cardiorespiratory fitness,cardiovascular disease,CRF,CVD,ET,exercise training,heart failure,HF,HF with preserved ejection fraction,HF with reduced ejection fraction,HFpEF,HFrEF,left ventricular,left ventricular ejection fraction,LV,LVEF,minute ventilation/carbon dioxide production,NCD,noncommunicable disease,oxygen consumption,VE/VCO2,VO2},
  file = {/Users/xx20081/Zotero/storage/VY9QS5FI/Carbone et al. - 2017 - Obesity and Heart Failure Focus on the Obesity Pa.pdf}
}

@article{cardiogramplusc4dconsortiumLargescaleAssociationAnalysis2013,
  title = {Large-Scale Association Analysis Identifies New Risk Loci for Coronary Artery Disease},
  author = {{CARDIoGRAMplusC4D Consortium} and Deloukas, Panos and Kanoni, Stavroula and Willenborg, Christina and Farrall, Martin and Assimes, Themistocles L. and Thompson, John R. and Ingelsson, Erik and Saleheen, Danish and Erdmann, Jeanette and Goldstein, Benjamin A. and Stirrups, Kathleen and K{\"o}nig, Inke R. and Cazier, Jean-Baptiste and Johansson, Asa and Hall, Alistair S. and Lee, Jong-Young and Willer, Cristen J. and Chambers, John C. and Esko, T{\~o}nu and Folkersen, Lasse and Goel, Anuj and Grundberg, Elin and Havulinna, Aki S. and Ho, Weang K. and Hopewell, Jemma C. and Eriksson, Niclas and Kleber, Marcus E. and Kristiansson, Kati and Lundmark, Per and Lyytik{\"a}inen, Leo-Pekka and Rafelt, Suzanne and Shungin, Dmitry and Strawbridge, Rona J. and Thorleifsson, Gudmar and Tikkanen, Emmi and Van Zuydam, Natalie and Voight, Benjamin F. and Waite, Lindsay L. and Zhang, Weihua and Ziegler, Andreas and Absher, Devin and Altshuler, David and Balmforth, Anthony J. and Barroso, In{\^e}s and Braund, Peter S. and Burgdorf, Christof and {Claudi-Boehm}, Simone and Cox, David and Dimitriou, Maria and Do, Ron and {DIAGRAM Consortium} and {CARDIOGENICS Consortium} and Doney, Alex S. F. and El Mokhtari, NourEddine and Eriksson, Per and Fischer, Krista and Fontanillas, Pierre and {Franco-Cereceda}, Anders and Gigante, Bruna and Groop, Leif and Gustafsson, Stefan and Hager, J{\"o}rg and Hallmans, G{\"o}ran and Han, Bok-Ghee and Hunt, Sarah E. and Kang, Hyun M. and Illig, Thomas and Kessler, Thorsten and Knowles, Joshua W. and Kolovou, Genovefa and Kuusisto, Johanna and Langenberg, Claudia and Langford, Cordelia and Leander, Karin and Lokki, Marja-Liisa and Lundmark, Anders and McCarthy, Mark I. and Meisinger, Christa and Melander, Olle and Mihailov, Evelin and Maouche, Seraya and Morris, Andrew D. and {M{\"u}ller-Nurasyid}, Martina and {MuTHER Consortium} and Nikus, Kjell and Peden, John F. and Rayner, N. William and Rasheed, Asif and Rosinger, Silke and Rubin, Diana and Rumpf, Moritz P. and Sch{\"a}fer, Arne and Sivananthan, Mohan and Song, Ci and Stewart, Alexandre F. R. and Tan, Sian-Tsung and Thorgeirsson, Gudmundur and {van der Schoot}, C. Ellen and Wagner, Peter J. and {Wellcome Trust Case Control Consortium} and Wells, George A. and Wild, Philipp S. and Yang, Tsun-Po and Amouyel, Philippe and Arveiler, Dominique and Basart, Hanneke and Boehnke, Michael and Boerwinkle, Eric and Brambilla, Paolo and Cambien, Francois and Cupples, Adrienne L. and {de Faire}, Ulf and Dehghan, Abbas and Diemert, Patrick and Epstein, Stephen E. and Evans, Alun and Ferrario, Marco M. and Ferri{\`e}res, Jean and Gauguier, Dominique and Go, Alan S. and Goodall, Alison H. and Gudnason, Villi and Hazen, Stanley L. and Holm, Hilma and Iribarren, Carlos and Jang, Yangsoo and K{\"a}h{\"o}nen, Mika and Kee, Frank and Kim, Hyo-Soo and Klopp, Norman and Koenig, Wolfgang and Kratzer, Wolfgang and Kuulasmaa, Kari and Laakso, Markku and Laaksonen, Reijo and Lee, Ji-Young and Lind, Lars and Ouwehand, Willem H. and Parish, Sarah and Park, Jeong E. and Pedersen, Nancy L. and Peters, Annette and Quertermous, Thomas and Rader, Daniel J. and Salomaa, Veikko and Schadt, Eric and Shah, Svati H. and Sinisalo, Juha and Stark, Klaus and Stefansson, Kari and Tr{\'e}gou{\"e}t, David-Alexandre and Virtamo, Jarmo and Wallentin, Lars and Wareham, Nicholas and Zimmermann, Martina E. and Nieminen, Markku S. and Hengstenberg, Christian and Sandhu, Manjinder S. and Pastinen, Tomi and Syv{\"a}nen, Ann-Christine and Hovingh, G. Kees and Dedoussis, George and Franks, Paul W. and Lehtim{\"a}ki, Terho and Metspalu, Andres and Zalloua, Pierre A. and Siegbahn, Agneta and Schreiber, Stefan and Ripatti, Samuli and Blankenberg, Stefan S. and Perola, Markus and Clarke, Robert and Boehm, Bernhard O. and O'Donnell, Christopher and Reilly, Muredach P. and M{\"a}rz, Winfried and Collins, Rory and Kathiresan, Sekar and Hamsten, Anders and Kooner, Jaspal S. and Thorsteinsdottir, Unnur and Danesh, John and Palmer, Colin N. A. and Roberts, Robert and Watkins, Hugh and Schunkert, Heribert and Samani, Nilesh J.},
  year = {2013},
  month = jan,
  journal = {Nature Genetics},
  volume = {45},
  number = {1},
  pages = {25--33},
  issn = {1546-1718},
  doi = {10.1038/ng.2480},
  abstract = {Coronary artery disease (CAD) is the commonest cause of death. Here, we report an association analysis in 63,746 CAD cases and 130,681 controls identifying 15 loci reaching genome-wide significance, taking the number of susceptibility loci for CAD to 46, and a further 104 independent variants (r(2) {$<$} 0.2) strongly associated with CAD at a 5\% false discovery rate (FDR). Together, these variants explain approximately 10.6\% of CAD heritability. Of the 46 genome-wide significant lead SNPs, 12 show a significant association with a lipid trait, and 5 show a significant association with blood pressure, but none is significantly associated with diabetes. Network analysis with 233 candidate genes (loci at 10\% FDR) generated 5 interaction networks comprising 85\% of these putative genes involved in CAD. The four most significant pathways mapping to these networks are linked to lipid metabolism and inflammation, underscoring the causal role of these activities in the genetic etiology of CAD. Our study provides insights into the genetic basis of CAD and identifies key biological pathways.},
  langid = {english},
  pmcid = {PMC3679547},
  pmid = {23202125},
  keywords = {Adult,Aged,Asian People,Cell Line,Coronary Artery Disease,Female,Gene Regulatory Networks,Genetic Predisposition to Disease,Genome-Wide Association Study,Humans,Male,Middle Aged,Polymorphism Single Nucleotide,Quantitative Trait Loci,Risk Factors,White People},
  file = {/Users/xx20081/Zotero/storage/V46NTUSV/CARDIoGRAMplusC4D Consortium et al. - 2013 - Large-scale association analysis identifies new ri.pdf}
}

@misc{cdcProductsDataBriefs2019,
  title = {Products - {{Data Briefs}} - {{Number}} 50 - {{December}} 2010},
  author = {CDC},
  year = {2019},
  month = jun,
  urldate = {2024-07-04},
  abstract = {Obesity and Socioeconomic Status in Adults: United States, 2005--2008},
  howpublished = {https://www.cdc.gov/nchs/products/databriefs/db50.htm},
  langid = {american},
  file = {/Users/xx20081/Zotero/storage/WF53HIPQ/db50.html}
}

@article{changSecondgenerationPLINKRising2015,
  title = {Second-Generation {{PLINK}}: Rising to the Challenge of Larger and Richer Datasets},
  shorttitle = {Second-Generation {{PLINK}}},
  author = {Chang, Christopher C and Chow, Carson C and Tellier, Laurent CAM and Vattikuti, Shashaank and Purcell, Shaun M and Lee, James J},
  year = {2015},
  month = dec,
  journal = {GigaScience},
  volume = {4},
  number = {1},
  pages = {s13742-015-0047-8},
  issn = {2047-217X},
  doi = {10.1186/s13742-015-0047-8},
  urldate = {2024-02-19},
  abstract = {PLINK 1 is a widely used open-source C/C++ toolset for genome-wide association studies (GWAS) and research in population genetics. However, the steady accumulation of data from imputation and whole-genome sequencing studies has exposed a strong need for faster and scalable implementations of key functions, such as logistic regression, linkage disequilibrium estimation, and genomic distance evaluation. In addition, GWAS and population-genetic data now frequently contain genotype likelihoods, phase information, and/or multiallelic variants, none of which can be represented by PLINK 1's primary data format.To address these issues, we are developing a second-generation codebase for PLINK. The first major release from this codebase, PLINK 1.9, introduces extensive use of bit-level parallelism, (n)-time/constant-space Hardy-Weinberg equilibrium and Fisher's exact tests, and many other algorithmic improvements. In combination, these changes accelerate most operations by 1-4 orders of magnitude, and allow the program to handle datasets too large to fit in RAM. We have also developed an extension to the data format which adds low-overhead support for genotype likelihoods, phase, multiallelic variants, and reference vs. alternate alleles, which is the basis of our planned second release (PLINK 2.0).The second-generation versions of PLINK will offer dramatic improvements in performance and compatibility. For the first time, users without access to high-end computing resources can perform several essential analyses of the feature-rich and very large genetic datasets coming into use.},
  file = {/Users/xx20081/Zotero/storage/5P3F7QB7/Chang et al. - 2015 - Second-generation PLINK rising to the challenge o.pdf;/Users/xx20081/Zotero/storage/3M8HLDWT/2707533.html}
}

@misc{chazaraAssessingRoleRare2023,
  title = {Assessing the Role of Rare Pathogenic Variants in Heart Failure Progression by Exome Sequencing in 8,089 Patients},
  author = {Chazara, Olympe and Dub{\'e}, Marie-Pierre and Wang, Quanli and Middleton, Lawrence and Vitsios, Dimitrios and Walentinsson, Anna and Wang, Qing-Dong and Hansson, Kenny M. and Granger, Christopher B. and Kjekshus, John and Haefliger, Carolina and Tardif, Jean-Claude and Paul, Dirk S. and Carss, Keren},
  year = {2023},
  month = aug,
  pages = {2023.07.28.23293350},
  publisher = {medRxiv},
  doi = {10.1101/2023.07.28.23293350},
  urldate = {2025-01-13},
  abstract = {Most therapeutic development is targeted at slowing disease progression, often long after the initiating events of disease incidence. Heart failure is a chronic, life-threatening disease and the most common reason for hospital admission in people over 65 years of age. Genetic factors that influence heart failure progression have not yet been identified. We performed an exome-wide association study in 8,089 patients with heart failure across two clinical trials, CHARM and CORONA, and one population-based cohort, the UK Biobank. We assessed the genetic determinants of the outcomes `time to cardiovascular death' and `time to cardiovascular death and/or hospitalisation', identifying seven independent exome-wide-significant associated genes, FAM221A, CUTC, IFIT5, STIMATE, TAS2R20, CALB2 and BLK. Leveraging public genomic data resources, transcriptomic and pathway analyses, as well as a machine-learning approach, we annotated and prioritised the identified genes for further target validation experiments. Together, these findings advance our understanding of the molecular underpinnings of heart failure progression and reveal putative new candidate therapeutic targets.},
  archiveprefix = {medRxiv},
  copyright = {{\copyright} 2023, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/KX5K7TR2/Chazara et al. - 2023 - Assessing the role of rare pathogenic variants in heart failure progression by exome sequencing in 8.pdf}
}

@misc{chazaraAssessingRoleRare2023a,
  title = {Assessing the Role of Rare Pathogenic Variants in Heart Failure Progression by Exome Sequencing in 8,089 Patients},
  author = {Chazara, Olympe and Dub{\'e}, Marie-Pierre and Wang, Quanli and Middleton, Lawrence and Vitsios, Dimitrios and Walentinsson, Anna and Wang, Qing-Dong and Hansson, Kenny M. and Granger, Christopher B. and Kjekshus, John and Haefliger, Carolina and Tardif, Jean-Claude and Paul, Dirk S. and Carss, Keren},
  year = {2023},
  month = aug,
  pages = {2023.07.28.23293350},
  publisher = {medRxiv},
  doi = {10.1101/2023.07.28.23293350},
  urldate = {2025-01-13},
  abstract = {Most therapeutic development is targeted at slowing disease progression, often long after the initiating events of disease incidence. Heart failure is a chronic, life-threatening disease and the most common reason for hospital admission in people over 65 years of age. Genetic factors that influence heart failure progression have not yet been identified. We performed an exome-wide association study in 8,089 patients with heart failure across two clinical trials, CHARM and CORONA, and one population-based cohort, the UK Biobank. We assessed the genetic determinants of the outcomes `time to cardiovascular death' and `time to cardiovascular death and/or hospitalisation', identifying seven independent exome-wide-significant associated genes, FAM221A, CUTC, IFIT5, STIMATE, TAS2R20, CALB2 and BLK. Leveraging public genomic data resources, transcriptomic and pathway analyses, as well as a machine-learning approach, we annotated and prioritised the identified genes for further target validation experiments. Together, these findings advance our understanding of the molecular underpinnings of heart failure progression and reveal putative new candidate therapeutic targets.},
  archiveprefix = {medRxiv},
  copyright = {{\copyright} 2023, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/DHUW8ZP4/Chazara et al. - 2023 - Assessing the role of rare pathogenic variants in heart failure progression by exome sequencing in 8.pdf}
}

@article{chedidAllelicVariantGlucagonlike2018,
  title = {Allelic Variant in the Glucagon-like Peptide 1 Receptor Gene Associated with Greater Effect of Liraglutide and Exenatide on Gastric Emptying: {{A}} Pilot Pharmacogenetics Study},
  shorttitle = {Allelic Variant in the Glucagon-like Peptide 1 Receptor Gene Associated with Greater Effect of Liraglutide and Exenatide on Gastric Emptying},
  author = {Chedid, V. and Vijayvargiya, P. and Carlson, P. and Van Malderen, K. and Acosta, A. and Zinsmeister, A. and Camilleri, M.},
  year = {2018},
  month = jul,
  journal = {Neurogastroenterology and Motility},
  volume = {30},
  number = {7},
  pages = {e13313},
  issn = {1365-2982},
  doi = {10.1111/nmo.13313},
  abstract = {BACKGROUND: Weight loss in response to the long-acting GLP-1 receptor (GLP1R) analog, liraglutide, is correlated with delay in gastric-emptying (GE). The aim of this pilot study was to assess whether specific genetic variants in GLP1R or TCF7L2 are associated with delayed GE and weight loss in obese patients treated with liraglutide or the short-acting GLP-1 agonist, exenatide. METHODS: We evaluated in obese individuals the associations of genetic variations of GLP1R (rs6923761) and TCF7L2 (rs7903146) on GE T1/2 and weight from two trials that evaluated separately exenatide, 5~{$\mu$}g BID for 30~days, or liraglutide, 3~mg daily for 5~weeks. Data were analyzed using the dominant genetic model and intention-to-treat analysis. KEY RESULTS: There was a significant correlation between changes in weight and GE T1/2 (rs ~=~-.382, P~=~.004). GLP1R rs6923761 minor allele A (AA\_AG) carriers who received either exenatide or liraglutide had greater delay in GE T1/2 relative to baseline (117.9~{\textpm}~27.5 [SEM] minutes and 128.9~{\textpm}~38.32~minutes) compared to GG genotype (95.8~{\textpm}~30.4~minutes and 61.4~{\textpm}~21.4~minutes, respectively; P~=~.11). There was a non-significant difference in weight loss based on GLP1R rs6923761 genotype after 5~weeks of treatment. There were no significant correlations with TCF7L2 (rs7903146) genotype. CONCLUSIONS \& INFERENCES: The minor A allele of GLP1R (rs6923761) is associated with greater delay in GE T1/2 in response to liraglutide and exenatide. These studies provide data to plan pharmacogenetics testing of the hypothesis that GLP1R (rs6923761) influences weight loss in response to GLP1R agonists.},
  langid = {english},
  pmcid = {PMC6003833},
  pmid = {29488276},
  keywords = {Adult,Alleles,Double-Blind Method,Exenatide,Female,gastric emptying,Gastric Emptying,Genetic Variation,glucagon-like peptide 1 receptor,Glucagon-Like Peptide-1 Receptor,Humans,Hypoglycemic Agents,liraglutide,Liraglutide,Male,Middle Aged,obesity,Obesity,Pharmacogenetics,Pilot Projects,rs6923761,Weight Loss},
  file = {/Users/xx20081/Zotero/storage/9ETTF8JD/Chedid et al. - 2018 - Allelic variant in the glucagon-like peptide 1 rec.pdf}
}

@article{Chen2013,
  title = {Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure with Renal Dysfunction: The {{ROSE}} Acute Heart Failure Randomized Trial},
  author = {Chen, Horng H. and Anstrom, Kevin J. and Givertz, Michael M. and Stevenson, Lynne W. and Semigran, Marc J. and Goldsmith, Steven R. and Bart, Bradley A. and Bull, David A. and Stehlik, Josef and LeWinter, Martin M. and Konstam, Marvin A. and Huggins, Gordon S. and Rouleau, Jean L. and O'Meara, Eileen and Tang, W. H.Wilson and Starling, Randall C. and Butler, Javed and Deswal, Anita and Felker, G. Michael and O'Connor, Christopher M. and Bonita, Raphael E. and Margulies, Kenneth B. and Cappola, Thomas P. and Ofili, Elizabeth O. and Mann, Douglas L. and {D{\'a}vila-Rom{\'a}n}, Victor G. and McNulty, Steven E. and Borlaug, Barry A. and Velazquez, Eric J. and Lee, Kerry L. and Shah, Monica R. and Hernandez, Adrian F. and Braunwald, Eugene and Redfield, Margaret M.},
  year = {2013},
  month = dec,
  journal = {JAMA : the journal of the American Medical Association},
  volume = {310},
  number = {23},
  pages = {2533--2543},
  publisher = {JAMA},
  issn = {1538-3598},
  doi = {10.1001/JAMA.2013.282190},
  abstract = {IMPORTANCE: Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested. OBJECTIVE: To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 {$\mu$}g/kg/min) or low-dose nesiritide (0.005 {$\mu$}g/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73m2), randomized within 24 hours of admission. Enrollment occurred from September 2010 to March 2013 across 26 sites in North America. INTERVENTIONS: Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy. Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo. The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119). MAIN OUTCOMES AND MEASURES: Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point). RESULTS: Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95\%CI, 7917-9131 vs placebo, 8296 mL; 95\% CI, 7762-8830 ; difference, 229 mL; 95\%CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12mg/L; 95\%CI, 0.06-0.18 vs placebo, 0.11mg/L; 95\%CI, 0.06-0.16; difference, 0.01; 95\%CI, -0.08 to 0.10; P = .72). Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95\%CI, 8014-9134 vs placebo, 8296 mL; 95\%CI, 7762-8830; difference, 279 mL; 95\%CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07mg/L; 95\%CI, 0.01-0.13 vs placebo, 0.11mg/L; 95\%CI, 0.06-0.16; difference, -0.04; 95\%CI, -0.13 to 0.05; P = .36). Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes. CONCLUSION AND RELEVANCE: In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01132846 Copyright 2013 American Medical Association. All rights reserved.},
  pmid = {24247300},
  keywords = {80 and over,Acute Disease,affs=[],affs=[]),Aged,Author(firstnames='Abdallah',Author(firstnames='Adefisayo',Author(firstnames='Adesoji',Author(firstnames='Akshay',Author(firstnames='Alfred',Author(firstnames='Andre',Author(firstnames='Andreas',Author(firstnames='Andrew',Author(firstnames='Anekwe',Author(firstnames='Anique',Author(firstnames='Anita',Author(firstnames='Anjali',Author(firstnames='Anju',Author(firstnames='Ayan',Author(firstnames='Barry',Author(firstnames='Biykem',Author(firstnames='Bonnie',Author(firstnames='Bradley',Author(firstnames='Carolyn',Author(firstnames='Cathi',Author(firstnames='Cathrine',Author(firstnames='Chetan',Author(firstnames='Christopher',Author(firstnames='Corinne',Author(firstnames='Dan',Author(firstnames='Daniel',Author(firstnames='David',Author(firstnames='Deborah',Author(firstnames='Denis',Author(firstnames='Divya',Author(firstnames='Diyana',Author(firstnames='Donna',Author(firstnames='Edward',Author(firstnames='Eileen',Author(firstnames='Eiran',Author(firstnames='Eldrin',Author(firstnames='Elizabeth',Author(firstnames='Emiliana',Author(firstnames='Feras',Author(firstnames='Garrick',Author(firstnames='Geoffrey',Author(firstnames='George',Author(firstnames='Georgios',Author(firstnames='Gordon',Author(firstnames='Gregory',Author(firstnames='Guilherme',Author(firstnames='Heidi',Author(firstnames='Horng',Author(firstnames='Inderjit',Author(firstnames='Jacqueline',Author(firstnames='James',Author(firstnames='Janice',Author(firstnames='Javed',Author(firstnames='Jean',Author(firstnames='Jeffrey',Author(firstnames='Jesus',Author(firstnames='Joel',Author(firstnames='Jordan',Author(firstnames='Josef',Author(firstnames='Joseph',Author(firstnames='Josephine',Author(firstnames='Joyce',Author(firstnames='Karen',Author(firstnames='Kathleen',Author(firstnames='Kathy',Author(firstnames='Kelley',Author(firstnames='Kenneth',Author(firstnames='Kimberly',Author(firstnames='Lana',Author(firstnames='Lazaros',Author(firstnames='Lee',Author(firstnames='Linda',Author(firstnames='Lisa',Author(firstnames='Lynne',Author(firstnames='Maggie',Author(firstnames='Marc',Author(firstnames='Margaret',Author(firstnames='Maria',Author(firstnames='Mark',Author(firstnames='Markus',Author(firstnames='Martin',Author(firstnames='Marvin',Author(firstnames='Matthew',Author(firstnames='Mazen',Author(firstnames='Michael',Author(firstnames='Michel',Author(firstnames='Mitchell',Author(firstnames='Molly',Author(firstnames='Monique',Author(firstnames='Nadia',Author(firstnames='Neal',Author(firstnames='Nizar',Author(firstnames='Normand',Author(firstnames='Pablo',Author(firstnames='Paul',Author(firstnames='Peter',Author(firstnames='Rami',Author(firstnames='Randall',Author(firstnames='Raphael',Author(firstnames='Rebecca',Author(firstnames='Rigobert',Author(firstnames='Robert',Author(firstnames='Roy',Author(firstnames='Sandra',Author(firstnames='Sangjin',Author(firstnames='Sharon',Author(firstnames='Simone',Author(firstnames='Sonjoy',Author(firstnames='Stephanie',Author(firstnames='Sulaiman',Author(firstnames='Susan',Author(firstnames='Syed',Author(firstnames='Tareck',Author(firstnames='Theo',Author(firstnames='Thomas',Author(firstnames='Vasiliki',Author(firstnames='Victor',Author(firstnames='Viorel',Author(firstnames='Wayne',Author(firstnames='William',Author(firstnames='Wilson',Brain / administration & dosage*,CollabAuthor(name='NHLBI Heart Failure Clinical Research Network',Combination,Cystatin C / blood,Diuretics / therapeutic use,doi:10.1001/jama.2013.282190,Dopamine / administration & dosage*,Double-Blind Method,Drug Therapy,equal<sub>c</sub>ontrib=False),equal<sub>c</sub>ontrib=False)],Extramural,Female,Glomerular Filtration Rate,Heart Failure / complications,Heart Failure / drug therapy*,Horng H Chen,Humans,initials='A',initials='B',initials='C',initials='D',initials='E',initials='F',initials='G',initials='H',initials='I',initials='J',initials='K',initials='L',initials='M',initials='N',initials='O',initials='P',initials='R',initials='S',initials='T',initials='V',initials='W',investigators=[Author(firstnames='Omar',iseditor=False,Kevin J Anstrom,Kidney / physiopathology,Kidney Diseases / complications,Kidney Diseases / drug therapy*,lastname='AbouEzzeddine',lastname='Aguilar',lastname='Alharethi',lastname='Amsler',lastname='Anand',lastname='Bader',lastname='Bart',lastname='Bartolini',lastname='Boddicker',lastname='Bonita',lastname='Borlaug',lastname='Bott-Silverman',lastname='Bove',lastname='Boxer',lastname='Bozkurt',lastname='Bradley',lastname='Budge',lastname='Burelle',lastname='Butler',lastname='Cabral',lastname='Cappola',lastname='Carlson',lastname='Catanzaro',lastname='Chang',lastname='Chen',lastname='Cole',lastname='Craddock',lastname='Davilla',lastname='DeNofrio',lastname='Desai',lastname='Deswal',lastname='Dias',lastname='Ducharme',lastname='Dunbar',lastname='Dunlap',lastname='Ewald',lastname='Fang',lastname='Felker',lastname='Fiorini',lastname='Fitzpatrick',lastname='Florea',lastname='Franco',lastname='Geltman',lastname='Georgiopoulou',lastname='Giannetti',lastname='Gilbert',lastname='Givertz',lastname='Goldberg',lastname='Gonczarek',lastname='Gorodeski',lastname='Gunawardena',lastname='Gupta',lastname='Hanna',lastname='Hardin',lastname='Hobbs',lastname='Holley',lastname='Hsich',lastname='Huggins',lastname='James',lastname='Joseph',lastname='Kalogeropoulous',lastname='Keller',lastname='Kfoury',lastname='Kiernan',lastname='Kociol',lastname='Konstam',lastname='Ky',lastname='Lakdawala',lastname='Lapu-Bula',lastname='Laskar',lastname='Lee',lastname='LeWinter',lastname='Lewis',lastname='Liszkowski',lastname='Mack',lastname='Mapara',lastname='Margulies',lastname='Marti',lastname='Mather',lastname='Meyer',lastname='Miller',lastname='Mills',lastname='Moffa',lastname='Moore',lastname='Mountis',lastname='Movesian',lastname='Movsesian',lastname='Nader',lastname='Nestor',lastname='Newton-Cheh',lastname='Nikolaidis',lastname='Nissley',lastname='Nohria',lastname='Nossuli',lastname='Oderinde',lastname='Oduwole',lastname='Ofili',lastname='Oliveira',lastname='Onwuanyi',lastname='Owens',lastname='Parks',lastname='Patel',lastname='Prokop',lastname='Quintero Pinzon',lastname='Racine',lastname='Rame',lastname='Rater',lastname='Rathman',lastname='Raza',lastname='Redfield',lastname='Rogers',lastname='Rouleau',lastname='Rubin',lastname='Ruppert',lastname='Saleh',lastname='Saltzberg',lastname='Schilling',lastname='Semigran',lastname='Shih',lastname='Shin',lastname='Sims',lastname='Small',lastname='Smith',lastname='Sorescu',lastname='Starling',lastname='Stehlik',lastname='Stevenson',lastname='Stewart',lastname='Stillabower',lastname='Syros',lastname='Tang',lastname='Taylor',lastname='Thanassoulis',lastname='Tsao',lastname='Udelson',lastname='Vanburen',lastname='Wald',lastname='Wang',lastname='Whellan',lastname='White',lastname='Wick',lastname="O'Connor",lastname="O'Meara",Male,MEDLINE,Middle Aged,Multicenter Study,N.I.H.,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,Natriuretic Agents / administration & dosage*,Natriuretic Peptide,NCBI,NIH,NLM,PMC3934929,pmid:24247300,PubMed Abstract,Randomized Controlled Trial,Research Support,suffix=None,Treatment Outcome,Urine,Vasodilator Agents / administration & dosage*}
}

@article{chenGenomicAtlasPlasma2023,
  title = {Genomic Atlas of the Plasma Metabolome Prioritizes Metabolites Implicated in Human Diseases},
  author = {Chen, Yiheng and Lu, Tianyuan and {Pettersson-Kymmer}, Ulrika and Stewart, Isobel D. and {Butler-Laporte}, Guillaume and Nakanishi, Tomoko and Cerani, Agustin and Liang, Kevin Y. H. and Yoshiji, Satoshi and Willett, Julian Daniel Sunday and Su, Chen-Yang and Raina, Parminder and Greenwood, Celia M. T. and Farjoun, Yossi and Forgetta, Vincenzo and Langenberg, Claudia and Zhou, Sirui and Ohlsson, Claes and Richards, J. Brent},
  year = {2023},
  month = jan,
  journal = {Nature Genetics},
  volume = {55},
  number = {1},
  pages = {44--53},
  issn = {1546-1718},
  doi = {10.1038/s41588-022-01270-1},
  abstract = {Metabolic processes can influence disease risk and provide therapeutic targets. By conducting genome-wide association studies of 1,091 blood metabolites and 309 metabolite ratios, we identified associations with 690 metabolites at 248 loci and associations with 143 metabolite ratios at 69 loci. Integrating metabolite-gene and gene expression information identified 94 effector genes for 109 metabolites and 48 metabolite ratios. Using Mendelian randomization (MR), we identified 22 metabolites and 20 metabolite ratios having estimated causal effect on 12 traits and diseases, including orotate for estimated bone mineral density, {$\alpha$}-hydroxyisovalerate for body mass index and ergothioneine for inflammatory bowel disease and asthma. We further measured the orotate level in a separate cohort and demonstrated that, consistent with MR, orotate levels were positively associated with incident hip fractures. This study provides a valuable resource describing the genetic architecture of metabolites and delivers insights into their roles in common diseases, thereby offering opportunities for therapeutic targets.},
  langid = {english},
  pmcid = {PMC7614162},
  pmid = {36635386},
  keywords = {Bone Density,Genome-Wide Association Study,Genomics,Humans,Metabolome,Phenotype,Polymorphism Single Nucleotide},
  file = {/Users/xx20081/Zotero/storage/ICL4NMNM/Chen et al. - 2023 - Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases.pdf}
}

@article{chenGenomicAtlasPlasma2023a,
  title = {Genomic Atlas of the Plasma Metabolome Prioritizes Metabolites Implicated in Human Diseases},
  author = {Chen, Yiheng and Lu, Tianyuan and {Pettersson-Kymmer}, Ulrika and Stewart, Isobel D. and {Butler-Laporte}, Guillaume and Nakanishi, Tomoko and Cerani, Agustin and Liang, Kevin Y. H. and Yoshiji, Satoshi and Willett, Julian Daniel Sunday and Su, Chen-Yang and Raina, Parminder and Greenwood, Celia M. T. and Farjoun, Yossi and Forgetta, Vincenzo and Langenberg, Claudia and Zhou, Sirui and Ohlsson, Claes and Richards, J. Brent},
  year = {2023},
  month = jan,
  journal = {Nature Genetics},
  volume = {55},
  number = {1},
  pages = {44--53},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-022-01270-1},
  urldate = {2025-05-21},
  abstract = {Metabolic processes can influence disease risk and provide therapeutic targets. By conducting genome-wide association studies of 1,091 blood metabolites and 309 metabolite ratios, we identified associations with 690 metabolites at 248 loci and associations with 143 metabolite ratios at 69 loci. Integrating metabolite-gene and gene expression information identified 94 effector genes for 109 metabolites and 48 metabolite ratios. Using Mendelian randomization (MR), we identified 22 metabolites and 20 metabolite ratios having estimated causal effect on 12 traits and diseases, including orotate for estimated bone mineral density, {$\alpha$}-hydroxyisovalerate for body mass index and ergothioneine for inflammatory bowel disease and asthma. We further measured the orotate level in a separate cohort and demonstrated that, consistent with MR, orotate levels were positively associated with incident hip fractures. This study provides a valuable resource describing the genetic architecture of metabolites and delivers insights into their roles in common diseases, thereby offering opportunities for therapeutic targets.},
  copyright = {2023 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  keywords = {Autoimmune diseases,Endocrine system and metabolic diseases,Genome-wide association studies,Metabolomics,Osteoporosis}
}

@article{chenMiR181dRegulatedMetalloproteinase2016,
  title = {The {{miR-181d-regulated}} Metalloproteinase {{Adamts1}} Enzymatically Impairs Adipogenesis via {{ECM}} Remodeling},
  author = {Chen, S.-Z. and Ning, L.-F. and Xu, X. and Jiang, W.-Y. and Xing, C. and Jia, W.-P. and Chen, X.-L. and Tang, Q.-Q. and Huang, H.-Y.},
  year = {2016},
  month = nov,
  journal = {Cell Death \& Differentiation},
  volume = {23},
  number = {11},
  pages = {1778--1791},
  publisher = {Nature Publishing Group},
  issn = {1476-5403},
  doi = {10.1038/cdd.2016.66},
  urldate = {2025-05-27},
  abstract = {The extracellular matrix (ECM) maintenance is crucial to the structural integrity of adipocytes and whole adipose tissue formation. However, the potential impact of the ECM on adipocyte lineage commitment is unclear. Herein, we demonstrate that forced expression of matrix-associated metalloproteinase Adamts1 (a disintegrin and metalloproteinase with thrombospondin motifs 1), which we show is targeted by microRNA-181d (miR-181d) during BMP4-induced adipocytic lineage commitment, markedly impairs adipocyte commitment. Conversely, siRNA-induced inhibition of Adamts1 promotes adipocyte commitment. Adamst1 metalloprotease activity is required for this inhibition and is determined to function via remodeling ECM components followed by activating FAK--ERK signaling pathway during the commitment process. Furthermore, ablation of Adamts1 in adipose tissue increases adipose tissue mass, reduces insulin sensitivity, and disrupts lipid homeostasis. This finding is consistent with Adamts1 decreased expression in the adipose tissue of obese mice and an inverse correlation of Adamts1 expression with body mass index in humans. Collectively, our results indicate that Adamts1 acts as an ECM `modifier', with miR-181d-induced downregulation, that regulates adipocyte lineage commitment and obesity.},
  copyright = {2016 Macmillan Publishers Limited, part of Springer Nature.},
  langid = {english},
  keywords = {Development,Epigenetics},
  file = {/Users/xx20081/Zotero/storage/7XAK42FH/Chen et al. - 2016 - The miR-181d-regulated metalloproteinase Adamts1 enzymatically impairs adipogenesis via ECM remodeli.pdf}
}

@article{chenRiskIncidentCardiovascular2024,
  title = {Risk of Incident Cardiovascular Disease among Patients with Gastrointestinal Disorder: A Prospective Cohort Study of 330\,751 Individuals},
  shorttitle = {Risk of Incident Cardiovascular Disease among Patients with Gastrointestinal Disorder},
  author = {Chen, Jie and Sun, Yuhao and Fu, Tian and Lu, Shiyuan and Shi, Wenming and Zhao, Jianhui and Li, Sen and Li, Xue and Yuan, Shuai and Larsson, Susanna C},
  year = {2024},
  month = jun,
  journal = {European Heart Journal - Quality of Care and Clinical Outcomes},
  volume = {10},
  number = {4},
  pages = {357--365},
  publisher = {Oxford University Press (OUP)},
  issn = {2058-5225, 2058-1742},
  doi = {10.1093/ehjqcco/qcad059},
  urldate = {2024-09-17},
  abstract = {Background The associations between gastrointestinal diseases (GIs) and cardiovascular disease (CVD) were unclear. We conducted and aims a prospective cohort study to explore their associations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Methods This study included 330 751 individuals without baseline CVD from the UK Biobank cohort. Individuals with and without GIs were followed up until the ascertainment of incident CVDs, including coronary heart disease (CHD), cerebrovascular disease (CeVD), heart failure (HF), and peripheral artery disease (PAD). The diagnosis of diseases was confirmed with combination of the nationwide inpatient data, primary care data, and cancer registries. A multivariable Cox proportional hazard regression model was used to estimate the associations between GIs and the risk of incident CVD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Results During a median follow-up of 11.8 years, 31 605 incident CVD cases were diagnosed. Individuals with GIs had an elevated risk of CVD (hazard ratio 1.37; 95\% confidence interval 1.34--1.41, P {$<$} 0.001). Eleven out of 15 GIs were associated with an increased risk of CVD after Bonferroni-correction, including cirrhosis, non-alcoholic fatty liver disease, gastritis and duodenitis, irritable bowel syndrome, Barrett's esophagus, gastroesophageal reflux disease, peptic ulcer, celiac disease, diverticulum, appendicitis, and biliary disease. The associations were stronger among women, individuals aged {$\leq$}60 years, and those with body mass index {$\geq$}25 kg/m2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Conclusions},
  copyright = {https://academic.oup.com/journals/pages/open\_access/funder\_policies/chorus/standard\_publication\_model},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/YK4B3GJ8/Chen et al. - 2024 - Risk of incident cardiovascular disease among pati.pdf}
}

@article{chenRiskIncidentCardiovascular2024a,
  title = {Risk of Incident Cardiovascular Disease among Patients with Gastrointestinal Disorder: A Prospective Cohort Study of 330\,751 Individuals},
  shorttitle = {Risk of Incident Cardiovascular Disease among Patients with Gastrointestinal Disorder},
  author = {Chen, Jie and Sun, Yuhao and Fu, Tian and Lu, Shiyuan and Shi, Wenming and Zhao, Jianhui and Li, Sen and Li, Xue and Yuan, Shuai and Larsson, Susanna C.},
  year = {2024},
  month = jun,
  journal = {European Heart Journal. Quality of Care \& Clinical Outcomes},
  volume = {10},
  number = {4},
  pages = {357--365},
  issn = {2058-1742},
  doi = {10.1093/ehjqcco/qcad059},
  abstract = {BACKGROUND AND AIMS: The associations between gastrointestinal diseases (GIs) and cardiovascular disease (CVD) were unclear. We conducted a prospective cohort study to explore their associations. METHODS: This study included 330\,751 individuals without baseline CVD from the UK Biobank cohort. Individuals with and without GIs were followed up until the ascertainment of incident CVDs, including coronary heart disease (CHD), cerebrovascular disease (CeVD), heart failure (HF), and peripheral artery disease (PAD). The diagnosis of diseases was confirmed with combination of the nationwide inpatient data, primary care data, and cancer registries. A multivariable Cox proportional hazard regression model was used to estimate the associations between GIs and the risk of incident CVD. RESULTS: During a median follow-up of 11.8 years, 31\,605 incident CVD cases were diagnosed. Individuals with GIs had an elevated risk of CVD (hazard ratio 1.37; 95\% confidence interval 1.34-1.41, P~{$<~$}0.001). Eleven out of 15 GIs were associated with an increased risk of CVD after Bonferroni-correction, including cirrhosis, non-alcoholic fatty liver disease, gastritis and duodenitis, irritable bowel syndrome, Barrett's esophagus, gastroesophageal reflux disease, peptic ulcer, celiac disease, diverticulum, appendicitis, and biliary disease. The associations were stronger among women, individuals aged~{$\leq$}60 years, and those with body mass index {$\geq$}25~kg/m2. CONCLUSIONS: This large-scale prospective cohort study revealed the associations of GIs with an increased risk of incident CVD, in particular CHD and PAD. These findings support the reinforced secondary CVD prevention among patients with gastrointestinal disorders.},
  langid = {english},
  pmid = {37777843},
  keywords = {Adult,Aged,Cardiovascular disease,Cardiovascular Diseases,Cohort,Female,Follow-Up Studies,Gastrointestinal disease,Gastrointestinal Diseases,Humans,Incidence,Male,Middle Aged,Prospective Studies,Risk Assessment,Risk Factors,United Kingdom},
  file = {/Users/xx20081/Zotero/storage/7UGJEZTU/Chen et al. - 2024 - Risk of incident cardiovascular disease among pati.pdf}
}

@article{chiesaGlycoproteinAcetylsNovel2022,
  title = {Glycoprotein {{Acetyls}}: {{A Novel Inflammatory Biomarker}} of {{Early Cardiovascular Risk}} in the {{Young}}},
  shorttitle = {Glycoprotein {{Acetyls}}},
  author = {Chiesa, Scott T. and Charakida, Marietta and Georgiopoulos, Georgios and Roberts, Justin D. and Stafford, Simon J. and Park, Chloe and Mykk{\"a}nen, Juha and K{\"a}h{\"o}nen, Mika and Lehtim{\"a}ki, Terho and Ala-Korpela, Mika and Raitakari, Olli and Pieti{\"a}inen, Milla and Pussinen, Pirkko and Muthurangu, Vivek and Hughes, Alun D. and Sattar, Naveed and Timpson, Nicholas J. and Deanfield, John E.},
  year = {2022},
  month = feb,
  journal = {Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease},
  volume = {11},
  number = {4},
  pages = {e024380},
  issn = {2047-9980},
  doi = {10.1161/JAHA.121.024380},
  urldate = {2025-05-28},
  abstract = {Background Low-grade inflammation in the young may contribute to the early development of cardiovascular disease. We assessed whether circulating levels of glycoprotein acetyls (GlycA) were better able to predict the development of adverse cardiovascular disease risk profiles compared with the more commonly used biomarker high-sensitivity CRP (C-reactive protein). Methods and Results A total of 3306 adolescents and young adults from the Avon Longitudinal Study of Parents and Children (mean age, 15.4{\textpm}0.3; n=1750) and Cardiovascular Risk in Young Finns Study (mean age, 32.1{\textpm}5.0; n=1556) were included. Baseline associations between inflammatory biomarkers, body composition, cardiovascular risk factors, and subclinical measures of vascular dysfunction were assessed cross-sectionally in both cohorts. Prospective risk of developing hypertension and metabolic syndrome during 9-to-10-year follow-up were also assessed as surrogate markers for future cardiovascular risk. GlycA showed greater within-subject correlation over 9-to-10-year follow-up in both cohorts compared with CRP, particularly in the younger adolescent group (r=0.36 versus 0.07). In multivariable analyses, GlycA was found to associate with multiple lifestyle-related cardiovascular disease risk factors, cardiometabolic risk factor burden, and vascular dysfunction (eg, mean difference in flow-mediated dilation=-1.2 [-1.8, -0.7]\% per z-score increase). In contrast, CRP levels appeared predominantly driven by body mass index and showed little relationship to any measured cardiovascular risk factors or phenotypes. In both cohorts, only GlycA predicted future risk of both hypertension (risk ratio [RR], {$\approx$}1.1 per z-score increase for both cohorts) and metabolic syndrome (RR, {$\approx$}1.2--1.3 per z-score increase for both cohorts) in 9-to-10-year follow-up. Conclusions Low-grade inflammation captured by the novel biomarker GlycA is associated with adverse cardiovascular risk profiles from as early as adolescence and predicts future risk of hypertension and metabolic syndrome in up to 10-year follow-up. GlycA is a stable inflammatory biomarker which may capture distinct sources of inflammation in the young and may provide a more sensitive measure than CRP for detecting early cardiovascular risk.},
  pmcid = {PMC9245818},
  pmid = {35156387},
  file = {/Users/xx20081/Zotero/storage/7SWET8BT/Chiesa et al. - 2022 - Glycoprotein Acetyls A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young.pdf}
}

@article{choiMonogenicPolygenicContributions2020,
  title = {Monogenic and {{Polygenic Contributions}} to {{Atrial Fibrillation Risk}}: {{Results}} from a {{National Biobank}}},
  shorttitle = {Monogenic and {{Polygenic Contributions}} to {{Atrial Fibrillation Risk}}},
  author = {Choi, Seung Hoan and Jurgens, Sean J. and Weng, Lu-Chen and Pirruccello, James P. and Roselli, Carolina and Chaffin, Mark and Lee, Christina and Hall, Amelia W. and Khera, Amit V. and Lunetta, Kathryn L. and Lubitz, Steven A. and Ellinor, Patrick T.},
  year = {2020},
  month = jan,
  journal = {Circulation research},
  volume = {126},
  number = {2},
  pages = {200--209},
  issn = {0009-7330},
  doi = {10.1161/CIRCRESAHA.119.315686},
  urldate = {2024-12-04},
  abstract = {, Over the last decade, great progress has been made in defining the genetic basis of AF. Common variants have been identified at more than 100 genetic loci, and rare mutations have implicated many genes in AF. However, the relative contribution of rare and common genetic variants to AF risk remains unclear. The population-based UK Biobank provides a unique opportunity to assess the genetic contributions to AF risk. In an exome wide analysis, we found that LOF mutations in TTN were strongly associated with AF risk and were highly penetrant. A polygenic risk score of common variants explains a great proportion of AF risk than mutations in TTN. Among TTN mutation carriers, it would be interesting in future work to determine if a subtle cardiomyopathy is present by cardiac imaging or to examine the progression to heart failure or other AF co-morbidities.},
  pmcid = {PMC7007701},
  pmid = {31691645},
  file = {/Users/xx20081/Zotero/storage/WITUY5UL/Choi et al. - 2020 - Monogenic and Polygenic Contributions to Atrial Fibrillation Risk Results from a National Biobank.pdf}
}

@article{choiTutorialGuidePerforming2020,
  title = {Tutorial: A Guide to Performing Polygenic Risk Score Analyses},
  shorttitle = {Tutorial},
  author = {Choi, Shing Wan and Mak, Timothy Shin-Heng and O'Reilly, Paul F.},
  year = {2020},
  month = sep,
  journal = {Nature Protocols},
  volume = {15},
  number = {9},
  pages = {2759--2772},
  publisher = {Nature Publishing Group},
  issn = {1750-2799},
  doi = {10.1038/s41596-020-0353-1},
  urldate = {2024-12-10},
  abstract = {A polygenic score (PGS) or polygenic risk score (PRS) is an estimate of an individual's genetic liability to a trait or disease, calculated according to their genotype profile and relevant genome-wide association study (GWAS) data. While present PRSs typically explain only a small fraction of trait variance, their correlation with the single largest contributor to phenotypic variation---genetic liability---has led to the routine application of PRSs across biomedical research. Among a range of applications, PRSs are exploited to assess shared etiology between phenotypes, to evaluate the clinical utility of genetic data for complex disease and as part of experimental studies in which, for example, experiments are performed that compare outcomes (e.g., gene expression and cellular response to treatment) between individuals with low and high PRS values. As GWAS sample sizes increase and PRSs become more powerful, PRSs are set to play a key role in research and stratified medicine. However, despite the importance and growing application of PRSs, there are limited guidelines for performing PRS analyses, which can lead to inconsistency between studies and misinterpretation of results. Here, we provide detailed guidelines for performing and interpreting PRS analyses. We outline standard quality control steps, discuss different methods for the calculation of PRSs, provide an introductory online tutorial, highlight common misconceptions relating to PRS results, offer recommendations for best practice and discuss future challenges.},
  copyright = {2020 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  keywords = {Genetic association study,Population genetics,Software},
  file = {/Users/xx20081/Zotero/storage/DW7WCMXU/Choi et al. - 2020 - Tutorial a guide to performing polygenic risk score analyses.pdf}
}

@article{chooiEpidemiologyObesity2019,
  title = {The Epidemiology of Obesity},
  author = {Chooi, Yu Chung and Ding, Cherlyn and Magkos, Faidon},
  year = {2019},
  month = mar,
  journal = {Metabolism: Clinical and Experimental},
  volume = {92},
  pages = {6--10},
  issn = {1532-8600},
  doi = {10.1016/j.metabol.2018.09.005},
  abstract = {Obesity is a complex multifactorial disease. The worldwide prevalence of overweight and obesity has doubled since 1980 to an extent that nearly a third of the world's population is now classified as overweight or obese. Obesity rates have increased in all ages and both sexes irrespective of geographical locality, ethnicity or socioeconomic status, although the prevalence of obesity is generally greater in older persons and women. This trend was similar across regions and countries, although absolute prevalence rates of overweight and obesity varied widely. For some developed countries, the prevalence rates of obesity seem to have levelled off during the past few years. Body mass index (BMI) is typically used to define overweight and obesity in epidemiological studies. However, BMI has low sensitivity and there is a large inter-individual variability in the percent body fat for any given BMI value, partly attributed to age, sex, and ethnicity. For instance, Asians have greater percent body fat than Caucasians for the same BMI. Greater cardiometabolic risk has also been associated with the localization of excess fat in the visceral adipose tissue and ectopic depots (such as muscle and liver), as well as in cases of increased fat to lean mass ratio (e.g. metabolically-obese normal-weight). These data suggest that obesity may be far more common and requires more urgent attention than what large epidemiological studies suggest. Simply relying on BMI to assess its prevalence could hinder future interventions aimed at obesity prevention and control.},
  langid = {english},
  pmid = {30253139},
  keywords = {Adiposity,Adult,Aged,Aged 80 and over,BMI,Body Mass Index,Female,Health risk,Humans,Male,Middle Aged,Obesity,Overweight,Prevalence},
  file = {/Users/xx20081/Zotero/storage/SJEZD3B4/Chooi et al. - 2019 - The epidemiology of obesity.pdf}
}

@article{cicoiraBodyMassIndex2007,
  title = {Body Mass Index, Prognosis and Mode of Death in Chronic Heart Failure: Results from the {{Valsartan Heart Failure Trial}}},
  shorttitle = {Body Mass Index, Prognosis and Mode of Death in Chronic Heart Failure},
  author = {Cicoira, Mariantonietta and Maggioni, Aldo Pietro and Latini, Roberto and Barlera, Simona and Carretta, Elisa and Janosi, Andras and Soler Soler, Jordi and Anand, Inder and Cohn, Jay N. and {Val-HeFT Investigators}},
  year = {2007},
  month = apr,
  journal = {European Journal of Heart Failure},
  volume = {9},
  number = {4},
  pages = {397--402},
  issn = {1388-9842},
  doi = {10.1016/j.ejheart.2006.10.016},
  abstract = {AIMS: To assess the relationship between body mass index (BMI), mortality and mode of death in chronic heart failure (CHF) patients; to define the shape of the relationship between BMI and mortality. METHODS AND RESULTS: We performed a post-hoc analysis of 5010 patients from the Valsartan Heart Failure Trial. The end-points of the study were all-cause and cardiovascular mortality. Mortality rate was 27.2\% in underweight patients (BMI{$<$}22 kg/m2), 21.7\% in normal weight patients (BMI 22-24.9 kg/m2), 17.9\% in overweight patients (BMI 25-29.9 kg/m2) and 16.5\% in obese patients (BMI{$>$}30 kg/m2) (p{$<$}0.0001). The rates of non-cardiovascular death did not differ among groups. The risk of death due to progressive heart failure was 3.4-fold higher in the underweight than in the obese patients (p{$<$}0.0001). Normal weight, overweight and obese patients had lower risk of death as compared with underweight patients (p=0.019, HR 0.76, 95\% CI 0.61-0.96; p=0.0005, HR 0.68, 95\% CI 0.55-0.84; p=0.003, HR 0.67, 95\% CI 0.52-0.88, respectively) independently of symptoms, ventricular function, beta-blocker use, C-reactive protein and brain natriuretic peptide levels. CONCLUSIONS: In CHF patients a higher BMI is associated with a better prognosis independently of other clinical variables. The relationship between mortality and BMI is monotonically decreasing.},
  langid = {english},
  pmid = {17166768},
  keywords = {Adolescent,Adult,Aged,Aged 80 and over,Body Mass Index,Disease Progression,Female,Heart Failure,Humans,Male,Middle Aged,Mortality,Obesity,Overweight,Prognosis,Risk Assessment,Risk Factors,Survival},
  file = {/Users/xx20081/Zotero/storage/Y45US87D/Cicoira et al. - 2007 - Body mass index, prognosis and mode of death in ch.pdf}
}

@article{clarkWaistCircumferenceBody2011,
  title = {Waist Circumference, Body Mass Index, and Survival in Systolic Heart Failure: The Obesity Paradox Revisited},
  shorttitle = {Waist Circumference, Body Mass Index, and Survival in Systolic Heart Failure},
  author = {Clark, Adrienne L. and Fonarow, Gregg C. and Horwich, Tamara B.},
  year = {2011},
  month = may,
  journal = {Journal of Cardiac Failure},
  volume = {17},
  number = {5},
  pages = {374--380},
  issn = {1532-8414},
  doi = {10.1016/j.cardfail.2011.01.009},
  abstract = {BACKGROUND: Higher body mass index (BMI) is associated with improved heart failure (HF) survival, but the role of waist circumference (WC) in HF outcomes has not been studied. METHODS AND RESULTS: A total of 344 patients with advanced systolic HF had WC and BMI measured at presentation. High WC was defined as {$\geq$}88 cm in women and {$\geq$}102 cm in men, and high BMI as {$\geq$}25 kg/m(2). Two-year urgent heart transplant (UT)-free survival in high vs normal WC groups was 77.9\% vs 64.3\% (P = .025) and in high vs normal BMI was 89.8\% vs 58.2\% (P {$<$} .001). After multivariable adjustment, normal WC compared with high WC was associated with higher all-cause mortality (risk ratio [RR] 2.76, 95\% confidence interval [CI] 1.34-5.71) and higher risk of death/UT (RR 2.14, 95\% CI 1.25-3.68). The best outcomes were seen in those with both high WC and high BMI. CONCLUSIONS: High WC, an alternative anthropometric index of obesity more specific to abdominal adiposity, high BMI, and the combination of high WC/high BMI were each associated with improved outcomes in this advanced HF cohort, lending further support for an obesity paradox in HF. The role of body composition in HF survival should be a focus of future investigation.},
  langid = {english},
  pmid = {21549293},
  keywords = {Abdominal Fat,Adult,Aged,Body Mass Index,Cohort Studies,Female,Follow-Up Studies,Heart Failure Systolic,Humans,Male,Middle Aged,Obesity,Risk Factors,Survival Rate,Waist Circumference},
  file = {/Users/xx20081/Zotero/storage/9D6TDIS2/Clark et al. - 2011 - Waist circumference, body mass index, and survival.pdf}
}

@article{claytonFrameworkAssessingSelection2023,
  title = {A Framework for Assessing Selection and Misclassification Bias in Mendelian Randomisation Studies: An Illustrative Example between Body Mass Index and Covid-19},
  shorttitle = {A Framework for Assessing Selection and Misclassification Bias in Mendelian Randomisation Studies},
  author = {Clayton, Gemma L. and Gon{\c c}alves, Ana and Soares and Goulding, Neil and Borges, Maria Carolina and Holmes, Michael V. and Davey, George and Smith and Tilling, Kate and Lawlor, Deborah A. and Carter, Alice R.},
  year = {2023},
  month = jun,
  journal = {BMJ},
  volume = {381},
  pages = {e072148},
  publisher = {British Medical Journal Publishing Group},
  issn = {1756-1833},
  doi = {10.1136/bmj-2022-072148},
  urldate = {2025-06-03},
  abstract = {{$<$}p{$>$}Mendelian randomisation (MR) studies, which investigate causal effects of exposures on disease, might be biased by sample selection and misclassification if phenotypes are not measured universally with the same definition in all study populations or participants. For example, in MR analyses of effects of exposures on covid-19, studies might include individuals with specific characteristics (eg, high socioeconomic position) meaning they are more likely to be tested for SARS-CoV-2 infection or respond to study questionnaires collecting data on infection and disease (selection bias). Alternatively, studies might assume those who were not tested have not been infected by SARS-CoV-2 or had covid-19 and are included as control participants (misclassification bias). In this article, a set of analyses to investigate the presence of selection or misclassification bias in MR studies is proposed and the implications of these on results is considered. The effect of body mass index on covid-19 susceptibility and severity is used as an illustrative example.{$<$}/p{$>$}},
  chapter = {Research Methods \&amp; Reporting},
  copyright = {{\copyright} Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.. http://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.},
  langid = {english},
  pmid = {37336561},
  file = {/Users/xx20081/Zotero/storage/8AH9TA46/Clayton et al. - 2023 - A framework for assessing selection and misclassification bias in mendelian randomisation studies a.pdf}
}

@article{cohenAssociationMidlifeCardiovascular2021,
  title = {Association of {{Midlife Cardiovascular Risk Factors With}} the {{Risk}} of {{Heart Failure Subtypes Later}} in {{Life}}},
  author = {Cohen, Laura P. and Vittinghoff, Eric and Pletcher, Mark J. and Allen, Norrina B. and Shah, Sanjiv J. and Wilkins, John T. and Chang, Patricia P. and Ndumele, Chiadi E. and Newman, Anne B. and Ives, Diane and Maurer, Mathew S. and Oelsner, Elizabeth C. and Moran, Andrew E. and Zhang, Yiyi},
  year = {2021},
  month = apr,
  journal = {Journal of Cardiac Failure},
  volume = {27},
  number = {4},
  pages = {435--444},
  issn = {1532-8414},
  doi = {10.1016/j.cardfail.2020.11.008},
  abstract = {BACKGROUND: Independent associations between cardiovascular risk factor exposures during midlife and later life development of heart failure (HF) with preserved ejection fraction (HFpEF) versus reduced EF (HFrEF) have not been previously studied. METHODS: We pooled data from 4 US cohort studies (Atherosclerosis Risk in Communities, Cardiovascular Health, Health , Aging and Body Composition, and Multi-Ethnic Study of Atherosclerosis) and imputed annual risk factor trajectories for body mass index, systolic and diastolic blood pressure, low-density lipoprotein and high-density lipoprotein cholesterol, and glucose starting from age 40 years. Time-weighted average exposures to each risk factor during midlife and later life were calculated and analyzed for associations with the development of HFpEF or HFrEF. RESULTS: A total of 23,861 participants were included (mean age at first in-person visit, 61.8 {\textpm}1 0.2 years; 56.6\% female). During a median follow-up of 12 years, there were 3666 incident HF events, of which 51\% had EF measured, including 934 with HFpEF and 739 with HFrEF. A high midlife systolic blood pressure and low midlife high-density lipoprotein cholesterol were associated with HFrEF, and a high midlife body mass index, systolic blood pressure, pulse pressure, and glucose were associated with HFpEF. After adjusting for later life exposures, only midlife pulse pressure remained independently associated with HFpEF. CONCLUSIONS: Midlife exposure to cardiovascular risk factors are differentially associated with HFrEF and HFpEF later in life. Having a higher pulse pressure during midlife is associated with a greater risk for HFpEF but not HFrEF, independent of later life exposures.},
  langid = {english},
  pmcid = {PMC7987686},
  pmid = {33238139},
  keywords = {Adult,Cardiovascular Diseases,Female,Heart Disease Risk Factors,Heart Failure,Heart failure subtype,heart failure with preserved ejection fraction,heart failure with reduced ejection fraction,Humans,Male,midlife,Prognosis,risk factors,Risk Factors,Stroke Volume},
  file = {/Users/xx20081/Zotero/storage/BPM9AE8K/Cohen et al. - 2021 - Association of Midlife Cardiovascular Risk Factors.pdf}
}

@article{Cohn2001,
  title = {A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure},
  author = {Cohn, Jay N. and Tognoni, Gianni},
  year = {2001},
  month = dec,
  journal = {The New England journal of medicine},
  volume = {345},
  number = {23},
  pages = {1667--1675},
  publisher = {N Engl J Med},
  issn = {0028-4793},
  doi = {10.1056/NEJMOA010713},
  pmid = {11759645},
  keywords = {Adrenergic beta-Antagonists / therapeutic use,affs=[]),Angiotensin Receptor Antagonists*,Angiotensin-Converting Enzyme Inhibitors / therapeutic use,Chronic Disease,Clinical Trial,CollabAuthor(name='Valsartan Heart Failure Trial Investigators',Combination,doi:10.1056/NEJMoa010713,Double-Blind Method,Drug Therapy,Female,G Tognoni,Heart Failure / drug therapy*,Heart Failure / mortality,Heart Failure / physiopathology,Hospitalization,Humans,investigators=[],J N Cohn,Male,MEDLINE,Middle Aged,Multicenter Study,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,Non-U.S. Gov't,pmid:11759645,Probability,PubMed Abstract,Quality of Life,Randomized Controlled Trial,Research Support,Stroke Volume / drug effects,Survival Analysis,Tetrazoles / therapeutic use*,Valine / analogs & derivatives*,Valine / therapeutic use*,Valsartan}
}

@article{cohnRandomizedTrialAngiotensinreceptor2001,
  title = {A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure},
  author = {Cohn, J. N. and Tognoni, G. and {Valsartan Heart Failure Trial Investigators}},
  year = {2001},
  month = dec,
  journal = {The New England Journal of Medicine},
  volume = {345},
  number = {23},
  pages = {1667--1675},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa010713},
  abstract = {BACKGROUND: Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure. METHODS: A total of 5010 patients with heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned to receive 160 mg of valsartan or placebo twice daily. The primary outcomes were mortality and the combined end point of mortality and morbidity, defined as the incidence of cardiac arrest with resuscitation, hospitalization for heart failure, or receipt of intravenous inotropic or vasodilator therapy for at least four hours. RESULTS: Overall mortality was similar in the two groups. The incidence of the combined end point, however, was 13.2 percent lower with valsartan than with placebo (relative risk, 0.87; 97.5 percent confidence interval, 0.77 to 0.97; P=0.009), predominantly because of a lower number of patients hospitalized for heart failure; 455 (18.2 percent) in the placebo group and 346 (13.8 percent) in the valsartan group (P{$<$}0.001). Treatment with valsartan also resulted in significant improvements in NYHA class, ejection fraction, signs and symptoms of heart failure, and quality of life as compared with placebo (P{$<$}0.01). In a post hoc analysis of the combined end point and mortality in subgroups defined according to base-line treatment with angiotensin-converting-enzyme (ACE) inhibitors or beta-blockers, valsartan had a favorable effect in patients receiving neither or one of these types of drugs but an adverse effect in patients receiving both types of drugs. CONCLUSIONS: Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy. However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination.},
  langid = {english},
  pmid = {11759645},
  keywords = {Adrenergic beta-Antagonists,Angiotensin Receptor Antagonists,Angiotensin-Converting Enzyme Inhibitors,Chronic Disease,Double-Blind Method,Drug Therapy Combination,Female,Heart Failure,Hospitalization,Humans,Male,Middle Aged,Probability,Quality of Life,Stroke Volume,Survival Analysis,Tetrazoles,Valine,Valsartan}
}

@article{coleIllustratingBiasDue2010,
  title = {Illustrating Bias Due to Conditioning on a Collider},
  author = {Cole, Stephen R. and Platt, Robert W. and Schisterman, Enrique F. and Chu, Haitao and Westreich, Daniel and Richardson, David and Poole, Charles},
  year = {2010},
  month = apr,
  journal = {International Journal of Epidemiology},
  volume = {39},
  number = {2},
  pages = {417--420},
  issn = {1464-3685},
  doi = {10.1093/ije/dyp334},
  abstract = {That conditioning on a common effect of exposure and outcome may cause selection, or collider-stratification, bias is not intuitive. We provide two hypothetical examples to convey concepts underlying bias due to conditioning on a collider. In the first example, fever is a common effect of influenza and consumption of a tainted egg-salad sandwich. In the second example, case-status is a common effect of a genotype and an environmental factor. In both examples, conditioning on the common effect imparts an association between two otherwise independent variables; we call this selection bias.},
  langid = {english},
  pmcid = {PMC2846442},
  pmid = {19926667},
  keywords = {Epidemiologic Research Design,Humans,Odds Ratio,Regression Analysis,Risk Assessment,Selection Bias},
  file = {/Users/xx20081/Zotero/storage/4QKCT7HD/Cole et al. - 2010 - Illustrating bias due to conditioning on a collide.pdf}
}

@article{collisRelationsStrokeVolume2001,
  title = {Relations of Stroke Volume and Cardiac Output to Body Composition: The Strong Heart Study},
  shorttitle = {Relations of Stroke Volume and Cardiac Output to Body Composition},
  author = {Collis, T. and Devereux, R. B. and Roman, M. J. and {de Simone}, G. and Yeh, J. and Howard, B. V. and Fabsitz, R. R. and Welty, T. K.},
  year = {2001},
  month = feb,
  journal = {Circulation},
  volume = {103},
  number = {6},
  pages = {820--825},
  issn = {1524-4539},
  doi = {10.1161/01.cir.103.6.820},
  abstract = {BACKGROUND: Although cardiac output (CO) plays the vital role of delivering nutrients to body tissues, few data are available concerning the relations of stroke volume (SV) and CO to body composition in large population samples. METHODS AND RESULTS: Doppler and 2D echocardiography and bioelectric impedance in 2744 Strong Heart Study participants were used to calculate SV and CO and to relate them to fat-free body mass (FFM), adipose mass, and demographic variables. Both SV and CO were higher in men than women and in overweight than normal-weight individuals, but these differences were diminished or even reversed by normalization for FFM or body surface area. In both sexes, SV and CO were more strongly related to FFM than adipose mass, other body habitus measures, arterial pressure, diabetes, or age. In multivariate analyses using the average of Doppler and left ventricular SV to minimize measurement variability, FFM was the strongest correlate of SV and CO; other independent correlates were adipose mass, systolic pressure, diabetes, age, and use of digoxin and calcium channel and beta-blockers. CONCLUSIONS: In a population-based sample, SV and CO are more strongly related to FFM than other variables; increased FFM may be the primary determinant of increased SV and CO in obesity.},
  langid = {english},
  pmid = {11171789},
  keywords = {Adipose Tissue,Aged,Aged 80 and over,Analysis of Variance,Body Composition,Body Mass Index,Body Surface Area,Body Water,Body Weight,Cardiac Output,Cardiography Impedance,Cardiovascular Diseases,Demography,Echocardiography,Female,Humans,Indians North American,Male,Mathematics,Middle Aged,Obesity,Risk Factors,Sex Factors,Stroke Volume,United States}
}

@article{commodore-mensahHighBurdenSubclinical2021,
  title = {High {{Burden}} of {{Subclinical}} and {{Cardiovascular Disease Risk}} in {{Adults With Metabolically Healthy Obesity}}: {{The Atherosclerosis Risk}} in {{Communities}} ({{ARIC}}) {{Study}}},
  shorttitle = {High {{Burden}} of {{Subclinical}} and {{Cardiovascular Disease Risk}} in {{Adults With Metabolically Healthy Obesity}}},
  author = {{Commodore-Mensah}, Y and M, Lazo and O, Tang and Jb, Echouffo-Tcheugui and Ce, Ndumele and V, Nambi and D, Wang and C, Ballantyne and E, Selvin},
  year = {2021},
  month = jul,
  journal = {Diabetes care},
  volume = {44},
  number = {7},
  publisher = {Diabetes Care},
  issn = {1935-5548},
  doi = {10.2337/dc20-2227},
  urldate = {2024-07-05},
  abstract = {The metabolically healthy obese phenotype was associated with excess burden of clinical CVD, primarily driven by an excess risk of HF. hs-cTnT was useful in stratifying CVD risk across all obesity phenotypes, even among obese individuals who appear otherwise metabolically healthy.},
  langid = {english},
  pmid = {33952606},
  file = {/Users/xx20081/Zotero/storage/HKUJ7KL6/Y et al. - 2021 - High Burden of Subclinical and Cardiovascular Dise.pdf;/Users/xx20081/Zotero/storage/NR4IRCS7/33952606.html}
}

@article{connerForwardGeneticAnalysis2008,
  title = {Forward Genetic Analysis of {{Toll-like}} Receptor Responses in Wild-Derived Mice Reveals a Novel Antiinflammatory Role for {{IRAK1BP1}}},
  author = {Conner, James R. and Smirnova, Irina I. and Poltorak, Alexander},
  year = {2008},
  month = feb,
  journal = {The Journal of Experimental Medicine},
  volume = {205},
  number = {2},
  pages = {305--314},
  issn = {0022-1007},
  doi = {10.1084/jem.20071499},
  urldate = {2024-04-12},
  abstract = {Although inflammatory cytokines produced by activation of Toll-like receptors (TLRs) are essential for early host defense against infection, they also mediate a vast array of pathologies, including autoimmune disease, hypersensitivity reactions, and sepsis. Thus, numerous regulatory mechanisms exist in parallel with proinflammatory pathways to prevent excessive release of these potent effector molecules. We report elucidation of a novel regulatory function for interleukin receptor--associated kinase (IRAK)-1 binding protein 1 (IRAK1BP1, also known as SIMPL) through quantitative trait locus mapping of the TLR response in wild-derived mouse strains. This gene emerged as a negative regulator of TLR2-mediated interleukin (IL)-6 production in MOLF/Ei mice, which expressed IRAK1BP1 mRNA in an allele-specific manner when crossed with the C57BL/6J strain. Human peripheral blood mononuclear cells and primary macrophages from two other wild-derived mouse strains also induced IRAK1BP1 mRNA by 4 hours after stimulation with agonists of various TLRs. Examination of its effects on IL-6 and other cytokines demonstrated that IRAK1BP1 regulates transcription of a specific subset of TLR-responsive genes, producing an overall antiinflammatory profile. Our results reveal that IRAK1BP1 is a critical factor in preventing dangerous overproduction of proinflammatory cytokines by the innate immune system and in influencing the specificity of TLR responses. Furthermore, these results show that the genetic diversity of wild-derived mouse strains makes them a valuable model of important human gene functions that have been lost in some laboratory-inbred strains.},
  pmcid = {PMC2271017},
  pmid = {18268037},
  file = {/Users/xx20081/Zotero/storage/JGXQRDIX/Conner et al. - 2008 - Forward genetic analysis of Toll-like receptor res.pdf}
}

@article{connerIRAK1BP1InhibitsInflammation2010,
  title = {{{IRAK1BP1}} Inhibits Inflammation by Promoting Nuclear Translocation of {{NF-$\kappa$B}} P50},
  author = {Conner, James R. and Smirnova, Irina I. and Moseman, Annie Park and Poltorak, Alexander},
  year = {2010},
  month = jun,
  journal = {Proceedings of the National Academy of Sciences of the United States of America},
  volume = {107},
  number = {25},
  pages = {11477--11482},
  issn = {0027-8424},
  doi = {10.1073/pnas.1006894107},
  urldate = {2024-04-12},
  abstract = {An orchestrated balance of pro- and antiinflammatory cytokine release is critical for an innate immune response sufficient for pathogen defense without excessive detriment to host tissues. By using an unbiased forward genetic approach, we previously reported that IL-1R--associated kinase 1 binding protein 1 (IRAK1BP1) down-modulates Toll-like receptor-mediated transcription of several proinflammatory cytokines. To gain insights into the physiological relevance of the inhibitory role of IRAK1BP1 in inflammation, we generated mutant mice lacking IRAK1BP1. Here we report that IRAK1BP1 does not inhibit signaling pathways generally but rather changes the transcriptional profile of activated cells, leading to an increase in IL-10 production and promoting LPS tolerance. This shift in cytokine transcription correlates with an increased ratio of functional NF-{$\kappa$}B subunit dimers comprised of p50/p50 homodimers relative to p50/p65 heterodimers. The increase in nuclear p50/p50 was consistent with the ability of IRAK1BP1 to bind to the p50 precursor molecule and I{$\kappa$}B family member p105. We conclude that IRAK1BP1 functions through its effects on NF-{$\kappa$}B as a molecular switch to bias innate immune pathways toward the resolution of inflammation.},
  pmcid = {PMC2895073},
  pmid = {20534545},
  file = {/Users/xx20081/Zotero/storage/SL2H4NG2/Conner et al. - 2010 - IRAK1BP1 inhibits inflammation by promoting nuclea.pdf}
}

@article{conradTrendsCardiovascularDisease2024,
  title = {Trends in Cardiovascular Disease Incidence among 22 Million People in the {{UK}} over 20 Years: Population Based Study},
  shorttitle = {Trends in Cardiovascular Disease Incidence among 22 Million People in the {{UK}} over 20 Years},
  author = {Conrad, Nathalie and Molenberghs, Geert and Verbeke, Geert and Zaccardi, Francesco and Lawson, Claire and Friday, Jocelyn M. and Su, Huimin and Jhund, Pardeep S. and Sattar, Naveed and Rahimi, Kazem and Cleland, John G. and Khunti, Kamlesh and Budts, Werner and McMurray, John J. V.},
  year = {2024},
  month = jun,
  journal = {BMJ},
  volume = {385},
  pages = {e078523},
  publisher = {British Medical Journal Publishing Group},
  issn = {1756-1833},
  doi = {10.1136/bmj-2023-078523},
  urldate = {2025-05-20},
  abstract = {Objective To investigate the incidence of cardiovascular disease (CVD) overall and by age, sex, and socioeconomic status, and its variation over time, in the UK during 2000-19. Design Population based study. Setting UK. Participants 1 650 052 individuals registered with a general practice contributing to Clinical Practice Research Datalink and newly diagnosed with at least one CVD from 1 January 2000 to 30 June 2019. Main outcome measures The primary outcome was incident diagnosis of CVD, comprising acute coronary syndrome, aortic aneurysm, aortic stenosis, atrial fibrillation or flutter, chronic ischaemic heart disease, heart failure, peripheral artery disease, second or third degree heart block, stroke (ischaemic, haemorrhagic, and unspecified), and venous thromboembolism (deep vein thrombosis or pulmonary embolism). Disease incidence rates were calculated individually and as a composite outcome of all 10 CVDs combined and were standardised for age and sex using the 2013 European standard population. Negative binomial regression models investigated temporal trends and variation by age, sex, and socioeconomic status. Results The mean age of the population was 70.5 years and 47.6\% (n=784 904) were women. The age and sex standardised incidence of all 10 prespecified CVDs declined by 19\% during 2000-19 (incidence rate ratio 2017-19 v 2000-02: 0.80, 95\% confidence interval 0.73 to 0.88). The incidence of coronary heart disease and stroke decreased by about 30\% (incidence rate ratios for acute coronary syndrome, chronic ischaemic heart disease, and stroke were 0.70 (0.69 to 0.70), 0.67 (0.66 to 0.67), and 0.75 (0.67 to 0.83), respectively). In parallel, an increasing number of diagnoses of cardiac arrhythmias, valve disease, and thromboembolic diseases were observed. As a result, the overall incidence of CVDs across the 10 conditions remained relatively stable from the mid-2000s. Age stratified analyses further showed that the observed decline in coronary heart disease incidence was largely restricted to age groups older than 60 years, with little or no improvement in younger age groups. Trends were generally similar between men and women. A socioeconomic gradient was observed for almost every CVD investigated. The gradient did not decrease over time and was most noticeable for peripheral artery disease (incidence rate ratio most deprived v least deprived: 1.98 (1.87 to 2.09)), acute coronary syndrome (1.55 (1.54 to 1.57)), and heart failure (1.50 (1.41 to 1.59)). Conclusions Despite substantial improvements in the prevention of atherosclerotic diseases in the UK, the overall burden of CVDs remained high during 2000-19. For CVDs to decrease further, future prevention strategies might need to consider a broader spectrum of conditions, including arrhythmias, valve diseases, and thromboembolism, and examine the specific needs of younger age groups and socioeconomically deprived populations.},
  chapter = {Research},
  copyright = {{\copyright} Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.. http://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.},
  langid = {english},
  pmid = {38925788},
  file = {/Users/xx20081/Zotero/storage/F75CUY8M/Conrad et al. - 2024 - Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years populati.pdf}
}

@misc{ContextualizingSelectionBias,
  title = {Contextualizing Selection Bias in {{Mendelian}} Randomization: How Bad Is It Likely to Be? {\textbar} {{International Journal}} of {{Epidemiology}} {\textbar} {{Oxford Academic}}},
  urldate = {2025-01-22},
  howpublished = {https://academic.oup.com/ije/article/48/3/691/5132989}
}

@article{corbinMetabolomicSignatureWeight2024,
  title = {The Metabolomic Signature of Weight Loss and Remission in the {{Diabetes Remission Clinical Trial}} ({{DiRECT}})},
  author = {Corbin, Laura J. and Hughes, David A. and Bull, Caroline J. and Vincent, Emma E. and Smith, Madeleine L. and McConnachie, Alex and Messow, Claudia-Martina and Welsh, Paul and Taylor, Roy and Lean, Michael E. J. and Sattar, Naveed and Timpson, Nicholas J.},
  year = {2024},
  month = jan,
  journal = {Diabetologia},
  volume = {67},
  number = {1},
  pages = {74--87},
  issn = {1432-0428},
  doi = {10.1007/s00125-023-06019-x},
  abstract = {AIMS/HYPOTHESIS: High-throughput metabolomics technologies in a variety of study designs have demonstrated a consistent metabolomic signature of overweight and type 2 diabetes. However, the extent to which these metabolomic patterns can be reversed with weight loss and diabetes remission has been weakly investigated. We aimed to characterise the metabolomic consequences of a weight-loss intervention in individuals with type 2 diabetes. METHODS: We analysed 574 fasted serum samples collected within an existing RCT (the Diabetes Remission Clinical Trial [DiRECT]) (N=298). In the trial, participating primary care practices were randomly assigned (1:1) to provide either a weight management programme (intervention) or best-practice care by guidelines (control) treatment to individuals with type 2 diabetes. Here, metabolomics analysis was performed on samples collected at baseline and 12 months using both untargeted MS and targeted 1H-NMR spectroscopy. Multivariable regression models were fitted to evaluate the effect of the intervention on metabolite levels. RESULTS: Decreases in branched-chain amino acids, sugars and LDL triglycerides, and increases in sphingolipids, plasmalogens and metabolites related to fatty acid metabolism were associated with the intervention (Holm-corrected p{$<$}0.05). In individuals who lost more than 9 kg between baseline and 12 months, those who achieved diabetes remission saw greater reductions in glucose, fructose and mannose, compared with those who did not achieve remission. CONCLUSIONS/INTERPRETATION: We have characterised the metabolomic effects of an integrated weight management programme previously shown to deliver weight loss and diabetes remission. A large proportion of the metabolome appears to be modifiable. Patterns of change were largely and strikingly opposite to perturbances previously documented with the development of type 2 diabetes. DATA AVAILABILITY: The data used for analysis are available on a research data repository ( https://researchdata.gla.ac.uk/ ) with access given to researchers subject to appropriate data sharing agreements. Metabolite data preparation, data pre-processing, statistical analyses and figure generation were performed in R Studio v.1.0.143 using R v.4.0.2. The R code for this study has been made publicly available on GitHub at: https://github.com/lauracorbin/metabolomics\_of\_direct .},
  langid = {english},
  pmcid = {PMC10709482},
  pmid = {37878066},
  keywords = {Diabetes Mellitus Type 2,Diabetes remission,DiRECT,Glucose,Humans,Metabolome,Metabolomics,Randomised controlled trial,Randomized Controlled Trials as Topic,Type 2 diabetes,Weight loss,Weight Loss}
}

@article{crawfordCerebrovascularDiseaseKnowledge2018,
  title = {Cerebrovascular {{Disease Knowledge Portal}}: {{An Open-Access Data Resource}} to {{Accelerate Genomic Discoveries}} in {{Stroke}}},
  shorttitle = {Cerebrovascular {{Disease Knowledge Portal}}},
  author = {Crawford, Katherine M. and {Gallego-Fabrega}, Cristina and Kourkoulis, Christina and Miyares, Laura and Marini, Sandro and Flannick, Jason and Burtt, Noel P. and {von Grotthuss}, Marcin and Alexander, Benjamin and Costanzo, Maria C. and Vaishnav, Neil H. and Malik, Rainer and Hall, Jennifer L. and Chong, Michael and Rosand, Jonathan and Falcone, Guido J. and {International Stroke Genetics Consortium}},
  year = {2018},
  month = feb,
  journal = {Stroke},
  volume = {49},
  number = {2},
  pages = {470--475},
  issn = {1524-4628},
  doi = {10.1161/STROKEAHA.117.018922},
  langid = {english},
  pmcid = {PMC5780219},
  pmid = {29335331},
  keywords = {cause of death,cerebral hemorrhage,Cerebral Hemorrhage,Cerebrovascular Disorders,Genetic Predisposition to Disease,Genomics,humans,Humans,Information Storage and Retrieval,research,stroke,Stroke},
  file = {/Users/xx20081/Zotero/storage/7CAASVWV/Crawford et al. - 2018 - Cerebrovascular Disease Knowledge Portal An Open-Access Data Resource to Accelerate Genomic Discove.pdf}
}

@article{curtisObesityParadoxBody2005,
  title = {The Obesity Paradox: Body Mass Index and Outcomes in Patients with Heart Failure},
  shorttitle = {The Obesity Paradox},
  author = {Curtis, Jeptha P. and Selter, Jared G. and Wang, Yongfei and Rathore, Saif S. and Jovin, Ion S. and Jadbabaie, Farid and Kosiborod, Mikhail and Portnay, Edward L. and Sokol, Seth I. and Bader, Feras and Krumholz, Harlan M.},
  year = {2005},
  month = jan,
  journal = {Archives of Internal Medicine},
  volume = {165},
  number = {1},
  pages = {55--61},
  issn = {0003-9926},
  doi = {10.1001/archinte.165.1.55},
  abstract = {BACKGROUND: In the general population, obesity is associated with increased risk of adverse outcomes. However, studies of patients with chronic disease suggest that overweight and obese patients may paradoxically have better outcomes than lean patients. We sought to examine the association of body mass index (BMI) and outcomes in stable outpatients with heart failure (HF). METHODS: We analyzed data from 7767 patients with stable HF enrolled in the Digitalis Investigation Group trial. Patients were categorized using baseline BMI (calculated as weight in kilograms divided by the square of height in meters) as underweight (BMI {$<$}18.5), healthy weight (BMI, 18.5-24.9, overweight (BMI, 25.0-29.9), and obese (BMI {$>$} or =30.0). Risks associated with BMI groups were evaluated using multivariable Cox proportional hazards models over a mean follow-up of 37 months. RESULTS: Crude all-cause mortality rates decreased in a near linear fashion across successively higher BMI groups, from 45.0\% in the underweight group to 28.4\% in the obese group (P for trend {$<$}.001). After multivariable adjustment, overweight and obese patients were at lower risk for death (hazard ratio [HR], 0.88; 95\% confidence interval [CI], 0.80-0.96, and HR, 0.81; 95\% CI, 0.72-0.92, respectively), compared with patients at a healthy weight (referent). In contrast, underweight patients with stable HF were at increased risk for death (HR 1.21; 95\% CI, 0.95-1.53). CONCLUSIONS: In a cohort of outpatients with established HF, higher BMIs were associated with lower mortality risks; overweight and obese patients had lower risk of death compared with those at a healthy weight. Understanding the mechanisms and impact of the "obesity paradox" in patients with HF is necessary before recommendations are made concerning weight and weight control in this population.},
  langid = {english},
  pmid = {15642875},
  keywords = {Aged,Body Mass Index,Clinical Trials as Topic,Female,Follow-Up Studies,Heart Failure,Humans,Male,Middle Aged,Multivariate Analysis,Obesity,Outpatients,Proportional Hazards Models},
  file = {/Users/xx20081/Zotero/storage/NZFRTMTQ/Curtis et al. - 2005 - The obesity paradox body mass index and outcomes .pdf}
}

@article{cuthbertOutcomesPatientsTreated2024,
  title = {Outcomes in Patients Treated with Loop Diuretics without a Diagnosis of Heart Failure: A Retrospective Cohort Study},
  shorttitle = {Outcomes in Patients Treated with Loop Diuretics without a Diagnosis of Heart Failure},
  author = {Cuthbert, Joseph James and Soyiri, Ireneous and Lomax, Stephanie Jayne and Turgoose, John and Fuat, Ahmet and Cohen, Judith and Clark, Andrew L.},
  year = {2024},
  month = may,
  journal = {Heart (British Cardiac Society)},
  volume = {110},
  number = {12},
  pages = {854--862},
  issn = {1468-201X},
  doi = {10.1136/heartjnl-2023-323577},
  abstract = {BACKGROUND: Loop diuretics are commonly prescribed in the community, not always to patients with a recorded diagnosis of heart failure (HF). The rate of HF events in patients prescribed loop diuretics without a diagnosis of HF is unknown. METHODS: This was a propensity-matched cohort study using data from the Clinical Practice Research Datalink, Hospital Episode Statistics and Office of National Statistics in the UK. Patients prescribed a loop diuretic without a diagnosis of HF (loop diuretic group) between 1 January 2010 and 31 December 2015 were compared with patients with HF (HF group)-analysis A, and patients with risk factors for HF (either ischaemic heart disease, or diabetes and hypertension-at-risk group)-analysis B. The primary endpoint was an HF event (a composite of presentation with HF symptoms, HF hospitalisation, HF diagnosis (analysis B only) and all-cause mortality). RESULTS: From a total population of 180\,384 patients (78\,968 in the loop diuretic group, 28\,177 in the HF group and 73\,239 in the at-risk group), there were 59\,694 patients, 22\,352 patients and 57\,219 patients in the loop diuretic, HF and at-risk groups, respectively, after exclusion criteria were applied. After propensity matching for age, sex and comorbidities, patients in the loop diuretic group had a similar rate of HF events as those in the HF group (71.9\% vs 72.1\%; HR=0.92 (95\% CI 0.90 to 0.94); p{$<$}0.001), and twice as those in the at-risk group (59.2\% vs 35.7\%; HR=2.04 (95\% CI 2.00 to 2.08); p{$<$}0.001). CONCLUSIONS: Patients prescribed a loop diuretic without a recorded diagnosis of HF experience HF events at a rate comparable with that of patients with a recorded diagnosis of HF; many of these patients may have undiagnosed HF.},
  langid = {english},
  pmid = {38631899},
  keywords = {Aged,Aged 80 and over,Electronic Health Records,Epidemiology,Female,Heart failure,Heart Failure,Hospitalization,Humans,Male,Middle Aged,Pharmacology Clinical,Propensity Score,Retrospective Studies,Risk Factors,Sodium Potassium Chloride Symporter Inhibitors,Treatment Outcome,United Kingdom}
}

@article{daghlasGeneticEvidenceRepurposing2021,
  title = {Genetic {{Evidence}} for {{Repurposing}} of {{GLP1R}} ({{Glucagon}}-{{Like Peptide}}-1 {{Receptor}}) {{Agonists}} to {{Prevent Heart Failure}}},
  author = {Daghlas, Iyas and Karhunen, Ville and Ray, Devleena and Zuber, Verena and Burgess, Stephen and Tsao, Philip S. and Lynch, Julie A. and Lee, Kyung Min and Voight, Benjamin F. and Chang, Kyong-Mi and Baker, Emma H. and Damrauer, Scott M. and Howson, Joanna M. M. and Vujkovic, Marijana and Gill, Dipender},
  year = {2021},
  month = jul,
  journal = {Journal of the American Heart Association},
  volume = {10},
  number = {13},
  pages = {e020331},
  publisher = {Wiley},
  doi = {10.1161/JAHA.120.020331},
  urldate = {2024-01-23},
  abstract = {Background This study was designed to investigate the genetic evidence for repurposing of GLP1R (glucagon-like peptide-1 receptor) agonists to prevent heart failure (HF) and whether the potential benefit exceeds the benefit conferred by more general glycemic control. Methods and Results We applied 2-sample Mendelian randomization of genetically proxied GLP1R agonism on HF as the main outcome and left ventricular ejection fraction as the secondary outcome. The associations were compared with those of general glycemic control on the same outcomes. Genetic associations were obtained from genome-wide association study summary statistics of type 2 diabetes mellitus (228~499 cases and 1~178~783 controls), glycated hemoglobin (n=344~182), HF (47,309 cases and 930~014 controls), and left ventricular ejection fraction (n=16~923). Genetic proxies for GLP1R agonism associated with reduced risk of HF (odds ratio per 1~mmol/mol decrease in glycated hemoglobin 0.75; 95\% CI, 0.64--0.87; P=1.69{\texttimes}10-4), and higher left ventricular ejection fraction (SD change in left ventricular ejection fraction per 1~mmol/mol decrease in glycated hemoglobin 0.22\%; 95\% CI, 0.03--0.42; P=0.03). The magnitude of these benefits exceeded those expected from improved glycemic control more generally. The results were similar in sensitivity analyses, and we did not find evidence to suggest that these associations were mediated by reduced coronary artery disease risk. Conclusions This genetic evidence supports the repurposing of GLP1R agonists for preventing HF.},
  keywords = {diabetes mellitus,ejection fraction,GLP1R,heart failure,Mendelian randomization},
  file = {/Users/xx20081/Zotero/storage/4FAG9KUI/Daghlas et al. - 2021 - Genetic Evidence for Repurposing of GLP1R (Glucago.pdf}
}

@article{dahabrehIndexEventBias2011,
  title = {Index Event Bias: An Explanation for the Paradoxes of Recurrence Risk Research},
  shorttitle = {Index Event Bias},
  author = {Dahabreh, Issa J. and Kent, David M.},
  year = {2011},
  month = feb,
  journal = {JAMA : the journal of the American Medical Association},
  volume = {305},
  number = {8},
  pages = {822--823},
  issn = {0098-7484},
  doi = {10.1001/jama.2011.163},
  urldate = {2024-08-08},
  pmcid = {PMC4115579},
  pmid = {21343582},
  file = {/Users/xx20081/Zotero/storage/XHQEPKTQ/Dahabreh and Kent - 2011 - Index event bias an explanation for the paradoxes.pdf}
}

@article{dahabrehIndexEventBias2011a,
  title = {Index Event Bias: An Explanation for the Paradoxes of Recurrence Risk Research},
  shorttitle = {Index Event Bias},
  author = {Dahabreh, Issa J. and Kent, David M.},
  year = {2011},
  month = feb,
  journal = {JAMA : the journal of the American Medical Association},
  volume = {305},
  number = {8},
  pages = {822},
  doi = {10.1001/jama.2011.163},
  urldate = {2024-11-19},
  langid = {english},
  pmid = {21343582},
  file = {/Users/xx20081/Zotero/storage/WSLA4LRA/Dahabreh and Kent - 2011 - Index event bias an explanation for the paradoxes of recurrence risk research.pdf}
}

@article{daviesReadingMendelianRandomisation2018,
  title = {Reading {{Mendelian}} Randomisation Studies: A Guide, Glossary, and Checklist for Clinicians},
  shorttitle = {Reading {{Mendelian}} Randomisation Studies},
  author = {Davies, Neil M. and Holmes, Michael V. and Davey Smith, George},
  year = {2018},
  month = jul,
  journal = {BMJ (Clinical research ed.)},
  volume = {362},
  pages = {k601},
  issn = {1756-1833},
  doi = {10.1136/bmj.k601},
  abstract = {Mendelian randomisation uses genetic variation as a natural experiment to investigate the causal relations between potentially modifiable risk factors and health outcomes in observational data. As with all epidemiological approaches, findings from Mendelian randomisation studies depend on specific assumptions. We provide explanations of the information typically reported in Mendelian randomisation studies that can be used to assess the plausibility of these assumptions and guidance on how to interpret findings from Mendelian randomisation studies in the context of other sources of evidence},
  langid = {english},
  pmcid = {PMC6041728},
  pmid = {30002074},
  keywords = {Causality,Confounding Factors Epidemiologic,Effect Modifier Epidemiologic,Genetic Variation,Genome-Wide Association Study,Humans,Mendelian Randomization Analysis,Observational Studies as Topic,Outcome Assessment Health Care,Public Health},
  file = {/Users/xx20081/Zotero/storage/3LEU6Y2A/Davies et al. - 2018 - Reading Mendelian randomisation studies a guide, .pdf}
}

@article{dawedPharmacogenomicsGLP1Receptor2023,
  title = {Pharmacogenomics of {{GLP-1}} Receptor Agonists: A Genome-Wide Analysis of Observational Data and Large Randomised Controlled Trials},
  shorttitle = {Pharmacogenomics of {{GLP-1}} Receptor Agonists},
  author = {Dawed, Adem Y. and Mari, Andrea and Brown, Andrew and McDonald, Timothy J. and Li, Lin and Wang, Shuaicheng and Hong, Mun-Gwan and Sharma, Sapna and Robertson, Neil R. and Mahajan, Anubha and Wang, Xuan and Walker, Mark and Gough, Stephen and Hart, Leen M. `t and Zhou, Kaixin and Forgie, Ian and Ruetten, Hartmut and Pavo, Imre and Bhatnagar, Pallav and Jones, Angus G. and Pearson, Ewan R. and 't Hart, L. M. and Abdalla, M. and Adam, J. and Adamski, J. and Adragni, K. and Allin, K. H. and Arumugam, M. and Pasdar, N. Atabaki and Baltauss, T. and Banasik, K. B. and Baum, P. and Bell, J. D. and Bergstrom, M. and Beulens, J. W. and Bianzano, S. and Bizzotto, R. and Bonneford, A. and Brorsson, C. a. B. and Brown, A. A. and Brunak, S. B. and Cabrelli, L. and Caiazzo, R. and Canouil, M. and Dale, M. and Davtian, D. and Dawed, A. Y. and Masi, F. M. De and de Preville, N. and Dekkers, K. F. and Dermitzakis, E. T. and Deshmukh, H. A. and Dings, C. and Donnelly, L. and Dutta, A. and Ehrhardt, B. and Elders, P. J. M. and Thomas, C. E. T. Engel and Engelbrechtsen, L. and Eriksen, R. G. and Eriksen, R. E. and Fan, Y. and Fernandez, J. and Ferrer, J. and Fitipaldi, H. and Forgie, I. M. and Forman, A. and Franks, P. W. and Frau, F. and Fritsche, A. and Froguel, P. and Frost, G. and Gassenhuber, J. and Giordano, G. N. and Giorgino, T. and Gough, S. and {Graefe-Mody}, U. and Grallert, H. and Grempler, R. and Groeneveld, L. and Groop, L. and Gudmundsd{\'o}ttir, V. G. and Gupta, R. G. and Haid, M. and Hansen, T. and Hansen, T. H. and Hattersley, A. T. and Haussler, R. S. and Heggie, A. J. and Hennige, A. M. and Hill, A. V. and Holl, R. W. and Hong, M.-G. and Hudson, M. and Jablonka, B. and Jennison, C. and Jiao, J. and Johansen, J. J. and Jones, A. G. and Jonsson, A. and Karaderi, T. K. and Kaye, J. and Klintenberg, M. and Koivula, R. W. and Kokkola, T. and Koopman, A. D. M. and Kurbasic, A. and Kuulasmaa, T. and Laakso, M. and Lehr, T. and Loftus, H. and Alles{\o}e, R. L. A. Lundbye and Mahajan, A. and Mari, A. and Mazzoni, G. M. and McCarthy, M. I. and McDonald, T. J. and McEvoy, D. and McRobert, N. and McVittie, I. and Mourby, M. and Musholt, P. and Mutie, P. and Nice, R. and Nicolay, C. and Nielsen, A. M. N. and Nilsson, B. N. and Palmer, C. N. and Pattou, F. and Pavo, I. and Pearson, E. R. and Pedersen, O. and Pedersen, H. K. P. and Perry, M. H. and {Pomares-Millan}, H. and Ramisch, A. and Rasmussen, S. R. and Raverdi, V. and Ridderstrale, M. and Robertson, N. and Roderick, R. C. and Rodriquez, M. and Ruetten, H. and Rutters, F. and Sackett, W. and Scherer, N. and Schwenk, J. M. and Shah, N. and Sharma, S. and Sihinevich, I. and Sondertoft, N. B. and Staerfeldt, H. and {Steckel-Hamann}, B. and Teare, H. and Thomas, M. K. and Thomas, E. L. and Thomsen, H. S. and Thorand, B. and Thorne, C. E. and Tillner, J. and Lundgaard, A. T. L. Troen and Troll, M. and Tsirigos, K. D. T. and Tura, A. and Uhlen, M. and van Leeuwen, N. and van Oort, S. and Verkindt, H. and Vestergaard, H. and Vi{\~n}uela, A. and Vogt, J. K. and Sackett, P. W. S. Wad and Wake, D. and Walker, M. and {Wesolowska-Andersen}, A. and Whitcher, B. and White, M. W. and Wu, H.},
  year = {2023},
  month = jan,
  journal = {The Lancet Diabetes \& Endocrinology},
  volume = {11},
  number = {1},
  pages = {33--41},
  publisher = {Elsevier},
  issn = {2213-8587, 2213-8595},
  doi = {10.1016/S2213-8587(22)00340-0},
  urldate = {2024-01-21},
  langid = {english},
  pmid = {36528349},
  file = {/Users/xx20081/Zotero/storage/TGHQ86CH/Dawed et al. - 2023 - Pharmacogenomics of GLP-1 receptor agonists a gen.pdf}
}

@article{deanfieldSemaglutideCardiovascularOutcomes2024,
  title = {Semaglutide and Cardiovascular Outcomes in Patients with Obesity and Prevalent Heart Failure: A Prespecified Analysis of the {{SELECT}} Trial},
  shorttitle = {Semaglutide and Cardiovascular Outcomes in Patients with Obesity and Prevalent Heart Failure},
  author = {Deanfield, John and Verma, Subodh and Scirica, Benjamin M and Kahn, Steven E and Emerson, Scott S and Ryan, Donna and Lingvay, Ildiko and Colhoun, Helen M and Plutzky, Jorge and Kosiborod, Mikhail N and Hovingh, G Kees and {Hardt-Lindberg}, S{\o}ren and Frenkel, Ofir and Weeke, Peter E and Rasmussen, S{\o}ren and Goudev, Assen and Lang, Chim C and {Urina-Triana}, Miguel and Pietil{\"a}, Mikko and Lincoff, A Michael and Abe, Mitsunori and Abhaichand, Rajpal K and Abhayaratna, Walter P and Abhyankar, Atul and Abidin, Imran B Zainal and Abou Assi, Hiba and Accini Mendoza, Jose L and Adas, Mine and Agaiby, John M and Agarwal, Devendra K and Agha, Maher and Ahmed, Azazuddin and Ahtiainen, Petteri and Aigner, Elmar and Ajay, Naik and Ali, Norsiah and {Al-Karadsheh}, Amer and Allison, Roy and Allison, Dale C and Alpenidze, Diana and Altuntas, Yuksel and {Al-Zoebi}, Ayham and Ambuj, Roy and Amerena, John and Anderson, Robert J and Ando, Toshiaki and Andrews, Robert and Antonova, Elizaveta and Appel, Karl-Friedrich and Arantes, Fl{\'a}via B and Araz, Mustafa and Arbel, Yaron and Arenas Le{\'o}n, Jos{\'e} L and Argyrakopoulou, Georgia and Ariani, Mehrdad and Arias Mendoza, Maria A and Arif, Ahmed A and Arneja, Jaspal and Aroda, Vanita R and Aronne, Louis J and Arstall, Margaret and Asamoah, Njaimeh and Asanin, Milika and Audish, Hanid and Avram, Rodica and Badat, Aysha and Badiu, Corin V and Bakdash, Wa'el and Bakiner, Okan S and Bandezi, Vuyokazi N and Bang, Liew H and Bansal, Sandeep and Baranyai, Marietta and Barbarash, Olga and Barber, Mark and Barnum, Otis and Barone Rochette, Gilles and Bashkin, Amir and Baum, Seth and Bays, Harold E and Bazzoni Ruiz, Alberto E and Beckowski, Maciej and Beerachee, Yaswin and Bellary, Srikanth and Belousova, Lidia and Berk, Martin and Bernstein, Marc and Berra, Cesare and Beshay, Isaac and Bhagwat, Ajit and Bhan, Arti and Biggs, William C and Billings, Liana and Bitar, Fahed and Block, Bradley and Bo, Simona and Bogdanski, Pawel and Bolshakova, Olga O and Boshchenko, Alla A and Bosworth, Hayden and Botero Lopez, Rodrigo and B{\^o}ttcher, Morten and Bourgeois, Ronald and Brautigam, Donald and Breton, Cristian F and Broadley, Andrew and Brockmyre, Andrew P and Brodie, Steven K and Bucci, Marco and Budincevic, Hrvoje and Budoff, Matthew J and Buffman, Barry and Buljubasic, Nediljka and Buranapin, Supawan and Burgess, Lesley and Burguera, Bartolom{\'e} and Buriakovska, Olena and Buscemi, Silvio and Busch, Robert and Buse, John B and Buynak, Robert and Byrne, Maria and Caceaune, Elena and Cadena Bonfanti, Alberto J and Calinescu, Cornell V and Call, Robert S and Canecki Varzic, Silvija and Cannon, Kevin and Capehorn, Matt and Cariou, Bertrand and Carr, Jeffrey and {Carrillo-Jimenez}, Rodolfo and Casas, Marcelo and Castro, Almudena and Celik, Ahmet and Cercato, Cintia and Cermak, Ondrej and Cha, James Y and Chacon, Carolina and {Chaicha-Brom}, Tira and Chandra, Sandeep and Chettibi, Mohamed and Chevts, Julia and Christopher, Johann and Chrustowski, Witold and Cif, Adriana and Clark, Rebecca and Clark, Wayne and Clifford, Piers and Coetzee, Kathleen and Cogni, Giulia and Colao, Anna Maria and Colquhoun, David M and Concha, Mauricio and Condit, Jonathan and Constance, Christian and Constantin, Ciprian and Constantinescu, Silviana and Corbett, Clive and Cornett, George M and Correia, Marcelo and Cortinovis, Fiorenzo and Cosma, Dana and Creely, Steven and Cross, David and Curtis, Brian and Czochra, Wojciech and Daboul, Nizar Y and Dagdelen, Selcuk and D'agostino, Ronald and Dang, Cuong and Datta, Sudip and Davuluri, Ashwini K and Dawood, Saleem Y and De Jong, Douwe M and De La Cuesta, Carmen and De Los Rios Ibarra, Manuel O and De Pablo, Carmen and De Pauw, Michel and Dela Llana, Alexander and Delibasic, Maja and {Delic-Brkljacic}, Diana and Demicheli, Thibaud and Denger, Ralf J and Desai, Devang and Desai, Piyush and Desouza, Cyrus V and Dicker, Dror and Djenic, Nemanja and Dobson, Simon and Doi, Masayuki and Doran, Jesse A and Dorman, Reinhart and Dotta, Francesco and Dukes, Carl E and Duronto, Ernesto and Durst, Ronen and Dvoryashina, Irina V and Ebrahim, Iftikhar O and Eggebrecht, Holger and Egstrup, Kenneth and Ekinci, Elif I and Eliasson, Bj{\"o}rn and Eliasson, Ken and Enache, Georgiana and Enculescu, Dan and English, Patrick and Ermakova, Polina and Ershova, Olga and Ezaki, Hirotaka and Ezhov, Marat and Farias, Eduardo and Farias, Javier M and Farsky, Pedro S and Ferreira, Daniel and Filteau, Pierre and Finneran, Matthew P and Folkens, Eric M and Fonseca, Alberto G and Fonseca, Luisa and Fordan, Steven and Fourie, Nyda and Fran{\c c}a, Sara and Franco, Denise R and Franek, Edward and Friedman, Keith and Frittitta, Lucia and Froer, Michael and Fuckar, Krunoslav and Fujii, Kenshi and Fujita, Ryoko and Fukushima, Yasushi and Fulat, Mohamed and Fulwani, Mahesh and Gajos, Grzegorz and Galyavich, Albert and Gambill, Michael L and Gandotra, Dheeraj and Winston, Gandy and Garcia Hernandez, Pedro A and Garc{\'i}a Reza, Raymundo and Garg, Naveen and Garg, Sandeep and Garvey, William T and Garza, Juan C and {Gatta-Cherifi}, Blandine and Gelev, Valeri and Geller, Steven A and Geohas, Jeffrey G and Georgiev, Borislav and Ghazi, Adline and Gilbert, Matthew P and Gilinskaya, Olga and Gislason, Gunnar and Gogas Yavuz, Dilek and Gonz{\'a}lez Albarr{\'a}n, Olga and Gordeev, Ivan G and Gorton, Sidney C and Goudev, Assen and Gretland Valderhaug, Tone and Groenemeijer, Bjorn and Gul, Ibrahim and Gullestad, Lars and Gurieva, Irina and Guseva, Galina N and Hagenow, Andreas and Haluzik, Martin and Halvorsen, Sigrun and Hammoudi, Naima and Hanaoka, Keiichi and Hancu, Nicolae and Hanusch, Ursula and Harris, Kathleen and Harris, Barry and Hartleib, Michael and Hartman, Aaron N and Hata, Yoshiki and Heimer, Brian and Herman, Lee and Herzog, William and Hewitt, Eric and Heymer, Peter and Hiremath, Shirish and Hjelmesaeth, Joeran and H{\o}galmen, Rasmus Geir and H{\o}ivik, Hans Olav and Holmer, Helene and Horoshko, Olha and Houser, Patricia M and Hove, Jens D and Hsieh, I-Chang and Hulot, Jean-S{\'e}bastien and Hussein, Zanariah and Ilashchuk, Tetiana and Ilveskoski, Erkki and Ipatko, Irina and Iranmanesh, Ali and Isawa, Tsuyoshi and Issa, Moises and Iteld, Bruce and Iwasawa, Takamasa and Jabbar, Danish and Jackson, Richard A and {Jackson-Voyzey}, Ewart and Jacob, Stephan and Jaffrani, Naseem A and Jardula, Michael F and Jastreboff, Ania and Jensen, Svend E and Jerkins, Terri and {Jimenez-Ramos}, Silvia A and Jitendra Pal Singh, Sawhney and Johnson, Wallace and Joyce, John M and Jozefowska, Malgorzata and Jugnundan, Prakash and Jungmair, Wolfgang and Jurowiecki, Jaroslaw and Kadokami, Toshiaki and Kahali, Dhiman and Kahrmann, Gerd and Kaiser, Sergio E and Kalmucki, Piotr and Kanadasi, Mehmet and Kandath, David and Kania, Grzegorz and Kannan, J and Kapp, Cornelia and Karczmarczyk, Agnieszka and Kartalis, Athanasios and Kaser, Susanne and Kasim, Sazzli Shahlan and Kastelic, Richard and Kato, Toshiaki and Katova, Tzvetana and Kaul, Upendra and {Kautzky-Willer}, Alexandra and Kawanishi, Masahiro and Kayikcioglu, Meral and Kazakova, Elena E and Keeling, Philip and Kempe, Hans-Peter and Kereiakes, Dean J and Kerneis, Mathieu and {Keski-Opas}, Tiina and Khadra, Suhail and Khaisheva, Larisa and Kharakhulakh, Marina and Khlevchuk, Tatiana and Khoo, Jeffrey and Kiatchoosakun, Songsak and Kinoshita, Noriyuki and Kinoshita, Masaharu and Kitamura, Ryoji and Kiyosue, Arihiro and Klavina, Irina and Klein, Eric J and Klimsa, Zdenek and Klonoff, David and Klug, Eric and Kobalava, Zhanna and Kodera, Satoshi and Koga, Tokushi and Kokkinos, Alexander and Koleckar, Pavel and K{\"o}nyves, L{\'a}szl{\'o} and Koren, Michael J and Kormann, Adrian P and Kostner, Karam and Kreutzmann, Kristin and Krishinan, Saravanan and Krishnasamy, Sathya S and Krivosheeva, Inga and Kruljac, Ivan and Kubicki, Ted and Kuchar, Ladislav and Kujawiak, Monika and Kunishige, Hideyuki and Kurtinecz, Melinda and Kurtz Lisboa, Hugo R and Kushnir, Mykola and Kyyak, Yulian and Lace, Arija and Lakka, Timo and Lalic, Nebojsa and Lalic, Katarina and Lambadiari, Vaia and Lanaras, Leonidas and Lang, Chim and Langlois, Marie-France and Lash, Joseph and Latkovskis, Gustavs and Lau, David and Lazcano Soto, Jos{\'e} Roberto and Le Roux, Carel and Ledesma, Gilbert N and Lee, Li Yuan and Lee, Thung-Lip and Lee, Kelvin and Lehrke, Michael and Leite, Silmara O and Leksycka, Agata and Lenzmeier, Thomas and Leonetti, Frida and Leonidova, Viktoriia and Lepor, Norman and Leung, Melissa and Levchenko, Olena and Levins, Peter and Levy, Louis J and Lewis, Matthew and Liberopoulos, Evangelos and Liberty, Idit and Lindholm, Carl-Johan and Lingvay, Ildiko and Linhart, Ales and Liu, Ming-En and Liu, Jenny and Lofton, Holly and Logemann, Timothy and Lombaard, Johannes J and Lombard, Landman and Lorraine, Richard and Lovell, Charles F and Ludvik, Bernhard and Lukaszewicz, Monika and Lupkovics, G{\'e}za and Lupovitch, Steven and Lupu, Sirona and Lynch, Mary and Lysak, Zoreslava and Lysenko, Tatyana A and Maeda, Hajime and Maeda, Itaru and M{\ae}ng, Michael and Mahajan, Ajay U and Maher, Vincent and Maia, Lilia N and Makotoko, Ellen M and Malavazos, Alexis and Malecha, Jan and Malicherova, Emilia and Manita, Mamoru and Mannucci, Edoardo and Mareev, Viacheslav and Marin, Liliana and Markova, Tatiana and Marso, Steven P and Martens, F.M.A.C. and Martinez, Cuper and Martinez Cano, Carlos A and Martins, Cristina and Masmiquel Comas, Luis and Matsumoto, Takashi and Mcdonald, Kenneth and Mcgowan, Barbara and Mcgrew, Frank and Mclean, Barry K and Mcpherson, David D and Merino Torres, Juan Francisco and Meyers, Peter and Meyh{\"o}fer, Sebastian and Mezquita Raya, Pedro and Milanova, Maria and Milicic, Davor and Miller, Gary and Mills, Richard E and M{\^i}ndrescu, Nicoleta M and Mingrone, Geltrude and Minkova, Dotska A and Mirani, Marco and Miras, Alexander and Mistodie, Cristina V and Mitomo, Satoru and Mittal, Sanjay and Miyake, Taiji and Miyamoto, Naomasa and Molony, David and Monteiro, Pedro and Mooe, Thomas and Moosa, Naeem and Morales Portillo, Cristobal and Morales Villegas, Enrique C and Morawski, Emily J and Morbey, Claire and Morin, Robert P and Morisaki, Kuniaki and Morosanu, Magdalena and Mosenzon, Ofri and Mostovoy, Yuriy and Munir, Iqbal and Muratori, Fabrizio and Murray, Ryan and Murthy, Avinash and Myint, Min and Myshanych, Galyna and Nafornita, Valerica and Nagano, Takuya and Nair, Sunil and Nakhle, Samer N and Natsuaki, Masahiro and Nayak, Bindu M and Nibouche, Djamel Eddine and Nicholls, Stephen and Nicolau, Jos{\'e} C and Nicolescu, Georgiana and Nierop, Peter and Niskanen, Leo and Ntaios, George and Nyg{\aa}rd, Ottar Kjell and Oaks, Joshua B and Obrezan, Andrey and O'donnell, Philip and Oguri, Mitsutoshi and Oguzhan, Abdurrahman and Oh, Fumiki and Ohsugi, Mitsuru and Okada, Yoshio and Okayama, Hideki and Onaca, Adriana and Onaka, Haruhiko and Oneil, Patrick and Ong, Tiong Kiam and Ong, Stephen and Ono, Yasuhiro and Opsahl, Paul J and Ostrowska, Lucyna and Oviedo, Alejandra and Ozdogan, Oner and Ozpelit, Ebru and Pagkalos, Emmanouil and Pagotto, Uberto and P{\'a}ll, D{\'e}nes and Pandey, Amritanshu- Shekhar and Parkhomenko, Oleksandr and Parvathareddy, Krishna Malakondareddy and Patel, Minesh B and Patsilinakos, Sotirios and Paul, Neil and Pedersen, Sue and Pereira, Isabel and Pereira, Edward Scott and Perez Terns, Paula and {Perez-Vargas}, Elba A and Pergaeva, Yulia and Perkelvald, Alexander and Peskov, Andrey B and Peter, Jonathan and Peters, Karina and Petit, Catherine and Petrov, Ivo and {Philis-Tsimikas}, Athena and Pietil{\"a}, Mikko and Pinto, Fausto and Piros, Annam{\'a}ria and Piyayotai, Dilok and Platonov, Dmitriy and Poirier, Paul and Pop, Lavinia and Popa, Bogdan and {Pop-Busui}, Rodica and Poremba, John and Porto, Alejandro and Postadzhiyan, Arman and Pothineni, Ramesh B and Potu, Ranganatha P and Powell, Talessa and Prafulla, Kerkar G and Prager, Rudolf and {Prakova-Teneva}, Zhulieta R and Pratley, Richard E and Price, Hermione and Pulka, Grazyna and Pullman, John and Punt, Zelda E and Purighalla, Raman S and Purnell, Peter and Qureshi, Mansoor and {Rabasa-Lhoret}, Remi and Raikhel, Marina A and Rancane, Gita and Randeva, Harpal and Rasouli, Neda and Reurean Pintilei, Delia V and Reyes, Ciro R and Rezgale, Inga and Rice, Eva and Riley, Thaddeus H and Risser, Joseph A and Ristic, Arsen and Rivas Fern{\'a}ndez, Margarita and Robbins, David and Robitaille, Yves and Rodbard, Helena W and Rodriguez Plazas, Jaime A and R{\"o}mer, T.J. and Rosen, Glenn and Rosman, Dr Azhari and Rossi, Paulo and Rudenko, Leonid and Ruffin, Omari and Ruhani, Anwar Irawan and Runev, Nikolay and Ruyatkin, Dmitriy and Ruzic, Alen and Ryabov, Vyacheslav V and Ryd{\'e}n, Lars and Saggar, Suraj and Sakamoto, Tomohiro and Salter, Tim and Samal, Aditya K and Samoilova, Yulia and Sanabria, Hugo D and Sancak, Seda and Sangrigoli, Renee and Sansanayudh, Nakarin and Santini, Ferruccio and Saraiva, Jos{\'e} F and Sardinov, Ruslan and Sargeant, William and Sari, Ramazan and Sathananthan, Airani and Sathyapalan, Thozhukat and Sato, Atsushi and Sauter, Joachim and Sbraccia, Paolo and Schaap, J. and Schaum, Thomas and Schiele, Fran{\c c}ois and Scott, John and Segal Lieberman, Gabriella and Segner, Alexander and Senior, Roxy and {Sergeeva-Kondrachenko}, Marina Y and Serota, Harvey and Serusclat, Pierre and Sethi, Rishi and Shah, Manoj K and Shah, Neerav and Shalaev, Sergey and Sharma, Raj and Sharma, Sumeet and Shaydyuk, Oksana and Shea, Heidi C and Shechter, Michael and Shehadeh, Naim and Shirazi, Mitra and Shlesinger, Yshay and Shneker, Ayham and Shutemova, Elena and Siasos, Gerasimos and Siddiqui, Imran A and Sidey, Jennifer and Sigal, Felix and Sime, Iveta and Singh, Narendra and Siraj, Elias and Sivalingam, Kanagaratnam and Skoczylas, Grzegorz and Smith, Stephen K and Smolenskaya, Olga and Snyder, Brian and Sofer, Yael and Sofley, C.W. and Solano, Royce and Sonmez, Yusuf A and Sorokin, Maxim and Soto Gonz{\'a}lez, Alfonso and Sotolongo, Carlos and Soufer, Joseph and Soyluk Selcukbiricik, Ozlem and Spaic, Tamara and Spriggs, Douglas and Sreenan, Seamus and Stahl, Hans-Detlev and Stamatelopoulos, Kimon and Stanislavchuk, Mykola and Stankovic, Goran and Stasek, Josef and Steg, Gabriel and Steindorf, Joerg and Stephan, Dominique and Stewart, John and Still, Christopher and {St-Maurice}, Francois and {Stogowska-Nikiciuk}, Barbara and Stoker, Jeff and Stokic, Edita and Strzelecka, Anna and Sturm, Kerstin and Sueyoshi, Atsushi and Sugiura, Toshiyuki and Sultan, Senan and Suplotova, Lyudmila A and Suwanagool, Arisara and Suwanwalaikorn, Sompongse and Sveklina, Tatiana and Swanson, Neil and Swart, Henk and Swenson, Bradley P and Szyprowska, Ewa and Tait, Graeme and Tak{\'a}cs, R{\'o}bert and Takeuchi, Yuzo and Tamirisa, Aparna and Tanaka, Hideki and Tatovic, Danijela and Tellier, Guy and Teragawa, Hiroki and Teterovska, Dace and Thomas, Nihal and Thuan, Jean-Francois and Tinahones, Francisco and {Tisheva-Gospodinova}, Snezhanka and Toarba, Cristina and Todoriuk, Liudmyla and Tokmakova, Mariya and Tonstad, Serena and Toplak, Hermann and Tran, Henry and Tripathy, Devjit and Trusau, Aliaksandr and Tsabedze, Nqoba and Tsougos, Elias and Tsoukas, George M and Tuccinardi, Dario and Tuna, Mazhar M and Turatti, Luiz A and Tziomalos, Konstantinos and Udommongkol, Chesda and Ueda, Osamu and Ukkola, Olavi and Unubol, Mustafa and Urbach, Dorothea and Urina Triana, Miguel A and Usdan, Lisa and Vaidya, Bijay and Vale, Noah and Vallieres, Gerald and Van Beek, Andre P and Van De Borne, Philippe and Van Der Walt, Eugene and Van Der Zwaan, C. and Van Nieuwenhuizen, Elane and Van Zyl, Louis and Vanduynhoven, Philippe and Varghese, Kiron and Vasileva, Svetla P and Vassilev, Dobrin and Vathesatogkit, Prin and Velychko, Valentyna and Vercammen, Chris and Verges, Bruno and Verma, Subodh and Verwerft, Jan and Vesela, Alica and Veselovskaya, Nadezhda G and Vettor, Roberto and Veze, Irina and Vijan, Vinod and Vijayaraghavan, Ram and Villarino, Adriana and Vincent, Royce and Vinogradova, Oksana and Vishlitzky, Victor and Vlad, Adrian and Vladu, Ionela Mihaela and Vo, Anthony and Von Engelhardt, Charlotte and Von M{\"u}nchhausen, Candy and Vorobyeva, Olga and Vossenberg, T. and Vrolix, Mathias and Vukicevic, Marjana and Vyshnyvetskyy, Ivan and Wadvalla, Shahid and Wagner, Jan and Wakeling, John and Wallace, James and Wan Mohamed, Wan Mohd Izani and Wander, Gurpreet S and Ward, Kathleen and Warren, Mark L and Watanabe, Atsuyuki and Weber, Bruce and Weintraub, Howard and Weisnagel, John and Welker, James and Wendisch, Ulrich and Wenocur, Howard S and Wierum, Craig and Wilding, John and William, Maged and Wilson, Pete and Wilson, Jonathan P and Wong, Yuk-Ki and Wongcharoen, Wanwarang and Wozniak, Iwona and Wu, Chau-Chung and Wyatt, Nell and Wynne, Alan and Yamaguchi, Hiroshi and Yamasaki, Masahiro and Yazici, Dilek and Yeh, Hung-I and Yotov, Yoto and Yuan, Qingyang and Zacher, Jeffrey and Zagrebelnaya, Olga and Zaidman, Cesar J and Zalevskaya, Alsu and Zarich, Stuart and Zatelli, Maria Chiara and Zeller, Helga and Zhdanova, Elena A and Zornitzki, Taiba and Zrazhevskiy, Konstantin and Zykov, Mikhail and Lincoff, A Michael and Ryan, Donna H and Colhoun, Helen M and Deanfield, John E and Emerson, Scott S and Kahn, Steven E and Kushner, Robert F and Plutzky, Jorge and {Brown-Frandsen}, Kirstine and Hovingh, G Kees and {Hardt-Lindberg}, Soren and Torn{\o}e, Christoffer W},
  year = {2024},
  month = aug,
  journal = {The Lancet},
  volume = {404},
  number = {10454},
  pages = {773--786},
  issn = {01406736},
  doi = {10.1016/S0140-6736(24)01498-3},
  urldate = {2025-03-17},
  abstract = {Background Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2{$\cdot$}4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure.},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/IBU5T7UU/mmc1.pdf;/Users/xx20081/Zotero/storage/XCWH8YYH/Deanfield et al. - 2024 - Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure a pres.pdf}
}

@article{deanfieldSemaglutideCardiovascularOutcomes2024a,
  title = {Semaglutide and Cardiovascular Outcomes in Patients with Obesity and Prevalent Heart Failure: A Prespecified Analysis of the {{SELECT}} Trial},
  shorttitle = {Semaglutide and Cardiovascular Outcomes in Patients with Obesity and Prevalent Heart Failure},
  author = {Deanfield, John and Verma, Subodh and Scirica, Benjamin M. and Kahn, Steven E. and Emerson, Scott S. and Ryan, Donna and Lingvay, Ildiko and Colhoun, Helen M. and Plutzky, Jorge and Kosiborod, Mikhail N. and Hovingh, G. Kees and {Hardt-Lindberg}, S{\o}ren and Frenkel, Ofir and Weeke, Peter E. and Rasmussen, S{\o}ren and Goudev, Assen and Lang, Chim C. and {Urina-Triana}, Miguel and Pietil{\"a}, Mikko and Lincoff, A. Michael and {SELECT Trial Investigators}},
  year = {2024},
  month = aug,
  journal = {Lancet (London, England)},
  volume = {404},
  number = {10454},
  pages = {773--786},
  issn = {1474-547X},
  doi = {10.1016/S0140-6736(24)01498-3},
  abstract = {BACKGROUND: Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2{$\cdot$}4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure. METHODS: The SELECT trial was a randomised, double-blind, multicentre, placebo-controlled, event-driven phase 3 trial in 41 countries. Adults aged 45 years and older, with a BMI of 27 kg/m2 or greater and established cardiovascular disease were eligible for the study. Patients were randomly assigned (1:1) with a block size of four using an interactive web response system in a double-blind manner to escalating doses of once-weekly subcutaneous semaglutide over 16 weeks to a target dose of 2{$\cdot$}4 mg, or placebo. In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure at enrolment, subclassified as heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, or unclassified heart failure. Endpoints comprised MACE (a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); a composite heart failure outcome (cardiovascular death or hospitalisation or urgent hospital visit for heart failure); cardiovascular death; and all-cause death. The study is registered with ClinicalTrials.gov, NCT03574597. FINDINGS: Between Oct 31, 2018, and March 31, 2021, 17\hphantom{,}604 patients with a mean age of 61{$\cdot$}6 years (SD 8{$\cdot$}9) and a mean BMI of 33{$\cdot$}4 kg/m2 (5{$\cdot$}0) were randomly assigned to receive semaglutide (8803 [50{$\cdot$}0\%] patients) or placebo (8801 [50{$\cdot$}0\%] patients). 4286 (24{$\cdot$}3\%) of 17\hphantom{,}604 patients had a history of investigator-defined heart failure at enrolment: 2273 (53{$\cdot$}0\%) of 4286 patients had heart failure with preserved ejection fraction, 1347 (31{$\cdot$}4\%) had heart failure with reduced ejection fraction, and 666 (15{$\cdot$}5\%) had unclassified heart failure. Baseline characteristics were similar between patients with and without heart failure. Patients with heart failure had a higher incidence of clinical events. Semaglutide improved all outcome measures in patients with heart failure at random assignment compared with those without heart failure (hazard ratio [HR] 0{$\cdot$}72, 95\% CI 0{$\cdot$}60-0{$\cdot$}87 for MACE; 0{$\cdot$}79, 0{$\cdot$}64-0{$\cdot$}98 for the heart failure composite endpoint; 0{$\cdot$}76, 0{$\cdot$}59-0{$\cdot$}97 for cardiovascular death; and 0{$\cdot$}81, 0{$\cdot$}66-1{$\cdot$}00 for all-cause death; all pinteraction{$>$}0{$\cdot$}19). Treatment with semaglutide resulted in improved outcomes in both the heart failure with reduced ejection fraction (HR 0{$\cdot$}65, 95\% CI 0{$\cdot$}49-0{$\cdot$}87 for MACE; 0{$\cdot$}79, 0{$\cdot$}58-1{$\cdot$}08 for the composite heart failure endpoint) and heart failure with preserved ejection fraction groups (0{$\cdot$}69, 0{$\cdot$}51-0{$\cdot$}91 for MACE; 0{$\cdot$}75, 0{$\cdot$}52-1{$\cdot$}07 for the composite heart failure endpoint), although patients with heart failure with reduced ejection fraction had higher absolute event rates than those with heart failure with preserved ejection fraction. For MACE and the heart failure composite, there were no significant differences in benefits across baseline age, sex, BMI, New York Heart Association status, and diuretic use. Serious adverse events were less frequent with semaglutide versus placebo, regardless of heart failure subtype. INTERPRETATION: In patients with atherosclerotic cardiovascular diease and overweight or obesity, treatment with semaglutide 2{$\cdot$}4 mg reduced MACE and composite heart failure endpoints compared with placebo in those with and without clinical heart failure, regardless of heart failure subtype. Our findings could facilitate prescribing and result in improved clinical outcomes for this patient group. FUNDING: Novo Nordisk.},
  langid = {english},
  pmid = {39181597},
  keywords = {Aged,Cardiovascular Diseases,Double-Blind Method,Female,Glucagon-Like Peptides,Heart Failure,Humans,Hypoglycemic Agents,Injections Subcutaneous,Male,Middle Aged,Obesity,Stroke Volume,Treatment Outcome},
  file = {/Users/xx20081/Zotero/storage/CWWCAIP6/Deanfield et al. - 2024 - Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure a pres.pdf}
}

@article{debacquerManagementOverweightObese2010,
  title = {Management of Overweight and Obese Patients with Coronary Heart Disease across {{Europe}}},
  author = {De Bacquer, Dirk and Dallongeville, Jean and Heidrich, Jan and Kotseva, Kornelia and Reiner, Zeljko and Gaita, Dan and Prugger, Christophe and Wellmann, J{\"u}rgen and Wood, David and De Backer, Guy and Keil, Ulrich and {EUROASPIRE III Study Group}},
  year = {2010},
  month = aug,
  journal = {European Journal of Cardiovascular Prevention and Rehabilitation: Official Journal of the European Society of Cardiology, Working Groups on Epidemiology \& Prevention and Cardiac Rehabilitation and Exercise Physiology},
  volume = {17},
  number = {4},
  pages = {447--454},
  issn = {1741-8275},
  doi = {10.1097/HJR.0b013e328336a05f},
  abstract = {AIMS: Several studies have reported increasing obesity rates in the general population. Using data from the EUROASPIRE III survey, we investigated as to what extent the obesity epidemic affects the high priority group of coronary heart disease patients. METHODS AND RESULTS: Data from 8924 patients, who had experienced a recent coronary acute event, from 22 countries in Europe participating in the EUROASPIRE III study were gathered in 2006-2007. Eight centres had also participated in the earlier two EUROASPIRE surveys carried out in 1994-1995 and 1999-2000. In these eight centres, obesity prevalence in coronary patients had increased from 25 to 38\% during the past decade. The most recent survey shows that obesity is more prevalent in women (45 vs. 32\% in men) and is a major health problem across all the 22 countries. Only 18\% of all the patients were found to reach a body mass index below 25 kg/m whereas 53\% were diagnosed with central obesity. Since their hospital discharge, only half of the obese patients reported to have followed the dietary recommendations and 48\% reported engagement in more physical activity. Only 13\% of the patients who were overweight at the time of the coronary event reached the target of {$>$}or=5\% weight loss whereas 21\% of them presented with a weight gain of 5\% or more. CONCLUSION: The prevalence of obesity is still increasing and reaching epidemic proportions in the high priority group of coronary patients all over Europe. Patients' awareness and current management of obesity seems inadequate. More intensive programs focusing on diet and especially physical activity are urgently required.},
  langid = {english},
  pmid = {20485181},
  keywords = {Aged,Body Mass Index,Coronary Disease,Energy Intake,Europe,Exercise Therapy,Female,Health Behavior,Health Care Surveys,Health Knowledge Attitudes Practice,Humans,Male,Middle Aged,Obesity,Overweight,Patient Compliance,Patient Education as Topic,Practice Guidelines as Topic,Prevalence,Retrospective Studies,Risk Assessment,Risk Factors,Risk Reduction Behavior,Time Factors,Treatment Outcome,Weight Loss},
  file = {/Users/xx20081/Zotero/storage/N3B9Z4BI/De Bacquer et al. - 2010 - Management of overweight and obese patients with c.pdf}
}

@article{dedenusGeneticAssociationStudy2020,
  title = {A Genetic Association Study of Heart Failure: More Evidence for the Role of {{BAG3}} in Idiopathic Dilated Cardiomyopathy},
  shorttitle = {A Genetic Association Study of Heart Failure},
  author = {{de Denus}, Simon and Mottet, Fannie and Korol, Sandra and Feroz Zada, Yassamin and Provost, Sylvie and Mongrain, Ian and Asselin, G{\'e}raldine and Oussa{\"i}d, Essa{\"i}d and Busseuil, David and Lettre, Guillaume and Rioux, John and Racine, Normand and O'Meara, Eileen and White, Michel and Rouleau, Jean and Tardif, Jean Claude and Dub{\'e}, Marie-Pierre},
  year = {2020},
  month = dec,
  journal = {ESC heart failure},
  volume = {7},
  number = {6},
  pages = {4384--4389},
  issn = {2055-5822},
  doi = {10.1002/ehf2.12934},
  abstract = {AIMS: Few investigations have been conducted to identify genetic determinants of common, polygenetic forms of heart failure (HF), and only a limited number of these genetic associations have been validated by multiple groups. METHODS AND RESULTS: We performed a case-control study to further investigate the potential impact of 14 previously reported candidate genes on the risk of HF and specific HF sub-types. We also performed an exploratory genome-wide study. We included 799 patients with HF and 1529 controls. After adjusting for age, sex, and genetic ancestry, we found that the C allele of rs2234962 in BAG3 was associated with a decreased risk of idiopathic dilated cardiomyopathy (odds ratio 0.42, 95\% confidence interval 0.25-0.68, P~=~0.0005), consistent with a previous report. No association for the other primary variants or exploratory genome-wide study was found. CONCLUSIONS: Our findings provide independent replication for the association between a common coding variant (rs2234962) in BAG3 and the risk of idiopathic dilated cardiomyopathy.},
  langid = {english},
  pmcid = {PMC7754954},
  pmid = {32869539},
  keywords = {B-cell lymphoma 2-associated anthanogene protein,Genetics,Heart failure},
  file = {/Users/xx20081/Zotero/storage/Q95ZUCZ7/de Denus et al. - 2020 - A genetic association study of heart failure more.pdf}
}

@article{dekleinBrainExpressionQuantitative2023,
  title = {Brain Expression Quantitative Trait Locus and Network Analyses Reveal Downstream Effects and Putative Drivers for Brain-Related Diseases},
  author = {{de Klein}, Niek and Tsai, Ellen A. and Vochteloo, Martijn and Baird, Denis and Huang, Yunfeng and Chen, Chia-Yen and {van Dam}, Sipko and Oelen, Roy and Deelen, Patrick and Bakker, Olivier B. and El Garwany, Omar and Ouyang, Zhengyu and Marshall, Eric E. and Zavodszky, Maria I. and {van Rheenen}, Wouter and Bakker, Mark K. and Veldink, Jan and Gaunt, Tom R. and Runz, Heiko and Franke, Lude and Westra, Harm-Jan},
  year = {2023},
  month = mar,
  journal = {Nature Genetics},
  volume = {55},
  number = {3},
  pages = {377--388},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-023-01300-6},
  urldate = {2024-02-19},
  abstract = {Identification of therapeutic targets from genome-wide association studies (GWAS) requires insights into downstream functional consequences. We harmonized 8,613 RNA-sequencing samples from 14 brain datasets to create the MetaBrain resource and performed cis- and trans-expression quantitative trait locus (eQTL) meta-analyses in multiple brain region- and ancestry-specific datasets (n\,{$\leq$}\,2,759). Many of the 16,169 cortex cis-eQTLs were tissue-dependent when compared with blood cis-eQTLs. We inferred brain cell types for 3,549 cis-eQTLs by interaction analysis. We prioritized 186 cis-eQTLs for 31 brain-related traits using Mendelian randomization and co-localization including 40 cis-eQTLs with an inferred cell type, such as a neuron-specific cis-eQTL (CYP24A1) for multiple sclerosis. We further describe 737 trans-eQTLs for 526 unique variants and 108 unique genes. We used brain-specific gene-co-regulation networks to link GWAS loci and prioritize additional genes for five central nervous system diseases. This study represents a valuable resource for post-GWAS research on central nervous system diseases.},
  copyright = {2023 The Author(s)},
  langid = {english},
  keywords = {Gene expression,Gene regulation,Transcriptomics},
  file = {/Users/xx20081/Zotero/storage/B457TGMA/de Klein et al. - 2023 - Brain expression quantitative trait locus and netw.pdf}
}

@article{deluisRoleRs6923761Gene2015,
  title = {Role of Rs6923761 Gene Variant in Glucagon-like Peptide 1 Receptor in Basal {{GLP-1}} Levels, Cardiovascular Risk Factor and Serum Adipokine Levels in Na{\"i}ve Type 2 Diabetic Patients},
  author = {{de Luis}, D. A. and Aller, R. and Izaola, O. and Bachiller, R.},
  year = {2015},
  month = feb,
  journal = {Journal of Endocrinological Investigation},
  volume = {38},
  number = {2},
  pages = {143--147},
  issn = {1720-8386},
  doi = {10.1007/s40618-014-0161-y},
  abstract = {BACKGROUND: Role of GLP-1 variants on basal GLP-1 levels, body weight and cardiovascular risk factors remains unclear in patients with diabetes mellitus type 2. OBJECTIVE: Our aim was to analyze the effects of rs6923761 GLP-1 receptor polymorphism on body weight, cardiovascular risk factors, basal GLP-1 levels and serum adipokine levels in na{\"i}ve patients with diabetes mellitus type 2. DESIGN: A sample of 104 na{\"i}ve patients with diabetes mellitus type 2 was enrolled in a prospective way. Basal fasting glucose, c-reactive protein (CRP), insulin, insulin resistance (HOMA), total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides concentration, basal GLP-1, HbA1c and adipokines (leptin, adiponectin, resistin) levels were determined. Weights, body mass index, waist circumference, fat mass by bioimpedance and blood pressure measures were measured. RESULTS: Forty-nine patients (47.1\%) had the genotype GG and 55 (52.9\%) diabetic subjects had the next genotypes; GA (44 patients, 42.3\%) or AA (11 study subjects, 10.6\%) (second group). In A allele carriers, basal GLP-1 levels were higher than non-carriers (2.9 {\textpm} 2.1 ng/ml; p {$<$} 0.05). No differences were detected between both genotype groups. CONCLUSION: Our cross-sectional study revealed an association between the rs6923761 GLP-1 receptor polymorphism (A allele carriers) and basal GLP-1 levels in na{\"i}ve patients with diabetes mellitus type 2.},
  langid = {english},
  pmid = {25200998},
  keywords = {Adipokines,Adult,Aged,Cardiovascular Diseases,Cardiovascular risk factors,Cross-Sectional Studies,Diabetes mellitus type 2,Diabetes Mellitus Type 2,Female,Genetic Variation,Glucagon-like peptide 1,Glucagon-Like Peptide 1,Glucagon-like peptide 1 receptor,Glucagon-Like Peptide-1 Receptor,Humans,Male,Middle Aged,Prospective Studies,Risk Factors,rs6923761}
}

@article{deluisRoleRs6923761Gene2015a,
  title = {Role of Rs6923761 Gene Variant in Glucagon-like Peptide 1 Receptor in Basal {{GLP-1}} Levels, Cardiovascular Risk Factor and Serum Adipokine Levels in Na{\"i}ve Type 2 Diabetic Patients},
  author = {{de Luis}, D. A. and Aller, R. and Izaola, O. and Bachiller, R.},
  year = {2015},
  month = feb,
  journal = {Journal of Endocrinological Investigation},
  volume = {38},
  number = {2},
  pages = {143--147},
  issn = {1720-8386},
  doi = {10.1007/s40618-014-0161-y},
  urldate = {2024-01-20},
  abstract = {Role of GLP-1 variants on basal GLP-1 levels, body weight and cardiovascular risk factors remains unclear in patients with diabetes mellitus type 2.},
  langid = {english},
  keywords = {Cardiovascular risk factors,Diabetes mellitus type 2,Glucagon-like peptide 1,Glucagon-like peptide 1 receptor,rs6923761}
}

@article{desikanGeneticAssessmentAgeassociated2017,
  title = {Genetic Assessment of Age-Associated {{Alzheimer}} Disease Risk: {{Development}} and Validation of a Polygenic Hazard Score},
  shorttitle = {Genetic Assessment of Age-Associated {{Alzheimer}} Disease Risk},
  author = {Desikan, Rahul S. and Fan, Chun Chieh and Wang, Yunpeng and Schork, Andrew J. and Cabral, Howard J. and Cupples, L. Adrienne and Thompson, Wesley K. and Besser, Lilah and Kukull, Walter A. and Holland, Dominic and Chen, Chi-Hua and Brewer, James B. and Karow, David S. and Kauppi, Karolina and Witoelar, Aree and Karch, Celeste M. and Bonham, Luke W. and Yokoyama, Jennifer S. and Rosen, Howard J. and Miller, Bruce L. and Dillon, William P. and Wilson, David M. and Hess, Christopher P. and {Pericak-Vance}, Margaret and Haines, Jonathan L. and Farrer, Lindsay A. and Mayeux, Richard and Hardy, John and Goate, Alison M. and Hyman, Bradley T. and Schellenberg, Gerard D. and McEvoy, Linda K. and Andreassen, Ole A. and Dale, Anders M.},
  year = {2017},
  month = mar,
  journal = {PLoS medicine},
  volume = {14},
  number = {3},
  pages = {e1002258},
  issn = {1549-1676},
  doi = {10.1371/journal.pmed.1002258},
  abstract = {BACKGROUND: Identifying individuals at risk for developing Alzheimer disease (AD) is of utmost importance. Although genetic studies have identified AD-associated SNPs in APOE and other genes, genetic information has not been integrated into an epidemiological framework for risk prediction. METHODS AND FINDINGS: Using genotype data from 17,008 AD cases and 37,154 controls from the International Genomics of Alzheimer's Project (IGAP Stage 1), we identified AD-associated SNPs (at p {$<$} 10-5). We then integrated these AD-associated SNPs into a Cox proportional hazard model using genotype data from a subset of 6,409 AD patients and 9,386 older controls from Phase 1 of the Alzheimer's Disease Genetics Consortium (ADGC), providing a polygenic hazard score (PHS) for each participant. By combining population-based incidence rates and the genotype-derived PHS for each individual, we derived estimates of instantaneous risk for developing AD, based on genotype and age, and tested replication in multiple independent cohorts (ADGC Phase 2, National Institute on Aging Alzheimer's Disease Center [NIA ADC], and Alzheimer's Disease Neuroimaging Initiative [ADNI], total n = 20,680). Within the ADGC Phase 1 cohort, individuals in the highest PHS quartile developed AD at a considerably lower age and had the highest yearly AD incidence rate. Among APOE {$\varepsilon$}3/3 individuals, the PHS modified expected age of AD onset by more than 10 y between the lowest and highest deciles (hazard ratio 3.34, 95\% CI 2.62-4.24, p = 1.0 {\texttimes} 10-22). In independent cohorts, the PHS strongly predicted empirical age of AD onset (ADGC Phase 2, r = 0.90, p = 1.1 {\texttimes} 10-26) and longitudinal progression from normal aging to AD (NIA ADC, Cochran-Armitage trend test, p = 1.5 {\texttimes} 10-10), and was associated with neuropathology (NIA ADC, Braak stage of neurofibrillary tangles, p = 3.9 {\texttimes} 10-6, and Consortium to Establish a Registry for Alzheimer's Disease score for neuritic plaques, p = 6.8 {\texttimes} 10-6) and in vivo markers of AD neurodegeneration (ADNI, volume loss within the entorhinal cortex, p = 6.3 {\texttimes} 10-6, and hippocampus, p = 7.9 {\texttimes} 10-5). Additional prospective validation of these results in non-US, non-white, and prospective community-based cohorts is necessary before clinical use. CONCLUSIONS: We have developed a PHS for quantifying individual differences in age-specific genetic risk for AD. Within the cohorts studied here, polygenic architecture plays an important role in modifying AD risk beyond APOE. With thorough validation, quantification of inherited genetic variation may prove useful for stratifying AD risk and as an enrichment strategy in therapeutic trials.},
  langid = {english},
  pmcid = {PMC5360219},
  pmid = {28323831},
  keywords = {Aged,Aged 80 and over,Alzheimer Disease,Apolipoproteins E,Female,Genotype,Geriatric Assessment,Humans,Longitudinal Studies,Male,Middle Aged,Multifactorial Inheritance,Polymorphism Single Nucleotide,United States},
  file = {/Users/xx20081/Zotero/storage/9ULQDYVH/Desikan et al. - 2017 - Genetic assessment of age-associated Alzheimer disease risk Development and validation of a polygen.pdf}
}

@article{desimoneObesityHypertensiveHeart2016,
  title = {Obesity and Hypertensive Heart Disease: Focus on Body Composition and Sex Differences},
  shorttitle = {Obesity and Hypertensive Heart Disease},
  author = {{de Simone}, Giovanni and Mancusi, Costantino and Izzo, Raffaele and Losi, Maria Angela and Aldo Ferrara, L.},
  year = {2016},
  month = nov,
  journal = {Diabetology \& Metabolic Syndrome},
  volume = {8},
  number = {1},
  pages = {79},
  issn = {1758-5996},
  doi = {10.1186/s13098-016-0193-x},
  urldate = {2024-07-03},
  abstract = {There is evidence that hypertension is frequently associated with overweight/obesity even in kids and adolescents. Either conditions influence development of left ventricular (LV) hypertrophy (LVH), through different biological and hemodynamic mechanisms: obesity is conventionally thought to elicit a coherent growth of LV chamber dimensions and myocardial wall thickness (eccentric LV geometry), whereas a more accentuated increase in wall-thickness (concentric LV geometry) is attributed to hypertension. While during youth these differences are visible, proportion of LV concentric geometry, the most harmful LV geometric pattern, sharply raises in obese individuals during middle age, and becomes the most frequent geometric patterns among obese-hypertensive individuals. Two conditions with elevated hemodynamic impact, severe obstructive sleep apnea and masked hypertension contribute to the development of such a geometric pattern, but non-hemodynamic factors, and specifically body composition, also influence prevalence of concentric LV geometry. Contrasting a general belief, it has been observed that adipose mass strongly influences LV mass, particularly in women, especially when fat-free mass is relatively deficient. Thus, though blood pressure control is mandatory for prevention and reduction of LVH in obese hypertensive patients, without reduction of visceral adiposity regression of LVH is difficult. Future researches should be addressed on (1) assessing whether LVH resulting from alteration of body composition carries the same prognosis as pressure overload LVH; (2) defining tissue characterization of the hypertrophic heart in obese-hypertensive patients; (3) evaluating whether assessment of hemodynamic loading conditions and biological markers can help defining management of the association of obesity with hypertension.},
  keywords = {Body composition,Hypertension,Left ventricular mass,Obesity},
  file = {/Users/xx20081/Zotero/storage/8AMJ9YZF/de Simone et al. - 2016 - Obesity and hypertensive heart disease focus on b.pdf;/Users/xx20081/Zotero/storage/LWG9KFTU/s13098-016-0193-x.html}
}

@article{desimoneRelativeFatfreeMass2013,
  title = {Relative Fat-Free Mass Deficiency and Left Ventricular Adaptation to Obesity: The {{Strong Heart Study}}},
  shorttitle = {Relative Fat-Free Mass Deficiency and Left Ventricular Adaptation to Obesity},
  author = {{de Simone}, Giovanni and Pasanisi, Fabrizio and Ferrara, Aldo L. and Roman, Mary J. and Lee, Elisa T. and Contaldo, Franco and Howard, Barbara V. and Devereux, Richard B.},
  year = {2013},
  month = sep,
  journal = {International Journal of Cardiology},
  volume = {168},
  number = {2},
  pages = {729--733},
  issn = {1874-1754},
  doi = {10.1016/j.ijcard.2012.09.055},
  abstract = {BACKGROUND: Relative fat-free mass (FFM) deficiency (RFFMD) can also occur in obesity, but the impact on left ventricular (LV) mass is unknown. METHODS: We assessed relations among reduced FFM, obesity and LV mass in a population with high prevalence of obesity. Echocardiograms were performed in 2625 participants (1694 women, 1199 non-obese) of the Strong Heart Study cohort, free of prevalent cardiovascular disease and kidney failure. FFM was estimated by bioelectric impedance and analyzed in the non-obese subpopulation in relation with sex, BMI and waist-to-hip ratio (WHR). RFFMD was estimated in the obese subpopulation as the percent of observed/predicted FFM{$<$}20th percentile of the non-obese distribution. RESULTS: RFFMD was more frequent in women than men. LV mass indices (by either height(2.7) or FFM) were greater in obese with than in those without RFFMD, even after adjusting for sex and diabetes (both p{$<$}0.0001). The greater LV mass index in obesity with RFFMD was related mostly to increased LV diastolic dimension paralleling increased stroke index and cardiac index, in the presence of normal ejection fraction. RFFMD remained associated with greater LV mass index (p{$<$}0.0001) even independently of older age, greater BMI, higher systolic and lower diastolic blood pressure (all p{$<$}0.007), with negligible effect of sex, waist/hip ratio and diabetes. CONCLUSION: In obese SHS participants, RFFMD is associated with higher levels of LV mass, an effect related to adiposity more than central fat distribution and typical of female gender. Biological mechanisms of this association have to be better explored.},
  langid = {english},
  pmcid = {PMC3606902},
  pmid = {23063139},
  keywords = {Adaptation Physiological,Aged,Blood Pressure,Body composition,Body Mass Index,Cardiac hypertrophy,Cohort Studies,Echocardiography,Female,Humans,Hypertrophy Left Ventricular,Male,Middle Aged,Obesity,Population Surveillance,Sex,Waist-Hip Ratio},
  file = {/Users/xx20081/Zotero/storage/76MAKWKZ/de Simone et al. - 2013 - Relative fat-free mass deficiency and left ventric.pdf}
}

@article{despresBodyFatDistribution2012,
  title = {Body {{Fat Distribution}} and {{Risk}} of {{Cardiovascular Disease}}},
  author = {Despr{\'e}s, Jean-Pierre},
  year = {2012},
  month = sep,
  journal = {Circulation},
  volume = {126},
  number = {10},
  pages = {1301--1313},
  publisher = {American Heart Association},
  doi = {10.1161/CIRCULATIONAHA.111.067264},
  urldate = {2024-08-06},
  file = {/Users/xx20081/Zotero/storage/SLQGRV5U/Desprs - 2012 - Body Fat Distribution and Risk of Cardiovascular D.pdf}
}

@article{dhindsaTranscriptomeBasedDrugDiscovery2021,
  title = {A {{Transcriptome-Based Drug Discovery Paradigm}} for {{Neurodevelopmental Disorders}}},
  author = {Dhindsa, Ryan S. and Zoghbi, Anthony W. and Krizay, Daniel K. and Vasavda, Chirag and Goldstein, David B.},
  year = {2021},
  journal = {Annals of Neurology},
  volume = {89},
  number = {2},
  pages = {199--211},
  issn = {1531-8249},
  doi = {10.1002/ana.25950},
  urldate = {2025-04-24},
  abstract = {Advances in genetic discoveries have created substantial opportunities for precision medicine in neurodevelopmental disorders. Many of the genes implicated in these diseases encode proteins that regulate gene expression, such as chromatin-associated proteins, transcription factors, and RNA-binding proteins. The identification of targeted therapeutics for individuals carrying mutations in these genes remains a challenge, as the encoded proteins can theoretically regulate thousands of downstream targets in a considerable number of cell types. Here, we propose the application of a drug discovery approach originally developed for cancer called ``transcriptome reversal'' for these neurodevelopmental disorders. This approach attempts to identify compounds that reverse gene-expression signatures associated with disease states. ANN NEUROL 2021;89:199--211},
  copyright = {{\copyright} 2020 American Neurological Association},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/2P9IML59/ana.html}
}

@article{digitaleKeyConceptsClinical2023,
  title = {Key Concepts in Clinical Epidemiology: Collider-Conditioning Bias},
  shorttitle = {Key Concepts in Clinical Epidemiology},
  author = {Digitale, Jean C. and Martin, Jeffrey N. and Glidden, David V. and Glymour, M. Maria},
  year = {2023},
  month = sep,
  journal = {Journal of Clinical Epidemiology},
  volume = {161},
  pages = {152--156},
  publisher = {Elsevier},
  issn = {0895-4356, 1878-5921},
  doi = {10.1016/j.jclinepi.2023.07.004},
  urldate = {2024-08-15},
  langid = {english},
  pmid = {37506950},
  file = {/Users/xx20081/Zotero/storage/TWY8YDNM/Digitale et al. - 2023 - Key concepts in clinical epidemiology collider-co.pdf}
}

@article{dudbridgeAdjustmentIndexEvent2019,
  title = {Adjustment for Index Event Bias in Genome-Wide Association Studies of Subsequent Events},
  author = {Dudbridge, Frank and Allen, Richard J. and Sheehan, Nuala A. and Schmidt, A. Floriaan and Lee, James C. and Jenkins, R. Gisli and Wain, Louise V. and Hingorani, Aroon D. and Patel, Riyaz S.},
  year = {2019},
  month = apr,
  journal = {Nature Communications},
  volume = {10},
  number = {1},
  pages = {1561},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-019-09381-w},
  urldate = {2024-03-08},
  abstract = {Following numerous genome-wide association studies of disease susceptibility, there is increasing interest in genetic associations with prognosis, survival or other subsequent events. Such associations are vulnerable to index event bias, by which selection of subjects according to disease status creates biased associations if common causes of incidence and prognosis are not accounted for. We propose an adjustment for index event bias using the residuals from the regression of genetic effects on prognosis on genetic effects on incidence. Our approach eliminates this bias when direct genetic effects on incidence and prognosis are independent, and otherwise reduces bias in realistic situations. In a study of idiopathic pulmonary fibrosis, we reverse a paradoxical association of the strong susceptibility gene MUC5B with increased survival, suggesting instead a significant association with decreased survival. In re-analysis of a study of Crohn's disease prognosis, four regions remain associated at genome-wide significance but with increased standard errors.},
  copyright = {2019 The Author(s)},
  langid = {english},
  keywords = {Epidemiology,Genetics research,Genome-wide association studies,Statistical methods},
  file = {/Users/xx20081/Zotero/storage/Y2QIZD3E/Dudbridge et al. - 2019 - Adjustment for index event bias in genome-wide ass.pdf}
}

@article{dunlayRiskFactorsHeart2009,
  title = {Risk {{Factors}} for {{Heart Failure}}: {{A Population-Based Case-Control Study}}},
  shorttitle = {Risk {{Factors}} for {{Heart Failure}}},
  author = {Dunlay, Shannon M. and Weston, Susan A. and Jacobsen, Steven J. and Roger, V{\'e}ronique L.},
  year = {2009},
  month = nov,
  journal = {The American Journal of Medicine},
  volume = {122},
  number = {11},
  pages = {1023--1028},
  issn = {0002-9343},
  doi = {10.1016/j.amjmed.2009.04.022},
  urldate = {2024-07-03},
  abstract = {Background The relative contribution of risk factors to the development of heart failure remains controversial. Further, whether these contributions have changed over time or differ by sex is unclear. Few population-based studies have been performed. We aimed to estimate the population attributable risk (PAR) associated with key risk factors for heart failure in the community. Methods Between 1979 and 2002, 962 incident heart failure cases in Olmsted County were age and sex-matched to population-based controls using Rochester Epidemiology Project resources. We determined the frequency of risk factors (coronary heart disease, hypertension, diabetes mellitus, obesity, and smoking), odds ratios, and PAR of each risk factor for heart failure. Results The mean number of risk factors for heart failure per case was 1.9{\textpm}1.1 and increased over time (P{$<$}.001). Hypertension was the most common (66\%), followed by smoking (51\%). The prevalence of hypertension, obesity, and smoking increased over time. The risk of heart failure was particularly high for coronary disease and diabetes with odds ratios (95\% confidence intervals) of 3.05 (2.36-3.95) and 2.65 (1.98-3.54), respectively. However, the PAR was highest for coronary disease and hypertension; each accounted for 20\% of heart failure cases in the population, although coronary disease accounted for the greatest proportion of cases in men (PAR 23\%) and hypertension was of greatest importance in women (PAR 28\%). Conclusion Preventing coronary disease and hypertension will have the greatest population impact in preventing heart failure. Sex-targeted prevention strategies might confer additional benefit. However, these relationships can change, underscoring the importance of continued surveillance of heart failure.},
  keywords = {Epidemiology,Heart failure,Risk factors},
  file = {/Users/xx20081/Zotero/storage/DC2MH22P/Dunlay et al. - 2009 - Risk Factors for Heart Failure A Population-Based.pdf;/Users/xx20081/Zotero/storage/ZMDTBR9K/S0002934309005786.html}
}

@article{eatonRiskFactorsIncident2016,
  title = {Risk {{Factors}} for {{Incident Hospitalized Heart Failure With Preserved Versus Reduced Ejection Fraction}} in a {{Multiracial Cohort}} of {{Postmenopausal Women}}},
  author = {Eaton, Charles B. and Pettinger, Mary and Rossouw, Jacques and Martin, Lisa Warsinger and Foraker, Randi and Quddus, Abdullah and Liu, Simin and Wampler, Nina S. and Hank Wu, Wen-Chih and Manson, JoAnn E. and Margolis, Karen and Johnson, Karen C. and Allison, Matthew and {Corbie-Smith}, Giselle and Rosamond, Wayne and Breathett, Khadijah and Klein, Liviu},
  year = {2016},
  month = oct,
  journal = {Circulation: Heart Failure},
  volume = {9},
  number = {10},
  pages = {e002883},
  publisher = {American Heart Association},
  doi = {10.1161/CIRCHEARTFAILURE.115.002883},
  urldate = {2024-07-03},
  abstract = {Background--- Heart failure is an important and growing public health problem in women. Risk factors for incident hospitalized heart failure with preserved ejection fraction (HFpEF) compared with heart failure with reduced ejection fraction (HFrEF) in women and differences by race/ethnicity are not well characterized. Methods and Results--- We prospectively evaluated the risk factors for incident hospitalized HFpEF and HFrEF in a multiracial cohort of 42\,170 postmenopausal women followed up for a mean of 13.2 years. Cox regression models with time-dependent covariate adjustment were used to define risk factors for HFpEF and HFrEF. Differences by race/ethnicity about incidence rates, baseline risk factors, and their population-attributable risk percentage were analyzed. Risk factors for both HFpEF and HFrEF were as follows: older age, white race, diabetes mellitus, cigarette smoking, and hypertension. Obesity, history of coronary heart disease (other than myocardial infarction), anemia, atrial fibrillation, and more than one comorbidity were associated with HFpEF but not with HFrEF. History of myocardial infarction was associated with HFrEF but not with HFpEF. Obesity was found to be a more potent risk factor for African American women compared with white women for HFpEF (P for interaction=0.007). For HFpEF, the population-attributable risk percentage was greatest for hypertension (40.9\%) followed by obesity (25.8\%), with the highest population-attributable risk percentage found in African Americans for these risk factors. Conclusions--- In this multiracial cohort of postmenopausal women, obesity stands out as a significant risk factor for HFpEF, with the strongest association in African American women. Clinical Trial Registration--- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000611.},
  file = {/Users/xx20081/Zotero/storage/MQMXA2HT/Eaton et al. - 2016 - Risk Factors for Incident Hospitalized Heart Failu.pdf}
}

@article{ehteshami-afsharClinicalCharacteristicsOutcomes2021,
  title = {Clinical {{Characteristics}} and {{Outcomes}} of {{Patients With Heart Failure With Reduced Ejection Fraction}} and {{Chronic Obstructive Pulmonary Disease}}: {{Insights From PARADIGM-HF}}},
  shorttitle = {Clinical {{Characteristics}} and {{Outcomes}} of {{Patients With Heart Failure With Reduced Ejection Fraction}} and {{Chronic Obstructive Pulmonary Disease}}},
  author = {{Ehteshami-Afshar}, Solmaz and Mooney, Leanne and Dewan, Pooja and Desai, Akshay S. and Lang, Ninian N. and Lefkowitz, Martin P. and Petrie, Mark C. and Rizkala, Adel R. and Rouleau, Jean L. and Solomon, Scott D. and Swedberg, Karl and Shi, Victor C. and Zile, Michael R. and Packer, Milton and McMurray, John J. V. and Jhund, Pardeep S. and Hawkins, Nathaniel M.},
  year = {2021},
  month = feb,
  journal = {Journal of the American Heart Association},
  volume = {10},
  number = {4},
  pages = {e019238},
  issn = {2047-9980},
  doi = {10.1161/JAHA.120.019238},
  abstract = {Background Chronic obstructive pulmonary disease (COPD) is a common comorbidity in heart failure with reduced ejection fraction, associated with undertreatment and worse outcomes. New treatments for heart failure with reduced ejection fraction may be particularly important in patients with concomitant COPD. Methods and Results We examined outcomes in 8399 patients with heart failure with reduced ejection fraction, according to COPD status, in the PARADIGM-HF (Prospective Comparison of Angiotensin Receptor Blocker-Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial. Cox regression models were used to compare COPD versus non-COPD subgroups and the effects of sacubitril/valsartan versus enalapril. Patients with COPD (n=1080, 12.9\%) were older than patients without COPD (mean 67 versus 63~years; P{$<$}0.001), with similar left ventricular ejection fraction (29.9\% versus 29.4\%), but higher NT-proBNP (N-terminal pro-B-type natriuretic peptide; median, 1741~pg/mL versus 1591~pg/mL; P=0.01), worse functional class (New York Heart Association III/IV 37\% versus 23\%; P{$<$}0.001) and Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (73 versus 81; P{$<$}0.001), and more congestion and comorbidity. Medical therapy was similar in patients with and without COPD except for beta-blockade (87\% versus 94\%; P{$<$}0.001) and diuretics (85\% versus 80\%; P{$<$}0.001). After multivariable adjustment, COPD was associated with higher risks of heart failure hospitalization (hazard ratio [HR], 1.32; 95\% CI, 1.13-1.54), and the composite of cardiovascular death or heart failure hospitalization (HR, 1.18; 95\% CI, 1.05-1.34), but not cardiovascular death (HR, 1.10; 95\% CI, 0.94-1.30), or all-cause mortality (HR, 1.14; 95\% CI, 0.99-1.31). COPD was also associated with higher risk of all cardiovascular hospitalization (HR, 1.17; 95\% CI, 1.05-1.31) and noncardiovascular hospitalization (HR, 1.45; 95\% CI, 1.29-1.64). The benefit of sacubitril/valsartan over enalapril was consistent in patients with and without COPD for all end points. Conclusions In PARADIGM-HF, COPD was associated with lower use of beta-blockers and worse health status and was an independent predictor of cardiovascular and noncardiovascular hospitalization. Sacubitril/valsartan was beneficial in this high-risk subgroup. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01035255.},
  langid = {english},
  pmcid = {PMC7955331},
  pmid = {33522249},
  keywords = {Aged,Aminobutyrates,Angiotensin Receptor Antagonists,Angiotensin-Converting Enzyme Inhibitors,Biomarkers,Biphenyl Compounds,chronic obstructive pulmonary disease,Dose-Response Relationship Drug,Double-Blind Method,Drug Administration Schedule,Drug Combinations,ejection fraction,Enalapril,Female,Follow-Up Studies,heart failure,Heart Failure,hospitalization,Hospitalization,Humans,Male,Middle Aged,mortality,Natriuretic Peptide Brain,neprilysin,Peptide Fragments,Prognosis,Prospective Studies,Pulmonary Disease Chronic Obstructive,right ventricle,Stroke Volume,Time Factors,Valsartan,Ventricular Function Left},
  file = {/Users/xx20081/Zotero/storage/3DKXB93D/Ehteshami-Afshar et al. - 2021 - Clinical Characteristics and Outcomes of Patients .pdf}
}

@article{eleidBiasedAgonismPolymorphic2022,
  title = {Biased Agonism and Polymorphic Variation at the {{GLP-1}} Receptor: {{Implications}} for the Development of Personalised Therapeutics},
  shorttitle = {Biased Agonism and Polymorphic Variation at the {{GLP-1}} Receptor},
  author = {El Eid, Liliane and Reynolds, Christopher A. and Tomas, Alejandra and {Ben Jones}},
  year = {2022},
  month = oct,
  journal = {Pharmacological Research},
  volume = {184},
  pages = {106411},
  issn = {1043-6618},
  doi = {10.1016/j.phrs.2022.106411},
  urldate = {2024-01-21},
  abstract = {Glucagon-like peptide-1 receptor (GLP-1R) is a well-studied incretin hormone receptor and target of several therapeutic drugs for type 2 diabetes (T2D), obesity and, more recently, cardiovascular disease. Some signalling pathways downstream of GLP-1R may be responsible for drug adverse effects such as nausea, while others mediate therapeutic outcomes of incretin-based T2D therapeutics. Understanding the interplay between different factors that alter signalling, trafficking, and receptor activity, including biased agonism, single nucleotide polymorphisms and structural modifications is key to develop the next-generation of personalised GLP-1R agonists. However, these interactions remain poorly described, especially for novel therapeutics such as dual and tri-agonists that target more than one incretin receptor. Comparison of GLP-1R structures in complex with G proteins and different peptide and non-peptide agonists has revealed novel insights into important agonist-residue interactions and networks crucial for receptor activation, recruitment of G proteins and engagement of specific signalling pathways. Here, we review the latest knowledge on GLP-1R structure and activation, providing structural evidence for biased agonism and delineating important networks associated with this phenomenon. We survey current biased agonists and multi-agonists at different stages of development, highlighting possible challenges in their translational potential. Lastly, we discuss findings related to non-synonymous genomic variants of GLP1R and the functional importance of specific residues involved in GLP-1R function. We propose that studies of GLP-1R polymorphisms, and specifically their effect on receptor dynamics and pharmacology in response to biased agonists, could have a significant impact in delineating precision medicine approaches and development of novel therapeutics.},
  keywords = {Arrestin,Bias,GLP-1,Polymorphisms},
  file = {/Users/xx20081/Zotero/storage/ZAX6J23N/El Eid et al. - 2022 - Biased agonism and polymorphic variation at the GL.pdf}
}

@article{elmoreProteinIdentificationStroke2024,
  title = {Protein {{Identification}} for {{Stroke Progression}} via {{Mendelian Randomization}} in {{Million Veteran Program}} and {{UK Biobank}}},
  author = {Elmore, Andrew R. and Adhikari, Nimish and Hartley, April E. and Aparicio, Hugo Javier and Posner, Daniel C. and Hemani, Gibran and Tilling, Kate and Gaunt, Tom R. and Wilson, Peter W.F. and Casas, Juan P. and Gaziano, John Michael and Davey Smith, George and Paternoster, Lavinia and Cho, Kelly and Peloso, Gina M.},
  year = {2024},
  month = aug,
  journal = {Stroke},
  volume = {55},
  number = {8},
  pages = {2045--2054},
  issn = {0039-2499, 1524-4628},
  doi = {10.1161/STROKEAHA.124.047103},
  urldate = {2024-08-08},
  abstract = {BACKGROUND: Individuals who have experienced a stroke, or transient ischemic attack, face a heightened risk of future cardiovascular events. Identification of genetic and molecular risk factors for subsequent cardiovascular outcomes may identify effective therapeutic targets to improve prognosis after an incident stroke. METHODS: We performed genome-wide association studies for subsequent major adverse cardiovascular events (MACE; ncases=51\,929; ncontrols=39\,980) and subsequent arterial ischemic stroke (AIS; ncases=45\,120; ncontrols=46\,789) after the first incident stroke within the Million Veteran Program and UK Biobank. We then used genetic variants associated with proteins (protein quantitative trait loci) to determine the effect of 1463 plasma protein abundances on subsequent MACE using Mendelian randomization. RESULTS: Two variants were significantly associated with subsequent cardiovascular events: rs76472767 near gene RNF220 (odds ratio, 0.75 [95\% CI, 0.64--0.85]; P=3.69{\texttimes}10-8) with subsequent AIS and rs13294166 near gene LINC01492 (odds ratio, 1.52 [95\% CI, 1.37--1.67]; P=3.77{\texttimes}10-8) with subsequent MACE. Using Mendelian randomization, we identified 2 proteins with an effect on subsequent MACE after a stroke: CCL27 ([C-C motif chemokine 27], effect odds ratio, 0.77 [95\% CI, 0.66--0.88]; adjusted P=0.05) and TNFRSF14 ([tumor necrosis factor receptor superfamily member 14], effect odds ratio, 1.42 [95\% CI, 1.24--1.60]; adjusted P=0.006). These proteins are not associated with incident AIS and are implicated to have a role in inflammation. CONCLUSIONS: We found evidence that 2 proteins with little effect on incident stroke appear to influence subsequent MACE after incident AIS. These associations suggest that inflammation is a contributing factor to subsequent MACE outcomes after incident AIS and highlights potential novel targets.},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/6V5STPSX/Elmore et al. - 2024 - Protein Identification for Stroke Progression via .pdf}
}

@misc{elsworthMRCIEUOpenGWAS2020,
  title = {The {{MRC IEU OpenGWAS}} Data Infrastructure},
  author = {Elsworth, Ben and Lyon, Matthew and Alexander, Tessa and Liu, Yi and Matthews, Peter and Hallett, Jon and Bates, Phil and Palmer, Tom and Haberland, Valeriia and Smith, George Davey and Zheng, Jie and Haycock, Philip and Gaunt, Tom R. and Hemani, Gibran},
  year = {2020},
  month = aug,
  primaryclass = {New Results},
  pages = {2020.08.10.244293},
  publisher = {bioRxiv},
  doi = {10.1101/2020.08.10.244293},
  urldate = {2024-09-12},
  abstract = {Data generated by genome-wide association studies (GWAS) are growing fast with the linkage of biobank samples to health records, and expanding capture of high-dimensional molecular phenotypes. However the utility of these efforts can only be fully realised if their complete results are collected from their heterogeneous sources and formats, harmonised and made programmatically accessible. Here we present the OpenGWAS database, an open source, open access, scalable and high-performance cloud-based data infrastructure that imports and publishes complete GWAS summary datasets and metadata for the scientific community. Our import pipeline harmonises these datasets against dbSNP and the human genome reference sequence, generates summary reports and standardises the format of results and metadata. Users can access the data via a website, an application programming interface, R and Python packages, and also as downloadable files that can be rapidly queried in high performance computing environments. OpenGWAS currently contains 126 billion genetic associations from 14,582 complete GWAS datasets representing a range of different human phenotypes and disease outcomes across different populations. We developed R and Python packages to serve as conduits between these GWAS data sources and a range of available analytical tools, enabling Mendelian randomization, genetic colocalisation analysis, fine mapping, genetic correlation and locus visualisation. OpenGWAS is freely accessible at https://gwas.mrcieu.ac.uk, and has been designed to facilitate integration with third party analytical tools.},
  archiveprefix = {bioRxiv},
  chapter = {New Results},
  copyright = {{\copyright} 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/CV5CVQ39/Elsworth et al. - 2020 - The MRC IEU OpenGWAS data infrastructure.pdf}
}

@article{esslingerExomewideAssociationStudy2017,
  title = {Exome-Wide Association Study Reveals Novel Susceptibility Genes to Sporadic Dilated Cardiomyopathy},
  author = {Esslinger, Ulrike and Garnier, Sophie and Korniat, Agathe and Proust, Carole and Kararigas, Georgios and {M{\"u}ller-Nurasyid}, Martina and Empana, Jean-Philippe and Morley, Michael P. and Perret, Claire and Stark, Klaus and Bick, Alexander G. and Prasad, Sanjay K. and Kriebel, Jennifer and Li, Jin and Tiret, Laurence and Strauch, Konstantin and O'Regan, Declan P. and Marguiles, Kenneth B. and Seidman, Jonathan G. and Boutouyrie, Pierre and Lacolley, Patrick and Jouven, Xavier and Hengstenberg, Christian and Komajda, Michel and Hakonarson, Hakon and Isnard, Richard and Arbustini, Eloisa and Grallert, Harald and Cook, Stuart A. and Seidman, Christine E. and {Regitz-Zagrosek}, Vera and Cappola, Thomas P. and Charron, Philippe and Cambien, Fran{\c c}ois and Villard, Eric},
  year = {2017},
  journal = {PloS One},
  volume = {12},
  number = {3},
  pages = {e0172995},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0172995},
  abstract = {AIMS: Dilated cardiomyopathy (DCM) is an important cause of heart failure with a strong familial component. We performed an exome-wide array-based association study (EWAS) to assess the contribution of missense variants to sporadic DCM. METHODS AND RESULTS: 116,855 single nucleotide variants (SNVs) were analyzed in 2796 DCM patients and 6877 control subjects from 6 populations of European ancestry. We confirmed two previously identified associations with SNVs in BAG3 and ZBTB17 and discovered six novel DCM-associated loci (Q-value{$<$}0.01). The lead-SNVs at novel loci are common and located in TTN, SLC39A8, MLIP, FLNC, ALPK3 and FHOD3. In silico fine mapping identified HSPB7 as the most likely candidate at the ZBTB17 locus. Rare variant analysis (MAF{$<$}0.01) demonstrated significant association for TTN variants only (P = 0.0085). All candidate genes but one (SLC39A8) exhibit preferential expression in striated muscle tissues and mutations in TTN, BAG3, FLNC and FHOD3 are known to cause familial cardiomyopathy. We also investigated a panel of 48 known cardiomyopathy genes. Collectively, rare (n = 228, P = 0.0033) or common (n = 36, P = 0.019) variants with elevated in silico severity scores were associated with DCM, indicating that the spectrum of genes contributing to sporadic DCM extends beyond those identified here. CONCLUSION: We identified eight loci independently associated with sporadic DCM. The functions of the best candidate genes at these loci suggest that proteostasis regulation might play a role in DCM pathophysiology.},
  langid = {english},
  pmcid = {PMC5351854},
  pmid = {28296976},
  keywords = {Cardiomyopathy Dilated,Exome,Genetic Predisposition to Disease,Humans,Mutation Missense,Polymorphism Single Nucleotide},
  file = {/Users/xx20081/Zotero/storage/8KPM83X6/Esslinger et al. - 2017 - Exome-wide association study reveals novel suscept.pdf}
}

@article{evangelouGeneticAnalysis12018,
  title = {Genetic Analysis of over 1 Million People Identifies 535 New Loci Associated with Blood Pressure Traits},
  author = {Evangelou, Evangelos and Warren, Helen R. and {Mosen-Ansorena}, David and Mifsud, Borbala and Pazoki, Raha and Gao, He and Ntritsos, Georgios and Dimou, Niki and Cabrera, Claudia P. and Karaman, Ibrahim and Ng, Fu Liang and Evangelou, Marina and Witkowska, Katarzyna and Tzanis, Evan and Hellwege, Jacklyn N. and Giri, Ayush and Velez Edwards, Digna R. and Sun, Yan V. and Cho, Kelly and Gaziano, J. Michael and Wilson, Peter W. F. and Tsao, Philip S. and Kovesdy, Csaba P. and Esko, Tonu and M{\"a}gi, Reedik and Milani, Lili and Almgren, Peter and Boutin, Thibaud and Debette, St{\'e}phanie and Ding, Jun and Giulianini, Franco and Holliday, Elizabeth G. and Jackson, Anne U. and {Li-Gao}, Ruifang and Lin, Wei-Yu and Luan, Jian'an and Mangino, Massimo and Oldmeadow, Christopher and Prins, Bram Peter and Qian, Yong and Sargurupremraj, Muralidharan and Shah, Nabi and Surendran, Praveen and Th{\'e}riault, S{\'e}bastien and Verweij, Niek and Willems, Sara M. and Zhao, Jing-Hua and Amouyel, Philippe and Connell, John and {de Mutsert}, Ren{\'e}e and Doney, Alex S. F. and Farrall, Martin and Menni, Cristina and Morris, Andrew D. and Noordam, Raymond and Par{\'e}, Guillaume and Poulter, Neil R. and Shields, Denis C. and Stanton, Alice and Thom, Simon and Abecasis, Gon{\c c}alo and Amin, Najaf and Arking, Dan E. and Ayers, Kristin L. and Barbieri, Caterina M. and Batini, Chiara and Bis, Joshua C. and Blake, Tineka and Bochud, Murielle and Boehnke, Michael and Boerwinkle, Eric and Boomsma, Dorret I. and Bottinger, Erwin P. and Braund, Peter S. and Brumat, Marco and Campbell, Archie and Campbell, Harry and Chakravarti, Aravinda and Chambers, John C. and Chauhan, Ganesh and Ciullo, Marina and Cocca, Massimiliano and Collins, Francis and Cordell, Heather J. and Davies, Gail and {de Borst}, Martin H. and {de Geus}, Eco J. and Deary, Ian J. and Deelen, Joris and Del Greco M, Fabiola and Demirkale, Cumhur Yusuf and D{\"o}rr, Marcus and Ehret, Georg B. and Elosua, Roberto and Enroth, Stefan and Erzurumluoglu, A. Mesut and Ferreira, Teresa and Fr{\aa}nberg, Mattias and Franco, Oscar H. and Gandin, Ilaria and Gasparini, Paolo and Giedraitis, Vilmantas and Gieger, Christian and Girotto, Giorgia and Goel, Anuj and Gow, Alan J. and Gudnason, Vilmundur and Guo, Xiuqing and Gyllensten, Ulf and Hamsten, Anders and Harris, Tamara B. and Harris, Sarah E. and Hartman, Catharina A. and Havulinna, Aki S. and Hicks, Andrew A. and Hofer, Edith and Hofman, Albert and Hottenga, Jouke-Jan and Huffman, Jennifer E. and Hwang, Shih-Jen and Ingelsson, Erik and James, Alan and Jansen, Rick and Jarvelin, Marjo-Riitta and Joehanes, Roby and Johansson, {\AA}sa and Johnson, Andrew D. and Joshi, Peter K. and Jousilahti, Pekka and Jukema, J. Wouter and Jula, Antti and K{\"a}h{\"o}nen, Mika and Kathiresan, Sekar and Keavney, Bernard D. and Khaw, Kay-Tee and Knekt, Paul and Knight, Joanne and Kolcic, Ivana and Kooner, Jaspal S. and Koskinen, Seppo and Kristiansson, Kati and Kutalik, Zoltan and Laan, Maris and Larson, Marty and Launer, Lenore J. and Lehne, Benjamin and Lehtim{\"a}ki, Terho and Liewald, David C. M. and Lin, Li and Lind, Lars and Lindgren, Cecilia M. and Liu, YongMei and Loos, Ruth J. F. and Lopez, Lorna M. and Lu, Yingchang and Lyytik{\"a}inen, Leo-Pekka and Mahajan, Anubha and Mamasoula, Chrysovalanto and Marrugat, Jaume and Marten, Jonathan and Milaneschi, Yuri and Morgan, Anna and Morris, Andrew P. and Morrison, Alanna C. and Munson, Peter J. and Nalls, Mike A. and Nandakumar, Priyanka and Nelson, Christopher P. and Niiranen, Teemu and Nolte, Ilja M. and Nutile, Teresa and Oldehinkel, Albertine J. and Oostra, Ben A. and O'Reilly, Paul F. and Org, Elin and Padmanabhan, Sandosh and Palmas, Walter and Palotie, Aarno and Pattie, Alison and Penninx, Brenda W. J. H. and Perola, Markus and Peters, Annette and Polasek, Ozren and Pramstaller, Peter P. and Nguyen, Quang Tri and Raitakari, Olli T. and Ren, Meixia and Rettig, Rainer and Rice, Kenneth and Ridker, Paul M. and Ried, Janina S. and Riese, Harri{\"e}tte and Ripatti, Samuli and Robino, Antonietta and Rose, Lynda M. and Rotter, Jerome I. and Rudan, Igor and Ruggiero, Daniela and Saba, Yasaman and Sala, Cinzia F. and Salomaa, Veikko and Samani, Nilesh J. and Sarin, Antti-Pekka and Schmidt, Reinhold and Schmidt, Helena and Shrine, Nick and Siscovick, David and Smith, Albert V. and Snieder, Harold and S{\~o}ber, Siim and Sorice, Rossella and Starr, John M. and Stott, David J. and Strachan, David P. and Strawbridge, Rona J. and Sundstr{\"o}m, Johan and Swertz, Morris A. and Taylor, Kent D. and Teumer, Alexander and Tobin, Martin D. and Tomaszewski, Maciej and Toniolo, Daniela and Traglia, Michela and Trompet, Stella and Tuomilehto, Jaakko and Tzourio, Christophe and Uitterlinden, Andr{\'e} G. and Vaez, Ahmad and {van der Most}, Peter J. and {van Duijn}, Cornelia M. and Vergnaud, Anne-Claire and Verwoert, Germaine C. and Vitart, Veronique and V{\"o}lker, Uwe and Vollenweider, Peter and Vuckovic, Dragana and Watkins, Hugh and Wild, Sarah H. and Willemsen, Gonneke and Wilson, James F. and Wright, Alan F. and Yao, Jie and Zemunik, Tatijana and Zhang, Weihua and Attia, John R. and Butterworth, Adam S. and Chasman, Daniel I. and Conen, David and Cucca, Francesco and Danesh, John and Hayward, Caroline and Howson, Joanna M. M. and Laakso, Markku and Lakatta, Edward G. and Langenberg, Claudia and Melander, Olle and {Mook-Kanamori}, Dennis O. and Palmer, Colin N. A. and Risch, Lorenz and Scott, Robert A. and Scott, Rodney J. and Sever, Peter and Spector, Tim D. and {van der Harst}, Pim and Wareham, Nicholas J. and Zeggini, Eleftheria and Levy, Daniel and Munroe, Patricia B. and {Newton-Cheh}, Christopher and Brown, Morris J. and Metspalu, Andres and Hung, Adriana M. and O'Donnell, Christopher J. and Edwards, Todd L. and Psaty, Bruce M. and Tzoulaki, Ioanna and Barnes, Michael R. and Wain, Louise V. and Elliott, Paul and Caulfield, Mark J. and {Million Veteran Program}},
  year = {2018},
  month = oct,
  journal = {Nature Genetics},
  volume = {50},
  number = {10},
  pages = {1412--1425},
  issn = {1546-1718},
  doi = {10.1038/s41588-018-0205-x},
  abstract = {High blood pressure is a highly heritable and modifiable risk factor for cardiovascular disease. We report the largest genetic association study of blood pressure traits (systolic, diastolic and pulse pressure) to date in over 1 million people of European ancestry. We identify 535 novel blood pressure loci that not only offer new biological insights into blood pressure regulation but also highlight shared genetic architecture between blood pressure and lifestyle exposures. Our findings identify new biological pathways for blood pressure regulation with potential for improved cardiovascular disease prevention in the future.},
  langid = {english},
  pmcid = {PMC6284793},
  pmid = {30224653},
  keywords = {Adult,Aged,Aged 80 and over,Blood Pressure,Cardiovascular Diseases,Cells Cultured,Female,Genetic Loci,Genetic Predisposition to Disease,Genetic Testing,Genetics Population,Genome-Wide Association Study,Human Umbilical Vein Endothelial Cells,Humans,Hypertension,Life Style,Male,Middle Aged,Polymorphism Single Nucleotide,Quantitative Trait Loci,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/6CWRBSRJ/Evangelou et al. - 2018 - Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure tra.pdf}
}

@article{evangelouGeneticAnalysisOne2018,
  title = {Genetic Analysis of over One Million People Identifies 535 New Loci Associated with Blood Pressure Traits},
  author = {Evangelou, Evangelos and Warren, Helen R and {Mosen-Ansorena}, David and Mifsud, Borbala and Pazoki, Raha and Gao, He and Ntritsos, Georgios and Dimou, Niki and Cabrera, Claudia P and Karaman, Ibrahim and Ng, Fu Liang and Evangelou, Marina and Witkowska, Katarzyna and Tzanis, Evan and Hellwege, Jacklyn N and Giri, Ayush and Velez Edwards, Digna R and Sun, Yan V and Cho, Kelly and Gaziano, J.Michael and Wilson, Peter WF and Tsao, Philip S and Kovesdy, Csaba P and Esko, Tonu and M{\"a}gi, Reedik and Milani, Lili and Almgren, Peter and Boutin, Thibaud and Debette, St{\'e}phanie and Ding, Jun and Giulianini, Franco and Holliday, Elizabeth G and Jackson, Anne U and {Li-Gao}, Ruifang and Lin, Wei-Yu and Luan, Jian'an and Mangino, Massimo and Oldmeadow, Christopher and Prins, Bram Peter and Qian, Yong and Sargurupremraj, Muralidharan and Shah, Nabi and Surendran, Praveen and Th{\'e}riault, S{\'e}bastien and Verweij, Niek and Willems, Sara M and Zhao, Jing-Hua and Amouyel, Philippe and Connell, John and {de Mutsert}, Ren{\'e}e and Doney, Alex SF and Farrall, Martin and Menni, Cristina and Morris, Andrew D and Noordam, Raymond and Par{\'e}, Guillaume and Poulter, Neil R and Shields, Denis C and Stanton, Alice and Thom, Simon and Abecasis, Gon{\c c}alo and Amin, Najaf and Arking, Dan E and Ayers, Kristin L and Barbieri, Caterina M and Batini, Chiara and Bis, Joshua C and Blake, Tineka and Bochud, Murielle and Boehnke, Michael and Boerwinkle, Eric and Boomsma, Dorret I and Bottinger, Erwin P and Braund, Peter S and Brumat, Marco and Campbell, Archie and Campbell, Harry and Chakravarti, Aravinda and Chambers, John C and Chauhan, Ganesh and Ciullo, Marina and Cocca, Massimiliano and Collins, Francis and Cordell, Heather J and Davies, Gail and {de Borst}, Martin H and {de Geus}, Eco J and Deary, Ian J and Deelen, Joris and Del Greco, M Fabiola and Demirkale, Cumhur Yusuf and D{\"o}rr, Marcus and Ehret, Georg B and Elosua, Roberto and Enroth, Stefan and Erzurumluoglu, A Mesut and Ferreira, Teresa and Fr{\aa}nberg, Mattias and Franco, Oscar H and Gandin, Ilaria and Gasparini, Paolo and Giedraitis, Vilmantas and Gieger, Christian and Girotto, Giorgia and Goel, Anuj and Gow, Alan J and Gudnason, Vilmundur and Guo, Xiuqing and Gyllensten, Ulf and Hamsten, Anders and Harris, Tamara B and Harris, Sarah E and Hartman, Catharina A and Havulinna, Aki S and Hicks, Andrew A and Hofer, Edith and Hofman, Albert and Hottenga, Jouke-Jan and Huffman, Jennifer E and Hwang, Shih-Jen and Ingelsson, Erik and James, Alan and Jansen, Rick and Jarvelin, Marjo-Riitta and Joehanes, Roby and Johansson, {\AA}sa and Johnson, Andrew D and Joshi, Peter K and Jousilahti, Pekka and Jukema, J Wouter and Jula, Antti and K{\"a}h{\"o}nen, Mika and Kathiresan, Sekar and Keavney, Bernard D and Khaw, Kay-Tee and Knekt, Paul and Knight, Joanne and Kolcic, Ivana and Kooner, Jaspal S and Koskinen, Seppo and Kristiansson, Kati and Kutalik, Zoltan and Laan, Maris and Larson, Marty and Launer, Lenore J and Lehne, Benjamin and Lehtim{\"a}ki, Terho and Liewald, David CM and Lin, Li and Lind, Lars and Lindgren, Cecilia M and Liu, YongMei and Loos, Ruth JF and Lopez, Lorna M and Lu, Yingchang and Lyytik{\"a}inen, Leo-Pekka and Mahajan, Anubha and Mamasoula, Chrysovalanto and Marrugat, Jaume and Marten, Jonathan and Milaneschi, Yuri and Morgan, Anna and Morris, Andrew P and Morrison, Alanna C and Munson, Peter J and Nalls, Mike A and Nandakumar, Priyanka and Nelson, Christopher P and Niiranen, Teemu and Nolte, Ilja M and Nutile, Teresa and Oldehinkel, Albertine J and Oostra, Ben A and O'Reilly, Paul F and Org, Elin and Padmanabhan, Sandosh and Palmas, Walter and Palotie, Aarno and Pattie, Alison and Penninx, Brenda WJH and Perola, Markus and Peters, Annette and Polasek, Ozren and Pramstaller, Peter P and Nguyen, Quang Tri and Raitakari, Olli T and Ren, Meixia and Rettig, Rainer and Rice, Kenneth and Ridker, Paul M and Ried, Janina S and Riese, Harri{\"e}tte and Ripatti, Samuli and Robino, Antonietta and Rose, Lynda M and Rotter, Jerome I and Rudan, Igor and Ruggiero, Daniela and Saba, Yasaman and Sala, Cinzia F and Salomaa, Veikko and Samani, Nilesh J and Sarin, Antti-Pekka and Schmidt, Reinhold and Schmidt, Helena and Shrine, Nick and Siscovick, David and Smith, Albert V and Snieder, Harold and S{\~o}ber, Siim and Sorice, Rossella and Starr, John M and Stott, David J and Strachan, David P and Strawbridge, Rona J and Sundstr{\"o}m, Johan and Swertz, Morris A and Taylor, Kent D and Teumer, Alexander and Tobin, Martin D and Tomaszewski, Maciej and Toniolo, Daniela and Traglia, Michela and Trompet, Stella and Tuomilehto, Jaakko and Tzourio, Christophe and Uitterlinden, Andr{\'e} G and Vaez, Ahmad and {van der Most}, Peter J and {van Duijn}, Cornelia M and Vergnaud, Anne-Claire and Verwoert, Germaine C and Vitart, Veronique and V{\"o}lker, Uwe and Vollenweider, Peter and Vuckovic, Dragana and Watkins, Hugh and Wild, Sarah H and Willemsen, Gonneke and Wilson, James F and Wright, Alan F and Yao, Jie and Zemunik, Tatijana and Zhang, Weihua and Attia, John R and Butterworth, Adam S and Chasman, Daniel I and Conen, David and Cucca, Francesco and Danesh, John and Hayward, Caroline and Howson, Joanna MM and Laakso, Markku and Lakatta, Edward G and Langenberg, Claudia and Melander, Olle and {Mook-Kanamori}, Dennis O and Palmer, Colin NA and Risch, Lorenz and Scott, Robert A and Scott, Rodney J and Sever, Peter and Spector, Tim D and {van der Harst}, Pim and Wareham, Nicholas J and Zeggini, Eleftheria and Levy, Daniel and Munroe, Patricia B and {Newton-Cheh}, Christopher and Brown, Morris J and Metspalu, Andres and Hung, Adriana M and O'Donnell, Christopher J and Edwards, Todd L and Psaty, Bruce M. and Tzoulaki, Ioanna and Barnes, Michael R and Wain, Louise V and Elliott, Paul and Caulfield, Mark J},
  year = {2018},
  month = oct,
  journal = {Nature genetics},
  volume = {50},
  number = {10},
  pages = {1412--1425},
  issn = {1061-4036},
  doi = {10.1038/s41588-018-0205-x},
  urldate = {2024-09-02},
  abstract = {High blood pressure is a highly heritable and modifiable risk factor for cardiovascular disease. We report the largest genetic association study of blood pressure traits (systolic, diastolic, pulse pressure) to date in over one million people of European ancestry. We identify 535 novel blood pressure loci that not only offer new biological insights into blood pressure regulation but also reveal shared genetic architecture between blood pressure and lifestyle exposures. Our findings identify new biological pathways for blood pressure regulation with potential for improved cardiovascular disease prevention in the future.},
  pmcid = {PMC6284793},
  pmid = {30224653},
  file = {/Users/xx20081/Zotero/storage/F4LLD2NT/Evangelou et al. - 2018 - Genetic analysis of over one million people identi.pdf}
}

@article{evangelouPublisherCorrectionGenetic2018,
  title = {Publisher {{Correction}}: {{Genetic}} Analysis of over 1 Million People Identifies 535 New Loci Associated with Blood Pressure Traits},
  shorttitle = {Publisher {{Correction}}},
  author = {Evangelou, Evangelos and Warren, Helen R. and {Mosen-Ansorena}, David and Mifsud, Borbala and Pazoki, Raha and Gao, He and Ntritsos, Georgios and Dimou, Niki and Cabrera, Claudia P. and Karaman, Ibrahim and Ng, Fu Liang and Evangelou, Marina and Witkowska, Katarzyna and Tzanis, Evan and Hellwege, Jacklyn N. and Giri, Ayush and Velez Edwards, Digna R. and Sun, Yan V. and Cho, Kelly and Gaziano, J. Michael and Wilson, Peter W. F. and Tsao, Philip S. and Kovesdy, Csaba P. and Esko, Tonu and M{\"a}gi, Reedik and Milani, Lili and Almgren, Peter and Boutin, Thibaud and Debette, St{\'e}phanie and Ding, Jun and Giulianini, Franco and Holliday, Elizabeth G. and Jackson, Anne U. and {Li-Gao}, Ruifang and Lin, Wei-Yu and Luan, Jian'an and Mangino, Massimo and Oldmeadow, Christopher and Prins, Bram Peter and Qian, Yong and Sargurupremraj, Muralidharan and Shah, Nabi and Surendran, Praveen and Th{\'e}riault, S{\'e}bastien and Verweij, Niek and Willems, Sara M. and Zhao, Jing-Hua and Amouyel, Philippe and Connell, John and {de Mutsert}, Ren{\'e}e and Doney, Alex S. F. and Farrall, Martin and Menni, Cristina and Morris, Andrew D. and Noordam, Raymond and Par{\'e}, Guillaume and Poulter, Neil R. and Shields, Denis C. and Stanton, Alice and Thom, Simon and Abecasis, Gon{\c c}alo and Amin, Najaf and Arking, Dan E. and Ayers, Kristin L. and Barbieri, Caterina M. and Batini, Chiara and Bis, Joshua C. and Blake, Tineka and Bochud, Murielle and Boehnke, Michael and Boerwinkle, Eric and Boomsma, Dorret I. and Bottinger, Erwin P. and Braund, Peter S. and Brumat, Marco and Campbell, Archie and Campbell, Harry and Chakravarti, Aravinda and Chambers, John C. and Chauhan, Ganesh and Ciullo, Marina and Cocca, Massimiliano and Collins, Francis and Cordell, Heather J. and Davies, Gail and {de Borst}, Martin H. and {de Geus}, Eco J. and Deary, Ian J. and Deelen, Joris and Del Greco M, Fabiola and Demirkale, Cumhur Yusuf and D{\"o}rr, Marcus and Ehret, Georg B. and Elosua, Roberto and Enroth, Stefan and Erzurumluoglu, A. Mesut and Ferreira, Teresa and Fr{\aa}nberg, Mattias and Franco, Oscar H. and Gandin, Ilaria and Gasparini, Paolo and Giedraitis, Vilmantas and Gieger, Christian and Girotto, Giorgia and Goel, Anuj and Gow, Alan J. and Gudnason, Vilmundur and Guo, Xiuqing and Gyllensten, Ulf and Hamsten, Anders and Harris, Tamara B. and Harris, Sarah E. and Hartman, Catharina A. and Havulinna, Aki S. and Hicks, Andrew A. and Hofer, Edith and Hofman, Albert and Hottenga, Jouke-Jan and Huffman, Jennifer E. and Hwang, Shih-Jen and Ingelsson, Erik and James, Alan and Jansen, Rick and Jarvelin, Marjo-Riitta and Joehanes, Roby and Johansson, {\AA}sa and Johnson, Andrew D. and Joshi, Peter K. and Jousilahti, Pekka and Jukema, J. Wouter and Jula, Antti and K{\"a}h{\"o}nen, Mika and Kathiresan, Sekar and Keavney, Bernard D. and Khaw, Kay-Tee and Knekt, Paul and Knight, Joanne and Kolcic, Ivana and Kooner, Jaspal S. and Koskinen, Seppo and Kristiansson, Kati and Kutalik, Zoltan and Laan, Maris and Larson, Marty and Launer, Lenore J. and Lehne, Benjamin and Lehtim{\"a}ki, Terho and Liewald, David C. M. and Lin, Li and Lind, Lars and Lindgren, Cecilia M. and Liu, YongMei and Loos, Ruth J. F. and Lopez, Lorna M. and Lu, Yingchang and Lyytik{\"a}inen, Leo-Pekka and Mahajan, Anubha and Mamasoula, Chrysovalanto and Marrugat, Jaume and Marten, Jonathan and Milaneschi, Yuri and Morgan, Anna and Morris, Andrew P. and Morrison, Alanna C. and Munson, Peter J. and Nalls, Mike A. and Nandakumar, Priyanka and Nelson, Christopher P. and Niiranen, Teemu and Nolte, Ilja M. and Nutile, Teresa and Oldehinkel, Albertine J. and Oostra, Ben A. and O'Reilly, Paul F. and Org, Elin and Padmanabhan, Sandosh and Palmas, Walter and Palotie, Aarno and Pattie, Alison and Penninx, Brenda W. J. H. and Perola, Markus and Peters, Annette and Polasek, Ozren and Pramstaller, Peter P. and Nguyen, Quang Tri and Raitakari, Olli T. and Ren, Meixia and Rettig, Rainer and Rice, Kenneth and Ridker, Paul M. and Ried, Janina S. and Riese, Harri{\"e}tte and Ripatti, Samuli and Robino, Antonietta and Rose, Lynda M. and Rotter, Jerome I. and Rudan, Igor and Ruggiero, Daniela and Saba, Yasaman and Sala, Cinzia F. and Salomaa, Veikko and Samani, Nilesh J. and Sarin, Antti-Pekka and Schmidt, Reinhold and Schmidt, Helena and Shrine, Nick and Siscovick, David and Smith, Albert V. and Snieder, Harold and S{\~o}ber, Siim and Sorice, Rossella and Starr, John M. and Stott, David J. and Strachan, David P. and Strawbridge, Rona J. and Sundstr{\"o}m, Johan and Swertz, Morris A. and Taylor, Kent D. and Teumer, Alexander and Tobin, Martin D. and Tomaszewski, Maciej and Toniolo, Daniela and Traglia, Michela and Trompet, Stella and Tuomilehto, Jaakko and Tzourio, Christophe and Uitterlinden, Andr{\'e} G. and Vaez, Ahmad and {van der Most}, Peter J. and {van Duijn}, Cornelia M. and Vergnaud, Anne-Claire and Verwoert, Germaine C. and Vitart, Veronique and V{\"o}lker, Uwe and Vollenweider, Peter and Vuckovic, Dragana and Watkins, Hugh and Wild, Sarah H. and Willemsen, Gonneke and Wilson, James F. and Wright, Alan F. and Yao, Jie and Zemunik, Tatijana and Zhang, Weihua and Attia, John R. and Butterworth, Adam S. and Chasman, Daniel I. and Conen, David and Cucca, Francesco and Danesh, John and Hayward, Caroline and Howson, Joanna M. M. and Laakso, Markku and Lakatta, Edward G. and Langenberg, Claudia and Melander, Olle and {Mook-Kanamori}, Dennis O. and Palmer, Colin N. A. and Risch, Lorenz and Scott, Robert A. and Scott, Rodney J. and Sever, Peter and Spector, Tim D. and {van der Harst}, Pim and Wareham, Nicholas J. and Zeggini, Eleftheria and Levy, Daniel and Munroe, Patricia B. and {Newton-Cheh}, Christopher and Brown, Morris J. and Metspalu, Andres and Hung, Adriana M. and O'Donnell, Christopher J. and Edwards, Todd L. and {Million Veteran Program} and Psaty, Bruce M. and Tzoulaki, Ioanna and Barnes, Michael R. and Wain, Louise V. and Elliott, Paul and Caulfield, Mark J.},
  year = {2018},
  month = dec,
  journal = {Nature Genetics},
  volume = {50},
  number = {12},
  pages = {1755},
  issn = {1546-1718},
  doi = {10.1038/s41588-018-0297-3},
  abstract = {In the version of this article originally published, the name of author Martin H. de Borst was coded incorrectly in the XML. The error has now been corrected in the HTML version of the paper.},
  langid = {english},
  pmid = {30429575},
  file = {/Users/xx20081/Zotero/storage/4CRH3UP6/Evangelou et al. - 2018 - Publisher Correction Genetic analysis of over 1 m.pdf}
}

@article{everettAntiInflammatoryTherapyCanakinumab2019,
  title = {Anti-{{Inflammatory Therapy With Canakinumab}} for the {{Prevention}} of {{Hospitalization}} for {{Heart Failure}}},
  author = {Everett, Brendan M. and Cornel, Jan H. and Lainscak, Mitja and Anker, Stefan D. and Abbate, Antonio and Thuren, Tom and Libby, Peter and Glynn, Robert J. and Ridker, Paul M.},
  year = {2019},
  month = mar,
  journal = {Circulation},
  volume = {139},
  number = {10},
  pages = {1289--1299},
  issn = {1524-4539},
  doi = {10.1161/CIRCULATIONAHA.118.038010},
  abstract = {BACKGROUND: Subclinical inflammation is associated with an increased risk of heart failure and with adverse prognosis in patients with established heart failure. Yet, treatments specifically directed at reducing inflammation in patients with heart failure have not yet shown improved clinical outcomes. We tested the hypothesis that the interleukin-1{$\beta$} inhibitor canakinumab would prevent hospitalization for heart failure (HHF) and the composite of HHF or heart failure-related mortality. METHODS: We randomized 10\,061 patients with prior myocardial infarction and high-sensitivity C-reactive protein {$\geq$}2 mg/L to canakinumab 50, 150, or 300 mg or placebo, given subcutaneously once every 3 months. In total, 2173 (22\%) reported a history of heart failure at baseline. We tested the hypothesis that canakinumab prevents prospectively collected HHF events and the composite of HHF or heart failure-related mortality. RESULTS: A total of 385 patients had an HHF event during a median follow-up of 3.7 years. Patients who had HHF were older, had higher body mass index, and were more likely to have diabetes mellitus, hypertension, and prior coronary bypass surgery. As anticipated, median (quartile 1, 3) baseline concentrations of high-sensitivity C-reactive protein were higher among those who had HHF during follow-up than those who did not (5.7 [3.5, 9.9] mg/L versus 4.2 [2.8, 6.9] mg/L, respectively; P{$<$}0.0001). The unadjusted hazard ratios for HHF with each dose of canakinumab compared with placebo were 1.04 (95\% CI, 0.79-1.36) for 50 mg, 0.86 (95\% CI, 0.65-1.13) for 150 mg, and 0.76 (95\% CI, 0.57-1.01) for 300 mg ( P for trend=0.025). The composite of HHF or heart failure-related mortality was also reduced by canakinumab, with unadjusted hazard ratios of 1.00 (95\% CI, 0.78-1.29) for 50 mg, 0.88 (95\% CI, 0.68-1.13) for 150 mg, and 0.78 (95\% CI, 0.60-1.02) for 300 mg ( P for trend=0.042). CONCLUSIONS: These randomized double-blind placebo-controlled data suggest that therapy with canakinumab, an interleukin-1{$\beta$} inhibitor, is related to a dose-dependent reduction in HHF and the composite of HHF or heart failure-related mortality in a population of patients with prior myocardial infarction and elevations in high-sensitivity C-reactive protein. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01327846.},
  langid = {english},
  pmid = {30586730},
  keywords = {Aged,Anti-Inflammatory Agents,Antibodies Monoclonal Humanized,Biomarkers,C-Reactive Protein,clinical trial [publication type],Disease Progression,Dose-Response Relationship Drug,Double-Blind Method,Female,heart failure,Heart Failure,Humans,inflammation,Inflammation Mediators,Male,Middle Aged,Patient Admission,Prospective Studies,Protective Factors,Risk Factors,Time Factors,Treatment Outcome}
}

@article{fallRoleAdiposityCardiometabolic2013,
  title = {The Role of Adiposity in Cardiometabolic Traits: A {{Mendelian}} Randomization Analysis},
  shorttitle = {The Role of Adiposity in Cardiometabolic Traits},
  author = {Fall, Tove and H{\"a}gg, Sara and M{\"a}gi, Reedik and Ploner, Alexander and Fischer, Krista and Horikoshi, Momoko and Sarin, Antti-Pekka and Thorleifsson, Gudmar and Ladenvall, Claes and Kals, Mart and Kuningas, Maris and Draisma, Harmen H. M. and Ried, Janina S. and {van Zuydam}, Natalie R. and Huikari, Ville and Mangino, Massimo and Sonestedt, Emily and Benyamin, Beben and Nelson, Christopher P. and Rivera, Natalia V. and Kristiansson, Kati and Shen, Huei-Yi and Havulinna, Aki S. and Dehghan, Abbas and Donnelly, Louise A. and Kaakinen, Marika and Nuotio, Marja-Liisa and Robertson, Neil and {de Bruijn}, Ren{\'e}e F. A. G. and Ikram, M. Arfan and Amin, Najaf and Balmforth, Anthony J. and Braund, Peter S. and Doney, Alexander S. F. and D{\"o}ring, Angela and Elliott, Paul and Esko, T{\~o}nu and Franco, Oscar H. and Gretarsdottir, Solveig and Hartikainen, Anna-Liisa and Heikkil{\"a}, Kauko and Herzig, Karl-Heinz and Holm, Hilma and Hottenga, Jouke Jan and Hypp{\"o}nen, Elina and Illig, Thomas and Isaacs, Aaron and Isomaa, Bo and Karssen, Lennart C. and Kettunen, Johannes and Koenig, Wolfgang and Kuulasmaa, Kari and Laatikainen, Tiina and Laitinen, Jaana and Lindgren, Cecilia and Lyssenko, Valeriya and L{\"a}{\"a}r{\"a}, Esa and Rayner, Nigel W. and M{\"a}nnist{\"o}, Satu and Pouta, Anneli and Rathmann, Wolfgang and Rivadeneira, Fernando and Ruokonen, Aimo and Savolainen, Markku J. and Sijbrands, Eric J. G. and Small, Kerrin S. and Smit, Jan H. and Steinthorsdottir, Valgerdur and Syv{\"a}nen, Ann-Christine and Taanila, Anja and Tobin, Martin D. and Uitterlinden, Andre G. and Willems, Sara M. and Willemsen, Gonneke and Witteman, Jacqueline and Perola, Markus and Evans, Alun and Ferri{\`e}res, Jean and Virtamo, Jarmo and Kee, Frank and Tregouet, David-Alexandre and Arveiler, Dominique and Amouyel, Philippe and Ferrario, Marco M. and Brambilla, Paolo and Hall, Alistair S. and Heath, Andrew C. and Madden, Pamela A. F. and Martin, Nicholas G. and Montgomery, Grant W. and Whitfield, John B. and Jula, Antti and Knekt, Paul and Oostra, Ben and {van Duijn}, Cornelia M. and Penninx, Brenda W. J. H. and Smith, George Davey and Kaprio, Jaakko and Samani, Nilesh J. and Gieger, Christian and Peters, Annette and Wichmann, H. Erich and Boomsma, Dorret I. and {de Geus}, Eco J. C. and Tuomi, TiinaMaija and Power, Chris and Hammond, Christopher J. and Spector, Tim D. and Lind, Lars and {Orho-Melander}, Marju and Palmer, Colin Neil Alexander and Morris, Andrew D. and Groop, Leif and J{\"a}rvelin, Marjo-Riitta and Salomaa, Veikko and Vartiainen, Erkki and Hofman, Albert and Ripatti, Samuli and Metspalu, Andres and Thorsteinsdottir, Unnur and Stefansson, Kari and Pedersen, Nancy L. and McCarthy, Mark I. and Ingelsson, Erik and Prokopenko, Inga and {European Network for Genetic and Genomic Epidemiology (ENGAGE) consortium}},
  year = {2013},
  journal = {PLoS medicine},
  volume = {10},
  number = {6},
  pages = {e1001474},
  issn = {1549-1676},
  doi = {10.1371/journal.pmed.1001474},
  abstract = {BACKGROUND: The association between adiposity and cardiometabolic traits is well known from epidemiological studies. Whilst the causal relationship is clear for some of these traits, for others it is not. We aimed to determine whether adiposity is causally related to various cardiometabolic traits using the Mendelian randomization approach. METHODS AND FINDINGS: We used the adiposity-associated variant rs9939609 at the FTO locus as an instrumental variable (IV) for body mass index (BMI) in a Mendelian randomization design. Thirty-six population-based studies of individuals of European descent contributed to the analyses. Age- and sex-adjusted regression models were fitted to test for association between (i) rs9939609 and BMI (n{$\mkern1mu$} ={$\mkern1mu$} 198,502), (ii) rs9939609 and 24 traits, and (iii) BMI and 24 traits. The causal effect of BMI on the outcome measures was quantified by IV estimators. The estimators were compared to the BMI-trait associations derived from the same individuals. In the IV analysis, we demonstrated novel evidence for a causal relationship between adiposity and incident heart failure (hazard ratio, 1.19 per BMI-unit increase; 95\% CI, 1.03-1.39) and replicated earlier reports of a causal association with type 2 diabetes, metabolic syndrome, dyslipidemia, and hypertension (odds ratio for IV estimator, 1.1-1.4; all p {$<$} 0.05). For quantitative traits, our results provide novel evidence for a causal effect of adiposity on the liver enzymes alanine aminotransferase and gamma-glutamyl transferase and confirm previous reports of a causal effect of adiposity on systolic and diastolic blood pressure, fasting insulin, 2-h post-load glucose from the oral glucose tolerance test, C-reactive protein, triglycerides, and high-density lipoprotein cholesterol levels (all p {$<$} 0.05). The estimated causal effects were in agreement with traditional observational measures in all instances except for type 2 diabetes, where the causal estimate was larger than the observational estimate (p{$\mkern1mu$} = {$\mkern1mu$}0.001). CONCLUSIONS: We provide novel evidence for a causal relationship between adiposity and heart failure as well as between adiposity and increased liver enzymes.},
  langid = {english},
  pmcid = {PMC3692470},
  pmid = {23824655},
  keywords = {Adiposity,Alpha-Ketoglutarate-Dependent Dioxygenase FTO,Body Mass Index,Cardiovascular Diseases,Case-Control Studies,Confounding Factors Epidemiologic,Genetic Association Studies,Humans,Mendelian Randomization Analysis,Meta-Analysis as Topic,Polymorphism Single Nucleotide,Proteins,Quantitative Trait Heritable},
  file = {/Users/xx20081/Zotero/storage/HIUNE3BZ/Fall et al. - 2013 - The role of adiposity in cardiometabolic traits a.pdf}
}

@article{fanNovelRecombinationProtein2023,
  title = {A Novel Recombination Protein {{C12ORF40}}/{{REDIC1}} Is Required for Meiotic Crossover Formation},
  author = {Fan, Suixing and Wang, Yuewen and Jiang, Hanwei and Jiang, Xiaohua and Zhou, Jianteng and Jiao, Yuying and Ye, Jingwei and Xu, Zishuo and Wang, Yue and Xie, Xuefeng and Zhang, Huan and Li, Yang and Liu, Wei and Zhang, Xiangjun and Ma, Hui and Shi, Baolu and Zhang, Yuanwei and Zubair, Muhammad and Shah, Wasim and Xu, Zhipeng and Xu, Bo and Shi, Qinghua},
  year = {2023},
  month = aug,
  journal = {Cell Discovery},
  volume = {9},
  number = {1},
  pages = {1--20},
  publisher = {Nature Publishing Group},
  issn = {2056-5968},
  doi = {10.1038/s41421-023-00577-5},
  urldate = {2024-04-12},
  abstract = {During meiosis, at least one crossover must occur per homologous chromosome pair to ensure normal progression of meiotic division and accurate chromosome segregation. However, the mechanism of crossover formation is not fully understood. Here, we report a novel recombination protein, C12ORF40/REDIC1, essential for meiotic crossover formation in mammals. A homozygous frameshift mutation in C12orf40 (c.232\_233insTT, p.Met78Ilefs*2) was identified in two infertile men with meiotic arrest. Spread mouse spermatocyte fluorescence immunostaining showed that REDIC1 forms discrete foci between the paired regions of homologous chromosomes depending on strand invasion and colocalizes with MSH4 and later with MLH1 at the crossover sites. Redic1 knock-in (KI) mice homozygous for mutation c.232\_233insTT are infertile in both sexes due to insufficient crossovers and consequent meiotic arrest, which is also observed in our patients. The foci of MSH4 and TEX11, markers of recombination intermediates, are significantly reduced numerically in the spermatocytes of Redic1 KI mice. More importantly, our biochemical results show that the N-terminus of REDIC1 binds branched DNAs present in recombination intermediates, while the identified mutation impairs this interaction. Thus, our findings reveal a crucial role for C12ORF40/REDIC1 in meiotic crossover formation by stabilizing the recombination intermediates, providing prospective molecular targets for the clinical diagnosis and therapy of infertility.},
  copyright = {2023 The Author(s)},
  langid = {english},
  keywords = {Homologous recombination,Meiosis},
  file = {/Users/xx20081/Zotero/storage/M2G6A3PB/Fan et al. - 2023 - A novel recombination protein C12ORF40REDIC1 is r.pdf}
}

@article{fauchierMetabolicallyHealthyObesity2021,
  title = {Metabolically Healthy Obesity and Cardiovascular Events: {{A}} Nationwide Cohort Study},
  shorttitle = {Metabolically Healthy Obesity and Cardiovascular Events},
  author = {Fauchier, Gr{\'e}goire and Bisson, Arnaud and Bodin, Alexandre and Herbert, Julien and Semaan, Carl and Angoulvant, Denis and Ducluzeau, Pierre Henri and Lip, Gregory Y. H. and Fauchier, Laurent},
  year = {2021},
  month = nov,
  journal = {Diabetes, Obesity \& Metabolism},
  volume = {23},
  number = {11},
  pages = {2492--2501},
  issn = {1463-1326},
  doi = {10.1111/dom.14492},
  abstract = {AIM: To evaluate the associations between metabolically healthy obesity (MHO) and different types of incident cardiovascular events in a contemporary population. MATERIALS AND METHODS: All patients discharged from French hospitals in 2013 with at least 5\,years of follow-up and without a history of major adverse cardiovascular event (MACE; myocardial infarction, heart failure [HF], ischaemic stroke or cardiovascular death [MACE-HF]) or underweight/malnutrition were identified. They were categorized by phenotypes defined by obesity and three metabolic abnormalities (diabetes, hypertension and hyperlipidaemia). Hazard ratios (HRs) for cardiovascular events during follow-up were adjusted on age, sex and smoking status at baseline. RESULTS: In total, 2\,873\,039 individuals were included in the analysis, among whom 272\,838 (9.5\%) had obesity. During a mean follow-up of 4.9\,years, when pooling men and women, individuals with MHO had a higher risk of MACE-HF (multivariate-adjusted HR 1.22, 95\% confidence interval [CI]: 1.19-1.24), new-onset HF (HR 1.34, 95\% CI 1.31-1.37) and atrial fibrillation (AF; HR 1.33, 95\% CI 1.30-1.37) compared with individuals with no obesity and zero metabolic abnormalities. By contrast, risks were not higher for myocardial infarction (HR 0.92, 95\% CI 0.87-0.98), ischaemic stroke (HR 0.93, 95\% CI 0.88-0.98) and cardiovascular death (HR 0.99, 95\% CI 0.93-1.04). MHO in men was associated with a higher risk of clinical events compared with metabolically healthy men of normal weight (HR 1.12-1.80), while women with MHO had a lower risk for most events than metabolically healthy women of normal weight (HR 0.49-0.99). CONCLUSIONS: In a large and contemporary analysis of patients seen in French hospitals, individuals with MHO did not have a higher risk of myocardial infarction, ischaemic stroke or cardiovascular death than metabolically healthy individuals with no obesity. By contrast, they had a higher risk of new-onset HF and new-onset AF. However, notable differences were observed in men and women in the sex-stratified analysis.},
  langid = {english},
  pmid = {34251088},
  keywords = {atrial fibrillation,Brain Ischemia,Cohort Studies,diabetes,Female,heart failure,Humans,ischaemic stroke,Male,myocardial infarction,obesity,Obesity,Obesity Metabolically Benign,Risk Factors,Stroke},
  file = {/Users/xx20081/Zotero/storage/U8R7WMTL/Fauchier et al. - 2021 - Metabolically healthy obesity and cardiovascular e.pdf}
}

@article{feldschuhPredictionNormalBlood1977,
  title = {Prediction of the Normal Blood Volume. {{Relation}} of Blood Volume to Body Habitus},
  author = {Feldschuh, J and Enson, Y},
  year = {1977},
  month = oct,
  journal = {Circulation},
  volume = {56},
  number = {4 Pt 1},
  publisher = {Circulation},
  issn = {0009-7322},
  doi = {10.1161/01.cir.56.4.605},
  urldate = {2024-07-05},
  abstract = {Predictions of blood volume (BV) assume the existence of a constant ratio between BV and body weight or surface area (SA). We examined the validity of this assumption by calculating BV from plasma volume and body hematocrit in 160 normal volunteers whose weights ranged from -38.7 to 210.8\% of desira {\dots}},
  langid = {english},
  pmid = {902387},
  file = {/Users/xx20081/Zotero/storage/EQPRIIP3/J and Y - 1977 - Prediction of the normal blood volume. Relation of.pdf;/Users/xx20081/Zotero/storage/X48VJSFB/902387.html}
}

@article{Felker2011,
  title = {Diuretic Strategies in Patients with Acute Decompensated Heart Failure},
  author = {GM, Felker and KL, Lee and DA, Bull and MM, Redfield and LW, Stevenson and SR, Goldsmith and MM, LeWinter and A, Deswal and JL, Rouleau and EO, Ofili and KJ, Anstrom and AF, Hernandez and SE, McNulty and EJ, Velazquez and AG, Kfoury and HH, Chen and MM, Givertz and MJ, Semigran and BA, Bart and AM, Mascette and E, Braunwald and CM, O'Connor},
  year = {2011},
  journal = {The New England journal of medicine},
  volume = {364},
  number = {9},
  pages = {E1},
  publisher = {N Engl J Med},
  issn = {1533-4406},
  doi = {10.1056/NEJMOA1005419},
  abstract = {Background: Clinical practice varies widely in the dosing and administration of loop diuretics for patients hospitalized with heart failure. Current guidelines are based primarily on expert opinion, although several small studies have suggested that continuous infusion is more effective than bolus administration in promoting diuresis and reducing the likelihood of renal dysfunction. Felker and colleagues conducted the Diuretic Optimization Strategies Evaluation trial to evaluate various diuretic strategies for acute decompensated heart failure. The Study: The trial prospectively examined diuretic doses and administration modes in 308 patients requiring hospitalization for acute exacerbation of chronic heart failure, despite having been on an oral loop diuretic for at least one month. Patients were excluded if they required intravenous vasodilators or inotropic agents other than digoxin, had hypotension, or had a serum creatinine level greater than 3.0 mg per dL (265.2 {$\mu$}mol per L). Patients were randomized to receive intravenous furosemide, which varied along two interventions: (1) low versus high dose (total daily dose either equivalent to or 2.5 times greater than the patient's previous daily loop diuretic dose, respectively); (2) and method of administration (continuous infusion versus boluses every 12 hours). The interventions were continued for up to 72 hours, with the treating physician having the option at 48 hours to adjust treatment if clinically warranted. Patients were monitored for 60 days after admission. The primary study outcomes included patients' global assessment of their symptoms, and changes in serum creatinine levels over the first 72 hours. Results: Regardless of intervention, no differences were seen between the groups with regard to median hospital length of stay, 60-day mortality, rehospitalization, or emergency department visits. Similarly, there were no differences in patients' reported symptoms or in mean changes in creatinine level. Patients receiving high-dose furosemide were more likely to be changed to oral diuretics at 48 hours than those assigned to the low-dose strategy (31 versus 17 percent; P {\textexclamdown}.001). They also had greater levels of fluid loss. High-dose furosemide was associated with a greater likelihood of a transient increase in serum creatinine of more than 0.3 mg per dL (26.52 {$\mu$}mol per L) during the initial 72 hours of treatment (23 versus 14 percent in the low-dose group; P =.04), which had resolved by day 60. Conclusion: In patients with acute decompensated heart failure, there were no significant differences in patients' global assessment of symptoms or in the change in creatinine level from baseline to 72 hours when intravenous loop diuretics were given via bolus versus continuous infusion, or with a low-dose versus high-dose strategy. {\copyright} 2012 American Academy of Family Physicians.},
  pmid = {21366472},
  keywords = {Acute Disease,affs=[],affs=[]),Aged,Area Under Curve,Author(firstnames='Abdallah G',Author(firstnames='Abiodun',Author(firstnames='Adefisayo',Author(firstnames='Adrian',Author(firstnames='Adrienne',Author(firstnames='Alice',Author(firstnames='Anekwe',Author(firstnames='Anita',Author(firstnames='Anthony',Author(firstnames='Barry',Author(firstnames='Bradley',Author(firstnames='Brenda',Author(firstnames='Christopher',Author(firstnames='David',Author(firstnames='Dennis',Author(firstnames='Diane',Author(firstnames='Donald',Author(firstnames='Douglas',Author(firstnames='Elaine',Author(firstnames='Elizabeth',Author(firstnames='Eric A',Author(firstnames='Eric',Author(firstnames='George',Author(firstnames='Helene',Author(firstnames='Horng',Author(firstnames='J Perren',Author(firstnames='Janet',Author(firstnames='Jean',Author(firstnames='Jessica Wilen',Author(firstnames='Jiawen',Author(firstnames='Joseph',Author(firstnames='Julianna',Author(firstnames='Julie',Author(firstnames='Kathleen',Author(firstnames='Kathryn Davis',Author(firstnames='Kerry',Author(firstnames='Kevin',Author(firstnames='Kimberly',Author(firstnames='Kirk',Author(firstnames='Linda',Author(firstnames='Lynne',Author(firstnames='Marc',Author(firstnames='Margaret',Author(firstnames='Martin',Author(firstnames='Mary Susan',Author(firstnames='Maryl R',Author(firstnames='Michael',Author(firstnames='Michaelanne',Author(firstnames='Minjung',Author(firstnames='Monica',Author(firstnames='Neal',Author(firstnames='Patrice',Author(firstnames='Patti',Author(firstnames='Patty',Author(firstnames='Paul',Author(firstnames='Priscilla',Author(firstnames='Raquel',Author(firstnames='Rebekah',Author(firstnames='Renu',Author(firstnames='Rigobert',Author(firstnames='Robin',Author(firstnames='Russell P',Author(firstnames='Ruth',Author(firstnames='Shari',Author(firstnames='Steve',Author(firstnames='Steven',Author(firstnames='Sunday',Author(firstnames='Susan',Author(firstnames='William',CollabAuthor(name='NHLBI Heart Failure Clinical Research Network',Comparative Study,Creatinine / blood,Diuretics / administration & dosage*,Diuretics / adverse effects,doi:10.1056/NEJMoa1005419,Double-Blind Method,Drug Administration Schedule,Dyspnea / etiology,equal<sub>c</sub>ontrib=False),equal<sub>c</sub>ontrib=False)],Extramural,Female,Furosemide / administration & dosage*,Furosemide / adverse effects,G Michael Felker,Heart Failure / blood,Heart Failure / complications,Heart Failure / drug therapy*,Humans,Infusions,initials='A',initials='AG',initials='B',initials='C',initials='D',initials='E',initials='EA',initials='G',initials='H',initials='J',initials='JP',initials='JW',initials='K',initials='KD',initials='L',initials='M',initials='MR',initials='MS',initials='N',initials='P',initials='R',initials='RP',initials='S',initials='W',Injections,Intention to Treat Analysis,Intravenous,investigators=[Author(firstnames='Eugene',iseditor=False,Kaplan-Meier Estimate,Kerry L Lee,lastname='Abraham',lastname='Adams',lastname='Agresti',lastname='Anello',lastname='Anstrom',lastname='Bart',lastname='Bennett',lastname='Berg',lastname='Boineau',lastname='Booth',lastname='Boyle',lastname='Braunwald',lastname='Brooks',lastname='Brown',lastname='Bull',lastname='Cai',lastname='Chadwick',lastname='Chee',lastname='Chen',lastname='Cobb',lastname='Cocca-Spofford',lastname='Cornell',lastname='Desvigne-Nickens',lastname='Deswal',lastname='Douglass',lastname='Felker',lastname='Gatzke',lastname='Givertz',lastname='Goldsmith',lastname='Greenberg',lastname='Hernandez',lastname='Johnson',lastname='Keleti',lastname='Kennedy',lastname='Kfoury',lastname='Kwak',lastname='Landry',lastname='Lankford',lastname='Lapu-Bula',lastname='Larson',lastname='Lee',lastname='LeWinter',lastname='Mackedanz',lastname='Mascette',lastname='McNamara',lastname='McNulty',lastname='Mehta',lastname='Meldrum',lastname='Nelson',lastname='Nkemdiche',lastname='Oduwole',lastname='Ofili',lastname='Olatidoye',lastname='Onwuanyi',lastname='Parrillo',lastname='Penn',lastname='Redfield',lastname='Rogers',lastname='Rohrback',lastname='Rose',lastname='Rouleau',lastname='Rowen',lastname='Semigran',lastname='Shah',lastname='Sopko',lastname='Stehlik',lastname='Stevenson',lastname='Tracy',lastname='Vaughan',lastname='Velazquez',lastname='Virmani',lastname='Volkman',lastname="O'Connor",Male,MEDLINE,Middle Aged,Multicenter Study,N.I.H.,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,PMC3412356,pmid:21366472,PubMed Abstract,Randomized Controlled Trial,Research Support,Sodium Potassium Chloride Symporter Inhibitors / administration & dosage*,Sodium Potassium Chloride Symporter Inhibitors / adverse effects,suffix=None}
}

@article{ferranniniAssociationBodyMass2023,
  title = {Association between Body Mass Index and Outcomes in Heart Failure across the Ejection Fraction Spectrum: Data from the {{Swedish Heart Failure Registry}}},
  shorttitle = {Association between Body Mass Index and Outcomes in Heart Failure across the Ejection Fraction Spectrum},
  author = {Ferrannini, G and Rodolico, D and Amario, D D and Dahlstrom, U and Lund, L H and Savarese, G},
  year = {2023},
  month = nov,
  journal = {European Heart Journal},
  volume = {44},
  number = {Supplement\_2},
  pages = {ehad655.2535},
  issn = {0195-668X},
  doi = {10.1093/eurheartj/ehad655.2535},
  urldate = {2025-01-07},
  abstract = {Despite overweight/obesity being a well-known cardiovascular (CV) risk factor, high body mass index (BMI) has been suggested to be associated with longer survival in patients with heart failure (HF). Data on large populations are lacking, as well as whether this advantage might be consistent across the ejection fraction (EF) spectrum, i.e. reduced (HFrEF), mildly reduced (HFmrEF) and preserved (HFpEF, where obesity may have a greater causative role).To assess the association between BMI and outcomes in a large and unselected contemporary cohort of patients with HF across the EF spectrum.Patients with HF registered in the Swedish HF Registry (SwedeHF) between May 2000 and December 2021, with no missing values for EF and BMI, were selected. Linkage with the Cause of Death Registry and the National Patient Registry provided data on mortality, hospitalizations and comorbidities. Patients were categorised according to BMI class (underweight \&lt;18.5 kg/m2; normal weight 18.5-24.9 kg/m2; overweight 25.0-29.9 kg/m2; obesity\&gt;30-34.9 kg/m2).The primary outcome was all-cause death, secondary outcomes were CV death and HF hospitalization (HHF). The associations between BMI categories and outcomes were analysed by univariable and multivariable Cox proportional hazards models, both in the whole cohort and according to EF classes; this association was also explored by modeling BMI as a continuous variable through restricted cubic splines. Missing data were handled by chained equation multiple imputation.69,874 patients (mean age 74 years, 36\% females) were included, of whom 3\% underweight, 35\% with normal weight, 35 \% overweight, obese 27\%. Figure 1 reports the proportions of the different BMI categories according to EF: obesity was significantly more common in HFpEF. Regardless of EF, obese patients were younger, with lower N-terminal B-type natriuretic peptide, higher New York Heart Association class, and with diabetes and hypertension as compared with the other three BMI classes.Compared with normal weight, both overweight and obesity were independently associated with lower mortality risk, while underweight with higher mortality, with consistent results in HFrEF, HFmrEF and HFpEF; the same associations were found for CV death or all three EF classes, while underweight only was associated with HHF in HFrEF. When BMI was modelled as restricted cubic splines, a reverse J-shaped adjusted association was found between BMI and risk of all-cause death (Figure 2).HF patients with overweight and obesity had a lower mortality risk compared with patients with normal or underweight patients across all EF classes, at least up to BMI\&gt;40 kg/m2. Our results are consistent with the previously suggested potential survival benefit in overweight patients, calling for future research to understand this apparent paradox.Figure 1},
  file = {/Users/xx20081/Zotero/storage/52AXTDZ2/Ferrannini et al. - 2023 - Association between body mass index and outcomes in heart failure across the ejection fraction spect.pdf;/Users/xx20081/Zotero/storage/M36CRKX9/7391901.html}
}

@article{ferreiraObesityParadoxInappropriate2012,
  title = {Obesity Paradox or Inappropriate Study Designs? {{Time}} for Life-Course Epidemiology},
  shorttitle = {Obesity Paradox or Inappropriate Study Designs?},
  author = {Ferreira, Isabel and Stehouwer, Coen D. A.},
  year = {2012},
  month = dec,
  journal = {Journal of Hypertension},
  volume = {30},
  number = {12},
  pages = {2271},
  issn = {0263-6352},
  doi = {10.1097/HJH.0b013e32835b4fe0},
  urldate = {2024-08-06},
  abstract = {An abstract is unavailable.},
  langid = {american},
  file = {/Users/xx20081/Zotero/storage/U4X52KQE/Ferreira and Stehouwer - 2012 - Obesity paradox or inappropriate study designs Ti.pdf;/Users/xx20081/Zotero/storage/BQBN8NLK/obesity_paradox_or_inappropriate_study_designs_.4.html}
}

@article{finucaneHeritabilityEnrichmentSpecifically2018,
  title = {Heritability Enrichment of Specifically Expressed Genes Identifies Disease-Relevant Tissues and Cell Types},
  author = {Finucane, Hilary K. and Reshef, Yakir A. and Anttila, Verneri and Slowikowski, Kamil and Gusev, Alexander and Byrnes, Andrea and Gazal, Steven and Loh, Po-Ru and Lareau, Caleb and Shoresh, Noam and Genovese, Giulio and Saunders, Arpiar and Macosko, Evan and Pollack, Samuela and Perry, John R.B. and Buenrostro, Jason D. and Bernstein, Bradley E. and Raychaudhuri, Soumya and McCarroll, Steven and Neale, Benjamin M. and Price, Alkes L.},
  year = {2018},
  month = apr,
  journal = {Nature genetics},
  volume = {50},
  number = {4},
  pages = {621--629},
  issn = {1061-4036},
  doi = {10.1038/s41588-018-0081-4},
  urldate = {2024-04-19},
  abstract = {We introduce an approach for identifying disease-relevant tissues and cell types by analyzing gene expression data together with genome-wide association study (GWAS) summary statistics. Our approach uses stratified LD score regression to test whether disease heritability is enriched in regions surrounding genes with the highest specific expression in a given tissue. We apply our approach to gene expression data from several sources together with GWAS summary statistics for 48 diseases and traits (average N=169K), detecting significant tissue-specific enrichments (FDR{$<$}5\%) for 34 traits. In our analysis of multiple tissues, we detect a broad range of enrichments that recapitulate known biology. In our brain-specific and immune-specific analyses, significant enrichments include an enrichment of inhibitory over excitatory neurons for bipolar disorder but excitatory over inhibitory neurons for schizophrenia and body mass index. Our results demonstrate that our polygenic approach is a powerful way to leverage gene expression data for interpreting GWAS signal.},
  pmcid = {PMC5896795},
  pmid = {29632380},
  file = {/Users/xx20081/Zotero/storage/KQGPF69S/Finucane et al. - 2018 - Heritability enrichment of specifically expressed .pdf}
}

@article{finucanePartitioningHeritabilityFunctional2015,
  title = {Partitioning Heritability by Functional Annotation Using Genome-Wide Association Summary Statistics},
  author = {Finucane, Hilary K. and {Bulik-Sullivan}, Brendan and Gusev, Alexander and Trynka, Gosia and Reshef, Yakir and Loh, Po-Ru and Anttila, Verneri and Xu, Han and Zang, Chongzhi and Farh, Kyle and Ripke, Stephan and Day, Felix R. and {ReproGen Consortium} and {Schizophrenia Working Group of the Psychiatric Genomics Consortium} and {RACI Consortium} and Purcell, Shaun and Stahl, Eli and Lindstrom, Sara and Perry, John R. B. and Okada, Yukinori and Raychaudhuri, Soumya and Daly, Mark J. and Patterson, Nick and Neale, Benjamin M. and Price, Alkes L.},
  year = {2015},
  month = nov,
  journal = {Nature Genetics},
  volume = {47},
  number = {11},
  pages = {1228--1235},
  issn = {1546-1718},
  doi = {10.1038/ng.3404},
  abstract = {Recent work has demonstrated that some functional categories of the genome contribute disproportionately to the heritability of complex diseases. Here we analyze a broad set of functional elements, including cell type-specific elements, to estimate their polygenic contributions to heritability in genome-wide association studies (GWAS) of 17 complex diseases and traits with an average sample size of 73,599. To enable this analysis, we introduce a new method, stratified LD score regression, for partitioning heritability from GWAS summary statistics while accounting for linked markers. This new method is computationally tractable at very large sample sizes and leverages genome-wide information. Our findings include a large enrichment of heritability in conserved regions across many traits, a very large immunological disease-specific enrichment of heritability in FANTOM5 enhancers and many cell type-specific enrichments, including significant enrichment of central nervous system cell types in the heritability of body mass index, age at menarche, educational attainment and smoking behavior.},
  langid = {english},
  pmcid = {PMC4626285},
  pmid = {26414678},
  keywords = {Algorithms,Computer Simulation,Disease,Female,Gene Frequency,Genetic Predisposition to Disease,Genome-Wide Association Study,Histones,Humans,Inheritance Patterns,Lysine,Male,Methylation,Models Genetic,Polymorphism Single Nucleotide},
  file = {/Users/xx20081/Zotero/storage/YLTBUC2Z/Finucane et al. - 2015 - Partitioning heritability by functional annotation.pdf}
}

@article{finucanePartitioningHeritabilityFunctional2015a,
  title = {Partitioning Heritability by Functional Annotation Using Genome-Wide Association Summary Statistics},
  author = {Finucane, Hilary K. and {Bulik-Sullivan}, Brendan and Gusev, Alexander and Trynka, Gosia and Reshef, Yakir and Loh, Po-Ru and Anttila, Verneri and Xu, Han and Zang, Chongzhi and Farh, Kyle and Ripke, Stephan and Day, Felix R. and Consortium, ReproGen and Purcell, Shaun and Stahl, Eli and Lindstrom, Sara and Perry, John R. B. and Okada, Yukinori and Raychaudhuri, Soumya and Daly, Mark and Patterson, Nick and Neale, Benjamin M. and Price, Alkes L.},
  year = {2015},
  month = nov,
  journal = {Nature genetics},
  volume = {47},
  number = {11},
  pages = {1228--1235},
  issn = {1061-4036},
  doi = {10.1038/ng.3404},
  urldate = {2024-04-19},
  abstract = {Recent work has demonstrated that some functional categories of the genome contribute disproportionately to the heritability of complex diseases. Here, we analyze a broad set of functional elements, including cell-type-specific elements, to estimate their polygenic contributions to heritability in genome-wide association studies (GWAS) of 17 complex diseases and traits with an average sample size of 73,599. To enable this analysis, we introduce a new method, stratified LD score regression, for partitioning heritability from GWAS summary statistics while accounting for linked markers. This new method is computationally tractable at very large sample sizes, and leverages genome-wide information. Our results include a large enrichment of heritability in conserved regions across many traits; a very large immunological disease-specific enrichment of heritability in FANTOM5 enhancers; and many cell-type-specific enrichments including significant enrichment of central nervous system cell types in body mass index, age at menarche, educational attainment, and smoking behavior.},
  pmcid = {PMC4626285},
  pmid = {26414678},
  file = {/Users/xx20081/Zotero/storage/FY3IU6RK/Finucane et al. - 2015 - Partitioning heritability by functional annotation.pdf}
}

@article{fischerBiomarkerProfilingNuclear2014,
  title = {Biomarker Profiling by Nuclear Magnetic Resonance Spectroscopy for the Prediction of All-Cause Mortality: An Observational Study of 17,345 Persons},
  shorttitle = {Biomarker Profiling by Nuclear Magnetic Resonance Spectroscopy for the Prediction of All-Cause Mortality},
  author = {Fischer, Krista and Kettunen, Johannes and W{\"u}rtz, Peter and Haller, Toomas and Havulinna, Aki S. and Kangas, Antti J. and Soininen, Pasi and Esko, T{\~o}nu and Tammesoo, Mari-Liis and M{\"a}gi, Reedik and Smit, Steven and Palotie, Aarno and Ripatti, Samuli and Salomaa, Veikko and {Ala-Korpela}, Mika and Perola, Markus and Metspalu, Andres},
  year = {2014},
  month = feb,
  journal = {PLoS medicine},
  volume = {11},
  number = {2},
  pages = {e1001606},
  issn = {1549-1676},
  doi = {10.1371/journal.pmed.1001606},
  abstract = {BACKGROUND: Early identification of ambulatory persons at high short-term risk of death could benefit targeted prevention. To identify biomarkers for all-cause mortality and enhance risk prediction, we conducted high-throughput profiling of blood specimens in two large population-based cohorts. METHODS AND FINDINGS: 106 candidate biomarkers were quantified by nuclear magnetic resonance spectroscopy of non-fasting plasma samples from a random subset of the Estonian Biobank (n{$\mkern1mu$}={$\mkern1mu$}9,842; age range 18-103 y; 508 deaths during a median of 5.4 y of follow-up). Biomarkers for all-cause mortality were examined using stepwise proportional hazards models. Significant biomarkers were validated and incremental predictive utility assessed in a population-based cohort from Finland (n{$\mkern1mu$}={$\mkern1mu$}7,503; 176 deaths during 5 y of follow-up). Four circulating biomarkers predicted the risk of all-cause mortality among participants from the Estonian Biobank after adjusting for conventional risk factors: alpha-1-acid glycoprotein (hazard ratio [HR] 1.67 per 1-standard deviation increment, 95\% CI 1.53-1.82, p{$\mkern1mu$}={$\mkern1mu$}5{\texttimes}10{$^{-31}$}), albumin (HR 0.70, 95\% CI 0.65-0.76, p{$\mkern1mu$}={$\mkern1mu$}2{\texttimes}10{$^{-18}$}), very-low-density lipoprotein particle size (HR 0.69, 95\% CI 0.62-0.77, p{$\mkern1mu$}={$\mkern1mu$}3{\texttimes}10{$^{-12}$}), and citrate (HR 1.33, 95\% CI 1.21-1.45, p{$\mkern1mu$}={$\mkern1mu$}5{\texttimes}10{$^{-10}$}). All four biomarkers were predictive of cardiovascular mortality, as well as death from cancer and other nonvascular diseases. One in five participants in the Estonian Biobank cohort with a biomarker summary score within the highest percentile died during the first year of follow-up, indicating prominent systemic reflections of frailty. The biomarker associations all replicated in the Finnish validation cohort. Including the four biomarkers in a risk prediction score improved risk assessment for 5-y mortality (increase in C-statistics 0.031, p{$\mkern1mu$}={$\mkern1mu$}0.01; continuous reclassification improvement 26.3\%, p{$\mkern1mu$}={$\mkern1mu$}0.001). CONCLUSIONS: Biomarker associations with cardiovascular, nonvascular, and cancer mortality suggest novel systemic connectivities across seemingly disparate morbidities. The biomarker profiling improved prediction of the short-term risk of death from all causes above established risk factors. Further investigations are needed to clarify the biological mechanisms and the utility of these biomarkers for guiding screening and prevention.},
  langid = {english},
  pmcid = {PMC3934819},
  pmid = {24586121},
  keywords = {Adolescent,Adult,Aged,Aged 80 and over,Biological Specimen Banks,Biomarkers,Cause of Death,Citric Acid,Estonia,Female,Finland,High-Throughput Screening Assays,Humans,Kaplan-Meier Estimate,Lipoproteins LDL,Magnetic Resonance Spectroscopy,Male,Middle Aged,Orosomucoid,Particle Size,Predictive Value of Tests,Prognosis,Proportional Hazards Models,Reproducibility of Results,Risk Assessment,Risk Factors,Serum Albumin,Serum Albumin Human,Time Factors,Young Adult},
  file = {/Users/xx20081/Zotero/storage/WX49IZU4/Fischer et al. - 2014 - Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause morta.pdf}
}

@article{flegalImpactSmokingPreexisting2007,
  title = {Impact of Smoking and Preexisting Illness on Estimates of the Fractions of Deaths Associated with Underweight, Overweight, and Obesity in the {{US}} Population},
  author = {Flegal, Katherine M. and Graubard, Barry I. and Williamson, David F. and Gail, Mitchell H.},
  year = {2007},
  month = oct,
  journal = {American Journal of Epidemiology},
  volume = {166},
  number = {8},
  pages = {975--982},
  issn = {0002-9262},
  doi = {10.1093/aje/kwm152},
  abstract = {Studies of body weight and mortality sometimes exclude participants who have ever smoked or who may have had preexisting illness at baseline. This exclusionary approach was applied to data from the National Health and Nutrition Examination Surveys to investigate the potential effects of smoking and preexisting illness on estimates of the attributable fractions of US deaths in 2000 that were associated with different levels of body mass index (BMI; weight (kg)/height (m2). Synthetic estimates were calculated by using postexclusion relative risks for BMI categories in place of BMI relative risks from the full sample, holding the relative risks for all other covariates constant. When the postexclusion relative risks were used, the attributable fractions of deaths associated with underweight and with higher levels of obesity increased slightly and the attributable fractions of deaths associated with overweight and with grade 1 obesity decreased slightly. The relative risks for BMI categories did not show large or systematic changes after simultaneous exclusion of ever smokers, persons with a history of cancer or cardiovascular disease, and persons who died early in the follow-up period or had their heights and weights measured at older ages. These analyses suggest that residual confounding by smoking or preexisting illness had little effect on previous estimates of attributable fractions from nationally representative data with measured heights and weights.},
  langid = {english},
  pmid = {17670912},
  keywords = {Adult,Aged,Body Height,Body Mass Index,Body Weight,Cardiovascular Diseases,Health Surveys,Humans,Middle Aged,Neoplasms,Nutrition Surveys,Obesity,Overweight,Risk Assessment,Risk Factors,Smoking,Thinness,United States},
  file = {/Users/xx20081/Zotero/storage/ALPBRBIM/Flegal et al. - 2007 - Impact of smoking and preexisting illness on estim.pdf}
}

@article{flegalReverseCausationIllnessrelated2011,
  title = {Reverse Causation and Illness-Related Weight Loss in Observational Studies of Body Weight and Mortality},
  author = {Flegal, Katherine M. and Graubard, Barry I. and Williamson, David F. and Cooper, Richard S.},
  year = {2011},
  month = jan,
  journal = {American Journal of Epidemiology},
  volume = {173},
  number = {1},
  pages = {1--9},
  issn = {1476-6256},
  doi = {10.1093/aje/kwq341},
  abstract = {In studies of weight and mortality, the construct of reverse causation has come to be used to imply that the exposure-outcome relation is biased by weight loss due to preexisting illness. Observed weight-mortality associations are sometimes thought to result from this bias. Evidence for the occurrence of such bias is weak and inconsistent, suggesting that either the analytical methods used have been inadequate or else illness-related weight loss is not an important source of bias. Deleting participants has been the most frequent approach to control possible bias. As implemented, this can lead to deletion of almost 90\% of all deaths in a sample and to deletion of more overweight and obese participants than participants with normal or below normal weight. Because it has not been demonstrated that the procedures used to adjust for reverse causation increase validity or have large or systematic effects on relative risks, it is premature to consider reverse causation as an important cause of bias. Further research would be useful to elucidate the potential effects and importance of reverse causation or illness-related weight loss as a source of bias in the observed associations between weight and mortality in cohort studies.},
  langid = {english},
  pmid = {21059807},
  keywords = {Body Weight,Causality,Cause of Death,Humans,Obesity,Risk Factors,Survival Rate,Weight Loss},
  file = {/Users/xx20081/Zotero/storage/6I46PH64/Flegal et al. - 2011 - Reverse causation and illness-related weight loss .pdf}
}

@article{folsomBodyMassIndex1998,
  title = {Body Mass Index, Waist/Hip Ratio, and Coronary Heart Disease Incidence in {{African Americans}} and Whites. {{Atherosclerosis Risk}} in {{Communities Study Investigators}}},
  author = {Folsom, A. R. and Stevens, J. and Schreiner, P. J. and McGovern, P. G.},
  year = {1998},
  month = dec,
  journal = {American Journal of Epidemiology},
  volume = {148},
  number = {12},
  pages = {1187--1194},
  issn = {0002-9262},
  doi = {10.1093/oxfordjournals.aje.a009608},
  abstract = {To study the relation of the amount and distribution of body fat with incident coronary heart disease in two ethnic groups, the authors analyzed prospective data from the Atherosclerosis Risk in Communities Study. Among 14,040 participants aged 45-64 years and free of coronary disease at baseline in 1987-1989, we identified 398 events through 1994, an average of 6.2 years of follow-up. Among African-American women, the multivariable-adjusted relative risks of coronary heart disease across quartiles of body mass index were 1.0, 1.91. 1.54, and 2.15 (p for trend=0.27), and those for waist/hip ratio were 1.0, 2.07, 2.33, and 4.22 (p for trend=0.02). Among African-American men, these respective relative risks were 1.0, 1.03, 0.83, and 1.20 (p for trend=0.76) for body mass index and 1.0, 1.08, 1.87, and 1.68 (p for trend=0.06) for waist/hip ratio. Relative risks for whites were generally similar to those for African Americans. Relative risks were stronger for never smokers than for the overall cohort. Unlike some previous studies, our results suggest that Africa Americans, like whites, are not spared from the coronary heart disease risks accompanying obesity.},
  langid = {english},
  pmid = {9867265},
  keywords = {Black or African American,Black People,Body Constitution,Body Mass Index,Coronary Disease,Female,Humans,Incidence,Male,Maryland,Middle Aged,Minnesota,Mississippi,North Carolina,Obesity,Prospective Studies,Risk,Sex Distribution,White People},
  file = {/Users/xx20081/Zotero/storage/EZWTYQA9/Folsom et al. - 1998 - Body mass index, waisthip ratio, and coronary hea.pdf}
}

@article{fonarowObesityParadoxAcute2007,
  title = {An Obesity Paradox in Acute Heart Failure: Analysis of Body Mass Index and Inhospital Mortality for 108,927 Patients in the {{Acute Decompensated Heart Failure National Registry}}},
  shorttitle = {An Obesity Paradox in Acute Heart Failure},
  author = {Fonarow, Gregg C. and Srikanthan, Preethi and Costanzo, Maria Rosa and Cintron, Guillermo B. and Lopatin, Margarita and {ADHERE Scientific Advisory Committee and Investigators}},
  year = {2007},
  month = jan,
  journal = {American Heart Journal},
  volume = {153},
  number = {1},
  pages = {74--81},
  issn = {1097-6744},
  doi = {10.1016/j.ahj.2006.09.007},
  abstract = {BACKGROUND: Prior studies on chronic systolic heart failure (HF) have demonstrated that body mass index (BMI) is inversely associated with mortality, the so-called obesity paradox. The aim of this study was to determine whether BMI influences the mortality risk in acute decompensated HF, a subject not previously studied. METHODS: The Acute Decompensated Heart Failure National Registry was analyzed for acute HF hospitalizations in 263 hospitals in the United States from October 2001 through December 2004. Patients with documented height and weight were divided into BMI (measured in kilograms per square meter) quartiles. Inhospital mortality by BMI quartile for all the patients and for those with reduced (n = 43,255) and preserved (n = 37,901) systolic function was assessed. RESULTS: Body mass index quartiles in the 108,927 hospitalizations were QI (16.0-23.6 kg/m2), QII (23.7-27.7 kg/m2), QIII (27.8-33.3 kg/m2), and QIV (33.4-60.0 kg/m2). Patients in the higher BMI quartiles were younger, had more diabetes, and had a higher left ventricular ejection fraction. Inhospital mortality rates decreased in a near-linear fashion across successively higher BMI quartiles. After adjustments for age, sex, blood urea nitrogen, blood pressure, creatinine, sodium, heart rate, and dyspnea at rest, BMI quartile still predicted mortality risk. For every 5-U increase in BMI, the odds of risk-adjusted mortality was 10\% lower (95\% CI 0.88-0.93, P {$<$} .0001). CONCLUSIONS: In this cohort of hospitalized patients with HF, higher BMI was associated with lower inhospital mortality risk. The relationship between BMI and adverse outcomes in HF appears to be complex and deserving of further study.},
  langid = {english},
  pmid = {17174642},
  keywords = {Aged,Aged 80 and over,Area Under Curve,Body Mass Index,Comorbidity,Female,Heart Failure,Hospital Mortality,Humans,Male,Multivariate Analysis,Obesity,Registries,ROC Curve,United States},
  file = {/Users/xx20081/Zotero/storage/5QESPL8J/Fonarow et al. - 2007 - An obesity paradox in acute heart failure analysi.pdf}
}

@article{friasEfficacySafetyLY32981762018,
  title = {Efficacy and Safety of {{LY3298176}}, a Novel Dual {{GIP}} and {{GLP-1}} Receptor Agonist, in Patients with Type 2 Diabetes: A Randomised, Placebo-Controlled and Active Comparator-Controlled Phase 2 Trial},
  shorttitle = {Efficacy and Safety of {{LY3298176}}, a Novel Dual {{GIP}} and {{GLP-1}} Receptor Agonist, in Patients with Type 2 Diabetes},
  author = {Frias, Juan Pablo and Nauck, Michael A. and Van, Joanna and Kutner, Mark E. and Cui, Xuewei and Benson, Charles and Urva, Shweta and Gimeno, Ruth E. and Milicevic, Zvonko and Robins, Deborah and Haupt, Axel},
  year = {2018},
  month = nov,
  journal = {The Lancet},
  volume = {392},
  number = {10160},
  pages = {2180--2193},
  publisher = {Elsevier},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(18)32260-8},
  urldate = {2024-07-04},
  langid = {english},
  pmid = {30293770},
  file = {/Users/xx20081/Zotero/storage/WWKTAA2Q/Frias et al. - 2018 - Efficacy and safety of LY3298176, a novel dual GIP.pdf}
}

@article{fryComparisonSociodemographicHealthRelated2017,
  title = {Comparison of {{Sociodemographic}} and {{Health-Related Characteristics}} of {{UK Biobank Participants With Those}} of the {{General Population}}},
  author = {Fry, Anna and Littlejohns, Thomas J. and Sudlow, Cathie and Doherty, Nicola and Adamska, Ligia and Sprosen, Tim and Collins, Rory and Allen, Naomi E.},
  year = {2017},
  month = nov,
  journal = {American Journal of Epidemiology},
  volume = {186},
  number = {9},
  pages = {1026--1034},
  issn = {1476-6256},
  doi = {10.1093/aje/kwx246},
  abstract = {The UK Biobank cohort is a population-based cohort of 500,000 participants recruited in the United Kingdom (UK) between 2006 and 2010. Approximately 9.2 million individuals aged 40-69 years who lived within 25 miles (40 km) of one of 22 assessment centers in England, Wales, and Scotland were invited to enter the cohort, and 5.5\% participated in the baseline assessment. The representativeness of the UK Biobank cohort was investigated by comparing demographic characteristics between nonresponders and responders. Sociodemographic, physical, lifestyle, and health-related characteristics of the cohort were compared with nationally representative data sources. UK Biobank participants were more likely to be older, to be female, and to live in less socioeconomically deprived areas than nonparticipants. Compared with the general population, participants were less likely to be obese, to smoke, and to drink alcohol on a daily basis and had fewer self-reported health conditions. At age 70-74 years, rates of all-cause mortality and total cancer incidence were 46.2\% and 11.8\% lower, respectively, in men and 55.5\% and 18.1\% lower, respectively, in women than in the general population of the same age. UK Biobank is not representative of the sampling population; there is evidence of a "healthy volunteer" selection bias. Nonetheless, valid assessment of exposure-disease relationships may be widely generalizable and does not require participants to be representative of the population at large.},
  langid = {english},
  pmcid = {PMC5860371},
  pmid = {28641372},
  keywords = {Adult,Aged,Biological Specimen Banks,cancer,Cause of Death,Female,Healthy Volunteers,Humans,Incidence,Life Style,lifestyle,Male,Middle Aged,mortality,Neoplasms,Prospective Studies,representativeness,Selection Bias,Self Report,Social Class,sociodemographic characteristics,UK Biobank,United Kingdom},
  file = {/Users/xx20081/Zotero/storage/8JIBKIVE/Fry et al. - 2017 - Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Th.pdf}
}

@article{fuAbdominalObesityAssociated2022,
  title = {Abdominal {{Obesity Is Associated}} with an {{Increased Risk}} of {{All-Cause Mortality}} in {{Males}} but {{Not}} in {{Females}} with {{HFpEF}}},
  author = {Fu, Liyao and Zhou, Ying and Sun, Jiaxing and Zhu, Zhaowei and Tai, Shi},
  year = {2022},
  month = apr,
  journal = {Cardiovascular Therapeutics},
  volume = {2022},
  pages = {2950055},
  issn = {1755-5914},
  doi = {10.1155/2022/2950055},
  urldate = {2024-08-08},
  abstract = {Background  Association between abdominal obesity and development of heart failure (HF) with preserved ejection fraction (HFpEF) between the sexes is not completely understood.  Objectives  This study evaluated the association between abdominal obesity and the risk of all-cause mortality in patients with HFpEF while performing a gender outcome comparison.  Methods  A post hoc analysis was undertaken from the American cohort of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT). The primary outcome (all-cause mortality) and the secondary outcomes (cardiovascular mortality, hospitalization for HF, stroke, and MI) were evaluated via Cox proportional hazards models to compare the hazard ratios (HRs) between sexes in HFpEF patients. Abdominal obesity was defined as a waist circumference of {$\geq$}102\,cm in men and {$\geq$}88\,cm in women.  Results  A total of 3320 HFpEF patients (1620 men [48.80\%] and 1700 women [51.20\%]) were included in the analysis. The mean follow-up period was 3.4 {\textpm} 1.7 years, with 503 patients dying during that time. After multivariable adjustment, abdominal obesity was significantly associated with an increased risk of all-cause mortality in males (adjusted HR: 1.32; 95\% confidence interval [CI]: 1.02 to 1.71; p = 0.038). Abdominal obesity was associated with hospitalization for HF in both male (adjusted HR: 1.39; 95\% CI: 1.01 to 1.93; p = 0.045) and female patients (adjusted HR: 1.15; 95\% CI: 1.18 to 3.28; p = 0.010).  Conclusions  Abdominal obesity is associated with increased risks of all-cause mortality in the male but not the female HFpEF population and is associated with increased risks of hospitalization for HF in both sexes.},
  pmcid = {PMC9013300},
  pmid = {35586579},
  file = {/Users/xx20081/Zotero/storage/ZAFJF2HA/Fu et al. - 2022 - Abdominal Obesity Is Associated with an Increased .pdf}
}

@article{gaglianotaliunExploringVisualizingLargescale2020,
  title = {Exploring and Visualizing Large-Scale Genetic Associations by Using {{PheWeb}}},
  author = {Gagliano Taliun, Sarah A. and VandeHaar, Peter and Boughton, Andrew P. and Welch, Ryan P. and Taliun, Daniel and Schmidt, Ellen M. and Zhou, Wei and Nielsen, Jonas B. and Willer, Cristen J. and Lee, Seunggeun and Fritsche, Lars G. and Boehnke, Michael and Abecasis, Gon{\c c}alo R.},
  year = {2020},
  month = jun,
  journal = {Nature Genetics},
  volume = {52},
  number = {6},
  pages = {550--552},
  issn = {1546-1718},
  doi = {10.1038/s41588-020-0622-5},
  langid = {english},
  pmcid = {PMC7754083},
  pmid = {32504056},
  keywords = {Data Visualization,Genome-Wide Association Study,Humans,Polymorphism Single Nucleotide,Software,Urinary Bladder Neoplasms,User-Computer Interface},
  file = {/Users/xx20081/Zotero/storage/867EK6TA/Gagliano Taliun et al. - 2020 - Exploring and visualizing large-scale genetic associations by using PheWeb.pdf}
}

@article{galperLRRK2LipidPathways2022,
  title = {{{LRRK2}} and {{Lipid Pathways}}: {{Implications}} for {{Parkinson}}'s {{Disease}}},
  shorttitle = {{{LRRK2}} and {{Lipid Pathways}}},
  author = {Galper, Jasmin and Kim, Woojin S. and Dzamko, Nicolas},
  year = {2022},
  month = oct,
  journal = {Biomolecules},
  volume = {12},
  number = {11},
  pages = {1597},
  issn = {2218-273X},
  doi = {10.3390/biom12111597},
  urldate = {2024-04-12},
  abstract = {Genetic alterations in the LRRK2 gene, encoding leucine-rich repeat kinase 2, are a common risk factor for Parkinson's disease. How LRRK2 alterations lead to cell pathology is an area of ongoing investigation, however, multiple lines of evidence suggest a role for LRRK2 in lipid pathways. It is increasingly recognized that in addition to being energy reservoirs and structural entities, some lipids, including neural lipids, participate in signaling cascades. Early investigations revealed that LRRK2 localized to membranous and vesicular structures, suggesting an interaction of LRRK2 and lipids or lipid-associated proteins. LRRK2 substrates from the Rab GTPase family play a critical role in vesicle trafficking, lipid metabolism and lipid storage, all processes which rely on lipid dynamics. In addition, LRRK2 is associated with the phosphorylation and activity of enzymes that catabolize plasma membrane and lysosomal lipids. Furthermore, LRRK2 knockout studies have revealed that blood, brain and urine exhibit lipid level changes, including alterations to sterols, sphingolipids and phospholipids, respectively. In human LRRK2 mutation carriers, changes to sterols, sphingolipids, phospholipids, fatty acyls and glycerolipids are reported in multiple tissues. This review summarizes the evidence regarding associations between LRRK2 and lipids, and the functional consequences of LRRK2-associated lipid changes are discussed.},
  pmcid = {PMC9687231},
  pmid = {36358947},
  file = {/Users/xx20081/Zotero/storage/ALA3PKFQ/Galper et al. - 2022 - LRRK2 and Lipid Pathways Implications for Parkins.pdf}
}

@article{gaoHumanGLP1RVariants2023,
  title = {Human {{GLP1R}} Variants Affecting {{GLP1R}} Cell Surface Expression Are Associated with Impaired Glucose Control and Increased Adiposity},
  author = {Gao, Wenwen and Liu, Lei and Huh, Eunna and Gbahou, Florence and Cecon, Erika and Oshima, Masaya and Houz{\'e}, Ludivine and Katsonis, Panagiotis and Hegron, Alan and Fan, Zhiran and Hou, Guofei and Charpentier, Guillaume and Boissel, Mathilde and Derhourhi, Mehdi and Marre, Michel and Balkau, Beverley and Froguel, Philippe and Scharfmann, Raphael and Lichtarge, Olivier and Dam, Julie and Bonnefond, Am{\'e}lie and Liu, Jianfeng and Jockers, Ralf},
  year = {2023},
  month = oct,
  journal = {Nature Metabolism},
  volume = {5},
  number = {10},
  pages = {1673--1684},
  publisher = {Nature Publishing Group},
  issn = {2522-5812},
  doi = {10.1038/s42255-023-00889-6},
  urldate = {2024-01-18},
  abstract = {The glucagon-like peptide 1 receptor (GLP1R) is a major drug target with several agonists being prescribed in individuals with type 2 diabetes and obesity1,2. The impact of genetic variability of GLP1R on receptor function and its association with metabolic traits are unclear with conflicting reports. Here, we show an unexpected diversity of phenotypes ranging from defective cell surface expression to complete or pathway-specific gain of function (GoF) and loss of function (LoF), after performing a functional profiling of 60 GLP1R variants across four signalling pathways. The defective insulin secretion of GLP1R LoF variants is rescued by allosteric GLP1R ligands or high concentrations of exendin-4/semaglutide in INS-1 823/3 cells. Genetic association studies in 200,000 participants from the UK Biobank show that impaired GLP1R cell surface expression contributes to poor glucose control and increased adiposity with increased glycated haemoglobin A1c and body mass index. This study defines impaired GLP1R cell surface expression as a risk factor for traits associated with type 2 diabetes and obesity and provides potential treatment options for GLP1R LoF variant carriers.},
  copyright = {2023 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  keywords = {Genetic association study,Metabolism,Next-generation sequencing,Obesity,Risk factors},
  file = {/Users/xx20081/Zotero/storage/FZN5AHLE/Gao et al NATMETABO 2023.pdf;/Users/xx20081/Zotero/storage/KGNP5J6A/Jockers-Gao Research Briefing 2023.pdf}
}

@article{gaoHumanGLP1RVariants2023a,
  title = {Human {{GLP1R}} Variants Affecting {{GLP1R}} Cell Surface Expression Are Associated with Impaired Glucose Control and Increased Adiposity},
  author = {Gao, Wenwen and Liu, Lei and Huh, Eunna and Gbahou, Florence and Cecon, Erika and Oshima, Masaya and Houz{\'e}, Ludivine and Katsonis, Panagiotis and Hegron, Alan and Fan, Zhiran and Hou, Guofei and Charpentier, Guillaume and Boissel, Mathilde and Derhourhi, Mehdi and Marre, Michel and Balkau, Beverley and Froguel, Philippe and Scharfmann, Raphael and Lichtarge, Olivier and Dam, Julie and Bonnefond, Am{\'e}lie and Liu, Jianfeng and Jockers, Ralf},
  year = {2023},
  month = oct,
  journal = {Nature Metabolism},
  volume = {5},
  number = {10},
  pages = {1673--1684},
  publisher = {Nature Publishing Group},
  issn = {2522-5812},
  doi = {10.1038/s42255-023-00889-6},
  urldate = {2025-05-27},
  abstract = {The glucagon-like peptide 1 receptor (GLP1R) is a major drug target with several agonists being prescribed in individuals with type 2 diabetes and obesity1,2. The impact of genetic variability of GLP1R on receptor function and its association with metabolic traits are unclear with conflicting reports. Here, we show an unexpected diversity of phenotypes ranging from defective cell surface expression to complete or pathway-specific gain of function (GoF) and loss of function (LoF), after performing a functional profiling of 60 GLP1R variants across four signalling pathways. The defective insulin secretion of GLP1R LoF variants is rescued by allosteric GLP1R ligands or high concentrations of exendin-4/semaglutide in INS-1 823/3 cells. Genetic association studies in 200,000 participants from the UK Biobank show that impaired GLP1R cell surface expression contributes to poor glucose control and increased adiposity with increased glycated haemoglobin A1c and body mass index. This study defines impaired GLP1R cell surface expression as a risk factor for traits associated with type 2 diabetes and obesity and provides potential treatment options for GLP1R LoF variant carriers.},
  copyright = {2023 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  keywords = {Genetic association study,Metabolism,Next-generation sequencing,Obesity,Risk factors}
}

@article{garfieldGuideSelectionGenetic2023,
  title = {A {{Guide}} for {{Selection}} of {{Genetic Instruments}} in {{Mendelian}} Randomisation ({{MR}}) Studies of {{Type-2}} Diabetes and {{HbA1c}}: Towards an Integrated Approach},
  shorttitle = {A {{Guide}} for {{Selection}} of {{Genetic Instruments}} in {{Mendelian}} Randomisation ({{MR}}) Studies of {{Type-2}} Diabetes and {{HbA1c}}},
  author = {Garfield, Victoria and Salzmann, Antoine and Burgess, Stephen and Chaturvedi, Nish},
  year = {2023},
  month = feb,
  journal = {Diabetes},
  volume = {72},
  number = {2},
  pages = {175},
  publisher = {Europe PMC Funders},
  doi = {10.2337/db22-0110},
  urldate = {2024-05-15},
  abstract = {This study examines the instrument selection strategies currently employed throughout the type-2 diabetes and HbA[1c]  MR literature. We then argue for a more integrated and thorough approach, providing a framework to do this in the context of HbA[1c] ...},
  langid = {english},
  pmid = {36669000}
}

@article{garfieldGuideSelectionGenetic2023a,
  title = {A {{Guide}} for {{Selection}} of {{Genetic Instruments}} in {{Mendelian Randomization Studies}} of {{Type}} 2 {{Diabetes}} and {{HbA1c}}: {{Toward}} an {{Integrated Approach}}},
  shorttitle = {A {{Guide}} for {{Selection}} of {{Genetic Instruments}} in {{Mendelian Randomization Studies}} of {{Type}} 2 {{Diabetes}} and {{HbA1c}}},
  author = {Garfield, Victoria and Salzmann, Antoine and Burgess, Stephen and Chaturvedi, Nish},
  year = {2023},
  month = feb,
  journal = {Diabetes},
  volume = {72},
  number = {2},
  pages = {175--183},
  issn = {0012-1797},
  doi = {10.2337/db22-0110},
  urldate = {2024-05-15},
  abstract = {In this study we examine the instrument selection strategies currently used throughout the type 2 diabetes and HbA1c Mendelian randomization (MR) literature. We then argue for a more integrated and thorough approach, providing a framework to do this in the context of HbA1c and diabetes. We conducted a literature search for MR studies that have instrumented diabetes and/or HbA1c. We also used data from the UK Biobank (UKB) (N = 349,326) to calculate instrument strength metrics that are key in MR studies (the F statistic for average strength and R2 for total strength) with two different methods (``individual-level data regression'' and Cragg-Donald formula). We used a 157--single nucleotide polymorphism (SNP) instrument for diabetes and a 51-SNP instrument (with partition into glycemic and erythrocytic as well) for HbA1c. Our literature search yielded 48 studies for diabetes and 22 for HbA1c. Our UKB empirical examples showed that irrespective of the method used to calculate metrics of strength and whether the instrument was the main one or included partition by function, the HbA1c genetic instrument is strong in terms of both average and total strength. For diabetes, a 157-SNP instrument was shown to have good average strength and total strength, but these were both substantially lesser than those of the HbA1c instrument. We provide a careful set of five recommendations to researchers who wish to genetically instrument type 2 diabetes and/or HbA1c. In MR studies of glycemia, investigators should take a more integrated approach when selecting genetic instruments, and we give specific guidance on how to do this.},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/XKS93S7L/Garfield et al. - 2023 - A Guide for Selection of Genetic Instruments in Me.pdf}
}

@article{gargDiseasePredictionMultiomics2024,
  title = {Disease Prediction with Multi-Omics and Biomarkers Empowers Case--Control Genetic Discoveries in the {{UK Biobank}}},
  author = {Garg, Manik and Karpinski, Marcin and Matelska, Dorota and Middleton, Lawrence and Burren, Oliver S. and Hu, Fengyuan and Wheeler, Eleanor and Smith, Katherine R. and Fabre, Margarete A. and Mitchell, Jonathan and O'Neill, Amanda and Ashley, Euan A. and Harper, Andrew R. and Wang, Quanli and Dhindsa, Ryan S. and Petrovski, Slav{\'e} and Vitsios, Dimitrios},
  year = {2024},
  month = sep,
  journal = {Nature Genetics},
  volume = {56},
  number = {9},
  pages = {1821--1831},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-024-01898-1},
  urldate = {2024-10-21},
  abstract = {The emergence of biobank-level datasets offers new opportunities to discover novel biomarkers and develop predictive algorithms for human disease. Here, we present an ensemble machine-learning framework (machine learning with phenotype associations, MILTON) utilizing a range of biomarkers to predict 3,213 diseases in the UK Biobank. Leveraging the UK Biobank's longitudinal health record data, MILTON predicts incident disease cases undiagnosed at time of recruitment, largely outperforming available polygenic risk scores. We further demonstrate the utility of MILTON in augmenting genetic association analyses in a phenome-wide association study of 484,230 genome-sequenced samples, along with 46,327 samples with matched plasma proteomics data. This resulted in improved signals for 88 known (P\,{$<$}\,1\,{\texttimes}\,10-8) gene--disease relationships alongside 182 gene--disease relationships that did not achieve genome-wide significance in the nonaugmented baseline cohorts. We validated these discoveries in the FinnGen biobank alongside two orthogonal machine-learning methods built for gene--disease prioritization. All extracted gene--disease associations and incident disease predictive biomarkers are publicly available (http://milton.public.cgr.astrazeneca.com).},
  copyright = {2024 The Author(s)},
  langid = {english},
  keywords = {Computational biology and bioinformatics,Genetics,Genetics research,Genomics},
  file = {/Users/xx20081/Zotero/storage/QFDKRIXU/Garg et al. - 2024 - Disease prediction with multi-omics and biomarkers empowers casecontrol genetic discoveries in the.pdf}
}

@article{garnierGenomewideAssociationAnalysis2021,
  title = {Genome-Wide Association Analysis in Dilated Cardiomyopathy Reveals Two New Players in Systolic Heart Failure on Chromosomes 3p25.1 and 22q11.23},
  author = {Garnier, Sophie and Harakalova, Magdalena and Weiss, Stefan and Mokry, Michal and {Regitz-Zagrosek}, Vera and Hengstenberg, Christian and Cappola, Thomas P. and Isnard, Richard and Arbustini, Eloisa and Cook, Stuart A. and {van Setten}, Jessica and Calis, Jorg J. A. and Hakonarson, Hakon and Morley, Michael P. and Stark, Klaus and Prasad, Sanjay K. and Li, Jin and O'Regan, Declan P. and Grasso, Maurizia and {M{\"u}ller-Nurasyid}, Martina and Meitinger, Thomas and Empana, Jean-Philippe and Strauch, Konstantin and Waldenberger, Melanie and Marguiles, Kenneth B. and Seidman, Christine E. and Kararigas, Georgios and Meder, Benjamin and Haas, Jan and Boutouyrie, Pierre and Lacolley, Patrick and Jouven, Xavier and Erdmann, Jeanette and Blankenberg, Stefan and Wichter, Thomas and Ruppert, Volker and Tavazzi, Luigi and Dubourg, Olivier and Roizes, G{\'e}rard and Dorent, Richard and {de Groote}, Pascal and Fauchier, Laurent and Trochu, Jean-No{\"e}l and Aupetit, Jean-Fran{\c c}ois and Bilinska, Zofia T. and Germain, Marine and V{\"o}lker, Uwe and Hemerich, Daiane and Raji, Ibticem and {Bacq-Daian}, Delphine and Proust, Carole and Remior, Paloma and {Gomez-Bueno}, Manuel and Lehnert, Kristin and Maas, Renee and Olaso, Robert and Saripella, Ganapathi Varma and Felix, Stephan B. and McGinn, Steven and {Duboscq-Bidot}, La{\"e}titia and {van Mil}, Alain and Besse, C{\'e}line and Fontaine, Vincent and Blanch{\'e}, H{\'e}l{\`e}ne and Ader, Flavie and Keating, Brendan and Curjol, Ang{\'e}lique and Boland, Anne and Komajda, Michel and Cambien, Fran{\c c}ois and Deleuze, Jean-Fran{\c c}ois and D{\"o}rr, Marcus and Asselbergs, Folkert W. and Villard, Eric and Tr{\'e}gou{\"e}t, David-Alexandre and Charron, Philippe},
  year = {2021},
  month = may,
  journal = {European Heart Journal},
  volume = {42},
  number = {20},
  pages = {2000--2011},
  issn = {1522-9645},
  doi = {10.1093/eurheartj/ehab030},
  abstract = {AIMS: Our objective was to better understand the genetic bases of dilated cardiomyopathy (DCM), a leading cause of systolic heart failure. METHODS AND RESULTS: We conducted the largest genome-wide association study performed so far in DCM, with 2719 cases and 4440 controls in the discovery population. We identified and replicated two new DCM-associated loci on chromosome 3p25.1 [lead single-nucleotide polymorphism (SNP) rs62232870, P\,=\,8.7 {\texttimes} 10-11 and 7.7 {\texttimes} 10-4 in the discovery and replication steps, respectively] and chromosome 22q11.23 (lead SNP rs7284877, P\,=\,3.3 {\texttimes} 10-8 and 1.4 {\texttimes} 10-3 in the discovery and replication steps, respectively), while confirming two previously identified DCM loci on chromosomes 10 and 1, BAG3 and HSPB7. A genetic risk score constructed from the number of risk alleles at these four DCM loci revealed a 3-fold increased risk of DCM for individuals with 8 risk alleles compared to individuals with 5 risk alleles (median of the referral population). In silico annotation and functional 4C-sequencing analyses on iPSC-derived cardiomyocytes identify SLC6A6 as the most likely DCM gene at the 3p25.1 locus. This gene encodes a taurine transporter whose involvement in myocardial dysfunction and DCM is supported by numerous observations in humans and animals. At the 22q11.23 locus, in silico and data mining annotations, and to a lesser extent functional analysis, strongly suggest SMARCB1 as the candidate culprit gene. CONCLUSION: This study provides a better understanding of the genetic architecture of DCM and sheds light on novel biological pathways underlying heart failure.},
  langid = {english},
  pmcid = {PMC8139853},
  pmid = {33677556},
  keywords = {4C-sequencing,Adaptor Proteins Signal Transducing,Animals,Apoptosis Regulatory Proteins,Cardiomyopathy Dilated,Chromosomes,Dilated cardiomyopathy,Genetic Predisposition to Disease,Genetic risk score,Genome-Wide Association Study,GWAS,Heart failure,Heart Failure Systolic,Humans,Imputation,Polymorphism Single Nucleotide},
  file = {/Users/xx20081/Zotero/storage/9MULTWU8/Garnier et al. - 2021 - Genome-wide association analysis in dilated cardio.pdf}
}

@article{gBodymassIndexCausespecific2009,
  title = {Body-Mass Index and Cause-Specific Mortality in 900 000 Adults: Collaborative Analyses of 57 Prospective Studies},
  shorttitle = {Body-Mass Index and Cause-Specific Mortality in 900 000 Adults},
  author = {G, Whitlock and S, Lewington and P, Sherliker and R, Clarke and J, Emberson and J, Halsey and N, Qizilbash and R, Collins and R, Peto},
  year = {2009},
  month = mar,
  journal = {Lancet (London, England)},
  volume = {373},
  number = {9669},
  publisher = {Lancet},
  issn = {1474-547X},
  doi = {10.1016/S0140-6736(09)60318-4},
  urldate = {2024-08-20},
  abstract = {Although other anthropometric measures (eg, waist circumference, waist-to-hip ratio) could well add extra information to BMI, and BMI to them, BMI is in itself a strong predictor of overall mortality both above and below the apparent optimum of about 22.5-25 kg/m(2). The progressive excess mortality {\dots}},
  langid = {english},
  pmid = {19299006},
  file = {/Users/xx20081/Zotero/storage/NUGVHM9S/G et al. - 2009 - Body-mass index and cause-specific mortality in 90.pdf;/Users/xx20081/Zotero/storage/R73ZXPJ9/19299006.html}
}

@misc{GeneralizedLinearMixed,
  title = {A Generalized Linear Mixed Model Association Tool for Biobank-Scale Data - {{PubMed}}},
  urldate = {2024-09-02},
  howpublished = {https://pubmed.ncbi.nlm.nih.gov/34737426/},
  file = {/Users/xx20081/Zotero/storage/7KVWT82B/34737426.html}
}

@misc{GeneticAnalysis1,
  title = {Genetic Analysis of over 1 Million People Identifies 535 New Loci Associated with Blood Pressure Traits {\textbar} {{Nature Genetics}}},
  urldate = {2025-01-22},
  howpublished = {https://www.nature.com/articles/s41588-018-0205-x},
  file = {/Users/xx20081/Zotero/storage/XSIEZM68/s41588-018-0205-x.html}
}

@misc{GenomicAtlasPlasma,
  title = {Genomic Atlas of the Plasma Metabolome Prioritizes Metabolites Implicated in Human Diseases - {{PubMed}}},
  urldate = {2025-05-21},
  howpublished = {https://pubmed.ncbi.nlm.nih.gov/36635386/},
  file = {/Users/xx20081/Zotero/storage/EPJ5ZSMB/36635386.html}
}

@article{ghigliottiAdiposeTissueImmune2014,
  title = {Adipose Tissue Immune Response: Novel Triggers and Consequences for Chronic Inflammatory Conditions},
  shorttitle = {Adipose Tissue Immune Response},
  author = {Ghigliotti, Giorgio and Barisione, Chiara and Garibaldi, Silvano and Fabbi, Patrizia and Brunelli, Claudio and Spallarossa, Paolo and Altieri, Paola and Rosa, Gianmarco and Spinella, Giovanni and Palombo, Domenico and Arsenescu, Razvan and Arsenescu, Violeta},
  year = {2014},
  month = aug,
  journal = {Inflammation},
  volume = {37},
  number = {4},
  pages = {1337--1353},
  issn = {1573-2576},
  doi = {10.1007/s10753-014-9914-1},
  abstract = {Adipose tissue inflammation mediates the association between excessive body fat accumulation and several chronic inflammatory diseases. A high prevalence of obesity-associated adipose tissue inflammation was observed not only in patients with cardiovascular conditions but also in patients with inflammatory bowel diseases, abdominal aortic aneurysm, or cardiorenal syndrome. In addition to excessive caloric intake, other triggers promote visceral adipose tissue inflammation followed by chronic, low-grade systemic inflammation. The infiltration and accumulation of immune cells in the inflamed and hypertrophied adipose tissue promote the production of inflammatory cytokines, contributing to target organ damages. This comorbidity seems to delimit subgroups of individuals with systemic adipose tissue inflammation and more severe chronic inflammatory diseases that are refractory to conventional treatment. This review highlights the association between adipose tissue immune response and the pathophysiology of visceral adiposity-related chronic inflammatory diseases, while suggesting several new therapeutic strategies.},
  langid = {english},
  pmcid = {PMC4077305},
  pmid = {24823865},
  keywords = {Adiponectin,Adipose Tissue,Angiotensins,Animals,Aortic Aneurysm Abdominal,Cardio-Renal Syndrome,Comorbidity,Dendritic Cells,Granulocytes,Humans,Immune System,Inflammation,Inflammatory Bowel Diseases,Intra-Abdominal Fat,Killer Cells Natural,Macrophages,Monocytes,Receptors Aryl Hydrocarbon,T-Lymphocytes,Uremia},
  file = {/Users/xx20081/Zotero/storage/QMP9J4ID/Ghigliotti et al. - 2014 - Adipose tissue immune response novel triggers and.pdf}
}

@misc{gillRobustUsePhenotypic2023,
  title = {Robust Use of Phenotypic Heterogeneity at Drug Target Genes for Mechanistic Insights: Application of Cis-Multivariable {{Mendelian}} Randomization to {{GLP1R}} Gene Region},
  shorttitle = {Robust Use of Phenotypic Heterogeneity at Drug Target Genes for Mechanistic Insights},
  author = {Gill, Dipender and Shungin, Dmitry and Mantzoros, Christos S. and Knudsen, Lotte Bjerre and Bowden, Jack and Burgess, Stephen},
  year = {2023},
  month = jul,
  pages = {2023.07.20.23292958},
  publisher = {medRxiv},
  doi = {10.1101/2023.07.20.23292958},
  urldate = {2024-01-13},
  abstract = {Phenotypic heterogeneity at genomic loci encoding drug targets can be exploited by multivariable Mendelian randomization to provide insight on the pathways by which pharmacological interventions may affect disease risk. However, statistical inference in such investigations may be poor if overdispersion heterogeneity in measured genetic associations is unaccounted for. In this work, we first develop conditional F-statistics for dimension-reduced genetic associations that enable more accurate measurement of phenotypic heterogeneity. We then develop a novel extension for two-sample multivariable Mendelian randomization that accounts for overdispersion heterogeneity in dimension-reduced genetic associations. Our empirical focus is to use genetic variants in the GLP1R gene region to understand the mechanism by which GLP1R agonism affects coronary artery disease (CAD) risk. Colocalization analyses indicate that distinct variants in the GLP1R gene region are associated with body mass index and type 2 diabetes. Multivariable Mendelian randomization analyses that were corrected for overdispersion heterogeneity suggest that bodyweight lowering rather than type 2 diabetes liability lowering effects of GLP1R agonism are more likely contributing to reduced CAD risk. Tissue-specific analyses prioritised brain tissue as the most likely to be relevant for CAD risk, of the tissues considered. We hope the multivariable Mendelian randomization approach illustrated here is widely applicable to better understand mechanisms linking drug targets to diseases outcomes, and hence to guide drug development efforts.},
  archiveprefix = {medRxiv},
  copyright = {{\copyright} 2023, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/C7SF42AC/Patel et al. - 2023 - Robust use of phenotypic heterogeneity at drug tar.pdf}
}

@article{Giugliano2013,
  title = {Edoxaban versus Warfarin in Patients with Atrial Fibrillation},
  author = {Giugliano, Robert P. and Ruff, Christian T. and Braunwald, Eugene and Murphy, Sabina A. and Wiviott, Stephen D. and Halperin, Jonathan L. and Waldo, Albert L. and Ezekowitz, Michael D. and Weitz, Jeffrey I. and {\v S}pinar, Jind{\v r}ich and Ruzyllo, Witold and Ruda, Mikhail and Koretsune, Yukihiro and Betcher, Joshua and Shi, Minggao and Grip, Laura T. and Patel, Shirali P. and Patel, Indravadan and Hanyok, James J. and Mercuri, Michele and Antman, Elliott M.},
  year = {2013},
  month = nov,
  journal = {The New England journal of medicine},
  volume = {369},
  number = {22},
  pages = {2093--2104},
  publisher = {N Engl J Med},
  issn = {1533-4406},
  doi = {10.1056/NEJMOA1310907},
  abstract = {BACKGROUND Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS The annualized rate of the primary end point during treatment was 1.50\% with warfarin (median time in the therapeutic range, 68.4\%), as compared with 1.18\% with high-dose edoxaban (hazard ratio, 0.79; 97.5\% confidence interval [CI], 0.63 to 0.99; P{\textexclamdown}0.001 for noninferiority) and 1.61\% with low-dose edoxaban (hazard ratio, 1.07; 97.5\% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5\% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5\% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43\% with warfarin versus 2.75\% with high-dose edoxaban (hazard ratio, 0.80; 95\% CI, 0.71 to 0.91; P{\textexclamdown}0.001) and 1.61\% with low-dose edoxaban (hazard ratio, 0.47; 95\% CI, 0.41 to 0.55; P{\textexclamdown}0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17\% versus 2.74\% (hazard ratio, 0.86; 95\% CI, 0.77 to 0.97; P=0.01), and 2.71\% (hazard ratio, 0.85; 95\% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43\% versus 3.85\% (hazard ratio, 0.87; 95\% CI, 0.78 to 0.96; P=0.005), and 4.23\% (hazard ratio, 0.95; 95\% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.).},
  pmid = {24251359},
  keywords = {Adult,affs=[],affs=[]),Aged,Anticoagulants / adverse effects,Anticoagulants / therapeutic use*,Atrial Fibrillation / complications,Atrial Fibrillation / drug therapy*,Author(firstnames='A D',Author(firstnames='A Leitao',Author(firstnames='A Manzanal',Author(firstnames='A Stener',Author(firstnames='A Y',Author(firstnames='A',Author(firstnames='B G',Author(firstnames='B Honores',Author(firstnames='B R',Author(firstnames='B Y',Author(firstnames='B',Author(firstnames='C C',Author(firstnames='C E',Author(firstnames='C H',Author(firstnames='C J',Author(firstnames='C L',Author(firstnames='C Lara',Author(firstnames='C M',Author(firstnames='C T',Author(firstnames='C W',Author(firstnames='C Z',Author(firstnames='C',Author(firstnames='D E',Author(firstnames='D G',Author(firstnames='D H',Author(firstnames='D Lopez',Author(firstnames='D M',Author(firstnames='D N',Author(firstnames='D R',Author(firstnames='D S',Author(firstnames='D',Author(firstnames='E B',Author(firstnames='E Burger',Author(firstnames='E M',Author(firstnames='E Moran',Author(firstnames='E Rivera',Author(firstnames='E S',Author(firstnames='E',Author(firstnames='F T',Author(firstnames='F',Author(firstnames='G Avraham',Author(firstnames='G L',Author(firstnames='G P',Author(firstnames='G S',Author(firstnames='G Stagi',Author(firstnames='G Torres',Author(firstnames='G',Author(firstnames='H H',Author(firstnames='H Horvathne',Author(firstnames='H I',Author(firstnames='H J',Author(firstnames='H K',Author(firstnames='H Q',Author(firstnames='H S',Author(firstnames='H W',Author(firstnames='H',Author(firstnames='I Aldana',Author(firstnames='I Perdomo',Author(firstnames='I Petrova',Author(firstnames='I',Author(firstnames='J A',Author(firstnames='J B',Author(firstnames='J C',Author(firstnames='J D',Author(firstnames='J Felfoldine',Author(firstnames='J Franco',Author(firstnames='J H',Author(firstnames='J J',Author(firstnames='J K',Author(firstnames='J L',Author(firstnames='J M',Author(firstnames='J Mayen',Author(firstnames='J O',Author(firstnames='J Q',Author(firstnames='J S',Author(firstnames='J T',Author(firstnames='J W',Author(firstnames='J Y',Author(firstnames='J Z',Author(firstnames='J Zapata',Author(firstnames='J',Author(firstnames='K Berndtsson',Author(firstnames='K C',Author(firstnames='K Cvitkusic',Author(firstnames='K Fernandez',Author(firstnames='K G',Author(firstnames='K Gonzalez',Author(firstnames='K H',Author(firstnames='K J',Author(firstnames='K Makar',Author(firstnames='K S',Author(firstnames='K',Author(firstnames='L Goncalves',Author(firstnames='L L',Author(firstnames='L Leon',Author(firstnames='L Manriquez',Author(firstnames='L Nevarez',Author(firstnames='L Retamal',Author(firstnames='L Veiga Pais',Author(firstnames='L',Author(firstnames='M Alcantara',Author(firstnames='M Carmona',Author(firstnames='M Cedano',Author(firstnames='M Dachs',Author(firstnames='M G',Author(firstnames='M Grandon',Author(firstnames='M H',Author(firstnames='M J',Author(firstnames='M Padinhare',Author(firstnames='M Perez',Author(firstnames='M Rubia',Author(firstnames='M S',Author(firstnames='M Tejada',Author(firstnames='M Vijan',Author(firstnames='M Y',Author(firstnames='M',Author(firstnames='N J',Author(firstnames='N',Author(firstnames='O',Author(firstnames='P Arratia',Author(firstnames='P Mondaca',Author(firstnames='P Y',Author(firstnames='P',Author(firstnames='R Esteves',Author(firstnames='R Fernandez',Author(firstnames='R Ferreira',Author(firstnames='R Franchin',Author(firstnames='R J',Author(firstnames='R Osorio',Author(firstnames='R P',Author(firstnames='R Romero',Author(firstnames='R Saa',Author(firstnames='R Velasco',Author(firstnames='R',Author(firstnames='S A',Author(firstnames='S Araoz',Author(firstnames='S Blanco',Author(firstnames='S C',Author(firstnames='S E',Author(firstnames='S H',Author(firstnames='S J',Author(firstnames='S Jaksic',Author(firstnames='S L',Author(firstnames='S M',Author(firstnames='S Padilla',Author(firstnames='S Rostasne',Author(firstnames='S W',Author(firstnames='S X',Author(firstnames='S Y',Author(firstnames='S',Author(firstnames='T C',Author(firstnames='T F',Author(firstnames='T H',Author(firstnames='T J',Author(firstnames='T Oude',Author(firstnames='T',Author(firstnames='U',Author(firstnames='V de Leon',Author(firstnames='V',Author(firstnames='W C',Author(firstnames='W K',Author(firstnames='W M',Author(firstnames='W S',Author(firstnames='W T',Author(firstnames='W',Author(firstnames='X D',Author(firstnames='X J',Author(firstnames='X L',Author(firstnames='X P',Author(firstnames='X',Author(firstnames='Y E',Author(firstnames='Y F',Author(firstnames='Y G',Author(firstnames='Y H',Author(firstnames='Y J',Author(firstnames='Y L',Author(firstnames='Y M',Author(firstnames='Y N',Author(firstnames='Y P',Author(firstnames='Y Q',Author(firstnames='Y S',Author(firstnames='Y W',Author(firstnames='Y Z',Author(firstnames='Y',Author(firstnames='Z G',Author(firstnames='Z H',Author(firstnames='Z Q',Author(firstnames='Z Y',Author(firstnames='Z',Author(firstnames=None,Cardiovascular Diseases / mortality,Cardiovascular Diseases / prevention & control,Christian T Ruff,CollabAuthor(name='ENGAGE AF-TIMI 48 Investigators',Comparative Study,doi:10.1056/NEJMoa1310907,Double-Blind Method,Embolism / prevention & control*,equal<sub>c</sub>ontrib=False),equal<sub>c</sub>ontrib=False)],Female,Follow-Up Studies,Hemorrhage / chemically induced,Humans,initials='A',initials='AD',initials='AL',initials='AM',initials='AS',initials='AY',initials='B',initials='BG',initials='BH',initials='BR',initials='BY',initials='C',initials='CC',initials='CE',initials='CH',initials='CJ',initials='CL',initials='CM',initials='CT',initials='CW',initials='CZ',initials='D',initials='DE',initials='DG',initials='DH',initials='DL',initials='DM',initials='DN',initials='DR',initials='DS',initials='E',initials='EB',initials='EM',initials='ER',initials='ES',initials='F',initials='FT',initials='G',initials='GA',initials='GL',initials='GP',initials='GS',initials='GT',initials='H',initials='HH',initials='HI',initials='HJ',initials='HK',initials='HQ',initials='HS',initials='HW',initials='I',initials='IA',initials='IP',initials='J',initials='JA',initials='JB',initials='JC',initials='JD',initials='JF',initials='JH',initials='JJ',initials='JK',initials='JL',initials='JM',initials='JO',initials='JQ',initials='JS',initials='JT',initials='JW',initials='JY',initials='JZ',initials='K',initials='KB',initials='KC',initials='KF',initials='KG',initials='KH',initials='KJ',initials='KM',initials='KS',initials='L',initials='LG',initials='LL',initials='LM',initials='LN',initials='LR',initials='LV',initials='M',initials='MA',initials='MC',initials='MD',initials='MG',initials='MH',initials='MJ',initials='MP',initials='MR',initials='MS',initials='MT',initials='MV',initials='MY',initials='N',initials='NJ',initials='O',initials='P',initials='PA',initials='PM',initials='PY',initials='R',initials='RE',initials='RF',initials='RJ',initials='RO',initials='RP',initials='RR',initials='RS',initials='RV',initials='S',initials='SA',initials='SB',initials='SC',initials='SE',initials='SH',initials='SJ',initials='SL',initials='SM',initials='SP',initials='SR',initials='SW',initials='SX',initials='SY',initials='T',initials='TC',initials='TF',initials='TH',initials='TJ',initials='U',initials='V',initials='Vde L',initials='W',initials='WC',initials='WK',initials='WM',initials='WS',initials='WT',initials='X',initials='XD',initials='XJ',initials='XL',initials='XP',initials='Y',initials='YE',initials='YF',initials='YG',initials='YH',initials='YJ',initials='YL',initials='YM',initials='YN',initials='YP',initials='YQ',initials='YS',initials='YW',initials='YZ',initials='Z',initials='ZG',initials='ZH',initials='ZQ',initials='ZY',initials=None,investigators=[Author(firstnames='E',iseditor=False,Kaplan-Meier Estimate,lastname='Abdullakutty',lastname='Abi-Mansour',lastname='Abril',lastname='Accini',lastname='Acikel',lastname='Adachi',lastname='Adams',lastname='Adamus',lastname='Adler',lastname='Agarwal',lastname='Aggarwal',lastname='Agirov',lastname='Agraou',lastname='Ahmad',lastname='Ahmadpour',lastname='Ahuad Guerrero',lastname='Ajioka',lastname='Akerberg',lastname='Akhter',lastname='Akihisa',lastname='Akilli',lastname='Al-Maliky',lastname='Al-Zoebi',lastname='Albisu',lastname='Albulescu',lastname='Alexander',lastname='Alexandrova',lastname='Alexopoulos',lastname='Alhakim',lastname='Aliyar',lastname='Allall',lastname='Allison',lastname='Allman',lastname='Almaraz',lastname='Almeida',lastname='Almquist',lastname='Aloni',lastname='Alsheikh',lastname='Altonen',lastname='Alvarez',lastname='Amarenco',lastname='Amato Vincenzo de Paola',lastname='Ambrovic',lastname='Ambrovicova',lastname='Ameriso',lastname='Amin',lastname='Amuchastegui',lastname='Anciu',lastname='Anderson',lastname='Andersson',lastname='Andor',lastname='Andrade Lotufo',lastname='Andresen',lastname='Andrews',lastname='Angel',lastname='Anscombe',lastname='Anthony',lastname='Antle',lastname='Antman',lastname='Antonino',lastname='Anzai',lastname='Apetrei',lastname='Apostolovic',lastname='Appelros',lastname='Aquino',lastname='Arakawa',lastname='Araujo',lastname='Archibald',lastname='Arcocha Torres',lastname='Ardelean',lastname='Arfaoui',lastname='Arias',lastname='Armas',lastname='Arneja',lastname='Arnold',lastname='Arora',lastname='Arouni',lastname='Arrieta',lastname='Arroyave',lastname='Arstall',lastname='Arutyunov',lastname='Asakura',lastname='Asensio',lastname='Astier',lastname='Ata',lastname='Atar',lastname='Atie',lastname='Atkinson',lastname='Attanti',lastname='Aude',lastname='Augusto Alves da Costa',lastname='Aull',lastname='Ault',lastname='Ausperger',lastname='Avellar',lastname='Averett',lastname='Avery',lastname='Avila',lastname='Avvaru',lastname='Awasty',lastname='Awtry',lastname='Ayasse',lastname='Ayau Milla',lastname='Ayesu',lastname='Aylward',lastname='Azhdari',lastname='Azua',lastname='Babbar',lastname='Babbolin',lastname='Babilonia',lastname='Babu',lastname='Babuty',lastname='Badenhorst',lastname='Badila',lastname='Bae',lastname='Bagatin',lastname='Bagby',lastname='Bai',lastname='Baine',lastname='Bakliza',lastname='Balboa',lastname='Baldwin',lastname='Ball',lastname='Ballyuzek',lastname='Baman',lastname='Bamhorst',lastname='Bamrungpong',lastname='Banaeian',lastname='Banikova',lastname='Banker',lastname='Bansal',lastname='Banville',lastname='Bar',lastname='Barai',lastname='Baranyai',lastname='Barash',lastname='Barbarash',lastname='Barber',lastname='Barbera',lastname='Barcinas',lastname='Barker',lastname='Barnhorst',lastname='Barquero',lastname='Barrington',lastname='Barros',lastname='Barroso',lastname='Bart',lastname='Bartholomaus',lastname='Bartkowiak',lastname='Bartos',lastname='Bashkireva',lastname='Basson',lastname='Baszak',lastname='Batchell',lastname='Batista',lastname='Batta',lastname='Battistelli',lastname='Batushkin',lastname='Bauch',lastname='Bauer',lastname='Bautista',lastname='Bayata',lastname='Baylacher',lastname='Bayram Llamas',lastname='Bazylevych',lastname='Beasley',lastname='Beck',lastname='Bedenko',lastname='Bedoya',lastname='Bedregal',lastname='Bedwell',lastname='Beerts',lastname='Beeton',lastname='Behm',lastname='Beinart',lastname='Bekal',lastname='Belatsky',lastname='Belcuore',lastname='Belenky',lastname='Belhassane',lastname='Beloscar',lastname='Belousova',lastname='Ben Ari',lastname='Benatar',lastname='Bengtsson',lastname='Bengus',lastname='Benicka',lastname='Benjarge',lastname='Bensimhon',lastname='Bentivenga',lastname='Benton',lastname='Berbari',lastname='Bereznyakov',lastname='Berger',lastname='Bergovec',lastname='Berk',lastname='Berka',lastname='Berli',lastname='Bernard',lastname='Bernhardt',lastname='Berni',lastname='Berns',lastname='Berrouschot',lastname='Bertolim Precoma',lastname='Betcher',lastname='Beyer-Westendorf',lastname='Bharani',lastname='Bhargava',lastname='Bhaskarwar',lastname='Bhuti',lastname='Bianchini',lastname='Bilal',lastname='Bilazarian',lastname='Bingham',lastname='Biniek',lastname='Biniwale',lastname='Binns',lastname='Biscardi',lastname='Bjelobrk',lastname='Blagden',lastname='Blanc',lastname='Blanco Coronado',lastname='Blihar',lastname='Block',lastname='Blom',lastname='Blomstrom',lastname='Blonder',lastname='Bloomberg',lastname='Blue',lastname='Bobade',lastname='Bobbie',lastname='Bobescu',lastname='Bocanera',lastname='Bognar',lastname='Bojanowska',lastname='Bokarev',lastname='Bollova',lastname='Bolohan',lastname='Bolton',lastname='Bonds',lastname='Bonin',lastname='Bonora',lastname='Boriani',lastname='Borowski',lastname='Borsheim',lastname='Borthwick',lastname='Bosco',lastname='Bose',lastname='Bossaers',lastname='Botelho',lastname='Botero',lastname='Botha',lastname='Bouchard',lastname='Bourlios',lastname='Boursin',lastname='Bouzo',lastname='Bowden',lastname='Bowen',lastname='Bowman',lastname='Boyer',lastname='Bozek',lastname='Bradley',lastname='Braemer',lastname='Braun',lastname='Braunwald',lastname='Breschi',lastname='Bridge',lastname='Brilakis',lastname='Briscoe',lastname='Broberg',lastname='Brodova',lastname='Brondani',lastname='Bronisz',lastname='Brown',lastname='Browning',lastname='Brtko',lastname='Brubaker',lastname='Bruguera Cortada',lastname='Bruning',lastname='Bruton',lastname='Buchholz',lastname='Budassi',lastname='Buelow-Johansen',lastname='Bugueno',lastname='Buhler',lastname='Buhr',lastname='Buiks',lastname='Builes',lastname='Buksa',lastname='Bulgari',lastname='Bulygin',lastname='Burianova',lastname='Bush',lastname='Bustamante Labarta',lastname='Bustamante',lastname='Busz-Papiez',lastname='Butcher',lastname='Buza',lastname='Buzzetti',lastname='Bybee',lastname='Cabero',lastname='Cabrera',lastname='Caccavo',lastname='Caceres',lastname='Cader',lastname='Cajulis',lastname='Cakmak',lastname='Calambur',lastname='Calderon',lastname='Calik',lastname='Calvo Vargas',lastname='Calvo',lastname='Camm',lastname='Cammell',lastname='Campbell',lastname='Campisto',lastname='Canaday',lastname='Cannoni',lastname='Cano',lastname='Canosa',lastname='Capasso-Gulve',lastname='Capiau',lastname='Caplan',lastname='Car',lastname='Cardona Munoz',lastname='Cardoza',lastname='Carevic',lastname='Carey',lastname='Carlsson',lastname='Carne',lastname='Carr',lastname='Carraro',lastname='Carrasco',lastname='Carrillo',lastname='Carrion',lastname='Carroll',lastname='Cartasegna',lastname='Caruso',lastname='Casares Ramirez',lastname='Casares',lastname='Casas',lastname='Castro',lastname='Caterini',lastname='Cavanna',lastname='Cayli',lastname='Ceirano',lastname='Celic',lastname='Cemerlic Adjic',lastname='Cendali',lastname='Cermak',lastname='Cervellione',lastname='Cervi',lastname='Ceyhan',lastname='Cha',lastname='Chacon',lastname='Champagne',lastname='Chang',lastname='Chapman',lastname='Charlat',lastname='Chaturvedi',lastname='Chaves Junior',lastname='Chavez',lastname='Chehayeb',lastname='Chen',lastname='Chendey',lastname='Cheng',lastname='Chernyavskaya',lastname='Cherrico',lastname='Chiang',lastname='Chilvers',lastname='Chiou',lastname='Chiu',lastname='Chmielowski',lastname='Cho',lastname='Choi',lastname='Chompalova',lastname='Chopda',lastname='Choy',lastname='Christensen',lastname='Chumakova',lastname='Chun',lastname='Chung',lastname='Ciaramita',lastname='Cieslak',lastname='Ciezak',lastname='Ciglenecki',lastname='Ciobotaru',lastname='Ciortea',lastname='Clapp',lastname='Claussen',lastname='Clay',lastname='Cleveland',lastname='Clifton',lastname='Clinckemaille',lastname='Cobos',lastname='Coching',lastname='Codutti',lastname='Cohen',lastname='Coisne',lastname='Colan',lastname='Cole',lastname='Colin',lastname='Colombo',lastname='Colquhoun',lastname='Coman',lastname='Comi',lastname='Concha',lastname='Connolly',lastname='Constance',lastname='Constantinescu',lastname='Contzen',lastname='Cook',lastname='Coombs',lastname='Copley',lastname='Corbalan',lastname='Corbett',lastname='Corbut',lastname='Corchado',lastname='Correia',lastname='Cossu',lastname='Costache',lastname='Costantini',lastname='Costi',lastname='Cottiero',lastname='Coutinho',lastname='Coutu',lastname='Cowan',lastname='Cox',lastname='Coyle',lastname='Cozma',lastname='Craft',lastname='Craig',lastname='Crerand',lastname='Creteanu',lastname='Crimmins',lastname='Cristaldi',lastname='Cristea',lastname='Crisu',lastname='Croce',lastname='Cuccia',lastname='Cuello',lastname='Cullen',lastname='Cuneo',lastname='Cunha',lastname='Curt',lastname='Curtis',lastname='Cury',lastname='Cush',lastname='Cymerman',lastname='Dabrowska',lastname='Dagan',lastname='Daitz',lastname='Dalby',lastname='Dandekar',lastname='Dang',lastname='Daniels',lastname='Dart',lastname='Daskalaki',lastname='Dastoli',lastname='Datta',lastname='Daut',lastname='Dave',lastname='Davicevic',lastname='David',lastname='Davids',lastname='Davies',lastname='Davis',lastname='Davolos',lastname='Davuluri',lastname='de Arce Borda',lastname='De Bleecker',lastname='De Bruyne',lastname='De Caterina',lastname='de Groot',lastname='de Koning',lastname='de la Mora',lastname='De Lemos',lastname='de Melo',lastname='De Pace',lastname='De Patta',lastname='De Servi',lastname='De Tollenaere',lastname='de Vos',lastname='Dean',lastname='Debes',lastname='Decoulx',lastname='Deenadayalu',lastname='DeGarmo',lastname='Degtyareva',lastname='Delgadillo',lastname='Delgado Restrepo',lastname='Delgado',lastname='Demir',lastname='Demko',lastname='Denchev',lastname='Denie',lastname='Denis',lastname='Dennison',lastname='Deokar',lastname='Derlaga',lastname='Deruche',lastname='Derycker',lastname='Desai',lastname='DeSalle',lastname='Desfontaines',lastname='Desire',lastname='Despotovic',lastname='Dettmann',lastname='Devenport',lastname='Dewar',lastname='Dhar',lastname='Dharmarao',lastname='Di Lenarda',lastname='Di Niro',lastname='Di Pasquale',lastname='Dias',lastname='Diaz-Pintado',lastname='Diaz',lastname='Dichristin',lastname='Dicker',lastname='Dickinson',lastname='DiCorcia',lastname='Dieckheuer',lastname='Diez Tejedor',lastname='DiGiovanna',lastname='Dimitra',lastname='Dinanian',lastname='Dioszeghy',lastname='Djokic',lastname='Djokovic',lastname='Djordjevic-Radojkovic',lastname='do Val',lastname='Dobre',lastname='Dobreanu',lastname='Doctor',lastname='Dodt',lastname='Doka',lastname='Domanska',lastname='Domingo',lastname='Donahue',lastname='Dong',lastname='Dongas',lastname='Donova',lastname='Donovan',lastname='Dorn',lastname='Dorobantu',lastname='Dotani',lastname='Dotsenko',lastname='Dougal',lastname='Doughty',lastname='Douglas',lastname='Dovgalevsky',lastname='Dovgan',lastname='Dowling',lastname='Dragomir',lastname='Dran',lastname='Drapchak',lastname='Drapkina',lastname='Drescher',lastname='Drew',lastname='Dreykluft',lastname='Dronov',lastname='Drozdiak',lastname='du Preez',lastname='Duda',lastname='Duff',lastname='Dufresne',lastname='Dugal',lastname='Duggal',lastname='Dukat',lastname='Duki',lastname='Dulka',lastname='Dulkova',lastname='Duncan',lastname='Dunn',lastname='Duprat',lastname='Duris',lastname='Dutka',lastname='Dutra',lastname='Dutter',lastname='Dvoieglazova',lastname='Dzublik',lastname='Dzupina',lastname='Dzupinova',lastname='Dzyak',lastname='Eade',lastname='Easton',lastname='Ebano',lastname='Ebert',lastname='Ebina',lastname='Ebreo',lastname='Edelstein',lastname='Eden',lastname='Edes',lastname='Edlund',lastname='Egorova',lastname='Eikelboom',lastname='El Jarroudi',lastname='Elbl',lastname='Eldadah',lastname='Eldred',lastname='Elias',lastname='Ellis',lastname='Enad',lastname='Endo',lastname='Engdahl',lastname='Engelbrecht',lastname='Enger',lastname='Ensminger',lastname='Erasmus',lastname='Erceg',lastname='Erdogan',lastname='Erenrich',lastname='Eriksson',lastname='Ermis',lastname='Erofeeva',lastname='Esip',lastname='Essop',lastname='Estol',lastname='Ettinger',lastname='Everhart',lastname='Ewing',lastname='Exarchou',lastname='Ezekowitz',lastname='Facello',lastname='Faghih',lastname='Fahmy',lastname='Faircloth',lastname='Falu',lastname='Fattore',lastname='Faucett',lastname='Faustino Saporito',lastname='Faynyk',lastname='Fedacko',lastname='Fedotov',lastname='Feil',lastname='Fekete',lastname='Feld',lastname='Feldman',lastname='Felsman',lastname='Felten',lastname='Femenia',lastname='Feng',lastname='Fenu',lastname='Ferguson',lastname='Ferkl',lastname='Fernandez Ruiz',lastname='Fernandez',lastname='Ferraz',lastname='Ferreira',lastname='Ferri Certic',lastname='Fialkow',lastname='Filatov',lastname='Finimundi',lastname='Fink',lastname='Finkel',lastname='Finkelstein',lastname='Finlayson',lastname='Finsterbusch',lastname='Fiok',lastname='Fischell',lastname='Fishbein',lastname='Fisher',lastname='Fleck',lastname='Flecknoe-Brown',lastname='Fleets',lastname='Flint',lastname='Florenzano',lastname='Flores',lastname='Florian',lastname='Fonseca',lastname='Forck-Boedeker',lastname='Forgione',lastname='Forman',lastname='Formoso',lastname='Fortin',lastname='Foster',lastname='Fracaro',lastname='Frahm',lastname='Frais',lastname='Francalacci',lastname='Francek',lastname='Francetic',lastname='Francis',lastname='Franco',lastname='Freeman',lastname='Freemyer',lastname='French',lastname='Frey',lastname='Friedlander',lastname='Frommhold',lastname='Frost',lastname='Fu',lastname='Fuchs',lastname='Fujii',lastname='Fujimoto',lastname='Fujita',lastname='Fujiwara',lastname='Fukamizu',lastname='Fuki',lastname='Fukuda',lastname='Funazaki',lastname='Funes',lastname='Furiozzi',lastname='Furukawa',lastname='Fuselli',lastname='Gabela',lastname='Gadepalli',lastname='Gaffney',lastname='Gaggioli',lastname='Gagliano',lastname='Gagliardi',lastname='Gamachek',lastname='Gandur',lastname='Gani',lastname='Gant Lopez',lastname='Gao',lastname='Garb',lastname='Garcia Duran',lastname='Garcia-Castillo',lastname='Garcia',lastname='Garman',lastname='Garner',lastname='Garrido',lastname='Garza',lastname='Gates',lastname='Gauthier',lastname='Gavrysyuk',lastname='Gelfand',lastname='Genin',lastname='Genova-Peeva',lastname='Gentry',lastname='George',lastname='Georgiev',lastname='Gerasimenko',lastname='Gerber',lastname='Gergova',lastname='Ghantous',lastname='Ghionea',lastname='Ghume',lastname='Giacomi',lastname='Giannaula',lastname='Gibson',lastname='Gieroba',lastname='Giesbrecht',lastname='Gil',lastname='Gilat',lastname='Gilchrist',lastname='Gilinskaya',lastname='Gillespie',lastname='Gilo',lastname='Giovannelli',lastname='Giraldo',lastname='Giugliano',lastname='Givoni',lastname='Glezer',lastname='Gniot',lastname='Godfrey',lastname='Godlevska',lastname='Godsey',lastname='Goessling',lastname='Gogia',lastname='Goicoechea',lastname='Golan',lastname='Gold',lastname='Goldhaber',lastname='Goldscher',lastname='Goldstein',lastname='Golitsyn',lastname='Goloboulicz',lastname='Goloshchekin',lastname='Golshmid',lastname='Gomes',lastname='Goncalves',lastname='Goncharov',lastname='Goncharova',lastname='Gonzales',lastname='Gonzalez Juanatey',lastname='Gonzalez',lastname='Goodman',lastname='Goosen',lastname='Gordon',lastname='Gorna',lastname='Gorry',lastname='Goto',lastname='Gottlieb',lastname='Goudev',lastname='Gowda',lastname='Goyal',lastname='Goza',lastname='Gozalo',lastname='Graham',lastname='Grajales',lastname='Grammer',lastname='Grande',lastname='Granzow',lastname='Grassia',lastname='Gratsiansky',lastname='Green',lastname='Greenberger',lastname='Gregor',lastname='Griffin',lastname='Grigat',lastname='Grip',lastname='Grosse',lastname='Grossman',lastname='Grove',lastname='Gryczan',lastname='Gu',lastname='Guarino',lastname='Guarnieri',lastname='Guerra',lastname='Guerrero',lastname='Guevara',lastname='Guillen',lastname='Guimaraes',lastname='Gunnarsson',lastname='Gupta',lastname='Gurusamy',lastname='Guthrie',lastname='Guziewicz',lastname='Guzman Melgar',lastname='Gvora',lastname='Habibi',lastname='Hack',lastname='Hadan',lastname='Hagiwara',lastname='Hakansson',lastname='Halperin',lastname='Hamer',lastname='Hamroff',lastname='Han',lastname='Hanna',lastname='Hanyok',lastname='Hara',lastname='Harada',lastname='Hardas',lastname='Harden',lastname='Harkins',lastname='Harrelson',lastname='Harris',lastname='Hart',lastname='Hartley',lastname='Hartmann',lastname='Hartranft',lastname='Haruna',lastname='Hashimoto',lastname='Hasin',lastname='Hassager',lastname='Hatala',lastname='Hatalova',lastname='Hatfield',lastname='Hatheway',lastname='Havlova',lastname='Hayashi',lastname='Hayek',lastname='Hays',lastname='Hazeleger',lastname='Hearne',lastname='Heath',lastname='Heidbuchel',lastname='Heiman',lastname='Helliwell',lastname='Hellmers',lastname='Hemmen',lastname='Henderson',lastname='Hengerer',lastname='Henry',lastname='Herfurth',lastname='Hergeldjieva',lastname='Herlitz',lastname='Hermany',lastname='Hermida',lastname='Hernandez Madrid',lastname='Hernandez',lastname='Herrod',lastname='Herson',lastname='Herwehe',lastname='Herzet',lastname='Heuer',lastname='Hiasa',lastname='Hickenbotham',lastname='Hicks',lastname='Higashikata',lastname='Higuchi',lastname='Hinchion',lastname='Hinchman',lastname='Hippert',lastname='Hirahara',lastname='Hirayama',lastname='Hiremath',lastname='Ho',lastname='Hoag',lastname='Hodnett',lastname='Hoefer',lastname='Hoekstra',lastname='Hoffman',lastname='Hoffmann',lastname='Hofmanova',lastname='Hofmeyer',lastname='Hofsoy',lastname='Hollihan',lastname='Holt',lastname='Homan',lastname='Homayouni',lastname='Hominal',lastname='Hong',lastname='Honkova',lastname='Horacek',lastname='Horbach',lastname='Horna',lastname='Horton',lastname='Hotchkiss',lastname='Houbraken',lastname='Houchin',lastname='Howard',lastname='Hranai',lastname='Hren',lastname='Hsia',lastname='Huang',lastname='Hubac',lastname='Huerta',lastname='Hughes',lastname='Hughett',lastname='Huikuri',lastname='Hundseth',lastname='Hunter',lastname='Hurst',lastname='Hurtado',lastname='Hussain',lastname='Hussi',lastname='Husyev',lastname='Huyberechts',lastname='Huynh',lastname='Hyon',lastname='Ibarra',lastname='Ibsen',lastname='Iby',lastname='Ichikawa',lastname='Ichishita',lastname='Iesaka',lastname='Igarashi',lastname='Iglesias',lastname='Iida',lastname='Iijima',lastname='Ilic',lastname='Ino',lastname='Inomata',lastname='Iosipescu',lastname='Iriarte',lastname='Isakov',lastname='Ise',lastname='Ishchuk',lastname='Ishibashi',lastname='Ishida',lastname='Ishii',lastname='Ishimaru',lastname='Ison',lastname='Isted',lastname='Itamoto',lastname='Ito',lastname='Iversen',lastname='Iwade',lastname='Iwasaki',lastname='Jacobs',lastname='Jadhav',lastname='Jaeger',lastname='Jaguszewska',lastname='Jain',lastname='Jakal',lastname='Jakala',lastname='Jakobsen',lastname='Jambula',lastname='Jameson',lastname='Janczewska',lastname='Jandik',lastname='Januszewicz',lastname='Jaramillo Munoz',lastname='Jaramillo',lastname='Jardula',lastname='Jarkovsky',lastname='Jasani',lastname='Jauregui',lastname='Jazwinska-Tarnawska',lastname='Jelic',lastname='Jelinek',lastname='Jemna',lastname='Jeon',lastname='Jerabek',lastname='Jeric',lastname='Jernhed',lastname='Jiang',lastname='Jimenez',lastname='Jin',lastname='Jirasirirojanakorn',lastname='Jirmar',lastname='Jirsova',lastname='Joaquin',lastname='Johansson',lastname='Johnson',lastname='Johnston',lastname='Jones',lastname='Jorge',lastname='Joseph',lastname='Joshi',lastname='Joung',lastname='Jovin',lastname='Judson',lastname='Jung',lastname='Junggeburth',lastname='Jungmair',lastname='Junko',lastname='Jurca',lastname='Jure',lastname='Jurinjak',lastname='Jurowiecki',lastname='Juul-Moller',lastname='Kaarleenkaski',lastname='Kabul',lastname='Kacet',lastname='Kaczmarek',lastname='Kaewsuwanna',lastname='Kahn',lastname='Kai',lastname='Kaik',lastname='Kailey',lastname='Kaiser',lastname='Kakinoki',lastname='Kale',lastname='Kalezic',lastname='Kalil',lastname='Kaliszczak',lastname='Kamakura',lastname='Kamenova',lastname='Kamijo',lastname='Kaminski',lastname='Kamitake',lastname='Kamiyama',lastname='Kanadasi',lastname='Kanakaridisz',lastname='Kandath',lastname='Kandekar',lastname='Kaneno',lastname='Kang',lastname='Kania',lastname='Kaplan',lastname='Kapoor',lastname='Kappelhof',lastname='Kara',lastname='Karabalieva',lastname='Karakai',lastname='Karamitsos',lastname='Karczmarczyk',lastname='Karlsson',lastname='Karnwal',lastname='Karny',lastname='Karoli',lastname='Karpenko',lastname='Karpov',lastname='Karpuram',lastname='Kartsagkoulis',lastname='Karunaratne',lastname='Kasperova',lastname='Kastelic',lastname='Kato',lastname='Kaur',lastname='Kawaguchi',lastname='Kay',lastname='Kaydashev',lastname='Kazatani',lastname='Keane-Richmond',lastname='Keene',lastname='Kelfkens',lastname='Keller',lastname='Kennard',lastname='Kennett',lastname='Kerkering',lastname='Kersh',lastname='Kesselbrenner',lastname='Kevorkian',lastname='Khan',lastname='Kharalkar',lastname='Khetarpal',lastname='Khirmanov',lastname='Khlevchuk',lastname='Khokhlov',lastname='Khromova',lastname='Khrustalev',lastname='Kiatchoosakun',lastname='Kietselaer',lastname='Kifnidis',lastname='Kikuchi',lastname='Kilcup',lastname='Kim',lastname='Kimizu',lastname='Kincses',lastname='Kindman',lastname='Kinova',lastname='Kireenkov',lastname='Kirgizova',lastname='Kirichek',lastname='Kirk',lastname='Kirner',lastname='Kis',lastname='Kishi',lastname='Kishore',lastname='Kisos',lastname='Kiss',lastname='Kitani',lastname='Kitazawa',lastname='Kitova',lastname='Kjentjes',lastname='Klainman',lastname='Kleinecke-Pohl',lastname='Kmec',lastname='Knezevic',lastname='Kobayashi',lastname='Kobza',lastname='Kochrt',lastname='Koczka',lastname='Koenig',lastname='Kohno',lastname='Kokles',lastname='Kolk',lastname='Kolomyyits',lastname='Kolumban',lastname='Kong',lastname='Konieczny',lastname='Kononenko',lastname='Kooiman',lastname='Kopytsya',lastname='Korantanis',lastname='Koretsune',lastname='Korpas',lastname='Korzeniak',lastname='Korzeniowska-Adamus',lastname='Kosek',lastname='Kosenko',lastname='Kositsyna',lastname='Koskinen',lastname='Kosmaczewska',lastname='Kosmalova',lastname='Kosmalska',lastname='Kosolapov',lastname='Kostedt',lastname='Kostenko',lastname='Kostkova',lastname='Kostov',lastname='Kostova',lastname='Kosztyu',lastname='Kotera',lastname='Kotha',lastname='Kotiwale',lastname='Kotseruba',lastname='Kouz',lastname='Kovacs',lastname='Koval',lastname='Kovar',lastname='Koya',lastname='Kozak',lastname='Kozeni',lastname='Koziolova',lastname='Kozlowski',lastname='Kozyrev',lastname='Kraiz',lastname='Kranz',lastname='Krater',lastname='Kratskina',lastname='Krauze',lastname='Kraydashenko',lastname='Krichmar',lastname='Krider',lastname='Krishnan',lastname='Krocova',lastname='Krotin',lastname='Krzystolik',lastname='Krzyzanowski',lastname='Kubanska',lastname='Kuchar',lastname='Kudlicki',lastname='Kuhlenborg',lastname='Kuhlmann',lastname='Kulkarni',lastname='Kulynych',lastname='Kumagai',lastname='Kumar',lastname='Kumbla',lastname='Kunkelova',lastname='Kunz Sebba Barroso de Souza',lastname='Kuo',lastname='Kupnovytska',lastname='Kurabayashi',lastname='Kuroda',lastname='Kus',lastname='Kuznetsov',lastname='Kvasnicka',lastname='Kwak',lastname='Kyyak',lastname='Laane',lastname='Labonte',lastname='Labrova',lastname='Lack',lastname='Ladenburger',lastname='Lafave',lastname='Laffi',lastname='Laguta',lastname='Lahav',lastname='Laheaar',lastname='Lai',lastname='Laimer',lastname='Lainesse',lastname='Laliotis',lastname='Lam',lastname='Lambert',lastname='Lamden',lastname='Lamoureux',lastname='Landau',lastname='Lane',lastname='Lang',lastname='Langevin',lastname='Langone',lastname='Lanternier',lastname='Lanz',lastname='Laothavorn',lastname='Lapidus',lastname='Lappalainen',lastname='Laptev',lastname='Lara',lastname='Larina',lastname='Laskowska-Derlaga',lastname='Lasri',lastname='Latteri',lastname='Lavhe',lastname='Lavrova',lastname='Lawande',lastname='Le Heuzey',lastname='le Roux',lastname='Leaes',lastname='Lebedev',lastname='Lebedynskaya',lastname='Ledbetter',lastname='Lee',lastname='Leeman',lastname='LeHeuzey',lastname='Lehman',lastname='Leipelt',lastname='Leiva-Pons',lastname='Leka',lastname='Lema',lastname='Lentz',lastname='Leo',lastname='Leonidova',lastname='Lepage',lastname='Leparree',lastname='Lesnik',lastname='Lesser',lastname='Letaeva',lastname='Levashov',lastname='Lewczuk',lastname='Lewinsky',lastname='Lewis',lastname='Li',lastname='Liang',lastname='Liao',lastname='Libis',lastname='Libov',lastname='Lichtenstein',lastname='Lie',lastname='Lila',lastname='Lillestol',lastname='Lim',lastname='Limon',lastname='Lin',lastname='Lindsay',lastname='Ling',lastname='Liniado',lastname='Link',lastname='Linker',lastname='Lioy',lastname='Lip',lastname='Lishner',lastname='Lisiecki',lastname='Littlefield',lastname='Litvak',lastname='Liu',lastname='Lizogub',lastname='Llamas Esperon',lastname='Llamas',lastname='Llanos',lastname='Llerena',lastname='Lo Pinto',lastname='Locklear',lastname='Logvinenko',lastname='Logvinov',lastname='Lohman',lastname='Lohrbaecher-Kozak',lastname='Lomnitz',lastname='Lone',lastname='Looby',lastname='Loof',lastname='Lopes',lastname='Lopetegui',lastname='Lopez Garcia-Aranda',lastname='Lorente',lastname='Lotti',lastname='Lowe',lastname='Lu',lastname='Lubinski',lastname='Lucijanic',lastname='Ludka',lastname='Ludwig',lastname='Lueders',lastname='Lui',lastname='Luis-Valdes',lastname='Luiz',lastname='Lukenda',lastname='Lukyanov',lastname='Luna',lastname='Lupkovics',lastname='Lurie',lastname='Lustosa',lastname='Luton',lastname='Luttermann',lastname='Lysek',lastname='Lyzohub',lastname='Ma',lastname='Mabe',lastname='Mabee',lastname='MacCallum',lastname='MacDonald',lastname='Machova',lastname='Mackin',lastname='Mackinnon',lastname='MacLeod',lastname='Macomber',lastname='Madeira',lastname='Madsen',lastname='Maenpaa',lastname='Magallanes',lastname='Magee',lastname='Mainigi',lastname='Mairesse',lastname='Majdoub',lastname='Majstorovic',lastname='Makam',lastname='Makowiecka-Ciesla',lastname='Malanska',lastname='Malette',lastname='Malhan',lastname='Mali',lastname='Malmendier',lastname='Malmqvist',lastname='Malynovsky',lastname='Mandviwala',lastname='Mankhaeva',lastname='Mannaerts',lastname='Manolova',lastname='Manoylov',lastname='Manriquez',lastname='Manuale',lastname='Manuela',lastname='Manzano',lastname='Manzur',lastname='Maranda',lastname='Marar',lastname='Marazzi',lastname='Marchand',lastname='Marciano',lastname='Marcoviciu',lastname='Mardikar',lastname='Marenberg',lastname='Mariani',lastname='Marino',lastname='Marosi',lastname='Marques',lastname='Marquez',lastname='Marti',lastname='Martin',lastname='Martinez',lastname='Martins',lastname='Masaki',lastname='Masin',lastname='Maslova',lastname='Mason',lastname='Massin',lastname='Masson',lastname='Masuyama',lastname='Matei',lastname='Mather',lastname='Mathur',lastname='Matias',lastname='Matiga',lastname='Matoltsy',lastname='Matsuda',lastname='Matsushita',lastname='Matthews',lastname='Matus',lastname='Matveeva',lastname='Matyszczak-Toniak',lastname='Maus',lastname='Mavronasiou',lastname='Mawji',lastname='Maxwell',lastname='Maymone',lastname='Mazovets',lastname='Mazur',lastname='Mazzone',lastname='McCartney',lastname='McClelland',lastname='McCormick',lastname='McGarvey',lastname='McGhee',lastname='McGuire',lastname='McKeirnan',lastname='McKenzie',lastname='McKnight',lastname='McLaurin',lastname='McLean',lastname='Medina Palomino',lastname='Medvegy',lastname='Meeusen',lastname='Mega',lastname='Meholick',lastname='Mehrle',lastname='Meiller',lastname='Meissner',lastname='Mejia',lastname='Mekara',lastname='Melbue',lastname='Melichar',lastname='Memon',lastname='Mendelson',lastname='Mendez-Machado',lastname='Mendoza',lastname='Meno',lastname='Menon',lastname='Mercado',lastname='Mercer',lastname='Mercuri',lastname='Merino',lastname='Merkely',lastname='Merlini',lastname='Mestdagh',lastname='Metra',lastname='Meusel',lastname='Mevissen',lastname='Meyer-Pannwitt',lastname='Meyer',lastname='Michlin',lastname='Miekus',lastname='Mihov',lastname='Milas',lastname='Milcheva',lastname='Milinkovic',lastname='Millard',lastname='Miller',lastname='Miloradovic',lastname='Milusheva',lastname='Mincheva',lastname='Minchola',lastname='Minescu',lastname='Mino',lastname='Miranda',lastname='Mita',lastname='Mitchell',lastname='Miteva',lastname='Mitha',lastname='Mitrovic',lastname='Miyamoto',lastname='Miyauchi',lastname='Miyazaki',lastname='Moccetti',lastname='Mody',lastname='Mohri',lastname='Moiseeva',lastname='Momchilova-Lozeva',lastname='Monaco',lastname='Moncada Corredor',lastname='Mondaca',lastname='Monkley',lastname='Montayne',lastname='Monteiro',lastname='Moodh',lastname='Morais',lastname='Morales',lastname='Moran',lastname='Morandini',lastname='Morara',lastname='More',lastname='Morell',lastname='Morelli',lastname='Morely',lastname='Moreno',lastname='Morgado',lastname='Morgan',lastname='Moriarty',lastname='Morin',lastname='Morissette',lastname='Moriyama',lastname='Morlando',lastname='Morledge',lastname='Morley',lastname='Morrison',lastname='Morsky',lastname='Morton',lastname='Moschos',lastname='Mosiewicz',lastname='Mostert',lastname='Motta',lastname='Motylev',lastname='Mouhaffel',lastname='Mounsey',lastname='Moure',lastname='Mowdy',lastname='Mroczkowski',lastname='Mucha',lastname='Mudruk',lastname='Muegge',lastname='Mueller-Glamann',lastname='Muijs',lastname='Mullen',lastname='Mullinax',lastname='Munemasa',lastname='Munnik',lastname='Muntaner',lastname='Murata',lastname='Murdoch',lastname='Murena',lastname='Murphy',lastname='Muskoczki',lastname='Muzalewski',lastname='Muzyk-Osikowicz',lastname='Myslinski',lastname='Na',lastname='Nadar',lastname='Nagai',lastname='Naganuma',lastname='Nagase',lastname='Nagatome',lastname='Nagy',lastname='Nahrebetskyy',lastname='Naidoo',lastname='Naidu',lastname='Naito',lastname='Najarali',lastname='Nakagawa',lastname='Nakahara',lastname='Nakamura',lastname='Nakano',lastname='Nakashima',lastname='Nallasivan',lastname='Namgung',lastname='Namjoshi',lastname='Napora',lastname='Nappila',lastname='Narendra',lastname='Nario',lastname='Narita',lastname='Narumi',lastname='Natarajan',lastname='Navarrete',lastname='Nawrot',lastname='Nechanicky',lastname='Neeper',lastname='Negron Miguel',lastname='Nej',lastname='Nekrasa',lastname='Nelson',lastname='Nessler',lastname='Nethercott',lastname='Neves',lastname='Nevolina',lastname='Newby',lastname='Nguyen',lastname='Nichols',lastname='Nicholson',lastname='Nicolau',lastname='Nielsen',lastname='Nieminen',lastname='Niezgoda',lastname='Nigro',lastname='Nikolaev',lastname='Nikolov',lastname='Nikolskaya',lastname='Nikulina',lastname='Nilk',lastname='Ninho',lastname='Nishi',lastname='Nishiya',lastname='Noguchi',lastname='Nomanee',lastname='Nomura',lastname='Norden',lastname='Norwa-Otto',lastname='Novas',lastname='Novikova',lastname='Nowak',lastname='Nozaki',lastname='Nul',lastname='Nunes',lastname='Nunkoo',lastname='Nyagina',lastname='Nyman',lastname='Oberoi',lastname='Obreque',lastname='Ochean',lastname='Ochiai',lastname='Oehmann',lastname='Oga',lastname='Ogawa',lastname='Oguro',lastname='Oh',lastname='Ohirko',lastname='Okada',lastname='Okajima',lastname='Okazaki',lastname='Okishige',lastname='Okumura',lastname='Oliveira',lastname='Olsen',lastname='Olson',lastname='Olsr',lastname='Olszewski',lastname='Olympios',lastname='Omae',lastname='Onaka',lastname='Onishi',lastname='Ooki',lastname='Oomaan',lastname='Oommen',lastname='Oosawa',lastname='Opazo',lastname='Ophuis',lastname='Oppenheimer',lastname='Orchard',lastname='Orlov',lastname='Orozco Linares',lastname='Ortiz',lastname='Osborne',lastname='Ostberg',lastname='Ostojic',lastname='Ostroske',lastname='Ostrovska',lastname='Otasevic',lastname='Otis',lastname='Oto',lastname='Otto',lastname='Ouzan',lastname='Ovando Lavagnino',lastname='Overgaard',lastname='Oyama',lastname='Oza',lastname='Ozaki',lastname='Pacholska',lastname='Pagnan',lastname='Pahuja',lastname='Pai',lastname='Palinkas',lastname='Pan',lastname='Panchenko',lastname='Pande',lastname='Pandurangi',lastname='Panella',lastname='Panov',lastname='Panpunuan',lastname='Paolasso',lastname='Parada',lastname='Paradiso',lastname='Paraskevaidis',lastname='Parasteac',lastname='Parekh',lastname='Parishev',lastname='Park',lastname='Parkash',lastname='Parker',lastname='Parkhomenko',lastname='Parque',lastname='Parrott',lastname='Parsons',lastname='Patel',lastname='Patki',lastname='Patnam',lastname='Patrusheva',lastname='Paul',lastname='Paumets',lastname='Pavon',lastname='Pazier',lastname='Pearlstein',lastname='Peitz',lastname='Pella',lastname='Pencheva',lastname='Penco',lastname='Pentz',lastname='Perebetiuk',lastname='Pereira',lastname='Perez',lastname='Perkins',lastname='Perlo',lastname='Perrett',lastname='Perrone Filardi',lastname='Persechino',lastname='Persson',lastname='Peruzzotti',lastname='Pesant',lastname='Peterka',lastname='Peters',lastname='Petranov',lastname='Petrochenko',lastname='Petrova',lastname='Petrovic',lastname='Petrucci',lastname='Petruzziello',lastname='Pettis',lastname='Petyunina',lastname='Pezzella',lastname='Phan',lastname='Phillips',lastname='Piechatzek',lastname='Pikalova',lastname='Pilipenko',lastname='Pimenta Almeida',lastname='Pincetti',lastname='Pineda',lastname='Pinto',lastname='Pirelli',lastname='Piseddu',lastname='Piskorz',lastname='Pisova',lastname='Piyayotai',lastname='Platner',lastname='Plosca',lastname='Podjacka',lastname='Podrazil',lastname='Pogorzelska',lastname='Pohl',lastname='Pointer',lastname='Pokutneva',lastname='Polasek',lastname='Polaszewska-Pulkownik',lastname='Polkanova',lastname='Polovina',lastname='Poluyanova',lastname='Polyanskaya',lastname='Pop',lastname='Popescu',lastname='Popov',lastname='Pornchaiyasit',lastname='Potapenko',lastname='Potpara',lastname='Potthoff',lastname='Poulard',lastname='Poulathas',lastname='Povedano',lastname='Poynton',lastname='Pozuelos',lastname='Pozzer',lastname='Prado',lastname='Pratt',lastname='Premchand',lastname='Preston',lastname='Pribble',lastname='Price-Smith',lastname='Price',lastname='Prior',lastname='Prokhorov',lastname='Proskynitopoulos',lastname='Ptak',lastname='Puchinyan',lastname='Pudi',lastname='Puertas',lastname='Pugeda',lastname='Purayil',lastname='Puripun',lastname='Purnell',lastname='Putnikovic',lastname='Pye',lastname='Pyrgakis',lastname='Qi',lastname='Qiang',lastname='Qiu',lastname='Qu',lastname='Quadrel',lastname='Quick',lastname='Quinlan',lastname='Quinn',lastname='Quintero',lastname='Qureshi',lastname='Raae',lastname='Rabadi-Marar',lastname='Rack',lastname='Raczak',lastname='Radaelli',lastname='Raddatz',lastname='Radder',lastname='Raepers',lastname='Rafala',lastname='Rafla',lastname='Raggi',lastname='Raimondi',lastname='Raisaro',lastname='Rajasalu',lastname='Rama',lastname='Ramasamy',lastname='Ramirez',lastname='Ramos',lastname='Randers',lastname='Ranka',lastname='Rao',lastname='Rasi',lastname='Raskina',lastname='Rasmussen',lastname='Rasura',lastname='Rathi',lastname='Ratnik',lastname='Raut',lastname='Rautio',lastname='Ravi Shankar',lastname='Raymond',lastname='Raziano',lastname='Rebolledo',lastname='Rebrov',lastname='Reddy',lastname='Redondo',lastname='Reed',lastname='Reguero',lastname='Reichert',lastname='Reiling',lastname='Reis Katz Weiand',lastname='Reis',lastname='Reissner',lastname='Renaud',lastname='Renzi',lastname='Repin',lastname='Reptova',lastname='Rewinska',lastname='Rey',lastname='Rha',lastname='Ricci',lastname='Richwine',lastname='Rim',lastname='Rinke',lastname='Riofrio',lastname='Rishko',lastname='Rivis',lastname='Roberts',lastname='Robinson',lastname='Rocha',lastname='Rodas Estrada',lastname='Rodina',lastname='Rodkey',lastname='Rodrigues',lastname='Rodriguez',lastname='Roehll',lastname='Rogelio',lastname='Romero-Colon',lastname='Romero',lastname='Romic',lastname='Ron',lastname='Ronkowski',lastname='Ronn',lastname='Roper',lastname='Rosado',lastname='Rosales',lastname='Rosell',lastname='Rosen',lastname='Rosenthal',lastname='Roshrosh',lastname='Ross',lastname='Rossi dos Santos',lastname='Rossovskaya',lastname='Rost',lastname='Roth',lastname='Roudaut',lastname='Rouwaida',lastname='Roxas',lastname='Roy',lastname='Royes',lastname='Royse',lastname='Rozenman',lastname='Rozmyslowicz-Szerminska',lastname='Ruberg',lastname='Ruda',lastname='Rudyk',lastname='Ruff',lastname='Ruffini',lastname='Ruggiero',lastname='Ruiz',lastname='Ruoff',lastname='Rupka',lastname='Ruzsa',lastname='Ruzyllo',lastname='Rychkov',lastname='Ryu',lastname='Sababathi',lastname='Sacco',lastname='Saha',lastname='Saini',lastname='Sakagami',lastname='Sakai',lastname='Sakamoto',lastname='Sakata',lastname='Sakuma',lastname='Sakuragi',lastname='Sakurai',lastname='Salas',lastname='Salgado',lastname='Salminen',lastname='Salpas',lastname='Samal',lastname='Samardzic',lastname='Sambaz',lastname='Samburg',lastname='Samkova',lastname='Sampaio',lastname='Sanchez Diaz',lastname='Sanchez Samayoa',lastname='Sanchez Vallejo',lastname='Sanchez',lastname='Sand',lastname='Sandberg',lastname='Sanders',lastname='Sandvik',lastname='Sanjurjo',lastname='Sankari',lastname='Sant',lastname='Santos',lastname='Sao Marcos',lastname='Sao Teotonio',lastname='Saraiva',lastname='Saravia Toledo',lastname='Saravia',lastname='Sardin',lastname='Sarna',lastname='Sarpola',lastname='Sasaki',lastname='Satake',lastname='Sato',lastname='Satoh',lastname='Savanth',lastname='Savin',lastname='Sawaya',lastname='Sawhney',lastname='Sayour',lastname='Scavee',lastname='Schaefer',lastname='Schellong',lastname='Schenkenberger',lastname='Schiewe',lastname='Schiff',lastname='Schmid',lastname='Schmidberg',lastname='Schmidt',lastname='Schneider',lastname='Schnelzer',lastname='Schoen',lastname='Schomburg',lastname='Schreckenberg',lastname='Schuler',lastname='Schulman',lastname='Schuppe',lastname='Schwarz',lastname='Schygiel',lastname='Scott',lastname='Seals',lastname='Seese',lastname='Seferovic',lastname='Sehnem',lastname='Sehr',lastname='Seib',lastname='Seibert',lastname='Seide',lastname='Seino',lastname='Selicato',lastname='Sendrowski',lastname='Senior',lastname='Seo',lastname='Serban',lastname='Serik',lastname='Seroqui',lastname='Serup-Hansen',lastname='Sethi',lastname='Sethia',lastname='Severi',lastname='Severino',lastname='Shah',lastname='Shaikh',lastname='Shalaby',lastname='Sham',lastname='Shams',lastname='Shandra',lastname='Shanes',lastname='Shaoulian',lastname='Shaposhnik',lastname='Sharma',lastname='Shatilo',lastname='Shatsky',lastname='Shcherbak',lastname='Sheehan',lastname='Sheikh',lastname='Shelke',lastname='Sheth',lastname='Shetty',lastname='Shi',lastname='Shigenari',lastname='Shih',lastname='Shimazu',lastname='Shin',lastname='Shipp',lastname='Shirai',lastname='Shoaf',lastname='Shochat',lastname='Shogenov',lastname='Shoji',lastname='Shoukfeh',lastname='Shree',lastname='Shriver',lastname='Shu',lastname='Shvetz',lastname='Shyu',lastname='Sidorenko',lastname='Siler',lastname='Silva',lastname='Silver',lastname='Silverio',lastname='Silverman',lastname='Simmons',lastname='Simoes',lastname='Simor',lastname='Simpson',lastname='Singh',lastname='Singhal',lastname='Sinitsina',lastname='Sinthusopa',lastname='Sipciu',lastname='Sipos',lastname='Sirbu',lastname='Sirenko',lastname='Sizova',lastname='Skelton',lastname='Skene',lastname='Skierka',lastname='Skinner',lastname='Sklyanna',lastname='Slaby',lastname='Slanina',lastname='Slater',lastname='Slattery',lastname='Slayton',lastname='Sloss',lastname='Smith',lastname='Snyders',lastname='Soares',lastname='Sobolev',lastname='Sobral Filho',lastname='Sohn',lastname='Soin',lastname='Solanki',lastname='Solis',lastname='Solovyev',lastname='Soma',lastname='Somaraju',lastname='SomaRaju',lastname='Sopher',lastname='Sorokivskyy',lastname='Sosa Liprandi',lastname='Sotomora',lastname='Southam',lastname='Spacek',lastname='Spangenthal',lastname='Sperling',lastname='Spinar',lastname='Spinu',lastname='Spitzer',lastname='Spivack',lastname='Springer',lastname='Spyra',lastname='Srinivas',lastname='Sripracha',lastname='Sriprasert',lastname='Sritara',lastname='St Laurent',lastname='St-Germain',lastname='St-Hilaire',lastname='Stafford',lastname='Stamate',lastname='Standring',lastname='Staneva',lastname='Staniloae',lastname='Stanislavchuk',lastname='Stanley',lastname='Staub',lastname='Steiner',lastname='Steljes',lastname='Stenberg',lastname='Stephenson',lastname='Sterlin',lastname='Stern',lastname='Stets',lastname='Steward',lastname='Stockins',lastname='Stockman',lastname='Stoehring',lastname='Stopyra-Poczatek',lastname='Storey',lastname='Stoyanovski',lastname='Strickland',lastname='Struble',lastname='Strugatsky',lastname='Stubbs',lastname='Studenikow',lastname='Sudheer',lastname='Sugeno',lastname='Sugi',lastname='Sukonthasarn',lastname='Sumii',lastname='Sundholm',lastname='Suprun',lastname='Suresh',lastname='Surushe',lastname='Sussman',lastname='Sutalo',lastname='Svadbik',lastname='Svenningsen',lastname='Swaim',lastname='Swauger',lastname='Swerchowsky',lastname='Swissa',lastname='Syan',lastname='Sychov',lastname='Szakal',lastname='Szatmari',lastname='Sznajder',lastname='Szolkiewicz',lastname='Szto',lastname='Szulawski',lastname='Szymanowski',lastname='Szymanska',lastname='Taggeselle',lastname='Tahirkheli',lastname='Takagi',lastname='Takahashi',lastname='Takata',lastname='Takeda',lastname='Takenaka',lastname='Takeuchi',lastname='Takiguchi',lastname='Talajic',lastname='Talano',lastname='Talbot-Lawson',lastname='Talbot',lastname='Taljaard',lastname='Tamayo',lastname='Tambawala',lastname='Tameron',lastname='Tami',lastname='Tamura',lastname='Tanabe',lastname='Tanaka',lastname='Tandogan',lastname='Tang',lastname='Tanikawa',lastname='Tanouchi',lastname='Tarasov',lastname='Tasic',lastname='Tatarko',lastname='Tavciovski',lastname='Tawney',lastname='Teague',lastname='Tee',lastname='Teitelbaum',lastname='Teixeira',lastname='Terakura',lastname='Tereschenko',lastname='Tereshenko',lastname='Terns',lastname='Terry',lastname='Tesic',lastname='Teves',lastname='Thakkar',lastname='Thakor',lastname='Thakur',lastname='Thankaraj',lastname='Thomas',lastname='Thomason',lastname='Thompson',lastname='Thrope',lastname='Thulin',lastname='Thunhaug',lastname='Tikhonova',lastname='Timofeev',lastname='Tincani',lastname='Tisdale',lastname='To',lastname='Todd',lastname='Todorov',lastname='Tomcsanyi',lastname='Tomita',lastname='Tomlinson',lastname='Tommasi',lastname='Topolnitchi',lastname='Torp-Pedersen',lastname='Torres',lastname='Toschi',lastname='Toth',lastname='Tremblay',lastname='Triano',lastname='Troughton',lastname='Truva',lastname='Tsai',lastname='Tsalihin',lastname='Tsareva',lastname='Tseluyko',lastname='Tseng',lastname='Tsuboi',lastname='Tsukimine',lastname='Tucker',lastname='Tudoran',lastname='Tumbev',lastname='Tumbeva',lastname='Turbak',lastname='Turgut',lastname='Turner',lastname='Turri',lastname='Tusek',lastname='Tveit',lastname='Tykhonova',lastname='Tymendorf',lastname='Tzekova',lastname='Tziortziotis',lastname='Uchida',lastname='Ucik',lastname='Ueda',lastname='Uematsu',lastname='Ueng',lastname='Ueyama',lastname='Ullig',lastname='Updegrove',lastname='Usan',lastname='Ushakova-Sokolova',lastname='Ustyugov',lastname='Usuda',lastname='Vahula',lastname='Vaillancourt',lastname='Vakaliuk',lastname='Val-Mejias',lastname='Valentine',lastname='Valle',lastname='Vallenas',lastname='Valles',lastname='Valley',lastname='Valovyeva',lastname='Valpas',lastname='Valuyshkih',lastname='van der Heijden',lastname='van der Merwe',lastname='van Welden',lastname='van Welsen',lastname='van Zyl',lastname='Vandekerckhove',lastname='Vankova',lastname='Vansickle',lastname='Vanwelden',lastname='Varga',lastname='Varma',lastname='Vasilev',lastname='Vasiljevic-Pokrajcic',lastname='Vasilyeva',lastname='Vasquez',lastname='Vasylets',lastname='Vatutin',lastname='Velasquez Camas',lastname='Velazquez',lastname='Velthuysen',lastname='Veltkamp',lastname='Vemireddy',lastname='Veng-Olsen',lastname='Venkataraman',lastname='Venneklaas',lastname='Venter',lastname='Venturini',lastname='Verdini',lastname='Verheugt',lastname='Verma',lastname='Vernon',lastname='Vertes',lastname='Vervoort',lastname='Viau',lastname='Vicari',lastname='Vicente',lastname='Vico',lastname='Vieira',lastname='Vierbeck',lastname='Vignau',lastname='Viitaniemi',lastname='Vijay',lastname='Villamor',lastname='Villas Boas',lastname='Villuendas',lastname='Vinod',lastname='Virtanen',lastname='Vishnevsky',lastname='Vita',lastname='Vittitow',lastname='Vizir',lastname='Vlasyuk',lastname='Vodnansky',lastname='Voehringer',lastname='Vogelmann',lastname='Vogt',lastname='Voicu',lastname='Voitk',lastname='Volkov',lastname='Volkova',lastname='von Wulffen',lastname='VonGerichten',lastname='Vorasettakarnkij',lastname='Vorontsova',lastname='Vossler',lastname='Vrazic',lastname='Vrolix',lastname='Vujisic Tesic',lastname='Vuriya',lastname='Wada',lastname='Wade',lastname='Wahby',lastname='Waldo',lastname='Walker',lastname='Wall',lastname='Walsh',lastname='Wang',lastname='Ward',lastname='Warmack',lastname='Warren',lastname='Waseem',lastname='Washam',lastname='Watanabe',lastname='Waters',lastname='Watkin',lastname='Watkins',lastname='Watts',lastname='Waxman',lastname='Wei',lastname='Weihrauch',lastname='Weiss',lastname='Weitz',lastname='Wessels',lastname='West',lastname='Westcott',lastname='Weyland',lastname='Wharton',lastname='White',lastname='Wierzykowski',lastname='Wiggers',lastname='Williams',lastname='Willis',lastname='Wilmot',lastname='Wilmott',lastname='Wilson',lastname='Winberg',lastname='Winkelmann',lastname='Winter',lastname='Witt',lastname='Wiviott',lastname='Wnetrzak-Michalska',lastname='Wofford',lastname='Wolde',lastname='Wollaert',lastname='Wood',lastname='Woodford',lastname='Worley',lastname='Wright',lastname='Wrobel',lastname='Wroblewski',lastname='Wu',lastname='Wulf',lastname='Wurow',lastname='Wysokinski',lastname='Xie',lastname='Xu',lastname='Yagensky',lastname='Yagi',lastname='Yahata',lastname='Yakusevich',lastname='Yakushin',lastname='Yalcin',lastname='Yamabe',lastname='Yamada',lastname='Yamagishi',lastname='Yamaguchi',lastname='Yamamoto',lastname='Yamano',lastname='Yamashina',lastname='Yamashita',lastname='Yanac Chavez',lastname='Yang',lastname='Yarows',lastname='Yasin',lastname='Yasumoto',lastname='Yeh',lastname='Yena',lastname='Yi',lastname='Yigit',lastname='Yin',lastname='Yonehara',lastname='York',lastname='Yoshida',lastname='Yoshino',lastname='Yoshioka',lastname='You',lastname='Young',lastname='Yousuf',lastname='Yovaniniz',lastname='Yu',lastname='Yuan',lastname='Yukhno',lastname='Yumoto',lastname='Zaca',lastname='Zachar',lastname='Zajac',lastname='Zakhary',lastname='Zamlynskyy',lastname='Zamorano',lastname='Zanotti',lastname='Zanwar',lastname='Zapanta',lastname='Zarandon',lastname='Zarebinski',lastname='Zareczky',lastname='Zarpentin',lastname='Zateyshchikov',lastname='Zateyshchikova',lastname='Zeig',lastname='Zellner',lastname='Zeltser',lastname='Zenin',lastname='Zhang',lastname='Zhao',lastname='Zharinov',lastname='Zheng',lastname='Zhou',lastname='Zhukova',lastname='Zhurba',lastname='Zidkova',lastname='Ziegler',lastname='Zielinski',lastname='Zienciuk-Krajka',lastname='Zimmermann',lastname='Zoghi',lastname='Zondag',lastname='Zotova',lastname='Zubeeva',lastname='Zyatenkova',lastname="D'Amico",lastname="D'Costa",lastname="D'Souza",lastname="Koval'",lastname="O'Brien",lastname="O'Hara",lastname="O'Mahony",lastname="O'Meeghan",lastname="O'Shea",Male,MEDLINE,Middle Aged,Multicenter Study,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,Non-U.S. Gov't,pmid:24251359,PubMed Abstract,Pyridines / adverse effects,Pyridines / therapeutic use*,Randomized Controlled Trial,Research Support,Robert P Giugliano,Stroke / prevention & control*,suffix='Jr',suffix=None,Thiazoles / adverse effects,Thiazoles / therapeutic use*,Warfarin / adverse effects,Warfarin / therapeutic use*}
}

@article{Givertz2015,
  title = {Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: {{The}} Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients ({{EXACT-HF}}) Study},
  author = {Givertz, Michael M. and Anstrom, Kevin J. and Redfield, Margaret M. and Deswal, Anita and Haddad, Haissam and Butler, Javed and Tang, W. H.Wilson and Dunlap, Mark E. and LeWinter, Martin M. and Mann, Douglas L. and Felker, G. Michael and O'Connor, Christopher M. and Goldsmith, Steven R. and Ofili, Elizabeth O. and Saltzberg, Mitchell T. and Margulies, Kenneth B. and Cappola, Thomas P. and Konstam, Marvin A. and Semigran, Marc J. and McNulty, Steven E. and Lee, Kerry L. and Shah, Monica R. and Hernandez, Adrian F.},
  year = {2015},
  journal = {Circulation},
  volume = {131},
  number = {20},
  pages = {1763--1771},
  publisher = {Circulation},
  issn = {1524-4539},
  doi = {10.1161/CIRCULATIONAHA.114.014536},
  abstract = {Background-Oxidative stress may contribute to heart failure (HF) progression. Inhibiting xanthine oxidase in hyperuricemic HF patients may improve outcomes. Methods and Results-We randomly assigned 253 patients with symptomatic HF, left ventricular ejection fraction {$\leq$}40\%, and serum uric acid levels {$\geq$}9.5 mg/dL to receive allopurinol (target dose, 600 mg daily) or placebo in a double-blind, multicenter trial. The primary composite end point at 24 weeks was based on survival, worsening HF, and patient global assessment. Secondary end points included change in quality of life, submaximal exercise capacity, and left ventricular ejection fraction. Uric acid levels were significantly reduced with allopurinoLin comparison with placebo (treatment difference,-4.2 [-4.9,-3.5] mg/dL and-3.5 [-4.2,-2.7] mg/dL at 12 and 24 weeks, respectively, both P{\textexclamdown}0.0001). At 24 weeks, there was no significant difference in clinical status between the allopurinol-and placebo-treated patients (worsened 45\% versus 46\%, unchanged 42\% versus 34\%, improved 13\% versus 19\%, respectively; P=0.68). At 12 and 24 weeks, there was no significant difference in change in Kansas City Cardiomyopathy Questionnaire scores or 6-minute walk distances between the 2 groups. At 24 weeks, left ventricular ejection fraction did not change in either group or between groups. Rash occurred more frequently with allopurinol (10\% versus 2\%, P=0.01), but there was no difference in serious adverse event rates between the groups (20\% versus 15\%, P=0.36). Conclusions-In high-risk HF patients with reduced ejection fraction and elevated uric acid levels, xanthine oxidase inhibition with allopurinol failed to improve clinical status, exercise capacity, quality of life, or left ventricular ejection fraction at 24 weeks.},
  pmid = {25986447},
  keywords = {affs=[],affs=[]),Aged,Allopurinol / adverse effects,Allopurinol / therapeutic use*,Author(firstnames='A',Author(firstnames='B',Author(firstnames='C',Author(firstnames='D',Author(firstnames='E A',Author(firstnames='E',Author(firstnames='F',Author(firstnames='G',Author(firstnames='H',Author(firstnames='I',Author(firstnames='J W',Author(firstnames='J',Author(firstnames='K D',Author(firstnames='K',Author(firstnames='L',Author(firstnames='M R',Author(firstnames='M',Author(firstnames='N',Author(firstnames='P',Author(firstnames='R',Author(firstnames='S',Author(firstnames='T',Author(firstnames='V',Biomarkers / blood,CollabAuthor(name='NHLBI Heart Failure Clinical Research Network',Comparative Study,Diuretics / therapeutic use,doi:10.1161/CIRCULATIONAHA.114.014536,Double-Blind Method,Endpoint Determination,equal<sub>c</sub>ontrib=False),equal<sub>c</sub>ontrib=False)],Exercise Test,Exercise Tolerance,Extramural,Female,Gout / drug therapy,Gout Suppressants / therapeutic use,Heart Failure / blood,Heart Failure / complications*,Heart Failure / diagnostic imaging,Hospitalization / statistics & numerical data,Humans,Hyperuricemia / complications,Hyperuricemia / drug therapy*,initials='A',initials='B',initials='C',initials='D',initials='E',initials='EA',initials='F',initials='G',initials='H',initials='I',initials='J',initials='JW',initials='K',initials='KD',initials='L',initials='M',initials='MR',initials='N',initials='P',initials='R',initials='S',initials='T',initials='V',investigators=[Author(firstnames='E',iseditor=False,Kevin J Anstrom,lastname='Adams',lastname='Agresti',lastname='Anello',lastname='Aristy',lastname='Baer',lastname='Baker',lastname='Barber',lastname='Bart',lastname='Berg',lastname='Bild',lastname='Boddicker',lastname='Bouscher',lastname='Bove',lastname='Boyajian',lastname='Braunwald',lastname='Brooks',lastname='Brown',lastname='Chadwick',lastname='Chee',lastname='Chen',lastname='Cocca-Spofford',lastname='Cross',lastname='Daher',lastname='Desvigne-Nickens',lastname='Dettmer',lastname='Diaz',lastname='DiSabatino',lastname='Donahue',lastname='Eckman',lastname='Ewald',lastname='Fang',lastname='Flaker',lastname='Flanagan',lastname='Florea',lastname='Gallagher',lastname='Gatzke',lastname='Giannetti',lastname='Greenberg',lastname='Haffey',lastname='Hauptman',lastname='Hu',lastname='Huggins',lastname='Humbert',lastname='Ibarra',lastname='Jamieson',lastname='Johnson',lastname='Jones',lastname='Kao',lastname='Keleti',lastname='Kennedy',lastname='Kiserow',lastname='Kono',lastname='Kwak',lastname='Lakdawala',lastname='Lapointe',lastname='Lewis',lastname='Lin',lastname='Mackedanz',lastname='Maher-Hines',lastname='Mascette',lastname='McGonagle',lastname='McKelvie',lastname='McNamara',lastname='Meyer',lastname='Michel',lastname='Milbrandt',lastname='Neva',lastname='Oh',lastname='Parillo',lastname='Penn',lastname='Pickering',lastname='Pointer',lastname='Racine',lastname='Rahmatullah',lastname='Rhode',lastname='Rose',lastname='Roy',lastname='Rubin',lastname='Scheutzow',lastname='Schuchard',lastname='Small',lastname='Snell',lastname='Sopko',lastname='Starling',lastname='Stehlik',lastname='Stevenson',lastname='Tracy',lastname='Vaughan',lastname='Velazquez',lastname='Virmani',lastname='Weber',lastname='Whipple',lastname='Wilder',Male,MEDLINE,Michael M Givertz,Middle Aged,Multicenter Study,N.I.H.,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,Oxidative Stress,PMC4438785,pmid:25986447,PubMed Abstract,Quality of Life,Randomized Controlled Trial,Research Support,Stroke Volume,suffix=None,Surveys and Questionnaires,Treatment Outcome,Ultrasonography,Xanthine Oxidase / antagonists & inhibitors*}
}

@article{gkatzionisContextualizingSelectionBias2019,
  title = {Contextualizing Selection Bias in {{Mendelian}} Randomization: How Bad Is It Likely to Be?},
  shorttitle = {Contextualizing Selection Bias in {{Mendelian}} Randomization},
  author = {Gkatzionis, Apostolos and Burgess, Stephen},
  year = {2019},
  month = jun,
  journal = {International Journal of Epidemiology},
  volume = {48},
  number = {3},
  pages = {691--701},
  issn = {0300-5771},
  doi = {10.1093/ije/dyy202},
  urldate = {2025-01-22},
  abstract = {Selection bias affects Mendelian randomization investigations when selection into the study sample depends on a collider between the genetic variant and confounders of the risk factor--outcome association. However, the relative importance of selection bias for Mendelian randomization compared with other potential biases is unclear.We performed an extensive simulation study to assess the impact of selection bias on a typical Mendelian randomization investigation. We considered inverse probability weighting as a potential method for reducing selection bias. Finally, we investigated whether selection bias may explain a recently reported finding that lipoprotein(a) is not a causal risk factor for cardiovascular mortality in individuals with previous coronary heart disease.Selection bias had a severe impact on bias and Type 1 error rates in our simulation study, but only when selection effects were large. For moderate effects of the risk factor on selection, bias was generally small and Type 1 error rate inflation was not considerable. Inverse probability weighting ameliorated bias when the selection model was correctly specified, but increased bias when selection bias was moderate and the model was misspecified. In the example of lipoprotein(a), strong genetic associations and strong confounder effects on selection mean the reported null effect on cardiovascular mortality could plausibly be explained by selection bias.Selection bias can adversely affect Mendelian randomization investigations, but its impact is likely to be less than other biases. Selection bias is substantial when the effects of the risk factor and confounders on selection are particularly large.},
  file = {/Users/xx20081/Zotero/storage/XAT9PGEB/Gkatzionis and Burgess - 2019 - Contextualizing selection bias in Mendelian randomization how bad is it likely to be.pdf;/Users/xx20081/Zotero/storage/SIRLCT29/5132989.html}
}

@article{gomesGeneticArchitectureCardiac2023,
  title = {Genetic Architecture of Cardiac Dynamic Flow Volumes},
  author = {Gomes, Bruna and Singh, Aditya and O'Sullivan, Jack W. and Schnurr, Theresia M. and Goddard, Pag{\'e} C. and Loong, Shaun and Amar, David and Hughes, J. Weston and Kostur, Mykhailo and Haddad, Francois and Salerno, Michael and Foo, Roger and Montgomery, Stephen B. and Parikh, Victoria N. and Meder, Benjamin and Ashley, Euan A.},
  year = {2023},
  month = dec,
  journal = {Nature Genetics},
  pages = {1--13},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-023-01587-5},
  urldate = {2024-01-18},
  abstract = {Cardiac blood flow is a critical determinant of human health. However, the definition of its genetic architecture is limited by the technical challenge of capturing dynamic flow volumes from cardiac imaging at scale. We present DeepFlow, a deep-learning system to extract cardiac flow and volumes from phase-contrast cardiac magnetic resonance imaging. A mixed-linear model applied to 37,653 individuals from the UK Biobank reveals genome-wide significant associations across cardiac dynamic flow volumes spanning from aortic forward velocity to aortic regurgitation fraction. Mendelian randomization reveals a causal role for aortic root size in aortic valve regurgitation. Among the most significant contributing variants, localizing genes (near ELN, PRDM6 and ADAMTS7) are implicated in connective tissue and blood pressure pathways. Here we show that DeepFlow cardiac flow phenotyping at scale, combined with genotyping data, reinforces the contribution of connective tissue genes, blood pressure and root size to aortic valve function.},
  copyright = {2023 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  keywords = {Cardiovascular diseases,Genetics research,Population genetics},
  file = {/Users/xx20081/Zotero/storage/JVHX4EWU/Gomes et al. - 2023 - Genetic architecture of cardiac dynamic flow volum.pdf}
}

@article{gorskiGeneticLociPrioritization2022,
  title = {Genetic Loci and Prioritization of Genes for Kidney Function Decline Derived from a Meta-Analysis of 62 Longitudinal Genome-Wide Association Studies},
  author = {Gorski, Mathias and Rasheed, Humaira and Teumer, Alexander and Thomas, Laurent F. and Graham, Sarah E. and Sveinbjornsson, Gardar and Winkler, Thomas W. and G{\"u}nther, Felix and Stark, Klaus J. and Chai, Jin-Fang and Tayo, Bamidele O. and Wuttke, Matthias and Li, Yong and Tin, Adrienne and Ahluwalia, Tarunveer S. and {\"A}rnl{\"o}v, Johan and {\AA}svold, Bj{\o}rn Olav and Bakker, Stephan J. L. and Banas, Bernhard and Bansal, Nisha and Biggs, Mary L. and Biino, Ginevra and B{\"o}hnke, Michael and Boerwinkle, Eric and Bottinger, Erwin P. and Brenner, Hermann and Brumpton, Ben and Carroll, Robert J. and Chaker, Layal and Chalmers, John and Chee, Miao-Li and Chee, Miao-Ling and Cheng, Ching-Yu and Chu, Audrey Y. and Ciullo, Marina and Cocca, Massimiliano and Cook, James P. and Coresh, Josef and Cusi, Daniele and {de Borst}, Martin H. and Degenhardt, Frauke and Eckardt, Kai-Uwe and Endlich, Karlhans and Evans, Michele K. and Feitosa, Mary F. and Franke, Andre and {Freitag-Wolf}, Sandra and Fuchsberger, Christian and Gampawar, Piyush and Gansevoort, Ron T. and Ghanbari, Mohsen and Ghasemi, Sahar and Giedraitis, Vilmantas and Gieger, Christian and Gudbjartsson, Daniel F. and Hallan, Stein and Hamet, Pavel and Hishida, Asahi and Ho, Kevin and Hofer, Edith and Holleczek, Bernd and Holm, Hilma and Hoppmann, Anselm and Horn, Katrin and {Hutri-K{\"a}h{\"o}nen}, Nina and Hveem, Kristian and Hwang, Shih-Jen and Ikram, M. Arfan and Josyula, Navya Shilpa and Jung, Bettina and K{\"a}h{\"o}nen, Mika and Karabegovi{\'c}, Irma and Khor, Chiea-Chuen and Koenig, Wolfgang and Kramer, Holly and Kr{\"a}mer, Bernhard K. and K{\"u}hnel, Brigitte and Kuusisto, Johanna and Laakso, Markku and Lange, Leslie A. and Lehtim{\"a}ki, Terho and Li, Man and Lieb, Wolfgang and Lind, Lars and Lindgren, Cecilia M. and Loos, Ruth J. F. and Lukas, Mary Ann and Lyytik{\"a}inen, Leo-Pekka and Mahajan, Anubha and {Matias-Garcia}, Pamela R. and Meisinger, Christa and Meitinger, Thomas and Melander, Olle and Milaneschi, Yuri and Mishra, Pashupati P. and Mononen, Nina and Morris, Andrew P. and Mychaleckyj, Josyf C. and Nadkarni, Girish N. and Naito, Mariko and Nakatochi, Masahiro and Nalls, Mike A. and Nauck, Matthias and Nikus, Kjell and Ning, Boting and Nolte, Ilja M. and Nutile, Teresa and O'Donoghue, Michelle L. and O'Connell, Jeffrey and Olafsson, Isleifur and {Orho-Melander}, Marju and Parsa, Afshin and Pendergrass, Sarah A. and Penninx, Brenda W. J. H. and Pirastu, Mario and Preuss, Michael H. and Psaty, Bruce M. and Raffield, Laura M. and Raitakari, Olli T. and Rheinberger, Myriam and Rice, Kenneth M. and Rizzi, Federica and Rosenkranz, Alexander R. and Rossing, Peter and Rotter, Jerome I. and Ruggiero, Daniela and Ryan, Kathleen A. and Sabanayagam, Charumathi and Salvi, Erika and Schmidt, Helena and Schmidt, Reinhold and Scholz, Markus and Sch{\"o}ttker, Ben and Schulz, Christina-Alexandra and Sedaghat, Sanaz and Shaffer, Christian M. and Sieber, Karsten B. and Sim, Xueling and Sims, Mario and Snieder, Harold and Stanzick, Kira J. and Thorsteinsdottir, Unnur and Stocker, Hannah and Strauch, Konstantin and Stringham, Heather M. and Sulem, Patrick and Szymczak, Silke and Taylor, Kent D. and Thio, Chris H. L. and Tremblay, Johanne and Vaccargiu, Simona and {van der Harst}, Pim and {van der Most}, Peter J. and Verweij, Niek and V{\"o}lker, Uwe and Wakai, Kenji and Waldenberger, Melanie and Wallentin, Lars and Wallner, Stefan and Wang, Judy and Waterworth, Dawn M. and White, Harvey D. and Willer, Cristen J. and Wong, Tien-Yin and Woodward, Mark and Yang, Qiong and {Yerges-Armstrong}, Laura M. and Zimmermann, Martina and Zonderman, Alan B. and Bergler, Tobias and Stefansson, Kari and B{\"o}ger, Carsten A. and Pattaro, Cristian and K{\"o}ttgen, Anna and Kronenberg, Florian and Heid, Iris M.},
  year = {2022},
  month = sep,
  journal = {Kidney International},
  volume = {102},
  number = {3},
  pages = {624--639},
  issn = {0085-2538},
  doi = {10.1016/j.kint.2022.05.021},
  urldate = {2024-08-14},
  abstract = {Estimated glomerular filtration rate (eGFR) reflects kidney function. Progressive eGFR-decline can lead to kidney failure, necessitating dialysis or transplantation. Hundreds of loci from genome-wide association studies (GWAS) for eGFR help explain population cross section variability. Since the contribution of these or other loci to eGFR-decline remains largely unknown, we derived GWAS for annual eGFR-decline and meta-analyzed 62 longitudinal studies with eGFR assessed twice over time in all 343,339 individuals and in high-risk groups. We also explored different covariate adjustment. Twelve genome-wide significant independent variants for eGFR-decline unadjusted or adjusted for eGFR-baseline (11 novel, one known for this phenotype), including nine variants robustly associated across models were identified. All loci for eGFR-decline were known for cross-sectional eGFR and thus distinguished a subgroup of eGFR loci. Seven of the nine variants showed variant-by-age interaction on eGFR cross section (further about 350,000 individuals), which linked genetic associations for eGFR-decline with age-dependency of genetic cross-section associations. Clinically important were two to four-fold greater genetic effects on eGFR-decline in high-risk subgroups. Five variants associated also with chronic kidney disease progression mapped to genes with functional in-silico evidence (UMOD, SPATA7, GALNTL5, TPPP). An unfavorable versus favorable nine-variant genetic profile showed increased risk odds ratios of 1.35 for kidney failure (95\% confidence intervals 1.03-1.77) and 1.27 for acute kidney injury (95\% confidence intervals 1.08-1.50) in over 2000 cases each, with matched controls). Thus, we provide a large data resource, genetic loci, and prioritized genes for kidney function decline, which help inform drug development pipelines revealing important insights into the age-dependency of kidney function genetics.},
  keywords = {acute kidney injury,chronic kidney disease,diabetes,gene expression},
  file = {/Users/xx20081/Zotero/storage/TRQVE9GF/Gorski et al. - 2022 - Genetic loci and prioritization of genes for kidne.pdf;/Users/xx20081/Zotero/storage/ZKTQLPVL/S0085253822004549.html}
}

@article{goudswaardUsingTrialsCaloric2023,
  title = {Using Trials of Caloric Restriction and Bariatric Surgery to Explore the Effects of Body Mass Index on the Circulating Proteome},
  author = {Goudswaard, Lucy J. and Smith, Madeleine L. and Hughes, David A. and Taylor, Roy and Lean, Michael and Sattar, Naveed and Welsh, Paul and McConnachie, Alex and Blazeby, Jane M. and Rogers, Chris A. and Suhre, Karsten and Zaghlool, Shaza B. and Hers, Ingeborg and Timpson, Nicholas J. and Corbin, Laura J.},
  year = {2023},
  month = nov,
  journal = {Scientific Reports},
  volume = {13},
  pages = {21077},
  doi = {10.1038/s41598-023-47030-x},
  urldate = {2025-04-11},
  abstract = {Thousands of proteins circulate in the bloodstream; identifying those which associate with weight and intervention-induced weight loss may help explain mechanisms of diseases associated with adiposity. We aimed to identify consistent protein ...},
  langid = {english},
  pmid = {38030643},
  file = {/Users/xx20081/Zotero/storage/D3L2STFB/Goudswaard et al. - 2023 - Using trials of caloric restriction and bariatric surgery to explore the effects of body mass index.pdf}
}

@article{grahamPowerGeneticDiversity2021,
  title = {The Power of Genetic Diversity in Genome-Wide Association Studies of Lipids},
  author = {Graham, Sarah E. and Clarke, Shoa L. and Wu, Kuan-Han H. and Kanoni, Stavroula and Zajac, Greg J. M. and Ramdas, Shweta and Surakka, Ida and Ntalla, Ioanna and Vedantam, Sailaja and Winkler, Thomas W. and Locke, Adam E. and Marouli, Eirini and Hwang, Mi Yeong and Han, Sohee and Narita, Akira and Choudhury, Ananyo and Bentley, Amy R. and Ekoru, Kenneth and Verma, Anurag and Trivedi, Bhavi and Martin, Hilary C. and Hunt, Karen A. and Hui, Qin and Klarin, Derek and Zhu, Xiang and Thorleifsson, Gudmar and Helgadottir, Anna and Gudbjartsson, Daniel F. and Holm, Hilma and Olafsson, Isleifur and Akiyama, Masato and Sakaue, Saori and Terao, Chikashi and Kanai, Masahiro and Zhou, Wei and Brumpton, Ben M. and Rasheed, Humaira and Ruotsalainen, Sanni E. and Havulinna, Aki S. and Veturi, Yogasudha and Feng, QiPing and Rosenthal, Elisabeth A. and Lingren, Todd and Pacheco, Jennifer Allen and Pendergrass, Sarah A. and Haessler, Jeffrey and Giulianini, Franco and Bradford, Yuki and Miller, Jason E. and Campbell, Archie and Lin, Kuang and Millwood, Iona Y. and Hindy, George and Rasheed, Asif and Faul, Jessica D. and Zhao, Wei and Weir, David R. and Turman, Constance and Huang, Hongyan and Graff, Mariaelisa and Mahajan, Anubha and Brown, Michael R. and Zhang, Weihua and Yu, Ketian and Schmidt, Ellen M. and Pandit, Anita and Gustafsson, Stefan and Yin, Xianyong and Luan, Jian'an and Zhao, Jing-Hua and Matsuda, Fumihiko and Jang, Hye-Mi and Yoon, Kyungheon and {Medina-Gomez}, Carolina and Pitsillides, Achilleas and Hottenga, Jouke Jan and Willemsen, Gonneke and Wood, Andrew R. and Ji, Yingji and Gao, Zishan and Haworth, Simon and Mitchell, Ruth E. and Chai, Jin Fang and Aadahl, Mette and Yao, Jie and Manichaikul, Ani and Warren, Helen R. and Ramirez, Julia and {Bork-Jensen}, Jette and K{\aa}rhus, Line L. and Goel, Anuj and {Sabater-Lleal}, Maria and Noordam, Raymond and Sidore, Carlo and Fiorillo, Edoardo and McDaid, Aaron F. and {Marques-Vidal}, Pedro and Wielscher, Matthias and Trompet, Stella and Sattar, Naveed and M{\o}llehave, Line T. and Thuesen, Betina H. and Munz, Matthias and Zeng, Lingyao and Huang, Jianfeng and Yang, Bin and Poveda, Alaitz and Kurbasic, Azra and Lamina, Claudia and Forer, Lukas and Scholz, Markus and Galesloot, Tessel E. and Bradfield, Jonathan P. and Daw, E. Warwick and Zmuda, Joseph M. and Mitchell, Jonathan S. and Fuchsberger, Christian and Christensen, Henry and Brody, Jennifer A. and Feitosa, Mary F. and Wojczynski, Mary K. and Preuss, Michael and Mangino, Massimo and Christofidou, Paraskevi and Verweij, Niek and Benjamins, Jan W. and Engmann, Jorgen and Kember, Rachel L. and Slieker, Roderick C. and Lo, Ken Sin and Zilhao, Nuno R. and Le, Phuong and Kleber, Marcus E. and Delgado, Graciela E. and Huo, Shaofeng and Ikeda, Daisuke D. and Iha, Hiroyuki and Yang, Jian and Liu, Jun and Leonard, Hampton L. and Marten, Jonathan and Schmidt, B{\"o}rge and Arendt, Marina and Smyth, Laura J. and {Ca{\~n}adas-Garre}, Marisa and Wang, Chaolong and Nakatochi, Masahiro and Wong, Andrew and {Hutri-K{\"a}h{\"o}nen}, Nina and Sim, Xueling and Xia, Rui and {Huerta-Chagoya}, Alicia and {Fernandez-Lopez}, Juan Carlos and Lyssenko, Valeriya and Ahmed, Meraj and Jackson, Anne U. and Yousri, Noha A. and Irvin, Marguerite R. and Oldmeadow, Christopher and Kim, Han-Na and Ryu, Seungho and Timmers, Paul R. H. J. and Arbeeva, Liubov and Dorajoo, Rajkumar and Lange, Leslie A. and Chai, Xiaoran and Prasad, Gauri and {Lor{\'e}s-Motta}, Laura and Pauper, Marc and Long, Jirong and Li, Xiaohui and Theusch, Elizabeth and Takeuchi, Fumihiko and Spracklen, Cassandra N. and Loukola, Anu and Bollepalli, Sailalitha and Warner, Sophie C. and Wang, Ya Xing and Wei, Wen B. and Nutile, Teresa and Ruggiero, Daniela and Sung, Yun Ju and Hung, Yi-Jen and Chen, Shufeng and Liu, Fangchao and Yang, Jingyun and Kentistou, Katherine A. and Gorski, Mathias and Brumat, Marco and Meidtner, Karina and Bielak, Lawrence F. and Smith, Jennifer A. and Hebbar, Prashantha and Farmaki, Aliki-Eleni and Hofer, Edith and Lin, Maoxuan and Xue, Chao and Zhang, Jifeng and Concas, Maria Pina and Vaccargiu, Simona and {van der Most}, Peter J. and Pitk{\"a}nen, Niina and Cade, Brian E. and Lee, Jiwon and {van der Laan}, Sander W. and Chitrala, Kumaraswamy Naidu and Weiss, Stefan and Zimmermann, Martina E. and Lee, Jong Young and Choi, Hyeok Sun and Nethander, Maria and {Freitag-Wolf}, Sandra and Southam, Lorraine and Rayner, Nigel W. and Wang, Carol A. and Lin, Shih-Yi and Wang, Jun-Sing and Couture, Christian and Lyytik{\"a}inen, Leo-Pekka and Nikus, Kjell and {Cuellar-Partida}, Gabriel and Vestergaard, Henrik and Hildalgo, Bertha and Giannakopoulou, Olga and Cai, Qiuyin and Obura, Morgan O. and {van Setten}, Jessica and Li, Xiaoyin and Schwander, Karen and Terzikhan, Natalie and Shin, Jae Hun and Jackson, Rebecca D. and Reiner, Alexander P. and Martin, Lisa Warsinger and Chen, Zhengming and Li, Liming and Highland, Heather M. and Young, Kristin L. and Kawaguchi, Takahisa and Thiery, Joachim and Bis, Joshua C. and Nadkarni, Girish N. and Launer, Lenore J. and Li, Huaixing and Nalls, Mike A. and Raitakari, Olli T. and Ichihara, Sahoko and Wild, Sarah H. and Nelson, Christopher P. and Campbell, Harry and J{\"a}ger, Susanne and Nabika, Toru and {Al-Mulla}, Fahd and Niinikoski, Harri and Braund, Peter S. and Kolcic, Ivana and Kovacs, Peter and Giardoglou, Tota and Katsuya, Tomohiro and Bhatti, Konain Fatima and {de Kleijn}, Dominique and {de Borst}, Gert J. and Kim, Eung Kweon and Adams, Hieab H. H. and Ikram, M. Arfan and Zhu, Xiaofeng and Asselbergs, Folkert W. and Kraaijeveld, Adriaan O. and Beulens, Joline W. J. and Shu, Xiao-Ou and Rallidis, Loukianos S. and Pedersen, Oluf and Hansen, Torben and Mitchell, Paul and Hewitt, Alex W. and K{\"a}h{\"o}nen, Mika and P{\'e}russe, Louis and Bouchard, Claude and T{\"o}njes, Anke and Chen, Yii-Der Ida and Pennell, Craig E. and Mori, Trevor A. and Lieb, Wolfgang and Franke, Andre and Ohlsson, Claes and Mellstr{\"o}m, Dan and Cho, Yoon Shin and Lee, Hyejin and Yuan, Jian-Min and Koh, Woon-Puay and Rhee, Sang Youl and Woo, Jeong-Taek and Heid, Iris M. and Stark, Klaus J. and V{\"o}lzke, Henry and Homuth, Georg and Evans, Michele K. and Zonderman, Alan B. and Polasek, Ozren and Pasterkamp, Gerard and Hoefer, Imo E. and Redline, Susan and Pahkala, Katja and Oldehinkel, Albertine J. and Snieder, Harold and Biino, Ginevra and Schmidt, Reinhold and Schmidt, Helena and Chen, Y. Eugene and Bandinelli, Stefania and Dedoussis, George and Thanaraj, Thangavel Alphonse and Kardia, Sharon L. R. and Kato, Norihiro and Schulze, Matthias B. and Girotto, Giorgia and Jung, Bettina and B{\"o}ger, Carsten A. and Joshi, Peter K. and Bennett, David A. and De Jager, Philip L. and Lu, Xiangfeng and Mamakou, Vasiliki and Brown, Morris and Caulfield, Mark J. and Munroe, Patricia B. and Guo, Xiuqing and Ciullo, Marina and Jonas, Jost B. and Samani, Nilesh J. and Kaprio, Jaakko and Pajukanta, P{\"a}ivi and Adair, Linda S. and Bechayda, Sonny Augustin and {de Silva}, H. Janaka and Wickremasinghe, Ananda R. and Krauss, Ronald M. and Wu, Jer-Yuarn and Zheng, Wei and {den Hollander}, Anneke I. and Bharadwaj, Dwaipayan and Correa, Adolfo and Wilson, James G. and Lind, Lars and Heng, Chew-Kiat and Nelson, Amanda E. and Golightly, Yvonne M. and Wilson, James F. and Penninx, Brenda and Kim, Hyung-Lae and Attia, John and Scott, Rodney J. and Rao, D. C. and Arnett, Donna K. and Hunt, Steven C. and Walker, Mark and Koistinen, Heikki A. and Chandak, Giriraj R. and Yajnik, Chittaranjan S. and Mercader, Josep M. and {Tusi{\'e}-Luna}, Teresa and {Aguilar-Salinas}, Carlos A. and Villalpando, Clicerio Gonzalez and Orozco, Lorena and Fornage, Myriam and Tai, E. Shyong and {van Dam}, Rob M. and Lehtim{\"a}ki, Terho and Chaturvedi, Nish and Yokota, Mitsuhiro and Liu, Jianjun and Reilly, Dermot F. and McKnight, Amy Jayne and Kee, Frank and J{\"o}ckel, Karl-Heinz and McCarthy, Mark I. and Palmer, Colin N. A. and Vitart, Veronique and Hayward, Caroline and Simonsick, Eleanor and {van Duijn}, Cornelia M. and Lu, Fan and Qu, Jia and Hishigaki, Haretsugu and Lin, Xu and M{\"a}rz, Winfried and Parra, Esteban J. and Cruz, Miguel and Gudnason, Vilmundur and Tardif, Jean-Claude and Lettre, Guillaume and {'t Hart}, Leen M. and Elders, Petra J. M. and Damrauer, Scott M. and Kumari, Meena and Kivimaki, Mika and {van der Harst}, Pim and Spector, Tim D. and Loos, Ruth J. F. and Province, Michael A. and Psaty, Bruce M. and Brandslund, Ivan and Pramstaller, Peter P. and Christensen, Kaare and Ripatti, Samuli and Wid{\'e}n, Elisabeth and Hakonarson, Hakon and Grant, Struan F. A. and Kiemeney, Lambertus A. L. M. and {de Graaf}, Jacqueline and Loeffler, Markus and Kronenberg, Florian and Gu, Dongfeng and Erdmann, Jeanette and Schunkert, Heribert and Franks, Paul W. and Linneberg, Allan and Jukema, J. Wouter and Khera, Amit V. and M{\"a}nnikk{\"o}, Minna and Jarvelin, Marjo-Riitta and Kutalik, Zoltan and Cucca, Francesco and {Mook-Kanamori}, Dennis O. and {van Dijk}, Ko Willems and Watkins, Hugh and Strachan, David P. and Grarup, Niels and Sever, Peter and Poulter, Neil and Rotter, Jerome I. and Dantoft, Thomas M. and Karpe, Fredrik and Neville, Matt J. and Timpson, Nicholas J. and Cheng, Ching-Yu and Wong, Tien-Yin and Khor, Chiea Chuen and Sabanayagam, Charumathi and Peters, Annette and Gieger, Christian and Hattersley, Andrew T. and Pedersen, Nancy L. and Magnusson, Patrik K. E. and Boomsma, Dorret I. and {de Geus}, Eco J. C. and Cupples, L. Adrienne and {van Meurs}, Joyce B. J. and Ghanbari, Mohsen and {Gordon-Larsen}, Penny and Huang, Wei and Kim, Young Jin and Tabara, Yasuharu and Wareham, Nicholas J. and Langenberg, Claudia and Zeggini, Eleftheria and Kuusisto, Johanna and Laakso, Markku and Ingelsson, Erik and Abecasis, Goncalo and Chambers, John C. and Kooner, Jaspal S. and {de Vries}, Paul S. and Morrison, Alanna C. and North, Kari E. and Daviglus, Martha and Kraft, Peter and Martin, Nicholas G. and Whitfield, John B. and Abbas, Shahid and Saleheen, Danish and Walters, Robin G. and Holmes, Michael V. and Black, Corri and Smith, Blair H. and Justice, Anne E. and Baras, Aris and Buring, Julie E. and Ridker, Paul M. and Chasman, Daniel I. and Kooperberg, Charles and Wei, Wei-Qi and Jarvik, Gail P. and Namjou, Bahram and Hayes, M. Geoffrey and Ritchie, Marylyn D. and Jousilahti, Pekka and Salomaa, Veikko and Hveem, Kristian and {\AA}svold, Bj{\o}rn Olav and Kubo, Michiaki and Kamatani, Yoichiro and Okada, Yukinori and Murakami, Yoshinori and Thorsteinsdottir, Unnur and Stefansson, Kari and Ho, Yuk-Lam and Lynch, Julie A. and Rader, Daniel J. and Tsao, Philip S. and Chang, Kyong-Mi and Cho, Kelly and O'Donnell, Christopher J. and Gaziano, John M. and Wilson, Peter and Rotimi, Charles N. and Hazelhurst, Scott and Ramsay, Mich{\`e}le and Trembath, Richard C. and {van Heel}, David A. and Tamiya, Gen and Yamamoto, Masayuki and Kim, Bong-Jo and Mohlke, Karen L. and Frayling, Timothy M. and Hirschhorn, Joel N. and Kathiresan, Sekar and Boehnke, Michael and Natarajan, Pradeep and Peloso, Gina M. and Brown, Christopher D. and Morris, Andrew P. and Assimes, Themistocles L. and Deloukas, Panos and Sun, Yan V. and Willer, Cristen J.},
  year = {2021},
  month = dec,
  journal = {Nature},
  volume = {600},
  number = {7890},
  pages = {675--679},
  publisher = {Nature Publishing Group},
  issn = {1476-4687},
  doi = {10.1038/s41586-021-04064-3},
  urldate = {2024-09-02},
  abstract = {Increased blood lipid levels are heritable risk factors of cardiovascular disease with varied prevalence worldwide owing to different dietary patterns and medication use1. Despite advances in prevention and treatment, in particular through reducing low-density lipoprotein cholesterol levels2, heart disease remains the leading cause of death worldwide3. Genome-wideassociation studies (GWAS) of blood lipid levels have led to important biological and clinical insights, as well as new drug targets, for cardiovascular disease. However, most previous GWAS4--23 have been conducted in European ancestry populations and may have missed genetic variants that contribute to lipid-level variation in other ancestry groups. These include differences in allele frequencies, effect sizes and linkage-disequilibrium patterns24. Here we conduct a multi-ancestry, genome-wide genetic discovery meta-analysis of lipid levels in approximately 1.65\,million individuals, including 350,000 of non-European ancestries. We quantify the gain in studying non-European ancestries and provide evidence to support the expansion of recruitment of additional ancestries, even with relatively small sample sizes. We find that increasing diversity rather than studying additional individuals of European ancestry results in substantial improvements in fine-mapping functional variants and portability of polygenic prediction (evaluated in approximately\,295,000 individuals from 7\,ancestry groupings). Modest gains in the number of discovered loci and ancestry-specific variants were also achieved. As GWAS expand emphasis beyond the identification of genes and fundamental biology towards the use of genetic variants for preventive and precision medicine25, we anticipate that increased diversity of participants will lead to more accurate and equitable26 application of polygenic scores in clinical practice.},
  copyright = {2021 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  keywords = {Computational models,Genome-wide association studies,Preventive medicine,Risk factors},
  file = {/Users/xx20081/Zotero/storage/ZVPF5H8V/Graham et al. - 2021 - The power of genetic diversity in genome-wide asso.pdf}
}

@article{grangerEffectsCandesartanPatients2003,
  title = {Effects of Candesartan in Patients with Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The {{CHARM-Alternative}} Trial},
  shorttitle = {Effects of Candesartan in Patients with Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors},
  author = {Granger, Christopher B. and McMurray, John J. V. and Yusuf, Salim and Held, Peter and Michelson, Eric L. and Olofsson, Bertil and Ostergren, Jan and Pfeffer, Marc A. and Swedberg, Karl and {CHARM Investigators and Committees}},
  year = {2003},
  month = sep,
  journal = {Lancet (London, England)},
  volume = {362},
  number = {9386},
  pages = {772--776},
  issn = {1474-547X},
  doi = {10.1016/S0140-6736(03)14284-5},
  abstract = {BACKGROUND: Angiotensin-converting-enzyme (ACE) inhibitors improve outcome of patients with chronic heart failure (CHF). A substantial proportion of patients, however, experience no benefit from ACE inhibitors because of previous intolerance. We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in such patients not taking an ACE inhibitor. METHODS: Between March, 1999, and March, 2001, we enrolled 2028 patients with symptomatic heart failure and left-ventricular ejection fraction 40\% or less who were not receiving ACE inhibitors because of previous intolerance. Patients were randomly assigned candesartan (target dose 32 mg once daily) or matching placebo. The primary outcome of the study was the composite of cardiovascular death or hospital admission for CHF. Analysis was by intention to treat. FINDINGS: The most common manifestation of ACE-inhibitor intolerance was cough (72\%), followed by symptomatic hypotension (13\%) and renal dysfunction (12\%). During a median follow-up of 33.7 months, 334 (33\%) of 1013 patients in the candesartan group and 406 (40\%) of 1015 in the placebo group had cardiovascular death or hospital admission for CHF (unadjusted hazard ratio 0.77 [95\% CI 0.67-0.89], p=0.0004; covariate adjusted 0.70 [0.60-0.81], p{$<$}0.0001). Each component of the primary outcome was reduced, as was the total number of hospital admissions for CHF. Study-drug discontinuation rates were similar in the candesartan (30\%) and placebo (29\%) groups. INTERPRETATION: Candesartan was generally well tolerated and reduced cardiovascular mortality and morbidity in patients with symptomatic chronic heart failure and intolerance to ACE inhibitors.},
  langid = {english},
  pmid = {13678870},
  keywords = {Aged,Angiotensin Receptor Antagonists,Angiotensin-Converting Enzyme Inhibitors,Antihypertensive Agents,Benzimidazoles,Biphenyl Compounds,Cardiac Output Low,Comorbidity,Cough,Female,Follow-Up Studies,Heart Failure,Humans,Hypotension,Kidney Diseases,Male,Tetrazoles,Treatment Outcome,Ventricular Dysfunction Left},
  file = {/Users/xx20081/Zotero/storage/35X6S867/Granger et al. - 2003 - Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic.pdf}
}

@article{grassiEffectsHypertensionObesity2003,
  title = {Effects of Hypertension and Obesity on the Sympathetic Activation of Heart Failure Patients},
  author = {Grassi, Guido and Seravalle, Gino and {Quarti-Trevano}, Fosca and Dell'Oro, Raffaella and Bolla, Gianbattista and Mancia, Giuseppe},
  year = {2003},
  month = nov,
  journal = {Hypertension (Dallas, Tex.: 1979)},
  volume = {42},
  number = {5},
  pages = {873--877},
  issn = {1524-4563},
  doi = {10.1161/01.HYP.0000098660.26184.63},
  abstract = {Previous studies have shown that congestive heart failure is characterized by sympathetic and reflex dysfunctions. Whether these alterations are potentiated in the presence of obesity and hypertension, two conditions that also display neuroadrenergic abnormalities and markedly increase the risk of heart failure, is unknown. In 14 healthy control subjects (C; age, 55.1+/-3.0 years; mean+/-SEM), 13 lean hypertensive subjects (H), 15 obese normotensive subjects (O), 14 lean normotensive subjects with congestive heart failure (CHF, New York Heart Association class II), 14 lean hypertensive subjects with CHF (CHFH), 14 obese normotensive subjects with CHF (CHFO), and 13 obese hypertensive subjects with CHF (CHFOH), all age-matched with C, we measured mean blood pressure (Finapres), heart rate (ECG), and muscle sympathetic nerve traffic (MSNA, microneurography) at rest and during baroreflex testing. Compared with C, body mass index was similarly increased in O, CHFO, and CHFOH, whereas mean blood pressure was similarly increased in HF, CHFH, and CHFOH, and left ventricular ejection fraction (echocardiography) was similarly reduced in CHF, CHFH, CHFO and CHFOH. Compared with C, MSNA was significantly increased in O, H, and CHF (43.0+/-2.2 versus 54.1+/-2.8, 53.1+/-2.5, and 57.4+/-2.8 bursts/100 heart beats, P{$<$}0.01). When O or H was combined with CHF, the MSNA increase was significantly more pronounced and maximal when O and H were concomitantly associated with CHF. Baroreflex sensitivity was reduced in O and H, with a further reduction in CHF and a minimal value in CHFOH. These data show that the sympathetic activation characterizing CHF is markedly potentiated when O and H alone or combined together are associated with a low cardiac output state and that this may depend on an arterial baroreflex impairment.},
  langid = {english},
  pmid = {14568999},
  keywords = {Blood Pressure,Heart Failure,Heart Rate,Humans,Hypertension,Male,Middle Aged,Muscles,Norepinephrine,Obesity,Pressoreceptors,Sympathetic Nervous System},
  file = {/Users/xx20081/Zotero/storage/BPVB2W98/Grassi et al. - 2003 - Effects of hypertension and obesity on the sympath.pdf}
}

@article{greggIntentionalWeightLoss2003,
  title = {Intentional Weight Loss and Death in Overweight and Obese {{U}}.{{S}}. Adults 35 Years of Age and Older},
  author = {Gregg, Edward W. and Gerzoff, Robert B. and Thompson, Theodore J. and Williamson, David F.},
  year = {2003},
  month = mar,
  journal = {Annals of Internal Medicine},
  volume = {138},
  number = {5},
  pages = {383--389},
  issn = {1539-3704},
  doi = {10.7326/0003-4819-138-5-200303040-00007},
  abstract = {BACKGROUND: Although weight loss improves risk factors for cardiovascular and metabolic disease, it is unclear whether intentional weight loss reduces mortality rates. OBJECTIVE: To examine the relationships among intention to lose weight, weight loss, and all-cause mortality. DESIGN: Prospective cohort study using a probability sample of the U.S. population. SETTING: Interviewer-administered survey. PARTICIPANTS: 6391 overweight and obese persons (body mass index {$>$} or = 25 kg/m2) who were at least 35 years of age. MEASUREMENTS: Intention to lose weight and weight change during the past year were assessed by self-report in 1989. Vital status was followed for 9 years. Hazard rate ratios (HRRs) were adjusted for age, sex, ethnicity, education, smoking, health status, health care utilization, and initial body mass index. RESULTS: Compared with persons not trying to lose weight and reporting no weight change, those reporting intentional weight loss had a 24\% lower mortality rate (HRR, 0.76 [95\% CI, 0.60 to 0.97]) and those with unintentional weight loss had a 31\% higher mortality rate (HRR, 1.31 [CI, 1.01 to 1.70]). However, mortality rates were lower in persons who reported trying to lose weight than those in not trying to lose weight, independent of actual weight change. Compared with persons not trying to lose weight and reporting no weight change, persons trying to lose weight had the following HRRs: no weight change, 0.80 (CI, 0.65 to 0.99); gained weight, 0.94 (CI, 0.65 to 1.37); and lost weight, 0.76 (CI, 0.60 to 0.97). CONCLUSIONS: Attempted weight loss is associated with lower all-cause mortality, independent of weight change. Self-reported intentional weight loss is associated with lower mortality rates, and weight loss is associated with higher mortality rates only if it is unintentional.},
  langid = {english},
  pmid = {12614090},
  keywords = {Adult,Female,Humans,Interviews as Topic,Male,Mortality,Obesity,Proportional Hazards Models,Prospective Studies,Risk Factors,Weight Loss}
}

@article{groenewegenEpidemiologyHeartFailure2020,
  title = {Epidemiology of Heart Failure},
  author = {Groenewegen, Amy and Rutten, Frans H. and Mosterd, Arend and Hoes, Arno W.},
  year = {2020},
  month = aug,
  journal = {European Journal of Heart Failure},
  volume = {22},
  number = {8},
  pages = {1342--1356},
  issn = {1879-0844},
  doi = {10.1002/ejhf.1858},
  abstract = {The heart failure syndrome has first been described as an emerging epidemic about 25\,years ago. Today, because of a growing and ageing population, the total number of heart failure patients still continues to rise. However, the case mix of heart failure seems to be evolving. Incidence has stabilized and may even be decreasing in some populations, but alarming opposite trends have been observed in the relatively young, possibly related to an increase in obesity. In addition, a clear transition towards heart failure with a preserved ejection fraction has occurred. Although this transition is partially artificial, due to improved recognition of heart failure as a disorder affecting the entire left ventricular ejection fraction spectrum, links can be made with the growing burden of obesity-related diseases and with the ageing of the population. Similarly, evidence suggests that the number of patients with heart failure may be on the rise in low-income countries struggling under the double burden of communicable diseases and conditions associated with a Western-type lifestyle. These findings, together with the observation that the mortality rate of heart failure is declining less rapidly than previously, indicate we have not reached the end of the epidemic yet. In this review, the evolving epidemiology of heart failure is put into perspective, to discern major trends and project future directions.},
  langid = {english},
  pmcid = {PMC7540043},
  pmid = {32483830},
  keywords = {Epidemiology,Heart failure,Heart Failure,Humans,Incidence,Medicare,Mortality,Nutrition Surveys,Prevalence,Stroke Volume,United States,Ventricular Function Left},
  file = {/Users/xx20081/Zotero/storage/IHWIHVT4/Groenewegen et al. - 2020 - Epidemiology of heart failure.pdf}
}

@misc{GTExConsortiumAtlas,
  title = {The {{GTEx Consortium}} Atlas of Genetic Regulatory Effects across Human Tissues {\textbar} {{Science}}},
  urldate = {2024-01-22},
  howpublished = {https://www.science.org/doi/10.1126/science.aaz1776},
  file = {/Users/xx20081/Zotero/storage/AMBSQWT5/science.html}
}

@article{guoCausalRelationshipAllergic2022,
  title = {The Causal Relationship between Allergic Diseases and Heart Failure: {{Evidence}} from {{Mendelian}} Randomization Study},
  shorttitle = {The Causal Relationship between Allergic Diseases and Heart Failure},
  author = {Guo, Yan-Ge and Zhang, Yan and Liu, Wei-Li},
  year = {2022},
  month = jul,
  journal = {PLoS ONE},
  volume = {17},
  number = {7},
  pages = {e0271985},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0271985},
  urldate = {2024-09-17},
  abstract = {Background Emerging evidence shows allergic diseases, such as atopic dermatitis and asthma, are risk factors of heart failure. However, the causal relationship between allergic diseases and heart failure is not clear. Methods We performed a two-sample Mendelian randomization analysis between allergic diseases and heart failure using summary statistics of genome-wide association studies from large GWAS consortia, with total sample size of 1.2 million. Independent instrumental variables for asthma and atopic dermatitis (P{$<$}1{\texttimes}10-5) were used as the exposure. We applied five models for the Mendelian randomization analysis. Finally, we performed the sensitivity analyses to assess the robustness of the results. Results We have identified 55 independent single nucleotide polymorphisms (SNPs) for asthma 54 independent SNPs for atopic dermatitis as our instrumental variables. The inverse variance-weighted (IVW) analysis showed asthma was significantly associated with increased risk of heart failure (ORIVW = 1.04, 95\% CI, 1.01--1.07, P = 0.03). The Mendelian randomization analysis using the other four models also showed consistent results with the IVW analysis. Similarly, atopic dermatitis was also significantly associated with an increased risk of heart failure (ORIVW = 1.03, 95\% CI, 1.01--1.06, P = 0.01), consistent with the other four models. The sensitivity analysis showed no evidence of horizontal pleiotropy or results were driven by single SNPs. Conclusion Our study identified asthma and atopic dermatitis as a causal risk factor for heart failure and suggest inflammatory pathogenesis as a key factor contributing to the underlying mechanism. These findings emphasize the importance of asthma and allergy control in the prevention and management of heart failure.},
  pmcid = {PMC9337678},
  pmid = {35905078},
  file = {/Users/xx20081/Zotero/storage/IBLVFCEQ/Guo et al. - 2022 - The causal relationship between allergic diseases .pdf}
}

@article{guoObesityParadoxPatients2022,
  title = {The ``{{Obesity Paradox}}'' in {{Patients With HFpEF With}} or {{Without Comorbid Atrial Fibrillation}}},
  author = {Guo, Linjuan and Liu, Xiao and Yu, Peng and Zhu, Wengen},
  year = {2022},
  month = jan,
  journal = {Frontiers in Cardiovascular Medicine},
  volume = {8},
  publisher = {Frontiers},
  issn = {2297-055X},
  doi = {10.3389/fcvm.2021.743327},
  urldate = {2025-01-07},
  abstract = {{$<$}p{$><$}bold{$>$}Background:{$<$}/bold{$>$} Overweight and mildly obese individuals have a lower risk of death than their normal-weight counterparts; this phenomenon is termed ``obesity paradox.'' Whether this ``obesity paradox'' exists in patients with heart failure (HF) or can be modified by comorbidities is still controversial. Our current study aimed to determine the association of body mass index (BMI) with outcomes with patients with HF with preserved ejection fraction (HFpEF) with or without coexisting atrial fibrillation (AF).{$<$}/p{$><$}p{$><$}bold{$>$}Methods:{$<$}/bold{$>$} Patients with HFpEF from the Americas in the TOPCAT trial were categorized into the 3 groups: normal weight (18.5--24.9 kg/m\textsuperscript{2}), overweight (25.0--29.9 kg/m\textsuperscript{2}), and obesity ({$\geq$}30 kg/m\textsuperscript{2}). The Cox proportional-hazards models were used to calculate the adjusted hazard ratios (HRs) and CIs.{$<$}/p{$><$}p{$><$}bold{$>$}Results:{$<$}/bold{$>$} We identified 1,749 patients with HFpEF, 42.1\% of which had baseline AF. In the total population of HFpEF, both overweight (HR = 0.59, 95\% CI: 0.42--0.83) and obesity (HR = 0.49, 95\% CI: 0.35--0.69) were associated with a reduced risk of all-cause death. Among patients with HFpEF without AF, overweight (HR = 0.51, 95\% CI: 0.27--0.95) and obesity (HR = 0.64, 95\% CI: 0.43--0.98) were associated with a lower risk of all-cause death. In those with AF, obesity (HR = 0.62, 95\% CI: 0.40--0.95) but not overweight (HR = 0.81, 95\% CI: 0.54--1.21) was associated with a decreased risk of all-cause death.{$<$}/p{$><$}p{$><$}bold{$>$}Conclusions:{$<$}/bold{$>$} The ``obesity paradox'' assessed by BMI exists in patients with HFpEF regardless of comorbid AF.{$<$}/p{$><$}p{$><$}bold{$>$}Clinical Trial Registration:{$<$}/bold{$><$}ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink"{$>$}https://clinicaltrials.gov{$<$}/ext-link{$>$}, identifier: NCT00094302.{$<$}/p{$>$}},
  langid = {english},
  keywords = {Atrial Fibrillation,Body Mass Index,Heart Failure,Obesity paradox,Outcome},
  file = {/Users/xx20081/Zotero/storage/MCDNA8KQ/Guo et al. - 2022 - The Obesity Paradox in Patients With HFpEF With or Without Comorbid Atrial Fibrillation.pdf}
}

@article{guoSMRPortalOnlinePlatform2024,
  title = {{{SMR-Portal}}: An Online Platform for Integrative Analysis of {{GWAS}} and {{xQTL}} Data to Identify Complex Trait Genes},
  shorttitle = {{{SMR-Portal}}},
  author = {Guo, Yazhou and Xu, Tao and Luo, Jie and Jiang, Zhuqing and Chen, Wenhao and Chen, Hui and Qi, Ting and Yang, Jian},
  year = {2024},
  month = dec,
  journal = {Nature Methods},
  pages = {1--3},
  publisher = {Nature Publishing Group},
  issn = {1548-7105},
  doi = {10.1038/s41592-024-02561-7},
  urldate = {2025-01-22},
  copyright = {2024 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  keywords = {Genetic databases,Population genetics,Quantitative trait,Software},
  file = {/Users/xx20081/Zotero/storage/JPUJIIGH/Guo et al. - 2024 - SMR-Portal an online platform for integrative analysis of GWAS and xQTL data to identify complex tr.pdf}
}

@article{haassBodyMassIndex2011,
  title = {Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients with Preserved Ejection Fraction: Results from the {{Irbesartan}} in {{Heart Failure}} with {{Preserved Ejection Fraction}} ({{I-PRESERVE}}) Trial},
  shorttitle = {Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients with Preserved Ejection Fraction},
  author = {Haass, Markus and Kitzman, Dalane W. and Anand, Inder S. and Miller, Alan and Zile, Michael R. and Massie, Barry M. and Carson, Peter E.},
  year = {2011},
  month = may,
  journal = {Circulation. Heart Failure},
  volume = {4},
  number = {3},
  pages = {324--331},
  issn = {1941-3297},
  doi = {10.1161/CIRCHEARTFAILURE.110.959890},
  abstract = {BACKGROUND: Obesity is a major risk factor for incident heart failure (HF). Paradoxically, in HF with reduced left ventricular ejection fraction (HFREF), a high body mass index (BMI) appears to be beneficial. Approximately 50\% of HF patients have a preserved left ventricular ejection fraction (HFPEF). However, there are few data regarding the relationship between BMI and outcomes in HFPEF. METHODS AND RESULTS: Baseline characteristics and cardiovascular outcomes were assessed in the 4109 patients (mean age, 72 years; mean follow-up, 49.5 months) in the Irbesartan in HF with Preserved Ejection Fraction (I-PRESERVE) trial. Based on the BMI distribution, 5 BMI categories were defined: {$<$}23.5, 23.5 to 26.4, 26.5 to 30.9, 31 to 34.9, and {$\geq$}35 kg/m(2). Most patients (71\%) had a BMI {$\geq$}26.5, 21\% had a BMI between 23.5 and 26.4, and 8\% had a BMI {$<$}23.5 kg/m(2). Patients with higher BMI were younger, more often women, and more likely to have hypertension and diabetes and higher left ventricular ejection fraction. Patients with BMI of 26.5 to 30.9 kg/m(2) had the lowest rate for the primary composite outcome (death or cardiovascular hospitalization) and were used as reference group. After adjustment for 21 risk variables including age, sex, and N-terminal pro-brain natriuretic peptide, the hazard ratio for the primary outcome was increased in patients with BMI {$<$}23.5 (hazard ratio, 1.27; 95\% confidence interval, 1.04 to 1.56; P=0.019) and in those with BMI {$\geq$}35 kg/m(2) (hazard ratio, 1.27; 95\% confidence interval, 1.06 to 1.52; P=0.011) compared with the referent group. A similar relationship was found for all-cause mortality and for HF hospitalization. CONCLUSIONS: Obesity is common in HFPEF patients and is accompanied by multiple differences in clinical characteristics. Independent of other key prognostic variables, there was a U-shaped relationship, with the greatest rate of adverse outcomes in the lowest and highest BMI categories. CLINICAL TRIAL REGISTRATION- URL: http://www.clinicaltrials.gov. Unique identifier: NCT000095238.},
  langid = {english},
  pmcid = {PMC3100162},
  pmid = {21350053},
  keywords = {Aged,Angiotensin II Type 1 Receptor Blockers,Biphenyl Compounds,Body Mass Index,Cardiovascular Diseases,Female,Heart Failure,Humans,Irbesartan,Male,Middle Aged,Obesity,Prognosis,Stroke Volume,Tetrazoles},
  file = {/Users/xx20081/Zotero/storage/283F8RMU/Haass et al. - 2011 - Body mass index and adverse cardiovascular outcome.pdf}
}

@article{haassBodyMassIndex2011a,
  title = {Body {{Mass Index}} and {{Adverse Cardiovascular Outcomes}} in {{Heart Failure Patients}} with {{Preserved Ejection Fraction}}: {{Results}} from the {{I-PRESERVE Trial}}},
  shorttitle = {Body {{Mass Index}} and {{Adverse Cardiovascular Outcomes}} in {{Heart Failure Patients}} with {{Preserved Ejection Fraction}}},
  author = {Haass, Markus and Kitzman, Dalane W. and Anand, Inder S. and Miller, Alan and Zile, Michael R. and Massie, Barry M. and Carson, Peter E.},
  year = {2011},
  month = may,
  journal = {Circulation. Heart failure},
  volume = {4},
  number = {3},
  pages = {324--331},
  issn = {1941-3289},
  doi = {10.1161/CIRCHEARTFAILURE.110.959890},
  urldate = {2024-08-08},
  abstract = {Background Obesity is a major risk factor for incident heart failure (HF). Paradoxically, in HF with reduced left ventricular ejection fraction (HFREF) a high body mass index (BMI) appears to be beneficial. Approximately 50\% of HF patients have a preserved LVEF (HFPEF). However, there are few data regarding the relationship between BMI and outcomes in HFPEF. Methods and Results Baseline characteristics and cardiovascular (CV) outcomes were assessed in the 4,109 patients (mean age 72 years, mean follow-up 49.5 months) in the irbesartan in HF with preserved ejection fraction (I-PRESERVE) trial. Based on the BMI distribution 5 BMI categories were defined: {$<$} 23.5, 23.5--26.4, 26.5--30.9, 31--34.9, and {$\geq$} 35 kg/m2. Most patients (71\%) had a BMI {$\geq$} 26.5, 21\% had a BMI between 23.5 and 26.4, and 8\% had a BMI {$<$} 23.5 kg/m2. Patients with higher BMI were younger, more often women, and more likely to have hypertension and diabetes, and higher LVEFs. Patients with BMI of 26.5--30.9 kg/m2 had the lowest rate for the primary composite outcome (death or CV hospitalization) and were used as reference group. After adjustment for 21 risk variables including age, gender, and NT-proBNP, the hazard ratio (HR) for the primary outcome was increased in patients with BMI {$<$} 23.5 (HR 1.27; CI 1.04--1.56; p = 0.019), and in those with BMI {$\geq$} 35 (HR 1.27; CI 1.06--1.52; p = 0.011), compared to the referent group. A similar relationship was found for all-cause mortality and for HF hospitalization. Conclusions Obesity is common in HFPEF patients and is accompanied by multiple differences in clinical characteristics. Independent of other key prognostic variables, there was a U-shaped relationship, with the greatest rate of adverse outcomes in the lowest and highest BMI categories.},
  pmcid = {PMC3100162},
  pmid = {21350053},
  file = {/Users/xx20081/Zotero/storage/ZH797XNK/Haass et al. - 2011 - Body Mass Index and Adverse Cardiovascular Outcome.pdf}
}

@article{hakanssonGeneticAssociationsRegulation2019,
  title = {Genetic Associations and Regulation of Expression Indicate an Independent Role for 14q32 {{snoRNAs}} in Human Cardiovascular Disease},
  author = {H{\aa}kansson, Kjell E J and Goossens, Eveline A C and Trompet, Stella and {van Ingen}, Eva and {de Vries}, Margreet R and {van der Kwast}, Reginald V C T and Ripa, Rasmus S and Kastrup, Jens and Hohensinner, Philipp J and Kaun, Christoph and Wojta, Johann and B{\"o}hringer, Stefan and Le Cessie, Saskia and Jukema, J Wouter and Quax, Paul H A and Nossent, A Ya{\"e}l},
  year = {2019},
  month = aug,
  journal = {Cardiovascular Research},
  volume = {115},
  number = {10},
  pages = {1519--1532},
  issn = {0008-6363},
  doi = {10.1093/cvr/cvy309},
  urldate = {2024-04-12},
  abstract = {We have shown that 14q32 microRNAs are highly involved in vascular remodelling and cardiovascular disease. However, the 14q32 locus also encodes 41 `orphan' small nucleolar RNAs (snoRNAs). We aimed to gather evidence for an independent role for 14q32 snoRNAs in human cardiovascular disease.We performed a lookup of the 14q32 region within the dataset of a genome wide association scan in 5244 participants of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Single nucleotide polymorphisms (SNPs) in the snoRNA-cluster were significantly associated with heart failure. These snoRNA-cluster SNPs were not linked to SNPs in the microRNA-cluster or in MEG3, indicating that snoRNAs modify the risk of cardiovascular disease independently. We looked at expression of 14q32 snoRNAs throughout the human cardio-vasculature. Expression profiles of the 14q32 snoRNAs appeared highly vessel specific. When we compared expression levels of 14q32 snoRNAs in human vena saphena magna (VSM) with those in failed VSM-coronary bypasses, we found that 14q32 snoRNAs were up-regulated. SNORD113.2, which showed a 17-fold up-regulation in failed bypasses, was also up-regulated two-fold in plasma samples drawn from patients with ST-elevation myocardial infarction directly after hospitalization compared with 30\,days after start of treatment. However, fitting with the genomic associations, 14q32 snoRNA expression was highest in failing human hearts. In vitro studies show that the 14q32 snoRNAs bind predominantly to methyl-transferase Fibrillarin, indicating that they act through canonical mechanisms, but on non-canonical RNA targets. The canonical C/D-box snoRNA seed sequences were highly conserved between humans and mice.14q32 snoRNAs appear to play an independent role in cardiovascular pathology. 14q32 snoRNAs are specifically regulated throughout the human vasculature and their expression is up-regulated during cardiovascular disease. Our data demonstrate that snoRNAs merit increased effort and attention in future basic and clinical cardiovascular research.},
  file = {/Users/xx20081/Zotero/storage/NWHKB7JU/Hkansson et al. - 2019 - Genetic associations and regulation of expression .pdf;/Users/xx20081/Zotero/storage/5ATHD9L7/5244092.html}
}

@article{hamaguchiBodyMassIndex2010,
  title = {Body Mass Index Is an Independent Predictor of Long-Term Outcomes in Patients Hospitalized with Heart Failure in {{Japan}}},
  author = {Hamaguchi, Sanae and {Tsuchihashi-Makaya}, Miyuki and Kinugawa, Shintaro and Goto, Daisuke and Yokota, Takashi and Goto, Kazutomo and Yamada, Satoshi and Yokoshiki, Hisashi and Takeshita, Akira and Tsutsui, Hiroyuki and {JCARE-CARD Investigators}},
  year = {2010},
  month = nov,
  journal = {Circulation Journal: Official Journal of the Japanese Circulation Society},
  volume = {74},
  number = {12},
  pages = {2605--2611},
  issn = {1347-4820},
  doi = {10.1253/circj.cj-10-0599},
  abstract = {BACKGROUND: Obesity is a risk factor for cardiovascular disease (CVD) and is also associated with an increased risk of death in subjects without CVD. However, in heart failure (HF), elevated body mass index (BMI) has been shown to be associated with better prognosis, but it is unknown whether this is the case in unselected HF patients encountered in routine clinical practice in Japan. METHODS AND RESULTS: The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) studied prospectively the characteristics and treatments in a broad sample of patients hospitalized with worsening HF and the outcomes were followed for 2.1 years. Study cohort (n=2,488) was classified into 3 groups according to baseline BMI: {$<$}20.3kg/m(2) (n=829), 20.3-23.49kg/m(2) (n=832), and {$\geq$}23.5kg/m(2) (n=827). The mean BMI was 22.3{\textpm}4.1kg/m(2). Patients with higher BMI had lower rates of all-cause death, cardiac death, and rehospitalization because of worsening HF. After multivariable adjustment, the risk for all-cause death and cardiac death significantly increased with decreased BMI levels compared with patients with BMI {$\geq$}23.5kg/m(2). However, BMI levels were not associated with rehospitalization for worsening HF. CONCLUSIONS: Lower BMI was independently associated with increased long-term all-cause, as well as cardiac, mortality in patients with HF encountered in routine clinical practice in Japan.},
  langid = {english},
  pmid = {21060207},
  keywords = {Aged,Aged 80 and over,Body Mass Index,Female,Heart Failure,Hospitalization,Humans,Japan,Male,Middle Aged,Obesity,Registries,Risk Factors,Time Factors},
  file = {/Users/xx20081/Zotero/storage/ZLMJ8BKX/Hamaguchi et al. - 2010 - Body mass index is an independent predictor of lon.pdf}
}

@article{hamanhEffectBodyMass2023,
  title = {Effect of Body Mass Index on {{N-terminal}} pro-Brain Natriuretic Peptide Values in Patients with Heart Failure},
  author = {Ha Manh, Tuan and Do Anh, Duong and Le Viet, Tung},
  year = {2023},
  month = aug,
  journal = {The Egyptian Heart Journal},
  volume = {75},
  pages = {75},
  issn = {1110-2608},
  doi = {10.1186/s43044-023-00401-1},
  urldate = {2024-07-04},
  abstract = {Background N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a biomarker used for the diagnosis of heart failure. There is a relationship between NT-proBNP levels and body mass index (BMI). The study aimed to explore the impact of BMI on NT-proBNP concentrations and to examine whether other factors independent of or combined with BMI affect NT-proBNP values in patients with heart failure. Results A total of 293 participants were recruited. The mean age was 68.9\,{\textpm}\,13.2~years, males accounted for 46.4\% of the total cohort, the mean BMI was 23.1\,{\textpm}\,4.0~kg/m2, and the median NT-proBNP level was 3776 (1672--8806) pg/ml. There was an inverse relationship between BMI and log NT-proBNP (r\,=\,-~0.29; p\,{$<$}\,0.001, Spearman correlation). Each standard deviation increase in BMI (4~kg/m2) was associated with a 7\% decrease in NT-proBNP values in the total cohort. The independent inverse determinants of NT-proBNP other than BMI were male gender and eGFR, while the variables directly correlated to NT-proBNP were LVEF\,{$\leq$}\,40\% and NYHA class III--IV heart failure. Conclusions There is an inverse association between BMI and NT-proBNP levels. However, the correlation is weak, and there are other variables that have a significant impact on the NT-proBNP values as well. The NT-proBNP levels are still valuable in the diagnosis of heart failure regardless of BMI status.},
  pmcid = {PMC10465415},
  pmid = {37642755},
  file = {/Users/xx20081/Zotero/storage/JNH5V3L9/Ha Manh et al. - 2023 - Effect of body mass index on N-terminal pro-brain .pdf}
}

@article{hamiltonTherapeuticPotentialIL6R2023,
  title = {Therapeutic Potential of {{IL6R}} Blockade for the Treatment of Sepsis and Sepsis-Related Death: {{A Mendelian}} Randomisation Study},
  shorttitle = {Therapeutic Potential of {{IL6R}} Blockade for the Treatment of Sepsis and Sepsis-Related Death},
  author = {Hamilton, Fergus W. and Thomas, Matt and Arnold, David and Palmer, Tom and Moran, Ed and Mentzer, Alexander J. and Maskell, Nick and Baillie, Kenneth and Summers, Charlotte and Hingorani, Aroon and MacGowan, Alasdair and Khandaker, Golam M. and Mitchell, Ruth and Davey Smith, George and Ghazal, Peter and Timpson, Nicholas J.},
  year = {2023},
  month = jan,
  journal = {PLoS medicine},
  volume = {20},
  number = {1},
  pages = {e1004174},
  issn = {1549-1676},
  doi = {10.1371/journal.pmed.1004174},
  abstract = {BACKGROUND: Sepsis is characterised by dysregulated, life-threatening immune responses, which are thought to be driven by cytokines such as interleukin 6 (IL-6). Genetic variants in IL6R known to down-regulate IL-6 signalling are associated with improved Coronavirus Disease 2019 (COVID-19) outcomes, a finding later confirmed in randomised trials of IL-6 receptor antagonists (IL6RAs). We hypothesised that blockade of IL6R could also improve outcomes in sepsis. METHODS AND FINDINGS: We performed a Mendelian randomisation (MR) analysis using single nucleotide polymorphisms (SNPs) in and near IL6R to evaluate the likely causal effects of IL6R blockade on sepsis (primary outcome), sepsis severity, other infections, and COVID-19 (secondary outcomes). We weighted SNPs by their effect on CRP and combined results across them in inverse variance weighted meta-analysis, proxying the effect of IL6RA. Our outcomes were measured in UK Biobank, FinnGen, the COVID-19 Host Genetics Initiative (HGI), and the GenOSept and GainS consortium. We performed several sensitivity analyses to test assumptions of our methods, including utilising variants around CRP and gp130 in a similar analysis. In the UK Biobank cohort (N = 486,484, including 11,643 with sepsis), IL6R blockade was associated with a decreased risk of our primary outcome, sepsis (odds ratio (OR) = 0.80; 95\% confidence interval (CI) 0.66 to 0.96, per unit of natural log-transformed CRP decrease). The size of this effect increased with severity, with larger effects on 28-day sepsis mortality (OR = 0.74; 95\% CI 0.47 to 1.15); critical care admission with sepsis (OR = 0.48, 95\% CI 0.30 to 0.78) and critical care death with sepsis (OR = 0.37, 95\% CI 0.14 to 0.98). Similar associations were seen with severe respiratory infection: OR for pneumonia in critical care 0.69 (95\% CI 0.49 to 0.97) and for sepsis survival in critical care (OR = 0.22; 95\% CI 0.04 to 1.31) in the GainS and GenOSept consortium, although this result had a large degree of imprecision. We also confirm the previously reported protective effect of IL6R blockade on severe COVID-19 (OR = 0.69, 95\% CI 0.57 to 0.84) in the COVID-19 HGI, which was of similar magnitude to that seen in sepsis. Sensitivity analyses did not alter our primary results. These results are subject to the limitations and assumptions of MR, which in this case reflects interpretation of these SNP effects as causally acting through blockade of IL6R, and reflect lifetime exposure to IL6R blockade, rather than the effect of therapeutic IL6R blockade. CONCLUSIONS: IL6R blockade is causally associated with reduced incidence of sepsis. Similar but imprecisely estimated results supported a causal effect also on sepsis related mortality and critical care admission with sepsis. These effects are comparable in size to the effect seen in severe COVID-19, where IL-6 receptor antagonists were shown to improve survival. These data suggest that a randomised trial of IL-6 receptor antagonists in sepsis should be considered.},
  langid = {english},
  pmcid = {PMC9925069},
  pmid = {36716318},
  keywords = {COVID-19,Hospitalization,Humans,Interleukin-6,Mendelian Randomization Analysis,Receptors Interleukin-6,Sepsis},
  file = {/Users/xx20081/Zotero/storage/GK44J35K/Hamilton et al. - 2023 - Therapeutic potential of IL6R blockade for the tre.pdf}
}

@article{hammoudPancreasContrastingCardiometabolic2023,
  title = {Beyond the Pancreas: Contrasting Cardiometabolic Actions of {{GIP}} and {{GLP1}}},
  shorttitle = {Beyond the Pancreas},
  author = {Hammoud, Rola and Drucker, Daniel J.},
  year = {2023},
  month = apr,
  journal = {Nature Reviews Endocrinology},
  volume = {19},
  number = {4},
  pages = {201--216},
  publisher = {Nature Publishing Group},
  issn = {1759-5037},
  doi = {10.1038/s41574-022-00783-3},
  urldate = {2024-01-18},
  abstract = {Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP1) exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion. The emergence of GIP receptor (GIPR)--GLP1 receptor (GLP1R) co-agonists has fostered growing interest in the actions of GIP and GLP1 in metabolically relevant tissues. Here, we update concepts of how these hormones act beyond the pancreas. The actions of GIP and GLP1 on liver, muscle and adipose tissue, in the control of glucose and lipid homeostasis, are discussed in the context of plausible mechanisms of action. Both the GIPR and GLP1R are expressed in the central nervous system, wherein receptor activation produces anorectic effects enabling weight loss. In preclinical studies, GIP and GLP1 reduce atherosclerosis. Furthermore, GIPR and GLP1R are expressed within the heart and immune system, and GLP1R within the kidney, revealing putative mechanisms linking GIP and GLP1R agonism to cardiorenal protection. We interpret the clinical and mechanistic data obtained for different agents that enable weight loss and glucose control for the treatment of obesity and type 2 diabetes mellitus, respectively, by activating or blocking GIPR signalling, including the GIPR--GLP1R co-agonist tirzepatide, as well as the GIPR antagonist--GLP1R~agonist AMG-133. Collectively, we update translational concepts of GIP and GLP1 action, while highlighting gaps, areas of uncertainty and controversies meriting ongoing investigation.},
  copyright = {2022 Springer Nature Limited},
  langid = {english},
  keywords = {Endocrine system,Endocrine system and metabolic diseases},
  file = {/Users/xx20081/Zotero/storage/IK2GTDNE/Hammoud and Drucker - 2023 - Beyond the pancreas contrasting cardiometabolic a.pdf}
}

@techreport{handleyRareVariantsGlucagonlike2023a,
  type = {Preprint},
  title = {Rare Variants of the Glucagon-like Peptide-1 Receptor ({{GLP1R}}) Gene Are Overrepresented in a Severe Obesity Cohort and Associated with Type 2 Diabetes in the {{UK Biobank}}},
  author = {Handley, Dale and Almansoori, Sumaya and Sato, Mitra S. and Amin, Hasnat and Alsters, Suzanne and Chahal, Harvinder and Purkayastha, Sanjay and Murphy, Kevin G. and Van Haelst, Mieke and Le Roux, Carel W and Tan, Tricia and Walters, Robin G and Drenos, Fotios and Blakemore, Alexandra I},
  year = {2023},
  month = may,
  institution = {{Endocrinology (including Diabetes Mellitus and Metabolic Disease)}},
  doi = {10.1101/2023.05.22.23290347},
  urldate = {2024-01-21},
  abstract = {Introduction: Glucagon-like peptide 1 (GLP1) agonists are highly effective agents for the treatment of obesity and type 2 diabetes (T2D). GLP-1 is also implicated in outcomes of bariatric surgery, including appetite changes and T2D remission. Rare, potentially deleterious mutations in the glucagon-like peptide 1 receptor gene (GLP1R) may, therefore, have important implications for pathogenesis of obesity and T2D, and for response to therapeutic interventions. Methods: A custom Axion genotyping array, including 117 rare predicted-deleterious GLP1R mutations (MAF{$<$}0.01 in gnomAD, CADD-PHRED {$>$}= 15), was used to screen 1714 unrelated adults with BMI {$>$}35 kg/m2 from the PMMO study. We also examined the UK Biobank (UKB) exome sequence dataset for rare, predicted-deleterious GLP1R variants and tested their effects on weight and glycaemia-related traits. Results: Thirty-four PMMO participants carried one of the 117 GLP1R variants screened (11 might have been expected using the sum of their gnomAD control MAFs). These 8 variants were associated with T2D in the UKB and subsequent gene-level analysis of the UKB exome sequence dataset (629/39,274 carriers) confirmed that rare GLP1R variants are associated with increased risk of T2D (OR=1.58), as well as with higher HbA1c levels (p= 0.039). Furthermore, our data highlight a potential interaction of these variants with body mass index. Conclusion: Rare, potentially deleterious GLP1R mutations is associated with increased T2D risk, as well as higher HbA1c in UKB participants without diabetes. Future studies should examine the implications of GLP1R mutations for response to GLP1 agonist treatment and explore the observed interactions with obesity in T2D risk, including in larger cohorts with obesity.},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/7GJI8E6C/Handley et al. - 2023 - Rare variants of the glucagon-like peptide-1 recep.pdf}
}

@article{hanGeneticVariantGLP1R2016,
  title = {A Genetic Variant in {{GLP1R}} Is Associated with Response to {{DPP-4}} Inhibitors in Patients with Type 2 Diabetes},
  author = {Han, Eugene and Park, Hye Sun and Kwon, Obin and Choe, Eun Yeong and Wang, Hye Jin and Lee, Yong-Ho and Lee, Sang-Hak and Kim, Chul Hoon and Kim, Lee-Kyung and Kwak, Soo Heon and Park, Kyong Soo and Kim, Chul Sik and Kang, Eun Seok},
  year = {2016},
  month = nov,
  journal = {Medicine},
  volume = {95},
  number = {44},
  pages = {e5155},
  issn = {1536-5964},
  doi = {10.1097/MD.0000000000005155},
  abstract = {Incretin hormone-based therapy in type 2 diabetes has been widely used, and dipepdityl peptidase-4 (DPP-4) inhibitors, which prevent incretin degradation, have become popular oral hypoglycemic agents. The efficacy of DPP-4 inhibitors varies from individuals, and factors determining responses to DPP-4 inhibitors have not been fully established. We aimed to investigate whether genetic variations in glucagon-like peptide (GLP-1) receptor are associated with responses to DPP-4 inhibitors in patients with type 2 diabetes.Genetic variations of rs3765467 in GLP-1 receptor were explored in 246 patients with type 2 diabetes who received DPP-4 inhibitors treatment for 24 weeks in addition to previous medication. Patients with glycated hemoglobin (HbA1c) {$>$} 7\% and who were naive to any DPP-4 inhibitors were enrolled. Responders were defined as those who showed a {$>$} 10\% reduction in HbA1c after DPP-4 inhibitor treatment.DPP-4 inhibitors improved glycemic parameters and lipid profiles. Compared to the major genotype (GG), a larger proportion of patients with the minor allele genotype (GA/AA) were responders (P{$\mkern1mu$}={$\mkern1mu$}0.018), and also showing greater HbA1c reductions (1.3{$\mkern1mu\pm\mkern1mu$}1.1 vs 0.9{$\mkern1mu\pm\mkern1mu$}1.2\%; P{$\mkern1mu$}={$\mkern1mu$}0.022). This genetic effect remained significant even after adjustment for other confounding factors (OR{$\mkern1mu$}={$\mkern1mu$}2.00, 95\% CI{$\mkern1mu$}={$\mkern1mu$}1.03-3.89).Polymorphism in the GLP-1 receptor may influence DPP-4 inhibitor response. Further studies in larger population will help determine the association between genetic variation and interindividual differences in DPP-4 inhibitor therapy.},
  langid = {english},
  pmcid = {PMC5591096},
  pmid = {27858848},
  keywords = {Diabetes Mellitus Type 2,Dipeptidyl-Peptidase IV Inhibitors,Female,Genetic Variation,Glucagon-Like Peptide-1 Receptor,Humans,Incretins,Male,Middle Aged},
  file = {/Users/xx20081/Zotero/storage/IC68JZV2/Han et al. - 2016 - A genetic variant in GLP1R is associated with resp.pdf}
}

@article{hanGenomewideAnalysisHighlights2020,
  title = {Genome-Wide Analysis Highlights Contribution of Immune System Pathways to the Genetic Architecture of Asthma},
  author = {Han, Yi and Jia, Qiong and Jahani, Pedram Shafiei and Hurrell, Benjamin P. and Pan, Calvin and Huang, Pin and Gukasyan, Janet and Woodward, Nicholas C. and Eskin, Eleazar and Gilliland, Frank D. and Akbari, Omid and Hartiala, Jaana A. and Allayee, Hooman},
  year = {2020},
  month = apr,
  journal = {Nature Communications},
  volume = {11},
  number = {1},
  pages = {1776},
  issn = {2041-1723},
  doi = {10.1038/s41467-020-15649-3},
  abstract = {Asthma is a chronic and genetically complex respiratory disease that affects over 300 million people worldwide. Here, we report a genome-wide analysis for asthma using data from the UK Biobank and the Trans-National Asthma Genetic Consortium. We identify 66 previously unknown asthma loci and demonstrate that the susceptibility alleles in these regions are, either individually or as a function of cumulative genetic burden, associated with risk to a greater extent in men than women. Bioinformatics analyses prioritize candidate causal genes at 52 loci, including CD52, and demonstrate that asthma-associated variants are enriched in regions of open chromatin in immune cells. Lastly, we show that a murine anti-CD52 antibody mimics the immune cell-depleting effects of a clinically used human anti-CD52 antibody and reduces allergen-induced airway hyperreactivity in mice. These results further elucidate the genetic architecture of asthma and provide important insight into the immunological and sex-specific relevance of asthma-associated risk variants.},
  langid = {english},
  pmcid = {PMC7160128},
  pmid = {32296059},
  keywords = {Adult,Aged,Animals,Asthma,Case-Control Studies,CD52 Antigen,Female,Genetic Predisposition to Disease,Genome-Wide Association Study,Humans,Immune System,Lymphocytes,Male,Mice,Middle Aged,Polymorphism Single Nucleotide,Quantitative Trait Loci,Risk Factors,Sex Factors,United Kingdom},
  file = {/Users/xx20081/Zotero/storage/ITJ5G4ME/Han et al. - 2020 - Genome-wide analysis highlights contribution of im.pdf}
}

@article{hannaInflammatoryCytokinesChemokines2020,
  title = {Inflammatory {{Cytokines}} and {{Chemokines}} as {{Therapeutic Targets}} in {{Heart Failure}}},
  author = {Hanna, Anis and Frangogiannis, Nikolaos G.},
  year = {2020},
  month = dec,
  journal = {Cardiovascular Drugs and Therapy},
  volume = {34},
  number = {6},
  pages = {849--863},
  issn = {1573-7241},
  doi = {10.1007/s10557-020-07071-0},
  abstract = {Heart failure exhibits remarkable pathophysiologic heterogeneity. A large body of evidence suggests that regardless of the underlying etiology, heart failure is associated with induction of cytokines and chemokines that may contribute to the pathogenesis of adverse remodeling, and systolic and diastolic dysfunction. The pro-inflammatory cytokines tumor necrosis factor (TNF)-{$\alpha$}, interleukin (IL)-1, and IL-6 have been extensively implicated in the pathogenesis of heart failure. Inflammatory cytokines modulate phenotype and function of all myocardial cells, suppressing contractile function in cardiomyocytes, inducing inflammatory activation in macrophages, stimulating microvascular inflammation and dysfunction, and promoting a matrix-degrading phenotype in fibroblasts. Moreover, cytokine-induced growth factor synthesis may exert chronic fibrogenic actions contributing to the pathogenesis of heart failure with preserved ejection fraction (HFpEF). In addition to their role in adverse cardiac remodeling, some inflammatory cytokines may also exert protective actions on cardiomyocytes under conditions of stress. Chemokines, such as CCL2, are also upregulated in failing hearts and may stimulate recruitment of pro-inflammatory leukocytes, promoting myocardial injury, fibrotic remodeling, and dysfunction. Although experimental evidence suggests that cytokine and chemokine targeting may hold therapeutic promise in heart failure, clinical translation remains challenging. This review manuscript summarizes our knowledge on the role of TNF-{$\alpha$}, IL-1, IL-6, and CCL2 in the pathogenesis of heart failure, and discusses the promises and challenges of targeted anti-cytokine therapy. Dissection of protective and maladaptive cellular actions of cytokines in the failing heart, and identification of patient subsets with overactive or dysregulated myocardial inflammatory responses are required for design of successful therapeutic approaches.},
  langid = {english},
  pmcid = {PMC7479403},
  pmid = {32902739},
  keywords = {Animals,Anti-Inflammatory Agents,Chemokine,Chemokines,Cytokine,Cytokines,Heart failure,Heart Failure,Humans,Inflammation,Interleukin-1,Molecular Targeted Therapy,Myocytes Cardiac,Signal Transduction,TNF-,Translational Research Biomedical,Ventricular Function Left,Ventricular Remodeling},
  file = {/Users/xx20081/Zotero/storage/28STXRXN/Hanna and Frangogiannis - 2020 - Inflammatory Cytokines and Chemokines as Therapeut.pdf}
}

@article{hartialaGenomewideAnalysisIdentifies2021,
  title = {Genome-Wide Analysis Identifies Novel Susceptibility Loci for Myocardial Infarction},
  author = {Hartiala, Jaana A. and Han, Yi and Jia, Qiong and Hilser, James R. and Huang, Pin and Gukasyan, Janet and Schwartzman, William S. and Cai, Zhiheng and Biswas, Subarna and Tr{\'e}gou{\"e}t, David-Alexandre and Smith, Nicholas L. and {INVENT Consortium} and {CHARGE Consortium Hemostasis Working Group} and {GENIUS-CHD Consortium} and Seldin, Marcus and Pan, Calvin and Mehrabian, Margarete and Lusis, Aldons J. and Bazeley, Peter and Sun, Yan V. and Liu, Chang and Quyyumi, Arshed A. and Scholz, Markus and Thiery, Joachim and Delgado, Graciela E. and Kleber, Marcus E. and M{\"a}rz, Winfried and Howe, Laurence J. and Asselbergs, Folkert W. and {van Vugt}, Marion and Vlachojannis, Georgios J. and Patel, Riyaz S. and Lyytik{\"a}inen, Leo-Pekka and K{\"a}h{\"o}nen, Mika and Lehtim{\"a}ki, Terho and Nieminen, Tuomo V. M. and Kuukasj{\"a}rvi, Pekka and Laurikka, Jari O. and Chang, Xuling and Heng, Chew-Kiat and Jiang, Rong and Kraus, William E. and Hauser, Elizabeth R. and Ferguson, Jane F. and Reilly, Muredach P. and Ito, Kaoru and Koyama, Satoshi and Kamatani, Yoichiro and Komuro, Issei and {Biobank Japan} and Stolze, Lindsey K. and Romanoski, Casey E. and Khan, Mohammad Daud and Turner, Adam W. and Miller, Clint L. and Aherrahrou, Redouane and Civelek, Mete and Ma, Lijiang and Bj{\"o}rkegren, Johan L. M. and Kumar, S. Ram and Tang, W. H. Wilson and Hazen, Stanley L. and Allayee, Hooman},
  year = {2021},
  month = mar,
  journal = {European Heart Journal},
  volume = {42},
  number = {9},
  pages = {919--933},
  issn = {1522-9645},
  doi = {10.1093/eurheartj/ehaa1040},
  abstract = {AIMS: While most patients with myocardial infarction (MI) have underlying coronary atherosclerosis, not all patients with coronary artery disease (CAD) develop MI. We sought to address the hypothesis that some of the genetic factors which establish atherosclerosis may be distinct from those that predispose to vulnerable plaques and thrombus formation. METHODS AND RESULTS: We carried out a genome-wide association study for MI in the UK Biobank (n{$\sim$}472~000), followed by a meta-analysis with summary statistics from the CARDIoGRAMplusC4D Consortium (n{$\sim$}167~000). Multiple independent replication analyses and functional approaches were used to prioritize loci and evaluate positional candidate genes. Eight novel regions were identified for MI at the genome wide significance level, of which effect sizes at six loci were more robust for MI than for CAD without the presence of MI. Confirmatory evidence for association of a locus on chromosome 1p21.3 harbouring choline-like transporter 3 (SLC44A3) with MI in the context of CAD, but not with coronary atherosclerosis itself, was obtained in Biobank Japan (n{$\sim$}165~000) and 16 independent angiography-based cohorts (n{$\sim$}27~000). Follow-up analyses did not reveal association of the SLC44A3 locus with CAD risk factors, biomarkers of coagulation, other thrombotic diseases, or plasma levels of a broad array of metabolites, including choline, trimethylamine N-oxide, and betaine. However, aortic expression of SLC44A3 was increased in carriers of the MI risk allele at chromosome 1p21.3, increased in ischaemic (vs. non-diseased) coronary arteries, up-regulated in human aortic endothelial cells treated with interleukin-1{$\beta$} (vs. vehicle), and associated with smooth muscle cell migration in vitro. CONCLUSIONS: A large-scale analysis comprising {$\sim$}831~000 subjects revealed novel genetic determinants of MI and implicated SLC44A3 in the pathophysiology of vulnerable plaques.},
  langid = {english},
  pmcid = {PMC7936531},
  pmid = {33532862},
  keywords = {Coronary Artery Disease,Endothelial Cells,Genetic factors,Genetic Predisposition to Disease,Genome-wide association study,Genome-Wide Association Study,Humans,Japan,Meta-analysis,Myocardial infarction,Myocardial Infarction,Polymorphism Single Nucleotide,Risk Factors,SLC44A3},
  file = {/Users/xx20081/Zotero/storage/V7ZLJ27D/Hartiala et al. - 2021 - Genome-wide analysis identifies novel susceptibili.pdf}
}

@article{hatoumMultivariateGenomewideAssociation2023,
  title = {Multivariate Genome-Wide Association Meta-Analysis of over 1 Million Subjects Identifies Loci Underlying Multiple Substance Use Disorders},
  author = {Hatoum, Alexander S. and Colbert, Sarah M. C. and Johnson, Emma C. and Huggett, Spencer B. and Deak, Joseph D. and Pathak, Gita and Jennings, Mariela V. and Paul, Sarah E. and Karcher, Nicole R. and Hansen, Isabella and Baranger, David A. A. and Edwards, Alexis and Grotzinger, Andrew and {Substance Use Disorder Working Group of the Psychiatric Genomics Consortium} and {Tucker-Drob}, Elliot M. and Kranzler, Henry R. and Davis, Lea K. and {Sanchez-Roige}, Sandra and Polimanti, Renato and Gelernter, Joel and Edenberg, Howard J. and Bogdan, Ryan and Agrawal, Arpana},
  year = {2023},
  month = mar,
  journal = {Nature. Mental Health},
  volume = {1},
  number = {3},
  pages = {210--223},
  issn = {2731-6076},
  doi = {10.1038/s44220-023-00034-y},
  abstract = {Genetic liability to substance use disorders can be parsed into loci that confer general or substance-specific addiction risk. We report a multivariate genome-wide association meta-analysis that disaggregates general and substance-specific loci for published summary statistics of problematic alcohol use, problematic tobacco use, cannabis use disorder, and opioid use disorder in a sample of 1,025,550 individuals of European descent and 92,630 individuals of African descent. Nineteen independent SNPs were genome-wide significant (P {$<$} 5e-8) for the general addiction risk factor (addiction-rf), which showed high polygenicity. Across ancestries, PDE4B was significant (among other genes), suggesting dopamine regulation as a cross-substance vulnerability. An addiction-rf polygenic risk score was associated with substance use disorders, psychopathologies, somatic conditions, and environments associated with the onset of addictions. Substance-specific loci (9 for alcohol, 32 for tobacco, 5 for cannabis, 1 for opioids) included metabolic and receptor genes. These findings provide insight into genetic risk loci for substance use disorders that could be leveraged as treatment targets.},
  langid = {english},
  pmcid = {PMC10217792},
  pmid = {37250466},
  file = {/Users/xx20081/Zotero/storage/XJF72APR/Hatoum et al. - 2023 - Multivariate genome-wide association meta-analysis.pdf}
}

@article{hazewinkelMendelianRandomizationAnalysis2022,
  title = {Mendelian Randomization Analysis of the Causal Impact of Body Mass Index and Waist-Hip Ratio on Rates of Hospital Admission},
  author = {Hazewinkel, Audinga-Dea and Richmond, Rebecca C. and Wade, Kaitlin H. and Dixon, Padraig},
  year = {2022},
  month = jan,
  journal = {Economics \& Human Biology},
  volume = {44},
  pages = {101088},
  issn = {1570-677X},
  doi = {10.1016/j.ehb.2021.101088},
  urldate = {2024-03-08},
  abstract = {We analyze how measures of adiposity -- body mass index (BMI) and waist~hip ratio (WHR) -- causally influence rates of hospital admission. Conventional analyses of this relationship are susceptible to omitted variable bias from variables that jointly influence both hospital admission and adipose status. We implement a novel quasi-Poisson instrumental variable model in a Mendelian randomization framework, identifying causal effects from random perturbations to germline genetic variation. We estimate the individual and joint effects of BMI, WHR, and WHR adjusted for BMI. We also implement multivariable instrumental variable methods in which the causal effect of one exposure is estimated conditionally on the causal effect of another exposure. Data on 310,471 participants and over 550,000 inpatient admissions in the UK Biobank were used to perform one-sample and two-sample Mendelian randomization analyses. The results supported a causal role of adiposity on hospital admissions, with consistency across all estimates and sensitivity analyses. Point estimates were generally larger than estimates from comparable observational specifications. We observed an attenuation of the BMI effect when adjusting for WHR in the multivariable Mendelian randomization analyses, suggesting that an adverse fat distribution, rather than a higher BMI itself, may drive the relationship between adiposity and risk of hospital admission.},
  keywords = {BMI,Body mass index,Hospital admissions,Instrumental variables,Mendelian randomization,Poisson models,Waist hip ratio,WHR},
  file = {/Users/xx20081/Zotero/storage/5CAH4DXY/Hazewinkel et al. - 2022 - Mendelian randomization analysis of the causal imp.pdf;/Users/xx20081/Zotero/storage/8DZW63A6/S1570677X21001131.html}
}

@article{heClinicalFeaturesMyocardial2022,
  title = {Clinical Features, Myocardial Strain and Tissue Characteristics of Heart Failure with Preserved Ejection Fraction in Patients with Obesity: {{A}} Prospective Cohort Study},
  shorttitle = {Clinical Features, Myocardial Strain and Tissue Characteristics of Heart Failure with Preserved Ejection Fraction in Patients with Obesity},
  author = {He, Jian and Yang, Wenjing and Wu, Weichun and Sun, Xiaoxin and Li, Shuang and Yin, Gang and Zhuang, Baiyan and Xu, Jing and Zhou, Di and Zhang, Yuhui and Wang, Yining and Zhu, Leyi and Sharma, Piyush and Sirajuddin, Arlene and Teng, Zhongzhao and Kureshi, Faraz and Zhao, Shihua and Lu, Minjie},
  year = {2022},
  month = nov,
  journal = {eClinicalMedicine},
  volume = {55},
  pages = {101723},
  issn = {2589-5370},
  doi = {10.1016/j.eclinm.2022.101723},
  urldate = {2024-07-05},
  abstract = {Background The pathophysiology and subsequent myocardial dysfunction of heart failure with preserved ejection fraction (HFpEF) with comorbid obesity has not been extensively described. This study aimed to investigate the clinical features and cardiovascular magnetic resonance (CMR) derived myocardial strain and tissue characteristics in patients with HFpEF and comorbid obesity phenotype. Methods In this prospective cohort study, we included consecutive patients admitted to Fuwai hospital in China who underwent CMR. Patients with HFpEF or obesity were diagnosed with demographic data, clinical presentation, laboratory test, and echocardiography or CMR imaging. The key exclusion criteria were cardiomyopathy, primary valvular heart disease, and significant coronary artery disease. Participant data were obtained from the electronic medical records database or inquiry. Comparisons of clinical features and CMR derived structural and functional parameters amongst different groups were made using one-way analysis of variance, or {$\chi$}2 tests, and post hoc Bonferroni analysis where appropriate. Findings Between January 1, 2019 and July 31, 2021, 280 participants (108 patients with HFpEF and obesity, 50 patients with HFpEF and normal weight, 72 patients with obesity, and 50 healthy controls) were enrolled. Compared with patients with HFpEF and normal weight, patients with HFpEF and obesity were younger males, and had higher plasma volume, uric acid and hemoglobin levels, yet less often atrial fibrillation, and lower NT-proBNP levels, and had higher left ventricular mass index, end-diastole/systole volume index, lower left atrial volume index, and worse myocardial strains (all p~{$\leq~$}0.05), but no remarkable difference in late gadolinium enhancement (LGE) presence and extracellular volume fraction (ECV). After adjusting for age, atrial fibrillation, and coronary artery disease, only global longitudinal strain (GLS, p~=~0.031) and early-diastolic global longitudinal strain rate (eGLSR, p~=~0.043) were considerably worse in patients with HFpEF and obesity versus patients with HFpEF and normal weight. Furthermore, early-diastolic strain rates showed no linear association with ECV in patients with HFpEF and obesity. Moreover, GLS demonstrated the highest diagnostic ability when compared with traditional CMR structural parameters and ECV to diagnose patients with HFpEF and obesity in the setting of obesity. Interpretation Higher systemic inflammation, and worse GLS and eGLSR may be the distinct features of obesity-related HFpEF phenotype; strains and ECV may represent different mechanisms of HFpEF with obesity, deserving further study. Funding The Construction Research Project of Key Laboratory (Cultivation) of Chinese Academy of Medical Sciences (2019PT310025); 10.13039/501100001809National Natural Science Foundation of China (81971588); Capital's Funds for Health Improvement and Research (CFH 2020-2-4034); Youth Key Program of High-level Hospital Clinical Research (2022-GSP-QZ-5).},
  pmcid = {PMC9646878},
  pmid = {36386034},
  file = {/Users/xx20081/Zotero/storage/LPW46GER/He et al. - 2022 - Clinical features, myocardial strain and tissue ch.pdf}
}

@article{heGenomeWideAssociationStudy2013,
  title = {Genome-{{Wide Association Study Identifies}} 8 {{Novel Loci Associated With Blood Pressure Responses}} to {{Interventions}} in {{Han Chinese}}},
  author = {He, Jiang and Kelly, Tanika N. and Zhao, Qi and Li, Hongfan and Huang, Jianfeng and Wang, Laiyuan and Jaquish, Cashell E. and Sung, Yun Ju and Shimmin, Lawrence C. and Lu, Fanghong and Mu, Jianjun and Hu, Dongsheng and Ji, Xu and Shen, Chong and Guo, Dongshuang and Ma, Jixiang and Wang, Renping and Shen, Jinjin and Li, Shengxu and Chen, Jing and Mei, Hao and Chen, Chung-Shiuan and Chen, Shufeng and Chen, Jichun and Li, Jianxin and Cao, Jie and Lu, Xiangfeng and Wu, Xigui and Rice, Treva K. and Gu, C. Charles and Schwander, Karen and Hamm, L. Lee and Liu, Depei and Rao, Dabeeru C. and Hixson, James E. and Gu, Dongfeng},
  year = {2013},
  month = dec,
  journal = {Circulation: Cardiovascular Genetics},
  volume = {6},
  number = {6},
  pages = {598--607},
  publisher = {American Heart Association},
  doi = {10.1161/CIRCGENETICS.113.000307},
  urldate = {2024-04-12},
  abstract = {Background--- Blood pressure (BP) responses to dietary sodium and potassium intervention and cold pressor test vary considerably among individuals. We aimed to identify novel genetic variants influencing individuals' BP responses to dietary intervention and cold pressor test. Methods and Results--- We conducted a genome-wide association study of BP responses in 1881 Han Chinese and de novo genotyped top findings in 698 Han Chinese. Diet-feeding study included a 7-day low-sodium (51.3 mmol/d), a 7-day high-sodium (307.8 mmol/d), and a 7-day high-sodium plus potassium supplementation (60 mmol/d). Nine BP measurements were obtained during baseline observation and each intervention period. The meta-analyses identified 8 novel loci for BP phenotypes, which physically mapped in or near PRMT6 (P=7.29{\texttimes}10--9), CDCA7 (P=3.57{\texttimes}10--8), PIBF1 (P=1.78{\texttimes}10--9), ARL4C (P=1.86{\texttimes}10--8), IRAK1BP1 (P=1.44{\texttimes}10-10), SALL1 (P=7.01{\texttimes}10--13), TRPM8 (P=2.68{\texttimes}10--8), and FBXL13 (P=3.74{\texttimes}10--9). There was a strong dose--response relationship between the number of risk alleles of these independent single-nucleotide polymorphisms and the risk of developing hypertension during the 7.5-year follow-up in the study participants. Compared with those in the lowest quartile of risk alleles, odds ratios (95\% confidence intervals) for those in the second, third, and fourth quartiles were 1.39 (0.97, 1.99), 1.72 (1.19, 2.47), and 1.84 (1.29, 2.62), respectively (P=0.0003 for trend). Conclusions--- Our study identified 8 novel loci for BP responses to dietary sodium and potassium intervention and cold pressor test. The effect size of these novel loci on BP phenotypes is much larger than those reported by the previously published studies. Furthermore, these variants predict the risk of developing hypertension among individuals with normal BP at baseline.},
  keywords = {blood pressure,genomics,potassium,sodium},
  file = {/Users/xx20081/Zotero/storage/CLXZY8Z8/He et al. - 2013 - Genome-Wide Association Study Identifies 8 Novel L.pdf}
}

@article{heidenreich2022AHAACC2022,
  title = {2022 {{AHA}}/{{ACC}}/{{HFSA Guideline}} for the {{Management}} of {{Heart Failure}}: {{A Report}} of the {{American College}} of {{Cardiology}}/{{American Heart Association Joint Committee}} on {{Clinical Practice Guidelines}}},
  shorttitle = {2022 {{AHA}}/{{ACC}}/{{HFSA Guideline}} for the {{Management}} of {{Heart Failure}}},
  author = {Heidenreich, Paul A. and Bozkurt, Biykem and Aguilar, David and Allen, Larry A. and Byun, Joni J. and Colvin, Monica M. and Deswal, Anita and Drazner, Mark H. and Dunlay, Shannon M. and Evers, Linda R. and Fang, James C. and Fedson, Savitri E. and Fonarow, Gregg C. and Hayek, Salim S. and Hernandez, Adrian F. and Khazanie, Prateeti and Kittleson, Michelle M. and Lee, Christopher S. and Link, Mark S. and Milano, Carmelo A. and Nnacheta, Lorraine C. and Sandhu, Alexander T. and Stevenson, Lynne Warner and Vardeny, Orly and Vest, Amanda R. and Yancy, Clyde W.},
  year = {2022},
  month = may,
  journal = {Circulation},
  volume = {145},
  number = {18},
  pages = {e895-e1032},
  issn = {1524-4539},
  doi = {10.1161/CIR.0000000000001063},
  abstract = {AIM: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" replaces the "2013 ACCF/AHA Guideline for the Management of Heart Failure" and the "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure." The 2022 guideline is intended to provide patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure. METHODS: A comprehensive literature search was conducted from May 2020 to December 2020, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (PubMed), EMBASE, the Cochrane Collaboration, the Agency for Healthcare Research and Quality, and other relevant databases. Additional relevant clinical trials and research studies, published through September 2021, were also considered. This guideline was harmonized with other American Heart Association/American College of Cardiology guidelines published through December 2021. Structure: Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with patients' interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence, and new recommendations have been created when supported by published data. Value statements are provided for certain treatments with high-quality published economic analyses.},
  langid = {english},
  pmid = {35363499},
  keywords = {ACE inhibitors,acute decompensated heart failure,AHA Scientific Statements,American Heart Association,angiotensin and neprilysin receptor antagonist,angiotensin receptor antagonist,atrial fibrillation,beta blockers,cardiac amyloidosis,cardiac failure,cardio-oncology,cardiogenic shock,Cardiology,cardiomyopathy,cardiomyopathy in pregnancy,Cardiovascular System,chronic heart failure,congestive heart failure,diabetes,guideline-directed medical therapy,heart failure,Heart Failure,heart failure rehabilitation,heart failure with mildly reduced ejection fraction,heart failure with preserved ejection fraction,heart failure with reduced ejection fraction,Humans,mineralocorticoid receptor antagonists,mitral regurgitation,palliative care,reduced ejection fraction,Research Report,right heart pressure,sacubitril valsartan,SGLT2 inhibitors,social determinants of health,sodium glucose co-transporter 2,systolic heart failure,United States,valvular heart disease},
  file = {/Users/xx20081/Zotero/storage/9KLDB98Y/Heidenreich et al. - 2022 - 2022 AHAACCHFSA Guideline for the Management of .pdf}
}

@article{hemaniMRBasePlatformSupports2018,
  title = {The {{MR-Base}} Platform Supports Systematic Causal Inference across the Human Phenome},
  author = {Hemani, Gibran and Zheng, Jie and Elsworth, Benjamin and Wade, Kaitlin H. and Haberland, Valeriia and Baird, Denis and Laurin, Charles and Burgess, Stephen and Bowden, Jack and Langdon, Ryan and Tan, Vanessa Y. and Yarmolinsky, James and Shihab, Hashem A. and Timpson, Nicholas J. and Evans, David M. and Relton, Caroline and Martin, Richard M. and Davey Smith, George and Gaunt, Tom R. and Haycock, Philip C.},
  year = {2018},
  month = may,
  journal = {eLife},
  volume = {7},
  pages = {e34408},
  issn = {2050-084X},
  doi = {10.7554/eLife.34408},
  abstract = {Results from genome-wide association studies (GWAS) can be used to infer causal relationships between phenotypes, using a strategy known as 2-sample Mendelian randomization (2SMR) and bypassing the need for individual-level data. However, 2SMR methods are evolving rapidly and GWAS results are often insufficiently curated, undermining efficient implementation of the approach. We therefore developed MR-Base ({$<$}ext-link ext-link-type="uri" xlink:href="http://www.mrbase.org"{$>$}http://www.mrbase.org{$<$}/ext-link{$>$}): a platform that integrates a curated database of complete GWAS results (no restrictions according to statistical significance) with an application programming interface, web app and R packages that automate 2SMR. The software includes several sensitivity analyses for assessing the impact of horizontal pleiotropy and other violations of assumptions. The database currently comprises 11 billion single nucleotide polymorphism-trait associations from 1673 GWAS and is updated on a regular basis. Integrating data with software ensures more rigorous application of hypothesis-driven analyses and allows millions of potential causal relationships to be efficiently evaluated in phenome-wide association studies.},
  langid = {english},
  pmcid = {PMC5976434},
  pmid = {29846171},
  keywords = {causal inference,Cholesterol LDL,computational biology,Coronary Disease,Databases Genetic,Genetic Pleiotropy,Genome-Wide Association Study,GWAS,human,human biology,Humans,medicine,Mendelian randomization,Mendelian Randomization Analysis,Models Genetic,Phenotype,Polymorphism Single Nucleotide,systems biology},
  file = {/Users/xx20081/Zotero/storage/VV6LNZZL/Hemani et al. - 2018 - The MR-Base platform supports systematic causal in.pdf}
}

@article{henryGenomewideAssociationStudy2025,
  title = {Genome-Wide Association Study Meta-Analysis Provides Insights into the Etiology of Heart Failure and Its Subtypes},
  author = {Henry, Albert and Mo, Xiaodong and Finan, Chris and Chaffin, Mark D. and Speed, Doug and Issa, Hanane and Denaxas, Spiros and Ware, James S. and Zheng, Sean L. and Malarstig, Anders and Gratton, Jasmine and Bond, Isabelle and Roselli, Carolina and Miller, David and Chopade, Sandesh and Schmidt, A. Floriaan and Abner, Erik and Adams, Lance and Andersson, Charlotte and Aragam, Krishna G. and {\"A}rnl{\"o}v, Johan and Asselin, Geraldine and Raja, Anna Axelsson and Backman, Joshua D. and Bartz, Traci M. and Biddinger, Kiran J. and Biggs, Mary L. and Bloom, Heather L. and Boersma, Eric and Brandimarto, Jeffrey and Brown, Michael R. and Brunak, S{\o}ren and Bruun, Mie Topholm and Buckbinder, Leonard and Bundgaard, Henning and Carey, David J. and Chasman, Daniel I. and Chen, Xing and Cook, James P. and Czuba, Tomasz and {de Denus}, Simon and Dehghan, Abbas and Delgado, Graciela E. and Doney, Alexander S. and D{\"o}rr, Marcus and Dowsett, Joseph and Dudley, Samuel C. and Engstr{\"o}m, Gunnar and Erikstrup, Christian and Esko, T{\~o}nu and {Farber-Eger}, Eric H. and Felix, Stephan B. and Finer, Sarah and Ford, Ian and Ghanbari, Mohsen and Ghasemi, Sahar and Ghouse, Jonas and Giedraitis, Vilmantas and Giulianini, Franco and Gottdiener, John S. and Gross, Stefan and Gu{\dh}bjartsson, Dan{\'i}el F. and Gui, Hongsheng and Gutmann, Rebecca and H{\"a}gg, Sara and Haggerty, Christopher M. and Hedman, {\AA}sa K. and Helgadottir, Anna and Hemingway, Harry and Hillege, Hans and Hyde, Craig L. and Aagaard Jensen, Bitten and Jukema, J. Wouter and Kardys, Isabella and Karra, Ravi and Kavousi, Maryam and Kizer, Jorge R. and Kleber, Marcus E. and K{\o}ber, Lars and Koekemoer, Andrea and Kuchenbaecker, Karoline and Lai, Yi-Pin and Lanfear, David and Langenberg, Claudia and Lin, Honghuang and Lind, Lars and Lindgren, Cecilia M. and Liu, Peter P. and London, Barry and Lowery, Brandon D. and Luan, Jian'an and Lubitz, Steven A. and Magnusson, Patrik and Margulies, Kenneth B. and Marston, Nicholas A. and Martin, Hilary and M{\"a}rz, Winfried and Melander, Olle and Mordi, Ify R. and Morley, Michael P. and Morris, Andrew P. and Morrison, Alanna C. and Morton, Lori and Nagle, Michael W. and Nelson, Christopher P. and Niessner, Alexander and Niiranen, Teemu and Noordam, Raymond and Nowak, Christoph and O'Donoghue, Michelle L. and Ostrowski, Sisse Rye and Owens, Anjali T. and Palmer, Colin N. A. and Par{\'e}, Guillaume and Pedersen, Ole Birger and Perola, Markus and Pigeyre, Marie and Psaty, Bruce M. and Rice, Kenneth M. and Ridker, Paul M. and Romaine, Simon P. R. and Rotter, Jerome I. and Ruff, Christian T. and Sabatine, Marc S. and Sallah, Neneh and Salomaa, Veikko and Sattar, Naveed and Shalaby, Alaa A. and Shekhar, Akshay and Smelser, Diane T. and Smith, Nicholas L. and S{\o}rensen, Erik and Srinivasan, Sundararajan and Stefansson, Kari and Sveinbj{\"o}rnsson, Gar{\dh}ar and Svensson, Per and Tammesoo, Mari-Liis and Tardif, Jean-Claude and {Teder-Laving}, Maris and Teumer, Alexander and Thorgeirsson, Gu{\dh}mundur and Thorsteinsdottir, Unnur and {Torp-Pedersen}, Christian and Tragante, Vinicius and Trompet, Stella and Uitterlinden, Andre G. and Ullum, Henrik and {van der Harst}, Pim and {van Heel}, David and {van Setten}, Jessica and {van Vugt}, Marion and Veluchamy, Abirami and Verschuuren, Monique and Verweij, Niek and Vissing, Christoffer Rasmus and V{\"o}lker, Uwe and Voors, Adriaan A. and Wallentin, Lars and Wang, Yunzhang and Weeke, Peter E. and Wiggins, Kerri L. and Williams, L. Keoki and Yang, Yifan and Yu, Bing and Zannad, Faiez and Zheng, Chaoqun and Asselbergs, Folkert W. and Cappola, Thomas P. and Dub{\'e}, Marie-Pierre and Dunn, Michael E. and Lang, Chim C. and Samani, Nilesh J. and Shah, Svati and Vasan, Ramachandran S. and Smith, J. Gustav and Holm, Hilma and Shah, Sonia and Ellinor, Patrick T. and Hingorani, Aroon D. and Wells, Quinn and Lumbers, R. Thomas},
  year = {2025},
  month = apr,
  journal = {Nature Genetics},
  volume = {57},
  number = {4},
  pages = {815--828},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-024-02064-3},
  urldate = {2025-06-02},
  abstract = {Heart failure (HF) is a major contributor to global morbidity and mortality. While distinct clinical subtypes, defined by etiology and left ventricular ejection fraction, are well recognized, their genetic determinants remain inadequately understood. In this study, we report a genome-wide association study of HF and its subtypes in a sample of 1.9 million individuals. A total of 153,174 individuals had HF, of whom 44,012 had a nonischemic etiology (ni-HF). A subset of patients with ni-HF were stratified based on left ventricular systolic function, where data were available, identifying 5,406 individuals with reduced ejection fraction and 3,841 with preserved ejection fraction. We identify 66 genetic loci associated with HF and its subtypes, 37 of which have not previously been reported. Using functionally informed gene prioritization methods, we predict effector genes for each identified locus, and map these to etiologic disease clusters through phenome-wide association analysis, network analysis and colocalization. Through heritability enrichment analysis, we highlight the role of extracardiac tissues in disease etiology. We then examine the differential associations of upstream risk factors with HF subtypes using Mendelian randomization. These findings extend our understanding of the mechanisms underlying HF etiology and may inform future approaches to prevention and treatment.},
  copyright = {2025 The Author(s)},
  langid = {english},
  keywords = {Genome-wide association studies,Heart failure},
  file = {/Users/xx20081/Zotero/storage/XIIR26AR/Henry et al. - 2025 - Genome-wide association study meta-analysis provides insights into the etiology of heart failure and.pdf}
}

@misc{henryMappingAetiologicalFoundations2023,
  title = {Mapping the Aetiological Foundations of the Heart Failure Spectrum Using Human Genetics},
  author = {Henry, Albert and Mo, Xiaodong and Finan, Chris and Chaffin, Mark D. and Speed, Doug and Issa, Hanane and Denaxas, Spiros and Ware, James S. and Zheng, Sean L. and Malarstig, Anders and Gratton, Jasmine and Bond, Isabelle and Roselli, Carolina and Miller, David and Chopade, Sandesh and Schmidt, A. Floriaan and Abner, Erik and Adams, Lance and Andersson, Charlotte and Aragam, Krishna G. and {\"A}rnl{\"o}v, Johan and Asselin, Geraldine and Raja, Anna Axelsson and Backman, Joshua D. and Bartz, Traci M. and Biddinger, Kiran J. and Biggs, Mary L. and Bloom, Heather L. and Boersma, Eric and Brandimarto, Jeffrey and Brown, Michael R. and Brunak, S{\o}ren and Bruun, Mie Topholm and Buckbinder, Leonard and Bundgaard, Henning and Carey, David J. and Chasman, Daniel I. and Chen, Xing and Cook, James P. and Czuba, Tomasz and de Denus, Simon and Dehghan, Abbas and Delgado, Graciela E. and Doney, Alexander S. and D{\"o}rr, Marcus and Dowsett, Joseph and Dudley, Samuel C. and Engstr{\"o}m, Gunnar and Erikstrup, Christian and Esko, T{\~o}nu and {Farber-Eger}, Eric H. and Felix, Stephan B. and Finer, Sarah and Ford, Ian and Ghanbari, Mohsen and Ghasemi, Sahar and Ghouse, Jonas and Giedraitis, Vilmantas and Giulianini, Franco and Gottdiener, John S. and Gross, Stefan and Gu{\dh}bjartsson, Dan{\'i}el F. and Gui, Hongsheng and Gutmann, Rebecca and H{\"a}gg, Sara and Haggerty, Christopher M. and Hedman, {\AA}sa K. and Helgadottir, Anna and Hemingway, Harry and Hillege, Hans and Hyde, Craig L. and Jensen, Bitten Aagaard and Jukema, J. Wouter and Kardys, Isabella and Karra, Ravi and Kavousi, Maryam and Kizer, Jorge R. and Kleber, Marcus E. and K{\o}ber, Lars and Koekemoer, Andrea and Kuchenbaecker, Karoline and Lai, Yi-Pin and Lanfear, David and Langenberg, Claudia and Lin, Honghuang and Lind, Lars and Lindgren, Cecilia M. and Liu, Peter P. and London, Barry and Lowery, Brandon D. and Luan, Jian'an and Lubitz, Steven A. and Magnusson, Patrik and Margulies, Kenneth B. and Marston, Nicholas A. and Martin, Hilary and M{\"a}rz, Winfried and Melander, Olle and Mordi, Ify R. and Morley, Michael P. and Morris, Andrew P. and Morrison, Alanna C. and Morton, Lori and Nagle, Michael W. and Nelson, Christopher P. and Niessner, Alexander and Niiranen, Teemu and Noordam, Raymond and Nowak, Christoph and O'Donoghue, Michelle L. and Ostrowski, Sisse Rye and Owens, Anjali T. and Palmer, Colin N. A. and Par{\'e}, Guillaume and Pedersen, Ole Birger and Perola, Markus and Pigeyre, Marie and Psaty, Bruce M. and Rice, Kenneth M. and Ridker, Paul M. and Romaine, Simon P. R. and Rotter, Jerome I. and Ruff, Christian T. and Sabatine, Mark S. and Sallah, Neneh and Salomaa, Veikko and Sattar, Naveed and Shalaby, Alaa A. and Shekhar, Akshay and Smelser, Diane T. and Smith, Nicholas L. and S{\o}rensen, Erik and Srinivasan, Sundararajan and Stefansson, Kari and Sveinbj{\"o}rnsson, Gar{\dh}ar and Svensson, Per and Tammesoo, Mari-Liis and Tardif, Jean-Claude and {Teder-Laving}, Maris and Teumer, Alexander and Thorgeirsson, Gu{\dh}mundur and Thorsteinsdottir, Unnur and {Torp-Pedersen}, Christian and Tragante, Vinicius and Trompet, Stella and Uitterlinden, Andre G. and Ullum, Henrik and van der Harst, Pim and van Heel, David and van Setten, Jessica and van Vugt, Marion and Veluchamy, Abirami and Verschuuren, Monique and Verweij, Niek and Vissing, Christoffer Rasmus and V{\"o}lker, Uwe and Voors, Adriaan A. and Wallentin, Lars and Wang, Yunzhang and Weeke, Peter E. and Wiggins, Kerri L. and Williams, L. Keoki and Yang, Yifan and Yu, Bing and Zannad, Faiez and Zheng, Chaoqun and Genes \&amp and Team, Health Research and Consortium, DBDS Genomic and Asselbergs, Folkert W. and Cappola, Thomas P. and Dub{\'e}, Marie-Pierre and Dunn, Michael E. and Lang, Chim C. and Samani, Nilesh J. and Shah, Svati and Vasan, Ramachandran S. and Smith, J. Gustav and Holm, Hilma and Shah, Sonia and Ellinor, Patrick T. and Hingorani, Aroon D. and Wells, Quinn and Lumbers, R. Thomas and Consortium, Hermes},
  year = {2023},
  month = oct,
  pages = {2023.10.01.23296379},
  publisher = {medRxiv},
  doi = {10.1101/2023.10.01.23296379},
  urldate = {2024-09-13},
  abstract = {{$<$}h3{$>$}Summary paragraph{$<$}/h3{$>$} {$<$}p{$>$}Heart failure (HF), a syndrome of symptomatic fluid overload due to cardiac dysfunction, is the most rapidly growing cardiovascular disorder. Despite recent advances, mortality and morbidity remain high and treatment innovation is challenged by limited understanding of aetiology in relation to disease subtypes. Here we harness the de-confounding properties of genetic variation to map causal biology underlying the HF phenotypic spectrum, to inform the development of more effective treatments. We report a genetic association analysis in 1.9 million ancestrally diverse individuals, including 153,174 cases of HF; 44,012 of non-ischaemic HF; 5,406 cases of non-ischaemic HF with reduced ejection fraction (HFrEF); and 3,841 cases of non-ischaemic HF with preserved ejection fraction (HFpEF). We identify 66 genetic susceptibility loci across HF subtypes, 37 of which have not previously been reported. We map the aetiologic contribution of risk factor traits and diseases as well as newly identified effector genes for HF, demonstrating differential risk factor effects on disease subtypes. Our findings highlight the importance of extra-cardiac tissues in HF, particularly the kidney and the vasculature in HFpEF. Pathways of cellular senescence and proteostasis are notably uncovered, including \emph{IGFBP7} as an effector gene for HFpEF. Using population approaches causally anchored in human genetics, we provide fundamental new insights into the aetiology of heart failure subtypes that may inform new approaches to prevention and treatment.{$<$}/p{$>$}},
  archiveprefix = {medRxiv},
  copyright = {{\copyright} 2023, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/G77U3NCV/Henry et al. - 2023 - Mapping the aetiological foundations of the heart .pdf}
}

@article{hernanSelectionBiasDue2023,
  title = {Selection Bias Due to Conditioning on a Collider},
  author = {Hern{\'a}n, Miguel A. and Monge, Susana},
  year = {2023},
  month = jun,
  journal = {BMJ},
  volume = {381},
  pages = {p1135},
  publisher = {British Medical Journal Publishing Group},
  issn = {1756-1833},
  doi = {10.1136/bmj.p1135},
  urldate = {2025-06-03},
  abstract = {{$<$}p{$>$}Effect estimates may be biased when the study design or the data analysis is conditional on a collider---a variable that is caused by two other variables. Causal directed acyclic graphs are a helpful tool to identify colliders that may introduce selection bias in observational research.{$<$}/p{$>$}},
  chapter = {Research Methods \&amp; Reporting},
  copyright = {{\copyright} Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.. http://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.},
  langid = {english},
  pmid = {37286200},
  file = {/Users/xx20081/Zotero/storage/UHKKTYE3/Hernn and Monge - 2023 - Selection bias due to conditioning on a collider.pdf}
}

@article{hernanStructuralApproachSelection2004,
  title = {A Structural Approach to Selection Bias},
  author = {Hern{\'a}n, Miguel A. and {Hern{\'a}ndez-D{\'i}az}, Sonia and Robins, James M.},
  year = {2004},
  month = sep,
  journal = {Epidemiology (Cambridge, Mass.)},
  volume = {15},
  number = {5},
  pages = {615--625},
  issn = {1044-3983},
  doi = {10.1097/01.ede.0000135174.63482.43},
  abstract = {The term "selection bias" encompasses various biases in epidemiology. We describe examples of selection bias in case-control studies (eg, inappropriate selection of controls) and cohort studies (eg, informative censoring). We argue that the causal structure underlying the bias in each example is essentially the same: conditioning on a common effect of 2 variables, one of which is either exposure or a cause of exposure and the other is either the outcome or a cause of the outcome. This structure is shared by other biases (eg, adjustment for variables affected by prior exposure). A structural classification of bias distinguishes between biases resulting from conditioning on common effects ("selection bias") and those resulting from the existence of common causes of exposure and outcome ("confounding"). This classification also leads to a unified approach to adjust for selection bias.},
  langid = {english},
  pmid = {15308962},
  keywords = {Case-Control Studies,Disease,Environmental Exposure,Epidemiologic Methods,Epidemiologic Research Design,Evaluation Studies as Topic,Humans,Longitudinal Studies,Models Theoretical,Research,Research Subjects,Risk Factors,Selection Bias}
}

@article{hicks2014ACCAHA2015,
  title = {2014 {{ACC}}/{{AHA Key Data Elements}} and {{Definitions}} for {{Cardiovascular Endpoint Events}} in {{Clinical Trials}}},
  author = {Hicks, Karen A. and Tcheng, James E. and Bozkurt, Biykem and Chaitman, Bernard R. and Cutlip, Donald E. and Farb, Andrew and Fonarow, Gregg C. and Jacobs, Jeffrey P. and Jaff, Michael R. and Lichtman, Judith H. and Limacher, Marian C. and Mahaffey, Kenneth W. and Mehran, Roxana and Nissen, Steven E. and Smith, Eric E. and Targum, Shari L.},
  year = {2015},
  month = jul,
  journal = {Circulation},
  volume = {132},
  number = {4},
  pages = {302--361},
  publisher = {American Heart Association},
  doi = {10.1161/CIR.0000000000000156},
  urldate = {2025-01-26},
  file = {/Users/xx20081/Zotero/storage/YZ4XHX69/Hicks et al. - 2015 - 2014 ACCAHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials.pdf}
}

@misc{HighBurdenSubclinical,
  title = {High {{Burden}} of {{Subclinical}} and {{Cardiovascular Disease Risk}} in {{Adults With Metabolically Healthy Obesity}}: {{The Atherosclerosis Risk}} in {{Communities}} ({{ARIC}}) {{Study}} {\textbar} {{Diabetes Care}} {\textbar} {{American Diabetes Association}}},
  urldate = {2024-07-05},
  howpublished = {https://diabetesjournals.org/care/article/44/7/1657/138798/High-Burden-of-Subclinical-and-Cardiovascular},
  file = {/Users/xx20081/Zotero/storage/FDG3T4EA/High-Burden-of-Subclinical-and-Cardiovascular.html}
}

@article{HighBurdenSubclinical2021,
  title = {High {{Burden}} of {{Subclinical}} and {{Cardiovascular Disease Risk}} in {{Adults With Metabolically Healthy Obesity}}: {{The Atherosclerosis Risk}} in {{Communities}} ({{ARIC}}) {{Study}}},
  year = {2021},
  volume = {44},
  abstract = {OBJECTIVE It is controversial whether adults who are obese but ``metabolically healthy'' have cardiovascular disease (CVD) risk comparable with that of normal-weight adults. High-sensitivity cardiac troponin T (hs-cTnT), a biomarker of myocardial damage, is useful in characterizing subclinical CVD. We categorized obesity phenotypes and studied their associations with subclinical and clinical CVD and CVD subtypes, including heart failure (HF). RESEARCH DESIGN AND METHODS We conducted cross-sectional and prospective analyses of 9,477 adults in the Atherosclerosis Risk in Communities (ARIC) study. We used the Adult Treatment Panel III criteria and BMI to define obesity phenotypes as follows: metabolically healthy normal weight, metabolically healthy overweight, metabolically healthy obese, metabolically unhealthy normal weight, metabolically unhealthy overweight, and metabolically unhealthy obese. RESULTS At baseline (1990--1992), mean age was 56 years, 56\% were female, 23\% were Black, and 25\% had detectable hs-cTnT ({$\geq$}6 ng/L). Over a median of 17 years of follow-up, there were 2,603 clinical CVD events. Those with the metabolically healthy obese (hazard ratio [HR] 1.38, 95\% CI 1.15--1.67), metabolically unhealthy normal weight (HR 1.51, 95\% CI 1.30--1.76), metabolically unhealthy overweight (HR 1.60, 95\% CI 1.41--1.82), and metabolically unhealthy obese (HR 2.14, 95\% CI 1.88--2.44) phenotypes had higher CVD risks in comparison with metabolically healthy normal weight. Detectable hs-cTnT ({$\geq$}6 ng/L) was associated with higher CVD risk, even among metabolically healthy normal-weight adults. Metabolically healthy obese adults had higher HF risk (HR 1.65, 95\% CI 1.30--2.09) in comparison with metabolically healthy normal weight. CONCLUSIONS The metabolically healthy obese phenotype was associated with excess burden of clinical CVD, primarily driven by an excess risk of HF. hs-cTnT was useful in stratifying CVD risk across all obesity phenotypes, even among obese individuals who appear otherwise metabolically healthy.},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/CICNS2C7/2021 - High Burden of Subclinical and Cardiovascular Dise.pdf}
}

@article{hingoraniPerformancePolygenicRisk2023,
  title = {Performance of Polygenic Risk Scores in Screening, Prediction, and Risk Stratification: Secondary Analysis of Data in the {{Polygenic Score Catalog}}},
  shorttitle = {Performance of Polygenic Risk Scores in Screening, Prediction, and Risk Stratification},
  author = {Hingorani, Aroon D. and Gratton, Jasmine and Finan, Chris and Schmidt, A. Floriaan and Patel, Riyaz and Sofat, Reecha and Kuan, Valerie and Langenberg, Claudia and Hemingway, Harry and Morris, Joan K. and Wald, Nicholas J.},
  year = {2023},
  journal = {BMJ medicine},
  volume = {2},
  number = {1},
  pages = {e000554},
  issn = {2754-0413},
  doi = {10.1136/bmjmed-2023-000554},
  abstract = {OBJECTIVE: To clarify the performance of polygenic risk scores in population screening, individual risk prediction, and population risk stratification. DESIGN: Secondary analysis of data in the Polygenic Score Catalog. SETTING: Polygenic Score Catalog, April 2022. Secondary analysis of 3915 performance metric estimates for 926 polygenic risk scores for 310 diseases to generate estimates of performance in population screening, individual risk, and population risk stratification. PARTICIPANTS: Individuals contributing to the published studies in the Polygenic Score Catalog. MAIN OUTCOME MEASURES: Detection rate for a 5\% false positive rate (DR5) and the population odds of becoming affected given a positive result; individual odds of becoming affected for a person with a particular polygenic score; and odds of becoming affected for groups of individuals in different portions of a polygenic risk score distribution. Coronary artery disease and breast cancer were used as illustrative examples. RESULTS: For performance in population screening, median DR5 for all polygenic risk scores and all diseases studied was 11\% (interquartile range 8-18\%). Median DR5 was 12\% (9-19\%) for polygenic risk scores for coronary artery disease and 10\% (9-12\%) for breast cancer. The population odds of becoming affected given a positive results were 1:8 for coronary artery disease and 1:21 for breast cancer, with background 10\,year odds of 1:19 and 1:41, respectively, which are typical for these diseases at age 50. For individual risk prediction, the corresponding 10\,year odds of becoming affected for individuals aged 50 with a polygenic risk score at the 2.5th, 25th, 75th, and 97.5th centiles were 1:54, 1:29, 1:15, and 1:8 for coronary artery disease and 1:91, 1:56, 1:34, and 1:21 for breast cancer. In terms of population risk stratification, at age 50, the risk of coronary artery disease was divided into five groups, with 10\,year odds of 1:41 and 1:11 for the lowest and highest quintile groups, respectively. The 10\,year odds was 1:7 for the upper 2.5\% of the polygenic risk score distribution for coronary artery disease, a group that contributed 7\% of cases. The corresponding estimates for breast cancer were 1:72 and 1:26 for the lowest and highest quintile groups, and 1:19 for the upper 2.5\% of the distribution, which contributed 6\% of cases. CONCLUSION: Polygenic risk scores performed poorly in population screening, individual risk prediction, and population risk stratification. Strong claims about the effect of polygenic risk scores on healthcare seem to be disproportionate to their performance.},
  langid = {english},
  pmcid = {PMC10582890},
  pmid = {37859783},
  keywords = {preventive medicine,public health},
  file = {/Users/xx20081/Zotero/storage/UP9B8P4I/Hingorani et al. - 2023 - Performance of polygenic risk scores in screening, prediction, and risk stratification secondary an.pdf}
}

@article{hingoraniPerformancePolygenicRisk2023a,
  title = {Performance of Polygenic Risk Scores in Screening, Prediction, and Risk Stratification: Secondary Analysis of Data in the {{Polygenic Score Catalog}}},
  shorttitle = {Performance of Polygenic Risk Scores in Screening, Prediction, and Risk Stratification},
  author = {Hingorani, Aroon and J, Gratton and C, Finan and Af, Schmidt and R, Patel and R, Sofat and V, Kuan and C, Langenberg and H, Hemingway and Jk, Morris and Nj, Wald},
  year = {2023},
  month = oct,
  journal = {BMJ medicine},
  volume = {2},
  number = {1},
  publisher = {BMJ Med},
  issn = {2754-0413},
  doi = {10.1136/bmjmed-2023-000554},
  urldate = {2024-12-04},
  abstract = {Polygenic risk scores performed poorly in population screening, individual risk prediction, and population risk stratification. Strong claims about the effect of polygenic risk scores on healthcare seem to be disproportionate to their performance.},
  langid = {english},
  pmid = {37859783},
  file = {/Users/xx20081/Zotero/storage/6VU5Y9UR/Ad et al. - 2023 - Performance of polygenic risk scores in screening, prediction, and risk stratification secondary an.pdf;/Users/xx20081/Zotero/storage/JR7Z3J2S/37859783.html}
}

@article{hodesAcceleratingMedicinesPartnership2016,
  title = {Accelerating {{Medicines Partnership}}: {{Alzheimer}}'s {{Disease}} ({{AMP-AD}}) {{Knowledge Portal Aids Alzheimer}}'s {{Drug Discovery}} through {{Open Data Sharing}}},
  shorttitle = {Accelerating {{Medicines Partnership}}},
  author = {Hodes, Richard J. and Buckholtz, Neil},
  year = {2016},
  journal = {Expert Opinion on Therapeutic Targets},
  volume = {20},
  number = {4},
  pages = {389--391},
  issn = {1744-7631},
  doi = {10.1517/14728222.2016.1135132},
  langid = {english},
  pmid = {26853544},
  keywords = {Alzheimer Disease,Animals,Drug Design,Drug Discovery,Humans,Information Dissemination,Public-Private Sector Partnerships},
  file = {/Users/xx20081/Zotero/storage/RC3CHWIF/Hodes and Buckholtz - 2016 - Accelerating Medicines Partnership Alzheimer's Di.pdf}
}

@article{hoffmannLargeElectronichealthrecordbasedGenomewide2018,
  title = {A Large Electronic-Health-Record-Based Genome-Wide Study of Serum Lipids},
  author = {Hoffmann, Thomas J. and Theusch, Elizabeth and Haldar, Tanushree and Ranatunga, Dilrini K. and Jorgenson, Eric and Medina, Marisa W. and Kvale, Mark N. and Kwok, Pui-Yan and Schaefer, Catherine and Krauss, Ronald M. and Iribarren, Carlos and Risch, Neil},
  year = {2018},
  month = mar,
  journal = {Nature Genetics},
  volume = {50},
  number = {3},
  pages = {401--413},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-018-0064-5},
  urldate = {2024-04-12},
  abstract = {A genome-wide association study~(GWAS) of 94,674 ancestrally diverse Kaiser Permanente members using 478,866 longitudinal electronic health record (EHR)-derived measurements for untreated serum lipid levels empowered multiple new findings: 121 new SNP associations (46 primary, 15 conditional, and 60 in meta-analysis with Global Lipids Genetic Consortium data); an increase of 33--42\% in variance explained with multiple measurements; sex differences in genetic impact (greater impact in females for LDL, HDL, and total cholesterol and the opposite for triglycerides); differences in variance explained among non-Hispanic whites, Latinos, African Americans, and East Asians; genetic dominance and epistatic interaction, with strong evidence for both at the ABO and FUT2 genes for LDL; and tissue-specific enrichment~of GWAS-associated SNPs among liver, adipose, and pancreas~eQTLs. Using EHR pharmacy data, both LDL and triglyceride genetic risk scores (477 SNPs) were strongly predictive of age at initiation of lipid-lowering treatment. These findings highlight the value of longitudinal EHRs for identifying new genetic features of cholesterol and lipoprotein metabolism with implications for lipid treatment and risk of coronary heart disease.},
  copyright = {2018 The Author(s)},
  langid = {english},
  keywords = {Dyslipidaemias,Genome-wide association studies},
  file = {/Users/xx20081/Zotero/storage/ZXCFD8QF/Hoffmann et al. - 2018 - A large electronic-health-record-based genome-wide.pdf}
}

@article{hoffmannLargeMultiethnicGenomeWide2018,
  title = {A {{Large Multiethnic Genome-Wide Association Study}} of {{Adult Body Mass Index Identifies Novel Loci}}},
  author = {Hoffmann, Thomas J. and Choquet, H{\'e}l{\`e}ne and Yin, Jie and Banda, Yambazi and Kvale, Mark N. and Glymour, Maria and Schaefer, Catherine and Risch, Neil and Jorgenson, Eric},
  year = {2018},
  month = oct,
  journal = {Genetics},
  volume = {210},
  number = {2},
  pages = {499--515},
  issn = {1943-2631},
  doi = {10.1534/genetics.118.301479},
  abstract = {Body mass index (BMI), a proxy measure for obesity, is determined by both environmental (including ethnicity, age, and sex) and genetic factors, with {$>$} 400 BMI-associated loci identified to date. However, the impact, interplay, and underlying biological mechanisms among BMI, environment, genetics, and ancestry are not completely understood. To further examine these relationships, we utilized 427,509 calendar year-averaged BMI measurements from 100,418 adults from the single large multiethnic Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort. We observed substantial independent ancestry and nationality differences, including ancestry principal component interactions and nonlinear effects. To increase the list of BMI-associated variants before assessing other differences, we conducted a genome-wide association study (GWAS) in GERA, with replication in the Genetic Investigation of Anthropomorphic Traits (GIANT) consortium combined with the UK Biobank (UKB), followed by GWAS in GERA combined with GIANT, with replication in the UKB. We discovered 30 novel independent BMI loci (P {$<$} 5.0 {\texttimes} 10-8) that replicated. We then assessed the proportion of BMI variance explained by sex in the UKB using previously identified loci compared to previously and newly identified loci and found slight increases: from 3.0 to 3.3\% for males and from 2.7 to 3.0\% for females. Further, the variance explained by previously and newly identified variants decreased with increasing age in the GERA and UKB cohorts, echoed in the variance explained by the entire genome, which also showed gene-age interaction effects. Finally, we conducted a tissue expression QTL enrichment analysis, which revealed that GWAS BMI-associated variants were enriched in the cerebellum, consistent with prior work in humans and mice.},
  langid = {english},
  pmcid = {PMC6216593},
  pmid = {30108127},
  keywords = {adult BMI,adult body mass index,Body Mass Index,Body Weight,Ethnicity,Female,Genetic Loci,genome-wide association study,Genome-Wide Association Study,Humans,Male,Middle Aged,Multifactorial Inheritance,obesity,Sex Factors},
  file = {/Users/xx20081/Zotero/storage/JQUJMASP/Hoffmann et al. - 2018 - A Large Multiethnic Genome-Wide Association Study of Adult Body Mass Index Identifies Novel Loci.pdf}
}

@article{hoPredictorsNewOnsetHeart2013,
  title = {Predictors of {{New-Onset Heart Failure}}: {{Differences}} in {{Preserved Versus Reduced Ejection Fraction}}},
  shorttitle = {Predictors of {{New-Onset Heart Failure}}},
  author = {Ho, Jennifer E. and Lyass, Asya and Lee, Douglas S. and Vasan, Ramachandran S. and Kannel, William B. and Larson, Martin G. and Levy, Daniel},
  year = {2013},
  month = mar,
  journal = {Circulation. Heart failure},
  volume = {6},
  number = {2},
  pages = {279--286},
  issn = {1941-3289},
  doi = {10.1161/CIRCHEARTFAILURE.112.972828},
  urldate = {2024-07-04},
  abstract = {Background About one half of patients with HF have preserved rather than reduced ejection fraction (HFPEF; HFREF). The differences in risk factors predisposing to the two subtypes of HF are poorly understood. We sought to identify clinical predictors of new-onset HF, and to explore differences in HFPEF versus HFREF. Methods and Results We studied new-onset HF cases between 1981 and 2008 in Framingham Heart Study participants, classified into HFPEF and HFREF (EF {$>$} 45\% vs {$\leq$} 45\%). We used Cox multivariable regression to examine predictors of 8-year risk of incident HF, and competing-risks analysis to identify predictors that differed between HFPEF and HFREF. Among 6,340 participants (60 {\textpm} 12 years) with 97,808 person-years of follow up, 512 developed incident HF. Of 457 participants with LVEF evaluation at the time of HF diagnosis, 196 (43\%) were classified as HFPEF and 261 (56\%) as HFREF. Fourteen predictors of overall HF were identified. Older age, diabetes mellitus, and a history of valvular disease predicted both types of HF (p {$\leq$} 0.0025 for all). Higher BMI, smoking, and atrial fibrillation predicted HFPEF only, whereas male sex, higher total cholesterol, higher heart rate, hypertension, cardiovascular disease, left ventricular hypertrophy, and left bundle branch block predicted risk of HFREF. Conclusions While multiple risk factors preceded overall HF, distinct clusters of risk factors determine risk for new-onset HFPEF versus HFREF. This knowledge may enable the design of clinical trials of targeted prevention and the introduction of therapeutic strategies for prevention of HF and its two major subtypes.},
  pmcid = {PMC3705220},
  pmid = {23271790},
  file = {/Users/xx20081/Zotero/storage/NJBUUPYP/Ho et al. - 2013 - Predictors of New-Onset Heart Failure Differences.pdf}
}

@article{horwichRelationshipObesityMortality2001,
  title = {The Relationship between Obesity and Mortality in Patients with Heart Failure},
  author = {Horwich, T. B. and Fonarow, G. C. and Hamilton, M. A. and MacLellan, W. R. and Woo, M. A. and Tillisch, J. H.},
  year = {2001},
  month = sep,
  journal = {Journal of the American College of Cardiology},
  volume = {38},
  number = {3},
  pages = {789--795},
  issn = {0735-1097},
  doi = {10.1016/s0735-1097(01)01448-6},
  abstract = {OBJECTIVES: The study aimed to evaluate the role of obesity in the prognosis of patients with heart failure (HF). BACKGROUND: Previous reports link obesity to the development of HF. However, the impact of obesity in patients with established HF has not been studied. METHODS: We analyzed 1,203 patients with advanced HF followed in a comprehensive HF management program. The patients were subclassified into categories of body mass index (BMI) defined as: underweight BMI {$<$}20.7 (n = 164), recommended BMI 20.7 to 27.7 (n = 692), overweight BMI 27.8 to 31 (n = 168) and obese BMI {$>$}31 (n = 179). This sample size allows the detection of small effects (0.02), with a power of 0.80 and an alpha level of 0.05 for comparing one-year survival between BMI groups. RESULTS: The four BMI groups had similar profiles in terms of ejection fraction (mean 0.22), sodium, creatinine and smoking. The obese and overweight groups had significantly higher rates of hypertension and diabetes, as well as higher levels of cholesterol, triglycerides and low density lipoprotein cholesterol. The four BMI groups had similar survival rates. Ejection fraction, HF etiology and angiotensin-converting enzyme inhibitor use predicted survival on univariate analysis (p {$<$} 0.01), although BMI did not. On multivariate analysis, cardiopulmonary exercise tests, pulmonary capillary wedge pressure and serum sodium were strong predictors of survival (p {$<$} 0.05). Higher BMI was not a risk factor for increased mortality, but was associated with a trend toward improved survival. CONCLUSIONS: In a large cohort of patients with advanced HF of multiple etiologies, obesity is not associated with increased mortality and may confer a more favorable prognosis. Further studies need to delineate whether weight loss promotion in medically optimized patients with HF is a worthwhile therapeutic goal.},
  langid = {english},
  pmid = {11527635},
  keywords = {Adult,Body Mass Index,Exercise Test,Female,Heart Failure,Hemodynamics,Humans,Male,Middle Aged,Obesity,Prognosis,Pulmonary Wedge Pressure,Regression Analysis},
  file = {/Users/xx20081/Zotero/storage/HUJXSGBU/Horwich et al. - 2001 - The relationship between obesity and mortality in .pdf}
}

@article{huangExaminingRoleCommon2024,
  title = {Examining the Role of Common Variants in Rare Neurodevelopmental Conditions},
  author = {Huang, Qin Qin and Wigdor, Emilie M. and Malawsky, Daniel S. and Campbell, Patrick and Samocha, Kaitlin E. and Chundru, V. Kartik and Danecek, Petr and Lindsay, Sarah and Marchant, Thomas and Koko, Mahmoud and Amanat, Sana and Bonfanti, Davide and Sheridan, Eamonn and Radford, Elizabeth J. and Barrett, Jeffrey C. and Wright, Caroline F. and Firth, Helen V. and Warrier, Varun and Strudwick Young, Alexander and Hurles, Matthew E. and Martin, Hilary C.},
  year = {2024},
  month = nov,
  journal = {Nature},
  pages = {1--8},
  publisher = {Nature Publishing Group},
  issn = {1476-4687},
  doi = {10.1038/s41586-024-08217-y},
  urldate = {2024-12-10},
  abstract = {Although rare neurodevelopmental conditions have a large Mendelian component1, common genetic variants also contribute to risk2,3. However, little is known about how this polygenic risk is distributed among patients with these conditions and their parents nor its interplay with rare variants. It is also unclear whether polygenic background affects risk directly through alleles transmitted from parents to children, or whether indirect genetic effects mediated through the family environment4 also play a role. Here we addressed these questions using genetic data from 11,573 patients with rare neurodevelopmental conditions, 9,128 of their parents and 26,869 controls. Common variants explained around 10\% of variance in risk. Patients with a monogenic diagnosis had significantly less polygenic risk than those without, supporting a liability threshold model5. A polygenic score for neurodevelopmental conditions showed only a direct genetic effect. By contrast, polygenic scores for educational attainment and cognitive performance showed no direct genetic effect, but the non-transmitted alleles in the parents were correlated with the child's risk, potentially due to indirect genetic effects and/or parental assortment for these traits4. Indeed, as expected under parental assortment, we show that common variant predisposition for neurodevelopmental conditions is correlated with the rare variant component of risk. These findings indicate that future studies should investigate the possible role and nature of indirect genetic effects on rare neurodevelopmental conditions, and consider the contribution of common and rare variants simultaneously when studying cognition-related phenotypes.},
  copyright = {2024 The Author(s)},
  langid = {english},
  keywords = {Behavioural genetics,Development of the nervous system,Genetic variation,Genetics of the nervous system,Medical genomics},
  file = {/Users/xx20081/Zotero/storage/EURUMWYJ/Huang et al. - 2024 - Examining the role of common variants in rare neurodevelopmental conditions.pdf}
}

@article{huangGenomewideDiscoveryGenetic2021,
  title = {Genome-Wide Discovery of Genetic Loci That Uncouple Excess Adiposity from Its Comorbidities},
  author = {Huang, Lam O. and Rauch, Alexander and Mazzaferro, Eugenia and Preuss, Michael and Carobbio, Stefania and Bayrak, Cigdem S. and Chami, Nathalie and Wang, Zhe and Schick, Ursula M. and Yang, Nancy and Itan, Yuval and {Vidal-Puig}, Antonio and {den Hoed}, Marcel and Mandrup, Susanne and Kilpel{\"a}inen, Tuomas O. and Loos, Ruth J. F.},
  year = {2021},
  month = feb,
  journal = {Nature Metabolism},
  volume = {3},
  number = {2},
  pages = {228--243},
  publisher = {Nature Publishing Group},
  issn = {2522-5812},
  doi = {10.1038/s42255-021-00346-2},
  urldate = {2024-08-15},
  abstract = {Obesity is a major risk factor for cardiometabolic diseases. Nevertheless, a substantial proportion of individuals with obesity do not suffer cardiometabolic comorbidities. The mechanisms that uncouple adiposity from its cardiometabolic complications are not fully understood. Here, we identify 62 loci of which the same allele is significantly associated with both higher adiposity and lower cardiometabolic risk. Functional analyses show that the 62 loci are enriched for genes expressed in adipose tissue, and for regulatory variants that influence nearby genes that affect adipocyte differentiation. Genes prioritized in each locus support a key role of fat distribution (FAM13A, IRS1 and PPARG) and adipocyte function (ALDH2, CCDC92, DNAH10, ESR1, FAM13A, MTOR, PIK3R1 and VEGFB). Several additional mechanisms are involved as well, such as insulin--glucose signalling (ADCY5, ARAP1, CREBBP, FAM13A, MTOR, PEPD, RAC1 and SH2B3), energy expenditure and fatty acid oxidation (IGF2BP2), browning of white adipose tissue (CSK, VEGFA, VEGFB and SLC22A3) and inflammation (SH2B3, DAGLB and ADCY9). Some of these genes may represent therapeutic targets to reduce cardiometabolic risk linked to excess adiposity.},
  copyright = {2021 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  keywords = {Cardiovascular diseases,Genome-wide association studies,Metabolic diseases,Obesity}
}

@article{huangSQCSecureQuality2017,
  title = {{{SQC}}: Secure Quality Control for Meta-Analysis of Genome-Wide Association Studies},
  shorttitle = {{{SQC}}},
  author = {Huang, Zhicong and Lin, Huang and Fellay, Jacques and Kutalik, Zolt{\'a}n and Hubaux, Jean-Pierre},
  year = {2017},
  month = aug,
  journal = {Bioinformatics},
  volume = {33},
  number = {15},
  pages = {2273--2280},
  issn = {1367-4803},
  doi = {10.1093/bioinformatics/btx193},
  urldate = {2024-10-08},
  abstract = {Due to the limited power of small-scale genome-wide association studies (GWAS), researchers tend to collaborate and establish a larger consortium in order to perform large-scale GWAS. Genome-wide association meta-analysis (GWAMA) is a statistical tool that aims to synthesize results from multiple independent studies to increase the statistical power and reduce false-positive findings of GWAS. However, it has been demonstrated that the aggregate data of individual studies are subject to inference attacks, hence privacy concerns arise when researchers share study data in GWAMA.In this article, we propose a secure quality control (SQC) protocol, which enables checking the quality of data in a privacy-preserving way without revealing sensitive information to a potential adversary. SQC employs state-of-the-art cryptographic and statistical techniques for privacy protection. We implement the solution in a meta-analysis pipeline with real data to demonstrate the efficiency and scalability on commodity machines. The distributed execution of SQC on a cluster of 128 cores for one million genetic variants takes less than one hour, which is a modest cost considering the 10-month time span usually observed for the completion of the QC procedure that includes timing of logistics.SQC is implemented in Java and is publicly available at https://github.com/acs6610987/secureqcSupplementary data are available at Bioinformatics online.}
}

@article{hubyAdipocyteDerivedHormoneLeptin2015,
  title = {Adipocyte-{{Derived Hormone Leptin Is}} a {{Direct Regulator}} of {{Aldosterone Secretion}}, {{Which Promotes Endothelial Dysfunction}} and {{Cardiac Fibrosis}}},
  author = {Huby, Anne-C{\'e}cile and Antonova, Galina and Groenendyk, Jake and {Gomez-Sanchez}, Celso E. and Bollag, Wendy B. and Filosa, Jessica A. and {Belin de Chantem{\`e}le}, Eric J.},
  year = {2015},
  month = dec,
  journal = {Circulation},
  volume = {132},
  number = {22},
  pages = {2134--2145},
  issn = {1524-4539},
  doi = {10.1161/CIRCULATIONAHA.115.018226},
  abstract = {BACKGROUND: In obesity, the excessive synthesis of aldosterone contributes to the development and progression of metabolic and cardiovascular dysfunctions. Obesity-induced hyperaldosteronism is independent of the known regulators of aldosterone secretion, but reliant on unidentified adipocyte-derived factors. We hypothesized that the adipokine leptin is a direct regulator of aldosterone synthase (CYP11B2) expression and aldosterone release and promotes cardiovascular dysfunction via aldosterone-dependent mechanisms. METHODS AND RESULTS: Immunostaining of human adrenal cross-sections and adrenocortical cells revealed that adrenocortical cells coexpress CYP11B2 and leptin receptors. Measurements of adrenal CYP11B2 expression and plasma aldosterone levels showed that increases in endogenous (obesity) or exogenous (infusion) leptin dose-dependently raised CYP11B2 expression and aldosterone without elevating plasma angiotensin II, potassium or corticosterone. Neither angiotensin II receptors blockade nor {$\alpha$} and {$\beta$} adrenergic receptors inhibition blunted leptin-induced aldosterone secretion. Identical results were obtained in cultured adrenocortical cells. Enhanced leptin signaling elevated CYP11B2 expression and plasma aldosterone, whereas deficiency in leptin or leptin receptors blunted obesity-induced increases in CYP11B2 and aldosterone, ruling out a role for obesity per se. Leptin increased intracellular calcium, elevated calmodulin and calmodulin-kinase II expression, whereas calcium chelation blunted leptin-mediated increases in CYP11B2, in adrenocortical cells. Mineralocorticoid receptor blockade blunted leptin-induced endothelial dysfunction and increases in cardiac fibrotic markers. CONCLUSIONS: Leptin is a newly described regulator of aldosterone synthesis that acts directly on adrenal glomerulosa cells to increase CYP11B2 expression and enhance aldosterone production via calcium-dependent mechanisms. Furthermore, leptin-mediated aldosterone secretion contributes to cardiovascular disease by promoting endothelial dysfunction and the expression of profibrotic markers in the heart.},
  langid = {english},
  pmid = {26362633},
  keywords = {Adipocytes,Adrenal Cortex,adrenal glands,aldosterone,Aldosterone,Animals,Cell Line Tumor,Cells Cultured,CYP11B2,endothelium,Endothelium Vascular,Female,Fibrosis,heart,Heart Diseases,Humans,leptin,Leptin,Mice,Mice Inbred C57BL,Mice Knockout,Mice Obese,obesity,Rats,Rats Inbred WKY,Rats Zucker},
  file = {/Users/xx20081/Zotero/storage/NDHCIHNF/Huby et al. - 2015 - Adipocyte-Derived Hormone Leptin Is a Direct Regul.pdf}
}

@article{hughesMetaboprepPackagePreanalysis2022,
  title = {Metaboprep: An {{R}} Package for Preanalysis Data Description and Processing},
  shorttitle = {Metaboprep},
  author = {Hughes, David A. and Taylor, Kurt and McBride, Nancy and Lee, Matthew A. and Mason, Dan and Lawlor, Deborah A. and Timpson, Nicholas J. and Corbin, Laura J.},
  year = {2022},
  month = mar,
  journal = {Bioinformatics (Oxford, England)},
  volume = {38},
  number = {7},
  pages = {1980--1987},
  issn = {1367-4811},
  doi = {10.1093/bioinformatics/btac059},
  abstract = {MOTIVATION: Metabolomics is an increasingly common part of health research and there is need for preanalytical data processing. Researchers typically need to characterize the data and to exclude errors within the context of the intended analysis. Whilst some preprocessing steps are common, there is currently a lack of standardization and reporting transparency for these procedures. RESULTS: Here, we introduce metaboprep, a standardized data processing workflow to extract and characterize high quality metabolomics datasets. The package extracts data from preformed worksheets, provides summary statistics and enables the user to select samples and metabolites for their analysis based on a set of quality metrics. A report summarizing quality metrics and the influence of available batch variables on the data are generated for the purpose of open disclosure. Where possible, we provide users flexibility in defining their own selection thresholds. AVAILABILITY AND IMPLEMENTATION: metaboprep is an open-source R package available at https://github.com/MRCIEU/metaboprep. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.},
  langid = {english},
  pmcid = {PMC8963298},
  pmid = {35134881},
  keywords = {Humans,Metabolomics,Research Personnel,Software,Workflow},
  file = {/Users/xx20081/Zotero/storage/WCBC2K2M/Hughes et al. - 2022 - metaboprep an R package for preanalysis data description and processing.pdf}
}

@article{hwangBodyMassIndex2022,
  title = {Body {{Mass Index}}, {{Muscle Mass}}, and {{All-Cause Mortality}} in {{Patients With Acute Heart Failure}}: {{The Obesity Paradox Revisited}}},
  shorttitle = {Body {{Mass Index}}, {{Muscle Mass}}, and {{All-Cause Mortality}} in {{Patients With Acute Heart Failure}}},
  author = {Hwang, In-Chang and Choi, Hong-Mi and Yoon, Yeonyee E. and Park, Jin Joo and Park, Jun-Bean and Park, Jae-Hyeong and Lee, Seung-Pyo and Kim, Hyung-Kwan and Kim, Yong-Jin and Cho, Goo-Yeong},
  year = {2022},
  month = apr,
  journal = {International Journal of Heart Failure},
  volume = {4},
  number = {2},
  pages = {95--109},
  issn = {2636-154X},
  doi = {10.36628/ijhf.2022.0007},
  urldate = {2025-01-06},
  abstract = {Hwang IC, et al. Int J Heart Fail. 2022 Apr;4(2):95-109. https://doi.org/10.36628/ijhf.2022.0007},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/RR6MEGPN/Hwang et al. - 2022 - Body Mass Index, Muscle Mass, and All-Cause Mortality in Patients With Acute Heart Failure The Obes.pdf}
}

@misc{IllustratingBiasDue,
  title = {Illustrating Bias Due to Conditioning on a Collider {\textbar} {{International Journal}} of {{Epidemiology}} {\textbar} {{Oxford Academic}}},
  urldate = {2024-08-08},
  howpublished = {https://academic.oup.com/ije/article/39/2/417/680407},
  file = {/Users/xx20081/Zotero/storage/FY67IR2H/680407.html}
}

@misc{ImpactSmokingPreexisting,
  title = {Impact of {{Smoking}} and {{Preexisting Illness}} on {{Estimates}} of the {{Fractions}} of {{Deaths Associated}} with {{Underweight}}, {{Overweight}}, and {{Obesity}} in the {{US Population}} {\textbar} {{American Journal}} of {{Epidemiology}} {\textbar} {{Oxford Academic}}},
  urldate = {2024-08-08},
  howpublished = {https://academic.oup.com/aje/article/166/8/975/108440}
}

@article{ImpairedCellSurface2023,
  title = {Impaired Cell Surface Expression of {{GLP1R}} Variants Determines {{T2D}} and Obesity Risk in Humans},
  year = {2023},
  month = oct,
  journal = {Nature Metabolism},
  volume = {5},
  number = {10},
  pages = {1654--1655},
  publisher = {Nature Publishing Group},
  issn = {2522-5812},
  doi = {10.1038/s42255-023-00888-7},
  urldate = {2024-01-20},
  abstract = {Glucagon-like peptide 1 (GLP-1) controls insulin secretion and body weight through activation of its receptor, GLP1R. Large-scale functional analysis of 60 GLP1R genetic variants revealed that loss-of-function (LoF) phenotypes, in particular of cell surface expression, are associated with impaired glucose control and increased adiposity.},
  copyright = {2023 Springer Nature Limited},
  langid = {english},
  keywords = {Obesity,Type 2 diabetes}
}

@article{iqbalComparisonMetaboliteNetworks2018,
  title = {Comparison of Metabolite Networks from Four {{German}} Population-Based Studies},
  author = {Iqbal, Khalid and Dietrich, Stefan and Wittenbecher, Clemens and Krumsiek, Jan and K{\"u}hn, Tilman and Lacruz, Maria Elena and Kluttig, Alexander and Prehn, Cornelia and Adamski, Jerzy and {von Bergen}, Martin and Kaaks, Rudolf and Schulze, Matthias B. and Boeing, Heiner and Floegel, Anna},
  year = {2018},
  month = dec,
  journal = {International Journal of Epidemiology},
  volume = {47},
  number = {6},
  pages = {2070--2081},
  issn = {1464-3685},
  doi = {10.1093/ije/dyy119},
  abstract = {BACKGROUND: Metabolite networks are suggested to reflect biological pathways in health and disease. However, it is unknown whether such metabolite networks are reproducible across different populations. Therefore, the current study aimed to investigate similarity of metabolite networks in four German population-based studies. METHODS: One hundred serum metabolites were quantified in European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam (n\,=\,2458), EPIC-Heidelberg (n\,=\,812), KORA (Cooperative Health Research in the Augsburg Region) (n\,=\,3029) and CARLA (Cardiovascular Disease, Living and Ageing in Halle) (n\,=\,1427) with targeted metabolomics. In a cross-sectional analysis, Gaussian graphical models were used to construct similar networks of 100 edges each, based on partial correlations of these metabolites. The four metabolite networks of the top 100 edges were compared based on (i) common features, i.e. number of common edges, Pearson correlation (r) and hamming distance (h); and (ii) meta-analysis of the four networks. RESULTS: Among the four networks, 57 common edges and 66 common nodes (metabolites) were identified. Pairwise network comparisons showed moderate to high similarity (r\,=\,63-0.96, h\,=\,7-72), among the networks. Meta-analysis of the networks showed that, among the 100 edges and 89 nodes of the meta-analytic network, 57 edges and 66 metabolites were present in all the four networks, 58-76 edges and 75-89 nodes were present in at least three networks, and 63-84 edges and 76-87 edges were present in at least two networks. The meta-analytic network showed clear grouping of 10 sphingolipids, 8 lyso-phosphatidylcholines, 31 acyl-alkyl-phosphatidylcholines, 30 diacyl-phosphatidylcholines, 8 amino acids and 2 acylcarnitines. CONCLUSIONS: We found structural similarity in metabolite networks from four large studies. Using a meta-analytic network, as a new approach for combining metabolite data from different studies, closely related metabolites could be identified, for some of which the biological relationships in metabolic pathways have been previously described. They are candidates for further investigation to explore their potential role in biological processes.},
  langid = {english},
  pmcid = {PMC6280930},
  pmid = {29982629},
  keywords = {Aged,Aging,Cardiovascular Diseases,Correlation of Data,Cross-Sectional Studies,Female,Germany,Humans,Male,Metabolic Networks and Pathways,Metabolome,Metabolomics,Middle Aged,Neoplasms,Normal Distribution,Nutrition Surveys},
  file = {/Users/xx20081/Zotero/storage/ZUBEFMRB/Iqbal et al. - 2018 - Comparison of metabolite networks from four German population-based studies.pdf}
}

@article{javorskyMissenseVariantGLP1R2016,
  title = {A Missense Variant in {{GLP1R}} Gene Is Associated with the Glycaemic Response to Treatment with Gliptins},
  author = {Javorsk{\'y}, M. and Gotthardov{\'a}, I. and Klim{\v c}{\'a}kov{\'a}, L. and Kvapil, M. and {\v Z}idzik, J. and Schroner, Z. and Doubravov{\'a}, P. and Gala, I. and Draveck{\'a}, I. and Tk{\'a}{\v c}, I.},
  year = {2016},
  month = sep,
  journal = {Diabetes, Obesity \& Metabolism},
  volume = {18},
  number = {9},
  pages = {941--944},
  issn = {1463-1326},
  doi = {10.1111/dom.12682},
  abstract = {Gliptins act by increasing endogenous incretin levels. Glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulinotropic peptide receptor (GIPR) are their indirect drug targets. Variants of GLP1R and GIPR have previously been associated with the incretin effect. The aim of the present pilot study was to examine associations of the GLP1R and GIPR gene variants with the glycaemic response to gliptins. A total of 140 consecutive patients with type 2 diabetes were followed-up 6\,months after initiation of gliptin treatment. GLP1R rs6923761 (Gly168Ser) and GIPR rs10423928 genotyping was performed using real-time PCR, with subsequent high-resolution melting analysis. The main study outcome was reduction in glycated haemoglobin (HbA1c) after treatment. GLP1R Gly168Ser variant was significantly associated with reduction in HbA1c in an additive model ({$\beta$}\,=\,-0.33, p\,=\,0.011). The mean reduction in HbA1c in Ser/Ser homozygotes was significantly lower compared with Gly-allele carriers [0.12\,{\textpm}\,0.23\% vs. 0.80\,{\textpm}\,0.09\% (1.3\,{\textpm}\,2.5\,mmol/mol vs. 8.7\,{\textpm}\,1.0\,mmol/mol); p\,=\,0.008]. In conclusion, GLP1R missense variant was associated with a reduced response to gliptin treatment. The genotype-related effect size of {$\sim$}0.7\% (8\,mmol/mol) is equal to an average effect of gliptin treatment and makes this variant a candidate for use in precision medicine.},
  langid = {english},
  pmid = {27160388},
  keywords = {Blood Glucose,Diabetes Mellitus Type 2,dipeptidyl peptidase inhibitor,Dipeptidyl-Peptidase IV Inhibitors,Female,Genotype,GLP1R polymorphism,Glucagon-Like Peptide-1 Receptor,Glycated Hemoglobin,Humans,Male,Middle Aged,Mutation Missense,oral antidiabetic drug,pharmacogenetics,Pharmacogenomic Variants,Pilot Projects,Precision Medicine,Real-Time Polymerase Chain Reaction,Receptors Gastrointestinal Hormone,Treatment Outcome},
  file = {/Users/xx20081/Zotero/storage/QKELUND5/Javorsk et al. - 2016 - A missense variant in GLP1R gene is associated wit.pdf}
}

@article{jCausalRelationshipHeart2023,
  title = {Causal Relationship from Heart Failure to Kidney Function and {{CKD}}: {{A}} Bidirectional Two-Sample Mendelian Randomization Study},
  shorttitle = {Causal Relationship from Heart Failure to Kidney Function and {{CKD}}},
  author = {J, Zhang and Z, Hu and Y, Tan and J, Ye},
  year = {2023},
  month = nov,
  journal = {PloS one},
  volume = {18},
  number = {12},
  publisher = {PLoS One},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0295532},
  urldate = {2024-04-18},
  abstract = {Our study demonstrates the significance of HF in CKD progression, thus having meaningful implications for treatment and the potential for discovering new therapies. To better understand the relationship between HF and CKD, we need to conduct research in a variety of populations.},
  langid = {english},
  pmid = {38079381},
  file = {/Users/xx20081/Zotero/storage/7KKC4FHK/J et al. - 2023 - Causal relationship from heart failure to kidney f.pdf;/Users/xx20081/Zotero/storage/QUMHITEQ/38079381.html}
}

@article{jcIntensiveLipidLowering2005,
  title = {Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease},
  author = {Jc, LaRosa and Sm, Grundy and Dd, Waters and C, Shear and P, Barter and Jc, Fruchart and Am, Gotto and H, Greten and Jj, Kastelein and J, Shepherd and Nk, Wenger},
  year = {2005},
  month = jul,
  journal = {The New England journal of medicine},
  volume = {352},
  number = {14},
  publisher = {N Engl J Med},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa050461},
  urldate = {2023-12-08},
  abstract = {Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg of atorvastatin per day. This occurred with a greater incidence of elevated aminotransferase levels.},
  langid = {english},
  pmid = {15755765},
  file = {/Users/xx20081/Zotero/storage/C68V7WTX/Jc et al. - 2005 - Intensive lipid lowering with atorvastatin in pati.pdf;/Users/xx20081/Zotero/storage/IDZJ62ED/15755765.html}
}

@article{jenkinsAdiposityMortalityRelationshipsType2018,
  title = {Adiposity-{{Mortality Relationships}} in {{Type}} 2 {{Diabetes}}, {{Coronary Heart Disease}}, and {{Cancer Subgroups}} in the {{UK Biobank}}, and {{Their Modification}} by {{Smoking}}},
  author = {Jenkins, David A. and Bowden, Jack and Robinson, Heather A. and Sattar, Naveed and Loos, Ruth J.F. and Rutter, Martin K. and Sperrin, Matthew},
  year = {2018},
  month = jul,
  journal = {Diabetes Care},
  volume = {41},
  number = {9},
  pages = {1878--1886},
  issn = {0149-5992},
  doi = {10.2337/dc17-2508},
  urldate = {2025-01-22},
  abstract = {The obesity paradox in which overweight/obesity is associated with mortality benefits is believed to be explained by confounding and reverse causality rather than by a genuine clinical benefit of excess body weight. We aimed to gain deeper insights into the paradox through analyzing mortality relationships with several adiposity measures; assessing subgroups with type 2 diabetes, with coronary heart disease (CHD), with cancer, and by smoking status; and adjusting for several confounders.We studied the general UK Biobank population (N = 502,631) along with three subgroups of people with type 2 diabetes (n = 23,842), CHD (n = 24,268), and cancer (n = 45,790) at baseline. A range of adiposity exposures were considered, including BMI (continuous and categorical), waist circumference, body fat percentage, and waist-to-hip ratio, and the outcome was all-cause mortality. We used Cox regression models adjusted for age, smoking status, deprivation index, education, and disease history.For BMI, the obesity paradox was observed among people with type 2 diabetes (adjusted hazard ratio for obese vs. normal BMI 0.78 [95\% CI 0.65, 0.95]) but not among those with CHD (1.00 [0.86, 1.17]). The obesity paradox was pronounced in current smokers, absent in never smokers, and more pronounced in men than in women. For other adiposity measures, there was less evidence for an obesity paradox, yet smoking status consistently modified the adiposity-mortality relationship.The obesity paradox was observed in people with type 2 diabetes and is heavily modified by smoking status. The results of subgroup analyses and statistical adjustments are consistent with reverse causality and confounding.},
  file = {/Users/xx20081/Zotero/storage/KXCBALA6/Jenkins et al. - 2018 - Adiposity-Mortality Relationships in Type 2 Diabetes, Coronary Heart Disease, and Cancer Subgroups i.pdf;/Users/xx20081/Zotero/storage/AYQF2RUN/Adiposity-Mortality-Relationships-in-Type-2.html}
}

@article{jenkinsEstimatingCausalEffect2021,
  title = {Estimating the Causal Effect of {{BMI}} on Mortality Risk in People with Heart Disease, Diabetes and Cancer Using {{Mendelian}} Randomization},
  author = {Jenkins, David A. and Wade, Kaitlin H. and Carslake, David and Bowden, Jack and Sattar, Naveed and Loos, Ruth J. F. and Timpson, Nicholas J. and Sperrin, Matthew and Rutter, Martin K.},
  year = {2021},
  month = may,
  journal = {International Journal of Cardiology},
  volume = {330},
  pages = {214--220},
  issn = {1874-1754},
  doi = {10.1016/j.ijcard.2021.02.027},
  abstract = {BACKGROUND: Observational data have reported that being overweight or obese, compared to being normal weight, is associated with a lower risk for death - the "obesity paradox". We used Mendelian randomization (MR) to estimate causal effects of body mass index (BMI) on mortality risks in people with coronary heart disease (CHD), type 2 diabetes mellitus (T2DM) or malignancy in whom this paradox has been often reported. METHODS: We studied 457,746 White British UK Biobank participants including three subgroups with T2DM (n~=~19,737), CHD (n~=~21,925) or cancer (n~=~42,612) at baseline and used multivariable-adjusted Cox models and MR approaches to describe relationships between BMI and mortality risk. RESULTS: Observational Cox models showed J-shaped relationships between BMI and mortality risk including within disease subgroups in which the BMI values associated with minimum mortality risk were within overweight/obese ranges (26.5-32.5~kg/m2). In all participants, MR analyses showed a positive linear causal effect of BMI on mortality risk (HR for mortality per unit higher BMI: 1.05; 95\% CI: 1.03-1.08), also evident in people with CHD (HR: 1.08; 95\% CI: 1.01-1.14). Point estimates for hazard ratios across all BMI values in participants with T2DM and cancer were consistent with overall positive linear effects but confidence intervals included the null. CONCLUSION: These data support the idea that population efforts to promote intentional weight loss towards the normal BMI range would reduce, not enhance, mortality risk in the general population including, importantly, individuals with CHD.},
  langid = {english},
  pmid = {33592239},
  keywords = {Body Mass Index,Coronary heart disease,Diabetes Mellitus Type 2,Humans,Mendelian Randomization Analysis,Mortality,Neoplasms,Obesity,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/UTQASITL/Jenkins et al. - 2021 - Estimating the causal effect of BMI on mortality risk in people with heart disease, diabetes and can.pdf}
}

@article{jensterleGeneticVariabilityGLP12015,
  title = {Genetic Variability in {{GLP-1}} Receptor Is Associated with Inter-Individual Differences in Weight Lowering Potential of Liraglutide in Obese Women with {{PCOS}}: A Pilot Study},
  shorttitle = {Genetic Variability in {{GLP-1}} Receptor Is Associated with Inter-Individual Differences in Weight Lowering Potential of Liraglutide in Obese Women with {{PCOS}}},
  author = {Jensterle, Mojca and Pir{\v s}, Bo{\v s}tjan and Gori{\v c}ar, Katja and Dol{\v z}an, Vita and Jane{\v z}, Andrej},
  year = {2015},
  month = jul,
  journal = {European Journal of Clinical Pharmacology},
  volume = {71},
  number = {7},
  pages = {817--824},
  issn = {1432-1041},
  doi = {10.1007/s00228-015-1868-1},
  abstract = {PURPOSE: The weight lowering potential of glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) is inter-individually different and clinically unpredictable. The potential role of genetic variability of GLP-1R on body weight response to GLP-1 RAs in obese women with polycystic ovary syndrome (PCOS) has not yet been evaluated. METHODS: Fifty-seven obese women with PCOS (aged 30.7 {\textpm} 7.0, BMI 38.6 {\textpm} 5.3 kg/m(2)) were assigned to liraglutide 1.2 mg QD s.c. for 12 weeks and classified as strong responders regarding weight loss if they lost 5\% or more of their initial body weight. They were genotyped for common GLP-1R single nucleotide polymorphisms (SNPs) rs6923761 and rs10305420. Changes of measures of obesity were measured before and at the end of the treatment. RESULTS: Twenty out of 57 subjects were strong responders and lost 7.38 {\textpm} 1.74 compared to 2.11 {\textpm} 2.17 kg lost in poor responders. Carriers of at least one polymorphic rs10305420 allele had poor treatment response compared to carriers of two wild type alleles (OR = 0.27, 95\% CI = 0.09-0.85, P = 0.025). Carriers of at least one polymorphic rs6923761 allele tended to have stronger treatment response compared to carriers of two wild type alleles (OR = 3.06, 95\% CI = 0.96-9.74, P = 0.058). Fasting glucose and glucose after oral glucose tolerance test (OGTT) comparably decreased in both groups when compared to baseline, whereas no within treatment differences were found in androgen profile. Gastrointestinal adverse events were transit and balanced between strong and poor responders. CONCLUSIONS: GLP-1R rs10305420 polymorphism explained some of the inter-individual differences in response to liraglutide regarding weight loss in obese PCOS women.},
  langid = {english},
  pmid = {25991051},
  keywords = {Adult,Female,Gene Frequency,Genotype,Glucagon-Like Peptide-1 Receptor,Humans,Incretins,Liraglutide,Logistic Models,Obesity,Odds Ratio,Phenotype,Pilot Projects,Polycystic Ovary Syndrome,Polymorphism Single Nucleotide,Slovenia,Treatment Outcome,Weight Loss,Young Adult},
  file = {/Users/xx20081/Zotero/storage/3YR2AYCB/Jensterle et al. - 2015 - Genetic variability in GLP-1 receptor is associate.pdf}
}

@article{jGenomewideAssociationStudy2013,
  title = {Genome-Wide Association Study Identifies 8 Novel Loci Associated with Blood Pressure Responses to Interventions in {{Han Chinese}}},
  author = {J, He and Tn, Kelly and Q, Zhao and H, Li and J, Huang and L, Wang and Ce, Jaquish and Yj, Sung and Lc, Shimmin and F, Lu and J, Mu and D, Hu and X, Ji and C, Shen and D, Guo and J, Ma and R, Wang and J, Shen and S, Li and J, Chen and H, Mei and Cs, Chen and S, Chen and J, Chen and J, Li and J, Cao and X, Lu and X, Wu and Tk, Rice and Cc, Gu and K, Schwander and Ll, Hamm and D, Liu and Dc, Rao and Je, Hixson and D, Gu},
  year = {2013},
  month = dec,
  journal = {Circulation. Cardiovascular genetics},
  volume = {6},
  number = {6},
  publisher = {Circ Cardiovasc Genet},
  issn = {1942-3268},
  doi = {10.1161/CIRCGENETICS.113.000307},
  urldate = {2024-04-12},
  abstract = {Our study identified 8 novel loci for BP responses to dietary sodium and potassium intervention and cold pressor test. The effect size of these novel loci on BP phenotypes is much larger than those reported by the previously published studies. Furthermore, these variants predict the risk of developi {\dots}},
  langid = {english},
  pmid = {24165912},
  file = {/Users/xx20081/Zotero/storage/KALAZY9Z/J et al. - 2013 - Genome-wide association study identifies 8 novel l.pdf}
}

@article{jiangGeneralizedLinearMixed2021,
  title = {A Generalized Linear Mixed Model Association Tool for Biobank-Scale Data},
  author = {Jiang, Longda and Zheng, Zhili and Fang, Hailing and Yang, Jian},
  year = {2021},
  month = nov,
  journal = {Nature Genetics},
  volume = {53},
  number = {11},
  pages = {1616--1621},
  issn = {1546-1718},
  doi = {10.1038/s41588-021-00954-4},
  abstract = {Compared with linear mixed model-based genome-wide association (GWA) methods, generalized linear mixed model (GLMM)-based methods have better statistical properties when applied to binary traits but are computationally much slower. In the present study, leveraging efficient sparse matrix-based algorithms, we developed a GLMM-based GWA tool, fastGWA-GLMM, that is severalfold to orders of magnitude faster than the state-of-the-art tools when applied to the UK Biobank (UKB) data and scalable to cohorts with millions of individuals. We show by simulation that the fastGWA-GLMM test statistics of both common and rare variants are well calibrated under the null, even for traits with extreme case-control ratios. We applied fastGWA-GLMM to the UKB data of 456,348 individuals, 11,842,647 variants and 2,989 binary traits (full summary statistics available at http://fastgwa.info/ukbimpbin ), and identified 259 rare variants associated with 75 traits, demonstrating the use of imputed genotype data in a large cohort to discover rare variants for binary complex traits.},
  langid = {english},
  pmid = {34737426},
  keywords = {Adult,Aged,Algorithms,Biological Specimen Banks,Case-Control Studies,Genetic Variation,Genome-Wide Association Study,Genotype,Humans,Linear Models,Middle Aged,Models Genetic,Phenotype,United Kingdom},
  file = {/Users/xx20081/Zotero/storage/JH569MJ7/Jiang et al. - 2021 - A generalized linear mixed model association tool .pdf}
}

@article{jIdentifyingBMIassociatedGenes2024,
  title = {Identifying {{BMI-associated}} Genes via a Genome-Wide Multi-Omics Integrative Approach Using Summary Data},
  author = {J, Tang and H, Xu and Z, Xin and Q, Mei and M, Gao and T, Yang and X, Zhang and D, Levy and Ct, Liu},
  year = {2024},
  month = aug,
  journal = {Human molecular genetics},
  volume = {33},
  number = {8},
  publisher = {Hum Mol Genet},
  issn = {1460-2083},
  doi = {10.1093/hmg/ddad212},
  urldate = {2024-12-28},
  abstract = {This study integrated three types of omics data and identified a group of genes that have not previously been reported to be associated with BMI. This strategy could provide new insights for future studies to identify molecular mechanisms contributing to BMI regulation.},
  langid = {english},
  pmid = {38215789},
  file = {/Users/xx20081/Zotero/storage/A4I86TLD/38215789.html}
}

@article{jinHeritabilityLeftVentricular2011,
  title = {Heritability of Left Ventricular Structure and Function in {{Caucasian}} Families},
  author = {Jin, Yu and Kuznetsova, Tatiana and Bochud, Murielle and Richart, Tom and Thijs, Lutgarde and Cusi, Daniele and Fagard, Robert and Staessen, Jan A.},
  year = {2011},
  month = apr,
  journal = {European Journal of Echocardiography: The Journal of the Working Group on Echocardiography of the European Society of Cardiology},
  volume = {12},
  number = {4},
  pages = {326--332},
  issn = {1532-2114},
  doi = {10.1093/ejechocard/jer019},
  abstract = {AIMS: The aim of this study was to investigate the heritability as well as genetic and environmental correlations of left ventricular (LV) structural and functional traits in complex pedigrees of a Caucasian population. METHODS AND RESULTS: We randomly recruited 459 white European subjects from 52 families (50\% women; mean age 45 years). LV structure was measured by M-mode and 2D echocardiography and LV function was measured by conventional Doppler and tissue Doppler imaging (TDI). Other measurements included blood pressure, anthropometric, and biochemical measurements. We estimated the heritability of LV traits while adjusting for covariables, including sex, age, body height and weight, systolic and diastolic blood pressures, and heart rate. With full adjustment, heritability of LV mass was 0.23 (P= 0.025). The TDI-derived mitral annular velocities Ea and Aa showed moderate heritability (h(2)= 0.36 and 0.53, respectively), whereas the mitral inflow A peak had weak heritability (h(2) = 0.25) and the E peak was not heritable (h(2) = 0.11). We partitioned the total phenotypic correlation when it reached significance, into a genetic and an environmental component. The genetic correlations were 0.61 between the E and Ea peaks and 0.90 between the A and Aa peaks. CONCLUSION: Our study demonstrated moderate heritability for LV mass as well as the mitral annular Ea and Aa peaks. We also found significant genetic correlations between the E and Ea peaks and between the A and Aa peaks. Our current findings support the ongoing research to map and detect genetic variants that contribute to the variation in LV mass and other LV structural and functional phenotypes.},
  langid = {english},
  pmcid = {PMC3106286},
  pmid = {21398654},
  keywords = {Adult,Anthropometry,Biomarkers,Blood Pressure,Echocardiography Doppler,Female,Genotype,Humans,Hypertrophy Left Ventricular,Male,Middle Aged,Phenotype,Regression Analysis,White People},
  file = {/Users/xx20081/Zotero/storage/W66AAGB3/Jin et al. - 2011 - Heritability of left ventricular structure and fun.pdf}
}

@article{JJ2014,
  title = {Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure},
  author = {JJ, McMurray and M, Packer and AS, Desai and J, Gong and MP, Lefkowitz and AR, Rizkala and JL, Rouleau and VC, Shi and SD, Solomon and K, Swedberg and MR, Zile},
  year = {2014},
  journal = {The New England journal of medicine},
  volume = {371},
  number = {11},
  pages = {132--133},
  publisher = {N Engl J Med},
  issn = {1533-4406},
  doi = {10.1056/NEJMOA1409077},
  abstract = {Background We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. Methods: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40\% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. Results: The trial was stopped early, according to prespecified rules, after a median followup of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8\%) in the LCZ696 group and 1117 patients (26.5\%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95\% confidence interval [CI], 0.73 to 0.87; P{\textexclamdown} 0.001). A total of 711 patients (17.0\%) receiving LCZ696 and 835 patients (19.8\%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95\% CI, 0.76 to 0.93; P{\textexclamdown} 0.001); of these patients, 558 (13.3\%) and 693 (16.5\%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95\% CI, 0.71 to 0.89; P{\textexclamdown} 0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21\% (P{\textexclamdown} 0.001) and decreased the symptoms and physical limitations of heart failure (P = 0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. Conclusions: LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure.},
  isbn = {1533-4406 (Electronic){\r 0}028-4793 (Linking)},
  pmid = {25176015},
  keywords = {affs=[],affs=[]),Aged,Aminobutyrates / adverse effects,Aminobutyrates / therapeutic use*,Angiotensin Receptor Antagonists / adverse effects,Angiotensin Receptor Antagonists / therapeutic use*,Angiotensin-Converting Enzyme Inhibitors / adverse effects,Angiotensin-Converting Enzyme Inhibitors / therapeutic use,Author(firstnames='A',Author(firstnames='Abdel',Author(firstnames='Akshay S',Author(firstnames='Alber-Alain',Author(firstnames='Albert Alain',Author(firstnames='Ali',Author(firstnames='Allen P',Author(firstnames='Andrej',Author(firstnames='Andrejs',Author(firstnames='Angel',Author(firstnames='Antonio S',Author(firstnames='Arend',Author(firstnames='Arvo',Author(firstnames='B H',Author(firstnames='B-J',Author(firstnames='B-S',Author(firstnames='B',Author(firstnames='Bela',Author(firstnames='Bruce',Author(firstnames='C H',Author(firstnames='C P',Author(firstnames='C-H',Author(firstnames='C',Author(firstnames='Carlos',Author(firstnames='Chau',Author(firstnames='D Eric',Author(firstnames='D Jansen',Author(firstnames='D K',Author(firstnames='D-G',Author(firstnames='D-H',Author(firstnames='D-S',Author(firstnames='D',Author(firstnames='David',Author(firstnames='Dragos',Author(firstnames='E',Author(firstnames='Ebrahim',Author(firstnames='Edmundo Bayram',Author(firstnames='Efrain',Author(firstnames='F L',Author(firstnames='F',Author(firstnames='Felipe',Author(firstnames='Felix',Author(firstnames='G S',Author(firstnames='G-R',Author(firstnames='G',Author(firstnames='Gary S',Author(firstnames='H D',Author(firstnames='H F',Author(firstnames='H M',Author(firstnames='H-G',Author(firstnames='H-H',Author(firstnames='H-J',Author(firstnames='H-M',Author(firstnames='H-Y',Author(firstnames='H',Author(firstnames='Henry',Author(firstnames='Howard',Author(firstnames='I H',Author(firstnames='I',Author(firstnames='Iain',Author(firstnames='Ivan',Author(firstnames='J A',Author(firstnames='J C',Author(firstnames='J H',Author(firstnames='J Silva',Author(firstnames='J-B',Author(firstnames='J-E',Author(firstnames='J-H',Author(firstnames='J-M',Author(firstnames='J-N',Author(firstnames='J',Author(firstnames='Jan',Author(firstnames='Jean',Author(firstnames='Jens',Author(firstnames='Johan',Author(firstnames='John',Author(firstnames='Jose',Author(firstnames='Juan Luis',Author(firstnames='Jun',Author(firstnames='K L',Author(firstnames='K-H',Author(firstnames='K',Author(firstnames='Karl',Author(firstnames='Kee-Sik',Author(firstnames='Keijo',Author(firstnames='L G',Author(firstnames='L Y',Author(firstnames='L',Author(firstnames='Larry',Author(firstnames='Lesley',Author(firstnames='M B',Author(firstnames='M G',Author(firstnames='M S',Author(firstnames='M Srinivasa',Author(firstnames='M',Author(firstnames='Malcolm',Author(firstnames='Marta',Author(firstnames='Martin',Author(firstnames='Michael',Author(firstnames='Michel',Author(firstnames='Michele',Author(firstnames='Milton',Author(firstnames='N L',Author(firstnames='N Srinivasa',Author(firstnames='N-T To',Author(firstnames='N',Author(firstnames='Nancy',Author(firstnames='Natalie',Author(firstnames='Nicola',Author(firstnames='O',Author(firstnames='Ole',Author(firstnames='Omer',Author(firstnames='P S',Author(firstnames='P V',Author(firstnames='P Y',Author(firstnames='P',Author(firstnames='Pardeep',Author(firstnames='Peter',Author(firstnames='R P',Author(firstnames='R',Author(firstnames='Randall',Author(firstnames='Raymond',Author(firstnames='Robert',Author(firstnames='S H',Author(firstnames='S K',Author(firstnames='S W',Author(firstnames='S-M',Author(firstnames='S',Author(firstnames='Scott',Author(firstnames='Sergey',Author(firstnames='Songsak',Author(firstnames='Stefan',Author(firstnames='Stuart',Author(firstnames='T',Author(firstnames='Tzvetana',Author(firstnames='U',Author(firstnames='V',Author(firstnames='W M',Author(firstnames='W',Author(firstnames='Walter',Author(firstnames='X D',Author(firstnames='X H',Author(firstnames='X L',Author(firstnames='Y N',Author(firstnames='Y',Author(firstnames='Yan Carlo',Author(firstnames='Yan Carlos',Author(firstnames='Z Y',Author(firstnames='Z',Author(firstnames='Zaneta',Biphenyl Compounds,CollabAuthor(name='PARADIGM-HF Investigators and Committees',Comparative Study,doi:10.1056/NEJMoa1409077,Double-Blind Method,Drug Combinations,Enalapril / adverse effects,Enalapril / therapeutic use*,equal<sub>c</sub>ontrib=False),equal<sub>c</sub>ontrib=False)],Female,Heart Failure / drug therapy*,Heart Failure / mortality,Hospitalization / statistics & numerical data,Humans,initials='A',initials='AA',initials='AP',initials='AS',initials='B',initials='BH',initials='BJ',initials='BS',initials='C',initials='CH',initials='CP',initials='D',initials='DE',initials='DG',initials='DH',initials='DJ',initials='DS',initials='E',initials='EB',initials='F',initials='FL',initials='G',initials='GR',initials='GS',initials='H',initials='HD',initials='HF',initials='HG',initials='HH',initials='HJ',initials='HM',initials='HY',initials='I',initials='IH',initials='J',initials='JB',initials='JC',initials='JE',initials='JH',initials='JL',initials='JM',initials='JN',initials='K',initials='KH',initials='KL',initials='KS',initials='L',initials='LG',initials='LY',initials='M',initials='MB',initials='MS',initials='N',initials='NL',initials='NS',initials='NT',initials='O',initials='P',initials='PS',initials='PY',initials='R',initials='RP',initials='S',initials='SH',initials='SK',initials='SM',initials='SW',initials='T',initials='U',initials='V',initials='W',initials='WM',initials='XD',initials='XH',initials='XL',initials='Y',initials='YC',initials='YN',initials='Z',initials='ZY',investigators=[Author(firstnames='John',iseditor=False,John J V McMurray,Kaplan-Meier Estimate,lastname='Abhyankar',lastname='Accini',lastname='Adamson',lastname='Adelberger',lastname='Agarwal',lastname='Ageev',lastname='Aggarwal',lastname='Aguilera',lastname='Ahlstrom',lastname='Ahmad',lastname='Ahmed',lastname='Akimov',lastname='Akinboboye',lastname='Aktoz',lastname='Akyea-Djamson',lastname='Al-Zoebi',lastname='Albisu',lastname='Albornoz',lastname='Alegre',lastname='Alexeeva-Kovalchuk',lastname='Almanzar',lastname='Almeida',lastname='Alvarez',lastname='Alvarisqueta',lastname='Amin',lastname='Amkieh',lastname='Amos',lastname='Amuchastegui',lastname='Anand',lastname='Anastasio',lastname='Andersen',lastname='Andor',lastname='Andrade',lastname='Andrassy',lastname='Andreka',lastname='Anonuevo',lastname='Antalik',lastname='Apostolakis',lastname='Arango',lastname='Arenas',lastname='Arias-Castano',lastname='Arnold',lastname='Aronson',lastname='Arriola',lastname='Astesiano',lastname='Atilano',lastname='Avendano',lastname='Averkov',lastname='Avila',lastname='Aviles',lastname='Awasty',lastname='Azanero',lastname='Baben',lastname='Badat',lastname='Baek',lastname='Bagirath',lastname='Bakai',lastname='Baldin',lastname='Ballyuzek',lastname='Banerjee',lastname='Banikova',lastname='Banish',lastname='Bank',lastname='Banker',lastname='Baranov',lastname='Baranova',lastname='Barbarash',lastname='Barcin',lastname='Bargout',lastname='Barkoudah',lastname='Barnard',lastname='Barr',lastname='Bartos',lastname='Basarab',lastname='Basart',lastname='Basavanagowdappa',lastname='Bassan',lastname='Basson',lastname='Bastian',lastname='Bauer',lastname='Beacom',lastname='Bebenek',lastname='Behrens',lastname='Bellersen',lastname='Bello',lastname='Belohlavek',lastname='Beloscar',lastname='Ben Gal',lastname='Benov',lastname='Berdague',lastname='Berg',lastname='Bergeron',lastname='Berk',lastname='Berkovich',lastname='Berli',lastname='Berneau',lastname='Berns',lastname='Bessler',lastname='Bessonova',lastname='Best',lastname='Bester',lastname='Bhatia',lastname='Bilazarian',lastname='Birdane',lastname='Bisne',lastname='Boeva-Chompalova',lastname='Bogle',lastname='Bohm',lastname='Bohra',lastname='Boitsov',lastname='Boos',lastname='Borelli',lastname='Borrego',lastname='Borromeo',lastname='Botelho',lastname='Bouchard',lastname='Bourgeois',lastname='Bouvier',lastname='Boyarkin',lastname='Boytsov',lastname='Bozkurt',lastname='Braga',lastname='Braganca',lastname='Brahimi',lastname='Braile',lastname='Braun',lastname='Brehm',lastname='Breisblatt',lastname='Brigden',lastname='Brookfield',lastname='Brown',lastname='Browne',lastname='Brunelli',lastname='Bruning',lastname='Brunner-la Rocca',lastname='Buhr',lastname='Bulashova',lastname='Bulugahapitiya',lastname='Burgess',lastname='Burianova',lastname='Bustos',lastname='Cabrera',lastname='Calella',lastname='Calvo',lastname='Camsari',lastname='Canadas-Zizzias',lastname='Carbajales',lastname='Carda',lastname='Cardoso',lastname='Carr',lastname='Carrillo',lastname='Caruso',lastname='Carvalho',lastname='Casabe',lastname='Casolo',lastname='Castillo',lastname='Cech',lastname='Cepelak',lastname='Cha',lastname='Chapman',lastname='Charytan',lastname='Chen',lastname='Chernetsov',lastname='Chew',lastname='Chobanska',lastname='Chopra',lastname='Chu',lastname='Chua',lastname='Chukaeva',lastname='Chung',lastname='Cieslinski',lastname='Cimbaro Canella',lastname='Cobos',lastname='Colan',lastname='Colombo Berra',lastname='Colque',lastname='Coman',lastname='Comin',lastname='Copaci',lastname='Coppolino',lastname='Corona',lastname='Coronel',lastname='Cosin',lastname='Cosmi',lastname='Costa',lastname='Costello',lastname='Cotes',lastname='Cremer',lastname='Crespo',lastname='Cristea',lastname='Csapo',lastname='Cymerman',lastname='Cziraki',lastname='Dabrowska',lastname='Damien',lastname='Damy',lastname='Dani',lastname='Danzi',lastname='Dargie',lastname='Daut',lastname='Davis',lastname='Davy',lastname='Dayer',lastname='de Nooijer',lastname='de Teresa',lastname='Deben',lastname='Decoulx',lastname='Decroly',lastname='DeGrace',lastname='Delgado',lastname='Delport',lastname='Demesova',lastname='Demmig',lastname='den Hartog',lastname='Denchev',lastname='Dendale',lastname='Denning',lastname='Denny',lastname='Derks',lastname='Desai',lastname='Deslongchamps',lastname='Destro',lastname='Dexter',lastname='Dharma',lastname='Dharmadhikari',lastname='Di Napoli',lastname='Dijkgraaf',lastname='Dimov',lastname='Dindar',lastname='Dion',lastname='Donova',lastname='Dormidontova',lastname='Dovgalevsky',lastname='Dovgolis',lastname='Dragulescu',lastname='Dran',lastname='Duarte',lastname='Duda',lastname='Dukat',lastname='Dunselman',lastname='Duong',lastname='Duplyakov',lastname='Dutka',lastname='Dvorzak',lastname='Ebert',lastname='Echeverria',lastname='Ector',lastname='Edes',lastname='Edwards',lastname='Efstratiadis',lastname='Eglite',lastname='Egstrup',lastname='Eisen',lastname='El-Harari',lastname='El-Mansour',lastname='Elming',lastname='Enache',lastname='Erglis',lastname='Ermis',lastname='Ermoshkina',lastname='Escobar',lastname='Eske',lastname='Etchecopar',lastname='Fattal',lastname='Fazekas',lastname='Fechtrup',lastname='Fenster',lastname='Fernandez-Aviles',lastname='Fernandez',lastname='Ferre Pacora',lastname='Ferrolino',lastname='Finn',lastname='Fischer',lastname='Fisher',lastname='Fitilev',lastname='Flores',lastname='Floro',lastname='Foccart',lastname='Foczpaniak',lastname='Foldiova',lastname='Foley',lastname='Fonseca',lastname='Forster',lastname='Frago',lastname='Francis',lastname='Freixa',lastname='Friart',lastname='Frick',lastname='Frivold',lastname='Fruntelata',lastname='Fu',lastname='Fucili',lastname='Fuhs',lastname='Fulop',lastname='Fulwani',lastname='Gaballa',lastname='Gabito',lastname='Gadkari',lastname='Galinier',lastname='Galve',lastname='Galyavich',lastname='Gani',lastname='Garcia',lastname='Gendlin',lastname='Genth-Zotz',lastname='Georgiev',lastname='Gerbaulet',lastname='Germann',lastname='Gerntholtz',lastname='Gessner',lastname='Ghaisas',lastname='Ghandi',lastname='Giannetti',lastname='Gibelin',lastname='Gigantino',lastname='Glenny',lastname='Glover',lastname='Godoy',lastname='Gofman',lastname='Gola',lastname='Goland',lastname='Goldscher',lastname='Goloschekin',lastname='Gomez-Huelgas',lastname='Gomez',lastname='Gomova',lastname='Gonzalez-Bueno',lastname='Gonzalez',lastname='Gordienko',lastname='Gosse',lastname='Gotchev',lastname='Gotzsche',lastname='Goudev',lastname='Gould',lastname='Grazette',lastname='Greco',lastname='Greenlaw',lastname='Gronefeld',lastname='Gruev',lastname='Gudnason',lastname='Guerrero',lastname='Guetlin',lastname='Gui',lastname='Gupta',lastname='Guray',lastname='Gurlek',lastname='Guzman',lastname='Haas',lastname='Habet',lastname='Hack',lastname='Hagege',lastname='Hagenow',lastname='Hagerman',lastname='Haidar',lastname='Hajimirsadeghi',lastname='Hajko',lastname='Halpern',lastname='Hampf',lastname='Hansson',lastname='Hanustiakova',lastname='Hargrove',lastname='Harris',lastname='Hart',lastname='Hartley',lastname='Hartmann',lastname='Hass',lastname='Hattler',lastname='Hauf',lastname='Hazelrigg',lastname='Hegeler-Molkewehrum',lastname='Hegemann',lastname='Heilman',lastname='Heiman',lastname='Hellstrom',lastname='Hengrussamee',lastname='Heredia',lastname='Hergeldjieva',lastname='Hermes',lastname='Hernandes',lastname='Heroux',lastname='Herzog',lastname='Heyse',lastname='Hidalgo',lastname='Himpel-Bonninghoff',lastname='Hiremath',lastname='Hoedemaker',lastname='Hoeltz',lastname='Hoffman',lastname='Hong',lastname='Horak',lastname='Horny',lastname='Hotchkiss',lastname='Hsu',lastname='Hu',lastname='Huang',lastname='Hunter',lastname='Huynh',lastname='Ibanez',lastname='Iliescu',lastname='Illes',lastname='Ingaramo',lastname='Ismail',lastname='Istratoaie',lastname='Iteld',lastname='Jaaskelainen',lastname='Jackson',lastname='Jaeger',lastname='Jaffrani',lastname='Jagtap',lastname='Jain',lastname='Jalil',lastname='James',lastname='Jamjam',lastname='Janik',lastname='Janoskuti',lastname='Jardula',lastname='Jazwinska-Tarnawska',lastname='Jensen',lastname='Jerwan-Keim',lastname='Jhund',lastname='Jimenez',lastname='Jindal',lastname='Johnston',lastname='Joseph',lastname='Kaasik',lastname='Kabaivanov',lastname='Kabara',lastname='Kadel',lastname='Kadr',lastname='Kaik',lastname='Kalina',lastname='Kalra',lastname='Kamensky',lastname='Kaneshige',lastname='Kang',lastname='Kania',lastname='Kaplan',lastname='Kapp',lastname='Kardos',lastname='Karle',lastname='Karpov',lastname='Kastanayan',lastname='Katova',lastname='Katz',lastname='Ke',lastname='Kempe',lastname='Keren',lastname='Kerkar',lastname='Khan',lastname='Khromtsova',lastname='Kiatchoosakun',lastname='Kiilavuori',lastname='Kim',lastname='Kindermann',lastname='Kisliak',lastname='Klapholz',lastname='Klinke',lastname='Knapp',lastname='Kobalava',lastname='Kober',lastname='Koehler',lastname='Kolaczyk',lastname='Kolar',lastname='Komajda',lastname='Konradi',lastname='Koolen',lastname='Koren',lastname='Kornder',lastname='Korolev',lastname='Kosmacheva',lastname='Kostenko',lastname='Kostis',lastname='Kotliar',lastname='Kovacs',lastname='Kozan',lastname='Koziolova',lastname='Krause',lastname='Krosse',lastname='Krupicka',lastname='Kucharski',lastname='Kudat',lastname='Kuhne',lastname='Kuhrs',lastname='Kuimov',lastname='Kulibaba',lastname='Kumbla',lastname='Kvasnicka',lastname='Laane',lastname='Labeque',lastname='Labonte',lastname='Lanas',lastname='Landa',lastname='Lang',lastname='Larrain',lastname='Lasala',lastname='Laszlo',lastname='Latiff',lastname='Laufer',lastname='Lauzon',lastname='Lazov',lastname='Leal',lastname='Lebedev',lastname='Lederballe',lastname='Lee',lastname='Lefkowitz',lastname='Leicht',lastname='Lembo',lastname='Leon de la Fuente',lastname='Leon',lastname='Leonen',lastname='Lepage',lastname='Lerumo',lastname='Leslie',lastname='Lesnov',lastname='Levy',lastname='Lewis',lastname='Li',lastname='Liberato',lastname='Liberman',lastname='Libis',lastname='Lieber',lastname='Liem',lastname='Lighezan',lastname='Lin',lastname='Lindovsky',lastname='Liniado',lastname='Liu',lastname='Livarek',lastname='Llamas',lastname='Llanos',lastname='Lobe',lastname='Lobo Marquez',lastname='Locnen',lastname='Logeart',lastname='Lombaard',lastname='Lombardi',lastname='Loos',lastname='Lopatin',lastname='Lopez',lastname='Lorenc',lastname='Lu',lastname='Luis-Arias',lastname='Luiz Rech',lastname='Luksiene',lastname='Lupkovics',lastname='Luquez',lastname='Lvova',lastname='Lynch',lastname='Ma',lastname='Macek',lastname='MacFadyen',lastname='Macias',lastname='Mackinnon',lastname='Magno',lastname='Magrini',lastname='Maher',lastname='Mahmood',lastname='Mainar',lastname='Maisel',lastname='Maislos',lastname='Majercak',lastname='Mak',lastname='Makukhin',lastname='Maleckas',lastname='Malek',lastname='Malik',lastname='Malipeddi',lastname='Malkowski',lastname='Mallagray',lastname='Mallis',lastname='Mamas',lastname='Mandovec',lastname='Mandviwala',lastname='Manga',lastname='Mani',lastname='Manlutac',lastname='Mannarino',lastname='Manukov',lastname='Manzur',lastname='Marchese',lastname='Marchev',lastname='Maria',lastname='Marin',lastname='Mariscal',lastname='Markham',lastname='Marmol',lastname='Marmor',lastname='Marple',lastname='Martelet',lastname='Martin',lastname='Martinez-Selles',lastname='Martinez',lastname='Martingano',lastname='Marzal',lastname='Masterov',lastname='Mathan',lastname='Matoltsy',lastname='Maurer',lastname='May',lastname='Mayler',lastname='Mazur',lastname='Mazutavicius',lastname='McKenzie',lastname='McMurray',lastname='Meaney',lastname='Megarry',lastname='Mehling',lastname='Mehrle',lastname='Mehta',lastname='Melchior',lastname='Mendez',lastname='Mendoza',lastname='Menzel',lastname='Mercado',lastname='Merkely',lastname='Mesquita',lastname='Mihalikova',lastname='Mihov',lastname='Milanova',lastname='Mileva-Manolova',lastname='Milhous',lastname='Militaru',lastname='Miliuniene',lastname='Miller',lastname='Mincheva-Kabakchieva',lastname='Minneci',lastname='Mirek-Bryniarska',lastname='Mishkin',lastname='Missault',lastname='Mitchell',lastname='Mkhwanazi',lastname='Modena',lastname='Mody',lastname='Moe',lastname='Mohamed',lastname='Mohan',lastname='Mohindra',lastname='Moiseeva',lastname='Moises Azize',lastname='Montgomery',lastname='Moraes',lastname='More',lastname='Moriarty',lastname='Morozova',lastname='Mos',lastname='Mosterd',lastname='Motylev',lastname='Mpe',lastname='Mulleners',lastname='Muller',lastname='Munoz',lastname='Munzel',lastname='Murashkina',lastname='Murphy',lastname='Murray',lastname='Murthy',lastname='Muthusamy',lastname='Nagy',lastname='Naidoo',lastname='Naidu',lastname='Nair',lastname='Nanea',lastname='Napoli',lastname='Natour',lastname='Naudts',lastname='Naumann',lastname='Nazeyrollas',lastname='Nechita',lastname='Negrusz-Kawecka',lastname='Neto',lastname='Neuder',lastname='Neuenschwander',lastname='Neutel',lastname='Neyses',lastname='Nguyen',lastname='Nieto',lastname='Nightingale',lastname='Nischik',lastname='Noori',lastname='Nosov',lastname='Nourredine',lastname='Nunez',lastname='Nyolczas',lastname='Oberoi',lastname='Olbrich',lastname='Olexa',lastname='Oleynikov',lastname='Oliveira',lastname='Olsen',lastname='Ong',lastname='Ooi',lastname='Opasich',lastname='Orchard',lastname='Orihuela',lastname='Ovando',lastname='Pacherova',lastname='Packer',lastname='Padayachee',lastname='Padua',lastname='Pai',lastname='Paiva',lastname='Pajes',lastname='Palatkina',lastname='Palinsky',lastname='Palka',lastname='Pandey',lastname='Paniagua',lastname='Papp',lastname='Park',lastname='Parker',lastname='Parmon',lastname='Parody',lastname='Parrott',lastname='Parvanova',lastname='Pascual',lastname='Paulino',lastname='Pavia',lastname='Pedersen',lastname='Pella',lastname='Pena',lastname='Pencheva',lastname='Perez Rey',lastname='Perticone',lastname='Petenian',lastname='Petersen',lastname='Petranov',lastname='Petrova',lastname='Petrulioniene',lastname='Peuhkurinen',lastname='Piepiorka',lastname='Pijanowski',lastname='Pileri',lastname='Pimenov',lastname='Piyayotai',lastname='Pocock',lastname='Poddighe',lastname='Podzemska',lastname='Pohl',lastname='Poling',lastname='Poulard',lastname='Povolny',lastname='Prakash',lastname='Price',lastname='Privalov',lastname='Prodafikas',lastname='Prohaska',lastname='Pronk',lastname='Proskynitopoulus',lastname='Ptacin',lastname='Purvis',lastname='Puschita',lastname='Quinlan',lastname='Quinn',lastname='Rabelo',lastname='Radvan',lastname='Raev',lastname='Rafalsky',lastname='RaidRihani',lastname='Rajda',lastname='Rama',lastname='Ramanathan',lastname='Ramires',lastname='Ramshev',lastname='Rancane',lastname='Ranjith',lastname='Rao',lastname='Rassi',lastname='Rawitscher',lastname='Rebrov',lastname='Reddy',lastname='Refsgaard',lastname='Regner',lastname='Reimer',lastname='Reis',lastname='Remisova',lastname='Reyes',lastname='Reynales',lastname='Reznik',lastname='Richter',lastname='Rickers',lastname='Riha',lastname='Robinson',lastname='Rodriguez',lastname='Roeder',lastname='Rogelio',lastname='Rojas',lastname='Roldan',lastname='Romano',lastname='Ronchi',lastname='Ronner',lastname='Rosado',lastname='Rosenthal',lastname='Rosita',lastname='Rossi',lastname='Rouleau',lastname='Ruales',lastname='Ruda',lastname='Rummel',lastname='Rupka',lastname='Ryding',lastname='Saaiman',lastname='Saba',lastname='Sabatier',lastname='Sabe-Affaki',lastname='Sabl',lastname='Saifutdinov',lastname='Salamon',lastname='Salbach',lastname='Salcido',lastname='Salerno Uriarte',lastname='Salvatierra Ruiz',lastname='Samal',lastname='Sanchez',lastname='Sanguanwong',lastname='Sanmartin',lastname='Saporito',lastname='Sarjanovich',lastname='Sarma',lastname='Sarries',lastname='Sayganov',lastname='Schaefer',lastname='Schafer',lastname='Schaum',lastname='Schenkenberger',lastname='Schiavi',lastname='Schichorova',lastname='Schindler',lastname='Schmalfuss',lastname='Schmidt',lastname='Schnabel',lastname='Schneider',lastname='Schreckenberg',lastname='Schreibmuller',lastname='Schreiner',lastname='Schroder',lastname='Schumacher',lastname='Schwartz',lastname='Sciborski',lastname='Seals',lastname='Sebopa',lastname='Segner',lastname='Seibert',lastname='Selektor',lastname='Senni',lastname='Sepulveda',lastname='Sessa',lastname='Sestier',lastname='Seto',lastname='Shah',lastname='Shamsudden',lastname='Shanes',lastname='Sharma',lastname='Sheppard',lastname='Shin',lastname='Shochat',lastname='Shpagina',lastname='Shustov',lastname='Shutemova',lastname='Shvarts',lastname='Siao',lastname='Sibulo',lastname='Sicuro',lastname='Sigurdsson',lastname='Silva-Cardoso',lastname='Silva',lastname='Silvestre',lastname='Silvestri',lastname='Sime',lastname='Simoes',lastname='Sims',lastname='Singh',lastname='Sinha',lastname='Sirakova',lastname='Sitnikova',lastname='Sizova',lastname='Slaby',lastname='Slapikas',lastname='Smik',lastname='Smith',lastname='Smolders',lastname='Smolenskaya',lastname='Soares',lastname='Sobkowicz',lastname='Sobolewska',lastname='Sohn',lastname='Sokolova',lastname='Solache',lastname='Soler',lastname='Solomon',lastname='Solovieva',lastname='Soo',lastname='Sooudi',lastname='Sotolongo',lastname='Sotomayor',lastname='Souza',lastname='Spagnuolo',lastname='Sprovieri',lastname='Squire',lastname='Staneva',lastname='Starling',lastname='Staroverov',lastname='Steffensen',lastname='Stockins',lastname='Stohring',lastname='Strain',lastname='Struk',lastname='Such',lastname='Suiter',lastname='Sun',lastname='Sunderam',lastname='Svejda',lastname='Svistov',lastname='Swart',lastname='Swedberg',lastname='Szantai',lastname='Szocs',lastname='Szpajer',lastname='Taddei',lastname='Tangerding',lastname='Tarasov',lastname='Tarlovskaya',lastname='Taubert',lastname='Taurio',lastname='Tayob',lastname='Teerlink',lastname='Telekes',lastname='Tereschenko',lastname='Terhorst',lastname='Terrosu',lastname='Tesch',lastname='Tespili',lastname='Thadani',lastname='Thakkar',lastname='Thanvi',lastname='Theron',lastname='Thomas',lastname='Thongsri',lastname='Thorgeirsson',lastname='Thorsen',lastname='Thrasher',lastname='Tisheva-Gospodinova',lastname='Tjeerdsma',lastname='Todorov',lastname='Tokmakova',lastname='Tomcsanyi',lastname='Tomescu',lastname='Torres',lastname='Toth',lastname='Toursarkissian',lastname='Tran',lastname='Trelawny',lastname='Trevelyan',lastname='Trichon',lastname='Trivedi',lastname='Trofimov',lastname='Tsao',lastname='Tse',lastname='Tudoran',lastname='Tyler',lastname='Tyminski',lastname='Tzekova',lastname='Tzeng',lastname='Uebel',lastname='Ulman',lastname='Ural',lastname='Uriarte',lastname='Urina',lastname='Urquiaga',lastname='Uspensky',lastname='Valchanova',lastname='Vally',lastname='van der Merwe',lastname='van Eck',lastname='van Rensburg',lastname='van Zyl',lastname='Vandekerckhove',lastname='Vanhaecke',lastname='Varju',lastname='Vasilieva',lastname='Vazir',lastname='Velasco',lastname='Velasquez',lastname='Velez',lastname='Venter',lastname='Veress',lastname='Vergara',lastname='Vergoni',lastname='Vertes',lastname='Vesga',lastname='Vezikova',lastname='Vico',lastname='Vicuna',lastname='Vida',lastname='Vijan',lastname='Vilas Boas',lastname='Vilela',lastname='Vinanska',lastname='Vincent',lastname='Vinereanu',lastname='Vishnevsky',lastname='Volkov',lastname='Volterrani',lastname='vom Dahl',lastname='Vomacka',lastname='Vranian',lastname='Wallach',lastname='Ward',lastname='Watkin',lastname='Weglarz',lastname='Weinrauch',lastname='Weinstein',lastname='Wellmann',lastname='Wells',lastname='Weyland',lastname='Weytjens',lastname='Wickemeyer',lastname='Wight',lastname='Wilke',lastname='Willems',lastname='Williams',lastname='Witherow',lastname='Wojciechowska',lastname='Woldman',lastname='Wollaert',lastname='Wong',lastname='Wronska',lastname='Wu',lastname='Wyss',lastname='Xu',lastname='Yakhontov',lastname='Yakovlev',lastname='Yan',lastname='Yang',lastname='Yannick',lastname='Yao',lastname='Yavdosyuk',lastname='Yavuzgil',lastname='Yenigun',lastname='Yeo',lastname='Yigit',lastname='Yilmaz',lastname='Yip',lastname='Yokusoglu',lastname='Yoo',lastname='Yotov',lastname='Yousef',lastname='Yovaniniz',lastname='Yuan',lastname='Yugandhar',lastname='Zaidman',lastname='Zamolyi',lastname='Zannad',lastname='Zateyshchikova',lastname='Zebrack',lastname='Zeh',lastname='Zemek',lastname='Zemmrich',lastname='Zethson-Hallden',lastname='Zhang',lastname='Zhao',lastname='Zharkov',lastname='Zhelev',lastname='Zhilyaev',lastname='Zilahi',lastname='Zile',lastname='Zo',lastname='Zotov',lastname='Zotz',lastname='Zrazhevsky',lastname='Zuraw',lastname="D'Ospina",lastname="O'Brien",lastname="O'Toole",Male,MEDLINE,Middle Aged,Milton Packer,Multicenter Study,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,Neprilysin / antagonists & inhibitors*,NIH,NLM,Non-U.S. Gov't,pmid:25176015,PubMed Abstract,Randomized Controlled Trial,Research Support,Stroke Volume,suffix='2nd',suffix='3rd',suffix='Jr',suffix=None,Tetrazoles / adverse effects,Tetrazoles / therapeutic use*,Valsartan}
}

@article{jonesBodyMassIndex2023,
  title = {Body Mass Index and Survival in People with Heart Failure},
  author = {Jones, Nicholas R. and {Ord{\'o}{\~n}ez-Mena}, Jos{\'e} M. and Roalfe, Andrea K. and Taylor, Kathryn S. and Goyder, Clare R. and Hobbs, FD Richard and Taylor, Clare J.},
  year = {2023},
  month = oct,
  journal = {Heart},
  volume = {109},
  number = {20},
  pages = {1542--1549},
  publisher = {{BMJ Publishing Group Ltd and British Cardiovascular Society}},
  issn = {1355-6037, 1468-201X},
  doi = {10.1136/heartjnl-2023-322459},
  urldate = {2024-08-29},
  abstract = {Aims In people with heart failure (HF), a high body mass index (BMI) has been linked with better outcomes (`obesity paradox'), but there is limited evidence in community populations across long-term follow-up. We aimed to examine the association between BMI and long-term survival in patients with HF in a large primary care cohort. Methods We included patients with incident HF aged {$\geq$}45 years from the Clinical Practice Research Datalink (2000--2017). We used Kaplan-Meier curves, Cox regression and penalised spline methods to assess the association of pre-diagnostic BMI, based on WHO classification, with all-cause mortality. Results There were 47 531 participants with HF (median age 78.0 years (IQR 70--84), 45.8\% female, 79.0\% white ethnicity, median BMI 27.1 (IQR 23.9--31.0)) and 25 013 (52.6\%) died during follow-up. Compared with healthy weight, people with overweight (HR 0.78, 95\% CI 0.75 to 0.81, risk difference (RD) -4.1\%), obesity class I (HR 0.76, 95\% CI 0.73 to 0.80, RD -4.5\%) and class II (HR 0.76, 95\% CI 0.71 to 0.81, RD -4.5\%) were at decreased risk of death, whereas people with underweight were at increased risk (HR 1.59, 95\% CI 1.45 to 1.75, RD 11.2\%). In those underweight, this risk was greater among men than women (p value for interaction=0.02). Class III obesity was associated with increased risk of all-cause mortality compared with overweight (HR 1.23, 95\% CI 1.17 to 1.29). Conclusion The U-shaped relationship between BMI and long-term all-cause mortality suggests a personalised approach to identifying optimal weight may be needed for patients with HF in primary care. Underweight people have the poorest prognosis and should be recognised as high-risk.},
  chapter = {Heart failure and cardiomyopathies},
  copyright = {{\copyright} Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:~https://creativecommons.org/licenses/by/4.0/.},
  langid = {english},
  pmid = {37290898},
  keywords = {Epidemiology,Heart failure,Obesity},
  file = {/Users/xx20081/Zotero/storage/52WUJAEI/Jones et al. - 2023 - Body mass index and survival in people with heart .pdf}
}

@article{jonesBodyMassIndex2023a,
  title = {Body Mass Index and Survival in People with Heart Failure},
  author = {Jones, Nicholas R. and {Ord{\'o}{\~n}ez-Mena}, Jos{\'e} M. and Roalfe, Andrea K. and Taylor, Kathryn S. and Goyder, Clare R. and Hobbs, FD Richard and Taylor, Clare J.},
  year = {2023},
  month = oct,
  journal = {Heart},
  volume = {109},
  number = {20},
  pages = {1542--1549},
  publisher = {{BMJ Publishing Group Ltd and British Cardiovascular Society}},
  issn = {1355-6037, 1468-201X},
  doi = {10.1136/heartjnl-2023-322459},
  urldate = {2025-01-06},
  abstract = {Aims In people with heart failure (HF), a high body mass index (BMI) has been linked with better outcomes (`obesity paradox'), but there is limited evidence in community populations across long-term follow-up. We aimed to examine the association between BMI and long-term survival in patients with HF in a large primary care cohort. Methods We included patients with incident HF aged {$\geq$}45 years from the Clinical Practice Research Datalink (2000--2017). We used Kaplan-Meier curves, Cox regression and penalised spline methods to assess the association of pre-diagnostic BMI, based on WHO classification, with all-cause mortality. Results There were 47 531 participants with HF (median age 78.0 years (IQR 70--84), 45.8\% female, 79.0\% white ethnicity, median BMI 27.1 (IQR 23.9--31.0)) and 25 013 (52.6\%) died during follow-up. Compared with healthy weight, people with overweight (HR 0.78, 95\% CI 0.75 to 0.81, risk difference (RD) -4.1\%), obesity class I (HR 0.76, 95\% CI 0.73 to 0.80, RD -4.5\%) and class II (HR 0.76, 95\% CI 0.71 to 0.81, RD -4.5\%) were at decreased risk of death, whereas people with underweight were at increased risk (HR 1.59, 95\% CI 1.45 to 1.75, RD 11.2\%). In those underweight, this risk was greater among men than women (p value for interaction=0.02). Class III obesity was associated with increased risk of all-cause mortality compared with overweight (HR 1.23, 95\% CI 1.17 to 1.29). Conclusion The U-shaped relationship between BMI and long-term all-cause mortality suggests a personalised approach to identifying optimal weight may be needed for patients with HF in primary care. Underweight people have the poorest prognosis and should be recognised as high-risk.},
  chapter = {Heart failure and cardiomyopathies},
  copyright = {{\copyright} Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:~https://creativecommons.org/licenses/by/4.0/.},
  langid = {english},
  pmid = {37290898},
  keywords = {Epidemiology,Heart failure,Obesity},
  file = {/Users/xx20081/Zotero/storage/WACPM232/Jones et al. - 2023 - Body mass index and survival in people with heart failure.pdf}
}

@article{josephGeneticArchitectureHeart2022,
  title = {Genetic Architecture of Heart Failure with Preserved versus Reduced Ejection Fraction},
  author = {Joseph, Jacob and Liu, Chang and Hui, Qin and Aragam, Krishna and Wang, Zeyuan and Charest, Brian and Huffman, Jennifer E. and Keaton, Jacob M. and Edwards, Todd L. and Demissie, Serkalem and Djousse, Luc and Casas, Juan P. and Gaziano, J. Michael and Cho, Kelly and Wilson, Peter W. F. and Phillips, Lawrence S. and Huffman, Jennifer E. and O'Donnell, Christopher J. and Sun, Yan V.},
  year = {2022},
  month = dec,
  journal = {Nature Communications},
  volume = {13},
  number = {1},
  pages = {7753},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-022-35323-0},
  urldate = {2025-01-30},
  abstract = {Pharmacologic clinical trials for heart failure with preserved ejection fraction have been largely unsuccessful as compared to those for heart failure with reduced ejection fraction. Whether differences in the genetic underpinnings of these major heart failure subtypes may provide insights into the disparate outcomes of clinical trials remains unknown. We utilize a large, uniformly phenotyped, single cohort of heart failure sub-classified into heart failure with reduced and with preserved ejection fractions based on current clinical definitions, to conduct detailed genetic analyses of the two heart failure sub-types. We find different genetic architectures and distinct genetic association profiles between heart failure with reduced and with preserved ejection fraction suggesting differences in underlying pathobiology. The modest genetic discovery for heart failure with preserved ejection fraction (one locus) compared to heart failure with reduced ejection fraction (13 loci) despite comparable sample sizes indicates that clinically defined heart failure with preserved ejection fraction likely represents the amalgamation of several, distinct pathobiological entities. Development of consensus sub-phenotyping of heart failure with preserved ejection fraction is paramount to better dissect the underlying genetic signals and contributors to this highly prevalent condition.},
  copyright = {2022 This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply},
  langid = {english},
  keywords = {Cardiovascular genetics,Genome-wide association studies,Medical genomics},
  file = {/Users/xx20081/Zotero/storage/SSWLQSYW/Joseph et al. - 2022 - Genetic architecture of heart failure with preserved versus reduced ejection fraction.pdf}
}

@article{kamangarEffectModificationEpidemiology2012,
  title = {Effect Modification in Epidemiology and Medicine},
  author = {Kamangar, Farin},
  year = {2012},
  month = sep,
  journal = {Archives of Iranian Medicine},
  volume = {15},
  number = {9},
  pages = {575--582},
  issn = {1735-3947},
  abstract = {Effect modification, also known as interaction or heterogeneity of effect, is an important concept in epidemiology.~ This article reviews the definition and types of effect modification, methods to detect effect modification, the reasons for observing effect modification in epidemiologic studies, the importance of choice of model in finding effect modifiers, and effect modifications that are important to public health.},
  langid = {english},
  pmid = {22924379},
  keywords = {Confounding Factors Epidemiologic,Data Interpretation Statistical,Effect Modifier Epidemiologic,Epidemiologic Research Design,Humans,Models Biological,Models Statistical,Public Health,Regression Analysis,Risk Factors,Sample Size}
}

@article{karasonEffectsObesityWeight1997,
  title = {Effects of Obesity and Weight Loss on Left Ventricular Mass and Relative Wall Thickness: Survey and Intervention Study},
  shorttitle = {Effects of Obesity and Weight Loss on Left Ventricular Mass and Relative Wall Thickness},
  author = {Karason, K. and Wallentin, I. and Larsson, B. and Sj{\"o}str{\"o}m, L.},
  year = {1997},
  month = oct,
  journal = {BMJ (Clinical research ed.)},
  volume = {315},
  number = {7113},
  pages = {912--916},
  issn = {0959-8138},
  doi = {10.1136/bmj.315.7113.912},
  abstract = {OBJECTIVES: To investigate the consequences of longstanding obesity on left ventricular mass and structure and to examine the effects of weight loss on these variables. DESIGN: Cross sectional survey and controlled intervention study. SETTING: City of Gothenburg and surrounding areas. Sweden. SUBJECTS: 41 obese patients treated with weight reducing gastric surgery, 31 obese patients treated conventionally, and 43 non-obese subjects. MAIN OUTCOME MEASURES: Changes in left ventricular mass and relative wall thickness. RESULTS: Obese patients had higher blood pressure, greater left ventricular mass, and increased relative wall thickness than did matched non-obese control subjects. Obese subjects treated with gastric surgery had a substantial weight loss and a significant reduction in all variables when compared with conventionally treated obese subjects. Univariate and multivariate analysis of pooled data from the two groups of obese subjects showed that changes in relative wall thickness and left ventricular mass were more closely related to the change in weight than to the concomitant change in blood pressure. CONCLUSIONS: Structural heart abnormalities occurring in conjunction with obesity diminish after weight loss. The regression in these structural aberrations is better predicted by the weight loss than by the accompanying reduction in blood pressure. To prevent or improve abnormalities of heart structure in obese people, weight control should be the primary goal; it should be regarded as at least as important as regulating blood pressure.},
  langid = {english},
  pmcid = {PMC2127625},
  pmid = {9361540},
  keywords = {Adult,Analysis of Variance,Blood Pressure,Body Mass Index,Cross-Sectional Studies,Female,Heart Ventricles,Humans,Male,Middle Aged,Obesity,Weight Loss},
  file = {/Users/xx20081/Zotero/storage/CMQ588IR/Karason et al. - 1997 - Effects of obesity and weight loss on left ventric.pdf}
}

@article{karhunenLeveragingHumanGenetic2021,
  title = {Leveraging Human Genetic Data to Investigate the Cardiometabolic Effects of Glucose-Dependent Insulinotropic Polypeptide Signalling},
  author = {Karhunen, Ville and Daghlas, Iyas and Zuber, Verena and Vujkovic, Marijana and Olsen, Anette K. and Knudsen, Lotte Bjerre and Haynes, William G. and Howson, Joanna M. M. and Gill, Dipender},
  year = {2021},
  month = dec,
  journal = {Diabetologia},
  volume = {64},
  number = {12},
  pages = {2773--2778},
  issn = {1432-0428},
  doi = {10.1007/s00125-021-05564-7},
  urldate = {2024-01-21},
  abstract = {The aim of this study was to leverage human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide (GIP) signalling.},
  langid = {english},
  keywords = {Cardiometabolic disease,Co-localisation,Glucose-dependent insulinotropic polypeptide,Mendelian randomisation,Type 2 diabetes mellitus},
  file = {/Users/xx20081/Zotero/storage/KWFHMQKG/Karhunen et al. - 2021 - Leveraging human genetic data to investigate the c.pdf}
}

@article{karjalainenGenomewideCharacterizationCirculating2024,
  title = {Genome-Wide Characterization of Circulating Metabolic Biomarkers},
  author = {Karjalainen, Minna K. and Karthikeyan, Savita and {Oliver-Williams}, Clare and Sliz, Eeva and Allara, Elias and Fung, Wing Tung and Surendran, Praveen and Zhang, Weihua and Jousilahti, Pekka and Kristiansson, Kati and Salomaa, Veikko and Goodwin, Matt and Hughes, David A. and Boehnke, Michael and Fernandes Silva, Lilian and Yin, Xianyong and Mahajan, Anubha and Neville, Matt J. and {van Zuydam}, Natalie R. and {de Mutsert}, Ren{\'e}e and {Li-Gao}, Ruifang and {Mook-Kanamori}, Dennis O. and Demirkan, Ayse and Liu, Jun and Noordam, Raymond and Trompet, Stella and Chen, Zhengming and Kartsonaki, Christiana and Li, Liming and Lin, Kuang and Hagenbeek, Fiona A. and Hottenga, Jouke Jan and Pool, Ren{\'e} and Ikram, M. Arfan and {van Meurs}, Joyce and Haller, Toomas and Milaneschi, Yuri and K{\"a}h{\"o}nen, Mika and Mishra, Pashupati P. and Joshi, Peter K. and {Macdonald-Dunlop}, Erin and Mangino, Massimo and Zierer, Jonas and Acar, Ilhan E. and Hoyng, Carel B. and Lechanteur, Yara T. E. and Franke, Lude and Kurilshikov, Alexander and Zhernakova, Alexandra and Beekman, Marian and {van den Akker}, Erik B. and Kolcic, Ivana and Polasek, Ozren and Rudan, Igor and Gieger, Christian and Waldenberger, Melanie and Asselbergs, Folkert W. and Hayward, Caroline and Fu, Jingyuan and {den Hollander}, Anneke I. and Menni, Cristina and Spector, Tim D. and Wilson, James F. and Lehtim{\"a}ki, Terho and Raitakari, Olli T. and Penninx, Brenda W. J. H. and Esko, Tonu and Walters, Robin G. and Jukema, J. Wouter and Sattar, Naveed and Ghanbari, Mohsen and {Willems van Dijk}, Ko and Karpe, Fredrik and McCarthy, Mark I. and Laakso, Markku and J{\"a}rvelin, Marjo-Riitta and Timpson, Nicholas J. and Perola, Markus and Kooner, Jaspal S. and Chambers, John C. and {van Duijn}, Cornelia and Slagboom, P. Eline and Boomsma, Dorret I. and Danesh, John and {Ala-Korpela}, Mika and Butterworth, Adam S. and Kettunen, Johannes},
  year = {2024},
  month = apr,
  journal = {Nature},
  volume = {628},
  number = {8006},
  pages = {130--138},
  publisher = {Nature Publishing Group},
  issn = {1476-4687},
  doi = {10.1038/s41586-024-07148-y},
  urldate = {2025-04-12},
  abstract = {Genome-wide association analyses using high-throughput metabolomics platforms have led to novel insights into the biology of human metabolism1--7. This detailed knowledge of the genetic determinants of systemic metabolism has been pivotal for uncovering how genetic pathways influence biological mechanisms and complex diseases8--11. Here we present a genome-wide association study for 233 circulating metabolic traits quantified by nuclear magnetic resonance spectroscopy in up to 136,016 participants from 33 cohorts. We identify more than 400 independent loci and assign probable causal genes at two-thirds of these using manual curation of plausible biological candidates. We highlight the importance of sample and participant characteristics that can have significant effects on genetic associations. We use detailed metabolic profiling of lipoprotein- and lipid-associated variants to better characterize how known lipid loci and novel loci affect lipoprotein metabolism at a granular level. We demonstrate the translational utility of comprehensively phenotyped molecular data, characterizing the metabolic associations of intrahepatic cholestasis of pregnancy. Finally, we observe substantial genetic pleiotropy for multiple metabolic pathways and illustrate the importance of careful instrument selection in Mendelian randomization analysis, revealing a putative causal relationship between acetone and hypertension. Our publicly available results provide a foundational resource for the community to examine the role of metabolism across diverse diseases.},
  copyright = {2024 The Author(s)},
  langid = {english},
  keywords = {Genetics research,Genome-wide association studies,Metabolomics,Predictive markers},
  file = {/Users/xx20081/Zotero/storage/GFYA42KP/Karjalainen et al. - 2024 - Genome-wide characterization of circulating metabolic biomarkers.pdf}
}

@article{kassensBIGwasSinglecommandQuality2021,
  title = {{{BIGwas}}: {{Single-command}} Quality Control and Association Testing for Multi-Cohort and Biobank-Scale {{GWAS}}/{{PheWAS}} Data},
  shorttitle = {{{BIGwas}}},
  author = {K{\"a}ssens, Jan Christian and Wienbrandt, Lars and Ellinghaus, David},
  year = {2021},
  month = jun,
  journal = {GigaScience},
  volume = {10},
  number = {6},
  pages = {giab047},
  issn = {2047-217X},
  doi = {10.1093/gigascience/giab047},
  abstract = {BACKGROUND: Genome-wide association studies (GWAS) and phenome-wide association studies (PheWAS) involving 1 million GWAS samples from dozens of population-based biobanks present a considerable computational challenge and are carried out by large scientific groups under great expenditure of time and personnel. Automating these processes requires highly efficient and scalable methods and software, but so far there is no workflow solution to easily process 1 million GWAS samples. RESULTS: Here we present BIGwas, a portable, fully automated quality control and association testing pipeline for large-scale binary and quantitative trait GWAS data provided by biobank resources. By using Nextflow workflow and Singularity software container technology, BIGwas performs resource-efficient and reproducible analyses on a local computer or any high-performance compute (HPC) system with just 1 command, with no need to manually install a software execution environment or various software packages. For a single-command GWAS analysis with 974,818 individuals and 92 million genetic markers, BIGwas takes {$\sim$}16~days on a small HPC system with only 7 compute nodes to perform a complete GWAS QC and association analysis protocol. Our dynamic parallelization approach enables shorter runtimes for large HPCs. CONCLUSIONS: Researchers without extensive bioinformatics knowledge and with few computer resources can use BIGwas to perform multi-cohort GWAS with 1 million GWAS samples and, if desired, use it to build their own (genome-wide) PheWAS resource. BIGwas is freely available for download from http://github.com/ikmb/gwas-qc and http://github.com/ikmb/gwas-assoc.},
  langid = {english},
  pmcid = {PMC8239664},
  pmid = {34184051},
  keywords = {association testing,biobank,Biological Specimen Banks,Genome,Genome-Wide Association Study,GWAS,Humans,Nextflow,Phenotype,PheWAS,pipeline,Polymorphism Single Nucleotide,quality control,Quality Control,scalability,Singularity,Software},
  file = {/Users/xx20081/Zotero/storage/QM5EWZAJ/Kssens et al. - 2021 - BIGwas Single-command quality control and association testing for multi-cohort and biobank-scale GW.pdf}
}

@article{katsanisContinuumCausalityHuman2016,
  title = {The Continuum of Causality in Human Genetic Disorders},
  author = {Katsanis, Nicholas},
  year = {2016},
  month = nov,
  journal = {Genome Biology},
  volume = {17},
  pages = {233},
  issn = {1474-7596},
  doi = {10.1186/s13059-016-1107-9},
  urldate = {2024-12-10},
  abstract = {Studies of human genetic disorders have traditionally followed a reductionist paradigm. Traits are defined as Mendelian or complex based on family pedigree and population data, whereas alleles are deemed rare, common, benign, or deleterious based on their population frequencies. The availability of exome and genome data, as well as gene and allele discovery for various conditions, is beginning to challenge classic definitions of genetic causality. Here, I discuss recent advances in our understanding of the overlap between rare and complex diseases and the context-dependent effect of both rare and common alleles that underscores the need for revising the traditional categorizations of genetic traits.},
  pmcid = {PMC5114767},
  pmid = {27855690},
  file = {/Users/xx20081/Zotero/storage/K5IWBZJ6/Katsanis - 2016 - The continuum of causality in human genetic disorders.pdf}
}

@article{katzourouGenomewideAssociationStudy2020,
  title = {Genome-Wide Association Study of Progression in {{Alzheimer}}'s Disease},
  author = {Katzourou, Ioanna and Leonenko, Ganna and Williams, Julie and Holmans, Peter and {Escott-Price}, Valentina},
  year = {2020},
  journal = {Alzheimer's \& Dementia},
  volume = {16},
  number = {S2},
  pages = {e040950},
  issn = {1552-5279},
  doi = {10.1002/alz.040950},
  urldate = {2024-08-14},
  abstract = {Background The rate of disease progression is an important factor to consider regarding Alzheimer's disease (AD), as people with a rapid decline are considerably more likely to require additional care resources. The rate of progression in AD has been found to vary widely between individuals, with numerous factors driving this heterogeneity. In this project, a genome-wide association study (GWAS) was performed to investigate the presence of a genetic liability to faster progression in patients with AD. Methods A subset of 543 individuals with AD from the Cardiff MRC centre cohorts that have been assessed at multiple timepoints was used in this analysis. A progression score for each individual was approximated by a random slope from a random effects regression model of Mini Mental State Examination (MMSE) using all available MMSE measurements. The score was subsequently used in a GWAS of progression. Quality control analysis was performed following standard GWAS protocols resulting in 304,448 variants to be included in the analysis. Results The sample was 67.37\% female, with mean age at recruitment being 80.2 years. Mean MMSE was 17.03 at first assessment and 11.54 at last assessment, and mean number of assessments was 3.16. After correcting for multiple testing, no variant was found to be significantly associated with progression in this GWAS. Furthermore, apolipoprotein E (ApoE) genotype was not associated with progression. Conclusion Preliminary results show that, after Bonferroni correction for multiple testing, no variant was significantly associated with progression in AD. Suggestive associated variants were found in chromosome 20:5843812 (p-value = 3.12 {\texttimes} 10-7), 1:62271962 (p-value = 6.30 {\texttimes} 10-7), 10:15452800 (p-value = 1.65 {\texttimes} 10-6) and 5:117646945 (p-value = 2.40 {\texttimes} 10-6). Moreover, ApoE genotype was not found to affect the rate progression, the lowest p-value in the ApoE region (19:44905791 - 19:44909393) being 0.23. This non-significant result might indicate that the genetic risk for accelerated cognitive decline within AD is separate from the genetic risk for developing AD. The sample size is one of the main limitations of this study. Replication in a larger dataset is necessary in order to validate these findings and uncover the presence of genetic variants that affect the rate of decline in AD.},
  copyright = {{\copyright} 2020 the Alzheimer's Association},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/GLJRUEDW/Katzourou et al. - 2020 - Genome-wide association study of progression in Al.pdf;/Users/xx20081/Zotero/storage/Q3I4NCIM/alz.html}
}

@misc{KbSafari_compatibilityZotero,
  title = {Kb:Safari\_compatibility [{{Zotero Documentation}}]},
  urldate = {2023-12-05},
  howpublished = {https://www.zotero.org/support/kb/safari\_compatibility},
  file = {/Users/xx20081/Zotero/storage/NWDXIJQV/safari_compatibility.html}
}

@article{keatonGenomewideAnalysisMillion2024,
  title = {Genome-Wide Analysis in over 1 Million Individuals of {{European}} Ancestry Yields Improved Polygenic Risk Scores for Blood Pressure Traits},
  author = {Keaton, Jacob M. and Kamali, Zoha and Xie, Tian and Vaez, Ahmad and Williams, Ariel and Goleva, Slavina B. and Ani, Alireza and Evangelou, Evangelos and Hellwege, Jacklyn N. and Yengo, Loic and Young, William J. and Traylor, Matthew and Giri, Ayush and Zheng, Zhili and Zeng, Jian and Chasman, Daniel I. and Morris, Andrew P. and Caulfield, Mark J. and Hwang, Shih-Jen and Kooner, Jaspal S. and Conen, David and Attia, John R. and Morrison, Alanna C. and Loos, Ruth J. F. and Kristiansson, Kati and Schmidt, Reinhold and Hicks, Andrew A. and Pramstaller, Peter P. and Nelson, Christopher P. and Samani, Nilesh J. and Risch, Lorenz and Gyllensten, Ulf and Melander, Olle and Riese, Harriette and Wilson, James F. and Campbell, Harry and Rich, Stephen S. and Psaty, Bruce M. and Lu, Yingchang and Rotter, Jerome I. and Guo, Xiuqing and Rice, Kenneth M. and Vollenweider, Peter and Sundstr{\"o}m, Johan and Langenberg, Claudia and Tobin, Martin D. and Giedraitis, Vilmantas and Luan, Jian'an and Tuomilehto, Jaakko and Kutalik, Zoltan and Ripatti, Samuli and Salomaa, Veikko and Girotto, Giorgia and Trompet, Stella and Jukema, J. Wouter and {van der Harst}, Pim and Ridker, Paul M. and Giulianini, Franco and Vitart, Veronique and Goel, Anuj and Watkins, Hugh and Harris, Sarah E. and Deary, Ian J. and {van der Most}, Peter J. and Oldehinkel, Albertine J. and Keavney, Bernard D. and Hayward, Caroline and Campbell, Archie and Boehnke, Michael and Scott, Laura J. and Boutin, Thibaud and Mamasoula, Chrysovalanto and J{\"a}rvelin, Marjo-Riitta and Peters, Annette and Gieger, Christian and Lakatta, Edward G. and Cucca, Francesco and Hui, Jennie and Knekt, Paul and Enroth, Stefan and De Borst, Martin H. and Pola{\v s}ek, Ozren and Concas, Maria Pina and Catamo, Eulalia and Cocca, Massimiliano and {Li-Gao}, Ruifang and Hofer, Edith and Schmidt, Helena and Spedicati, Beatrice and Waldenberger, Melanie and Strachan, David P. and Laan, Maris and Teumer, Alexander and D{\"o}rr, Marcus and Gudnason, Vilmundur and Cook, James P. and Ruggiero, Daniela and Kolcic, Ivana and Boerwinkle, Eric and Traglia, Michela and Lehtim{\"a}ki, Terho and Raitakari, Olli T. and Johnson, Andrew D. and {Newton-Cheh}, Christopher and Brown, Morris J. and Dominiczak, Anna F. and Sever, Peter J. and Poulter, Neil and Chambers, John C. and Elosua, Roberto and Siscovick, David and Esko, T{\~o}nu and Metspalu, Andres and Strawbridge, Rona J. and Laakso, Markku and Hamsten, Anders and Hottenga, Jouke-Jan and {de Geus}, Eco and Morris, Andrew D. and Palmer, Colin N. A. and Nolte, Ilja M. and Milaneschi, Yuri and Marten, Jonathan and Wright, Alan and Zeggini, Eleftheria and Howson, Joanna M. M. and O'Donnell, Christopher J. and Spector, Tim and Nalls, Mike A. and Simonsick, Eleanor M. and Liu, Yongmei and {van Duijn}, Cornelia M. and Butterworth, Adam S. and Danesh, John N. and Menni, Cristina and Wareham, Nicholas J. and Khaw, Kay-Tee and Sun, Yan V. and Wilson, Peter W. F. and Cho, Kelly and Visscher, Peter M. and Denny, Joshua C. and {Million Veteran Program} and {Lifelines Cohort Study} and {CHARGE consortium} and {ICBP Consortium} and Levy, Daniel and Edwards, Todd L. and Munroe, Patricia B. and Snieder, Harold and Warren, Helen R.},
  year = {2024},
  month = may,
  journal = {Nature Genetics},
  volume = {56},
  number = {5},
  pages = {778--791},
  issn = {1546-1718},
  doi = {10.1038/s41588-024-01714-w},
  abstract = {Hypertension affects more than one billion people worldwide. Here we identify 113 novel loci, reporting a total of 2,103 independent genetic signals (P\,{$<$}\,5\,{\texttimes}\,10-8) from the largest single-stage blood pressure (BP) genome-wide association study to date (n\,=\,1,028,980 European individuals). These associations explain more than 60\% of single nucleotide polymorphism-based BP heritability. Comparing top versus bottom deciles of polygenic risk scores (PRSs) reveals clinically meaningful differences in BP (16.9\,mmHg systolic BP, 95\% CI, 15.5-18.2\,mmHg, P\,=\,2.22\,{\texttimes}\,10-126) and more than a sevenfold higher odds of hypertension risk (odds ratio, 7.33; 95\% CI, 5.54-9.70; P\,=\,4.13\,{\texttimes}\,10-44) in an independent dataset. Adding PRS into hypertension-prediction models increased the area under the receiver operating characteristic curve (AUROC) from 0.791 (95\% CI, 0.781-0.801) to 0.826 (95\% CI, 0.817-0.836, AUROC, 0.035, P\,=\,1.98\,{\texttimes}\,10-34). We compare the 2,103 loci results in non-European ancestries and show significant PRS associations in a large African-American sample. Secondary analyses implicate 500 genes previously unreported for BP. Our study highlights the role of increasingly large genomic studies for precision health research.},
  langid = {english},
  pmcid = {PMC11096100},
  pmid = {38689001},
  keywords = {Blood Pressure,Female,Genetic Predisposition to Disease,Genetic Risk Score,Genome-Wide Association Study,Humans,Hypertension,Male,Multifactorial Inheritance,Polymorphism Single Nucleotide,Risk Factors}
}

@article{kellyGlobalBurdenObesity2008,
  title = {Global Burden of Obesity in 2005 and Projections to 2030},
  author = {Kelly, T. and Yang, W. and Chen, C.-S. and Reynolds, K. and He, J.},
  year = {2008},
  month = sep,
  journal = {International Journal of Obesity},
  volume = {32},
  number = {9},
  pages = {1431--1437},
  publisher = {Nature Publishing Group},
  issn = {1476-5497},
  doi = {10.1038/ijo.2008.102},
  urldate = {2024-07-03},
  abstract = {To estimate the overall prevalence and absolute burden of overweight and obesity in the world and in various regions in 2005 and to project the global burden in 2030.},
  copyright = {2008 Macmillan Publishers Limited},
  langid = {english},
  keywords = {Epidemiology,general,Health Promotion and Disease Prevention,Internal Medicine,Medicine/Public Health,Metabolic Diseases,Public Health},
  file = {/Users/xx20081/Zotero/storage/YYR8FWYP/Kelly et al. - 2008 - Global burden of obesity in 2005 and projections t.pdf}
}

@article{kenchaiahBodyMassIndex2007,
  title = {Body Mass Index and Prognosis in Patients with Chronic Heart Failure: Insights from the {{Candesartan}} in {{Heart}} Failure: {{Assessment}} of {{Reduction}} in {{Mortality}} and Morbidity ({{CHARM}}) Program},
  shorttitle = {Body Mass Index and Prognosis in Patients with Chronic Heart Failure},
  author = {Kenchaiah, Satish and Pocock, Stuart J. and Wang, Duolao and Finn, Peter V. and Zornoff, Leonardo A. M. and Skali, Hicham and Pfeffer, Marc A. and Yusuf, Salim and Swedberg, Karl and Michelson, Eric L. and Granger, Christopher B. and McMurray, John J. V. and Solomon, Scott D. and {CHARM Investigators}},
  year = {2007},
  month = aug,
  journal = {Circulation},
  volume = {116},
  number = {6},
  pages = {627--636},
  issn = {1524-4539},
  doi = {10.1161/CIRCULATIONAHA.106.679779},
  abstract = {BACKGROUND: In individuals without known cardiovascular disease, elevated body mass index (BMI) (weight/height2) is associated with an increased risk of death. However, in patients with certain specific chronic diseases, including heart failure, low BMI has been associated with increased mortality. METHODS AND RESULTS: We examined the influence of BMI on prognosis using Cox proportional hazards models in 7599 patients (mean age, 65 years; 35\% women) with symptomatic heart failure (New York Heart Association class II to IV) and a broad spectrum of left ventricular ejection fractions (mean, 39\%) in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. During a median follow-up of 37.7 months, 1831 patients died. After adjustment for potential confounders, compared with patients with BMI between 30 and 34.9, patients in lower BMI categories had a graded increase in the risk of death. The hazard ratios (95\% confidence intervals) were 1.22 (1.06 to 1.41), 1.46 (1.24 to 1.71), and 1.69 (1.43 to 2.01) among those with BMI of 25 to 29.9, 22.5 to 24.9, and {$<$} 22.5, respectively. The increase in risk of death among patients with BMI {$>$} or = 35 was not statistically significant (hazard ratio, 1.17; 95\% confidence interval, 0.95 to 1.43). The association between BMI and mortality was not altered by age, smoking status, or left ventricular ejection fraction (P for interaction {$>$}0.20). However, lower BMI was associated with a greater risk of all-cause death in patients without edema but not in patients with edema (P for interaction {$<$}0.0001). Lower BMI was associated with a greater risk of cardiovascular death and noncardiovascular death. Baseline BMI did not influence the risk of hospitalization for worsening heart failure or due to all causes. CONCLUSIONS: In patients with symptomatic heart failure and either reduced or preserved left ventricular systolic function, underweight or low BMI was associated with increased mortality, primarily in patients without evidence of fluid overload (edema).},
  langid = {english},
  pmid = {17638930},
  keywords = {Aged,Aged 80 and over,Benzimidazoles,Biphenyl Compounds,Body Mass Index,Cohort Studies,Double-Blind Method,Female,Follow-Up Studies,Heart Failure,Humans,Internationality,Male,Middle Aged,Morbidity,Prognosis,Survival Rate,Tetrazoles}
}

@article{kenchaiahBodyMassIndex2007a,
  title = {Body Mass Index and Prognosis in Patients with Chronic Heart Failure: Insights from the {{Candesartan}} in {{Heart}} Failure: {{Assessment}} of {{Reduction}} in {{Mortality}} and Morbidity ({{CHARM}}) Program},
  shorttitle = {Body Mass Index and Prognosis in Patients with Chronic Heart Failure},
  author = {Kenchaiah, Satish and Pocock, Stuart J. and Wang, Duolao and Finn, Peter V. and Zornoff, Leonardo A. M. and Skali, Hicham and Pfeffer, Marc A. and Yusuf, Salim and Swedberg, Karl and Michelson, Eric L. and Granger, Christopher B. and McMurray, John J. V. and Solomon, Scott D. and {CHARM Investigators}},
  year = {2007},
  month = aug,
  journal = {Circulation},
  volume = {116},
  number = {6},
  pages = {627--636},
  issn = {1524-4539},
  doi = {10.1161/CIRCULATIONAHA.106.679779},
  abstract = {BACKGROUND: In individuals without known cardiovascular disease, elevated body mass index (BMI) (weight/height2) is associated with an increased risk of death. However, in patients with certain specific chronic diseases, including heart failure, low BMI has been associated with increased mortality. METHODS AND RESULTS: We examined the influence of BMI on prognosis using Cox proportional hazards models in 7599 patients (mean age, 65 years; 35\% women) with symptomatic heart failure (New York Heart Association class II to IV) and a broad spectrum of left ventricular ejection fractions (mean, 39\%) in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. During a median follow-up of 37.7 months, 1831 patients died. After adjustment for potential confounders, compared with patients with BMI between 30 and 34.9, patients in lower BMI categories had a graded increase in the risk of death. The hazard ratios (95\% confidence intervals) were 1.22 (1.06 to 1.41), 1.46 (1.24 to 1.71), and 1.69 (1.43 to 2.01) among those with BMI of 25 to 29.9, 22.5 to 24.9, and {$<$} 22.5, respectively. The increase in risk of death among patients with BMI {$>$} or = 35 was not statistically significant (hazard ratio, 1.17; 95\% confidence interval, 0.95 to 1.43). The association between BMI and mortality was not altered by age, smoking status, or left ventricular ejection fraction (P for interaction {$>$}0.20). However, lower BMI was associated with a greater risk of all-cause death in patients without edema but not in patients with edema (P for interaction {$<$}0.0001). Lower BMI was associated with a greater risk of cardiovascular death and noncardiovascular death. Baseline BMI did not influence the risk of hospitalization for worsening heart failure or due to all causes. CONCLUSIONS: In patients with symptomatic heart failure and either reduced or preserved left ventricular systolic function, underweight or low BMI was associated with increased mortality, primarily in patients without evidence of fluid overload (edema).},
  langid = {english},
  pmid = {17638930},
  keywords = {Aged,Aged 80 and over,Benzimidazoles,Biphenyl Compounds,Body Mass Index,Cohort Studies,Double-Blind Method,Female,Follow-Up Studies,Heart Failure,Humans,Internationality,Male,Middle Aged,Morbidity,Prognosis,Survival Rate,Tetrazoles},
  file = {/Users/xx20081/Zotero/storage/CI6PT5XN/Kenchaiah et al. - 2007 - Body mass index and prognosis in patients with chr.pdf}
}

@article{kenchaiahBodyMassIndex2007b,
  title = {Body Mass Index and Prognosis in Patients with Chronic Heart Failure: Insights from the {{Candesartan}} in {{Heart}} Failure: {{Assessment}} of {{Reduction}} in {{Mortality}} and Morbidity ({{CHARM}}) Program},
  shorttitle = {Body Mass Index and Prognosis in Patients with Chronic Heart Failure},
  author = {Kenchaiah, Satish and Pocock, Stuart J. and Wang, Duolao and Finn, Peter V. and Zornoff, Leonardo A. M. and Skali, Hicham and Pfeffer, Marc A. and Yusuf, Salim and Swedberg, Karl and Michelson, Eric L. and Granger, Christopher B. and McMurray, John J. V. and Solomon, Scott D. and {CHARM Investigators}},
  year = {2007},
  month = aug,
  journal = {Circulation},
  volume = {116},
  number = {6},
  pages = {627--636},
  issn = {1524-4539},
  doi = {10.1161/CIRCULATIONAHA.106.679779},
  abstract = {BACKGROUND: In individuals without known cardiovascular disease, elevated body mass index (BMI) (weight/height2) is associated with an increased risk of death. However, in patients with certain specific chronic diseases, including heart failure, low BMI has been associated with increased mortality. METHODS AND RESULTS: We examined the influence of BMI on prognosis using Cox proportional hazards models in 7599 patients (mean age, 65 years; 35\% women) with symptomatic heart failure (New York Heart Association class II to IV) and a broad spectrum of left ventricular ejection fractions (mean, 39\%) in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. During a median follow-up of 37.7 months, 1831 patients died. After adjustment for potential confounders, compared with patients with BMI between 30 and 34.9, patients in lower BMI categories had a graded increase in the risk of death. The hazard ratios (95\% confidence intervals) were 1.22 (1.06 to 1.41), 1.46 (1.24 to 1.71), and 1.69 (1.43 to 2.01) among those with BMI of 25 to 29.9, 22.5 to 24.9, and {$<$} 22.5, respectively. The increase in risk of death among patients with BMI {$>$} or = 35 was not statistically significant (hazard ratio, 1.17; 95\% confidence interval, 0.95 to 1.43). The association between BMI and mortality was not altered by age, smoking status, or left ventricular ejection fraction (P for interaction {$>$}0.20). However, lower BMI was associated with a greater risk of all-cause death in patients without edema but not in patients with edema (P for interaction {$<$}0.0001). Lower BMI was associated with a greater risk of cardiovascular death and noncardiovascular death. Baseline BMI did not influence the risk of hospitalization for worsening heart failure or due to all causes. CONCLUSIONS: In patients with symptomatic heart failure and either reduced or preserved left ventricular systolic function, underweight or low BMI was associated with increased mortality, primarily in patients without evidence of fluid overload (edema).},
  langid = {english},
  pmid = {17638930},
  keywords = {Aged,Aged 80 and over,Benzimidazoles,Biphenyl Compounds,Body Mass Index,Cohort Studies,Double-Blind Method,Female,Follow-Up Studies,Heart Failure,Humans,Internationality,Male,Middle Aged,Morbidity,Prognosis,Survival Rate,Tetrazoles}
}

@article{kenchaiahHeartFailureWomen2015,
  title = {Heart {{Failure}} in {{Women--Insights}} from the {{Framingham Heart Study}}},
  author = {Kenchaiah, Satish and Vasan, Ramachandran S.},
  year = {2015},
  month = aug,
  journal = {Cardiovascular Drugs and Therapy},
  volume = {29},
  number = {4},
  pages = {377--390},
  issn = {1573-7241},
  doi = {10.1007/s10557-015-6599-0},
  abstract = {In the latter half of the 20th century, among participants of the Framingham Heart Study, incidence of heart failure (HF) has declined by about a third in women but not in men and survival after the onset of HF has improved in both sexes; however, HF remains highly lethal with over 50\% dying within 5 years after onset of HF. Overall, the 8-year relative risk of HF is 24\% lower in women compared with men. The 8-year incidence rates of HF with preserved ejection fraction (HFPEF; EF {$>$}45\%) and HF with reduced EF (HFREF; EF {$\leq$} 45\%) in women and HFPEF in men are similar; however, men have a 2-fold higher cumulative incidence of HFREF than HFPEF. The lifetime risk of HF is about 20\% in both women and men at 40, 50, 60, 70, and 80 years of age. Contribution of hypertension and diabetes mellitus to the risk of HF was more prominent in women than in men. Serum levels of several biomarkers were distinctly different in women compared with men and had differential effects on left ventricular structure and function; however, the strength and direction of the association between biomarkers levels and HF risk were generally similar in women and men. In individuals with HF, about two-thirds of the underlying cause of death and about one-half of the immediate cause of death were due to cardiovascular causes. Non-cardiovascular underlying and immediate causes of death were more evident in HFPEF.},
  langid = {english},
  pmcid = {PMC5303703},
  pmid = {26245740},
  keywords = {Biomarkers,Echocardiography,Electrocardiography,Female,Heart Failure,Humans,Incidence,Risk,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/BCWFBXF2/Kenchaiah and Vasan - 2015 - Heart Failure in Women--Insights from the Framingh.pdf}
}

@article{kenchaiahImpactObesityRisk2004,
  title = {Impact of Obesity on the Risk of Heart Failure and Survival after the Onset of Heart Failure},
  author = {Kenchaiah, Satish and Gaziano, J. Michael and Vasan, Ramachandran S.},
  year = {2004},
  month = sep,
  journal = {The Medical Clinics of North America},
  volume = {88},
  number = {5},
  pages = {1273--1294},
  issn = {0025-7125},
  doi = {10.1016/j.mcna.2004.04.011},
  abstract = {Obesity has reached epidemic proportions in the United States and worldwide. Heart failure (HF) is also a major public health problem, which, despite therapeutic advances, is associated with substantial mortality. The adverse impact of obesity on the cardiovascular system is being increasingly recognized, and includes a hyperdynamic circulation, subclinical cardiac structural and functional changes, and overt HF. At the same time, the possible protective effect of obesity in patients with established HF has been emphasized in recent studies. This article reviews evidence from epidemiologic studies evaluating the impact of overweight and obesity on the risk of HF, appraises published data on the prognostic significance of overweight and obesity after the onset of HF, describes the potential mechanisms underlying these associations,speculates on the clinical implications of current evidence, and suggests directions for future research.},
  langid = {english},
  pmid = {15331317},
  keywords = {Body Mass Index,Cause of Death,Chronic Disease,Comorbidity,Epidemiologic Studies,Evidence-Based Medicine,Forecasting,Heart Failure,Humans,Kidney Diseases,Multivariate Analysis,Obesity,Prognosis,Proportional Hazards Models,Proteinuria,Research,Risk Factors,Sleep Apnea Syndromes,Survival Analysis,Survival Rate,United States}
}

@article{kenchaiahObesityRiskHeart2002,
  title = {Obesity and the Risk of Heart Failure},
  author = {Kenchaiah, Satish and Evans, Jane C. and Levy, Daniel and Wilson, Peter W. F. and Benjamin, Emelia J. and Larson, Martin G. and Kannel, William B. and Vasan, Ramachandran S.},
  year = {2002},
  month = aug,
  journal = {The New England Journal of Medicine},
  volume = {347},
  number = {5},
  pages = {305--313},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa020245},
  abstract = {BACKGROUND: Extreme obesity is recognized to be a risk factor for heart failure. It is unclear whether overweight and lesser degrees of obesity also pose a risk. METHODS: We investigated the relation between the body-mass index (the weight in kilograms divided by the square of the height in meters) and the incidence of heart failure among 5881 participants in the Framingham Heart Study (mean age, 55 years; 54 percent women). With the use of Cox proportional-hazards models, the body-mass index was evaluated both as a continuous variable and as a categorical variable (normal, 18.5 to 24.9; overweight, 25.0 to 29.9; and obese, 30.0 or more). RESULTS: During follow-up (mean, 14 years), heart failure developed in 496 subjects (258 women and 238 men). After adjustment for established risk factors, there was an increase in the risk of heart failure of 5 percent for men and 7 percent for women for each increment of 1 in body-mass index. As compared with subjects with a normal body-mass index, obese subjects had a doubling of the risk of heart failure. For women, the hazard ratio was 2.12 (95 percent confidence interval, 1.51 to 2.97); for men, the hazard ratio was 1.90 (95 percent confidence interval, 1.30 to 2.79). A graded increase in the risk of heart failure was observed across categories of body-mass index. The hazard ratios per increase in category were 1.46 in women (95 percent confidence interval, 1.23 to 1.72) and 1.37 in men (95 percent confidence interval, 1.13 to 1.67). CONCLUSIONS: In our large, community-based sample, increased body-mass index was associated with an increased risk of heart failure. Given the high prevalence of obesity in the United States, strategies to promote optimal body weight may reduce the population burden of heart failure.},
  langid = {english},
  pmid = {12151467},
  keywords = {Body Mass Index,Echocardiography,Female,Heart Failure,Humans,Incidence,Longitudinal Studies,Male,Middle Aged,Obesity,Proportional Hazards Models,Risk Factors,Thinness}
}

@article{khanKidneyDiseaseProgression2022,
  title = {Kidney Disease Progression and Collider Bias in {{GWAS}}},
  author = {Khan, Atlas and Kiryluk, Krzysztof},
  year = {2022},
  month = sep,
  journal = {Kidney International},
  volume = {102},
  number = {3},
  pages = {476--478},
  issn = {0085-2538},
  doi = {10.1016/j.kint.2022.06.018},
  urldate = {2024-04-05},
  abstract = {New genome-wide meta-analysis for longitudinal kidney function decline identified several genetic loci related to kidney disease progression. The study illustrated the complexity of modeling longitudinal traits in genome-wide association studies and highlighted the issue of a collider bias that can be introduced when a kidney disease progression phenotype is adjusted for baseline kidney function. Herein, we briefly outline the key findings of this study, their limitations, and implications for future studies.},
  file = {/Users/xx20081/Zotero/storage/5MXR3DPF/Khan and Kiryluk - 2022 - Kidney disease progression and collider bias in GW.pdf;/Users/xx20081/Zotero/storage/GFKHBARS/S0085253822005233.html}
}

@article{khChallengesUndertakingNonlinear2023,
  title = {Challenges in Undertaking Nonlinear {{Mendelian}} Randomization},
  author = {Kh, Wade and Fw, Hamilton and D, Carslake and N, Sattar and G, Davey Smith and Nj, Timpson},
  year = {2023},
  month = dec,
  journal = {Obesity (Silver Spring, Md.)},
  volume = {31},
  number = {12},
  publisher = {Obesity (Silver Spring)},
  issn = {1930-739X},
  doi = {10.1002/oby.23927},
  urldate = {2025-01-22},
  abstract = {Mendelian randomization (MR) is a widely used method that exploits the unique properties of germline genetic variation to strengthen causal inference in relationships between exposures and outcomes. Nonlinear MR allows estimation of the shape of these relationships. In a previous paper, the authors {\dots}},
  langid = {english},
  pmid = {37845826},
  file = {/Users/xx20081/Zotero/storage/RZH8R4EJ/Kh et al. - 2023 - Challenges in undertaking nonlinear Mendelian randomization.pdf;/Users/xx20081/Zotero/storage/UU9ZZSWB/37845826.html}
}

@article{Khush2007,
  title = {Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the {{Treating}} to {{New Targets}} ({{TNT}}) Study},
  author = {Khush, Kiran K. and Waters, David D. and Bittner, Vera and Deedwania, Prakash C. and Kastelein, John J.P. and Lewis, Sandra J. and Wenger, Nanette K.},
  year = {2007},
  month = feb,
  journal = {Circulation},
  volume = {115},
  number = {5},
  pages = {576--583},
  publisher = {Circulation},
  issn = {1524-4539},
  doi = {10.1161/CIRCULATIONAHA.106.625574},
  abstract = {BACKGROUND - Statins reduce the rate of major cardiovascular events in high-risk patients, but their potential benefit as treatment for heart failure (HF) is less clear. METHODS AND RESULTS - Patients (n=10 001) with stable coronary disease were randomized to treatment with atorvastatin 80 or 10 mg/d and followed up for a median of 4.9 years. A history of HF was present in 7.8\% of patients. A known ejection fraction {\textexclamdown}30\% and advanced HF were exclusion criteria for the study. A predefined secondary end point of the study was hospitalization for HF. The incidence of hospitalization for HF was 2.4\% in the 80-mg arm and 3.3\% in the 10-mg arm (hazard ratio, 0.74; 95\% confidence interval, 0.59 to 0.94; P=0.0116). The treatment effect of the higher dose was more marked in patients with a history of HF: 17.3\% versus 10.6\% in the 10- and 80-mg arms, respectively (hazard ratio, 0.59; 95\% confidence interval, 0.4 to 0.88; P=0.009). Among patients without a history of HF, the rates of hospitalization for HF were much lower: 1.8\% in the 80-mg group and 2.0\% in the 10-mg group (hazard ratio, 0.87; 95\% confidence interval, 0.64 to 1.16; P=0.34). Only one third of patients hospitalized for HF had evidence of preceding angina or myocardial infarction during the study period. Blood pressure was almost identical during follow-up in the treatment groups. CONCLUSIONS - Compared with a lower dose, intensive treatment with atorvastatin in patients with stable coronary disease significantly reduces hospitalizations for HF. In a post hoc analysis, this benefit was observed only in patients with a history of HF. The mechanism accounting for this benefit is unlikely to be due primarily to a reduction in interim coronary events or differences in blood pressure. {\copyright} 2007 American Heart Association, Inc.},
  pmid = {17261662},
  keywords = {Aged,Atorvastatin,Comparative Study,David D Waters,doi:10.1161/CIRCULATIONAHA.106.625574,Drug Delivery Systems / methods*,Female,Follow-Up Studies,Heart Failure / drug therapy*,Heart Failure / epidemiology*,Heptanoic Acids / administration & dosage*,Hospitalization*,Humans,Kiran K Khush,Male,MEDLINE,Middle Aged,Nanette K Wenger,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,Non-U.S. Gov't,pmid:17261662,PubMed Abstract,Pyrroles / administration & dosage*,Randomized Controlled Trial,Research Support}
}

@article{kibingeCharacterizingCausalPathway2020,
  title = {Characterizing the {{Causal Pathway}} for {{Genetic Variants Associated}} with {{Neurological Phenotypes Using Human Brain-Derived Proteome Data}}},
  author = {Kibinge, Nelson K. and Relton, Caroline L. and Gaunt, Tom R. and Richardson, Tom G.},
  year = {2020},
  month = jun,
  journal = {The American Journal of Human Genetics},
  volume = {106},
  number = {6},
  pages = {885--892},
  issn = {0002-9297},
  doi = {10.1016/j.ajhg.2020.04.007},
  urldate = {2024-02-19},
  abstract = {Leveraging high-dimensional molecular datasets can help us develop mechanistic insight into associations between genetic variants and complex traits. In this study, we integrated human proteome data derived from brain tissue to evaluate whether targeted proteins putatively mediate the effects of genetic variants on seven neurological phenotypes (Alzheimer disease, amyotrophic lateral sclerosis, depression, insomnia, intelligence, neuroticism, and schizophrenia). Applying the principles of Mendelian randomization (MR) systematically across the genome highlighted 43 effects between genetically predicted proteins derived from the dorsolateral prefrontal cortex and these outcomes. Furthermore, genetic colocalization provided evidence that the same causal variant at 12 of these loci was responsible for variation in both protein and neurological phenotype. This included genes such as DCC, which encodes the netrin-1 receptor and has an important role in the development of the nervous system (p = 4.29~{\texttimes} 10-11 with neuroticism), as well as SARM1, which has been previously implicated in axonal degeneration (p = 1.76~{\texttimes} 10-08 with amyotrophic lateral sclerosis). We additionally conducted a phenome-wide MR study for each of these 12 genes to assess potential pleiotropic effects on 700 complex traits and diseases. Our findings suggest that genes such as SNX32, which was initially associated with increased risk of Alzheimer disease, may potentially influence other complex traits in the opposite direction. In contrast, genes such as CTSH (which was also associated with Alzheimer disease) and SARM1 may make worthwhile therapeutic targets because they did not have genetically predicted effects on any of the other phenotypes after correcting for multiple testing.},
  keywords = {brain-derived proteins,cognitive,genetic colocalization,Mendelian randomization,neurological,phenome-wide association study,protein quantitative trait loci,psychaitric},
  file = {/Users/xx20081/Zotero/storage/293HWZ3X/Kibinge et al. - 2020 - Characterizing the Causal Pathway for Genetic Vari.pdf;/Users/xx20081/Zotero/storage/73FXXWUA/S0002929720301166.html}
}

@article{kiiskinenGeneticPredictorsLifelong2023,
  title = {Genetic Predictors of Lifelong Medication-Use Patterns in Cardiometabolic Diseases},
  author = {Kiiskinen, Tuomo and Helkkula, Pyry and Krebs, Kristi and Karjalainen, Juha and Saarentaus, Elmo and Mars, Nina and Lehisto, Arto and Zhou, Wei and Cordioli, Mattia and Jukarainen, Sakari and R{\"a}m{\"o}, Joel T. and Mehtonen, Juha and Veerapen, Kumar and R{\"a}s{\"a}nen, Markus and Ruotsalainen, Sanni and Maasha, Mutaamba and Niiranen, Teemu and Tuomi, Tiinamaija and Salomaa, Veikko and Kurki, Mitja and Pirinen, Matti and Palotie, Aarno and Daly, Mark and Ganna, Andrea and Havulinna, Aki S. and Milani, Lili and Ripatti, Samuli},
  year = {2023},
  month = jan,
  journal = {Nature Medicine},
  volume = {29},
  number = {1},
  pages = {209--218},
  publisher = {Nature Publishing Group},
  issn = {1546-170X},
  doi = {10.1038/s41591-022-02122-5},
  urldate = {2025-03-14},
  abstract = {Little is known about the genetic determinants of medication use in preventing cardiometabolic diseases. Using the Finnish nationwide drug purchase registry with follow-up since 1995, we performed genome-wide association analyses of longitudinal patterns of medication use in hyperlipidemia, hypertension and type 2 diabetes in up to 193,933 individuals (55\% women) in the FinnGen study. In meta-analyses of up to 567,671 individuals combining FinnGen with the Estonian Biobank and the UK Biobank, we discovered 333 independent loci (P\,{$<$}\,5\,{\texttimes}\,10--9) associated with medication use. Fine-mapping revealed 494 95\% credible sets associated with the total number of medication purchases, changes in medication combinations or treatment discontinuation, including 46 credible sets in 40 loci not associated with the underlying treatment targets. The polygenic risk scores (PRS) for cardiometabolic risk factors were strongly associated with the medication-use behavior. A medication-use enhanced multitrait PRS for coronary artery disease matched the performance of a risk factor-based multitrait coronary artery disease PRS in an independent sample (UK Biobank, n\,=\,343,676). In summary, we demonstrate medication-based strategies for identifying cardiometabolic risk loci and provide genome-wide tools for preventing cardiovascular diseases.},
  copyright = {2023 The Author(s)},
  langid = {english},
  keywords = {Ischaemia,Pharmacogenomics,Risk factors},
  file = {/Users/xx20081/Zotero/storage/4I8K92CJ/Kiiskinen et al. - 2023 - Genetic predictors of lifelong medication-use patterns in cardiometabolic diseases.pdf}
}

@article{kimballMetabolismEpigeneticsCausal2020,
  title = {Metabolism, {{Epigenetics}}, and {{Causal Inference}} in {{Heart Failure}}},
  author = {Kimball, Todd H. and Vondriska, Thomas M.},
  year = {2020},
  month = mar,
  journal = {Trends in endocrinology and metabolism: TEM},
  volume = {31},
  number = {3},
  pages = {181--191},
  issn = {1879-3061},
  doi = {10.1016/j.tem.2019.11.009},
  abstract = {Eukaryotes must balance the metabolic and cell death actions of mitochondria via control of gene expression and cell fate by chromatin, thereby functionally binding the metabolome and epigenome. This interaction has far-reaching implications for chronic diseases in humans, the most common of which are those of the cardiovascular system. The most devastating consequence of cardiovascular disease, heart failure, is not a single disease, diagnosis, or endpoint. Human and animal studies have revealed that, regardless of etiology and symptoms, heart failure is universally associated with abnormal metabolism and gene expression - to frame this as cause or consequence, however, may be to wrongfoot the question. This essay aims to challenge current thinking on metabolic-epigenetic crosstalk in heart failure, presenting hypotheses for how chronic diseases arise, take hold, and persist. We unpack assumptions about the order of operations for gene expression and metabolism, exploring recent findings in noncardiac systems that link metabolic intermediates directly to chromatin remodeling. Lastly, we discuss potential mechanisms by which chromatin may serve as a substrate for metabolic memory, and how changes in cellular transcriptomes (and hence in cellular behavior) in response to stress correspond to global changes in chromatin accessibility and structure.},
  langid = {english},
  pmcid = {PMC7035178},
  pmid = {31866216},
  keywords = {Animals,cardiovascular disease,Cardiovascular System,chromatin,Energy Metabolism,Epigenesis Genetic,epigenome,Gene Expression,Heart Failure,Humans,metabolism,mitochondria,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/Y3FWPSNA/Kimball and Vondriska - 2020 - Metabolism, Epigenetics, and Causal Inference in Heart Failure.pdf}
}

@article{Kjekshus2007,
  title = {Rosuvastatin in Older Patients with Systolic Heart Failure},
  author = {Kjekshus, John and Apetrei, Eduard and Barrios, Vivencio and B{\"o}hm, Michael and Cleland, John G.F. and Cornel, Jan H. and Dunselman, Peter and Fonseca, C{\^a}ndida and Goudev, Assen and Grande, Peer and Gullestad, Lars and Hjalmarson, {\AA}ke and Hradec, Jaromir and J{\'a}nosi, Andr{\'a}s and Kamensk{\'y}, Gabriel and Komajda, Michel and Korewicki, Jerzy and Kuusi, Timo and Mach, Fran{\c c}ois and Mareev, Vyacheslav and McMurray, John J.V. and Ranjith, Naresh and Schaufelberger, Maria and Vanhaecke, Johan and {van Veldhuisen}, Dirk J. and Waagstein, Finn and Wedel, Hans and Wikstrand, John},
  year = {2007},
  month = nov,
  journal = {The New England journal of medicine},
  volume = {357},
  number = {22},
  pages = {2248--2261},
  publisher = {N Engl J Med},
  issn = {1533-4406},
  doi = {10.1056/NEJMOA0706201},
  abstract = {BACKGROUND: Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients. METHODS: A total of 5011 patients at least 60 years of age with New York Heart Association class II, III, or IV ischemic, systolic heart failure were randomly assigned to receive 10 mg of rosuvastatin or placebo per day. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary outcomes included death from any cause, any coronary event, death from cardiovascular causes, and the number of hospitalizations. RESULTS: As compared with the placebo group, patients in the rosuvastatin group had decreased levels of low-density lipoprotein cholesterol (difference between groups, 45.0\%; P{\textexclamdown}0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1\%; P{\textexclamdown}0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95\% confidence interval [CI], 0.83 to 1.02; P=0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95\% CI, 0.86 to 1.05; P=0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P{\textexclamdown}0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. CONCLUSIONS: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.) Copyright ? 2007 Massachusetts Medical Society.},
  pmid = {17984166},
  keywords = {affs=[]),Aged,Cardiovascular Diseases / epidemiology,Cardiovascular Diseases / mortality,CollabAuthor(name='CORONA Group',doi:10.1056/NEJMoa0706201,Eduard Apetrei,Female,Fluorobenzenes / adverse effects,Fluorobenzenes / therapeutic use*,Follow-Up Studies,Heart Failure / drug therapy*,Heart Failure / etiology,Hospitalization / statistics & numerical data,Humans,Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects,Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*,investigators=[],John Kjekshus,Male,MEDLINE,Middle Aged,Multicenter Study,Myocardial Ischemia / complications,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,Non-U.S. Gov't,pmid:17984166,Proportional Hazards Models,PubMed Abstract,Pyrimidines / adverse effects,Pyrimidines / therapeutic use*,Randomized Controlled Trial,Research Support,Rosuvastatin Calcium,Single-Blind Method,Sulfonamides / adverse effects,Sulfonamides / therapeutic use*,Systole,Treatment Outcome}
}

@article{klarinClinicalUtilityPolygenic2022,
  title = {Clinical Utility of Polygenic Risk Scores for Coronary Artery Disease},
  author = {Klarin, Derek and Natarajan, Pradeep},
  year = {2022},
  month = may,
  journal = {Nature Reviews. Cardiology},
  volume = {19},
  number = {5},
  pages = {291--301},
  issn = {1759-5010},
  doi = {10.1038/s41569-021-00638-w},
  abstract = {Over the past decade, substantial progress has been made in the discovery of alleles contributing to the risk of coronary artery disease. In addition to providing causal insights into disease, these endeavours have yielded and enabled the refinement of polygenic risk scores. These scores can be used to predict incident coronary artery disease in multiple cohorts and indicate the clinical response to some preventive therapies in post hoc analyses of clinical trials. These observations and the widespread ability to calculate polygenic risk scores from direct-to-consumer and health-care-associated biobanks have raised many questions about responsible clinical adoption. In this Review, we describe technical and downstream considerations for the derivation and validation of polygenic risk scores and current evidence for their efficacy and safety. We discuss the implementation of these scores in clinical medicine for uses including risk prediction and screening algorithms for coronary artery disease, prioritization of patient subgroups that are likely to derive benefit from treatment, and efficient prospective clinical trial designs.},
  langid = {english},
  pmcid = {PMC10150334},
  pmid = {34811547},
  keywords = {Coronary Artery Disease,Genetic Predisposition to Disease,Humans,Multifactorial Inheritance,Prospective Studies,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/FV8JMYD3/Klarin and Natarajan - 2022 - Clinical utility of polygenic risk scores for coronary artery disease.pdf}
}

@article{klarinGeneticsBloodLipids2018,
  title = {Genetics of Blood Lipids among {\textasciitilde}300,000 Multi-Ethnic Participants of the {{Million Veteran Program}}},
  author = {Klarin, Derek and Damrauer, Scott M. and Cho, Kelly and Sun, Yan V. and Teslovich, Tanya M. and Honerlaw, Jacqueline and Gagnon, David R. and DuVall, Scott L. and Li, Jin and Peloso, Gina M. and Chaffin, Mark and Small, Aeron M. and Huang, Jie and Tang, Hua and Lynch, Julie A. and Ho, Yuk-Lam and Liu, Dajiang J. and Emdin, Connor A. and Li, Alexander H. and Huffman, Jennifer E. and Lee, Jennifer S. and Natarajan, Pradeep and Chowdhury, Rajiv and Saleheen, Danish and Vujkovic, Marijana and Baras, Aris and Pyarajan, Saiju and Di Angelantonio, Emanuele and Neale, Benjamin M. and Naheed, Aliya and Khera, Amit V. and Danesh, John and Chang, Kyong-Mi and Abecasis, Gon{\c c}alo and Willer, Cristen and Dewey, Frederick E. and Carey, David J. and {Global Lipids Genetics Consortium} and {Myocardial Infarction Genetics (MIGen) Consortium} and {Geisinger-Regeneron DiscovEHR Collaboration} and {VA Million Veteran Program} and Concato, John and Gaziano, J. Michael and O'Donnell, Christopher J. and Tsao, Philip S. and Kathiresan, Sekar and Rader, Daniel J. and Wilson, Peter W. F. and Assimes, Themistocles L.},
  year = {2018},
  month = nov,
  journal = {Nature Genetics},
  volume = {50},
  number = {11},
  pages = {1514--1523},
  issn = {1546-1718},
  doi = {10.1038/s41588-018-0222-9},
  abstract = {The Million Veteran Program (MVP) was established in 2011 as a national research initiative to determine how genetic variation influences the health of US military veterans. Here we genotyped 312,571 MVP participants using a custom biobank array and linked the genetic data to laboratory and clinical phenotypes extracted from electronic health records covering a median of 10.0 years of follow-up. Among 297,626 veterans with at least one blood lipid measurement, including 57,332 black and 24,743 Hispanic participants, we tested up to around 32 million variants for association with lipid levels and identified 118 novel genome-wide significant loci after meta-analysis with data from the Global Lipids Genetics Consortium (total n\,{$>$}\,600,000). Through a focus on mutations predicted to result in a loss of gene function and a phenome-wide association study, we propose novel indications for pharmaceutical inhibitors targeting PCSK9 (abdominal aortic aneurysm), ANGPTL4 (type 2 diabetes) and PDE3B (triglycerides and coronary disease).},
  langid = {english},
  pmcid = {PMC6521726},
  pmid = {30275531},
  keywords = {Aged,Black People,Cardiovascular Diseases,Diabetes Mellitus Type 2,Ethnicity,Female,Genome-Wide Association Study,Genotype,Hispanic or Latino,Humans,Lipid Metabolism,Lipids,Male,Middle Aged,Polymorphism Single Nucleotide,Veterans,White People},
  file = {/Users/xx20081/Zotero/storage/XEHQEZGJ/Klarin et al. - 2018 - Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program.pdf}
}

@article{Klimczak-Tomaniak2020,
  title = {Temporal Patterns of Macrophage- and Neutrophil-Related Markers Are Associated with Clinical Outcome in Heart Failure Patients},
  author = {{Klimczak-Tomaniak}, Dominika and Bouwens, Elke and Schuurman, Anne Sophie and Akkerhuis, K. Martijn and Constantinescu, Alina and Brugts, Jasper and Westenbrink, B. Daan and {van Ramshorst}, Jan and Germans, Tjeerd and P{\k a}czek, Leszek and Umans, Victor and Boersma, Eric and Kardys, Isabella},
  year = {2020},
  month = jun,
  journal = {ESC heart failure},
  volume = {7},
  number = {3},
  pages = {1190--1200},
  publisher = {ESC Heart Fail},
  issn = {2055-5822},
  doi = {10.1002/EHF2.12678},
  abstract = {Aims: Evidence on the association of macrophage- and neutrophil-related blood biomarkers with clinical outcome in heart failure patients is limited, and, with the exception of C-reactive protein, no data exist on their temporal evolution. We aimed to investigate whether temporal patterns of these biomarkers are related to clinical outcome in patients with stable chronic heart failure (CHF). Methods and Results: In 263 patients with CHF, we performed serial plasma measurements of scavenger receptor cysteine-rich type 1 protein M130 (CD163), tartrate-resistant acid phosphatase type 5 (TRAP), granulins (GRN), spondin-1 (SPON1), peptidoglycan recognition protein 1 (PGLYRP1), and tissue factor pathway inhibitor (TFPI). The Cardiovascular Panel III (Olink Proteomics AB, Uppsala, Sweden) was used. During 2.2 years of follow-up, we collected 1984 samples before the occurrence of the composite primary endpoint (PE) or censoring. For efficiency, we selected 567 samples for the measurements (all baseline samples, the last two samples preceding the PE, and the last sample before censoring in event-free patients). The relationship between repeatedly measured biomarker levels and the PE was evaluated by joint models. Mean ({\textpm}standard deviation) age was 67 {\textpm} 13 years; 189 (72\%) were men; left ventricular ejection fraction (\%) was 32 {\textpm} 11. During follow-up, 70 (27\%) patients experienced the PE. Serially measured biomarkers predicted the PE in a multivariable model adjusted for baseline clinical characteristics [hazard ratio (95\% confidence interval) per 1-standard deviation change in biomarker]: CD163 [2.07(1.47--2.98), P {\textexclamdown} 0.001], TRAP [0.62 (0.43--0.90), P = 0.009], GRN [2.46 (1.64--3.84), P {\textexclamdown} 0.001], SPON1 [3.94 (2.50--6.50), P {\textexclamdown} 0.001], and PGLYRP1 [1.62 (1.14--2.31), P = 0.006]. Conclusions: Changes in plasma levels of CD163, TRAP, GRN, SPON1, and PGLYRP1 precede adverse cardiovascular events in patients with CHF.},
  pmid = {32196993},
  keywords = {80 and over,Aged,Biomarkers,doi:10.1002/ehf2.12678,Dominika Klimczak-Tomaniak,Elke Bouwens,Heart Failure*,Humans,Isabella Kardys,Left,Macrophages,Male,MEDLINE,Middle Aged,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,Neutrophils*,NIH,NLM,Non-U.S. Gov't,PMC7261550,pmid:32196993,Prognosis,PubMed Abstract,Research Support,Stroke Volume,Sweden,Ventricular Function}
}

@article{kokkinosCardiorespiratoryFitnessBody2019,
  title = {Cardiorespiratory Fitness, Body Mass Index and Heart Failure Incidence},
  author = {Kokkinos, Peter and Faselis, Charles and Franklin, Barry and Lavie, Carl J. and Sidossis, Labros and Moore, Hans and Karasik, Pamela and Myers, Jonathan},
  year = {2019},
  month = apr,
  journal = {European Journal of Heart Failure},
  volume = {21},
  number = {4},
  pages = {436--444},
  issn = {1879-0844},
  doi = {10.1002/ejhf.1433},
  abstract = {AIMS: Obesity is associated with increased risk of heart failure (HF). This risk may be modulated by improved cardiorespiratory fitness (CRF) as CRF is associated with favourable health outcomes. Thus, we assessed the interaction between body mass index (BMI), CRF and HF. METHODS AND RESULTS: Cardiorespiratory fitness and BMI were assessed in 20 254 US male veterans (mean age 58.0 {\textpm} 11.3 years), who completed a maximal exercise treadmill test between 1987 and 2017. All had no evidence of ischaemia or HF prior to the exercise test. They were classified based on age-stratified quartiles of peak metabolic equivalents (METs) achieved as: least-fit (4.5 {\textpm} 1.3), low-fit (6.7 {\textpm} 1.3), moderate-fit (8.1 {\textpm} 1.1), and high-fit (11.2 {\textpm} 2.4); and according to BMI as normal weight (18.5-24.9 kg/m2 ), overweight (25-29.9 kg/m2 ), and obese ({$\geq$} 30.0 kg/m2 ). During a median follow-up of 13.4 years, there were 2979 HF events (10.8 events/1000 person-years). HF risk was significantly higher in the obese category [hazard ratio (HR) 1.22, 95\% confidence interval (CI) 1.10-1.36; P {$<$} 0.001], but was no longer significant after further adjustment for METs. When compared to the least-fit, HF risk declined progressively with increased CRF within all BMI categories. The risk was 63\% (HR 0.37, 95\% CI 0.30-0.47; P {$<$} 0.001), 66\% (HR 0.37, 95\% CI 0.28-0.40; P {$<$} 0.001), and 73\% (HR 0.27, 95\% CI 0.22-0.34; P {$<$} 0.001) lower for high-fit individuals within normal weight, overweight and obese categories, respectively. CONCLUSIONS: Increased CRF was associated with progressively lower HF risk regardless of BMI, suggesting that the elevated HF risk associated with obesity may be modulated by improved CRF.},
  langid = {english},
  pmid = {30779281},
  keywords = {Aged,Body Mass Index,Cardiorespiratory fitness,Cardiorespiratory Fitness,Exercise Test,Follow-Up Studies,Heart failure,Heart Failure,Humans,Incidence,Male,Middle Aged,Obesity,Overweight,Physical Fitness,Risk Assessment,Risk Factors,Veterans},
  file = {/Users/xx20081/Zotero/storage/UD6HSDEV/Kokkinos et al. - 2019 - Cardiorespiratory fitness, body mass index and hea.pdf}
}

@article{komajdaIncrementalBenefitDrug2018,
  title = {Incremental Benefit of Drug Therapies for Chronic Heart Failure with Reduced Ejection Fraction: A Network Meta-Analysis},
  shorttitle = {Incremental Benefit of Drug Therapies for Chronic Heart Failure with Reduced Ejection Fraction},
  author = {Komajda, Michel and B{\"o}hm, Michael and Borer, Jeffrey S. and Ford, Ian and Tavazzi, Luigi and Pannaux, Matthieu and Swedberg, Karl},
  year = {2018},
  month = sep,
  journal = {European Journal of Heart Failure},
  volume = {20},
  number = {9},
  pages = {1315--1322},
  issn = {1879-0844},
  doi = {10.1002/ejhf.1234},
  abstract = {AIMS: A network meta-analysis (NMA) of all recommended drug groups for the treatment of heart failure with reduced ejection fraction (HFrEF), including their combinations, was performed to assess the relative efficacy and incremental benefit. METHODS AND RESULTS: A search was made in biomedical databases for randomized controlled trials published between 1987 and 2017 on angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers (BBs), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), ivabradine (IVA), or angiotensin receptor-neprilysin inhibitors (ARNI). A total of 58 relevant trials were identified. The relative efficacy of each treatment group (or combination) in terms of all-cause mortality, cardiovascular mortality, all-cause hospitalizations and hospitalizations for heart failure, per patient-year of follow-up, were combined in a random-effects Bayesian NMA. The pairwise comparison between each regimen and for each outcome was estimated. The NMA was dominated by 15 large-scale trials with between 1984 and 18\,898 patient-years of follow-up. Combinations of drug groups showed incremental benefits on outcomes over single groups. The most effective combinations were ARNI+BB\,+\,MRA and ACEI+BB\,+\,MRA\,+\,IVA, showing reductions in all-cause mortality (vs. placebo) of 62\% and 59\%, respectively; hazard ratios were 0.38 [credible interval (CrI) 0.20-0.65] and 0.41 (CrI 0.21-0.70); and in all-cause hospitalizations with reductions of 42\% for both. These two combinations were also the most effective for the other outcomes studied. CONCLUSION: Our analysis shows that the incremental use of combinations of disease-modifying therapies has resulted in the progressive improvement in mortality and hospitalization outcomes in HFrEF. Our findings support the current guideline recommendations.},
  langid = {english},
  pmid = {29806165},
  keywords = {Cardiovascular Agents,Drug therapy,Heart failure,Heart Failure,Humans,Network meta-analysis,Network Meta-Analysis,Practice Guidelines as Topic,Randomized controlled trials,Randomized Controlled Trials as Topic,Stroke Volume,Treatment Outcome},
  file = {/Users/xx20081/Zotero/storage/XDMGGPJ2/Komajda et al. - 2018 - Incremental benefit of drug therapies for chronic .pdf}
}

@article{koolePolymorphismLigandDependent2011,
  title = {Polymorphism and {{Ligand Dependent Changes}} in {{Human Glucagon-Like Peptide-1 Receptor}} ({{GLP-1R}}) {{Function}}: {{Allosteric Rescue}} of {{Loss}} of {{Function Mutation}}},
  shorttitle = {Polymorphism and {{Ligand Dependent Changes}} in {{Human Glucagon-Like Peptide-1 Receptor}} ({{GLP-1R}}) {{Function}}},
  author = {Koole, Cassandra and Wootten, Denise and Simms, John and Valant, Celine and Miller, Laurence J. and Christopoulos, Arthur and Sexton, Patrick M.},
  year = {2011},
  month = sep,
  journal = {Molecular Pharmacology},
  volume = {80},
  number = {3},
  pages = {486--497},
  publisher = {{American Society for Pharmacology and Experimental Therapeutics}},
  issn = {0026-895X, 1521-0111},
  doi = {10.1124/mol.111.072884},
  urldate = {2024-01-25},
  abstract = {The glucagon-like peptide-1 receptor (GLP-1R) is a key physiological regulator of insulin secretion and a major therapeutic target for the treatment of type II diabetes. However, regulation of GLP-1R function is complex with multiple endogenous peptides that interact with the receptor, including full-length (1--37) and truncated (7--37) forms of GLP-1 that can exist in an amidated form (GLP-1(1--36)NH2 and GLP-1(7--36)NH2) and the related peptide oxyntomodulin. In addition, the GLP-1R possesses exogenous agonists, including exendin-4, and the allosteric modulator, compound 2 (6,7-dichloro-2-methylsulfonyl-3-tert-butylaminoquinoxaline). The complexity of this ligand-receptor system is further increased by the presence of several single nucleotide polymorphisms (SNPs) that are distributed across the receptor. We have investigated 10 GLP-1R SNPs, which were characterized in three physiologically relevant signaling pathways (cAMP accumulation, extracellular signal-regulated kinase 1/2 phosphorylation, and intracellular Ca2+ mobilization); ligand binding and cell surface receptor expression were also determined. We demonstrate both ligand- and pathway-specific effects for multiple SNPs, with the most dramatic effect observed for the Met149 receptor variant. At the Met149 variant, there was selective loss of peptide-induced responses across all pathways examined, but preservation of response to the small molecule compound 2. In contrast, at the Cys333 variant, peptide responses were preserved but there was attenuated response to compound 2. Strikingly, the loss of peptide function at the Met149 receptor variant could be allosterically rescued by compound 2, providing proof-of-principle evidence that allosteric drugs could be used to treat patients with this loss of function variant.},
  chapter = {Article},
  copyright = {Copyright {\copyright} 2011 The American Society for Pharmacology and Experimental Therapeutics},
  langid = {english},
  pmid = {21616920},
  file = {/Users/xx20081/Zotero/storage/RPL4XVBN/Koole et al. - 2011 - Polymorphism and Ligand Dependent Changes in Human.pdf}
}

@article{kosiborodSemaglutidePatientsHeart2023,
  title = {Semaglutide in {{Patients}} with {{Heart Failure}} with {{Preserved Ejection Fraction}} and {{Obesity}}},
  author = {Kosiborod, Mikhail N. and Abildstr{\o}m, Steen Z. and Borlaug, Barry A. and Butler, Javed and Rasmussen, S{\o}ren and Davies, Melanie and Hovingh, G. Kees and Kitzman, Dalane W. and Lindegaard, Marie L. and M{\o}ller, Dani{\'e}l V. and Shah, Sanjiv J. and Treppendahl, Marianne B. and Verma, Subodh and Abhayaratna, Walter and Ahmed, Fozia Z. and Chopra, Vijay and Ezekowitz, Justin and Fu, Michael and Ito, Hiroshi and Lelonek, Ma{\l}gorzata and Melenovsky, Vojtech and Merkely, Bela and N{\'u}{\~n}ez, Julio and Perna, Eduardo and Schou, Morten and Senni, Michele and Sharma, Kavita and der Meer, Peter Van and von Lewinski, Dirk and Wolf, Dennis and Petrie, Mark C.},
  year = {2023},
  month = sep,
  journal = {New England Journal of Medicine},
  volume = {389},
  number = {12},
  pages = {1069--1084},
  publisher = {Massachusetts Medical Society},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa2306963},
  urldate = {2025-01-20},
  abstract = {In patients with heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg) led to greater reductions in symptoms and physical limitations and greater improvements in exercise function than placebo.},
  file = {/Users/xx20081/Zotero/storage/MIC5YXYG/Kosiborod et al. - 2023 - Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.pdf}
}

@article{kosmalaFibrosisCardiacFunction2013,
  title = {Fibrosis and Cardiac Function in Obesity: A Randomised Controlled Trial of Aldosterone Blockade},
  shorttitle = {Fibrosis and Cardiac Function in Obesity},
  author = {Kosmala, Wojciech and {Przewlocka-Kosmala}, Monika and {Szczepanik-Osadnik}, Hanna and Mysiak, Andrzej and Marwick, Thomas H.},
  year = {2013},
  month = mar,
  journal = {Heart (British Cardiac Society)},
  volume = {99},
  number = {5},
  pages = {320--326},
  issn = {1468-201X},
  doi = {10.1136/heartjnl-2012-303329},
  abstract = {OBJECTIVES: As myocardial fibrosis might be an important contributor to the association of obesity with left ventricular (LV) dysfunction and heart failure, we investigated the effects of spironolactone on LV function and serological fibrosis markers (procollagen type III N-terminal propeptide (PIIINP) and procollagen type I C-terminal propeptide (PICP)) in patients with obesity and abnormal LV performance. DESIGN: A prospective, randomised, double-blind, placebo-controlled study. SETTING: A university hospital. PATIENTS AND INTERVENTION: 113 patients (mean{\textpm}SD age 58{\textpm}8 years) with body mass index{$\geq$}30, without any comorbidities, with impaired early diastolic mitral annular velocity, randomised to spironolactone 25 mg/day or placebo for 6 months. MAIN OUTCOME MEASURES: Echocardiographically derived indices of LV systolic (strain and strain rate) and diastolic (E velocity, tissue e' and E/e' ratio) function, myocardial reflectivity (calibrated integrated backscatter (IB)), and serum PICP and PIIINP. RESULTS: In the spironolactone group, significant improvements in myocardial deformation, peak early diastolic velocity (Em), E/e' and IB were noted with a simultaneous decrease in PICP and PIIINP. No corresponding alterations were found with placebo. Improvement in LV systolic function (increase in strain) was independently associated with baseline strain ({$\beta$}=-0.43, p{$<$}0.001), change in IB ({$\beta$}=0.26, p{$<$}0.02) and baseline PICP ({$\beta$}=0.24, p{$<$}0.04). Among the independent determinants of LV diastolic improvement were for increase in Em - baseline Em ({$\beta$}=-0.44, p{$<$}0.001) and baseline PICP ({$\beta$}=0.35, p{$<$}0.002), and for decrease in E/e' - baseline E/e' ({$\beta$}=-0.35, p{$<$}0.005) and change in PICP ({$\beta$}=0.25, p{$<$}0.04). CONCLUSIONS: In patients with obesity without other comorbidities, aldosterone antagonism improves LV function and myocardial acoustic properties, and reduces circulating procollagen levels. Beneficial changes in cardiac performance are independently predicted by baseline LV dysfunction and baseline disturbances, as well as treatment-induced improvements in fibrosis markers. CLINICAL TRIAL REGISTRATION: http://www.anzctr.org.au ACTRN12609000655246.},
  langid = {english},
  pmid = {23343682},
  keywords = {Body Mass Index,Double-Blind Method,Echocardiography Doppler,Female,Fibrosis,Follow-Up Studies,Heart Ventricles,Humans,Male,Middle Aged,Mineralocorticoid Receptor Antagonists,Myocardium,Obesity,Prospective Studies,Spironolactone,Treatment Outcome,Ventricular Dysfunction Left,Ventricular Function Left},
  file = {/Users/xx20081/Zotero/storage/9N348VZI/Kosmala et al. - 2013 - Fibrosis and cardiac function in obesity a random.pdf}
}

@article{kotsisMechanismsObesityinducedHypertension2010,
  title = {Mechanisms of Obesity-Induced Hypertension},
  author = {Kotsis, Vasilios and Stabouli, Stella and Papakatsika, Sofia and Rizos, Zoe and Parati, Gianfranco},
  year = {2010},
  month = may,
  journal = {Hypertension Research: Official Journal of the Japanese Society of Hypertension},
  volume = {33},
  number = {5},
  pages = {386--393},
  issn = {1348-4214},
  doi = {10.1038/hr.2010.9},
  abstract = {The relationship between obesity and hypertension is well established both in children and adults. The mechanisms through which obesity directly causes hypertension are still an area of research. Activation of the sympathetic nervous system has been considered to have an important function in the pathogenesis of obesity-related hypertension. The arterial-pressure control mechanism of diuresis and natriuresis, according to the principle of infinite feedback gain, seems to be shifted toward higher blood-pressure levels in obese individuals. During the early phases of obesity, primary sodium retention exists as a result of increase in renal tubular reabsorption. Extracellular-fluid volume is expanded and the kidney-fluid apparatus is resetted to a hypertensive level, consistent with a model of hypertension because of volume overload. Plasma renin activity, angiotensinogen, angiotensin II and aldosterone values display significant increase during obesity. Insulin resistance and inflammation may promote an altered profile of vascular function and consequently hypertension. Leptin and other neuropeptides are possible links between obesity and the development of hypertension. Obesity should be considered as a chronic medical condition, which is likely to require long-term treatment. Understanding of the mechanisms associated with obesity-related hypertension is essential for successful treatment strategies.},
  langid = {english},
  pmid = {20442753},
  keywords = {Blood Pressure,Humans,Hypertension,Insulin Resistance,Leptin,Natriuresis,Obesity,Sympathetic Nervous System},
  file = {/Users/xx20081/Zotero/storage/9XE6G9G9/Kotsis et al. - 2010 - Mechanisms of obesity-induced hypertension.pdf}
}

@article{kotsisObesityDaytimePulse2010,
  title = {Obesity and Daytime Pulse Pressure Are Predictors of Left Ventricular Hypertrophy in True Normotensive Individuals},
  author = {Kotsis, Vasilios and Stabouli, Stella and Toumanidis, Savvas and Tsivgoulis, George and Rizos, Zoe and Trakateli, Christine and Zakopoulos, Nikos and Sion, Michael},
  year = {2010},
  month = may,
  journal = {Journal of Hypertension},
  volume = {28},
  number = {5},
  pages = {1065--1073},
  issn = {1473-5598},
  doi = {10.1097/hjh.0b013e3283370e5e},
  abstract = {OBJECTIVE: To investigate predictors of left ventricular mass corrected for height2.7 (LVMI) and left ventricular hypertrophy in patients who were found to be normotensive with both office and 24-h ambulatory blood pressure (BP) measurements. METHODS: A total of 805 consecutive patients were analyzed. All patients underwent office BP measurements, 24-h ambulatory BP monitoring, laboratory measurements for cardiovascular risk factors and echocardiography. Individuals with both office and ambulatory normotension were characterized as true normotensive. RESULTS: LVMI was found to be 34.5 +/- 10.9 g/m2.7 in normal-weight patients and 48.7 +/- 13.0 g/m2.7 in obese patients (P {$<$} 0.0001). LVMI was found to be 41.7 +/- 10 g/m2.7 in overweight patients, significantly lower than the values of obese patients (P {$<$} 0.005) and higher than the values of normal-weight patients (P {$<$} 0.001). These results remained significant even after adjustment for age, sex, daytime and nighttime SBP, daytime and nighttime DBP, daytime and nighttime BP variability and daytime and nighttime pulse pressure (PP). In a multivariate analysis model, in which LVMI was the dependent variable and office SBP, office DBP, daytime and nighttime SBP and DBP, daytime and nighttime PPs and variabilities, day-night SBP ratio, fasting serum glucose, triglycerides, total cholesterol, age and BMI were inserted as independent variables with weighted least squares regression by sex, the predictors of LVMI were age, BMI and daytime PP (r2 = 0.31). Left ventricular hypertrophy was 17.67 times more likely in obese patients as compared with normal-weight true normotensive individuals. CONCLUSION: Obesity may represent a significant cardiovascular risk factor even in normotensive individuals. Other predictors of LVMI were ageing and daytime PP.},
  langid = {english},
  pmid = {20411600},
  keywords = {Adult,Aged,Blood Pressure,Blood Pressure Monitoring Ambulatory,Circadian Rhythm,Cross-Sectional Studies,Echocardiography,Female,Humans,Hypertrophy Left Ventricular,Male,Middle Aged,Multivariate Analysis,Obesity,Risk Factors,Young Adult}
}

@article{kranendonkExtracellularVesicleMarkers2014,
  title = {Extracellular Vesicle Markers in Relation to Obesity and Metabolic Complications in Patients with Manifest Cardiovascular Disease},
  author = {Kranendonk, Mari{\"e}tte EG and {de Kleijn}, Dominique PV and Kalkhoven, Eric and Kanhai, Danny A. and Uiterwaal, Cuno SPM and {van der Graaf}, Yolanda and Pasterkamp, Gerard and Visseren, Frank LJ},
  year = {2014},
  month = feb,
  journal = {Cardiovascular Diabetology},
  volume = {13},
  number = {1},
  pages = {37},
  issn = {1475-2840},
  doi = {10.1186/1475-2840-13-37},
  urldate = {2025-05-27},
  abstract = {Alterations in extracellular vesicles (EVs), including exosomes and microparticles, contribute to cardiovascular disease. We hypothesized that obesity could favour enhanced release of EVs from adipose tissue, and thereby contribute to cardiovascular risk via obesity-induced metabolic complications. The objectives of this study were: 1) to investigate the relation between the quantity, distribution and (dys) function of adipose tissue and plasma concentrations of atherothrombotic EV-markers; 2) to determine the relation between these EV-markers and the prevalence of the metabolic syndrome; and 3) to assess the contribution of EV markers to the risk of incident type 2 diabetes.},
  keywords = {Extracellular vesicle markers,hsCRP,Metabolic syndrome,Obesity,Type 2 diabetes},
  file = {/Users/xx20081/Zotero/storage/6Q2VBU78/Kranendonk et al. - 2014 - Extracellular vesicle markers in relation to obesity and metabolic complications in patients with ma.pdf;/Users/xx20081/Zotero/storage/KUGYBR97/1475-2840-13-37.html}
}

@article{kristensenCardiovascularMortalityKidney2019,
  title = {Cardiovascular, Mortality, and Kidney Outcomes with {{GLP-1}} Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials},
  shorttitle = {Cardiovascular, Mortality, and Kidney Outcomes with {{GLP-1}} Receptor Agonists in Patients with Type 2 Diabetes},
  author = {Kristensen, S{\o}ren L. and R{\o}rth, Rasmus and Jhund, Pardeep S. and Docherty, Kieran F. and Sattar, Naveed and Preiss, David and K{\o}ber, Lars and Petrie, Mark C. and McMurray, John J. V.},
  year = {2019},
  month = oct,
  journal = {The Lancet. Diabetes \& Endocrinology},
  volume = {7},
  number = {10},
  pages = {776--785},
  issn = {2213-8595},
  doi = {10.1016/S2213-8587(19)30249-9},
  abstract = {BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes reported. We aimed to synthesise the available evidence by doing a systematic review and meta-analysis of cardiovascular outcome trials of these drugs. METHODS: We searched MEDLINE (via PubMed) and the Cochrane Central Register of Controlled Trials for eligible placebo-controlled trials reporting major adverse cardiovascular events (MACE; ie, cardiovascular death, stroke, or myocardial infarction) up to June 15, 2019. We did a meta-analysis using a random-effects model to estimate overall hazard ratios (HRs) for MACE, its components, death from any cause, hospital admission for heart failure, kidney outcomes, and key safety outcomes (severe hypoglycaemia, pancreatitis, and pancreatic cancer). We also examined MACE in several subgroups based on patient characteristics (history of cardiovascular disease, BMI, age, baseline HbA1c, and baseline estimated glomerular filtration rate), trial duration, treatment dosing interval, and structural homology. FINDINGS: Of 27 publications screened, seven trials, with a combined total of 56\hphantom{,}004 participants, were included: ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide), EXSCEL (exenatide), Harmony Outcomes (albiglutide), REWIND (dulaglutide), and PIONEER 6 (oral semaglutide). Overall, GLP-1 receptor agonist treatment reduced MACE by 12\% (HR 0{$\cdot$}88, 95\% CI 0{$\cdot$}82-0{$\cdot$}94; p{$<$}0{$\cdot$}0001). There was no statistically significant heterogeneity across the subgroups examined. HRs were 0{$\cdot$}88 (95\% CI 0{$\cdot$}81-0{$\cdot$}96; p=0{$\cdot$}003) for death from cardiovascular causes, 0{$\cdot$}84 (0{$\cdot$}76-0{$\cdot$}93; p{$<$}0{$\cdot$}0001) for fatal or non-fatal stroke, and 0{$\cdot$}91 (0{$\cdot$}84-1{$\cdot$}00; p=0{$\cdot$}043) for fatal or non-fatal myocardial infarction. GLP-1 receptor agonist treatment reduced all-cause mortality by 12\% (0{$\cdot$}88, 0{$\cdot$}83-0{$\cdot$}95; p=0{$\cdot$}001), hospital admission for heart failure by 9\% (0{$\cdot$}91, 0{$\cdot$}83-0{$\cdot$}99; p=0{$\cdot$}028), and a broad composite kidney outcome (development of new-onset macroalbuminuria, decline in estimated glomerular filtration rate [or increase in creatinine], progression to end-stage kidney disease, or death attributable to kidney causes) by 17\% (0{$\cdot$}83, 0{$\cdot$}78-0{$\cdot$}89; p{$<$}0{$\cdot$}0001), mainly due to a reduction in urinary albumin excretion. There was no increase in risk of severe hypoglycaemia, pancreatitis, or pancreatic cancer. INTERPRETATION: Treatment with GLP-1 receptor agonists has beneficial effects on cardiovascular, mortality, and kidney outcomes in patients with type 2 diabetes. FUNDING: None.},
  langid = {english},
  pmid = {31422062},
  keywords = {Diabetes Mellitus Type 2,Diabetic Angiopathies,Diabetic Nephropathies,Glucagon-Like Peptide-1 Receptor,Humans,Hypoglycemic Agents,Randomized Controlled Trials as Topic,Treatment Outcome},
  file = {/Users/xx20081/Zotero/storage/DQTLB8GF/Kristensen et al. - 2019 - Cardiovascular, mortality, and kidney outcomes wit.pdf}
}

@article{kristensenCardiovascularMortalityKidney2019a,
  title = {Cardiovascular, Mortality, and Kidney Outcomes with {{GLP-1}} Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials},
  shorttitle = {Cardiovascular, Mortality, and Kidney Outcomes with {{GLP-1}} Receptor Agonists in Patients with Type 2 Diabetes},
  author = {Kristensen, S{\o}ren L. and R{\o}rth, Rasmus and Jhund, Pardeep S. and Docherty, Kieran F. and Sattar, Naveed and Preiss, David and K{\o}ber, Lars and Petrie, Mark C. and McMurray, John J. V.},
  year = {2019},
  month = oct,
  journal = {The Lancet. Diabetes \& Endocrinology},
  volume = {7},
  number = {10},
  pages = {776--785},
  issn = {2213-8595},
  doi = {10.1016/S2213-8587(19)30249-9},
  abstract = {BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their structure and duration of action and have been studied in trials of varying sizes and with different patient populations, with inconsistent effects on cardiovascular outcomes reported. We aimed to synthesise the available evidence by doing a systematic review and meta-analysis of cardiovascular outcome trials of these drugs. METHODS: We searched MEDLINE (via PubMed) and the Cochrane Central Register of Controlled Trials for eligible placebo-controlled trials reporting major adverse cardiovascular events (MACE; ie, cardiovascular death, stroke, or myocardial infarction) up to June 15, 2019. We did a meta-analysis using a random-effects model to estimate overall hazard ratios (HRs) for MACE, its components, death from any cause, hospital admission for heart failure, kidney outcomes, and key safety outcomes (severe hypoglycaemia, pancreatitis, and pancreatic cancer). We also examined MACE in several subgroups based on patient characteristics (history of cardiovascular disease, BMI, age, baseline HbA1c, and baseline estimated glomerular filtration rate), trial duration, treatment dosing interval, and structural homology. FINDINGS: Of 27 publications screened, seven trials, with a combined total of 56\hphantom{,}004 participants, were included: ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide), EXSCEL (exenatide), Harmony Outcomes (albiglutide), REWIND (dulaglutide), and PIONEER 6 (oral semaglutide). Overall, GLP-1 receptor agonist treatment reduced MACE by 12\% (HR 0{$\cdot$}88, 95\% CI 0{$\cdot$}82-0{$\cdot$}94; p{$<$}0{$\cdot$}0001). There was no statistically significant heterogeneity across the subgroups examined. HRs were 0{$\cdot$}88 (95\% CI 0{$\cdot$}81-0{$\cdot$}96; p=0{$\cdot$}003) for death from cardiovascular causes, 0{$\cdot$}84 (0{$\cdot$}76-0{$\cdot$}93; p{$<$}0{$\cdot$}0001) for fatal or non-fatal stroke, and 0{$\cdot$}91 (0{$\cdot$}84-1{$\cdot$}00; p=0{$\cdot$}043) for fatal or non-fatal myocardial infarction. GLP-1 receptor agonist treatment reduced all-cause mortality by 12\% (0{$\cdot$}88, 0{$\cdot$}83-0{$\cdot$}95; p=0{$\cdot$}001), hospital admission for heart failure by 9\% (0{$\cdot$}91, 0{$\cdot$}83-0{$\cdot$}99; p=0{$\cdot$}028), and a broad composite kidney outcome (development of new-onset macroalbuminuria, decline in estimated glomerular filtration rate [or increase in creatinine], progression to end-stage kidney disease, or death attributable to kidney causes) by 17\% (0{$\cdot$}83, 0{$\cdot$}78-0{$\cdot$}89; p{$<$}0{$\cdot$}0001), mainly due to a reduction in urinary albumin excretion. There was no increase in risk of severe hypoglycaemia, pancreatitis, or pancreatic cancer. INTERPRETATION: Treatment with GLP-1 receptor agonists has beneficial effects on cardiovascular, mortality, and kidney outcomes in patients with type 2 diabetes. FUNDING: None.},
  langid = {english},
  pmid = {31422062},
  keywords = {Diabetes Mellitus Type 2,Diabetic Angiopathies,Diabetic Nephropathies,Glucagon-Like Peptide-1 Receptor Agonists,Humans,Hypoglycemic Agents,Randomized Controlled Trials as Topic,Treatment Outcome},
  file = {/Users/xx20081/Zotero/storage/7KT6XUFZ/Kristensen et al. - 2019 - Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2.pdf}
}

@article{kuchenbaeckerEvaluationPolygenicRisk2017,
  title = {Evaluation of {{Polygenic Risk Scores}} for {{Breast}} and {{Ovarian Cancer Risk Prediction}} in {{BRCA1}} and {{BRCA2 Mutation Carriers}}},
  author = {Kuchenbaecker, Karoline B. and McGuffog, Lesley and Barrowdale, Daniel and Lee, Andrew and Soucy, Penny and Healey, Sue and Dennis, Joe and Lush, Michael and Robson, Mark and Spurdle, Amanda B. and Ramus, Susan J. and Mavaddat, Nasim and Terry, Mary Beth and Neuhausen, Susan L. and Hamann, Ute and Southey, Melissa and John, Esther M. and Chung, Wendy K. and Daly, Mary B. and Buys, Saundra S. and Goldgar, David E. and Dorfling, Cecilia M. and {van Rensburg}, Elizabeth J. and Ding, Yuan Chun and Ejlertsen, Bent and Gerdes, Anne-Marie and Hansen, Thomas V. O. and Slager, Susan and Hallberg, Emily and Benitez, Javier and Osorio, Ana and Cohen, Nancy and Lawler, William and Weitzel, Jeffrey N. and Peterlongo, Paolo and Pensotti, Valeria and Dolcetti, Riccardo and Barile, Monica and Bonanni, Bernardo and Azzollini, Jacopo and Manoukian, Siranoush and Peissel, Bernard and Radice, Paolo and Savarese, Antonella and Papi, Laura and Giannini, Giuseppe and Fostira, Florentia and Konstantopoulou, Irene and Adlard, Julian and Brewer, Carole and Cook, Jackie and Davidson, Rosemarie and Eccles, Diana and Eeles, Ros and Ellis, Steve and Frost, Debra and Hodgson, Shirley and Izatt, Louise and Lalloo, Fiona and Ong, Kai-ren and Godwin, Andrew K. and Arnold, Norbert and Dworniczak, Bernd and Engel, Christoph and Gehrig, Andrea and Hahnen, Eric and Hauke, Jan and Kast, Karin and Meindl, Alfons and Niederacher, Dieter and Schmutzler, Rita Katharina and {Varon-Mateeva}, Raymonda and {Wang-Gohrke}, Shan and Wappenschmidt, Barbara and Barjhoux, Laure and {Collonge-Rame}, Marie-Agn{\`e}s and Elan, Camille and Golmard, Lisa and {Barouk-Simonet}, Emmanuelle and Lesueur, Fabienne and Mazoyer, Sylvie and Sokolowska, Joanna and {Stoppa-Lyonnet}, Dominique and Isaacs, Claudine and Claes, Kathleen B. M. and Poppe, Bruce and {de la Hoya}, Miguel and {Garcia-Barberan}, Vanesa and Aittom{\"a}ki, Kristiina and Nevanlinna, Heli and Ausems, Margreet G. E. M. and {de Lange}, J. L. and G{\'o}mez Garcia, Encarna B. and Hogervorst, Frans B. L. and Kets, Carolien M. and {Meijers-Heijboer}, Hanne E. J. and Oosterwijk, Jan C. and Rookus, Matti A. and {van Asperen}, Christi J. and {van den Ouweland}, Ans M. W. and {van Doorn}, Helena C. and {van Os}, Theo A. M. and Kwong, Ava and Olah, Edith and Diez, Orland and Brunet, Joan and Lazaro, Conxi and Teul{\'e}, Alex and Gronwald, Jacek and Jakubowska, Anna and Kaczmarek, Katarzyna and Lubinski, Jan and Sukiennicki, Grzegorz and Barkardottir, Rosa B. and Chiquette, Jocelyne and Agata, Simona and Montagna, Marco and Teixeira, Manuel R. and Park, Sue Kyung and Olswold, Curtis and Tischkowitz, Marc and Foretova, Lenka and Gaddam, Pragna and Vijai, Joseph and Pfeiler, Georg and {Rappaport-Fuerhauser}, Christine and Singer, Christian F. and Tea, Muy-Kheng M. and Greene, Mark H. and Loud, Jennifer T. and Rennert, Gad and Imyanitov, Evgeny N. and Hulick, Peter J. and Hays, John L. and Piedmonte, Marion and Rodriguez, Gustavo C. and Martyn, Julie and Glendon, Gord and Mulligan, Anna Marie and Andrulis, Irene L. and Toland, Amanda Ewart and Jensen, Uffe Birk and Kruse, Torben A. and Pedersen, Inge Sokilde and Thomassen, Mads and Caligo, Maria A. and Teo, Soo-Hwang and Berger, Raanan and Friedman, Eitan and Laitman, Yael and Arver, Brita and Borg, Ake and Ehrencrona, Hans and Rantala, Johanna and Olopade, Olufunmilayo I. and Ganz, Patricia A. and Nussbaum, Robert L. and Bradbury, Angela R. and Domchek, Susan M. and Nathanson, Katherine L. and Arun, Banu K. and James, Paul and Karlan, Beth Y. and Lester, Jenny and Simard, Jacques and Pharoah, Paul D. P. and Offit, Kenneth and Couch, Fergus J. and {Chenevix-Trench}, Georgia and Easton, Douglas F. and Antoniou, Antonis C.},
  year = {2017},
  month = mar,
  journal = {JNCI Journal of the National Cancer Institute},
  volume = {109},
  number = {7},
  pages = {djw302},
  issn = {0027-8874},
  doi = {10.1093/jnci/djw302},
  urldate = {2024-12-10},
  abstract = {Background: Genome-wide association studies (GWAS) have identified 94 common single-nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk and 18 associated with ovarian cancer (OC) risk. Several of these are also associated with risk of BC or OC for women who carry a pathogenic mutation in the high-risk BC and OC genes BRCA1 or BRCA2. The combined effects of these variants on BC or OC risk for BRCA1 and BRCA2 mutation carriers have not yet been assessed while their clinical management could benefit from improved personalized risk estimates.,  Methods: We constructed polygenic risk scores (PRS) using BC and OC susceptibility SNPs identified through population-based GWAS: for BC (overall, estrogen receptor [ER]--positive, and ER-negative) and for OC. Using data from 15 252 female BRCA1 and 8211 BRCA2 carriers, the association of each PRS with BC or OC risk was evaluated using a weighted cohort approach, with time to diagnosis as the outcome and estimation of the hazard ratios (HRs) per standard deviation increase in the PRS.,  Results: The PRS for ER-negative BC displayed the strongest association with BC risk in BRCA1 carriers (HR\,=\,1.27, 95\% confidence interval [CI] = 1.23 to 1.31, P\,=\,8.2{\texttimes}10-53). In BRCA2 carriers, the strongest association with BC risk was seen for the overall BC PRS (HR\,=\,1.22, 95\% CI\,=\,1.17 to 1.28, P\,=\,7.2{\texttimes}10-20). The OC PRS was strongly associated with OC risk for both BRCA1 and BRCA2 carriers. These translate to differences in absolute risks (more than 10\% in each case) between the top and bottom deciles of the PRS distribution; for example, the OC risk was 6\% by age 80 years for BRCA2 carriers at the 10th percentile of the OC PRS compared with 19\% risk for those at the 90th percentile of PRS.,  Conclusions: BC and OC PRS are predictive of cancer risk in BRCA1 and BRCA2 carriers. Incorporation of the PRS into risk prediction models has promise to better inform decisions on cancer risk management.},
  pmcid = {PMC5408990},
  pmid = {28376175},
  file = {/Users/xx20081/Zotero/storage/RECKRIUS/Kuchenbaecker et al. - 2017 - Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2.pdf}
}

@article{kuoBoneBiomarkerClinical2017,
  title = {Bone Biomarker for the Clinical Assessment of Osteoporosis: Recent Developments and Future Perspectives},
  shorttitle = {Bone Biomarker for the Clinical Assessment of Osteoporosis},
  author = {Kuo, Tsung-Rong and Chen, Chih-Hwa},
  year = {2017},
  month = may,
  journal = {Biomarker Research},
  volume = {5},
  number = {1},
  pages = {18},
  issn = {2050-7771},
  doi = {10.1186/s40364-017-0097-4},
  urldate = {2025-05-28},
  abstract = {Bone biomarkers included formation, resorption and regulator are released during the bone remodeling processes. These bone biomarkers have attracted much attention in the clinical assessment of osteoporosis treatment in the past decade. Combination with the measurement of bone mineral density, the clinical applications of bone biomarkers have provided comprehensive information for diagnosis of osteoporosis. However, the analytical approaches of the bone biomarkers are still the challenge for further clinical trials. In this mini-review, we have introduced the functions of bone biomarkers and then recently developed techniques for bone biomarker measurements have been systematically integrated to discuss the possibility for osteoporosis assessment in the early stage.},
  keywords = {Bone biomarker,Bone formation,Bone resorption,Bone turnover,Osteoporosis,Regulators},
  file = {/Users/xx20081/Zotero/storage/ZT5PRVIB/Kuo and Chen - 2017 - Bone biomarker for the clinical assessment of osteoporosis recent developments and future perspecti.pdf;/Users/xx20081/Zotero/storage/TS5TAF8R/s40364-017-0097-4.html}
}

@article{lagouGWASRandomGlucose2023,
  title = {{{GWAS}} of Random Glucose in 476,326 Individuals Provide Insights into Diabetes Pathophysiology, Complications and Treatment Stratification},
  author = {Lagou, Vasiliki and Jiang, Longda and Ulrich, Anna and Zudina, Liudmila and Gonz{\'a}lez, Karla Sofia Guti{\'e}rrez and Balkhiyarova, Zhanna and Faggian, Alessia and Maina, Jared G. and Chen, Shiqian and Todorov, Petar V. and Sharapov, Sodbo and David, Alessia and Marullo, Letizia and M{\"a}gi, Reedik and Rujan, Roxana-Maria and Ahlqvist, Emma and Thorleifsson, Gudmar and Gao, {$H$}e and {$E$}vangelou, {$E$}vangelos and Benyamin, Beben and Scott, Robert A. and Isaacs, Aaron and Zhao, Jing Hua and Willems, Sara M. and Johnson, Toby and Gieger, Christian and Grallert, Harald and Meisinger, Christa and {M{\"u}ller-Nurasyid}, Martina and Strawbridge, Rona J. and Goel, Anuj and Rybin, Denis and Albrecht, Eva and Jackson, Anne U. and Stringham, Heather M. and Corr{\^e}a, Ivan R. and {Farber-Eger}, Eric and Steinthorsdottir, Valgerdur and Uitterlinden, Andr{\'e} G. and Munroe, Patricia B. and Brown, Morris J. and Schmidberger, Julian and Holmen, Oddgeir and Thorand, Barbara and Hveem, Kristian and Wilsgaard, Tom and Mohlke, Karen L. and Wang, Zhe and {Aleksey Shmeliov} and {den Hoed}, Marcel and Loos, Ruth J. F. and Kratzer, Wolfgang and Haenle, Mark and Koenig, Wolfgang and Boehm, Bernhard O. and Tan, Tricia M. and Tomas, Alejandra and Salem, Victoria and Barroso, In{\^e}s and Tuomilehto, Jaakko and Boehnke, Michael and Florez, Jose C. and Hamsten, Anders and Watkins, Hugh and Nj{\o}lstad, Inger and Wichmann, H.-Erich and Caulfield, Mark J. and Khaw, Kay-Tee and {van Duijn}, Cornelia M. and Hofman, Albert and Wareham, Nicholas J. and Langenberg, Claudia and Whitfield, John B. and Martin, Nicholas G. and Montgomery, Grant and Scapoli, Chiara and Tzoulaki, Ioanna and Elliott, Paul and Thorsteinsdottir, Unnur and Stefansson, Kari and Brittain, Evan L. and McCarthy, Mark I. and Froguel, Philippe and Sexton, Patrick M. and Wootten, Denise and Groop, Leif and Dupuis, Jos{\'e}e and Meigs, James B. and Deganutti, Giuseppe and Demirkan, Ayse and Pers, Tune H. and Reynolds, Christopher A. and Aulchenko, Yurii S. and Kaakinen, Marika A. and Jones, Ben and Prokopenko, Inga},
  year = {2023},
  month = sep,
  journal = {Nature Genetics},
  volume = {55},
  number = {9},
  pages = {1448--1461},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-023-01462-3},
  urldate = {2024-01-15},
  abstract = {Conventional measurements of fasting and postprandial blood glucose levels investigated in genome-wide association studies (GWAS) cannot capture the effects of DNA variability on `around the clock' glucoregulatory processes. Here we show that GWAS meta-analysis of glucose measurements under nonstandardized conditions (random glucose (RG)) in 476,326 individuals of diverse ancestries and without diabetes enables locus discovery and innovative pathophysiological observations. We discovered 120 RG loci represented by 150 distinct signals, including 13 with sex-dimorphic effects, two cross-ancestry and seven rare frequency signals. Of these, 44 loci are new for glycemic traits. Regulatory, glycosylation and metagenomic annotations highlight ileum and colon tissues, indicating an underappreciated role of the gastrointestinal tract in controlling blood glucose. Functional follow-up and molecular dynamics simulations of lower frequency coding variants in glucagon-like peptide-1 receptor (GLP1R), a type 2 diabetes treatment target, reveal that optimal selection of GLP-1R agonist therapy will benefit from tailored genetic stratification. We also provide evidence from Mendelian randomization that lung function is modulated by blood glucose and that pulmonary dysfunction is a diabetes complication. Our investigation yields new insights into the biology of glucose regulation, diabetes complications and pathways for treatment stratification.},
  copyright = {2023 The Author(s)},
  langid = {english},
  keywords = {Diseases,Genetics},
  file = {/Users/xx20081/Zotero/storage/BQU5WB5U/Lagou et al. - 2023 - GWAS of random glucose in 476,326 individuals prov.pdf}
}

@article{lahmCongenitalHeartDisease2021,
  title = {Congenital Heart Disease Risk Loci Identified by Genome-Wide Association Study in {{European}} Patients},
  author = {Lahm, Harald and Jia, Meiwen and Dre{\ss}en, Martina and Wirth, Felix and Puluca, Nazan and Gilsbach, Ralf and Keavney, Bernard D. and Cleuziou, Julie and Beck, Nicole and Bondareva, Olga and Dzilic, Elda and Burri, Melchior and K{\"o}nig, Karl C. and Ziegelm{\"u}ller, Johannes A. and {Abou-Ajram}, Claudia and Neb, Irina and Zhang, Zhong and Doppler, Stefanie A. and Mastantuono, Elisa and Lichtner, Peter and Eckstein, Gertrud and H{\"o}rer, J{\"u}rgen and Ewert, Peter and Priest, James R. and Hein, Lutz and Lange, R{\"u}diger and Meitinger, Thomas and Cordell, Heather J. and {M{\"u}ller-Myhsok}, Bertram and Krane, Markus},
  year = {2021},
  month = jan,
  journal = {The Journal of Clinical Investigation},
  volume = {131},
  number = {2},
  pages = {e141837, 141837},
  issn = {1558-8238},
  doi = {10.1172/JCI141837},
  abstract = {Genetic factors undoubtedly affect the development of congenital heart disease (CHD) but still remain ill defined. We sought to identify genetic risk factors associated with CHD and to accomplish a functional analysis of SNP-carrying genes. We performed a genome-wide association study (GWAS) of 4034 White patients with CHD and 8486 healthy controls. One SNP on chromosome 5q22.2 reached genome-wide significance across all CHD phenotypes and was also indicative for septal defects. One region on chromosome 20p12.1 pointing to the MACROD2 locus identified 4 highly significant SNPs in patients with transposition of the great arteries (TGA). Three highly significant risk variants on chromosome 17q21.32 within the GOSR2 locus were detected in patients with anomalies of thoracic arteries and veins (ATAV). Genetic variants associated with ATAV are suggested to influence the expression of WNT3, and the variant rs870142 related to septal defects is proposed to influence the expression of MSX1. We analyzed the expression of all 4 genes during cardiac differentiation of human and murine induced pluripotent stem cells in vitro and by single-cell RNA-Seq analyses of developing murine and human hearts. Our data show that MACROD2, GOSR2, WNT3, and MSX1 play an essential functional role in heart development at the embryonic and newborn stages.},
  langid = {english},
  pmcid = {PMC7810487},
  pmid = {33201861},
  keywords = {Adolescent,Adult,Animals,Cardiology,Cardiovascular disease,Female,Genetic Loci,Genetics,Genome-Wide Association Study,Germany,Heart Defects Congenital,Humans,iPS cells,Male,Mice,Molecular genetics,Polymorphism Single Nucleotide,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/S6F8ZNK4/Lahm et al. - 2021 - Congenital heart disease risk loci identified by g.pdf}
}

@article{lajousBodyMassIndex2014,
  title = {Body Mass Index, Diabetes, and Mortality in {{French}} Women: Explaining Away a ``Paradox''},
  shorttitle = {Body Mass Index, Diabetes, and Mortality in {{French}} Women},
  author = {Lajous, Martin and Bijon, Anne and Fagherazzi, Guy and {Boutron-Ruault}, Marie-Christine and Balkau, Beverley and {Clavel-Chapelon}, Fran{\c c}oise and Hern{\'a}n, Miguel A.},
  year = {2014},
  month = jan,
  journal = {Epidemiology (Cambridge, Mass.)},
  volume = {25},
  number = {1},
  pages = {10--14},
  issn = {1044-3983},
  doi = {10.1097/EDE.0000000000000031},
  urldate = {2024-08-06},
  abstract = {Background Obesity is associated with increased mortality in the general population but, paradoxically, with decreased mortality in individuals with diabetes. Methods Among 88,373 French women participating in the E3N-EPIC study who were free of diabetes in 1990, we estimated the mortality hazard ratios (HR) and 95\% confidence intervals (CI) for body-mass index (BMI) levels by diabetes status. Results During an average 16.7 years of follow-up, 3,750 deaths and 2,421 incident diabetes cases occurred. In overweight/obese versus normal weight women, the mortality HR (95\%CI) was 1.42 (1.32,1.53) in women without diabetes, and 0.69 (0.40,1.18) in women with incident diabetes. Mortality increased with BMI among women without diabetes and decreased as BMI increased in women with diabetes. Conclusions We found a direct association between BMI and mortality among women without diabetes but not among those with incident diabetes in the same population. Selection bias may be a simple explanation for this ``paradox''.},
  pmcid = {PMC4122290},
  pmid = {24270963},
  file = {/Users/xx20081/Zotero/storage/2KG397ZJ/Lajous et al. - 2014 - Body mass index, diabetes, and mortality in French.pdf}
}

@article{lappalainenGeneticMolecularArchitecture2024,
  title = {Genetic and Molecular Architecture of Complex Traits},
  author = {Lappalainen, Tuuli and Li, Yang I. and Ramachandran, Sohini and Gusev, Alexander},
  year = {2024},
  month = feb,
  journal = {Cell},
  volume = {187},
  number = {5},
  pages = {1059--1075},
  issn = {1097-4172},
  doi = {10.1016/j.cell.2024.01.023},
  abstract = {Human genetics has emerged as one of the most dynamic areas of biology, with a broadening societal impact. In this review, we discuss recent achievements, ongoing efforts, and future challenges in the field. Advances in technology, statistical methods, and the growing scale of research efforts have all provided many insights into the processes that have given rise to the current patterns of genetic variation. Vast maps of genetic associations with human traits and diseases have allowed characterization of their genetic architecture. Finally, studies of molecular and cellular effects of genetic variants have provided insights into biological processes underlying disease. Many outstanding questions remain, but the field is well poised for groundbreaking discoveries as it increases the use of genetic data to understand both the history of our species and its applications to improve human health.},
  langid = {english},
  pmcid = {PMC10977002},
  pmid = {38428388},
  keywords = {Genetic Variation,Human Genetics,Humans,Multifactorial Inheritance,Phenotype},
  file = {/Users/xx20081/Zotero/storage/XGNZVRLF/Lappalainen et al. - 2024 - Genetic and molecular architecture of complex trai.pdf}
}

@article{larssonBodyMassIndex2020,
  title = {Body Mass Index and Body Composition in Relation to 14 Cardiovascular Conditions in {{UK Biobank}}: A {{Mendelian}} Randomization Study},
  shorttitle = {Body Mass Index and Body Composition in Relation to 14 Cardiovascular Conditions in {{UK Biobank}}},
  author = {Larsson, Susanna C and B{\"a}ck, Magnus and Rees, Jessica M B and Mason, Amy M and Burgess, Stephen},
  year = {2020},
  month = jan,
  journal = {European Heart Journal},
  volume = {41},
  number = {2},
  pages = {221--226},
  issn = {0195-668X},
  doi = {10.1093/eurheartj/ehz388},
  urldate = {2024-09-17},
  abstract = {Aims The causal role of adiposity for several cardiovascular diseases (CVDs) is unclear. Our primary aim was to apply the Mendelian randomization design to investigate the associations of body mass index (BMI) with 13 CVDs and arterial hypertension. We also assessed the roles of fat mass and fat-free mass on the same outcomes. Methods and results Single-nucleotide polymorphisms associated with BMI and fat mass and fat-free mass indices were used as instrumental variables to estimate the associations with the cardiovascular conditions among 367 703 UK Biobank participants. After correcting for multiple testing, genetically predicted BMI was significantly positively associated with eight outcomes, including and with decreasing magnitude of association: aortic valve stenosis, heart failure, deep vein thrombosis, arterial hypertension, peripheral artery disease, coronary artery disease, atrial fibrillation, and pulmonary embolism. The odds ratio (OR) per 1\,kg/m2 increase in BMI ranged from 1.06 [95\% confidence interval (CI) 1.02--1.11; P\,=\,2.6\,{\texttimes}\,10-3] for pulmonary embolism to 1.13 (95\% CI 1.05--1.21; P\,=\,1.2\,{\texttimes}\,10-3) for aortic valve stenosis. There was suggestive evidence of positive associations of genetically predicted fat mass index with nine outcomes (P\,{$<$}\,0.05). The strongest magnitude of association was with aortic valve stenosis (OR per 1\,kg/m2 increase in fat mass index 1.46, 95\% CI 1.13--1.88; P\,=\,3.9\,{\texttimes}\,10-3). There was suggestive evidence of inverse associations of fat-free mass index with atrial fibrillation, ischaemic stroke, and abdominal aortic aneurysm. Conclusion This study provides evidence that higher BMI and particularly fat mass index are associated with increased risk of aortic valve stenosis and most other cardiovascular conditions.,},
  pmcid = {PMC6945523},
  pmid = {31195408},
  file = {/Users/xx20081/Zotero/storage/2Q2NLXU5/Larsson et al. - 2020 - Body mass index and body composition in relation t.pdf}
}

@article{lavieBodyCompositionPrognosis2003,
  title = {Body Composition and Prognosis in Chronic Systolic Heart Failure: The Obesity Paradox},
  shorttitle = {Body Composition and Prognosis in Chronic Systolic Heart Failure},
  author = {Lavie, Carl J. and Osman, Ahmed F. and Milani, Richard V. and Mehra, Mandeep R.},
  year = {2003},
  month = apr,
  journal = {The American Journal of Cardiology},
  volume = {91},
  number = {7},
  pages = {891--894},
  issn = {0002-9149},
  doi = {10.1016/S0002-9149(03)00031-6},
  urldate = {2024-08-08},
  file = {/Users/xx20081/Zotero/storage/R4I39YS2/Lavie et al. - 2003 - Body composition and prognosis in chronic systolic.pdf;/Users/xx20081/Zotero/storage/EFTZEAPA/S0002914903000316.html}
}

@article{lavieImpactCardiorespiratoryFitness2013,
  title = {Impact of Cardiorespiratory Fitness on the Obesity Paradox in Patients with Heart Failure},
  author = {Lavie, Carl J. and Cahalin, Lawrence P. and Chase, Paul and Myers, Jonathan and Bensimhon, Daniel and Peberdy, Mary Ann and Ashley, Euan and West, Erin and Forman, Daniel E. and Guazzi, Marco and Arena, Ross},
  year = {2013},
  month = mar,
  journal = {Mayo Clinic Proceedings},
  volume = {88},
  number = {3},
  pages = {251--258},
  issn = {1942-5546},
  doi = {10.1016/j.mayocp.2012.11.020},
  abstract = {OBJECTIVE: To determine the impact of cardiorespiratory fitness (FIT) on survival in relation to the obesity paradox in patients with systolic heart failure (HF). PATIENTS AND METHODS: We studied 2066 patients with systolic HF (body mass index [BMI] {$\geq$}18.5 kg/m(2)) between April 1, 1993 and May 11, 2011 (with 1784 [86\%] tested after January 31, 2000) from a multicenter cardiopulmonary exercise testing database who were followed for up to 5 years (mean {\textpm} SD, 25.0{\textpm}17.5 months) to determine the impact of FIT (peak oxygen consumption {$<$}14 vs {$\geq$}14 mL O2 {$\bullet$} kg(-1) {$\bullet$} min(-1)) on the obesity paradox. RESULTS: There were 212 deaths during follow-up (annual mortality, 4.5\%). In patients with low FIT, annual mortality was 8.2\% compared with 2.8\% in those with high FIT (P{$<$}.001). After adjusting for age and sex, BMI was a significant predictor of survival in the low FIT subgroup when expressed as a continuous (P=.03) and dichotomous ({$<$}25.0 vs {$\geq$}25.0 kg/m(2)) (P=.01) variable. Continuous and dichotomous BMI expressions were not significant predictors of survival in the overall and high FIT groups after adjusting for age and sex. In patients with low FIT, progressively worse survival was noted with BMI of 30.0 or greater, 25.0 to 29.9, and 18.5 to 24.9 (log-rank, 11.7; P=.003), whereas there was no obesity paradox noted in those with high FIT (log-rank, 1.72; P=.42). CONCLUSION: These results indicate that FIT modifies the relationship between BMI and survival. Thus, assessing the obesity paradox in systolic HF may be misleading unless FIT is considered.},
  langid = {english},
  pmcid = {PMC7242812},
  pmid = {23489451},
  keywords = {Adult,Aged,Body Mass Index,Databases Factual,Exercise Test,Female,Follow-Up Studies,Heart Failure Systolic,Humans,Kaplan-Meier Estimate,Male,Middle Aged,Obesity,Oxygen Consumption,Physical Fitness,Proportional Hazards Models},
  file = {/Users/xx20081/Zotero/storage/2BV2TCPQ/Lavie et al. - 2013 - Impact of cardiorespiratory fitness on the obesity.pdf}
}

@article{laviePeakExerciseOxygen2004,
  title = {Peak Exercise Oxygen Pulse and Prognosis in Chronic Heart Failure},
  author = {Lavie, Carl J. and Milani, Richard V. and Mehra, Mandeep R.},
  year = {2004},
  month = mar,
  journal = {The American Journal of Cardiology},
  volume = {93},
  number = {5},
  pages = {588--593},
  issn = {0002-9149},
  doi = {10.1016/j.amjcard.2003.11.023},
  abstract = {Cardiopulmonary variables, particularly peak oxygen consumption (peak VO(2)) corrected for total and lean body weight, have been confirmed to predict prognosis in patients with chronic systolic heart failure (HF). Only limited data are available on the prognostic ability of maximal oxygen (O(2)) pulse, an indicator of stroke volume and arteriovenous O(2) difference, especially when corrected for lean body mass. Cardiopulmonary exercise tests were performed in 209 consecutive patients with mild-to-moderate HF (mean ejection fraction 23\%), followed for 19 +/- 12 months to determine the impact of maximal O(2) pulse in relation to other cardiopulmonary variables on major clinical events (13 cardiovascular deaths and 15 urgent transplantations). Compared with patients with clinical events, those without major events had a higher peak O(2) pulse (11.4 +/- 4.1 vs 9.2 +/- 2.3 ml/beat, p {$<$}0.0001) and body fat-adjusted peak O(2) pulse (15.6 +/- 5.6 vs 11.9 +/- 3.4 ml/beat, p {$<$}0.0001). In multivariate analysis, a low peak O(2) pulse was the strongest independent predictor of clinical events (chi-square 10.5, p {$<$}0.01). Although peak O(2) pulse was a stronger predictor for clinical events than any other exercise cardiopulmonary variable, including peak VO(2), peak VO(2) lean (defined as the VO(2) corrected for lean body mass), and percentage of predicted peak VO(2), this relation was further strengthened by correcting peak O(2) pulse for percent body fat (chi-square 12.4, p {$<$}0.001). In most subgroups (including women, obese subjects, those receiving beta blockers, and those with class III HF), peak O(2) pulse lean was similar to or superior to peak VO(2) lean for predicting major clinical events. Especially in patients who were class III HF and who were receiving beta blockers, peak VO(2) (cutoff 14 ml/kg/min) poorly predicted prognosis; risk stratification was best with peak O(2) pulse lean (cutoff 14 ml/beat). These data indicate the potential usefulness of peak O(2) pulse and lean body mass-adjusted O(2) pulse for predicting prognosis in patients with systolic HF.},
  langid = {english},
  pmid = {14996584},
  keywords = {Adult,Aged,Blood Pressure,Exercise,Exercise Test,Female,Heart Failure,Heart Rate,Humans,Male,Middle Aged,Oxygen Consumption,Prognosis,Retrospective Studies,Stroke Volume},
  file = {/Users/xx20081/Zotero/storage/KHIY6228/Lavie et al. - 2004 - Peak exercise oxygen pulse and prognosis in chroni.pdf}
}

@article{leeAssociationParentalHeart2006,
  title = {Association of Parental Heart Failure with Risk of Heart Failure in Offspring},
  author = {Lee, Douglas S. and Pencina, Michael J. and Benjamin, Emelia J. and Wang, Thomas J. and Levy, Daniel and O'Donnell, Christopher J. and Nam, Byung-Ho and Larson, Martin G. and D'Agostino, Ralph B. and Vasan, Ramachandran S.},
  year = {2006},
  month = jul,
  journal = {The New England Journal of Medicine},
  volume = {355},
  number = {2},
  pages = {138--147},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa052948},
  abstract = {BACKGROUND: The association between heart failure in parents and the prevalence of left ventricular systolic dysfunction and the risk of heart failure in their offspring has not been investigated in a community-based setting. METHODS: We examined the cross-sectional association of heart failure in parents with the prevalence of left ventricular systolic dysfunction, as well as left ventricular mass, internal dimensions, and wall thickness, in 1497 participants of the Framingham Offspring Study (mean age, 57 years; 819 women) who underwent routine echocardiography. We also investigated prospectively whether heart failure in parents increased the risk of heart failure in 2214 offspring (mean age, 44 years; 1150 women). RESULTS: As compared with the 1039 participants whose parents did not have heart failure, the 458 participants in the cross-sectional cohort who had at least one parent with heart failure were more likely to have increased left ventricular mass (17.0 percent vs. 26.9 percent), left ventricular internal dimensions (18.6 percent vs. 23.4 percent), and left ventricular systolic dysfunction (3.1 percent vs. 5.7 percent); the multivariable-adjusted odds ratios were 1.35 (95 percent confidence interval, 0.99 to 1.84), 1.29 (95 percent confidence interval, 0.96 to 1.72), and 2.37 (95 percent confidence interval, 1.22 to 4.61), respectively. In the longitudinal cohort, heart failure developed in 90 offspring during follow-up (mean length of follow-up, 20 years). The age- and sex-adjusted 10-year incidence rates of heart failure were 2.72 percent among offspring with a parent with heart failure, as compared with 1.62 percent among those without a parent with heart failure. This increase in risk persisted after multivariable adjustment (hazard ratio, 1.70; 95 percent confidence interval, 1.11 to 2.60). CONCLUSIONS: Heart failure in parents is associated with an increased prevalence of left ventricular systolic dysfunction cross-sectionally and an elevated risk of heart failure longitudinally. Our data emphasize the contribution of familial factors to the heart-failure burden in the community.},
  langid = {english},
  pmid = {16837677},
  keywords = {Adult Children,Aged,Cohort Studies,Cross-Sectional Studies,Echocardiography Doppler Color,Female,Heart Failure,Humans,Hypertrophy Left Ventricular,Incidence,Longitudinal Studies,Male,Middle Aged,Parents,Prevalence,Proportional Hazards Models,Risk,Ventricular Dysfunction Left},
  file = {/Users/xx20081/Zotero/storage/ZVUQ5HNB/Lee et al. - 2006 - Association of parental heart failure with risk of.pdf}
}

@article{leeCardiovascularKidneyOutcomes2025,
  title = {Cardiovascular and {{Kidney Outcomes}} and {{Mortality With Long-Acting Injectable}} and {{Oral Glucagon-Like Peptide}} 1 {{Receptor Agonists}} in {{Individuals With Type}} 2 {{Diabetes}}: {{A Systematic Review}} and {{Meta-analysis}} of {{Randomized Trials}}},
  shorttitle = {Cardiovascular and {{Kidney Outcomes}} and {{Mortality With Long-Acting Injectable}} and {{Oral Glucagon-Like Peptide}} 1 {{Receptor Agonists}} in {{Individuals With Type}} 2 {{Diabetes}}},
  author = {Lee, Matthew M. Y. and Sattar, Naveed and {Pop-Busui}, Rodica and Deanfield, John and Emerson, Scott S. and Inzucchi, Silvio E. and Mann, Johannes F. E. and Marx, Nikolaus and Mulvagh, Sharon L. and Poulter, Neil R. and Badve, Sunil V. and Pratley, Richard E. and Perkovic, Vlado and Buse, John B. and McGuire, Darren K. and {SOUL Trial Investigators}},
  year = {2025},
  month = mar,
  journal = {Diabetes Care},
  pages = {dc250241},
  issn = {1935-5548},
  doi = {10.2337/dc25-0241},
  abstract = {BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce the incidence of major adverse cardiovascular events (MACE) in type 2 diabetes (T2D), although whether benefits extend to both subcutaneous and oral formulations remains unclear. PURPOSE: In these meta-analyses, including new data from the Semaglutide cardiOvascular oUtcomes triaL (SOUL) (oral semaglutide) and Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial, we examined cardiovascular (CV) and kidney benefits and risks of long-acting (defined as having pharmacokinetics sufficient to provide 24-h activity) GLP-1RA in T2D. DATA SOURCES: A systematic review of PubMed was conducted (to 7 February 2025). STUDY SELECTION: Randomized placebo-controlled CV and kidney outcomes trials of GLP-1RA with {$\geq$}500 individuals with T2D were included. DATA EXTRACTION: A random-effects model was used to estimate hazard ratios (HRs) for MACE, its components, all-cause mortality, hospitalization for heart failure (HHF), a composite kidney outcome (kidney failure [kidney replacement therapy or persistent estimated glomerular filtration rate [eGFR] {$<$}15 mL/min/1.73 m2], sustained {$\geq$}50\% eGFR decline or nearest equivalent, or kidney-related death), worsening kidney function, and safety outcomes. DATA SYNTHESIS: Across 10 trials (n = 71,351), long-acting GLP-1RA reduced incidence rate of MACE by 14\% (HR 0.86 [95\% CI 0.81, 0.90]; I2 = 27.6\%), HHF by 14\% (0.86 [0.79, 0.93]; I2 = 2.1\%), and the composite kidney outcome by 17\% (0.83 [0.75, 0.92]; I2 = 20.4\%) and all-cause mortality by 12\% (0.88 [0.82, 0.93]; I2 = 17.5\%). A consistent 14\% reduction was seen for all MACE components. There was no significant heterogeneity by GLP-1RA administration route (subcutaneous vs. oral). There were no increased risks of severe hypoglycemia, retinopathy, or pancreatic events. LIMITATIONS: Trial-level meta-analyses preclude detailed subgroup analyses and may introduce ecological bias. CONCLUSIONS: As a group, long-acting GLP-1RA, including both injectable and oral formulations, reduce incidence of MACE, HHF, and kidney events and all-cause mortality in T2D.},
  langid = {english},
  pmid = {40156846}
}

@article{leeCardiovascularKidneyOutcomes2025a,
  title = {Cardiovascular and {{Kidney Outcomes}} and {{Mortality With Long-Acting Injectable}} and {{Oral Glucagon-Like Peptide}} 1 {{Receptor Agonists}} in {{Individuals With Type}} 2 {{Diabetes}}: {{A Systematic Review}} and {{Meta-analysis}} of {{Randomized Trials}}},
  shorttitle = {Cardiovascular and {{Kidney Outcomes}} and {{Mortality With Long-Acting Injectable}} and {{Oral Glucagon-Like Peptide}} 1 {{Receptor Agonists}} in {{Individuals With Type}} 2 {{Diabetes}}},
  author = {Lee, Matthew M. Y. and Sattar, Naveed and {Pop-Busui}, Rodica and Deanfield, John and Emerson, Scott S. and Inzucchi, Silvio E. and Mann, Johannes F. E. and Marx, Nikolaus and Mulvagh, Sharon L. and Poulter, Neil R. and Badve, Sunil V. and Pratley, Richard E. and Perkovic, Vlado and Buse, John B. and McGuire, Darren K. and {SOUL Trial Investigators}},
  year = {2025},
  month = mar,
  journal = {Diabetes Care},
  pages = {dc250241},
  issn = {1935-5548},
  doi = {10.2337/dc25-0241},
  abstract = {BACKGROUND: Glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce the incidence of major adverse cardiovascular events (MACE) in type 2 diabetes (T2D), although whether benefits extend to both subcutaneous and oral formulations remains unclear. PURPOSE: In these meta-analyses, including new data from the Semaglutide cardiOvascular oUtcomes triaL (SOUL) (oral semaglutide) and Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial, we examined cardiovascular (CV) and kidney benefits and risks of long-acting (defined as having pharmacokinetics sufficient to provide 24-h activity) GLP-1RA in T2D. DATA SOURCES: A systematic review of PubMed was conducted (to 7 February 2025). STUDY SELECTION: Randomized placebo-controlled CV and kidney outcomes trials of GLP-1RA with {$\geq$}500 individuals with T2D were included. DATA EXTRACTION: A random-effects model was used to estimate hazard ratios (HRs) for MACE, its components, all-cause mortality, hospitalization for heart failure (HHF), a composite kidney outcome (kidney failure [kidney replacement therapy or persistent estimated glomerular filtration rate [eGFR] {$<$}15 mL/min/1.73 m2], sustained {$\geq$}50\% eGFR decline or nearest equivalent, or kidney-related death), worsening kidney function, and safety outcomes. DATA SYNTHESIS: Across 10 trials (n = 71,351), long-acting GLP-1RA reduced incidence rate of MACE by 14\% (HR 0.86 [95\% CI 0.81, 0.90]; I2 = 27.6\%), HHF by 14\% (0.86 [0.79, 0.93]; I2 = 2.1\%), and the composite kidney outcome by 17\% (0.83 [0.75, 0.92]; I2 = 20.4\%) and all-cause mortality by 12\% (0.88 [0.82, 0.93]; I2 = 17.5\%). A consistent 14\% reduction was seen for all MACE components. There was no significant heterogeneity by GLP-1RA administration route (subcutaneous vs. oral). There were no increased risks of severe hypoglycemia, retinopathy, or pancreatic events. LIMITATIONS: Trial-level meta-analyses preclude detailed subgroup analyses and may introduce ecological bias. CONCLUSIONS: As a group, long-acting GLP-1RA, including both injectable and oral formulations, reduce incidence of MACE, HHF, and kidney events and all-cause mortality in T2D.},
  langid = {english},
  pmid = {40156846}
}

@misc{leeCommonRarevariantGenetic2023,
  title = {Common- and Rare-Variant Genetic Architecture of Heart Failure across the Allele Frequency Spectrum},
  author = {Lee, David S. M. and Cardone, Katie M. and Zhang, David Y. and Abramowitz, Sarah and DePaolo, John S. and Aragam, Krishna G. and Biddinger, Kiran and Conery, Mitchell and Dilitikas, Ozan and {Hoffman-Andrews}, Lily and Judy, Renae L. and Khan, Atlas and Kulo, Iftikhar and Puckelwartz, Megan J. and Reza, Nosheen and Satterfield, Benjamin A. and Singhal, Pankhuri and Center, Regeneron Genetics and Arany, Zoltan P. and Cappola, Thomas P. and Carruth, Eric and Day, Sharlene M. and Do, Ron and Haggarty, Christopher M. and Joseph, Jacob and McNally, Elizabeth and Nadkarni, Girish and Owens, Anjali T. and Rader, Daniel J. and Ritchie, Marylyn D. and Sun, Yan and Voight, Benjamin F. and Levin, Michael G. and Damrauer, Scott M.},
  year = {2023},
  month = oct,
  pages = {2023.07.16.23292724},
  publisher = {medRxiv},
  doi = {10.1101/2023.07.16.23292724},
  urldate = {2024-12-27},
  abstract = {Heart failure (HF) is a complex trait, influenced by environmental and genetic factors, that affects over 30 million individuals worldwide. Historically, the genetics of HF have been studied in Mendelian forms of disease, where rare genetic variants have been linked to familial cardiomyopathies. More recently, genome-wide association studies (GWAS) have successfully identified common genetic variants associated with risk of HF. However, the relative importance of genetic variants across the allele-frequency spectrum remains incompletely characterized. Here, we report the results of common- and rare-variant association studies of all-cause heart failure, applying recently developed methods to quantify the heritability of HF attributable to different classes of genetic variation. We combine GWAS data across multiple populations including 207,346 individuals with HF and 2,151,210 without, identifying 176 risk loci at genome-wide significance (p {$<$} 5{\texttimes}10-8). Signals at newly identified common-variant loci include coding variants in Mendelian cardiomyopathy genes (MYBPC3, BAG3), as well as regulators of lipoprotein (LPL) and glucose metabolism (GIPR, GLP1R), and are enriched in cardiac, muscle, nerve, and vascular tissues, as well as myocyte and adipocyte cell types. Gene burden studies across three biobanks (PMBB, UKB, AOU) including 27,208 individuals with HF and 349,126 without uncover exome-wide significant (p {$<$} 3.15{\texttimes}10-6) associations for HF and rare predicted loss-of-function (pLoF) variants in TTN, MYBPC3, FLNC, and BAG3. Total burden heritability of rare coding variants (2.2\%, 95\% CI 0.99-3.5\%) is highly concentrated in a small set of Mendelian cardiomyopathy genes, and is lower than heritability attributable to common variants (4.3\%, 95\% CI 3.9-4.7\%) which is more diffusely spread throughout the genome. Finally, we demonstrate that common-variant background, in the form of a polygenic risk score (PRS), significantly modifies the risk of HF among carriers of pathogenic truncating variants in the Mendelian cardiomyopathy gene TTN. These findings suggest a significant polygenic component to HF exists that is not captured by current clinical genetic testing.},
  archiveprefix = {medRxiv},
  copyright = {{\copyright} 2023, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/SS22KNS9/Lee et al. - 2023 - Common- and rare-variant genetic architecture of heart failure across the allele frequency spectrum.pdf}
}

@article{leeObesityParadoxCancer2019,
  title = {The {{Obesity Paradox}} in {{Cancer}}: {{Epidemiologic Insights}} and {{Perspectives}}},
  shorttitle = {The {{Obesity Paradox}} in {{Cancer}}},
  author = {Lee, Dong Hoon and Giovannucci, Edward L.},
  year = {2019},
  month = sep,
  journal = {Current Nutrition Reports},
  volume = {8},
  number = {3},
  pages = {175--181},
  issn = {2161-3311},
  doi = {10.1007/s13668-019-00280-6},
  abstract = {PURPOSE OF REVIEW: Controversy exists whether excess body fatness (measured by body mass index (BMI)) is associated with better cancer survival ("obesity paradox"). Here, we review the obesity paradox in cancer research and discuss potential explanations and future research directions. RECENT FINDINGS: Overweight and obese cancer patients have better survival for diverse cancers. This apparent obesity paradox may be largely explained by methodological limitations including reverse causation, selection bias, confounding, and reliance of BMI as a measure of adiposity in cancer patients. A growing number of studies show promising evidence that precisely quantified body composition can provide important prognostic information in cancer care, such that low muscle and high adiposity are associated with worse clinical outcomes in cancer patients. The term obesity paradox in cancer, implying a causally beneficial role of adiposity, is misleading. Understanding the role of muscle and adiposity may reduce the confusion and inform precision oncology care.},
  langid = {english},
  pmid = {31129887},
  keywords = {Adipose Tissue,Adiposity,Body composition,Body Composition,Body mass index,Body Mass Index,Cancer,Humans,Muscle,Neoplasms,Obesity,Obesity paradox,Overweight,Precision Medicine,Prognosis,Risk Factors,Survival,Survival Rate}
}

@article{lemboObesityPerfectStorm2024,
  title = {Obesity: The Perfect Storm for Heart Failure},
  shorttitle = {Obesity},
  author = {Lembo, Maria and Strisciuglio, Teresa and Fonderico, Celeste and Mancusi, Costantino and Izzo, Raffaele and Trimarco, Valentina and Bellis, Alessandro and Barbato, Emanuele and Esposito, Giovanni and Morisco, Carmine and Rubattu, Speranza},
  year = {2024},
  month = mar,
  journal = {ESC heart failure},
  issn = {2055-5822},
  doi = {10.1002/ehf2.14641},
  abstract = {Obesity condition causes morphological and functional alterations involving the cardiovascular system. These can represent the substrates for different cardiovascular diseases, such as atrial fibrillation, coronary artery disease, sudden cardiac death, and heart failure (HF) with both preserved ejection fraction (EF) and reduced EF. Different pathogenetic mechanisms may help to explain the association between obesity and HF including left ventricular remodelling and epicardial fat accumulation, endothelial dysfunction, and coronary microvascular dysfunction. Multi-imaging modalities are required for appropriate recognition of subclinical systolic dysfunction typically associated with obesity, with echocardiography being the most cost-effective technique. Therapeutic approach in patients with obesity and HF is challenging, particularly regarding patients with preserved EF in which few strategies with high level of evidence are available. Weight loss is of extreme importance in patients with obesity and HF, being a primary therapeutic intervention. Sodium-glucose co-transporter-2 inhibitors have been recently introduced as a novel tool in the management of HF patients. The present review aims at analysing the most recent studies supporting pathogenesis, diagnosis, and management in patients with obesity and HF.},
  langid = {english},
  pmid = {38491741},
  keywords = {Atrial fibrillation,Direct-acting oral anticoagulants,Heart failure,Implantable cardioverter-defibrillators,Left ventricular remodelling,Natriuretic peptides,Obesity,Sacubitril/valsartan,Sodium-glucose co-transporter-2 inhibitors,Sudden cardiac death},
  file = {/Users/xx20081/Zotero/storage/3UP4ZDLG/Lembo et al. - 2024 - Obesity the perfect storm for heart failure.pdf}
}

@article{lennonObesityParadoxCancer2016,
  title = {The {{Obesity Paradox}} in {{Cancer}}: A {{Review}}},
  shorttitle = {The {{Obesity Paradox}} in {{Cancer}}},
  author = {Lennon, Hannah and Sperrin, Matthew and Badrick, Ellena and Renehan, Andrew G.},
  year = {2016},
  month = jul,
  journal = {Current Oncology Reports},
  volume = {18},
  number = {9},
  pages = {56},
  issn = {1534-6269},
  doi = {10.1007/s11912-016-0539-4},
  urldate = {2025-01-22},
  abstract = {There is a common perception that excess adiposity, commonly approximated by body mass index (BMI), is associated with reduced cancer survival. A number of studies have emerged challenging this by demonstrating that overweight and early obese states are associated with improved survival. This finding is termed the ``obesity paradox'' and is well recognized in the cardio-metabolic literature but less so in oncology. Here, we summarize the epidemiological findings related to the obesity paradox in cancer. Our review highlights that many observations of the obesity paradox in cancer reflect methodological mechanisms including the crudeness of BMI as an obesity measure, confounding, detection bias, reverse causality, and a specific form of the selection bias, known as collider bias. It is imperative for the oncologist to interpret the observation of the obesity paradox against the above methodological framework and avoid the misinterpretation that being obese might be ``good'' or ``protective'' for cancer patients.},
  langid = {english},
  keywords = {Adiposity,BMI,Body mass index,Cancer,Cancer survival,Epidemiology,Excess weight,Mortality,Obesity,Overweight,Prognosis},
  file = {/Users/xx20081/Zotero/storage/8IIZFMMU/Lennon et al. - 2016 - The Obesity Paradox in Cancer a Review.pdf}
}

@article{leslieDiabetesRemissionClinical2016,
  title = {The {{Diabetes Remission Clinical Trial}} ({{DiRECT}}): Protocol for a Cluster Randomised Trial},
  shorttitle = {The {{Diabetes Remission Clinical Trial}} ({{DiRECT}})},
  author = {Leslie, Wilma S. and Ford, Ian and Sattar, Naveed and Hollingsworth, Kieren G. and Adamson, Ashley and Sniehotta, Falko F. and McCombie, Louise and Brosnahan, Naomi and Ross, Hazel and Mathers, John C. and Peters, Carl and Thom, George and Barnes, Alison and Kean, Sharon and McIlvenna, Yvonne and Rodrigues, Angela and Rehackova, Lucia and Zhyzhneuskaya, Sviatlana and Taylor, Roy and Lean, Mike E. J.},
  year = {2016},
  month = feb,
  journal = {BMC family practice},
  volume = {17},
  pages = {20},
  issn = {1471-2296},
  doi = {10.1186/s12875-016-0406-2},
  abstract = {BACKGROUND: Despite improving evidence-based practice following clinical guidelines to optimise drug therapy, Type 2 diabetes (T2DM) still exerts a devastating toll from vascular complications and premature death. Biochemical remission of T2DM has been demonstrated with weight loss around 15kg following bariatric surgery and in several small studies of non-surgical energy-restriction treatments. The non-surgical Counterweight-Plus programme, running in Primary Care where obesity and T2DM are routinely managed, produces {$>$}15 kg weight loss in 33\% of all enrolled patients. The Diabetes UK-funded Counterpoint study suggested that this should be sufficient to reverse T2DM by removing ectopic fat in liver and pancreas, restoring first-phase insulin secretion. The Diabetes Remission Clinical Trial (DiRECT) was designed to determine whether a structured, intensive, weight management programme, delivered in a routine Primary Care setting, is a viable treatment for achieving durable normoglycaemia. Other aims are to understand the mechanistic basis of remission and to identify psychological predictors of response. METHODS/DESIGN: Cluster-randomised design with GP practice as the unit of randomisation: 280 participants from around 30 practices in Scotland and England will be allocated either to continue usual guideline-based care or to add the Counterweight-Plus weight management programme, which includes primary care nurse or dietitian delivery of 12-20weeks low calorie diet replacement, food reintroduction, and long-term weight loss maintenance. Main inclusion criteria: men and women aged 20-65 years, all ethnicities, T2DM 0-6years duration, BMI 27-45 kg/m(2). Tyneside participants will undergo Magnetic Resonance (MR) studies of pancreatic and hepatic fat, and metabolic studies to determine mechanisms underlying T2DM remission. Co-primary endpoints: weight reduction\,{$\geq$}\,15 kg and HbA1c {$<$}48 mmol/mol at one year. Further follow-up at 2 years. DISCUSSION: This study will establish whether a structured weight management programme, delivered in Primary Care by practice nurses or dietitians, is a viable treatment to achieve T2DM remission. Results, available from 2018 onwards, will inform future service strategy. TRIAL REGISTRATION: Current Controlled Trials ISRCTN03267836 . Date of Registration 20/12/2013.},
  langid = {english},
  pmcid = {PMC4754868},
  pmid = {26879684},
  keywords = {Adult,Aged,Diabetes Mellitus Type 2,Diet Reducing,England,Female,Glycated Hemoglobin,Humans,Hypoglycemic Agents,Male,Middle Aged,Obesity,Primary Health Care,Remission Induction,Scotland,Weight Reduction Programs,Young Adult},
  file = {/Users/xx20081/Zotero/storage/8A8BI47Z/Leslie et al. - 2016 - The Diabetes Remission Clinical Trial (DiRECT) protocol for a cluster randomised trial.pdf}
}

@article{lesserMeasurementAdiposeTissue1967,
  title = {Measurement of Adipose Tissue Blood Flow and Perfusion in Man by Uptake of {{85Kr}}},
  author = {Lesser, G and Deutsch, S},
  year = {1967},
  month = nov,
  journal = {Journal of applied physiology},
  volume = {23},
  number = {5},
  publisher = {J Appl Physiol},
  issn = {0021-8987},
  doi = {10.1152/jappl.1967.23.5.621},
  urldate = {2024-07-05},
  abstract = {Measurement of adipose tissue blood flow and perfusion in man by uptake of 85Kr},
  langid = {english},
  pmid = {6061376},
  file = {/Users/xx20081/Zotero/storage/N5TBSK42/6061376.html}
}

@article{levinGenomewideAssociationMultitrait2022,
  title = {Genome-Wide Association and Multi-Trait Analyses Characterize the Common Genetic Architecture of Heart Failure},
  author = {Levin, Michael G. and Tsao, Noah L. and Singhal, Pankhuri and Liu, Chang and Vy, Ha My T. and Paranjpe, Ishan and Backman, Joshua D. and Bellomo, Tiffany R. and Bone, William P. and Biddinger, Kiran J. and Hui, Qin and Dikilitas, Ozan and Satterfield, Benjamin A. and Yang, Yifan and Morley, Michael P. and Bradford, Yuki and Burke, Megan and Reza, Nosheen and Charest, Brian and Judy, Renae L. and Puckelwartz, Megan J. and Hakonarson, Hakon and Khan, Atlas and Kottyan, Leah C. and Kullo, Iftikhar and Luo, Yuan and McNally, Elizabeth M. and {Rasmussen-Torvik}, Laura J. and Day, Sharlene M. and Do, Ron and Phillips, Lawrence S. and Ellinor, Patrick T. and Nadkarni, Girish N. and Ritchie, Marylyn D. and Arany, Zoltan and Cappola, Thomas P. and Margulies, Kenneth B. and Aragam, Krishna G. and Haggerty, Christopher M. and Joseph, Jacob and Sun, Yan V. and Voight, Benjamin F. and Damrauer, Scott M.},
  year = {2022},
  month = nov,
  journal = {Nature Communications},
  volume = {13},
  number = {1},
  pages = {6914},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-022-34216-6},
  urldate = {2024-08-15},
  abstract = {Heart failure is a leading cause of cardiovascular morbidity and mortality. However, the contribution of common genetic variation to heart failure risk has not been fully elucidated, particularly in comparison to other common cardiometabolic traits. We report a multi-ancestry genome-wide association study meta-analysis of all-cause heart failure including up to 115,150 cases and 1,550,331 controls of diverse genetic ancestry, identifying 47 risk loci. We also perform multivariate genome-wide association studies that integrate heart failure with related cardiac magnetic resonance imaging endophenotypes, identifying 61 risk loci. Gene-prioritization analyses including colocalization and transcriptome-wide association studies identify known and previously unreported candidate cardiomyopathy genes and cellular processes, which we validate in gene-expression profiling of failing and healthy human hearts. Colocalization, gene expression profiling, and Mendelian randomization provide convergent evidence for the roles of BCKDHA and circulating branch-chain amino acids in heart failure and cardiac structure. Finally, proteome-wide Mendelian randomization identifies 9 circulating proteins associated with heart failure or quantitative imaging traits. These analyses highlight similarities and differences among heart failure and associated cardiovascular imaging endophenotypes, implicate common genetic variation in the pathogenesis of heart failure, and identify circulating proteins that may represent cardiomyopathy treatment targets.},
  copyright = {2022 This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply},
  langid = {english},
  keywords = {Cardiology,Cardiomyopathies,Genetic association study,Genomics,Heart failure},
  file = {/Users/xx20081/Zotero/storage/MCEKZDW5/Levin et al. - 2022 - Genome-wide association and multi-trait analyses c.pdf}
}

@article{Lewis2017,
  title = {Effect of Oral Iron Repletion on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency: {{The IRONOUT HF}} Randomized Clinical Trial},
  author = {Lewis, Gregory D. and Malhotra, Rajeev and Hernandez, Adrian F. and McNulty, Steven E. and Smith, Andrew and Felker, G. Michael and Tang, W. H. Wilson and LaRue, Shane J. and Redfield, Margaret M. and Semigran, Marc J. and Givertz, Michael M. and Buren, Peter Van and Whellan, David and Anstrom, Kevin J. and Shah, Monica R. and {Desvigne-Nickens}, Patrice and Butler, Javed and Braunwald, Eugene},
  year = {2017},
  month = may,
  journal = {JAMA : the journal of the American Medical Association},
  volume = {317},
  number = {19},
  pages = {1958--1966},
  publisher = {JAMA},
  issn = {1538-3598},
  doi = {10.1001/JAMA.2017.5427},
  abstract = {IMPORTANCE Iron deficiency is present in approximately 50\% of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) and is an independent predictor of reduced functional capacity and mortality. However, the efficacy of inexpensive readily available oral iron supplementation in heart failure is unknown. OBJECTIVE To test whether therapy with oral iron improves peak exercise capacity in patients with HFrEF and iron deficiency. DESIGN, SETTING, AND PARTICIPANTS Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with HFrEF ({\textexclamdown}40\%) and iron deficiency, defined as a serum ferritin level of 15 to 100 ng/mL or a serum ferritin level of 101 to 299 ng/mL with transferrin saturation of less than 20\%. Participants were enrolled between September 2014 and November 2015 at 23 US sites. INTERVENTIONS Oral iron polysaccharide (n = 111) or placebo (n = 114), 150 mg twice daily for 16 weeks. MAIN OUTCOMES AND MEASURES The primary end point was a change in peak oxygen uptake (V O2) from baseline to 16 weeks. Secondary end points were change in 6-minute walk distance, plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and health status as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ, range 0-100, higher scores reflect better quality of life). RESULTS Among 225 randomized participants (median age, 63 years; 36\% women) 203 completed the study. The median baseline peak V O2 was 1196 mL/min (interquartile range [IQR], 887-1448 mL/min) in the oral iron group and 1167 mL/min (IQR, 887-1449 mL/min) in the placebo group. The primary end point, change in peak V O2 at 16 weeks, did not significantly differ between the oral iron and placebo groups (+23 mL/min vs-2 mL/min; difference, 21 mL/min [95\% CI,-34 to +76 mL/min]; P =.46). Similarly, at 16 weeks, there were no significant differences between treatment groups in changes in 6-minute walk distance (-13 m; 95\% CI,-32 to 6 m), NT-proBNP levels (159; 95\% CI,-280 to 599 pg/mL), or KCCQ score (1; 95\% CI,-2.4 to 4.4), all P {\textquestiondown}.05. CONCLUSIONS AND RELEVANCE Among participants with HFrEF with iron deficiency, high-dose oral iron did not improve exercise capacity over 16 weeks. These results do not support use of oral iron supplementation in patients with HFrEF.},
  pmid = {28510680},
  keywords = {Administration,affs=[]),Aged,Brain / blood,Clinical Trial,CollabAuthor(name='NHLBI Heart Failure Clinical Research Network',doi:10.1001/jama.2017.5427,Double-Blind Method,Exercise Tolerance*,Female,Ferritins / blood*,Gregory D Lewis,Health Status,Heart Failure / complications,Heart Failure / metabolism,Heart Failure / physiopathology*,Humans,investigators=[],Iron Compounds / administration & dosage*,Iron Compounds / adverse effects,Iron Deficiencies*,Male,MEDLINE,Middle Aged,Multicenter Study,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,Natriuretic Peptide,NCBI,NIH,NLM,Oral,Oxygen Consumption*,Peptide Fragments / blood,Phase II,PMC5703044,pmid:28510680,PubMed Abstract,Quality of Life,Rajeev Malhotra,Randomized Controlled Trial,Stroke Volume / physiology*,Time Factors,Transferrin / metabolism,Treatment Outcome,Walk Test}
}

@article{lewisBiologicalPhenotypesHeart2017,
  title = {Biological {{Phenotypes}} of {{Heart Failure With Preserved Ejection Fraction}}},
  author = {Lewis, Gavin A. and Schelbert, Erik B. and Williams, Simon G. and Cunnington, Colin and Ahmed, Fozia and McDonagh, Theresa A. and Miller, Christopher A.},
  year = {2017},
  month = oct,
  journal = {Journal of the American College of Cardiology},
  volume = {70},
  number = {17},
  pages = {2186--2200},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2017.09.006},
  abstract = {Heart failure with preserved ejection fraction (HFpEF) involves multiple pathophysiological mechanisms, which result in the heterogeneous phenotypes that are evident clinically, and which have potentially confounded previous HFpEF trials. A greater understanding of the in~vivo human processes involved, and in particular, which are the causes and which are the downstream effects, may allow the syndrome of HFpEF to be distilled into distinct diagnoses based on the underlying biology. From this, specific interventions can follow, targeting individuals identified on the basis of their biological phenotype. This review describes the biological phenotypes of HFpEF and therapeutic interventions aimed at targeting these phenotypes.},
  langid = {english},
  pmid = {29050567},
  keywords = {Blood Vessels,diastolic dysfunction,ejection fraction,Extracellular Matrix,heart failure,Heart Failure,heart failure with preserved ejection fraction,Humans,Kidney Diseases,Lung Diseases,myocardial fibrosis,Obesity,Phenotype,Pulmonary Artery,Stroke Volume,titin}
}

@article{lewisEffectOralIron2017,
  title = {Effect of {{Oral Iron Repletion}} on {{Exercise Capacity}} in {{Patients With Heart Failure With Reduced Ejection Fraction}} and {{Iron Deficiency}}: {{The IRONOUT HF Randomized Clinical Trial}}},
  shorttitle = {Effect of {{Oral Iron Repletion}} on {{Exercise Capacity}} in {{Patients With Heart Failure With Reduced Ejection Fraction}} and {{Iron Deficiency}}},
  author = {Lewis, Gregory D. and Malhotra, Rajeev and Hernandez, Adrian F. and McNulty, Steven E. and Smith, Andrew and Felker, G. Michael and Tang, W. H. Wilson and LaRue, Shane J. and Redfield, Margaret M. and Semigran, Marc J. and Givertz, Michael M. and Van Buren, Peter and Whellan, David and Anstrom, Kevin J. and Shah, Monica R. and {Desvigne-Nickens}, Patrice and Butler, Javed and Braunwald, Eugene and {NHLBI Heart Failure Clinical Research Network}},
  year = {2017},
  month = may,
  journal = {JAMA},
  volume = {317},
  number = {19},
  pages = {1958--1966},
  issn = {1538-3598},
  doi = {10.1001/jama.2017.5427},
  abstract = {IMPORTANCE: Iron deficiency is present in approximately 50\% of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) and is an independent predictor of reduced functional capacity and mortality. However, the efficacy of inexpensive readily available oral iron supplementation in heart failure is unknown. OBJECTIVE: To test whether therapy with oral iron improves peak exercise capacity in patients with HFrEF and iron deficiency. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with HFrEF ({$<$}40\%) and iron deficiency, defined as a serum ferritin level of 15 to 100 ng/mL or a serum ferritin level of 101 to 299 ng/mL with transferrin saturation of less than 20\%. Participants were enrolled between September 2014 and November 2015 at 23 US sites. INTERVENTIONS: Oral iron polysaccharide (n\,=\,111) or placebo (n\,=\,114), 150 mg twice daily for 16 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was a change in peak oxygen uptake ({\.V}o2) from baseline to 16 weeks. Secondary end points were change in 6-minute walk distance, plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and health status as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ, range 0-100, higher scores reflect better quality of life). RESULTS: Among 225 randomized participants (median age, 63 years; 36\% women) 203 completed the study. The median baseline peak {\.V}o2 was 1196 mL/min (interquartile range [IQR], 887-1448 mL/min) in the oral iron group and 1167 mL/min (IQR, 887-1449 mL/min) in the placebo group. The primary end point, change in peak {\.V}o2 at 16 weeks, did not significantly differ between the oral iron and placebo groups (+23 mL/min vs -2 mL/min; difference, 21 mL/min [95\% CI, -34 to +76 mL/min]; P\,=\,.46). Similarly, at 16 weeks, there were no significant differences between treatment groups in changes in 6-minute walk distance (-13 m; 95\% CI, -32 to 6 m), NT-proBNP levels (159; 95\% CI, -280 to 599 pg/mL), or KCCQ score (1; 95\% CI, -2.4 to 4.4), all P\,{$>$}\,.05. CONCLUSIONS AND RELEVANCE: Among participants with HFrEF with iron deficiency, high-dose oral iron did not improve exercise capacity over 16 weeks. These results do not support use of oral iron supplementation in patients with HFrEF. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02188784.},
  langid = {english},
  pmcid = {PMC5703044},
  pmid = {28510680},
  keywords = {Administration Oral,Aged,Double-Blind Method,Exercise Tolerance,Female,Ferritins,Health Status,Heart Failure,Humans,Iron Compounds,Iron Deficiencies,Male,Middle Aged,Natriuretic Peptide Brain,Oxygen Consumption,Peptide Fragments,Quality of Life,Stroke Volume,Time Factors,Transferrin,Treatment Outcome,Walk Test},
  file = {/Users/xx20081/Zotero/storage/UPD8UTVF/Lewis et al. - 2017 - Effect of Oral Iron Repletion on Exercise Capacity.pdf}
}

@article{leydenDisentanglingAetiologicalPathways2023,
  title = {Disentangling the Aetiological Pathways between Body Mass Index and Site-Specific Cancer Risk Using Tissue-Partitioned {{Mendelian}} Randomisation},
  author = {Leyden, Genevieve M. and Greenwood, Michael P. and Gaborieau, Val{\'e}rie and Han, Younghun and Amos, Christopher I. and Brennan, Paul and Murphy, David and Davey Smith, George and Richardson, Tom G.},
  year = {2023},
  month = feb,
  journal = {British Journal of Cancer},
  volume = {128},
  number = {4},
  pages = {618--625},
  publisher = {Nature Publishing Group},
  issn = {1532-1827},
  doi = {10.1038/s41416-022-02060-6},
  urldate = {2024-02-19},
  abstract = {Body mass index (BMI) is known to influence the risk of various site-specific cancers, however, dissecting which subcomponents of this heterogenous risk factor are predominantly responsible for driving disease effects has proven difficult to establish. We have leveraged tissue-specific gene expression to separate the effects of distinct phenotypes underlying BMI on the risk of seven site-specific cancers.},
  copyright = {2022 The Author(s)},
  langid = {english},
  keywords = {Cancer,Cancer epidemiology,Cancer genetics,Gene expression,Risk factors},
  file = {/Users/xx20081/Zotero/storage/3QTNANFG/Leyden et al. - 2023 - Disentangling the aetiological pathways between bo.pdf}
}

@article{leydenHarnessingTissuespecificGenetic2022,
  title = {Harnessing Tissue-Specific Genetic Variation to Dissect Putative Causal Pathways between Body Mass Index and Cardiometabolic Phenotypes},
  author = {Leyden, Genevieve M. and Shapland, Chin Yang and Davey Smith, George and Sanderson, Eleanor and Greenwood, Michael P. and Murphy, David and Richardson, Tom G.},
  year = {2022},
  month = feb,
  journal = {American Journal of Human Genetics},
  volume = {109},
  number = {2},
  pages = {240--252},
  issn = {1537-6605},
  doi = {10.1016/j.ajhg.2021.12.013},
  abstract = {Body mass index (BMI) is a complex disease risk factor known to be influenced by genes acting via both metabolic pathways and appetite regulation. In this study, we aimed to gain insight into the phenotypic consequences of BMI-associated genetic variants, which may be mediated by their expression in different tissues. First, we harnessed meta-analyzed gene expression datasets derived from subcutaneous adipose (n = 1257) and brain (n = 1194) tissue to identify 86 and 140 loci, respectively, which provided evidence of genetic colocalization with BMI. These two sets of tissue-partitioned loci had differential effects with respect to waist-to-hip ratio, suggesting that the way they influence fat distribution might vary despite their having very similar average magnitudes of effect on BMI itself (adipose = 0.0148 and brain = 0.0149 standard deviation change in BMI per effect allele). For instance, BMI-associated variants colocalized with TBX15 expression in adipose tissue (posterior probability [PPA] = 0.97), but not when we used TBX15 expression data derived from brain tissue (PPA = 0.04) This gene putatively influences BMI via its role in skeletal development. Conversely, there were loci where BMI-associated variants provided evidence of colocalization with gene expression in brain tissue (e.g., NEGR1, PPA = 0.93), but not when we used data derived from adipose tissue, suggesting that these genes might be more likely to influence BMI via energy balance. Leveraging these tissue-partitioned variant sets through a multivariable Mendelian randomization framework provided strong evidence that the brain-tissue-derived variants are predominantly responsible for driving the genetically predicted effects of BMI on cardiovascular-disease endpoints (e.g., coronary artery disease: odds ratio = 1.05, 95\% confidence interval = 1.04-1.07, p~= 4.67~{\texttimes} 10-14). In contrast, our analyses suggested that the adipose tissue variants might predominantly be responsible for the underlying relationship between BMI and measures of cardiac function, such as left ventricular stroke volume (beta = 0.21, 95\% confidence interval = 0.09-0.32, p = 6.43~{\texttimes} 10-4).},
  langid = {english},
  pmcid = {PMC8874216},
  pmid = {35090585},
  keywords = {Adipose Tissue,adiposity,Body Mass Index,Brain,cardiovascular disease,Cell Adhesion Molecules Neuronal,complex-trait genetics,Coronary Artery Disease,Diabetes Mellitus Type 2,fat distribution,Gene Expression Profiling,Gene Expression Regulation,genetic colocalization,genetic epidemiology,Genetic Loci,Genetic Variation,Genome Human,Genome-Wide Association Study,GPI-Linked Proteins,Humans,Mendelian randomization,Mendelian Randomization Analysis,Metabolic Networks and Pathways,Obesity,Stroke Volume,T-Box Domain Proteins,tissue specificity,transcriptome-wide,Waist-Hip Ratio},
  file = {/Users/xx20081/Zotero/storage/X46QTD8Q/Leyden et al. - 2022 - Harnessing tissue-specific genetic variation to di.pdf}
}

@article{lincoffa.michaelSemaglutideCardiovascularOutcomes2023,
  title = {Semaglutide and {{Cardiovascular Outcomes}} in {{Obesity}} without {{Diabetes}}},
  author = {{Lincoff A. Michael} and {Brown-Frandsen Kirstine} and {Colhoun Helen M.} and {Deanfield John} and {Emerson Scott S.} and {Esbjerg Sille} and {Hardt-Lindberg S{\o}ren} and {Hovingh G. Kees} and {Kahn Steven E.} and {Kushner Robert F.} and {Lingvay Ildiko} and {Oral Tugce K.} and {Michelsen Marie M.} and {Plutzky Jorge} and {Torn{\o}e Christoffer W.} and {Ryan Donna H.}},
  year = {2023},
  month = dec,
  journal = {New England Journal of Medicine},
  volume = {389},
  number = {24},
  pages = {2221--2232},
  publisher = {Massachusetts Medical Society},
  doi = {10.1056/NEJMoa2307563},
  urldate = {2024-07-03},
  abstract = {In a trial in patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 months.},
  file = {/Users/xx20081/Zotero/storage/KXS6XZXD/Lincoff A. Michael et al. - 2023 - Semaglutide and Cardiovascular Outcomes in Obesity.pdf}
}

@article{lincoffSemaglutideCardiovascularOutcomes2023,
  title = {Semaglutide and {{Cardiovascular Outcomes}} in {{Obesity}} without {{Diabetes}}},
  author = {Lincoff, A. Michael and {Brown-Frandsen}, Kirstine and Colhoun, Helen M. and Deanfield, John and Emerson, Scott S. and Esbjerg, Sille and {Hardt-Lindberg}, S{\o}ren and Hovingh, G. Kees and Kahn, Steven E. and Kushner, Robert F. and Lingvay, Ildiko and Oral, Tugce K. and Michelsen, Marie M. and Plutzky, Jorge and Torn{\o}e, Christoffer W. and Ryan, Donna H.},
  year = {2023},
  month = dec,
  journal = {New England Journal of Medicine},
  volume = {389},
  number = {24},
  pages = {2221--2232},
  publisher = {Massachusetts Medical Society},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa2307563},
  urldate = {2024-08-15},
  abstract = {In a trial in patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8 months.},
  file = {/Users/xx20081/Zotero/storage/ZTRC5SVJ/Lincoff et al. - 2023 - Semaglutide and Cardiovascular Outcomes in Obesity.pdf}
}

@article{lindImpactRiskFactors2021,
  title = {Impact of Risk Factors for Major Cardiovascular Diseases: A Comparison of Life-Time Observational and {{Mendelian}} Randomisation Findings},
  shorttitle = {Impact of Risk Factors for Major Cardiovascular Diseases},
  author = {Lind, Lars and Ingelsson, Martin and Sundstrom, Johan and {\"A}rnl{\"o}v, Johan},
  year = {2021},
  month = sep,
  journal = {Open Heart},
  volume = {8},
  number = {2},
  publisher = {British Cardiovascular Society},
  issn = {2053-3624},
  doi = {10.1136/openhrt-2021-001735},
  urldate = {2025-01-15},
  abstract = {Background This study compared the strength and causality of associations between major risk factors for cardiovascular disease (CVD) and the four major CVDs: myocardial infarction, ischaemic stroke, heart failure and atrial fibrillation. Both a long-term follow-up in an observational cohort and Mendelian randomisation (MR) were used for this aim.Methods In the Uppsala Longitudinal Study of Adult Men study, 2322 men, all aged 50 years, were assessed for CVD risk factors and then followed for four decades regarding incident CVDs. The two-sample MR part used public available Genome-Wide Association Study (GWAS) data.Results In multivariate analyses, systolic blood pressure was overall by far the most important risk factor, since it was related to all four CVDs, both in observational and MR analyses. Body mass index was the second most overall important risk factor, being linked to all four CVDs, except ischaemic stroke, both in observational and MR analyses. Smoking was an important risk factor for ischaemic stroke and heart failure, both in observational and MR analyses, while low-density lipoprotein-cholesterol mainly was related to myocardial infarction. Diabetes was mainly a causal risk factor for incident myocardial infarction and heart failure. Neither HDL-cholesterol nor triglycerides were of major importance as risk factors in these multivariable models.Conclusion By combining long-term observational data with genetic data, we show that the impact and causal role of specific established cardiovascular risk factors varies between different major CVDs. Systolic blood pressure was causally related to all four cardiovascular outcomes and was therefore, overall, the most important risk factor.},
  copyright = {This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license},
  langid = {english},
  pmid = {10.1136/openhrt-2021-001735},
  file = {/Users/xx20081/Zotero/storage/MRTEB8XJ/Lind et al. - 2021 - Impact of risk factors for major cardiovascular diseases a comparison of life-time observational an.pdf}
}

@article{linPolymorphismsGLP1Receptor2015,
  title = {Polymorphisms of {{GLP-1 Receptor Gene}} and {{Response}} to {{GLP-1 Analogue}} in {{Patients}} with {{Poorly Controlled Type}} 2 {{Diabetes}}},
  author = {Lin, Chia-Hung and Lee, Yun-Shien and Huang, Yu-Yao and Hsieh, Sheng-Hwu and Chen, Zih-Syuan and Tsai, Chi-Neu},
  year = {2015},
  month = feb,
  journal = {Journal of Diabetes Research},
  volume = {2015},
  pages = {e176949},
  publisher = {Hindawi},
  issn = {2314-6745},
  doi = {10.1155/2015/176949},
  urldate = {2024-01-21},
  abstract = {Aim. The relationship between genetic polymorphisms of the glucagon-like peptide-1 (GLP-1) receptor (GLP1R) gene and unresponsiveness to GLP-1 analogue treatment in patients with poorly controlled type 2 diabetes mellitus (DM) is unclear. Methods. Thirty-six patients with poorly controlled type 2 DM were enrolled and they received six days of continuous subcutaneous insulin infusion for this study. After the normalization of blood glucose in the first 3 days, the patients then received a combination therapy with injections of the GLP-1 analogue, exenatide, for another 3 days. All 13 exons and intron-exon boundaries of the GLP1R gene were amplified to investigate the association. Results. The short tandem repeat at 8GA/7GA (rs5875654) had complete linkage disequilibrium (LD, with ) with single nucleotide polymorphism (SNP) rs761386. Quantitative trait loci analysis of GLP1R gene variation with clinical response of GLP1 analogue showed the missense rs3765467 and rs761386 significantly associated with changes in the standard deviation of plasma glucose () ( and 0.019, resp.). The reported values became insignificant after multiple testing adjustments. Conclusion. The variable response to the GLP-1 analogue was not statistically correlated with polymorphisms of the GLP1R gene in patients with poorly controlled type 2 DM.},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/LQJBMHGZ/Lin et al. - 2015 - Polymorphisms of GLP-1 Receptor Gene and Response .pdf}
}

@article{liuAssociationsTimevaryingObesity2021,
  title = {Associations of Time-Varying Obesity and Metabolic Syndrome with Risk of Incident Heart Failure and Its Subtypes: {{Findings}} from the {{Multi-Ethnic Study}} of {{Atherosclerosis}}},
  shorttitle = {Associations of Time-Varying Obesity and Metabolic Syndrome with Risk of Incident Heart Failure and Its Subtypes},
  author = {Liu, Longjian and Lima, Joao A. C. and Post, Wendy S. and Szklo, Moyses},
  year = {2021},
  month = sep,
  journal = {International Journal of Cardiology},
  volume = {338},
  pages = {127--135},
  issn = {1874-1754},
  doi = {10.1016/j.ijcard.2021.05.051},
  abstract = {OBJECTIVE: Most previous studies have examined associations between metabolic disorders measured at a single point in time and risk of heart failure (HF). However, there are many situations where the values of exposures vary over time before HF occurs. We aimed to examine the associations of time-varying obesity and metabolic syndrome (MetSyn) measured at multiple points in time with HF. METHODS: A total of 6750 participants in the Multi-Ethnic Study of Atherosclerosis from 2000 were included in the study. Follow-up was completed through December 2015. MetSyn was defined using the American Heart Association criteria. Incident HF was diagnosed by clinical criteria. Subtypes HF (reduced ejection fraction (HFrEF) and preserved (HFpEF) were classified by left ventricular EF. RESULTS: A total of 331 HF cases were identified during 82,609 person-years of observation. The incidence (95\%CI) of total HF was 4.0 (3.4-4.4) per 1000 person-years. Of the total HF cases, 45.6\% were HFrEF (n = 151), 40.8\% HFpEF (n = 135), and 13.6\% were unclassified HF subtypes (n = 45). After adjusting for key covariates, time-varying obesity (BMI {$\geq$} 30 kg/m2) and MetSyn were significantly associated with HF, with a stronger association for HFpEF than for HFrEF. The corresponding hazards ratios (HR, 95\%CI) were 1.97 (1.43-2.72) and 1.86 (1.43-2.42) for HFpEF, and 1.46 (1.07-1.98), and 1.39 (1.06-1.82) for HFrEF respectively. Time-varying large waist circumference was significantly associated with for HFpEF, but not with HFrEF. CONCLUSION: Time-varying obesity and MetSyn were significantly associated with HF risk, with a stronger association with HFpEF than with HFrEF. Continued effort to control these risk factors is recommended.},
  langid = {english},
  pmid = {34089770},
  keywords = {Atherosclerosis,Heart failure,Heart Failure,Humans,Metabolic syndrome,Metabolic Syndrome,Obesity,Prognosis,Risk Factors,Stroke Volume,Time-varying obesity,United States},
  file = {/Users/xx20081/Zotero/storage/9Z65ZCKU/Liu et al. - 2021 - Associations of time-varying obesity and metabolic.pdf}
}

@article{liuAssociationStudiesMillion2019,
  title = {Association Studies of up to 1.2 Million Individuals Yield New Insights into the Genetic Etiology of Tobacco and Alcohol Use},
  author = {Liu, Mengzhen and Jiang, Yu and Wedow, Robbee and Li, Yue and Brazel, David M. and Chen, Fang and Datta, Gargi and {Davila-Velderrain}, Jose and McGuire, Daniel and Tian, Chao and Zhan, Xiaowei and Choquet, H{\'e}l{\`e}ne and Docherty, Anna R. and Faul, Jessica D. and Foerster, Johanna R. and Fritsche, Lars G. and Gabrielsen, Maiken Elvestad and Gordon, Scott D. and Haessler, Jeffrey and Hottenga, Jouke-Jan and Huang, Hongyan and Jang, Seon-Kyeong and Jansen, Philip R. and Ling, Yueh and M{\"a}gi, Reedik and Matoba, Nana and McMahon, George and Mulas, Antonella and Orr{\`u}, Valeria and Palviainen, Teemu and Pandit, Anita and Reginsson, Gunnar W. and Skogholt, Anne Heidi and Smith, Jennifer A. and Taylor, Amy E. and Turman, Constance and Willemsen, Gonneke and Young, Hannah and Young, Kendra A. and Zajac, Gregory J. M. and Zhao, Wei and Zhou, Wei and Bjornsdottir, Gyda and Boardman, Jason D. and Boehnke, Michael and Boomsma, Dorret I. and Chen, Chu and Cucca, Francesco and Davies, Gareth E. and Eaton, Charles B. and Ehringer, Marissa A. and Esko, T{\~o}nu and Fiorillo, Edoardo and Gillespie, Nathan A. and Gudbjartsson, Daniel F. and Haller, Toomas and Harris, Kathleen Mullan and Heath, Andrew C. and Hewitt, John K. and Hickie, Ian B. and Hokanson, John E. and Hopfer, Christian J. and Hunter, David J. and Iacono, William G. and Johnson, Eric O. and Kamatani, Yoichiro and Kardia, Sharon L. R. and Keller, Matthew C. and Kellis, Manolis and Kooperberg, Charles and Kraft, Peter and Krauter, Kenneth S. and Laakso, Markku and Lind, Penelope A. and Loukola, Anu and Lutz, Sharon M. and Madden, Pamela A. F. and Martin, Nicholas G. and McGue, Matt and McQueen, Matthew B. and Medland, Sarah E. and Metspalu, Andres and Mohlke, Karen L. and Nielsen, Jonas B. and Okada, Yukinori and Peters, Ulrike and Polderman, Tinca J. C. and Posthuma, Danielle and Reiner, Alexander P. and Rice, John P. and Rimm, Eric and Rose, Richard J. and Runarsdottir, Valgerdur and Stallings, Michael C. and Stan{\v c}{\'a}kov{\'a}, Alena and Stefansson, Hreinn and Thai, Khanh K. and Tindle, Hilary A. and Tyrfingsson, Thorarinn and Wall, Tamara L. and Weir, David R. and Weisner, Constance and Whitfield, John B. and Winsvold, Bendik Slagsvold and Yin, Jie and Zuccolo, Luisa and Bierut, Laura J. and Hveem, Kristian and Lee, James J. and Munafo, Marcus R. and Saccone, Nancy L. and Willer, Cristen J. and Cornelis, Marilyn C. and David, Sean P. and Hinds, David and Jorgenson, Eric and Kaprio, Jaakko and Stitzel, Jerry A. and Stefansson, Kari and Thorgeirsson, Thorgeir E. and Abecasis, Goncalo and Liu, Dajiang J. and Vrieze, Scott},
  year = {2019},
  month = feb,
  journal = {Nature genetics},
  volume = {51},
  number = {2},
  pages = {237--244},
  issn = {1061-4036},
  doi = {10.1038/s41588-018-0307-5},
  urldate = {2024-09-02},
  abstract = {Tobacco and alcohol use are leading causes of mortality that influence risk for many complex diseases and disorders. They are heritable, and etiologically related, behaviors that have been resistant to gene discovery efforts--. In sample sizes up to 1.2 million individuals, we discovered 566 genetic variants in 406 loci associated with multiple stages of tobacco use (initiation, cessation, and heaviness) as well as alcohol use, with 150 loci evidencing pleiotropic association. Smoking phenotypes were positively genetically correlated with many health conditions, whereas alcohol use was negatively correlated with these conditions, such that increased genetic risk for alcohol use is associated with lower disease risk. We report evidence for the involvement of many systems in tobacco and alcohol use, including genes involved in nicotinic, dopaminergic, and glutamatergic neurotransmission. The results provide a solid starting point to evaluate the effects of these loci in model organisms and more precise substance use measures.},
  pmcid = {PMC6358542},
  pmid = {30643251},
  file = {/Users/xx20081/Zotero/storage/HXKTNGRU/Liu et al. - 2019 - Association studies of up to 1.2 million individua.pdf}
}

@article{liuGenomewideSurvivalStudy2021,
  title = {Genome-Wide Survival Study Identifies a Novel Synaptic Locus and Polygenic Score for Cognitive Progression in {{Parkinson}}'s Disease},
  author = {Liu, Ganqiang and Peng, Jiajie and Liao, Zhixiang and Locascio, Joseph J. and Corvol, Jean-Christophe and Zhu, Frank and Dong, Xianjun and {Maple-Gr{\o}dem}, Jodi and Campbell, Meghan C. and Elbaz, Alexis and Lesage, Suzanne and Brice, Alexis and Mangone, Graziella and Growdon, John H. and Hung, Albert Y. and Schwarzschild, Michael A. and Hayes, Michael T. and Wills, Anne-Marie and Herrington, Todd M. and Ravina, Bernard and Shoulson, Ira and Taba, Pille and K{\~o}ks, Sulev and Beach, Thomas G. and {Cormier-Dequaire}, Florence and Alves, Guido and Tysnes, Ole-Bj{\o}rn and Perlmutter, Joel S. and Heutink, Peter and Amr, Sami S. and {van Hilten}, Jacobus J. and Kasten, Meike and Mollenhauer, Brit and Trenkwalder, Claudia and Klein, Christine and Barker, Roger A. and {Williams-Gray}, Caroline H. and Marinus, Johan and {van Hilten}, Jacobus J. and Scherzer, Clemens R.},
  year = {2021},
  month = jun,
  journal = {Nature Genetics},
  volume = {53},
  number = {6},
  pages = {787--793},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-021-00847-6},
  urldate = {2024-04-05},
  abstract = {A key driver of patients' well-being and clinical trials for Parkinson's disease (PD) is the course that the disease takes over time (progression and prognosis). To assess how genetic variation influences the progression of PD over time to dementia, a major determinant for quality of life, we performed a longitudinal genome-wide survival study of 11.2 million variants in 3,821 patients with PD over 31,053 visits. We discover RIMS2 as a progression locus and confirm this in a replicate population (hazard ratio (HR)\,=\,4.77, P\,=\,2.78\,{\texttimes}\,10-11), identify suggestive evidence for TMEM108 (HR\,=\,2.86, P\,=\,2.09\,{\texttimes}\,10-8) and WWOX (HR\,=\,2.12, P\,=\,2.37\,{\texttimes}\,10-8) as progression loci, and confirm associations for GBA (HR\,=\,1.93, P\,=\,0.0002) and APOE (HR\,=\,1.48, P\,=\,0.001). Polygenic progression scores exhibit a substantial aggregate association with dementia risk, while polygenic susceptibility scores are not predictive. This study identifies a novel synaptic locus and polygenic score for cognitive disease progression in PD and proposes diverging genetic architectures of progression and susceptibility.},
  copyright = {2021 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  keywords = {Genome-wide association studies,Parkinson's disease},
  file = {/Users/xx20081/Zotero/storage/R6EEQSZ7/Liu et al. - 2021 - Genome-wide survival study identifies a novel syna.pdf}
}

@article{liuGenomewideSurvivalStudy2021a,
  title = {Genome-Wide Survival Study Identifies a Novel Synaptic Locus and Polygenic Score for Cognitive Progression in {{Parkinson}}'s Disease},
  author = {Liu, Ganqiang and Peng, Jiajie and Liao, Zhixiang and Locascio, Joseph J. and Corvol, Jean-Christophe and Zhu, Frank and Dong, Xianjun and {Maple-Gr{\o}dem}, Jodi and Campbell, Meghan C. and Elbaz, Alexis and Lesage, Suzanne and Brice, Alexis and Mangone, Graziella and Growdon, John H. and Hung, Albert Y. and Schwarzschild, Michael A. and Hayes, Michael T. and Wills, Anne-Marie and Herrington, Todd M. and Ravina, Bernard and Shoulson, Ira and Taba, Pille and K{\~o}ks, Sulev and Beach, Thomas G. and {Cormier-Dequaire}, Florence and Alves, Guido and Tysnes, Ole-Bj{\o}rn and Perlmutter, Joel S. and Heutink, Peter and Amr, Sami S. and {van Hilten}, Jacobus J. and Kasten, Meike and Mollenhauer, Brit and Trenkwalder, Claudia and Klein, Christine and Barker, Roger A. and {Williams-Gray}, Caroline H. and Marinus, Johan and {van Hilten}, Jacobus J. and Scherzer, Clemens R.},
  year = {2021},
  month = jun,
  journal = {Nature Genetics},
  volume = {53},
  number = {6},
  pages = {787--793},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-021-00847-6},
  urldate = {2024-08-14},
  abstract = {A key driver of patients' well-being and clinical trials for Parkinson's disease (PD) is the course that the disease takes over time (progression and prognosis). To assess how genetic variation influences the progression of PD over time to dementia, a major determinant for quality of life, we performed a longitudinal genome-wide survival study of 11.2 million variants in 3,821 patients with PD over 31,053 visits. We discover RIMS2 as a progression locus and confirm this in a replicate population (hazard ratio (HR)\,=\,4.77, P\,=\,2.78\,{\texttimes}\,10-11), identify suggestive evidence for TMEM108 (HR\,=\,2.86, P\,=\,2.09\,{\texttimes}\,10-8) and WWOX (HR\,=\,2.12, P\,=\,2.37\,{\texttimes}\,10-8) as progression loci, and confirm associations for GBA (HR\,=\,1.93, P\,=\,0.0002) and APOE (HR\,=\,1.48, P\,=\,0.001). Polygenic progression scores exhibit a substantial aggregate association with dementia risk, while polygenic susceptibility scores are not predictive. This study identifies a novel synaptic locus and polygenic score for cognitive disease progression in PD and proposes diverging genetic architectures of progression and susceptibility.},
  copyright = {2021 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  keywords = {Genome-wide association studies,Parkinson's disease},
  file = {/Users/xx20081/Zotero/storage/LVW9RZAX/Liu et al. - 2021 - Genome-wide survival study identifies a novel syna.pdf}
}

@article{liuHN1LPromotesTripleNegative2017,
  title = {{{HN1L Promotes Triple-Negative Breast Cancer Stem Cells}} through {{LEPR-STAT3 Pathway}}},
  author = {Liu, Yi and Choi, Dong Soon and Sheng, Jianting and Ensor, Joe E. and Liang, Diana Hwang and {Rodriguez-Aguayo}, Cristian and Polley, Amanda and Benz, Steve and Elemento, Olivier and Verma, Akanksha and Cong, Yang and Wong, Helen and Qian, Wei and Li, Zheng and {Granados-Principal}, Sergio and {Lopez-Berestein}, Gabriel and Landis, Melissa D. and Rosato, Roberto R. and Dave, Bhuvanesh and Wong, Stephen and Marchetti, Dario and Sood, Anil K. and Chang, Jenny C.},
  year = {2017},
  month = dec,
  journal = {Stem Cell Reports},
  volume = {10},
  number = {1},
  pages = {212--227},
  issn = {2213-6711},
  doi = {10.1016/j.stemcr.2017.11.010},
  urldate = {2025-05-27},
  abstract = {Here, we show that HEMATOLOGICAL AND NEUROLOGICAL EXPRESSED 1-LIKE (HN1L) is a targetable breast cancer stem cell (BCSC) gene that is altered in 25\% of whole breast cancer and significantly correlated with shorter overall or relapse-free survival in triple-negative breast cancer (TNBC) patients. HN1L silencing reduced the population of BCSCs, inhibited tumor initiation, resensitized chemoresistant tumors to docetaxel, and hindered cancer progression in multiple TNBC cell line-derived xenografts. Additionally, gene signatures associated with HN1L correlated with shorter disease-free survival of TNBC patients. We defined HN1L as a BCSC transcription regulator for genes involved in the LEPR-STAT3 signaling axis as HN1L binds to a putative consensus upstream sequence of STAT3, LEPTIN RECEPTOR, and MIR-150. Our data reveal that BCSCs in TNBC depend on the transcription regulator HN1L for the sustained activation of the LEPR-STAT3 pathway, which makes it a potentially important target for both prognosis and BCSC therapy., {$\bullet$}HN1L expression is correlated with shorter survival of TNBC patients{$\bullet$}HN1L regulates BCSCs by promoting the STAT3 signaling pathway{$\bullet$}HN1L: novel transcription regulator of LEPR and miR-150, upstream regulators of STAT3{$\bullet$}HN1L-regulated gene signatures can predict clinical outcomes in TNBC patients, Yi et~al. describe HN1L as a novel transcription regulator for breast cancer stem cells (BCSCs) in triple-negative breast cancer (TNBC), promoting LEPR and miR-150 expression and activating the STAT3 pathway. Since BCSCs contribute to chemoresistance and metastasis in TNBC, further investigation of HN1L will offer new therapeutic strategies.},
  pmcid = {PMC5768915},
  pmid = {29249663},
  file = {/Users/xx20081/Zotero/storage/Z7FVPM9G/Liu et al. - 2017 - HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.pdf}
}

@article{liuMyocardialSteatosisIts2014,
  title = {Myocardial Steatosis and Its Association with Obesity and Regional Ventricular Dysfunction: Evaluated by Magnetic Resonance Tagging and {{1H}} Spectroscopy in Healthy {{African Americans}}},
  shorttitle = {Myocardial Steatosis and Its Association with Obesity and Regional Ventricular Dysfunction},
  author = {Liu, Chia-Ying and Bluemke, David A. and Gerstenblith, Gary and Zimmerman, Stefan L. and Li, Ji and Zhu, Hong and Lai, Shenghan and Lai, Hong},
  year = {2014},
  month = mar,
  journal = {International Journal of Cardiology},
  volume = {172},
  number = {2},
  pages = {381--387},
  issn = {1874-1754},
  doi = {10.1016/j.ijcard.2014.01.074},
  abstract = {BACKGROUND: Cardiac steatosis is common in patients with diabetes or obesity, and cardiac steatosis may result in cardiomyopathy. However, factors associated with cardiac steatosis have not been reported in healthy individuals without diabetes and hypertension. The objectives of this study were to explore factors associated with myocardial triglyceride levels, and to examine the association between myocardial triglyceride and regional left ventricular (LV) function in healthy African Americans (AAs). METHODS: Between November 2010 and June 2012, 92 healthy AAs aged 21 years or older, without clinical evidence of cardiac dysfunction, coronary artery disease, diabetes, or hypertension from Baltimore, Maryland, were enrolled in an observational proton magnetic resonance spectroscopy and imaging study investigating factors associated with cardiac steatosis, and the relationships between cardiac steatosis and LV volumes and LV function. RESULTS: Among the participants, all had a low Framingham risk; 31 had a normal BMI, 23 were overweight and 38 were obese. The median myocardial triglyceride content was 0.5\% (IQR: 0.3-1.0\%). Among the factors investigated, BMI (R2=0.43, p={$<$}0.0001) was independently associated with myocardial triglyceride. Overall, myocardial triglyceride was not associated with LV EF/structure, but may be associated with regional LV function. CONCLUSIONS: In healthy AA adults, obesity is associated with cardiac steatosis. In contrast to studies in patients with diabetes suggesting a link between cardiac steatosis and LV dysfunction, this study found no relationship between cardiac steatosis and left ventricular volumes or EF, though there is some evidence suggesting that cardiac steatosis may be associated with LV regional function in healthy AA women.},
  langid = {english},
  pmcid = {PMC5520535},
  pmid = {24507737},
  keywords = {Adult,African Americans,Black or African American,Cardiac steatosis,Cardiomyopathies,Female,Humans,LV regional function,Magnetic Resonance Imaging,Magnetic Resonance Spectroscopy,Male,MR spectroscopy,MR tagging,Myocardium,Triglycerides,Ventricular Dysfunction Left},
  file = {/Users/xx20081/Zotero/storage/VNJCXM2C/Liu et al. - 2014 - Myocardial steatosis and its association with obes.pdf}
}

@article{liuObesityParadoxAcute2021,
  title = {``{{Obesity Paradox}}'' in {{Acute Respiratory Distress Syndrome Among Patients Undergoing Cardiac Surgery}}: {{A Retrospective Study}}},
  shorttitle = {``{{Obesity Paradox}}'' in {{Acute Respiratory Distress Syndrome Among Patients Undergoing Cardiac Surgery}}},
  author = {Liu, Yan and Song, Man and Huang, Lixue and Zhu, Guangfa},
  year = {2021},
  month = aug,
  journal = {Medical Science Monitor},
  volume = {27},
  pages = {0--0},
  publisher = {International Scientific Information, Inc.},
  issn = {1234-1010, 1643-3750},
  doi = {10.12659/MSM.931808},
  urldate = {2024-08-06},
  abstract = {The ``obesity paradox'' exists in many diseases. It is unclear whether it also exists in acute respiratory distress syndrome (ARDS). The purpose of ...},
  langid = {english},
  pmid = {34429393},
  file = {/Users/xx20081/Zotero/storage/TRIPUS6Y/Liu et al. - 2021 - Obesity Paradox in Acute Respiratory Distress Sy.pdf}
}

@article{ljContinuedTreatmentTirzepatide2024,
  title = {Continued {{Treatment With Tirzepatide}} for {{Maintenance}} of {{Weight Reduction}} in {{Adults With Obesity}}: {{The SURMOUNT-4 Randomized Clinical Trial}}},
  shorttitle = {Continued {{Treatment With Tirzepatide}} for {{Maintenance}} of {{Weight Reduction}} in {{Adults With Obesity}}},
  author = {Lj, Aronne and N, Sattar and Db, Horn and He, Bays and S, Wharton and Wy, Lin and Nn, Ahmad and S, Zhang and R, Liao and Mc, Bunck and I, Jouravskaya and Ma, Murphy},
  year = {2024},
  month = feb,
  journal = {JAMA},
  volume = {331},
  number = {1},
  publisher = {JAMA},
  issn = {1538-3598},
  doi = {10.1001/jama.2023.24945},
  urldate = {2025-03-17},
  abstract = {ClinicalTrials.gov Identifier: NCT04660643.},
  langid = {english},
  pmid = {38078870},
  file = {/Users/xx20081/Zotero/storage/8UH549HY/38078870.html}
}

@article{ljMetabolomicSignatureWeight2024,
  title = {The Metabolomic Signature of Weight Loss and Remission in the {{Diabetes Remission Clinical Trial}} ({{DiRECT}})},
  author = {Lj, Corbin and Da, Hughes and Cj, Bull and Ee, Vincent and Ml, Smith and A, McConnachie and Cm, Messow and P, Welsh and R, Taylor and Mej, Lean and N, Sattar and Nj, Timpson},
  year = {2024},
  month = jan,
  journal = {Diabetologia},
  volume = {67},
  number = {1},
  publisher = {Diabetologia},
  issn = {1432-0428},
  doi = {10.1007/s00125-023-06019-x},
  urldate = {2025-04-07},
  abstract = {The data used for analysis are available on a research data repository ( https://researchdata.gla.ac.uk/ ) with access given to researchers subject to appropriate data sharing agreements. Metabolite data preparation, data pre-processing, statistical analyses and figure generation were performed in R {\dots}},
  langid = {english},
  pmid = {37878066},
  file = {/Users/xx20081/Zotero/storage/DA5ABXXM/Lj et al. - 2024 - The metabolomic signature of weight loss and remission in the Diabetes Remission Clinical Trial (DiR.pdf;/Users/xx20081/Zotero/storage/EG7HFWGD/37878066.html}
}

@article{lockeGeneticStudiesBody2015,
  title = {Genetic Studies of Body Mass Index Yield New Insights for Obesity Biology},
  author = {Locke, Adam E. and Kahali, Bratati and Berndt, Sonja I. and Justice, Anne E. and Pers, Tune H. and Day, Felix R. and Powell, Corey and Vedantam, Sailaja and Buchkovich, Martin L. and Yang, Jian and {Croteau-Chonka}, Damien C. and Esko, Tonu and Fall, Tove and Ferreira, Teresa and Gustafsson, Stefan and Kutalik, Zolt{\'a}n and Luan, Jian'an and M{\"a}gi, Reedik and Randall, Joshua C. and Winkler, Thomas W. and Wood, Andrew R. and Workalemahu, Tsegaselassie and Faul, Jessica D. and Smith, Jennifer A. and Zhao, Jing Hua and Zhao, Wei and Chen, Jin and Fehrmann, Rudolf and Hedman, {\AA}sa K. and Karjalainen, Juha and Schmidt, Ellen M. and Absher, Devin and Amin, Najaf and Anderson, Denise and Beekman, Marian and Bolton, Jennifer L. and {Bragg-Gresham}, Jennifer L. and Buyske, Steven and Demirkan, Ayse and Deng, Guohong and Ehret, Georg B. and Feenstra, Bjarke and Feitosa, Mary F. and Fischer, Krista and Goel, Anuj and Gong, Jian and Jackson, Anne U. and Kanoni, Stavroula and Kleber, Marcus E. and Kristiansson, Kati and Lim, Unhee and Lotay, Vaneet and Mangino, Massimo and Leach, Irene Mateo and {Medina-Gomez}, Carolina and Medland, Sarah E. and Nalls, Michael A. and Palmer, Cameron D. and Pasko, Dorota and Pechlivanis, Sonali and Peters, Marjolein J. and Prokopenko, Inga and Shungin, Dmitry and Stan{\v c}{\'a}kov{\'a}, Alena and Strawbridge, Rona J. and Sung, Yun Ju and Tanaka, Toshiko and Teumer, Alexander and Trompet, Stella and {van der Laan}, Sander W. and {van Setten}, Jessica and {Van Vliet-Ostaptchouk}, Jana V. and Wang, Zhaoming and Yengo, Lo{\"i}c and Zhang, Weihua and Isaacs, Aaron and Albrecht, Eva and {\"A}rnl{\"o}v, Johan and Arscott, Gillian M. and Attwood, Antony P. and Bandinelli, Stefania and Barrett, Amy and Bas, Isabelita N. and Bellis, Claire and Bennett, Amanda J. and Berne, Christian and Blagieva, Roza and Bl{\"u}her, Matthias and B{\"o}hringer, Stefan and Bonnycastle, Lori L. and B{\"o}ttcher, Yvonne and Boyd, Heather A. and Bruinenberg, Marcel and Caspersen, Ida H. and Chen, Yii-Der Ida and Clarke, Robert and Daw, E. Warwick and {de Craen}, Anton J. M. and Delgado, Graciela and Dimitriou, Maria and Doney, Alex S. F. and Eklund, Niina and Estrada, Karol and Eury, Elodie and Folkersen, Lasse and Fraser, Ross M. and Garcia, Melissa E. and Geller, Frank and Giedraitis, Vilmantas and Gigante, Bruna and Go, Alan S. and Golay, Alain and Goodall, Alison H. and Gordon, Scott D. and Gorski, Mathias and Grabe, Hans-J{\"o}rgen and Grallert, Harald and Grammer, Tanja B. and Gr{\"a}{\ss}ler, J{\"u}rgen and Gr{\"o}nberg, Henrik and Groves, Christopher J. and Gusto, Ga{\"e}lle and Haessler, Jeffrey and Hall, Per and Haller, Toomas and Hallmans, Goran and Hartman, Catharina A. and Hassinen, Maija and Hayward, Caroline and {Heard-Costa}, Nancy L. and Helmer, Quinta and Hengstenberg, Christian and Holmen, Oddgeir and Hottenga, Jouke-Jan and James, Alan L. and Jeff, Janina M. and Johansson, {\AA}sa and Jolley, Jennifer and Juliusdottir, Thorhildur and Kinnunen, Leena and Koenig, Wolfgang and Koskenvuo, Markku and Kratzer, Wolfgang and Laitinen, Jaana and Lamina, Claudia and Leander, Karin and Lee, Nanette R. and Lichtner, Peter and Lind, Lars and Lindstr{\"o}m, Jaana and Lo, Ken Sin and Lobbens, St{\'e}phane and Lorbeer, Roberto and Lu, Yingchang and Mach, Fran{\c c}ois and Magnusson, Patrik K. E. and Mahajan, Anubha and McArdle, Wendy L. and McLachlan, Stela and Menni, Cristina and Merger, Sigrun and Mihailov, Evelin and Milani, Lili and Moayyeri, Alireza and Monda, Keri L. and Morken, Mario A. and Mulas, Antonella and M{\"u}ller, Gabriele and {M{\"u}ller-Nurasyid}, Martina and Musk, Arthur W. and Nagaraja, Ramaiah and N{\"o}then, Markus M. and Nolte, Ilja M. and Pilz, Stefan and Rayner, Nigel W. and Renstrom, Frida and Rettig, Rainer and Ried, Janina S. and Ripke, Stephan and Robertson, Neil R. and Rose, Lynda M. and Sanna, Serena and Scharnagl, Hubert and Scholtens, Salome and Schumacher, Fredrick R. and Scott, William R. and Seufferlein, Thomas and Shi, Jianxin and Smith, Albert Vernon and Smolonska, Joanna and Stanton, Alice V. and Steinthorsdottir, Valgerdur and Stirrups, Kathleen and Stringham, Heather M. and Sundstr{\"o}m, Johan and Swertz, Morris A. and Swift, Amy J. and Syv{\"a}nen, Ann-Christine and Tan, Sian-Tsung and Tayo, Bamidele O. and Thorand, Barbara and Thorleifsson, Gudmar and Tyrer, Jonathan P. and Uh, Hae-Won and Vandenput, Liesbeth and Verhulst, Frank C. and Vermeulen, Sita H. and Verweij, Niek and Vonk, Judith M. and Waite, Lindsay L. and Warren, Helen R. and Waterworth, Dawn and Weedon, Michael N. and Wilkens, Lynne R. and Willenborg, Christina and Wilsgaard, Tom and Wojczynski, Mary K. and Wong, Andrew and Wright, Alan F. and Zhang, Qunyuan and Brennan, Eoin P. and Choi, Murim and Dastani, Zari and Drong, Alexander W. and Eriksson, Per and {Franco-Cereceda}, Anders and G{\aa}din, Jesper R. and Gharavi, Ali G. and Goddard, Michael E. and Handsaker, Robert E. and Huang, Jinyan and Karpe, Fredrik and Kathiresan, Sekar and Keildson, Sarah and Kiryluk, Krzysztof and Kubo, Michiaki and Lee, Jong-Young and Liang, Liming and Lifton, Richard P. and Ma, Baoshan and McCarroll, Steven A. and McKnight, Amy J. and Min, Josine L. and Moffatt, Miriam F. and Montgomery, Grant W. and Murabito, Joanne M. and Nicholson, George and Nyholt, Dale R. and Okada, Yukinori and Perry, John R. B. and Dorajoo, Rajkumar and Reinmaa, Eva and Salem, Rany M. and Sandholm, Niina and Scott, Robert A. and Stolk, Lisette and Takahashi, Atsushi and Tanaka, Toshihiro and {van 't Hooft}, Ferdinand M. and Vinkhuyzen, Anna A. E. and Westra, Harm-Jan and Zheng, Wei and Zondervan, Krina T. and Heath, Andrew C. and Arveiler, Dominique and Bakker, Stephan J. L. and Beilby, John and Bergman, Richard N. and Blangero, John and Bovet, Pascal and Campbell, Harry and Caulfield, Mark J. and Cesana, Giancarlo and Chakravarti, Aravinda and Chasman, Daniel I. and Chines, Peter S. and Collins, Francis S. and Crawford, Dana C. and Cupples, L. Adrienne and Cusi, Daniele and Danesh, John and {de Faire}, Ulf and {den Ruijter}, Hester M. and Dominiczak, Anna F. and Erbel, Raimund and Erdmann, Jeanette and Eriksson, Johan G. and Farrall, Martin and Felix, Stephan B. and Ferrannini, Ele and Ferri{\`e}res, Jean and Ford, Ian and Forouhi, Nita G. and Forrester, Terrence and Franco, Oscar H. and Gansevoort, Ron T. and Gejman, Pablo V. and Gieger, Christian and Gottesman, Omri and Gudnason, Vilmundur and Gyllensten, Ulf and Hall, Alistair S. and Harris, Tamara B. and Hattersley, Andrew T. and Hicks, Andrew A. and Hindorff, Lucia A. and Hingorani, Aroon D. and Hofman, Albert and Homuth, Georg and Hovingh, G. Kees and Humphries, Steve E. and Hunt, Steven C. and Hypp{\"o}nen, Elina and Illig, Thomas and Jacobs, Kevin B. and Jarvelin, Marjo-Riitta and J{\"o}ckel, Karl-Heinz and Johansen, Berit and Jousilahti, Pekka and Jukema, J. Wouter and Jula, Antti M. and Kaprio, Jaakko and Kastelein, John J. P. and {Keinanen-Kiukaanniemi}, Sirkka M. and Kiemeney, Lambertus A. and Knekt, Paul and Kooner, Jaspal S. and Kooperberg, Charles and Kovacs, Peter and Kraja, Aldi T. and Kumari, Meena and Kuusisto, Johanna and Lakka, Timo A. and Langenberg, Claudia and Marchand, Loic Le and Lehtim{\"a}ki, Terho and Lyssenko, Valeriya and M{\"a}nnist{\"o}, Satu and Marette, Andr{\'e} and Matise, Tara C. and McKenzie, Colin A. and McKnight, Barbara and Moll, Frans L. and Morris, Andrew D. and Morris, Andrew P. and Murray, Jeffrey C. and Nelis, Mari and Ohlsson, Claes and Oldehinkel, Albertine J. and Ong, Ken K. and Madden, Pamela A. F. and Pasterkamp, Gerard and Peden, John F. and Peters, Annette and Postma, Dirkje S. and Pramstaller, Peter P. and Price, Jackie F. and Qi, Lu and Raitakari, Olli T. and Rankinen, Tuomo and Rao, D. C. and Rice, Treva K. and Ridker, Paul M. and Rioux, John D. and Ritchie, Marylyn D. and Rudan, Igor and Salomaa, Veikko and Samani, Nilesh J. and Saramies, Jouko and Sarzynski, Mark A. and Schunkert, Heribert and Schwarz, Peter E. H. and Sever, Peter and Shuldiner, Alan R. and Sinisalo, Juha and Stolk, Ronald P. and Strauch, Konstantin and T{\"o}njes, Anke and Tr{\'e}gou{\"e}t, David-Alexandre and Tremblay, Angelo and Tremoli, Elena and Virtamo, Jarmo and Vohl, Marie-Claude and V{\"o}lker, Uwe and Waeber, G{\'e}rard and Willemsen, Gonneke and Witteman, Jacqueline C. and Zillikens, M. Carola and Adair, Linda S. and Amouyel, Philippe and Asselbergs, Folkert W. and Assimes, Themistocles L. and Bochud, Murielle and Boehm, Bernhard O. and Boerwinkle, Eric and Bornstein, Stefan R. and Bottinger, Erwin P. and Bouchard, Claude and Cauchi, St{\'e}phane and Chambers, John C. and Chanock, Stephen J. and Cooper, Richard S. and {de Bakker}, Paul I. W. and Dedoussis, George and Ferrucci, Luigi and Franks, Paul W. and Froguel, Philippe and Groop, Leif C. and Haiman, Christopher A. and Hamsten, Anders and Hui, Jennie and Hunter, David J. and Hveem, Kristian and Kaplan, Robert C. and Kivimaki, Mika and Kuh, Diana and Laakso, Markku and Liu, Yongmei and Martin, Nicholas G. and M{\"a}rz, Winfried and Melbye, Mads and Metspalu, Andres and Moebus, Susanne and Munroe, Patricia B. and Nj{\o}lstad, Inger and Oostra, Ben A. and Palmer, Colin N. A. and Pedersen, Nancy L. and Perola, Markus and P{\'e}russe, Louis and Peters, Ulrike and Power, Chris and Quertermous, Thomas and Rauramaa, Rainer and Rivadeneira, Fernando and Saaristo, Timo E. and Saleheen, Danish and Sattar, Naveed and Schadt, Eric E. and Schlessinger, David and Slagboom, P. Eline and Snieder, Harold and Spector, Tim D. and Thorsteinsdottir, Unnur and Stumvoll, Michael and Tuomilehto, Jaakko and Uitterlinden, Andr{\'e} G. and Uusitupa, Matti and {van der Harst}, Pim and Walker, Mark and Wallaschofski, Henri and Wareham, Nicholas J. and Watkins, Hugh and Weir, David R. and Wichmann, H-Erich and Wilson, James F. and Zanen, Pieter and Borecki, Ingrid B. and Deloukas, Panos and Fox, Caroline S. and Heid, Iris M. and O'Connell, Jeffrey R. and Strachan, David P. and Stefansson, Kari and {van Duijn}, Cornelia M. and Abecasis, Gon{\c c}alo R. and Franke, Lude and Frayling, Timothy M. and McCarthy, Mark I. and Visscher, Peter M. and Scherag, Andr{\'e} and Willer, Cristen J. and Boehnke, Michael and Mohlke, Karen L. and Lindgren, Cecilia M. and Beckmann, Jacques S. and Barroso, In{\^e}s and North, Kari E. and Ingelsson, Erik and Hirschhorn, Joel N. and Loos, Ruth J. F. and Speliotes, Elizabeth K.},
  year = {2015},
  month = feb,
  journal = {Nature},
  volume = {518},
  number = {7538},
  pages = {197--206},
  issn = {0028-0836},
  doi = {10.1038/nature14177},
  urldate = {2024-09-24},
  abstract = {Obesity is heritable and predisposes to many diseases. To understand the genetic basis of obesity better, here we conduct a genome-wide association study and Metabochip meta-analysis of body mass index (BMI), a measure commonly used to define obesity and assess adiposity, in up to 339,224 individuals. This analysis identifies 97 BMI-associated loci (P {$<$} 5 {\texttimes} 10-8), 56 of which are novel. Five loci demonstrate clear evidence of several independent association signals, and many loci have significant effects on other metabolic phenotypes. The 97 loci account for {\textasciitilde}2.7\% of BMI variation, and genome-wide estimates suggest that common variation accounts for {$>$}20\% of BMI variation. Pathway analyses provide strong support for a role of the central nervous system in obesity susceptibility and implicate new genes and pathways, including those related to synaptic function, glutamate signalling, insulin secretion/action, energy metabolism, lipid biology and adipogenesis.},
  pmcid = {PMC4382211},
  pmid = {25673413},
  file = {/Users/xx20081/Zotero/storage/7M6K4CW4/Locke et al. - 2015 - Genetic studies of body mass index yield new insights for obesity biology.pdf}
}

@article{longwellIdentificationNTerminallyDiversified2021,
  title = {Identification of {{N-Terminally Diversified GLP-1R Agonists Using Saturation Mutagenesis}} and {{Chemical Design}}},
  author = {Longwell, Chelsea K. and Hanna, Stephanie and Hartrampf, Nina and Sperberg, R. Andres Parra and Huang, Po-Ssu and Pentelute, Bradley L. and Cochran, Jennifer R.},
  year = {2021},
  month = jan,
  journal = {ACS Chemical Biology},
  volume = {16},
  number = {1},
  pages = {58--66},
  publisher = {American Chemical Society},
  issn = {1554-8929},
  doi = {10.1021/acschembio.0c00722},
  urldate = {2024-01-21},
  abstract = {The glucagon-like peptide 1 receptor (GLP-1R) is a class B G-protein coupled receptor (GPCR) and diabetes drug target expressed mainly in pancreatic {$\beta$}-cells that, when activated by its agonist glucagon-like peptide 1 (GLP-1) after a meal, stimulates insulin secretion and {$\beta$}-cell survival and proliferation. The N-terminal region of GLP-1 interacts with membrane-proximal residues of GLP-1R, stabilizing its active conformation to trigger intracellular signaling. The best-studied agonist peptides, GLP-1 and exendin-4, share sequence homology at their N-terminal region; however, modifications that can be tolerated here are not fully understood. In this work, a functional screen of GLP-1 variants with randomized N-terminal domains reveals new GLP-1R agonists and uncovers a pattern whereby a negative charge is preferred at the third position in various sequence contexts. We further tested this sequence--structure--activity principle by synthesizing peptide analogues where this position was mutated to both canonical and noncanonical amino acids. We discovered a highly active GLP-1 analogue in which the native glutamate residue three positions from the N-terminus was replaced with the sulfo-containing amino acid cysteic acid (GLP-1-CYA). The receptor binding and downstream signaling properties elicited by GLP-1-CYA were similar to the wild type GLP-1 peptide. Computational modeling identified a likely mode of interaction of the negatively charged side chain in GLP-1-CYA with an arginine on GLP-1R. This work highlights a strategy of combinatorial peptide screening coupled with chemical exploration that could be used to generate novel agonists for other receptors with peptide ligands.},
  file = {/Users/xx20081/Zotero/storage/2H2L2IU9/Longwell et al. - 2021 - Identification of N-Terminally Diversified GLP-1R .pdf}
}

@article{loosGenesThatMake2018,
  title = {Genes That Make You Fat, but Keep You Healthy},
  author = {Loos, Ruth J.F. and Kilpel{\"a}inen, Tuomas O.},
  year = {2018},
  month = nov,
  journal = {Journal of internal medicine},
  volume = {284},
  number = {5},
  pages = {450--463},
  issn = {0954-6820},
  doi = {10.1111/joim.12827},
  urldate = {2024-08-14},
  abstract = {Obesity prevalence continues to rise worldwide, posing a substantial burden on people's health and wellbeing. However, up to 45\% of obese individuals do not suffer from cardiometabolic complications, also referred to as the metabolically healthy obese (MHO). Concurrently, up to 30\% of normal weight individuals demonstrate cardiometabolic risk factors that are typically only seen in obese individuals; the so called metabolically obese normal weight (MONW). Besides lifestyle factors (physical activity, diet, smoking, {\dots}) and demographic (age, sex, ancestry) factors, innate biological mechanisms are known to contribute to the etiology of the MHO and MONW phenotypes, as well. Experimental studies in animal models have shown that adipose tissue and adipocyte biology are key players, and mechanisms such as adipose tissue expandability, fat distribution, adipogenesis, vascularization of adipose tissue, inflammation, and mitochondrial function are the main mechanisms that uncouple adiposity from its cardiometabolic comorbidities. We reviewed the current studies that take advantage of genetic association data to expand insights into the biology of MHO/MONW phenotypes. At least four genetic loci were identified through genome-wide association studies for body fat percentage (BF\%) of which the BF\%-increasing allele was associated with a protective effect on glycemic and lipid outcomes. For some -- but not all -- this association was mediated through favorable effect on body fat distribution. Other studies that aimed to characterize the genetic susceptibility of insulin resistance, found that a higher genetic susceptibility was associated with lower overall adiposity due to less fat accumulation at hips and legs, suggesting that an impaired capacity to store fat in adipose tissue may be metabolically harmful. While these genetic association studies have started to provide new insights into the biology of MHO/MONW phenotypes, purposefully designed genome-wide association studies to discover new genes in a hypothesis-free manner have not yet been performed. Clearly, a lot more work remains to be done in this field, first through gene discovery, and subsequently through functional follow-up of identified genes.},
  pmcid = {PMC6566096},
  pmid = {30144199},
  file = {/Users/xx20081/Zotero/storage/TTXH4DIU/Loos and Kilpelinen - 2018 - Genes that make you fat, but keep you healthy.pdf}
}

@article{loosGeneticsObesityDiscovery2022,
  title = {The Genetics of Obesity: From Discovery to Biology},
  shorttitle = {The Genetics of Obesity},
  author = {Loos, Ruth J. F. and Yeo, Giles S. H.},
  year = {2022},
  month = feb,
  journal = {Nature Reviews Genetics},
  volume = {23},
  number = {2},
  pages = {120--133},
  publisher = {Nature Publishing Group},
  issn = {1471-0064},
  doi = {10.1038/s41576-021-00414-z},
  urldate = {2024-04-19},
  abstract = {The prevalence of obesity has tripled over the past four decades, imposing an enormous burden on people's health. Polygenic (or common) obesity and rare, severe, early-onset monogenic obesity are often polarized as distinct diseases. However, gene discovery studies for both forms of obesity show that they have shared genetic and biological underpinnings, pointing to a key role for the brain in the control of body weight. Genome-wide association studies (GWAS) with increasing sample sizes and advances in sequencing technology are the main drivers behind a recent flurry of new discoveries. However, it is the post-GWAS, cross-disciplinary collaborations, which combine new omics technologies and analytical approaches, that have started to facilitate translation of genetic loci into meaningful biology and new avenues for treatment.},
  copyright = {2021 Springer Nature Limited},
  langid = {english},
  keywords = {Disease genetics,Endocrine system and metabolic diseases,Genetic association study,Genetic variation,Genomics},
  file = {/Users/xx20081/Zotero/storage/PQ55PQEN/Loos and Yeo - 2022 - The genetics of obesity from discovery to biology.pdf}
}

@misc{lumbersBodyMassIndex2020,
  title = {Body Mass Index and Heart Failure Risk: A Cohort Study in 1.5 Million Individuals and {{Mendelian}} Randomisation Analysis},
  shorttitle = {Body Mass Index and Heart Failure Risk},
  author = {Lumbers, R. Thomas and Katsoulis, Michail and Henry, Albert and Mordi, Ify and Lang, Chim and Hemingway, Harry and Langenberg, Claudia and Holmes, Michael V. and Sattar, Naveed and Consortium, on behalf of the HERMES},
  year = {2020},
  month = sep,
  pages = {2020.09.23.20200360},
  publisher = {medRxiv},
  doi = {10.1101/2020.09.23.20200360},
  urldate = {2025-01-06},
  abstract = {{$<$}img class="highwire-fragment fragment-image" alt="Figure" src="https://www.medrxiv.org/content/medrxiv/early/2020/09/25/2020.09.23.20200360.1/F1.medium.gif" width="440" height="228"/{$>$}Download figureOpen in new tab Aims Elevated body mass index (BMI) is a known risk factor for heart failure (HF), however, the underlying mechanisms are incompletely understood. The aim of this study was to investigate the role of common HF risk factors as potential mediators. Methods and Results Electronic health record data from primary care, hospital admissions and death registrations in England were used to perform an observational analysis. Data for 1.5 million individuals aged {$\geq$}18 years, with BMI measurements and free from heart failure at baseline, were included between 1998 and 2016. Cox models were used to estimate the association between BMI and HF with and without adjustment for atrial fibrillation (AF), diabetes mellitus (DM), coronary heart disease (CHD), and hypertension (HTN). Univariable and multivariable two-sample Mendelian randomisation was performed to estimate causal effects.Among non-underweight individuals, BMI was positively associated with HF with a 1-SD ({$\sim$} 4.8kg/m2) higher BMI associated with a hazard ratio (HR) of 1.31 (1.30, 1.32). Genetically predicted BMI yielded a causal odds ratio (OR) of 1.64 per 4.8 kg/m2 BMI (1.58, 1.70) which attenuated by 41\% (to OR of 1.38 (95\% CI 1.31-1.45), when simultaneously accounting for AF, DM, CHD and SBP. Conclusion About 40\% of the excess risk of HF due to adiposity is driven by SBP, AF, DM and CHD. These findings highlight the importance of the prevention and treatment of excess adiposity and downstream HF risk factors to prevent HF, even in people in whom the above risk factors are well managed. One-sentence summary This study of the role of excess adiposity as a risk factor for HF, including an observational analysis of measured BMI 1.5 million individuals and multivariable MR analysis of genetically elevated BMI, provides evidence that adiposity is causally associated with HF, with approximately 40\% of the effect being mediated by conventional risk pathways.},
  archiveprefix = {medRxiv},
  copyright = {{\copyright} 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/CBGAXGA2/Lumbers et al. - 2020 - Body mass index and heart failure risk a cohort study in 1.5 million individuals and Mendelian rand.pdf}
}

@article{lumbersGenomicsHeartFailure2021,
  title = {The Genomics of Heart Failure: Design and Rationale of the {{HERMES}} Consortium},
  shorttitle = {The Genomics of Heart Failure},
  author = {Lumbers, R. Thomas and Shah, Sonia and Lin, Honghuang and Czuba, Tomasz and Henry, Albert and Swerdlow, Daniel I. and M{\"a}larstig, Anders and Andersson, Charlotte and Verweij, Niek and Holmes, Michael V. and {\"A}rnl{\"o}v, Johan and Svensson, Per and Hemingway, Harry and Sallah, Neneh and Almgren, Peter and Aragam, Krishna G. and Asselin, Geraldine and Backman, Joshua D. and Biggs, Mary L. and Bloom, Heather L. and Boersma, Eric and Brandimarto, Jeffrey and Brown, Michael R. and {Brunner-La Rocca}, Hans-Peter and Carey, David J. and Chaffin, Mark D. and Chasman, Daniel I. and Chazara, Olympe and Chen, Xing and Chen, Xu and Chung, Jonathan H. and Chutkow, William and Cleland, John G.F. and Cook, James P. and {de Denus}, Simon and Dehghan, Abbas and Delgado, Graciela E. and Denaxas, Spiros and Doney, Alexander S. and D{\"o}rr, Marcus and Dudley, Samuel C. and Engstr{\"o}m, Gunnar and Esko, T{\~o}nu and Fatemifar, Ghazaleh and Felix, Stephan B. and Finan, Chris and Ford, Ian and Fougerousse, Francoise and Fouodjio, Ren{\'e} and Ghanbari, Mohsen and Ghasemi, Sahar and Giedraitis, Vilmantas and Giulianini, Franco and Gottdiener, John S. and Gross, Stefan and Gu{\dh}bjartsson, Dan{\'i}el F. and Gui, Hongsheng and Gutmann, Rebecca and Haggerty, Christopher M. and {van der Harst}, Pim and Hedman, {\AA}sa K. and Helgadottir, Anna and Hillege, Hans and Hyde, Craig L. and Jacob, Jaison and Jukema, J. Wouter and Kamanu, Frederick and Kardys, Isabella and Kavousi, Maryam and Khaw, Kay-Tee and Kleber, Marcus E. and K{\o}ber, Lars and Koekemoer, Andrea and Kraus, Bill and Kuchenbaecker, Karoline and Langenberg, Claudia and Lind, Lars and Lindgren, Cecilia M. and London, Barry and Lotta, Luca A. and Lovering, Ruth C. and Luan, Jian'an and Magnusson, Patrik and Mahajan, Anubha and Mann, Douglas and Margulies, Kenneth B. and Marston, Nicholas A. and M{\"a}rz, Winfried and McMurray, John J.V. and Melander, Olle and Melloni, Giorgio and Mordi, Ify R. and Morley, Michael P. and Morris, Andrew D. and Morris, Andrew P. and Morrison, Alanna C. and Nagle, Michael W. and Nelson, Christopher P. and {Newton-Cheh}, Christopher and Niessner, Alexander and Niiranen, Teemu and Nowak, Christoph and O'Donoghue, Michelle L. and Owens, Anjali T. and Palmer, Colin N.A. and Par{\'e}, Guillaume and Perola, Markus and Perreault, Louis-Philippe Lemieux and {Portilla-Fernandez}, Eliana and Psaty, Bruce M. and Rice, Kenneth M. and Ridker, Paul M. and Romaine, Simon P.R. and Roselli, Carolina and Rotter, Jerome I. and Ruff, Christian T. and Sabatine, Marc S. and Salo, Perttu and Salomaa, Veikko and {van Setten}, Jessica and Shalaby, Alaa A. and Smelser, Diane T. and Smith, Nicholas L. and Stefansson, Kari and Stender, Steen and Stott, David J. and Sveinbj{\"o}rnsson, Gar{\dh}ar and Tammesoo, Mari-Liis and Tardif, Jean-Claude and Taylor, Kent D. and {Teder-Laving}, Maris and Teumer, Alexander and Thorgeirsson, Gu{\dh}mundur and Thorsteinsdottir, Unnur and {Torp-Pedersen}, Christian and Trompet, Stella and Tuckwell, Danny and Tyl, Benoit and Uitterlinden, Andre G. and Vaura, Felix and Veluchamy, Abirami and Visscher, Peter M. and V{\"o}lker, Uwe and Voors, Adriaan A. and Wang, Xiaosong and Wareham, Nicholas J. and Weeke, Peter E. and Weiss, Raul and White, Harvey D. and Wiggins, Kerri L. and Xing, Heming and Yang, Jian and Yang, Yifan and {Yerges-Armstrong}, Laura M. and Yu, Bing and Zannad, Faiez and Zhao, Faye and Center, Regeneron Genetics and Wilk, Jemma B. and Holm, Hilma and Sattar, Naveed and Lubitz, Steven A. and Lanfear, David E. and Shah, Svati and Dunn, Michael E. and Wells, Quinn S. and Asselbergs, Folkert W. and Hingorani, Aroon D. and Dub{\'e}, Marie-Pierre and Samani, Nilesh J. and Lang, Chim C. and Cappola, Thomas P. and Ellinor, Patrick T. and Vasan, Ramachandran S. and Smith, J. Gustav},
  year = {2021},
  journal = {ESC Heart Failure},
  volume = {8},
  number = {6},
  pages = {5531--5541},
  issn = {2055-5822},
  doi = {10.1002/ehf2.13517},
  urldate = {2024-08-09},
  abstract = {Aims The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34--90\%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80\% power to genetic variant associations with risk of heart failure with an odds ratio of {$\geq$}1.10 for common variants (allele frequency {$\geq$} 0.05) and {$\geq$}1.20 for low-frequency variants (allele frequency 0.01--0.05) at P {$<$} 5 {\texttimes} 10-8 under an additive genetic model. Conclusions HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.},
  copyright = {{\copyright} 2021 The Authors. ESC Heart Failure published by John Wiley \& Sons Ltd on behalf of European Society of Cardiology.},
  langid = {english},
  keywords = {Association studies,Biomarkers,Cardiomyopathy,Genetics,Heart failure},
  file = {/Users/xx20081/Zotero/storage/F6GGB84J/Lumbers et al. - 2021 - The genomics of heart failure design and rational.pdf;/Users/xx20081/Zotero/storage/PW7AD3YR/ehf2.html}
}

@article{lvBodyMassIndex2024,
  title = {Body Mass Index, Waist Circumference, and Mortality in Subjects Older than 80 Years: A {{Mendelian}} Randomization Study},
  shorttitle = {Body Mass Index, Waist Circumference, and Mortality in Subjects Older than 80 Years},
  author = {Lv, Yuebin and Zhang, Yue and Li, Xinwei and Gao, Xiang and Ren, Yongyong and Deng, Luojia and Xu, Lanjing and Zhou, Jinhui and Wu, Bing and Wei, Yuan and Cui, Xingyao and Xu, Zinan and Guo, Yanbo and Qiu, Yidan and Ye, Lihong and Chen, Chen and Wang, Jun and Li, Chenfeng and Luo, Yufei and Yin, Zhaoxue and Mao, Chen and Yu, Qiong and Lu, Hui and Kraus, Virginia Byers and Zeng, Yi and Tong, Shilu and Shi, Xiaoming},
  year = {2024},
  month = jun,
  journal = {European Heart Journal},
  volume = {45},
  number = {24},
  pages = {2145--2154},
  issn = {1522-9645},
  doi = {10.1093/eurheartj/ehae206},
  abstract = {BACKGROUND AND AIMS: Emerging evidence has raised an obesity paradox in observational studies of body mass index (BMI) and health among the oldest-old (aged {$\geq$}80 years), as an inverse relationship of BMI with mortality was reported. This study was to investigate the causal associations of BMI, waist circumference (WC), or both with mortality in the oldest-old people in China. METHODS: A total of 5306 community-based oldest-old (mean age 90.6 years) were enrolled in the Chinese Longitudinal Healthy Longevity Survey (CLHLS) between 1998 and 2018. Genetic risk scores were constructed from 58 single-nucleotide polymorphisms (SNPs) associated with BMI and 49 SNPs associated with WC to subsequently derive causal estimates for Mendelian randomization (MR) models. One-sample linear MR along with non-linear MR analyses were performed to explore the associations of genetically predicted BMI, WC, and their joint effect with all-cause mortality, cardiovascular disease (CVD) mortality, and non-CVD mortality. RESULTS: During 24 337 person-years of follow-up, 3766 deaths were documented. In observational analyses, higher BMI and WC were both associated with decreased mortality risk [hazard ratio (HR) 0.963, 95\% confidence interval (CI) 0.955-0.971 for a 1-kg/m2 increment of BMI and HR 0.971 (95\% CI 0.950-0.993) for each 5\>cm increase of WC]. Linear MR models indicated that each 1 kg/m2 increase in genetically predicted BMI was monotonically associated with a 4.5\% decrease in all-cause mortality risk [HR 0.955 (95\% CI 0.928-0.983)]. Non-linear curves showed the lowest mortality risk at the BMI of around 28.0\>kg/m2, suggesting that optimal BMI for the oldest-old may be around overweight or mild obesity. Positive monotonic causal associations were observed between WC and all-cause mortality [HR 1.108 (95\% CI 1.036-1.185) per 5\>cm increase], CVD mortality [HR 1.193 (95\% CI 1.064-1.337)], and non-CVD mortality [HR 1.110 (95\% CI 1.016-1.212)]. The joint effect analyses indicated that the lowest risk was observed among those with higher BMI and lower WC. CONCLUSIONS: Among the oldest-old, opposite causal associations of BMI and WC with mortality were observed, and a body figure with higher BMI and lower WC could substantially decrease the mortality risk. Guidelines for the weight management should be cautiously designed and implemented among the oldest-old people, considering distinct roles of BMI and WC.},
  langid = {english},
  pmcid = {PMC11212828},
  pmid = {38626306},
  keywords = {Aged 80 and over,Body mass index,Body Mass Index,Cardiovascular Diseases,Causal inference,Cause of Death,China,Female,Humans,Male,Mendelian randomization,Mendelian Randomization Analysis,Mortality,Obesity,Polymorphism Single Nucleotide,Risk Factors,Waist circumference,Waist Circumference}
}

@article{lyuIdentificationCausalPlasma2025,
  title = {Identification of Causal Plasma Metabolite Biomarkers for Ischemic Stroke Using {{Mendelian}} Randomization and Mediation Analysis},
  author = {Lyu, Jian and Liu, Fumei and Chai, Yan and Wang, Xiting and Liu, Yi and Xie, Yanming},
  year = {2025},
  month = may,
  journal = {Scientific Reports},
  volume = {15},
  number = {1},
  pages = {16789},
  publisher = {Nature Publishing Group},
  issn = {2045-2322},
  doi = {10.1038/s41598-025-01329-z},
  urldate = {2025-06-10},
  abstract = {The Global Burden of Disease Study 2021 reports that stroke remains a leading cause of death, with ischemic stroke (IS) presenting significant challenges in screening, prevention, and treatment. We explored the causal effects of 1,400 plasma metabolites on IS outcomes using a two-sample Mendelian randomization (MR) framework. We assessed causal relationships between IS and 11 common clinical risk factors and further examined these relationships for metabolites. Mediation analysis identified mechanisms for metabolites affecting both IS and its risk factors. Finally, a phenome-wide association study (PheWAS) MR analysis evaluated the side effects and additional indications of IS-associated metabolites across 3,948 phenotypes from the UKBB GWAS. Nineteen metabolites showed a causal relationship with IS. MR analysis confirmed body mass index (BMI), high-density lipoprotein (HDL), systolic blood pressure (SBP), diastolic blood pressure (DBP), and type 2 diabetes (T2D) as risk factors for IS. Among 136 metabolites associated with at least one IS risk factor, 132 were linked to risk factors but not directly to IS. BMI, DBP, and coffee intake mediated the causal relationship between IS and the levels of 1-stearoyl-GPG (18:0), 1-oleoyl-2-linoleoyl-GPE (18:1/18:2), Octadecadienedioate (C18:2-DC), and X-24,951. Phe-MR analysis indicated that these metabolites were protective and affected other indications similarly to IS. Our findings reveal causal pathways and identify four potential biomarkers for IS, providing new insights for its screening, prevention, and treatment.},
  copyright = {2025 The Author(s)},
  langid = {english},
  keywords = {Biomarkers,Neuroscience,Risk factors},
  file = {/Users/xx20081/Zotero/storage/MQ7UHTJ5/Lyu et al. - 2025 - Identification of causal plasma metabolite biomarkers for ischemic stroke using Mendelian randomizat.pdf}
}

@article{maEffectsWeightLoss2017,
  title = {Effects of Weight Loss Interventions for Adults Who Are Obese on Mortality, Cardiovascular Disease, and Cancer: Systematic Review and Meta-Analysis},
  shorttitle = {Effects of Weight Loss Interventions for Adults Who Are Obese on Mortality, Cardiovascular Disease, and Cancer},
  author = {Ma, Chenhan and Avenell, Alison and Bolland, Mark and Hudson, Jemma and Stewart, Fiona and Robertson, Clare and Sharma, Pawana and Fraser, Cynthia and MacLennan, Graeme},
  year = {2017},
  month = nov,
  journal = {BMJ},
  volume = {359},
  pages = {j4849},
  publisher = {British Medical Journal Publishing Group},
  issn = {0959-8138, 1756-1833},
  doi = {10.1136/bmj.j4849},
  urldate = {2024-08-06},
  abstract = {Objective To assess whether weight loss interventions for adults with obesity affect all cause, cardiovascular, and cancer mortality, cardiovascular disease, cancer, and body weight. Design Systematic review and meta-analysis of randomised controlled trials (RCTs) using random effects, estimating risk ratios, and mean differences. Heterogeneity investigated using Cochran's Q and I2 statistics. Quality of evidence assessed by GRADE criteria. Data sources Medline, Embase, the Cochrane Central Register of Controlled Trials, and full texts in our trials' registry for data not evident in databases. Authors were contacted for unpublished data. Eligibility criteria for selecting studies RCTs of dietary interventions targeting weight loss, with or without exercise advice or programmes, for adults with obesity and follow-up {$\geq$}1 year. Results 54 RCTs with 30 206 participants were identified. All but one trial evaluated low fat, weight reducing diets. For the primary outcome, high quality evidence showed that weight loss interventions decrease all cause mortality (34 trials, 685 events; risk ratio 0.82, 95\% confidence interval 0.71 to 0.95), with six fewer deaths per 1000 participants (95\% confidence interval two to 10). For other primary outcomes moderate quality evidence showed an effect on cardiovascular mortality (eight trials, 134 events; risk ratio 0.93, 95\% confidence interval 0.67 to 1.31), and very low quality evidence showed an effect on cancer mortality (eight trials, 34 events; risk ratio 0.58, 95\% confidence interval 0.30 to 1.11). Twenty four trials (15 176 participants) reported high quality evidence on participants developing new cardiovascular events (1043 events; risk ratio 0.93, 95\% confidence interval 0.83 to 1.04). Nineteen trials (6330 participants) provided very low quality evidence on participants developing new cancers (103 events; risk ratio 0.92, 95\% confidence interval 0.63 to 1.36). Conclusions Weight reducing diets, usually low in fat and saturated fat, with or without exercise advice or programmes, may reduce premature all cause mortality in adults with obesity. Systematic review registration PROSPERO CRD42016033217.},
  chapter = {Research},
  copyright = {Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.},
  langid = {english},
  pmid = {29138133},
  file = {/Users/xx20081/Zotero/storage/ET8LCIZF/Ma et al. - 2017 - Effects of weight loss interventions for adults wh.pdf}
}

@article{magiGWAMASoftwareGenomewide2010,
  title = {{{GWAMA}}: Software for Genome-Wide Association Meta-Analysis},
  shorttitle = {{{GWAMA}}},
  author = {M{\"a}gi, Reedik and Morris, Andrew P.},
  year = {2010},
  month = may,
  journal = {BMC Bioinformatics},
  volume = {11},
  number = {1},
  pages = {288},
  issn = {1471-2105},
  doi = {10.1186/1471-2105-11-288},
  urldate = {2024-04-08},
  abstract = {Despite the recent success of genome-wide association studies in identifying novel loci contributing effects to complex human traits, such as type 2 diabetes and obesity, much of the genetic component of variation in these phenotypes remains unexplained. One way to improving power to detect further novel loci is through meta-analysis of studies from the same population, increasing the sample size over any individual study. Although statistical software analysis packages incorporate routines for meta-analysis, they are ill equipped to meet the challenges of the scale and complexity of data generated in genome-wide association studies.},
  keywords = {Allelic Effect,Manhattan Plot,Reference Allele,Reference Panel,Wellcome Trust Case Control Consortium},
  file = {/Users/xx20081/Zotero/storage/3LHFHWHQ/Mgi and Morris - 2010 - GWAMA software for genome-wide association meta-a.pdf;/Users/xx20081/Zotero/storage/LXPM56IZ/1471-2105-11-288.html}
}

@article{mahajanMultiancestryGeneticStudy2022,
  title = {Multi-Ancestry Genetic Study of Type 2 Diabetes Highlights the Power of Diverse Populations for Discovery and Translation},
  author = {Mahajan, Anubha and Spracklen, Cassandra N. and Zhang, Weihua and Ng, Maggie C. Y. and Petty, Lauren E. and Kitajima, Hidetoshi and Yu, Grace Z. and R{\"u}eger, Sina and Speidel, Leo and Kim, Young Jin and Horikoshi, Momoko and Mercader, Josep M. and Taliun, Daniel and Moon, Sanghoon and Kwak, Soo-Heon and Robertson, Neil R. and Rayner, Nigel W. and Loh, Marie and Kim, Bong-Jo and Chiou, Joshua and {Miguel-Escalada}, Irene and {della Briotta Parolo}, Pietro and Lin, Kuang and Bragg, Fiona and Preuss, Michael H. and Takeuchi, Fumihiko and Nano, Jana and Guo, Xiuqing and Lamri, Amel and Nakatochi, Masahiro and Scott, Robert A. and Lee, Jung-Jin and {Huerta-Chagoya}, Alicia and Graff, Mariaelisa and Chai, Jin-Fang and Parra, Esteban J. and Yao, Jie and Bielak, Lawrence F. and Tabara, Yasuharu and Hai, Yang and Steinthorsdottir, Valgerdur and Cook, James P. and Kals, Mart and Grarup, Niels and Schmidt, Ellen M. and Pan, Ian and Sofer, Tamar and Wuttke, Matthias and Sarnowski, Chloe and Gieger, Christian and Nousome, Darryl and Trompet, Stella and Long, Jirong and Sun, Meng and Tong, Lin and Chen, Wei-Min and Ahmad, Meraj and Noordam, Raymond and Lim, Victor J. Y. and Tam, Claudia H. T. and Joo, Yoonjung Yoonie and Chen, Chien-Hsiun and Raffield, Laura M. and Lecoeur, C{\'e}cile and Prins, Bram Peter and Nicolas, Aude and Yanek, Lisa R. and Chen, Guanjie and Jensen, Richard A. and Tajuddin, Salman and Kabagambe, Edmond K. and An, Ping and Xiang, Anny H. and Choi, Hyeok Sun and Cade, Brian E. and Tan, Jingyi and Flanagan, Jack and Abaitua, Fernando and Adair, Linda S. and Adeyemo, Adebowale and {Aguilar-Salinas}, Carlos A. and Akiyama, Masato and Anand, Sonia S. and Bertoni, Alain and Bian, Zheng and {Bork-Jensen}, Jette and Brandslund, Ivan and Brody, Jennifer A. and Brummett, Chad M. and Buchanan, Thomas A. and Canouil, Micka{\"e}l and Chan, Juliana C. N. and Chang, Li-Ching and Chee, Miao-Li and Chen, Ji and Chen, Shyh-Huei and Chen, Yuan-Tsong and Chen, Zhengming and Chuang, Lee-Ming and Cushman, Mary and Das, Swapan K. and {de Silva}, H. Janaka and Dedoussis, George and Dimitrov, Latchezar and Doumatey, Ayo P. and Du, Shufa and Duan, Qing and Eckardt, Kai-Uwe and Emery, Leslie S. and Evans, Daniel S. and Evans, Michele K. and Fischer, Krista and Floyd, James S. and Ford, Ian and Fornage, Myriam and Franco, Oscar H. and Frayling, Timothy M. and Freedman, Barry I. and Fuchsberger, Christian and Genter, Pauline and Gerstein, Hertzel C. and Giedraitis, Vilmantas and {Gonz{\'a}lez-Villalpando}, Clicerio and {Gonz{\'a}lez-Villalpando}, Maria Elena and Goodarzi, Mark O. and {Gordon-Larsen}, Penny and Gorkin, David and Gross, Myron and Guo, Yu and Hackinger, Sophie and Han, Sohee and Hattersley, Andrew T. and Herder, Christian and Howard, Annie-Green and Hsueh, Willa and Huang, Mengna and Huang, Wei and Hung, Yi-Jen and Hwang, Mi Yeong and Hwu, Chii-Min and Ichihara, Sahoko and Ikram, Mohammad Arfan and Ingelsson, Martin and Islam, Md Tariqul and Isono, Masato and Jang, Hye-Mi and Jasmine, Farzana and Jiang, Guozhi and Jonas, Jost B. and J{\o}rgensen, Marit E. and J{\o}rgensen, Torben and Kamatani, Yoichiro and Kandeel, Fouad R. and Kasturiratne, Anuradhani and Katsuya, Tomohiro and Kaur, Varinderpal and Kawaguchi, Takahisa and Keaton, Jacob M. and Kho, Abel N. and Khor, Chiea-Chuen and Kibriya, Muhammad G. and Kim, Duk-Hwan and Kohara, Katsuhiko and Kriebel, Jennifer and Kronenberg, Florian and Kuusisto, Johanna and L{\"a}ll, Kristi and Lange, Leslie A. and Lee, Myung-Shik and Lee, Nanette R. and Leong, Aaron and Li, Liming and Li, Yun and {Li-Gao}, Ruifang and Ligthart, Symen and Lindgren, Cecilia M. and Linneberg, Allan and Liu, Ching-Ti and Liu, Jianjun and Locke, Adam E. and Louie, Tin and Luan, Jian'an and Luk, Andrea O. and Luo, Xi and Lv, Jun and Lyssenko, Valeriya and Mamakou, Vasiliki and Mani, K. Radha and Meitinger, Thomas and Metspalu, Andres and Morris, Andrew D. and Nadkarni, Girish N. and Nadler, Jerry L. and Nalls, Michael A. and Nayak, Uma and Nongmaithem, Suraj S. and Ntalla, Ioanna and Okada, Yukinori and Orozco, Lorena and Patel, Sanjay R. and Pereira, Mark A. and Peters, Annette and Pirie, Fraser J. and Porneala, Bianca and Prasad, Gauri and Preissl, Sebastian and {Rasmussen-Torvik}, Laura J. and Reiner, Alexander P. and Roden, Michael and Rohde, Rebecca and Roll, Kathryn and Sabanayagam, Charumathi and Sander, Maike and Sandow, Kevin and Sattar, Naveed and Sch{\"o}nherr, Sebastian and Schurmann, Claudia and Shahriar, Mohammad and Shi, Jinxiu and Shin, Dong Mun and Shriner, Daniel and Smith, Jennifer A. and So, Wing Yee and Stan{\v c}{\'a}kov{\'a}, Alena and Stilp, Adrienne M. and Strauch, Konstantin and Suzuki, Ken and Takahashi, Atsushi and Taylor, Kent D. and Thorand, Barbara and Thorleifsson, Gudmar and Thorsteinsdottir, Unnur and Tomlinson, Brian and Torres, Jason M. and Tsai, Fuu-Jen and Tuomilehto, Jaakko and {Tusie-Luna}, Teresa and Udler, Miriam S. and {Valladares-Salgado}, Adan and {van Dam}, Rob M. and {van Klinken}, Jan B. and Varma, Rohit and Vujkovic, Marijana and {Wacher-Rodarte}, Niels and Wheeler, Eleanor and Whitsel, Eric A. and Wickremasinghe, Ananda R. and {van Dijk}, Ko Willems and Witte, Daniel R. and Yajnik, Chittaranjan S. and Yamamoto, Ken and Yamauchi, Toshimasa and Yengo, Lo{\"i}c and Yoon, Kyungheon and Yu, Canqing and Yuan, Jian-Min and Yusuf, Salim and Zhang, Liang and Zheng, Wei and Raffel, Leslie J. and Igase, Michiya and Ipp, Eli and Redline, Susan and Cho, Yoon Shin and Lind, Lars and Province, Michael A. and Hanis, Craig L. and Peyser, Patricia A. and Ingelsson, Erik and Zonderman, Alan B. and Psaty, Bruce M. and Wang, Ya-Xing and Rotimi, Charles N. and Becker, Diane M. and Matsuda, Fumihiko and Liu, Yongmei and Zeggini, Eleftheria and Yokota, Mitsuhiro and Rich, Stephen S. and Kooperberg, Charles and Pankow, James S. and Engert, James C. and Chen, Yii-Der Ida and Froguel, Philippe and Wilson, James G. and Sheu, Wayne H. H. and Kardia, Sharon L. R. and Wu, Jer-Yuarn and Hayes, M. Geoffrey and Ma, Ronald C. W. and Wong, Tien-Yin and Groop, Leif and {Mook-Kanamori}, Dennis O. and Chandak, Giriraj R. and Collins, Francis S. and Bharadwaj, Dwaipayan and Par{\'e}, Guillaume and Sale, Mich{\`e}le M. and Ahsan, Habibul and Motala, Ayesha A. and Shu, Xiao-Ou and Park, Kyong-Soo and Jukema, J. Wouter and Cruz, Miguel and {McKean-Cowdin}, Roberta and Grallert, Harald and Cheng, Ching-Yu and Bottinger, Erwin P. and Dehghan, Abbas and Tai, E.-Shyong and Dupuis, Jos{\'e}e and Kato, Norihiro and Laakso, Markku and K{\"o}ttgen, Anna and Koh, Woon-Puay and Palmer, Colin N. A. and Liu, Simin and Abecasis, Goncalo and Kooner, Jaspal S. and Loos, Ruth J. F. and North, Kari E. and Haiman, Christopher A. and Florez, Jose C. and Saleheen, Danish and Hansen, Torben and Pedersen, Oluf and M{\"a}gi, Reedik and Langenberg, Claudia and Wareham, Nicholas J. and Maeda, Shiro and Kadowaki, Takashi and Lee, Juyoung and Millwood, Iona Y. and Walters, Robin G. and Stefansson, Kari and Myers, Simon R. and Ferrer, Jorge and Gaulton, Kyle J. and Meigs, James B. and Mohlke, Karen L. and Gloyn, Anna L. and Bowden, Donald W. and Below, Jennifer E. and Chambers, John C. and Sim, Xueling and Boehnke, Michael and Rotter, Jerome I. and McCarthy, Mark I. and Morris, Andrew P.},
  year = {2022},
  month = may,
  journal = {Nature Genetics},
  volume = {54},
  number = {5},
  pages = {560--572},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-022-01058-3},
  urldate = {2024-09-02},
  abstract = {We assembled an ancestrally diverse collection of genome-wide association studies (GWAS) of type 2 diabetes (T2D) in 180,834 affected individuals and 1,159,055 controls (48.9\% non-European descent) through the Diabetes Meta-Analysis of Trans-Ethnic association studies (DIAMANTE) Consortium. Multi-ancestry GWAS meta-analysis identified 237 loci attaining stringent genome-wide significance (P\,{$<$}\,5\,{\texttimes}\,10-9), which were delineated to 338 distinct association signals. Fine-mapping of these signals was enhanced by the increased sample size and expanded population diversity of the multi-ancestry meta-analysis, which localized 54.4\% of T2D associations to a single variant with {$>$}50\% posterior probability. This improved fine-mapping enabled systematic assessment of candidate causal genes and molecular mechanisms through which T2D associations are mediated, laying the foundations for functional investigations. Multi-ancestry genetic risk scores enhanced transferability of T2D prediction across diverse populations. Our study provides a step toward more effective clinical translation of T2D GWAS to improve global health for all, irrespective of genetic background.},
  copyright = {2022 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  keywords = {Genome-wide association studies,Type 2 diabetes},
  file = {/Users/xx20081/Zotero/storage/P3TDDTFU/Mahajan et al. - 2022 - Multi-ancestry genetic study of type 2 diabetes hi.pdf}
}

@article{mahmoudRobustMethodCollider2022,
  title = {A Robust Method for Collider Bias Correction in Conditional Genome-Wide Association Studies},
  author = {Mahmoud, Osama and Dudbridge, Frank and Davey Smith, George and Munafo, Marcus and Tilling, Kate},
  year = {2022},
  month = feb,
  journal = {Nature Communications},
  volume = {13},
  number = {1},
  pages = {619},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-022-28119-9},
  urldate = {2024-03-08},
  abstract = {Estimated genetic associations with prognosis, or conditional on a phenotype (e.g. disease incidence), may be affected by collider bias, whereby conditioning on the phenotype induces associations between causes of the phenotype and prognosis. We propose a method, `Slope-Hunter', that uses model-based clustering to identify and utilise the class of variants only affecting the phenotype to estimate the adjustment factor, assuming this class explains more variation in the phenotype than any other variant classes. Simulation studies show that our approach eliminates the bias and outperforms alternatives even in the presence of genetic correlation. In a study of fasting blood insulin levels (FI) conditional on body mass index, we eliminate paradoxical associations of the underweight loci: COBLLI; PPARG with increased FI, and reveal an association for the locus rs1421085 (FTO). In an analysis of a case-only study for breast cancer mortality, a single region remains associated with more pronounced results.},
  copyright = {2022 The Author(s)},
  langid = {english},
  keywords = {Computational models,Epidemiology,Genetics research,Machine learning,Risk factors},
  file = {/Users/xx20081/Zotero/storage/WBHRXICU/Mahmoud et al. - 2022 - A robust method for collider bias correction in co.pdf}
}

@article{mandviwalaObesityParadoxMortality2020,
  title = {Obesity and the Paradox of Mortality and Heart Failure Hospitalization in Heart Failure with Preserved Ejection Fraction},
  author = {Mandviwala, Taher M. and Basra, Sukhdeep S. and Khalid, Umair and Pickett, June K. and Przybylowicz, Ryle and Shah, Tina and Nambi, Vijay and Virani, Salim S. and Deswal, Anita},
  year = {2020},
  month = jul,
  journal = {International Journal of Obesity (2005)},
  volume = {44},
  number = {7},
  pages = {1561--1567},
  issn = {1476-5497},
  doi = {10.1038/s41366-020-0563-1},
  abstract = {BACKGROUND: Limited data exist on the association of obesity with both hospitalization and mortality in patients with heart failure with preserved ejection fraction (HFpEF), especially in the real-world ambulatory setting. We hypothesized that increasing body-mass index (BMI) in ambulatory heart failure with preserved ejection fraction would have a protective effect on these patients leading to decreased mortality and hospitalizations. METHODS: We studied the relationship between BMI and the time to all-cause mortality, time to heart failure (HF) hospitalization, and time to all-cause hospitalization over a 2-year follow-up in a national cohort of 2501 ambulatory HFpEF patients at 153 Veterans Affairs medical centers. RESULTS: Compared with normal BMI, overweight (HR 0.72; 95\%\,CI 0.57-0.91), obesity class I (HR 0.59; 95\%\,CI 0.45-0.77), obesity class II (HR 0.56; 95\%\,CI 0.40-0.77), and obesity class III (HR 0.53; 95\%\,CI 0.36-0.77) were associated with improved survival after adjustment for demographics and comorbidities. In contrast, the time to HF hospitalization showed an inverse relationship, with shorter time to HF hospitalization with increasing BMI compared with normal BMI; overweight (adjusted HR 1.30; 95\%\,CI 0.88-1.90), obesity class I (HR 1.57; 95\%\,CI 1.05-2.34), obesity class II (HR 1.79; 95\%\,CI 1.15-2.78), and obesity class III (HR 1.96; 95\%\,CI 1.23-3.12). However, time to first all-cause hospitalization was not significantly different by BMI groups. CONCLUSIONS: In a large, national ambulatory HFpEF cohort, despite the presence of the obesity paradox with respect to survival, increasing BMI was independently associated with an increased risk of HF hospitalization and similar risk of all-cause hospitalization. Future longer-term prospective trials evaluating the safety and efficacy of weight loss on morbidity and mortality, in patients with severe obesity and HFpEF are needed.},
  langid = {english},
  pmid = {32483205},
  keywords = {Aged,Aged 80 and over,Body Mass Index,Female,Heart Failure,Hospitalization,Hospitals Veterans,Humans,Male,Middle Aged,Obesity,Overweight,Retrospective Studies,United States},
  file = {/Users/xx20081/Zotero/storage/DHXE4CVQ/Mandviwala et al. - 2020 - Obesity and the paradox of mortality and heart fai.pdf}
}

@article{mansellChangeAdiposityAssociated2023,
  title = {Change in Adiposity Is Associated with Change in Glycoprotein Acetyls but Not {{hsCRP}} in Adolescents with Severe Obesity},
  author = {Mansell, Toby and Bekkering, Siroon and Longmore, Danielle and Magnussen, Costan G. and Vlahos, Amanda and Harcourt, Brooke E. and McCallum, Zoe and Kao, Kung-Ting and Sabin, Matthew A. and Juonala, Markus and Saffery, Richard and Burgner, David P. and Saner, Christoph},
  year = {2023},
  month = jul,
  journal = {Obesity Research \& Clinical Practice},
  volume = {17},
  number = {4},
  pages = {343--348},
  issn = {1871-403X},
  doi = {10.1016/j.orcp.2023.08.003},
  urldate = {2025-05-28},
  abstract = {Background Obesity-associated chronic inflammation mediates the development of adverse cardiometabolic outcomes. There are sparse data on associations between severe obesity and inflammatory biomarkers in adolescence; most are cross-sectional and limited to acute phase reactants. Here, we investigate associations between adiposity measures and inflammatory biomarkers in children and adolescents with severe obesity both cross-sectionally and longitudinally. Methods From the Childhood Overweight Biorepository of Australia (COBRA) study, a total of n~=~262 participants, mean age 11.5 years (SD 3.5) with obesity had measures of adiposity (body mass index, BMI; \%~above the 95th BMI-centile, \%{$>$}95th BMI-centile; waist circumference, WC; waist/height ratio, WtH; \%~total body fat, \%BF; \%~truncal body fat, \%TF) and inflammation biomarkers (glycoprotein acetyls, GlycA; high-sensitivity C-Reactive Protein, hsCRP; white blood cell count, WBC; and neutrophil/lymphocyte ratio, NLR) assessed at baseline. Ninety-eight individuals at mean age of 15.9 years (3.7) participated in a follow-up study 5.6 (2.1) years later. Sixty-two individuals had longitudinal data. Linear regression models, adjusted for age and sex for cross-sectional analyses were applied. To estimate longitudinal associations between change in adiposity measures with inflammation biomarkers, models were adjusted for baseline measures of adiposity and inflammation. Results All adiposity measures were cross-sectionally associated with GlycA, hsCRP and WBC at both time points. Change in BMI, \%{$>$}95th BMI-centile, WC, WtH and \%TF were associated with concomitant change in GlycA and WBC, but not in hsCRP and NLR. Conclusion GlycA and WBC but not hsCRP and NLR may be useful in assessing adiposity-related severity of chronic inflammation over time.},
  keywords = {Adiposity,Adolescence,Children,GlycA,HsCRP,Inflammation},
  file = {/Users/xx20081/Zotero/storage/TGCVXYAH/Mansell et al. - 2023 - Change in adiposity is associated with change in glycoprotein acetyls but not hsCRP in adolescents w.pdf;/Users/xx20081/Zotero/storage/XMPEY2TV/S1871403X23000686.html}
}

@misc{Manuscript_v01,
  title = {Manuscript\_v0.1},
  journal = {Google Docs},
  urldate = {2025-05-28},
  abstract = {Metabolomic signature of weight loss and association with disease outcomes Authors - TBC   Corresponding Author: Name:                         {\dots} Address:                     {\dots} Email:                        {\dots}@...ac.uk    Institutions:       Abstract {\dots}   Keywords Metabolomics, obesity, weight loss...},
  howpublished = {https://docs.google.com/document/d/1AYnFM7OAMLLRrHBj9fZ-LtZ1BACPkdRbPUjwgmvFAuk/edit?usp=drive\_fs\&ouid=102264126090114090145\&usp=embed\_facebook},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/77ZT5GCT/edit.html}
}

@article{maoCausalRelationshipsGLP12024,
  title = {Causal Relationships between {{GLP1}} Receptor Agonists, Blood Lipids, and Heart Failure: A Drug-Target Mendelian Randomization and Mediation Analysis},
  shorttitle = {Causal Relationships between {{GLP1}} Receptor Agonists, Blood Lipids, and Heart Failure},
  author = {Mao, Tianshi and Chen, Jie and Su, Tong and Xie, Long and Qu, Xinyan and Feng, Ruli and Pan, Yi and Wan, Jie and Cui, Xiaoyun and Jia, Wenhao and Gao, Qun and Lin, Qian},
  year = {2024},
  month = aug,
  journal = {Diabetology \& Metabolic Syndrome},
  volume = {16},
  number = {1},
  pages = {208},
  issn = {1758-5996},
  doi = {10.1186/s13098-024-01448-z},
  urldate = {2025-01-21},
  abstract = {Glucagon-like peptide-1 receptor (GLP1R) agonists have been shown to reduce major cardiovascular events in diabetic patients, but their role in heart failure (HF) remains controversial. Recent evidence implies their potential benefits on cardiometabolism such as lipid metabolism, which may contribute to lowering the risk of HF. Consequently, we designed a Mendelian randomization (MR) study to investigate the causal relationships of circulating lipids mediating GLP1R agonists in HF.},
  keywords = {Blood lipids,Glucagon-like peptide-1 receptor agonists,Heart failure,Mendelian randomization},
  file = {/Users/xx20081/Zotero/storage/JZT9VIFZ/Mao et al. - 2024 - Causal relationships between GLP1 receptor agonists, blood lipids, and heart failure a drug-target.pdf;/Users/xx20081/Zotero/storage/2LHUMUCS/s13098-024-01448-z.html}
}

@article{maoCausalRelationshipsGLP12024a,
  title = {Causal Relationships between {{GLP1}} Receptor Agonists, Blood Lipids, and Heart Failure: A Drug-Target Mendelian Randomization and Mediation Analysis},
  shorttitle = {Causal Relationships between {{GLP1}} Receptor Agonists, Blood Lipids, and Heart Failure},
  author = {Mao, Tianshi and Chen, Jie and Su, Tong and Xie, Long and Qu, Xinyan and Feng, Ruli and Pan, Yi and Wan, Jie and Cui, Xiaoyun and Jia, Wenhao and Gao, Qun and Lin, Qian},
  year = {2024},
  month = aug,
  journal = {Diabetology \& Metabolic Syndrome},
  volume = {16},
  number = {1},
  pages = {208},
  issn = {1758-5996},
  doi = {10.1186/s13098-024-01448-z},
  urldate = {2025-01-21},
  abstract = {Glucagon-like peptide-1 receptor (GLP1R) agonists have been shown to reduce major cardiovascular events in diabetic patients, but their role in heart failure (HF) remains controversial. Recent evidence implies their potential benefits on cardiometabolism such as lipid metabolism, which may contribute to lowering the risk of HF. Consequently, we designed a Mendelian randomization (MR) study to investigate the causal relationships of circulating lipids mediating GLP1R agonists in HF.},
  keywords = {Blood lipids,Glucagon-like peptide-1 receptor agonists,Heart failure,Mendelian randomization},
  file = {/Users/xx20081/Zotero/storage/NRN5CUX5/Mao et al. - 2024 - Causal relationships between GLP1 receptor agonists, blood lipids, and heart failure a drug-target.pdf;/Users/xx20081/Zotero/storage/7VYKHTEY/s13098-024-01448-z.html}
}

@article{marchiniNewMultipointMethod2007,
  title = {A New Multipoint Method for Genome-Wide Association Studies by Imputation of Genotypes},
  author = {Marchini, Jonathan and Howie, Bryan and Myers, Simon and McVean, Gil and Donnelly, Peter},
  year = {2007},
  month = jul,
  journal = {Nature Genetics},
  volume = {39},
  number = {7},
  pages = {906--913},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/ng2088},
  urldate = {2024-06-18},
  abstract = {Genome-wide association studies are set to become the method of choice for uncovering the genetic basis of human diseases. A central challenge in this area is the development of powerful multipoint methods that can detect causal variants that have not been directly genotyped. We propose a coherent analysis framework that treats the problem as one involving missing or uncertain genotypes. Central to our approach is a model-based imputation method for inferring genotypes at observed or unobserved SNPs, leading to improved power over existing methods for multipoint association mapping. Using real genome-wide association study data, we show that our approach (i) is accurate and well calibrated, (ii) provides detailed views of associated regions that facilitate follow-up studies and (iii) can be used to validate and correct data at genotyped markers. A notable future use of our method will be to boost power by combining data from genome-wide scans that use different SNP sets.},
  copyright = {2007 Springer Nature America, Inc.},
  langid = {english},
  keywords = {Agriculture,Animal Genetics and Genomics,Biomedicine,Cancer Research,Gene Function,general,Human Genetics},
  file = {/Users/xx20081/Zotero/storage/HP92DYZQ/Marchini et al. - 2007 - A new multipoint method for genome-wide associatio.pdf}
}

@article{marcksReappraisalObesityParadox2021,
  title = {Re-Appraisal of the Obesity Paradox in Heart Failure: A Meta-Analysis of Individual Data},
  shorttitle = {Re-Appraisal of the Obesity Paradox in Heart Failure},
  author = {Marcks, Nick and Aimo, Alberto and Januzzi, James L. and Vergaro, Giuseppe and Clerico, Aldo and Latini, Roberto and Meessen, Jennifer and Anand, Inder S. and Cohn, Jay N. and Gravning, J{\o}rgen and Ueland, Thor and {Bayes-Genis}, Antoni and Lup{\'o}n, Josep and {de Boer}, Rudolf A. and Yoshihisa, Akiomi and Takeishi, Yasuchika and Egstrup, Michael and Gustafsson, Ida and Gaggin, Hanna K. and Eggers, Kai M. and Huber, Kurt and Tentzeris, Ioannis and Ripoli, Andrea and Passino, Claudio and {Sanders-van Wijk}, Sandra and Emdin, Michele and {Brunner-La Rocca}, Hans-Peter},
  year = {2021},
  month = aug,
  journal = {Clinical Research in Cardiology},
  volume = {110},
  number = {8},
  pages = {1280--1291},
  issn = {1861-0692},
  doi = {10.1007/s00392-021-01822-1},
  urldate = {2025-01-31},
  abstract = {Higher body mass index (BMI) is associated with better outcome compared with normal weight in patients with HF and other chronic diseases. It remains uncertain whether the apparent protective role of obesity relates to the absence of comorbidities. Therefore, we investigated the effect of BMI on outcome in younger patients without co-morbidities as compared to older patients with co-morbidities in a large heart failure (HF) population.},
  langid = {english},
  keywords = {Biomarkers,Body mass index,Co-morbidities,Disease severity,Heart failure,Obesity},
  file = {/Users/xx20081/Zotero/storage/XGL7W2RM/Marcks et al. - 2021 - Re-appraisal of the obesity paradox in heart failure a meta-analysis of individual data.pdf}
}

@article{Margulies2016,
  title = {Effects of Liraglutide on Clinical Stability among Patients with Advanced Heart Failure and Reduced Ejection Fraction: {{A}} Randomized Clinical Trial},
  author = {Margulies, Kenneth B. and Hernandez, Adrian F. and Redfield, Margaret M. and Givertz, Michael M. and Oliveira, Guilherme H. and Cole, Robert and Mann, Douglas L. and Whellan, David J. and Kiernan, Michael S. and Felker, G. Michael and McNulty, Steven E. and Anstrom, Kevin J. and Shah, Monica R. and Braunwald, Eugene and Cappola, Thomas P.},
  year = {2016},
  month = aug,
  journal = {JAMA : the journal of the American Medical Association},
  volume = {316},
  number = {5},
  pages = {500--508},
  publisher = {JAMA},
  issn = {1538-3598},
  doi = {10.1001/JAMA.2016.10260},
  abstract = {Importance: Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status. Objective: To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure. Design, Setting, and Participants: Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites. Interventions: The GLP-1 agonist liraglutide (n = 154) or placebo (n = 146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8mg/d during the first 30 days as tolerated and continued for 180 days. Main Outcomes and Measures: The primary end point was a global rank score in which all patients, regardless of treatment assignment, were ranked across 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 days. Higher values indicate better health (stability). Exploratory secondary outcomes included primary end point components, cardiac structure and function, 6-minute walk distance, quality of life, and combined events. Results: Among the 300 patients whowere randomized (median age, 61 years [interquartile range \{IQR\}, 52-68 years]; 64 [21\%] women; 178 [59\%] with type 2 diabetes; median LVEF of 25\% [IQR, 19\%-33\%]; median N-terminal pro-B-type natriuretic peptide level of 2049 pg/mL [IQR, 1054-4235 pg/mL]), 271 completed the study. Compared with placebo, liraglutide had no significant effect on the primary end point (mean rank of 146 for the liraglutide group vs 156 for the placebo group, P = .31). Therewere no significant between-group differences in the number of deaths (19 [12\%] in the liraglutide group vs 16 [11\%] in the placebo group; hazard ratio, 1.10 [95\%CI, 0.57-2.14]; P = .78) or rehospitalizations for heart failure (63 [41\%] vs 50 [34\%], respectively; hazard ratio, 1.30 [95\%CI, 0.89-1.88]; P = .17) or for the exploratory secondary end points. Prespecified subgroup analyses in patients with diabetes did not reveal any significant between-group differences. The number of investigator-reported hyperglycemic eventswas 16 (10\%) in the liraglutide group vs 27 (18\%) in the placebo group and hypoglycemic eventswere infrequent (2 [1\%] vs 4 [3\%], respectively). Conclusions and Relevance: Among patients recently hospitalized with heart failure and reduced LVEF, the use of liraglutide did not lead to greater posthospitalization clinical stability. These findings do not support the use of liraglutide in this clinical situation.},
  pmid = {27483064},
  keywords = {Adrian F Hernandez,affs=[],affs=[]),Aged,Author(firstnames='A',Author(firstnames='B',Author(firstnames='C',Author(firstnames='D',Author(firstnames='E',Author(firstnames='F',Author(firstnames='G',Author(firstnames='H-K',Author(firstnames='H',Author(firstnames='J-M',Author(firstnames='J',Author(firstnames='K Davis',Author(firstnames='K',Author(firstnames='L',Author(firstnames='M A',Author(firstnames='M',Author(firstnames='N',Author(firstnames='P',Author(firstnames='R',Author(firstnames='S-Y',Author(firstnames='S',Author(firstnames='T',Author(firstnames='W',Clinical Trial,CollabAuthor(name='NHLBI Heart Failure Clinical Research Network',Diabetes Mellitus,doi:10.1001/jama.2016.10260,Double-Blind Method,equal<sub>c</sub>ontrib=False),equal<sub>c</sub>ontrib=False)],Extramural,Female,Glucagon-Like Peptide 1 / agonists*,Heart Failure / complications*,Heart Failure / mortality,Heart Failure / physiopathology*,Humans,Hypoglycemic Agents / therapeutic use*,initials='A',initials='B',initials='C',initials='D',initials='E',initials='F',initials='G',initials='H',initials='HK',initials='J',initials='JM',initials='K',initials='L',initials='M',initials='MA',initials='N',initials='P',initials='R',initials='S',initials='SY',initials='T',initials='W',investigators=[Author(firstnames='N',iseditor=False,Kenneth B Margulies,lastname='Abraham',lastname='Adams',lastname='Agarwal',lastname='Alenezi',lastname='Alvarez',lastname='Ambrose',lastname='Anello',lastname='Atwood',lastname='Bacher',lastname='Berg',lastname='Bosier',lastname='Brooks',lastname='Bult',lastname='Burns',lastname='Cai',lastname='Cappola',lastname='Chee',lastname='Cho',lastname='Cocca-Spofford',lastname='Cooper-Arnold',lastname='Corona-Cox',lastname='Cronkright',lastname='Damon',lastname='Desvigne-Nickens',lastname='Deswal',lastname='DeVore',lastname='Dickson',lastname='Do',lastname='Dunlap',lastname='Echols',lastname='Ewald',lastname='Felker',lastname='Flanagan',lastname='Fonk',lastname='Fox',lastname='Gallagher',lastname='Gatzke',lastname='Geither',lastname='Gibbs',lastname='Givertz',lastname='Greenberg',lastname='Grow',lastname='Haddock',lastname='Hauptman',lastname='Heckard',lastname='Herman',lastname='Hernandez',lastname='Hwang',lastname='Jamieson',lastname='Johnson',lastname='Kamil',lastname='Kennedy',lastname='Kiernan',lastname='Kim',lastname='Kirk',lastname='Konstam',lastname='Lakdawala',lastname='Leo',lastname='Lesko',lastname='LeWinter',lastname='Ly',lastname='Mann',lastname='Margulies',lastname='Mather',lastname='Mbugua',lastname='McGonagle',lastname='McNamara',lastname='McNeill',lastname='Mkrdichian',lastname='Monds',lastname='Nichols',lastname='Nossuli',lastname='Oliveira',lastname='Olt',lastname='Parrillo',lastname='Penn',lastname='Phillips',lastname='Pickering',lastname='Pointer',lastname='Powers',lastname='Redfield',lastname='Rose',lastname='Roth',lastname='Rowen',lastname='Russell',lastname='Saltzberg',lastname='Scheutzow',lastname='Sellers',lastname='Semenec',lastname='Semigran',lastname='Shah',lastname='Smith',lastname='Snell',lastname='Starling',lastname='Stehlik',lastname='Tang',lastname='Testa',lastname='Tracy',lastname='Vaughan',lastname='Velazquez',lastname='Verkouw',lastname='Virmani',lastname='Wall',lastname='Weber',lastname='Whellan',lastname='Whitehead',lastname='Willis',lastname='Zihlman',lastname="O'Kelly",Left / complications*,Left / physiopathology,Liraglutide / therapeutic use*,Male,MEDLINE,Middle Aged,Multicenter Study,N.I.H.,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,Odds Ratio,Patient Readmission / statistics & numerical data,Phase II,PMC5021525,pmid:27483064,PubMed Abstract,Quality of Life,Randomized Controlled Trial,Research Support,Stroke Volume*,suffix=None,Treatment Outcome,Type 2 / drug therapy*,United States,Ventricular Dysfunction}
}

@article{marguliesEffectsLiraglutideClinical2016,
  title = {Effects of {{Liraglutide}} on {{Clinical Stability Among Patients With Advanced Heart Failure}} and {{Reduced Ejection Fraction}}: {{A Randomized Clinical Trial}}},
  shorttitle = {Effects of {{Liraglutide}} on {{Clinical Stability Among Patients With Advanced Heart Failure}} and {{Reduced Ejection Fraction}}},
  author = {Margulies, Kenneth B. and Hernandez, Adrian F. and Redfield, Margaret M. and Givertz, Michael M. and Oliveira, Guilherme H. and Cole, Robert and Mann, Douglas L. and Whellan, David J. and Kiernan, Michael S. and Felker, G. Michael and McNulty, Steven E. and Anstrom, Kevin J. and Shah, Monica R. and Braunwald, Eugene and Cappola, Thomas P. and {for the NHLBI Heart Failure Clinical Research Network}},
  year = {2016},
  month = aug,
  journal = {JAMA},
  volume = {316},
  number = {5},
  pages = {500--508},
  issn = {0098-7484},
  doi = {10.1001/jama.2016.10260},
  urldate = {2024-07-04},
  abstract = {Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status.To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure.Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites.The GLP-1 agonist liraglutide (n\,=\,154) or placebo (n\,=\,146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days.The primary end point was a global rank score in which all patients, regardless of treatment assignment, were ranked across 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 days. Higher values indicate better health (stability). Exploratory secondary outcomes included primary end point components, cardiac structure and function, 6-minute walk distance, quality of life, and combined events.Among the 300 patients who were randomized (median age, 61 years [interquartile range \{IQR\}, 52-68 years]; 64 [21\%] women; 178 [59\%] with type 2 diabetes; median LVEF of 25\% [IQR, 19\%-33\%]; median N-terminal pro-B-type natriuretic peptide level of 2049 pg/mL [IQR, 1054-4235 pg/mL]), 271 completed the study. Compared with placebo, liraglutide had no significant effect on the primary end point (mean rank of 146 for the liraglutide group vs 156 for the placebo group, P\,=\,.31). There were no significant between-group differences in the number of deaths (19 [12\%] in the liraglutide group vs 16 [11\%] in the placebo group; hazard ratio, 1.10 [95\% CI, 0.57-2.14]; P\,=\,.78) or rehospitalizations for heart failure (63 [41\%] vs 50 [34\%], respectively; hazard ratio, 1.30 [95\% CI, 0.89-1.88]; P\,=\,.17) or for the exploratory secondary end points. Prespecified subgroup analyses in patients with diabetes did not reveal any significant between-group differences. The number of investigator-reported hyperglycemic events was 16 (10\%) in the liraglutide group vs 27 (18\%) in the placebo group and hypoglycemic events were infrequent (2 [1\%] vs 4 [3\%], respectively). Among patients recently hospitalized with heart failure and reduced LVEF, the use of liraglutide did not lead to greater posthospitalization clinical stability. These findings do not support the use of liraglutide in this clinical situation.clinicaltrials.gov Identifier: NCT01800968},
  file = {/Users/xx20081/Zotero/storage/SMDSK6G4/Margulies et al. - 2016 - Effects of Liraglutide on Clinical Stability Among.pdf;/Users/xx20081/Zotero/storage/H2R2FDC6/2540402.html}
}

@article{marguliesEffectsLiraglutideClinical2016a,
  title = {Effects of {{Liraglutide}} on {{Clinical Stability Among Patients With Advanced Heart Failure}} and {{Reduced Ejection Fraction}}: {{A Randomized Clinical Trial}}},
  shorttitle = {Effects of {{Liraglutide}} on {{Clinical Stability Among Patients With Advanced Heart Failure}} and {{Reduced Ejection Fraction}}},
  author = {Margulies, Kenneth B. and Hernandez, Adrian F. and Redfield, Margaret M. and Givertz, Michael M. and Oliveira, Guilherme H. and Cole, Robert and Mann, Douglas L. and Whellan, David J. and Kiernan, Michael S. and Felker, G. Michael and McNulty, Steven E. and Anstrom, Kevin J. and Shah, Monica R. and Braunwald, Eugene and Cappola, Thomas P. and {for the NHLBI Heart Failure Clinical Research Network}},
  year = {2016},
  month = aug,
  journal = {JAMA},
  volume = {316},
  number = {5},
  pages = {500--508},
  issn = {0098-7484},
  doi = {10.1001/jama.2016.10260},
  urldate = {2025-01-22},
  abstract = {Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status.To test whether therapy with a GLP-1 agonist improves clinical stability following hospitalization for acute heart failure.Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with established heart failure and reduced LVEF who were recently hospitalized. Patients were enrolled between August 2013 and March 2015 at 24 US sites.The GLP-1 agonist liraglutide (n\,=\,154) or placebo (n\,=\,146) via a daily subcutaneous injection; study drug was advanced to a dosage of 1.8 mg/d during the first 30 days as tolerated and continued for 180 days.The primary end point was a global rank score in which all patients, regardless of treatment assignment, were ranked across 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 days. Higher values indicate better health (stability). Exploratory secondary outcomes included primary end point components, cardiac structure and function, 6-minute walk distance, quality of life, and combined events.Among the 300 patients who were randomized (median age, 61 years [interquartile range \{IQR\}, 52-68 years]; 64 [21\%] women; 178 [59\%] with type 2 diabetes; median LVEF of 25\% [IQR, 19\%-33\%]; median N-terminal pro-B-type natriuretic peptide level of 2049 pg/mL [IQR, 1054-4235 pg/mL]), 271 completed the study. Compared with placebo, liraglutide had no significant effect on the primary end point (mean rank of 146 for the liraglutide group vs 156 for the placebo group, P\,=\,.31). There were no significant between-group differences in the number of deaths (19 [12\%] in the liraglutide group vs 16 [11\%] in the placebo group; hazard ratio, 1.10 [95\% CI, 0.57-2.14]; P\,=\,.78) or rehospitalizations for heart failure (63 [41\%] vs 50 [34\%], respectively; hazard ratio, 1.30 [95\% CI, 0.89-1.88]; P\,=\,.17) or for the exploratory secondary end points. Prespecified subgroup analyses in patients with diabetes did not reveal any significant between-group differences. The number of investigator-reported hyperglycemic events was 16 (10\%) in the liraglutide group vs 27 (18\%) in the placebo group and hypoglycemic events were infrequent (2 [1\%] vs 4 [3\%], respectively). Among patients recently hospitalized with heart failure and reduced LVEF, the use of liraglutide did not lead to greater posthospitalization clinical stability. These findings do not support the use of liraglutide in this clinical situation.clinicaltrials.gov Identifier: NCT01800968},
  file = {/Users/xx20081/Zotero/storage/B63USX7L/Margulies et al. - 2016 - Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced.pdf;/Users/xx20081/Zotero/storage/8AW6P97A/2540402.html}
}

@article{martinezcarrascoGenomewideAnalysisMotor2023,
  title = {Genome-Wide {{Analysis}} of {{Motor Progression}} in {{Parkinson Disease}}},
  author = {Mart{\'i}nez Carrasco, Alejandro and Real, Raquel and Lawton, Michael and Hertfelder Reynolds, Regina and Tan, Manuela and Wu, Lesley and Williams, Nigel and Carroll, Camille and Corvol, Jean-Christophe and Hu, Michele and Grosset, Donald and Hardy, John and Ryten, Mina and {Ben-Shlomo}, Yoav and Shoai, Maryam and Morris, Huw R.},
  year = {2023},
  month = aug,
  journal = {Neurology: Genetics},
  volume = {9},
  number = {5},
  pages = {e200092},
  issn = {2376-7839},
  doi = {10.1212/NXG.0000000000200092},
  urldate = {2023-12-05},
  abstract = {Background and Objectives The genetic basis of Parkinson disease (PD) motor progression is largely unknown. Previous studies of the genetics of PD progression have included small cohorts and shown a limited overlap with genetic PD risk factors from case-control studies. Here, we have studied genomic variation associated with PD motor severity and early-stage progression in large longitudinal cohorts to help to define the biology of PD progression and potential new drug targets. Methods We performed a GWAS meta-analysis of early PD motor severity and progression up to 3 years from study entry. We used linear mixed-effect models with additive effects, corrected for age at diagnosis, sex, and the first 5 genetic principal components to assess variability in axial, limb, and total Movement Disorder Society--Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III scores. Results We included 3,572 unrelated European ancestry patients with PD from 5 observational cohorts and 1 drug trial. The average AAO was 62.6 years (SD = 9.83), and 63\% of participants were male. We found an average increase in the total MDS-UPDRS III score of 2.3 points/year. We identified an association between PD axial motor progression and variation at the GJA5 locus at 1q12 ({$\beta$} = -0.25, SE = 0.04, p = 3.4e-10). Exploration of the regulation of gene expression in the region (cis-expression quantitative trait loci [eQTL] analysis) showed that the lead variant was associated with expression of ACP6, a lysophosphatidic acid phosphatase that regulates mitochondrial lipid biosynthesis (cis-eQTL p-values in blood and brain RNA expression data sets: {$<$}10-14 in eQTLGen and 10-7 in PsychEncode). Discussion Our study highlights the potential role of mitochondrial lipid homeostasis in the progression of PD, which may be important in establishing new drug targets that might modify disease progression.},
  pmcid = {PMC10409573},
  pmid = {37560120},
  file = {/Users/xx20081/Zotero/storage/MJD5HZZ7/Martnez Carrasco et al. - 2023 - Genome-wide Analysis of Motor Progression in Parki.pdf}
}

@article{martinezcarrascoGenomewideAnalysisMotor2023a,
  title = {Genome-Wide {{Analysis}} of {{Motor Progression}} in {{Parkinson Disease}}},
  author = {Mart{\'i}nez Carrasco, Alejandro and Real, Raquel and Lawton, Michael and Hertfelder Reynolds, Regina and Tan, Manuela and Wu, Lesley and Williams, Nigel and Carroll, Camille and Corvol, Jean-Christophe and Hu, Michele and Grosset, Donald and Hardy, John and Ryten, Mina and {Ben-Shlomo}, Yoav and Shoai, Maryam and Morris, Huw R.},
  year = {2023},
  month = oct,
  journal = {Neurology. Genetics},
  volume = {9},
  number = {5},
  pages = {e200092},
  issn = {2376-7839},
  doi = {10.1212/NXG.0000000000200092},
  abstract = {BACKGROUND AND OBJECTIVES: The genetic basis of Parkinson disease (PD) motor progression is largely unknown. Previous studies of the genetics of PD progression have included small cohorts and shown a limited overlap with genetic PD risk factors from case-control studies. Here, we have studied genomic variation associated with PD motor severity and early-stage progression in large longitudinal cohorts to help to define the biology of PD progression and potential new drug targets. METHODS: We performed a GWAS meta-analysis of early PD motor severity and progression up to 3 years from study entry. We used linear mixed-effect models with additive effects, corrected for age at diagnosis, sex, and the first 5 genetic principal components to assess variability in axial, limb, and total Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III scores. RESULTS: We included 3,572 unrelated European ancestry patients with PD from 5 observational cohorts and 1 drug trial. The average AAO was 62.6 years (SD = 9.83), and 63\% of participants were male. We found an average increase in the total MDS-UPDRS III score of 2.3 points/year. We identified an association between PD axial motor progression and variation at the GJA5 locus at 1q12 ({$\beta$} = -0.25, SE = 0.04, p = 3.4e-10). Exploration of the regulation of gene expression in the region (cis-expression quantitative trait loci [eQTL] analysis) showed that the lead variant was associated with expression of ACP6, a lysophosphatidic acid phosphatase that regulates mitochondrial lipid biosynthesis (cis-eQTL p-values in blood and brain RNA expression data sets: {$<$}10-14 in eQTLGen and 10-7 in PsychEncode). DISCUSSION: Our study highlights the potential role of mitochondrial lipid homeostasis in the progression of PD, which may be important in establishing new drug targets that might modify disease progression.},
  langid = {english},
  pmcid = {PMC10409573},
  pmid = {37560120},
  file = {/Users/xx20081/Zotero/storage/JSNW946H/Martnez Carrasco et al. - 2023 - Genome-wide Analysis of Motor Progression in Parki.pdf}
}

@article{martinezcarrascoGenomewideAnalysisMotor2023b,
  title = {Genome-Wide {{Analysis}} of {{Motor Progression}} in {{Parkinson Disease}}},
  author = {Mart{\'i}nez Carrasco, Alejandro and Real, Raquel and Lawton, Michael and Hertfelder Reynolds, Regina and Tan, Manuela and Wu, Lesley and Williams, Nigel and Carroll, Camille and Corvol, Jean-Christophe and Hu, Michele and Grosset, Donald and Hardy, John and Ryten, Mina and {Ben-Shlomo}, Yoav and Shoai, Maryam and Morris, Huw R.},
  year = {2023},
  month = oct,
  journal = {Neurology. Genetics},
  volume = {9},
  number = {5},
  pages = {e200092},
  issn = {2376-7839},
  doi = {10.1212/NXG.0000000000200092},
  abstract = {BACKGROUND AND OBJECTIVES: The genetic basis of Parkinson disease (PD) motor progression is largely unknown. Previous studies of the genetics of PD progression have included small cohorts and shown a limited overlap with genetic PD risk factors from case-control studies. Here, we have studied genomic variation associated with PD motor severity and early-stage progression in large longitudinal cohorts to help to define the biology of PD progression and potential new drug targets. METHODS: We performed a GWAS meta-analysis of early PD motor severity and progression up to 3 years from study entry. We used linear mixed-effect models with additive effects, corrected for age at diagnosis, sex, and the first 5 genetic principal components to assess variability in axial, limb, and total Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III scores. RESULTS: We included 3,572 unrelated European ancestry patients with PD from 5 observational cohorts and 1 drug trial. The average AAO was 62.6 years (SD = 9.83), and 63\% of participants were male. We found an average increase in the total MDS-UPDRS III score of 2.3 points/year. We identified an association between PD axial motor progression and variation at the GJA5 locus at 1q12 ({$\beta$} = -0.25, SE = 0.04, p = 3.4e-10). Exploration of the regulation of gene expression in the region (cis-expression quantitative trait loci [eQTL] analysis) showed that the lead variant was associated with expression of ACP6, a lysophosphatidic acid phosphatase that regulates mitochondrial lipid biosynthesis (cis-eQTL p-values in blood and brain RNA expression data sets: {$<$}10-14 in eQTLGen and 10-7 in PsychEncode). DISCUSSION: Our study highlights the potential role of mitochondrial lipid homeostasis in the progression of PD, which may be important in establishing new drug targets that might modify disease progression.},
  langid = {english},
  pmcid = {PMC10409573},
  pmid = {37560120}
}

@article{mathieuGeneticAssociationMendelian2022,
  title = {Genetic Association and {{Mendelian}} Randomization for Hypothyroidism Highlight Immune Molecular Mechanisms},
  author = {Mathieu, Samuel and Briend, Mewen and Abner, Erik and Couture, Christian and Li, Zhonglin and Boss{\'e}, Yohan and Th{\'e}riault, S{\'e}bastien and Esko, T{\~o}nu and Arsenault, Benoit J. and Mathieu, Patrick},
  year = {2022},
  month = aug,
  journal = {iScience},
  volume = {25},
  number = {9},
  pages = {104992},
  issn = {2589-0042},
  doi = {10.1016/j.isci.2022.104992},
  urldate = {2024-09-02},
  abstract = {We carried out a genome-wide association analysis including 51,194 cases of hypothyroidism and 443,383 controls. In total, 139 risk loci were associated to hypothyroidism with genes involved in lymphocyte function. Candidate genes associated with hypothyroidism were identified by using molecular quantitative trait loci, colocalization, and enhancer-promoter chromatin looping. Mendelian randomization (MR) identified 42 blood expressed genes and circulating proteins as candidate causal molecules in hypothyroidism. Drug-gene interaction analysis provided evidence that immune checkpoint and tyrosine kinase inhibitors used in cancer therapy increase the risk of hypothyroidism. Hence, integrative mapping and MR support that expression of genes and proteins enriched in lymphocyte function are associated with the risk of hypothyroidism and provide genetic evidence for drug-induced hypothyroidism and identify actionable potential drug targets.,                                        {$\bullet$}               GWAS for hypothyroidism identified 139 risk loci including 76 novel associations                                         {$\bullet$}               GWAS was enriched in pathways related to lymphocyte function                                         {$\bullet$}               In total, 28 potentially deleterious missense variants were identified                                         {$\bullet$}               Mendelian randomization and colocalization identified 61 blood causal candidate genes                                 , Clinical genetics; Genomics; Molecular genetics},
  pmcid = {PMC9460554},
  pmid = {36093044},
  file = {/Users/xx20081/Zotero/storage/TYNGH95J/Mathieu et al. - 2022 - Genetic association and Mendelian randomization fo.pdf}
}

@article{matushynSumStatsRehabEfficientAlgorithm2022,
  title = {{{SumStatsRehab}}: An Efficient Algorithm for {{GWAS}} Summary Statistics Assessment and Restoration},
  shorttitle = {{{SumStatsRehab}}},
  author = {Matushyn, Mykyta and Bose, Madhuchanda and Mahmoud, Abdallah Amr and Cuthbertson, Lewis and Tello, Carlos and Bircan, Karatu{\u g} Ozan and Terpolovsky, Andrew and Bamunusinghe, Varuna and Khan, Umar and Novkovi{\'c}, Biljana and Grabherr, Manfred G. and Yazdi, Puya G.},
  year = {2022},
  month = oct,
  journal = {BMC Bioinformatics},
  volume = {23},
  number = {1},
  pages = {443},
  issn = {1471-2105},
  doi = {10.1186/s12859-022-04920-7},
  urldate = {2024-10-02},
  abstract = {Generating polygenic risk scores for diseases and complex traits requires high quality GWAS summary statistic files. Often, these files can be difficult to acquire either as a result of unshared or incomplete data. To date, bioinformatics tools which focus on restoring missing columns containing identification and association data are limited, which has the potential to increase the number of usable GWAS summary statistics files.},
  keywords = {Bioinformatics,Genetics,GWAS,PRS,Summary statistics},
  file = {/Users/xx20081/Zotero/storage/GXNKP74C/Matushyn et al. - 2022 - SumStatsRehab an efficient algorithm for GWAS summary statistics assessment and restoration.pdf}
}

@article{mccawPitfallsPerformingGenomewide2025,
  title = {Pitfalls in Performing Genome-Wide Association Studies on Ratio Traits},
  author = {McCaw, Zachary R. and Dey, Rounak and Somineni, Hari and Amar, David and Mukherjee, Sumit and Sandor, Kaitlin and Karaletsos, Theofanis and Koller, Daphne and Aschard, Hugues and Smith, George Davey and MacArthur, Daniel and O'Dushlaine, Colm and Soare, Thomas W.},
  year = {2025},
  month = apr,
  journal = {Human Genetics and Genomics Advances},
  volume = {6},
  number = {2},
  publisher = {Elsevier},
  issn = {2666-2477},
  doi = {10.1016/j.xhgg.2025.100406},
  urldate = {2025-03-10},
  langid = {english},
  pmid = {39818621},
  keywords = {body mass index,collider bias,covariate adjustment,genetic discovery,genome-wide association study,heritable covariate bias,polygenic scores,proportion,quotient,ratio},
  file = {/Users/xx20081/Zotero/storage/YKXGTDJV/McCaw et al. - 2025 - Pitfalls in performing genome-wide association studies on ratio traits.pdf}
}

@article{mcdonaldNovelGeneticLoci2022,
  title = {Novel Genetic Loci Associated with Osteoarthritis in Multi-Ancestry Analyses in the {{Million Veteran Program}} and {{UK Biobank}}},
  author = {McDonald, Merry-Lynn N. and Lakshman Kumar, Preeti and Srinivasasainagendra, Vinodh and Nair, Ashwathy and Rocco, Alison P. and Wilson, Ava C. and Chiles, Joe W. and Richman, Joshua S. and Pinson, Sarah A. and Dennis, Richard A. and Jagadale, Vivek and Brown, Cynthia J. and Pyarajan, Saiju and Tiwari, Hemant K. and Bamman, Marcas M. and Singh, Jasvinder A.},
  year = {2022},
  month = dec,
  journal = {Nature Genetics},
  volume = {54},
  number = {12},
  pages = {1816--1826},
  issn = {1546-1718},
  doi = {10.1038/s41588-022-01221-w},
  abstract = {Osteoarthritis is a common progressive joint disease. As no effective medical interventions are available, osteoarthritis often progresses to the end stage, in which only surgical options such as total joint replacement are available. A more thorough understanding of genetic influences of osteoarthritis is essential to develop targeted personalized approaches to treatment, ideally long before the end stage is reached. To date, there have been no large multiancestry genetic studies of osteoarthritis. Here, we leveraged the unique resources of 484,374 participants in the Million Veteran Program and UK Biobank to address this gap. Analyses included participants of European, African, Asian and Hispanic descent. We discovered osteoarthritis-associated genetic variation at 10 loci and replicated findings from previous osteoarthritis studies. We also present evidence that some osteoarthritis-associated regions are robust to population ancestry. Drug repurposing analyses revealed enrichment of targets of several medication classes and provide potential insight into the etiology of beneficial effects of antiepileptics on osteoarthritis pain.},
  langid = {english},
  pmid = {36411363},
  keywords = {Biological Specimen Banks,Genetic Loci,Humans,United Kingdom}
}

@article{mcgillObesityAcceleratesProgression2002,
  title = {Obesity Accelerates the Progression of Coronary Atherosclerosis in Young Men},
  author = {McGill, Henry C. and McMahan, C. Alex and Herderick, Edward E. and Zieske, Arthur W. and Malcom, Gray T. and Tracy, Richard E. and Strong, Jack P. and {Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group}},
  year = {2002},
  month = jun,
  journal = {Circulation},
  volume = {105},
  number = {23},
  pages = {2712--2718},
  issn = {1524-4539},
  doi = {10.1161/01.cir.0000018121.67607.ce},
  abstract = {BACKGROUND: Obesity is a risk factor for adult coronary heart disease and is increasing in prevalence among youths as well as adults. Results regarding the association of obesity with atherosclerosis are conflicting, particularly when analyses account for other risk factors. METHODS AND RESULTS: The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study collected arteries, blood, and other tissue from approximately 3000 persons aged 15 to 34 years dying of external causes and autopsied in forensic laboratories. We measured gross atherosclerotic lesions in the right coronary artery (RCA), American Heart Association (AHA) lesion grade in the left anterior descending coronary artery (LAD), serum lipid concentrations, serum thiocyanate (for smoking), intimal thickness of renal arteries (for hypertension), glycohemoglobin (for hyperglycemia), and adiposity by body mass index (BMI) and thickness of the panniculus adiposus. BMI in young men was associated with both fatty streaks and raised lesions in the RCA and with AHA grade and stenosis in the LAD. The effect of obesity (BMI{$>$}30 kg/m(2)) on RCA raised lesions was greater in young men with a thick panniculus adiposus. Obesity was associated with non-HDL and HDL (inversely) cholesterol concentrations, smoking (inversely), hypertension, and glycohemoglobin concentration, and these variables accounted for approximately 15\% of the effect of obesity on coronary atherosclerosis in young men. BMI was not associated with coronary atherosclerosis in young women although there was trend among those with a thick panniculus adiposus. CONCLUSIONS: Obesity is associated with accelerated coronary atherosclerosis in adolescent and young adult men. These observations support the current emphasis on controlling obesity to prevent adult coronary heart disease.},
  langid = {english},
  pmid = {12057983},
  keywords = {Adipose Tissue,Adolescent,Adult,Body Mass Index,Coronary Artery Disease,Coronary Disease,Coronary Vessels,Disease Progression,Female,Humans,Male,Obesity,Risk Factors,Sex Factors},
  file = {/Users/xx20081/Zotero/storage/B76VBXJD/McGill et al. - 2002 - Obesity accelerates the progression of coronary at.pdf}
}

@article{mcguireAssociationSGLT2Inhibitors2021,
  title = {Association of {{SGLT2 Inhibitors With Cardiovascular}} and {{Kidney Outcomes}} in {{Patients With Type}} 2 {{Diabetes}}: {{A Meta-analysis}}},
  shorttitle = {Association of {{SGLT2 Inhibitors With Cardiovascular}} and {{Kidney Outcomes}} in {{Patients With Type}} 2 {{Diabetes}}},
  author = {McGuire, Darren K. and Shih, Weichung J. and Cosentino, Francesco and Charbonnel, Bernard and Cherney, David Z. I. and {Dagogo-Jack}, Samuel and Pratley, Richard and Greenberg, Michelle and Wang, Shuai and Huyck, Susan and Gantz, Ira and Terra, Steven G. and Masiukiewicz, Urszula and Cannon, Christopher P.},
  year = {2021},
  month = feb,
  journal = {JAMA cardiology},
  volume = {6},
  number = {2},
  pages = {148--158},
  issn = {2380-6591},
  doi = {10.1001/jamacardio.2020.4511},
  abstract = {IMPORTANCE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the class remains uncertain. OBJECTIVE: To perform meta-analyses that assess the CV and kidney outcomes of all 4 available SGLT2 inhibitors in patients with type 2 diabetes. DATA SOURCES: A systematic literature search was conducted in PubMed from January 1, 2015, to January 31, 2020. STUDY SELECTION: One hundred forty-five records were initially identified; 137 were excluded because of study design or topic of interest. As a result, a total of 6 randomized, placebo-controlled CV and kidney outcomes trials of SGLT2 inhibitors in patients with type 2 diabetes were identified, with contributory data from 9 publications. All analyses were conducted on the total patient population of these trials. DATA EXTRACTION AND SYNTHESIS: Standardized data search and abstraction were performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement. Data were analyzed using a fixed-effect model. MAIN OUTCOMES AND MEASURES: Outcomes included time to the first event of (1) the composite of major adverse CV events of myocardial infarction, stroke, or CV death, and each component, (2) the composite of hospitalization for heart failure (HHF) or CV death (HHF/CV death) and each component, and (3) kidney composite outcomes. For outcomes in the overall trial populations and in selected subgroups, hazard ratios (HRs) and 95\% CIs were pooled and meta-analyzed across trials. RESULTS: Data from 6 trials comprised 46\,969 unique patients with type 2 diabetes, including 31\,116 (66.2\%) with atherosclerotic CV disease. The mean (SD) age of all trial participants was 63.7 (7.9) years; 30 939 (65.9\%) were men, and 36 849 (78.5\%) were White. The median number of participants per trial was 8246 (range, 4401-17\,160). Overall, SGLT2 inhibitors were associated with a reduced risk of major adverse CV events (HR, 0.90; 95\% CI, 0.85-0.95; Q statistic, P\,=\,.27), HHF/CV death (HR, 0.78; 95\% CI, 0.73-0.84; Q statistic, P\,=\,.09), and kidney outcomes (HR, 0.62; 95\% CI, 0.56-0.70; Q statistic, P\,=\,.09), with no significant heterogeneity of associations with outcome. Associated risk reduction for HHF was consistent across the trials (HR, 0.68; 95\% CI, 0.61-0.76; I2\,=\,0.0\%), whereas significant heterogeneity of associations with outcome was observed for CV death (HR, 0.85; 95\% CI, 0.78-0.93; Q statistic, P\,=\,.02; I2\,=\,64.3\%). The presence or absence of atherosclerotic CV disease did not modify the association with outcomes for major adverse CV events (HR, 0.89; 95\% CI, 0.84-0.95 and HR, 0.94; 95\% CI, 0.83-1.07, respectively; P\,=\,.63 for interaction), with similar absence of associations with outcome modification by prevalent atherosclerotic CV disease for HHF/CV death (P\,=\,.62 for interaction), HHF (P\,=\,.26 for interaction), or kidney outcomes (P\,=\,.73 for interaction). CONCLUSIONS AND RELEVANCE: In this meta-analysis, SGLT2 inhibitors were associated with a reduced risk of major adverse CV events; in addition, results suggest significant heterogeneity in associations with CV death. The largest benefit across the class was for an associated reduction in risk for HHF and kidney outcomes, with benefits for HHF risk being the most consistent observation across the trials.},
  langid = {english},
  pmcid = {PMC7542529},
  pmid = {33031522},
  keywords = {Cardiovascular Diseases,Diabetes Mellitus Type 2,Disease Progression,Heart Failure,Hospitalization,Humans,Proportional Hazards Models,Renal Insufficiency Chronic,Sodium-Glucose Transporter 2 Inhibitors}
}

@article{mcguireAssociationSGLT2Inhibitors2021a,
  title = {Association of {{SGLT2 Inhibitors With Cardiovascular}} and {{Kidney Outcomes}} in {{Patients With Type}} 2 {{Diabetes}}: {{A Meta-analysis}}},
  shorttitle = {Association of {{SGLT2 Inhibitors With Cardiovascular}} and {{Kidney Outcomes}} in {{Patients With Type}} 2 {{Diabetes}}},
  author = {McGuire, Darren K. and Shih, Weichung J. and Cosentino, Francesco and Charbonnel, Bernard and Cherney, David Z. I. and {Dagogo-Jack}, Samuel and Pratley, Richard and Greenberg, Michelle and Wang, Shuai and Huyck, Susan and Gantz, Ira and Terra, Steven G. and Masiukiewicz, Urszula and Cannon, Christopher P.},
  year = {2021},
  month = feb,
  journal = {JAMA cardiology},
  volume = {6},
  number = {2},
  pages = {148--158},
  issn = {2380-6591},
  doi = {10.1001/jamacardio.2020.4511},
  abstract = {IMPORTANCE: Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the class remains uncertain. OBJECTIVE: To perform meta-analyses that assess the CV and kidney outcomes of all 4 available SGLT2 inhibitors in patients with type 2 diabetes. DATA SOURCES: A systematic literature search was conducted in PubMed from January 1, 2015, to January 31, 2020. STUDY SELECTION: One hundred forty-five records were initially identified; 137 were excluded because of study design or topic of interest. As a result, a total of 6 randomized, placebo-controlled CV and kidney outcomes trials of SGLT2 inhibitors in patients with type 2 diabetes were identified, with contributory data from 9 publications. All analyses were conducted on the total patient population of these trials. DATA EXTRACTION AND SYNTHESIS: Standardized data search and abstraction were performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement. Data were analyzed using a fixed-effect model. MAIN OUTCOMES AND MEASURES: Outcomes included time to the first event of (1) the composite of major adverse CV events of myocardial infarction, stroke, or CV death, and each component, (2) the composite of hospitalization for heart failure (HHF) or CV death (HHF/CV death) and each component, and (3) kidney composite outcomes. For outcomes in the overall trial populations and in selected subgroups, hazard ratios (HRs) and 95\% CIs were pooled and meta-analyzed across trials. RESULTS: Data from 6 trials comprised 46\,969 unique patients with type 2 diabetes, including 31\,116 (66.2\%) with atherosclerotic CV disease. The mean (SD) age of all trial participants was 63.7 (7.9) years; 30 939 (65.9\%) were men, and 36 849 (78.5\%) were White. The median number of participants per trial was 8246 (range, 4401-17\,160). Overall, SGLT2 inhibitors were associated with a reduced risk of major adverse CV events (HR, 0.90; 95\% CI, 0.85-0.95; Q statistic, P\,=\,.27), HHF/CV death (HR, 0.78; 95\% CI, 0.73-0.84; Q statistic, P\,=\,.09), and kidney outcomes (HR, 0.62; 95\% CI, 0.56-0.70; Q statistic, P\,=\,.09), with no significant heterogeneity of associations with outcome. Associated risk reduction for HHF was consistent across the trials (HR, 0.68; 95\% CI, 0.61-0.76; I2\,=\,0.0\%), whereas significant heterogeneity of associations with outcome was observed for CV death (HR, 0.85; 95\% CI, 0.78-0.93; Q statistic, P\,=\,.02; I2\,=\,64.3\%). The presence or absence of atherosclerotic CV disease did not modify the association with outcomes for major adverse CV events (HR, 0.89; 95\% CI, 0.84-0.95 and HR, 0.94; 95\% CI, 0.83-1.07, respectively; P\,=\,.63 for interaction), with similar absence of associations with outcome modification by prevalent atherosclerotic CV disease for HHF/CV death (P\,=\,.62 for interaction), HHF (P\,=\,.26 for interaction), or kidney outcomes (P\,=\,.73 for interaction). CONCLUSIONS AND RELEVANCE: In this meta-analysis, SGLT2 inhibitors were associated with a reduced risk of major adverse CV events; in addition, results suggest significant heterogeneity in associations with CV death. The largest benefit across the class was for an associated reduction in risk for HHF and kidney outcomes, with benefits for HHF risk being the most consistent observation across the trials.},
  langid = {english},
  pmcid = {PMC7542529},
  pmid = {33031522},
  keywords = {Cardiovascular Diseases,Diabetes Mellitus Type 2,Disease Progression,Heart Failure,Hospitalization,Humans,Proportional Hazards Models,Renal Insufficiency Chronic,Sodium-Glucose Transporter 2 Inhibitors}
}

@article{mcmurrayEffectsCandesartanPatients2003,
  title = {Effects of Candesartan in Patients with Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The {{CHARM-Added}} Trial},
  shorttitle = {Effects of Candesartan in Patients with Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors},
  author = {McMurray, John JV and {\"O}stergren, Jan and Swedberg, Karl and Granger, Christopher B. and Held, Peter and Michelson, Eric L. and Olofsson, Bertil and Yusuf, Salim and Pfeffer, Marc A.},
  year = {2003},
  month = sep,
  journal = {The Lancet},
  volume = {362},
  number = {9386},
  pages = {767--771},
  publisher = {Elsevier},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(03)14283-3},
  urldate = {2025-02-26},
  langid = {english},
  pmid = {13678869}
}

@article{mcmurrayEffectsCandesartanPatients2003a,
  title = {Effects of Candesartan in Patients with Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The {{CHARM-Added}} Trial},
  shorttitle = {Effects of Candesartan in Patients with Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors},
  author = {McMurray, John JV and {\"O}stergren, Jan and Swedberg, Karl and Granger, Christopher B. and Held, Peter and Michelson, Eric L. and Olofsson, Bertil and Yusuf, Salim and Pfeffer, Marc A.},
  year = {2003},
  month = sep,
  journal = {The Lancet},
  volume = {362},
  number = {9386},
  pages = {767--771},
  publisher = {Elsevier},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(03)14283-3},
  urldate = {2025-02-26},
  langid = {english},
  pmid = {13678869},
  file = {/Users/xx20081/Zotero/storage/H5RIM2TY/McMurray et al. - 2003 - Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic.pdf}
}

@article{mcmurrayjohnj.v.AngiotensinNeprilysinInhibition2014,
  title = {Angiotensin--{{Neprilysin Inhibition}} versus {{Enalapril}} in {{Heart Failure}}},
  author = {{McMurray John J.V.} and {Packer Milton} and {Desai Akshay S.} and {Gong Jianjian} and {Lefkowitz Martin P.} and {Rizkala Adel R.} and {Rouleau Jean L.} and {Shi Victor C.} and {Solomon Scott D.} and {Swedberg Karl} and {Zile Michael R.}},
  year = {2014},
  journal = {New England Journal of Medicine},
  volume = {371},
  number = {11},
  pages = {993--1004},
  publisher = {Massachusetts Medical Society},
  doi = {10.1056/NEJMoa1409077},
  urldate = {2024-07-04},
  abstract = {The angiotensin receptor--neprilysin inhibitor LCZ696 was compared with the ACE inhibitor enalapril in patients with advanced heart failure. LCZ696 was superior to enalapril in all outcomes. Neprilysin inhibition may replace ACE inhibition for the treatment of heart failure. Angiotensin-converting--enzyme (ACE) inhibitors have been the cornerstone of the treatment for heart failure and a reduced ejection fraction for nearly 25 years, since enalapril was shown to reduce the risk of death in two trials.1,2 Long-term treatment with enalapril decreased the relative risk of death by 16\% among patients with mild-to-moderate symptoms.2 The effect of angiotensin-receptor blockers (ARBs) on mortality has been inconsistent,3,4 and thus, these drugs are recommended primarily for patients who have unacceptable side effects (primarily cough) while receiving ACE inhibitors. Subsequent studies showed that the use of beta-blockers and mineralocorticoid-receptor antagonists, when added to ACE .~.~.},
  file = {/Users/xx20081/Zotero/storage/TP7HHBVC/McMurray John J.V. et al. - 2014 - AngiotensinNeprilysin Inhibition versus Enalapril.pdf}
}

@article{meiImpactsObesityGlobal2023,
  title = {Impacts of Obesity on Global Subclinical Left Cardiac Function Represented by {{CMR-derived}} Myocardial Strain, {{TyG}} Index May Be a Predictor},
  author = {Mei, Jiajie and Li, Yanhua and Dong, Jianli and Bai, Miaomiao and Jiang, Yinong and Qu, Xiaofeng and Yin, Lili},
  year = {2023},
  month = sep,
  journal = {Scientific Reports},
  volume = {13},
  number = {1},
  pages = {16031},
  issn = {2045-2322},
  doi = {10.1038/s41598-023-43343-z},
  abstract = {Obesity is a recognized risk factor for heart failure. People with similar weights may have different metabolic health. Notably, insulin resistance is a hallmark of obesity and a feature of heart failure. We aimed to evaluate the effects of obesity and metabolic health status on subclinical left cardiac function. We also investigated whether insulin resistance (TyG index) plays a role in BMI-linked subclinical left cardiac dysfunction. The study involved 403 volunteers. Hierarchical multiple regression models were used to assess associations between obesity, metabolic health, and overall subclinical left cardiac function. Mediating analysis was used to explore the role of the TyG index in the association between BMI and left cardiac function. Finally, ROC analysis was performed to explore the predictive value of the TyG index in subclinical left cardiac dysfunction. The correlation analysis showed that metabolic unhealth increased the risk of subclinical left ventricular (LV) dysfunction; obesity was associated with an increased risk of global left cardiac dysfunction regardless of metabolic health status. The TyG index mediated 25\% of the associations between BMI and Left atrial (LA) functional parameters. ROC analysis exhibited that the TyG index can be used as a predictor of LA dysfunction (AUC\,=\,0.63), and the optimal cut-off point for the TyG index is 9.33. Even a "non-obese metabolically unhealthy" is a detrimental state of early LV function; obesity remains a major risk factor for global subclinical left cardiac dysfunction. Using the TyG index could allow early identification of individuals at high risk of subclinical left cardiac dysfunction.Registration number: ChiCTR2200057991; Date of registration: 2022-03-25. URL: http://www.chictr.org.cn/showproj.aspx?proj=162316 .},
  langid = {english},
  pmcid = {PMC10519967},
  pmid = {37749172},
  keywords = {Heart,Heart Failure,Humans,Insulin Resistance,Obesity,Risk Factors,Triglycerides,Ventricular Dysfunction Left},
  file = {/Users/xx20081/Zotero/storage/89ZK8JLI/Mei et al. - 2023 - Impacts of obesity on global subclinical left card.pdf}
}

@article{melchiorsenRareHeterozygousLossofFunction2023,
  title = {Rare {{Heterozygous Loss-of-Function Variants}} in the {{Human GLP-1 Receptor Are Not Associated With Cardiometabolic Phenotypes}}},
  author = {Melchiorsen, Josefine U. and S{\o}rensen, Kimmie V. and {Bork-Jensen}, Jette and Kizilkaya, H{\"u}s{\"u}n S. and Gasbjerg, L{\ae}rke S. and Hauser, Alexander S. and Rungby, J{\o}rgen and S{\o}rensen, Henrik T. and Vaag, Allan and Nielsen, Jens S. and Pedersen, Oluf and Linneberg, Allan and Hartmann, Bolette and Gjesing, Anette P. and Holst, Jens J. and Hansen, Torben and Rosenkilde, Mette M. and Grarup, Niels},
  year = {2023},
  month = oct,
  journal = {The Journal of Clinical Endocrinology and Metabolism},
  volume = {108},
  number = {11},
  pages = {2821--2833},
  issn = {1945-7197},
  doi = {10.1210/clinem/dgad290},
  abstract = {CONTEXT: Lost glucagon-like peptide 1 receptor (GLP-1R) function affects human physiology. OBJECTIVE: This work aimed to identify coding nonsynonymous GLP1R variants in Danish individuals to link their in vitro phenotypes and clinical phenotypic associations. METHODS: We sequenced GLP1R in 8642 Danish individuals with type 2 diabetes or normal glucose tolerance and examined the ability of nonsynonymous variants to bind GLP-1 and to signal in transfected cells via cyclic adenosine monophosphate (cAMP) formation and {$\beta$}-arrestin recruitment. We performed a cross-sectional study between the burden of loss-of-signaling (LoS) variants and cardiometabolic phenotypes in 2930 patients with type 2 diabetes and 5712 participants in a population-based cohort. Furthermore, we studied the association between cardiometabolic phenotypes and the burden of the LoS variants and 60 partly overlapping predicted loss-of-function (pLoF) GLP1R variants found in 330 566 unrelated White exome-sequenced participants in the UK Biobank cohort. RESULTS: We identified 36 nonsynonymous variants in GLP1R, of which 10 had a statistically significant loss in GLP-1-induced cAMP signaling compared to wild-type. However, no association was observed between the LoS variants and type 2 diabetes, although LoS variant carriers had a minor increased fasting plasma glucose level. Moreover, pLoF variants from the UK Biobank also did not reveal substantial cardiometabolic associations, despite a small effect on glycated hemoglobin A1c. CONCLUSION: Since no homozygous LoS nor pLoF variants were identified and heterozygous carriers had similar cardiometabolic phenotype as noncarriers, we conclude that GLP-1R may be of particular importance in human physiology, due to a potential evolutionary intolerance of harmful homozygous GLP1R variants.},
  langid = {english},
  pmcid = {PMC10584003},
  pmid = {37235780},
  keywords = {Cardiovascular Diseases,Cross-Sectional Studies,Diabetes Mellitus Type 2,functional study,genetic association,GLP-1R,Glucagon-Like Peptide 1,glucagon-like peptide 1 receptor,Glucagon-Like Peptide-1 Receptor,Humans,Phenotype,type 2 diabetes},
  file = {/Users/xx20081/Zotero/storage/XEYP9JP7/Melchiorsen et al. - 2023 - Rare Heterozygous Loss-of-Function Variants in the.pdf}
}

@misc{MendelianRandomizationStudying,
  title = {Mendelian Randomization for Studying the Effects of Perturbing Drug Targets - {{PMC}}},
  urldate = {2024-01-18},
  howpublished = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903200/},
  file = {/Users/xx20081/Zotero/storage/23QL9FZU/PMC7903200.html}
}

@article{mengMultiancestryGenomewideAssociation2024,
  title = {Multi-Ancestry Genome-Wide Association Study of Major Depression Aids Locus Discovery, Fine Mapping, Gene Prioritization and Causal Inference},
  author = {Meng, Xiangrui and Navoly, Georgina and Giannakopoulou, Olga and Levey, Daniel F. and Koller, Dora and Pathak, Gita A. and Koen, Nastassja and Lin, Kuang and Adams, Mark J. and Renter{\'i}a, Miguel E. and Feng, Yanzhe and Gaziano, J. Michael and Stein, Dan J. and Zar, Heather J. and Campbell, Megan L. and {van Heel}, David A. and Trivedi, Bhavi and Finer, Sarah and McQuillin, Andrew and Bass, Nick and Chundru, V. Kartik and Martin, Hilary C. and Huang, Qin Qin and Valkovskaya, Maria and Chu, Chia-Yi and Kanjira, Susan and Kuo, Po-Hsiu and Chen, Hsi-Chung and Tsai, Shih-Jen and Liu, Yu-Li and Kendler, Kenneth S. and Peterson, Roseann E. and Cai, Na and Fang, Yu and Sen, Srijan and Scott, Laura J. and Burmeister, Margit and Loos, Ruth J. F. and Preuss, Michael H. and Actkins, Ky'Era V. and Davis, Lea K. and Uddin, Monica and Wani, Agaz H. and Wildman, Derek E. and Aiello, Allison E. and Ursano, Robert J. and Kessler, Ronald C. and Kanai, Masahiro and Okada, Yukinori and Sakaue, Saori and Rabinowitz, Jill A. and Maher, Brion S. and Uhl, George and Eaton, William and {Cruz-Fuentes}, Carlos S. and {Martinez-Levy}, Gabriela A. and Campos, Adrian I. and Millwood, Iona Y. and Chen, Zhengming and Li, Liming and {Wassertheil-Smoller}, Sylvia and Jiang, Yunxuan and Tian, Chao and Martin, Nicholas G. and Mitchell, Brittany L. and Byrne, Enda M. and Awasthi, Swapnil and Coleman, Jonathan R. I. and Ripke, Stephan and {PGC-MDD Working Group} and {China Kadoorie Biobank Collaborative Group} and {23andMe Research Team} and {Genes and Health Research Team} and {BioBank Japan Project} and Sofer, Tamar and Walters, Robin G. and McIntosh, Andrew M. and Polimanti, Renato and Dunn, Erin C. and Stein, Murray B. and Gelernter, Joel and Lewis, Cathryn M. and Kuchenbaecker, Karoline},
  year = {2024},
  month = feb,
  journal = {Nature Genetics},
  volume = {56},
  number = {2},
  pages = {222--233},
  issn = {1546-1718},
  doi = {10.1038/s41588-023-01596-4},
  abstract = {Most genome-wide association studies (GWAS) of major depression (MD) have been conducted in samples of European ancestry. Here we report a multi-ancestry GWAS of MD, adding data from 21 cohorts with 88,316 MD cases and 902,757 controls to previously reported data. This analysis used a range of measures to define MD and included samples of African (36\% of effective sample size), East Asian (26\%) and South Asian (6\%) ancestry and Hispanic/Latin American participants (32\%). The multi-ancestry GWAS identified 53 significantly associated novel loci. For loci from GWAS in European ancestry samples, fewer than expected were transferable to other ancestry groups. Fine mapping benefited from additional sample diversity. A transcriptome-wide association study identified 205 significantly associated novel genes. These findings suggest that, for MD, increasing ancestral and global diversity in genetic studies may be particularly important to ensure discovery of core genes and inform about transferability of findings.},
  langid = {english},
  pmcid = {PMC10864182},
  pmid = {38177345},
  keywords = {Chromosome Mapping,Depression,Depressive Disorder Major,Genetic Predisposition to Disease,Genome-Wide Association Study,Humans,Polymorphism Single Nucleotide},
  file = {/Users/xx20081/Zotero/storage/39R5PCTU/Meng et al. - 2024 - Multi-ancestry genome-wide association study of ma.pdf}
}

@article{meta-analysisglobalgroupinchronicheartfailuremaggicSurvivalPatientsHeart2012,
  title = {The Survival of Patients with Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction: An Individual Patient Data Meta-Analysis},
  shorttitle = {The Survival of Patients with Heart Failure with Preserved or Reduced Left Ventricular Ejection Fraction},
  author = {{Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)}},
  year = {2012},
  month = jul,
  journal = {European Heart Journal},
  volume = {33},
  number = {14},
  pages = {1750--1757},
  issn = {1522-9645},
  doi = {10.1093/eurheartj/ehr254},
  abstract = {AIMS: A substantial proportion of patients with heart failure have preserved left ventricular ejection fraction (HF-PEF). Previous studies have reported mixed results whether survival is similar to those patients with heart failure and reduced EF (HF-REF). METHODS AND RESULTS: We compared survival in patients with HF-PEF with that in patients with HF-REF in a meta-analysis using individual patient data. Preserved EF was defined as an EF {$\geq$} 50\%. The 31 studies included 41 972 patients: 10 347 with HF-PEF and 31 625 with HF-REF. Compared with patients with HF-REF, those with HF-PEF were older (mean age 71 vs. 66 years), were more often women (50 vs. 28\%), and have a history of hypertension (51 vs. 41\%). Ischaemic aetiology was less common (43 vs. 59\%) in patients with HF-PEF. There were 121 [95\% confidence interval (CI): 117, 126] deaths per 1000 patient-years in those with HF-PEF and 141 (95\% CI: 138, 144) deaths per 1000 patient-years in those with HF-REF. Patients with HF-PEF had lower mortality than those with HF-REF (adjusted for age, gender, aetiology, and history of hypertension, diabetes, and atrial fibrillation); hazard ratio 0.68 (95\% CI: 0.64, 0.71). The risk of death did not increase notably until EF fell below 40\%. CONCLUSION: Patients with HF-PEF have a lower risk of death than patients with HF-REF, and this difference is seen regardless of age, gender, and aetiology of HF. However, absolute mortality is still high in patients with HF-PEF highlighting the need for a treatment to improve prognosis.},
  langid = {english},
  pmid = {21821849},
  keywords = {Aged,Cause of Death,Female,Heart Failure,Humans,Male,Randomized Controlled Trials as Topic,Risk Factors,Stroke Volume},
  file = {/Users/xx20081/Zotero/storage/9ECRNU3L/Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) - 2012 - The survival of patients with heart failure with p.pdf}
}

@misc{MetaanalysisGenomewideAssociation,
  title = {Meta-Analysis of Genome-Wide Association Studies for Height and Body Mass Index in {$\sim$}700000 Individuals of {{European}} Ancestry - {{PubMed}}},
  urldate = {2024-02-19},
  howpublished = {https://pubmed.ncbi.nlm.nih.gov/30124842/},
  file = {/Users/xx20081/Zotero/storage/DVWCQPIM/30124842.html}
}

@article{michalowskaAssociationGLP1RVariants2022,
  title = {Association of {{GLP1R}} Variants Rs2268641 and Rs6923761 with Obesity and Other Metabolic Parameters in a {{Polish}} Cohort},
  author = {Micha{\l}owska, Joanna and {Miller-Kasprzak}, Ewa and {Seraszek-Jaros}, Agnieszka and Mostowska, Adrianna and Bogda{\'n}ski, Pawe{\l}},
  year = {2022},
  month = oct,
  journal = {Frontiers in Endocrinology},
  volume = {13},
  pages = {1000185},
  issn = {1664-2392},
  doi = {10.3389/fendo.2022.1000185},
  urldate = {2024-01-18},
  abstract = {Introduction Obesity is a complex disease associated with excessive fat accumulation and numerous metabolic complications. So far, many factors leading to the development of this disorder have been identified, including genetic susceptibility. Various studies linked GLP1R variants with anthropometric and metabolic parameters, suggesting the role of the variation in this gene in metabolic health. Objective The aim of this study is to investigate the association of two single nucleotide variants of GLP1R gene, rs2268641 and rs6923761, with excessive weight, metabolic syndrome, anthropometric measurements and selected metabolic parameters. Methods Normal-weight subjects (n= 340, control group) and subjects with excessive body mass (n = 600, study group) participated in this study. For all participants, anthropometric measurements and metabolic parameters were collected, and genotyping of the two single nucleotide variants of GLP1R gene, rs2268641 and rs6923761, was performed using the high-resolution melting curve analysis. Results Significant differences in the genotype distribution of rs2268641 were found, where homozygous TT genotype was significantly less frequent in the study group with excessive body mass (OR=0.66; p=0.0298). For rs6923761, A allele and homozygous AA genotype were significantly more frequent in the study group with excessive weight than in the control group (OR=1.27; p=0.0239 and OR=1.69; p=0.0205, respectively). The association of studied variants with metabolic parameters was found for rs6923761. For this variant, AA carriers had higher body mass in comparison to GG carriers (p=0.0246), and AA carriers had higher glucose concentration in comparison to AG carriers (p=0.0498). We did not find an association of rs2268641 and rs6923761 with metabolic syndrome. Conclusion In our study, AA carriers of rs6923761 had higher risk of excessive body mass, whereas TT carriers of rs2268641 had lower risk of being overweight. Moreover, homozygous carriers of the minor allele of rs6923761 had higher glucose concentration in comparison to heterozygous subjects. None of the studied variants were associated with metabolic syndrome in the studied population.},
  pmcid = {PMC9626533},
  pmid = {36339410},
  keywords = {read},
  file = {/Users/xx20081/Zotero/storage/H6XXDNJY/Michaowska et al. - 2022 - Association of GLP1R variants rs2268641 and rs6923.pdf}
}

@article{mitchellStrategiesInvestigateMitigate2023,
  title = {Strategies to Investigate and Mitigate Collider Bias in Genetic and {{Mendelian}} Randomisation Studies of Disease Progression},
  author = {Mitchell, Ruth E. and Hartley, April E. and Walker, Venexia M. and Gkatzionis, Apostolos and Yarmolinsky, James and Bell, Joshua A. and Chong, Amanda H. W. and Paternoster, Lavinia and Tilling, Kate and Smith, George Davey},
  year = {2023},
  month = feb,
  journal = {PLoS genetics},
  volume = {19},
  number = {2},
  pages = {e1010596},
  issn = {1553-7404},
  doi = {10.1371/journal.pgen.1010596},
  abstract = {Genetic studies of disease progression can be used to identify factors that may influence survival or prognosis, which may differ from factors that influence on disease susceptibility. Studies of disease progression feed directly into therapeutics for disease, whereas studies of incidence inform prevention strategies. However, studies of disease progression are known to be affected by collider (also known as "index event") bias since the disease progression phenotype can only be observed for individuals who have the disease. This applies equally to observational and genetic studies, including genome-wide association studies and Mendelian randomisation (MR) analyses. In this paper, our aim is to review several statistical methods that can be used to detect and adjust for index event bias in studies of disease progression, and how they apply to genetic and MR studies using both individual- and summary-level data. Methods to detect the presence of index event bias include the use of negative controls, a comparison of associations between risk factors for incidence in individuals with and without the disease, and an inspection of Miami plots. Methods to adjust for the bias include inverse probability weighting (with individual-level data), or Slope-Hunter and Dudbridge et al.'s index event bias adjustment (when only summary-level data are available). We also outline two approaches for sensitivity analysis. We then illustrate how three methods to minimise bias can be used in practice with two applied examples. Our first example investigates the effects of blood lipid traits on mortality from coronary heart disease, while our second example investigates genetic associations with breast cancer mortality.},
  langid = {english},
  pmcid = {PMC9949638},
  pmid = {36821633},
  keywords = {Bias,Disease Progression,Genome-Wide Association Study,Humans,Mendelian Randomization Analysis,Phenotype,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/S24F8W7I/Mitchell et al. - 2023 - Strategies to investigate and mitigate collider bi.pdf}
}

@article{mitchellStrategiesInvestigateMitigate2023a,
  title = {Strategies to Investigate and Mitigate Collider Bias in Genetic and {{Mendelian}} Randomisation Studies of Disease Progression},
  author = {Mitchell, Ruth E. and Hartley, April E. and Walker, Venexia M. and Gkatzionis, Apostolos and Yarmolinsky, James and Bell, Joshua A. and Chong, Amanda H. W. and Paternoster, Lavinia and Tilling, Kate and Smith, George Davey},
  year = {2023},
  month = feb,
  journal = {PLOS Genetics},
  volume = {19},
  number = {2},
  pages = {e1010596},
  publisher = {Public Library of Science},
  issn = {1553-7404},
  doi = {10.1371/journal.pgen.1010596},
  urldate = {2024-03-08},
  abstract = {Genetic studies of disease progression can be used to identify factors that may influence survival or prognosis, which may differ from factors that influence on disease susceptibility. Studies of disease progression feed directly into therapeutics for disease, whereas studies of incidence inform prevention strategies. However, studies of disease progression are known to be affected by collider (also known as ``index event'') bias since the disease progression phenotype can only be observed for individuals who have the disease. This applies equally to observational and genetic studies, including genome-wide association studies and Mendelian randomisation (MR) analyses. In this paper, our aim is to review several statistical methods that can be used to detect and adjust for index event bias in studies of disease progression, and how they apply to genetic and MR studies using both individual- and summary-level data. Methods to detect the presence of index event bias include the use of negative controls, a comparison of associations between risk factors for incidence in individuals with and without the disease, and an inspection of Miami plots. Methods to adjust for the bias include inverse probability weighting (with individual-level data), or Slope-Hunter and Dudbridge et al.'s index event bias adjustment (when only summary-level data are available). We also outline two approaches for sensitivity analysis. We then illustrate how three methods to minimise bias can be used in practice with two applied examples. Our first example investigates the effects of blood lipid traits on mortality from coronary heart disease, while our second example investigates genetic associations with breast cancer mortality.},
  langid = {english},
  keywords = {Breast cancer,Cancer risk factors,Colliders,Epidemiology,Genetics of disease,Genome-wide association studies,Medical risk factors,Prognosis},
  file = {/Users/xx20081/Zotero/storage/FI8TWL7Y/Mitchell et al. - 2023 - Strategies to investigate and mitigate collider bi.pdf}
}

@article{miyazawaCrossancestryGenomewideAnalysis2023,
  title = {Cross-Ancestry Genome-Wide Analysis of Atrial Fibrillation Unveils Disease Biology and Enables Cardioembolic Risk Prediction},
  author = {Miyazawa, Kazuo and Ito, Kaoru and Ito, Masamichi and Zou, Zhaonan and Kubota, Masayuki and Nomura, Seitaro and Matsunaga, Hiroshi and Koyama, Satoshi and Ieki, Hirotaka and Akiyama, Masato and Koike, Yoshinao and Kurosawa, Ryo and Yoshida, Hiroki and Ozaki, Kouichi and Onouchi, Yoshihiro and {BioBank Japan Project} and Takahashi, Atsushi and Matsuda, Koichi and Murakami, Yoshinori and Aburatani, Hiroyuki and Kubo, Michiaki and Momozawa, Yukihide and Terao, Chikashi and Oki, Shinya and Akazawa, Hiroshi and Kamatani, Yoichiro and Komuro, Issei},
  year = {2023},
  month = feb,
  journal = {Nature Genetics},
  volume = {55},
  number = {2},
  pages = {187--197},
  issn = {1546-1718},
  doi = {10.1038/s41588-022-01284-9},
  abstract = {Atrial fibrillation (AF) is a common cardiac arrhythmia resulting in increased risk of stroke. Despite highly heritable etiology, our understanding of the genetic architecture of AF remains incomplete. Here we performed a genome-wide association study in the Japanese population comprising 9,826 cases among 150,272 individuals and identified East Asian-specific rare variants associated with AF. A cross-ancestry meta-analysis of {$>$}1 million individuals, including 77,690 cases, identified 35 new susceptibility loci. Transcriptome-wide association analysis identified IL6R as a putative causal gene, suggesting the involvement of immune responses. Integrative analysis with ChIP-seq data and functional assessment using human induced pluripotent stem cell-derived cardiomyocytes demonstrated ERRg as having a key role in the transcriptional regulation of AF-associated genes. A polygenic risk score derived from the cross-ancestry meta-analysis predicted increased risks of cardiovascular and stroke mortalities and segregated individuals with cardioembolic stroke in undiagnosed AF patients. Our results provide new biological and clinical insights into AF genetics and suggest their potential for clinical applications.},
  langid = {english},
  pmcid = {PMC9925380},
  pmid = {36653681},
  keywords = {Atrial Fibrillation,Biology,Genetic Predisposition to Disease,Genome Human,Genome-Wide Association Study,Humans,Induced Pluripotent Stem Cells,Polymorphism Single Nucleotide,Stroke},
  file = {/Users/xx20081/Zotero/storage/9EAPRBAF/Miyazawa et al. - 2023 - Cross-ancestry genome-wide analysis of atrial fibr.pdf}
}

@article{miyazawaCrossancestryGenomewideAnalysis2023a,
  title = {Cross-Ancestry Genome-Wide Analysis of Atrial Fibrillation Unveils Disease Biology and Enables Cardioembolic Risk Prediction},
  author = {Miyazawa, Kazuo and Ito, Kaoru and Ito, Masamichi and Zou, Zhaonan and Kubota, Masayuki and Nomura, Seitaro and Matsunaga, Hiroshi and Koyama, Satoshi and Ieki, Hirotaka and Akiyama, Masato and Koike, Yoshinao and Kurosawa, Ryo and Yoshida, Hiroki and Ozaki, Kouichi and Onouchi, Yoshihiro and {BioBank Japan Project} and Takahashi, Atsushi and Matsuda, Koichi and Murakami, Yoshinori and Aburatani, Hiroyuki and Kubo, Michiaki and Momozawa, Yukihide and Terao, Chikashi and Oki, Shinya and Akazawa, Hiroshi and Kamatani, Yoichiro and Komuro, Issei},
  year = {2023},
  month = feb,
  journal = {Nature Genetics},
  volume = {55},
  number = {2},
  pages = {187--197},
  issn = {1546-1718},
  doi = {10.1038/s41588-022-01284-9},
  abstract = {Atrial fibrillation (AF) is a common cardiac arrhythmia resulting in increased risk of stroke. Despite highly heritable etiology, our understanding of the genetic architecture of AF remains incomplete. Here we performed a genome-wide association study in the Japanese population comprising 9,826 cases among 150,272 individuals and identified East Asian-specific rare variants associated with AF. A cross-ancestry meta-analysis of {$>$}1 million individuals, including 77,690 cases, identified 35 new susceptibility loci. Transcriptome-wide association analysis identified IL6R as a putative causal gene, suggesting the involvement of immune responses. Integrative analysis with ChIP-seq data and functional assessment using human induced pluripotent stem cell-derived cardiomyocytes demonstrated ERRg as having a key role in the transcriptional regulation of AF-associated genes. A polygenic risk score derived from the cross-ancestry meta-analysis predicted increased risks of cardiovascular and stroke mortalities and segregated individuals with cardioembolic stroke in undiagnosed AF patients. Our results provide new biological and clinical insights into AF genetics and suggest their potential for clinical applications.},
  langid = {english},
  pmcid = {PMC9925380},
  pmid = {36653681},
  keywords = {Atrial Fibrillation,Biology,Genetic Predisposition to Disease,Genome Human,Genome-Wide Association Study,Humans,Induced Pluripotent Stem Cells,Polymorphism Single Nucleotide,Stroke},
  file = {/Users/xx20081/Zotero/storage/FPQZKS2F/Miyazawa et al. - 2023 - Cross-ancestry genome-wide analysis of atrial fibr.pdf}
}

@article{molderSustainableDataAnalysis2021,
  title = {Sustainable Data Analysis with {{Snakemake}}},
  author = {M{\"o}lder, Felix and Jablonski, Kim Philipp and Letcher, Brice and Hall, Michael B. and {Tomkins-Tinch}, Christopher H. and Sochat, Vanessa and Forster, Jan and Lee, Soohyun and Twardziok, Sven O. and Kanitz, Alexander and Wilm, Andreas and Holtgrewe, Manuel and Rahmann, Sven and Nahnsen, Sven and K{\"o}ster, Johannes},
  year = {2021},
  journal = {F1000Research},
  volume = {10},
  pages = {33},
  issn = {2046-1402},
  doi = {10.12688/f1000research.29032.2},
  abstract = {Data analysis often entails a multitude of heterogeneous steps, from the application of various command line tools to the usage of scripting languages like R or Python for the generation of plots and tables. It is widely recognized that data analyses should ideally be conducted in a reproducible way.~Reproducibility enables technical validation and regeneration of results on the original or even new data. However, reproducibility alone is by no means sufficient to deliver an analysis that is of lasting impact (i.e., sustainable) for the field, or even just one research group. We postulate that it is equally important to ensure adaptability and transparency. The former describes the ability to modify the analysis to answer extended or slightly different research questions. The latter describes the ability to understand the analysis in order to judge whether it is not only technically, but methodologically valid. Here, we analyze the properties needed for a data analysis to become reproducible, adaptable, and transparent. We show how the popular workflow management system Snakemake can be used to guarantee this, and how it enables an ergonomic, combined, unified representation of all steps involved in data analysis, ranging from raw data processing, to quality control and fine-grained, interactive exploration and plotting of final results.},
  langid = {english},
  pmcid = {PMC8114187},
  pmid = {34035898},
  keywords = {adaptability,data analysis,Data Analysis,reproducibility,Reproducibility of Results,scalability,Software,sustainability,transparency,Workflow,workflow management},
  file = {/Users/xx20081/Zotero/storage/TTC3QQTE/Mlder et al. - 2021 - Sustainable data analysis with Snakemake.pdf}
}

@article{moraDeficiencyPDK1Liver2005,
  title = {Deficiency of {{PDK1}} in Liver Results in Glucose Intolerance, Impairment of Insulin-Regulated Gene Expression and Liver Failure},
  author = {Mora, Alfonso and Lipina, Christopher and Tronche, Fran{\c c}ois and Sutherland, Calum and Alessi, Dario~R.},
  year = {2005},
  month = feb,
  journal = {Biochemical Journal},
  volume = {385},
  number = {Pt 3},
  pages = {639--648},
  issn = {0264-6021},
  doi = {10.1042/BJ20041782},
  urldate = {2025-05-27},
  abstract = {The liver plays an important role in insulin-regulated glucose homoeostasis. To study the function of the PDK1 (3-phosphoinositide-dependent protein kinase-1) signalling pathway in mediating insulin's actions in the liver, we employed CRE recombinase/loxP technology to generate L(liver)-PDK1-/- mice, which lack expression of PDK1 in hepatocytes and in which insulin failed to induce activation of PKB in liver. The L-PDK1-/- mice were not insulin-intolerant, possessed normal levels of blood glucose and insulin under normal feeding conditions, but were markedly glucose-intolerant when injected with glucose. The L-PDK1-/- mice also possessed 10-fold lower levels of hepatic glycogen compared with control littermates, and were unable to normalize their blood glucose levels within 2~h after injection of insulin. The glucose intolerance of the L-PDK1-/- mice may be due to an inability of glucose to suppress hepatic glucose output through the gluconeogenic pathway, since the mRNA encoding hepatic PEPCK (phosphoenolpyruvate carboxykinase), G6Pase (glucose-6-phosphatase) and SREBP1 (sterol-regulatory-element-binding protein 1), which regulate gluconeogenesis, are no longer controlled by feeding. Furthermore, three other insulin-controlled genes, namely IGFBP1 (insulin-like-growth-factor-binding protein-1), IRS2 (insulin receptor substrate 2) and glucokinase, were regulated abnormally by feeding in the liver of PDK1-deficient mice. Finally, the L-PDK1-/- mice died between 4--16~weeks of age due to liver failure. These results establish that the PDK1 signalling pathway plays an important role in regulating glucose homoeostasis and controlling expression of insulin-regulated genes. They suggest that a deficiency of the PDK1 pathway in the liver could contribute to development of diabetes, as well as to liver failure.},
  pmcid = {PMC1134738},
  pmid = {15554902},
  file = {/Users/xx20081/Zotero/storage/CJ4JGG23/Mora et al. - 2005 - Deficiency of PDK1 in liver results in glucose intolerance, impairment of insulin-regulated gene exp.pdf}
}

@article{morkedalRiskMyocardialInfarction2014,
  title = {Risk of Myocardial Infarction and Heart Failure among Metabolically Healthy but Obese Individuals: {{HUNT}} ({{Nord-Tr{\o}ndelag Health Study}}), {{Norway}}},
  shorttitle = {Risk of Myocardial Infarction and Heart Failure among Metabolically Healthy but Obese Individuals},
  author = {M{\o}rkedal, Bj{\o}rn and Vatten, Lars J. and Romundstad, P{\aa}l R. and Laugsand, Lars E. and Janszky, Imre},
  year = {2014},
  month = mar,
  journal = {Journal of the American College of Cardiology},
  volume = {63},
  number = {11},
  pages = {1071--1078},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2013.11.035},
  abstract = {OBJECTIVES: This study sought to investigate whether obesity in the absence of metabolic abnormalities might be a relatively benign condition in relation to acute myocardial infarction (AMI) and heart failure (HF). BACKGROUND: The results of previous studies are conflicting for AMI and largely unknown for HF, and the role of the duration of obesity has not been investigated. METHODS: In a population-based prospective cohort study, a total of 61,299 men and women free of cardiovascular disease were classified according to body mass index (BMI) and metabolic status at baseline. BMI also was measured 10 and 30 years before baseline for 27,196 participants. RESULTS: During 12 years of follow-up, 2,547 participants had a first AMI, and 1,201 participants had a first HF. Compared with being normal weight (BMI {$<$}25 kg/m(2)) and metabolically healthy, the multivariable-adjusted hazard ratio (HR) for AMI was 1.1 (95\% confidence interval [CI]: 0.9 to 1.4) among obese (BMI~{$\geq$}30 kg/m(2)) and metabolically healthy participants and 2.0 (95\% CI: 1.7 to 2.3) among obese and metabolically unhealthy participants. We found similar results for severe (BMI~{$\geq$}35 kg/m(2)), long-lasting ({$>$}30 years), and abdominal obesity stratified for metabolic status. For HF, the HRs associated with obesity were 1.7 (95\% CI: 1.3 to 2.3) and 1.7 (95\% CI: 1.4 to 2.2) for metabolically healthy and unhealthy participants, respectively. Severe and long-lasting obesity were particularly harmful in relation to HF, regardless of metabolic status. CONCLUSIONS: In relation to AMI, obesity without metabolic abnormalities did not confer substantial excess risk, not even for severe or long-lasting obesity. For HF, even metabolically healthy obesity was associated with increased risk, particularly for long-lasting or severe obesity.},
  langid = {english},
  pmid = {24345592},
  keywords = {Adult,Age Factors,Aged,Body Mass Index,Case-Control Studies,Cause of Death,epidemiology,Female,heart failure,Heart Failure,Humans,Male,Metabolic Syndrome,Middle Aged,myocardial infarction,Myocardial Infarction,obesity,Obesity,Obesity Morbid,Prognosis,Prospective Studies,Risk Assessment,Severity of Illness Index,Sex Factors,Survival Rate,Time Factors},
  file = {/Users/xx20081/Zotero/storage/5SDWYFLI/Mrkedal et al. - 2014 - Risk of myocardial infarction and heart failure am.pdf}
}

@article{MostFrequentPrincipal,
  title = {Most {{Frequent Principal Diagnoses}} for {{Inpatient Stays}} in {{U}}.{{S}}. {{Hospitals}}, 2018},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/YGW276AU/Most Frequent Principal Diagnoses for Inpatient St.pdf}
}

@article{mottetPharmacogenomicsHeartFailure2016,
  title = {Pharmacogenomics of Heart Failure: A Systematic Review},
  shorttitle = {Pharmacogenomics of Heart Failure},
  author = {Mottet, Fannie and Vardeny, Orly and {de Denus}, Simon},
  year = {2016},
  month = nov,
  journal = {Pharmacogenomics},
  volume = {17},
  number = {16},
  pages = {1817--1858},
  issn = {1744-8042},
  doi = {10.2217/pgs-2016-0118},
  abstract = {BACKGROUND: Heart failure (HF) and multiple HF-related phenotypes are heritable. Genes implicated in the HF pathophysiology would be expected to influence the response to treatment. METHODS: We conducted a series of systematic literature searches on the pharmacogenetics of HF therapy to assess the current knowledge on this field. RESULTS: Existing data related to HF pharmacogenomics are still limited. The ADRB1 gene is a likely candidate to predict response to {$\beta$}-blockers. Moreover, the cytochrome P450 2D6 coding gene (CYP2D6) clearly affects the pharmacokinetics of metoprolol, although the clinical impact of this association remains to be established. CONCLUSION: Given the rising prevalence of HF and related costs, a more personalized use of HF drugs could have a remarkable benefit for patients, caregivers and healthcare systems.},
  langid = {english},
  pmid = {27813451},
  keywords = {Adrenergic beta-Antagonists,Angiotensin-Converting Enzyme Inhibitors,Cytochrome P-450 CYP2D6,Heart Failure,Humans,Pharmacogenetics,Polymorphism Genetic,Receptors Adrenergic beta-1}
}

@article{muellerHeartFailureAssociation2019,
  title = {Heart {{Failure Association}} of the {{European Society}} of {{Cardiology}} Practical Guidance on the Use of Natriuretic Peptide Concentrations},
  author = {Mueller, Christian and McDonald, Kenneth and {de Boer}, Rudolf A. and Maisel, Alan and Cleland, John G.F. and Kozhuharov, Nikola and Coats, Andrew J.S. and Metra, Marco and Mebazaa, Alexandre and Ruschitzka, Frank and Lainscak, Mitja and Filippatos, Gerasimos and Seferovic, Petar M. and Meijers, Wouter C. and {Bayes-Genis}, Antoni and Mueller, Thomas and Richards, Mark and Januzzi Jr, James L. and of Cardiology, on behalf of the Heart Failure Association of the European Society},
  year = {2019},
  journal = {European Journal of Heart Failure},
  volume = {21},
  number = {6},
  pages = {715--731},
  issn = {1879-0844},
  doi = {10.1002/ejhf.1494},
  urldate = {2024-07-03},
  abstract = {Natriuretic peptide [NP; B-type NP (BNP), N-terminal proBNP (NT-proBNP), and midregional proANP (MR-proANP)] concentrations are quantitative plasma biomarkers for the presence and severity of haemodynamic cardiac stress and heart failure (HF). End-diastolic wall stress, intracardiac filling pressures, and intracardiac volumes seem to be the dominant triggers. This paper details the most important indications for NPs and highlights 11 key principles underlying their clinical use shown below. NPs should always be used in conjunction with all other clinical information. NPs are reasonable surrogates for intracardiac volumes and filling pressures. NPs should be measured in all patients presenting with symptoms suggestive of HF such as dyspnoea and/or fatigue, as their use facilitates the early diagnosis and risk stratification of HF. NPs have very high diagnostic accuracy in discriminating HF from other causes of dyspnoea: the higher the NP, the higher the likelihood that dyspnoea is caused by HF. Optimal NP cut-off concentrations for the diagnosis of acute HF (very high filling pressures) in patients presenting to the emergency department with acute dyspnoea are higher compared with those used in the diagnosis of chronic HF in patients with dyspnoea on exertion (mild increase in filling pressures at rest). Obese patients have lower NP concentrations, mandating the use of lower cut-off concentrations (about 50\% lower). In stable HF patients, but also in patients with other cardiac disorders such as myocardial infarction, valvular heart disease, atrial fibrillation or pulmonary embolism, NP concentrations have high prognostic accuracy for death and HF hospitalization. Screening with NPs for the early detection of relevant cardiac disease including left ventricular systolic dysfunction in patients with cardiovascular risk factors may help to identify patients at increased risk, therefore allowing targeted preventive measures to prevent HF. BNP, NT-proBNP and MR-proANP have comparable diagnostic and prognostic accuracy. In patients with shock, NPs cannot be used to identify cause (e.g. cardiogenic vs. septic shock), but remain prognostic. NPs cannot identify the underlying cause of HF and, therefore, if elevated, must always be used in conjunction with cardiac imaging.},
  copyright = {{\copyright} 2019 The Authors. European Journal of Heart Failure {\copyright} 2019 European Society of Cardiology},
  langid = {english},
  keywords = {Cut-off concentrations,Heart failure,Natriuretic peptides},
  file = {/Users/xx20081/Zotero/storage/52CDEI7L/Mueller et al. - 2019 - Heart Failure Association of the European Society .pdf;/Users/xx20081/Zotero/storage/5TVAZK5I/ejhf.html}
}

@article{mukhopadhyayGeneticFactorsInfluencing2024,
  title = {The {{Genetic Factors Influencing Cardiomyopathies}} and {{Heart Failure}} across the {{Allele Frequency Spectrum}}},
  author = {Mukhopadhyay, Srinjay and Dixit, Prithvi and Khanom, Najiyah and Sanghera, Gianluca and McGurk, Kathryn A.},
  year = {2024},
  month = oct,
  journal = {Journal of Cardiovascular Translational Research},
  volume = {17},
  number = {5},
  pages = {1119--1139},
  issn = {1937-5395},
  doi = {10.1007/s12265-024-10520-y},
  urldate = {2024-12-27},
  abstract = {Heart failure (HF) remains a major cause of mortality and morbidity worldwide. Understanding the genetic basis of HF allows for the development of disease-modifying therapies, more appropriate risk stratification, and personalised management of patients. The advent of next-generation sequencing has enabled genome-wide association studies; moving beyond rare variants identified in a Mendelian fashion and detecting common DNA variants associated with disease. We summarise the latest GWAS and rare variant data on mixed and refined HF aetiologies, and cardiomyopathies. We describe the recent understanding of the functional impact of titin variants and highlight FHOD3 as a novel cardiomyopathy-associated gene. We describe future directions of research in this field and how genetic data can be leveraged to improve the care of patients with HF.},
  langid = {english},
  keywords = {Cardiomyopathy,Genetics,Heart failure},
  file = {/Users/xx20081/Zotero/storage/9UR29CFR/Mukhopadhyay et al. - 2024 - The Genetic Factors Influencing Cardiomyopathies and Heart Failure across the Allele Frequency Spect.pdf}
}

@article{musunuruGeneticTestingInherited2020,
  title = {Genetic {{Testing}} for {{Inherited Cardiovascular Diseases}}: {{A Scientific Statement From}} the {{American Heart Association}}},
  shorttitle = {Genetic {{Testing}} for {{Inherited Cardiovascular Diseases}}},
  author = {Musunuru, Kiran and Hershberger, Ray E. and Day, Sharlene M. and Klinedinst, N. Jennifer and Landstrom, Andrew P. and Parikh, Victoria N. and Prakash, Siddharth and Semsarian, Christopher and Sturm, Amy C. and {American Heart Association Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology}},
  year = {2020},
  month = aug,
  journal = {Circulation. Genomic and Precision Medicine},
  volume = {13},
  number = {4},
  pages = {e000067},
  issn = {2574-8300},
  doi = {10.1161/HCG.0000000000000067},
  abstract = {Advances in human genetics are improving the understanding of a variety of inherited cardiovascular diseases, including cardiomyopathies, arrhythmic disorders, vascular disorders, and lipid disorders such as familial hypercholesterolemia. However, not all cardiovascular practitioners are fully aware of the utility and potential pitfalls of incorporating genetic test results into the care of patients and their families. This statement summarizes current best practices with respect to genetic testing and its implications for the management of inherited cardiovascular diseases.},
  langid = {english},
  pmid = {32698598},
  keywords = {AHA Scientific Statements,American Heart Association,aneurysm,arrhythmia,Arrhythmias Cardiac,Cardiomyopathies,cardiomyopathy,cardiovascular diseases,Cardiovascular Diseases,channelopathy,genetic testing,Genetic Testing,genetics,Humans,Hyperlipoproteinemia Type II,Risk Factors,United States,Vascular Diseases}
}

@article{naatanenMetabolicProfilesReflect2023,
  title = {Metabolic Profiles Reflect Weight Loss Maintenance and the Composition of Diet after Very-Low-Energy Diet},
  author = {N{\"a}{\"a}t{\"a}nen, Mari and K{\aa}rlund, Anna and Mikkonen, Santtu and Kl{\aa}vus, Anton and Savolainen, Otto and Lehtonen, Marko and Karhunen, Leila and Hanhineva, Kati and Kolehmainen, Marjukka},
  year = {2023},
  month = jul,
  journal = {Clinical Nutrition},
  volume = {42},
  number = {7},
  pages = {1126--1141},
  issn = {0261-5614},
  doi = {10.1016/j.clnu.2023.05.011},
  urldate = {2025-05-28},
  abstract = {Background \& aims Diet and weight loss affect circulating metabolome. However, metabolite profiles induced by different weight loss maintenance diets and underlying longer term weight loss maintenance remain unknown. Herein, we investigated after-weight-loss metabolic signatures of two isocaloric 24-wk weight maintenance diets differing in satiety value due to dietary fibre, protein and fat contents and identified metabolite features that associated with successful weight loss maintenance. Methods Non-targeted LC-MS metabolomics approach was used to analyse plasma metabolites of 79 women and men (mean age~{\textpm}~SD 49.7~{\textpm}~9.0 years; BMI 34.2~{\textpm}~2.5~kg/m2) participating in a weight management study. Participants underwent a 7-week very-low-energy diet (VLED) and were thereafter randomised into two groups for a 24-week weight maintenance phase. Higher satiety food (HSF) group consumed high-fibre, high-protein, and low-fat products, while lower satiety food (LSF) group consumed isocaloric low-fibre products with average protein and fat content as a part of their weight maintenance diets. Plasma metabolites were analysed before the VLED and before and after the weight maintenance phase. Metabolite features discriminating HSF and LSF groups were annotated. We also analysed metabolite features that discriminated participants who maintained {$\geq$}10\% weight loss (HWM) and participants who maintained {$<$}10\% weight loss (LWM) at the end of the study, irrespective of the diet. Finally, we assessed robust linear regression between metabolite features and anthropometric and food group variables. Results We annotated 126 metabolites that discriminated the HSF and LSF groups and HWM and LWM groups (p~{$<~$}0.05). Compared to LSF, the HSF group had lower levels of several amino acids, e.g. glutamine, arginine, and glycine, short-, medium- and long-chain acylcarnitines (CARs), odd- and even-chain lysoglycerophospholipids, and higher levels of fatty amides. Compared to LWM, the HWM group in general showed higher levels of glycerophospholipids with a saturated long-chain and a C20:4 fatty acid tail, and unsaturated free fatty acids (FFAs). Changes in several saturated odd- and even-chain LPCs and LPEs and fatty amides were associated with the intake of many food groups, particularly grain and dairy products. Increase in several (lyso)glycerophospholipids was associated with decrease in body weight and adiposity. Increased short- and medium-chain CARs were related to decreased body fat-free mass. Conclusions Our results show that isocaloric weight maintenance diets differing in dietary fibre, protein, and fat content affected amino acid and lipid metabolism. Increased abundances of several phospholipid species and FFAs were related with greater weight loss maintenance. Our findings indicate common and distinct metabolites for weight and dietary related variables in the context of weight reduction and weight management. The study was registered in isrctn.org with identifier 67529475.},
  keywords = {Diet,LC-MS,Metabolome,Obesity,Weight loss,Weight maintenance},
  file = {/Users/xx20081/Zotero/storage/82A4TAVD/Ntnen et al. - 2023 - Metabolic profiles reflect weight loss maintenance and the composition of diet after very-low-energy.pdf;/Users/xx20081/Zotero/storage/MYMJEYHY/S026156142300153X.html}
}

@article{naderiObesityParadoxAdvanced2018,
  title = {Obesity {{Paradox}} in {{Advanced Kidney Disease}}: {{From Bedside}} to the {{Bench}}},
  shorttitle = {Obesity {{Paradox}} in {{Advanced Kidney Disease}}},
  author = {Naderi, Neda and Kleine, Carola-Ellen and Park, Christina and Hsiung, Jui-Ting and Soohoo, Melissa and Tantisattamo, Ekamol and Streja, Elani and {Kalantar-Zadeh}, Kamyar and Moradi, Hamid},
  year = {2018},
  journal = {Progress in Cardiovascular Diseases},
  volume = {61},
  number = {2},
  pages = {168--181},
  issn = {1873-1740},
  doi = {10.1016/j.pcad.2018.07.001},
  abstract = {While obesity is associated with a variety of complications including diabetes, hypertension, cardiovascular disease and premature death, observational studies have also found that obesity and increasing body mass index (BMI) can be linked with improved survival in certain patient populations, including those with conditions marked by protein-energy wasting and dysmetabolism that ultimately lead to cachexia. The latter observations have been reported in various clinical settings including end-stage renal disease (ESRD) and have been described as the "obesity paradox" or "reverse epidemiology", engendering controversy. While some have attributed the obesity paradox to residual confounding in an effort to "debunk" these observations, recent experimental discoveries provide biologically plausible mechanisms in which higher BMI can be linked to longevity in certain groups of patients. In addition, sophisticated epidemiologic methods that extensively adjusted for confounding have found that the obesity paradox remains robust in ESRD. Furthermore, novel hypotheses suggest that weight loss and cachexia can be linked to adverse outcomes including cardiomyopathy, arrhythmias, sudden death and poor outcomes. Therefore, the survival benefit observed in obese ESRD patients can at least partly be derived from mechanisms that protect against inefficient energy utilization, cachexia and protein-energy wasting. Given that in ESRD patients, treatment of traditional risk factors has failed to alter outcomes, detailed translational studies of the obesity paradox may help identify innovative pathways that can be targeted to improve survival. We have reviewed recent clinical evidence detailing the association of BMI with outcomes in patients with chronic kidney disease, including ESRD, and discuss potential mechanisms underlying the obesity paradox with potential for clinical applicability.},
  langid = {english},
  pmcid = {PMC6131022},
  pmid = {29981348},
  keywords = {Adipose Tissue,Adiposity,Animals,Body mass index,Cachexia,Chronic kidney disease,End stage renal disease,Energy Metabolism,Health Status,Hemodynamics,Humans,Kidney,Kidney Failure Chronic,Mortality,Obesity,Obesity paradox,Prognosis,Protective Factors,Renal Insufficiency Chronic,Risk Factors,Translational Research Biomedical,Weight Loss},
  file = {/Users/xx20081/Zotero/storage/BQFI5LWQ/Naderi et al. - 2018 - Obesity Paradox in Advanced Kidney Disease From B.pdf}
}

@article{nagarajanObesityParadoxHeart2016,
  title = {Obesity Paradox in Heart Failure: A Heavy Matter},
  shorttitle = {Obesity Paradox in Heart Failure},
  author = {Nagarajan, Vijaiganesh and Kohan, Luke and Holland, Eric and Keeley, Ellen C. and Mazimba, Sula},
  year = {2016},
  month = oct,
  journal = {ESC Heart Failure},
  volume = {3},
  number = {4},
  pages = {227--234},
  issn = {2055-5822},
  doi = {10.1002/ehf2.12120},
  urldate = {2024-07-03},
  abstract = {Obesity and heart failure are two of the leading causes of morbidity and mortality in the world. The relationship between obesity and cardiovascular diseases is complex and not fully understood. While the risk of developing heart failure has been shown to be higher in patients who are obese, there is a survival advantage for obese and overweight patients compared with normal weight or low weight patients. This phenomenon was first described by Horwich et al. and was subsequently confirmed in other large trials. The advantage exists irrespective of the type, aetiology, or stage of heart failure. Patients with morbid obesity (body mass index {$>$}40~kg/m2), however, do not have the same survival advantage of their obese counterparts. There are several alternative indices of obesity available that may be more accurate than body mass index. The role of weight loss in patients with heart failure is unclear; thus, providing sound clinical advice to patients remains difficult. Future prospective trials designed to evaluate the link between obesity and heart failure will help us understand more fully this complex relationship.},
  pmcid = {PMC5107969},
  pmid = {27867523},
  file = {/Users/xx20081/Zotero/storage/8R65U396/Nagarajan et al. - 2016 - Obesity paradox in heart failure a heavy matter.pdf}
}

@article{narkiewiczSympatheticActivityObese1998,
  title = {Sympathetic Activity in Obese Subjects with and without Obstructive Sleep Apnea},
  author = {Narkiewicz, K. and {van de Borne}, P. J. and Cooley, R. L. and Dyken, M. E. and Somers, V. K.},
  year = {1998},
  month = aug,
  journal = {Circulation},
  volume = {98},
  number = {8},
  pages = {772--776},
  issn = {0009-7322},
  doi = {10.1161/01.cir.98.8.772},
  abstract = {BACKGROUND: Obese humans are reported to have increased muscle sympathetic nerve activity (MSNA). Obstructive sleep apnea (OSA) may also be accompanied by increased MSNA. Because there is a high prevalence of OSA in obese humans, it is possible that high MSNA reported in obese subjects may in fact reflect the presence of OSA in these subjects. We tested the hypothesis that obesity, per se, in the absence of OSA, is not accompanied by increased MSNA. METHODS AND RESULTS: We measured MSNA in 25 healthy normal-weight subjects and 30 healthy sedentary obese subjects. All subjects were screened by history and examination to exclude subjects with OSA or hypertension. OSA was further excluded by overnight polysomnographic studies. Despite careful screening, polysomnography revealed that 1 of 25 normal-weight subjects and 9 of 30 obese subjects had occult OSA (P=0.015). MSNA was similar in normal-weight subjects (41+/-3 bursts per 100 heartbeats) and obese subjects without sleep apnea (42+/-3 bursts per 100 heartbeats, P=0.99). MSNA in the 9 obese subjects with occult OSA was 61+/-8 bursts per 100 heartbeats, which was higher than MSNA in normal-weight subjects without sleep apnea (P=0.02) and higher than MSNA in obese subjects without sleep apnea (P=0.02). CONCLUSIONS: Obesity alone, in the absence of OSA, is not accompanied by increased sympathetic activity to muscle blood vessels.},
  langid = {english},
  pmid = {9727547},
  keywords = {Adult,Analysis of Variance,Case-Control Studies,Female,Humans,Linear Models,Male,Muscle Skeletal,Obesity,Polysomnography,Prevalence,Reference Values,Sleep Apnea Syndromes,Sympathetic Nervous System}
}

@article{naserHospitalisationProfileEngland2023,
  title = {Hospitalisation Profile in {{England}} and {{Wales}}, 1999 to 2019: An Ecological Study},
  shorttitle = {Hospitalisation Profile in {{England}} and {{Wales}}, 1999 to 2019},
  author = {Naser, Abdallah Y},
  year = {2023},
  month = apr,
  journal = {BMJ Open},
  volume = {13},
  number = {4},
  pages = {e068393},
  issn = {2044-6055},
  doi = {10.1136/bmjopen-2022-068393},
  urldate = {2024-08-06},
  abstract = {Objective Hospital-related indicators are used to prioritise, benchmark and monitor certain healthcare components to improve quality. This study aimed to determine the hospital admissions profile in England and Wales between 1999 and 2019. Design Ecological study. Setting A population-based study of hospitalised patients in England and Wales. Participants All patients of all ages and genders who were hospitalised in National Health Service (NHS) hospitals and NHS-funded independent sector hospitals. Outcome measure Hospital admission rates in England and Wales related to various diseases/causes, which were identified using the diagnostic codes (A00-Z99). Results There was a 48.5\% rise in hospital admission rates from 246\,366.7 (95\% CI 246 249.8 to 246 483.7) in 1999 to 365 858.7 (95\% CI 365 736.3 to 365 981.2) in 2019 per million persons (p{$<$}0.05). The most common causes of hospital admissions were diseases of the digestive system; symptoms, signs, and abnormal clinical and laboratory findings; and neoplasms, which accounted for 11.5\%, 11.4\% and 10.5\%, respectively. The age range of 15--59 years accounted for 43.4\% of all hospital admissions. Around 56.0\% of all hospital admissions were by female patients. In comparison to 1999, the hospital admission rate for males grew by 53.7\%, from 218\,363.7 (95\% CI 218 203.2 to 218 524.3) to 335\,618.9 (95\% CI 335 448.1 to 335 789.6) per million persons in 2019. When compared with 1999, the hospital admission rate for females increased by 44.7\%, rising from 273\,032.5 (95\% CI 272 863.5 to 273 201.5) to 395\,154.6 (95\% CI 394 979.9 to 395 329.4) per million persons. Conclusion A notable increase was observed in the rate of hospital admissions for all causes in England and Wales. Elderly age and female gender were significant factors that influenced the rate of hospital admissions. Future research is required to identify preventable risk factors for hospital admission.},
  pmcid = {PMC10083742},
  pmid = {37024246},
  file = {/Users/xx20081/Zotero/storage/HDPXSJIC/Naser - 2023 - Hospitalisation profile in England and Wales, 1999.pdf}
}

@article{ndumeleObesitySubtypesIncident2016,
  title = {Obesity and {{Subtypes}} of {{Incident Cardiovascular Disease}}},
  author = {Ndumele, Chiadi E. and Matsushita, Kunihiro and Lazo, Mariana and Bello, Natalie and Blumenthal, Roger S. and Gerstenblith, Gary and Nambi, Vijay and Ballantyne, Christie M. and Solomon, Scott D. and Selvin, Elizabeth and Folsom, Aaron R. and Coresh, Josef},
  year = {2016},
  month = aug,
  journal = {Journal of the American Heart Association},
  volume = {5},
  number = {8},
  pages = {e003921},
  publisher = {Wiley},
  doi = {10.1161/JAHA.116.003921},
  urldate = {2024-07-04},
  abstract = {Background Obesity is a risk factor for various subtypes of cardiovascular disease (CVD), including coronary heart disease (CHD), heart failure (HF), and stroke. Nevertheless, there are limited comparisons of the associations of obesity with each of these CVD subtypes, particularly regarding the extent to which they are unexplained by traditional CVD mediators. Methods and Results We followed 13~730 participants in the Atherosclerosis Risk in Communities (ARIC) study who had a body mass index {$\geq$}18.5~and no CVD at baseline (visit 1, 1987--1989). We compared the association of higher body mass index with incident HF, CHD, and stroke before and after adjusting for traditional CVD mediators (including systolic blood pressure, diabetes mellitus, and lipid measures). Over a median follow-up of 23~years, there were 2235 HF events, 1653 CHD events, and 986 strokes. After adjustment for demographics, smoking, physical activity, and alcohol intake, higher body mass index had the strongest association with incident HF among CVD subtypes, with hazard ratios for severe obesity (body mass index {$\geq$}35 versus normal weight) of 3.74 (95\% CI 3.24--4.31) for HF, 2.00 (95\% CI 1.67--2.40) for CHD, and 1.75 (95\% CI 1.40--2.20) for stroke (P{$<$}0.0001 for comparisons of HF versus CHD or stroke). Further adjustment for traditional mediators fully explained the association of higher body mass index with CHD and stroke but not with HF (hazard ratio 2.27, 95\% CI 1.94--2.64). Conclusions The link between obesity and HF was stronger than those for other CVD subtypes and was uniquely unexplained by traditional risk factors. Weight management is likely critical for optimal HF prevention, and nontraditional pathways linking obesity to HF need to be elucidated.},
  file = {/Users/xx20081/Zotero/storage/YRXJZZZX/Ndumele et al. - 2016 - Obesity and Subtypes of Incident Cardiovascular Di.pdf}
}

@article{ndumeleWeightHistorySubclinical2018,
  title = {Weight {{History}} and {{Subclinical Myocardial Damage}}},
  author = {Ndumele, Chiadi E. and Cobb, Laura and Lazo, Mariana and Bello, Natalie A. and Shah, Amil and Nambi, Vijay and Blumenthal, Roger S. and Gerstenblith, Gary and Solomon, Scott D. and Ballantyne, Christie M. and Selvin, Elizabeth and Coresh, Josef},
  year = {2018},
  month = jan,
  journal = {Clinical Chemistry},
  volume = {64},
  number = {1},
  pages = {201--209},
  issn = {1530-8561},
  doi = {10.1373/clinchem.2017.282798},
  abstract = {BACKGROUND: Excess weight is associated with subclinical myocardial damage, as reflected by high-sensitivity cardiac troponin T (hs-cTnT) concentrations, which portends high heart failure risk. However, the association between weight history and myocardial damage is unknown. METHODS: We evaluated 9062 Atherosclerosis Risk in Communities (ARIC) visit 4 (1996-1999) participants with a body mass index (BMI) {$\geq$} 18.5 kg/m2 and no previous cardiovascular disease. We cross-tabulated visit 4 ("current") BMI categories of normal weight, overweight, and obese with those at visit 1 (1987-1989) and with BMI categories calculated from self-reported weight at age 25 years. Duration of obesity was calculated in years. A cumulative weight measure of "excess BMI-years" was also calculated [product of mean BMI (centered at 25 kg/m2) over all ARIC time points {\texttimes} follow-up duration]. We used logistic regression to estimate associations of weight history metrics with increased hs-cTnT ({$\geq$}14 ng/L) at visit 4. RESULTS: Overall, 623 individuals (7\%) had increased hs-cTnT at visit 4. Within each current BMI category, previous excess weight was associated with increased hs-cTnT, with the strongest associations for those with past and current obesity [odds ratio (OR), 3.85; 95\% CI, 2.51-5.90 for obesity at age 25 years and visit 4]. Each 10-year longer obesity duration was associated with increased hs-cTnT (OR, 1.26; 95\% CI, 1.17-1.35). Each 100 higher excess BMI-years was also progressively associated with increased hs-cTnT (OR, 1.21; 95\% CI, 1.14-1.27). CONCLUSIONS: Previous obesity and greater cumulative weight from young adulthood increase the likelihood of myocardial damage, indicating long-term toxic effects of adiposity on the myocardium and the need for weight maintenance strategies targeting the entire life span.},
  langid = {english},
  pmcid = {PMC6219376},
  pmid = {29158254},
  keywords = {Adult,Atherosclerosis,Body Mass Index,Female,Heart Failure,Humans,Male,Middle Aged,Myocardium,Obesity,Troponin T},
  file = {/Users/xx20081/Zotero/storage/XN79P34W/Ndumele et al. - 2018 - Weight History and Subclinical Myocardial Damage.pdf}
}

@article{nealCanagliflozinCardiovascularRenal2017,
  title = {Canagliflozin and {{Cardiovascular}} and {{Renal Events}} in {{Type}} 2 {{Diabetes}}},
  author = {Neal, Bruce and Perkovic, Vlado and Mahaffey, Kenneth W. and {de Zeeuw}, Dick and Fulcher, Greg and Erondu, Ngozi and Shaw, Wayne and Law, Gordon and Desai, Mehul and Matthews, David R. and {CANVAS Program Collaborative Group}},
  year = {2017},
  month = aug,
  journal = {The New England Journal of Medicine},
  volume = {377},
  number = {7},
  pages = {644--657},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1611925},
  abstract = {Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. Methods The CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Results The mean age of the participants was 63.3 years, 35.8\% were women, the mean duration of diabetes was 13.5 years, and 65.6\% had a history of cardiovascular disease. The rate of the primary outcome was lower with canagliflozin than with placebo (occurring in 26.9 vs. 31.5 participants per 1000 patient-years; hazard ratio, 0.86; 95\% confidence interval [CI], 0.75 to 0.97; P{$<$}0.001 for noninferiority; P=0.02 for superiority). Although on the basis of the prespecified hypothesis testing sequence the renal outcomes are not viewed as statistically significant, the results showed a possible benefit of canagliflozin with respect to the progression of albuminuria (hazard ratio, 0.73; 95\% CI, 0.67 to 0.79) and the composite outcome of a sustained 40\% reduction in the estimated glomerular filtration rate, the need for renal-replacement therapy, or death from renal causes (hazard ratio, 0.60; 95\% CI, 0.47 to 0.77). Adverse reactions were consistent with the previously reported risks associated with canagliflozin except for an increased risk of amputation (6.3 vs. 3.4 participants per 1000 patient-years; hazard ratio, 1.97; 95\% CI, 1.41 to 2.75); amputations were primarily at the level of the toe or metatarsal. Conclusions In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal. (Funded by Janssen Research and Development; CANVAS and CANVAS-R ClinicalTrials.gov numbers, NCT01032629 and NCT01989754 , respectively.).},
  langid = {english},
  pmid = {28605608},
  keywords = {Aged,Albuminuria,Amputation Surgical,Canagliflozin,Cardiovascular Diseases,Diabetes Mellitus Type 2,Disease Progression,Female,Foot,Glomerular Filtration Rate,Hospitalization,Humans,Hypoglycemic Agents,Kidney Diseases,Male,Middle Aged},
  file = {/Users/xx20081/Zotero/storage/JPKX5ED5/Neal et al. - 2017 - Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.pdf}
}

@article{nelsonAssociationAnalysesBased2017,
  title = {Association Analyses Based on False Discovery Rate Implicate New Loci for Coronary Artery Disease},
  author = {Nelson, Christopher P. and Goel, Anuj and Butterworth, Adam S. and Kanoni, Stavroula and Webb, Tom R. and Marouli, Eirini and Zeng, Lingyao and Ntalla, Ioanna and Lai, Florence Y. and Hopewell, Jemma C. and Giannakopoulou, Olga and Jiang, Tao and Hamby, Stephen E. and Di Angelantonio, Emanuele and Assimes, Themistocles L. and Bottinger, Erwin P. and Chambers, John C. and Clarke, Robert and Palmer, Colin N. A. and Cubbon, Richard M. and Ellinor, Patrick and Ermel, Raili and Evangelou, Evangelos and Franks, Paul W. and Grace, Christopher and Gu, Dongfeng and Hingorani, Aroon D. and Howson, Joanna M. M. and Ingelsson, Erik and Kastrati, Adnan and Kessler, Thorsten and Kyriakou, Theodosios and Lehtim{\"a}ki, Terho and Lu, Xiangfeng and Lu, Yingchang and M{\"a}rz, Winfried and McPherson, Ruth and Metspalu, Andres and {Pujades-Rodriguez}, Mar and Ruusalepp, Arno and Schadt, Eric E. and Schmidt, Amand F. and Sweeting, Michael J. and Zalloua, Pierre A. and AlGhalayini, Kamal and Keavney, Bernard D. and Kooner, Jaspal S. and Loos, Ruth J. F. and Patel, Riyaz S. and Rutter, Martin K. and Tomaszewski, Maciej and Tzoulaki, Ioanna and Zeggini, Eleftheria and Erdmann, Jeanette and Dedoussis, George and Bj{\"o}rkegren, Johan L. M. and {EPIC-CVD Consortium} and {CARDIoGRAMplusC4D} and {UK Biobank CardioMetabolic Consortium CHD working group} and Schunkert, Heribert and Farrall, Martin and Danesh, John and Samani, Nilesh J. and Watkins, Hugh and Deloukas, Panos},
  year = {2017},
  month = sep,
  journal = {Nature Genetics},
  volume = {49},
  number = {9},
  pages = {1385--1391},
  issn = {1546-1718},
  doi = {10.1038/ng.3913},
  abstract = {Genome-wide association studies (GWAS) in coronary artery disease (CAD) had identified 66 loci at 'genome-wide significance' (P {$<$} 5 {\texttimes} 10-8) at the time of this analysis, but a much larger number of putative loci at a false discovery rate (FDR) of 5\% (refs. 1,2,3,4). Here we leverage an interim release of UK Biobank (UKBB) data to evaluate the validity of the FDR approach. We tested a CAD phenotype inclusive of angina (SOFT; ncases = 10,801) as well as a stricter definition without angina (HARD; ncases = 6,482) and selected cases with the former phenotype to conduct a meta-analysis using the two most recent CAD GWAS. This approach identified 13 new loci at genome-wide significance, 12 of which were on our previous list of loci meeting the 5\% FDR threshold, thus providing strong support that the remaining loci identified by FDR represent genuine signals. The 304 independent variants associated at 5\% FDR in this study explain 21.2\% of CAD heritability and identify 243 loci that implicate pathways in blood vessel morphogenesis as well as lipid metabolism, nitric oxide signaling and inflammation.},
  langid = {english},
  pmid = {28714975},
  keywords = {Coronary Artery Disease,Genetic Association Studies,Genetic Loci,Genetic Predisposition to Disease,Genome-Wide Association Study,Genotype,Health Information Systems,Humans,Meta-Analysis as Topic,Phenotype,Polymorphism Single Nucleotide,Reproducibility of Results,Risk Factors,United Kingdom},
  file = {/Users/xx20081/Zotero/storage/TIYBGUKS/Nelson et al. - 2017 - Association analyses based on false discovery rate.pdf}
}

@article{neumannHeartFailureCommonest2009,
  title = {Heart {{Failure}}: The {{Commonest Reason}} for {{Hospital Admission}} in {{Germany}}},
  shorttitle = {Heart {{Failure}}},
  author = {Neumann, Till and Biermann, Janine and Erbel, Raimund and Neumann, Anja and Wasem, J{\"u}rgen and Ertl, Georg and Dietz, Rainer},
  year = {2009},
  month = apr,
  journal = {Deutsches {\"A}rzteblatt International},
  volume = {106},
  number = {16},
  pages = {269--275},
  issn = {1866-0452},
  doi = {10.3238/arztebl.2009.0269},
  urldate = {2024-08-06},
  abstract = {Background Heart failure is now the commonest reason for hospitalization in Germany (German Federal Statistical Office, 2008). Heart failure will continue to be a central public health issue in the future as the population ages. This article focuses on regional differences, the costs of the disease, and the expected rate of increase in cases in the near future. Methods This analysis is based on diagnosis statistics, cause-of-death statistics, and cost of illness data, as reported by the German Federal Statistical Office. Age- and sex-specific differences are taken into account. Results 2006 was the first year in which heart failure led to more hospital admissions in Germany (317 000) than any other diagnosis. At present, about 141 000 persons in Germany aged 80 and over have heart failure; by the year 2050, it is predicted that more than 350 000 persons in this age group will be affected. The rate of diagnosis of heart failure, its frequency as a cause of death, and the costs associated with it all vary across the individual states of the Federal Republic of Germany. The nationwide cost of heart failure in 2006 was estimated at 2.9 billion euros. Conclusions These findings reveal that heart failure has become more common as an admission diagnosis of hospitalized patients in Germany. Because the population is aging, new concepts for prevention and treatment will be needed in the near future so that the affected patients can continue to receive adequate care.},
  pmcid = {PMC2689573},
  pmid = {19547628},
  file = {/Users/xx20081/Zotero/storage/FD92H8QY/Neumann et al. - 2009 - Heart Failure the Commonest Reason for Hospital A.pdf}
}

@article{nevesIncreasedRiskHeart2023,
  title = {Increased {{Risk}} of {{Heart Failure Hospitalization With GLP-1 Receptor Agonists}} in {{Patients With Reduced Ejection Fraction}}: {{A Meta-Analysis}} of the {{EXSCEL}} and {{FIGHT Trials}}},
  shorttitle = {Increased {{Risk}} of {{Heart Failure Hospitalization With GLP-1 Receptor Agonists}} in {{Patients With Reduced Ejection Fraction}}},
  author = {Neves, JO{\~A}O S{\'E}RGIO and Packer, {\relax MILTON} and Ferreira, JO{\~A}O PEDRO},
  year = {2023},
  month = jul,
  journal = {Journal of Cardiac Failure},
  volume = {29},
  number = {7},
  pages = {1107--1109},
  issn = {1071-9164},
  doi = {10.1016/j.cardfail.2023.03.017},
  urldate = {2024-07-04},
  file = {/Users/xx20081/Zotero/storage/ZQHRM4SI/S1071916423001100.html}
}

@article{ngGlobalRegionalNational2014,
  title = {Global, Regional, and National Prevalence of Overweight and Obesity in Children and Adults during 1980--2013: A Systematic Analysis for the {{Global Burden}} of {{Disease Study}} 2013},
  shorttitle = {Global, Regional, and National Prevalence of Overweight and Obesity in Children and Adults during 1980--2013},
  author = {Ng, Marie and Fleming, Tom and Robinson, Margaret and Thomson, Blake and Graetz, Nicholas and Margono, Christopher and Mullany, Erin C. and Biryukov, Stan and Abbafati, Cristiana and Abera, Semaw Ferede and Abraham, Jerry P. and {Abu-Rmeileh}, Niveen M. E. and Achoki, Tom and AlBuhairan, Fadia S. and Alemu, Zewdie A. and Alfonso, Rafael and Ali, Mohammed K. and Ali, Raghib and Guzman, Nelson Alvis and Ammar, Walid and Anwari, Palwasha and Banerjee, Amitava and Barquera, Simon and Basu, Sanjay and Bennett, Derrick A. and Bhutta, Zulfiqar and Blore, Jed and Cabral, Norberto and Nonato, Ismael Campos and Chang, Jung-Chen and Chowdhury, Rajiv and Courville, Karen J. and Criqui, Michael H. and Cundiff, David K. and Dabhadkar, Kaustubh C. and Dandona, Lalit and Davis, Adrian and Dayama, Anand and Dharmaratne, Samath D. and Ding, Eric L. and Durrani, Adnan M. and Esteghamati, Alireza and Farzadfar, Farshad and Fay, Derek F. J. and Feigin, Valery L. and Flaxman, Abraham and Forouzanfar, Mohammad H. and Goto, Atsushi and Green, Mark A. and Gupta, Rajeev and {Hafezi-Nejad}, Nima and Hankey, Graeme J. and Harewood, Heather C. and Havmoeller, Rasmus and Hay, Simon and Hernandez, Lucia and Husseini, Abdullatif and Idrisov, Bulat T. and Ikeda, Nayu and Islami, Farhad and Jahangir, Eiman and Jassal, Simerjot K. and Jee, Sun Ha and Jeffreys, Mona and Jonas, Jost B. and Kabagambe, Edmond K. and Khalifa, Shams Eldin Ali Hassan and Kengne, Andre Pascal and Khader, Yousef Saleh and Khang, Young-Ho and Kim, Daniel and Kimokoti, Ruth W. and Kinge, Jonas M. and Kokubo, Yoshihiro and Kosen, Soewarta and Kwan, Gene and Lai, Taavi and Leinsalu, Mall and Li, Yichong and Liang, Xiaofeng and Liu, Shiwei and Logroscino, Giancarlo and Lotufo, Paulo A. and Lu, Yuan and Ma, Jixiang and Mainoo, Nana Kwaku and Mensah, George A. and Merriman, Tony R. and Mokdad, Ali H. and Moschandreas, Joanna and Naghavi, Mohsen and Naheed, Aliya and Nand, Devina and Narayan, K. M. Venkat and Nelson, Erica Leigh and Neuhouser, Marian L. and Nisar, Muhammad Imran and Ohkubo, Takayoshi and Oti, Samuel O. and Pedroza, Andrea and Prabhakaran, Dorairaj and Roy, Nobhojit and Sampson, Uchechukwu and Seo, Hyeyoung and Sepanlou, Sadaf G. and Shibuya, Kenji and Shiri, Rahman and Shiue, Ivy and Singh, Gitanjali M. and Singh, Jasvinder A. and Skirbekk, Vegard and Stapelberg, Nicolas J. C. and Sturua, Lela and Sykes, Bryan L. and Tobias, Martin and Tran, Bach X. and Trasande, Leonardo and Toyoshima, Hideaki and van de Vijver, Steven and Vasankari, Tommi J. and Veerman, J. Lennert and {Velasquez-Melendez}, Gustavo and Vlassov, Vasiliy Victorovich and Vollset, Stein Emil and Vos, Theo and Wang, Claire and Wang, XiaoRong and Weiderpass, Elisabete and Werdecker, Andrea and Wright, Jonathan L. and Yang, Y. Claire and Yatsuya, Hiroshi and Yoon, Jihyun and Yoon, Seok-Jun and Zhao, Yong and Zhou, Maigeng and Zhu, Shankuan and Lopez, Alan D. and Murray, Christopher J. L. and Gakidou, Emmanuela},
  year = {2014},
  month = aug,
  journal = {The Lancet},
  volume = {384},
  number = {9945},
  pages = {766--781},
  publisher = {Elsevier},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(14)60460-8},
  urldate = {2024-08-14},
  langid = {english},
  pmid = {24880830},
  file = {/Users/xx20081/Zotero/storage/ATWSVGVH/Ng et al. - 2014 - Global, regional, and national prevalence of overw.pdf}
}

@article{nicklasAbdominalObesityIndependent2006,
  title = {Abdominal Obesity Is an Independent Risk Factor for Chronic Heart Failure in Older People},
  author = {Nicklas, Barbara J. and Cesari, Matteo and Penninx, Brenda W. J. H. and Kritchevsky, Stephen B. and Ding, Jingzhong and Newman, Anne and Kitzman, Dalane W. and Kanaya, Alka M. and Pahor, Marco and Harris, Tamara B.},
  year = {2006},
  month = mar,
  journal = {Journal of the American Geriatrics Society},
  volume = {54},
  number = {3},
  pages = {413--420},
  issn = {0002-8614},
  doi = {10.1111/j.1532-5415.2005.00624.x},
  abstract = {OBJECTIVES: To examine whether total and abdominal adiposity are risk factors for the development of chronic heart failure (CHF) in older men and women. DESIGN: Prospective, longitudinal cohort: The Health, Aging and Body Composition study. SETTING: Memphis, Tennessee, and Pittsburgh, Pennsylvania, metropolitan areas. PARTICIPANTS: Three thousand seventy-five well-functioning community-dwelling older adults aged 70 to 79. MEASUREMENTS: Body composition using dual energy X-ray absorptiometry, visceral adipose tissue area using computed tomography, adjudicated CHF. RESULTS: Of the remaining (640 participants excluded from original group of 3,075) 2,435 participants (1,081 men, 1,354 women) without coronary heart disease or CHF at baseline, there were 166 confirmed diagnoses of CHF during the median+/-standard deviation (SD) follow-up of 6.1+/-1.4 years. After adjustment for age, race, sex, site, education, smoking, and chronic obstructive pulmonary disorder, all adiposity variables (body mass index (BMI), adipose tissue mass, percentage body fat, waist-to-thigh ratio, waist circumference, and visceral and subcutaneous abdominal adipose tissue) were significant predictors of the development of CHF. In a model that included waist circumference and BMI, waist circumference was associated with incident CHF (hazard ratio (HR)=1.27, 95\% confidence interval (CI)=1.04-1.54 per SD increase, P=.02), but BMI was not (HR=1.08, 95\% CI=0.86-1.35). When waist circumference and percentage fat were included together, both variables were significant predictors of CHF (waist: HR=1.17, 95\% CI=1.00-1.36 per SD increase, P=.05; percentage fat: HR=1.47, 95\% CI=1.16-1.87 per SD increase, P=.002). Stepwise adjustment for inflammation, hypertension, insulin resistance, and diabetes mellitus did not decrease the relative risk of a greater waist circumference for the development of CHF (all HR=1.27-1.32, 95\% CI=1.02-1.61 per SD increase). CONCLUSION: Abdominal body fat distribution may be a stronger risk factor for CHF than overall obesity.},
  langid = {english},
  pmid = {16551307},
  keywords = {Absorptiometry Photon,Age Factors,Aged,Body Fat Distribution,Body Mass Index,Female,Follow-Up Studies,Heart Failure,Humans,Incidence,Male,Obesity,Prospective Studies,Risk Factors,Severity of Illness Index,Tomography X-Ray Computed},
  file = {/Users/xx20081/Zotero/storage/4SMSFJBZ/Nicklas et al. - 2006 - Abdominal obesity is an independent risk factor fo.pdf}
}

@article{nickolaLeptinAttenuatesCardiac2000,
  title = {Leptin {{Attenuates Cardiac Contraction}} in {{Rat Ventricular Myocytes}}},
  author = {Nickola, Marvie W. and Wold, Loren E. and Colligan, Peter B. and Wang, Guei-Jane and Samson, Willis K. and Ren, Jun},
  year = {2000},
  month = oct,
  journal = {Hypertension},
  volume = {36},
  number = {4},
  pages = {501--505},
  publisher = {American Heart Association},
  doi = {10.1161/01.HYP.36.4.501},
  urldate = {2024-07-05},
  abstract = {Abstract---Obesity is commonly associated with impaired myocardial contractile function. However, a direct link between these 2 states has not yet been established. There has been an indication that leptin, the product of the human obesity gene, may play a role in obesity-related metabolic and cardiovascular dysfunctions. The purpose of this study was to determine whether leptin exerts any direct cardiac contractile action that may contribute to altered myocardial function. Ventricular myocytes were isolated from adult male Sprague-Dawley rats. Contractile responses were evaluated by use of video-based edge detection. Contractile properties analyzed in cells electrically stimulated at 0.5 Hz included peak shortening, time to 90\% peak shortening, time to 90\% relengthening, and fluorescence intensity change. Leptin exhibited a dose-dependent inhibition in myocyte shortening and intracellular Ca2+ change, with maximal inhibitions of 22.4\% and 26.2\%, respectively. Pretreatment with the NO synthase inhibitor N{$\omega$}-nitro-l-arginine methyl ester (L-NAME, 100 {$\mu$}mol/L) blocked leptin-induced inhibition of both peak shortening and fluorescence intensity change. Leptin also stimulated NO synthase activity in a time- and concentration-dependent manner, as reflected in the dose-related increase in NO accumulation in these cells. Addition of an NO donor (S-nitroso-N-acetyl-penicillamine [SNAP]) to the medium mimicked the effects of leptin administration. In summary, this study demonstrated a direct action of leptin on cardiomyocyte contraction, possibly through an increased NO production. These data suggest that leptin may play a role in obesity-related cardiac contractile dysfunction.},
  file = {/Users/xx20081/Zotero/storage/MSNJS3YU/Nickola et al. - 2000 - Leptin Attenuates Cardiac Contraction in Rat Ventr.pdf}
}

@article{nochiokaBothHighLow2010,
  title = {Both {{High}} and {{Low Body Mass Indexes}} Are {{Prognostic Risks}} in {{Japanese Patients With Chronic Heart Failure}}: {{Implications From}} the {{CHART Study}}},
  shorttitle = {Both {{High}} and {{Low Body Mass Indexes}} Are {{Prognostic Risks}} in {{Japanese Patients With Chronic Heart Failure}}},
  author = {Nochioka, Kotaro and Shiba, Nobuyuki and Kohno, Haruka and Miura, Masanobu and Shimokawa, Hiroaki},
  year = {2010},
  month = nov,
  journal = {Journal of Cardiac Failure},
  volume = {16},
  number = {11},
  pages = {880--887},
  issn = {1071-9164},
  doi = {10.1016/j.cardfail.2010.06.413},
  urldate = {2024-08-08},
  abstract = {Background Prognostic impact of body mass index (BMI) in Japanese patients with chronic heart failure (HF) remains unclear. Methods and Results We examined the relationship between BMI and the prognosis of Japanese HF patients in the Chronic Heart Failure Analysis and Registry in the Tohoku District (CHART) study. The study sample was 972 Japanese chronic HF patients (mean age, 68.2 {\textpm} 13.5; male 65.2\%). We categorized them into 5 groups; BMI {$<$}18.5, 18.5 to 22.9, 23.0 to 24.9 (reference), 25.0 to 29.9, and {$\geq$}30.0. Using a Cox hazards model, the relationships between BMI and deaths or admission for worsening HF were studied in detail. Mean follow-up period was 3.4 {\textpm} 1.7 years. Multivariate analysis showed that, as compared with reference group (BMI 23.0 to 24.9), hazard ratios (HR) for all-cause death showed a U-shaped association with 1.70 (95\% confidence interval; 1.04--2.76), 1.23 (0.85--1.78), 1.26 (0.84--1.90), and 2.75 (1.51--5.00) among those with BMI{$<$}18.5, 18.5 to 22.9, 25.0 to 29.9, and {$\geq$}30.0, respectively. There were significant and suggestive U-shaped associations between BMI and cardiac-cause death or admission for worsening HF. Conclusions Both high and low BMIs were associated with increased outcomes, suggesting that extreme obesity is not beneficial in improving the prognosis of Japanese chronic HF patients.},
  file = {/Users/xx20081/Zotero/storage/WF75763G/Nochioka et al. - 2010 - Both High and Low Body Mass Indexes are Prognostic.pdf;/Users/xx20081/Zotero/storage/VSA5DR6T/S1071916410007116.html}
}

@article{nossentPlasmaLevelsSnoRNAs2019,
  title = {Plasma {{Levels}} of {{snoRNAs}} Are {{Associated}} with {{Platelet Activation}} in {{Patients}} with {{Peripheral Artery Disease}}},
  author = {Nossent, Anne Ya{\"e}l and Ektefaie, Neda and Wojta, Johann and Eichelberger, Beate and Kopp, Christoph and Panzer, Simon and Gremmel, Thomas},
  year = {2019},
  month = dec,
  journal = {International Journal of Molecular Sciences},
  volume = {20},
  number = {23},
  publisher = {Multidisciplinary Digital Publishing Institute  (MDPI)},
  doi = {10.3390/ijms20235975},
  urldate = {2024-04-12},
  abstract = {In addition to supervised walking therapy, antithrombotic therapy and the management of risk factors, the treatment of peripheral artery disease (PAD) is limited to endovascular and surgical interventions, i.e., angioplasty with stent implantation and ...},
  langid = {english},
  pmid = {31783567},
  file = {/Users/xx20081/Zotero/storage/DNQZFYGK/Nossent et al. - 2019 - Plasma Levels of snoRNAs are Associated with Plate.pdf;/Users/xx20081/Zotero/storage/MVEYZTIT/PMC6929168.html}
}

@article{OConnor2009,
  title = {Efficacy and Safety of Exercise Training in Patients with Chronic Heart Failure: {{HF-ACTION}} Randomized Controlled Trial},
  author = {O'Connor, Christopher M. and Whellan, David J. and Lee, Kerry L. and Keteyian, Steven J. and Cooper, Lawton S. and Ellis, Stephen J. and Leifer, Eric S. and Kraus, William E. and Kitzman, Dalane W. and Blumenthal, James A. and Rendall, David S. and Miller, Nancy Houston and Fleg, Jerome L. and Schulman, Kevin A. and McKelvie, Robert S. and Zannad, Faiez and Pi{\~n}a, Ileana L.},
  year = {2009},
  month = apr,
  journal = {JAMA : the journal of the American Medical Association},
  volume = {301},
  number = {14},
  pages = {1439--1450},
  publisher = {JAMA},
  issn = {1538-3598},
  doi = {10.1001/JAMA.2009.454},
  abstract = {Guidelines recommend that exercise training be considered for medically stable outpatients with heart failure. Previous studies have not had adequate statistical power to measure the effects of exercise training on clinical outcomes. Objective To test the efficacy and safety of exercise training among patients with heart failure. Design, Setting, and Patients Multicenter, randomized controlled trial of 2331 medically stable outpatients with heart failure and reduced ejection fraction. Participants in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) were randomized from April 2003 through February 2007 at 82 centers within the United States, Canada, and France; median follow-up was 30 months. Interventions Usual care plus aerobic exercise training, consisting of 36 supervised sessions followed by home-based training, or usual care alone. Main Outcome Measures Composite primary end point of all-cause mortality or hospitalization and prespecified secondary end points of all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or heart failure hospitalization. Results The median age was 59 years, 28\% were women, and 37\% had New York Heart Association class III or IV symptoms. Heart failure etiology was ischemic in 51\%, and median left ventricular ejection fraction was 25\%. Exercise adherence decreased from a median of 95 minutes per week during months 4 through 6 of follow-up to 74 minutes per week during months 10 through 12. A total of 759 patients (65\%) in the exercise training group died or were hospitalized compared with 796 patients (68\%) in the usual care group (hazard ratio [HR], 0.93 [95\% confidence interval \{Cl\}, 0.84-1.02]; P=.13). There were nonsignificant reductions in the exercise training group for mortality (189 patients [16\%] in the exercise training group vs 198 patients [17\%] in the usual care group; HR, 0.96 [95\% Cl, 0.79-1.17]; P=.7O), cardiovascular mortality or cardiovascular hospitalization (632 [55\%] in the exercise training group vs 677 [58\%] in the usual care group; HR, 0.92 [95\% Cl, 0.83-1.03]; P=.14), and cardiovascular mortality or heart failure hospitalization (344 [30\%] in the exercise training group vs 393 [34\%] in the usual care group; HR, 0.87 [95\% Cl, 0.75-1.00]; P=.O6). In prespecified supplementary analyses adjusting for highly prognostic baseline characteristics, the HRs were 0.89 (95\% Cl, 0.81-0.99; P=.03) for all-cause mortality or hospitalization, 0.91 (95\% Cl, 0.82-1.01; P=.O9) for cardiovascular mortality or cardiovascular hospitalization, and 0.85 (95\% Cl, 0.74-0.99; P= .03) for cardiovascular mortality or heart failure hospitalization. Other adverse events were similar between the groups. Conclusions In the protocol-specified primary analysis, exercise training resulted in nonsignificant reductions in the primary end point of all-cause mortality or hospitalization and in key secondary clinical end points. After adjustment for highly prognostic predictors of the primary end point, exercise training was associated with modest significant reductions for both all-cause mortality or hospitalization and cardiovascular mortality or heart failure hospitalization. {\copyright} 2009 American Medical Association. All rights reserved.},
  pmid = {19351941},
  keywords = {affs=[],affs=[]),Aged,Ambulatory Care,Author(firstnames='A Bleakley',Author(firstnames='Adam',Author(firstnames='Alain',Author(firstnames='Alice',Author(firstnames='Allison',Author(firstnames='Alyce',Author(firstnames='Andrew',Author(firstnames='Anekwe',Author(firstnames='Anil',Author(firstnames='Ann M',Author(firstnames='Ann',Author(firstnames='Anne',Author(firstnames='Annette',Author(firstnames='Anthony',Author(firstnames='April',Author(firstnames='Barry M',Author(firstnames='Barry',Author(firstnames='Bertram',Author(firstnames='Bess',Author(firstnames='Beth',Author(firstnames='Betsy',Author(firstnames='Bobbett',Author(firstnames='Brenda S',Author(firstnames='Brian D',Author(firstnames='Brian',Author(firstnames='Brittney L',Author(firstnames='Bruce',Author(firstnames='Camille',Author(firstnames='Carol',Author(firstnames='Carrie',Author(firstnames='Cassandra',Author(firstnames='Cassondra',Author(firstnames='Cathy',Author(firstnames='Cheri',Author(firstnames='Christine',Author(firstnames='Christopher M',Author(firstnames='Christy',Author(firstnames='Cindy',Author(firstnames='Clinton A',Author(firstnames='Cynthia',Author(firstnames='Dalane W',Author(firstnames='Dalynn',Author(firstnames='Daniel R',Author(firstnames='Daniel',Author(firstnames='Danuta',Author(firstnames='Darlene',Author(firstnames='David J',Author(firstnames='David S',Author(firstnames='David W',Author(firstnames='David',Author(firstnames='Deb',Author(firstnames='Debbie',Author(firstnames='Debra',Author(firstnames='Deirdre',Author(firstnames='Delores',Author(firstnames='Denise',Author(firstnames='Dennis',Author(firstnames='Diane',Author(firstnames='Dione',Author(firstnames='Douglas',Author(firstnames='Eduardo',Author(firstnames='Edward T',Author(firstnames='Eileen',Author(firstnames='Elena',Author(firstnames='Elisse',Author(firstnames='Elizabeth',Author(firstnames='Emily',Author(firstnames='Eric S',Author(firstnames='Eric',Author(firstnames='Estrellita',Author(firstnames='Eugene',Author(firstnames='Eve',Author(firstnames='Ezra A',Author(firstnames='Faiez',Author(firstnames='Frank G',Author(firstnames='Gail',Author(firstnames='Gerald I',Author(firstnames='Gerald',Author(firstnames='Glen',Author(firstnames='Gordon',Author(firstnames='Greg',Author(firstnames='Gregg',Author(firstnames='Gregory',Author(firstnames='Hector',Author(firstnames='Heidi',Author(firstnames='Hoss',Author(firstnames='Howard',Author(firstnames='Ileana L',Author(firstnames='Jack L',Author(firstnames='Jacqueline',Author(firstnames='Jalal K',Author(firstnames='James A',Author(firstnames='James',Author(firstnames='Jana',Author(firstnames='Jane',Author(firstnames='Janice',Author(firstnames='Jean',Author(firstnames='Jeannette',Author(firstnames='Jennie',Author(firstnames='Jennifer',Author(firstnames='Jenny',Author(firstnames='Jerome L',Author(firstnames='Jessica',Author(firstnames='Jill',Author(firstnames='Jim',Author(firstnames='Joann',Author(firstnames='Joel',Author(firstnames='Joelle Y',Author(firstnames='Johanna',Author(firstnames='John',Author(firstnames='Johnny',Author(firstnames='Jonathan G',Author(firstnames='Jonathan K',Author(firstnames='Jonathan',Author(firstnames='Joseph',Author(firstnames='Joyce',Author(firstnames='Judith',Author(firstnames='Julie K',Author(firstnames='Julie',Author(firstnames='Julius M',Author(firstnames='Justine',Author(firstnames='Karen',Author(firstnames='Karim',Author(firstnames='Kate',Author(firstnames='Kathryn E',Author(firstnames='Kathy',Author(firstnames='Kelly',Author(firstnames='Kenneth',Author(firstnames='Kerry L',Author(firstnames='Kevin A',Author(firstnames='Kevin P',Author(firstnames='Kim',Author(firstnames='Kimberly A',Author(firstnames='Kirkwood',Author(firstnames='Krista',Author(firstnames='Lauren',Author(firstnames='Lawrence J',Author(firstnames='Lawton S',Author(firstnames='Lee R',Author(firstnames='Lemuel',Author(firstnames='Leslie',Author(firstnames='Leway',Author(firstnames='Li',Author(firstnames='Linda',Author(firstnames='Lisa',Author(firstnames='Lori',Author(firstnames='Lotfy L',Author(firstnames='Luc',Author(firstnames='Lucy',Author(firstnames='Ludmila',Author(firstnames='Lynda H',Author(firstnames='Lynn',Author(firstnames='Lynne',Author(firstnames='Malcolm',Author(firstnames='Mandeep R',Author(firstnames='Marcia',Author(firstnames='Marcy',Author(firstnames='Margarett',Author(firstnames='Maria M',Author(firstnames='Marianne',Author(firstnames='Marie Christine',Author(firstnames='Marie-Helene',Author(firstnames='Marie',Author(firstnames='Mark E',Author(firstnames='Mark',Author(firstnames='Marvin W',Author(firstnames='Mary Elizabeth',Author(firstnames='Mary J',Author(firstnames='Mary N',Author(firstnames='Maryl R',Author(firstnames='Matthew',Author(firstnames='Melanie',Author(firstnames='Melissa',Author(firstnames='Meredith',Author(firstnames='Michael',Author(firstnames='Michele',Author(firstnames='Michelle',Author(firstnames='Mihai',Author(firstnames='Mike',Author(firstnames='Molly',Author(firstnames='Mona',Author(firstnames='Monica',Author(firstnames='Myrvin',Author(firstnames='Nancy Houston',Author(firstnames='Nancy Z',Author(firstnames='Nancy',Author(firstnames='Neil',Author(firstnames='Nora M',Author(firstnames='Omar',Author(firstnames='Page',Author(firstnames='Pam',Author(firstnames='Pamela',Author(firstnames='Pat',Author(firstnames='Patrick',Author(firstnames='Patty',Author(firstnames='Paul D',Author(firstnames='Paul',Author(firstnames='Paula J',Author(firstnames='Peggy',Author(firstnames='Peter',Author(firstnames='Phil',Author(firstnames='Philip A',Author(firstnames='Rachel',Author(firstnames='Ralph H',Author(firstnames='Rami',Author(firstnames='Ravi K',Author(firstnames='Ray',Author(firstnames='Rebecca A',Author(firstnames='Regina',Author(firstnames='Remi',Author(firstnames='Renee L',Author(firstnames='Robert S',Author(firstnames='Robert',Author(firstnames='Robin',Author(firstnames='Ron M',Author(firstnames='Savitri',Author(firstnames='Scott',Author(firstnames='Shanda Browning',Author(firstnames='Sharon K',Author(firstnames='Sharon',Author(firstnames='Sheila',Author(firstnames='Shelby',Author(firstnames='Sherri',Author(firstnames='Stephen J',Author(firstnames='Stephen',Author(firstnames='Steven J',Author(firstnames='Steven K',Author(firstnames='Steven',Author(firstnames='Stuart',Author(firstnames='Sunday',Author(firstnames='Susan K',Author(firstnames='Susan',Author(firstnames='Tamika',Author(firstnames='Tanya M',Author(firstnames='Tehmina',Author(firstnames='Theresa',Author(firstnames='Timothy R',Author(firstnames='Tina',Author(firstnames='Tracey',Author(firstnames='Udho',Author(firstnames='Valerie',Author(firstnames='Vera',Author(firstnames='Victor',Author(firstnames='Virginia',Author(firstnames='William E',Author(firstnames='William',Author(firstnames='Wilson',Author(firstnames='Wyatt',Author(firstnames='Yanhong',Author(firstnames='Yemi',Christopher M O'Connor,Chronic Disease,CollabAuthor(name='HF-ACTION Investigators',David J Whellan,doi:10.1001/jama.2009.454,equal<sub>c</sub>ontrib=False),equal<sub>c</sub>ontrib=False)],Exercise,Exercise Therapy* / adverse effects,Extramural,Female,Heart Failure / mortality,Heart Failure / rehabilitation*,Hospitalization,Humans,initials='A',initials='AB',initials='AM',initials='B',initials='BD',initials='BL',initials='BM',initials='BS',initials='C',initials='CA',initials='CM',initials='D',initials='DJ',initials='DR',initials='DS',initials='DW',initials='E',initials='EA',initials='ES',initials='ET',initials='F',initials='FG',initials='G',initials='GI',initials='H',initials='IL',initials='J',initials='JA',initials='JG',initials='JK',initials='JL',initials='JM',initials='JY',initials='K',initials='KA',initials='KE',initials='KL',initials='KP',initials='L',initials='LH',initials='LJ',initials='LL',initials='LR',initials='LS',initials='M',initials='MC',initials='ME',initials='MH',initials='MJ',initials='MM',initials='MN',initials='MR',initials='MW',initials='N',initials='NH',initials='NM',initials='NZ',initials='O',initials='P',initials='PA',initials='PD',initials='PJ',initials='R',initials='RA',initials='RH',initials='RK',initials='RL',initials='RM',initials='RS',initials='S',initials='SB',initials='SJ',initials='SK',initials='T',initials='TM',initials='TR',initials='U',initials='V',initials='W',initials='WE',initials='Y',investigators=[Author(firstnames='Christopher M',iseditor=False,lastname='Abraham',lastname='Adams',lastname='Ades',lastname='Aebehard',lastname='Agruss',lastname='Alharethi',lastname='Amsterdam',lastname='Arnold',lastname='Azevedo',lastname='Badenhop',lastname='Bakos',lastname='Barbour',lastname='Barnard',lastname='Basta',lastname='Baumann',lastname='Beare',lastname='Belin',lastname='Bennett',lastname='Bensimhon',lastname='Bess',lastname='Biniakiewicz',lastname='Bittner',lastname='Blackburn',lastname='Blumenthal',lastname='Boineau',lastname='Bond',lastname='Boozer',lastname='Boyette',lastname='Brawner',lastname='Buchter',lastname='Burnette',lastname='Burns',lastname='Cabuay',lastname='Campbell',lastname='Cantu',lastname='Chandler',lastname='Chen',lastname='Clancy',lastname='Cohen-Solal',lastname='Cohen',lastname='Coleman',lastname='Collins',lastname='Colucci',lastname='Colvin-Adams',lastname='Connolly',lastname='Contasti',lastname='Cooley-Warnell',lastname='Cooper',lastname='Cosgrove',lastname='Cosio-Lima',lastname='Craddock',lastname='Cullinane',lastname='Cymet',lastname='David',lastname='Davidson-Ray',lastname='Dekerlegand',lastname='Dimick',lastname='Djaballah',lastname='Doll',lastname='Donahue',lastname='Dorrell',lastname='Drobot',lastname='Duderstadt',lastname='Dunlap',lastname='Duscha',lastname='Easler',lastname='Ehrman',lastname='Eichhorn',lastname='Eisen',lastname='Ellestad',lastname='Ellis',lastname='Erickson',lastname='Esposito',lastname='Estrella-Holder',lastname='Ewald',lastname='Fedson',lastname='Felker',lastname='Fine',lastname='Fitz-Gerald',lastname='Fitzpatrick',lastname='Flanagan',lastname='Fleg',lastname='Fletcher',lastname='Flynn',lastname='Fonarow',lastname='Forman',lastname='Fortman',lastname='Fray',lastname='Frazier',lastname='Friedman',lastname='Froelicher',lastname='Gardin',lastname='Garg',lastname='Geither',lastname='Ghali',lastname='Gheorghiade',lastname='Gillespie',lastname='Glenn',lastname='Glotzer',lastname='Goldberg',lastname='Golob',lastname='Gordon',lastname='Gottlieb',lastname='Grant',lastname='Greenberg',lastname='Gruendler',lastname='Haffey',lastname='Hale-Stenson',lastname='Hamel',lastname='Hancock',lastname='Handberg',lastname='Harris',lastname='Hartwick',lastname='Hastings',lastname='Heck',lastname='Heiss',lastname='Herman',lastname='Hershberger',lastname='Hill',lastname='Hittinger',lastname='Homan',lastname='Howlett',lastname='Hutchins',lastname='Iliou',lastname='Isaac',lastname='Johnson',lastname='Kaczkowski',lastname='Kao',lastname='Kaping',lastname='Keane-Richmond',lastname='Kern',lastname='Keteyian',lastname='Kitzman',lastname='Kokkinos',lastname='Korsak',lastname='Kostis',lastname='Kraus',lastname='Kronenberg',lastname='Krueger',lastname='Lachmann',lastname='Lagasse',lastname='LaLonge',lastname='Landzberg',lastname='Langley',lastname='Lawless',lastname='Lawrence',lastname='Leathes',lastname='LeBlanc',lastname='Lee',lastname='Leifer',lastname='Lenz',lastname='Leonard',lastname='Letterer',lastname='Li',lastname='Lim',lastname='Lin',lastname='Lippman',lastname='Lopez',lastname='Lyzun',lastname='Madison',lastname='Mandacina',lastname='Manire',lastname='Marcus',lastname='Margiotti',lastname='Mark',lastname='Massie',lastname='Mathus',lastname='McClanahan-Crowder',lastname='McConnell',lastname='McCullough',lastname='McKelvie',lastname='McLaughlin',lastname='McNamara',lastname='Mehra',lastname='Melvin',lastname='Meyer',lastname='Mickley',lastname='Miller',lastname='Moe',lastname='Moore',lastname='Moye',lastname='Mueller',lastname='Nauman',lastname='Naz',lastname='Nigam',lastname='Nkemdiche',lastname='Ofili',lastname='Oldano',lastname='Onwuanyi',lastname='Oren',lastname='Palevo',lastname='Parks',lastname='Pearce',lastname='Peasley',lastname='Pina',lastname='Piner',lastname='Pitt',lastname='Powell',lastname='Raczynski',lastname='Reed',lastname='Rendall',lastname='Renton',lastname='Rich',lastname='Rogan',lastname='Roll',lastname='Rostami',lastname='Russell',lastname='Sabatier',lastname='Sagerian',lastname='Saval',lastname='Schneider',lastname='Schrack',lastname='Schroeder',lastname='Schulman',lastname='Schumacher',lastname='Scovel',lastname='Serfass',lastname='Settles',lastname='Sklar',lastname='Smith',lastname='Snell',lastname='Spinella',lastname='Spruill',lastname='Staib',lastname='Steger',lastname='Stevens',lastname='Stewart',lastname='Strzelczyk',lastname='Swank',lastname='Talabi-Oates',lastname='Taylor',lastname='Teller',lastname='Thadani',lastname='Thompson',lastname='Thresher',lastname='Tokareva',lastname='Truitte',lastname='Turner',lastname='Vander Ark',lastname='Vaughn',lastname='Ventura',lastname='Vest',lastname='Vienneau',lastname='Voyles',lastname='Wagoner',lastname='Wald',lastname='Walker',lastname='Walsh',lastname='Walter',lastname='Wantz',lastname='Washington',lastname='Weinfurt',lastname='Wells',lastname='Wertheimer',lastname='Whellan',lastname='Williams',lastname='Willoughby',lastname='Wolfel',lastname='Wong',lastname='Worley',lastname='Yanowitz',lastname='Yarn',lastname='Zannad',lastname='Zile',lastname="O'Bryan",lastname="O'Connor",lastname="O'Neal",Male,MEDLINE,Middle Aged,Multicenter Study,N.I.H.,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,PMC2916661,pmid:19351941,Prognosis,PubMed Abstract,Quality of Life,Randomized Controlled Trial,Research Support,Self Care,suffix='Jr',suffix=None}
}

@article{odonoghueEffectDarapladibMajor2014,
  title = {Effect of Darapladib on Major Coronary Events after an Acute Coronary Syndrome: The {{SOLID-TIMI}} 52 Randomized Clinical Trial},
  shorttitle = {Effect of Darapladib on Major Coronary Events after an Acute Coronary Syndrome},
  author = {O'Donoghue, Michelle L. and Braunwald, Eugene and White, Harvey D. and Lukas, Mary Ann and Tarka, Elizabeth and Steg, P. Gabriel and Hochman, Judith S. and Bode, Christoph and Maggioni, Aldo P. and Im, KyungAh and Shannon, Jennifer B. and Davies, Richard Y. and Murphy, Sabina A. and Crugnale, Sharon E. and Wiviott, Stephen D. and Bonaca, Marc P. and Watson, David F. and Weaver, W. Douglas and Serruys, Patrick W. and Cannon, Christopher P. and {SOLID-TIMI 52 Investigators} and Steen, Dylan L.},
  year = {2014},
  month = sep,
  journal = {JAMA},
  volume = {312},
  number = {10},
  pages = {1006--1015},
  issn = {1538-3598},
  doi = {10.1001/jama.2014.11061},
  abstract = {IMPORTANCE: Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been hypothesized to be involved in atherogenesis through pathways related to inflammation. Darapladib is an oral, selective inhibitor of the Lp-PLA2 enzyme. OBJECTIVE: To evaluate the efficacy and safety of darapladib in patients after an acute coronary syndrome (ACS) event. DESIGN, SETTING, AND PARTICIPANTS: SOLID-TIMI 52 was a multinational, double-blind, placebo-controlled trial that randomized 13,026 participants within 30 days of hospitalization with an ACS (non-ST-elevation or ST-elevation myocardial infarction [MI]) at 868 sites in 36 countries. INTERVENTIONS: Patients were randomized to either once-daily darapladib (160 mg) or placebo on a background of guideline-recommended therapy. Patients were followed up for a median of 2.5 years between December 7, 2009, and December 6, 2013. MAIN OUTCOMES AND MEASURES: The primary end point (major coronary events) was the composite of coronary heart disease (CHD) death, MI, or urgent coronary revascularization for myocardial ischemia. Kaplan-Meier event rates are reported at 3 years. RESULTS: During a median duration of 2.5 years, the primary end point occurred in 903 patients in the darapladib group and 910 in the placebo group (16.3\% vs 15.6\% at 3 years; hazard ratio [HR], 1.00 [95\% CI, 0.91-1.09]; P\,=\,.93). The composite of cardiovascular death, MI, or stroke occurred in 824 in the darapladib group and 838 in the placebo group (15.0\% vs 15.0\% at 3 years; HR, 0.99 [95\% CI, 0.90-1.09]; P\,=\,.78). There were no differences between the treatment groups for additional secondary end points, for individual components of the primary end point, or in all-cause mortality (371 events in the darapladib group and 395 in the placebo group [7.3\% vs 7.1\% at 3 years; HR, 0.94 [95\% CI, 0.82-1.08]; P\,=\,.40). Patients were more likely to report an odor-related concern in the darapladib group vs the placebo group (11.5\% vs 2.5\%) and also more likely to report diarrhea (10.6\% vs 5.6\%). CONCLUSIONS AND RELEVANCE: In patients who experienced an ACS event, direct inhibition of Lp-PLA2 with darapladib added to optimal medical therapy and initiated within 30 days of hospitalization did not reduce the risk of major coronary events. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01000727.},
  langid = {english},
  pmid = {25173516},
  keywords = {Acute Coronary Syndrome,Aged,Benzaldehydes,Blood Proteins,Cardiovascular Diseases,Double-Blind Method,Female,Follow-Up Studies,Humans,Incidence,Kaplan-Meier Estimate,Male,Middle Aged,Myocardial Infarction,Myocardial Ischemia,Oximes,Secondary Prevention}
}

@article{oguntadeAdiposityFatfreeMass2024,
  title = {Adiposity, Fat-Free Mass and Incident Heart Failure in 500 000 Individuals},
  author = {Oguntade, Ayodipupo S. and Taylor, Hannah and Lacey, Ben and Lewington, Sarah},
  year = {2024},
  month = jul,
  journal = {Open Heart},
  volume = {11},
  number = {2},
  publisher = {British Cardiovascular Society},
  issn = {2053-3624},
  doi = {10.1136/openhrt-2024-002711},
  urldate = {2025-01-08},
  abstract = {Background and aims The independent role of body fat distribution and fat-free mass in heart failure (HF) risk is unclear. We investigated the role of different body composition compartments in risk of HF.Methods Present analyses include 428 087 participants (mean age 55.9 years, 44\% male) from the UK Biobank. Associations of long-term average levels of body composition measures with incident HF were determined using adjusted Cox proportional hazards regression models.Results Over a median follow-up of 13.8 years, there were 10 455 first-ever incident HF events. Overall, HF risk was more strongly associated with central adiposity (waist circumference (WC) adjusted for body mass index (BMI); HR 1.38, 95\% CI 1.32 to 1.45) than general adiposity (BMI adjusted for WC; HR 1.22, 95\% CI 1.16 to 1.27). Although dual X-ray absorptiometry-derived body fat remained positively related to HF after adjustment for fat-free mass (HR 1.37, 95\% CI 1.18 to 1.59), the association of fat-free mass with HF was substantially attenuated by fat mass (HR 1.12, 95\% CI 1.01 to 1.26) while visceral fat (VAT) remained associated with HF independent of subcutaneous fat (HR 1.20, 95\% CI 1.09 to 1.33). In analyses of HF subtypes, HF with preserved ejection fraction was independently associated with all fat measures (eg, VAT: HR 1.23, 95\% CI 1.12 to 1.35; body fat: HR 1.36, 95\% CI 1.17 to 1.57) while HF with reduced ejection fraction was not independently associated with fat measures (eg, VAT: HR 1.29, 95\% CI 0.98 to 1.68; body fat: HR 1.29, 95\% CI 0.80 to 2.07).Conclusions This large-scale study shows that excess adiposity and fat mass are associated with higher HF risk while the association of fat-free mass with HF could be explained largely by its correlation with fat mass. The study also describes the independent relevance of body fat distribution to HF subtypes, suggesting different mechanisms may be driving their aetiopathogenesis.},
  copyright = {This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license},
  langid = {english},
  pmid = {10.1136/openhrt-2024-002711},
  file = {/Users/xx20081/Zotero/storage/278YEBYS/Oguntade et al. - 2024 - Adiposity, fat-free mass and incident heart failure in 500 000 individuals.pdf}
}

@article{oguntadeAdiposityFatfreeMass2024a,
  title = {Adiposity, Fat-Free Mass and Incident Heart Failure in 500 000 Individuals},
  author = {Oguntade, Ayodipupo S. and Taylor, Hannah and Lacey, Ben and Lewington, Sarah},
  year = {2024},
  month = jul,
  journal = {Open Heart},
  volume = {11},
  number = {2},
  issn = {2053-3624},
  doi = {10.1136/openhrt-2024-002711},
  urldate = {2025-01-08},
  abstract = {Background and aims The independent role of body fat distribution and fat-free mass in heart failure (HF) risk is unclear. We investigated the role of different body composition compartments in risk of HF.Methods Present analyses include 428 087 participants (mean age 55.9 years, 44\% male) from the UK Biobank. Associations of long-term average levels of body composition measures with incident HF were determined using adjusted Cox proportional hazards regression models.Results Over a median follow-up of 13.8 years, there were 10 455 first-ever incident HF events. Overall, HF risk was more strongly associated with central adiposity (waist circumference (WC) adjusted for body mass index (BMI); HR 1.38, 95\% CI 1.32 to 1.45) than general adiposity (BMI adjusted for WC; HR 1.22, 95\% CI 1.16 to 1.27). Although dual X-ray absorptiometry-derived body fat remained positively related to HF after adjustment for fat-free mass (HR 1.37, 95\% CI 1.18 to 1.59), the association of fat-free mass with HF was substantially attenuated by fat mass (HR 1.12, 95\% CI 1.01 to 1.26) while visceral fat (VAT) remained associated with HF independent of subcutaneous fat (HR 1.20, 95\% CI 1.09 to 1.33). In analyses of HF subtypes, HF with preserved ejection fraction was independently associated with all fat measures (eg, VAT: HR 1.23, 95\% CI 1.12 to 1.35; body fat: HR 1.36, 95\% CI 1.17 to 1.57) while HF with reduced ejection fraction was not independently associated with fat measures (eg, VAT: HR 1.29, 95\% CI 0.98 to 1.68; body fat: HR 1.29, 95\% CI 0.80 to 2.07).Conclusions This large-scale study shows that excess adiposity and fat mass are associated with higher HF risk while the association of fat-free mass with HF could be explained largely by its correlation with fat mass. The study also describes the independent relevance of body fat distribution to HF subtypes, suggesting different mechanisms may be driving their aetiopathogenesis.},
  copyright = {This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license},
  langid = {english},
  pmid = {10.1136/openhrt-2024-002711}
}

@article{oguntadeBodyCompositionRisk2023,
  title = {Body {{Composition}} and {{Risk}} of {{Incident Heart Failure}} in 1 {{Million Adults}}: {{A Systematic Review}} and {{Dose-Response Meta-Analysis}} of {{Prospective Cohort Studies}}},
  shorttitle = {Body {{Composition}} and {{Risk}} of {{Incident Heart Failure}} in 1 {{Million Adults}}},
  author = {Oguntade, {\relax AS} and N, Islam and R, Malouf and H, Taylor and D, Jin and S, Lewington and B, Lacey},
  year = {2023},
  month = apr,
  journal = {Journal of the American Heart Association},
  volume = {12},
  number = {13},
  publisher = {J Am Heart Assoc},
  issn = {2047-9980},
  doi = {10.1161/JAHA.122.029062},
  urldate = {2025-01-07},
  abstract = {Background The aim of this systematic review was to quantify the associations between body composition measures and risk of incident heart failure (HF) and its subtypes in the general population. Methods and Results We searched Medline, Embase, and Global Health databases from each database inceptio {\dots}},
  langid = {english},
  pmid = {37345755},
  file = {/Users/xx20081/Zotero/storage/PTND753M/As et al. - 2023 - Body Composition and Risk of Incident Heart Failure in 1 Million Adults A Systematic Review and Dos.pdf;/Users/xx20081/Zotero/storage/CWU3NRIH/37345755.html}
}

@article{okbayGeneticVariantsAssociated2016,
  title = {Genetic Variants Associated with Subjective Well-Being, Depressive Symptoms, and Neuroticism Identified through Genome-Wide Analyses},
  author = {Okbay, Aysu and Baselmans, Bart M. L. and De Neve, Jan-Emmanuel and Turley, Patrick and Nivard, Michel G. and Fontana, Mark Alan and Meddens, S. Fleur W. and Linn{\'e}r, Richard Karlsson and Rietveld, Cornelius A. and Derringer, Jaime and Gratten, Jacob and Lee, James J. and Liu, Jimmy Z. and {de Vlaming}, Ronald and Ahluwalia, Tarunveer S. and Buchwald, Jadwiga and Cavadino, Alana and {Frazier-Wood}, Alexis C. and Furlotte, Nicholas A. and Garfield, Victoria and Geisel, Marie Henrike and Gonzalez, Juan R. and Haitjema, Saskia and Karlsson, Robert and {van der Laan}, Sander W. and Ladwig, Karl-Heinz and Lahti, Jari and {van der Lee}, Sven J. and Lind, Penelope A. and Liu, Tian and Matteson, Lindsay and Mihailov, Evelin and Miller, Michael B. and Minica, Camelia C. and Nolte, Ilja M. and {Mook-Kanamori}, Dennis and {van der Most}, Peter J. and Oldmeadow, Christopher and Qian, Yong and Raitakari, Olli and Rawal, Rajesh and Realo, Anu and Rueedi, Rico and Schmidt, B{\"o}rge and Smith, Albert V. and Stergiakouli, Evie and Tanaka, Toshiko and Taylor, Kent and Thorleifsson, Gudmar and Wedenoja, Juho and Wellmann, Juergen and Westra, Harm-Jan and Willems, Sara M. and Zhao, Wei and {LifeLines Cohort Study} and Amin, Najaf and Bakshi, Andrew and Bergmann, Sven and Bjornsdottir, Gyda and Boyle, Patricia A. and Cherney, Samantha and Cox, Simon R. and Davies, Gail and Davis, Oliver S. P. and Ding, Jun and Direk, Nese and Eibich, Peter and Emeny, Rebecca T. and Fatemifar, Ghazaleh and Faul, Jessica D. and Ferrucci, Luigi and Forstner, Andreas J. and Gieger, Christian and Gupta, Richa and Harris, Tamara B. and Harris, Juliette M. and Holliday, Elizabeth G. and Hottenga, Jouke-Jan and De Jager, Philip L. and Kaakinen, Marika A. and Kajantie, Eero and Karhunen, Ville and Kolcic, Ivana and Kumari, Meena and Launer, Lenore J. and Franke, Lude and {Li-Gao}, Ruifang and Liewald, David C. and Koini, Marisa and Loukola, Anu and {Marques-Vidal}, Pedro and Montgomery, Grant W. and Mosing, Miriam A. and Paternoster, Lavinia and Pattie, Alison and Petrovic, Katja E. and {Pulkki-R{\aa}back}, Laura and Quaye, Lydia and R{\"a}ikk{\"o}nen, Katri and Rudan, Igor and Scott, Rodney J. and Smith, Jennifer A. and Sutin, Angelina R. and Trzaskowski, Maciej and Vinkhuyzen, Anna E. and Yu, Lei and Zabaneh, Delilah and Attia, John R. and Bennett, David A. and Berger, Klaus and Bertram, Lars and Boomsma, Dorret I. and Snieder, Harold and Chang, Shun-Chiao and Cucca, Francesco and Deary, Ian J. and {van Duijn}, Cornelia M. and Eriksson, Johan G. and B{\"u}ltmann, Ute and {de Geus}, Eco J. C. and Groenen, Patrick J. F. and Gudnason, Vilmundur and Hansen, Torben and Hartman, Catharine A. and Haworth, Claire M. A. and Hayward, Caroline and Heath, Andrew C. and Hinds, David A. and Hypp{\"o}nen, Elina and Iacono, William G. and J{\"a}rvelin, Marjo-Riitta and J{\"o}ckel, Karl-Heinz and Kaprio, Jaakko and Kardia, Sharon L. R. and {Keltikangas-J{\"a}rvinen}, Liisa and Kraft, Peter and Kubzansky, Laura D. and Lehtim{\"a}ki, Terho and Magnusson, Patrik K. E. and Martin, Nicholas G. and McGue, Matt and Metspalu, Andres and Mills, Melinda and {de Mutsert}, Ren{\'e}e and Oldehinkel, Albertine J. and Pasterkamp, Gerard and Pedersen, Nancy L. and Plomin, Robert and Polasek, Ozren and Power, Christine and Rich, Stephen S. and Rosendaal, Frits R. and {den Ruijter}, Hester M. and Schlessinger, David and Schmidt, Helena and Svento, Rauli and Schmidt, Reinhold and Alizadeh, Behrooz Z. and S{\o}rensen, Thorkild I. A. and Spector, Tim D. and Starr, John M. and Stefansson, Kari and Steptoe, Andrew and Terracciano, Antonio and Thorsteinsdottir, Unnur and Thurik, A. Roy and Timpson, Nicholas J. and Tiemeier, Henning and Uitterlinden, Andr{\'e} G. and Vollenweider, Peter and Wagner, Gert G. and Weir, David R. and Yang, Jian and Conley, Dalton C. and Smith, George Davey and Hofman, Albert and Johannesson, Magnus and Laibson, David I. and Medland, Sarah E. and Meyer, Michelle N. and Pickrell, Joseph K. and Esko, T{\~o}nu and Krueger, Robert F. and Beauchamp, Jonathan P. and Koellinger, Philipp D. and Benjamin, Daniel J. and Bartels, Meike and Cesarini, David},
  year = {2016},
  month = jun,
  journal = {Nature Genetics},
  volume = {48},
  number = {6},
  pages = {624--633},
  issn = {1546-1718},
  doi = {10.1038/ng.3552},
  abstract = {Very few genetic variants have been associated with depression and neuroticism, likely because of limitations on sample size in previous studies. Subjective well-being, a phenotype that is genetically correlated with both of these traits, has not yet been studied with genome-wide data. We conducted genome-wide association studies of three phenotypes: subjective well-being (n = 298,420), depressive symptoms (n = 161,460), and neuroticism (n = 170,911). We identify 3 variants associated with subjective well-being, 2 variants associated with depressive symptoms, and 11 variants associated with neuroticism, including 2 inversion polymorphisms. The two loci associated with depressive symptoms replicate in an independent depression sample. Joint analyses that exploit the high genetic correlations between the phenotypes ({\textbar}{$\rho$}{\textasciicircum}{\textbar} {$\approx$} 0.8) strengthen the overall credibility of the findings and allow us to identify additional variants. Across our phenotypes, loci regulating expression in central nervous system and adrenal or pancreas tissues are strongly enriched for association.},
  langid = {english},
  pmcid = {PMC4884152},
  pmid = {27089181},
  keywords = {Anxiety Disorders,Bayes Theorem,Depression,Genome-Wide Association Study,Humans,Neuroticism,Phenotype,Polymorphism Single Nucleotide},
  file = {/Users/xx20081/Zotero/storage/SWUS87D6/Okbay et al. - 2016 - Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identif.pdf}
}

@article{okoroduduDiagnosticPerformanceBody2010,
  title = {Diagnostic Performance of Body Mass Index to Identify Obesity as Defined by Body Adiposity: A Systematic Review and Meta-Analysis},
  shorttitle = {Diagnostic Performance of Body Mass Index to Identify Obesity as Defined by Body Adiposity},
  author = {Okorodudu, D. O. and Jumean, M. F. and Montori, V. M. and {Romero-Corral}, A. and Somers, V. K. and Erwin, P. J. and {Lopez-Jimenez}, F.},
  year = {2010},
  month = may,
  journal = {International Journal of Obesity (2005)},
  volume = {34},
  number = {5},
  pages = {791--799},
  issn = {1476-5497},
  doi = {10.1038/ijo.2010.5},
  abstract = {OBJECTIVE: We performed a systematic review and meta-analysis of studies that assessed the performance of body mass index (BMI) to detect body adiposity. DESIGN: Data sources were MEDLINE, EMBASE, Cochrane, Database of Systematic Reviews, Cochrane CENTRAL, Web of Science, and SCOPUS. To be included, studies must have assessed the performance of BMI to measure body adiposity, provided standard values of diagnostic performance, and used a body composition technique as the reference standard for body fat percent (BF\%) measurement. We obtained pooled summary statistics for sensitivity, specificity, positive and negative likelihood ratios (LRs), and diagnostic odds ratio (DOR). The inconsistency statistic (I2) assessed potential heterogeneity. RESULTS: The search strategy yielded 3341 potentially relevant abstracts, and 25 articles met our predefined inclusion criteria. These studies evaluated 32 different samples totaling 31 968 patients. Commonly used BMI cutoffs to diagnose obesity showed a pooled sensitivity to detect high adiposity of 0.50 (95\% confidence interval (CI): 0.43-0.57) and a pooled specificity of 0.90 (CI: 0.86-0.94). Positive LR was 5.88 (CI: 4.24-8.15), I (2)=97.8\%; the negative LR was 0.43 (CI: 0.37-0.50), I (2)=98.5\%; and the DOR was 17.91 (CI: 12.56-25.53), I (2)=91.7\%. Analysis of studies that used BMI cutoffs {$>$}or=30 had a pooled sensitivity of 0.42 (CI: 0.31-0.43) and a pooled specificity of 0.97 (CI: 0.96-0.97). Cutoff values and regional origin of the studies can only partially explain the heterogeneity seen in pooled DOR estimates. CONCLUSION: Commonly used BMI cutoff values to diagnose obesity have high specificity, but low sensitivity to identify adiposity, as they fail to identify half of the people with excess BF\%.},
  langid = {english},
  pmid = {20125098},
  keywords = {Adiposity,Body Composition,Body Mass Index,Humans,Obesity,Predictive Value of Tests,United States}
}

@article{okoroduduDiagnosticPerformanceBody2010a,
  title = {Diagnostic Performance of Body Mass Index to Identify Obesity as Defined by Body Adiposity: A Systematic Review and Meta-Analysis},
  shorttitle = {Diagnostic Performance of Body Mass Index to Identify Obesity as Defined by Body Adiposity},
  author = {Okorodudu, D. O. and Jumean, M. F. and Montori, V. M. and {Romero-Corral}, A. and Somers, V. K. and Erwin, P. J. and {Lopez-Jimenez}, F.},
  year = {2010},
  month = may,
  journal = {International Journal of Obesity},
  volume = {34},
  number = {5},
  pages = {791--799},
  publisher = {Nature Publishing Group},
  issn = {1476-5497},
  doi = {10.1038/ijo.2010.5},
  urldate = {2024-07-04},
  abstract = {We performed a systematic review and meta-analysis of studies that assessed the performance of body mass index (BMI) to detect body adiposity.},
  copyright = {2010 Macmillan Publishers Limited},
  langid = {english},
  keywords = {Obesity,Physical examination,Statistical methods},
  file = {/Users/xx20081/Zotero/storage/6S8RL4ZC/Okorodudu et al. - 2010 - Diagnostic performance of body mass index to ident.pdf}
}

@article{olivierEffectEplerenonePatients2017,
  title = {Effect of Eplerenone in Patients with Heart Failure and Reduced Ejection Fraction: Potential Effect Modification by Abdominal Obesity. {{Insight}} from the {{EMPHASIS-HF}} Trial},
  shorttitle = {Effect of Eplerenone in Patients with Heart Failure and Reduced Ejection Fraction},
  author = {Olivier, Arnaud and Pitt, Bertram and Girerd, Nicolas and Lamiral, Zohra and Machu, Jean-Loup and McMurray, John J. V. and Swedberg, Karl and {van Veldhuisen}, Dirk J. and Collier, Timothy J. and Pocock, Stuart J. and Rossignol, Patrick and Zannad, Faiez and Pizard, Anne},
  year = {2017},
  month = sep,
  journal = {European Journal of Heart Failure},
  volume = {19},
  number = {9},
  pages = {1186--1197},
  issn = {1879-0844},
  doi = {10.1002/ejhf.792},
  abstract = {AIMS: An excessive production of aldosterone influences outcome in patients with heart failure (HF) and in obese patients. Findings from laboratory studies suggest that chronic aldosterone blockade maybe more beneficial in abdominally obese HF-prone rats. In the current study, we investigated if the clinical response to a mineralocorticoid receptor antagonist in mildly symptomatic HF patients varied by abdominal obesity. METHODS AND RESULTS: A total of 2587 NYHA class II, reduced ejection fraction HF (HFrEF) patients enrolled in the EMPHASIS-HF trial were randomly assigned to eplerenone and placebo. In this post hoc analysis, patients were categorized according to waist circumference (WC) (normal if WC {$<$} 102\,cm in men and\,{$<$}\,88\,cm in women; abdominal obesity if WC {$\geq$} 102\,cm in men and\,{$\geq$}\,88\,cm women). The potential statistical interaction between the treatment and WC was assessed on the primary endpoint of death from cardiovascular causes or hospitalization for HF and other secondary endpoints. Over a median follow-up of 21 months, a significant benefit of eplerenone for the primary outcome was noted in both normal [hazard ratio (HR) 0.77, 95\% confidence interval (CI) 0.61-0.98, P = 0.03] and increased (HR 0.48, 95\% CI 0.37-0.63, P {$<$} 0.0001) WC subgroups, but the latter patients appeared to receive greater benefit than patients with normal WC (P for interaction = 0.01). This suggests a significant quantitative (treatment effect varies in magnitude by subgroup, but is always in same direction) rather than a qualitative interaction (direction of the treatment effect varies by subgroup) between eplerenone and WC in the adjusted analysis. Mean doses of eplerenone, blood pressure and serum potassium changes and adverse events were similar between WC subgroups. CONCLUSION: In EMPHASIS-HF, eplerenone improved outcomes in HFrEF patients with and without abdominal obesity, although the benefit appeared to be more pronounced among those with abdominal obesity. The findings are potentially hypothesis generating and need to be replicated in other HFrEF populations.},
  langid = {english},
  pmid = {28303624},
  keywords = {Abdominal obesity,Aged,Aldosterone,Drug Monitoring,Eplerenone,Female,Heart Failure Systolic,Heart failure with reduced ejection fraction,Humans,Male,Middle Aged,Mineralocorticoid Receptor Antagonists,Obesity Abdominal,Spironolactone,Stroke Volume,Treatment Outcome,Ventricular Dysfunction Left},
  file = {/Users/xx20081/Zotero/storage/CWRUKSSZ/Olivier et al. - 2017 - Effect of eplerenone in patients with heart failur.pdf}
}

@article{ongenEstimatingCausalTissues2017,
  title = {Estimating the Causal Tissues for Complex Traits and Diseases},
  author = {Ongen, Halit and Brown, Andrew A. and Delaneau, Olivier and Panousis, Nikolaos I. and Nica, Alexandra C. and {GTEx Consortium} and Dermitzakis, Emmanouil T.},
  year = {2017},
  month = dec,
  journal = {Nature Genetics},
  volume = {49},
  number = {12},
  pages = {1676--1683},
  issn = {1546-1718},
  doi = {10.1038/ng.3981},
  abstract = {How to interpret the biological causes underlying the predisposing markers identified through genome-wide association studies (GWAS) remains an open question. One direct and powerful way to assess the genetic causality behind GWAS is through analysis of expression quantitative trait loci (eQTLs). Here we describe a new approach to estimate the tissues behind the genetic causality of a variety of GWAS traits, using the cis-eQTLs in 44 tissues from the Genotype-Tissue Expression (GTEx) Consortium. We have adapted the regulatory trait concordance (RTC) score to measure the probability of eQTLs being active in multiple tissues and to calculate the probability that a GWAS-associated variant and an eQTL tag the same functional effect. By normalizing the GWAS-eQTL probabilities by the tissue-sharing estimates for eQTLs, we generate relative tissue-causality profiles for GWAS traits. Our approach not only implicates the gene likely mediating individual GWAS signals, but also highlights tissues where the genetic causality for an individual trait is likely manifested.},
  langid = {english},
  pmid = {29058715},
  keywords = {Gene Expression Profiling,Genetic Association Studies,Genetic Predisposition to Disease,Genome-Wide Association Study,Genotype,Humans,Organ Specificity,Phenotype,Polymorphism Single Nucleotide,Quantitative Trait Loci},
  file = {/Users/xx20081/Zotero/storage/Z8KNC8LS/Ongen et al. - 2017 - Estimating the causal tissues for complex traits a.pdf}
}

@article{ongenEstimatingCausalTissues2017a,
  title = {Estimating the Causal Tissues for Complex Traits and Diseases},
  author = {Ongen, Halit and Brown, Andrew A. and Delaneau, Olivier and Panousis, Nikolaos I. and Nica, Alexandra C. and Dermitzakis, Emmanouil T.},
  year = {2017},
  month = dec,
  journal = {Nature Genetics},
  volume = {49},
  number = {12},
  pages = {1676--1683},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/ng.3981},
  urldate = {2024-04-19},
  abstract = {This study presents a new approach to estimate the tissues contributing to the genetic causality for complex traits and diseases. The method assesses tissue sharing of eQTLs among 44 tissues and then uses these tissue-sharing estimates to infer the tissues where trait-associated variants likely exert their function.},
  copyright = {2017 Springer Nature America, Inc.},
  langid = {english},
  keywords = {Genome-wide association studies,Population genetics,Transcriptomics},
  file = {/Users/xx20081/Zotero/storage/DBLFBTQY/Ongen et al. - 2017 - Estimating the causal tissues for complex traits a.pdf}
}

@article{onunainLifecourseMendelianRandomization2022,
  title = {A Lifecourse Mendelian Randomization Study Highlights the Long-Term Influence of Childhood Body Size on Later Life Heart Structure},
  author = {O'Nunain, Katie and Park, Chloe and Urquijo, Helena and Leyden, Genevieve M. and Hughes, Alun D. and Davey Smith, George and Richardson, Tom G.},
  year = {2022},
  month = jun,
  journal = {PLoS Biology},
  volume = {20},
  number = {6},
  pages = {e3001656},
  issn = {1544-9173},
  doi = {10.1371/journal.pbio.3001656},
  urldate = {2024-08-14},
  abstract = {Children with obesity typically have larger left ventricular heart dimensions during adulthood. However, whether this is due to a persistent effect of adiposity extending into adulthood is challenging to disentangle due to confounding factors throughout the lifecourse. We conducted a multivariable mendelian randomization (MR) study to separate the independent effects of childhood and adult body size on 4 magnetic resonance imaging (MRI) measures of heart structure and function in the UK Biobank (UKB) study. Strong evidence of a genetically predicted effect of childhood body size on all measures of adulthood heart structure was identified, which remained robust upon accounting for adult body size using a multivariable MR framework (e.g., left ventricular end-diastolic volume (LVEDV), Beta = 0.33, 95\% confidence interval (CI) = 0.23 to 0.43, P = 4.6 {\texttimes} 10-10). Sensitivity analyses did not suggest that other lifecourse measures of body composition were responsible for these effects. Conversely, evidence of a genetically predicted effect of childhood body size on various other MRI-based measures, such as fat percentage in the liver (Beta = 0.14, 95\% CI = 0.05 to 0.23, P = 0.002) and pancreas (Beta = 0.21, 95\% CI = 0.10 to 0.33, P = 3.9 {\texttimes} 10-4), attenuated upon accounting for adult body size. Our findings suggest that childhood body size has a long-term (and potentially immutable) influence on heart structure in later life. In contrast, effects of childhood body size on other measures of adulthood organ size and fat percentage evaluated in this study are likely explained by the long-term consequence of remaining overweight throughout the lifecourse., Children with obesity typically have larger left ventricular heart dimensions during adulthood, but this is challenging to disentangle due to confounding factors throughout life. This study uses Mendelian randomization to provide evidence that being overweight in early life may indeed have a long-term influence on cardiac structure.},
  pmcid = {PMC9182693},
  pmid = {35679339},
  file = {/Users/xx20081/Zotero/storage/PRFPADJW/ONunain et al. - 2022 - A lifecourse mendelian randomization study highlig.pdf}
}

@article{Oreopoulos2008,
  type = {Journal Article},
  title = {Body Mass Index and Mortality in Heart Failure: A Meta-Analysis},
  author = {Oreopoulos, A and Padwal, R and {Kalantar-Zadeh}, K and Fonarow, G C and Norris, C M and McAlister, F A},
  year = {2008},
  journal = {Am Hear. J},
  volume = {156},
  number = {1},
  eprint = {18585492},
  eprinttype = {pubmed},
  pages = {13--22},
  issn = {1097-6744},
  doi = {10.1016/j.ahj.2008.02.014},
  abstract = {In patients with chronic heart failure (CHF), previous studies have reported reduced mortality rates in patients with increased body mass index (BMI). The potentially protective effect of increased BMI in CHF has been termed the obesity paradox or reverse epidemiology. This meta-analysis was conducted to examine the relationship between increased BMI and mortality in patients with CHF.{\textbar}We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Scopus, and Web of Science to identify studies with contemporaneous control groups (cohort, case-control, or randomized controlled trials) that examined the effect of obesity on all-cause and cardiovascular mortality. Two reviewers independently assessed studies for inclusion and performed data extraction.{\textbar}Nine observational studies met final inclusion criteria (total n = 28,209). Mean length of follow-up was 2.7 years. Compared to individuals without elevated BMI levels, both overweight (BMI approximately 25.0-29.9 kg/m(2), RR 0.84, 95\% CI 0.79-0.90) and obesity (BMI approximately {$>$} or =30 kg/m(2), RR 0.67, 95\% CI 0.62-0.73) were associated with lower all-cause mortality. Overweight (RR 0.81, 95\% CI 0.72-0.92) and obesity (RR 0.60, 95\% CI 0.53-0.69) were also associated with lower cardiovascular mortality. In a risk-adjusted sensitivity analysis, both obesity (adjusted HR 0.88, 95\% CI 0.83-0.93) and overweight (adjusted HR 0.93, 95\% CI 0.89-0.97) remained protective against mortality.{\textbar}Overweight and obesity were associated with lower all-cause and cardiovascular mortality rates in patients with CHF and were not associated with increased mortality in any study. There is a need for prospective studies to elucidate mechanisms for this relationship.},
  keywords = {Body Mass Index Cause of Death Female Heart Failur}
}

@article{oreopoulosAnthropometricIndicesAccurately2011,
  title = {Do Anthropometric Indices Accurately Reflect Directly Measured Body Composition in Men and Women with Chronic Heart Failure?},
  author = {Oreopoulos, Antigone and Fonarow, Gregg C. and Ezekowitz, Justin A. and McAlister, Finlay A. and Sharma, Arya M. and {Kalantar-Zadeh}, Kamyar and Norris, Colleen M. and Johnson, Jeffery A. and Padwal, Raj S.},
  year = {2011},
  journal = {Congestive Heart Failure (Greenwich, Conn.)},
  volume = {17},
  number = {2},
  pages = {90--92},
  issn = {1751-7133},
  doi = {10.1111/j.1751-7133.2010.00204.x},
  abstract = {How well anthropometric indices such as body mass index (BMI), waist circumference, waist-stature ratio, and waist index correlate with direct measures of body composition (lean body mass, body fat) in men and women with chronic heart failure (CHF) has not been reported. Body composition was assessed by dual-energy x-ray absorptiometry in 140 patients with CHF. Age-adjusted Pearson correlations between each index and measures of body composition for men and women were calculated. Diagnostic accuracy of detecting obesity or high central fat was also examined. In men, all of the anthropometric indices except waist index were just as strongly correlated with lean body mass (correlation coefficients varied between 0.56 for waist-stature ratio to 0.74 for BMI) as with percentage of body fat (correlation coefficients varied between 0.72 for BMI to 0.79 for waist circumference). In women, all 4 anthropometric measures were unable to significantly differentiate between body fat and lean body mass. The positive likelihood ratios for the detection of obesity varied between 2.26 for waist circumference and 3.42 for BMI, waist-stature ratio, and waist index. Anthropometric indices do not accurately reflect body composition in patients with CHF, especially in women. When accurate assessment of body composition is required, direct measurements should be obtained.},
  langid = {english},
  pmid = {21449998},
  keywords = {Absorptiometry Photon,Adipose Tissue,Anthropometry,Body Composition,Body Constitution,Body Mass Index,Body Weight,Cross-Sectional Studies,Female,Heart Failure,Humans,Male,Middle Aged,Obesity,Waist Circumference},
  file = {/Users/xx20081/Zotero/storage/B9BFHHFV/Oreopoulos et al. - 2011 - Do anthropometric indices accurately reflect direc.pdf}
}

@article{oreopoulosBodyMassIndex2008,
  title = {Body Mass Index and Mortality in Heart Failure: A Meta-Analysis},
  shorttitle = {Body Mass Index and Mortality in Heart Failure},
  author = {Oreopoulos, Antigone and Padwal, Raj and {Kalantar-Zadeh}, Kamyar and Fonarow, Gregg C. and Norris, Colleen M. and McAlister, Finlay A.},
  year = {2008},
  month = jul,
  journal = {American Heart Journal},
  volume = {156},
  number = {1},
  pages = {13--22},
  issn = {1097-6744},
  doi = {10.1016/j.ahj.2008.02.014},
  abstract = {BACKGROUND: In patients with chronic heart failure (CHF), previous studies have reported reduced mortality rates in patients with increased body mass index (BMI). The potentially protective effect of increased BMI in CHF has been termed the obesity paradox or reverse epidemiology. This meta-analysis was conducted to examine the relationship between increased BMI and mortality in patients with CHF. METHODS: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Scopus, and Web of Science to identify studies with contemporaneous control groups (cohort, case-control, or randomized controlled trials) that examined the effect of obesity on all-cause and cardiovascular mortality. Two reviewers independently assessed studies for inclusion and performed data extraction. RESULTS: Nine observational studies met final inclusion criteria (total n = 28,209). Mean length of follow-up was 2.7 years. Compared to individuals without elevated BMI levels, both overweight (BMI approximately 25.0-29.9 kg/m(2), RR 0.84, 95\% CI 0.79-0.90) and obesity (BMI approximately {$>$} or =30 kg/m(2), RR 0.67, 95\% CI 0.62-0.73) were associated with lower all-cause mortality. Overweight (RR 0.81, 95\% CI 0.72-0.92) and obesity (RR 0.60, 95\% CI 0.53-0.69) were also associated with lower cardiovascular mortality. In a risk-adjusted sensitivity analysis, both obesity (adjusted HR 0.88, 95\% CI 0.83-0.93) and overweight (adjusted HR 0.93, 95\% CI 0.89-0.97) remained protective against mortality. CONCLUSIONS: Overweight and obesity were associated with lower all-cause and cardiovascular mortality rates in patients with CHF and were not associated with increased mortality in any study. There is a need for prospective studies to elucidate mechanisms for this relationship.},
  langid = {english},
  pmid = {18585492},
  keywords = {Body Mass Index,Cause of Death,Female,Heart Failure,Humans,Male,Obesity,Prognosis,Reference Values,Risk Assessment,Survival Analysis},
  file = {/Users/xx20081/Zotero/storage/MGZQ3SJU/Oreopoulos et al. - 2008 - Body mass index and mortality in heart failure a .pdf}
}

@article{ozkanExploringMechanisticLink2023,
  title = {Exploring the {{Mechanistic Link Between Obesity}} and {{Heart Failure}}},
  author = {Ozkan, Bige and Ndumele, Chiadi E.},
  year = {2023},
  month = dec,
  journal = {Current Diabetes Reports},
  volume = {23},
  number = {12},
  pages = {347--360},
  issn = {1539-0829},
  doi = {10.1007/s11892-023-01526-y},
  abstract = {PURPOSE OF REVIEW: Among subtypes of cardiovascular disease, obesity has a potent and unique association with heart failure (HF) that is unexplained by traditional cardiovascular risk mediators. The concomitant rise in the prevalence of obesity and HF necessitates better understanding of their relationship to develop effective prevention and treatment strategies. The purpose of this review is to provide mechanistic insight regarding the link between obesity and HF by elucidating the direct and indirect pathways linking the two conditions. RECENT FINDINGS: Several direct pathophysiologic mechanisms contribute to HF risk in individuals with excess weight, including hemodynamic alterations, neurohormonal activation, hormonal effects of dysfunctional adipose tissue, ectopic fat deposition with resulting lipotoxicity and microvascular dysfunction. Obesity further predisposes to HF indirectly through causal associations with hypertension, dyslipidemia, and most importantly, diabetes via insulin resistance. Low levels of physical activity and fitness further influence HF risk in the context of obesity. These various processes lead to myocardial injury and cardiac remodeling that are reflected by abnormalities in cardiac biomarkers and cardiac function on myocardial imaging. Understanding and addressing obesity-associated HF is a pressing clinical and public health challenge which can be informed by a deeper understanding of the complex pathways linking these two conditions together.},
  langid = {english},
  pmid = {38100052},
  keywords = {Adipokines,Adipose tissue,Adipose Tissue,Cardiovascular Diseases,Heart failure,Heart Failure,Humans,Hypertension,Obesity,Ventricular dysfunction,Ventricular remodeling}
}

@article{ozkanExploringMechanisticLink2023a,
  title = {Exploring the {{Mechanistic Link Between Obesity}} and {{Heart Failure}}},
  author = {Ozkan, Bige and Ndumele, Chiadi E.},
  year = {2023},
  month = dec,
  journal = {Current Diabetes Reports},
  volume = {23},
  number = {12},
  pages = {347--360},
  issn = {1539-0829},
  doi = {10.1007/s11892-023-01526-y},
  abstract = {PURPOSE OF REVIEW: Among subtypes of cardiovascular disease, obesity has a potent and unique association with heart failure (HF) that is unexplained by traditional cardiovascular risk mediators. The concomitant rise in the prevalence of obesity and HF necessitates better understanding of their relationship to develop effective prevention and treatment strategies. The purpose of this review is to provide mechanistic insight regarding the link between obesity and HF by elucidating the direct and indirect pathways linking the two conditions. RECENT FINDINGS: Several direct pathophysiologic mechanisms contribute to HF risk in individuals with excess weight, including hemodynamic alterations, neurohormonal activation, hormonal effects of dysfunctional adipose tissue, ectopic fat deposition with resulting lipotoxicity and microvascular dysfunction. Obesity further predisposes to HF indirectly through causal associations with hypertension, dyslipidemia, and most importantly, diabetes via insulin resistance. Low levels of physical activity and fitness further influence HF risk in the context of obesity. These various processes lead to myocardial injury and cardiac remodeling that are reflected by abnormalities in cardiac biomarkers and cardiac function on myocardial imaging. Understanding and addressing obesity-associated HF is a pressing clinical and public health challenge which can be informed by a deeper understanding of the complex pathways linking these two conditions together.},
  langid = {english},
  pmid = {38100052},
  keywords = {Adipokines,Adipose tissue,Adipose Tissue,Cardiovascular Diseases,Heart failure,Heart Failure,Humans,Hypertension,Obesity,Ventricular dysfunction,Ventricular remodeling},
  file = {/Users/xx20081/Zotero/storage/PI9PRQXE/Ozkan and Ndumele - 2023 - Exploring the Mechanistic Link Between Obesity and.pdf}
}

@article{packerEpicardialAdiposeTissue2018,
  title = {Epicardial {{Adipose Tissue May Mediate Deleterious Effects}} of {{Obesity}} and {{Inflammation}} on the {{Myocardium}}},
  author = {Packer, Milton},
  year = {2018},
  month = may,
  journal = {Journal of the American College of Cardiology},
  volume = {71},
  number = {20},
  pages = {2360--2372},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2018.03.509},
  abstract = {Epicardial adipose tissue has unique properties that distinguish it from other depots of visceral fat. Rather than having distinct boundaries, the epicardium shares an unobstructed microcirculation with the underlying myocardium, and in healthy conditions, produces cytokines that nourish the heart. However, in chronic inflammatory disorders (especially those leading to heart failure with preserved ejection fraction), the epicardium becomes a site of deranged adipogenesis, leading to the secretion of proinflammatory adipokines that can cause atrial and ventricular fibrosis. Accordingly, in patients at risk of heart failure with preserved ejection fraction, drugs that promote the accumulation or inflammation of epicardial adipocytes may lead to heart failure, whereas treatments that ameliorate the proinflammatory characteristics of epicardial fat may reduce the risk of heart failure. These observations suggest that epicardial adipose tissue is a transducer of the adverse effects of systemic inflammation and metabolic disorders on the heart, and thus, represents an important target for therapeutic interventions.},
  langid = {english},
  pmid = {29773163},
  keywords = {Adipose Tissue,epicardial adipose tissue,heart failure,Humans,Inflammation,Inflammation Mediators,Intra-Abdominal Fat,Myocardium,obesity,Obesity,Pericardium,Randomized Controlled Trials as Topic},
  file = {/Users/xx20081/Zotero/storage/VHS45ZHH/Packer - 2018 - Epicardial Adipose Tissue May Mediate Deleterious .pdf}
}

@article{packerTirzepatideHeartFailure2024,
  title = {Tirzepatide for {{Heart Failure}} with {{Preserved Ejection Fraction}} and {{Obesity}}},
  author = {Packer, Milton and Zile, Michael R. and Kramer, Christopher M. and Baum, Seth J. and Litwin, Sheldon E. and Menon, Venu and Ge, Junbo and Weerakkody, Govinda J. and Ou, Yang and Bunck, Mathijs C. and Hurt, Karla C. and Murakami, Masahiro and Borlaug, Barry A. and {SUMMIT Trial Study Group}},
  year = {2024},
  month = nov,
  journal = {The New England Journal of Medicine},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa2410027},
  abstract = {BACKGROUND: Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS: In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50\%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS: A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9\%) in the tirzepatide group and in 56 patients (15.3\%) in the placebo group (hazard ratio, 0.62; 95\% confidence interval [CI], 0.41 to 0.95; P\,=\,0.026). Worsening heart-failure events occurred in 29 patients (8.0\%) in the tirzepatide group and in 52 patients (14.2\%) in the placebo group (hazard ratio, 0.54; 95\% CI, 0.34 to 0.85), and adjudicated death from cardiovascular causes occurred in 8 patients (2.2\%) and 5 patients (1.4\%), respectively (hazard ratio, 1.58; 95\% CI, 0.52 to 4.83). At 52 weeks, the mean ({\textpm}SD) change in the KCCQ-CSS was 19.5{\textpm}1.2 in the tirzepatide group as compared with 12.7{\textpm}1.3 in the placebo group (between-group difference, 6.9; 95\% CI, 3.3 to 10.6; P{$<$}0.001). Adverse events (mainly gastrointestinal) leading to discontinuation of the trial drug occurred in 23 patients (6.3\%) in the tirzepatide group and in 5 patients (1.4\%) in the placebo group. CONCLUSIONS: Treatment with tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure than placebo and improved health status in patients with heart failure with preserved ejection fraction and obesity. (Funded by Eli Lilly; SUMMIT ClinicalTrials.gov number, NCT04847557.).},
  langid = {english},
  pmid = {39555826},
  file = {/Users/xx20081/Zotero/storage/KYIA7H34/nejmoa2410027_appendix.pdf;/Users/xx20081/Zotero/storage/RR4R3BN4/Packer et al. - 2024 - Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.pdf}
}

@article{padwalObesityParadoxHeart2014,
  title = {The Obesity Paradox in Heart Failure Patients with Preserved versus Reduced Ejection Fraction: A Meta-Analysis of Individual Patient Data},
  shorttitle = {The Obesity Paradox in Heart Failure Patients with Preserved versus Reduced Ejection Fraction},
  author = {Padwal, R. and McAlister, F. A. and McMurray, J. J. V. and Cowie, M. R. and Rich, M. and Pocock, S. and Swedberg, K. and Maggioni, A. and Gamble, G. and Ariti, C. and Earle, N. and Whalley, G. and Poppe, K. K. and Doughty, R. N. and {Bayes-Genis}, A. and {Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)}},
  year = {2014},
  month = aug,
  journal = {International Journal of Obesity (2005)},
  volume = {38},
  number = {8},
  pages = {1110--1114},
  issn = {1476-5497},
  doi = {10.1038/ijo.2013.203},
  abstract = {BACKGROUND: In heart failure (HF), obesity, defined as body mass index (BMI) {$\geq$}30\,kg\,m(-2), is paradoxically associated with higher survival rates compared with normal-weight patients (the 'obesity paradox'). We sought to determine if the obesity paradox differed by HF subtype (reduced ejection fraction (HF-REF) versus preserved ejection fraction (HF-PEF)). PATIENTS AND METHODS: A sub-analysis of the MAGGIC meta-analysis of patient-level data from 14 HF studies was performed. Subjects were divided into five BMI groups: {$<$}22.5, 22.5-24.9 (referent), 25-29.9, 30-34.9 and {$\geq$}35\,kg\,m(-2). Cox proportional hazards models adjusted for age, sex, aetiology (ischaemic or non-ischaemic), hypertension, diabetes and baseline blood pressure, stratified by study, were used to examine the independent association between BMI and 3-year total mortality. Analyses were conducted for the overall group and within HF-REF and HF-PEF groups. RESULTS: BMI data were available for 23\,967 subjects (mean age, 66.8 years; 32\% women; 46\% NYHA Class II; 50\% Class III) and 5609 (23\%) died by 3 years. Obese patients were younger, more likely to receive cardiovascular (CV) drug treatment, and had higher comorbidity burdens. Compared with BMI levels between 22.5 and 24.9\,kg\,m(-2), the adjusted relative hazards for 3-year mortality in subjects with HF-REF were: hazard ratios (HR)=1.31 (95\% confidence interval=1.15-1.50) for BMI {$<$}22.5, 0.85 (0.76-0.96) for BMI 25.0-29.9, 0.64 (0.55-0.74) for BMI 30.0-34.9 and 0.95 (0.78-1.15) for BMI {$\geq$}35. Corresponding adjusted HRs for those with HF-PEF were: 1.12 (95\% confidence interval=0.80-1.57) for BMI {$<$}22.5, 0.74 (0.56-0.97) for BMI 25.0-29.9, 0.64 (0.46-0.88) for BMI 30.0-34.9 and 0.71 (0.49-1.05) for BMI {$\geq$}35. CONCLUSIONS: In patients with chronic HF, the obesity paradox was present in both those with reduced and preserved ventricular systolic function. Mortality in both HF subtypes was U-shaped, with a nadir at 30.0-34.9\,kg\,m(-2).},
  langid = {english},
  pmid = {24173404},
  keywords = {Adult,Body Mass Index,Comorbidity,Female,Heart Failure,Humans,Male,Obesity,Prognosis,Proportional Hazards Models,Risk Factors,Stroke Volume,Survival Analysis},
  file = {/Users/xx20081/Zotero/storage/83ZCA78F/Padwal et al. - 2014 - The obesity paradox in heart failure patients with.pdf}
}

@article{padwalObesityParadoxHeart2014a,
  title = {The Obesity Paradox in Heart Failure Patients with Preserved versus Reduced Ejection Fraction: A Meta-Analysis of Individual Patient Data},
  shorttitle = {The Obesity Paradox in Heart Failure Patients with Preserved versus Reduced Ejection Fraction},
  author = {Padwal, R. and McAlister, F. A. and McMurray, J. J. V. and Cowie, M. R. and Rich, M. and Pocock, S. and Swedberg, K. and Maggioni, A. and Gamble, G. and Ariti, C. and Earle, N. and Whalley, G. and Poppe, K. K. and Doughty, R. N. and {Bayes-Genis}, A. and {Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)}},
  year = {2014},
  month = aug,
  journal = {International Journal of Obesity (2005)},
  volume = {38},
  number = {8},
  pages = {1110--1114},
  issn = {1476-5497},
  doi = {10.1038/ijo.2013.203},
  abstract = {BACKGROUND: In heart failure (HF), obesity, defined as body mass index (BMI) {$\geq$}30\,kg\,m(-2), is paradoxically associated with higher survival rates compared with normal-weight patients (the 'obesity paradox'). We sought to determine if the obesity paradox differed by HF subtype (reduced ejection fraction (HF-REF) versus preserved ejection fraction (HF-PEF)). PATIENTS AND METHODS: A sub-analysis of the MAGGIC meta-analysis of patient-level data from 14 HF studies was performed. Subjects were divided into five BMI groups: {$<$}22.5, 22.5-24.9 (referent), 25-29.9, 30-34.9 and {$\geq$}35\,kg\,m(-2). Cox proportional hazards models adjusted for age, sex, aetiology (ischaemic or non-ischaemic), hypertension, diabetes and baseline blood pressure, stratified by study, were used to examine the independent association between BMI and 3-year total mortality. Analyses were conducted for the overall group and within HF-REF and HF-PEF groups. RESULTS: BMI data were available for 23\,967 subjects (mean age, 66.8 years; 32\% women; 46\% NYHA Class II; 50\% Class III) and 5609 (23\%) died by 3 years. Obese patients were younger, more likely to receive cardiovascular (CV) drug treatment, and had higher comorbidity burdens. Compared with BMI levels between 22.5 and 24.9\,kg\,m(-2), the adjusted relative hazards for 3-year mortality in subjects with HF-REF were: hazard ratios (HR)=1.31 (95\% confidence interval=1.15-1.50) for BMI {$<$}22.5, 0.85 (0.76-0.96) for BMI 25.0-29.9, 0.64 (0.55-0.74) for BMI 30.0-34.9 and 0.95 (0.78-1.15) for BMI {$\geq$}35. Corresponding adjusted HRs for those with HF-PEF were: 1.12 (95\% confidence interval=0.80-1.57) for BMI {$<$}22.5, 0.74 (0.56-0.97) for BMI 25.0-29.9, 0.64 (0.46-0.88) for BMI 30.0-34.9 and 0.71 (0.49-1.05) for BMI {$\geq$}35. CONCLUSIONS: In patients with chronic HF, the obesity paradox was present in both those with reduced and preserved ventricular systolic function. Mortality in both HF subtypes was U-shaped, with a nadir at 30.0-34.9\,kg\,m(-2).},
  langid = {english},
  pmid = {24173404},
  keywords = {Adult,Body Mass Index,Comorbidity,Female,Heart Failure,Humans,Male,Obesity,Prognosis,Proportional Hazards Models,Risk Factors,Stroke Volume,Survival Analysis}
}

@article{pandeyAssociationIntensiveLifestyle2020,
  title = {Association of {{Intensive Lifestyle Intervention}}, {{Fitness}} and {{Body Mass Index}} with {{Risk}} of {{Heart Failure}} in {{Overweight}} or {{Obese Adults}} with {{Type}} 2 {{Diabetes Mellitus}}: {{An Analysis}} from the {{Look AHEAD}} Trial},
  shorttitle = {Association of {{Intensive Lifestyle Intervention}}, {{Fitness}} and {{Body Mass Index}} with {{Risk}} of {{Heart Failure}} in {{Overweight}} or {{Obese Adults}} with {{Type}} 2 {{Diabetes Mellitus}}},
  author = {Pandey, Ambarish and Patel, Kershaw V. and Bahnson, Judy L. and Gaussoin, Sarah A. and Martin, Corby K. and Balasubramanyam, Ashok and Johnson, Karen C. and McGuire, Darren K. and Bertoni, Alain G. and Kitzman, Dalane and Berry, Jarett D.},
  year = {2020},
  month = apr,
  journal = {Circulation},
  volume = {141},
  number = {16},
  pages = {1295--1306},
  issn = {0009-7322},
  doi = {10.1161/CIRCULATIONAHA.119.044865},
  urldate = {2024-07-04},
  abstract = {Background: Type 2 diabetes mellitus (T2DM) is associated with higher risk for heart failure (HF). The impact of a lifestyle intervention and changes in cardiorespiratory fitness (CRF), and body mass index (BMI) on risk for HF is not well-established. Methods: Participants from the Look AHEAD (Action for Health in Diabetes) trial without prevalent HF were included. Time to event analyses were used to compare the risk of incident HF between the intensive lifestyle intervention (ILI) vs. diabetes support and education (DSE) groups. The associations of baseline measures of CRF estimated from a maximal treadmill test, BMI, and longitudinal changes in these parameters with risk of HF were evaluated using multivariable adjusted Cox models. Results: Among the 5,109 trial participants, there was no significant difference in the risk of incident HF (n = 257) between the ILI vs. DSE groups [HR (95\% CI) = 0.96 (0.75 to 1.23)] over a median follow-up of 12.4 years. In the most adjusted Cox models, the risk of HF was 39\% and 62\% lower among moderate fit [Tertile 2: HR (95\% CI) = 0.61 (0.44 to 0.83)] and high fit [Tertile 3: HR (95\% CI) = 0.38 (0.24 to 0.59)] groups, respectively (referent group: low fit, Tertile 1). Among HF subtypes, after adjustment for traditional CV risk factors and interval incidence of MI, baseline CRF was not significantly associated with risk of incident HFrEF. In contrast, the risk of incident HFpEF was 40\% lower in moderate fit and 77\% lower in the high fit groups. Baseline BMI was also not associated with risk of incident HF, HFpEF, or HFrEF after adjustment for CRF and traditional CV risk factors. Among participants with repeat CRF assessments (n = 3,902), improvements in CRF and weight loss over 4-year follow-up was significantly associated with lower risk of HF [HR (95\% CI) per 10\% increase in CRF = 0.90 (0.82 to 0.99), per 10\% decrease in BMI = 0.80 (0.69 to 0.94)]. Conclusions: Among participants with T2DM in the Look AHEAD trial, the ILI did not appear to modify the risk of HF. Higher baseline CRF and sustained improvements in CRF and weight loss were associated with lower risk of HF.},
  pmcid = {PMC9976290},
  pmid = {32134326},
  file = {/Users/xx20081/Zotero/storage/22QS7RXU/Pandey et al. - 2020 - Association of Intensive Lifestyle Intervention, F.pdf}
}

@article{pandeyRelationshipPhysicalActivity2017,
  title = {Relationship {{Between Physical Activity}}, {{Body Mass Index}}, and {{Risk}} of {{Heart Failure}}},
  author = {Pandey, Ambarish and LaMonte, Michael and Klein, Liviu and Ayers, Colby and Psaty, Bruce M. and Eaton, Charles B. and Allen, Norrina B. and {de Lemos}, James A. and Carnethon, Mercedes and Greenland, Philip and Berry, Jarett D.},
  year = {2017},
  month = mar,
  journal = {Journal of the American College of Cardiology},
  volume = {69},
  number = {9},
  pages = {1129--1142},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2016.11.081},
  abstract = {BACKGROUND: Lower leisure-time physical activity (LTPA) and higher body mass index (BMI) are independently associated with risk of heart failure (HF). However, it is unclear if this relationship is consistent for both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). OBJECTIVES: This study sought to quantify dose-response associations between LTPA, BMI, and the risk of different HF subtypes. METHODS: Individual-level data from 3 cohort studies (WHI [Women's Health Initiative], MESA [Multi-Ethnic Study of Atherosclerosis], and CHS [Cardiovascular Health Study]) were pooled and participants were stratified into guideline-recommended categories of LTPA and BMI. Associations between LTPA, BMI, and risk of overall HF, HFpEF (ejection fraction~{$\geq$}45\%), and HFrEF (ejection fraction~{$<$}45\%) were assessed by using multivariable adjusted Cox models and restricted cubic splines. RESULTS: The study included 51,451 participants with 3,180 HF events (1,252 HFpEF, 914 HFrEF, and 1,014 unclassified HF). In the adjusted analysis, there was a dose-dependent association between higher LTPA levels, lower BMI, and overall~HF risk. Among HF subtypes, LTPA in any dose range was not associated with HFrEF risk. In contrast, lower levels of LTPA ({$<$}500 MET-min/week) were not associated with HFpEF risk, and dose-dependent associations with lower HFpEF risk were observed at higher levels. Compared with no LTPA, higher than twice the guideline-recommended minimum LTPA levels ({$>$}1,000 MET-min/week) were associated with an 19\% lower risk of HFpEF (hazard ratio: 0.81; 95\% confidence interval: 0.68 to 0.97). The dose-response relationship for BMI with HFpEF risk was also more consistent than with HFrEF risk, such that increasing BMI above the normal range ({$\geq$}25 kg/m2) was associated with a greater increase in risk of HFpEF than HFrEF. CONCLUSIONS: Our study findings show strong, dose-dependent associations between LTPA levels, BMI, and risk~of~overall HF. Among HF subtypes, higher LTPA levels and lower BMI were more consistently associated with~lower~risk of HFpEF compared with HFrEF.},
  langid = {english},
  pmcid = {PMC5848099},
  pmid = {28254175},
  keywords = {Aged,body mass index,Body Mass Index,Cohort Studies,dose-response relationship,Exercise,Female,heart failure,Heart Failure,Humans,Male,Middle Aged,physical activity,Proportional Hazards Models,Risk Factors,Stroke Volume},
  file = {/Users/xx20081/Zotero/storage/7Y2UCHXU/Pandey et al. - 2017 - Relationship Between Physical Activity, Body Mass .pdf}
}

@article{pandeyRelationshipPhysicalActivity2017a,
  title = {Relationship {{Between Physical Activity}}, {{Body Mass Index}}, and {{Risk}} of {{Heart Failure}}},
  author = {Pandey, Ambarish and LaMonte, Michael and Klein, Liviu and Ayers, Colby and Psaty, Bruce M. and Eaton, Charles B. and Allen, Norrina B. and {de Lemos}, James A. and Carnethon, Mercedes and Greenland, Philip and Berry, Jarett D.},
  year = {2017},
  month = mar,
  journal = {Journal of the American College of Cardiology},
  series = {{{SPECIAL FOCUS ISSUE}}: {{CARDIOVASCULAR HEALTH PROMOTION}}},
  volume = {69},
  number = {9},
  pages = {1129--1142},
  issn = {0735-1097},
  doi = {10.1016/j.jacc.2016.11.081},
  urldate = {2024-08-08},
  abstract = {Background Lower leisure-time physical activity (LTPA) and higher body mass index (BMI) are independently associated with risk of heart failure (HF). However, it is unclear if this relationship is consistent for both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Objectives This study sought to quantify dose--response associations between LTPA, BMI, and the risk of different HF subtypes. Methods Individual-level data from 3 cohort studies (WHI [Women's Health Initiative], MESA [Multi-Ethnic Study of Atherosclerosis], and CHS [Cardiovascular Health Study]) were pooled and participants were stratified into guideline-recommended categories of LTPA and BMI. Associations between LTPA, BMI, and risk of overall HF, HFpEF (ejection fraction~{$\geq$}45\%), and HFrEF (ejection fraction~{$<$}45\%) were assessed by using multivariable adjusted Cox models and restricted cubic splines. Results The study included 51,451 participants with 3,180 HF events (1,252 HFpEF, 914 HFrEF, and 1,014 unclassified HF). In the adjusted analysis, there was a dose-dependent association between higher LTPA levels, lower BMI, and overall~HF risk. Among HF subtypes, LTPA in any dose range was not associated with HFrEF risk. In contrast, lower levels of LTPA ({$<$}500 MET-min/week) were not associated with HFpEF risk, and dose-dependent associations with lower HFpEF risk were observed at higher levels. Compared with no LTPA, higher than twice the guideline-recommended minimum LTPA levels ({$>$}1,000 MET-min/week) were associated with an 19\% lower risk of HFpEF (hazard ratio: 0.81; 95\% confidence interval: 0.68 to 0.97). The dose--response relationship for BMI with HFpEF risk was also more consistent than with HFrEF risk, such that increasing BMI above the normal range ({$\geq$}25 kg/m2) was associated with a greater increase in risk of HFpEF than HFrEF. Conclusions Our study findings show strong, dose--dependent associations between LTPA levels, BMI, and risk~of~overall HF. Among HF subtypes, higher LTPA levels and lower BMI were more consistently associated with~lower~risk of HFpEF compared with HFrEF.},
  keywords = {body mass index,dose-response relationship,heart failure,physical activity},
  file = {/Users/xx20081/Zotero/storage/5WG5WPX8/Pandey et al. - 2017 - Relationship Between Physical Activity, Body Mass .pdf;/Users/xx20081/Zotero/storage/DZ9WJEYE/S0735109717301821.html}
}

@article{parkPerformanceECGDerivedDigital2024,
  title = {Performance of {{ECG-Derived Digital Biomarker}} for {{Screening Coronary Occlusion}} in {{Resuscitated Out-of-Hospital Cardiac Arrest Patients}}: {{A Comparative Study}} between {{Artificial Intelligence}} and a {{Group}} of {{Experts}}},
  shorttitle = {Performance of {{ECG-Derived Digital Biomarker}} for {{Screening Coronary Occlusion}} in {{Resuscitated Out-of-Hospital Cardiac Arrest Patients}}},
  author = {Park, Min Ji and Choi, Yoo Jin and Shim, Moonki and Cho, Youngjin and Park, Jiesuck and Choi, Jina and Kim, Joonghee and Lee, Eunkyoung and Kim, Seo-Yoon},
  year = {2024},
  month = feb,
  journal = {Journal of Clinical Medicine},
  volume = {13},
  number = {5},
  pages = {1354},
  issn = {2077-0383},
  doi = {10.3390/jcm13051354},
  abstract = {Acute coronary syndrome is a significant part of cardiac etiology contributing to out-of-hospital cardiac arrest (OHCA), and immediate coronary angiography has been proposed to improve survival. This study evaluated the effectiveness of an AI algorithm in diagnosing near-total or total occlusion of coronary arteries in OHCA patients who regained spontaneous circulation. Conducted from 1 July 2019 to 30 June 2022 at a tertiary university hospital emergency department, it involved 82 OHCA patients, with 58 qualifying after exclusions. The AI used was the Quantitative ECG (QCG) system, which provides a STEMI diagnostic score ranging from 0 to 100. The QCG score's diagnostic performance was compared to assessments by two emergency physicians and three cardiologists. Among the patients, coronary occlusion was identified in 24. The QCG score showed a significant difference between occlusion and non-occlusion groups, with the former scoring higher. The QCG biomarker had an area under the curve (AUC) of 0.770, outperforming the expert group's AUC of 0.676. It demonstrated 70.8\% sensitivity and 79.4\% specificity. These findings suggest that the AI-based ECG biomarker could predict coronary occlusion in resuscitated OHCA patients, and it was non-inferior to the consensus of the expert group.},
  langid = {english},
  pmcid = {PMC10932362},
  pmid = {38592195},
  keywords = {artificial intelligence,electrocardiography,out-of-hospital cardiac arrest,ST elevation myocardial infarction},
  file = {/Users/xx20081/Zotero/storage/82WRZNPH/Park et al. - 2024 - Performance of ECG-Derived Digital Biomarker for Screening Coronary Occlusion in Resuscitated Out-of.pdf}
}

@article{patelAssociationBaselineLongitudinal2020,
  title = {Association of {{Baseline}} and {{Longitudinal Changes}} in {{Body Composition Measures With Risk}} of {{Heart Failure}} and {{Myocardial Infarction}} in {{Type}} 2 {{Diabetes}}: {{Findings From}} the {{Look AHEAD Trial}}},
  shorttitle = {Association of {{Baseline}} and {{Longitudinal Changes}} in {{Body Composition Measures With Risk}} of {{Heart Failure}} and {{Myocardial Infarction}} in {{Type}} 2 {{Diabetes}}},
  author = {Patel, Kershaw V. and Bahnson, Judy L. and Gaussoin, Sarah A. and Johnson, Karen C. and {Pi-Sunyer}, Xavier and White, Ursula and Olson, KayLoni L. and Bertoni, Alain G. and Kitzman, Dalane W. and Berry, Jarett D. and Pandey, Ambarish and {Look AHEAD Research Group}},
  year = {2020},
  month = dec,
  journal = {Circulation},
  volume = {142},
  number = {25},
  pages = {2420--2430},
  issn = {1524-4539},
  doi = {10.1161/CIRCULATIONAHA.120.050941},
  abstract = {BACKGROUND: Intentional weight loss is associated with lower risk of heart failure (HF) and atherosclerotic cardiovascular disease among patients with type 2 diabetes. However, the contribution of baseline measures and longitudinal changes in fat mass (FM), lean mass (LM), and waist circumference (WC) to the risk of HF and myocardial infarction (MI) in type 2 diabetes is not well established. METHODS: Adults from the Look AHEAD trial (Action for Health in Diabetes) without prevalent HF were included. FM and LM were predicted using validated equations and compared with dual-energy x-ray absorptiometry measurements in a subgroup. Adjusted Cox models were used to evaluate the associations of baseline and longitudinal changes in FM, LM, and WC over 1- and 4-year follow-up with risk of overall HF, HF with preserved ejection fraction (EF; EF {$\geq$}50\%), HF with reduced EF (EF {$<$}50\%), and MI. RESULTS: Among 5103 participants, there were 257 incident HF events over 12.4 years of follow-up. Predicted and measured FM/LM were highly correlated (R2=0.87-0.90; n=1369). FM and LM decreased over 4-year follow-up with greater declines in the intensive lifestyle intervention arm. In adjusted analysis, baseline body composition measures were not significantly associated with HF risk. Decline in FM and WC, but not LM, over 1 year were each significantly associated with lower risk of overall HF (adjusted hazard ratio per 10\% decrease in FM, 0.80 [95\% CI, 0.68-0.95]; adjusted hazard ratio per 10\% decrease in WC, 0.77 [95\% CI, 0.62-0.95]). Decline in FM was significantly associated with lower risk of both HF subtypes. In contrast, decline in WC was significantly associated with lower risk of HF with preserved EF but not HF with reduced EF. Similar patterns of association were observed for 4-year changes in body composition and HF risk. Longitudinal changes in body composition were not significantly associated with risk of MI. CONCLUSIONS: In adults with type 2 diabetes, a lifestyle intervention is associated with significant loss of FM and LM. Declines in FM and WC, but not LM, were each significantly associated with lower risk of HF but not MI. Furthermore, decline in WC was significantly associated with lower risk of HF with preserved EF but not HF with reduced EF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00017953.},
  langid = {english},
  pmcid = {PMC8366747},
  pmid = {33164570},
  keywords = {Adiposity,Aged,Body Composition,Diabetes Mellitus Type 2,Exercise,Female,Healthy Lifestyle,Heart Disease Risk Factors,heart failure,Heart Failure,Humans,Incidence,Male,Middle Aged,myocardial infarction,Myocardial Infarction,Prognosis,Protective Factors,Risk Assessment,Risk Reduction Behavior,Stroke Volume,Time Factors,type 2 diabetes mellitus,Ventricular Function Left,Waist Circumference,Weight Loss},
  file = {/Users/xx20081/Zotero/storage/K9YP5KPK/Patel et al. - 2020 - Association of Baseline and Longitudinal Changes i.pdf}
}

@article{patelMendelianRandomizationV0Updates2023,
  title = {{{MendelianRandomization}} v0.9.0: Updates to an {{R}} Package for Performing {{Mendelian}} Randomization Analyses Using Summarized Data},
  shorttitle = {{{MendelianRandomization}} v0.9.0},
  author = {Patel, Ashish and Ye, Ting and Xue, Haoran and Lin, Zhaotong and Xu, Siqi and Woolf, Benjamin and Mason, Amy M. and Burgess, Stephen},
  year = {2023},
  journal = {Wellcome Open Research},
  volume = {8},
  pages = {449},
  issn = {2398-502X},
  doi = {10.12688/wellcomeopenres.19995.1},
  abstract = {The MendelianRandomization package is a software package written for the R software environment that implements methods for Mendelian randomization based on summarized data. In this manuscript, we describe functions that have been added or edited in the package since version 0.5.0, when we last described the package and its contents. The main additions to the package since that time are: 1) new robust methods for performing Mendelian randomization, particularly in the cases of bias from weak instruments and/or winner's curse, and pleiotropic variants, 2) methods for performing Mendelian randomization with correlated variants using dimension reduction to summarize large numbers of highly correlated variants into a limited set of principal components, 3) functions for calculating first-stage F statistics, representing instrument strength, in both univariable and multivariable contexts, and with uncorrelated and correlated genetic variants. We also discuss some pragmatic issues relating to the use of correlated variants in Mendelian randomization.},
  langid = {english},
  pmcid = {PMC10616660},
  pmid = {37915953},
  keywords = {causal inference,genetic associations,genetic epidemiology,instrumental variable,Mendelian randomization,post-GWAS analysis,summarized data},
  file = {/Users/xx20081/Zotero/storage/BXD2DK6B/Patel et al. - 2023 - MendelianRandomization v0.9.0 updates to an R pac.pdf}
}

@misc{patelRobustUsePhenotypic2023,
  title = {Robust Use of Phenotypic Heterogeneity at Drug Target Genes for Mechanistic Insights: Application of Cis-Multivariable {{Mendelian}} Randomization to {{GLP1R}} Gene Region},
  shorttitle = {Robust Use of Phenotypic Heterogeneity at Drug Target Genes for Mechanistic Insights},
  author = {Patel, Ashish and Gill, Dipender and Shungin, Dmitry and Mantzoros, Christos S. and Knudsen, Lotte Bjerre and Bowden, Jack and Burgess, Stephen},
  year = {2023},
  month = jul,
  pages = {2023.07.20.23292958},
  publisher = {medRxiv},
  doi = {10.1101/2023.07.20.23292958},
  urldate = {2024-01-13},
  abstract = {Phenotypic heterogeneity at genomic loci encoding drug targets can be exploited by multivariable Mendelian randomization to provide insight on the pathways by which pharmacological interventions may affect disease risk. However, statistical inference in such investigations may be poor if overdispersion heterogeneity in measured genetic associations is unaccounted for. In this work, we first develop conditional F-statistics for dimension-reduced genetic associations that enable more accurate measurement of phenotypic heterogeneity. We then develop a novel extension for two-sample multivariable Mendelian randomization that accounts for overdispersion heterogeneity in dimension-reduced genetic associations. Our empirical focus is to use genetic variants in the GLP1R gene region to understand the mechanism by which GLP1R agonism affects coronary artery disease (CAD) risk. Colocalization analyses indicate that distinct variants in the GLP1R gene region are associated with body mass index and type 2 diabetes. Multivariable Mendelian randomization analyses that were corrected for overdispersion heterogeneity suggest that bodyweight lowering rather than type 2 diabetes liability lowering effects of GLP1R agonism are more likely contributing to reduced CAD risk. Tissue-specific analyses prioritised brain tissue as the most likely to be relevant for CAD risk, of the tissues considered. We hope the multivariable Mendelian randomization approach illustrated here is widely applicable to better understand mechanisms linking drug targets to diseases outcomes, and hence to guide drug development efforts.},
  archiveprefix = {medRxiv},
  copyright = {{\copyright} 2023, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/SKB3NCNQ/Patel et al. - 2023 - Robust use of phenotypic heterogeneity at drug tar.pdf}
}

@article{paternosterGeneticEpidemiologyMendelian2017,
  title = {Genetic Epidemiology and {{Mendelian}} Randomization for Informing Disease Therapeutics: {{Conceptual}} and Methodological Challenges},
  shorttitle = {Genetic Epidemiology and {{Mendelian}} Randomization for Informing Disease Therapeutics},
  author = {Paternoster, Lavinia and Tilling, Kate and Davey Smith, George},
  year = {2017},
  month = oct,
  journal = {PLoS genetics},
  volume = {13},
  number = {10},
  pages = {e1006944},
  issn = {1553-7404},
  doi = {10.1371/journal.pgen.1006944},
  abstract = {The past decade has been proclaimed as a hugely successful era of gene discovery through the high yields of many genome-wide association studies (GWAS). However, much of the perceived benefit of such discoveries lies in the promise that the identification of genes that influence disease would directly translate into the identification of potential therapeutic targets, but this has yet to be realized at a level reflecting expectation. One reason for this, we suggest, is that GWAS, to date, have generally not focused on phenotypes that directly relate to the progression of disease and thus speak to disease treatment.},
  langid = {english},
  pmcid = {PMC5628782},
  pmid = {28981501},
  keywords = {Coronary Disease,Disease Progression,Genetic Diseases Inborn,Genetic Predisposition to Disease,Genome-Wide Association Study,Humans,Mendelian Randomization Analysis,Phenotype,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/995GCGNL/Paternoster et al. - 2017 - Genetic epidemiology and Mendelian randomization f.pdf}
}

@article{paternosterGeneticEpidemiologyMendelian2017a,
  title = {Genetic Epidemiology and {{Mendelian}} Randomization for Informing Disease Therapeutics: {{Conceptual}} and Methodological Challenges},
  shorttitle = {Genetic Epidemiology and {{Mendelian}} Randomization for Informing Disease Therapeutics},
  author = {Paternoster, Lavinia and Tilling, Kate and Davey Smith, George},
  year = {2017},
  month = oct,
  journal = {PLoS Genetics},
  volume = {13},
  number = {10},
  pages = {e1006944},
  issn = {1553-7390},
  doi = {10.1371/journal.pgen.1006944},
  urldate = {2024-08-21},
  abstract = {The past decade has been proclaimed as a hugely successful era of gene discovery through the high yields of many genome-wide association studies (GWAS). However, much of the perceived benefit of such discoveries lies in the promise that the identification of genes that influence disease would directly translate into the identification of potential therapeutic targets, but this has yet to be realized at a level reflecting expectation. One reason for this, we suggest, is that GWAS, to date, have generally not focused on phenotypes that directly relate to the progression of disease and thus speak to disease treatment.},
  pmcid = {PMC5628782},
  pmid = {28981501},
  file = {/Users/xx20081/Zotero/storage/7TYQEGX4/Paternoster et al. - 2017 - Genetic epidemiology and Mendelian randomization f.pdf}
}

@misc{PathophysiologyHumanVisceral,
  title = {Pathophysiology of {{Human Visceral Obesity}}: {{An Update}} {\textbar} {{Physiological Reviews}}},
  urldate = {2024-08-06},
  howpublished = {https://journals.physiology.org/doi/full/10.1152/physrev.00033.2011},
  file = {/Users/xx20081/Zotero/storage/BGG7SBCC/physrev.00033.html}
}

@article{Pedersen2005,
  title = {High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention after Myocardial Infarction: The {{IDEAL}} Study: A Randomized Controlled Trial},
  author = {Pedersen, Terje R. and Faergeman, Ole and Kastelein, John J.P. and Olsson, Anders G. and Tikkanen, Matti J. and Holme, Ingar and Larsen, Mogens Lytken and Bendiksen, Fredrik S. and Lindahl, Christina and Szarek, Michael and Tsai, John},
  year = {2005},
  month = nov,
  journal = {JAMA : the journal of the American Medical Association},
  volume = {294},
  number = {19},
  pages = {2437--2445},
  publisher = {JAMA},
  issn = {1538-3598},
  doi = {10.1001/JAMA.294.19.2437},
  abstract = {Context: Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied clinically will provide further benefit in stable coronary artery disease. Objective: To compare the effects of 2 strategies of lipid lowering on the risk of cardiovascular disease among patients with a previous myocardial infarction (MI). Design, Setting, and Participants: The IDEAL study, a prospective, randomized, open-label, blinded end-point evaluation trial conducted at 190 ambulatory cardiology care and specialist practices in northern Europe between March 1999 and March 2005 with a median follow-up of 4.8 years, which enrolled 8888 patients aged 80 years or younger with a history of acute MI. Interventions: Patients were randomly assigned to receive a high dose of atorvastatin (80 mg/d; n=4439), or usual-dose simvastatin (20 mg/d; n=4449). Main Outcome Measure: Occurrence of a major coronary event, defined as coronary death, confirmed nonfatal acute MI, or cardiac arrest with resuscitation. Results: During treatment, mean LDL-C levels were 104 (SE, 0.3) mg/dL in the simvastatin group and 81 (SE, 0.3) mg/dL in the atorvastatin group. A major coronary event occurred in 463 simvastatin patients (10.4\%) and in 411 atorvastatin patients (9.3\%) (hazard ratio [HR], 0.89; 95\% CI, 0.78-1.01; P=.07). Nonfatal acute MI occurred in 321 (7.2\%) and 267 (6.0\%) in the 2 groups (HR, 0.83; 95\% CI, 0.71-0.98; P=.02), but no differences were seen in the 2 other components of the primary end point. Major cardiovascular events occurred in 608 and 533 in the 2 groups, respectively (HR, 0.87; 95\% CI, 0.77-0.98; P=.02). Occurrence of any coronary event was reported in 1059 simvastatin and 898 atorvastatin patients (HR, 0.84; 95\% CI, 0.76-0.91; P{\textexclamdown}.001). Noncardiovascular death occurred in 156 (3.5\%) and 143 (3.2\%) in the 2 groups (HR, 0.92; 95\% CI, 0.73-1.15; P=.47). Death from any cause occurred in 374 (8.4\%) in the simvastatin group and 366 (8.2\%) in the atorvastatin group (HR, 0.98; 95\% CI, 0.85-1.13; P=.81). Patients in the atorvastatin group had higher rates of drug discontinuation due to nonserious adverse events; transaminase elevation resulted in 43 (1.0\%) vs 5 (0.1\%) withdrawals (P{\textexclamdown}.001). Serious myopathy and rhabdomyolysis were rare in both groups. Conclusions: In this study of patients with previous MI, intensive lowering of LDL-C did not result in a significant reduction in the primary outcome of major coronary events, but did reduce the risk of other composite secondary end points and nonfatal acute MI. There were no differences in cardiovascular or all-cause mortality. Patients with MI may benefit from intensive lowering of LDL-C without an increase in noncardiovascular mortality or other serious adverse reactions. Trial Registration: ClinicalTrials.gov Identifier: NCT00159835. {\copyright}2005 American Medical Association. All rights reserved.},
  pmid = {16287954},
  keywords = {affs=[]),Aged,Atorvastatin,Cardiovascular Diseases / epidemiology,Cardiovascular Diseases / prevention & control,Cholesterol,Comparative Study,doi:10.1001/jama.294.19.2437,Female,Heptanoic Acids / administration & dosage,Heptanoic Acids / therapeutic use*,Humans,Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage,Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*,investigators=[],LDL / blood,Male,MEDLINE,Middle Aged,Multicenter Study,Myocardial Infarction / prevention & control*,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,Non-U.S. Gov't,Ole Faergeman,pmid:16287954,Proportional Hazards Models,Prospective Studies,PubMed Abstract,Pyrroles / administration & dosage,Pyrroles / therapeutic use*,Randomized Controlled Trial,Research Support,Risk,Simvastatin / administration & dosage,Simvastatin / therapeutic use*,Terje R Pedersen}
}

@article{pGeneticDeterminantsCirculating2017,
  title = {Genetic Determinants of Circulating {{GIP}} and {{GLP-1}} Concentrations},
  author = {P, Almgren and A, Lindqvist and U, Krus and L, Hakaste and E, Ottosson-Laakso and O, Asplund and E, Sonestedt and Rb, Prasad and E, Laurila and M, Orho-Melander and O, Melander and T, Tuomi and Jj, Holst and Pm, Nilsson and N, Wierup and L, Groop and E, Ahlqvist},
  year = {2017},
  month = feb,
  journal = {JCI insight},
  volume = {2},
  number = {21},
  publisher = {JCI Insight},
  issn = {2379-3708},
  doi = {10.1172/jci.insight.93306},
  urldate = {2025-05-30},
  abstract = {The secretion of insulin and glucagon from the pancreas and the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) from the gastrointestinal tract is essential for glucose homeostasis. Several novel treatment strategies for type 2 diabetes (T2D) mimi {\dots}},
  langid = {english},
  pmid = {29093273},
  file = {/Users/xx20081/Zotero/storage/NPR36VTE/P et al. - 2017 - Genetic determinants of circulating GIP and GLP-1 concentrations.pdf;/Users/xx20081/Zotero/storage/T7FQ6EBW/29093273.html}
}

@article{pilarczykConnectingOmicsSignatures2022,
  title = {Connecting Omics Signatures and Revealing Biological Mechanisms with {{iLINCS}}},
  author = {Pilarczyk, Marcin and {Fazel-Najafabadi}, Mehdi and Kouril, Michal and Shamsaei, Behrouz and Vasiliauskas, Juozas and Niu, Wen and Mahi, Naim and Zhang, Lixia and Clark, Nicholas A. and Ren, Yan and White, Shana and Karim, Rashid and Xu, Huan and Biesiada, Jacek and Bennett, Mark F. and Davidson, Sarah E. and Reichard, John F. and Roberts, Kurt and Stathias, Vasileios and Koleti, Amar and Vidovic, Dusica and Clarke, Daniel J. B. and Sch{\"u}rer, Stephan C. and Ma'ayan, Avi and Meller, Jarek and Medvedovic, Mario},
  year = {2022},
  month = aug,
  journal = {Nature Communications},
  volume = {13},
  number = {1},
  pages = {4678},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-022-32205-3},
  urldate = {2025-05-27},
  abstract = {There are only a few platforms that integrate multiple omics data types, bioinformatics tools, and interfaces for integrative analyses and visualization that do not require programming skills. Here we present iLINCS (http://ilincs.org), an integrative web-based platform for analysis of omics data and signatures of cellular perturbations. The platform facilitates mining and re-analysis of the large collection of omics datasets ({$>$}34,000), pre-computed signatures ({$>$}200,000), and their connections, as well as the analysis of user-submitted omics signatures of diseases and cellular perturbations. iLINCS analysis workflows integrate vast omics data resources and a range of analytics and interactive visualization tools into a comprehensive platform for analysis of omics signatures. iLINCS user-friendly interfaces enable execution of sophisticated analyses of omics signatures, mechanism of action analysis, and signature-driven drug repositioning. We illustrate the utility of iLINCS with three use cases involving analysis of cancer proteogenomic signatures, COVID 19 transcriptomic signatures and mTOR signaling.},
  copyright = {2022 The Author(s)},
  langid = {english},
  keywords = {Computational platforms and environments,Data mining,Drug development,Target identification,Translational research},
  file = {/Users/xx20081/Zotero/storage/YPVCSBK3/Pilarczyk et al. - 2022 - Connecting omics signatures and revealing biological mechanisms with iLINCS.pdf}
}

@article{Pitt2003,
  title = {Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction},
  author = {Pitt, Bertram and Remme, Willem and Zannad, Faiez and Neaton, James and Martinez, Felipe and Roniker, Barbara and Bittman, Richard and Hurley, Steve and Kleiman, Jay and Gatlin, Marjorie},
  year = {2003},
  month = apr,
  journal = {New England Journal of Medicine},
  volume = {348},
  number = {14},
  pages = {1309--1321},
  publisher = {New England Journal of Medicine (NEJM/MMS)},
  issn = {0028-4793},
  doi = {10.1056/NEJMOA030207/SUPPL_FILE/1309SA1.PDF},
  abstract = {BACKGROUND Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. METHODS Patients were randomly assigned to eplerenone (25 mg per day initially, titrated to a maximum of 50 mg per day; 3319 patients) or placebo (3313 patients) [correction] in addition to optimal medical therapy. The study continued until 1012 deaths occurred. The primary end points were death from any cause and death from cardiovascular causes or hospitalization for heart failure, acute myocardial infarction, stroke, or ventricular arrhythmia. RESULTS During a mean follow-up of 16 months, there were 478 deaths in the eplerenone group and 554 deaths in the placebo group (relative risk, 0.85; 95 percent confidence interval, 0.75 to 0.96; P=0.008). Of these deaths, 407 in the eplerenone group and 483 in the placebo group were attributed to cardiovascular causes (relative risk, 0.83; 95 percent confidence interval, 0.72 to 0.94; P=0.005). The rate of the other primary end point, death from cardiovascular causes or hospitalization for cardiovascular events, was reduced by eplerenone (relative risk, 0.87; 95 percent confidence interval, 0.79 to 0.95; P=0.002), as was the secondary end point of death from any cause or any hospitalization (relative risk, 0.92; 95 percent confidence interval, 0.86 to 0.98; P=0.02). There was also a reduction in the rate of sudden death from cardiac causes (relative risk, 0.79; 95 percent confidence interval, 0.64 to 0.97; P=0.03). The rate of serious hyperkalemia was 5.5 percent in the eplerenone group and 3.9 percent in the placebo group (P=0.002), whereas the rate of hypokalemia was 8.4 percent in the eplerenone group and 13.1 percent in the placebo group (P{\textexclamdown}0.001). CONCLUSIONS The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.},
  pmid = {12668699}
}

@article{pMetabolomicProfilingStatin2016,
  title = {Metabolomic {{Profiling}} of {{Statin Use}} and {{Genetic Inhibition}} of {{HMG-CoA Reductase}}},
  author = {P, W{\"u}rtz and Q, Wang and P, Soininen and Aj, Kangas and G, Fatemifar and T, Tynkkynen and M, Tiainen and M, Perola and T, Tillin and Ad, Hughes and P, M{\"a}ntyselk{\"a} and M, K{\"a}h{\"o}nen and T, Lehtim{\"a}ki and N, Sattar and Ad, Hingorani and Jp, Casas and V, Salomaa and M, Kivim{\"a}ki and Mr, J{\"a}rvelin and G, Davey Smith and M, Vanhala and Da, Lawlor and Ot, Raitakari and N, Chaturvedi and J, Kettunen and M, Ala-Korpela},
  year = {2016},
  month = mar,
  journal = {Journal of the American College of Cardiology},
  volume = {67},
  number = {10},
  publisher = {J Am Coll Cardiol},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2015.12.060},
  urldate = {2024-12-10},
  abstract = {Statin use leads to extensive lipid changes beyond LDL-C and appears efficacious for lowering remnant cholesterol. Metabolomic profiling, however, suggested minimal effects on amino acids. The results exemplify how detailed metabolic characterization of genetic proxies for drug targets can inform in {\dots}},
  langid = {english},
  pmid = {26965542},
  file = {/Users/xx20081/Zotero/storage/RTPZQDAA/P et al. - 2016 - Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase.pdf}
}

@article{polhemusRenalSympatheticDenervation2017,
  title = {Renal {{Sympathetic Denervation Protects}}~the {{Failing Heart Via Inhibition}} of~{{Neprilysin~Activity}} in the {{Kidney}}},
  author = {Polhemus, David J. and Trivedi, Rishi K. and Gao, Juan and Li, Zhen and Scarborough, Amy L. and Goodchild, Traci T. and Varner, Kurt J. and Xia, Huijing and Smart, Frank W. and Kapusta, Daniel R. and Lefer, David J.},
  year = {2017},
  month = oct,
  journal = {Journal of the American College of Cardiology},
  volume = {70},
  number = {17},
  pages = {2139--2153},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2017.08.056},
  abstract = {BACKGROUND: Sustained sympathetic activation contributes to the progression of myocardial cell injury, cardiac fibrosis, and left ventricular (LV) dysfunction in heart failure (HF). OBJECTIVES: This study investigated the effects of radiofrequency renal nerve denervation (RF-RDN) on the pathobiology of HF and the interaction between the renal sympathetic nerves and natriuretic peptide (NP) metabolism. METHODS: Spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto rats (WKY) were subjected to 45~min of coronary artery ligation and reperfusion for 12~weeks. At 4~weeks post-reperfusion, SHR and WKY underwent either bilateral RF-RDN or sham-RDN. RESULTS: Following RF-RDN in both strains, LV ejection fraction remained significantly above those levels in respective sham-RDN rats, and at the end of the 12-week study, rats in both strains had significantly reduced LV fibrosis and improved vascular function. RF-RDN therapy significantly improved vascular reactivity to endothelium-dependent and~-independent vasodilators as well as vascular compliance in the setting of severe HF. Improvements in LV function were accompanied by significant elevations in circulating NP as compared to those associated with sham-RDN. Further investigation into the cause of increased circulating NP levels demonstrated that RF-RDN significantly inhibited renal neprilysin activity in SHR and WKY with HF. Likewise, chronic treatment with the beta1 antagonist bisoprolol inhibited renal neprilysin activity and increased circulation NP levels in WKY with HF. CONCLUSIONS: This study identifies a novel endogenous pathway by which the renal nerves participate in the degradation of cardioprotective NP. Furthermore, removal of the influence of the renal nerves on kidney function attenuates renal neprilysin activity, augments circulating NP levels, reduces myocardial fibrosis, and improves LV function in the setting of HF.},
  langid = {english},
  pmid = {29050562},
  keywords = {Aminobutyrates,Angiotensin II,Animals,Biphenyl Compounds,Bisoprolol,Blood Pressure,Drug Combinations,Echocardiography,fibrosis,heart failure,Heart Failure,Kidney,Myocardium,Neprilysin,Nitrites,Norepinephrine,Rats,Rats Inbred SHR,Rats Inbred WKY,Renal Artery,renal denervation,Renin,Reperfusion Injury,Sympathectomy,sympathetic nervous system,Tetrazoles,Valsartan,vascular function,Ventricular Function Left}
}

@article{porcuMendelianRandomizationIntegrating2019,
  title = {Mendelian Randomization Integrating {{GWAS}} and {{eQTL}} Data Reveals Genetic Determinants of Complex and Clinical Traits},
  author = {Porcu, Eleonora and R{\"u}eger, Sina and Lepik, Kaido and Santoni, Federico A. and Reymond, Alexandre and Kutalik, Zolt{\'a}n},
  year = {2019},
  month = jul,
  journal = {Nature Communications},
  volume = {10},
  number = {1},
  pages = {3300},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-019-10936-0},
  urldate = {2024-01-18},
  abstract = {Genome-wide association studies (GWAS) have identified thousands of variants associated with complex traits, but their biological interpretation often remains unclear. Most of these variants overlap with expression QTLs, indicating their potential involvement in regulation of gene expression. Here, we propose a transcriptome-wide summary statistics-based Mendelian Randomization approach (TWMR) that uses multiple SNPs as instruments and multiple gene expression traits as exposures, simultaneously. Applied to 43 human phenotypes, it uncovers 3,913 putatively causal gene--trait associations, 36\% of which have no genome-wide significant SNP nearby in previous GWAS. Using independent association summary statistics, we find that the majority of these loci were missed by GWAS due to power issues. Noteworthy among these links is educational attainment-associated BSCL2, known to carry mutations leading to a Mendelian form of encephalopathy. We also find pleiotropic causal effects suggestive of mechanistic connections. TWMR better accounts for pleiotropy and has the potential to identify biological mechanisms underlying complex traits.},
  copyright = {2019 The Author(s)},
  langid = {english},
  keywords = {Gene expression,Quantitative trait,Statistical methods},
  file = {/Users/xx20081/Zotero/storage/UY3XU6HV/Porcu et al. - 2019 - Mendelian randomization integrating GWAS and eQTL .pdf}
}

@article{postHeritabilityLeftVentricular1997,
  title = {Heritability of Left Ventricular Mass: The {{Framingham Heart Study}}},
  shorttitle = {Heritability of Left Ventricular Mass},
  author = {Post, W. S. and Larson, M. G. and Myers, R. H. and Galderisi, M. and Levy, D.},
  year = {1997},
  month = nov,
  journal = {Hypertension (Dallas, Tex.: 1979)},
  volume = {30},
  number = {5},
  pages = {1025--1028},
  issn = {0194-911X},
  doi = {10.1161/01.hyp.30.5.1025},
  abstract = {Left ventricular hypertrophy is associated with an increased risk for cardiovascular disease. The known determinants of left ventricular hypertrophy only partially explain its variability. The purpose of this study was to estimate heritability of left ventricular mass. The study sample included adults in the original Framingham Heart Study and the Framingham Offspring Study who were not receiving antihypertensive medications and who were free of coronary heart disease, congestive heart failure, diabetes mellitus, renal insufficiency, valvular heart disease, and severe left ventricular hypertrophy. Intraclass correlations for left ventricular mass among first-degree relatives, second-degree relatives, and unrelated spouse pairs were calculated to determine the contribution of heredity to the variability in left ventricular mass. After adjustments for age, height, weight, and systolic blood pressure, the intraclass correlations between first-degree relatives were .15 (parent-child, P{$<$}.001) to .16 (siblings, P{$<$}.001), between second-degree relatives the correlation was .06 (P=NS), and between spouses it was .05 (P=NS). The estimated heritability of adjusted left ventricular mass was between .24 and .32. The proportion of the variance in sex-specific left ventricular mass explained by age, height, weight, and systolic blood pressure was .26 in men and .34 in women. On the basis of intraclass correlations for left ventricular mass, incorporation of adjusted left ventricular mass of a parent or sibling would increase the explained variance by an additional .02 to .03. Heredity explains a small, but discernible proportion of the variance in left ventricular mass. Studies are currently under way to identify genetic markers that predict an individual's predisposition to left ventricular hypertrophy. This knowledge may lead to advances in the prevention of left ventricular hypertrophy, which is strongly associated with cardiovascular morbidity and mortality.},
  langid = {english},
  pmid = {9369250},
  keywords = {Adult,Aged,Cohort Studies,Echocardiography,Epidemiologic Methods,Female,Genetic Variation,Heart,Humans,Male,Middle Aged,Prospective Studies,Regression Analysis}
}

@article{prausmullerObesityHeartFailure2023,
  title = {Obesity in Heart Failure with Preserved Ejection Fraction with and without Diabetes: Risk Factor or Innocent Bystander?},
  shorttitle = {Obesity in Heart Failure with Preserved Ejection Fraction with and without Diabetes},
  author = {Prausm{\"u}ller, Suriya and Weidenhammer, Annika and Heitzinger, Gregor and Spinka, Georg and Goliasch, Georg and Arfsten, Henrike and Abdel Mawgoud, Ramy and Gabler, Cornelia and Strunk, Guido and Hengstenberg, Christian and H{\"u}lsmann, Martin and Bartko, Philipp E and Pavo, Noemi},
  year = {2023},
  month = sep,
  journal = {European Journal of Preventive Cardiology},
  volume = {30},
  number = {12},
  pages = {1247--1254},
  issn = {2047-4873},
  doi = {10.1093/eurjpc/zwad140},
  urldate = {2025-01-06},
  abstract = {Heart failure with preserved ejection fraction (HFpEF) is a condition that commonly coexists with type 2 diabetes mellitus (T2DM) and obesity. Whether the obesity-related survival benefit generally observed in HFpEF extends to individuals with concomitant T2DM is unclear. This study sought to examine the prognostic role of overweight and obesity in a large cohort of HFpEF with and without T2DM.This large-scale cohort study included patients with HFpEF enrolled between 2010 and 2020. The relationship between body mass index (BMI), T2DM, and survival was assessed. A total of 6744 individuals with HFpEF were included, of which 1702 (25\%) had T2DM. Patients with T2DM had higher BMI values (29.4 kg/m2 vs. 27.1 kg/m2, P \&lt; 0.001), higher N-terminal pro-brain natriuretic peptide values (864 mg/dL vs. 724 mg/dL, P \&lt; 0.001), and a higher prevalence of numerous risk factors/comorbidities than those without T2DM. During a median follow-up time of 47 months (Q1--Q3: 20--80), 2014 (30\%) patients died. Patients with T2DM had a higher incidence of fatal events compared with those without T2DM, with a mortality rate of 39.2\% and 26.7\%, respectively (P \&lt; 0.001). In the overall cohort, using the BMI category 22.5--24.9 kg/m2 as the reference group, the unadjusted hazard ratio (HR) for all-cause death was increased in patients with BMI \&lt;22.5 kg/m2 [HR: 1.27 (confidence interval 1.09--1.48), P = 0.003] and decreased in BMI categories {$\geq$}25 kg/m2. After multivariate adjustment, BMI remained significantly inversely associated with survival in non-T2DM, whereas survival was unaltered at a wide range of BMI in patients with T2DM.Among the various phenotypes of HFpEF, the T2DM phenotype is specifically associated with a greater disease burden. Higher BMI is linked to improved survival in HFpEF overall, while this effect neutralises in patients with concomitant T2DM. Advising BMI--based weight targets and weight loss may be pursued with different intensity in the management of HFpEF, particularly in the presence of T2DM.Individuals with HFpEF and concomitant diabetes show a distinct phenotype particularly associated with a higher disease burden and worse outcome. The obesity paradox observed in individuals with heart failure may not be generalized to HFpEF patients with concomitant diabetes.},
  file = {/Users/xx20081/Zotero/storage/XBB8R2TR/Prausmller et al. - 2023 - Obesity in heart failure with preserved ejection fraction with and without diabetes risk factor or.pdf;/Users/xx20081/Zotero/storage/W7C69YRL/7175080.html}
}

@article{prospectivestudiescollaborationBodymassIndexCausespecific2009,
  title = {Body-Mass Index and Cause-Specific Mortality in 900 000 Adults: Collaborative Analyses of 57 Prospective Studies},
  shorttitle = {Body-Mass Index and Cause-Specific Mortality in 900 000 Adults},
  author = {{Prospective Studies Collaboration} and Whitlock, Gary and Lewington, Sarah and Sherliker, Paul and Clarke, Robert and Emberson, Jonathan and Halsey, Jim and Qizilbash, Nawab and Collins, Rory and Peto, Richard},
  year = {2009},
  month = mar,
  journal = {Lancet (London, England)},
  volume = {373},
  number = {9669},
  pages = {1083--1096},
  issn = {1474-547X},
  doi = {10.1016/S0140-6736(09)60318-4},
  abstract = {BACKGROUND: The main associations of body-mass index (BMI) with overall and cause-specific mortality can best be assessed by long-term prospective follow-up of large numbers of people. The Prospective Studies Collaboration aimed to investigate these associations by sharing data from many studies. METHODS: Collaborative analyses were undertaken of baseline BMI versus mortality in 57 prospective studies with 894 576 participants, mostly in western Europe and North America (61\% [n=541 452] male, mean recruitment age 46 [SD 11] years, median recruitment year 1979 [IQR 1975-85], mean BMI 25 [SD 4] kg/m(2)). The analyses were adjusted for age, sex, smoking status, and study. To limit reverse causality, the first 5 years of follow-up were excluded, leaving 66 552 deaths of known cause during a mean of 8 (SD 6) further years of follow-up (mean age at death 67 [SD 10] years): 30 416 vascular; 2070 diabetic, renal or hepatic; 22 592 neoplastic; 3770 respiratory; 7704 other. FINDINGS: In both sexes, mortality was lowest at about 22.5-25 kg/m(2). Above this range, positive associations were recorded for several specific causes and inverse associations for none, the absolute excess risks for higher BMI and smoking were roughly additive, and each 5 kg/m(2) higher BMI was on average associated with about 30\% higher overall mortality (hazard ratio per 5 kg/m(2) [HR] 1.29 [95\% CI 1.27-1.32]): 40\% for vascular mortality (HR 1.41 [1.37-1.45]); 60-120\% for diabetic, renal, and hepatic mortality (HRs 2.16 [1.89-2.46], 1.59 [1.27-1.99], and 1.82 [1.59-2.09], respectively); 10\% for neoplastic mortality (HR 1.10 [1.06-1.15]); and 20\% for respiratory and for all other mortality (HRs 1.20 [1.07-1.34] and 1.20 [1.16-1.25], respectively). Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer. These inverse associations were much stronger for smokers than for non-smokers, despite cigarette consumption per smoker varying little with BMI. INTERPRETATION: Although other anthropometric measures (eg, waist circumference, waist-to-hip ratio) could well add extra information to BMI, and BMI to them, BMI is in itself a strong predictor of overall mortality both above and below the apparent optimum of about 22.5-25 kg/m(2). The progressive excess mortality above this range is due mainly to vascular disease and is probably largely causal. At 30-35 kg/m(2), median survival is reduced by 2-4 years; at 40-45 kg/m(2), it is reduced by 8-10 years (which is comparable with the effects of smoking). The definite excess mortality below 22.5 kg/m(2) is due mainly to smoking-related diseases, and is not fully explained.},
  langid = {english},
  pmcid = {PMC2662372},
  pmid = {19299006},
  keywords = {Adult,Aged,Aged 80 and over,Body Mass Index,Cause of Death,Female,Humans,Male,Middle Aged,Mortality,Myocardial Ischemia,Prospective Studies,Respiratory Tract Diseases,Stroke},
  file = {/Users/xx20081/Zotero/storage/KJNL73AV/Prospective Studies Collaboration et al. - 2009 - Body-mass index and cause-specific mortality in 900 000 adults collaborative analyses of 57 prospec.pdf}
}

@article{pulitMetaanalysisGenomewideAssociation2019,
  title = {Meta-Analysis of Genome-Wide Association Studies for Body Fat Distribution in 694~649 Individuals of {{European}} Ancestry},
  author = {Pulit, Sara L and Stoneman, Charli and Morris, Andrew P and Wood, Andrew R and Glastonbury, Craig A and Tyrrell, Jessica and Yengo, Lo{\"i}c and Ferreira, Teresa and Marouli, Eirini and Ji, Yingjie and Yang, Jian and Jones, Samuel and Beaumont, Robin and {Croteau-Chonka}, Damien C and Winkler, Thomas W and {GIANT Consortium} and Hattersley, Andrew T and Loos, Ruth J F and Hirschhorn, Joel N and Visscher, Peter M and Frayling, Timothy M and Yaghootkar, Hanieh and Lindgren, Cecilia M},
  year = {2019},
  month = jan,
  journal = {Human Molecular Genetics},
  volume = {28},
  number = {1},
  pages = {166--174},
  issn = {0964-6906},
  doi = {10.1093/hmg/ddy327},
  urldate = {2024-04-08},
  abstract = {More than one in three adults worldwide is either overweight or obese. Epidemiological studies indicate that the location and distribution of excess fat, rather than general adiposity, are more informative for predicting risk of obesity sequelae, including cardiometabolic disease and cancer. We performed a genome-wide association study meta-analysis of body fat distribution, measured by waist-to-hip ratio (WHR) adjusted for body mass index (WHRadjBMI), and identified 463 signals in 346 loci. Heritability and variant effects were generally stronger in women than men, and we found approximately one-third of all signals to be sexually dimorphic. The 5\% of individuals carrying the most WHRadjBMI-increasing alleles were 1.62 times more likely than the bottom 5\% to have a WHR above the thresholds used for metabolic syndrome. These data, made publicly available, will inform the biology of body fat distribution and its relationship with disease.},
  file = {/Users/xx20081/Zotero/storage/7ZY59VCE/Pulit et al. - 2019 - Meta-analysis of genome-wide association studies f.pdf;/Users/xx20081/Zotero/storage/CAB8IPS8/5098227.html}
}

@article{purcellPLINKToolSet2007,
  title = {{{PLINK}}: {{A Tool Set}} for {{Whole-Genome Association}} and {{Population-Based Linkage Analyses}}},
  shorttitle = {{{PLINK}}},
  author = {Purcell, Shaun and Neale, Benjamin and {Todd-Brown}, Kathe and Thomas, Lori and Ferreira, Manuel~A.~R. and Bender, David and Maller, Julian and Sklar, Pamela and {de~Bakker}, Paul~I.~W. and Daly, Mark~J. and Sham, Pak~C.},
  year = {2007},
  month = sep,
  journal = {American Journal of Human Genetics},
  volume = {81},
  number = {3},
  pages = {559--575},
  issn = {0002-9297},
  urldate = {2024-02-19},
  abstract = {Whole-genome association studies (WGAS) bring new computational, as well as analytic, challenges to researchers. Many existing genetic-analysis tools are not designed to handle such large data sets in a convenient manner and do not necessarily exploit the new opportunities that whole-genome data bring. To address these issues, we developed PLINK, an open-source C/C++ WGAS tool set. With PLINK, large data sets comprising hundreds of thousands of markers genotyped for thousands of individuals can be rapidly manipulated and analyzed in their entirety. As well as providing tools to make the basic analytic steps computationally efficient, PLINK also supports some novel approaches to whole-genome data that take advantage of whole-genome coverage. We introduce PLINK and describe the five main domains of function: data management, summary statistics, population stratification, association analysis, and identity-by-descent estimation. In particular, we focus on the estimation and use of identity-by-state and identity-by-descent information in the context of population-based whole-genome studies. This information can be used to detect and correct for population stratification and to identify extended chromosomal segments that are shared identical by descent between very distantly related individuals. Analysis of the patterns of segmental sharing has the potential to map disease loci that contain multiple rare variants in a population-based linkage analysis.},
  pmcid = {PMC1950838},
  pmid = {17701901},
  file = {/Users/xx20081/Zotero/storage/FG6X292H/Purcell et al. - 2007 - PLINK A Tool Set for Whole-Genome Association and.pdf}
}

@article{qiGeneticControlRNA2022,
  title = {Genetic Control of {{RNA}} Splicing and Its Distinct Role in Complex Trait Variation},
  author = {Qi, Ting and Wu, Yang and Fang, Hailing and Zhang, Futao and Liu, Shouye and Zeng, Jian and Yang, Jian},
  year = {2022},
  month = sep,
  journal = {Nature Genetics},
  volume = {54},
  number = {9},
  pages = {1355--1363},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-022-01154-4},
  urldate = {2024-02-19},
  abstract = {Most genetic variants identified from genome-wide association studies (GWAS) in humans are noncoding, indicating their role in gene regulation. Previous studies have shown considerable links of GWAS signals to expression quantitative trait loci (eQTLs) but the links to other genetic regulatory mechanisms, such as splicing QTLs (sQTLs), are underexplored. Here, we introduce an sQTL mapping method, testing for heterogeneity between isoform-eQTL effects (THISTLE), with improved power over competing methods. Applying THISTLE together with a complementary sQTL mapping strategy to brain transcriptomic (n\,=\,2,865) and genotype data, we identified 12,794 genes with cis-sQTLs at P\,{$<$}\,5\,{\texttimes}\,10-8, approximately 61\% of which were distinct from eQTLs. Integrating the sQTL data into GWAS for 12 brain-related complex traits (including diseases), we identified 244 genes associated with the traits through cis-sQTLs, approximately 61\% of which could not be discovered using the corresponding eQTL data. Our study demonstrates the distinct role of most sQTLs in the genetic regulation of transcription and complex trait variation.},
  copyright = {2022 The Author(s)},
  langid = {english},
  keywords = {Gene expression,Genome-wide association studies},
  file = {/Users/xx20081/Zotero/storage/LD2HAS7Q/Qi et al. - 2022 - Genetic control of RNA splicing and its distinct r.pdf}
}

@article{qiIdentifyingGeneTargets2018,
  title = {Identifying Gene Targets for Brain-Related Traits Using Transcriptomic and Methylomic Data from Blood},
  author = {Qi, Ting and Wu, Yang and Zeng, Jian and Zhang, Futao and Xue, Angli and Jiang, Longda and Zhu, Zhihong and Kemper, Kathryn and Yengo, Loic and Zheng, Zhili and Marioni, Riccardo E. and Montgomery, Grant W. and Deary, Ian J. and Wray, Naomi R. and Visscher, Peter M. and McRae, Allan F. and Yang, Jian},
  year = {2018},
  month = jun,
  journal = {Nature Communications},
  volume = {9},
  number = {1},
  pages = {2282},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-018-04558-1},
  urldate = {2024-02-19},
  abstract = {Understanding the difference in genetic regulation of gene expression between brain and blood is important for discovering genes for brain-related traits and disorders. Here, we estimate the correlation of genetic effects at the top-associated cis-expression or -DNA methylation (DNAm) quantitative trait loci (cis-eQTLs or cis-mQTLs) between brain and blood (rb). Using publicly available data, we find that genetic effects at the top cis-eQTLs or mQTLs are highly correlated between independent brain and blood samples (\$\${\textbackslash}hat r\_b = 0.70\$\$for cis-eQTLs and \$\${\textbackslash}hat r\_ b = 0.78\$\$for cis-mQTLs). Using meta-analyzed brain cis-eQTL/mQTL data (n =\,526~to~1194), we identify 61 genes and 167 DNAm sites associated with four brain-related phenotypes, most of which are a subset of the discoveries (97 genes and 295 DNAm sites) using data from blood with larger sample sizes (n\,=\,1980~to~14,115). Our results demonstrate the gain of power in gene discovery for brain-related phenotypes using blood cis-eQTL/mQTL data with large sample sizes.},
  copyright = {2018 The Author(s)},
  langid = {english},
  keywords = {DNA methylation,Gene regulation,Genetics of the nervous system,Genome-wide association studies},
  file = {/Users/xx20081/Zotero/storage/4QH52DN5/Qi et al. - 2018 - Identifying gene targets for brain-related traits .pdf}
}

@article{rajapurohitamObesityAssociatedPeptideLeptin2003,
  title = {The {{Obesity-Associated Peptide Leptin Induces Hypertrophy}} in {{Neonatal Rat Ventricular Myocytes}}},
  author = {Rajapurohitam, Venkatesh and Gan, Xiaohong Tracey and Kirshenbaum, Lorrie A. and Karmazyn, Morris},
  year = {2003},
  month = aug,
  journal = {Circulation Research},
  volume = {93},
  number = {4},
  pages = {277--279},
  publisher = {American Heart Association},
  doi = {10.1161/01.RES.0000089255.37804.72},
  urldate = {2024-07-05},
  abstract = {One of the major manifestations of obesity is increased production of the adipocyte-derived 16-kDa peptide leptin, which is also elevated in heart disease, including congestive heart failure. However, whether leptin can directly alter the cardiac phenotype is not known. We therefore studied the effect of leptin as a potential hypertrophic factor in cultured myocytes from 1- to 4-day-old neonatal rat heart ventricles. Using RT-PCR, we demonstrate that these cells express the short-form (OB-Ra) leptin receptor. Twenty-four hours of exposure to leptin (0.31 to 31.3 nmol/L) produces a significantly increased cell surface area that peaked at 0.63 nmol/L. Subsequent experiments were done with 3.1 nmol/L leptin, which significantly increased cell area by 42\%, protein synthesis by 32\%, and {$\alpha$}-skeletal actin and myosin light chain-2 expression by 250\% and 300\%, respectively. These events occurred in the absence of any increased cell death. Hypertrophy was preceded by rapid activation of the mitogen-activated protein kinase system including p38 and p44/42 as early as 5 minutes after leptin addition, whereas hypertrophy was inhibited by the p38 inhibitor SB203580 but not by the p44/42 inhibitor PD98059. Our results demonstrate a direct hypertrophic effect of leptin and may offer a biological link between hypertrophy and hyperleptinemic conditions such as obesity.},
  file = {/Users/xx20081/Zotero/storage/I5FGKW98/Rajapurohitam et al. - 2003 - The Obesity-Associated Peptide Leptin Induces Hype.pdf}
}

@article{raoAdiposityIncidentHeart2018,
  title = {Adiposity and {{Incident Heart Failure}} and~Its {{Subtypes}}: {{MESA}} ({{Multi-Ethnic Study}} of {{Atherosclerosis}})},
  shorttitle = {Adiposity and {{Incident Heart Failure}} and~Its {{Subtypes}}},
  author = {Rao, Vishal N. and Zhao, Di and Allison, Matthew A. and Guallar, Eliseo and Sharma, Kavita and Criqui, Michael H. and Cushman, Mary and Blumenthal, Roger S. and Michos, Erin D.},
  year = {2018},
  month = dec,
  journal = {JACC. Heart failure},
  volume = {6},
  number = {12},
  pages = {999--1007},
  issn = {2213-1787},
  doi = {10.1016/j.jchf.2018.07.009},
  abstract = {OBJECTIVES: This study sought to compare various measures of adiposity with risk for incident hospitalized heart failure (HF) with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). BACKGROUND: Obesity is a risk factor for HF, particularly HFpEF. It is unknown which measures of adiposity, including anthropometrics and computed tomography (CT)-measured fat area, are most predictive of HF subtypes. METHODS: The authors studied 1,806 participants of the MESA (Multi-Ethnic Study of Atherosclerosis) study without baseline cardiovascular disease who underwent anthropometrics (body mass index [BMI] and waist circumference) and an abdominal CT. Subcutaneous and visceral adipose tissue (VAT) were measured from a single CT slice at L2-L3. Cox hazard models were used to examine associations of adiposity with incident hospitalized HFpEF and HFrEF events. Fully adjusted models included demographics, HF risk factors, and N-terminal pro-B-type natriuretic peptide. RESULTS: Over a mean follow-up of 11 years, there were 34 HFpEF and 36 HFrEF events. The fully adjusted hazard ratio (95\% confidence interval [CI]) per 1-SD higher of each anthropometric and CT-measured adiposity measures for incident HFpEF were as follows: BMI HR: 1.66; 95\% CI: 1.12 to 2.45; waist circumference HR: 1.59; 95\% CI: 1.05 to 2.40; and VAT HR: 2.24; 95\% CI: 1.44 to 3.49. None of these adiposity measures were associated with HFrEF. Even among overweight/obese adults (BMI~{$\geq$}25 kg/m2), assessment of VAT (per 1-SD) was strongly associated with HFpEF (HR: 2.78; 95\% CI: 1.62 to 4.76). Subcutaneous adipose tissue was neither associated with HFpEF nor HFrEF. CONCLUSIONS: In a multiethnic cohort free of cardiovascular disease, CT-measured VAT was independently associated~with incident hospitalized HFpEF but not HFrEF. Measuring visceral fat at the time of CT imaging for other~indications may offer additional prognostication of HF risk. (Multi-Ethnic Study of Atherosclerosis [MESA]; NCT00005487).},
  langid = {english},
  pmcid = {PMC6269197},
  pmid = {30316935},
  keywords = {Abdomen,Adipose Tissue,Adiposity,anthropometry,Anthropometry,Atherosclerosis,Body Mass Index,Ethnicity,heart failure,Heart Failure,HFpEF,Humans,obesity,Stroke Volume,Tomography X-Ray Computed,visceral adiposity},
  file = {/Users/xx20081/Zotero/storage/95M33UBI/Rao et al. - 2018 - Adiposity and Incident Heart Failure andits Subty.pdf}
}

@article{rashidBloodPressureReduction2003,
  title = {Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events: A Systematic Review},
  shorttitle = {Blood Pressure Reduction and Secondary Prevention of Stroke and Other Vascular Events},
  author = {Rashid, Parveen and {Leonardi-Bee}, Jo and Bath, Philip},
  year = {2003},
  month = nov,
  journal = {Stroke},
  volume = {34},
  number = {11},
  pages = {2741--2748},
  issn = {1524-4628},
  doi = {10.1161/01.STR.0000092488.40085.15},
  abstract = {BACKGROUND: High blood pressure is a risk factor for stroke recurrence. We assessed the effectiveness of lowering blood pressure in preventing recurrent vascular events in patients with previous stroke or transient ischemic attack. SUMMARY OF REVIEW: We performed a systematic review and meta-regression of completed randomized controlled trials that investigated the effect of lowering blood pressure on recurrent vascular events in patients with prior ischemic or hemorrhagic stroke or transient ischemic attack. Trials were identified from searches of 3 electronic databases (Cochrane Library, EMBASE, MEDLINE). Seven randomized controlled trials, with 8 comparison groups, were included. Lowering blood pressure or treating hypertension with a variety of antihypertensive agents reduced stroke (odds ratio [OR], 0.76; 95\% CI, 0.63 to 0.92), nonfatal stroke (OR, 0.79; 95\% CI, 0.65 to 0.95), myocardial infarction (OR, 0.79; 95\% CI, 0.63 to 0.98), and total vascular events (OR, 0.79; 95\% CI, 0.66 to 0.95). No effect was seen on vascular or all-cause mortality. Heterogeneity was present for several outcomes and was partly related to the class of antihypertensive drugs used; angiotensin-converting enzyme inhibitors and diuretics separately, and especially together, reduced vascular events, while beta-receptor antagonists had no discernable effect. The reduction in stroke was related to the difference in systolic blood pressure between treatment and control groups (P=0.002). CONCLUSIONS: Evidence from randomized controlled trials supports the use of antihypertensive agents in lowering blood pressure for the prevention of vascular events in patients with previous stroke or transient ischemic attack. Vascular prevention is associated positively with the magnitude by which blood pressure is reduced.},
  langid = {english},
  pmid = {14576382},
  keywords = {Antihypertensive Agents,Blood Pressure,Humans,Odds Ratio,Randomized Controlled Trials as Topic,Risk Factors,Risk Reduction Behavior,Secondary Prevention,Stroke,Treatment Outcome}
}

@article{rasoolyLargescaleMendelianRandomization,
  title = {Large-Scale {{Mendelian}} Randomization Identifies Novel Pathways as Therapeutic Targets for Heart Failure with Reduced Ejection Fraction and with Preserved Ejection Fraction},
  author = {Rasooly, Danielle and Giambartolomei, Claudia and Peloso, Gina M and Ferolito, Brian R and Golden, Daniel and {Farber-Eger}, Eric H and Wells, Quinn Stanton and Bini, Giorgio and Tartaglia, Gian Gaetano and Kosik, Nicole M and Wilson, Peter W F and Phillips, S and Munroe, Patricia B and Petersen, Steffen E and Cho, Kelly and Michael, John and Leach, Andrew R and Aung, Nay and Sun, Yan V and Pereira, Alexandre C and Casas, Juan P},
  abstract = {We used expression quantitative trait loci (eQTLs) and protein quantitative trait loci (pQTLs) to conduct genome-wide Mendelian randomization (MR) using 27,799 cases of heart failure (HF) with reduced ejection fraction (HFrEF), 27,579 cases of HF with preserved ejection fraction (HFpEF), and 367,267 control individuals from the Million Veteran Program (MVP). We identified 70 HFrEF and 10 HFpEF gene-hits, of which 58 are novel. In 14 known loci for unclassified HF, we identified HFrEF as the subtype responsible for the signal. HFrEF hits ZBTB17, MTSS1, PDLIM5, and MLIP and novel HFpEF hits NFATC2IP, and PABPC4 showed robustness to MR assumptions, support from orthogonal sources, compelling evidence on mechanism of action needed for therapeutic efficacy, and no evidence of an unacceptable safety profile. We strengthen the value of pathways such as ubiquitin-proteasome system, small ubiquitin-related modifier pathway, inflammation, and mitochondrial metabolism as potential therapeutic targets for HF management. We identified IL6R, ADM, and EDNRA as suggestive hits for HFrEF and LPA for HFrEF and HFpEF, which enhances the odds of success for existing cardiovascular investigational drugs targeting. These findings confirm the unique value of human genetic studies in HFrEF and HFpEF for discovery of novel targets and generation of therapeutic target profiles needed to initiate new validation programs in HFrEF and HFpEF preclinical models.},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/B3IBLMSZ/Rasooly et al. - Large-scale Mendelian randomization identifies nov.pdf}
}

@article{reddyINDIEHFpEFInorganicNitrite2017,
  title = {{{INDIE-HFpEF}} ({{Inorganic Nitrite Delivery}} to {{Improve Exercise Capacity}} in {{Heart Failure With Preserved Ejection Fraction}}): {{Rationale}} and {{Design}}},
  shorttitle = {{{INDIE-HFpEF}} ({{Inorganic Nitrite Delivery}} to {{Improve Exercise Capacity}} in {{Heart Failure With Preserved Ejection Fraction}})},
  author = {Reddy, Yogesh N. V. and Lewis, Gregory D. and Shah, Sanjiv J. and LeWinter, Martin and Semigran, Marc and {Davila-Roman}, Victor G. and Anstrom, Kevin and Hernandez, Adrian and Braunwald, Eugene and Redfield, Margaret M. and Borlaug, Barry A.},
  year = {2017},
  month = may,
  journal = {Circulation. Heart Failure},
  volume = {10},
  number = {5},
  pages = {e003862},
  issn = {1941-3297},
  doi = {10.1161/CIRCHEARTFAILURE.117.003862},
  abstract = {Approximately half of patients with heart failure have preserved ejection fraction. There is no proven treatment that improves outcome. The pathophysiology of heart failure with preserved ejection fraction is complex and includes left ventricular systolic and diastolic dysfunction, pulmonary vascular disease, endothelial dysfunction, and peripheral abnormalities. Multiple lines of evidence point to impaired nitric oxide (NO)-cGMP bioavailability as playing a central role in each of these abnormalities. In contrast to traditional organic nitrate therapies, an alternative strategy to restore NO-cGMP signaling is via inorganic nitrite. Inorganic nitrite, previously considered to be an inert byproduct of NO metabolism, functions as an important in vivo reservoir for NO generation, particularly under hypoxic and acidosis conditions. As such, inorganic nitrite becomes most active at times of greater need for NO signaling, as during exercise when left ventricular filling pressures and pulmonary artery pressures increase. Herein, we present the rationale and design for the INDIE-HFpEF trial (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure with Preserved Ejection Fraction), which is a multicenter, randomized, double-blind, placebo-controlled cross-over study assessing the effect of inhaled inorganic nitrite on peak exercise capacity, conducted in the National Heart, Lung, and Blood Institute-sponsored Heart Failure Clinical Research Network. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02742129.},
  langid = {english},
  pmcid = {PMC5484533},
  pmid = {28476756},
  keywords = {clinical trial,exercise,Exercise Test,Exercise Tolerance,heart failure,Heart Failure,heart failure with preserved ejection fraction,Humans,metabolism,Nitrates,nitric oxide,Randomized Controlled Trials as Topic,Stroke Volume,Ventricular Function Left},
  file = {/Users/xx20081/Zotero/storage/DFKHWVIA/Reddy et al. - 2017 - INDIE-HFpEF (Inorganic Nitrite Delivery to Improve.pdf}
}

@article{Redfield2013,
  title = {Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction: A Randomized Clinical Trial},
  author = {Redfield, Margaret M. and Chen, Horng H. and Borlaug, Barry A. and Semigran, Marc J. and Lee, Kerry L. and Lewis, Gregory and LeWinter, Martin M. and Rouleau, Jean L. and Bull, David A. and Mann, Douglas L. and Deswal, Anita and Stevenson, Lynne W. and Ofili, Michael M. Givertz Elizabeth O and O'Connor, Christopher M. and Felker, G. Michael and Goldsmith, Steven R. and Bart, Bradley A. and McNulty, Steven E. and Ibarra, Jenny C. and Lin, Grace and Oh, Jae K. and Patel, Manesh R. and Kim, Raymond J. and Tracy, Russell P. and Velazquez, Eric J. and Anstrom, Kevin J. and Hernandez, Adrian F. and Mascette, Alice M. and Braunwald, Eugene},
  year = {2013},
  month = mar,
  journal = {JAMA : the journal of the American Medical Association},
  volume = {309},
  number = {12},
  pages = {1268--1277},
  publisher = {JAMA},
  issn = {1538-3598},
  doi = {10.1001/JAMA.2013.2024},
  abstract = {Importance: Studies in experimental and human heart failure suggest that phos-phodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise capacity in heart failure with preserved ejection fraction (HFPEF). Objective: To determine the effect of the phosphodiesterase-5 inhibitor sildenafil compared with placebo on exercise capacity and clinical status in HFPEF. Design: Multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial of 216 stable outpatients with HF, ejection fraction {$\geq$}50\%, elevated N-terminal brain-type natriuretic peptide or elevated invasively measured filling pressures, and reduced exercise capacity. Participants were randomized from October 2008 through February 2012 at 26 centers in North America. Follow-up was through August 30, 2012. Interventions: Sildenafil (n=113) or placebo (n=103) administered orally at 20 mg, 3 times daily for 12 weeks, followed by 60 mg, 3 times daily for 12 weeks. Main Outcome Measures: Primary end point was change in peak oxygen consumption after 24 weeks of therapy. Secondary end points included change in 6-minute walk distance and a hierarchical composite clinical status score (range, 1-n, a higher value indicates better status; expected value with no treatment effect, 95) based on time to death, time to cardiovascular or cardiorenal hospitalization, and change in quality of life for participants without cardiovascular or cardiorenal hospitalization at 24 weeks. Results: Median age was 69 years, and 48\% of patients were women. At baseline, median peak oxygen consumption (11.7 mL/kg/min) and 6-minute walk distance (308 m) were reduced. The median E/e{$\prime$} (16), left atrial volume index (44 mL/m2), and pulmonary artery systolic pressure (41 mm Hg) were consistent with chronically elevated left ventricular filling pressures. At 24 weeks, median (IQR) changes in peak oxygen consumption (mL/kg/min) in patients who received placebo (-0.20 [IQR, -0.70 to 1.00]) or sildenafil (-0.20 [IQR, -1.70 to 1.11]) were not significantly different (P=.90) in analyses in which patients with missing week-24 data were excluded, and in sensitivity analysis based on intention to treat with multiple imputation for missing values (mean between-group difference, 0.01 mL/kg/min, [95\% CI, -0.60 to 0.61]). The mean clinical status rank score was not significantly different at 24 weeks between placebo (95.8) and sildenafil (94.2) (P=.85). Changes in 6-minute walk distance at 24 weeks in patients who received placebo (15.0 m [IQR, -26.0 to 45.0]) or sildenafil (5.0 m [IQR, -37.0 to 55.0]; P=.92) were also not significantly different. Adverse events occurred in 78 placebo patients (76\%) and 90 sildenafil patients (80\%). Serious adverse events occurred in 16 placebo patients (16\%) and 25 sildenafil patients (22\%). Conclusion and Relevance: Among patients with HFPEF, phosphodiesterase-5 inhibition with administration of sildenafil for 24 weeks, compared with placebo, did not result in significant improvement in exercise capacity or clinical status. Trial Registration: clinicaltrials.gov Identifier: NCT00763867 {\copyright}2013 American Medical Association. All rights reserved.},
  pmid = {23478662},
  keywords = {affs=[],affs=[]),Aged,Author(firstnames='A',Author(firstnames='B',Author(firstnames='C',Author(firstnames='D',Author(firstnames='E A',Author(firstnames='E',Author(firstnames='F',Author(firstnames='G',Author(firstnames='H',Author(firstnames='J W',Author(firstnames='J',Author(firstnames='K D',Author(firstnames='K',Author(firstnames='L',Author(firstnames='M R',Author(firstnames='M',Author(firstnames='P',Author(firstnames='Q',Author(firstnames='R',Author(firstnames='S',Author(firstnames='T',Author(firstnames='V',Author(firstnames='W',Blood Pressure,CollabAuthor(name='RELAX Trial',doi:10.1001/jama.2013.2024,Double-Blind Method,equal<sub>c</sub>ontrib=False),equal<sub>c</sub>ontrib=False)],Exercise Tolerance*,Extramural,Female,Health Status,Heart Failure / drug therapy*,Heart Failure / physiopathology*,Horng H Chen,Humans,initials='A',initials='B',initials='C',initials='D',initials='E',initials='EA',initials='F',initials='G',initials='H',initials='J',initials='JW',initials='K',initials='KD',initials='L',initials='M',initials='MR',initials='P',initials='Q',initials='R',initials='S',initials='T',initials='V',initials='W',investigators=[Author(firstnames='E',iseditor=False,lastname='Abraham',lastname='Adams',lastname='Agresti',lastname='Anstrom',lastname='Araujo',lastname='Baker',lastname='Bart',lastname='Berg',lastname='Bild',lastname='Borlaug',lastname='Bowen',lastname='Boyle',lastname='Braunwald',lastname='Brooks',lastname='Brown',lastname='Bull',lastname='Cai',lastname='Chadwick',lastname='Chee',lastname='Chen',lastname='Cocca-Spofford',lastname='Colvin-Adams',lastname='Cornell',lastname='Cross',lastname='Dahiya',lastname='DeNofrio',lastname='Desvigne-Nickens',lastname='Deswal',lastname='Ezekowitz',lastname='Felker',lastname='Florea',lastname='Forfia',lastname='Foster',lastname='Gatzke',lastname='Geyen',lastname='Givertz',lastname='Goldsmith',lastname='Greenberg',lastname='Grossi',lastname='Haddad',lastname='Hamel',lastname='Hernandez',lastname='Ibarra',lastname='Jansen',lastname='Johnson',lastname='Kaping',lastname='Keleti',lastname='Kennedy',lastname='Kfoury',lastname='Kim',lastname='Knight',lastname='Koelling',lastname='Konig',lastname='Kurrelmeyer',lastname='Kushnerik',lastname='Kwak',lastname='Lascewski',lastname='Lee',lastname='LeWinter',lastname='Lewis',lastname='Lin',lastname='MacFarlane',lastname='Mackedanz',lastname='Mascette',lastname='McNamara',lastname='McNulty',lastname='Milbrandt',lastname='Ofili',lastname='Oh',lastname='Olatidoye',lastname='Parillo',lastname='Patel',lastname='Penn',lastname='Proulx',lastname='Rajda',lastname='Redfield',lastname='Rhode',lastname='Rice',lastname='Rose',lastname='Rosenberg',lastname='Rouleau',lastname='Semigran',lastname='Shah',lastname='Sharp',lastname='Skrifvars',lastname='Sogade',lastname='Sopko',lastname='Steidley',lastname='Stevenson',lastname='Tracy',lastname='Tunei',lastname='Vaughan',lastname='Velazquez',lastname='Vienneau',lastname='Virmani',lastname='Waters',lastname='White',lastname="O'Connor",Male,Margaret M Redfield,MEDLINE,Middle Aged,Multicenter Study,N.I.H.,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,Outpatients,Oxygen Consumption,Phosphodiesterase 5 Inhibitors / therapeutic use*,Piperazines / therapeutic use*,PMC3835156,pmid:23478662,PubMed Abstract,Purines / therapeutic use,Randomized Controlled Trial,Research Support,Sildenafil Citrate,Stroke Volume,suffix=None,Sulfones / therapeutic use*,Treatment Outcome,Walking}
}

@article{Redfield2015,
  title = {Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction},
  author = {Redfield, Margaret M. and Anstrom, Kevin J. and Levine, James A. and Koepp, Gabe A. and Borlaug, Barry A. and Chen, Horng H. and LeWinter, Martin M. and Joseph, Susan M. and Shah, Sanjiv J. and Semigran, Marc J. and Felker, G. Michael and Cole, Robert T. and Reeves, Gordon R. and Tedford, Ryan J. and Tang, W.H. Wilson and McNulty, Steven E. and Velazquez, Eric J. and Shah, Monica R. and Braunwald, Eugene},
  year = {2015},
  month = dec,
  journal = {The New England journal of medicine},
  volume = {373},
  number = {24},
  pages = {2314--2324},
  publisher = {N Engl J Med},
  issn = {1533-4406},
  doi = {10.1056/NEJMOA1510774},
  abstract = {Copyright {\copyright} 2015 Massachusetts Medical Society. All rights reserved. BACKGROUND Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients. METHODS In this multicenter, double-blind, crossover study, 110 patients with heart failure and a preserved ejection fraction were randomly assigned to a 6-week dose-escalation regimen of isosorbide mononitrate (from 30 mg to 60 mg to 120 mg once daily) or placebo, with subsequent crossover to the other group for 6 weeks. The primary end point was the daily activity level, quantified as the average daily accelerometer units during the 120-mg phase, as assessed by patient-worn accelerometers. Secondary end points included hours of activity per day during the 120-mg phase, daily accelerometer units during all three dose regimens, quality-of-life scores, 6-minute walk distance, and levels of N-terminal pro-brain natriuretic peptide (NT-proBNP). RESULTS In the group receiving the 120-mg dose of isosorbide mononitrate, as compared with the placebo group, there was a nonsignificant trend toward lower daily activity (-381 accelerometer units; 95\% confidence interval [CI], -780 to 17; P = 0.06) and a significant decrease in hours of activity per day (-0.30 hours; 95\% CI, -0.55 to -0.05; P = 0.02). During all dose regimens, activity in the isosorbide mononitrate group was lower than that in the placebo group (-439 accelerometer units; 95\% CI, -792 to -86; P = 0.02). Activity levels decreased progressively and significantly with increased doses of isosorbide mononitrate (but not placebo). There were no significant between-group differences in the 6-minute walk distance, quality-of-life scores, or NT-proBNP levels. CONCLUSIONS Patients with heart failure and a preserved ejection fraction who received isosorbide mononitrate were less active and did not have better quality of life or submaximal exercise capacity than did patients who received placebo.},
  pmid = {26549714},
  keywords = {Accelerometry,affs=[]),Aged,Brain / blood,CollabAuthor(name='NHLBI Heart Failure Clinical Research Network',Comparative Study,Cross-Over Studies,doi:10.1056/NEJMoa1510774,Double-Blind Method,Exercise Tolerance,Extramural,Female,Heart Failure / drug therapy*,Heart Failure / physiopathology,Humans,investigators=[],Isosorbide Dinitrate / adverse effects,Isosorbide Dinitrate / analogs & derivatives*,Isosorbide Dinitrate / therapeutic use,Kevin J Anstrom,Male,Margaret M Redfield,MEDLINE,Middle Aged,Motor Activity,Multicenter Study,N.I.H.,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,Natriuretic Peptide,NCBI,NIH,NLM,Peptide Fragments / blood,PMC4712067,pmid:26549714,PubMed Abstract,Quality of Life,Randomized Controlled Trial,Research Support,Stroke Volume,Vasodilator Agents / adverse effects,Vasodilator Agents / therapeutic use*,Walking}
}

@article{redfieldEffectPhosphodiesterase5Inhibition2013,
  title = {Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction: A Randomized Clinical Trial},
  shorttitle = {Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure with Preserved Ejection Fraction},
  author = {Redfield, Margaret M. and Chen, Horng H. and Borlaug, Barry A. and Semigran, Marc J. and Lee, Kerry L. and Lewis, Gregory and LeWinter, Martin M. and Rouleau, Jean L. and Bull, David A. and Mann, Douglas L. and Deswal, Anita and Stevenson, Lynne W. and Givertz, Michael M. and Ofili, Elizabeth O. and O'Connor, Christopher M. and Felker, G. Michael and Goldsmith, Steven R. and Bart, Bradley A. and McNulty, Steven E. and Ibarra, Jenny C. and Lin, Grace and Oh, Jae K. and Patel, Manesh R. and Kim, Raymond J. and Tracy, Russell P. and Velazquez, Eric J. and Anstrom, Kevin J. and Hernandez, Adrian F. and Mascette, Alice M. and Braunwald, Eugene and {RELAX Trial}},
  year = {2013},
  month = mar,
  journal = {JAMA},
  volume = {309},
  number = {12},
  pages = {1268--1277},
  issn = {1538-3598},
  doi = {10.1001/jama.2013.2024},
  abstract = {IMPORTANCE: Studies in experimental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise capacity in heart failure with preserved ejection fraction (HFPEF). OBJECTIVE: To determine the effect of the phosphodiesterase-5 inhibitor sildenafil compared with placebo on exercise capacity and clinical status in HFPEF. DESIGN: Multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial of 216 stable outpatients with HF, ejection fraction {$\geq$}50\%, elevated N-terminal brain-type natriuretic peptide or elevated invasively measured filling pressures, and reduced exercise capacity. Participants were randomized from October 2008 through February 2012 at 26 centers in North America. Follow-up was through August 30, 2012. INTERVENTIONS: Sildenafil (n = 113) or placebo (n = 103) administered orally at 20 mg, 3 times daily for 12 weeks, followed by 60 mg, 3 times daily for 12 weeks. MAIN OUTCOME MEASURES: Primary end point was change in peak oxygen consumption after 24 weeks of therapy. Secondary end points included change in 6-minute walk distance and a hierarchical composite clinical status score (range, 1-n, a higher value indicates better status; expected value with no treatment effect, 95) based on time to death, time to cardiovascular or cardiorenal hospitalization, and change in quality of life for participants without cardiovascular or cardiorenal hospitalization at 24 weeks. RESULTS: Median age was 69 years, and 48\% of patients were women. At baseline, median peak oxygen consumption (11.7 mL/kg/min) and 6-minute walk distance (308 m) were reduced. The median E/e' (16), left atrial volume index (44 mL/m2), and pulmonary artery systolic pressure (41 mm Hg) were consistent with chronically elevated left ventricular filling pressures. At 24 weeks, median (IQR) changes in peak oxygen consumption (mL/kg/min) in patients who received placebo (-0.20 [IQR, -0.70 to 1.00]) or sildenafil (-0.20 [IQR, -1.70 to 1.11]) were not significantly different (P = .90) in analyses in which patients with missing week-24 data were excluded, and in sensitivity analysis based on intention to treat with multiple imputation for missing values (mean between-group difference, 0.01 mL/kg/min, [95\% CI, -0.60 to 0.61]). The mean clinical status rank score was not significantly different at 24 weeks between placebo (95.8) and sildenafil (94.2) (P = .85). Changes in 6-minute walk distance at 24 weeks in patients who received placebo (15.0 m [IQR, -26.0 to 45.0]) or sildenafil (5.0 m [IQR, -37.0 to 55.0]; P = .92) were also not significantly different. Adverse events occurred in 78 placebo patients (76\%) and 90 sildenafil patients (80\%). Serious adverse events occurred in 16 placebo patients (16\%) and 25 sildenafil patients (22\%). CONCLUSION AND RELEVANCE: Among patients with HFPEF, phosphodiesterase-5 inhibition with administration of sildenafil for 24 weeks, compared with placebo, did not result in significant improvement in exercise capacity or clinical status. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00763867.},
  langid = {english},
  pmcid = {PMC3835156},
  pmid = {23478662},
  keywords = {Aged,Blood Pressure,Double-Blind Method,Exercise Tolerance,Female,Health Status,Heart Failure,Humans,Male,Middle Aged,Outpatients,Oxygen Consumption,Phosphodiesterase 5 Inhibitors,Piperazines,Purines,Sildenafil Citrate,Stroke Volume,Sulfones,Treatment Outcome,Walking},
  file = {/Users/xx20081/Zotero/storage/WEYABUYB/Redfield et al. - 2013 - Effect of phosphodiesterase-5 inhibition on exerci.pdf}
}

@article{redfieldIsosorbideMononitrateHeart2015,
  title = {Isosorbide {{Mononitrate}} in {{Heart Failure}} with {{Preserved Ejection Fraction}}},
  author = {Redfield, Margaret M. and Anstrom, Kevin J. and Levine, James A. and Koepp, Gabe A. and Borlaug, Barry A. and Chen, Horng H. and LeWinter, Martin M. and Joseph, Susan M. and Shah, Sanjiv J. and Semigran, Marc J. and Felker, G. Michael and Cole, Robert T. and Reeves, Gordon R. and Tedford, Ryan J. and Tang, W. H. Wilson and McNulty, Steven E. and Velazquez, Eric J. and Shah, Monica R. and Braunwald, Eugene and {NHLBI Heart Failure Clinical Research Network}},
  year = {2015},
  month = dec,
  journal = {The New England Journal of Medicine},
  volume = {373},
  number = {24},
  pages = {2314--2324},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1510774},
  abstract = {BACKGROUND: Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbide mononitrate or placebo on daily activity in such patients. METHODS: In this multicenter, double-blind, crossover study, 110 patients with heart failure and a preserved ejection fraction were randomly assigned to a 6-week dose-escalation regimen of isosorbide mononitrate (from 30 mg to 60 mg to 120 mg once daily) or placebo, with subsequent crossover to the other group for 6 weeks. The primary end point was the daily activity level, quantified as the average daily accelerometer units during the 120-mg phase, as assessed by patient-worn accelerometers. Secondary end points included hours of activity per day during the 120-mg phase, daily accelerometer units during all three dose regimens, quality-of-life scores, 6-minute walk distance, and levels of N-terminal pro-brain natriuretic peptide (NT-proBNP). RESULTS: In the group receiving the 120-mg dose of isosorbide mononitrate, as compared with the placebo group, there was a nonsignificant trend toward lower daily activity (-381 accelerometer units; 95\% confidence interval [CI], -780 to 17; P=0.06) and a significant decrease in hours of activity per day (-0.30 hours; 95\% CI, -0.55 to -0.05; P=0.02). During all dose regimens, activity in the isosorbide mononitrate group was lower than that in the placebo group (-439 accelerometer units; 95\% CI, -792 to -86; P=0.02). Activity levels decreased progressively and significantly with increased doses of isosorbide mononitrate (but not placebo). There were no significant between-group differences in the 6-minute walk distance, quality-of-life scores, or NT-proBNP levels. CONCLUSIONS: Patients with heart failure and a preserved ejection fraction who received isosorbide mononitrate were less active and did not have better quality of life or submaximal exercise capacity than did patients who received placebo. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT02053493.).},
  langid = {english},
  pmcid = {PMC4712067},
  pmid = {26549714},
  keywords = {Accelerometry,Aged,Cross-Over Studies,Double-Blind Method,Exercise Tolerance,Female,Heart Failure,Humans,Isosorbide Dinitrate,Male,Middle Aged,Motor Activity,Natriuretic Peptide Brain,Peptide Fragments,Quality of Life,Stroke Volume,Vasodilator Agents,Walking},
  file = {/Users/xx20081/Zotero/storage/Y2ZNIYUM/Redfield et al. - 2015 - Isosorbide Mononitrate in Heart Failure with Prese.pdf}
}

@article{reinhardtObesityParadoxHeart2024,
  title = {Obesity {{Paradox}} in {{Heart Failure}} with {{Mildly Reduced Ejection Fraction}}},
  author = {Reinhardt, Marielen and Schupp, Tobias and Abumayyaleh, Mohammad and Lau, Felix and Schmitt, Alexander and Abel, Noah and Akin, Muharrem and Rusnak, Jonas and Akin, Ibrahim and Behnes, Michael},
  year = {2024},
  journal = {Pragmatic and Observational Research},
  volume = {15},
  pages = {31--43},
  issn = {1179-7266},
  doi = {10.2147/POR.S444361},
  abstract = {OBJECTIVE: The study investigates the prognostic impact of body mass index (BMI) in patients hospitalized with heart failure with mildly reduced ejection fraction (HFmrEF). BACKGROUND: Limited data regarding the prognostic impact of BMI in patients with HFmrEF is available. METHODS: Consecutive patients with HFmrEF (ie, left ventricular ejection fraction 41-49\% and signs and/or symptoms of HF) were retrospectively included at one institution from 2016 to 2022. Risk stratification was performed according to WHO-defined BMI groups. The primary endpoint was all-cause mortality at 30 months (median follow-up). Kaplan-Meier, uni- and multivariable Cox proportional regression analyses were applied for statistics. RESULTS: 1832 consecutive patients with HFmrEF were included with a median BMI of 26.7 kg/m2 (IQR 24.0-30.8 kg/m2). Patients with lowest BMI (ie, 18.5-24.9 kg/m2) were associated with highest risk of all-cause mortality at 30 months compared to patients with higher BMI values (40.0\% vs 29.0\% vs 21.4\% vs 20.9\%; log rank p = 0.001; HR = 0.721; 95\% CI 0.656-0.793; p = 0.001). Even after multivariable adjustment, higher BMI values were associated with improved survival at 30 months (HR = 0.963; 95\% CI 0.943-0.985; p = 0.001). In contrast, the risk of HF- related rehospitalization at 30 months was not affected by BMI (log rank p = 0.064). CONCLUSION: In patients hospitalized with HFmrEF, lower BMI was associated with increased risk of all-cause mortality at 30 months, suggesting an obesity paradox in HFmrEF.},
  langid = {english},
  pmcid = {PMC10933520},
  pmid = {38481568},
  keywords = {BMI,body mass index,heart failure with mildly reduced ejection fraction,HFmrEF,mortality,obesity},
  file = {/Users/xx20081/Zotero/storage/3CRC2EQW/Reinhardt et al. - 2024 - Obesity Paradox in Heart Failure with Mildly Reduc.pdf}
}

@article{reisExcessBodyMass2015,
  title = {Excess Body Mass Index- and Waist Circumference-Years and Incident Cardiovascular Disease: The {{CARDIA}} Study},
  shorttitle = {Excess Body Mass Index- and Waist Circumference-Years and Incident Cardiovascular Disease},
  author = {Reis, Jared P. and Allen, Norrina and Gunderson, Erica P. and Lee, Joyce M. and Lewis, Cora E. and Loria, Catherine M. and {Powell-Wiley}, Tiffany M. and Rana, Jamal S. and Sidney, Stephen and Wei, Gina and Yano, Yuichiro and Liu, Kiang},
  year = {2015},
  month = apr,
  journal = {Obesity (Silver Spring, Md.)},
  volume = {23},
  number = {4},
  pages = {879--885},
  issn = {1930-739X},
  doi = {10.1002/oby.21023},
  abstract = {OBJECTIVE: To determine the influence of the total cumulative exposure to excess overall and abdominal adiposity on the incidence of cardiovascular disease (CVD). METHODS: Prospective study of 4,061 white and black adults without CVD at baseline in 1985-1986 (age 18-30 years) from the multicenter, community-based CARDIA study. Time-varying excess body mass index (BMI)- and waist circumference (WC)-years were calculated as products of the degree and duration of excess overall (BMI\,{$\geq$}\,25 kg/m(2)) and abdominal adiposity [WC {$>$}94 cm (men) and {$>$}80 cm (women)], respectively, collected at up to eight examinations. RESULTS: During a median of 24.8 years, there were 125 incident CVD, 62 coronary heart disease (CHD), and 33 heart failure (HF) events. Adjusted hazard ratios for CVD, CHD, and HF for each additional 50 excess BMI-years were 1.20 (1.08, 1.34), 1.25 (1.07, 1.46), and 1.45 (1.23, 1.72), respectively. For each 50 excess WC-years, these hazard ratios were 1.10 (1.04, 1.18), 1.13 (1.03, 1.24), and 1.22 (1.11, 1.34), respectively. Akaike information criterion values were lowest in models containing time-varying excess BMI- or WC-years compared to those including time-varying BMI or WC only. CONCLUSIONS: Excess BMI- and WC-years are predictors of the risk of CVD and may provide a better indicator of the cumulative exposure to excess adiposity than BMI or WC only.},
  langid = {english},
  pmcid = {PMC4380633},
  pmid = {25755157},
  keywords = {Adult,Aged,Black People,Body Mass Index,Cardiovascular Diseases,Comorbidity,Coronary Artery Disease,Coronary Disease,Female,Follow-Up Studies,Heart Failure,Humans,Incidence,Male,Middle Aged,Obesity,Obesity Abdominal,Prospective Studies,Risk Factors,Waist Circumference,White People},
  file = {/Users/xx20081/Zotero/storage/ZYKPSERC/Reis et al. - 2015 - Excess body mass index- and waist circumference-ye.pdf}
}

@article{riceCirculatingActivitiesAngiotensinconverting2006,
  title = {Circulating Activities of Angiotensin-Converting Enzyme, Its Homolog, Angiotensin-Converting Enzyme 2, and Neprilysin in a Family Study},
  author = {Rice, Gillian I. and Jones, Amy L. and Grant, Peter J. and Carter, Angela M. and Turner, Anthony J. and Hooper, Nigel M.},
  year = {2006},
  month = nov,
  journal = {Hypertension (Dallas, Tex.: 1979)},
  volume = {48},
  number = {5},
  pages = {914--920},
  issn = {1524-4563},
  doi = {10.1161/01.HYP.0000244543.91937.79},
  abstract = {The renin-angiotensin system is a key regulator of blood pressure (BP), with inhibitors of angiotensin-converting enzyme (ACE) used clinically to treat hypertension and other cardiovascular conditions. ACE2 is a newly identified member of this system, which converts angiotensin II to angiotensin, and of which the occurrence in plasma has not been investigated. The aim of this study was to determine the heritability of circulating ACE, ACE2, and neprilysin (NEP), which may also be a regulator of BP, in a family study, and to determine covariates that contribute to the variation in plasma activity. ACE, ACE2, and NEP activities were measured in plasma from 534 subjects in the Leeds Family Study using selective fluorogenic substrates. Genetic factors accounted for 24.5\%, 67\%, and 22.7\% of the phenotypic variation in circulating ACE, ACE2, and NEP, respectively. ACE insertion/deletion polymorphism and other measured covariates accounted for 23.8\% of variance in circulating ACE. High-density lipoprotein cholesterol was a significant determinant of circulating ACE2. Measured covariates accounted for 17.3\% of variation in circulating NEP. ACE and NEP were associated with systolic and diastolic BP in univariate analyses; however, only ACE was independently associated with systolic and diastolic BP after accounting for covariates and shared childhood household.},
  langid = {english},
  pmid = {17000927},
  keywords = {Adult,Angiotensin-Converting Enzyme 2,Blood Pressure,Female,Genetic Predisposition to Disease,Humans,Hypertension,Male,Neprilysin,Pedigree,Peptidyl-Dipeptidase A,Sequence Homology Amino Acid},
  file = {/Users/xx20081/Zotero/storage/DFFA89CP/Rice et al. - 2006 - Circulating activities of angiotensin-converting e.pdf}
}

@article{robertsonHigherBodyMass2019,
  title = {Higher {{Body Mass Index}} in {{Adolescence Predicts Cardiomyopathy Risk}} in {{Midlife}}},
  author = {Robertson, Josefina and Schaufelberger, Maria and Lindgren, Martin and Adiels, Martin and Schi{\"o}ler, Linus and Tor{\'e}n, Kjell and McMurray, John and Sattar, Naveed and {\AA}berg, Maria and Rosengren, Annika},
  year = {2019},
  month = jul,
  journal = {Circulation},
  volume = {140},
  number = {2},
  pages = {117--125},
  issn = {1524-4539},
  doi = {10.1161/CIRCULATIONAHA.118.039132},
  abstract = {BACKGROUND: Modifiable lifestyle factors in relation to risk for cardiomyopathy, a common and increasing cause of heart failure in the young, have not been widely studied. We sought to investigate a potential link between obesity, a recognized predictor of early heart failure, in adolescence and being diagnosed with cardiomyopathy in adulthood. METHODS: This was a nationwide register-based prospective cohort study of 1\,668\,893 adolescent men (mean age, 18.3 years; SD, 0.7 years) who enlisted for compulsory military service from 1969 to 2005. At baseline, body mass index (BMI), blood pressure, and medical disorders were registered, along with test results for fitness and muscle strength. Cardiomyopathy diagnoses were identified from the National Hospital Register and Cause of Death Register during an up to 46-year follow-up and divided into categories: dilated, hypertrophic, alcohol/drug-induced, and other. Hazard ratios were calculated with Cox proportional hazards models. RESULTS: During follow-up (median, 27 years; Q1-Q3, 19-35 years), 4477 cases of cardiomyopathy were identified, of which 2631 (59\%) were dilated, 673 (15\%) were hypertrophic, and 480 (11\%) were alcohol/drug-induced. Increasing BMI was strongly associated with elevated risk of cardiomyopathy, especially dilated, starting at levels considered normal (BMI, 22.5-{$<$}25 kg/m2; hazard ratio, 1.38 [95\% CI, 1.22-1.57]), adjusted for age, year, center, and baseline comorbidities, and with a {$>$}8-fold increased risk at BMI {$\geq$}35 kg/m2 compared with BMI of 18.5 to {$<$}20 kg/m2. For each 1-unit increase in BMI, similarly adjusted hazard ratios were 1.15 (95\% CI, 1.14-1.17) for dilated cardiomyopathy, 1.09 (95\% CI, 1.06-1.12) for hypertrophic cardiomyopathy, and 1.10 (1.06-1.13) for alcohol/drug-induced cardiomyopathy. CONCLUSIONS: Even mildly elevated body weight in late adolescence may contribute to being diagnosed with cardiomyopathy in adulthood. The already marked importance of weight control in youth is further strengthened by these findings, as well as greater evidence for obesity as a potential important cause of adverse cardiac remodeling that is independent of clinically evident ischemic heart disease.},
  langid = {english},
  pmcid = {PMC6635044},
  pmid = {31132859},
  keywords = {adolescent,Adolescent,Adult,Body Mass Index,Body Weight,cardiomyopathies,Cardiomyopathies,Cohort Studies,Follow-Up Studies,Humans,Male,Middle Aged,obesity,Obesity,overweight,population groups,Predictive Value of Tests,Prospective Studies,Registries,Risk Factors,Sweden},
  file = {/Users/xx20081/Zotero/storage/SRN8Q7LV/Robertson et al. - 2019 - Higher Body Mass Index in Adolescence Predicts Car.pdf}
}

@article{robinson-cohenGenomeWideAssociationStudy2023,
  title = {Genome-{{Wide Association Study}} of {{CKD Progression}}},
  author = {{Robinson-Cohen}, Cassianne and Triozzi, Jefferson L. and Rowan, Bryce and He, Jing and Chen, Hua C. and Zheng, Neil S. and Wei, Wei-Qi and Wilson, Otis D. and Hellwege, Jacklyn N. and Tsao, Philip S. and Gaziano, J. Michael and Bick, Alexander and Matheny, Michael E. and Chung, Cecilia P. and Lipworth, Loren and Siew, Edward D. and Ikizler, T. Alp and Tao, Ran and Hung, Adriana M.},
  year = {2023},
  month = sep,
  journal = {Journal of the American Society of Nephrology: JASN},
  volume = {34},
  number = {9},
  pages = {1547--1559},
  issn = {1533-3450},
  doi = {10.1681/ASN.0000000000000170},
  abstract = {SIGNIFICANCE STATEMENT: Rapid progression of CKD is associated with poor clinical outcomes. Most previous studies looking for genetic factors associated with low eGFR have used cross-sectional data. The authors conducted a meta-analysis of genome-wide association studies of eGFR decline among 116,870 participants with CKD, focusing on longitudinal data. They identified three loci (two of them novel) associated with longitudinal eGFR decline. In addition to the known UMOD/PDILT locus, variants within BICC1 were associated with significant differences in longitudinal eGFR slope. Variants within HEATR4 also were associated with differences in eGFR decline, but only among Black/African American individuals without diabetes. These findings help characterize molecular mechanisms of eGFR decline in CKD and may inform new therapeutic approaches for progressive kidney disease. BACKGROUND: Rapid progression of CKD is associated with poor clinical outcomes. Despite extensive study of the genetics of cross-sectional eGFR, only a few loci associated with eGFR decline over time have been identified. METHODS: We performed a meta-analysis of genome-wide association studies of eGFR decline among 116,870 participants with CKD-defined by two outpatient eGFR measurements of {$<$}60 ml/min per 1.73 m 2 , obtained 90-365 days apart-from the Million Veteran Program and Vanderbilt University Medical Center's DNA biobank. The primary outcome was the annualized relative slope in outpatient eGFR. Analyses were stratified by ethnicity and diabetes status and meta-analyzed thereafter. RESULTS: In cross-ancestry meta-analysis, the strongest association was rs77924615, near UMOD / PDILT ; each copy of the G allele was associated with a 0.30\%/yr faster eGFR decline ( P = 4.9{\texttimes}10 -27 ). We also observed an association within BICC1 (rs11592748), where every additional minor allele was associated with a 0.13\%/yr slower eGFR decline ( P = 5.6{\texttimes}10 -9 ). Among participants without diabetes, the strongest association was the UMOD/PDILT variant rs36060036, associated with a 0.27\%/yr faster eGFR decline per copy of the C allele ( P = 1.9{\texttimes}10 -17 ). Among Black participants, a significantly faster eGFR decline was associated with variant rs16996674 near APOL1 (R 2 =0.29 with the G1 high-risk genotype); among Black participants with diabetes, lead variant rs11624911 near HEATR4 also was associated with a significantly faster eGFR decline. We also nominally replicated loci with known associations with eGFR decline, near PRKAG2, FGF5, and C15ORF54. CONCLUSIONS: Three loci were significantly associated with longitudinal eGFR change at genome-wide significance. These findings help characterize molecular mechanisms of eGFR decline and may contribute to the development of new therapeutic approaches for progressive CKD.},
  langid = {english},
  pmcid = {PMC10482057},
  pmid = {37261792},
  keywords = {Apolipoprotein L1,Cross-Sectional Studies,Disease Progression,Genome-Wide Association Study,Genotype,Glomerular Filtration Rate,Humans,Kidney,Protein Disulfide-Isomerases,Renal Insufficiency Chronic}
}

@article{robinson-cohenGenomeWideAssociationStudy2023a,
  title = {Genome-{{Wide Association Study}} of {{CKD Progression}}},
  author = {{Robinson-Cohen}, Cassianne and Triozzi, Jefferson L. and Rowan, Bryce and He, Jing and Chen, Hua C. and Zheng, Neil S. and Wei, Wei-Qi and Wilson, Otis D. and Hellwege, Jacklyn N. and Tsao, Philip S. and Gaziano, J. Michael and Bick, Alexander and Matheny, Michael E. and Chung, Cecilia P. and Lipworth, Loren and Siew, Edward D. and Ikizler, T. Alp and Tao, Ran and Hung, Adriana M.},
  year = {2023},
  month = sep,
  journal = {Journal of the American Society of Nephrology: JASN},
  volume = {34},
  number = {9},
  pages = {1547--1559},
  issn = {1533-3450},
  doi = {10.1681/ASN.0000000000000170},
  abstract = {SIGNIFICANCE STATEMENT: Rapid progression of CKD is associated with poor clinical outcomes. Most previous studies looking for genetic factors associated with low eGFR have used cross-sectional data. The authors conducted a meta-analysis of genome-wide association studies of eGFR decline among 116,870 participants with CKD, focusing on longitudinal data. They identified three loci (two of them novel) associated with longitudinal eGFR decline. In addition to the known UMOD/PDILT locus, variants within BICC1 were associated with significant differences in longitudinal eGFR slope. Variants within HEATR4 also were associated with differences in eGFR decline, but only among Black/African American individuals without diabetes. These findings help characterize molecular mechanisms of eGFR decline in CKD and may inform new therapeutic approaches for progressive kidney disease. BACKGROUND: Rapid progression of CKD is associated with poor clinical outcomes. Despite extensive study of the genetics of cross-sectional eGFR, only a few loci associated with eGFR decline over time have been identified. METHODS: We performed a meta-analysis of genome-wide association studies of eGFR decline among 116,870 participants with CKD-defined by two outpatient eGFR measurements of {$<$}60 ml/min per 1.73 m 2 , obtained 90-365 days apart-from the Million Veteran Program and Vanderbilt University Medical Center's DNA biobank. The primary outcome was the annualized relative slope in outpatient eGFR. Analyses were stratified by ethnicity and diabetes status and meta-analyzed thereafter. RESULTS: In cross-ancestry meta-analysis, the strongest association was rs77924615, near UMOD / PDILT ; each copy of the G allele was associated with a 0.30\%/yr faster eGFR decline ( P = 4.9{\texttimes}10 -27 ). We also observed an association within BICC1 (rs11592748), where every additional minor allele was associated with a 0.13\%/yr slower eGFR decline ( P = 5.6{\texttimes}10 -9 ). Among participants without diabetes, the strongest association was the UMOD/PDILT variant rs36060036, associated with a 0.27\%/yr faster eGFR decline per copy of the C allele ( P = 1.9{\texttimes}10 -17 ). Among Black participants, a significantly faster eGFR decline was associated with variant rs16996674 near APOL1 (R 2 =0.29 with the G1 high-risk genotype); among Black participants with diabetes, lead variant rs11624911 near HEATR4 also was associated with a significantly faster eGFR decline. We also nominally replicated loci with known associations with eGFR decline, near PRKAG2, FGF5, and C15ORF54. CONCLUSIONS: Three loci were significantly associated with longitudinal eGFR change at genome-wide significance. These findings help characterize molecular mechanisms of eGFR decline and may contribute to the development of new therapeutic approaches for progressive CKD.},
  langid = {english},
  pmcid = {PMC10482057},
  pmid = {37261792},
  keywords = {Apolipoprotein L1,Cross-Sectional Studies,Disease Progression,Genome-Wide Association Study,Genotype,Glomerular Filtration Rate,Humans,Kidney,Protein Disulfide-Isomerases,Renal Insufficiency Chronic}
}

@article{robinson-cohenGenomeWideAssociationStudy2023b,
  title = {Genome-{{Wide Association Study}} of {{CKD Progression}}},
  author = {{Robinson-Cohen}, Cassianne and Triozzi, Jefferson L. and Rowan, Bryce and He, Jing and Chen, Hua C. and Zheng, Neil S. and Wei, Wei-Qi and Wilson, Otis D. and Hellwege, Jacklyn N. and Tsao, Philip S. and Gaziano, J. Michael and Bick, Alexander and Matheny, Michael E. and Chung, Cecilia P. and Lipworth, Loren and Siew, Edward D. and Ikizler, T. Alp and Tao, Ran and Hung, Adriana M.},
  year = {2023},
  month = sep,
  journal = {Journal of the American Society of Nephrology},
  volume = {34},
  number = {9},
  pages = {1547},
  issn = {1046-6673},
  doi = {10.1681/ASN.0000000000000170},
  urldate = {2024-08-14},
  abstract = {Significance Statement~           Rapid progression of CKD is associated with poor clinical outcomes. Most previous studies looking for genetic factors associated with low eGFR have used cross-sectional data. The authors conducted a meta-analysis of genome-wide association studies of eGFR decline among 116,870 participants with CKD, focusing on longitudinal data. They identified three loci (two of them novel) associated with longitudinal eGFR decline. In addition to the known UMOD/PDILT locus, variants within BICC1 were associated with significant differences in longitudinal eGFR slope. Variants within HEATR4 also were associated with differences in eGFR decline, but only among Black/African American individuals without diabetes. These findings help characterize molecular mechanisms of eGFR decline in CKD and may inform new therapeutic approaches for progressive kidney disease.           Background~           Rapid progression of CKD is associated with poor clinical outcomes. Despite extensive study of the genetics of cross-sectional eGFR, only a few loci associated with eGFR decline over time have been identified.           Methods~           We performed a meta-analysis of genome-wide association studies of eGFR decline among 116,870 participants with CKD---defined by two outpatient eGFR measurements of {$<$}60 ml/min per 1.73 m2, obtained 90--365 days apart---from the Million Veteran Program and Vanderbilt University Medical Center's DNA biobank. The primary outcome was the annualized relative slope in outpatient eGFR. Analyses were stratified by ethnicity and diabetes status and meta-analyzed thereafter.           Results~           In cross-ancestry meta-analysis, the strongest association was rs77924615, near UMOD/PDILT; each copy of the G allele was associated with a 0.30\%/yr faster eGFR decline (P = 4.9{\texttimes}10-27). We also observed an association within BICC1 (rs11592748), where every additional minor allele was associated with a 0.13\%/yr slower eGFR decline (P = 5.6{\texttimes}10-9). Among participants without diabetes, the strongest association was the UMOD/PDILT variant rs36060036, associated with a 0.27\%/yr faster eGFR decline per copy of the C allele (P = 1.9{\texttimes}10-17). Among Black participants, a significantly faster eGFR decline was associated with variant rs16996674 near APOL1 (R2=0.29 with the G1 high-risk genotype); among Black participants with diabetes, lead variant rs11624911 near HEATR4 also was associated with a significantly faster eGFR decline. We also nominally replicated loci with known associations with eGFR decline, near PRKAG2, FGF5, and C15ORF54.           Conclusions~           Three loci were significantly associated with longitudinal eGFR change at genome-wide significance. These findings help characterize molecular mechanisms of eGFR decline and may contribute to the development of new therapeutic approaches for progressive CKD.                                          Visual Abstract                      Export},
  langid = {american},
  file = {/Users/xx20081/Zotero/storage/K8MMMCJF/genome_wide_association_study_of_ckd_progression.12.html}
}

@article{robinsonSelectionBiasMissing2014,
  title = {Selection Bias: {{A}} Missing Factor in the {{Obesity Paradox}} Debate},
  shorttitle = {Selection Bias},
  author = {Robinson, Whitney R. and Furberg, Helena and Banack, Hailey R.},
  year = {2014},
  month = mar,
  journal = {Obesity (Silver Spring, Md.)},
  volume = {22},
  number = {3},
  pages = {625},
  issn = {1930-7381},
  urldate = {2024-04-04},
  pmcid = {PMC4102427},
  pmid = {24738156},
  file = {/Users/xx20081/Zotero/storage/8Y9EZ24Z/Robinson et al. - 2014 - Selection bias A missing factor in the Obesity Pa.pdf}
}

@article{rodondiSubclinicalThyroidDysfunction2008,
  title = {Subclinical Thyroid Dysfunction, Cardiac Function, and the Risk of Heart Failure. {{The Cardiovascular Health}} Study},
  author = {Rodondi, Nicolas and Bauer, Douglas C. and Cappola, Anne R. and Cornuz, Jacques and Robbins, John and Fried, Linda P. and Ladenson, Paul W. and Vittinghoff, Eric and Gottdiener, John S. and Newman, Anne B.},
  year = {2008},
  month = sep,
  journal = {Journal of the American College of Cardiology},
  volume = {52},
  number = {14},
  pages = {1152--1159},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2008.07.009},
  abstract = {OBJECTIVES: The goal of this study was to determine whether subclinical thyroid dysfunction was associated with incident heart failure (HF) and echocardiogram abnormalities. BACKGROUND: Subclinical hypothyroidism and hyperthyroidism have been associated with cardiac dysfunction. However, long-term data on the risk of HF are limited. METHODS: We studied 3,044 adults{$>$}or=65 years of age who initially were free of HF in the Cardiovascular Health Study. We compared adjudicated HF events over a mean 12-year follow-up and changes in cardiac function over the course of 5 years among euthyroid participants, those with subclinical hypothyroidism (subdivided by thyroid-stimulating hormone [TSH] levels: 4.5 to 9.9, {$>$}or=10.0 mU/l), and those with subclinical hyperthyroidism. RESULTS: Over the course of 12 years, 736 participants developed HF events. Participants with TSH{$>$}or=10.0 mU/l had a greater incidence of HF compared with euthyroid participants (41.7 vs. 22.9 per 1,000 person years, p=0.01; adjusted hazard ratio: 1.88; 95\% confidence interval: 1.05 to 3.34). Baseline peak E velocity, which is an echocardiographic measurement of diastolic function associated with incident HF in the CHS cohort, was greater in those patients with TSH{$>$}or=10.0 mU/l compared with euthyroid participants (0.80 m/s vs. 0.72 m/s, p=0.002). Over the course of 5 years, left ventricular mass increased among those with TSH{$>$}or=10.0 mU/l, but other echocardiographic measurements were unchanged. Those patients with TSH 4.5 to 9.9 mU/l or with subclinical hyperthyroidism had no increase in risk of HF. CONCLUSIONS: Compared with euthyroid older adults, those adults with TSH{$>$}or=10.0 mU/l have a moderately increased risk of HF and alterations in cardiac function but not older adults with TSH{$<$}10.0 mU/l. Clinical trials should assess whether the risk of HF might be ameliorated by thyroxine replacement in individuals with TSH{$>$}or=10.0 mU/l.},
  langid = {english},
  pmcid = {PMC2874755},
  pmid = {18804743},
  keywords = {Aged,Aged 80 and over,Cohort Studies,Echocardiography,Female,Heart,Heart Failure,Heart Function Tests,Humans,Hyperthyroidism,Hypertrophy Left Ventricular,Hypothyroidism,Male,Risk Factors,Time Factors},
  file = {/Users/xx20081/Zotero/storage/MH33YHB8/Rodondi et al. - 2008 - Subclinical thyroid dysfunction, cardiac function,.pdf}
}

@article{rogersByBandStudyGastric2014,
  title = {The {{By-Band}} Study: Gastric Bypass or Adjustable Gastric Band Surgery to Treat Morbid Obesity: Study Protocol for a Multi-Centre Randomised Controlled Trial with an Internal Pilot Phase},
  shorttitle = {The {{By-Band}} Study},
  author = {Rogers, Chris A. and Welbourn, Richard and Byrne, James and Donovan, Jenny L. and Reeves, Barnaby C. and Wordsworth, Sarah and Andrews, Robert and Thompson, Janice L. and Roderick, Paul and Mahon, David and Noble, Hamish and Kelly, Jamie and Mazza, Graziella and Pike, Katie and Paramasivan, Sangeetha and Blencowe, Natalie and Perkins, Mary and Porter, Tanya and Blazeby, Jane M.},
  year = {2014},
  month = feb,
  journal = {Trials},
  volume = {15},
  pages = {53},
  issn = {1745-6215},
  doi = {10.1186/1745-6215-15-53},
  abstract = {BACKGROUND: The prevalence of severe and complex obesity is increasing worldwide and surgery may offer an effective and lasting treatment. Laparoscopic adjustable gastric band and Roux-en-Y gastric bypass surgery are the two main surgical procedures performed. DESIGN: This open parallel-group randomised controlled trial will compare the effectiveness, cost-effectiveness and acceptability of gastric band (Band) versus gastric bypass (Bypass) in adults with severe and complex obesity. It has an internal pilot phase (in two centres) with integrated qualitative research to establish effective and optimal methods for recruitment. Adults with a body mass index (BMI) of 40 kg/m2 or more, or a BMI of 35 kg/m2 or more and other co-morbidities will be recruited. At the end of the internal pilot the study will expand into more centres if the pre-set progression criteria of numbers and rates of eligible patients screened and randomised are met and if the expected rates of retention and adherence to treatment allocation are achieved. The trial will test the joint hypotheses that Bypass is non-inferior to Band with respect to more than 50\% excess weight loss and that Bypass is superior to Band with respect to health related quality of life (HRQOL, EQ-5D) at three years. Secondary outcomes include other weight loss measures, waist circumference and remission/resolution of co-morbidities; generic and symptom-specific HRQOL; nutritional blood test results; resource use; eating behaviours and adverse events. A core outcome set for reporting the results of obesity surgery will be developed and a systematic review of the evidence for sleeve gastrectomy undertaken to inform the main study design. DISCUSSION: By-Band is the first pragmatic study to compare the two most commonly performed bariatric surgical procedures for severe and complex obesity. The design will enable and empower surgeons to learn to recruit and participate in a randomised study. Early evidence shows that timely recruitment is possible. TRIAL REGISTRATION: Current Controlled Trials ISRCTN00786323.},
  langid = {english},
  pmcid = {PMC3942168},
  pmid = {24517309},
  keywords = {Body Mass Index,Clinical Protocols,Cost-Benefit Analysis,Equipment Design,Female,Gastric Bypass,Health Care Costs,Humans,Laparoscopy,Male,Obesity Morbid,Pilot Projects,Quality of Life,Research Design,Time Factors,Treatment Outcome,United Kingdom,Waist Circumference,Weight Loss},
  file = {/Users/xx20081/Zotero/storage/AVNDYVBJ/Rogers et al. - 2014 - The By-Band study gastric bypass or adjustable gastric band surgery to treat morbid obesity study.pdf}
}

@article{rogerTrendsHeartFailure2004,
  title = {Trends in Heart Failure Incidence and Survival in a Community-Based Population},
  author = {Roger, V{\'e}ronique L. and Weston, Susan A. and Redfield, Margaret M. and {Hellermann-Homan}, Jens P. and Killian, Jill and Yawn, Barbara P. and Jacobsen, Steven J.},
  year = {2004},
  month = jul,
  journal = {JAMA},
  volume = {292},
  number = {3},
  pages = {344--350},
  issn = {1538-3598},
  doi = {10.1001/jama.292.3.344},
  abstract = {CONTEXT: The epidemic of heart failure has yet to be fully investigated, and data on incidence, survival, and sex-specific temporal trends in community-based populations are limited. OBJECTIVE: To test the hypothesis that the incidence of heart failure has declined and survival after heart failure diagnosis has improved over time but that secular trends have diverged by sex. DESIGN, SETTING, AND PARTICIPANTS: Population-based cohort study using the resources of the Rochester Epidemiology Project conducted in Olmsted County, Minnesota. Patients were 4537 Olmsted County residents (57\% women; mean [SD] age, 74 [14] years) with a diagnosis of heart failure between 1979 and 2000. Framingham criteria and clinical criteria were used to validate the diagnosis MAIN OUTCOME MEASURES: Incidence of heart failure and survival after heart failure diagnosis. RESULTS: The incidence of heart failure was higher among men (378/100 000 persons; 95\% confidence interval [CI], 361-395 for men; 289/100 000 persons; 95\% CI, 277-300 for women) and did not change over time among men or women. After a mean follow-up of 4.2 years (range, 0-23.8 years), 3347 deaths occurred, including 1930 among women and 1417 among men. Survival after heart failure diagnosis was worse among men than women (relative risk, 1.33; 95\% CI, 1.24-1.43) but overall improved over time (5-year age-adjusted survival, 43\% in 1979-1984 vs 52\% in 1996-2000, P{$<$}.001). However, men and younger persons experienced larger survival gains, contrasting with less or no improvement for women and elderly persons. CONCLUSION: In this community-based cohort, the incidence of heart failure has not declined during 2 decades, but survival after onset of heart failure has increased overall, with less improvement among women and elderly persons.},
  langid = {english},
  pmid = {15265849},
  keywords = {Age Factors,Aged,Female,Heart Failure,Humans,Incidence,Male,Middle Aged,Minnesota,Poisson Distribution,Proportional Hazards Models,Risk,Sex Factors,Survival Analysis}
}

@article{rosengrenBodyWeightAdolescence2017,
  title = {Body Weight in Adolescence and Long-Term Risk of Early Heart Failure in Adulthood among Men in {{Sweden}}},
  author = {Rosengren, Annika and {\AA}berg, Maria and Robertson, Josefina and Waern, Margda and Schaufelberger, Maria and Kuhn, Georg and {\AA}berg, David and Schi{\"o}ler, Linus and Tor{\'e}n, Kjell},
  year = {2017},
  month = jun,
  journal = {European Heart Journal},
  volume = {38},
  number = {24},
  pages = {1926--1933},
  issn = {1522-9645},
  doi = {10.1093/eurheartj/ehw221},
  abstract = {AIMS: To study the relation between body mass index (BMI) in young men and risk of early hospitalization with heart failure. METHODS AND RESULTS: In a prospective cohort study, men from the Swedish Conscript Registry investigated 1968-2005 (n = 1 610 437; mean age, 18.6 years were followed 5-42 years (median, 23.0 years; interquartile range, 15.0-32.0), 5492 first hospitalizations for heart failure occurred (mean age at diagnosis, 46.6 (SD 8.0) years). Compared with men with a body mass index (BMI) of 18.5-20.0 kg/m2, men with a BMI 20.0-22.5 kg/m2 had an hazard ratio (HR) of 1.22 (95\% CI, 1.10-1.35), after adjustment for age, year of conscription, comorbidities at baseline, parental education, blood pressure, IQ, muscle strength, and fitness. The risk rose incrementally with increasing BMI such that men with a BMI of 30-35 kg/m2 had an adjusted HR of 6.47 (95\% CI, 5.39-7.77) and those with a BMI of {$\geq$}35 kg/m2 had an HR of 9.21 (95\% CI, 6.57-12.92). The multiple-adjusted risk of heart failure per 1 unit increase in BMI ranged from 1.06 (95\% CI, 1.02-1.11) in heart failure associated with valvular disease to 1.20 (95\% CI, 1.18-1.22) for cases associated with coronary heart disease, diabetes, or hypertension. CONCLUSION: We found a steeply rising risk of early heart failure detectable already at a normal body weight, increasing nearly 10-fold in the highest weight category. Given the current obesity epidemic, heart failure in the young may increase substantially in the future and physicians need to be aware of this.},
  langid = {english},
  pmcid = {PMC5837553},
  pmid = {27311731},
  keywords = {Adolescence,Adolescent,Adult,Blood Pressure,Body Mass Index,Body Weight,Educational Status,Epidemiology,Heart failure,Heart Failure,Hospital admission,Hospitalization,Humans,Incidence,Male,Middle Aged,Muscle Strength,Obesity,Physical Fitness,Prospective Studies,Risk Factors,Sweden,Young Adult},
  file = {/Users/xx20081/Zotero/storage/P8ZNI2QT/Rosengren et al. - 2017 - Body weight in adolescence and long-term risk of e.pdf}
}

@article{rpEdoxabanWarfarinPatients2013,
  title = {Edoxaban versus Warfarin in Patients with Atrial Fibrillation},
  author = {Rp, Giugliano and Ct, Ruff and E, Braunwald and Sa, Murphy and Sd, Wiviott and Jl, Halperin and Al, Waldo and Md, Ezekowitz and Ji, Weitz and J, {\v S}pinar and W, Ruzyllo and M, Ruda and Y, Koretsune and J, Betcher and M, Shi and Lt, Grip and Sp, Patel and I, Patel and Jj, Hanyok and M, Mercuri and Em, Antman},
  year = {2013},
  month = nov,
  journal = {The New England journal of medicine},
  volume = {369},
  number = {22},
  publisher = {N Engl J Med},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1310907},
  urldate = {2023-12-08},
  abstract = {Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 Clinica {\dots}},
  langid = {english},
  pmid = {24251359},
  file = {/Users/xx20081/Zotero/storage/C2TZBLPR/Rp et al. - 2013 - Edoxaban versus warfarin in patients with atrial f.pdf;/Users/xx20081/Zotero/storage/HC3SYRDU/24251359.html}
}

@article{rukavinamikusicRoleNatriureticPeptides2022,
  title = {Role of Natriuretic Peptides in the Cardiovascular-Adipose Communication: A Tale of Two Organs},
  shorttitle = {Role of Natriuretic Peptides in the Cardiovascular-Adipose Communication},
  author = {Rukavina Mikusic, Natalia Luc{\'i}a and Kouyoumdzian, Nicol{\'a}s Mart{\'i}n and Puy{\'o}, Ana Mar{\'i}a and Fern{\'a}ndez, Belisario Enrique and Choi, Marcelo Roberto},
  year = {2022},
  month = jan,
  journal = {Pflugers Archiv: European Journal of Physiology},
  volume = {474},
  number = {1},
  pages = {5--19},
  issn = {1432-2013},
  doi = {10.1007/s00424-021-02596-1},
  abstract = {Natriuretic peptides have long been known for their cardiovascular function. However, a growing body of evidence emphasizes the role of natriuretic peptides in the energy metabolism of several substrates in humans and animals, thus interrelating the heart, as an endocrine organ, with various insulin-sensitive tissues and organs such as adipose tissue, muscle skeletal, and liver. Adipose tissue dysfunction is associated with altered regulation of the natriuretic peptide system, also indicated as a natriuretic disability. Evidence points to a contribution of this natriuretic disability to the development of obesity, type 2 diabetes mellitus, and cardiometabolic complications; although the causal relationship is not fully understood at present. However, targeting the natriuretic peptide pathway may improve metabolic health in obesity and type 2 diabetes mellitus. This review will focus on the current literature on the metabolic functions of natriuretic peptides with emphasis on lipid metabolism and insulin sensitivity. Natriuretic peptide system alterations could be proposed as one of the linking mechanisms between adipose tissue dysfunction and cardiovascular disease.},
  langid = {english},
  pmid = {34173888},
  keywords = {Adipose tissue,Adipose Tissue,Animals,Cardiovascular Diseases,Cardiovascular System,Humans,Insulin resistance,Insulin Resistance,Lipid Metabolism,Natriuretic peptides,Natriuretic Peptides,Obesity}
}

@article{salahCausesHospitalizationUSA2021,
  title = {Causes of Hospitalization in the {{USA}} between 2005 and 2018},
  author = {Salah, Husam M and Minhas, Abdul Mannan Khan and Khan, Muhammad Shahzeb and Pandey, Ambarish and Michos, Erin D and Mentz, Robert J and Fudim, Marat},
  year = {2021},
  month = aug,
  journal = {European Heart Journal Open},
  volume = {1},
  number = {1},
  pages = {oeab001},
  issn = {2752-4191},
  doi = {10.1093/ehjopen/oeab001},
  urldate = {2024-08-06},
  abstract = {In this report, we identify the 10 most common causes of hospitalizations in the USA in 2005--2018 using the discharge data from the National Inpatient Sample database. We show that sepsis has been the leading cause of hospitalizations in the USA followed by heart failure, which has consistently been within the three most common causes of hospitalizations since 2005. In addition, we show a high burden of cardiovascular diseases as a cause of hospitalization over the study period with a consistent presence of cardiac arrhythmias as one of the top 10 causes of hospitalizations in the USA and emergence of acute myocardial infarction as one of the top 10 causes after 2014.},
  file = {/Users/xx20081/Zotero/storage/8IWS9MMI/Salah et al. - 2021 - Causes of hospitalization in the USA between 2005 .pdf;/Users/xx20081/Zotero/storage/UGCA8K3B/6294753.html}
}

@article{saleemPlasmaAminoAcid2021,
  title = {Plasma Amino Acid Metabolomic Pattern in Heart Failure Patients with Either Preserved or Reduced Ejection Fraction: {{The}} Relation to Established Risk Variables and Prognosis},
  shorttitle = {Plasma Amino Acid Metabolomic Pattern in Heart Failure Patients with Either Preserved or Reduced Ejection Fraction},
  author = {Saleem, Tahia H. and Algowhary, Magdy and Kamel, Fatma Elzahraa M and {El-Mahdy}, Reham I},
  year = {2021},
  journal = {Biomedical Chromatography},
  volume = {35},
  number = {7},
  pages = {e5012},
  issn = {1099-0801},
  doi = {10.1002/bmc.5012},
  urldate = {2025-06-11},
  abstract = {Communication between amino acids (AAs) and heart failure (HF) is unclear. We evaluate the plasma metabolomic profile of AAs in HF and its subgroups and association with clinical features. This is a case--control study in which 90 patients with HF, 63 with reduced ejection fraction (HFrEF) and 27 with preserved ejection fraction (HFpEF), were compared with 60 controls. The quantitative measurement of plasma concentrations of AA metabolites was performed using an AA analyzer. Compared with controls, HF patients had significantly higher levels of nine AAs and significantly lower levels of seven AAs. Leu, phenylalanine (Phe), and methionine (Met) were the independent predictors of HF that remained significant after adjustment for confounding factors in multivariate analysis. There was a significant difference in 10 AAs and some clinical features between HFpEF and HFrEF. The plasma levels of six AAs were significantly increased across the different New York Heart Association (NYHA) classes, (class II, class III, class IV) but they were not predictor of reduced EF and NYHA in multivariate regression analysis. There were significant associations between Leu, Phe, and Met with cardiovascular risk variables and prognosis. In conclusion, plasma Leu, Phe, and Met provide early prediction and prognostic values of HF. The plasma AAs could have significant impact on the risk-stratifying HFrEF and HFpEF and NYHA functional class but do not predict them.},
  copyright = {{\copyright} 2020 John Wiley \& Sons, Ltd.},
  langid = {english},
  keywords = {chromatography,heart failure,heart failure with preserved ejection fraction,heart failure with reduced ejection fraction,metabolomic profile,prediction},
  file = {/Users/xx20081/Zotero/storage/TETBBT8J/bmc.html}
}

@article{salihGenomeWideAssociationStudy2023,
  title = {Genome-{{Wide Association Study}} of {{Pericardial Fat Area}} in 28\,161 {{UK Biobank Participants}}},
  author = {Salih, Ahmed and Ardissino, Maddalena and Wagen, Aaron Z. and Bard, Andrew and Szabo, Liliana and Ryten, Mina and Petersen, Steffen E. and Altmann, Andr{\'e} and {Raisi-Estabragh}, Zahra},
  year = {2023},
  month = nov,
  journal = {Journal of the American Heart Association},
  volume = {12},
  number = {21},
  pages = {e030661},
  issn = {2047-9980},
  doi = {10.1161/JAHA.123.030661},
  abstract = {BACKGROUND Pericardial adipose tissue (PAT) is the visceral adipose tissue compartment surrounding the heart. Experimental and observational research has suggested that greater PAT deposition might mediate cardiovascular disease, independent of general or subcutaneous adiposity. We characterize the genetic architecture of adiposity-adjusted PAT and identify causal associations between PAT and adverse cardiac magnetic resonance imaging measures of cardiac structure and function in 28\,161 UK Biobank participants. METHODS AND RESULTS The PAT phenotype was extracted from cardiac magnetic resonance images using an automated image analysis tool previously developed and validated in this cohort. A genome-wide association study was performed with PAT area set as the phenotype, adjusting for age, sex, and other measures of obesity. Functional mapping and Bayesian colocalization were used to understand the biologic role of identified variants. Mendelian randomization analysis was used to examine potential causal links between genetically determined PAT and cardiac magnetic resonance-derived measures of left ventricular structure and function. We discovered 12 genome-wide significant variants, with 2 independent sentinel variants (rs6428792, P=4.20{\texttimes}10-9 and rs11992444, P=1.30{\texttimes}10-12) at 2 distinct genomic loci, that were mapped to 3 potentially causal genes: T-box transcription factor 15 (TBX15), tryptophanyl tRNA synthetase 2, mitochondrial (WARS2) and early B-cell factor-2 (EBF2) through functional annotation. Bayesian colocalization additionally suggested a role of RP4-712E4.1. Genetically predicted differences in adiposity-adjusted PAT were causally associated with adverse left ventricular remodeling. CONCLUSIONS This study provides insights into the genetic architecture determining differential PAT deposition, identifies causal links with left structural and functional parameters, and provides novel data about the pathophysiological importance of adiposity distribution.},
  langid = {english},
  pmcid = {PMC10727393},
  pmid = {37889180},
  keywords = {Adipose Tissue,Bayes Theorem,Biological Specimen Banks,cardiovascular disease,genome-wide association study,Genome-Wide Association Study,Humans,Intra-Abdominal Fat,Obesity,pericardial adipose tissue,Pericardium,T-Box Domain Proteins,United Kingdom},
  file = {/Users/xx20081/Zotero/storage/YEQEKRAX/Salih et al. - 2023 - Genome-Wide Association Study of Pericardial Fat A.pdf}
}

@article{sandersonMultivariableMendelianRandomization2021,
  title = {Multivariable {{Mendelian Randomization}} and {{Mediation}}},
  author = {Sanderson, Eleanor},
  year = {2021},
  month = feb,
  journal = {Cold Spring Harbor Perspectives in Medicine},
  volume = {11},
  number = {2},
  pages = {a038984},
  issn = {2157-1422},
  doi = {10.1101/cshperspect.a038984},
  urldate = {2024-04-18},
  abstract = {Mendelian randomization (MR) is the use of genetic variants associated with an exposure to estimate the causal effect of that exposure on an outcome. Mediation analysis is the method of decomposing the effects of an exposure on an outcome, which act directly, and those that act via mediating variables. These effects are decomposed through the use of multivariable analysis to estimate the causal effects between three types of variables: exposures, mediators, and an outcome. Multivariable MR (MVMR) is a recent extension to MR that uses genetic variants associated with multiple, potentially related exposures to estimate the effect of each exposure on a single outcome. MVMR allows for equivalent analysis to mediation within the MR framework and therefore can also be used to estimate mediation effects. This approach retains the benefits of using genetic instruments for causal inference, such as avoiding bias due to confounding, while allowing for estimation of the different effects required for mediation analysis. This review explains MVMR, what is estimated when one exposure is a mediator of another in an MVMR estimation, and how MR and MVMR can therefore be used to estimate mediated effects. This review then goes on to consider the advantages and limitations of using MR and MVMR to conduct mediation analysis.},
  pmcid = {PMC7849347},
  pmid = {32341063},
  file = {/Users/xx20081/Zotero/storage/AH7B4998/Sanderson - 2021 - Multivariable Mendelian Randomization and Mediatio.pdf}
}

@article{sandersonMultivariableMendelianRandomization2021a,
  title = {Multivariable {{Mendelian Randomization}} and {{Mediation}}},
  author = {Sanderson, Eleanor},
  year = {2021},
  month = feb,
  journal = {Cold Spring Harbor Perspectives in Medicine},
  volume = {11},
  number = {2},
  pages = {a038984},
  issn = {2157-1422},
  doi = {10.1101/cshperspect.a038984},
  urldate = {2024-09-13},
  abstract = {Mendelian randomization (MR) is the use of genetic variants associated with an exposure to estimate the causal effect of that exposure on an outcome. Mediation analysis is the method of decomposing the effects of an exposure on an outcome, which act directly, and those that act via mediating variables. These effects are decomposed through the use of multivariable analysis to estimate the causal effects between three types of variables: exposures, mediators, and an outcome. Multivariable MR (MVMR) is a recent extension to MR that uses genetic variants associated with multiple, potentially related exposures to estimate the effect of each exposure on a single outcome. MVMR allows for equivalent analysis to mediation within the MR framework and therefore can also be used to estimate mediation effects. This approach retains the benefits of using genetic instruments for causal inference, such as avoiding bias due to confounding, while allowing for estimation of the different effects required for mediation analysis. This review explains MVMR, what is estimated when one exposure is a mediator of another in an MVMR estimation, and how MR and MVMR can therefore be used to estimate mediated effects. This review then goes on to consider the advantages and limitations of using MR and MVMR to conduct mediation analysis.},
  pmcid = {PMC7849347},
  pmid = {32341063},
  file = {/Users/xx20081/Zotero/storage/DP63T7CE/Sanderson - 2021 - Multivariable Mendelian Randomization and Mediatio.pdf}
}

@article{sandhuObesityParadoxAtrial2016,
  title = {The 'obesity Paradox' in Atrial Fibrillation: Observations from the {{ARISTOTLE}} ({{Apixaban}} for {{Reduction}} in {{Stroke}} and {{Other Thromboembolic Events}} in {{Atrial Fibrillation}}) Trial},
  shorttitle = {The 'obesity Paradox' in Atrial Fibrillation},
  author = {Sandhu, Roopinder K. and Ezekowitz, Justin and Andersson, Ulrika and Alexander, John H. and Granger, Christopher B. and Halvorsen, Sigrun and Hanna, Michael and Hijazi, Ziad and Jansky, Petr and Lopes, Renato D. and Wallentin, Lars},
  year = {2016},
  month = oct,
  journal = {European Heart Journal},
  volume = {37},
  number = {38},
  pages = {2869--2878},
  issn = {1522-9645},
  doi = {10.1093/eurheartj/ehw124},
  abstract = {AIMS: The prognostic implication of adiposity on clinical outcomes in atrial fibrillation (AF) patients treated with oral anticoagulation is unclear. METHODS AND RESULTS: A total of 17 913 patients in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial had body mass index (BMI) measured at baseline. For the primary analysis, BMI was categorized as normal (18.5 to {$<$}25 kg/m2), overweight (25 to {$<$}30 kg/m2), and obese ({$\geq$}30 kg/m2). Waist circumference (WC) was defined as high if {$>$}102 cm for men and {$>$}88 cm in women. Outcomes were stroke or systemic embolism, a composite endpoint (stroke, systemic embolism, myocardial infarction, or all-cause mortality), all-cause mortality, and major bleeding. Cox models were used to estimate hazard ratios (HRs) and 95\% confidence intervals (CIs) across categories of BMI and WC adjusting for established risk factors and treatment allocation. At baseline, 4052 (22.6\%) patients had a normal BMI, 6702 (37.4\%) were overweight, and 7159 (40.0\%) were obese. In multivariable analyses, higher BMI was associated with a lower risk of all-cause mortality [overweight: HR 0.67 (95\% CI 0.59-0.78); obese: HR 0.63 (95\% CI 0.54-0.74), P {$<$} 0.0001] and the composite endpoint [overweight: HR 0.74 (95\% CI 0.65-0.84); obese: HR 0.68 (95\% CI 0.60-0.78), P {$<$} 0.0001] compared with normal BMI. In women, high WC was associated with a 31\% lower risk of all-cause mortality (P = 0.001), 27\% lower risk of the composite endpoint (P = 0.001), and 28\% lower risk of stroke or systemic embolism (P = 0.048) but not in men. There was no significant association between adiposity and major bleeding. CONCLUSION: In patients with AF treated with oral anticoagulants, higher BMI and WC are associated with a more favourable prognosis.},
  langid = {english},
  pmid = {27071819},
  keywords = {Adiposity,Anticoagulants,Atrial fibrillation,Atrial Fibrillation,Female,Humans,Male,Obesity,Outcomes,Pyrazoles,Pyridones,Stroke,Treatment Outcome,Warfarin},
  file = {/Users/xx20081/Zotero/storage/7GTU8SNQ/Sandhu et al. - 2016 - The 'obesity paradox' in atrial fibrillation obse.pdf}
}

@article{sanyalHypothyroidismObesityIntriguing2016,
  title = {Hypothyroidism and Obesity: {{An}} Intriguing Link},
  shorttitle = {Hypothyroidism and Obesity},
  author = {Sanyal, Debmalya and Raychaudhuri, Moutusi},
  year = {2016},
  journal = {Indian Journal of Endocrinology and Metabolism},
  volume = {20},
  number = {4},
  pages = {554--557},
  issn = {2230-8210},
  doi = {10.4103/2230-8210.183454},
  urldate = {2024-09-17},
  abstract = {According to common perception, hypothyroidism is held responsible for obesity. However, linking them causally is controversial. Overt hypothyroidism is associated with modest weight gain, but there is a lack of clarity regarding subclinical hypothyroidism. Novel view indicates that changes in thyroid-stimulating hormone (TSH) could well be secondary to obesity. The increasing prevalence of obesity further confounds definition of normal TSH range in population studies. Thyroid autoantibody status may help in establishing the diagnosis of subclinical hypothyroidism in obesity. High leptin levels may play a role in the hyperthyrotropinemia of obesity and also increase susceptibility to thyroid autoimmunity and subsequent hypothyroidism. There is at most a modest effect of L-T4 treatment in overt hypothyroidism in inducing weight loss; benefit in subclinical hypothyroidism is not established with no data supporting thyroid hormone use in euthyroid obese patients.},
  pmcid = {PMC4911848},
  pmid = {27366725},
  file = {/Users/xx20081/Zotero/storage/CVLPIA8H/Sanyal and Raychaudhuri - 2016 - Hypothyroidism and obesity An intriguing link.pdf}
}

@article{satoRevisitingObesityParadox2023,
  title = {Revisiting the Obesity Paradox in Heart Failure: What Is the Best Anthropometric Index to Gauge Obesity?},
  shorttitle = {Revisiting the Obesity Paradox in Heart Failure},
  author = {Sato, Ryosuke and Von Haehling, Stephan},
  year = {2023},
  month = apr,
  journal = {European Heart Journal},
  volume = {44},
  number = {13},
  pages = {1154--1156},
  issn = {0195-668X, 1522-9645},
  doi = {10.1093/eurheartj/ehad079},
  urldate = {2024-01-16},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/CSYNN8LP/Sato and Von Haehling - 2023 - Revisiting the obesity paradox in heart failure w.pdf}
}

@article{sattarCardiologyCommunityBegins2025,
  title = {The Cardiology Community Begins to Embrace Obesity as an Important Target for Cardiovascular Health},
  author = {Sattar, Naveed and Rutter, Martin K.},
  year = {2025},
  month = apr,
  journal = {PLOS Medicine},
  volume = {22},
  number = {4},
  pages = {e1004578},
  publisher = {Public Library of Science},
  issn = {1549-1676},
  doi = {10.1371/journal.pmed.1004578},
  urldate = {2025-05-20},
  abstract = {Naveed Sattar and Martin K Rutter discuss the contributory role of obesity in the development and progression of cardiovascular disease, and prospects for tackling the obesity epidemic.},
  langid = {english},
  keywords = {Cardiology,Cardiovascular disease risk,Cardiovascular diseases,Epidemiology,Heart failure,Obesity,Type 2 diabetes risk,Weight loss},
  file = {/Users/xx20081/Zotero/storage/UANSSMZC/Sattar and Rutter - 2025 - The cardiology community begins to embrace obesity as an important target for cardiovascular health.pdf}
}

@article{sattarCardiovascularMortalityKidney2021,
  title = {Cardiovascular, Mortality, and Kidney Outcomes with {{GLP-1}} Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Trials},
  shorttitle = {Cardiovascular, Mortality, and Kidney Outcomes with {{GLP-1}} Receptor Agonists in Patients with Type 2 Diabetes},
  author = {Sattar, Naveed and Lee, Matthew M. Y. and Kristensen, S{\o}ren L. and Branch, Kelley R. H. and Del Prato, Stefano and Khurmi, Nardev S. and Lam, Carolyn S. P. and Lopes, Renato D. and McMurray, John J. V. and Pratley, Richard E. and Rosenstock, Julio and Gerstein, Hertzel C.},
  year = {2021},
  month = oct,
  journal = {The Lancet. Diabetes \& Endocrinology},
  volume = {9},
  number = {10},
  pages = {653--662},
  issn = {2213-8595},
  doi = {10.1016/S2213-8587(21)00203-5},
  abstract = {BACKGROUND: GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists and whether benefits extend to exendin-4-based GLP-1 receptor remains uncertain. We aimed to meta-analyse the most up-to-date evidence on the cardiovascular benefits and risks of GLP-1 receptor agonists from outcome trials in patients with type 2 diabetes. METHODS: We did a meta-analysis, including new data from AMPLITUDE-O, using a random effects model to estimate overall hazard ratio (HR) for MACE; its components; all-cause mortality; hospital admission for heart failure; a composite kidney outcome consisting of development of macroalbuminuria, doubling of serum creatinine, or at least 40\% decline in estimated glomerular filtration rate (eGFR), kidney replacement therapy, or death due to kidney disease; worsening of kidney function, based on eGFR change; and odds ratios for key safety outcomes (severe hypoglycaemia, retinopathy, pancreatitis, and pancreatic cancer). We also examined MACE outcome in patient subgroups on the basis of MACE incidence rates in the placebo group, presence or absence of cardiovascular disease, HbA1c level, trial duration, treatment dosing interval, structural homology to human GLP-1 or exendin-4, BMI, age, and eGFR. We searched PubMed for eligible trials reporting MACE (ie, cardiovascular death, myocardial infarction, or stroke), up to June 9, 2021. We meta-analysed data from published randomised placebo-controlled trials testing either injectable or oral GLP-1 receptor agonists in patients with type 2 diabetes. We restricted the search to trials of more than 500 patients with a primary outcome that included cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. This meta-analysis was registered on PROSPERO, CRD42021259711. FINDINGS: Of 98 articles screened, eight trials comprising 60\,080 patients fulfilled the prespecified criteria and were included. Overall, GLP-1 receptor agonists reduced MACE by 14\% (HR 0{$\cdot$}86 [95\% CI 0{$\cdot$}80-0{$\cdot$}93]; p{$<$}0{$\cdot$}0001), with no significant heterogeneity across GLP-1 receptor agonist structural homology or eight other examined subgroups (all pinteraction{$\geq$}0{$\cdot$}14). GLP-1 receptor agonists reduced all-cause mortality by 12\% (HR 0{$\cdot$}88 [95\% CI 0{$\cdot$}82-0{$\cdot$}94]; p=0{$\cdot$}0001), hospital admission for heart failure by 11\% (HR 0{$\cdot$}89 [95\% CI 0{$\cdot$}82-0{$\cdot$}98]; p=0{$\cdot$}013), and the composite kidney outcome by 21\% (HR 0{$\cdot$}79 [95\% CI 0{$\cdot$}73-0{$\cdot$}87]; p{$<$}0{$\cdot$}0001), with no increase in risk of severe hypoglycaemia, retinopathy, or pancreatic adverse effects. In sensitivity analyses removing the only trial restricted to patients with an acute coronary syndrome (ELIXA), all benefits marginally increased, including the outcome of worsening of kidney function, based on eGFR change (HR 0{$\cdot$}82 [95\% CI 0{$\cdot$}69-0{$\cdot$}98]; p=0{$\cdot$}030). INTERPRETATION: GLP-1 receptor agonists, regardless of structural homology, reduced the risk of individual MACE components, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes. FUNDING: None.},
  langid = {english},
  pmid = {34425083},
  keywords = {Cardiovascular Diseases,Cardiovascular System,Diabetes Mellitus Type 2,Glucagon-Like Peptide-1 Receptor,Humans,Hypoglycemic Agents,Kidney},
  file = {/Users/xx20081/Zotero/storage/IG6R3T7S/Sattar et al. - 2021 - Cardiovascular, mortality, and kidney outcomes wit.pdf}
}

@article{sattarEstimatingDirectTissue2025,
  title = {Estimating Direct Tissue Effects versus Weight Loss Effects of Incretin-Based Drugs for Obesity on Various Chronic Conditions},
  author = {Sattar, Naveed and Lee, Matthew M. Y.},
  year = {2025},
  month = apr,
  journal = {The Lancet. Diabetes \& Endocrinology},
  volume = {13},
  number = {4},
  pages = {347--354},
  issn = {2213-8595},
  doi = {10.1016/S2213-8587(24)00363-2},
  abstract = {The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in major adverse cardiovascular events appear to be predominantly driven by the direct tissue effects of such drugs, the associated weight loss effects must be relevant to the benefits observed in other major outcomes, albeit to differing extents. In this Personal View, we draw on evidence to support that weight loss is at least partly responsible (albeit to differing extents) for the reported benefits of incretin-based drugs for obesity in people living with heart failure with preserved ejection fraction, hypertension, chronic kidney disease, and type 2 diabetes. Concurrently, we propose that drug-induced weight loss is largely responsible for the reported improvements in osteoarthritis, obstructive sleep apnoea, and metabolic dysfunction-associated steatohepatitis outcomes. However, more evidence is needed to solidify these observations, including, when possible, trials comparing the effects of incretin-based drugs for obesity with calorie-reduced diets on both outcomes and mechanistic pathways. Such evidence has implications for public health and the design of future trials of novel drugs for obesity.},
  langid = {english},
  pmid = {39870097},
  keywords = {Chronic Disease,Diabetes Mellitus Type 2,Humans,Incretins,Obesity,Weight Loss}
}

@article{sattarEstimatingDirectTissue2025a,
  title = {Estimating Direct Tissue Effects versus Weight Loss Effects of Incretin-Based Drugs for Obesity on Various Chronic Conditions},
  author = {Sattar, Naveed and Lee, Matthew M Y},
  year = {2025},
  month = apr,
  journal = {The Lancet Diabetes \& Endocrinology},
  volume = {13},
  number = {4},
  pages = {347--354},
  issn = {2213-8587},
  doi = {10.1016/S2213-8587(24)00363-2},
  urldate = {2025-06-03},
  abstract = {The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct effects of these drugs is the subject of intense interest. Although reductions in major adverse cardiovascular events appear to be predominantly driven by the direct tissue effects of such drugs, the associated weight loss effects must be relevant to the benefits observed in other major outcomes, albeit to differing extents. In this Personal View, we draw on evidence to support that weight loss is at least partly responsible (albeit to differing extents) for the reported benefits of incretin-based drugs for obesity in people living with heart failure with preserved ejection fraction, hypertension, chronic kidney disease, and type 2 diabetes. Concurrently, we propose that drug-induced weight loss is largely responsible for the reported improvements in osteoarthritis, obstructive sleep apnoea, and metabolic dysfunction-associated steatohepatitis outcomes. However, more evidence is needed to solidify these observations, including, when possible, trials comparing the effects of incretin-based drugs for obesity with calorie-reduced diets on both outcomes and mechanistic pathways. Such evidence has implications for public health and the design of future trials of novel drugs for obesity.},
  file = {/Users/xx20081/Zotero/storage/EX93ZH2P/S2213858724003632.html}
}

@article{sattarTreatingChronicDiseases2023,
  title = {Treating Chronic Diseases without Tackling Excess Adiposity Promotes Multimorbidity},
  author = {Sattar, Naveed and McMurray, John J V and McInnes, Iain B and Aroda, Vanita R and Lean, Mike E J},
  year = {2023},
  month = jan,
  journal = {The Lancet Diabetes \& Endocrinology},
  volume = {11},
  number = {1},
  pages = {58--62},
  issn = {2213-8587},
  doi = {10.1016/S2213-8587(22)00317-5},
  urldate = {2025-05-20},
  abstract = {Few people now reach old age without taking multiple drugs, often attending various clinics, and undergoing secondary or tertiary investigations. Most chronic conditions are, to differing extents, caused or exacerbated by excess adiposity, but weight management is rarely discussed or attempted for patients. Furthermore, progressive symptoms usually attributed to ageing (eg, musculoskeletal pains, fatigue, and breathlessness), and which create considerable health-care demands, can also be attributed to the accumulation of body fat over time. For many symptoms and diseases that are more frequently reported in people with excess adiposity (such as depression), there exist potentially multidirectional, causal relationships that generate a cycle of clinical and social deterioration. There is insufficient research on the effects of effective weight management on these clinically demanding, age and weight-mediated symptoms. Based on current evidence, we suggest that policy makers need to be more proactive in obesity prevention and effective weight management should receive research funding to match the search for novel therapeutics for secondary chronic diseases.},
  file = {/Users/xx20081/Zotero/storage/LILFV5IJ/Sattar et al. - 2023 - Treating chronic diseases without tackling excess adiposity promotes multimorbidity.pdf;/Users/xx20081/Zotero/storage/9XBVJ8L8/S2213858722003175.html}
}

@article{savjiAssociationObesityCardiometabolic2018,
  title = {The {{Association}} of {{Obesity}} and {{Cardiometabolic Traits With Incident~HFpEF}} and {{HFrEF}}},
  author = {Savji, Nazir and Meijers, Wouter C. and Bartz, Traci M. and Bhambhani, Vijeta and Cushman, Mary and Nayor, Matthew and Kizer, Jorge R. and Sarma, Amy and Blaha, Michael J. and Gansevoort, Ron T. and Gardin, Julius M. and Hillege, Hans L. and Ji, Fei and Kop, Willem J. and Lau, Emily S. and Lee, Douglas S. and Sadreyev, Ruslan and {van Gilst}, Wiek H. and Wang, Thomas J. and Zanni, Markella V. and Vasan, Ramachandran S. and Allen, Norrina B. and Psaty, Bruce M. and {van der Harst}, Pim and Levy, Daniel and Larson, Martin and Shah, Sanjiv J. and {de Boer}, Rudolf A. and Gottdiener, John S. and Ho, Jennifer E.},
  year = {2018},
  month = aug,
  journal = {JACC. Heart failure},
  volume = {6},
  number = {8},
  pages = {701--709},
  issn = {2213-1787},
  doi = {10.1016/j.jchf.2018.05.018},
  abstract = {OBJECTIVES: This study evaluated the associations of obesity and cardiometabolic traits with incident heart failure with preserved versus reduced ejection fraction (HFpEF vs. HFrEF). Given known sex differences in HF subtype, we examined men and women separately. BACKGROUND: Recent studies suggest that obesity confers greater risk of HFpEF versus HFrEF. Contributions of associated metabolic traits to HFpEF are less clear. METHODS: We studied 22,681 participants from 4 community-based cohorts followed for incident HFpEF versus HFrEF (ejection fraction {$\geq$}50\% vs.~{$<$}50\%). We evaluated the association of body mass index (BMI) and cardiometabolic traits with incident HF subtype using Cox models. RESULTS: The mean age was 60 {\textpm} 13 years, and 53\% were women. Over a median follow-up of 12 years, 628 developed incident HFpEF and 835 HFrEF. Greater BMI portended higher risk of HFpEF compared with HFrEF (hazard ratio [HR]: 1.34 per 1-SD increase in BMI; 95\% confidence interval [CI]: 1.24 to 1.45 vs. HR: 1.18; 95\% CI: 1.10 to 1.27). Similarly, insulin resistance (homeostatic model assessment of insulin resistance) was associated with HFpEF (HR: 1.20 per 1-SD; 95\% CI: 1.05 to 1.37), but not HFrEF (HR: 0.99; 95\% CI: 0.88 to 1.11; p~{$<$} 0.05 for difference HFpEF vs. HFrEF). We found that the differential association of BMI with HFpEF versus HFrEF was more pronounced among women (p for difference HFpEF vs. HFrEF~= 0.01) when compared with men (p~= 0.34). CONCLUSIONS: Obesity and related cardiometabolic traits including insulin resistance are more strongly associated with risk of future HFpEF versus HFrEF. The differential risk of HFpEF with obesity seems particularly pronounced among~women and may underlie sex differences in HF subtypes.},
  langid = {english},
  pmcid = {PMC6076337},
  pmid = {30007554},
  keywords = {Adult,Aged,Blood Glucose,Body Mass Index,Cholesterol,Cholesterol HDL,Female,heart failure,Heart Failure,HFpEF,Humans,Incidence,insulin resistance,Insulin Resistance,Male,Metabolic Syndrome,Middle Aged,obesity,Obesity,Proportional Hazards Models,sex differences,Sex Factors,Stroke Volume,Triglycerides},
  file = {/Users/xx20081/Zotero/storage/5792EA4G/Savji et al. - 2018 - The Association of Obesity and Cardiometabolic Tra.pdf}
}

@article{schindlerRelationshipIncreasingBody2006,
  title = {Relationship between Increasing Body Weight, Insulin Resistance, Inflammation, Adipocytokine Leptin, and Coronary Circulatory Function},
  author = {Schindler, Thomas H. and Cardenas, Jerson and Prior, John O. and Facta, Alvaro D. and Kreissl, Michael C. and Zhang, Xiao-Li and Sayre, James and Dahlbom, Magnus and Licinio, Julio and Schelbert, Heinrich R.},
  year = {2006},
  month = mar,
  journal = {Journal of the American College of Cardiology},
  volume = {47},
  number = {6},
  pages = {1188--1195},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2005.10.062},
  abstract = {OBJECTIVES: We sought to evaluate effects of obesity, insulin resistance, and inflammation on coronary circulatory function and its relationship to leptin plasma levels. BACKGROUND: It is not known whether obesity, commonly paralleled by insulin resistance, inflammation, and leptin, is independently associated with coronary circulatory dysfunction. METHODS: Myocardial blood flow (MBF) responses to cold pressor test (CPT) and pharmacologic vasodilation was measured with positron emission tomography and 13N-ammonia. Study participants were divided into three groups based on their body mass index (BMI, kg/m2): control, 20 {$<$} or = BMI {$<$}25 (n = 19); overweight, 25 {$<$} or = BMI {$<$}30 (n = 21); and obese, BMI {$>$}30 (n = 32). RESULTS: Body mass index was significantly correlated to the Homeostasis Model Assessment Index of insulin resistance and C-reactive protein levels (r = 0.60 and r = 0.47, p {$<$} 0.0001). Compared with control subjects, endothelium-related change in MBF (DeltaMBF) to CPT progressively declined in overweight and obese groups (0.32 +/- 0.09 vs. 0.21 +/- 0.19 and 0.07 +/- 0.16 ml/g/min; p {$<$} 0.03 and p {$<$} 0.0001). The dipyridamole-induced total vasodilator capacity was significantly lower in obese than in control subjects (1.77 +/- 0.51 vs. 2.04 +/- 0.37 ml/g/min, p {$<$} 0.02). On multivariate analysis, BMI (p {$<$} 0.012) and age (p {$<$} 0.035) were significant independent predictors of DeltaMBF. Finally, only in the obese group leptin plasma levels significantly correlated with DeltaMBF (r = 0.37, p {$<$} 0.036). CONCLUSIONS: Increased body weight is independently associated with abnormal coronary circulatory function that progresses from an impairment in endothelium-related coronary vasomotion in overweight individuals to an impairment of the total vasodilator capacity in obese individuals. The findings that elevated leptin plasma levels in patients that are obese might exert beneficial effects on the coronary endothelium to counterbalance the adverse effects of increases in body weight on coronary circulatory function should be tested.},
  langid = {english},
  pmid = {16545651},
  keywords = {Adult,Coronary Circulation,Female,Humans,Inflammation,Insulin Resistance,Leptin,Male,Obesity,Overweight},
  file = {/Users/xx20081/Zotero/storage/8FGJZWS5/Schindler et al. - 2006 - Relationship between increasing body weight, insul.pdf}
}

@article{schlingHumanAdiposeTissue2002,
  title = {Human Adipose Tissue Cells Keep Tight Control on the Angiotensin {{II}} Levels in Their Vicinity},
  author = {Schling, Petra and Sch{\"a}fer, Thorsten},
  year = {2002},
  month = dec,
  journal = {The Journal of Biological Chemistry},
  volume = {277},
  number = {50},
  pages = {48066--48075},
  issn = {0021-9258},
  doi = {10.1074/jbc.M204058200},
  abstract = {Human adipose tissue expresses all components necessary for the local production of angiotensin II, which has multiple functions in adipose tissue, ranging from regulation of local blood flow to complex influences on tissue homeostasis. Still the mechanisms controlling human adipose tissue angiotensin II concentrations are not yet known. We investigated whether angiotensin II is degraded by human primary cultured preadipocytes and adipocytes and which enzymes are responsible for its metabolism. Distinct but transient angiotensin II production was limited by degradation due to consecutive proteolytic cleavage by endopeptidase and aminopeptidase activities. The endopeptidase could be identified as neprilysin expressed on the surface of both preadipocytes and adipocytes. Degradation of angiotensin II was preceded by a lag phase that was considerably longer in preadipocytes. This time span could not be explained by an induction of neprilysin nor by an increase in its surface localization. Following the lag phase, adipocytes showed a higher degradation activity than preadipocytes as mirrored by increased neprilysin levels and activity measured in their membrane fractions. Our findings demonstrate that human preadipocytes and adipocytes differentially express functional neprilysin and aminopeptidase activity involved in the regulation of angiotensin II concentrations in human adipose tissue.},
  langid = {english},
  pmid = {12196514},
  keywords = {Adipocytes,Angiotensin II,Cells Cultured,Chromatography High Pressure Liquid,Humans,Hydrolysis,Immunoenzyme Techniques,Immunohistochemistry,Neprilysin},
  file = {/Users/xx20081/Zotero/storage/3HVW9R9X/Schling and Schfer - 2002 - Human adipose tissue cells keep tight control on t.pdf}
}

@article{schmidtGeneticDrugTarget2020,
  title = {Genetic Drug Target Validation Using {{Mendelian}} Randomisation},
  author = {Schmidt, Amand F. and Finan, Chris and {Gordillo-Mara{\~n}{\'o}n}, Maria and Asselbergs, Folkert W. and Freitag, Daniel F. and Patel, Riyaz S. and Tyl, Beno{\^i}t and Chopade, Sandesh and Faraway, Rupert and Zwierzyna, Magdalena and Hingorani, Aroon D.},
  year = {2020},
  month = jun,
  journal = {Nature Communications},
  volume = {11},
  number = {1},
  pages = {3255},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-020-16969-0},
  urldate = {2024-01-18},
  abstract = {Mendelian randomisation (MR) analysis is an important tool to elucidate the causal relevance of environmental and biological risk factors for disease. However, causal inference is undermined if genetic variants used to instrument a risk factor also influence alternative disease-pathways (horizontal pleiotropy). Here we report how the `no horizontal pleiotropy assumption' is strengthened when proteins are the risk factors of interest. Proteins are typically the proximal effectors of biological processes encoded in the genome. Moreover, proteins are the targets of most medicines, so MR studies of drug targets are becoming a fundamental tool in drug development. To enable such studies, we introduce a mathematical framework that contrasts MR analysis of proteins with that of risk factors located more distally in the causal chain from gene to disease. We illustrate key model decisions and introduce an analytical framework for maximising power and evaluating the robustness of analyses.},
  copyright = {2020 The Author(s)},
  langid = {english},
  keywords = {Drug development,Personalized medicine,Target validation},
  file = {/Users/xx20081/Zotero/storage/9MDIIWUS/Schmidt et al. - 2020 - Genetic drug target validation using Mendelian ran.pdf}
}

@article{schoelerParticipationBiasUK2023,
  title = {Participation Bias in the {{UK Biobank}} Distorts Genetic Associations and Downstream Analyses},
  author = {Schoeler, Tabea and Speed, Doug and Porcu, Eleonora and Pirastu, Nicola and Pingault, Jean-Baptiste and Kutalik, Zolt{\'a}n},
  year = {2023},
  month = jul,
  journal = {Nature Human Behaviour},
  volume = {7},
  number = {7},
  pages = {1216--1227},
  issn = {2397-3374},
  doi = {10.1038/s41562-023-01579-9},
  abstract = {While volunteer-based studies such as the UK Biobank have become the cornerstone of genetic epidemiology, the participating individuals are rarely representative of their target population. To evaluate the impact of selective participation, here we derived UK Biobank participation probabilities on the basis of 14 variables harmonized across the UK Biobank and a representative sample. We then conducted weighted genome-wide association analyses on 19 traits. Comparing the output from weighted genome-wide association analyses (neffective\,=\,94,643 to 102,215) with that from standard genome-wide association analyses (n\,=\,263,464 to 283,749), we found that increasing representativeness led to changes in SNP effect sizes and identified novel SNP associations for 12 traits. While heritability estimates were less impacted by weighting (maximum change in h2, 5\%), we found substantial discrepancies for genetic correlations (maximum change in rg, 0.31) and Mendelian randomization estimates (maximum change in {$\beta$}STD, 0.15) for socio-behavioural traits. We urge the field to increase representativeness in biobank samples, especially when studying genetic correlates of behaviour, lifestyles and social outcomes.},
  langid = {english},
  pmcid = {PMC10365993},
  pmid = {37106081},
  keywords = {Biological Specimen Banks,Genome-Wide Association Study,Humans,Phenotype,United Kingdom},
  file = {/Users/xx20081/Zotero/storage/STMIWUWA/Schoeler et al. - 2023 - Participation bias in the UK Biobank distorts gene.pdf}
}

@article{schoenfeldPartialResidualsProportional1982,
  title = {Partial Residuals for the Proportional Hazards Regression Model {\textbar} {{Biometrika}} {\textbar} {{Oxford Academic}}},
  author = {Schoenfeld, David},
  year = {1982},
  journal = {Biometrika},
  volume = {69},
  pages = {239--41},
  urldate = {2024-08-08},
  file = {/Users/xx20081/Zotero/storage/84H9TLWT/Partial residuals for the proportional hazards reg.pdf;/Users/xx20081/Zotero/storage/5X74ZHBR/243012.html}
}

@article{Schwartz2012,
  title = {Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome},
  author = {Schwartz, Gregory G. and Olsson, Anders G. and Abt, Markus and Ballantyne, Christie M. and Barter, Philip J. and Brumm, Jochen and Chaitman, Bernard R. and Holme, Ingar M. and Kallend, David and Leiter, Lawrence A. and Leitersdorf, Eran and McMurray, John J.V. and Mundl, Hardi and Nicholls, Stephen J. and Shah, Prediman K. and Tardif, Jean-Claude and Wright, R. Scott},
  year = {2012},
  month = nov,
  journal = {New England Journal of Medicine},
  volume = {367},
  number = {22},
  pages = {2089--2099},
  publisher = {New England Journal of Medicine (NEJM/MMS)},
  issn = {0028-4793},
  doi = {10.1056/NEJMOA1206797/SUPPL_FILE/NEJMOA1206797_DISCLOSURES.PDF},
  abstract = {BACKGROUND:In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes. METHODS:We randomly assigned 15,871 patients who had had a recent acute coronary syndrome to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, in addition to the best available evidence-based care. The primary efficacy end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation. RESULTS:At the time of randomization, the mean HDL cholesterol level was 42 mg per deciliter (1.1 mmol per liter), and the mean low-density lipoprotein (LDL) cholesterol level was 76 mg per deciliter (2.0 mmol per liter). Over the course of the trial, HDL cholesterol levels increased from baseline by 4 to 11\% in the placebo group and by 31 to 40\% in the dalcetrapib group. Dalcetrapib had a minimal effect on LDL cholesterol levels. Patients were followed for a median of 31 months. At a prespecified interim analysis that included 1135 primary end-point events (71\% of the projected total number), the independent data and safety monitoring board recommended termination of the trial for futility. As compared with placebo, dalcetrapib did not alter the risk of the primary end point (cumulative event rate, 8.0\% and 8.3\%, respectively; hazard ratio with dalcetrapib, 1.04; 95\% confidence interval, 0.93 to 1.16; P = 0.52) and did not have a significant effect on any component of the primary end point or total mortality. The median C-reactive protein level was 0.2 mg per liter higher and the mean systolic blood pressure was 0.6 mm Hg higher with dalcetrapib as compared with placebo (P{\textexclamdown}0.001 for both comparisons). CONCLUSIONS:In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. (Funded by F. Hoffmann-La Roche; dal-OUTCOMES ClinicalTrials.gov number, NCT00658515.) Copyright {\copyright} 2012 Massachusetts Medical Society.},
  pmid = {23126252}
}

@article{Scirica2013,
  title = {Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus},
  author = {Scirica, Benjamin M. and Bhatt, Deepak L. and Braunwald, Eugene and Steg, P. Gabriel and Davidson, Jaime and Hirshberg, Boaz and Ohman, Peter and Frederich, Robert and Wiviott, Stephen D. and Hoffman, Elaine B. and Cavender, Matthew A. and Udell, Jacob A. and Desai, Nihar R. and Mosenzon, Ofri and McGuire, Darren K. and Ray, Kausik K. and Leiter, Lawrence A. and Raz, Itamar},
  year = {2013},
  month = oct,
  journal = {The New England journal of medicine},
  volume = {369},
  number = {14},
  pages = {1317--1326},
  publisher = {N Engl J Med},
  issn = {1533-4406},
  doi = {10.1056/NEJMOA1307684},
  pmid = {23992601},
  keywords = {80 and over,Adamantane / adverse effects,Adamantane / analogs & derivatives*,Adamantane / therapeutic use,affs=[],affs=[]),Aged,Author(firstnames='A Castro',Author(firstnames='A',Author(firstnames='Akshay S',Author(firstnames='Alena',Author(firstnames='Alexandra',Author(firstnames='Alona',Author(firstnames='Angelo',Author(firstnames='Anthony',Author(firstnames='Armando',Author(firstnames='B E',Author(firstnames='B Gil',Author(firstnames='B J B',Author(firstnames='B P M',Author(firstnames='B',Author(firstnames='Basil',Author(firstnames='Benjamin M',Author(firstnames='Bernard',Author(firstnames='Boaz',Author(firstnames='C Aguilar',Author(firstnames='C Hernandez',Author(firstnames='C',Author(firstnames='Carlos',Author(firstnames='Chaicharn',Author(firstnames='Chern-En',Author(firstnames='Cheryl',Author(firstnames='Christina',Author(firstnames='Clifford',Author(firstnames='D C G',Author(firstnames='D E P',Author(firstnames='D Herrera',Author(firstnames='D Reyes',Author(firstnames='D',Author(firstnames='Daniel',Author(firstnames='Darren',Author(firstnames='David',Author(firstnames='Deborah',Author(firstnames='Deepak L',Author(firstnames='Diego',Author(firstnames='E Bayram',Author(firstnames='E Cardona',Author(firstnames='E Garcia',Author(firstnames='E Lopez',Author(firstnames='E R',Author(firstnames='E',Author(firstnames='Elaine',Author(firstnames='Eli',Author(firstnames='Elinor',Author(firstnames='Eran',Author(firstnames='Eric',Author(firstnames='Ernesto',Author(firstnames='Eugene',Author(firstnames='F Padilla',Author(firstnames='F',Author(firstnames='Felix',Author(firstnames='Freddy',Author(firstnames='Frederick',Author(firstnames='G Arroyo',Author(firstnames='G Llamas',Author(firstnames='G M Rojas',Author(firstnames='G Melendez',Author(firstnames='G Mendez',Author(firstnames='G Rivera',Author(firstnames='G',Author(firstnames='Grzegorz',Author(firstnames='Gyorgy',Author(firstnames='H A H',Author(firstnames='H J',Author(firstnames='H W O Roeters',Author(firstnames='H',Author(firstnames='Harald',Author(firstnames='I Rodriguez',Author(firstnames='I',Author(firstnames='Itamar',Author(firstnames='J Bruguera',Author(firstnames='J Chevaile',Author(firstnames='J Cruz',Author(firstnames='J Garcia',Author(firstnames='J Garza',Author(firstnames='J Gonzalez',Author(firstnames='J J',Author(firstnames='J M',Author(firstnames='J Nunez',Author(firstnames='J Perez',Author(firstnames='J Segura',Author(firstnames='J',Author(firstnames='Jaakko',Author(firstnames='Jacob A',Author(firstnames='Jaime A',Author(firstnames='Jaime E',Author(firstnames='Jane',Author(firstnames='Jindrich',Author(firstnames='Joel',Author(firstnames='John',Author(firstnames='Joost',Author(firstnames='Jose C',Author(firstnames='Jose',Author(firstnames='Joseph',Author(firstnames='K M P',Author(firstnames='K M Prasanna',Author(firstnames='K',Author(firstnames='Karin',Author(firstnames='Kausik K',Author(firstnames='Krysztof',Author(firstnames='Kyungah',Author(firstnames='L de Teresa',Author(firstnames='L',Author(firstnames='Lawrence',Author(firstnames='Leon',Author(firstnames='M Alcocer',Author(firstnames='M Lazaretti',Author(firstnames='M Odin de los Rios',Author(firstnames='M P M',Author(firstnames='M W J',Author(firstnames='M',Author(firstnames='Marina',Author(firstnames='Mark',Author(firstnames='Markku',Author(firstnames='Markus M',Author(firstnames='Matthew A',Author(firstnames='Michael',Author(firstnames='Michel',Author(firstnames='Michelle',Author(firstnames='Mikael',Author(firstnames='Mikalea',Author(firstnames='Mikhail',Author(firstnames='N Caracas',Author(firstnames='N Rodriguez',Author(firstnames='N',Author(firstnames='Natalia',Author(firstnames='Nayyar',Author(firstnames='Nihar',Author(firstnames='Norton J',Author(firstnames='O',Author(firstnames='Ofri',Author(firstnames='Oleg',Author(firstnames='P R',Author(firstnames='P',Author(firstnames='Patrick',Author(firstnames='Peter',Author(firstnames='Ph Gabriel',Author(firstnames='Piyamitr',Author(firstnames='R Burgos',Author(firstnames='R',Author(firstnames='Ramon',Author(firstnames='Reinhard',Author(firstnames='Richard',Author(firstnames='Robert',Author(firstnames='Ronald',Author(firstnames='S H K',Author(firstnames='S',Author(firstnames='Sandy',Author(firstnames='Scott',Author(firstnames='Sheryl',Author(firstnames='Solveig',Author(firstnames='Stefano',Author(firstnames='Stephen D',Author(firstnames='Suzanne',Author(firstnames='T',Author(firstnames='Timothy',Author(firstnames='Ton',Author(firstnames='U',Author(firstnames='V',Author(firstnames='Verner',Author(firstnames='W W',Author(firstnames='W',Author(firstnames='Wayne H-H',Author(firstnames='Weiping',Author(firstnames='Y',Author(firstnames='Young',Author(firstnames='Z',Benjamin M Scirica,Cardiovascular Diseases / epidemiology*,Cardiovascular Diseases / etiology,Cardiovascular Diseases / mortality,Clinical Trial,CollabAuthor(name='SAVOR-TIMI 53 Steering Committee and Investigators',Deepak L Bhatt,Diabetes Mellitus,Dipeptides / adverse effects,Dipeptides / therapeutic use*,Dipeptidyl-Peptidase IV Inhibitors / adverse effects,Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*,doi:10.1056/NEJMoa1307684,Double-Blind Method,equal<sub>c</sub>ontrib=False),equal<sub>c</sub>ontrib=False)],Female,Heart Failure / epidemiology,Hospitalization / statistics & numerical data,Humans,Hypoglycemia / chemically induced,Hypoglycemic Agents / adverse effects,Hypoglycemic Agents / therapeutic use*,initials='A',initials='AS',initials='B',initials='BE',initials='BJ',initials='BM',initials='BP',initials='C',initials='CE',initials='D',initials='DC',initials='DE',initials='DL',initials='E',initials='F',initials='G',initials='GM',initials='H',initials='HA',initials='HJ',initials='HW',initials='I',initials='J',initials='JA',initials='JC',initials='JE',initials='JJ',initials='K',initials='KK',initials='KM',initials='L',initials='Lde T',initials='M',initials='MA',initials='MM',initials='MO',initials='MP',initials='MW',initials='N',initials='NJ',initials='O',initials='P',initials='PG',initials='PR',initials='R',initials='S',initials='SD',initials='SH',initials='T',initials='U',initials='V',initials='W',initials='WH',initials='WW',initials='Y',initials='Z',investigators=[Author(firstnames='Eugene',iseditor=False,Kaplan-Meier Estimate,lastname='Abbott',lastname='Abhayaratna',lastname='Abrahamsen',lastname='Acevedo',lastname='Achyuthan',lastname='Adams',lastname='Adawi',lastname='Agous',lastname='Aguilar-Salinas',lastname='Aguirre',lastname='Albert',lastname='Albin',lastname='Allemant',lastname='Allison',lastname='Altschuller',lastname='Alvarado',lastname='Alvarisqueta',lastname='Alvarsson',lastname='Ambrosio',lastname='Amerena',lastname='Ametov',lastname='Amodeo',lastname='Anderson',lastname='Angesjo',lastname='Antonishen',lastname='Antsiferov',lastname='Aoki',lastname='Appel',lastname='Applegate',lastname='Arakaki',lastname='Arbanil',lastname='Ardissino',lastname='Arkhipov',lastname='Armaganijan',lastname='Aronoff',lastname='Arya',lastname='Atar',lastname='Atassi',lastname='Aude',lastname='Averkov',lastname='Avogaro',lastname='Awasty',lastname='Awtry',lastname='Baccaro',lastname='Bailey',lastname='Bajaj',lastname='Bako',lastname='Ballantyne',lastname='Bandeira',lastname='Banker',lastname='Bao',lastname='Baquerizo',lastname='Barker',lastname='Barnett',lastname='Bartkowiak',lastname='Bartolacci',lastname='Basart',lastname='Bayron',lastname='Beavins',lastname='Beberashvili',lastname='Bedard',lastname='Bell',lastname='Benchetrit',lastname='Benczur',lastname='Benitez-Colon',lastname='Benjamin',lastname='Benjasuratwong',lastname='Berg',lastname='Berger',lastname='Berglund',lastname='Berli',lastname='Berrospi',lastname='Betti',lastname='Bhargava',lastname='Bhatt',lastname='Bhorat',lastname='Bhupati',lastname='Bilazarian',lastname='Billing-Clason',lastname='Bilodeau',lastname='Biton',lastname='Blank',lastname='Blombery',lastname='Blonder',lastname='Bloomberg',lastname='Blumenthal',lastname='Boccalandro',lastname='Bodalia',lastname='Bogdanowicz',lastname='Boldueva',lastname='Bonnici',lastname='Borgencrantz',lastname='Borges',lastname='Borts',lastname='Bose',lastname='Brada',lastname='Bramucci',lastname='Braun',lastname='Braunwald',lastname='Bretton',lastname='Bretzel',lastname='Briones',lastname='Brito',lastname='Brosseau',lastname='Brown',lastname='Bruschetta',lastname='Brychta',lastname='Burgess',lastname='Busch',lastname='Buskila',lastname='Butcher',lastname='Byars',lastname='Cabral',lastname='Calabrese',lastname='Calatayud',lastname='Calderon',lastname='Calvert',lastname='Calvo',lastname='Camilo Vazquez',lastname='Cantu',lastname='Carr',lastname='Carrol',lastname='Casagrande',lastname='Casanova',lastname='Cash',lastname='Castro',lastname='Cavender',lastname='Cesar',lastname='Cha',lastname='Chacra',lastname='Chajek-Shaul',lastname='Chalavarya',lastname='Chandna',lastname='Chandrashekhar',lastname='Chapman',lastname='Chehayeb',lastname='Chen',lastname='Chiang',lastname='Chiasson',lastname='Chilka',lastname='Chinn',lastname='Chiu',lastname='Chochinov',lastname='Chochola',lastname='Chotinaiwattarakul',lastname='Christofferson',lastname='Chu',lastname='Chuang',lastname='Clark',lastname='Cobos',lastname='Codoceo',lastname='Cohen',lastname='Colquhoun',lastname='Comerota',lastname='Comulada-Rivera',lastname='Conde',lastname='Conradie',lastname='Conter',lastname='Conway',lastname='Corbalan',lastname='Corbett',lastname='Corey',lastname='Cortada',lastname='Couffinhal',lastname='Creevy',lastname='Cuadrado',lastname='Curiac',lastname='Cutuli',lastname='Dagogo-Jack',lastname='Dalby',lastname='Darawsha',lastname='Darius',lastname='Das',lastname='Dattani',lastname='Davidson',lastname='De Cosmo',lastname='de la Morera',lastname='de Looze',lastname='de Waard',lastname='Deerochanawong',lastname='Del Prato',lastname='Delgado',lastname='Dellborg',lastname='Demattia',lastname='Demchenko',lastname='Derwahl',lastname='Desai',lastname='Di Bartolo',lastname='Di Lorenzo',lastname='Diab',lastname='Diaczok',lastname='Diaz',lastname='Distiller',lastname='Dixon',lastname='Dong',lastname='Donovan',lastname='Dreval',lastname='Drozdiak',lastname='Duda',lastname='Dudas',lastname='Duengen',lastname='Dumas',lastname='Dworkin',lastname='Dzongowski',lastname='Ebrahim',lastname='Eder',lastname='Edwards',lastname='Eisner',lastname='Ekelund',lastname='Elbaz',lastname='Elbert',lastname='Eliaschewitz',lastname='Elinoff',lastname='Ellison',lastname='Ervin',lastname='Esperon',lastname='Evola',lastname='Extremera',lastname='Faller',lastname='Fares',lastname='Farias',lastname='Farnsworth',lastname='Fattore',lastname='Feinglos',lastname='Feldman',lastname='Felicio',lastname='Fendri',lastname='Ferenczi',lastname='Fernandez',lastname='Fialkow',lastname='Fink',lastname='First',lastname='Fiscella',lastname='Fischer',lastname='Fitt',lastname='Fitz-Patrick',lastname='Florenzano',lastname='Fortin',lastname='Fragoso',lastname='Franken',lastname='Frechtel',lastname='Frederich',lastname='French',lastname='Fretes',lastname='Frontoni',lastname='Fuchs',lastname='Furda',lastname='Gabovitch',lastname='Galyavich',lastname='Gamba',lastname='Garcia-Castillo',lastname='Gastman',lastname='Gaudet',lastname='Gavrisheva',lastname='Gelernt',lastname='Gelfand',lastname='George',lastname='Gersh',lastname='Gill',lastname='Gimness',lastname='Giusti',lastname='Glandt',lastname='Glover',lastname='Godoy',lastname='Gogia',lastname='Golebiowski',lastname='Gomis',lastname='Gonkel',lastname='Gonzalez Ortiz',lastname='Gonzalez-Campoy',lastname='Gonzalez',lastname='Goral',lastname='Gorman',lastname='Gottlieb',lastname='Grassia',lastname='Greenberger',lastname='Grineva',lastname='Groenemeijer',lastname='Grossman',lastname='Grunfeldova',lastname='Guerreros',lastname='Guimaraes Filho',lastname='Gupta',lastname='Gutmann',lastname='Gyimesi',lastname='Hack',lastname='Hagan',lastname='Hage-Korban',lastname='Hall',lastname='Halter',lastname='Hamann',lastname='Hamer',lastname='Hamoud',lastname='Hamroff',lastname='Handel',lastname='Hartman',lastname='Heller',lastname='Hemzsky',lastname='Henderson',lastname='Henry',lastname='Henson',lastname='Heredia',lastname='Hermida',lastname='Herrera',lastname='Hershon',lastname='Herskovits',lastname='Hetey',lastname='Hidvegi',lastname='Hirshberg',lastname='Hodson',lastname='Hoekstra',lastname='Hoffman',lastname='Hoogendijk',lastname='Horak',lastname='Horton',lastname='Hou',lastname='Houlden',lastname='House',lastname='Hradec',lastname='Hramiak',lastname='Hung',lastname='Huo',lastname='Ibarra',lastname='Illyes',lastname='Im',lastname='Imholz',lastname='Iqbal',lastname='Ison',lastname='Issa',lastname='Isserman',lastname='Iteld',lastname='Jain',lastname='Jayasinghe',lastname='Jermendy',lastname='Jia',lastname='Jiang',lastname='Jones',lastname='Jung',lastname='Kaasjager',lastname='Kabour',lastname='Kahn',lastname='Kandath',lastname='Karasova',lastname='Karnieli',lastname='Karpov',lastname='Kastelein',lastname='Kastelic',lastname='Kaster',lastname='Kay',lastname='Kaye',lastname='Keech',lastname='Kelsey',lastname='Kempler',lastname='Kentgens',lastname='Kereiakes',lastname='Kerenyi',lastname='Kerstein',lastname='Khalimov',lastname='Khovidhunkit',lastname='Kinstrey',lastname='Kislyak',lastname='Kiss',lastname='Klainman',lastname='Klausmann',lastname='Knobler',lastname='Kobalava',lastname='Kooy',lastname='Koranyi',lastname='Kose',lastname='Kosinski',lastname='Kotha',lastname='Kotova',lastname='Kouz',lastname='Kozman',lastname='Krause',lastname='Krempf',lastname='Krichmar',lastname='Kruik',lastname='Krzyzagorska',lastname='Kuanprasert',lastname='Kubica',lastname='Kucera',lastname='Kuesters',lastname='Kukharchuk',lastname='Kumar',lastname='Kundert',lastname='Kung',lastname='Kutner',lastname='Kuzmanic',lastname='La Greca',lastname='Laakso',lastname='Labonte',lastname='Labrador',lastname='Ladanyi',lastname='Lagrutta',lastname='Lai',lastname='Lam',lastname='Lambiase',lastname='Lamy',lastname='Landers',lastname='Lannemyr',lastname='Lano',lastname='Laothavorn',lastname='Larenas',lastname='Larnefeldt',lastname='LaRochelle-Gryseels',lastname='Lau',lastname='Leach',lastname='Leaes',lastname='Lee',lastname='Leeman',lastname='Lehman',lastname='Lei',lastname='Leiter',lastname='Leitersdorf',lastname='Lengyel',lastname='Leon',lastname='Lerch',lastname='Leu',lastname='Levin',lastname='Levinsky',lastname='Levy',lastname='Lewis',lastname='Li',lastname='Linderfalk',lastname='Lingan',lastname='Link',lastname='Lisson',lastname='Littlefield',lastname='Litwak',lastname='Llamas',lastname='Longshaw',lastname='Lonneborg',lastname='Lopez-Sendon',lastname='Lopez',lastname='Lorenc',lastname='Lorenzatti',lastname='Lowe',lastname='Lu',lastname='Lucero',lastname='Lukac',lastname='Lukyanov',lastname='Luquez',lastname='Ma',lastname='Machado',lastname='Mader',lastname='Maffei',lastname='Makan',lastname='Makkar',lastname='Malakhina',lastname='Mamanasiri',lastname='Mangoo-Karim',lastname='Mannucci',lastname='Manrique',lastname='Mansouri',lastname='Mardikar',lastname='Marechaud',lastname='Markus',lastname='Marmolejo',lastname='Martin',lastname='Martinez',lastname='Masmiquel',lastname='Matoltsy',lastname='Mauricio',lastname='Mazurek',lastname='McGill',lastname='McGuinn',lastname='McGuire',lastname='McKenzie',lastname='McKnight',lastname='McNally',lastname='Medina',lastname='Mehta',lastname='Menon',lastname='Mercado',lastname='Merlini',lastname='Middleton',lastname='Mier',lastname='Mihills',lastname='Mikulkova',lastname='Milek',lastname='Miller',lastname='Minchola',lastname='Minor',lastname='Mishra',lastname='Miszczyszyn',lastname='Mitha',lastname='Mkrtumyan',lastname='Mohiuddin',lastname='Mohr',lastname='Montana',lastname='Monyak',lastname='Mooe',lastname='Moore',lastname='Mora',lastname='Morin',lastname='Mosenzon',lastname='Moses',lastname='Mosseri',lastname='Mostel',lastname='Moulin',lastname='Moursi',lastname='Mudaliar',lastname='Mueller',lastname='Muirhead',lastname='Munoz',lastname='Mystkowski',lastname='Naplava',lastname='Narayan',lastname='Naygandhi',lastname='Nazeyrollas',lastname='Nesto',lastname='Nicolau',lastname='Nierop',lastname='Nieuwdorp',lastname='Nikas',lastname='Nikolsky',lastname='Nilsson',lastname='Nischik',lastname='Nitiyanant',lastname='Nortje',lastname='Oberoi',lastname='Ocampo',lastname='Odhav',lastname='Ohman',lastname='Okenka',lastname='Olsson',lastname='Opolski',lastname='Orlikova',lastname='Ortega',lastname='Osborne',lastname='Oschepkova',lastname='Osei',lastname='Ott',lastname='Oude Ophuis',lastname='Ouellet',lastname='Ovalle',lastname='Oznerova',lastname='Pacheco',lastname='Padayachee',lastname='Padilla',lastname='Panov',lastname='Paolasso',lastname='Papini',lastname='Parikh',lastname='Parreno',lastname='Paschen',lastname='Pasternak',lastname='Patel',lastname='Pavlickova',lastname='Pavlova',lastname='Pavlysh',lastname='Pavon',lastname='Pearce',lastname='Penzes',lastname='Perkins',lastname='Perlman',lastname='Perron',lastname='Petit',lastname='Piatti',lastname='Pieters',lastname='Pieterse',lastname='Pillai',lastname='Pillay',lastname='Pincetti',lastname='Pinto',lastname='Pistek',lastname='Pitts',lastname='Platt',lastname='Podlecki',lastname='Podzimek',lastname='Poirier',lastname='Polaszewska-Muszynska',lastname='Poling',lastname='Pollak',lastname='Pomiecko',lastname='Ponciano',lastname='Poonawala',lastname='Popeil',lastname='Popovtzer',lastname='Portilla',lastname='Potakowska',lastname='Powell',lastname='Pratipanawatr',lastname='Pratt',lastname='Prentiss',lastname='Presbitero',lastname='Price',lastname='Pricken',lastname='Prieto',lastname='Puig',lastname='Qureshi',lastname='Raad',lastname='Racicka',lastname='Raclavska',lastname='Raichlen',lastname='Raikhel',lastname='Rais',lastname='Raisinghani',lastname='Ramos',lastname='Ranjith',lastname='Rapi',lastname='Raskin',lastname='Rassi',lastname='Ray',lastname='Raz',lastname='Rea',lastname='Rebrov',lastname='Reddy',lastname='Redon',lastname='Reed',lastname='Reinhardt',lastname='Remmen',lastname='Rewa',lastname='Richwine',lastname='Rihacek',lastname='Rios',lastname='Riske',lastname='Rista',lastname='Robinson',lastname='Rodriguez',lastname='Rogers',lastname='Romanczuk',lastname='Ronner',lastname='Rosado',lastname='Rosas',lastname='Rosendorff',lastname='Rosinska-Migda',lastname='Rossi',lastname='Rost',lastname='Roth',lastname='Rozenman',lastname='Ruberg',lastname='Ruda',lastname='Ruff',lastname='Ruiz-Rivera',lastname='Ruiz',lastname='Rupka',lastname='Russo',lastname='Saavedra',lastname='Saba',lastname='Sabel',lastname='Sadikot',lastname='Salacata',lastname='Salinas',lastname='Salvioni',lastname='Samad',lastname='Sanchez',lastname='Sanderlin',lastname='Saniuk',lastname='Santos',lastname='Sarbochova',lastname='Sathe',lastname='Savin',lastname='Sazonova',lastname='Schaer',lastname='Schenkenberger',lastname='Schima',lastname='Schmid',lastname='Schmidt',lastname='Schneider',lastname='Sciborski',lastname='Scirica',lastname='Segura',lastname='Seide',lastname='Semenova',lastname='Shah',lastname='Shamanna',lastname='Shapiro',lastname='Sharda',lastname='Sharma',lastname='Sharp',lastname='Shestakova',lastname='Sheu',lastname='Shi',lastname='Shore',lastname='Shustov',lastname='Shyu',lastname='Siage',lastname='Sidorenko',lastname='Sidorowicz-Bialynicka',lastname='Sierra',lastname='Sigalas',lastname='Silverman',lastname='Silvestri',lastname='Simmons',lastname='Simon',lastname='Singh',lastname='Sjostrand',lastname='Skierkowska',lastname='Sklaver',lastname='Skopecek',lastname='Skorski',lastname='Smahelova',lastname='Smith',lastname='Smolenskaya',lastname='Soba Nouel',lastname='Sohal',lastname='Soltani',lastname='Soma Raju Bhupathiraju',lastname='Somaraju',lastname='Somogyi',lastname='Sonel',lastname='Sosale',lastname='Soucie',lastname='Sowinski',lastname='Speer',lastname='Spiering',lastname='Spinar',lastname='Spinarova',lastname='Srikanta',lastname='Srinivas',lastname='Sritara',lastname='Sritata',lastname='St Pierre',lastname='St-Maurice',lastname='Stachlewski',lastname='Stahre',lastname='Stamatin',lastname='Stasinska',lastname='Steele',lastname='Steg',lastname='Stegemoller',lastname='Steljes',lastname='Stern',lastname='Stich',lastname='Stonesifer',lastname='Strang',lastname='Strikwerda',lastname='Strojeck',lastname='Strojek',lastname='Strotmann',lastname='Sulistio',lastname='Sun',lastname='Suraamornkul',lastname='Sussex',lastname='Sussman',lastname='Svacina',lastname='Svensson',lastname='Syan',lastname='Sydo',lastname='Szto',lastname='Takacs',lastname='Takhar',lastname='Talano',lastname='Tam',lastname='Tan',lastname='Taylor',lastname='Teitelbaum',lastname='Tejada',lastname='The',lastname='Thomas',lastname='Tien',lastname='Ting',lastname='Tishler',lastname='Tobe',lastname='Tomlinson',lastname='Torres',lastname='Toursarkissian',lastname='Trevisan',lastname='Trzepla',lastname='Tsalihin',lastname='Tsang',lastname='Tschoepe',lastname='Tsur',lastname='Tuomilehto',lastname='Turner',lastname='Tytus',lastname='Tyurina',lastname='Udell',lastname='Ueng',lastname='Urbancova',lastname='Uzoaga',lastname='Uzunow',lastname='Valco',lastname='van Dijk',lastname='van Hessen',lastname='van Kempen',lastname='van Lennep',lastname='Vandorfi',lastname='Varleta',lastname='Varma',lastname='Vawda',lastname='Velasquez',lastname='Ver Lee',lastname='Villena-Chavez',lastname='Villena',lastname='Vita',lastname='Vlasicova',lastname='Voors-Pette',lastname='Vorokhobina',lastname='Voros',lastname='Wainstein',lastname='Wainwright',lastname='Walder',lastname='Wang',lastname='Ward',lastname='Wasserburger',lastname='Waszyrowski',lastname='Waxman',lastname='Wefald',lastname='Wei',lastname='Weinstock',lastname='Weiss',lastname='Wellmann',lastname='Wendisch',lastname='Wenzl-Bauer',lastname='Whittier',lastname='Williams',lastname='Willis',lastname='Wilson',lastname='Wing',lastname='Winkler',lastname='Witmann',lastname='Wiviott',lastname='Wojnowski',lastname='Woo',lastname='Wood',lastname='Wright',lastname='Wu',lastname='Wyne',lastname='Xu',lastname='Yagil',lastname='Yajnik',lastname='Yale',lastname='Yazdani',lastname='Yerushalmi',lastname='Yin',lastname='Young Chang',lastname='Zadra',lastname='Zahumensky',lastname='Zanella',lastname='Zarich',lastname='Zenari',lastname='Zengotita',lastname='Zhao',lastname='Zhelninova',lastname='Zheng',lastname='Zieve',lastname='Zigrang',lastname='Zimlichman',lastname='Zubiate',lastname="O'Connor",Male,MEDLINE,Middle Aged,Multicenter Study,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,Non-U.S. Gov't,Pancreatitis / chemically induced,Pancreatitis / epidemiology,Phase IV,pmid:23992601,PubMed Abstract,Randomized Controlled Trial,Research Support,suffix='2nd',suffix='3rd',suffix='Jr',suffix=None,Type 2 / complications,Type 2 / drug therapy*}
}

@misc{SemaglutideCardiovascularOutcomes,
  title = {Semaglutide and Cardiovascular Outcomes in Patients with Obesity and Prevalent Heart Failure: A Prespecified Analysis of the {{SELECT}} Trial - {{The Lancet}}},
  urldate = {2025-03-17},
  howpublished = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01498-3/fulltext},
  file = {/Users/xx20081/Zotero/storage/P8NJ8ZKZ/fulltext.html}
}

@misc{SensitivityAnalysesRobust,
  title = {Sensitivity {{Analyses}} for {{Robust Causal Inference}} from {{Mendelian Randomization Analyses}} with {{Multiple Genetic Variants}} - {{PubMed}}},
  urldate = {2024-04-11},
  howpublished = {https://pubmed.ncbi.nlm.nih.gov/27749700/}
}

@article{shahBodyMassIndex2014,
  title = {Body {{Mass Index}} and {{Mortality}} in {{Acutely Decompensated Heart Failure Across}} the {{World}}: {{A Global Obesity Paradox}}},
  shorttitle = {Body {{Mass Index}} and {{Mortality}} in {{Acutely Decompensated Heart Failure Across}} the {{World}}},
  author = {Shah, Ravi and Gayat, Etienne and Januzzi, James L. and Sato, Naoki and {Cohen-Solal}, Alain and {diSomma}, Salvatore and Fairman, Enrique and Harjola, Veli-Pekka and Ishihara, Shiro and Lassus, Johan and Maggioni, Aldo and Metra, Marco and Mueller, Christian and Mueller, Thomas and Parenica, Jiri and {Pascual-Figal}, Domingo and Peacock, William Frank and Spinar, Jindrich and {van Kimmenade}, Roland and Mebazaa, Alexandre},
  year = {2014},
  month = mar,
  journal = {Journal of the American College of Cardiology},
  volume = {63},
  number = {8},
  pages = {778--785},
  issn = {0735-1097},
  doi = {10.1016/j.jacc.2013.09.072},
  urldate = {2024-04-04},
  abstract = {Objectives This study sought to define the relationship between body mass index (BMI) and mortality in heart failure (HF) across the world and to identify specific groups in whom BMI may differentially mediate risk. Background Obesity is associated with incident HF, but it is paradoxically associated with better prognosis during chronic HF. Methods We studied 6,142 patients with acute decompensated HF from 12 prospective observational cohorts followed-up across 4 continents. Primary outcome was all-cause mortality. Cox proportional hazards models and net reclassification index described associations of BMI with all-cause mortality. Results Normal-weight patients (BMI 18.5 to 25 kg/m2) were older with more advanced HF and lower cardiometabolic risk. Despite worldwide heterogeneity in clinical features across obesity categories, a higher BMI remained associated with decreased 30-day and 1-year mortality (11\% decrease at 30 days; 9\% decrease at 1 year per 5 kg/m2; p~{$<~$}0.05), after adjustment for clinical risk. The BMI obtained at index admission provided effective 1-year risk reclassification beyond current markers of clinical risk (net reclassification index 0.119, p~{$<$} 0.001). Notably, the ``protective'' association of BMI with mortality was confined to persons with older age ({$>$}75 years; hazard ratio [HR]: 0.82; p~= 0.006), decreased cardiac function (ejection fraction~{$<$}50\%; HR: 0.85; p~{$<$} 0.001), no diabetes (HR: 0.86; p~{$<$} 0.001), and de novo HF (HR: 0.89; p~= 0.004). Conclusions A lower BMI is associated with age, disease severity, and a higher risk of death in acute decompensated HF. The ``obesity paradox'' is confined to older persons, with decreased cardiac function, less cardiometabolic illness, and recent-onset HF, suggesting that aging, HF severity/chronicity, and metabolism may explain the obesity paradox.},
  keywords = {heart failure,obesity,obesity paradox},
  file = {/Users/xx20081/Zotero/storage/VARL88E4/Shah et al. - 2014 - Body Mass Index and Mortality in Acutely Decompens.pdf;/Users/xx20081/Zotero/storage/R2HFWX3V/S0735109713062074.html}
}

@article{shahGenomewideAssociationMendelian2020,
  title = {Genome-Wide Association and {{Mendelian}} Randomisation Analysis Provide Insights into the Pathogenesis of Heart Failure},
  author = {Shah, Sonia and Henry, Albert and Roselli, Carolina and Lin, Honghuang and Sveinbj{\"o}rnsson, Gar{\dh}ar and Fatemifar, Ghazaleh and Hedman, {\AA}sa K. and Wilk, Jemma B. and Morley, Michael P. and Chaffin, Mark D. and Helgadottir, Anna and Verweij, Niek and Dehghan, Abbas and Almgren, Peter and Andersson, Charlotte and Aragam, Krishna G. and {\"A}rnl{\"o}v, Johan and Backman, Joshua D. and Biggs, Mary L. and Bloom, Heather L. and Brandimarto, Jeffrey and Brown, Michael R. and Buckbinder, Leonard and Carey, David J. and Chasman, Daniel I. and Chen, Xing and Chen, Xu and Chung, Jonathan and Chutkow, William and Cook, James P. and Delgado, Graciela E. and Denaxas, Spiros and Doney, Alexander S. and D{\"o}rr, Marcus and Dudley, Samuel C. and Dunn, Michael E. and Engstr{\"o}m, Gunnar and Esko, T{\~o}nu and Felix, Stephan B. and Finan, Chris and Ford, Ian and Ghanbari, Mohsen and Ghasemi, Sahar and Giedraitis, Vilmantas and Giulianini, Franco and Gottdiener, John S. and Gross, Stefan and Gu{\dh}bjartsson, Dan{\'i}el F. and Gutmann, Rebecca and Haggerty, Christopher M. and {van der Harst}, Pim and Hyde, Craig L. and Ingelsson, Erik and Jukema, J. Wouter and Kavousi, Maryam and Khaw, Kay-Tee and Kleber, Marcus E. and K{\o}ber, Lars and Koekemoer, Andrea and Langenberg, Claudia and Lind, Lars and Lindgren, Cecilia M. and London, Barry and Lotta, Luca A. and Lovering, Ruth C. and Luan, Jian'an and Magnusson, Patrik and Mahajan, Anubha and Margulies, Kenneth B. and M{\"a}rz, Winfried and Melander, Olle and Mordi, Ify R. and Morgan, Thomas and Morris, Andrew D. and Morris, Andrew P. and Morrison, Alanna C. and Nagle, Michael W. and Nelson, Christopher P. and Niessner, Alexander and Niiranen, Teemu and O'Donoghue, Michelle L. and Owens, Anjali T. and Palmer, Colin N. A. and Parry, Helen M. and Perola, Markus and {Portilla-Fernandez}, Eliana and Psaty, Bruce M. and {Regeneron Genetics Center} and Rice, Kenneth M. and Ridker, Paul M. and Romaine, Simon P. R. and Rotter, Jerome I. and Salo, Perttu and Salomaa, Veikko and {van Setten}, Jessica and Shalaby, Alaa A. and Smelser, Diane T. and Smith, Nicholas L. and Stender, Steen and Stott, David J. and Svensson, Per and Tammesoo, Mari-Liis and Taylor, Kent D. and {Teder-Laving}, Maris and Teumer, Alexander and Thorgeirsson, Gu{\dh}mundur and Thorsteinsdottir, Unnur and {Torp-Pedersen}, Christian and Trompet, Stella and Tyl, Benoit and Uitterlinden, Andre G. and Veluchamy, Abirami and V{\"o}lker, Uwe and Voors, Adriaan A. and Wang, Xiaosong and Wareham, Nicholas J. and Waterworth, Dawn and Weeke, Peter E. and Weiss, Raul and Wiggins, Kerri L. and Xing, Heming and {Yerges-Armstrong}, Laura M. and Yu, Bing and Zannad, Faiez and Zhao, Jing Hua and Hemingway, Harry and Samani, Nilesh J. and McMurray, John J. V. and Yang, Jian and Visscher, Peter M. and {Newton-Cheh}, Christopher and Malarstig, Anders and Holm, Hilma and Lubitz, Steven A. and Sattar, Naveed and Holmes, Michael V. and Cappola, Thomas P. and Asselbergs, Folkert W. and Hingorani, Aroon D. and Kuchenbaecker, Karoline and Ellinor, Patrick T. and Lang, Chim C. and Stefansson, Kari and Smith, J. Gustav and Vasan, Ramachandran S. and Swerdlow, Daniel I. and Lumbers, R. Thomas},
  year = {2020},
  month = jan,
  journal = {Nature Communications},
  volume = {11},
  number = {1},
  pages = {163},
  issn = {2041-1723},
  doi = {10.1038/s41467-019-13690-5},
  abstract = {Heart failure (HF) is a leading cause of morbidity and mortality worldwide. A small proportion of HF cases are attributable to monogenic cardiomyopathies and existing genome-wide association studies (GWAS) have yielded only limited insights, leaving the observed heritability of HF largely unexplained. We report results from a GWAS meta-analysis of HF comprising 47,309 cases and 930,014 controls. Twelve independent variants at 11 genomic loci are associated with HF, all of which demonstrate one or more associations with coronary artery disease (CAD), atrial fibrillation, or reduced left ventricular function, suggesting shared genetic aetiology. Functional analysis of non-CAD-associated loci implicate genes involved in cardiac development (MYOZ1, SYNPO2L), protein homoeostasis (BAG3), and cellular senescence (CDKN1A). Mendelian randomisation analysis supports causal roles for several HF risk factors, and demonstrates CAD-independent effects for atrial fibrillation, body mass index, and~hypertension. These findings extend our knowledge of the pathways underlying HF and may inform new therapeutic strategies.},
  langid = {english},
  pmcid = {PMC6952380},
  pmid = {31919418},
  keywords = {Adaptor Proteins Signal Transducing,Apoptosis Regulatory Proteins,Atrial Fibrillation,Cardiomyopathies,Carrier Proteins,Case-Control Studies,Coronary Artery Disease,Cyclin-Dependent Kinase Inhibitor p21,Genome-Wide Association Study,Heart Failure,Humans,Mendelian Randomization Analysis,Microfilament Proteins,Muscle Proteins,Risk Factors,Ventricular Function Left},
  file = {/Users/xx20081/Zotero/storage/2RNNXZUL/Shah et al. - 2020 - Genome-wide association and Mendelian randomisatio.pdf}
}

@article{shahGenomewideAssociationMendelian2020a,
  title = {Genome-Wide Association and {{Mendelian}} Randomisation Analysis Provide Insights into the Pathogenesis of Heart Failure},
  author = {Shah, Sonia and Henry, Albert and Roselli, Carolina and Lin, Honghuang and Sveinbj{\"o}rnsson, Gar{\dh}ar and Fatemifar, Ghazaleh and Hedman, {\AA}sa K. and Wilk, Jemma B. and Morley, Michael P. and Chaffin, Mark D. and Helgadottir, Anna and Verweij, Niek and Dehghan, Abbas and Almgren, Peter and Andersson, Charlotte and Aragam, Krishna G. and {\"A}rnl{\"o}v, Johan and Backman, Joshua D. and Biggs, Mary L. and Bloom, Heather L. and Brandimarto, Jeffrey and Brown, Michael R. and Buckbinder, Leonard and Carey, David J. and Chasman, Daniel I. and Chen, Xing and Chen, Xu and Chung, Jonathan and Chutkow, William and Cook, James P. and Delgado, Graciela E. and Denaxas, Spiros and Doney, Alexander S. and D{\"o}rr, Marcus and Dudley, Samuel C. and Dunn, Michael E. and Engstr{\"o}m, Gunnar and Esko, T{\~o}nu and Felix, Stephan B. and Finan, Chris and Ford, Ian and Ghanbari, Mohsen and Ghasemi, Sahar and Giedraitis, Vilmantas and Giulianini, Franco and Gottdiener, John S. and Gross, Stefan and Gu{\dh}bjartsson, Dan{\'i}el F. and Gutmann, Rebecca and Haggerty, Christopher M. and {van der Harst}, Pim and Hyde, Craig L. and Ingelsson, Erik and Jukema, J. Wouter and Kavousi, Maryam and Khaw, Kay-Tee and Kleber, Marcus E. and K{\o}ber, Lars and Koekemoer, Andrea and Langenberg, Claudia and Lind, Lars and Lindgren, Cecilia M. and London, Barry and Lotta, Luca A. and Lovering, Ruth C. and Luan, Jian'an and Magnusson, Patrik and Mahajan, Anubha and Margulies, Kenneth B. and M{\"a}rz, Winfried and Melander, Olle and Mordi, Ify R. and Morgan, Thomas and Morris, Andrew D. and Morris, Andrew P. and Morrison, Alanna C. and Nagle, Michael W. and Nelson, Christopher P. and Niessner, Alexander and Niiranen, Teemu and O'Donoghue, Michelle L. and Owens, Anjali T. and Palmer, Colin N. A. and Parry, Helen M. and Perola, Markus and {Portilla-Fernandez}, Eliana and Psaty, Bruce M. and Rice, Kenneth M. and Ridker, Paul M. and Romaine, Simon P. R. and Rotter, Jerome I. and Salo, Perttu and Salomaa, Veikko and {van Setten}, Jessica and Shalaby, Alaa A. and Smelser, Diane T. and Smith, Nicholas L. and Stender, Steen and Stott, David J. and Svensson, Per and Tammesoo, Mari-Liis and Taylor, Kent D. and {Teder-Laving}, Maris and Teumer, Alexander and Thorgeirsson, Gu{\dh}mundur and Thorsteinsdottir, Unnur and {Torp-Pedersen}, Christian and Trompet, Stella and Tyl, Benoit and Uitterlinden, Andre G. and Veluchamy, Abirami and V{\"o}lker, Uwe and Voors, Adriaan A. and Wang, Xiaosong and Wareham, Nicholas J. and Waterworth, Dawn and Weeke, Peter E. and Weiss, Raul and Wiggins, Kerri L. and Xing, Heming and {Yerges-Armstrong}, Laura M. and Yu, Bing and Zannad, Faiez and Zhao, Jing Hua and Hemingway, Harry and Samani, Nilesh J. and McMurray, John J. V. and Yang, Jian and Visscher, Peter M. and {Newton-Cheh}, Christopher and Malarstig, Anders and Holm, Hilma and Lubitz, Steven A. and Sattar, Naveed and Holmes, Michael V. and Cappola, Thomas P. and Asselbergs, Folkert W. and Hingorani, Aroon D. and Kuchenbaecker, Karoline and Ellinor, Patrick T. and Lang, Chim C. and Stefansson, Kari and Smith, J. Gustav and Vasan, Ramachandran S. and Swerdlow, Daniel I. and Lumbers, R. Thomas},
  year = {2020},
  month = jan,
  journal = {Nature Communications},
  volume = {11},
  number = {1},
  pages = {163},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-019-13690-5},
  urldate = {2024-02-04},
  abstract = {Heart failure (HF) is a leading cause of morbidity and mortality worldwide. A small proportion of HF cases are attributable to monogenic cardiomyopathies and existing genome-wide association studies (GWAS) have yielded only limited insights, leaving the observed heritability of HF largely unexplained. We report results from a GWAS meta-analysis of HF comprising 47,309 cases and 930,014 controls. Twelve independent variants at 11 genomic loci are associated with HF, all of which demonstrate one or more associations with coronary artery disease (CAD), atrial fibrillation, or reduced left ventricular function, suggesting shared genetic aetiology. Functional analysis of non-CAD-associated loci implicate genes involved in cardiac development (MYOZ1, SYNPO2L), protein homoeostasis (BAG3), and cellular senescence (CDKN1A). Mendelian randomisation analysis supports causal roles for several HF risk factors, and demonstrates CAD-independent effects for atrial fibrillation, body mass index, and~hypertension. These findings extend our knowledge of the pathways underlying HF and may inform new therapeutic strategies.},
  copyright = {2020 The Author(s)},
  langid = {english},
  keywords = {Cardiovascular genetics,Epidemiology,Genome-wide association studies,Heart failure},
  file = {/Users/xx20081/Zotero/storage/X7YZCEDZ/Shah et al. - 2020 - Genome-wide association and Mendelian randomisatio.pdf}
}

@article{shahGenomewideAssociationMendelian2020b,
  title = {Genome-Wide Association and {{Mendelian}} Randomisation Analysis Provide Insights into the Pathogenesis of Heart Failure},
  author = {Shah, Sonia and Henry, Albert and Roselli, Carolina and Lin, Honghuang and Sveinbj{\"o}rnsson, Gar{\dh}ar and Fatemifar, Ghazaleh and Hedman, {\AA}sa K. and Wilk, Jemma B. and Morley, Michael P. and Chaffin, Mark D. and Helgadottir, Anna and Verweij, Niek and Dehghan, Abbas and Almgren, Peter and Andersson, Charlotte and Aragam, Krishna G. and {\"A}rnl{\"o}v, Johan and Backman, Joshua D. and Biggs, Mary L. and Bloom, Heather L. and Brandimarto, Jeffrey and Brown, Michael R. and Buckbinder, Leonard and Carey, David J. and Chasman, Daniel I. and Chen, Xing and Chen, Xu and Chung, Jonathan and Chutkow, William and Cook, James P. and Delgado, Graciela E. and Denaxas, Spiros and Doney, Alexander S. and D{\"o}rr, Marcus and Dudley, Samuel C. and Dunn, Michael E. and Engstr{\"o}m, Gunnar and Esko, T{\~o}nu and Felix, Stephan B. and Finan, Chris and Ford, Ian and Ghanbari, Mohsen and Ghasemi, Sahar and Giedraitis, Vilmantas and Giulianini, Franco and Gottdiener, John S. and Gross, Stefan and Gu{\dh}bjartsson, Dan{\'i}el F. and Gutmann, Rebecca and Haggerty, Christopher M. and {van der Harst}, Pim and Hyde, Craig L. and Ingelsson, Erik and Jukema, J. Wouter and Kavousi, Maryam and Khaw, Kay-Tee and Kleber, Marcus E. and K{\o}ber, Lars and Koekemoer, Andrea and Langenberg, Claudia and Lind, Lars and Lindgren, Cecilia M. and London, Barry and Lotta, Luca A. and Lovering, Ruth C. and Luan, Jian'an and Magnusson, Patrik and Mahajan, Anubha and Margulies, Kenneth B. and M{\"a}rz, Winfried and Melander, Olle and Mordi, Ify R. and Morgan, Thomas and Morris, Andrew D. and Morris, Andrew P. and Morrison, Alanna C. and Nagle, Michael W. and Nelson, Christopher P. and Niessner, Alexander and Niiranen, Teemu and O'Donoghue, Michelle L. and Owens, Anjali T. and Palmer, Colin N. A. and Parry, Helen M. and Perola, Markus and {Portilla-Fernandez}, Eliana and Psaty, Bruce M. and Rice, Kenneth M. and Ridker, Paul M. and Romaine, Simon P. R. and Rotter, Jerome I. and Salo, Perttu and Salomaa, Veikko and {van Setten}, Jessica and Shalaby, Alaa A. and Smelser, Diane T. and Smith, Nicholas L. and Stender, Steen and Stott, David J. and Svensson, Per and Tammesoo, Mari-Liis and Taylor, Kent D. and {Teder-Laving}, Maris and Teumer, Alexander and Thorgeirsson, Gu{\dh}mundur and Thorsteinsdottir, Unnur and {Torp-Pedersen}, Christian and Trompet, Stella and Tyl, Benoit and Uitterlinden, Andre G. and Veluchamy, Abirami and V{\"o}lker, Uwe and Voors, Adriaan A. and Wang, Xiaosong and Wareham, Nicholas J. and Waterworth, Dawn and Weeke, Peter E. and Weiss, Raul and Wiggins, Kerri L. and Xing, Heming and {Yerges-Armstrong}, Laura M. and Yu, Bing and Zannad, Faiez and Zhao, Jing Hua and Hemingway, Harry and Samani, Nilesh J. and McMurray, John J. V. and Yang, Jian and Visscher, Peter M. and {Newton-Cheh}, Christopher and Malarstig, Anders and Holm, Hilma and Lubitz, Steven A. and Sattar, Naveed and Holmes, Michael V. and Cappola, Thomas P. and Asselbergs, Folkert W. and Hingorani, Aroon D. and Kuchenbaecker, Karoline and Ellinor, Patrick T. and Lang, Chim C. and Stefansson, Kari and Smith, J. Gustav and Vasan, Ramachandran S. and Swerdlow, Daniel I. and Lumbers, R. Thomas},
  year = {2020},
  month = jan,
  journal = {Nature Communications},
  volume = {11},
  number = {1},
  pages = {163},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-019-13690-5},
  urldate = {2025-01-15},
  abstract = {Heart failure (HF) is a leading cause of morbidity and mortality worldwide. A small proportion of HF cases are attributable to monogenic cardiomyopathies and existing genome-wide association studies (GWAS) have yielded only limited insights, leaving the observed heritability of HF largely unexplained. We report results from a GWAS meta-analysis of HF comprising 47,309 cases and 930,014 controls. Twelve independent variants at 11 genomic loci are associated with HF, all of which demonstrate one or more associations with coronary artery disease (CAD), atrial fibrillation, or reduced left ventricular function, suggesting shared genetic aetiology. Functional analysis of non-CAD-associated loci implicate genes involved in cardiac development (MYOZ1, SYNPO2L), protein homoeostasis (BAG3), and cellular senescence (CDKN1A). Mendelian randomisation analysis supports causal roles for several HF risk factors, and demonstrates CAD-independent effects for atrial fibrillation, body mass index, and~hypertension. These findings extend our knowledge of the pathways underlying HF and may inform new therapeutic strategies.},
  copyright = {2020 The Author(s)},
  langid = {english},
  keywords = {Cardiovascular genetics,Epidemiology,Genome-wide association studies,Heart failure},
  file = {/Users/xx20081/Zotero/storage/BYUZSD9X/Shah et al. - 2020 - Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis.pdf}
}

@article{shahImpairedFastingGlucose2014,
  title = {Impaired Fasting Glucose and Body Mass Index as Determinants of Mortality in {{ALLHAT}}: Is the Obesity Paradox Real?},
  shorttitle = {Impaired Fasting Glucose and Body Mass Index as Determinants of Mortality in {{ALLHAT}}},
  author = {Shah, Ravi V. and Abbasi, Siddique A. and Yamal, Jos{\'e}-Miguel and Davis, Barry R. and Barzilay, Joshua and Einhorn, Paula T. and Goldfine, Alison B. and {ALLHAT Collaborative Research Group}},
  year = {2014},
  month = jun,
  journal = {Journal of Clinical Hypertension (Greenwich, Conn.)},
  volume = {16},
  number = {6},
  pages = {451--458},
  issn = {1751-7176},
  doi = {10.1111/jch.12325},
  abstract = {Emerging literature suggests that obesity may be "protective" against mortality and cardiovascular outcomes, while dysglycemia may worsen outcomes regardless of obesity. The authors measured the association of weight, smoking, and glycemia with mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Among 5423 ALLHAT participants without established diabetes or cardiovascular disease, 3980 (73\%) had normal fasting glucose and 1443 (27\%) had impaired fasting glucose (IFG) levels at study entry. After a median of 4.9 years follow-up, 554 (10\%) had died (37\% cardiovascular). IFG was associated with higher all-cause mortality (adjusted hazard ratio [HR], 1.23; 95\% confidence interval [CI], 1.02-1.50), while obesity was associated with lower all-cause mortality (adjusted HR, 0.76; 95\% CI, 0.60-0.96). However, after excluding underweight individuals (body mass index [BMI] {$<$}22 kg/m(2) ) and smokers, neither obesity nor IFG was associated with all-cause mortality [corrected]. Although obesity appeared protective against mortality, this association was not significant in never-smokers or after exclusion of BMI {$<$}22 kg/m(2) . The obesity paradox may result from confounding by a sicker, underweight referent population and smoking.},
  langid = {english},
  pmcid = {PMC4091725},
  pmid = {24779706},
  keywords = {Aged,Antihypertensive Agents,Blood Glucose,Body Mass Index,Cause of Death,Double-Blind Method,Fasting,Female,Humans,Hypertension,Male,Middle Aged,Obesity,Prognosis,Survival Rate,United States},
  file = {/Users/xx20081/Zotero/storage/MY9BALZX/Shah et al. - 2014 - Impaired fasting glucose and body mass index as de.pdf}
}

@article{sharmaLiraglutideWeightLoss2018,
  title = {Liraglutide and Weight Loss among Patients with Advanced Heart Failure and a Reduced Ejection Fraction: Insights from the {{FIGHT}} Trial},
  shorttitle = {Liraglutide and Weight Loss among Patients with Advanced Heart Failure and a Reduced Ejection Fraction},
  author = {Sharma, Abhinav and Ambrosy, Andrew P. and DeVore, Adam D. and Margulies, Kenneth B. and McNulty, Steven E. and Mentz, Robert J. and Hernandez, Adrian F. and Michael Felker, Gary and Cooper, Lauren B. and Lala, Anuradha and Vader, Justin and Groake, John D. and Borlaug, Barry A. and Velazquez, Eric J.},
  year = {2018},
  month = dec,
  journal = {ESC heart failure},
  volume = {5},
  number = {6},
  pages = {1035--1043},
  issn = {2055-5822},
  doi = {10.1002/ehf2.12334},
  abstract = {AIMS: Obesity is present in up to 45\% of patients with heart failure (HF). Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, facilitates weight loss in obese patients. The efficacy of liraglutide as a weight loss agent among patients with HF and reduced ejection fraction (HFrEF) and a recent acute HF hospitalization remains unknown. METHODS AND RESULTS: The Functional Impact of GLP-1 for Heart Failure Treatment study randomized 300 patients with HFrEF (ejection fraction~{$\leq~$}40\%), both with and without diabetes and a recent HF hospitalization to liraglutide or placebo. The primary outcome for this post hoc analysis was the change in weight from baseline to last study visit. We conducted an 'on-treatment' analysis of patients with at least one follow-up visit on study drug (123 on liraglutide and 124 on placebo). The median age was 61~years, 21\% were female, and 69\% of patients had New York Heart Association functional Class III or IV symptoms. The median ejection fraction was 25\% (25th, 75th percentile 19-32\%). Liraglutide use was associated with a significant weight reduction [liraglutide -1.00~lbs vs. placebo 2.00~lbs; treatment difference -4.10~lbs; 95\% confidence interval (CI) -7.94, -0.25; P~=~0.0367; percentage treatment difference -2.07\%, 95\% CI -3.86, -0.28; P~=~0.0237]. Similar results were seen after multivariable adjustments. Liraglutide also significantly reduced triglyceride levels (liraglutide 7.5~mg/dL vs. placebo 12.0~mg/dL; treatment difference -33.1~mg/dL; 95\% CI -60.7, -5.6; P~=~0.019). CONCLUSIONS: Liraglutide is an efficacious weight loss agent in patients with HFrEF. These findings will require further exploration in a well-powered cardiovascular outcomes trial.},
  langid = {english},
  pmcid = {PMC6300815},
  pmid = {30120812},
  keywords = {Aged,Body Weight,Diabetes,Double-Blind Method,Drug Administration Schedule,Female,Follow-Up Studies,Heart failure,Heart Failure,Humans,Hypoglycemic Agents,Injections Subcutaneous,Liraglutide,Male,Middle Aged,Obesity,Stroke Volume,Treatment Outcome,Weight loss,Weight Loss},
  file = {/Users/xx20081/Zotero/storage/NVYMSVIZ/Sharma et al. - 2018 - Liraglutide and weight loss among patients with ad.pdf}
}

@article{sharmaMetaanalysisRelationBody2015,
  title = {Meta-Analysis of the Relation of Body Mass Index to All-Cause and Cardiovascular Mortality and Hospitalization in Patients with Chronic Heart Failure},
  author = {Sharma, Abhishek and Lavie, Carl J. and Borer, Jeffrey S. and Vallakati, Ajay and Goel, Sunny and {Lopez-Jimenez}, Francisco and {Arbab-Zadeh}, Armin and Mukherjee, Debabrata and Lazar, Jason M.},
  year = {2015},
  month = may,
  journal = {The American Journal of Cardiology},
  volume = {115},
  number = {10},
  pages = {1428--1434},
  issn = {1879-1913},
  doi = {10.1016/j.amjcard.2015.02.024},
  abstract = {Clinical studies have indicated the existence of an "obesity paradox" in patients with chronic heart failure (HF), that is, reduced mortality in patients who have elevated body mass index (BMI) scores compared with normal-weight reference groups. The aim of this study was to investigate the relation of BMI with all-cause and cardiovascular (CV) mortality and hospitalization in patients with chronic HF though a systematic review and meta-analysis of published research. PubMed, the Cumulative Index to Nursing and Allied Health Literature, Cochrane Central, Scopus, web of science and Embase were searched for studies reporting rates of total mortality, cardiac mortality, and risk for hospitalization in patients with HF in various BMI categories ({$<$}20 kg/m(2) [low], 20 to 24.9 kg/m(2) [normal reference], 25 to 29.9 kg/m(2) [overweight], 30 to 34.9 [obese], and {$\geq$}35 kg/m(2) [severely obese]). Event rates were compared using a forest plot of relative risk (RR) using a random-effects model assuming interstudy heterogeneity. Two study investigators independently reviewed the 124 reports retrieved and identified 6 for final analyses (n = 22,807). After a mean follow-up period of 2.85 years, the risk for adverse events was highest in patients with low BMIs: total mortality RR 1.27 (95\% confidence interval [CI] 1.17 to 1.37), CV mortality RR 1.20 (95\% CI 1.01 to 1.43), and hospitalization RR 1.19 (95\% CI 1.09 to 1.30). Risk for CV mortality and hospitalization was lowest in overweight patients (RR 0.79, 95\% CI 0.70 to 0.90, and RR 0.92, 95\% CI 0.86 to 0.97, respectively). Increasing degree of obesity failed to achieve a statistically significant effect on CV mortality (RR 0.82, 95\% CI 0.64 to 1.05, and RR 0.71, 95\% CI 0.50 to 1.01, for obese and severely obese, respectively) and on hospitalization (RR 0.99, 95\% CI 0.92 to 1.07, and RR 1.28, 95\% CI 0.88 to 1.87, for obese and severely obese, respectively). In conclusion, risk for total mortality and CV mortality and hospitalization was highest in patients with chronic HF who were underweight as defined by low BMI, whereas risk for CV mortality and hospitalization was lowest in overweight subjects.},
  langid = {english},
  pmid = {25772740},
  keywords = {Body Mass Index,Cause of Death,Global Health,Heart Failure,Hospitalization,Humans,Obesity,Survival Rate},
  file = {/Users/xx20081/Zotero/storage/G9ZWFLSX/Sharma et al. - 2015 - Meta-analysis of the relation of body mass index t.pdf}
}

@article{shrierReducingBiasDirected2008,
  title = {Reducing Bias through Directed Acyclic Graphs},
  author = {Shrier, Ian and Platt, Robert W.},
  year = {2008},
  month = oct,
  journal = {BMC Medical Research Methodology},
  volume = {8},
  number = {1},
  pages = {70},
  issn = {1471-2288},
  doi = {10.1186/1471-2288-8-70},
  urldate = {2024-08-13},
  abstract = {The objective of most biomedical research is to determine an unbiased estimate of effect for an exposure on an outcome, i.e. to make causal inferences about the exposure. Recent developments in epidemiology have shown that traditional methods of identifying confounding and adjusting for confounding may be inadequate.},
  keywords = {Causal Diagram,Causal Structure,Contact Sport,Directed Acyclic Graph,Previous Injury},
  file = {/Users/xx20081/Zotero/storage/56AMCAWS/Shrier and Platt - 2008 - Reducing bias through directed acyclic graphs.pdf}
}

@article{smithAssociationGenomewideVariation2010,
  title = {Association of Genome-Wide Variation with the Risk of Incident Heart Failure in Adults of {{European}} and {{African}} Ancestry: A Prospective Meta-Analysis from the Cohorts for Heart and Aging Research in Genomic Epidemiology ({{CHARGE}}) Consortium},
  shorttitle = {Association of Genome-Wide Variation with the Risk of Incident Heart Failure in Adults of {{European}} and {{African}} Ancestry},
  author = {Smith, Nicholas L. and Felix, Janine F. and Morrison, Alanna C. and Demissie, Serkalem and Glazer, Nicole L. and Loehr, Laura R. and Cupples, L. Adrienne and Dehghan, Abbas and Lumley, Thomas and Rosamond, Wayne D. and Lieb, Wolfgang and Rivadeneira, Fernando and Bis, Joshua C. and Folsom, Aaron R. and Benjamin, Emelia and Aulchenko, Yurii S. and Haritunians, Talin and Couper, David and Murabito, Joanne and Wang, Ying A. and Stricker, Bruno H. and Gottdiener, John S. and Chang, Patricia P. and Wang, Thomas J. and Rice, Kenneth M. and Hofman, Albert and Heckbert, Susan R. and Fox, Ervin R. and O'Donnell, Christopher J. and Uitterlinden, Andre G. and Rotter, Jerome I. and Willerson, James T. and Levy, Daniel and {van Duijn}, Cornelia M. and Psaty, Bruce M. and Witteman, Jacqueline C. M. and Boerwinkle, Eric and Vasan, Ramachandran S.},
  year = {2010},
  month = jun,
  journal = {Circulation. Cardiovascular Genetics},
  volume = {3},
  number = {3},
  pages = {256--266},
  issn = {1942-3268},
  doi = {10.1161/CIRCGENETICS.109.895763},
  abstract = {BACKGROUND: Although genetic factors contribute to the onset of heart failure (HF), no large-scale genome-wide investigation of HF risk has been published to date. We have investigated the association of 2,478,304 single-nucleotide polymorphisms with incident HF by meta-analyzing data from 4 community-based prospective cohorts: the Atherosclerosis Risk in Communities Study, the Cardiovascular Health Study, the Framingham Heart Study, and the Rotterdam Study. METHODS AND RESULTS: Eligible participants for these analyses were of European or African ancestry and free of clinical HF at baseline. Each study independently conducted genome-wide scans and imputed data to the approximately 2.5 million single-nucleotide polymorphisms in HapMap. Within each study, Cox proportional hazards regression models provided age- and sex-adjusted estimates of the association between each variant and time to incident HF. Fixed-effect meta-analyses combined results for each single-nucleotide polymorphism from the 4 cohorts to produce an overall association estimate and P value. A genome-wide significance P value threshold was set a priori at 5.0x10(-7). During a mean follow-up of 11.5 years, 2526 incident HF events (12\%) occurred in 20 926 European-ancestry participants. The meta-analysis identified a genome-wide significant locus at chromosomal position 15q22 (1.4x10(-8)), which was 58.8 kb from USP3. Among 2895 African-ancestry participants, 466 incident HF events (16\%) occurred during a mean follow-up of 13.7 years. One genome-wide significant locus was identified at 12q14 (6.7x10(-8)), which was 6.3 kb from LRIG3. CONCLUSIONS: We identified 2 loci that were associated with incident HF and exceeded genome-wide significance. The findings merit replication in other community-based settings of incident HF.},
  langid = {english},
  pmcid = {PMC3025695},
  pmid = {20445134},
  keywords = {Aged,Aged 80 and over,Black or African American,Cohort Studies,Endopeptidases,Female,Genome-Wide Association Study,Heart Failure,Humans,Incidence,Male,Middle Aged,Polymorphism Single Nucleotide,Risk,Ubiquitin-Specific Proteases,White People},
  file = {/Users/xx20081/Zotero/storage/I2EUT8EK/Smith et al. - 2010 - Association of genome-wide variation with the risk.pdf}
}

@article{smithDiscoveryGeneticVariation2016,
  title = {Discovery of {{Genetic Variation}} on {{Chromosome}} 5q22 {{Associated}} with {{Mortality}} in {{Heart Failure}}},
  author = {Smith, J. Gustav and Felix, Janine F. and Morrison, Alanna C. and Kalogeropoulos, Andreas and Trompet, Stella and Wilk, Jemma B. and Gidl{\"o}f, Olof and Wang, Xinchen and Morley, Michael and Mendelson, Michael and Joehanes, Roby and Ligthart, Symen and Shan, Xiaoyin and Bis, Joshua C. and Wang, Ying A. and Sj{\"o}gren, Marketa and Ngwa, Julius and Brandimarto, Jeffrey and Stott, David J. and Aguilar, David and Rice, Kenneth M. and Sesso, Howard D. and Demissie, Serkalem and Buckley, Brendan M. and Taylor, Kent D. and Ford, Ian and Yao, Chen and Liu, Chunyu and Consortium, Charge-Scd and Consortium, EchoGen and Consortium, Qt-Igc and Consortium, Charge-Qrs and Sotoodehnia, Nona and van der Harst, Pim and Stricker, Bruno H. Ch and Kritchevsky, Stephen B. and Liu, Yongmei and Gaziano, J. Michael and Hofman, Albert and Moravec, Christine S. and Uitterlinden, Andr{\'e} G. and Kellis, Manolis and van Meurs, Joyce B. and Margulies, Kenneth B. and Dehghan, Abbas and Levy, Daniel and Olde, Bj{\"o}rn and Psaty, Bruce M. and Cupples, L. Adrienne and Jukema, J. Wouter and Djousse, Luc and Franco, Oscar H. and Boerwinkle, Eric and Boyer, Laurie A. and {Newton-Cheh}, Christopher and Butler, Javed and Vasan, Ramachandran S. and Cappola, Thomas P. and Smith, Nicholas L.},
  year = {2016},
  month = may,
  journal = {PLOS Genetics},
  volume = {12},
  number = {5},
  pages = {e1006034},
  publisher = {Public Library of Science},
  issn = {1553-7404},
  doi = {10.1371/journal.pgen.1006034},
  urldate = {2025-01-06},
  abstract = {Failure of the human heart to maintain sufficient output of blood for the demands of the body, heart failure, is a common condition with high mortality even with modern therapeutic alternatives. To identify molecular determinants of mortality in patients with new-onset heart failure, we performed a meta-analysis of genome-wide association studies and follow-up genotyping in independent populations. We identified and replicated an association for a genetic variant on chromosome 5q22 with 36\% increased risk of death in subjects with heart failure (rs9885413, P = 2.7x10-9). We provide evidence from reporter gene assays, computational predictions and epigenomic marks that this polymorphism increases activity of an enhancer region active in multiple human tissues. The polymorphism was further reproducibly associated with a DNA methylation signature in whole blood (P = 4.5x10-40) that also associated with allergic sensitization and expression in blood of the cytokine TSLP (P = 1.1x10-4). Knockdown of the transcription factor predicted to bind the enhancer region (NHLH1) in a human cell line (HEK293) expressing NHLH1 resulted in lower TSLP expression. In addition, we observed evidence of recent positive selection acting on the risk allele in populations of African descent. Our findings provide novel genetic leads to factors that influence mortality in patients with heart failure.},
  langid = {english},
  keywords = {Blood,Death rates,DNA methylation,Gene expression,Genetic loci,Genome-wide association studies,Heart failure,Single nucleotide polymorphisms},
  file = {/Users/xx20081/Zotero/storage/2BXNIF7R/Smith et al. - 2016 - Discovery of Genetic Variation on Chromosome 5q22 Associated with Mortality in Heart Failure.pdf}
}

@article{smithItMatterFat2023,
  title = {It's a {{Matter}} of {{Fat}}: {{The Obesity Paradox}} in {{Heart Failure}}},
  shorttitle = {It's a {{Matter}} of {{Fat}}},
  author = {Smith, Hannah R. and Roberts, Lee D. and Witte, Klaus K.},
  year = {2023},
  month = dec,
  journal = {The American Journal of Cardiology},
  volume = {209},
  pages = {247--249},
  issn = {1879-1913},
  doi = {10.1016/j.amjcard.2023.09.117},
  langid = {english},
  pmid = {37884267},
  keywords = {Heart Failure,Humans,Obesity,Obesity Paradox},
  file = {/Users/xx20081/Zotero/storage/5MUXAZ3W/Smith et al. - 2023 - It's a Matter of Fat The Obesity Paradox in Heart.pdf}
}

@article{smithMendelianRandomizationStrengthening2010,
  title = {Mendelian {{Randomization}} for {{Strengthening Causal Inference}} in {{Observational Studies}}: {{Application}} to {{Gene}} {\texttimes} {{Environment Interactions}}},
  shorttitle = {Mendelian {{Randomization}} for {{Strengthening Causal Inference}} in {{Observational Studies}}},
  author = {Smith, George Davey},
  year = {2010},
  month = sep,
  journal = {Perspectives on Psychological Science: A Journal of the Association for Psychological Science},
  volume = {5},
  number = {5},
  pages = {527--545},
  issn = {1745-6916},
  doi = {10.1177/1745691610383505},
  abstract = {Identification of environmentally modifiable factors causally influencing disease risk is fundamental to public-health improvement strategies. Unfortunately, observational epidemiological studies are limited in their ability to reliably identify such causal associations, reflected in the many cases in which conventional epidemiological studies have apparently identified associations that randomized controlled trials have failed to verify. The use of genetic variants as proxy measures of exposure -an application of the Mendelian randomization principle-can contribute to strengthening causal inference. Genetic variants are not subject to bias due to reverse causation (disease processes influencing exposure, rather than vice versa) or recall bias, and if simple precautions are applied, they are not influenced by confounding or attenuation by errors. The principles of Mendelian randomization are illustrated with specific reference to studies of the effects of alcohol intake on various health-related outcomes through the utilization of genetic variants related to alcohol metabolism (in ALDH2 and ADH1B). Ways of incorporating Gene {\texttimes} Environment interactions into the Mendelian randomization framework are developed, and the strengths and limitations of the approach discussed.},
  langid = {english},
  pmid = {26162196},
  keywords = {alcohol,causal inference,confounding,epidemiology,Gene  Envrionment interactions,Mendelian randomization}
}

@article{smithMendelianRandomizationStrengthening2010a,
  title = {Mendelian {{Randomization}} for {{Strengthening Causal Inference}} in {{Observational Studies}}: {{Application}} to {{Gene}} {\texttimes} {{Environment Interactions}}},
  shorttitle = {Mendelian {{Randomization}} for {{Strengthening Causal Inference}} in {{Observational Studies}}},
  author = {Smith, George Davey},
  year = {2010},
  month = sep,
  journal = {Perspectives on Psychological Science: A Journal of the Association for Psychological Science},
  volume = {5},
  number = {5},
  pages = {527--545},
  issn = {1745-6916},
  doi = {10.1177/1745691610383505},
  abstract = {Identification of environmentally modifiable factors causally influencing disease risk is fundamental to public-health improvement strategies. Unfortunately, observational epidemiological studies are limited in their ability to reliably identify such causal associations, reflected in the many cases in which conventional epidemiological studies have apparently identified associations that randomized controlled trials have failed to verify. The use of genetic variants as proxy measures of exposure -an application of the Mendelian randomization principle-can contribute to strengthening causal inference. Genetic variants are not subject to bias due to reverse causation (disease processes influencing exposure, rather than vice versa) or recall bias, and if simple precautions are applied, they are not influenced by confounding or attenuation by errors. The principles of Mendelian randomization are illustrated with specific reference to studies of the effects of alcohol intake on various health-related outcomes through the utilization of genetic variants related to alcohol metabolism (in ALDH2 and ADH1B). Ways of incorporating Gene {\texttimes} Environment interactions into the Mendelian randomization framework are developed, and the strengths and limitations of the approach discussed.},
  langid = {english},
  pmid = {26162196},
  keywords = {alcohol,causal inference,confounding,epidemiology,Gene  Envrionment interactions,Mendelian randomization}
}

@article{smitsIndexEventBias2013,
  title = {Index Event Bias---a Numerical Example},
  author = {Smits, Luc J. M. and {van Kuijk}, Sander M. J. and Leffers, Pieter and Peeters, Louis L. and Prins, Martin H. and Sep, Simone J. S.},
  year = {2013},
  month = feb,
  journal = {Journal of Clinical Epidemiology},
  volume = {66},
  number = {2},
  pages = {192--196},
  issn = {0895-4356},
  doi = {10.1016/j.jclinepi.2012.06.023},
  urldate = {2025-01-19},
  abstract = {Studies of determinants of recurrent disease often give unexpected results. In particular, well-established risk factors may seem not to have much influence on the recurrence risk. Recently, it has been argued that such paradoxical findings may be because of the bias caused by the selection of patients based on the occurrence of an earlier episode of the disease. This bias was referred to as index event bias. Here, we give a theoretical quantitative example of index event bias, showing that, as a result of selection of patients on the basis of previous disease: (1) risk factors become inversely associated when they are not in the unselected population, and (2) the crude association between the risk factor of interest and disease becomes biased toward the null.},
  keywords = {Bias (epidemiology),Epidemiologic methods,Models theoretical,Multifactorial causality,Recurrence,Risk factors},
  file = {/Users/xx20081/Zotero/storage/IN45WUCP/S0895435612002831.html}
}

@misc{smr-gtex-v8,
  title = {{{GTEx}} v8 {{eQTL}} Summary Data},
  author = {SMR},
  urldate = {2024-02-19}
}

@article{sollisNHGRIEBIGWASCatalog2023,
  title = {The {{NHGRI-EBI GWAS Catalog}}: Knowledgebase and Deposition Resource},
  shorttitle = {The {{NHGRI-EBI GWAS Catalog}}},
  author = {Sollis, Elliot and Mosaku, Abayomi and Abid, Ala and Buniello, Annalisa and Cerezo, Maria and Gil, Laurent and Groza, Tudor and G{\"u}ne{\c s}, Osman and Hall, Peggy and Hayhurst, James and Ibrahim, Arwa and Ji, Yue and John, Sajo and Lewis, Elizabeth and MacArthur, Jacqueline~A L and McMahon, Aoife and {Osumi-Sutherland}, David and Panoutsopoulou, Kalliope and Pendlington, Zo{\"e} and Ramachandran, Santhi and Stefancsik, Ray and Stewart, Jonathan and Whetzel, Patricia and Wilson, Robert and Hindorff, Lucia and Cunningham, Fiona and Lambert, Samuel~A and Inouye, Michael and Parkinson, Helen and Harris, Laura~W},
  year = {2023},
  month = jan,
  journal = {Nucleic Acids Research},
  volume = {51},
  number = {D1},
  pages = {D977-D985},
  issn = {0305-1048},
  doi = {10.1093/nar/gkac1010},
  urldate = {2024-09-12},
  abstract = {The NHGRI-EBI GWAS Catalog (www.ebi.ac.uk/gwas) is a FAIR knowledgebase providing detailed, structured, standardised and interoperable genome-wide association study (GWAS) data to~\&gt;200 000 users per year from academic research, healthcare and industry. The Catalog contains variant-trait associations and supporting metadata for~\&gt;45 000 published GWAS across~\&gt;5000 human traits, and~\&gt;40 000 full P-value summary statistics datasets. Content is curated from publications or acquired via author submission of prepublication summary statistics through a new submission portal and validation tool. GWAS data volume has vastly increased in recent years. We have updated our software to meet this scaling challenge and to enable rapid release of submitted summary statistics. The scope of the repository has expanded to include additional data types of high interest to the community, including sequencing-based GWAS, gene-based analyses and copy number variation analyses. Community outreach has increased the number of shared datasets from under-represented traits, e.g. cancer, and we continue to contribute to awareness of the lack of population diversity in GWAS. Interoperability of the Catalog has been enhanced through links to other resources including the Polygenic Score Catalog and the International Mouse Phenotyping Consortium, refinements to GWAS trait annotation, and the development of a standard format for GWAS data.},
  file = {/Users/xx20081/Zotero/storage/48BXVLYZ/Sollis et al. - 2023 - The NHGRI-EBI GWAS Catalog knowledgebase and depo.pdf;/Users/xx20081/Zotero/storage/I8S3ETIL/6814460.html}
}

@article{sollisNHGRIEBIGWASCatalog2023a,
  title = {The {{NHGRI-EBI GWAS Catalog}}: Knowledgebase and Deposition Resource},
  shorttitle = {The {{NHGRI-EBI GWAS Catalog}}},
  author = {Sollis, Elliot and Mosaku, Abayomi and Abid, Ala and Buniello, Annalisa and Cerezo, Maria and Gil, Laurent and Groza, Tudor and G{\"u}ne{\c s}, Osman and Hall, Peggy and Hayhurst, James and Ibrahim, Arwa and Ji, Yue and John, Sajo and Lewis, Elizabeth and MacArthur, Jacqueline A. L. and McMahon, Aoife and {Osumi-Sutherland}, David and Panoutsopoulou, Kalliope and Pendlington, Zo{\"e} and Ramachandran, Santhi and Stefancsik, Ray and Stewart, Jonathan and Whetzel, Patricia and Wilson, Robert and Hindorff, Lucia and Cunningham, Fiona and Lambert, Samuel A. and Inouye, Michael and Parkinson, Helen and Harris, Laura W.},
  year = {2023},
  month = jan,
  journal = {Nucleic Acids Research},
  volume = {51},
  number = {D1},
  pages = {D977-D985},
  issn = {1362-4962},
  doi = {10.1093/nar/gkac1010},
  abstract = {The NHGRI-EBI GWAS Catalog (www.ebi.ac.uk/gwas) is a FAIR knowledgebase providing detailed, structured, standardised and interoperable genome-wide association study (GWAS) data to~{$>$}200 000 users per year from academic research, healthcare and industry. The Catalog contains variant-trait associations and supporting metadata for~{$>$}45 000 published GWAS across~{$>$}5000 human traits, and~{$>$}40 000 full P-value summary statistics datasets. Content is curated from publications or acquired via author submission of prepublication summary statistics through a new submission portal and validation tool. GWAS data volume has vastly increased in recent years. We have updated our software to meet this scaling challenge and to enable rapid release of submitted summary statistics. The scope of the repository has expanded to include additional data types of high interest to the community, including sequencing-based GWAS, gene-based analyses and copy number variation analyses. Community outreach has increased the number of shared datasets from under-represented traits, e.g. cancer, and we continue to contribute to awareness of the lack of population diversity in GWAS. Interoperability of the Catalog has been enhanced through links to other resources including the Polygenic Score Catalog and the International Mouse Phenotyping Consortium, refinements to GWAS trait annotation, and the development of a standard format for GWAS data.},
  langid = {english},
  pmcid = {PMC9825413},
  pmid = {36350656},
  keywords = {Animals,DNA Copy Number Variations,Genome-Wide Association Study,Humans,Knowledge Bases,Mice,National Human Genome Research Institute (U.S.),Phenotype,Polymorphism Single Nucleotide,Software,United States},
  file = {/Users/xx20081/Zotero/storage/85IUHWHB/Sollis et al. - 2023 - The NHGRI-EBI GWAS Catalog knowledgebase and deposition resource.pdf}
}

@article{solomonscottd.AngiotensinNeprilysinInhibition2019,
  title = {Angiotensin--{{Neprilysin Inhibition}} in {{Heart Failure}} with {{Preserved Ejection Fraction}}},
  author = {{Solomon Scott D.} and {McMurray John J.V.} and {Anand Inder S.} and {Ge Junbo} and {Lam Carolyn S.P.} and {Maggioni Aldo P.} and {Martinez Felipe} and {Packer Milton} and {Pfeffer Marc A.} and {Pieske Burkert} and {Redfield Margaret M.} and {Rouleau Jean L.} and {van Veldhuisen Dirk J.} and {Zannad Faiez} and {Zile Michael R.} and {Desai Akshay S.} and {Claggett Brian} and {Jhund Pardeep S.} and {Boytsov Sergey A.} and {Comin-Colet Josep} and {Cleland John} and {D{\"u}ngen Hans-Dirk} and {Goncalvesova Eva} and {Katova Tzvetana} and {Kerr Saraiva Jose F.} and {Lelonek Ma{\l}gorzata} and {Merkely Bela} and {Senni Michele} and {Shah Sanjiv J.} and {Zhou Jingmin} and {Rizkala Adel R.} and {Gong Jianjian} and {Shi Victor C.} and {Lefkowitz Martin P.}},
  year = {2019},
  month = oct,
  journal = {New England Journal of Medicine},
  volume = {381},
  number = {17},
  pages = {1609--1620},
  publisher = {Massachusetts Medical Society},
  doi = {10.1056/NEJMoa1908655},
  urldate = {2024-07-04},
  abstract = {Patients with heart failure with preserved ejection fraction were assigned to receive sacubitril--valsartan or valsartan. At a median of 35 months, there was no significant between-group difference in the composite outcome of total hospitalizations for heart failure or death from cardiovascular causes.},
  file = {/Users/xx20081/Zotero/storage/MSIWXSKY/Solomon Scott D. et al. - 2019 - AngiotensinNeprilysin Inhibition in Heart Failure.pdf}
}

@article{soltaniIdentificationHeartFailure2024,
  title = {Identification of Heart Failure Hospitalization from {{NHS Digital}} Data: Comparison with Expert Adjudication},
  shorttitle = {Identification of Heart Failure Hospitalization from {{NHS Digital}} Data},
  author = {Soltani, Fardad and Bradley, Joshua and Bonandi, Antonio and Black, Nicholas and Farrant, John P. and Pailing, Adam and Orsborne, Christopher and Williams, Simon G. and Schelbert, Erik B. and Dodd, Susanna and Williams, Richard and Peek, Niels and Schmitt, Matthias and McDonagh, Theresa and Miller, Christopher A.},
  year = {2024},
  month = jan,
  journal = {ESC Heart Failure},
  volume = {11},
  number = {2},
  pages = {1022--1029},
  issn = {2055-5822},
  doi = {10.1002/ehf2.14669},
  urldate = {2024-08-16},
  abstract = {Aims Population-wide, person-level, linked electronic health record data are increasingly used to estimate epidemiology, guide resource allocation, and identify events in clinical trials. The accuracy of data from NHS Digital (now part of NHS England) for identifying hospitalization for heart failure (HHF), a key HF standard, is not clear. This study aimed to evaluate the accuracy of NHS Digital data for identifying HHF. Methods and results Patients experiencing at least one HHF, as determined by NHS Digital data, and age- and sex-matched patients not experiencing HHF, were identified from a prospective cohort study and underwent expert adjudication. Three code sets commonly used to identify HHF were applied to the data and compared with expert adjudication (I50: International Classification of Diseases-10 codes beginning I50; OIS: Clinical Commissioning Groups Outcomes Indicator Set; and NICOR: National Institute for Cardiovascular Outcomes Research, used as the basis for the National Heart Failure Audit in England and Wales). Five hundred four patients underwent expert adjudication, of which 10 (2\%) were adjudicated to have experienced HHF. Specificity was high across all three code sets in the first diagnosis position \{I50: 96.2\% [95\% confidence interval (CI) 94.1--97.7\%]; NICOR: 93.3\% [CI 90.8--95.4\%]; OIS: 95.6\% [CI 93.3--97.2\%]\} but decreased substantially as the number of diagnosis positions expanded. Sensitivity [40.0\% (CI 12.2--73.8\%)] and positive predictive value (PPV) [highest with I50: 17.4\% (CI 8.1--33.6\%)] were low in the first diagnosis position for all coding sets. PPV was higher for the National Heart Failure Audit criteria, albeit modestly [36.4\% (CI 16.6--62.2\%)]. Conclusions NHS Digital data were not able to accurately identify HHF and should not be used in isolation for this purpose.},
  pmcid = {PMC10966211},
  pmid = {38232976},
  file = {/Users/xx20081/Zotero/storage/9KB9H8P4/Soltani et al. - 2024 - Identification of heart failure hospitalization fr.pdf}
}

@article{speltaBodyWeightMortality2018,
  title = {Body Weight and Mortality in {{COPD}}: Focus on the Obesity Paradox},
  shorttitle = {Body Weight and Mortality in {{COPD}}},
  author = {Spelta, Francesco and Fratta Pasini, A. M. and Cazzoletti, L. and Ferrari, M.},
  year = {2018},
  month = feb,
  journal = {Eating and weight disorders: EWD},
  volume = {23},
  number = {1},
  pages = {15--22},
  issn = {1590-1262},
  doi = {10.1007/s40519-017-0456-z},
  abstract = {The positive association between overweight, obesity, and cardiovascular and all-cause mortality is well established, even though this relation is typically U shaped with an increased risk also in low-weight subjects. However, being overweight or obese has been associated with a better prognosis in subjects suffering from chronic diseases, id est the "obesity paradox". In both community-dwelling and hospitalized patients with COPD, several studies have reported a significant protective effect of obesity on all-cause mortality, indicating that also in obstructive pulmonary diseases, an obesity paradox may be present. Interestingly, the "paradox" is more evident for subjects with severe bronchial obstruction (i.e., a lower FEV1), while in mild-moderate conditions, the weight-related mortality shows a behavior similar to that observed in the general population. Several factors may confound the relation between COPD, obesity and mortality. The lower FEV1 found in obese people may be linked to a restrictive defect rather than to an obstructive one. Due to the modified chest wall mechanical properties-related to increased fat mass-obese COPD patients may present, respect to their lean counterpart, a lower lung hyperinflation which is associated with higher mortality. The traditional classification of COPD attributes to obese "blue bloaters" a low-grade emphysema in opposition to lean "pink puffers"; the fact that emphysema extent is related to mortality may bias the relationship between weight and survival. It is also to underline that the majority of the studies, consider BMI rather than body composition (a better predictor of mortality) when studying the intriguing relation between weight, COPD, and mortality. Reverse bias has also to be taken into account, hypothesizing that an unintentional weight loss may be the deleterious factor related to mortality, rather than considering obesity a protective one. Further prospective studies are needed to shed light on the complexity of this emerging issue. LEVEL OF EVIDENCE: Level V: Narrative Review.},
  langid = {english},
  pmid = {29110280},
  keywords = {Body Mass Index,Body Weight,COPD,Humans,Obesity,Obesity paradox,Overweight,Prognosis,Pulmonary Disease Chronic Obstructive,Pulmonary function,Survival Rate,Visceral obesity}
}

@article{sperrinColliderBiasOnly2016,
  title = {Collider {{Bias Is Only}} a {{Partial Explanation}} for the {{Obesity Paradox}}},
  author = {Sperrin, Matthew and Candlish, Jane and Badrick, Ellena and Renehan, Andrew and Buchan, Iain},
  year = {2016},
  month = jul,
  journal = {Epidemiology},
  volume = {27},
  number = {4},
  pages = {525},
  issn = {1044-3983},
  doi = {10.1097/EDE.0000000000000493},
  urldate = {2024-08-08},
  abstract = {Background:~           ``Obesity paradox'' refers to an association between obesity and reduced mortality (contrary to an expected increased mortality). A common explanation is collider stratification bias: unmeasured confounding induced by selection bias. Here, we test this supposition through a realistic generative model.           Methods:~           We quantify the collider stratification bias in a selected population using counterfactual causal analysis. We illustrate the bias for a range of scenarios, describing associations between exposure (obesity), outcome (mortality), mediator (in this example, diabetes) and an unmeasured confounder.           Results:~           Collider stratification leads to biased estimation of the causal effect of exposure on outcome. However, the bias is small relative to the causal relationships between the variables.           Conclusions:~           Collider bias can be a partial explanation of the obesity paradox, but unlikely to be the main explanation for a reverse direction of an association to a true causal relationship. Alternative explanations of the obesity paradox should be explored. See Video Abstract at https://links.lww.com/EDE/B51.},
  langid = {american},
  file = {/Users/xx20081/Zotero/storage/LQB54BH6/Sperrin et al. - 2016 - Collider Bias Is Only a Partial Explanation for th.pdf;/Users/xx20081/Zotero/storage/SK6AYZC3/collider_bias_is_only_a_partial_explanation_for.12.html}
}

@article{standevenNeprilysinObesityMetabolic2011,
  title = {Neprilysin, Obesity and the Metabolic Syndrome},
  author = {Standeven, K. F. and Hess, K. and Carter, A. M. and Rice, G. I. and Cordell, P. A. and Balmforth, A. J. and Lu, B. and Scott, D. J. and Turner, A. J. and Hooper, N. M. and Grant, P. J.},
  year = {2011},
  month = aug,
  journal = {International Journal of Obesity (2005)},
  volume = {35},
  number = {8},
  pages = {1031--1040},
  issn = {1476-5497},
  doi = {10.1038/ijo.2010.227},
  abstract = {OBJECTIVE: Neprilysin (NEP), a zinc metalloendopeptidase, has a role in blood pressure control and lipid metabolism. The present study tested the hypothesis that NEP is associated with insulin resistance and features of the metabolic syndrome (MetS) in a study of 318 healthy human subjects and in murine obesity, and investigated NEP production by adipocytes in-vitro. METHODS AND RESULTS: In 318 white European males, plasma NEP was elevated in the MetS and increased progressively with increasing MetS components. Plasma NEP activity correlated with insulin, homoeostasis model assessment and body mass index (BMI) in all subjects (P{$<$}0.01). Quantitative reverse transcriptase PCR (RT-PCR) and western blotting showed that in human pre-adipocytes NEP expression is upregulated 25- to 30-fold during differentiation into adipocytes. Microarray analysis of mRNA from differentiated human adipocytes confirmed high-NEP expression comparable with adiponectin and plasminogen activator inhibitor-1. In a murine model of diet-induced insulin resistance, plasma NEP levels were significantly higher in high-fat diet (HFD)-fed compared with normal chow diet (NCD)-fed animals (1642 {\textpm} 529 and 820 {\textpm} 487 pg {$\mu$}l(-1), respectively; P{$<$}0.01). Tissue NEP was increased in mesenteric fat in HFD compared with NCD-fed mice (P{$<$}0.05). NEP knockout mice did not display any changes in insulin resistance, glucose tolerance, or body and epididymal fat pad weight compared with wild-type mice. CONCLUSION: In humans, NEP activity correlated with BMI and measures of insulin resistance with increasing levels in subjects with multiple cardiovascular risk factors. NEP protein production in human adipocytes increased during cell differentiation and plasma and adipose tissue levels of NEP were increased in obese insulin-resistant mice. Our results indicate that NEP associates with cardiometabolic risk in the presence of insulin resistance and increases with obesity.},
  langid = {english},
  pmcid = {PMC3040694},
  pmid = {21042321},
  keywords = {Adipocytes,Animals,Blotting Western,Body Mass Index,Cardiovascular Diseases,Child,Dietary Fats,Humans,Insulin Resistance,Male,Metabolic Syndrome,Mice,Mice Knockout,Neprilysin,Obesity,Protein Array Analysis,Reverse Transcriptase Polymerase Chain Reaction},
  file = {/Users/xx20081/Zotero/storage/N4PK4LBQ/Standeven et al. - 2011 - Neprilysin, obesity and the metabolic syndrome.pdf}
}

@article{stenholmSarcopenicObesityDefinition2008,
  title = {Sarcopenic Obesity: Definition, Cause and Consequences},
  shorttitle = {Sarcopenic Obesity},
  author = {Stenholm, Sari and Harris, Tamara B. and Rantanen, Taina and Visser, Marjolein and Kritchevsky, Stephen B. and Ferrucci, Luigi},
  year = {2008},
  month = nov,
  journal = {Current Opinion in Clinical Nutrition and Metabolic Care},
  volume = {11},
  number = {6},
  pages = {693--700},
  issn = {1363-1950},
  doi = {10.1097/MCO.0b013e328312c37d},
  abstract = {PURPOSE OF REVIEW: Older obese persons with decreased muscle mass or strength are at special risk for adverse outcomes. We discuss potential pathways to muscle impairment in obese individuals and the consequences that joint obesity and muscle impairment may have on health and disability. Tantamount to this discussion is whether low muscle mass or, rather, muscle weakness should be used for the definition. RECENT FINDINGS: Excess energy intake, physical inactivity, low-grade inflammation, insulin resistance and changes in hormonal milieu may lead to the development of so-called 'sarcopenic obesity'. It was originally believed that the culprit of age-related muscle weakness was a reduction in muscle mass, but it is now clear that changes in muscle composition and quality are predominant. We propose that the risk of adverse outcomes, such as functional limitation and mortality, is better estimated by considering jointly obesity and muscle strength rather than obesity and muscle mass and the term 'sarcopenic obesity' should be revisited. SUMMARY: Recognition of obese patients who have associated muscle problems is an essential goal for clinicians. Further research is needed to identify new target for prevention and cure of this important geriatric syndrome.},
  langid = {english},
  pmcid = {PMC2633408},
  pmid = {18827572},
  keywords = {Aged,Aging,Comorbidity,Exercise,Female,Health Status,Humans,Male,Muscle Skeletal,Muscle Strength,Muscular Atrophy,Obesity,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/P23YVSFC/Stenholm et al. - 2008 - Sarcopenic obesity definition, cause and conseque.pdf}
}

@article{stovitzSelectionBiasUnseen2022,
  title = {Selection Bias: ``{{The}} Unseen Enemy Is Always the Most Fearsome''},
  shorttitle = {Selection Bias},
  author = {Stovitz, Steven D. and Banack, Hailey R. and Kaufman, Jay S.},
  year = {2022},
  month = jun,
  journal = {International Journal of Obesity},
  volume = {46},
  number = {6},
  pages = {1247--1247},
  publisher = {Nature Publishing Group},
  issn = {1476-5497},
  doi = {10.1038/s41366-021-00981-5},
  urldate = {2024-08-06},
  copyright = {2021 The Author(s), under exclusive licence to Springer Nature Limited},
  langid = {english},
  keywords = {Epidemiology,Nutrition disorders},
  file = {/Users/xx20081/Zotero/storage/SX995G36/Stovitz et al. - 2022 - Selection bias The unseen enemy is always the mo.pdf}
}

@article{stryeckSerumConcentrationsCitrate2019,
  title = {Serum {{Concentrations}} of {{Citrate}}, {{Tyrosine}}, 2- and 3- {{Hydroxybutyrate}} Are {{Associated}} with {{Increased}} 3-{{Month Mortality}} in {{Acute Heart Failure Patients}}},
  author = {Stryeck, Sarah and Gastrager, Michaela and Degoricija, Vesna and Trbu{\v s}i{\'c}, Matias and Poto{\v c}njak, Ines and Radulovi{\'c}, Bojana and Pregartner, Gudrun and Berghold, Andrea and Madl, Tobias and Frank, Sa{\v s}a},
  year = {2019},
  month = may,
  journal = {Scientific Reports},
  volume = {9},
  number = {1},
  pages = {6743},
  publisher = {Nature Publishing Group},
  issn = {2045-2322},
  doi = {10.1038/s41598-019-42937-w},
  urldate = {2025-06-11},
  abstract = {Considering the already established relationship between the extent of the metabolic dysfunction and the severity of heart failure (HF), it is conceivable that the metabolomic profile of the serum may have a prognostic capacity for 3-month mortality in acute heart failure (AHF). Out of 152 recruited patients, 130 serum samples were subjected to the metabolomic analyses. The 3-month mortality rate was 24.6\% (32 patients). Metabolomic profiling by nuclear magnetic resonance spectroscopy found that the serum levels of 2-hydroxybutyrate (2-HB), 3-hydoxybutyrate (3-HB), lactate, citrate, and tyrosine, were higher in patients who died within 3 months compared to those who were alive 3 months after onset of AHF, which was confirmed by univariable logistic regression analyses (p\,=\,0.009, p\,=\,0.005, p\,=\,0.008, p{$<$}0.001, and p{$<$}0.001, respectively). These associations still remained significant for all tested metabolites except for lactate after adjusting for established prognostic parameters in HF. In conclusion, serum levels of 2-HB, 3-HB, tyrosine, and citrate measured at admission are associated with an increased 3-month mortality rate in AHF patients and might thus be of prognostic value in AHF.},
  copyright = {2019 The Author(s)},
  langid = {english},
  keywords = {Heart failure,Outcomes research,Prognostic markers},
  file = {/Users/xx20081/Zotero/storage/7QVQJ4A9/Stryeck et al. - 2019 - Serum Concentrations of Citrate, Tyrosine, 2- and 3- Hydroxybutyrate are Associated with Increased 3.pdf}
}

@article{sudlowUKBiobankOpen2015,
  title = {{{UK}} Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age},
  shorttitle = {{{UK}} Biobank},
  author = {Sudlow, Cathie and Gallacher, John and Allen, Naomi and Beral, Valerie and Burton, Paul and Danesh, John and Downey, Paul and Elliott, Paul and Green, Jane and Landray, Martin and Liu, Bette and Matthews, Paul and Ong, Giok and Pell, Jill and Silman, Alan and Young, Alan and Sprosen, Tim and Peakman, Tim and Collins, Rory},
  year = {2015},
  month = mar,
  journal = {PLoS medicine},
  volume = {12},
  number = {3},
  pages = {e1001779},
  issn = {1549-1676},
  doi = {10.1371/journal.pmed.1001779},
  abstract = {Cathie Sudlow and colleagues describe the UK Biobank, a large population-based prospective study, established to allow investigation of the genetic and non-genetic determinants of the diseases of middle and old age.},
  langid = {english},
  pmcid = {PMC4380465},
  pmid = {25826379},
  keywords = {Access to Information,Adult,Aged,Aging,Biological Specimen Banks,Databases Factual,Genotype,Humans,Middle Aged,Neoplasms,Phenotype,Prospective Studies,Research,United Kingdom},
  file = {/Users/xx20081/Zotero/storage/74FY3A75/Sudlow et al. - 2015 - UK biobank an open access resource for identifyin.pdf}
}

@article{sulcHeterogeneityObesityGenetic2020,
  title = {Heterogeneity in {{Obesity}}: {{Genetic Basis}} and {{Metabolic Consequences}}},
  shorttitle = {Heterogeneity in {{Obesity}}},
  author = {Sulc, Jonathan and Winkler, Thomas W. and Heid, Iris M. and Kutalik, Zolt{\'a}n},
  year = {2020},
  month = jan,
  journal = {Current Diabetes Reports},
  volume = {20},
  number = {1},
  pages = {1},
  issn = {1539-0829},
  doi = {10.1007/s11892-020-1285-4},
  abstract = {PURPOSE OF REVIEW: Our review provides a brief summary of the most recent advances towards the identification of the genetic basis of specific aspects of obesity and the quantification of their consequences on health. We also highlight the most promising avenues to be explored in the future. RECENT FINDINGS: While obesity has been demonstrated to lead to adverse cardio-metabolic consequences, the determinants of inter-individual variability remain largely unknown. The elucidation of the molecular underpinnings of this relationship is hampered by the extremely heterogeneous nature of obesity as a human trait. Recent technological advances have facilitated a more in-depth characterization of body composition at large-scale. At the pace of current data acquisition and resolution, it is realistic to improve characterization of obesity and to advise individuals based on detailed body composition combined with tissue-specific molecular signatures. Individualized predictions of health implications would enable more personalized and effective public health interventions.},
  langid = {english},
  pmid = {31970540},
  keywords = {Adiposity,Body Composition,Body Fat Distribution,Body Mass Index,Genetic Heterogeneity,GWAS,Humans,Mendelian randomization,Metabolic disease,Obesity,Obesity genetics,Obesity subtypes,Phenotype,Sex Factors,Waist Circumference}
}

@article{sunMendelianRandomizationStudy2022,
  title = {A {{Mendelian}} Randomization Study to Assess the Genetic Liability of Gastroesophageal Reflux Disease for Cardiovascular Diseases and Risk Factors},
  author = {Sun, Xingang and Chen, Lu and Zheng, Liangrong},
  year = {2022},
  month = dec,
  journal = {Human Molecular Genetics},
  volume = {31},
  number = {24},
  pages = {4275--4285},
  issn = {1460-2083},
  doi = {10.1093/hmg/ddac162},
  abstract = {Observational studies have reported that gastroesophageal reflux disease (GERD) is a risk factor for cardiovascular diseases (CVD); however, the causal inferences between them remain unknown. We conducted a Mendelian randomization (MR) study to estimate the causal associations between GERD and 10 CVD outcomes, as well as 14 cardiovascular risk factors. We used summary statistics from genome-wide association studies for GERD and the FinnGen consortium for CVD. We further investigated whether GERD correlated with cardiovascular risk factors and performed multivariable MR and mediation analyses to estimate the mediating effects of these risk factors on GERD-CVD progression. Sensitivity analyses and replication analyses were also performed. Our results indicated that GERD was positively associated with seven CVD outcomes with odds ratios of 1.26 [95\% confidence interval (CI), 1.15, 1.37] for coronary artery disease, 1.41 (95\% CI, 1.28, 1.57) for myocardial infarction, 1.34 (95\% CI, 1.19, 1.51) for atrial fibrillation, 1.34 (95\% CI, 1.21, 1.50) for heart failure, 1.30 (95\% CI, 1.18, 1.43) for any stroke, 1.19 (95\% CI, 1.06, 1.34) for ischemic stroke and 1.29 (95\% CI, 1.16, 1.44) for venous thromboembolism. Furthermore, GERD was associated with nine cardiovascular risk factors and major depressive disorder demonstrated significant mediation effects on the causal pathway linking GERD and any stroke. This study demonstrates that GERD is associated with seven CVD outcomes and nine cardiovascular risk factors. Importantly, GERD treatment may help prevent common CVD events.},
  langid = {english},
  pmid = {35861629},
  keywords = {Cardiovascular Diseases,Depressive Disorder Major,Gastroesophageal Reflux,Genome-Wide Association Study,Humans,Mendelian Randomization Analysis,Polymorphism Single Nucleotide,Risk Factors,Stroke}
}

@article{sunSmallStrongEmerging2023,
  title = {Small but Strong: The Emerging Role of Small Nucleolar {{RNA}} in Cardiovascular Diseases},
  shorttitle = {Small but Strong},
  author = {Sun, Xue and Wang, Gebang and Luo, Wenting and Gu, Hui and Ma, Wei and Wei, Xiaowei and Liu, Dan and Jia, Shanshan and Cao, Songying and Wang, Yu and Yuan, Zhengwei},
  year = {2023},
  month = nov,
  journal = {Frontiers in Cell and Developmental Biology},
  volume = {11},
  pages = {1292925},
  issn = {2296-634X},
  doi = {10.3389/fcell.2023.1292925},
  urldate = {2024-04-12},
  abstract = {Cardiovascular diseases (CVDs) are the leading cause of mortality and disability worldwide. Numerous studies have demonstrated that non-coding RNAs (ncRNAs) play a primary role in CVD development. Therefore, studies on the mechanisms of ncRNAs are essential for further efforts to prevent and treat CVDs. Small nucleolar RNAs (snoRNAs) are a novel species of non-conventional ncRNAs that guide post-transcriptional modifications and the subsequent maturation of small nuclear RNA and ribosomal RNA. Evidently, snoRNAs are extensively expressed in human tissues and may regulate different illnesses. Particularly, as the next-generation sequencing techniques have progressed, snoRNAs have been shown to be differentially expressed in CVDs, suggesting that they may play a role in the occurrence and progression of cardiac illnesses. However, the molecular processes and signaling pathways underlying the function of snoRNAs remain unidentified. Therefore, it is of great value to comprehensively investigate the association between snoRNAs and CVDs. The aim of this review was to collate existing literature on the biogenesis, characteristics, and potential regulatory mechanisms of snoRNAs. In particular, we present a scientific update on these snoRNAs and their relevance to CVDs in an effort to cast new light on the functions of snoRNAs in the clinical diagnosis of CVDs.},
  pmcid = {PMC10682241},
  pmid = {38033868},
  file = {/Users/xx20081/Zotero/storage/6LDTABBF/Sun et al. - 2023 - Small but strong the emerging role of small nucle.pdf}
}

@article{surendranRareCommonGenetic2022,
  title = {Rare and Common Genetic Determinants of Metabolic Individuality and Their Effects on Human Health},
  author = {Surendran, Praveen and Stewart, Isobel D. and Au Yeung, Victoria P. W. and Pietzner, Maik and Raffler, Johannes and W{\"o}rheide, Maria A. and Li, Chen and Smith, Rebecca F. and Wittemans, Laura B. L. and Bomba, Lorenzo and Menni, Cristina and Zierer, Jonas and Rossi, Niccol{\`o} and Sheridan, Patricia A. and Watkins, Nicholas A. and Mangino, Massimo and Hysi, Pirro G. and Di Angelantonio, Emanuele and Falchi, Mario and Spector, Tim D. and Soranzo, Nicole and Michelotti, Gregory A. and Arlt, Wiebke and Lotta, Luca A. and Denaxas, Spiros and Hemingway, Harry and Gamazon, Eric R. and Howson, Joanna M. M. and Wood, Angela M. and Danesh, John and Wareham, Nicholas J. and Kastenm{\"u}ller, Gabi and Fauman, Eric B. and Suhre, Karsten and Butterworth, Adam S. and Langenberg, Claudia},
  year = {2022},
  month = nov,
  journal = {Nature Medicine},
  volume = {28},
  number = {11},
  pages = {2321--2332},
  issn = {1546-170X},
  doi = {10.1038/s41591-022-02046-0},
  abstract = {Garrod's concept of 'chemical individuality' has contributed to comprehension of the molecular origins of human diseases. Untargeted high-throughput metabolomic technologies provide an in-depth snapshot of human metabolism at scale. We studied the genetic architecture of the human plasma metabolome using 913 metabolites assayed in 19,994 individuals and identified 2,599 variant-metabolite associations (P\,{$<$}\,1.25\,{\texttimes}\,10-11) within 330 genomic regions, with rare variants (minor allele frequency\,{$\leq$}\,1\%) explaining 9.4\% of associations. Jointly modeling metabolites in each region, we identified 423 regional, co-regulated, variant-metabolite clusters called genetically influenced metabotypes. We assigned causal genes for 62.4\% of these genetically influenced metabotypes, providing new insights into fundamental metabolite physiology and clinical relevance, including metabolite-guided discovery of potential adverse drug effects (DPYD and SRD5A2). We show strong enrichment of inborn errors of metabolism-causing genes, with examples of metabolite associations and clinical phenotypes of non-pathogenic variant carriers matching characteristics of the inborn errors of metabolism. Systematic, phenotypic follow-up of metabolite-specific genetic scores revealed multiple potential etiological relationships.},
  langid = {english},
  pmcid = {PMC9671801},
  pmid = {36357675},
  keywords = {3-Oxo-5-alpha-Steroid 4-Dehydrogenase,Humans,Membrane Proteins,Metabolism Inborn Errors,Metabolome,Metabolomics,Phenotype,Plasma},
  file = {/Users/xx20081/Zotero/storage/YEA7PZXC/Surendran et al. - 2022 - Rare and common genetic determinants of metabolic individuality and their effects on human health.pdf}
}

@misc{SystematicDifferencesDiscovery,
  title = {Systematic Differences in Discovery of Genetic Effects on Gene Expression and Complex Traits {\textbar} {{Nature Genetics}}},
  urldate = {2023-12-05},
  howpublished = {https://www.nature.com/articles/s41588-023-01529-1},
  file = {/Users/xx20081/Zotero/storage/HIUHBC4A/s41588-023-01529-1.html}
}

@article{Table4Logistic,
  title = {Table 4 {{Logistic}} Regression Analyses of 3-Month Mortality for 2-{{HB}}, 3-{{HB}}, Lactate, Citrate, and Tyrosine.},
  urldate = {2025-06-11},
  langid = {english}
}

@article{tanGenomeWideAssociationStudies2021,
  title = {Genome-{{Wide Association Studies}} of {{Cognitive}} and {{Motor Progression}} in {{Parkinson}}'s {{Disease}}},
  author = {Tan, Manuela M.X. and Lawton, Michael A. and Jabbari, Edwin and Reynolds, Regina H. and Iwaki, Hirotaka and Blauwendraat, Cornelis and Kanavou, Sofia and Pollard, Miriam I. and Hubbard, Leon and Malek, Naveed and Grosset, Katherine A. and Marrinan, Sarah L. and Bajaj, Nin and Barker, Roger A. and Burn, David J. and Bresner, Catherine and Foltynie, Thomas and Wood, Nicholas W. and {Williams-Gray}, Caroline H. and Hardy, John and Nalls, Michael A. and Singleton, Andrew B. and Williams, Nigel M. and {Ben-Shlomo}, Yoav and Hu, Michele T.M. and Grosset, Donald G. and Shoai, Maryam and Morris, Huw R.},
  year = {2021},
  journal = {Movement Disorders},
  volume = {36},
  number = {2},
  pages = {424--433},
  issn = {1531-8257},
  doi = {10.1002/mds.28342},
  urldate = {2024-04-05},
  abstract = {Background There are currently no treatments that stop or slow the progression of Parkinson's disease (PD). Case--control genome-wide association studies have identified variants associated with disease risk, but not progression. The objective of the current study was to identify genetic variants associated with PD progression. Methods We analyzed 3 large longitudinal cohorts: Tracking Parkinson's, Oxford Discovery, and the Parkinson's Progression Markers Initiative. We included clinical data for 3364 patients with 12,144 observations (mean follow-up 4.2 years). We used a new method in PD, following a similar approach in Huntington's disease, in which we combined multiple assessments using a principal components analysis to derive scores for composite, motor, and cognitive progression. These scores were analyzed in linear regression in genome-wide association studies. We also performed a targeted analysis of the 90 PD risk loci from the latest case--control meta-analysis. Results There was no overlap between variants associated with PD risk, from case--control studies, and PD age at onset versus PD progression. The APOE {$\varepsilon$}4 tagging variant, rs429358, was significantly associated with composite and cognitive progression in PD. Conditional analysis revealed several independent signals in the APOE locus for cognitive progression. No single variants were associated with motor progression. However, in gene-based analysis, ATP8B2, a phospholipid transporter related to vesicle formation, was nominally associated with motor progression (P = 5.3 {\texttimes} 10-6). Conclusions We provide early evidence that this new method in PD improves measurement of symptom progression. We show that the APOE {$\varepsilon$}4 allele drives progressive cognitive impairment in PD. Replication of this method and results in independent cohorts are needed. {\copyright} 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society},
  copyright = {{\copyright} 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society},
  langid = {english},
  keywords = {genetics,genome-wide association study,Parkinson's disease,progression},
  file = {/Users/xx20081/Zotero/storage/64CJFVMN/Tan et al. - 2021 - Genome-Wide Association Studies of Cognitive and M.pdf;/Users/xx20081/Zotero/storage/VT4EVY69/mds.html}
}

@article{tanoliComputationalDrugRepurposing2025,
  title = {Computational Drug Repurposing: Approaches, Evaluation of in Silico Resources and Case Studies},
  shorttitle = {Computational Drug Repurposing},
  author = {Tanoli, Ziaurrehman and {Fern{\'a}ndez-Torras}, Adri{\`a} and {\"O}zcan, Umut Onur and Kushnir, Aleksandr and Nader, Kristen Michelle and Gadiya, Yojana and Fiorenza, Laura and Ianevski, Aleksandr and {V{\"a}h{\"a}-Koskela}, Markus and Miihkinen, Mitro and Seemab, Umair and Leinonen, Henri and {Seashore-Ludlow}, Brinton and Tampere, Marianna and Kalman, Adelinn and Ballante, Flavio and Benfenati, Emilio and Saunders, Gary and Potdar, Swapnil and G{\'o}mez Garc{\'i}a, Ismael and {Garc{\'i}a-Serna}, Ricard and Talarico, Carmine and Beccari, Andrea Rosario and Schaal, Wesley and Polo, Andrea and Costantini, Susan and Cabri, Enrico and Jacobs, Marc and Saarela, Jani and Budillon, Alfredo and Spjuth, Ola and {\"O}stling, P{\"a}ivi and Xhaard, Henri and Quintana, Jordi and Mestres, Jordi and Gribbon, Philip and Ussi, Anton E. and Lo, Donald C. and {de Kort}, Martin and Wennerberg, Krister and Fratelli, Maddalena and {Carreras-Puigvert}, Jordi and Aittokallio, Tero},
  year = {2025},
  month = mar,
  journal = {Nature Reviews Drug Discovery},
  pages = {1--22},
  publisher = {Nature Publishing Group},
  issn = {1474-1784},
  doi = {10.1038/s41573-025-01164-x},
  urldate = {2025-06-09},
  abstract = {Repurposing of existing drugs for new indications has attracted substantial attention owing to its potential to accelerate drug development and reduce costs. Hundreds of computational resources such as databases and predictive platforms have been developed that can be applied for drug repurposing, making it challenging to select the right resource for a specific drug repurposing project. With the aim of helping to address this challenge, here we overview computational approaches to drug repurposing based on a comprehensive survey of available in silico resources using a purpose-built drug repurposing ontology that classifies the resources into hierarchical categories and provides application-specific information. We also present an expert evaluation of selected resources and three drug repurposing case studies implemented within the Horizon Europe REMEDi4ALL project to demonstrate the practical use of the resources. This comprehensive Review with expert evaluations and case studies provides guidelines and recommendations on the best use of various in silico resources for drug repurposing and establishes a basis for a sustainable and extendable drug repurposing web catalogue.},
  copyright = {2025 Springer Nature Limited},
  langid = {english},
  keywords = {Databases,Pharmaceutics},
  file = {/Users/xx20081/Zotero/storage/WZSVTIEZ/Tanoli et al. - 2025 - Computational drug repurposing approaches, evaluation of in silico resources and case studies.pdf}
}

@article{taylorClinicalMetabolicFeatures2018,
  title = {Clinical and Metabolic Features of the Randomised Controlled {{Diabetes Remission Clinical Trial}} ({{DiRECT}}) Cohort},
  author = {Taylor, Roy and Leslie, Wilma S. and Barnes, Alison C. and Brosnahan, Naomi and Thom, George and McCombie, Louise and Sattar, Naveed and Welsh, Paul and Peters, Carl and Zhyzhneuskaya, Sviatlana and Hollingsworth, Kieren G. and {Al-Mrabeh}, Ahmad and Rodrigues, Angela M. and Rehackova, Lucia and Adamson, Ashley J. and Sniehotta, Falko F. and Mathers, John C. and Ross, Hazel M. and McIlvenna, Yvonne and Kean, Sharon and Ford, Ian and McConnachie, Alex and Lean, Michael E. J.},
  year = {2018},
  month = mar,
  journal = {Diabetologia},
  volume = {61},
  number = {3},
  pages = {589--598},
  issn = {1432-0428},
  doi = {10.1007/s00125-017-4503-0},
  abstract = {AIMS/HYPOTHESIS: Substantial weight loss in type 2 diabetes can achieve a return to non-diabetic biochemical status, without the need for medication. The Diabetes Remission Clinical Trial (DiRECT), a cluster-randomised controlled trial, is testing a structured intervention designed to achieve and sustain this over 2~years in a primary care setting to determine practicability for routine clinical practice. This paper reports the characteristics of the baseline cohort. METHODS: People with type 2 diabetes for {$<$}6~years with a BMI of 27-45~kg/m2 were recruited in 49 UK primary care practices, randomised to either best-practice diabetes care alone or with an additional evidence-based weight management programme (Counterweight-Plus). The co-primary outcomes, at 12~months, are weight loss {$\geq$}15~kg and diabetes remission (HbA1c {$<$}48~mmol/mol [6.5\%]) without glucose-lowering therapy for at least 2~months. Outcome assessors are blinded to group assignment. RESULTS: Of 1510 people invited, 423 (28\%) accepted; of whom, 306 (72\%) were eligible at screening and gave informed consent. Seven participants were later found to have been randomised in error and one withdrew consent, leaving 298 (176 men, 122 women) who will form the intention to treat (ITT) population for analysis. Mean (SD) age was 54.4 (7.6) years, duration of diabetes 3.0 (1.7) years, BMI 34.6 (4.4) kg/m2 for all participants (34.2 (4.2) kg/m2 in men and 35.3 (4.6) kg/m2 in women) and baseline HbA1c (on treatment) 59.3 (12.7) mmol/mol (7.6\% [1.2\%]). The recruitment rate in the intervention and control groups, and comparisons between the subgroups recruited in Scotland and England, showed few differences. CONCLUSIONS/INTERPRETATION: DiRECT has recruited a cohort of people with type 2 diabetes with characteristics similar to those seen in routine practice, indicating potential widespread applicability. Over 25\% of the eligible population wished to participate in the study, including a high proportion of men, in line with the prevalence distribution of type 2 diabetes. TRIAL REGISTRATION: www.controlled-trials.com/ISRCTN03267836 ; date of registration 20 December 2013.},
  langid = {english},
  pmcid = {PMC6448967},
  pmid = {29188339},
  keywords = {Adult,Aged,Blood Glucose,Cohort Studies,Diabetes Mellitus Type 2,England,Female,Formula diet,Glycated Hemoglobin,Humans,Hypoglycemic Agents,Male,Middle Aged,Quality of Life,Remission,Scotland,Type 2 diabetes,Weight Loss,Weight management,Young Adult},
  file = {/Users/xx20081/Zotero/storage/PGBD92QB/Taylor et al. - 2018 - Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRE.pdf}
}

@article{tchernofPathophysiologyHumanVisceral2013,
  title = {Pathophysiology of Human Visceral Obesity: An Update},
  shorttitle = {Pathophysiology of Human Visceral Obesity},
  author = {Tchernof, Andr{\'e} and Despr{\'e}s, Jean-Pierre},
  year = {2013},
  month = jan,
  journal = {Physiological Reviews},
  volume = {93},
  number = {1},
  pages = {359--404},
  issn = {1522-1210},
  doi = {10.1152/physrev.00033.2011},
  abstract = {Excess intra-abdominal adipose tissue accumulation, often termed visceral obesity, is part of a phenotype including dysfunctional subcutaneous adipose tissue expansion and ectopic triglyceride storage closely related to clustering cardiometabolic risk factors. Hypertriglyceridemia; increased free fatty acid availability; adipose tissue release of proinflammatory cytokines; liver insulin resistance and inflammation; increased liver VLDL synthesis and secretion; reduced clearance of triglyceride-rich lipoproteins; presence of small, dense LDL particles; and reduced HDL cholesterol levels are among the many metabolic alterations closely related to this condition. Age, gender, genetics, and ethnicity are broad etiological factors contributing to variation in visceral adipose tissue accumulation. Specific mechanisms responsible for proportionally increased visceral fat storage when facing positive energy balance and weight gain may involve sex hormones, local cortisol production in abdominal adipose tissues, endocannabinoids, growth hormone, and dietary fructose. Physiological characteristics of abdominal adipose tissues such as adipocyte size and number, lipolytic responsiveness, lipid storage capacity, and inflammatory cytokine production are significant correlates and even possible determinants of the increased cardiometabolic risk associated with visceral obesity. Thiazolidinediones, estrogen replacement in postmenopausal women, and testosterone replacement in androgen-deficient men have been shown to favorably modulate body fat distribution and cardiometabolic risk to various degrees. However, some of these therapies must now be considered in the context of their serious side effects. Lifestyle interventions leading to weight loss generally induce preferential mobilization of visceral fat. In clinical practice, measuring waist circumference in addition to the body mass index could be helpful for the identification and management of a subgroup of overweight or obese patients at high cardiometabolic risk.},
  langid = {english},
  pmid = {23303913},
  keywords = {Adiposity,Adolescent,Adult,Age Factors,Aged,Aged 80 and over,Energy Metabolism,Ethnicity,Female,Genetic Predisposition to Disease,Humans,Intra-Abdominal Fat,Life Style,Male,Middle Aged,Obesity Abdominal,Phenotype,Prognosis,Risk Factors,Sex Factors,Young Adult}
}

@article{tchetgentchetgenInstrumentalVariableEstimation2015,
  title = {Instrumental {{Variable Estimation}} in a {{Survival Context}}},
  author = {Tchetgen Tchetgen, Eric J. and Walter, Stefan and Vansteelandt, Stijn and Martinussen, Torben and Glymour, Maria},
  year = {2015},
  month = may,
  journal = {Epidemiology},
  volume = {26},
  number = {3},
  pages = {402},
  issn = {1044-3983},
  doi = {10.1097/EDE.0000000000000262},
  urldate = {2024-08-21},
  abstract = {Bias due to unobserved confounding can seldom be ruled out with certainty when estimating the causal effect of a nonrandomized treatment. The instrumental variable (IV) design offers, under certain assumptions, the opportunity to tame confounding bias, without directly observing all confounders. The IV approach is very well developed in the context of linear regression and also for certain generalized linear models with a nonlinear link function. However, IV methods are not as well developed for regression analysis with a censored survival outcome. In this article, we develop the IV approach for regression analysis in a survival context, primarily under an additive hazards model, for which we describe 2 simple methods for estimating causal effects. The first method is a straightforward 2-stage regression approach analogous to 2-stage least squares commonly used for IV analysis in linear regression. In this approach, the fitted value from a first-stage regression of the exposure on the IV is entered in place of the exposure in the second-stage hazard model to recover a valid estimate of the treatment effect of interest. The second method is a so-called control function approach, which entails adding to the additive hazards outcome model, the residual from a first-stage regression of the exposure on the IV. Formal conditions are given justifying each strategy, and the methods are illustrated in a novel application to a Mendelian randomization study to evaluate the effect of diabetes on mortality using data from the Health and Retirement Study. We also establish that analogous strategies can also be used under a proportional hazards model specification, provided the outcome is rare over the entire follow-up.},
  langid = {american},
  file = {/Users/xx20081/Zotero/storage/CNX8NZA4/Tchetgen Tchetgen et al. - 2015 - Instrumental Variable Estimation in a Survival Con.pdf;/Users/xx20081/Zotero/storage/YDJW5J8B/instrumental_variable_estimation_in_a_survival.16.html}
}

@article{tgCharacterisingMetabolomicSignatures2022,
  title = {Characterising Metabolomic Signatures of Lipid-Modifying Therapies through Drug Target Mendelian Randomisation},
  author = {Tg, Richardson and Gm, Leyden and Q, Wang and Ja, Bell and B, Elsworth and G, Davey Smith and Mv, Holmes},
  year = {2022},
  month = feb,
  journal = {PLoS biology},
  volume = {20},
  number = {2},
  publisher = {PLoS Biol},
  issn = {1545-7885},
  doi = {10.1371/journal.pbio.3001547},
  urldate = {2025-04-12},
  abstract = {Large-scale molecular profiling and genotyping provide a unique opportunity to systematically compare the genetically predicted effects of therapeutic targets on the human metabolome. We firstly constructed genetic risk scores for 8 drug targets on the basis that they primarily modify low-density li {\dots}},
  langid = {english},
  pmid = {35213538},
  file = {/Users/xx20081/Zotero/storage/79HXMP68/Tg et al. - 2022 - Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian ran.pdf}
}

@misc{TirzepatideHeartFailure,
  title = {Tirzepatide for {{Heart Failure}} with {{Preserved Ejection Fraction}} and {{Obesity}} {\textbar} {{New England Journal}} of {{Medicine}}},
  urldate = {2025-01-20},
  howpublished = {https://www.nejm.org/doi/full/10.1056/NEJMoa2410027},
  file = {/Users/xx20081/Zotero/storage/BGXCJ4QE/NEJMoa2410027.html}
}

@article{tokolyiContributionGeneticDeterminants2025,
  title = {The Contribution of Genetic Determinants of Blood Gene Expression and Splicing to Molecular Phenotypes and Health Outcomes},
  author = {Tokolyi, Alex and Persyn, Elodie and Nath, Artika P. and Burnham, Katie L. and Marten, Jonathan and Vanderstichele, Thomas and Tardaguila, Manuel and Stacey, David and Farr, Ben and Iyer, Vivek and Jiang, Xilin and Lambert, Samuel A. and Noell, Guillaume and Quail, Michael A. and Rajan, Diana and Ritchie, Scott C. and Sun, Benjamin B. and Thurston, Scott A. J. and Xu, Yu and Whelan, Christopher D. and Runz, Heiko and Petrovski, Slav{\'e} and Gaffney, Daniel J. and Roberts, David J. and Di Angelantonio, Emanuele and Peters, James E. and Soranzo, Nicole and Danesh, John and Butterworth, Adam S. and Inouye, Michael and Davenport, Emma E. and Paul, Dirk S.},
  year = {2025},
  month = mar,
  journal = {Nature Genetics},
  volume = {57},
  number = {3},
  pages = {616--625},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-025-02096-3},
  urldate = {2025-04-13},
  abstract = {The biological mechanisms through which most nonprotein-coding genetic variants affect disease risk are unknown. To investigate gene-regulatory mechanisms, we mapped blood gene expression and splicing quantitative trait loci (QTLs) through bulk RNA sequencing in 4,732 participants and integrated protein, metabolite and lipid data from the same individuals. We identified cis-QTLs for the expression of 17,233 genes and 29,514 splicing events (in 6,853 genes). Colocalization analyses revealed 3,430 proteomic and metabolomic traits with a shared association signal with either gene expression or splicing. We quantified the relative contribution of the genetic effects at loci with shared etiology, observing 222 molecular phenotypes significantly mediated by gene expression or splicing. We uncovered gene-regulatory mechanisms at disease loci with therapeutic implications, such as WARS1 in hypertension, IL7R in dermatitis and IFNAR2 in COVID-19. Our study provides an open-access resource on the shared genetic etiology across transcriptional phenotypes, molecular traits and health outcomes in humans (https://IntervalRNA.org.uk).},
  copyright = {2025 The Author(s)},
  langid = {english},
  keywords = {Gene expression,Gene regulation,Transcriptomics},
  file = {/Users/xx20081/Zotero/storage/F7FYID6I/41588_2025_2096_MOESM1_ESM copy.pdf;/Users/xx20081/Zotero/storage/GPE6CP8U/Tokolyi et al. - 2025 - The contribution of genetic determinants of blood gene expression and splicing to molecular phenotyp.pdf}
}

@article{torkamaniPersonalClinicalUtility2018,
  title = {The Personal and Clinical Utility of Polygenic Risk Scores},
  author = {Torkamani, Ali and Wineinger, Nathan E. and Topol, Eric J.},
  year = {2018},
  month = sep,
  journal = {Nature Reviews Genetics},
  volume = {19},
  number = {9},
  pages = {581--590},
  publisher = {Nature Publishing Group},
  issn = {1471-0064},
  doi = {10.1038/s41576-018-0018-x},
  urldate = {2024-12-10},
  abstract = {Initial expectations for genome-wide association studies were high, as such studies promised to rapidly transform personalized medicine with individualized disease risk predictions, prevention strategies and treatments. Early findings, however, revealed a more complex genetic architecture than was anticipated for most common diseases --- complexity that seemed to limit the immediate utility of these findings. As a result, the practice of utilizing the DNA of an individual to predict disease has been judged to provide little to no useful information. Nevertheless, recent efforts have begun to demonstrate the utility of polygenic risk profiling to identify groups of individuals who could benefit from the knowledge of their probabilistic susceptibility to disease. In this context, we review the evidence supporting the personal and clinical utility of polygenic risk profiling.},
  copyright = {2018 Macmillan Publishers Ltd., part of Springer Nature},
  langid = {english},
  keywords = {DNA sequencing,Genetic testing,Genetic variation,Genome-wide association studies,Medical genetics,Personalized medicine},
  file = {/Users/xx20081/Zotero/storage/3B76ZCWY/Torkamani et al. - 2018 - The personal and clinical utility of polygenic risk scores.pdf}
}

@article{triozziGLP1RGeneExpression2024,
  title = {{{GLP1R Gene Expression}} and {{Kidney Disease Progression}}},
  author = {Triozzi, Jefferson L. and Yu, Zhihong and Giri, Ayush and Chen, Hua-Chang and Wilson, Otis D. and Ferolito, Brian and Ikizler, T. Alp and Akwo, Elvis A. and {Robinson-Cohen}, Cassianne and Gaziano, John Michael and Cho, Kelly and Phillips, Lawrence S. and Tao, Ran and Pereira, Alexandre C. and Hung, Adriana M. and {VA Million Veteran Program}},
  year = {2024},
  month = oct,
  journal = {JAMA Network Open},
  volume = {7},
  number = {10},
  pages = {e2440286},
  issn = {2574-3805},
  doi = {10.1001/jamanetworkopen.2024.40286},
  urldate = {2025-04-13},
  abstract = {Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have nephroprotective properties beyond those related to weight loss and glycemic control.To investigate the association of genetically proxied GLP-1RAs with kidney disease progression.This genetic association study assembled a national retrospective cohort of veterans aged 18 years or older from the US Department of Veterans Affairs Million Veteran Program between January 10, 2011, and December 31, 2021. Data were analyzed from November 2023 to February 2024.Genetic risk score for systemic GLP1R gene expression that was calculated for each study participant based on genetic variants associated with GLP1R mRNA levels across all tissue samples within the Genotype-Tissue Expression project.The primary composite outcome was incident end-stage kidney disease or a 40\% decline in estimated glomerular filtration rate. Cox proportional hazards regression survival analysis assessed the association between genetically proxied GLP-1RAs and kidney disease progression.Among 353\,153 individuals (92.5\% men), median age was 66 years (IQR, 58.0-72.0 years) and median follow-up was 5.1 years (IQR, 3.1-7.2 years). Overall, 25.7\% had diabetes, and 45.0\% had obesity. A total of 4.6\% experienced kidney disease progression. Overall, higher genetic GLP1R gene expression was associated with a lower risk of kidney disease progression in the unadjusted model (hazard ratio [HR], 0.96; 95\% CI, 0.92-0.99; P\,=\,.02) and in the fully adjusted model accounting for baseline patient characteristics, body mass index, and the presence or absence of diabetes (HR, 0.96; 95\% CI, 0.92-1.00; P\,=\,.04). The results were similar in sensitivity analyses stratified by diabetes or obesity status.In this genetic association study, higher GLP1R gene expression was associated with a small reduction in risk of kidney disease progression. These findings support pleiotropic nephroprotective mechanisms of GLP-1RAs independent of their effects on body weight and glycemic control.},
  file = {/Users/xx20081/Zotero/storage/RJ38TU7J/Triozzi et al. - 2024 - GLP1R Gene Expression and Kidney Disease Progression.pdf;/Users/xx20081/Zotero/storage/78TXGC48/2825345.html}
}

@article{tsujimotoAbdominalObesityAssociated2017,
  title = {Abdominal {{Obesity Is Associated With}}~an~{{Increased Risk}} of {{All-Cause Mortality}} in {{Patients With HFpEF}}},
  author = {Tsujimoto, Tetsuro and Kajio, Hiroshi},
  year = {2017},
  month = dec,
  journal = {Journal of the American College of Cardiology},
  volume = {70},
  number = {22},
  pages = {2739--2749},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2017.09.1111},
  abstract = {BACKGROUND: There is a lack of studies that evaluate the association between abdominal obesity and subsequent outcomes in patients with heart failure with preserved ejection fraction (HFpEF). OBJECTIVES: The present study aimed to assess the association between abdominal obesity and risk of all-cause mortality in patients with HFpEF. METHODS: The present study used data from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist) trial. The primary outcome was all-cause mortality. We analyzed and compared the hazard ratios (HRs) in patients with abdominal obesity and those without abdominal obesity using multivariable Cox proportional hazard models. Abdominal obesity was defined as a waist circumference of~{$\geq$}102~cm in men and~{$\geq$}88~cm in women. RESULTS: The present study included 3,310 patients with HFpEF: 2,413 patients with abdominal obesity and 897 without abdominal obesity. The mean follow-up was 3.4 {\textpm} 1.7 years. During follow-up, 500 patients died. All-cause mortality rates in patients with and without abdominal obesity were 46.1 and 40.7 events per 1,000 person-years, respectively. After multivariable adjustment, the risk of all-cause mortality was significantly higher in patients with abdominal obesity than in those without abdominal obesity (adjusted HR: 1.52; 95\% confidence interval [CI]: 1.16 to 1.99; p~=~0.002). The risk of cardiovascular and noncardiovascular mortality was also significantly higher in patients with abdominal obesity than in those without abdominal obesity (adjusted HR: 1.50; 95\% CI: 1.08 to 2.08; p~=~0.01 and adjusted HR: 1.58; 95\% CI: 1.00 to 2.51; p~=~0.04, respectively). CONCLUSIONS: The risk of all-cause mortality was significantly higher in patients with HFpEF with abdominal obesity than in those without abdominal obesity.},
  langid = {english},
  pmid = {29191321},
  keywords = {abdominal obesity,Aged,all-cause mortality,Double-Blind Method,Female,Heart Failure,heart failure with preserved ejection fraction,Humans,inflammation,Japan,Male,Middle Aged,Mineralocorticoid Receptor Antagonists,Mortality,Obesity Abdominal,Proportional Hazards Models,Risk Assessment,Risk Factors,Stroke Volume,TOPCAT trial},
  file = {/Users/xx20081/Zotero/storage/KRPM2JJS/Tsujimoto and Kajio - 2017 - Abdominal Obesity Is Associated WithanIncreased .pdf}
}

@article{turkbeyImpactObesityLeft2010,
  title = {The Impact of Obesity on the Left Ventricle: The {{Multi-Ethnic Study}} of {{Atherosclerosis}} ({{MESA}})},
  shorttitle = {The Impact of Obesity on the Left Ventricle},
  author = {Turkbey, Evrim B. and McClelland, Robyn L. and Kronmal, Richard A. and Burke, Gregory L. and Bild, Diane E. and Tracy, Russell P. and Arai, Andrew E. and Lima, Jo{\~a}o A. C. and Bluemke, David A.},
  year = {2010},
  month = mar,
  journal = {JACC. Cardiovascular imaging},
  volume = {3},
  number = {3},
  pages = {266--274},
  issn = {1876-7591},
  doi = {10.1016/j.jcmg.2009.10.012},
  abstract = {OBJECTIVES: The purpose of this study was to evaluate the relationship of left ventricular (LV) remodeling assessed by cardiac magnetic resonance to various measures of obesity in a large population-based study. BACKGROUND: Obesity is a well-known risk factor for cardiovascular disease, yet its relationship with LV size and function is poorly understood. METHODS: A total of 5,098 participants (age 45 to 84 years; 48\% men) in the Multi-Ethnic Study of Atherosclerosis who were free of clinically apparent cardiovascular disease underwent cardiac magnetic resonance to assess LV size and function as well as measures of obesity, including body mass index, waist-to-hip ratio and waist circumference, and cardiovascular risk factors. Fat mass (FM) was estimated based on height-weight models derived from bioelectrical impedance studies. The associations of obesity measures with LV size and function were evaluated using linear spline regression models for body mass index and multivariable regression models for other measures of obesity; they were displayed graphically using generalized additive models. RESULTS: LV mass and end-diastolic volume were positively associated with measures of obesity in both sexes after adjustment for risk factors (e.g., 5.7-g and 6.9-g increase in LV mass per 10-kg increase in FM in women and men, respectively [p {$<$} 0.001]). LV mass-to-volume ratio was positively associated with increased body mass index, waist-to-hip ratio, waist circumference, and estimated FM (e.g., 0.02-g/ml and 0.06-g/ml increase in mass-to-volume ratio per 10-kg increase in FM in women and men, respectively [p {$<$} 0.001]). The increased mass-to-volume ratio was due to a greater increase in LV mass relative to LV end-diastolic volume. All associations were stronger for men than for women. Ejection fraction showed no significant association with measures of obesity. CONCLUSIONS: Obesity was associated with concentric LV remodeling without change in ejection fraction in a large, multiethnic cohort study.},
  langid = {english},
  pmcid = {PMC3037096},
  pmid = {20223423},
  keywords = {Aged,Aged 80 and over,Atherosclerosis,Body Mass Index,Female,Heart Diseases,Heart Ventricles,Humans,Linear Models,Magnetic Resonance Imaging Cine,Male,Middle Aged,Obesity,Risk Assessment,Risk Factors,Stroke Volume,United States,Ventricular Remodeling,Waist Circumference,Waist-Hip Ratio},
  file = {/Users/xx20081/Zotero/storage/ZFP9BVSW/Turkbey et al. - 2010 - The impact of obesity on the left ventricle the M.pdf}
}

@article{tutorUpdatesObesityObesity2023,
  title = {Updates on Obesity and the Obesity Paradox in Cardiovascular Diseases},
  author = {Tutor, Austin W. and Lavie, Carl J. and Kachur, Sergey and Milani, Richard V. and Ventura, Hector O.},
  year = {2023},
  month = may,
  journal = {Progress in Cardiovascular Diseases},
  volume = {78},
  pages = {2--10},
  issn = {0033-0620},
  doi = {10.1016/j.pcad.2022.11.013},
  urldate = {2024-08-06},
  abstract = {The prevalence of obesity has reached pandemic proportions worldwide and certainly in the United States. Obesity is a well-established independent risk factor for development of many cardiovascular diseases (CVD), including heart failure, coronary heart disease, atrial fibrillation, and hypertension. Therefore, it is logical to expect obesity would have a strong correlation with CVD mortality. However, a substantial body of literature demonstrates a paradox with improved prognosis of overweight and obese patients with established CVD compared to lean patients with the identical CVD. Surprisingly, similar data has also shown that cardiovascular fitness, rather than weight loss alone, influences the relationship between obesity and mortality in those with established CVD. The impact of fitness, exercise, physical activity (PA), and weight loss and their relationship to the obesity paradox are all reviewed here.},
  keywords = {Cardiac fitness,Cardiorespiratory fitness,Fitness outcomes,Obesity paradox},
  file = {/Users/xx20081/Zotero/storage/FJ32TLEP/Tutor et al. - 2023 - Updates on obesity and the obesity paradox in card.pdf;/Users/xx20081/Zotero/storage/FA2X4Z4M/S0033062022001347.html}
}

@article{uretskyObesityParadoxPatients2007,
  title = {Obesity Paradox in Patients with Hypertension and Coronary Artery Disease},
  author = {Uretsky, Seth and Messerli, Franz H. and Bangalore, Sripal and Champion, Annette and {Cooper-Dehoff}, Rhonda M. and Zhou, Qian and Pepine, Carl J.},
  year = {2007},
  month = oct,
  journal = {The American Journal of Medicine},
  volume = {120},
  number = {10},
  pages = {863--870},
  issn = {1555-7162},
  doi = {10.1016/j.amjmed.2007.05.011},
  abstract = {PURPOSE: An obesity paradox, a "paradoxical" decrease in morbidity and mortality with increasing body mass index (BMI), has been shown in patients with heart failure and those undergoing percutaneous coronary intervention. However, whether this phenomenon exists in patients with hypertension and coronary artery disease is not known. METHODS: A total of 22,576 hypertensive patients with coronary artery disease (follow-up 61,835 patient years, mean age 66+/-9.8 years) were randomized to a verapamil-SR or atenolol strategy. Dose titration and additional drugs (trandolapril and/or hydrochlorothiazide) were added to achieve target blood pressure control according to the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure targets. Patients were classified into 5 groups according to baseline BMI: less than 20 kg/m2 (thin), 20 to 25 kg/m2 (normal weight), 25 to 30 kg/m2 (overweight), 30 to 35 kg/m2 (class I obesity), and 35 kg/m2 or more (class II-III obesity). The primary outcome was first occurrence of death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: With patients of normal weight (BMI 20 to{$<$}25 kg/m2) as the reference group, the risk of primary outcome was lower in the overweight patients (adjusted hazard ratio [HR] 0.77, 95\% confidence interval [CI], 0.70-0.86, P{$<$}.001), class I obese patients (adjusted HR 0.68, 95\% CI, 0.59-0.78, P{$<$}.001), and class II to III obese patients (adjusted HR 0.76, 95\% CI, 0.65-0.88, P {$<$}.001). Class I obese patients had the lowest rate of primary outcome and death despite having smaller blood pressure reduction compared with patients of normal weight at 24 months (-17.5+/-21.9 mm Hg/-9.8+/-12.4 mm Hg vs -20.7+/-23.1 mm Hg /-10.6+/-12.5 mm Hg, P{$<$}.001). CONCLUSION: In a population with hypertension and coronary artery disease, overweight and obese patients had a decreased risk of primary outcome compared with patients of normal weight, which was driven primarily by a decreased risk of all-cause mortality. Our results further suggest a protective effect of obesity in patients with known cardiovascular disease in concordance with data in patients with heart failure and those undergoing percutaneous coronary intervention.},
  langid = {english},
  pmid = {17904457},
  keywords = {Age Distribution,Aged,Antihypertensive Agents,Atenolol,Body Mass Index,Causality,Cohort Studies,Comorbidity,Coronary Artery Disease,Female,Humans,Hypertension,Male,Middle Aged,Multivariate Analysis,Obesity,Outcome and Process Assessment Health Care,Risk Factors,Sex Distribution,Survival Analysis,United States,Vasodilator Agents,Verapamil}
}

@article{vanDenBerge2022,
  title = {Determinants of Quality of Life in Acute Heart Failure Patients with and without Comorbidities: A Prospective, Observational Study},
  author = {Berge, Jan C. Van Den and Vark, Laura C. Van and Postmus, Douwe and Utens, Elisabeth M.W.J. and Hillege, Hans L. and Boersma, Eric and {Lesman-Leegte}, Ivonne and Akkerhuis, K. Martijn},
  year = {2022},
  month = mar,
  journal = {European journal of cardiovascular nursing},
  volume = {21},
  number = {3},
  pages = {205--212},
  publisher = {Eur J Cardiovasc Nurs},
  issn = {1873-1953},
  doi = {10.1093/EURJCN/ZVAB061},
  abstract = {Aims: The relation between non-cardiac comorbidities and health-related quality of life (HRQoL) in patients with heart failure (HF) has been studied to a limited extent. To investigate the HRQoL and their determinants among HF patients with and without comorbidities. Methods and results: TRIUMPH (TRanslational Initiative on Unique and novel strategies for Management of Patients with Heart failure) is a Dutch prospective, multicentre study enrolling 496 acute HF patients between 2009 and 2014. We included 334 patients who had completed the HRQoL questionnaires at baseline. The HRQoL was measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) en EuroQuality-of-life five Dimensions (EQ-5D). Comorbidity was defined as having a history of at least one of the following comorbidities: chronic kidney disease, diabetes mellitus, chronic obstructive pulmonary disease (COPD), and/or cerebrovascular accident. Patients with comorbidity (n = 205, 61\%) had lower scores on the physical limitation scale and clinical summary score of the KCCQ (P = 0.03 and P = 0.01, respectively). Female sex, COPD, previous HF, increasing body mass index (BMI), elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP), high systolic blood pressure, and the presence of anxiety and/or depression negatively influenced the HRQoL among HF patients with comorbidity. Besides anxiety and depression, we hardly found any other determinant of HRQoL in patients without comorbidity. Conclusion: Heart failure patients without comorbidity had better HRQoL than patients with comorbidity. Sex, previous HF, BMI, COPD, systolic blood pressure, NT-proBNP levels, and also anxiety and depression were determinants of HRQoL in patients with comorbidity. In those without comorbidity, apart from anxiety and depression, no further determinants of HRQoL were found.},
  pmid = {34392355},
  keywords = {Chronic Obstructive* / epidemiology,Comorbidity,doi:10.1093/eurjcn/zvab061,Female,Heart Failure* / complications,Heart Failure* / epidemiology,Humans,Jan C van den Berge,K Martijn Akkerhuis,Laura C van Vark,MEDLINE,Multicenter Study,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,Non-U.S. Gov't,Observational Study,pmid:34392355,Prospective Studies,PubMed Abstract,Pulmonary Disease,Quality of Life,Research Support}
}

@article{vanoortModifiableLifestyleFactors2020,
  title = {Modifiable Lifestyle Factors and Heart Failure: {{A Mendelian}} Randomization Study},
  shorttitle = {Modifiable Lifestyle Factors and Heart Failure},
  author = {{van Oort}, Sabine and Beulens, Joline W. J. and {van Ballegooijen}, Adriana J. and Handoko, M. Louis and Larsson, Susanna C.},
  year = {2020},
  month = sep,
  journal = {American Heart Journal},
  volume = {227},
  pages = {64--73},
  issn = {0002-8703},
  doi = {10.1016/j.ahj.2020.06.007},
  urldate = {2025-01-15},
  abstract = {Background Lifestyle factors may be important targets in the prevention of heart failure. The current knowledge on the relationship between lifestyle factors and heart failure originates mostly from observational studies. The objective of this study was to investigate causal associations of multiple lifestyle factors with heart failure risk by using Mendelian randomization. Methods We obtained summary statistics data for single nucleotide polymorphisms associated with the following 5 lifestyle factors at genome-wide significance in genome-wide association studies of European-descent individuals: smoking, alcohol consumption, coffee consumption, physical activity, and sleep duration. The corresponding data for heart failure were acquired from a genome-wide association study comprising 47,309 cases and 930,014 controls of European ancestry. For the primary analyses, we used the inverse-variance weighted method. Results Genetic predisposition to smoking initiation (ever smoked regularly) was robustly associated with a higher odds of heart failure (odds ratio: 1.28; 99\% CI: 1.21-1.35). Genetically predicted longer sleep duration was associated with a lower odds of heart failure (odds ratio per hour/day: 0.73; 99\% CI: 0.60-0.89). We found no associations of alcohol consumption, coffee consumption, and physical activity with heart failure. Conclusions This Mendelian randomization study showed that smoking initiation increases heart failure risk, whereas longer sleep duration decreases the risk of heart failure. Sleep duration should be regarded as novel risk factor in heart failure prevention guidelines. The potential causal role of alcohol and coffee consumption and physical activity for heart failure warrants further investigation in future larger Mendelian randomization analyses.},
  file = {/Users/xx20081/Zotero/storage/IU9MAGAR/van Oort et al. - 2020 - Modifiable lifestyle factors and heart failure A Mendelian randomization study.pdf}
}

@article{vanveldhuisenBariatricSurgeryCardiovascular2022,
  title = {Bariatric Surgery and Cardiovascular Disease: A Systematic Review and Meta-Analysis},
  shorttitle = {Bariatric Surgery and Cardiovascular Disease},
  author = {{van Veldhuisen}, Sophie L. and Gorter, Thomas M. and {van Woerden}, Gijs and {de Boer}, Rudolf A. and Rienstra, Michiel and Hazebroek, Eric J. and {van Veldhuisen}, Dirk J.},
  year = {2022},
  month = may,
  journal = {European Heart Journal},
  volume = {43},
  number = {20},
  pages = {1955--1969},
  issn = {1522-9645},
  doi = {10.1093/eurheartj/ehac071},
  abstract = {AIMS: Obesity is a global health problem, associated with significant morbidity and mortality, often due to cardiovascular (CV) diseases. While bariatric surgery is increasingly performed in patients with obesity and reduces CV risk factors, its effect on CV disease is not established. We conducted a systematic review and meta-analysis to evaluate the effect of bariatric surgery on CV outcomes, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. METHODS AND RESULTS: PubMed and Embase were searched for literature until August 2021 which compared bariatric surgery patients to non-surgical controls. Outcomes of interest were all-cause and CV mortality, atrial fibrillation (AF), heart failure (HF), myocardial infarction, and stroke. We included 39 studies, all prospective or retrospective cohort studies, but randomized outcome trials were not available. Bariatric surgery was associated with a beneficial effect on all-cause mortality [pooled hazard ratio (HR) of 0.55; 95\% confidence interval (CI) 0.49-0.62, P {$<$} 0.001 vs. controls], and CV mortality (HR 0.59, 95\% CI 0.47-0.73, P {$<$} 0.001). In addition, bariatric surgery was also associated with a reduced incidence of HF (HR 0.50, 95\% CI 0.38-0.66, P {$<$} 0.001), myocardial infarction (HR 0.58, 95\% CI 0.43-0.76, P {$<$} 0.001), and stroke (HR 0.64, 95\% CI 0.53-0.77, P {$<$} 0.001), while its association with AF was not statistically significant (HR 0.82, 95\% CI 0.64-1.06, P = 0.12). CONCLUSION: The present systematic review and meta-analysis suggests that bariatric surgery is associated with reduced all-cause and CV mortality, and lowered incidence of several CV diseases in patients with obesity. Bariatric surgery should therefore be considered in these patients.},
  langid = {english},
  pmcid = {PMC9123239},
  pmid = {35243488},
  keywords = {Atrial fibrillation,Atrial Fibrillation,Bariatric surgery,Bariatric Surgery,Cardiovascular disease,Cardiovascular Diseases,Heart failure,Heart Failure,Humans,Metabolic surgery,Myocardial infarction,Myocardial Infarction,Obesity,Outcome,Prospective Studies,Retrospective Studies,Stroke},
  file = {/Users/xx20081/Zotero/storage/GRB68PH4/van Veldhuisen et al. - 2022 - Bariatric surgery and cardiovascular disease a sy.pdf}
}

@article{vazMetabolomicSignaturesBariatric2022,
  title = {Metabolomic Signatures after Bariatric Surgery -- a Systematic Review},
  author = {Vaz, Matilde and Pereira, Sofia S. and Monteiro, Mariana P.},
  year = {2022},
  journal = {Reviews in Endocrine \& Metabolic Disorders},
  volume = {23},
  number = {3},
  pages = {503--519},
  issn = {1389-9155},
  doi = {10.1007/s11154-021-09695-5},
  urldate = {2025-05-28},
  abstract = {Metabolomics emerged as an important tool to gain insights on how the body responds to therapeutic interventions. Bariatric surgery is the most effective treatment for severe obesity and obesity-related co-morbidities. Our aim was to conduct a systematic review of the available data on metabolomics profiles that characterize patients submitted to different bariatric surgery procedures, which could be useful to predict clinical outcomes including weight loss and type 2 diabetes remission. For that, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses - PRISMA guidelines were followed. Data from forty-seven original study reports addressing metabolomics profiles induced by bariatric surgery that met eligibility criteria were compiled and summarized. Amino acids, lipids, energy-related and gut microbiota-related were the metabolite classes most influenced by bariatric surgery. Among these, higher pre-operative levels of specific lipids including phospholipids, long-chain fatty acids and bile acids were associated with post-operative T2D remission. As conclusion, metabolite profiling could become a useful tool to predict long term response to different bariatric surgery procedures, allowing more personalized interventions and improved healthcare resources allocation.},
  pmcid = {PMC9156502},
  pmid = {34855133},
  file = {/Users/xx20081/Zotero/storage/M5599FHN/Vaz et al. - 2022 - Metabolomic signatures after bariatric surgery  a systematic review.pdf}
}

@article{vazMetabolomicSignaturesBariatric2022a,
  title = {Metabolomic Signatures after Bariatric Surgery - a Systematic Review},
  author = {Vaz, Matilde and Pereira, Sofia S. and Monteiro, Mariana P.},
  year = {2022},
  month = jun,
  journal = {Reviews in Endocrine \& Metabolic Disorders},
  volume = {23},
  number = {3},
  pages = {503--519},
  issn = {1573-2606},
  doi = {10.1007/s11154-021-09695-5},
  abstract = {Metabolomics emerged as an important tool to gain insights on how the body responds to therapeutic interventions. Bariatric surgery is the most effective treatment for severe obesity and obesity-related co-morbidities. Our aim was to conduct a systematic review of the available data on metabolomics profiles that characterize patients submitted to different bariatric surgery procedures, which could be useful to predict clinical outcomes including weight loss and type 2 diabetes remission. For that, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses - PRISMA guidelines were followed. Data from forty-seven original study reports addressing metabolomics profiles induced by bariatric surgery that met eligibility criteria were compiled and summarized. Amino acids, lipids, energy-related and gut microbiota-related were the metabolite classes most influenced by bariatric surgery. Among these, higher pre-operative levels of specific lipids including phospholipids, long-chain fatty acids and bile acids were associated with post-operative T2D remission. As conclusion, metabolite profiling could become a useful tool to predict long term response to different bariatric surgery procedures, allowing more personalized interventions and improved healthcare resources allocation.},
  langid = {english},
  pmcid = {PMC9156502},
  pmid = {34855133},
  keywords = {Bariatric surgery,Bariatric Surgery,Diabetes Mellitus Type 2,Humans,Lipids,Metabolomics,Obesity Morbid,Type 2 diabetes remission,Weight loss},
  file = {/Users/xx20081/Zotero/storage/LHFWXW3C/Vaz et al. - 2022 - Metabolomic signatures after bariatric surgery - a systematic review.pdf}
}

@article{vestHeartFailureOverweight2015,
  title = {The {{Heart Failure Overweight}}/{{Obesity Survival Paradox}}: {{The Missing Sex Link}}},
  shorttitle = {The {{Heart Failure Overweight}}/{{Obesity Survival Paradox}}},
  author = {Vest, Amanda R. and Wu, Yuping and Hachamovitch, Rory and Young, James B. and Cho, Leslie},
  year = {2015},
  month = nov,
  journal = {JACC. Heart failure},
  volume = {3},
  number = {11},
  pages = {917--926},
  issn = {2213-1787},
  doi = {10.1016/j.jchf.2015.06.009},
  abstract = {OBJECTIVES: This study sought to determine whether body mass index (BMI) has a differential impact on survival for females versus males with advanced systolic heart failure (HF). BACKGROUND: Females have a survival advantage in HF, the mechanisms of which are unclear. There is also a proposed "obesity survival paradox" in which excess adiposity promotes HF survival. METHODS: We reviewed 3,811 patients with left ventricular ejection fraction~{$\leq$}40\% who had undergone cardiopulmonary exercise testing between 1995 and 2011. The endpoint was all-cause mortality. Multivariable analysis was performed using a Cox proportional hazards model. Because of the nonlinearity of BMI, a restricted cubic spline was used. An interaction term was added to investigate the impact of BMI on mortality by sex. RESULTS: The unadjusted data demonstrated an overall obesity survival paradox in HF. This survival paradox disappeared for males after adjustment for potential confounders, with overweight and obese males showing higher adjusted mortality hazard ratios compared with normal weight males. Conversely, females in the overweight BMI range (25.0 to 29.9 kg/m(2)) had the lowest adjusted mortality (hazard ratio: 0.84; 95\% confidence interval: 0.77 to 0.93; p~= 0.0005 compared with normal weight females) with a nadir in mortality hazard just below BMI 30 kg/m(2). The multivariable model supported a differential impact of BMI on mortality in males versus females (p for interaction~{$<$}0.0001). CONCLUSIONS: In this advanced HF cohort, an unadjusted obesity survival paradox disappeared after adjustment for confounders. Overweight and obese males had higher adjusted mortality than normal weight males, whereas a BMI in the overweight range was associated with a significant survival benefit in females.},
  langid = {english},
  pmid = {26454846},
  keywords = {Adult,Aged,Body Mass Index,Exercise Test,female,Female,Follow-Up Studies,gender,heart failure,Heart Failure Systolic,Humans,Male,Middle Aged,obesity,Obesity,overweight,Overweight,Prognosis,Proportional Hazards Models,Prospective Studies,Risk Assessment,Risk Factors,Sex Distribution,Stroke Volume,Survival Analysis},
  file = {/Users/xx20081/Zotero/storage/9BE9CUKN/Vest et al. - 2015 - The Heart Failure OverweightObesity Survival Para.pdf}
}

@article{vGuideSelectionGenetic2023,
  title = {A {{Guide}} for {{Selection}} of {{Genetic Instruments}} in {{Mendelian Randomization Studies}} of {{Type}} 2 {{Diabetes}} and {{HbA1c}}: {{Toward}} an {{Integrated Approach}}},
  shorttitle = {A {{Guide}} for {{Selection}} of {{Genetic Instruments}} in {{Mendelian Randomization Studies}} of {{Type}} 2 {{Diabetes}} and {{HbA1c}}},
  author = {V, Garfield and A, Salzmann and S, Burgess and N, Chaturvedi},
  year = {2023},
  month = jan,
  journal = {Diabetes},
  volume = {72},
  number = {2},
  publisher = {Diabetes},
  issn = {1939-327X},
  doi = {10.2337/db22-0110},
  urldate = {2024-05-15},
  abstract = {In this study we examine the instrument selection strategies currently used throughout the type 2 diabetes and HbA1c Mendelian randomization (MR) literature. We then argue for a more integrated and thorough approach, providing a framework to do this in the context of HbA1c and diabetes. We conducted {\dots}},
  langid = {english},
  pmid = {36669000}
}

@misc{viallonCanColliderBias2016,
  title = {Can Collider Bias Fully Explain the Obesity Paradox?},
  author = {Viallon, Vivian and Dufournet, Marine},
  year = {2016},
  month = dec,
  number = {arXiv:1612.06547},
  eprint = {1612.06547},
  primaryclass = {stat},
  publisher = {arXiv},
  doi = {10.48550/arXiv.1612.06547},
  urldate = {2024-08-13},
  abstract = {The "obesity paradox" has been reported in several observational studies, where obesity was shown to be associated to a decreased mortality in individuals suffering from a chronic disease, such as diabetes or heart failure. Causal arguments have recently been given to explain this apparently paradoxical fact: because the chronic disease is caused by obesity, the observed "protective effect" of obesity among patients with, say, diabetes, actually has no causal value. Recently, Sperrin et al. (2016) relaunched the debate and claimed that the resulting bias, the so-called collider bias, was unlikely to be the main explanation for the obesity paradox. However, a number of issues in their work make their conclusions questionable. In this article, we first study the bias between (i) the association between obesity and early death among patients suffering from the chronic disease \${\textbackslash}Delta\_\{AS\}\$ and (ii) the causal effect considered by Sperrin et al. Under the usual framework of structural causal models, we explain why this bias can be much higher than what these authors reported. We further consider alternative causal effects of potential interest and study their difference with \${\textbackslash}Delta\_\{AS\}\$. Numerical examples are presented to illustrate the magnitude of these differences under realistic scenarios. We show that it is possible to have a negative \${\textbackslash}Delta\_\{AS\}\$, while the causal effects we considered are all positive. Therefore, even under the very simple generative model we considered, collider bias can be the sole cause of the obesity paradox.},
  archiveprefix = {arXiv},
  keywords = {Statistics - Methodology},
  file = {/Users/xx20081/Zotero/storage/PZLCKBGF/Viallon and Dufournet - 2016 - Can collider bias fully explain the obesity parado.pdf;/Users/xx20081/Zotero/storage/6SJKEFYL/1612.html}
}

@article{vinckHeritabilityPlasmaRenin2002,
  title = {Heritability of Plasma Renin Activity and Plasma Concentration of Angiotensinogen and Angiotensin-Converting Enzyme},
  author = {Vinck, W. J. and Fagard, R. H. and Vlietinck, R. and Lijnen, P.},
  year = {2002},
  month = jun,
  journal = {Journal of Human Hypertension},
  volume = {16},
  number = {6},
  pages = {417--422},
  issn = {0950-9240},
  doi = {10.1038/sj.jhh.1001410},
  abstract = {The purpose of the present investigation was to describe the relative impact of genes and environment on the variance of the plasma constituents of the renin angiotensin system. We ascertained 56 male and 80 female adult same-sex twin pairs from the Flemish population. Plasma renin activity (PRA), the concentration of angiotensinogen (AGT) and angiotensin-converting enzyme (ACE) were measured, and path analysis was applied, after transformation toward normality. For PRA and AGT significant heritability was only detected in the male subgroup, with heritability estimates of 66\% and 90\%, respectively. Angiotensin-converting enzyme concentration was determined by additive genes for 43\% of its variance, by shared environmental influences for 42\%, and by specific environmental influences for 15\%. The high heritability found for AGT is compatible with the results of earlier studies linking the M235T polymorphism of the angiotensinogen gene to plasma AGT levels. For PRA, we are the first to show significant heritability. Our results regarding ACE confirm the findings in other populations.},
  langid = {english},
  pmid = {12037697},
  keywords = {Aged,Analysis of Variance,Angiotensinogen,Belgium,Female,Humans,Male,Middle Aged,Peptidyl-Dipeptidase A,Renin,Renin-Angiotensin System}
}

@article{Voors2016,
  title = {A Systems {{BIOlogy}} Study to {{TAilored}} Treatment in Chronic Heart Failure: Rationale, Design, and Baseline Characteristics of {{BIOSTAT-CHF}}},
  author = {Voors, Adriaan A. and Anker, Stefan D. and Cleland, John G. and Dickstein, Kenneth and Filippatos, Gerasimos and {van der Harst}, Pim and Hillege, Hans L. and Lang, Chim C. and {ter Maaten}, Jozine M. and Ng, Leong and Ponikowski, Piotr and Samani, Nilesh J. and {van Veldhuisen}, Dirk J. and Zannad, Faiz and Zwinderman, Aeilko H. and Metra, Marco},
  year = {2016},
  month = jun,
  journal = {European Journal of Heart Failure},
  volume = {18},
  number = {6},
  pages = {716--726},
  publisher = {John Wiley \& Sons, Ltd},
  issn = {1879-0844},
  doi = {10.1002/EJHF.531},
  abstract = {Aims: Despite major improvements in pharmacological and device treatments, heart failure remains a syndrome with high morbidity and mortality, poor quality of life, and high health-care costs. Given the extensive heterogeneity among patients with heart failure, substantial differences in the response to therapy can be expected. We hypothesize that individualized therapy is an essential next step to improve outcomes in patients with heart failure. Methods: The BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) included 2516 patients with worsening signs and/or symptoms of heart failure from 11 European countries, who were considered to be on suboptimal medical treatment. Another 1738 patients from Scotland were included in a validation cohort. Overall, both patient cohorts were well matched. The majority of patients were hospitalized for acute heart failure, and the remainder presented with worsening signs and/or symptoms of heart failure at outpatient clinics. Approximately half of the patients were in New York Heart Association class III, and 7\% vs 34\% of patients of the index vs validation cohort had heart failure with preserved ejection fraction. According to study design, all patients used diuretics, but owing to the inclusion criteria of both cohorts, patients were not on optimal, evidence-based medical therapy. In the follow-up phase, uptitration to guideline-recommended doses was encouraged. Conclusion: By using a novel systems biology approach, incorporating demographics, biomarkers, genome-wide analysis, and proteomics, a model that predicts response to therapy will be developed, which should be instrumental in developing alternative therapies for patients with suboptimal response to currently recommended therapies and thus further improve care for patients with heart failure.},
  pmid = {27126231},
  keywords = {Heart failure,Individualized treatment,Systems biology,Treatment response}
}

@article{wadeAssessingCausalRole2018,
  title = {Assessing the {{Causal Role}} of {{Body Mass Index}} on {{Cardiovascular Health}} in {{Young Adults}}},
  author = {Wade, Kaitlin H. and Chiesa, Scott T. and Hughes, Alun D. and Chaturvedi, Nish and Charakida, Marietta and Rapala, Alicja and Muthurangu, Vivek and Khan, Tauseef and Finer, Nicholas and Sattar, Naveed and Howe, Laura D. and Fraser, Abigail and Lawlor, Debbie A. and Davey Smith, George and Deanfield, John E. and Timpson, Nicholas J.},
  year = {2018},
  month = nov,
  journal = {Circulation},
  volume = {138},
  number = {20},
  pages = {2187--2201},
  issn = {0009-7322},
  doi = {10.1161/CIRCULATIONAHA.117.033278},
  urldate = {2024-03-08},
  abstract = {Supplemental Digital Content is available in the text.},
  pmcid = {PMC6250296},
  pmid = {30524135},
  file = {/Users/xx20081/Zotero/storage/ECS4WVBU/Wade et al. - 2018 - Assessing the Causal Role of Body Mass Index on Ca.pdf}
}

@article{wadeBMIMortalityUK2018,
  title = {{{BMI}} and {{Mortality}} in {{UK Biobank}}: {{Revised Estimates Using Mendelian Randomization}}},
  shorttitle = {{{BMI}} and {{Mortality}} in {{UK Biobank}}},
  author = {Wade, Kaitlin H. and Carslake, David and Sattar, Naveed and Davey Smith, George and Timpson, Nicholas J.},
  year = {2018},
  month = nov,
  journal = {Obesity (Silver Spring, Md.)},
  volume = {26},
  number = {11},
  pages = {1796--1806},
  issn = {1930-7381},
  doi = {10.1002/oby.22313},
  urldate = {2025-01-22},
  abstract = {Objective The aim of this study was to obtain estimates of the causal relationship between BMI and mortality. Methods Mendelian randomization (MR) with BMI-associated genotypic variation was used to test the causal effect of BMI on all-cause and cause-specific mortality in UK Biobank participants of White British ancestry. Results MR analyses supported a causal association between higher BMI and greater risk of all-cause mortality (hazard ratio [HR] per 1 kg/m2: 1.03; 95\% CI: 0.99-1.07) and mortality from cardiovascular diseases (HR: 1.10; 95\% CI: 1.01-1.19), specifically coronary heart disease (HR: 1.12; 95\% CI: 1.00-1.25) and those excluding coronary heart disease/stroke/aortic aneurysm (HR: 1.24; 95\% CI: 1.03-1.48), stomach cancer (HR: 1.18; 95\% CI: 0.87-1.62), and esophageal cancer (HR: 1.22; 95\% CI: 0.98-1.53), and a decreased risk of lung cancer mortality (HR: 0.96; 95\% CI: 0.85-1.08). Sex stratification supported the causal role of higher BMI increasing bladder cancer mortality risk (males) but decreasing respiratory disease mortality risk (males). The J-shaped observational association between BMI and mortality was visible with MR analyses, but the BMI at which mortality was minimized was lower and the association was flatter over a larger BMI range. Conclusions Results support a causal role of higher BMI in increasing the risk of all-cause mortality and mortality from several specific causes.},
  pmcid = {PMC6334168},
  pmid = {30358150},
  file = {/Users/xx20081/Zotero/storage/K2EPFRV9/Wade et al. - 2018 - BMI and Mortality in UK Biobank Revised Estimates Using Mendelian Randomization.pdf}
}

@article{wadeChallengesUndertakingNonlinear2023,
  title = {Challenges in Undertaking Nonlinear {{Mendelian}} Randomization},
  author = {Wade, Kaitlin H. and Hamilton, Fergus W. and Carslake, David and Sattar, Naveed and Davey Smith, George and Timpson, Nicholas J.},
  year = {2023},
  month = dec,
  journal = {Obesity (Silver Spring, Md.)},
  volume = {31},
  number = {12},
  pages = {2887--2890},
  issn = {1930-739X},
  doi = {10.1002/oby.23927},
  abstract = {Mendelian randomization (MR) is a widely used method that exploits the unique properties of germline genetic variation to strengthen causal inference in relationships between exposures and outcomes. Nonlinear MR allows estimation of the shape of these relationships. In a previous paper, the authors applied linear and nonlinear MR to estimate the effect of BMI on mortality in UK Biobank, providing evidence for a J-shaped association. However, it is now clear that there are problems with widely used nonlinear MR methods, which draws attention to the likely erroneous nature of the conclusions regarding the shapes of several explored relationships. Here, the authors explore the utility and likely biases of these nonlinear MR methods with the use of a negative control design. Although there remains good evidence for a causal effect of higher BMI increasing the risk of mortality, the pattern of this association across different levels of BMI requires further characterization.},
  langid = {english},
  pmcid = {PMC7615556},
  pmid = {37845826},
  keywords = {Body Mass Index,Causality,Genome-Wide Association Study,Mendelian Randomization Analysis},
  file = {/Users/xx20081/Zotero/storage/FVAR8G2K/Wade et al. - 2023 - Challenges in undertaking nonlinear Mendelian randomization.pdf}
}

@article{wainschteinAssessingContributionRare2022,
  title = {Assessing the Contribution of Rare Variants to Complex Trait Heritability from Whole-Genome Sequence Data},
  author = {Wainschtein, Pierrick and Jain, Deepti and Zheng, Zhili and Cupples, L. Adrienne and Shadyab, Aladdin H. and McKnight, Barbara and Shoemaker, Benjamin M. and Mitchell, Braxton D. and Psaty, Bruce M. and Kooperberg, Charles and Liu, Ching-Ti and Albert, Christine M. and Roden, Dan and Chasman, Daniel I. and Darbar, Dawood and {Lloyd-Jones}, Donald M. and Arnett, Donna K. and Regan, Elizabeth A. and Boerwinkle, Eric and Rotter, Jerome I. and O'Connell, Jeffrey R. and Yanek, Lisa R. and {de Andrade}, Mariza and Allison, Matthew A. and McDonald, Merry-Lynn N. and Chung, Mina K. and Fornage, Myriam and Chami, Nathalie and Smith, Nicholas L. and Ellinor, Patrick T. and Vasan, Ramachandran S. and Mathias, Rasika A. and Loos, Ruth J. F. and Rich, Stephen S. and Lubitz, Steven A. and Heckbert, Susan R. and Redline, Susan and Guo, Xiuqing and Chen, Y.-D. Ida and Laurie, Cecelia A. and Hernandez, Ryan D. and McGarvey, Stephen T. and Goddard, Michael E. and Laurie, Cathy C. and North, Kari E. and Lange, Leslie A. and Weir, Bruce S. and Yengo, Loic and Yang, Jian and Visscher, Peter M.},
  year = {2022},
  month = mar,
  journal = {Nature Genetics},
  volume = {54},
  number = {3},
  pages = {263--273},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-021-00997-7},
  urldate = {2024-12-04},
  abstract = {Analyses of data from genome-wide association studies on unrelated individuals have shown that, for human traits and diseases, approximately one-third to two-thirds of heritability is captured by common SNPs. However, it is not known whether the remaining heritability is due to the imperfect tagging of causal variants by common SNPs, in particular whether the causal variants are rare, or whether it is overestimated due to bias in inference from pedigree data. Here we estimated heritability for height and body mass index (BMI) from whole-genome sequence data on 25,465 unrelated individuals of European ancestry. The estimated heritability was 0.68 (standard error 0.10) for height and 0.30 (standard error 0.10) for body mass index. Low minor allele frequency variants in low linkage disequilibrium (LD) with neighboring variants were enriched for heritability, to a greater extent for protein-altering variants, consistent with negative selection. Our results imply that rare variants, in particular those in regions of low linkage disequilibrium, are a major source of the still missing heritability of complex traits and disease.},
  copyright = {2022 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  keywords = {Genetic association study,Population genetics},
  file = {/Users/xx20081/Zotero/storage/CRZ8RYAP/Wainschtein et al. - 2022 - Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence.pdf}
}

@article{waldAssessingRiskFactors2011,
  title = {Assessing Risk Factors as Potential Screening Tests: A Simple Assessment Tool},
  shorttitle = {Assessing Risk Factors as Potential Screening Tests},
  author = {Wald, Nicholas J. and Morris, Joan K.},
  year = {2011},
  month = feb,
  journal = {Archives of Internal Medicine},
  volume = {171},
  number = {4},
  pages = {286--291},
  issn = {1538-3679},
  doi = {10.1001/archinternmed.2010.378},
  abstract = {Many risk factors for disease are suggested as screening tests when there is little prospect that they could be useful in predicting disease. To avoid this, it is useful to know the relationship between the relative risk of a disease or disorder in people with high and low values of a risk factor, and the equivalent screening performance in terms of the detection rate (sensitivity) for a specified false-positive rate. We describe an interactive Risk-Screening Converter, accessible from the Internet (http://www.wolfson.qmul.ac.uk/rsc/), that transforms an odds ratio into the equivalent estimates of detection and false-positive rates. The converter is intended for general clinicians, for people engaged in research into risk factors and disease, and for those who give advice on applying such research findings into medical practice. It should help to distinguish effective screening methods from ineffective ones, and so improve clinical guidelines relating to screening and the prediction and prevention of disease.},
  langid = {english},
  pmid = {20975013},
  keywords = {Cardiovascular Diseases,Humans,Mass Screening,Odds Ratio,Risk Assessment,Risk Factors}
}

@article{wandImprovingReportingStandards2021,
  title = {Improving Reporting Standards for Polygenic Scores in Risk Prediction Studies},
  author = {Wand, Hannah and Lambert, Samuel A. and Tamburro, Cecelia and Iacocca, Michael A. and O'Sullivan, Jack W. and Sillari, Catherine and Kullo, Iftikhar J. and Rowley, Robb and Dron, Jacqueline S. and Brockman, Deanna and Venner, Eric and McCarthy, Mark I. and Antoniou, Antonis C. and Easton, Douglas F. and Hegele, Robert A. and Khera, Amit V. and Chatterjee, Nilanjan and Kooperberg, Charles and Edwards, Karen and Vlessis, Katherine and Kinnear, Kim and Danesh, John N. and Parkinson, Helen and Ramos, Erin M. and Roberts, Megan C. and Ormond, Kelly E. and Khoury, Muin J. and Janssens, A. Cecile J. W. and Goddard, Katrina A. B. and Kraft, Peter and MacArthur, Jaqueline A. L. and Inouye, Michael and Wojcik, Genevieve L.},
  year = {2021},
  month = mar,
  journal = {Nature},
  volume = {591},
  number = {7849},
  pages = {211--219},
  publisher = {Nature Publishing Group},
  issn = {1476-4687},
  doi = {10.1038/s41586-021-03243-6},
  urldate = {2024-12-10},
  abstract = {Polygenic risk scores (PRSs), which often aggregate results from genome-wide association studies, can bridge the gap between initial discovery efforts and clinical applications for the estimation of disease risk using genetics. However, there is notable heterogeneity in the application and reporting of these risk scores, which hinders the translation of PRSs into clinical care. Here, in a collaboration between the Clinical Genome Resource (ClinGen) Complex Disease Working Group and the Polygenic Score (PGS) Catalog, we present the Polygenic Risk Score Reporting Standards (PRS-RS), in which we update the Genetic Risk Prediction Studies (GRIPS) Statement to reflect the present state of the field. Drawing on the input of experts in epidemiology, statistics, disease-specific applications, implementation and policy, this comprehensive reporting framework defines the minimal information that is needed to interpret and evaluate PRSs, especially with respect to downstream clinical applications. Items span detailed descriptions of study populations, statistical methods for the development and validation of PRSs and considerations for the potential limitations of these scores. In addition, we emphasize the need for data availability and transparency, and we encourage researchers to deposit and share PRSs through the PGS Catalog to facilitate reproducibility and comparative benchmarking. By providing these criteria in a structured format that builds on existing standards and ontologies, the use of this framework in publishing PRSs will facilitate translation into clinical care and progress towards defining best practice.},
  copyright = {2021 Springer Nature Limited},
  langid = {english},
  keywords = {Clinical genetics,Genetic association study,Medical genetics,Risk factors},
  file = {/Users/xx20081/Zotero/storage/CX75Y2WM/Wand et al. - 2021 - Improving reporting standards for polygenic scores in risk prediction studies.pdf}
}

@article{wangAngiotensinIISympathetic2014,
  title = {Angiotensin {{II}}, Sympathetic Nerve Activity and Chronic Heart Failure},
  author = {Wang, Yutang and Seto, Sai-Wang and Golledge, Jonathan},
  year = {2014},
  month = mar,
  journal = {Heart Failure Reviews},
  volume = {19},
  number = {2},
  pages = {187--198},
  issn = {1573-7322},
  doi = {10.1007/s10741-012-9368-1},
  abstract = {Sympathetic nerve activity has been reported to be increased in both humans and animals with chronic heart failure. One of the mechanisms believed to be responsible for this phenomenon is increased systemic and cerebral angiotensin II signaling. Plasma angiotensin II is increased in humans and animals with chronic heart failure. The increase in angiotensin II signaling enhances sympathetic nerve activity through actions on both central and peripheral sites during chronic heart failure. Angiotensin II signaling is enhanced in different brain sites such as the paraventricular nucleus, the rostral ventrolateral medulla and the area postrema. Blocking angiotensin II type 1 receptors decreases sympathetic nerve activity and cardiac sympathetic afferent reflex when therapy is administered to the paraventricular nucleus. Injection of an angiotensin receptor blocker into the area postrema activates the sympathoinhibitory baroreflex. In peripheral regions, angiotensin II elevates both norepinephrine release and synthesis and inhibits norepinephrine uptake at nerve endings, which may contribute to the increase in sympathetic nerve activity seen in chronic heart failure. Increased circulating angiotensin II during chronic heart failure may enhance the sympathoexcitatory chemoreflex and inhibit the sympathoinhibitory baroreflex. In addition, increased circulating angiotensin II can directly act on the central nervous system via the subfornical organ and the area postrema to increase sympathetic outflow. Inhibition of angiotensin II formation and its type 1 receptor has been shown to have beneficial effects in chronic heart failure patients.},
  langid = {english},
  pmid = {23225134},
  keywords = {Angiotensin II,Chronic Disease,Heart,Heart Failure,Humans,Sympathetic Nervous System},
  file = {/Users/xx20081/Zotero/storage/Y5ELFJ8V/Wang et al. - 2014 - Angiotensin II, sympathetic nerve activity and chr.pdf}
}

@article{wangAssessmentCausalDirection2022,
  title = {Assessment of Causal Direction between Thyroid Function and Cardiometabolic Health: A {{Mendelian}} Randomization Study},
  shorttitle = {Assessment of Causal Direction between Thyroid Function and Cardiometabolic Health},
  author = {WANG, Jing-Jia and ZHUANG, Zhen-Huang and YU, Can-Qing and WANG, Wen-Yao and WANG, Wen-Xiu and ZHANG, Kuo and MENG, Xiang-Bin and GAO, Jun and TIAN, Jian and ZHENG, Ji-Lin and YANG, Jie and HUANG, Tao and SHAO, Chun-Li and TANG, Yi-Da},
  year = {2022},
  month = jan,
  journal = {Journal of Geriatric Cardiology : JGC},
  volume = {19},
  number = {1},
  pages = {61--70},
  issn = {1671-5411},
  doi = {10.11909/j.issn.1671-5411.2022.01.004},
  urldate = {2024-09-17},
  abstract = {BACKGROUND Growing evidence have demonstrated that thyroid hormones have been involved in the processes of cardiovascular metabolism. However, the causal relationship of thyroid function and cardiometabolic health remains partly unknown. METHODS The Mendelian randomization (MR) was used to test genetic, potentially causal relationships between instrumental variables and cardiometabolic traits. Genetic variants of free thyroxine (FT4) and thyrotropin (TSH) levels within the reference range were used as instrumental variables. Data for genetic associations with cardiometabolic diseases were acquired from the genome-wide association studies of the FinnGen, CARDIoGRAM and CARDIoGRAMplusC4D, CHARGE, and MEGASTROKE. This study was conducted using summary statistic data from large, previously described cohorts. Association between thyroid function and essential hypertension (EHTN), secondary hypertension (SHTN), hyperlipidemia (HPL), type 2 diabetes mellitus (T2DM), ischemic heart disease (IHD), myocardial infarction (MI), heart failure (HF), pulmonary heart disease (PHD), stroke, and non-rheumatic valve disease (NRVD) were examined. RESULTS Genetically predicted FT4 levels were associated with SHTN (odds ratio = 0.48; 95\% CI = 0.04-0.82,P = 0.027), HPL (odds ratio = 0.67; 95\% CI = 0.18-0.88,P = 0.023), T2DM (odds ratio = 0.80; 95\% CI = 0.42-0.86,P = 0.005), IHD (odds ratio = 0.85; 95\% CI = 0.49-0.98,P = 0.039), NRVD (odds ratio = 0.75; 95\% CI = 0.27-0.97,P = 0.039). Additionally, genetically predicted TSH levels were associated with HF (odds ratio = 0.82; 95\% CI = 0.68-0.99,P = 0.042), PHD (odds ratio = 0.75; 95\% CI = 0.32-0.82,P = 0.006), stroke (odds ratio = 0.95; 95\% CI = 0.81-0.97,P = 0.007). However, genetically predicted thyroid function traits were not associated with EHTN and MI. CONCLUSIONS Our study suggests FT4 and TSH are associated with cardiometabolic diseases, underscoring the importance of the pituitary-thyroid-cardiac axis in cardiometabolic health susceptibility.},
  pmcid = {PMC8832047},
  pmid = {35233224},
  file = {/Users/xx20081/Zotero/storage/UYBS9GAX/WANG et al. - 2022 - Assessment of causal direction between thyroid fun.pdf}
}

@article{wangAssociationBodyMass2015,
  title = {Association of Body Mass Index with Mortality and Cardiovascular Events for Patients with Coronary Artery Disease: A Systematic Review and Meta-Analysis},
  shorttitle = {Association of Body Mass Index with Mortality and Cardiovascular Events for Patients with Coronary Artery Disease},
  author = {Wang, Zhi Jian and Zhou, Yu Jie and Galper, Benjamin Z. and Gao, Fei and Yeh, Robert W. and Mauri, Laura},
  year = {2015},
  month = oct,
  journal = {Heart},
  volume = {101},
  number = {20},
  pages = {1631--1638},
  publisher = {{BMJ Publishing Group Ltd and British Cardiovascular Society}},
  issn = {1355-6037, 1468-201X},
  doi = {10.1136/heartjnl-2014-307119},
  urldate = {2024-08-06},
  abstract = {Objectives The association between obesity and prognosis in patients with coronary artery disease (CAD) remains uncertain. We undertook a meta-analysis for the effects of body mass index (BMI) on mortality and cardiovascular events in these patients. Methods We identified studies that provided risk estimates for mortality or cardiovascular events on the basis of BMI in patients with CAD. Summary estimates of relative risks were obtained for five BMI groups: underweight, normal-weight, overweight, obese and grade II/III obese. Mortality was analysed separately as short-term ({$<$}6 months) and long-term ({$\geq$}6 months). Results Data from 89 studies with 1 300 794 patients were included. Mean follow-up of long-term estimates was 3.2 years. Using normal-weight as the reference, underweight was associated with higher risk of short-term mortality (2.24 (1.85 to 2.72)) and long-term mortality (1.70 (1.56 to 1.86)), overweight and obesity were both associated with lower risk of short-term mortality (0.69 (0.64 to 0.75); 0.68 (0.61 to 0.75)) and long-term mortality (0.78 (0.74 to 0.82); 0.79 (0.73 to 0.85)), but the long-term benefit of obesity disappeared after 5 years of follow-up (0.99 (0.91 to 1.08)). Grade II/III obesity was associated with lower risk of mortality in the short term (0.76 (0.62 to 0.91)) but higher risk after 5 years of follow-up (1.25 (1.14 to 1.38)). The similar J-shaped pattern was also seen for cardiovascular mortality and across different treatment strategies. Meta-regression found an attenuation of the inverse association between BMI and risk of mortality over longer follow-up. Conclusions Our data support a J-shaped relationship between mortality and BMI in patients with CAD. The limitation of current literature warrants better design of future studies.},
  chapter = {Coronary artery disease},
  copyright = {Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions},
  langid = {english},
  pmid = {26025084}
}

@article{wangImpactObesityPlasma2004,
  title = {Impact of Obesity on Plasma Natriuretic Peptide Levels},
  author = {Wang, Thomas J. and Larson, Martin G. and Levy, Daniel and Benjamin, Emelia J. and Leip, Eric P. and Wilson, Peter W. F. and Vasan, Ramachandran S.},
  year = {2004},
  month = feb,
  journal = {Circulation},
  volume = {109},
  number = {5},
  pages = {594--600},
  issn = {1524-4539},
  doi = {10.1161/01.CIR.0000112582.16683.EA},
  abstract = {BACKGROUND: The mechanisms linking obesity to hypertension have not been established, but sodium retention and excessive sympathetic tone are key contributors. The natriuretic peptides are important regulators of sodium homeostasis and neurohormonal activation, raising the possibility that obese individuals have an impaired natriuretic peptide response. METHODS AND RESULTS: We examined the relations of plasma B-type natriuretic peptide (BNP) and N-terminal proatrial natriuretic peptide (N-ANP) to body mass index in 3389 Framingham Study participants (1803 women) without heart failure. Multivariable regression analyses were performed, adjusting for clinical and echocardiographic covariates. BNP levels below the assay detection limit and N-ANP levels in the lowest sex-specific quartile were categorized as low. Multivariable-adjusted mean plasma BNP levels in lean ({$<$}25 kg/m2), overweight (25 to 29.9 kg/m2), and obese ({$>$} or =30 kg/m2) men were 21.4, 15.5, and 12.7 pg/mL, respectively (trend P{$<$}0.0001). Corresponding values in women were 21.1, 16.3, and 13.1 pg/mL (trend P{$<$}0.001). A similar pattern was noted for plasma N-ANP. Obese individuals had higher odds of having low plasma BNP (multivariable-adjusted odds ratios: men, 2.51; 95\% CI, 1.71 to 3.68; women, 1.84; 95\% CI, 1.32 to 2.58) and low plasma N-ANP (odds ratios: men, 4.81; 95\% CI, 2.98 to 7.76; women, 2.85; 95\% CI, 2.01 to 4.04) compared with lean individuals. Diabetes also was associated with low plasma natriuretic peptide levels, and the negative effects of obesity and diabetes on natriuretic peptide levels were additive. CONCLUSIONS: Obese individuals have low circulating natriuretic peptide levels, which may contribute to their susceptibility to hypertension and hypertension-related disorders.},
  langid = {english},
  pmid = {14769680},
  keywords = {Atrial Natriuretic Factor,Body Constitution,Body Mass Index,Diabetes Complications,Female,Humans,Hypertension,Male,Middle Aged,Natriuretic Peptide Brain,Obesity,Protein Precursors},
  file = {/Users/xx20081/Zotero/storage/C284KBC6/Wang et al. - 2004 - Impact of obesity on plasma natriuretic peptide le.pdf}
}

@article{wangPrevalencePrehypertensionHypertension2004,
  title = {The Prevalence of Prehypertension and Hypertension among {{US}} Adults According to the New Joint National Committee Guidelines: New Challenges of the Old Problem},
  shorttitle = {The Prevalence of Prehypertension and Hypertension among {{US}} Adults According to the New Joint National Committee Guidelines},
  author = {Wang, Youfa and Wang, Qiong Joanna},
  year = {2004},
  month = oct,
  journal = {Archives of Internal Medicine},
  volume = {164},
  number = {19},
  pages = {2126--2134},
  issn = {0003-9926},
  doi = {10.1001/archinte.164.19.2126},
  abstract = {BACKGROUND: The recently released Seventh Report of the Joint National Committee (JNC) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure provides a new classification of blood pressure levels. Little is known about the current situation of elevated blood pressure in the United States, according to the new guidelines. METHODS: Cross-sectional analysis of national representative data collected from 4805 adults 18 years and older surveyed in the 1999-2000 National Health and Nutrition Examination Survey. We examined the prevalence of prehypertension and hypertension according to the new JNC guidelines, people's awareness and management of hypertension, and the differences across sociodemographic and body weight groups. RESULTS: Elevated blood pressure is a serious problem in the United States. Approximately 60\% of American adults have prehypertension or hypertension, and some population groups, such as African Americans, older people, low-socioeconomic-status groups, and overweight groups, are disproportionately affected. The prevalence of hypertension has increased by approximately 10 percentage points during the past decade. The awareness and appropriate management of hypertension among hypertensive patients remain low: 31\% were not aware of their disease, only two thirds (66\%) were told by health professionals to adopt lifestyle modifications or take drugs to control hypertension, and only 31\% controlled their hypertension. CONCLUSIONS: With 60\% of the population affected, the United States is facing a serious challenge in the prevention and management of prehypertension and hypertension. People's awareness and control of hypertension remain poor. This study highlights the seriousness of the problem and the importance of promoting lifestyle modifications.},
  langid = {english},
  pmid = {15505126},
  keywords = {Adult,Attitude to Health,Awareness,Body Weight,Cross-Sectional Studies,Demography,Disease Progression,Female,Humans,Hypertension,Male,Practice Guidelines as Topic,Prevalence,Socioeconomic Factors,United States},
  file = {/Users/xx20081/Zotero/storage/IB7AXMIQ/Wang and Wang - 2004 - The prevalence of prehypertension and hypertension.pdf}
}

@article{wangProgrammedCellDeath42013,
  title = {Programmed Cell Death-4 Deficiency Prevents Diet-Induced Obesity, Adipose Tissue Inflammation, and Insulin Resistance},
  author = {Wang, Qun and Dong, Zhaojing and Liu, Xianglan and Song, Xingguo and Song, Qiang and Shang, Qianwen and Jiang, Yang and Guo, Chun and Zhang, Lining},
  year = {2013},
  month = dec,
  journal = {Diabetes},
  volume = {62},
  number = {12},
  pages = {4132--4143},
  issn = {1939-327X},
  doi = {10.2337/db13-0097},
  abstract = {Programmed cell death-4 (PDCD4), a selective protein translation inhibitor, has shown proinflammatory effect in some inflammatory diseases, but its roles in obesity remain unestablished. This study aims to investigate the effects of PDCD4 on obesity, inflammation, and insulin resistance. Surprisingly, high-fat diet (HFD)-fed PDCD4-deficient (PDCD4(-/-)) mice exhibited an absolutely lean phenotype together with improved insulin sensitivity. Compared with wild-type obese mice, HFD-fed PDCD4(-/-) mice showed higher energy expenditure, lower epididymal fat weight, and reduced macrophage infiltration inflammatory cytokine secretion in white adipose tissue (WAT). Alleviated hepatic steatosis along with decreased plasma levels of triglyceride and cholesterol was also observed in these mice. Importantly, PDCD4 appeared to disturb lipid metabolism via inhibiting the expression of liver X receptor (LXR)-{$\alpha$}, a master modulator of lipid homeostasis, which was elevated in HFD-fed PDCD4(-/-) mice accompanied by upregulation of its target genes and relieved endoplasmic reticulum stress in WAT. These data demonstrate that PDCD4 deficiency protects mice against diet-induced obesity, WAT inflammation, and insulin resistance through restoring the expression of LXR-{$\alpha$}, thereby proposing PDCD4 as a potential target for treating obesity-associated diseases.},
  langid = {english},
  pmcid = {PMC3837052},
  pmid = {23990362},
  keywords = {Adipose Tissue,Animals,Apoptosis Regulatory Proteins,Cholesterol,Diet High-Fat,Endoplasmic Reticulum Stress,Fatty Liver,Inflammation,Insulin Resistance,Lipid Metabolism,Liver,Liver X Receptors,Mice,Mice Knockout,Obesity,Orphan Nuclear Receptors,RNA-Binding Proteins,Triglycerides},
  file = {/Users/xx20081/Zotero/storage/F4TL3TVK/Wang et al. - 2013 - Programmed cell death-4 deficiency prevents diet-induced obesity, adipose tissue inflammation, and i.pdf}
}

@article{wangSystematicApproachOutcome2022,
  title = {Systematic Approach to Outcome Assessment from Coded Electronic Healthcare Records in the {{DaRe2THINK NHS-embedded}} Randomized Trial},
  author = {Wang, Xiaoxia and Mobley, Alastair R. and Tica, Otilia and Okoth, Kelvin and Ghosh, Rebecca E. and Myles, Puja and Williams, Tim and Haynes, Sandra and Nirantharakumar, Krishnarajah and Shukla, David and Kotecha, Dipak and Committees, the DaRe2THINK Trial},
  year = {2022},
  month = sep,
  journal = {European Heart Journal. Digital Health},
  volume = {3},
  number = {3},
  pages = {426},
  publisher = {Oxford University Press},
  doi = {10.1093/ehjdh/ztac046},
  urldate = {2024-05-20},
  abstract = {Improving the efficiency of clinical trials is key to their continued importance in directing evidence-based patient care. Digital innovations, in particular the use of electronic healthcare records (EHRs), allow for large-scale screening and follow up ...},
  langid = {english},
  pmid = {36712153},
  file = {/Users/xx20081/Zotero/storage/DYLKLRKI/Wang et al. - 2022 - Systematic approach to outcome assessment from cod.pdf}
}

@article{wangSystematicApproachOutcome2022a,
  title = {Systematic Approach to Outcome Assessment from Coded Electronic Healthcare Records in the {{DaRe2THINK NHS-embedded}} Randomized Trial},
  author = {Wang, Xiaoxia and Mobley, Alastair R and Tica, Otilia and Okoth, Kelvin and Ghosh, Rebecca E and Myles, Puja and Williams, Tim and Haynes, Sandra and Nirantharakumar, Krishnarajah and Shukla, David and Kotecha, Dipak},
  year = {2022},
  month = sep,
  journal = {European Heart Journal. Digital Health},
  volume = {3},
  number = {3},
  pages = {426--436},
  issn = {2634-3916},
  doi = {10.1093/ehjdh/ztac046},
  urldate = {2024-06-17},
  abstract = {Graphical Abstract},
  pmcid = {PMC9708037},
  pmid = {36712153},
  file = {/Users/xx20081/Zotero/storage/QT8JYJNT/Wang et al. - 2022 - Systematic approach to outcome assessment from cod.pdf}
}

@article{wannametheeObesityRiskIncident2011,
  title = {Obesity and Risk of Incident Heart Failure in Older Men with and without Pre-Existing Coronary Heart Disease: Does Leptin Have a Role?},
  shorttitle = {Obesity and Risk of Incident Heart Failure in Older Men with and without Pre-Existing Coronary Heart Disease},
  author = {Wannamethee, S. Goya and Shaper, A. Gerald and Whincup, Peter H. and Lennon, Lucy and Sattar, Naveed},
  year = {2011},
  month = oct,
  journal = {Journal of the American College of Cardiology},
  volume = {58},
  number = {18},
  pages = {1870--1877},
  issn = {1558-3597},
  doi = {10.1016/j.jacc.2011.06.057},
  abstract = {OBJECTIVES: We examined the relationship between body mass index (BMI), waist circumference, and incident HF in men with and without pre-existing coronary heart disease (CHD) and assessed the contribution of plasma leptin concentration to these associations. BACKGROUND: Leptin has been proposed as a potential link between obesity and heart failure (HF). METHODS: This was a prospective study of 4,080 men age 60 to 79 years with no diagnosed HF followed for a mean period of 9 years, in whom there were 228 incident HF cases. RESULTS: Increased BMI was associated with significantly increased risk of HF in men with and without pre-existing CHD (myocardial infarction or angina) after adjustment for cardiovascular risk factors including C-reactive protein. The adjusted hazard ratios (HRs) associated with a 1-SD increase in BMI were 1.37 (95\% confidence interval [CI]: 1.09 to 1.72) and 1.18 (95\% CI: 1.00 to 1.39) in men with and without CHD, respectively. Increased leptin was significantly associated with an increased risk of HF in men without pre-existing CHD, independent of BMI and potential mediators (adjusted HR for a 1-SD increase in log leptin: 1.30 [95\% CI: 1.06 to 1.61]; p = 0.01). However, no association was seen in those with pre-existing CHD (corresponding HR: 1.06 [95\% CI: 0.77 to 1.45]; p = 0.72). Adjustment for leptin abolished the association between BMI and HF in men with no CHD; in those with CHD, the association between BMI and HF remained significant (p = 0.03). Similar patterns were seen for waist circumference. CONCLUSIONS: In the absence of established CHD, the association between obesity and HF may be mediated by plasma leptin. In those with CHD, obesity appears to increase the risk of HF independent of leptin.},
  langid = {english},
  pmid = {22018297},
  keywords = {Aged,Body Mass Index,Comorbidity,Coronary Disease,Heart Failure,Humans,Leptin,Male,Middle Aged,Obesity,Prospective Studies,Risk Factors,Waist Circumference},
  file = {/Users/xx20081/Zotero/storage/NPLDAWTW/Wannamethee et al. - 2011 - Obesity and risk of incident heart failure in olde.pdf}
}

@article{wareRoleTitinCardiomyopathy2018,
  title = {Role of Titin in Cardiomyopathy: From {{DNA}} Variants to Patient Stratification},
  shorttitle = {Role of Titin in Cardiomyopathy},
  author = {Ware, James S. and Cook, Stuart A.},
  year = {2018},
  month = apr,
  journal = {Nature Reviews. Cardiology},
  volume = {15},
  number = {4},
  pages = {241--252},
  issn = {1759-5010},
  doi = {10.1038/nrcardio.2017.190},
  abstract = {Dilated cardiomyopathy (DCM) affects approximately 1 in 250 individuals and is the leading indication for heart transplantation. DCM is often familial, and the most common genetic predisposition is a truncating variation in the giant sarcomeric protein, titin, which occurs in up to 15\% of ambulant patients with DCM and 25\% of end-stage or familial cases. In this article, we review the evidence for the role of titin truncation in the pathogenesis of DCM and our understanding of the molecular mechanisms and pathophysiological consequences of variation in the gene encoding titin (TTN). Such variation is common in the general population (up to 1\% of individuals), and we consider key features that discriminate variants with disease-causing potential from those that are benign. We summarize strategies for clinical interpretation of genetic variants for use in the diagnosis of patients and the evaluation of their relatives. Finally, we consider the contemporary and potential future role for genetic stratification in cardiomyopathy and in the general population, evaluating titin variation as a predictor of outcome and treatment response for precision medicine.},
  langid = {english},
  pmid = {29238064},
  keywords = {Animals,Cardiomyopathy Dilated,Clinical Decision-Making,Connectin,Genetic Markers,Genetic Predisposition to Disease,Genetic Testing,Genetic Variation,Humans,Phenotype,Precision Medicine,Predictive Value of Tests,Prognosis,Risk Assessment,Risk Factors}
}

@article{wareRoleTitinCardiomyopathy2018a,
  title = {Role of Titin in Cardiomyopathy: From {{DNA}} Variants to Patient Stratification},
  shorttitle = {Role of Titin in Cardiomyopathy},
  author = {Ware, James S. and Cook, Stuart A.},
  year = {2018},
  month = apr,
  journal = {Nature Reviews. Cardiology},
  volume = {15},
  number = {4},
  pages = {241--252},
  issn = {1759-5010},
  doi = {10.1038/nrcardio.2017.190},
  abstract = {Dilated cardiomyopathy (DCM) affects approximately 1 in 250 individuals and is the leading indication for heart transplantation. DCM is often familial, and the most common genetic predisposition is a truncating variation in the giant sarcomeric protein, titin, which occurs in up to 15\% of ambulant patients with DCM and 25\% of end-stage or familial cases. In this article, we review the evidence for the role of titin truncation in the pathogenesis of DCM and our understanding of the molecular mechanisms and pathophysiological consequences of variation in the gene encoding titin (TTN). Such variation is common in the general population (up to 1\% of individuals), and we consider key features that discriminate variants with disease-causing potential from those that are benign. We summarize strategies for clinical interpretation of genetic variants for use in the diagnosis of patients and the evaluation of their relatives. Finally, we consider the contemporary and potential future role for genetic stratification in cardiomyopathy and in the general population, evaluating titin variation as a predictor of outcome and treatment response for precision medicine.},
  langid = {english},
  pmid = {29238064},
  keywords = {Animals,Cardiomyopathy Dilated,Clinical Decision-Making,Connectin,Genetic Markers,Genetic Predisposition to Disease,Genetic Testing,Genetic Variation,Humans,Phenotype,Precision Medicine,Predictive Value of Tests,Prognosis,Risk Assessment,Risk Factors}
}

@article{Waters2004,
  title = {Treating to {{New Targets}} ({{TNT}}) {{Study}}: Does Lowering Low-Density Lipoprotein Cholesterol Levels below Currently Recommended Guidelines Yield Incremental Clinical Benefit?},
  author = {Waters, David D. and Guyton, John R. and Herrington, David M. and McGowan, Mary P. and Wenger, Nanette K. and Shear, Charles},
  year = {2004},
  month = jan,
  journal = {The American Journal of Cardiology},
  volume = {93},
  number = {2},
  pages = {154--158},
  publisher = {Excerpta Medica},
  issn = {0002-9149},
  doi = {10.1016/J.AMJCARD.2003.09.031},
  abstract = {The Treating to New Targets (TNT) trial is a parallel-group study that has randomized 10,003 patients from 14 countries to double-blind treatment with either atorvastatin 10 or 80 mg. During the double-blind period, low-density lipoprotein (LDL) cholesterol levels are expected to reach approximate mean values of 100 mg/dl (2.6 mmol/L) for the low-dose atorvastatin group and 75 mg/dl (1.9 mmol/L) for the high-dose group. Randomized patients are expected to be followed for an average of 5 years. The primary end point is the time to occurrence of a major cardiovascular event, defined as coronary heart disease death, nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke. The large patient numbers in the TNT study and long follow-up should ensure that there is adequate power to definitively determine if reducing LDL cholesterol levels to approximately 75 mg/dl (1.9 mmol/L) can provide additional clinical benefit. {\copyright} 2004 by Excerpta Medica, Inc.},
  pmid = {14715339}
}

@article{Waters2006,
  title = {Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients with Stable Coronary Disease in the {{TNT}} (Treating to New Targets) Study},
  author = {Waters, David D. and LaRosa, John C. and Barter, Philip and Fruchart, Jean Charles and Gotto, Antonio M. and Carter, Roddy and Breazna, Andrei and Kastelein, John J.P. and Grundy, Scott M.},
  year = {2006},
  month = nov,
  journal = {Journal of the American College of Cardiology},
  volume = {48},
  number = {9},
  pages = {1793--1799},
  publisher = {J Am Coll Cardiol},
  issn = {1558-3597},
  doi = {10.1016/J.JACC.2006.07.041},
  abstract = {Objective: We sought to assess the effects on cerebrovascular events of treating patients with stable coronary disease with low-density lipoprotein cholesterol (LDL-C) levels substantially below 100 mg/dl. Background: Lowering LDL-C with statins has been shown to reduce the risk of stroke in patients with stable coronary disease. In observational studies, naturally low cholesterol levels have been associated with an increased risk of hemorrhagic stroke. The cerebrovascular benefits of treating patients with stable coronary disease to LDL-C levels substantially below 100 mg/dl have not been previously investigated. Methods: We describe an analysis of cerebrovascular events in the Treating to New Targets study, a trial where 10,001 patients with documented coronary disease were randomized to treatment with atorvastatin at 10 mg/day or 80 mg/day and followed for a median of 4.9 years. Results: Mean LDL-C levels were 101 mg/dl on 10 mg atorvastatin and 77 mg/dl on 80 mg. In addition to the reduction in major cardiovascular events (hazard ratio 0.78, 95\% confidence interval [CI] 0.69 to 0.89; p = 0.0002), the primary end point of the trial, patients in the 80-mg arm experienced a reduction in cerebrovascular events (hazard ratio 0.77, 95\% CI 0.64 to 0.93; p = 0.007) and stroke (hazard ratio 0.75, 95\% CI 0.59 to 0.96; p = 0.02). Each 1-mg/dl reduction in LDL-C with treatment was associated with a 0.6\% relative risk reduction in cerebrovascular events (p = 0.002) and a 0.5\% relative risk reduction in stroke (p = 0.041). The incidence of hemorrhagic stroke was similar in the 80-mg and 10-mg groups, 16 and 18 respectively, and the hemorrhagic strokes were distributed evenly across quintiles of achieved LDL-C during treatment. Conclusions: Among patients with established coronary disease, treating to an LDL-cholesterol substantially below 100 mg/dl with 80 mg/day atorvastatin reduces both stroke and cerebrovascular events by an additional 20\% to 25\% compared with the 10 mg/day dose. An increase in hemorrhagic stroke was not seen at low LDL-C levels. (Treating to New Targets; http://www.clinicaltrials.gov; NCT00327691). {\copyright} 2006 American College of Cardiology Foundation.},
  pmid = {17084252},
  keywords = {Aged,Atorvastatin,Cerebrovascular Disorders / blood,Cerebrovascular Disorders / drug therapy*,Cerebrovascular Disorders / mortality,Cholesterol,Comparative Study,Coronary Disease / blood,Coronary Disease / drug therapy*,Coronary Disease / mortality,David D Waters,doi:10.1016/j.jacc.2006.07.041,Double-Blind Method,Drug Administration Schedule,Drug Delivery Systems / methods*,Female,Heptanoic Acids / administration & dosage*,Humans,John C LaRosa,LDL / blood*,Male,MEDLINE,Middle Aged,Multicenter Study,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,Non-U.S. Gov't,pmid:17084252,PubMed Abstract,Pyrroles / administration & dosage*,Randomized Controlled Trial,Research Support,Scott M Grundy}
}

@article{watersTreatingNewTargets,
  title = {Treating to New Targets ({{TNT}}) Study: {{Does}} Lowering Low-Density Lipoprotein Cholesterol Levels below Currently Recommended Guidelines Yield Incremental Clinical Benefit?},
  author = {Waters, David D and Guyton, John R and Herrington, David M and Mcgowan, Mary P and Wenger, Nanette K and Shear, Charles},
  doi = {10.1016/j.amjcard.2003.09.031},
  abstract = {for the TNT Steering Committee Members and Investigators The Treating to New Targets (TNT) trial is a parallel-group study that has randomized 10,003 patients from 14 countries to double-blind treatment with either ator-vastatin 10 or 80 mg. During the double-blind period, low-density lipoprotein (LDL) cholesterol levels are expected to reach approximate mean values of 100 mg/dl (2.6 mmol/L) for the low-dose atorvastatin group and 75 mg/dl (1.9 mmol/L) for the high-dose group. Ran-domized patients are expected to be followed for an average of 5 years. The primary end point is the time to occurrence of a major cardiovascular event, defined as coronary heart disease death, nonfatal myocardial in-farction, resuscitated cardiac arrest, or stroke. The large patient numbers in the TNT study and long follow-up should ensure that there is adequate power to definitively determine if reducing LDL cholesterol levels to approximately 75 mg/dl (1.9 mmol/L) can provide additional clinical benefit. 2004 by Excerpta Medica, Inc. (Am J Cardiol 2004;93:154-158)}
}

@article{wellsCommentaryParadoxBody2014,
  title = {Commentary: {{The}} Paradox of Body Mass Index in Obesity Assessment: Not a Good Index of Adiposity, but Not a Bad Index of Cardio-Metabolic Risk},
  shorttitle = {Commentary},
  author = {Wells, Jonathan CK},
  year = {2014},
  month = jun,
  journal = {International Journal of Epidemiology},
  volume = {43},
  number = {3},
  pages = {672--674},
  issn = {0300-5771},
  doi = {10.1093/ije/dyu060},
  urldate = {2024-08-07},
  pmcid = {PMC4052141},
  pmid = {24691953},
  file = {/Users/xx20081/Zotero/storage/2LFTDCRE/Wells - 2014 - Commentary The paradox of body mass index in obes.pdf}
}

@article{werdyaniEndotypesPrimaryOsteoarthritis2021,
  title = {Endotypes of Primary Osteoarthritis Identified by Plasma Metabolomics Analysis},
  author = {Werdyani, Salem and Liu, Ming and Zhang, Hongwei and Sun, Guang and Furey, Andrew and Randell, Edward W. and Rahman, Proton and Zhai, Guangju},
  year = {2021},
  month = jun,
  journal = {Rheumatology (Oxford, England)},
  volume = {60},
  number = {6},
  pages = {2735--2744},
  issn = {1462-0332},
  doi = {10.1093/rheumatology/keaa693},
  abstract = {OBJECTIVE: To identify endotypes of osteoarthritis (OA) by a metabolomics analysis. METHODS: Study participants included hip/knee OA patients and controls. Fasting plasma samples were metabolomically profiled. Common factor analysis and K-means clustering were applied to the metabolomics data to identify the endotypes of OA patients. Logistic regression was utilized to identify the most significant metabolites contributing to the endotypes. Clinical and epidemiological factors were examined in relation to the identified OA endotypes. RESULTS: Six hundred and fifteen primary OA patients and 237 controls were included. Among the 186 metabolites measured, 162 passed the quality control analysis. The 615 OA patients were classified in three clusters (A, 66; B, 200; and C, 349). Patients in cluster A had a significantly higher concentration of butyrylcarnitine (C4) than other clusters and controls (all P\,{$<$}\,0.0002). Elevated C4 is thought to be related to muscle weakness and wasting. Patients in cluster B had a significantly lower arginine concentration than other clusters and controls (all P\,{$<$}\,7.98\,{\texttimes}\,10-11). Cluster C patients had a significantly lower concentration of lysophosphatidylcholine (with palmitic acid), which is a pro-inflammatory bioactive compound, than other clusters and controls (P\,{$<$}\,3.79\,{\texttimes}\,10-6). Further, cluster A had a higher BMI and prevalence of diabetes than other clusters (all P\,{$\leq$}\,0.0009), and also a higher prevalence of coronary heart disease than cluster C (P\,=\,0.04). Cluster B had a higher prevalence of coronary heart disease than cluster C (P\,=\,0.003) whereas cluster C had a higher prevalence of osteoporosis (P\,=\,0.009). CONCLUSION: Our data suggest three possible clinically actionable endotypes in primary OA: muscle weakness, arginine deficit and low inflammatory OA.},
  langid = {english},
  pmcid = {PMC8213424},
  pmid = {33159799},
  keywords = {Aged,arginine,Arginine,Body Mass Index,butyrylcarnitine,Carnitine,Case-Control Studies,Coronary Disease,Diabetes Mellitus,endotypes,Factor Analysis Statistical,Fasting,Female,Humans,Logistic Models,lysophosphatidylcholine,Lysophosphatidylcholines,Male,Metabolomics,Muscle Weakness,osteoarthritis,Osteoarthritis Hip,Osteoarthritis Knee,Osteoporosis,Palmitic Acid,Prevalence,Quality Control,Wasting Syndrome},
  file = {/Users/xx20081/Zotero/storage/DD44YVLL/Werdyani et al. - 2021 - Endotypes of primary osteoarthritis identified by plasma metabolomics analysis.pdf}
}

@article{wildingOnceWeeklySemaglutideAdults2021,
  title = {Once-{{Weekly Semaglutide}} in {{Adults}} with {{Overweight}} or {{Obesity}}},
  author = {Wilding, John P. H. and Batterham, Rachel L. and Calanna, Salvatore and Davies, Melanie and Gaal, Luc F. Van and Lingvay, Ildiko and McGowan, Barbara M. and Rosenstock, Julio and Tran, Marie T. D. and Wadden, Thomas A. and Wharton, Sean and Yokote, Koutaro and Zeuthen, Niels and Kushner, Robert F.},
  year = {2021},
  month = mar,
  journal = {New England Journal of Medicine},
  volume = {384},
  number = {11},
  pages = {989--1002},
  publisher = {Massachusetts Medical Society},
  issn = {0028-4793},
  doi = {10.1056/NEJMoa2032183},
  urldate = {2025-01-20},
  abstract = {This double-blind study randomly assigned adults with obesity (or overweight and with one or more weight-related coexisting conditions) without diabetes to 68 weeks of once-weekly subcutaneous semaglutide (2.4 mg) or placebo, plus lifestyle intervention. Semaglutide therapy was associated with sustained, clinically relevant weight reduction.},
  file = {/Users/xx20081/Zotero/storage/6TC2VVIH/Wilding et al. - 2021 - Once-Weekly Semaglutide in Adults with Overweight or Obesity.pdf}
}

@article{willerMETALFastEfficient2010,
  title = {{{METAL}}: Fast and Efficient Meta-Analysis of Genomewide Association Scans},
  shorttitle = {{{METAL}}},
  author = {Willer, Cristen J. and Li, Yun and Abecasis, Gon{\c c}alo R.},
  year = {2010},
  month = jul,
  journal = {Bioinformatics},
  volume = {26},
  number = {17},
  pages = {2190},
  doi = {10.1093/bioinformatics/btq340},
  urldate = {2025-01-28},
  abstract = {Summary: METAL provides a computationally efficient tool for meta-analysis of genome-wide association scans, which is a commonly used approach for improving power complex traits gene mapping studies. METAL provides a rich scripting interface and ...},
  langid = {english},
  pmid = {20616382},
  file = {/Users/xx20081/Zotero/storage/8RPJZS2Y/Willer et al. - 2010 - METAL fast and efficient meta-analysis of genomewide association scans.pdf}
}

@article{willyardHeritabilityFamilyRoots2014,
  title = {Heritability: {{The}} Family Roots of Obesity},
  shorttitle = {Heritability},
  author = {Willyard, Cassandra},
  year = {2014},
  month = apr,
  journal = {Nature},
  volume = {508},
  number = {7496},
  pages = {S58-S60},
  publisher = {Nature Publishing Group},
  issn = {1476-4687},
  doi = {10.1038/508S58a},
  urldate = {2025-01-26},
  abstract = {Scores of genes are implicated in obesity, but they cannot account for a family's predisposition to obesity. Are there other ways parents can influence their children?},
  copyright = {2014 Springer Nature Limited},
  langid = {english},
  keywords = {Epigenetics,Genetics,Obesity},
  file = {/Users/xx20081/Zotero/storage/MSQ85BRZ/Willyard - 2014 - Heritability The family roots of obesity.pdf}
}

@article{wingoSexDifferencesBrain2023,
  title = {Sex Differences in Brain Protein Expression and Disease},
  author = {Wingo, Aliza P. and Liu, Yue and Gerasimov, Ekaterina S. and Vattathil, Selina M. and Liu, Jiaqi and Cutler, David J. and Epstein, Michael P. and Blokland, Gabri{\"e}lla A. M. and Thambisetty, Madhav and Troncoso, Juan C. and Duong, Duc M. and Bennett, David A. and Levey, Allan I. and Seyfried, Nicholas T. and Wingo, Thomas S.},
  year = {2023},
  month = sep,
  journal = {Nature Medicine},
  volume = {29},
  number = {9},
  pages = {2224--2232},
  publisher = {Nature Publishing Group},
  issn = {1546-170X},
  doi = {10.1038/s41591-023-02509-y},
  urldate = {2024-02-06},
  abstract = {Most complex human traits differ by sex, but we have limited insight into the underlying mechanisms. Here, we investigated the influence of biological sex on protein expression and its genetic regulation in 1,277 human brain proteomes. We found that 13.2\% (1,354) of brain proteins had sex-differentiated abundance and 1.5\% (150) of proteins had sex-biased protein quantitative trait loci (sb-pQTLs). Among genes with sex-biased expression, we found 67\% concordance between sex-differentiated protein and transcript levels; however, sex effects on the genetic regulation of expression were more evident at the protein level. Considering 24 psychiatric, neurologic and brain morphologic traits, we found that an average of 25\% of their putatively causal genes had sex-differentiated protein abundance and 12 putatively causal proteins had sb-pQTLs. Furthermore, integrating sex-specific pQTLs with sex-stratified genome-wide association studies of six psychiatric and neurologic conditions, we uncovered another 23 proteins contributing to these traits in one sex but not the other. Together, these findings begin to provide insights into mechanisms underlying sex differences in brain protein expression and disease.},
  copyright = {2023 This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply},
  langid = {english},
  keywords = {Alzheimer's disease,Gene expression profiling,Gene regulation},
  file = {/Users/xx20081/Zotero/storage/4MKEMMFQ/Wingo et al. - 2023 - Sex differences in brain protein expression and di.pdf}
}

@article{winklerQualityControlConduct2014,
  title = {Quality Control and Conduct of Genome-Wide Association Meta-Analyses},
  author = {Winkler, Thomas W. and Day, Felix R. and {Croteau-Chonka}, Damien C. and Wood, Andrew R. and Locke, Adam E. and M{\"a}gi, Reedik and Ferreira, Teresa and Fall, Tove and Graff, Mariaelisa and Justice, Anne E. and Luan, Jian'an and Gustafsson, Stefan and Randall, Joshua C. and Vedantam, Sailaja and Workalemahu, Tsegaselassie and Kilpel{\"a}inen, Tuomas O. and Scherag, Andr{\'e} and Esko, Tonu and Kutalik, Zolt{\'a}n and Consortium, the GIANT and Heid, Iris M. and Loos, Ruth JF},
  year = {2014},
  month = may,
  journal = {Nature protocols},
  volume = {9},
  number = {5},
  pages = {1192},
  publisher = {NIH Public Access},
  doi = {10.1038/nprot.2014.071},
  urldate = {2024-10-02},
  abstract = {Rigorous organization and quality control (QC) are necessary to facilitate successful genome-wide association meta-analyses (GWAMAs) of statistics aggregated across multiple genome-wide association studies. This protocol provides guidelines for [1] organizational ...},
  langid = {english},
  pmid = {24762786},
  file = {/Users/xx20081/Zotero/storage/MVQG5335/Winkler et al. - 2014 - Quality control and conduct of genome-wide association meta-analyses.pdf;/Users/xx20081/Zotero/storage/4AMRHNGE/PMC4083217.html}
}

@article{winklerQualityControlConduct2014a,
  title = {Quality Control and Conduct of Genome-Wide Association Meta-Analyses},
  author = {Winkler, Thomas W. and Day, Felix R. and {Croteau-Chonka}, Damien C. and Wood, Andrew R. and Locke, Adam E. and M{\"a}gi, Reedik and Ferreira, Teresa and Fall, Tove and Graff, Mariaelisa and Justice, Anne E. and Luan, Jian'an and Gustafsson, Stefan and Randall, Joshua C. and Vedantam, Sailaja and Workalemahu, Tsegaselassie and Kilpel{\"a}inen, Tuomas O. and Scherag, Andr{\'e} and Esko, Tonu and Kutalik, Zolt{\'a}n and Heid, Iris M. and Loos, Ruth J. F.},
  year = {2014},
  month = may,
  journal = {Nature Protocols},
  volume = {9},
  number = {5},
  pages = {1192--1212},
  publisher = {Nature Publishing Group},
  issn = {1750-2799},
  doi = {10.1038/nprot.2014.071},
  urldate = {2025-01-22},
  abstract = {A protocol providing guidelines on the organizational aspects of genome-wide association meta-analyses and to implement quality control at the study file level, the meta-level across studies, and the meta-analysis output level.},
  copyright = {2014 Springer Nature Limited},
  langid = {english},
  keywords = {Bioinformatics,Genome-wide association studies},
  file = {/Users/xx20081/Zotero/storage/V35BGQ4C/Winkler et al. - 2014 - Quality control and conduct of genome-wide association meta-analyses.pdf}
}

@article{wiviottDapagliflozinCardiovascularOutcomes2019,
  title = {Dapagliflozin and {{Cardiovascular Outcomes}} in {{Type}} 2 {{Diabetes}}},
  author = {Wiviott, Stephen D. and Raz, Itamar and Bonaca, Marc P. and Mosenzon, Ofri and Kato, Eri T. and Cahn, Avivit and Silverman, Michael G. and Zelniker, Thomas A. and Kuder, Julia F. and Murphy, Sabina A. and Bhatt, Deepak L. and Leiter, Lawrence A. and McGuire, Darren K. and Wilding, John P. H. and Ruff, Christian T. and {Gause-Nilsson}, Ingrid A. M. and Fredriksson, Martin and Johansson, Peter A. and Langkilde, Anna-Maria and Sabatine, Marc S. and {DECLARE--TIMI 58 Investigators}},
  year = {2019},
  month = jan,
  journal = {The New England Journal of Medicine},
  volume = {380},
  number = {4},
  pages = {347--357},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1812389},
  abstract = {BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke. The primary efficacy outcomes were MACE and a composite of cardiovascular death or hospitalization for heart failure. Secondary efficacy outcomes were a renal composite ({$\geq$}40\% decrease in estimated glomerular filtration rate to {$<$}60 ml per minute per 1.73 m2 of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes) and death from any cause. RESULTS: We evaluated 17,160 patients, including 10,186 without atherosclerotic cardiovascular disease, who were followed for a median of 4.2 years. In the primary safety outcome analysis, dapagliflozin met the prespecified criterion for noninferiority to placebo with respect to MACE (upper boundary of the 95\% confidence interval [CI], {$<$}1.3; P{$<$}0.001 for noninferiority). In the two primary efficacy analyses, dapagliflozin did not result in a lower rate of MACE (8.8\% in the dapagliflozin group and 9.4\% in the placebo group; hazard ratio, 0.93; 95\% CI, 0.84 to 1.03; P=0.17) but did result in a lower rate of cardiovascular death or hospitalization for heart failure (4.9\% vs. 5.8\%; hazard ratio, 0.83; 95\% CI, 0.73 to 0.95; P=0.005), which reflected a lower rate of hospitalization for heart failure (hazard ratio, 0.73; 95\% CI, 0.61 to 0.88); there was no between-group difference in cardiovascular death (hazard ratio, 0.98; 95\% CI, 0.82 to 1.17). A renal event occurred in 4.3\% in the dapagliflozin group and in 5.6\% in the placebo group (hazard ratio, 0.76; 95\% CI, 0.67 to 0.87), and death from any cause occurred in 6.2\% and 6.6\%, respectively (hazard ratio, 0.93; 95\% CI, 0.82 to 1.04). Diabetic ketoacidosis was more common with dapagliflozin than with placebo (0.3\% vs. 0.1\%, P=0.02), as was the rate of genital infections that led to discontinuation of the regimen or that were considered to be serious adverse events (0.9\% vs. 0.1\%, P{$<$}0.001). CONCLUSIONS: In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure. (Funded by AstraZeneca; DECLARE-TIMI 58 ClinicalTrials.gov number, NCT01730534 .).},
  langid = {english},
  pmid = {30415602},
  keywords = {Aged,Benzhydryl Compounds,Cardiovascular Diseases,Diabetes Mellitus Type 2,Female,Glucosides,Heart Failure,Hospitalization,Humans,Male,Middle Aged,Sodium-Glucose Transporter 2 Inhibitors}
}

@article{woolfRoleEstimationMendelian2025,
  title = {The Role of Estimation in {{Mendelian}} Randomization: Should {{Mendelian}} Randomization Investigations Provide Estimates?},
  shorttitle = {The Role of Estimation in {{Mendelian}} Randomization},
  author = {Woolf, Benjamin and Burgess, Stephen},
  year = {2025},
  month = may,
  journal = {AJE Advances: Research in Epidemiology},
  pages = {uuaf003},
  issn = {2977-0548},
  doi = {10.1093/ajeadv/uuaf003},
  urldate = {2025-06-02},
  abstract = {Mendelian randomization (MR) makes causal claims by treating genetic variation in an analogous way to randomization in a clinical trial. MR investigations can be viewed as analogous to a randomized encouragement design, in that genetic variants do not determine the precise level of an exposure, but increase liability to it. As such, an MR estimate typically does not represent an achievable or well-defined causal effect in terms of the exposure, as it reflects the impact of a life-long shift in the trajectory of the exposure, which likely differs between individuals. We advocate for MR investigations to be performed to assess evidence for a causal hypothesis, rather than to estimate a well-defined causal quantity. MR estimates are useful to combine evidence across genetic variants, to assess the validity of variants as instruments, to provide confidence intervals, and to compare estimates across outcomes. However, numerical estimates from MR should not be over-interpreted. The value of an MR investigation is not to quantify the magnitude of effect for a well-defined intervention in the exposure. Instead, it provides a distinct source of evidence to increase or decrease confidence in a causal hypothesis, which can be triangulated with evidence from other sources.},
  file = {/Users/xx20081/Zotero/storage/K4PJWHJY/Woolf and Burgess - 2025 - The role of estimation in Mendelian randomization should Mendelian randomization investigations pro.pdf;/Users/xx20081/Zotero/storage/8AIY9Q4C/8131753.html}
}

@article{wuIntegratingGeneExpression2022,
  title = {Integrating Gene Expression and Clinical Data to Identify Drug Repurposing Candidates for Hyperlipidemia and Hypertension},
  author = {Wu, Patrick and Feng, QiPing and Kerchberger, Vern Eric and Nelson, Scott D. and Chen, Qingxia and Li, Bingshan and Edwards, Todd L. and Cox, Nancy J. and Phillips, Elizabeth J. and Stein, C. Michael and Roden, Dan M. and Denny, Joshua C. and Wei, Wei-Qi},
  year = {2022},
  month = jan,
  journal = {Nature Communications},
  volume = {13},
  number = {1},
  pages = {46},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-021-27751-1},
  urldate = {2025-05-27},
  abstract = {Discovering novel uses for existing drugs, through drug repurposing, can reduce the time, costs, and risk of failure associated with new drug development. However, prioritizing drug repurposing candidates for downstream studies remains challenging. Here, we present a high-throughput approach to identify and validate drug repurposing candidates. This approach integrates human gene expression, drug perturbation, and clinical data from publicly available resources. We apply this approach to find drug repurposing candidates for two diseases, hyperlipidemia and hypertension. We screen {$>$}21,000 compounds and replicate ten approved drugs. We also identify 25 (seven for hyperlipidemia, eighteen for hypertension) drugs approved for other indications with therapeutic effects on clinically relevant biomarkers. For five of these drugs, the therapeutic effects are replicated in the All of Us Research Program database. We anticipate our approach will enable researchers to integrate multiple publicly available datasets to identify high priority drug repurposing opportunities for human diseases.},
  copyright = {2022 The Author(s)},
  langid = {english},
  keywords = {Data integration,Gene expression,High-throughput screening,Software,Virtual drug screening},
  file = {/Users/xx20081/Zotero/storage/PZH34RUD/Wu et al. - 2022 - Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipid.pdf}
}

@article{xieAssociation23Drugs2023,
  title = {Association between 23 Drugs and {{Parkinson}}'s Disease: {{A}} Two-Sample {{Mendelian}} Randomization Study},
  shorttitle = {Association between 23 Drugs and {{Parkinson}}'s Disease},
  author = {Xie, Zhixin and Zhou, Haobin and Qiu, Ziyu and Fan, Zhongxi and Yang, Weisheng and Zhang, Jingbai and Wang, Yezhong and Ye, Yongyi},
  year = {2023},
  month = nov,
  journal = {Brain and Behavior},
  volume = {13},
  number = {11},
  pages = {e3225},
  issn = {2162-3279},
  doi = {10.1002/brb3.3225},
  abstract = {BACKGROUND: Parkinson's disease (PD) is a common degenerative nervous system disease. At present, there are certain limitations in various treatment options aimed at preventing or delaying the progression of PD. Therefore, the exploration of new drugs for PD is beneficial. Mendelian randomization (MR) analysis can be used to explore the association between drugs and diseases. In this study, MR analysis was adopted to investigate the causal relationship between 23 drugs and PD. These drugs have been approved for the treatment of different diseases, such as salicylic acid and derivatives (collectively called salicylates, e.g., aspirin, used for fever and pain relief), antithrombotic agents (e.g., warfarin, aspirin, used for preventing thrombotic events). METHODS: The GWAS data for the 23 drugs were obtained from the UK Biobank (UKB) project, while the GWAS data for PD were sourced from FinnGen. Single-Nucleotide Polymorphisms (SNPs) were selected as instrumental variables (IVs). We first performed a series of quality control steps (including MR-PRESSO) to select the appropriate SNPs. Two-sample MR analysis was performed using five different methods, including inverse variance weighting (IVW) with random-effects model, weighted median, MR-Egger, simple model, and weighted model. At the same time, sensitivity analysis was carried out using the MR-Egger and Cochran's Q test to ensure the authenticity and reliability of the results. RESULTS: In MR-PRESSO, salicylates and antithrombotic agents showed statistically significant associations with PD, respectively. In the main MR analysis (IVW), there was a negative causal relationship between salicylates and PD (OR~=~0.73, 95\% CI~=~0.54-0.98, p~=~.039). Similarly, there was a negative causal relationship between antithrombotic agents and PD (OR~=~0.70, 95\%CI~=~0.52-0.96, p~=~.027). No statistically significant association was found between the remaining 21 drugs and PD. CONCLUSION: This MR study demonstrated that salicylates and antithrombotic agents can reduce the risk of PD, thus providing a novel avenue for future drug exploration in PD.},
  langid = {english},
  pmcid = {PMC10636399},
  pmid = {37654024},
  keywords = {Aspirin,drug,Fibrinolytic Agents,Genome-Wide Association Study,Humans,Mendelian Randomization Analysis,Parkinson Disease,Parkinson's disease,Reproducibility of Results,Salicylic Acid,two-sample Mendelian randomization},
  file = {/Users/xx20081/Zotero/storage/D27LBGH4/Xie et al. - 2023 - Association between 23 drugs and Parkinson's disea.pdf}
}

@article{xingRelationshipRegionalAdiposity2023,
  title = {Relationship {{Between Regional Adiposity Distribution}} and {{Incident Heart Failure}} in {{General Populations}} without {{Cardiovascular Disease}}},
  author = {Xing, Zhenhua and Xiao, Bing and Hu, Xinqun and Chai, Xiangping},
  year = {2023},
  month = mar,
  journal = {The American Journal of Medicine},
  volume = {136},
  number = {3},
  pages = {277-283.e2},
  publisher = {Elsevier},
  issn = {0002-9343, 1555-7162},
  doi = {10.1016/j.amjmed.2022.11.017},
  urldate = {2025-01-08},
  langid = {english},
  pmid = {36495933},
  keywords = {Bioimpedance analysis,Cardiovascular disease,Heart failure,Obesity},
  file = {/Users/xx20081/Zotero/storage/IFRJ9L29/Xing et al. - 2023 - Relationship Between Regional Adiposity Distribution and Incident Heart Failure in General Populatio.pdf}
}

@article{xingRelationshipRegionalAdiposity2023a,
  title = {Relationship {{Between Regional Adiposity Distribution}} and {{Incident Heart Failure}} in {{General Populations}} without {{Cardiovascular Disease}}},
  author = {Xing, Zhenhua and Xiao, Bing and Hu, Xinqun and Chai, Xiangping},
  year = {2023},
  month = mar,
  journal = {The American Journal of Medicine},
  volume = {136},
  number = {3},
  pages = {277-283.e2},
  issn = {0002-9343, 1555-7162},
  doi = {10.1016/j.amjmed.2022.11.017},
  urldate = {2025-01-08},
  langid = {english},
  pmid = {36495933},
  keywords = {Bioimpedance analysis,Cardiovascular disease,Heart failure,Obesity}
}

@article{yaghootkarGeneticEvidenceLink2016,
  title = {Genetic {{Evidence}} for a {{Link Between Favorable Adiposity}} and {{Lower Risk}} of {{Type}} 2 {{Diabetes}}, {{Hypertension}}, and {{Heart Disease}}},
  author = {Yaghootkar, Hanieh and Lotta, Luca A. and Tyrrell, Jessica and Smit, Roelof A. J. and Jones, Sam E. and Donnelly, Louise and Beaumont, Robin and Campbell, Archie and Tuke, Marcus A. and Hayward, Caroline and Ruth, Katherine S. and Padmanabhan, Sandosh and Jukema, J. Wouter and Palmer, Colin C. and Hattersley, Andrew and Freathy, Rachel M. and Langenberg, Claudia and Wareham, Nicholas J. and Wood, Andrew R. and Murray, Anna and Weedon, Michael N. and Sattar, Naveed and Pearson, Ewan and Scott, Robert A. and Frayling, Timothy M.},
  year = {2016},
  month = aug,
  journal = {Diabetes},
  volume = {65},
  number = {8},
  pages = {2448--2460},
  issn = {1939-327X},
  doi = {10.2337/db15-1671},
  abstract = {Recent genetic studies have identified some alleles that are associated with higher BMI but lower risk of type 2 diabetes, hypertension, and heart disease. These "favorable adiposity" alleles are collectively associated with lower insulin levels and higher subcutaneous-to-visceral adipose tissue ratio and may protect from disease through higher adipose storage capacity. We aimed to use data from 164,609 individuals from the UK Biobank and five other studies to replicate associations between a genetic score of 11 favorable adiposity variants and adiposity and risk of disease, to test for interactions between BMI and favorable adiposity genetics, and to test effects separately in men and women. In the UK Biobank, the 50\% of individuals carrying the most favorable adiposity alleles had higher BMIs (0.120 kg/m(2) [95\% CI 0.066, 0.174]; P = 1E-5) and higher body fat percentage (0.301\% [0.230, 0.372]; P = 1E-16) compared with the 50\% of individuals carrying the fewest alleles. For a given BMI, the 50\% of individuals carrying the most favorable adiposity alleles were at lower risk of type 2 diabetes (odds ratio [OR] 0.837 [0.784, 0.894]; P = 1E-7), hypertension (OR 0.935 [0.911, 0.958]; P = 1E-7), and heart disease (OR 0.921 [0.872, 0.973]; P = 0.003) and had lower blood pressure (systolic -0.859 mmHg [-1.099, -0.618]; P = 3E-12 and diastolic -0.394 mmHg [-0.534, -0.254]; P = 4E-8). In women, these associations could be explained by the observation that the alleles associated with higher BMI but lower risk of disease were also associated with a favorable body fat distribution, with a lower waist-to-hip ratio (-0.004 cm [95\% CI -0.005, -0.003] 50\% vs. 50\%; P = 3E-14), but in men, the favorable adiposity alleles were associated with higher waist circumference (0.454 cm [0.267, 0.641] 50\% vs. 50\%; P = 2E-6) and higher waist-to-hip ratio (0.0013 [0.0003, 0.0024] 50\% vs. 50\%; P = 0.01). Results were strengthened when a meta-analysis with five additional studies was conducted. There was no evidence of interaction between a genetic score consisting of known BMI variants and the favorable adiposity genetic score. In conclusion, different molecular mechanisms that lead to higher body fat percentage (with greater subcutaneous storage capacity) can have different impacts on cardiometabolic disease risk. Although higher BMI is associated with higher risk of diseases, better fat storage capacity could reduce the risk.},
  langid = {english},
  pmcid = {PMC5386140},
  pmid = {27207519},
  keywords = {Adiposity,Adult,Aged,Body Mass Index,Diabetes Mellitus Type 2,Female,Genetic Predisposition to Disease,Heart Diseases,Humans,Hypertension,Male,Middle Aged,Obesity,Odds Ratio,Risk Factors,Sex Factors,Waist Circumference,Waist-Hip Ratio},
  file = {/Users/xx20081/Zotero/storage/9S96TJLP/Yaghootkar et al. - 2016 - Genetic Evidence for a Link Between Favorable Adip.pdf}
}

@article{yancy2013ACCFAHA2013,
  title = {2013 {{ACCF}}/{{AHA Guideline}} for the {{Management}} of {{Heart Failure}}: {{Executive Summary}}},
  shorttitle = {2013 {{ACCF}}/{{AHA Guideline}} for the {{Management}} of {{Heart Failure}}},
  author = {Yancy, Clyde W. and Jessup, Mariell and Bozkurt, Biykem and Butler, Javed and Casey, Donald E. and Drazner, Mark H. and Fonarow, Gregg C. and Geraci, Stephen A. and Horwich, Tamara and Januzzi, James L. and Johnson, Maryl R. and Kasper, Edward K. and Levy, Wayne C. and Masoudi, Frederick A. and McBride, Patrick E. and McMurray, John J.V. and Mitchell, Judith E. and Peterson, Pamela N. and Riegel, Barbara and Sam, Flora and Stevenson, Lynne W. and Tang, W.H. Wilson and Tsai, Emily J. and Wilkoff, Bruce L.},
  year = {2013},
  month = oct,
  journal = {Circulation},
  volume = {128},
  number = {16},
  pages = {1810--1852},
  publisher = {American Heart Association},
  doi = {10.1161/CIR.0b013e31829e8807},
  urldate = {2025-01-26},
  file = {/Users/xx20081/Zotero/storage/37FRYCHY/Yancy et al. - 2013 - 2013 ACCFAHA Guideline for the Management of Heart Failure Executive Summary.pdf}
}

@article{yanGenomewideAnalysisDisease2018,
  title = {Genome-Wide Analysis of Disease Progression in Age-Related Macular Degeneration},
  author = {Yan, Qi and Ding, Ying and Liu, Yi and Sun, Tao and Fritsche, Lars G and Clemons, Traci and Ratnapriya, Rinki and Klein, Michael L and Cook, Richard J and Liu, Yu and Fan, Ruzong and Wei, Lai and Abecasis, Gon{\c c}alo R and Swaroop, Anand and Chew, Emily Y and Weeks, Daniel E and Chen, Wei},
  year = {2018},
  month = mar,
  journal = {Human Molecular Genetics},
  volume = {27},
  number = {5},
  pages = {929--940},
  issn = {0964-6906},
  doi = {10.1093/hmg/ddy002},
  urldate = {2024-04-05},
  abstract = {Family- and population-based genetic studies have successfully identified multiple disease-susceptibility loci for Age-related macular degeneration (AMD), one of the first batch and most successful examples of genome-wide association study. However, most genetic studies to date have focused on case--control studies of late AMD (choroidal neovascularization or geographic atrophy). The genetic influences on disease progression are largely unexplored. We assembled unique resources to perform a genome-wide bivariate time-to-event analysis to test for association of time-to-late-AMD with {$\sim$}9 million variants on 2721 Caucasians from a large multi-center randomized clinical trial, the Age-Related Eye Disease Study. To our knowledge, this is the first genome-wide association study of disease progression (bivariate survival outcome) in AMD genetic studies, thus providing novel insights to AMD genetics. We used a robust Cox proportional hazards model to appropriately account for between-eye correlation when analyzing the progression time in the two eyes of each participant. We identified four previously reported susceptibility loci showing genome-wide significant association with AMD progression: ARMS2-HTRA1 (P\,=\,8.1 {\texttimes} 10-43), CFH (P = 3.5 {\texttimes} 10-37), C2-CFB-SKIV2L (P = 8.1 {\texttimes} 10-10) and C3 (P = 1.2 {\texttimes} 10-9). Furthermore, we detected association of rs58978565 near TNR (P = 2.3 {\texttimes} 10-8), rs28368872 near ATF7IP2 (P = 2.9 {\texttimes} 10-8) and rs142450006 near MMP9 (P = 0.0006) with progression to choroidal neovascularization but not geographic atrophy. Secondary analysis limited to 34 reported risk variants revealed that LIPC and CTRB2-CTRB1 were also associated with AMD progression (P {$<$} 0.0015). Our genome-wide analysis thus expands the genetics in both development and progression of AMD and should assist in early identification of high risk individuals.},
  pmcid = {PMC6059197},
  pmid = {29346644},
  file = {/Users/xx20081/Zotero/storage/CRMU9TP4/Yan et al. - 2018 - Genome-wide analysis of disease progression in age.pdf}
}

@article{yanGenomewideAnalysisDisease2018a,
  title = {Genome-Wide Analysis of Disease Progression in Age-Related Macular Degeneration},
  author = {Yan, Qi and Ding, Ying and Liu, Yi and Sun, Tao and Fritsche, Lars G and Clemons, Traci and Ratnapriya, Rinki and Klein, Michael L and Cook, Richard J and Liu, Yu and Fan, Ruzong and Wei, Lai and Abecasis, Gon{\c c}alo R and Swaroop, Anand and Chew, Emily Y and Weeks, Daniel E and Chen, Wei},
  year = {2018},
  month = mar,
  journal = {Human Molecular Genetics},
  volume = {27},
  number = {5},
  pages = {929--940},
  issn = {0964-6906},
  doi = {10.1093/hmg/ddy002},
  urldate = {2024-08-14},
  abstract = {Family- and population-based genetic studies have successfully identified multiple disease-susceptibility loci for Age-related macular degeneration (AMD), one of the first batch and most successful examples of genome-wide association study. However, most genetic studies to date have focused on case--control studies of late AMD (choroidal neovascularization or geographic atrophy). The genetic influences on disease progression are largely unexplored. We assembled unique resources to perform a genome-wide bivariate time-to-event analysis to test for association of time-to-late-AMD with {$\sim$}9 million variants on 2721 Caucasians from a large multi-center randomized clinical trial, the Age-Related Eye Disease Study. To our knowledge, this is the first genome-wide association study of disease progression (bivariate survival outcome) in AMD genetic studies, thus providing novel insights to AMD genetics. We used a robust Cox proportional hazards model to appropriately account for between-eye correlation when analyzing the progression time in the two eyes of each participant. We identified four previously reported susceptibility loci showing genome-wide significant association with AMD progression: ARMS2-HTRA1 (P\,=\,8.1 {\texttimes} 10-43), CFH (P = 3.5 {\texttimes} 10-37), C2-CFB-SKIV2L (P = 8.1 {\texttimes} 10-10) and C3 (P = 1.2 {\texttimes} 10-9). Furthermore, we detected association of rs58978565 near TNR (P = 2.3 {\texttimes} 10-8), rs28368872 near ATF7IP2 (P = 2.9 {\texttimes} 10-8) and rs142450006 near MMP9 (P = 0.0006) with progression to choroidal neovascularization but not geographic atrophy. Secondary analysis limited to 34 reported risk variants revealed that LIPC and CTRB2-CTRB1 were also associated with AMD progression (P {$<$} 0.0015). Our genome-wide analysis thus expands the genetics in both development and progression of AMD and should assist in early identification of high risk individuals.},
  pmcid = {PMC6059197},
  pmid = {29346644},
  file = {/Users/xx20081/Zotero/storage/JVN9MZFY/Yan et al. - 2018 - Genome-wide analysis of disease progression in age.pdf}
}

@misc{yangGlucagonlikePeptide1Receptor2025,
  title = {Glucagon-like Peptide-1 Receptor Activation and Mental Health: A Drug-Target {{Mendelian}} Randomization Study},
  shorttitle = {Glucagon-like Peptide-1 Receptor Activation and Mental Health},
  author = {Yang, Guoyi and Burgess, Stephen and Schooling, C. Mary},
  year = {2025},
  month = feb,
  pages = {2025.02.12.25322150},
  publisher = {medRxiv},
  doi = {10.1101/2025.02.12.25322150},
  urldate = {2025-04-14},
  abstract = {Concerns have been raised about the psychiatric safety of glucagon-like peptide-1 receptor (GLP-1R) agonists, but trial evidence suggests that they ameliorate depressive symptoms. We aimed to assess the associations of GLP-1R activation with mental health well-being and the risk of mental health disorders and substance use disorders. We performed drug-target Mendelian randomization and colocalization analyses using the largest relevant publicly available genome-wide association studies in European ancestry individuals. After correcting for multiple comparisons, genetically predicted lower body mass index (BMI) via GLP-1R activation was associated with a better well-being spectrum (0.06 standard deviation [95\% confidence interval 0.03-0.08]) and lower risk of depression (odds ratio 0.83 [0.74-0.94]) and bipolar disorder (odds ratio 0.61 [0.47-0.79]) per 1-kg/m2 decrease in BMI. There was also suggestive evidence that genetically predicted lower BMI via GLP-1R activation was associated with lower risk of post-partum depression, attention deficit hyperactivity disorder, and substance use disorders, and that genetically predicted lower glycated hemoglobin (HbA1c) via GLP-1R activation was associated with higher risk of anorexia nervosa but lower risk of Tourette syndrome. These associations were stronger than the associations for genetically predicted lower BMI and lower HbA1c based on genome-wide variants. The posterior probabilities of a shared causal variant affecting both BMI and the outcome at the GLP1R gene were 59.3\% for the well-being spectrum, 3.8\% for depression, and 45.9\% for bipolar disorder. GLP-1R activation was associated with better mental health well-being and lower risk of depression and bipolar disorder beyond that expected from the reduction in BMI and HbA1c.},
  archiveprefix = {medRxiv},
  copyright = {{\copyright} 2025, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), CC BY-NC 4.0, as described at http://creativecommons.org/licenses/by-nc/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/F94B38AZ/Yang et al. - 2025 - Glucagon-like peptide-1 receptor activation and mental health a drug-target Mendelian randomization.pdf}
}

@misc{yangLimitedOverlapGenetic2023,
  title = {Limited Overlap between Genetic Effects on Disease Susceptibility and Disease Survival},
  author = {Yang, Zhiyu and Pajuste, Fanny-Dhelia and Zguro, Kristina and Cheng, Yipeng and Kurant, Danielle E. and Eoli, Andrea and Wanner, Julian and Jermy, Bradley and FinnGen and research Team, Estonian Biobank and Kanoni, Stavroula and van Heel, David A. and Genes \&amp and Team, Health Research and Hayward, Caroline and Marioni, Riccardo E. and McCartney, Daniel L. and Renieri, Alessandra and Furini, Simone and Consortium, Genomics England Research and M{\"a}gi, Reedik and Gusev, Alexander and Drineas, Petros and Paschou, Peristera and Heyne, Henrike and Ripatti, Samuli and Mars, Nina and Ganna, Andrea},
  year = {2023},
  month = oct,
  pages = {2023.10.10.23296544},
  publisher = {medRxiv},
  doi = {10.1101/2023.10.10.23296544},
  urldate = {2024-08-14},
  abstract = {Understanding disease progression is of a high biological and clinical interest. Unlike disease susceptibility whose genetic basis has been abundantly studied, less is known about the genetics of disease progression and its overlap with disease susceptibility. Considering ten common diseases (N cases ranging from 17,152 to 99,666) across seven biobanks, we systematically compared the genetic architecture of susceptibility and progression, defined as disease-specific mortality. We identified only one locus significantly associated with disease-specific mortality and show that, at a similar sample size, more genome-wide significant loci can be identified in a GWAS of disease susceptibility. Variants that were significantly affecting disease susceptibility were weakly or not associated with disease-specific mortality. Moreover, susceptibility polygenic scores (PGSs) were weak predictor of disease-specific mortality while a PGS for general lifespan was significantly associated with disease-specific mortality for five out of ten diseases. We used theoretical derivation and simulation to propose plausible explanations for our empirical observations and account for potential index-event bias. Overall, our findings point to little similarity in genetic effects between disease susceptibility and disease-specific mortality and suggest that either larger sample sizes or different measures of progression are needed to identify the genetic underpinning of disease progression.},
  archiveprefix = {medRxiv},
  copyright = {{\copyright} 2023, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/VE5E2Z2A/Yang et al. - 2023 - Limited overlap between genetic effects on disease.pdf}
}

@article{yangSexstratifiedGenomewideAssociation2024,
  title = {Sex-Stratified Genome-Wide Association and Transcriptome-Wide {{Mendelian}} Randomization Studies Reveal Drug Targets of Heart Failure},
  author = {Yang, Qianqian and Yang, Qian and Wu, Xueyan and Zheng, Ruizhi and Lin, Hong and Wang, Shuangyuan and Joseph, Jacob and Sun, Yan V. and Li, Mian and Wang, Tiange and Zhao, Zhiyun and Xu, Min and Lu, Jieli and Chen, Yuhong and Ning, Guang and Wang, Weiqing and Bi, Yufang and Zheng, Jie and Xu, Yu},
  year = {2024},
  month = feb,
  journal = {Cell Reports Medicine},
  volume = {5},
  number = {2},
  publisher = {Elsevier},
  issn = {2666-3791},
  doi = {10.1016/j.xcrm.2023.101382},
  urldate = {2024-05-08},
  abstract = {{$<$}h2{$>$}Summary{$<$}/h2{$><$}p{$>$}The prevalence of heart failure (HF) subtypes, which are classified by left ventricular ejection fraction (LVEF), demonstrate significant sex differences. Here, we perform sex-stratified genome-wide association studies (GWASs) on LVEF and transcriptome-wide Mendelian randomization (MR) on LVEF, all-cause HF, HF with reduced ejection fraction (HFrEF), and HF with preserved ejection fraction (HFpEF). The sex-stratified GWASs of LVEF identified three sex-specific loci that were exclusively detected in the sex-stratified GWASs. Three drug target genes show sex-differential effects on HF/HFrEF via influencing LVEF, with \emph{NPR2} as the target gene for the HF drug Cenderitide under phase 2 clinical trial. Our study highlights the importance of considering sex-differential genetic effects in sex-balanced diseases such as HF and emphasizes the value of sex-stratified GWASs and MR in identifying putative genetic variants, causal genes, and candidate drug targets for HF, which is not identifiable using a sex-combined strategy.{$<$}/p{$>$}},
  langid = {english},
  pmid = {38237596},
  file = {/Users/xx20081/Zotero/storage/5DMQMXE7/Yang et al. - 2024 - Sex-stratified genome-wide association and transcr.pdf}
}

@article{yanRibosomalModificationProtein2024,
  title = {Ribosomal Modification Protein {{rimK-like}} Family Member {{A}} Activates Betaine-Homocysteine {{S-methyltransferase}} 1 to Ameliorate Hepatic Steatosis},
  author = {Yan, Han and Liu, Wenjun and Xiang, Rui and Li, Xin and Hou, Song and Xu, Luzheng and Wang, Lin and Zhao, Dong and Liu, Xingkai and Wang, Guoqing and Chi, Yujing and Yang, Jichun},
  year = {2024},
  month = aug,
  journal = {Signal Transduction and Targeted Therapy},
  volume = {9},
  number = {1},
  pages = {214},
  issn = {2059-3635},
  doi = {10.1038/s41392-024-01914-0},
  abstract = {Nonalcoholic fatty liver disease (NAFLD) is a serious threat to public health, but its underlying mechanism remains poorly understood. In screening important genes using Gene Importance Calculator (GIC) we developed previously, ribosomal modification protein rimK-like family member A (RIMKLA) was predicted as one essential gene but its functions remained largely unknown. The current study determined the roles of RIMKLA in regulating glucose and lipid metabolism. RIMKLA expression was reduced in livers of human and mouse with NAFLD. Hepatic RIMKLA overexpression ameliorated steatosis and hyperglycemia in obese mice. Hepatocyte-specific RIMKLA knockout aggravated high-fat diet (HFD)-induced dysregulated glucose/lipid metabolism in mice. Mechanistically, RIMKLA is a new protein kinase that phosphorylates betaine-homocysteine S-methyltransferase 1 (BHMT1) at threonine 45 (Thr45) site. Upon phosphorylation at Thr45 and activation, BHMT1 eliminated homocysteine (Hcy) to inhibit the activity of transcription factor activator protein 1 (AP1) and its induction on fatty acid synthase (FASn) and cluster of differentiation 36 (CD36) gene transcriptions, concurrently repressing lipid synthesis and uptake in hepatocytes. Thr45 to alanine (T45A) mutation inactivated BHMT1 to abolish RIMKLA's repression on Hcy level, AP1 activity, FASn/CD36 expressions, and lipid deposition. BHMT1 overexpression rescued the dysregulated lipid metabolism in RIMKLA-deficient hepatocytes. In summary, RIMKLA is a novel protein kinase that phosphorylates BHMT1 at Thr45 to repress lipid synthesis and uptake. Under obese condition, inhibition of RIMKLA impairs BHMT1 activity to promote hepatic lipid deposition.},
  langid = {english},
  pmcid = {PMC11310345},
  pmid = {39117631},
  keywords = {Amide Synthases,Animals,Betaine-Homocysteine S-Methyltransferase,Diet High-Fat,Hepatocytes,Humans,Lipid Metabolism,Male,Mice,Mice Knockout,Non-alcoholic Fatty Liver Disease,Phosphorylation},
  file = {/Users/xx20081/Zotero/storage/QSVWUWXQ/Yan et al. - 2024 - Ribosomal modification protein rimK-like family member A activates betaine-homocysteine S-methyltran.pdf}
}

@article{yengoMetaanalysisGenomewideAssociation2018,
  title = {Meta-Analysis of Genome-Wide Association Studies for Height and Body Mass Index in {$\sim$}700000 Individuals of {{European}} Ancestry},
  author = {Yengo, Loic and Sidorenko, Julia and Kemper, Kathryn E. and Zheng, Zhili and Wood, Andrew R. and Weedon, Michael N. and Frayling, Timothy M. and Hirschhorn, Joel and Yang, Jian and Visscher, Peter M. and {GIANT Consortium}},
  year = {2018},
  month = oct,
  journal = {Human Molecular Genetics},
  volume = {27},
  number = {20},
  pages = {3641--3649},
  issn = {1460-2083},
  doi = {10.1093/hmg/ddy271},
  abstract = {Recent genome-wide association studies (GWAS) of height and body mass index (BMI) in {$\sim$}250000 European participants have led to the discovery of {$\sim$}700 and {$\sim$}100 nearly independent single nucleotide polymorphisms (SNPs) associated with these traits, respectively. Here we combine summary statistics from those two studies with GWAS of height and BMI performed in {$\sim$}450000 UK Biobank participants of European ancestry. Overall, our combined GWAS meta-analysis reaches N~{$\sim$}700000 individuals and substantially increases the number of GWAS signals associated with these traits. We identified 3290 and 941 near-independent SNPs associated with height and BMI, respectively (at a revised genome-wide significance threshold of P~{$<~$}1~{\texttimes}~10-8), including 1185 height-associated SNPs and 751 BMI-associated SNPs located within loci not previously identified by these two GWAS. The near-independent genome-wide significant SNPs explain {$\sim$}24.6\% of the variance of height and {$\sim$}6.0\% of the variance of BMI in an independent sample from the Health and Retirement Study (HRS). Correlations between polygenic scores based upon these SNPs with actual height and BMI in HRS participants were {$\sim$}0.44 and {$\sim$}0.22, respectively. From analyses of integrating GWAS and expression quantitative trait loci (eQTL) data by summary-data-based Mendelian randomization, we identified an enrichment of eQTLs among lead height and BMI signals, prioritizing 610 and 138 genes, respectively. Our study demonstrates that, as previously predicted, increasing GWAS sample sizes continues to deliver, by the discovery of new loci, increasing prediction accuracy and providing additional data to achieve deeper insight into complex trait biology. All summary statistics are made available for follow-up studies.},
  langid = {english},
  pmcid = {PMC6488973},
  pmid = {30124842},
  keywords = {Body Height,Body Mass Index,Body Weight,Female,Genome Human,Genome-Wide Association Study,Humans,Male,Polymorphism Single Nucleotide,Quantitative Trait Loci,White People},
  file = {/Users/xx20081/Zotero/storage/F2Q2B374/Yengo et al. - 2018 - Meta-analysis of genome-wide association studies f.pdf}
}

@article{yesilaltayLossPDZK1Causes2009,
  title = {Loss of {{PDZK1 Causes Coronary Artery Occlusion}} and {{Myocardial Infarction}} in {{Paigen Diet-Fed Apolipoprotein E Deficient Mice}}},
  author = {Yesilaltay, Ayce and Daniels, Kathleen and Pal, Rinku and Krieger, Monty and Kocher, Olivier},
  year = {2009},
  month = dec,
  journal = {PLoS ONE},
  volume = {4},
  number = {12},
  pages = {e8103},
  issn = {1932-6203},
  doi = {10.1371/journal.pone.0008103},
  urldate = {2025-05-27},
  abstract = {Background PDZK1 is a four PDZ-domain containing protein that binds to the carboxy terminus of the HDL receptor, scavenger receptor class B type I (SR-BI), and regulates its expression, localization and function in a tissue-specific manner. PDZK1 knockout (KO) mice are characterized by a marked reduction of SR-BI protein expression ({$\sim$}95\%) in the liver (lesser or no reduction in other organs) with a concomitant 1.7 fold increase in plasma cholesterol. PDZK1 has been shown to be atheroprotective using the high fat/high cholesterol (`Western') diet-fed murine apolipoprotein E (apoE) KO model of atherosclerosis, presumably because of its role in promoting reverse cholesterol transport via SR-BI. Principal Findings Here, we have examined the effects of PDZK1 deficiency in apoE KO mice fed with the atherogenic `Paigen' diet for three months. Relative to apoE KO, PDZK1/apoE double KO (dKO) mice showed increased plasma lipids (33\% increase in total cholesterol; 49 \% increase in unesterified cholesterol; and 36\% increase in phospholipids) and a 26\% increase in aortic root lesions. Compared to apoE KO, dKO mice exhibited substantial occlusive coronary artery disease: 375\% increase in severe occlusions. Myocardial infarctions, not observed in apoE KO mice (although occasional minimal fibrosis was noted), were seen in 7 of 8 dKO mice, resulting in 12 times greater area of fibrosis in dKO cardiac muscle. Conclusions These results show that Paigen-diet fed PDZK1/apoE dKO mice represent a new animal model useful for studying coronary heart disease and suggest that PDZK1 may represent a valuable target for therapeutic intervention.},
  pmcid = {PMC2779610},
  pmid = {19956623},
  file = {/Users/xx20081/Zotero/storage/K96RUWAF/Yesilaltay et al. - 2009 - Loss of PDZK1 Causes Coronary Artery Occlusion and Myocardial Infarction in Paigen Diet-Fed Apolipop.pdf}
}

@article{ygRoleGeneticTesting2017,
  title = {The Role of Genetic Testing in Epilepsy Diagnosis and Management},
  author = {Yg, Weber and S, Biskup and Kl, Helbig and S, Von Spiczak and H, Lerche},
  year = {2017},
  month = aug,
  journal = {Expert review of molecular diagnostics},
  volume = {17},
  number = {8},
  publisher = {Expert Rev Mol Diagn},
  issn = {1744-8352},
  doi = {10.1080/14737159.2017.1335598},
  urldate = {2023-08-09},
  abstract = {Epilepsy is a common neurological disorder characterized by recurrent unprovoked seizures. More than 500 epilepsy-associated genes have been described in the literature. Most of these genes play an important role in neuronal excitability, cortical development or synaptic transmission. A growing numb {\dots}},
  langid = {english},
  pmid = {28548558},
  file = {/Users/xx20081/Zotero/storage/DT7ISGQG/28548558.html}
}

@article{yiannakourisThe2548GPolymorphismHuman2003,
  title = {The-{{2548G}}/{{A}} Polymorphism in the Human Leptin Gene Promoter Region Is Associated with Plasma Free Leptin Levels; Interaction with Adiposity and Gender in Healthy Subjects},
  author = {Yiannakouris, Nikos and Melistas, Lambros and Yannakoulia, Mary and Mungal, Keisha and Mantzoros, Christos S.},
  year = {2003},
  journal = {Hormones (Athens, Greece)},
  volume = {2},
  number = {4},
  pages = {229--236},
  issn = {1109-3099},
  doi = {10.14310/horm.2002.11104},
  abstract = {A common -2548G/A promoter variant of the human leptin gene has recently been shown to be associated with variations in circulating leptin levels but available data are still conflicting. The aim of this study was to explore potential associations between the -2548G/A polymorphism and adiposity-related variables, plasma total leptin levels, as well as soluble leptin receptor (sOB-R) levels and free leptin in a group of healthy Greek subjects. One hundred eighteen consecutively enrolled subjects [62 females, 56 males; mean age+/-SD: 17.7+/-1.8 years; body mass index (BMI) range: 15.4-35.9 kg/m2] were genotyped for the -2548G/A polymorphism and their BMI, fat free mass, \% fat mass, fasting plasma total leptin and sOB-R levels were determined. The ratio leptin/sOB-R was used as an index of free leptin. No significant differences in genotype and allele frequencies of the -2548G/A polymorphism were detected between normal weight and overweight subjects, and no association was found between this polymorphism and BMI, fat mass or plasma total leptin levels. However, the -2548G/A polymorphism was found to be associated with circulating free leptin levels in a gender specific manner. More specifically, compared to carriers of the -2548G allele, female subjects with the A/A genotype had higher age and fat mass adjusted mean (+/-SE) plasma concentrations of sOB-R (32.9+/-7.2 vs. 25.6+/-3.8 ng/ml, P=0.05), and significantly lower (approx. 50\%) leptin/sOB-R values (0.74+/-0.25 vs. 1.42+/-0.13, P=0.02). Furthermore, multiple regression analysis revealed that, after adjustment to fat mass, the -2548G/A genotype and gender are significantly associated with free leptin index in the entire study sample. Similar regression models revealed a significant interaction of gender and genotype when considered in addition to fat mass, or fat mass and genotype when considered in addition to gender, as predictors of free leptin index. In conclusion, the common -2548G/A promoter variant of the human leptin gene is associated with plasma free leptin levels through an interaction with adiposity and gender in healthy subjects.},
  langid = {english},
  pmid = {17003027},
  file = {/Users/xx20081/Zotero/storage/ES72EKC5/Yiannakouris et al. - 2003 - The-2548GA polymorphism in the human leptin gene .pdf}
}

@article{Young2004,
  title = {Mortality and Morbidity Reduction with {{Candesartan}} in Patients with Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the {{CHARM}} Low-Left Ventricular Ejection Fraction Trials},
  author = {Young, James B. and Dunlap, Mark E. and Pfeffer, Marc A. and Probstfield, Jeffrey L. and {Cohen-Solal}, Alain and Dietz, Rainer and Granger, Christopher B. and Hradec, Jaromir and Kuch, Jerzy and McKelvie, Robert S. and McMurray, John J.V. and Michelson, Eric L. and Olofsson, Bertil and Ostergren, Jan and Held, Peter and Solomon, Scott D. and Yusuf, Salim and Swedberg, Karl},
  year = {2004},
  month = oct,
  journal = {Circulation},
  volume = {110},
  number = {17},
  pages = {2618--2626},
  publisher = {Circulation},
  issn = {1524-4539},
  doi = {10.1161/01.CIR.0000146819.43235.A9},
  abstract = {Background-Patients with symptomatic chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF) have a high risk of death and hospitalization for CHF deterioration despite therapies with angiotensin-converting enzyme (ACE) inhibitors, {$\beta$}-blockers, and even an aldosterone antagonist. To determine whether the angiotensin-receptor blocker (ARB) candesartan decreases cardiovascular mortality, morbidity, and all-cause mortality in patients with CHF and depressed LVEF, a prespecified analysis of the combined Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) low LVEF trials was performed. CHARM is a randomized, double-blind, placebo-controlled, multicenter, international trial program. Methods and Results-New York Heart Association (NYHA) class II through IV CHF patients with an LVEF of {$\leq$}40\% were randomized to candesartan or placebo in 2 complementary parallel trials (CHARM-Alternative, for patients who cannot tolerate ACE inhibitors, and CHARM-Added, for patients who were receiving ACE inhibitors). Mortality and morbidity were determined in 4576 low LVEF patients (2289 candesartan and 2287 placebo), titrated as tolerated to a target dose of 32 mg once daily, and observed for 2 to 4 years (median, 40 months). The primary outcome (time to first event by intention to treat) was cardiovascular death or CHF hospitalization for each trial, with all-cause mortality a secondary end point in the pooled analysis of the low LVEF trials. Of the patients in the candesartan group, 817 (35.7\%) experienced cardiovascular death or a CHF hospitalization as compared with 944 (41.3\%) in the placebo group (HR 0.82; 95\% CI 0.74 to 0.90; P{\textexclamdown}0.001) with reduced risk for both cardiovascular deaths (521 [22.8\%] versus 599 [26.2\%]; HR 0.84 [95\% CI 0.75 to 0.95]; P=0.005) and CHF hospitalizations (516 [22.5\%] versus 642 [28.1\%]; HR 0.76 [95\% CI 0.68 to 0.85]; P{\textexclamdown}0.001). It is important to note that all-cause mortality also was significantly reduced by candesartan (642 [28.0\%] versus 708 [31.0\%]; HR 0.88 [95\% CI 0.79 to 0.98]; P=0.018). No significant heterogeneity for the beneficial effects of candesartan was found across prespecified and subsequently identified subgroups including treatment with ACE inhibitors, {$\beta$}-blockers, an aldosterone antagonist, or their combinations. The study drug was discontinued because of adverse effects by 23.1\% of patients in the candesartan group and 18.8\% in the placebo group; the reasons included increased creatinine (7.1\% versus 3.5\%), hypotension (4.2\% versus 2.1\%), and hyperkalemia (2.8\% versus 0.5\%), respectively (all P{\textexclamdown}0.001). Conclusion-Candesartan significantly reduces all-cause mortality, cardiovascular death, and heart failure hospitalizations in patients with CHF and LVEF s40\% when added to standard therapies including ACE inhibitors, {$\beta$}-blockers, and an aldosterone antagonist. Routine monitoring of blood pressure, serum creatinine, and serum potassium is warranted.},
  pmid = {15492298},
  keywords = {affs=[]),Aged,Angiotensin II Type 1 Receptor Blockers / antagonists & inhibitors*,Benzimidazoles / therapeutic use*,Biphenyl Compounds,Cardiac Output,Chronic Disease,Clinical Trial,doi:10.1161/01.CIR.0000146819.43235.A9,Female,Hospitalization,Humans,investigators=[],James B Young,Left / diagnosis,Left / drug therapy*,Left / mortality*,Low / diagnosis,Low / drug therapy*,Low / mortality*,Male,Mark E Dunlap,MEDLINE,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,Non-U.S. Gov't,pmid:15492298,PubMed Abstract,Randomized Controlled Trial,Randomized Controlled Trials as Topic,Research Support,Stroke Volume,Systole,Tetrazoles / therapeutic use*,Ventricular Dysfunction}
}

@article{Yusuf2003,
  title = {Effects of Candesartan in Patients with Chronic Heart Failure and Preserved Left-Ventricular Ejection Fraction: The {{CHARM-Preserved Trial}}},
  author = {Yusuf, Salim and Pfeffer, Marc A. and Swedberg, Karl and Granger, Christopher B. and Held, Peter and McMurray, John J.V. and Michelson, Eric L. and Olofsson, Bertil and {\"O}stergren, Jan},
  year = {2003},
  month = sep,
  journal = {Lancet (London, England)},
  volume = {362},
  number = {9386},
  pages = {777--781},
  publisher = {Lancet},
  issn = {1474-547X},
  doi = {10.1016/S0140-6736(03)14285-7},
  abstract = {Background: Half of patients with chronic heart failure (CHF) have preserved left-ventricular ejection fraction (LVEF), but few treatments have specifically been assessed in such patients. In previous studies of patients with CHF and low LVEF or vascular disease and preserved LVEF, inhibition of the renin-angiotensin system is beneficial. We investigated the effect of addition of an angiotensin-receptor blocker to current treatments. Methods: Between March, 1999, and July, 2000, we randomly assigned 3023 patients candesartan (n=1514, target dose 32 mg once daily) or matching placebo (n=1509). Patients had New York Heart Association functional class II-IV CHF and LVEF higher than 40\%. The primary outcome was cardiovascular death or admission to hospital for CHF. Anaysis was done by intention to treat. Findings: Median follow-up was 36. 6 months. 333 (22\%) patients in the candesartan and 366 (24\%) in the placebo group experienced the primary outcome (unadjusted hazard ratio 0.89 [95\% CI 0.77-1.03], p=0.118; covariate adjusted 0.86 [0.74-1.0], p=0.051). Cardiovascular death did not differ between groups (170 vs 170), but fewer patients in the candesartan group than in the placebo group were admitted to hospital for CHF once (230 vs 279, p=0.017) or multiple times. Composite outcomes that included non-fatal myocardial infarction and non-fatal stroke showed similar results to the primary composite (388 vs 429; unadjusted 0.88 [0.77-1.01], p=0.078; covariate adjusted 0.86 [0.75-0.99], p=0.037). Interpretation: Candesartan has a moderate impact in preventing admissions for CHF among patients who have heart failure and LVEF higher than 40\%.},
  pmid = {13678871},
  keywords = {Adolescent,Adult,affs=[]),Aged,Angiotensin Receptor Antagonists,Antihypertensive Agents / therapeutic use*,Benzimidazoles / therapeutic use*,Biphenyl Compounds,Cardiovascular Diseases / mortality,Clinical Trial,CollabAuthor(name='CHARM Investigators and Committees',Comparative Study,doi:10.1016/S0140-6736(03)14285-7,Double-Blind Method,Female,Follow-Up Studies,Health Care,Heart Failure / drug therapy*,Heart Failure / mortality,Hospitalization,Humans,investigators=[],Left / physiology*,Male,Marc A Pfeffer,MEDLINE,Middle Aged,Multicenter Study,National Center for Biotechnology Information,National Institutes of Health,National Library of Medicine,NCBI,NIH,NLM,Non-U.S. Gov't,Outcome Assessment,Placebos,pmid:13678871,PubMed Abstract,Randomized Controlled Trial,Research Support,Salim Yusuf,Stroke Volume / physiology,Tetrazoles / therapeutic use*,Treatment Outcome,Ventricular Function}
}

@article{yusufEffectPotentiallyModifiable2004,
  title = {Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction in 52 Countries (the {{INTERHEART}} Study): Case-Control Study},
  shorttitle = {Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction in 52 Countries (the {{INTERHEART}} Study)},
  author = {Yusuf, Salim and Hawken, Steven and {\^O}unpuu, Stephanie and Dans, Tony and Avezum, Alvaro and Lanas, Fernando and McQueen, Matthew and Budaj, Andrzej and Pais, Prem and Varigos, John and Lisheng, Liu},
  year = {2004},
  month = sep,
  journal = {The Lancet},
  volume = {364},
  number = {9438},
  pages = {937--952},
  publisher = {Elsevier},
  issn = {0140-6736, 1474-547X},
  doi = {10.1016/S0140-6736(04)17018-9},
  urldate = {2024-12-04},
  langid = {english},
  pmid = {15364185},
  file = {/Users/xx20081/Zotero/storage/HE5G7NND/Yusuf et al. - 2004 - Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries.pdf}
}

@article{yusufEffectsCandesartanPatients2003,
  title = {Effects of Candesartan in Patients with Chronic Heart Failure and Preserved Left-Ventricular Ejection Fraction: The {{CHARM-Preserved Trial}}},
  shorttitle = {Effects of Candesartan in Patients with Chronic Heart Failure and Preserved Left-Ventricular Ejection Fraction},
  author = {Yusuf, Salim and Pfeffer, Marc A. and Swedberg, Karl and Granger, Christopher B. and Held, Peter and McMurray, John J. V. and Michelson, Eric L. and Olofsson, Bertil and Ostergren, Jan and {CHARM Investigators and Committees}},
  year = {2003},
  month = sep,
  journal = {Lancet (London, England)},
  volume = {362},
  number = {9386},
  pages = {777--781},
  issn = {1474-547X},
  doi = {10.1016/S0140-6736(03)14285-7},
  abstract = {BACKGROUND: Half of patients with chronic heart failure (CHF) have preserved left-ventricular ejection fraction (LVEF), but few treatments have specifically been assessed in such patients. In previous studies of patients with CHF and low LVEF or vascular disease and preserved LVEF, inhibition of the renin-angiotensin system is beneficial. We investigated the effect of addition of an angiotensin-receptor blocker to current treatments. METHODS: Between March, 1999, and July, 2000, we randomly assigned 3023 patients candesartan (n=1514, target dose 32 mg once daily) or matching placebo (n=1509). Patients had New York Heart Association functional class II-IV CHF and LVEF higher than 40\%. The primary outcome was cardiovascular death or admission to hospital for CHF. Analysis was done by intention to treat. FINDINGS: Median follow-up was 36.6 months. 333 (22\%) patients in the candesartan and 366 (24\%) in the placebo group experienced the primary outcome (unadjusted hazard ratio 0.89 [95\% CI 0.77-1.03], p=0.118; covariate adjusted 0.86 [0.74-1.0], p=0.051). Cardiovascular death did not differ between groups (170 vs 170), but fewer patients in the candesartan group than in the placebo group were admitted to hospital for CHF once (230 vs 279, p=0.017) or multiple times. Composite outcomes that included non-fatal myocardial infarction and non-fatal stroke showed similar results to the primary composite (388 vs 429; unadjusted 0.88 [0.77-1.01], p=0.078; covariate adjusted 0.86 [0.75-0.99], p=0.037). INTERPRETATION: Candesartan has a moderate impact in preventing admissions for CHF among patients who have heart failure and LVEF higher than 40\%.},
  langid = {english},
  pmid = {13678871},
  keywords = {Adolescent,Adult,Aged,Angiotensin Receptor Antagonists,Antihypertensive Agents,Benzimidazoles,Biphenyl Compounds,Cardiovascular Diseases,Double-Blind Method,Female,Follow-Up Studies,Heart Failure,Hospitalization,Humans,Male,Middle Aged,Outcome Assessment Health Care,Placebos,Stroke Volume,Tetrazoles,Treatment Outcome,Ventricular Function Left},
  file = {/Users/xx20081/Zotero/storage/DBUH4AU9/Yusuf et al. - 2003 - Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejectio.pdf}
}

@article{zamoraWeightLossObese2016,
  title = {Weight {{Loss}} in {{Obese Patients With Heart Failure}}},
  author = {Zamora, Elisabet and {D{\'i}ez-L{\'o}pez}, Carles and Lup{\'o}n, Josep and {de Antonio}, Marta and Domingo, Mar and Santesmases, Javier and Troya, Mar{\'i}a Isabel and {D{\'i}ez-Quevedo}, Crisanto and Altimir, Salvador and {Bayes-Genis}, Antoni},
  year = {2016},
  month = mar,
  journal = {Journal of the American Heart Association},
  volume = {5},
  number = {3},
  pages = {e002468},
  issn = {2047-9980},
  doi = {10.1161/JAHA.115.002468},
  abstract = {BACKGROUND: In heart failure (HF), weight loss (WL) has been associated with an adverse prognosis whereas obesity has been linked to lower mortality (the obesity paradox). The impact of WL in obese patients with HF is incompletely understood. Our objective was to explore the prevalence of WL and its impact on long-term mortality, with an emphasis on obese patients, in a cohort of patients with chronic HF. METHODS AND RESULTS: Weight at first visit and the 1-year follow-up and vital status after 3~years were assessed in 1000 consecutive ambulatory, chronic HF patients (72.7\% men; mean age 65.8{\textpm}12.1~years). Significant WL was defined as a loss of {$\geq$}5\% weight between baseline and 1 year. Obesity was defined as body mass index {$\geq$}30~kg/m(2) (N=272). Of the 1000 patients included, 170 experienced significant WL during the first year of follow-up. Mortality was significantly higher in patients with significant WL (27.6\% versus 15.3\%, P{$<$}0.001). In univariable Cox regression analysis, patients with significant WL had 2-fold higher mortality (hazard ratio 1.95 [95\% CI 1.39-2.72], P{$<$}0.001). In multivariable analysis, adjusting for age, sex, body mass index, New York Heart Association functional class, left ventricular ejection fraction, HF duration, ischemic etiology, diabetes, and treatment, significant WL remained independently associated with higher mortality (hazard ratio 1.89 [95\% CI 1.32-2.68], P{$<$}0.001). Among obese patients with HF, significant WL was associated with an even more ominous prognosis (adjusted hazard ratio for death of 2.38 [95\% CI 1.31-4.32], P=0.004) than that observed in nonobese patients (adjusted hazard ratio 1.83 [95\% CI 1.16-2.89], P=0.01). CONCLUSIONS: Weight loss {$\geq$}5\% in patients with chronic HF was associated with high long-term mortality, particularly among obese patients with HF.},
  langid = {english},
  pmcid = {PMC4943237},
  pmid = {27013541},
  keywords = {Aged,Body Mass Index,cachexia,Chi-Square Distribution,Female,heart failure,Heart Failure,Humans,Male,Middle Aged,mortality,Multivariate Analysis,obesity,Obesity,Proportional Hazards Models,Risk Assessment,Risk Factors,Spain,Time Factors,Treatment Outcome,weight,Weight Loss},
  file = {/Users/xx20081/Zotero/storage/N8HCRN5L/Zamora et al. - 2016 - Weight Loss in Obese Patients With Heart Failure.pdf}
}

@article{zengDissectingSharedGenetic2023,
  title = {Dissecting Shared Genetic Architecture between Obesity and Multiple Sclerosis},
  author = {Zeng, Ruijie and Jiang, Rui and Huang, Wentao and Wang, Jiaxuan and Zhang, Lijun and Ma, Yuying and Wu, Yanjun and Meng, Meijun and Lan, Hekui and Lian, Qizhou and Leung, Felix W. and Sha, Weihong and Chen, Hao},
  year = {2023},
  month = jul,
  journal = {eBioMedicine},
  volume = {93},
  publisher = {Elsevier},
  issn = {2352-3964},
  doi = {10.1016/j.ebiom.2023.104647},
  urldate = {2025-01-04},
  langid = {english},
  pmid = {37300932},
  keywords = {Body mass index,Multiple sclerosis,Obesity,Shared genetic architecture},
  file = {/Users/xx20081/Zotero/storage/ZKDZUHIE/Zeng et al. - 2023 - Dissecting shared genetic architecture between obesity and multiple sclerosis.pdf}
}

@article{zengMultiancestryEQTLMetaanalysis2022,
  title = {Multi-Ancestry {{eQTL}} Meta-Analysis of Human Brain Identifies Candidate Causal Variants for Brain-Related Traits},
  author = {Zeng, Biao and Bendl, Jaroslav and Kosoy, Roman and Fullard, John F. and Hoffman, Gabriel E. and Roussos, Panos},
  year = {2022},
  month = feb,
  journal = {Nature genetics},
  volume = {54},
  number = {2},
  pages = {161--169},
  issn = {1061-4036},
  doi = {10.1038/s41588-021-00987-9},
  urldate = {2025-01-13},
  abstract = {While large-scale genome-wide association studies (GWAS) have identified hundreds of loci associated with brain-related traits, identifying the variants, genes and molecular mechanisms underlying these traits remains challenging. Integrating GWAS with expression quantitative trait loci (eQTLs) and identifying shared genetic architecture has been widely adopted to nominate genes and candidate causal variants. However, this approach is limited by sample size, statistical power, and linkage disequilibrium. We developed the multivariate multiple QTL (mmQTL) approach and performed a large-scale multi-ancestry eQTL meta-analysis to increase power and fine-mapping resolution. Analyzing 3,983 RNA-seq samples from 2,119 donors, including 474 non-European individuals, yields an effective sample size of 3,154. Joint statistical fine-mapping of eQTL and GWAS identified 329 variant-trait pairs for 24 brain-related traits driven by 204 unique candidate causal variants for 189 unique genes. This integrative analysis identifies candidate causal variants and elucidates potential regulatory mechanisms for genes underlying schizophrenia, bipolar disorder and Alzheimer's disease.},
  pmcid = {PMC8852232},
  pmid = {35058635}
}

@article{zengMultiancestryEQTLMetaanalysis2022a,
  title = {Multi-Ancestry {{eQTL}} Meta-Analysis of Human Brain Identifies Candidate Causal Variants for Brain-Related Traits},
  author = {Zeng, Biao and Bendl, Jaroslav and Kosoy, Roman and Fullard, John F. and Hoffman, Gabriel E. and Roussos, Panos},
  year = {2022},
  month = feb,
  journal = {Nature Genetics},
  volume = {54},
  number = {2},
  pages = {161--169},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-021-00987-9},
  urldate = {2025-01-13},
  abstract = {While large-scale, genome-wide association studies (GWAS) have identified hundreds of loci associated with brain-related traits, identification of the variants, genes and molecular mechanisms underlying these traits remains challenging. Integration of GWAS with expression quantitative trait loci (eQTLs) and identification of shared genetic architecture have been widely adopted to nominate genes and candidate causal variants. However, this approach is limited by sample size, statistical power and linkage disequilibrium. We developed the multivariate multiple QTL approach and performed a large-scale, multi-ancestry eQTL meta-analysis to increase power and fine-mapping resolution. Analysis of 3,983\,RNA-sequenced samples from 2,119\,donors, including 474\,non-European individuals, yielded an effective sample size of 3,154. Joint statistical fine-mapping of eQTL and GWAS identified 329\,variant--trait pairs for 24\,brain-related traits driven by 204\,unique candidate causal variants for 189\,unique genes. This integrative analysis identifies candidate causal variants and elucidates potential regulatory mechanisms for genes underlying schizophrenia, bipolar disorder and Alzheimer's disease.},
  copyright = {2022 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  keywords = {Gene expression,Software},
  file = {/Users/xx20081/Zotero/storage/EEUUY2ZL/Zeng et al. - 2022 - Multi-ancestry eQTL meta-analysis of human brain identifies candidate causal variants for brain-rela.pdf}
}

@article{zengMultiancestryEQTLMetaanalysis2022b,
  title = {Multi-Ancestry {{eQTL}} Meta-Analysis of Human Brain Identifies Candidate Causal Variants for Brain-Related Traits},
  author = {Zeng, Biao and Bendl, Jaroslav and Kosoy, Roman and Fullard, John F. and Hoffman, Gabriel E. and Roussos, Panos},
  year = {2022},
  month = feb,
  journal = {Nature Genetics},
  volume = {54},
  number = {2},
  pages = {161--169},
  issn = {1546-1718},
  doi = {10.1038/s41588-021-00987-9},
  urldate = {2025-01-13},
  abstract = {While large-scale, genome-wide association studies (GWAS) have identified hundreds of loci associated with brain-related traits, identification of the variants, genes and molecular mechanisms underlying these traits remains challenging. Integration of GWAS with expression quantitative trait loci (eQTLs) and identification of shared genetic architecture have been widely adopted to nominate genes and candidate causal variants. However, this approach is limited by sample size, statistical power and linkage disequilibrium. We developed the multivariate multiple QTL approach and performed a large-scale, multi-ancestry eQTL meta-analysis to increase power and fine-mapping resolution. Analysis of 3,983\,RNA-sequenced samples from 2,119\,donors, including 474\,non-European individuals, yielded an effective sample size of 3,154. Joint statistical fine-mapping of eQTL and GWAS identified 329\,variant--trait pairs for 24\,brain-related traits driven by 204\,unique candidate causal variants for 189\,unique genes. This integrative analysis identifies candidate causal variants and elucidates potential regulatory mechanisms for genes underlying schizophrenia, bipolar disorder and Alzheimer's disease.},
  copyright = {2022 The Author(s), under exclusive licence to Springer Nature America, Inc.},
  langid = {english},
  keywords = {Gene expression,Software}
}

@article{zengMultiancestryEQTLMetaanalysis2022c,
  title = {Multi-Ancestry {{eQTL}} Meta-Analysis of Human Brain Identifies Candidate Causal Variants for Brain-Related Traits},
  author = {Zeng, Biao and Bendl, Jaroslav and Kosoy, Roman and Fullard, John F. and Hoffman, Gabriel E. and Roussos, Panos},
  year = {2022},
  month = feb,
  journal = {Nature genetics},
  volume = {54},
  number = {2},
  pages = {161--169},
  issn = {1061-4036},
  doi = {10.1038/s41588-021-00987-9},
  urldate = {2025-01-13},
  abstract = {While large-scale genome-wide association studies (GWAS) have identified hundreds of loci associated with brain-related traits, identifying the variants, genes and molecular mechanisms underlying these traits remains challenging. Integrating GWAS with expression quantitative trait loci (eQTLs) and identifying shared genetic architecture has been widely adopted to nominate genes and candidate causal variants. However, this approach is limited by sample size, statistical power, and linkage disequilibrium. We developed the multivariate multiple QTL (mmQTL) approach and performed a large-scale multi-ancestry eQTL meta-analysis to increase power and fine-mapping resolution. Analyzing 3,983 RNA-seq samples from 2,119 donors, including 474 non-European individuals, yields an effective sample size of 3,154. Joint statistical fine-mapping of eQTL and GWAS identified 329 variant-trait pairs for 24 brain-related traits driven by 204 unique candidate causal variants for 189 unique genes. This integrative analysis identifies candidate causal variants and elucidates potential regulatory mechanisms for genes underlying schizophrenia, bipolar disorder and Alzheimer's disease.},
  pmcid = {PMC8852232},
  pmid = {35058635}
}

@article{zhangCausalRelationshipHeart2023,
  title = {Causal Relationship from Heart Failure to Kidney Function and {{CKD}}: {{A}} Bidirectional Two-Sample Mendelian Randomization Study},
  shorttitle = {Causal Relationship from Heart Failure to Kidney Function and {{CKD}}},
  author = {Zhang, Junyu and Hu, Zhixi and Tan, Yuquan and Ye, Jiahao},
  year = {2023},
  journal = {PLOS ONE},
  volume = {18},
  number = {12},
  publisher = {PLOS},
  doi = {10.1371/journal.pone.0295532},
  urldate = {2024-04-18},
  abstract = {Heart Failure (HF) is a widespread condition that affects millions of people, and it is caused by issues with the heart and blood vessels. Even though we know hypertension, coronary artery disease, obesity, diabetes, and genetics can increase the risk ...},
  langid = {english},
  pmid = {38079381},
  file = {/Users/xx20081/Zotero/storage/3WBHMSUS/Zhang et al. - 2023 - Causal relationship from heart failure to kidney f.pdf}
}

@article{zhangGeneticallyPredictedHypothyroidism2024,
  title = {Genetically Predicted Hypothyroidism, Thyroid Hormone Treatment, and the Risk of Cardiovascular Diseases: A Mendelian Randomization Study},
  shorttitle = {Genetically Predicted Hypothyroidism, Thyroid Hormone Treatment, and the Risk of Cardiovascular Diseases},
  author = {Zhang, Shuaidan and Yu, Hangtian and Zhao, Yan and Gong, Angwei and Guan, Chengjian and Chen, Shuchen and Xiao, Bing and Lu, Jingchao},
  year = {2024},
  month = sep,
  journal = {BMC Cardiovascular Disorders},
  volume = {24},
  number = {1},
  pages = {479},
  issn = {1471-2261},
  doi = {10.1186/s12872-024-04132-2},
  urldate = {2024-09-17},
  abstract = {In this study, we explored the impact of hypothyroidism and thyroid hormone replacement therapy on the risk of developing cardiovascular diseases, including myocardial infarction, heart failure, and cardiac death, via Mendelian randomization analysis.},
  keywords = {Heart failure,Hypothyroidism,Levothyroxine,Mendelian randomization,Myocardial infarction},
  file = {/Users/xx20081/Zotero/storage/GHVHDDC8/Zhang et al. - 2024 - Genetically predicted hypothyroidism, thyroid horm.pdf;/Users/xx20081/Zotero/storage/N5CVYAGT/s12872-024-04132-2.html}
}

@article{zhaoNuclearATRLysinetyrosylation2023,
  title = {Nuclear {{ATR}} Lysine-Tyrosylation Protects against Heart Failure by Activating {{DNA}} Damage Response},
  author = {Zhao, Rui and Cai, Ke and Yang, Jing-Jing and Zhou, Qian and Cao, Wei and Xiang, Jie and Shen, Yi-Hui and Cheng, Lei-Lei and Zang, Wei-Dong and Lin, Yan and Yuan, Yi-Yuan and Xu, Wei and Tao, Hui and Zhao, Shi-Min and Zhao, Jian-Yuan},
  year = {2023},
  month = apr,
  journal = {Cell Reports},
  volume = {42},
  number = {4},
  pages = {112400},
  issn = {2211-1247},
  doi = {10.1016/j.celrep.2023.112400},
  urldate = {2025-06-11},
  abstract = {Dysregulated amino acid increases the risk for heart failure (HF) via unclear mechanisms. Here, we find that increased plasma tyrosine and phenylalanine levels are associated with HF. Increasing tyrosine or phenylalanine by high-tyrosine or high-phenylalanine chow feeding exacerbates HF phenotypes in transverse aortic constriction and isoproterenol infusion mice models. Knocking down phenylalanine dehydrogenase abolishes the effect of phenylalanine, indicating that phenylalanine functions by converting to tyrosine. Mechanistically, tyrosyl-tRNA synthetase (YARS) binds to ataxia telangiectasia and Rad3-related gene (ATR), catalyzes lysine tyrosylation (K-Tyr) of ATR, and activates the DNA damage response (DDR) in the nucleus. Increased tyrosine inhibits the nuclear localization of YARS, inhibits the ATR-mediated DDR, accumulates DNA damage, and elevates cardiomyocyte apoptosis. Enhancing ATR K-Tyr by overexpressing YARS, restricting tyrosine, or supplementing tyrosinol, a structural analog of tyrosine, promotes YARS nuclear localization and alleviates HF in mice. Our findings implicate facilitating YARS nuclear translocation as a potential preventive and/or interfering measure against HF.},
  keywords = {ATR,DNA damage response,heart failure,protein tyrosylation,tyrosyl-tRNA synthetase},
  file = {/Users/xx20081/Zotero/storage/CUCJ7XYA/Zhao et al. - 2023 - Nuclear ATR lysine-tyrosylation protects against heart failure by activating DNA damage response.pdf;/Users/xx20081/Zotero/storage/CD445Y38/S2211124723004114.html}
}

@article{zhaoSodiumglucoseCotransporterInhibition2022,
  title = {Sodium-Glucose Cotransporter 1 Inhibition and Gout: {{Mendelian}} Randomisation Study},
  shorttitle = {Sodium-Glucose Cotransporter 1 Inhibition and Gout},
  author = {Zhao, Sizheng Steven and Rajasundaram, Skanda and Karhunen, Ville and Alam, Uazman and Gill, Dipender},
  year = {2022},
  month = oct,
  journal = {Seminars in Arthritis and Rheumatism},
  volume = {56},
  pages = {152058},
  issn = {0049-0172},
  doi = {10.1016/j.semarthrit.2022.152058},
  urldate = {2024-01-18},
  abstract = {Objective Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce serum urate, but their efficacy depends on renal function which is often impaired in people with gout. SGLT1 is primarily expressed in the small intestine and its inhibition may be a more suitable therapeutic target. We aimed to investigate the association of genetically proxied SGLT1i with gout risk, serum urate levels and cardiovascular safety using Mendelian randomisation (MR). Methods Leveraging data from a genome-wide association study of 344,182 individuals in the UK Biobank, we identified a missense variant in the SLC5A1 gene that associated with glycated haemoglobin (HbA1c) to proxy SGLT1i. Outcome genetic data comprised 13,179 gout cases and 750,634 controls, 457,690 individuals for serum urate levels, and up to 977,323 individuals for cardiovascular safety outcomes. We applied the Wald ratio method and investigated potential genetic confounding using colocalization. Results The rs17683430 missense variant was selected to instrument SGLT1i. Genetically proxied SGLT1i was associated with 75\% reduction in gout risk (OR 0.25; 95\%CI 0.06, 0.99; p~=~0.048) and 32.0~{$\mu$}mol/L reduction in serum urate (95\%CI -56.7, -7.3; p~=~0.01), per 6.7~mmol/mol reduction in HbA1c. SGLT1i was associated with increased levels of low-density lipoprotein cholesterol (0.37~mmol/L; 95\%CI 0.17, 0.56; p~=~0.0002) but not risk of coronary heart disease, stroke, or chronic kidney disease. Colocalization did not suggest that results are attributable to genetic confounding. Conclusion SGLT1 inhibition may represent a novel therapeutic option for preventing gout in people with or without comorbid diabetes. Randomised trials are needed to formally investigate efficacy and safety.},
  keywords = {Cholesterol,Diabetes,Glycated haemoglobin,Gout,SGLT1,Sodium-glucose cotransporter,Urate},
  file = {/Users/xx20081/Zotero/storage/RKI5FDX5/S0049017222001093.html}
}

@article{zhengEvaluatingEfficacyMechanism2022,
  title = {Evaluating the Efficacy and Mechanism of Metformin Targets on Reducing {{Alzheimer}}'s Disease Risk in the General Population: A {{Mendelian}} Randomisation Study},
  shorttitle = {Evaluating the Efficacy and Mechanism of Metformin Targets on Reducing {{Alzheimer}}'s Disease Risk in the General Population},
  author = {Zheng, Jie and Xu, Min and Walker, Venexia and Yuan, Jinqiu and {Korologou-Linden}, Roxanna and Robinson, Jamie and Huang, Peiyuan and Burgess, Stephen and Au Yeung, Shiu Lun and Luo, Shan and Holmes, Michael V. and Davey Smith, George and Ning, Guang and Wang, Weiqing and Gaunt, Tom R. and Bi, Yufang},
  year = {2022},
  month = oct,
  journal = {Diabetologia},
  volume = {65},
  number = {10},
  pages = {1664--1675},
  issn = {1432-0428},
  doi = {10.1007/s00125-022-05743-0},
  urldate = {2024-01-18},
  abstract = {Metformin use has been associated with reduced incidence of dementia in diabetic individuals in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomisation (MR) to investigate the causal effect of metformin targets on Alzheimer's disease and potential causal mechanisms in the brain linking the two.},
  langid = {english},
  keywords = {Alzheimer's disease,Brain expression,Cognitive function,Dementia,Mendelian randomisation,Metformin targets,Mitochondrial function},
  file = {/Users/xx20081/Zotero/storage/LU6P3HXD/Zheng et al. - 2022 - Evaluating the efficacy and mechanism of metformin.pdf}
}

@misc{zhengEvaluationPolygenicScore2023,
  title = {Evaluation of Polygenic Score for Hypertrophic Cardiomyopathy in the General Population and across Clinical Settings},
  author = {Zheng, Sean L. and Jurgens, Sean J. and McGurk, Kathryn A. and Xu, Xiao and Grace, Chris and Theotokis, Pantazis I. and Buchan, Rachel J. and Francis, Catherine and de Marvao, Antonio and Curran, Lara and Bai, Wenjia and Pua, Chee Jian and Chiaw, Tang Hak and Jorda, Paloma and van Slegtenhorst, Marjon A. and Verhagen, Judith MA and Harper, Andrew R. and Ormondroyd, Elizabeth and Chin, Calvin WL and Consortium, Genomics England Research and Collaborators, Hcm Gwas and Pantazis, Antonis and Baksi, John and Halliday, Brian P. and Matthews, Paul and Pinto, Yigal M. and Walsh, Roddy and Amin, Ahmad S. and Wilde, Arthur AM and Cook, Stuart A. and Prasad, Sanjay K. and Barton, Paul JR and O'Regan, Declan P. and Lumbers, R. T. and Goel, Anuj and Tadros, Rafik and Michels, Michelle and Watkins, Hugh and Bezzina, Connie R. and Ware, James S.},
  year = {2023},
  month = mar,
  pages = {2023.03.14.23286621},
  publisher = {medRxiv},
  doi = {10.1101/2023.03.14.23286621},
  urldate = {2024-12-04},
  abstract = {Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality, with rare pathogenic variants found in about a third of cases (sarcomere-positive). Large-scale genome-wide association studies (GWAS) demonstrate that common genetic variation contributes substantially to HCM risk. Here, we derive polygenic scores (PGS) from HCM GWAS, and multi-trait analysis of GWAS incorporating genetically-correlated traits, and test their performance in the UK Biobank, 100,000 Genomes Project, and across clinical cohorts. Higher PGS substantially increases population risk of HCM, particularly amongst sarcomere-positive carriers where HCM penetrance differs 10-fold between those in the highest and lowest PGS quintiles. In relatives of HCM patients, PGS stratifies risks of developing HCM and adverse outcomes. Finally, PGS strongly predicts risk of adverse outcomes in HCM, with a 4 to 6-fold increase in death between cases in the highest and lowest PGS quintiles. These findings promise broad clinical utility of PGS in the general population, in cases, and in families with HCM, enabling tailored screening and surveillance, and stratification of risk of adverse outcomes.},
  archiveprefix = {medRxiv},
  copyright = {{\copyright} 2023, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at http://creativecommons.org/licenses/by/4.0/},
  langid = {english},
  file = {/Users/xx20081/Zotero/storage/JGMCFAAW/Zheng et al. - 2023 - Evaluation of polygenic score for hypertrophic cardiomyopathy in the general population and across c.pdf}
}

@article{zhengGenomewideAssociationAnalysis2024,
  title = {Genome-Wide Association Analysis Provides Insights into the Molecular Etiology of Dilated Cardiomyopathy},
  author = {Zheng, Sean L. and Henry, Albert and Cannie, Douglas and Lee, Michael and Miller, David and McGurk, Kathryn A. and Bond, Isabelle and Xu, Xiao and Issa, Hanane and Francis, Catherine and De Marvao, Antonio and Theotokis, Pantazis I. and Buchan, Rachel J. and Speed, Doug and Abner, Erik and Adams, Lance and Aragam, Krishna G. and {\"A}rnl{\"o}v, Johan and Raja, Anna Axelsson and Backman, Joshua D. and Baksi, John and Barton, Paul J. R. and Biddinger, Kiran J. and Boersma, Eric and Brandimarto, Jeffrey and Brunak, S{\o}ren and Bundgaard, Henning and Carey, David J. and Charron, Philippe and Cook, James P. and Cook, Stuart A. and Denaxas, Spiros and Deleuze, Jean-Fran{\c c}ois and Doney, Alexander S. and Elliott, Perry and Erikstrup, Christian and Esko, T{\~o}nu and {Farber-Eger}, Eric H. and Finan, Chris and Garnier, Sophie and Ghouse, Jonas and Giedraitis, Vilmantas and Gu{\dh}bjartsson, Daniel F. and Haggerty, Christopher M. and Halliday, Brian P. and Helgadottir, Anna and Hemingway, Harry and Hillege, Hans L. and Kardys, Isabella and Lind, Lars and Lindgren, Cecilia M. and Lowery, Brandon D. and Manisty, Charlotte and Margulies, Kenneth B. and Moon, James C. and Mordi, Ify R. and Morley, Michael P. and Morris, Andrew D. and Morris, Andrew P. and Morton, Lori and Noursadeghi, Mahdad and Ostrowski, Sisse R. and Owens, Anjali T. and Palmer, Colin N. A. and Pantazis, Antonis and Pedersen, Ole B. V. and Prasad, Sanjay K. and Shekhar, Akshay and Smelser, Diane T. and Srinivasan, Sundararajan and Stefansson, Kari and Sveinbj{\"o}rnsson, Gar{\dh}ar and Syrris, Petros and Tammesoo, Mari-Liis and Tayal, Upasana and {Teder-Laving}, Maris and Thorgeirsson, Gu{\dh}mundur and Thorsteinsdottir, Unnur and Tragante, Vinicius and Tr{\'e}gou{\"e}t, David-Alexandre and Treibel, Thomas A. and Ullum, Henrik and Valdes, Ana M. and {van Setten}, Jessica and {van Vugt}, Marion and Veluchamy, Abirami and Verschuren, W. M. Monique and Villard, Eric and Yang, Yifan and Asselbergs, Folkert W. and Cappola, Thomas P. and Dube, Marie-Pierre and Dunn, Michael E. and Ellinor, Patrick T. and Hingorani, Aroon D. and Lang, Chim C. and Samani, Nilesh J. and Shah, Svati H. and Smith, J. Gustav and Vasan, Ramachandran S. and O'Regan, Declan P. and Holm, Hilma and Noseda, Michela and Wells, Quinn and Ware, James S. and Lumbers, R. Thomas},
  year = {2024},
  month = nov,
  journal = {Nature Genetics},
  pages = {1--13},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/s41588-024-01952-y},
  urldate = {2024-12-10},
  abstract = {Dilated cardiomyopathy (DCM) is a leading cause of heart failure and cardiac transplantation. We report a genome-wide association study and multi-trait analysis of DCM (14,256 cases) and three left ventricular traits (36,203 UK Biobank participants). We identified 80 genomic risk loci and prioritized 62 putative effector genes, including several with rare variant DCM associations (MAP3K7, NEDD4L and SSPN). Using single-nucleus transcriptomics, we identify cellular states, biological pathways, and intracellular communications that drive pathogenesis. We demonstrate that polygenic scores predict DCM in the general population and modify penetrance in carriers of rare DCM variants. Our findings may inform the design of genetic testing strategies that incorporate polygenic background. They also provide insights into the molecular etiology of DCM that may facilitate the development of targeted therapeutics.},
  copyright = {2024 The Author(s)},
  langid = {english},
  keywords = {Cardiomyopathies,Genome-wide association studies},
  file = {/Users/xx20081/Zotero/storage/ALC8XP59/Zheng et al. - 2024 - Genome-wide association analysis provides insights into the molecular etiology of dilated cardiomyop.pdf}
}

@article{zhengRecentDevelopmentsMendelian2017,
  title = {Recent {{Developments}} in {{Mendelian Randomization Studies}}},
  author = {Zheng, Jie and Baird, Denis and Borges, Maria-Carolina and Bowden, Jack and Hemani, Gibran and Haycock, Philip and Evans, David M. and Smith, George Davey},
  year = {2017},
  journal = {Current Epidemiology Reports},
  volume = {4},
  number = {4},
  pages = {330--345},
  issn = {2196-2995},
  doi = {10.1007/s40471-017-0128-6},
  abstract = {PURPOSE OF REVIEW: Mendelian randomization (MR) is a strategy for evaluating causality in observational epidemiological studies. MR exploits the fact that genotypes are not generally susceptible to reverse causation and confounding, due to their fixed nature and Mendel's First and Second Laws of Inheritance. MR has the potential to provide information on causality in many situations where randomized controlled trials are not possible, but the results of MR studies must be interpreted carefully to avoid drawing erroneous conclusions. RECENT FINDINGS: In this review, we outline the principles behind MR, as well as assumptions and limitations of the method. Extensions to the basic approach are discussed, including two-sample MR, bidirectional MR, two-step MR, multivariable MR, and factorial MR. We also consider some new applications and recent developments in the methodology, including its ability to inform drug development, automation of the method using tools such as MR-Base, and phenome-wide and hypothesis-free MR. SUMMARY: In conjunction with the growing availability of large-scale genomic databases, higher level of automation and increased robustness of the methods, MR promises to be a valuable strategy to examine causality in complex biological/omics networks, inform drug development and prioritize intervention targets for disease prevention in the future.},
  langid = {english},
  pmcid = {PMC5711966},
  pmid = {29226067},
  keywords = {Databases and automation tools for causal inference,Disease progression,Drug development,Hypothesis-free causality,Mendelian randomization}
}

@article{zhengRecentDevelopmentsMendelian2017a,
  title = {Recent {{Developments}} in {{Mendelian Randomization Studies}}},
  author = {Zheng, Jie and Baird, Denis and Borges, Maria-Carolina and Bowden, Jack and Hemani, Gibran and Haycock, Philip and Evans, David M. and Smith, George Davey},
  year = {2017},
  journal = {Current Epidemiology Reports},
  volume = {4},
  number = {4},
  pages = {330--345},
  issn = {2196-2995},
  doi = {10.1007/s40471-017-0128-6},
  abstract = {PURPOSE OF REVIEW: Mendelian randomization (MR) is a strategy for evaluating causality in observational epidemiological studies. MR exploits the fact that genotypes are not generally susceptible to reverse causation and confounding, due to their fixed nature and Mendel's First and Second Laws of Inheritance. MR has the potential to provide information on causality in many situations where randomized controlled trials are not possible, but the results of MR studies must be interpreted carefully to avoid drawing erroneous conclusions. RECENT FINDINGS: In this review, we outline the principles behind MR, as well as assumptions and limitations of the method. Extensions to the basic approach are discussed, including two-sample MR, bidirectional MR, two-step MR, multivariable MR, and factorial MR. We also consider some new applications and recent developments in the methodology, including its ability to inform drug development, automation of the method using tools such as MR-Base, and phenome-wide and hypothesis-free MR. SUMMARY: In conjunction with the growing availability of large-scale genomic databases, higher level of automation and increased robustness of the methods, MR promises to be a valuable strategy to examine causality in complex biological/omics networks, inform drug development and prioritize intervention targets for disease prevention in the future.},
  langid = {english},
  pmcid = {PMC5711966},
  pmid = {29226067},
  keywords = {Databases and automation tools for causal inference,Disease progression,Drug development,Hypothesis-free causality,Mendelian randomization}
}

@article{zhengRecentDevelopmentsMendelian2017b,
  title = {Recent {{Developments}} in {{Mendelian Randomization Studies}}},
  author = {Zheng, Jie and Baird, Denis and Borges, Maria-Carolina and Bowden, Jack and Hemani, Gibran and Haycock, Philip and Evans, David M. and Smith, George Davey},
  year = {2017},
  journal = {Current Epidemiology Reports},
  volume = {4},
  number = {4},
  pages = {330--345},
  issn = {2196-2995},
  doi = {10.1007/s40471-017-0128-6},
  abstract = {PURPOSE OF REVIEW: Mendelian randomization (MR) is a strategy for evaluating causality in observational epidemiological studies. MR exploits the fact that genotypes are not generally susceptible to reverse causation and confounding, due to their fixed nature and Mendel's First and Second Laws of Inheritance. MR has the potential to provide information on causality in many situations where randomized controlled trials are not possible, but the results of MR studies must be interpreted carefully to avoid drawing erroneous conclusions. RECENT FINDINGS: In this review, we outline the principles behind MR, as well as assumptions and limitations of the method. Extensions to the basic approach are discussed, including two-sample MR, bidirectional MR, two-step MR, multivariable MR, and factorial MR. We also consider some new applications and recent developments in the methodology, including its ability to inform drug development, automation of the method using tools such as MR-Base, and phenome-wide and hypothesis-free MR. SUMMARY: In conjunction with the growing availability of large-scale genomic databases, higher level of automation and increased robustness of the methods, MR promises to be a valuable strategy to examine causality in complex biological/omics networks, inform drug development and prioritize intervention targets for disease prevention in the future.},
  langid = {english},
  pmcid = {PMC5711966},
  pmid = {29226067},
  keywords = {Databases and automation tools for causal inference,Disease progression,Drug development,Hypothesis-free causality,Mendelian randomization},
  file = {/Users/xx20081/Zotero/storage/LDQUCHG7/Zheng et al. - 2017 - Recent Developments in Mendelian Randomization Studies.pdf}
}

@article{zhuangSharedGeneticEtiology2021,
  title = {Shared Genetic Etiology and Causality between Body Fat Percentage and Cardiovascular Diseases: A Large-Scale Genome-Wide Cross-Trait Analysis},
  shorttitle = {Shared Genetic Etiology and Causality between Body Fat Percentage and Cardiovascular Diseases},
  author = {Zhuang, Zhenhuang and Yao, Minhao and Wong, Jason Y. Y. and Liu, Zhonghua and Huang, Tao},
  year = {2021},
  month = apr,
  journal = {BMC Medicine},
  volume = {19},
  number = {1},
  pages = {100},
  issn = {1741-7015},
  doi = {10.1186/s12916-021-01972-z},
  urldate = {2024-12-27},
  abstract = {Accumulating evidences have suggested that high body fat percentage (BF\%) often occurs in parallel with cardiovascular diseases (CVDs), implying a common etiology between them. However, the shared genetic etiology underlying BF\% and CVDs remains unclear.},
  keywords = {Body fat percentage,Cardiovascular diseases,Genetic correlation,Mendelian randomization,Shared genetics},
  file = {/Users/xx20081/Zotero/storage/NWP33ZUT/Zhuang et al. - 2021 - Shared genetic etiology and causality between body fat percentage and cardiovascular diseases a lar.pdf;/Users/xx20081/Zotero/storage/WGTS7CEU/s12916-021-01972-z.html}
}

@article{zhuIntegrationSummaryData2016,
  title = {Integration of Summary Data from {{GWAS}} and {{eQTL}} Studies Predicts Complex Trait Gene Targets},
  author = {Zhu, Zhihong and Zhang, Futao and Hu, Han and Bakshi, Andrew and Robinson, Matthew R. and Powell, Joseph E. and Montgomery, Grant W. and Goddard, Michael E. and Wray, Naomi R. and Visscher, Peter M. and Yang, Jian},
  year = {2016},
  month = may,
  journal = {Nature Genetics},
  volume = {48},
  number = {5},
  pages = {481--487},
  publisher = {Nature Publishing Group},
  issn = {1546-1718},
  doi = {10.1038/ng.3538},
  urldate = {2024-02-19},
  abstract = {Jian Yang and colleagues propose a method that integrates summary data from GWAS and eQTL studies to identify genes whose expression levels are associated with complex traits because of pleiotropy. They apply the method to five human complex traits and prioritize 126 genes for future functional studies.},
  copyright = {2016 Springer Nature America, Inc.},
  langid = {english},
  keywords = {Gene expression,Genome-wide association studies}
}

@article{ziaeianEpidemiologyAetiologyHeart2016,
  title = {Epidemiology and Aetiology of Heart Failure},
  author = {Ziaeian, Boback and Fonarow, Gregg C.},
  year = {2016},
  month = jun,
  journal = {Nature Reviews. Cardiology},
  volume = {13},
  number = {6},
  pages = {368--378},
  issn = {1759-5010},
  doi = {10.1038/nrcardio.2016.25},
  abstract = {Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of {$>$}37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience numerous symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance, and fluid retention. Although the underlying causes of HF vary according to sex, age, ethnicity, comorbidities, and environment, the majority of cases remain preventable. HF is associated with increased morbidity and mortality, and confers a substantial burden to the health-care system. HF is a leading cause of hospitalization among adults and the elderly. In the USA, the total medical costs for patients with HF are expected to rise from US\$20.9 billion in 2012 to \$53.1 billion by 2030. Improvements in the medical management of risk factors and HF have stabilized the incidence of this disease in many countries. In this Review, we provide an overview of the latest epidemiological data on HF, and propose future directions for reducing the ever-increasing HF burden.},
  langid = {english},
  pmcid = {PMC4868779},
  pmid = {26935038},
  keywords = {Cost of Illness,Health Care Costs,Heart Failure,Humans,Incidence,Prevalence,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/RZUN6Q6Z/Ziaeian and Fonarow - 2016 - Epidemiology and aetiology of heart failure.pdf}
}

@article{zinmanEmpagliflozinCardiovascularOutcomes2015,
  title = {Empagliflozin, {{Cardiovascular Outcomes}}, and {{Mortality}} in {{Type}} 2 {{Diabetes}}},
  author = {Zinman, Bernard and Wanner, Christoph and Lachin, John M. and Fitchett, David and Bluhmki, Erich and Hantel, Stefan and Mattheus, Michaela and Devins, Theresa and Johansen, Odd Erik and Woerle, Hans J. and Broedl, Uli C. and Inzucchi, Silvio E. and {EMPA-REG OUTCOME Investigators}},
  year = {2015},
  month = nov,
  journal = {The New England Journal of Medicine},
  volume = {373},
  number = {22},
  pages = {2117--2128},
  issn = {1533-4406},
  doi = {10.1056/NEJMoa1504720},
  abstract = {BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS: We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, as analyzed in the pooled empagliflozin group versus the placebo group. The key secondary composite outcome was the primary outcome plus hospitalization for unstable angina. RESULTS: A total of 7020 patients were treated (median observation time, 3.1 years). The primary outcome occurred in 490 of 4687 patients (10.5\%) in the pooled empagliflozin group and in 282 of 2333 patients (12.1\%) in the placebo group (hazard ratio in the empagliflozin group, 0.86; 95.02\% confidence interval, 0.74 to 0.99; P=0.04 for superiority). There were no significant between-group differences in the rates of myocardial infarction or stroke, but in the empagliflozin group there were significantly lower rates of death from cardiovascular causes (3.7\%, vs. 5.9\% in the placebo group; 38\% relative risk reduction), hospitalization for heart failure (2.7\% and 4.1\%, respectively; 35\% relative risk reduction), and death from any cause (5.7\% and 8.3\%, respectively; 32\% relative risk reduction). There was no significant between-group difference in the key secondary outcome (P=0.08 for superiority). Among patients receiving empagliflozin, there was an increased rate of genital infection but no increase in other adverse events. CONCLUSIONS: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. (Funded by Boehringer Ingelheim and Eli Lilly; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.).},
  langid = {english},
  pmid = {26378978},
  keywords = {Aged,Benzhydryl Compounds,Cardiovascular Diseases,Cause of Death,Diabetes Mellitus Type 2,Female,Glucosides,Hospitalization,Humans,Hypoglycemic Agents,Intention to Treat Analysis,Kaplan-Meier Estimate,Male,Middle Aged,Risk Factors},
  file = {/Users/xx20081/Zotero/storage/96S7G77H/Zinman et al. - 2015 - Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.pdf}
}

@article{zotero-3,
  type = {Article}
}

@article{zuberHighthroughputMultivariableMendelian2021,
  title = {High-Throughput Multivariable {{Mendelian}} Randomization Analysis Prioritizes Apolipoprotein {{B}} as Key Lipid Risk Factor for Coronary Artery Disease},
  author = {Zuber, Verena and Gill, Dipender and {Ala-Korpela}, Mika and Langenberg, Claudia and Butterworth, Adam and Bottolo, Leonardo and Burgess, Stephen},
  year = {2021},
  month = jun,
  journal = {International Journal of Epidemiology},
  volume = {50},
  number = {3},
  pages = {893--901},
  issn = {0300-5771},
  doi = {10.1093/ije/dyaa216},
  urldate = {2024-12-23},
  abstract = {Genetic variants can be used to prioritize risk factors as potential therapeutic targets via Mendelian randomization (MR). An agnostic statistical framework using Bayesian model averaging (MR-BMA) can disentangle the causal role of correlated risk factors with shared genetic predictors. Here, our objective is to identify lipoprotein measures as mediators between lipid-associated genetic variants and coronary artery disease (CAD) for the purpose of detecting therapeutic targets for CAD.As risk factors we consider 30 lipoprotein measures and metabolites derived from a high-throughput metabolomics study including 24~925 participants. We fit multivariable MR models of genetic associations with CAD estimated in 453~595 participants (including 113~937 cases) regressed on genetic associations with the risk factors. MR-BMA assigns to each combination of risk factors a model score quantifying how well the genetic associations with CAD are explained. Risk factors are ranked by their marginal score and selected using false-discovery rate (FDR) criteria. We perform supplementary and sensitivity analyses varying the dataset for genetic associations with CAD.In the main analysis, the top combination of risk factors ranked by the model score contains apolipoprotein B (ApoB) only. ApoB is also the highest ranked risk factor with respect to the marginal score (FDR \&lt;0.005). Additionally, ApoB is selected in all sensitivity analyses. No other measure of cholesterol or triglyceride is consistently selected otherwise.Our agnostic genetic investigation prioritizes ApoB across all datasets considered, suggesting that ApoB, representing the total number of hepatic-derived lipoprotein particles, is the primary lipid determinant of CAD.},
  file = {/Users/xx20081/Zotero/storage/G44ZJTM6/Zuber et al. - 2021 - High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key l.pdf}
}

@article{zuberSelectingLikelyCausal2020,
  title = {Selecting Likely Causal Risk Factors from High-Throughput Experiments Using Multivariable {{Mendelian}} Randomization},
  author = {Zuber, Verena and Colijn, Johanna Maria and Klaver, Caroline and Burgess, Stephen},
  year = {2020},
  month = jan,
  journal = {Nature Communications},
  volume = {11},
  number = {1},
  pages = {29},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-019-13870-3},
  urldate = {2024-06-18},
  abstract = {Modern high-throughput experiments provide a rich resource to investigate causal determinants of disease risk. Mendelian randomization (MR) is the use of genetic variants as instrumental variables to infer the causal effect of a specific risk factor on an outcome. Multivariable MR is an extension of the standard MR framework to consider multiple potential risk factors in a single model. However, current implementations of multivariable MR use standard linear regression and hence perform poorly with many risk factors. Here, we propose a two-sample multivariable MR approach based on Bayesian model averaging (MR-BMA) that scales to high-throughput experiments. In a realistic simulation study, we show that MR-BMA can detect true causal risk factors even when the candidate risk factors are highly correlated. We illustrate MR-BMA by analysing publicly-available summarized data on metabolites to prioritise likely causal biomarkers for age-related macular degeneration.},
  copyright = {2020 The Author(s)},
  langid = {english},
  keywords = {Biomarkers,Epidemiology,Genome-wide association studies,Statistical methods},
  file = {/Users/xx20081/Zotero/storage/P5B2SIQY/Zuber et al. - 2020 - Selecting likely causal risk factors from high-thr.pdf}
}

@article{zuberSelectingLikelyCausal2020a,
  title = {Selecting Likely Causal Risk Factors from High-Throughput Experiments Using Multivariable {{Mendelian}} Randomization},
  author = {Zuber, Verena and Colijn, Johanna Maria and Klaver, Caroline and Burgess, Stephen},
  year = {2020},
  month = jan,
  journal = {Nature Communications},
  volume = {11},
  number = {1},
  pages = {29},
  publisher = {Nature Publishing Group},
  issn = {2041-1723},
  doi = {10.1038/s41467-019-13870-3},
  urldate = {2024-12-23},
  abstract = {Modern high-throughput experiments provide a rich resource to investigate causal determinants of disease risk. Mendelian randomization (MR) is the use of genetic variants as instrumental variables to infer the causal effect of a specific risk factor on an outcome. Multivariable MR is an extension of the standard MR framework to consider multiple potential risk factors in a single model. However, current implementations of multivariable MR use standard linear regression and hence perform poorly with many risk factors. Here, we propose a two-sample multivariable MR approach based on Bayesian model averaging (MR-BMA) that scales to high-throughput experiments. In a realistic simulation study, we show that MR-BMA can detect true causal risk factors even when the candidate risk factors are highly correlated. We illustrate MR-BMA by analysing publicly-available summarized data on metabolites to prioritise likely causal biomarkers for age-related macular degeneration.},
  copyright = {2020 The Author(s)},
  langid = {english},
  keywords = {Biomarkers,Epidemiology,Genome-wide association studies,Statistical methods},
  file = {/Users/xx20081/Zotero/storage/D9QWRWPJ/Zuber et al. - 2020 - Selecting likely causal risk factors from high-throughput experiments using multivariable Mendelian.pdf}
}
